PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	LEBWOHL, DE; MUISEHELMERICKS, R; SEPPLORENZINO, L; SERVE, S; TIMAUL, M; BOL, R; BORGEN, P; ROSEN, N				LEBWOHL, DE; MUISEHELMERICKS, R; SEPPLORENZINO, L; SERVE, S; TIMAUL, M; BOL, R; BORGEN, P; ROSEN, N			A TRUNCATED CYCLIN D1 GENE ENCODES A STABLE MESSENGER-RNA IN A HUMAN BREAST-CANCER CELL-LINE	ONCOGENE			English	Article							GROWTH-FACTORS; MESSENGER-RNA; MOLECULAR-CLONING; HUMAN-TUMORS; BCL-1 GENE; AMPLIFICATION; EXPRESSION; HST; CARCINOMAS; ONCOGENE	The G1 cyclin D1 is amplified in approximately 20% of human breast cancers and is frequently overexpressed as part of an amplicon in these tumors, suggesting a potential role for this gene in the pathogenesis of breast cancer. Although amplification of cyclin D1 occurs in human breast cancer, it is possible that another gene in the amplicon is the relevant oncogene in these cancers. We now report a truncation of the cyclin D1 gene in a human breast cancer cell line, associated with overexpression of a short cyclin D1 mRNA. In a survey of breast cancer cell lines and tumors by Southern blot hybridization, using a 1.2 kb human cyclin D1 cDNA, we observed that genomic DNA derived from the MDA MB-453 cell line contains an extra band in the Bg1II and BamHI digests, suggesting that one allele of gene is altered. Moreover, the altered allele is amplified three-fold relative to the normal allele, and contains a 3' deletion. On Northern analysis, the MDA MB-453 line has a marked increase in 1.1 to 1.3 kb transcripts, which are truncated at the 3' end, in contrast to the normally predominant 4.2 kb transcript. The 1.1 - 1.3 kb cyclin D1 mRNA has a longer half-life than the 4.2 kb mRNA, indicating that the 3' truncation may contribute an increased stability and therefore an elevated steady-state level of the short mRNA. These alterations in the cyclin D1 gene and mRNA suggest that altered expression of cyclin D1 may be important in the malignant transformation of this cell line, and support the identification of cyclin D1 as a dominant oncogene at 11q13 in human breast cancer.	MEM SLOAN KETTERING CANC CTR, DEPT SURG, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	LEBWOHL, DE (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT MED, 1275 YORK AVE, NEW YORK, NY 10021 USA.		Rosen, Neal/ABF-2677-2020					ALI IU, 1989, ONCOGENE, V4, P89; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; CULLEN KJ, 1991, CANCER INVEST, V9, P443, DOI 10.3109/07357909109084643; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FAUST JB, 1992, CANCER RES, V52, P2460; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAMMIE GA, 1991, ONCOGENE, V6, P439; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; LISCIA DS, 1989, ONCOGENE, V4, P1219; Maniatis T., 1982, MOL CLONING; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHUURING E, 1992, ONCOGENE, V7, P355; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THEILLET C, 1989, ONCOGENE, V4, P915; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	29	101	101	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1925	1929						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208539				2022-12-25	WOS:A1994NR68500016
J	TIEMANN, F; DEPPERT, W				TIEMANN, F; DEPPERT, W			IMMORTALIZATION OF BALB/C MOUSE EMBRYO FIBROBLASTS ALTERS SV40 LARGE T-ANTIGEN INTERACTIONS WITH THE TUMOR-SUPPRESSOR P53 AND RESULTS IN A REDUCED SV40 TRANSFORMATION-EFFICIENCY	ONCOGENE			English	Article							ADENOVIRUS E1A PROTEINS; SIMIAN VIRUS-40; MONOCLONAL-ANTIBODIES; WILD-TYPE; ONCOGENIC TRANSFORMATION; CELLULAR-TRANSFORMATION; BINDING-SITES; MUTANT P53; CELLS; COOPERATION	In order to analyse the immortalizing and transforming potential of simian virus 40 (SV40), we compared the transformation efficiencies of SV40 in primary and in established BALB/c mouse fibroblasts. Five independently isolated clones of freshly immortalized normal fibroblasts (FTE cells) were established from precrisis BALB/c mouse embryo fibroblasts (pMEF cells) according to the protocol for establishing 3T3 cells (Todaro & Green, 1963). These cells expressed a wild-type p53 and were indistinguishable in all parameters analysed from original 3T3 cells kept in our laboratory. Using abortive infection to control gene dosage, followed by selection of transformed cells by cloning in soft agar, SV40 was able to transform primary cells with a much higher efficiency than 3T3 or FTE cells. Analysis of this unexpected result revealed that the different transformation efficiencies of SV40 in primary and established cells correlated with an altered cellular response to SV40 infection regarding metabolic stabilization of p53 complexed to large T during abortive infection. Whereas p53 in pMEF cells became stabilized upon abortive infection with SV40, p53 in 3T3 and FTE cells remained unstable. Our results strongly favour the hypothesis that metabolic stabilization and the ensuing higher levels of p53 in abortively infected cells enhance the transforming competence of large T.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY	Heinrich Pette Institute; University of Hamburg								AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1989, ONCOGENE, V4, P1103; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DEPPERT W, 1989, NATO ASI SERIES; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ECKHART W, 1989, ONCOGENES MOL ORIGIN, P223; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUKUSAWA K, 1991, MOL CELL BIOL, V11, P3472; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MANFREDI JJ, 1993, J VIROL, V67, P4750, DOI 10.1128/JVI.67.8.4750-4759.1993; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MONTENARH M, 1985, EMBO J, V4, P2941, DOI 10.1002/j.1460-2075.1985.tb04027.x; OLSON DC, 1993, ONCOGENE, V8, P2353; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; PRIVES C, 1991, COLD SH Q B, V56, P227; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; REIHSAUS E, 1992, EXP CELL RES, V199, P10, DOI 10.1016/0014-4827(92)90456-I; RICHTER W, 1990, VIROLOGY, V174, P543, DOI 10.1016/0042-6822(90)90108-4; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRMBECK R, 1987, J VIROL, V61, P3561, DOI 10.1128/JVI.61.11.3561-3569.1987; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WALSER A, 1986, EMBO J, V5, P883, DOI 10.1002/j.1460-2075.1986.tb04299.x; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERG RA, 1989, CANCER RES, V49, P3713; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZERRAHN J, 1992, ONCOGENE, V7, P1371; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	74	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1907	1915						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208537				2022-12-25	WOS:A1994NR68500014
J	CHEN, J; ISHII, M; WANG, L; ISHII, K; COUGHLIN, SR				CHEN, J; ISHII, M; WANG, L; ISHII, K; COUGHLIN, SR			THROMBIN RECEPTOR ACTIVATION - CONFIRMATION OF THE INTRAMOLECULAR TETHERED LIGANDING HYPOTHESIS AND DISCOVERY OF AN ALTERNATIVE INTERMOLECULAR LIGANDING MODE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; EXTRACELLULAR DOMAIN; TERNARY COMPLEX; RHODOPSIN; MUTATIONS; CHIMERAS; CLONING; BINDING; MUTANTS; STATE	Cleavage of the thrombin receptor's amino-terminal exodomain at the Arg(41)Ser(42) peptide bond within the sequence...LDPR(41)/S(42)FLLRN... is necessary and sufficient for receptor activation by proteases. The synthetic peptide SFLLRN activates the receptor independent of proteolysis. We proposed that the SPLLRN sequence is a tethered peptide ligand; receptor cleavage unmasks this agonist which then binds intramolecularly to effect receptor activation. The alternative hypothesis that receptor cleavage or exogenous SFLLRN effect receptor activation by disrupting tonic inhibitory interactions exerted by the receptor's amino-terminal exodomain has not been excluded. We report that Delta AMINO, a mutant thrombin receptor lacking the amino-terminal exodomain, was not constitutively active and responded to SFLLRN but not thrombin when expressed in Xenopus oocytes or mammalian cells. Thrombin signaling was restored when Delta AMINO was co-expressed with ATE-CD8 which encoded the receptor's amino-terminal exodomain fused to the transmembrane domain of CD8. Co expression of a thrombin receptor lacking a functional tethered ligand domain (''F43A'') with a non-signaling receptor mutant bearing an intact tethered ligand domain (''YYY'') also reconstituted thrombin signaling. However, the EC(50) for thrombin activation of cells co-expressing F43A and YYY was > 1000-fold that for cells expressing comparable levels of wild type receptor, while EC(50)s for activation by SFLLRN were similar. These and other data refute the release hom inhibition hypothesis and suggest that while intermolecular liganding between two thrombin receptor molecules can occur, the intramolecular tethered liganding mechanism is the predominant mode of thrombin receptor activation.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821, R01HL044907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907, HL43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CONKLIN BR, 1994, NATURE, V367, P22, DOI 10.1038/367022a0; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; ISHII K, 1993, J BIOL CHEM, V268, P9780; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; MOYLE WR, 1991, J BIOL CHEM, V266, P10807; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	26	177	182	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16041	16045						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206902				2022-12-25	WOS:A1994NQ72900017
J	FORMISANO, P; DENOVELLIS, G; MIELE, C; TRIPODI, F; CARUSO, M; PALUMBO, G; BEGUINOT, L; BEGUINOT, F				FORMISANO, P; DENOVELLIS, G; MIELE, C; TRIPODI, F; CARUSO, M; PALUMBO, G; BEGUINOT, L; BEGUINOT, F			INTERNALIZATION OF THE CONSTITUTIVELY ACTIVE ARGININE-1152-]GLUTAMINE INSULIN-RECEPTOR OCCURS INDEPENDENTLY OF INSULIN AT AN ACCELERATED RATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUXTAMEMBRANE REGION; KINASE-ACTIVITY; BETA-SUBUNIT; ENDOCYTOSIS; AUTOPHOSPHORYLATION; FIBROBLASTS; ADIPOCYTES; REQUIRES; PATHWAYS; MUTATION	Signals controlling the insulin receptor endocytotic pathway have been investigated using the R1152Q insulin receptor mutant (M). This mutant receptor exhibits high levels of insulin-independent kinase activity, im paired autophosphorylation, and lack of an insulin stimulatory effect on both auto- and substrate phosphorylation. NIH-3T3 fibroblasts expressing M receptors displayed a 2.5-fold higher I-125-insulin internalization rate than wild type (WT) but lacked insulin-induced receptor internalization and down-regulation. Cell surface recycling of internalized receptors also occurred at a higher rate in M cells and was unaffected by insulin. Cell preincubation with 35 mM Tris, which inhibits the insulin receptor degradative route, elicited no effect on M receptor recycling but inhibited that of WT by 40%. In contrast, the energy depleter 2,4-dinitrophenol, which inhibits normal insulin receptor retroendocytosis, impaired M receptor recycling 4-fold more effectively than that of WT. The release of internalized intact I-125-insulin was 6-fold greater in M than in WT fibroblasts and was almost completely inhibited by dinitrophenol, whereas insulin degradation by M cells was 4-fold decreased as compared with WT. Thus, internalization and recycling of the constitutively active Gln(1152) receptor kinase occur in the absence of autophosphorylation. However, tyrosine phosphorylation appears to be required for proper sorting of endocytosed insulin receptors.	UNIV NAPLES,FAC MED,SCH MED,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; HOSP SAN RAFFAELE,DIBIT,MOLEC ONCOL LAB,I-20132 MILAN,ITALY; HOSP SAN RAFFAELE,CNR,CTR NEUROSCI & BIOIMMAGINI,I-20132 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			Formisano, Pietro/J-4237-2018; Palumbo, Giuseppe/N-3136-2016	Formisano, Pietro/0000-0001-7020-6870; Palumbo, Giuseppe/0000-0001-9380-8436				BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1990, J BIOL CHEM, V265, P16450; CARPENTIER JL, 1989, DIABETOLOGIA, V32, P627; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; GEIGER D, 1989, EXP CELL RES, V185, P33, DOI 10.1016/0014-4827(89)90034-7; GRAKO KA, 1992, ENDOCRINOLOGY, V130, P3441, DOI 10.1210/en.130.6.3441; HARI J, 1987, J BIOL CHEM, V262, P15341; LUND KA, 1990, J BIOL CHEM, V265, P15713; MARSHALL S, 1981, J BIOL CHEM, V256, P1464; MARSHALL S, 1987, J BIOL CHEM, V262, P12005; MARSHALL S, 1985, J BIOL CHEM, V260, P3517; MARSHALL S, 1985, J BIOL CHEM, V260, P3524; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1988, DIABETES, V37, P806, DOI 10.2337/diabetes.37.6.806; MCCLAIN DA, 1992, AM J MED SCI, V304, P192, DOI 10.1097/00000441-199209000-00009; PETRUZZIELLO A, 1993, J CLIN ENDOCR METAB, V77, P409, DOI 10.1210/jc.77.2.409; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RUSSELL DS, 1987, J BIOL CHEM, V262, P11830; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; THIES RS, 1990, J BIOL CHEM, V265, P10132; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777	24	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16242	16246						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206928				2022-12-25	WOS:A1994NQ72900046
J	MOFFAT, GJ; MCLAREN, AW; WOLF, CR				MOFFAT, GJ; MCLAREN, AW; WOLF, CR			INVOLVEMENT OF JUN AND FOS PROTEINS IN REGULATING TRANSCRIPTIONAL ACTIVATION OF THE HUMAN PI CLASS GLUTATHIONE-S-TRANSFERASE GENE IN MULTIDRUG-RESISTANT MCF7 BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFERS RESISTANCE; EXPRESSION; RNA; DNA; ELEMENTS; SEQUENCES; ACID	Elevated levels of the human pi class glutathione S-transferase (GSTP1-1) have been implicated in the development of antineoplastic drug resistance. Using GSTP1 promoter deletion constructs we have shown that enhanced GSTP1 transcription (up to 18-fold) is the predominant mechanism responsible for increased GSTP1-1 levels in a multidrug resistant derivative (VCREMS) of the human mammary carcinoma cell line MCF7. Furthermore, disruption of a putative AP-1 response element within the GSTP1 promoter (nucleotides -69 to -63) abrogated GSTP1 transcription in both cell lines. In addition, band shift assays demonstrated binding of a VCREMS nuclear complex to the promoter region C1 (-73 to -54) which could be competed for by a DNA fragment containing a known AP-1 binding site from the human collagenase promoter. However, no such competition was observed for the major MCF7 C1 complex. The role of a Fos-Jun like complex in regulating GSTP1 transcription in VCREMS cells was further emphasized by the introduction of point mutations within the C1 region which were known to inhibit AP-1 binding and the interaction of antisera raised against human c-Jun and c-Fos with the major C1 complex in VCREMS cells. These studies therefore highlight cell-specific differences in the binding pattern of Jun and Fos proteins to the GSTP1 promoter which are likely to play an important role in regulating transcriptional activation of the GSTP1 gene in drug-resistant breast cancer cells.			MOFFAT, GJ (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, BIOMED RES CTR, IMPERIAL CANC RES FUND, MOLEC PHARMACOL UNIT, DUNDEE DD1 9SY, SCOTLAND.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BATIST G, 1986, J BIOL CHEM, V261, P5544; BLACK SM, 1990, BIOCHEM J, V268, P309, DOI 10.1042/bj2680309; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DICCIANNI MB, 1992, NUCLEIC ACIDS RES, V20, P5153, DOI 10.1093/nar/20.19.5153; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIXON KH, 1989, BIOCHEM BIOPH RES CO, V163, P815, DOI 10.1016/0006-291X(89)92295-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GORMAN C, 1986, DNA CLONING PRACTICA, V3; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; KANO T, 1987, CANCER RES, V47, P5626; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MORROW CS, 1992, J BIOL CHEM, V267, P10544; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; OKUDA A, 1989, J BIOL CHEM, V264, P16919; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1989, ADV CANCER RES, V52, P205; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WHELAN RDH, 1992, INT J CANCER, V52, P241, DOI 10.1002/ijc.2910520215; XIA CL, 1991, BIOCHEM BIOPH RES CO, V176, P233, DOI 10.1016/0006-291X(91)90914-S; XIA CL, 1993, BIOCHEM J, V292, P845, DOI 10.1042/bj2920845	36	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16397	16402						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206948				2022-12-25	WOS:A1994NQ72900067
J	MATSUDA, C; ENDO, H; OHTA, S; KAGAWA, Y				MATSUDA, C; ENDO, H; OHTA, S; KAGAWA, Y			GENE STRUCTURE OF HUMAN MITOCHONDRIAL ATP SYNTHASE GAMMA-SUBUNIT - TISSUE-SPECIFICITY PRODUCED BY ALTERNATIVE RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ADP/ATP TRANSLOCATOR; ADENOSINE-TRIPHOSPHATE SYNTHASE; BETA-SUBUNIT; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ESCHERICHIA-COLI; BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; PROMOTER SEQUENCES; IMPORT PRECURSOR	We completely sequenced the human gene for ATP synthase gamma-subunit, which was approximately 23 kilobases long and was composed of 10 exons. Exons 1 and 2 encoded the N-terminal presequence required for mitochondrial import, while exons 9 and 10 encoded the C-terminal portions of mature protein. Enzymatic amplification of human heart and liver cDNAs using the polymerase chain reaction revealed two mRNA transcripts that were predicted to encode two 30-kDa isoforms of the gamma-subunit, which differed by the addition of a single amino acid (Asp273) at the C terminus of the liver type isoform. These two mRNA transcripts of the heart (H) type and liver (L) type were generated by alternative splicing of an exon. The same alternative splicing event was observed in bovine tissue. In human tissues, the H type mRNA devoid of exon 9 was expressed specifically in the heart and skeletal muscle, which require rapid energy supply. The L type mRNA was expressed in the brain, liver, kidney etc. Both transcripts were expressed in the skin, intestine, stomach, and aorta. This tissue specificity of transcript heterogeneity suggests the distinct functional or regulatory roles of the gamma-subunit isoforms in the catalysis of ATP synthase. This is the first report on tissue-specific isoforms generated by alternative splicing in an energy transducing mitochondrial protein.	JICHI MED SCH, DEPT BIOCHEM, 3311-1 MINAMIKAWACHI MACHI, MINAMI KAWACHI, TOCHIGI 32904, JAPAN	Jichi Medical University								ALOISE P, 1991, J BIOL CHEM, V266, P10368; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; DODGSON JB, 1983, J BIOL CHEM, V258, P4623; DUNN SD, 1980, J BIOL CHEM, V255, P113; DYER MR, 1989, BIOCHEMISTRY-US, V28, P3670, DOI 10.1021/bi00435a008; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; IVEY DM, 1991, MOL GEN GENET, V229, P292, DOI 10.1007/BF00272169; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; JORDAN EM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P123, DOI 10.1016/0167-4781(92)90477-H; KAGAWA Y, 1989, FEBS LETT, V249, P67, DOI 10.1016/0014-5793(89)80017-1; KAGAWA Y, 1992, ANN NY ACAD SCI, V671, P366, DOI 10.1111/j.1749-6632.1992.tb43810.x; KAGAWA Y, 1984, BIOENERGETICS, P149; KATAOKA H, 1991, BIOCHIM BIOPHYS ACTA, V1089, P393, DOI 10.1016/0167-4781(91)90183-M; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEVANON D, 1985, EMBO J, V4, P77, DOI 10.1002/j.1460-2075.1985.tb02320.x; LI K, 1989, J BIOL CHEM, V264, P13998; LI K, 1990, J BIOL CHEM, V265, P20585; LUTTER R, 1993, J MOL BIOL, V229, P787, DOI 10.1006/jmbi.1993.1081; Maniatis T., 1982, MOL CLONING; MATSUDA C, 1993, FEBS LETT, V325, P281, DOI 10.1016/0014-5793(93)81089-I; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MITCHELL P, 1979, SCIENCE, V206, P1148, DOI 10.1126/science.388618; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; OHTA S, 1988, J BIOL CHEM, V263, P11257; OHTA S, 1986, J BIOCHEM-TOKYO, V99, P135, DOI 10.1093/oxfordjournals.jbchem.a135452; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; PIERCE DJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P265, DOI 10.1016/0167-4781(92)90160-2; RACKER E, 1976, NEW LOOK MECHANISMS; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEJA K, 1992, BIOCHIM BIOPHYS ACTA, V1132, P91, DOI 10.1016/0167-4781(92)90059-9; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; SEELAN RS, 1991, J BIOL CHEM, V266, P19752; SHIBAHARA S, 1985, EUR J BIOCHEM, V146, P15, DOI 10.1111/j.1432-1033.1985.tb08614.x; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; TOMURA H, 1990, J BIOL CHEM, V265, P6525; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; WALKER JE, 1990, PHILOS T ROY SOC B, V326, P367, DOI 10.1098/rstb.1990.0018; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; YOSHIDA M, 1979, J BIOL CHEM, V254, P9525	55	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24950	24958						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227057				2022-12-25	WOS:A1993MG67300065
J	WYMAN, C; VASILIKIOTIS, C; ANG, D; GEORGOPOULOS, C; ECHOLS, H				WYMAN, C; VASILIKIOTIS, C; ANG, D; GEORGOPOULOS, C; ECHOLS, H			FUNCTION OF THE GRPE HEAT-SHOCK PROTEIN IN BIDIRECTIONAL UNWINDING AND REPLICATION FROM THE ORIGIN OF PHAGE-GAMMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-DNA-REPLICATION; SPECIALIZED NUCLEOPROTEIN STRUCTURES; POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI DNAK; BACTERIOPHAGE-LAMBDA; O-PROTEIN; INITIATION; PURIFICATION; STABILITY	The initiation of DNA replication by phage lambda depends on a specialized nucleoprotein structure that provides for the precise localization and activity of the Escherichia coli DnaB helicase at the lambda replication origin. Previous work has shown that the DnaJ and DnaK heat shock proteins function in the initiation pathway by releasing the DnaB helicase from the initiation complex to carry out localized unwinding of origin DNA. This DnaJ.DnaK pathway results in mainly unidirectional DNA unwinding and replication, whereas replication in vivo is mainly bidirectional. Based on recent replication work indicating an important role for the GrpE heat shock protein, we have used electron microscopy to study the action of GrpE in the DNA unwinding and replication reactions. We have found that GrpE acts with DnaJ and DnaK to facilitate the unwinding reaction at low concentrations of DnaK. In the presence of GrpE, bidirectional unwinding occurs in approximately half of the unwound DNA molecules. In addition, GrpE significantly increases the frequency of replication proceeding leftward from the origin. We suggest that reactions including GrpE result in more complete disassembly of the preinitiation nucleoprotein structure, thus allowing replication to proceed in both directions from the origin.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, 401 BARKER HALL, BERKELEY, CA 94720 USA; UNIV GENEVA, MED CTR, DEPT BIOCHIM MED, CH-1211 GENEVA 4, SWITZERLAND	University of California System; University of California Berkeley; University of Geneva					NCI NIH HHS [CA09278] Funding Source: Medline; NIGMS NIH HHS [GM17078] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; Davis R.W., 1971, METHODS ENZYMOL, V21, P413; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; DODSON M, 1989, J BIOL CHEM, V264, P10719; ECHOLS H, 1990, UCLA SYM BI, V127, P1; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; Furth M., 1983, LAMBDA 2, P145; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; KORNBERG A, 1988, J BIOL CHEM, V263, P1; Kornberg A., 1992, DNA REPLICATION; LEBOWITZ JH, 1985, P NATL ACAD SCI USA, V82, P3988, DOI 10.1073/pnas.82.12.3988; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MAKI H, 1988, J BIOL CHEM, V263, P6570; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; MANIATIS T, 1982, MOL CLONING LABORATO, P90; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; OTTER R, 1983, METHOD ENZYMOL, V100, P171; ROBERTS JD, 1983, NUCLEIC ACIDS RES, V11, P7435, DOI 10.1093/nar/11.21.7435; SAITO H, 1977, J MOL BIOL, V113, P1, DOI 10.1016/0022-2836(77)90038-9; SCHNOS M, 1970, J MOL BIOL, V51, P61, DOI 10.1016/0022-2836(70)90270-6; SCHNOS M, 1982, J MOL BIOL, V159, P441, DOI 10.1016/0022-2836(82)90293-5; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; TILLY K, 1989, J BACTERIOL, V171, P1585, DOI 10.1128/jb.171.3.1585-1589.1989; TSURIMOTO T, 1981, NUCLEIC ACIDS RES, V9, P1789, DOI 10.1093/nar/9.8.1789; WICKNER SH, 1979, COLD SPRING HARB SYM, V43, P303, DOI 10.1101/SQB.1979.043.01.037; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P6176, DOI 10.1073/pnas.79.20.6176; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	39	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25192	25196						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227083				2022-12-25	WOS:A1993MG67300096
J	YAN, H; GROSSMAN, A; WANG, H; DEUSTACHIO, P; MOSSIE, K; MUSACCHIO, JM; SILVENNOINEN, O; SCHLESSINGER, J				YAN, H; GROSSMAN, A; WANG, H; DEUSTACHIO, P; MOSSIE, K; MUSACCHIO, JM; SILVENNOINEN, O; SCHLESSINGER, J			A NOVEL RECEPTOR TYROSINE PHOSPHATASE-SIGMA THAT IS HIGHLY EXPRESSED IN THE NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; IMMUNOGLOBULIN SUPERFAMILY; HUMAN-PLACENTA; DOMAINS; LINKAGE; FIBRONECTIN; DROSOPHILA; BINDING; MEMBER; MOUSE	A novel transmembrane receptor protein tyrosine phosphatase-sigma (RPTP-sigma) was cloned from a rat brain stem cDNA library. The extracellular segment of one form of RPTP-sigma contains 824 amino acids and is composed of three immunoglobulin-like and five fibronectin type III (FNIII)-like repeats. The 627-amino acid cytoplasmic region of RPTP-sigma consists of two catalytic domains oriented in tandem. Northern blot analyses indicate that RPTP-sigma is highly expressed in the brain as two major transcripts of 5.7 and 6.9 kilobases (kb). The 5.7-kb transcript is expressed exclusively in the brain while the 6.9-kb species can be detected in the lung and heart, but at significantly lower levels. In situ hybridization studies confirm that RPTP-sigma is localized predominately in the nervous system and can be detected in the rat as early as embryonic day 12. During embryonic development, RPTP-sigma is expressed extensively in the central and peripheral nervous systems, including the trigeminal and dorsal root ganglia as well as the retina. In adult rat brain, expression is restricted primarily to the olfactory tubercule, cerebellum, and hippocampus. Within the latter structure, RPTP-sigma is present in the pyramidal cell layer and granular layer of the dentate gyrus. Transfection of RPTP-sigma cDNA into human embryonic kidney 293 cells results in the synthesis of a protein with an apparent molecular mass of 200 kDa as detected by immunoprecipitation and immunoblot analyses using polyclonal antibodies against the FNIII-like repeats present in the extracellular domain of RPTP-sigma. The gene for RPTP-sigma has been mapped to distal chromosome 17 in the mouse.	NYU MED CTR,DEPT PHARMACOL,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016; SUGEN INC,REDWOOD CITY,CA 94063	New York University; New York University				D'Eustachio, Peter/0000-0002-5494-626X	NIMH NIH HHS [MH-17785] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BARR PJ, 1991, CELL, V68, P1; BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BLANK RD, 1988, GENETICS, V120, P1073; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DESAI DV, 1993, CELL, V73, P1; DEUSTACHIO P, 1987, IMMUNOGENETICS, V26, P339, DOI 10.1007/BF00343701; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; POT DA, 1992, J BIOL CHEM, V267, P140; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Shaw A, 1991, CURR OPIN CELL BIOL, V3, P862, DOI 10.1016/0955-0674(91)90061-3; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SILVER J, 1985, J HERED, V76, P436, DOI 10.1093/oxfordjournals.jhered.a110140; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STREULI M, 1992, EMBO J, V11, P879; SUDOL M, 1989, MOL CELL BIOL, V9, P4545, DOI 10.1128/MCB.9.10.4545; Taylor B. A., 1978, ORIGINS INBRED MICE, P423, DOI [10.1016/B978-0-12-507850-4.50032-9, DOI 10.1016/B978-0-12-507850-4.50032-9]; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8; YU Q, 1992, ONCOGENE, V7, P1051	53	106	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24880	24886						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227050				2022-12-25	WOS:A1993MG67300056
J	GIANNAKOUROS, T; NEWMAN, CMH; CRAIGHEAD, MW; ARMSTRONG, J; MAGEE, AI				GIANNAKOUROS, T; NEWMAN, CMH; CRAIGHEAD, MW; ARMSTRONG, J; MAGEE, AI			POSTTRANSLATIONAL PROCESSING OF SCHIZOSACCHAROMYCES-POMBE YPT5-PROTEIN - IN-VITRO AND IN-VIVO ANALYSIS OF PROCESSING MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; RAB GERANYLGERANYL TRANSFERASE; CARBOXYL-METHYLATION; VESICULAR TRANSPORT; TERMINAL CYSTEINE; C-TERMINUS; MEMBRANE; YEAST; MOTIF; PROTEOLYSIS	SpYPT5p is a member of the rab/YPT small GTP-binding protein family, which is believed to be involved in the regulation of intracellular trafficking. The protein sequence terminates with a CXC motif, and in our previous report (Newman, C. M. H., Giannakouros, T., Hancock, J. F., Fawell, E. H., Armstrong, J., and Magee, A. I. (1992) J. Biol. Chem. 267, 11329-11336) we have shown that SpYPT5p is prenylated both in vivo and in vitro, where geranylgeranylation was confirmed, and carboxyl-methylated. In order to dissect the role of prenylation of each cysteine, we have generated C-terminal mutants where either one or both cysteine(s) were replaced by serine and expressed them in vitro in reticulocyte lysates and in vivo in transfected COS cells. Our results suggest that both cysteines of the CXC motif are prenylated but that the rate of prenylation of the two cysteines is different. The upstream cysteine was found to be preferentially prenylated in reticulocyte lysates unless cytosol from COS cells was added. A separate activity could therefore be required for prenylation of the second cysteine, or the presence of an additional factor is needed to allow accumulation of doubly prenylated SpYPT5p. However, the modification of the upstream cysteine is not a prerequisite for the prenylation of the other. Furthermore, gene replacement in Schizosaccharomyces pombe revealed that each cysteine of the CXC motif can individually support function. Carboxyl methylation occurred only on protein which had been prenylated on the C-terminal cysteine and was required for efficient membrane binding in vitro.	NATL INST MED RES, RIDGEWAY, MILL HILL, LONDON NW7 1AA, ENGLAND; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	MRC National Institute for Medical Research; Cancer Research UK			Magee, Anthony/V-8345-2019; GIANNAKOUROS, THOMAS/R-3204-2019					BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROKER M, 1987, BIOTECHNIQUES, V5, P516; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHELSKY D, 1989, J BIOL CHEM, V264, P7637; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GIANNAKOUROS T, 1992, LIPID MODIFICATIONS, P135; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; MCGEOCH C, 1991, TECHNIQUE PHILA, V3, P179; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MUSHA T, 1992, J BIOL CHEM, V267, P9821; NEWMAN CMH, 1992, J BIOL CHEM, V267, P11329; PEREZSALA D, 1992, BIOCHEM J, V284, P835, DOI 10.1042/bj2840835; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WEI C, 1992, ONCOGENE, V7, P467	39	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24467	24474						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226998				2022-12-25	WOS:A1993MF29400111
J	IUCHI, S				IUCHI, S			PHOSPHORYLATION DEPHOSPHORYLATION OF THE RECEIVER MODULE AT THE CONSERVED ASPARTATE RESIDUE CONTROLS TRANSPHOSPHORYLATION ACTIVITY OF HISTIDINE KINASE IN SENSOR PROTEIN ARCB OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; BORDETELLA-PERTUSSIS; RESPONSE REGULATOR; AEROBIC PATHWAYS; GENE-EXPRESSION; MEDIATING REPRESSION; ANAEROBIC REPRESSION; PHOSPHATE REGULON; BACTERIA; CHEMOTAXIS	A membrane sensor protein, ArcB, recognizes anaerobic environments and signals the information to the cognate regulator, ArcA. This in vitro study presents the process and control of the signal-transduction phosphorylation. In the presence of ATP, the ArcB transmitter module undergoes autophosphorylation and then transfers the phosphoryl group to its own receiver module as well as to the ArcA receiver module. Results suggest that the phosphoryl group of the ArcB receiver module is released by an intrinsic phosphatase activity. D-Lactate inhibits the phosphatase activity that removes phosphoaspartate groups from the receiver module in ArcB, and the associated increase in phosphorylation of this module leads to an activation of transphosphorylation of subsequently added phosphohistidine groups on ArcB to the receiver module of ArcA. A similar effect was also observed in the presence of pyruvate, acetate, or NADH. Conversely, the non-phosphorylated ArcB receiver module completely inhibits the intermolecular transphosphorylation. Thus, the phosphorylation state of the ArcB receiver module controls signal transduction from ArcB to ArcA. Since the intrinsic phosphatase activity is inhibited by cellular metabolites that increasingly accumulate by anaerobiosis, the enzyme portion of ArcB may be involved in sensing anaerobic environments through cellular metabolites in vivo.			IUCHI, S (corresponding author), HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA.				NIGMS NIH HHS [R01-GM11983, R01-GM40993] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040993, R01GM011983] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GF, 1989, J BIOL CHEM, V264, P3998; ARICO B, 1989, P NATL ACAD SCI USA, V86, P6671, DOI 10.1073/pnas.86.17.6671; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; FU HA, 1991, MOL GEN GENET, V226, P209, DOI 10.1007/BF00273605; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; IUCHI S, 1991, CELL, V66, P5, DOI 10.1016/0092-8674(91)90130-Q; IUCHI S, 1989, J BACTERIOL, V171, P868, DOI 10.1128/jb.171.2.868-873.1989; IUCHI S, 1992, J BACTERIOL, V174, P3972, DOI 10.1128/jb.174.12.3972-3980.1992; IUCHI S, 1990, J BACTERIOL, V172, P6020, DOI 10.1128/jb.172.10.6020-6025.1990; IUCHI S, 1990, MOL MICROBIOL, V4, P715, DOI 10.1111/j.1365-2958.1990.tb00642.x; IUCHI S, 1988, P NATL ACAD SCI USA, V85, P1888, DOI 10.1073/pnas.85.6.1888; IUCHI S, 1992, J BACTERIOL, V174, P5617, DOI 10.1128/JB.174.17.5617-5623.1992; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; LEROUX B, 1987, EMBO J, V6, P849, DOI 10.1002/j.1460-2075.1987.tb04830.x; LIN ECC, 1991, ANNU REV GENET, V25, P361, DOI 10.1146/annurev.ge.25.120191.002045; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; Maniatis T., 1982, MOL CLONING LAB MANU, P250; MCCLEARY WR, 1990, J BACTERIOL, V172, P6661, DOI 10.1128/jb.172.12.6661-6668.1990; MILLER JF, 1992, J BACTERIOL, V174, P970, DOI 10.1128/jb.174.3.970-979.1992; NINFA AJ, 1991, J BIOL CHEM, V266, P6888; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; RONSON CW, 1987, CELL, V49, P579, DOI 10.1016/0092-8674(87)90530-7; SANDERS DA, 1992, J BACTERIOL, V174, P5117, DOI 10.1128/JB.174.15.5117-5122.1992; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SANWAL BD, 1970, BACTERIOL REV, V34, P20, DOI 10.1128/MMBR.34.1.20-39.1970; SAWERS G, 1992, J BACTERIOL, V174, P3474, DOI 10.1128/JB.174.11.3474-3478.1992; STACHEL SE, 1986, CELL, V46, P325, DOI 10.1016/0092-8674(86)90653-7; STIBITZ S, 1991, J BACTERIOL, V173, P4288, DOI 10.1128/JB.173.14.4288-4296.1991; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; STOUT V, 1990, J BACTERIOL, V172, P659, DOI 10.1128/jb.172.2.659-669.1990; WANNER BL, 1992, J BACTERIOL, V174, P2124, DOI 10.1128/JB.174.7.2124-2130.1992; WIMPENNY JW, 1972, J BACTERIOL, V11, P24, DOI 10.1128/JB.111.1.24-32.1972; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057	38	92	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23972	23980						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226939				2022-12-25	WOS:A1993MF29400042
J	SUNDSTROM, M; LINDQVIST, Y; SCHNEIDER, G; HELLMAN, U; RONNE, H				SUNDSTROM, M; LINDQVIST, Y; SCHNEIDER, G; HELLMAN, U; RONNE, H			YEAST TKL1 GENE ENCODES A TRANSKETOLASE THAT IS REQUIRED FOR EFFICIENT GLYCOLYSIS AND BIOSYNTHESIS OF AROMATIC-AMINO-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PYRUVATE-DEHYDROGENASE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; MIG1 REPRESSOR; ALPHA-SUBUNIT; GLUCOSE; COMPONENT; CLONING; DNA; ENZYMES	A gene encoding transketolase, TKL1, was cloned from the budding yeast Saccharomyces cerevisiae using oligonucleotide primers derived from protein sequence data. The TKL1 sequence predicts a 74-kDa polypeptide which is related to other transketolases. A sequence comparison revealed that the transketolases can be subdivided into three evolutionary branches. We also found that the transketolases are related to another vitamin B1-dependent enzyme: the E1 subunit of pyruvate dehydrogenase from Escherichia coli. Gene disruption and overexpression experiments were used to investigate the function of transketolase in yeast. We found that growth on fermentable carbon sources, but not on gluconeogenic carbon sources, is reduced in cells disrupted for TKL1. This suggests that the glycolytic efficiency is impaired. Growth on fermentable carbon sources is also reduced in cells that overexpress TKL1. Finally, we found that cells disrupted for TKL1 are unable to grow in the absence of aromatic amino acids. This is most likely due to the fact that transketolase is required for the synthesis of erythrose-4-P, a precursor of the aromatic amino acids.	SWEDISH UNIV AGR SCI,UPPSALA BIOMED CTR,DEPT MOLEC BIOL,S-75124 UPPSALA,SWEDEN; UPPSALA BIOMED CTR,LUDWIG INST CANC RES,UPPSALA BRANCH,S-75124 UPPSALA,SWEDEN	Swedish University of Agricultural Sciences; Ludwig Institute for Cancer Research			Lindqvist, Ylva/F-9009-2010	Schneider, Gunter/0000-0003-0622-5713; Ronne, Hans/0000-0002-1645-6091; Lindqvist, Ylva/0000-0003-3162-8661				ABEDINIA M, 1992, BIOCHEM BIOPH RES CO, V183, P1159, DOI 10.1016/S0006-291X(05)80312-2; AGUILERA A, 1986, MOL GEN GENET, V204, P310, DOI 10.1007/BF00425515; BLANSJAAR BA, 1991, J NEUROL SCI, V106, P88, DOI 10.1016/0022-510X(91)90199-H; BRAUS GH, 1991, MICROBIOL REV, V55, P349, DOI 10.1128/MMBR.55.3.349-370.1991; CHEN JH, 1991, J BIOL CHEM, V266, P20447; de la HABA G., 1955, JOUR BIOL CHEM, V214, P409; ERHART E, 1983, J BACTERIOL, V156, P625, DOI 10.1128/JB.156.2.625-635.1983; FLETCHER TS, 1992, BIOCHEMISTRY-US, V31, P1892, DOI 10.1021/bi00121a044; GUBLER CJ, 1991, BIOCHEMISTRY AND PHYSIOLOGY OF THIAMIN DIPHOSPHATE ENZYMES, P311; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HAWKINS CF, 1990, EUR J BIOCHEM, V191, P337, DOI 10.1111/j.1432-1033.1990.tb19128.x; HO L, 1989, P NATL ACAD SCI USA, V86, P5330, DOI 10.1073/pnas.86.14.5330; JANOWICZ ZA, 1985, NUCLEIC ACIDS RES, V13, P3043, DOI 10.1093/nar/13.9.3043; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KOCHETOV GA, 1982, METHOD ENZYMOL, V90, P209; KOIKE K, 1988, P NATL ACAD SCI USA, V85, P41, DOI 10.1073/pnas.85.1.41; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; MAITRA PK, 1971, J BACTERIOL, V107, P759, DOI 10.1128/JB.107.3.759-769.1971; MCCOOL BA, 1993, J BIOL CHEM, V268, P1397; NEHLIN JO, 1989, GENE, V85, P313, DOI 10.1016/0378-1119(89)90423-X; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; NIXON PF, 1984, ALCOHOL ALCOHOLISM, V19, P219; PAOLETTI F, 1991, J NEUROL SCI, V105, P211, DOI 10.1016/0022-510X(91)90147-Y; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P244; RADNIS BA, 1990, J BACTERIOL, V172, P3669, DOI 10.1128/jb.172.7.3669-3674.1990; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHNEIDER G, 1989, J BIOL CHEM, V264, P21619; SHEU KFR, 1988, ARCH NEUROL-CHICAGO, V45, P841, DOI 10.1001/archneur.1988.00520320027010; SLONIMSKI PP, 1968, BIOCHEM BIOPH RES CO, V30, P232, DOI 10.1016/0006-291X(68)90440-3; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P155, DOI 10.1111/j.1432-1033.1983.tb07441.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; VINOPAL RT, 1975, J BACTERIOL, V122, P1172, DOI 10.1128/JB.122.3.1172-1174.1975; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	35	95	99	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24346	24352						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226984				2022-12-25	WOS:A1993MF29400094
J	CHENCLELAND, TA; BOFFA, LC; CARPANETO, EM; MARIANI, MR; VALENTIN, E; MENDEZ, E; ALLFREY, VG				CHENCLELAND, TA; BOFFA, LC; CARPANETO, EM; MARIANI, MR; VALENTIN, E; MENDEZ, E; ALLFREY, VG			RECOVERY OF TRANSCRIPTIONALLY ACTIVE CHROMATIN RESTRICTION FRAGMENTS BY BINDING TO ORGANOMERCURIAL-AGAROSE MAGNETIC BEADS - A RAPID AND SENSITIVE METHOD FOR MONITORING CHANGES IN HIGHER-ORDER CHROMATIN STRUCTURE DURING GENE ACTIVATION AND REPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME STRUCTURE; C-MYC; AFFINITY-CHROMATOGRAPHY; HISTONE ACETYLATION; SODIUM-BUTYRATE; DNA-SEQUENCES; YEAST; CELLS; FOS; RNA	The unfolding of nucleosomes along transcriptionally active DNA sequences uncovers previously shielded cysteinyl-thiol groups of histone H3 molecules located at the center of the nucleosome core. This change in conformation and SH reactivity of nucleosomes along transcribed DNA sequences makes it possible to separate active from inactive nucleosomes by mercury affinity chromatography. The binding of thiol-reactive nucleosomes to an organomercurial-agarose column has been shown previously to reflect, with accuracy, both the timing and extent of transcription of the associated DNA sequences (Chen, T. A., and Allfrey, V. G. (1987) Proc. Natl. Acad. Sci. U. S. A. 84,5252-5256). Here, we extend this experimental approach to the analysis of higher order chromatin structures. Large chromatin fragments released by treating isolated nuclei with restriction endonucleases are fractionated on mercurated agarose magnetic beads that capture nucleosomes with accessible histone H3 thiols, but do not react with the hidden H3 thiols of the compactly beaded nucleosomes of inactive genes. The SH-reactive domains of c-myc and other genes are rapidly separated from the non-SH-reactive restriction fragments by the magnetic bead technique. The new method also overcomes a major limitation of mercurated agarose column chromatography, which is not suitable for studies of higher order chromatin structure because large chromatin fragments occlude the mercury column; occlusion is not a problem in magnetic separations using suspended mercurated agarose beads. Here, we describe the synthesis of mercurated agarose magnetic beads with high capacity for SH groups and test their application to the recovery of chromatin restriction fragments of c-myc and the growth arrest gene gas1.	ROCKEFELLER UNIV, CELL BIOL LAB, NEW YORK, NY 10021 USA; IST NAZL RIC CANC, I-16132 GENOA, ITALY	Rockefeller University; University of Genoa; IRCCS AOU San Martino IST					NATIONAL CANCER INSTITUTE [R01CA014908] Funding Source: NIH RePORTER; NCI NIH HHS [CA14908] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALFAGEME CR, 1974, J BIOL CHEM, V249, P3729; ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ALLFREY VG, 1991, METHOD CELL BIOL, V35, P315; BODE J, 1980, EUR J BIOCHEM, V110, P143, DOI 10.1111/j.1432-1033.1980.tb04849.x; BOFFA LC, 1981, J BIOL CHEM, V256, P9612; BOFFA LC, 1990, EUR J BIOCHEM, V194, P811, DOI 10.1111/j.1432-1033.1990.tb19474.x; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; BRANDT WF, 1982, EUR J BIOCHEM, V121, P501, DOI 10.1111/j.1432-1033.1982.tb05815.x; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; CHAN S, 1988, J BIOL CHEM, V263, P15643; CHEN TA, 1991, J BIOL CHEM, V266, P6489; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHENCLELAND TA, 1993, J BIOL CHEM, V268, P1118; DAVIE JR, 1981, NUCLEIC ACIDS RES, V9, P3205, DOI 10.1093/nar/9.13.3205; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HEROLD KM, 1988, ONCOGENE, V3, P423; HORZ W, 1976, NUCLEIC ACIDS RES, V3, P3213, DOI 10.1093/nar/3.11.3213; JOHNSON EM, 1987, J BIOL CHEM, V262, P6943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIPCHITZ L, 1976, CELL, V9, P355, DOI 10.1016/0092-8674(76)90125-2; MANIATIS T, 1975, BIOCHEMISTRY-US, V14, P3787, DOI 10.1021/bi00688a010; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARDIAN JKW, 1978, BIOCHEMISTRY-US, V17, P3825, DOI 10.1021/bi00611a023; NELSON DA, 1982, J BIOL CHEM, V257, P1565; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PFEIFFER W, 1975, NATURE, V258, P450, DOI 10.1038/258450a0; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; RUIZCARR.A, 1973, ARCH BIOCHEM BIOPHYS, V154, P185, DOI 10.1016/0003-9861(73)90047-7; Sambrook J, 1989, MOL CLONING LABORATO; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SIMPSON RT, 1978, CELL, V13, P691, DOI 10.1016/0092-8674(78)90219-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOPER TS, 1979, J BIOL CHEM, V254, P901; STERNER R, 1981, J BIOL CHEM, V256, P8892; STERNER R, 1987, NUCLEIC ACIDS RES, V15, P4375, DOI 10.1093/nar/15.11.4375; VICENZ C, 1991, NUCLEIC ACIDS RES, V19, P1325; WALKER J, 1990, J BIOL CHEM, V265, P5736; WORKMAN JL, 1985, BIOCHEMISTRY-US, V24, P4731, DOI 10.1021/bi00339a004; YAU P, 1982, EUR J BIOCHEM, V129, P281, DOI 10.1111/j.1432-1033.1982.tb07050.x	47	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23409	23416						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226865				2022-12-25	WOS:A1993MF51500070
J	KIM, MK; MCCLASKEY, JH; BODENNER, DL; WEINTRAUB, BD				KIM, MK; MCCLASKEY, JH; BODENNER, DL; WEINTRAUB, BD			AN AP-1-LIKE FACTOR AND THE PITUITARY-SPECIFIC FACTOR PIT-1 ARE BOTH NECESSARY TO MEDIATE HORMONAL INDUCTION OF HUMAN THYROTROPIN BETA-GENE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PIT-1/GHF-1; TRANSDUCTION PATHWAYS CONVERGE; FOS-PROTEIN COMPLEXES; DNA-BINDING ACTIVITY; POU-SPECIFIC DOMAIN; ALPHA-SUBUNIT GENE; THYROID-HORMONE; C-JUN; PHORBOL-ESTER; CYCLIC-AMP	The human thyrotropin beta (hTSHbeta) gene is inducible by various agents including thyrotropin-releasing hormone, phorbol esters, or the adenylyl cyclase activator forskolin. In this study, we have characterized the functional properties of the TGGGTCA motif at -1/+6 of the hTSHbeta gene that is similar to the consensus phorbol ester response element (TRE) or the consensus cyclic AMP response element (CRE). We suggest that both protein kinases C and A as well as TRH share common mediator which recognizes the TGGGTCA element in activating the hTSHbeta promoter. Following stimulation by phorbol esters, forskolin, or TRH, the TGGGTCA-specific factor acts together with the pituitary-specific transcription factor Pit-1 (or GHF-1) bound to upstream sequences at -128 to -61 to mediate the induction of the hTSHbeta promoter. The induction requires that both factors bind to their own binding sites, but Pit-1 neither increases the binding of the TGGGTCA-specific factor to its target sequences nor associates with this factor to form a heterodimer. The TGGGTCA-specific factor is present in three cell lines tested and is composed of protein(s) immunologically related to c-Jun and c-Fos but not to the CRE-binding protein, CREB. By using the hTSHbeta reporter plasmids in which the TGGGTCA element is converted to consensus TRE or CRE motifs, we found that, within the context of the hTSHbeta promoter, the TGGGTCA element is a more potent TRE or CRE than the consensus TRE or CRE sequences. Based upon the results of this study, we propose a model in which the TGGGTCA-specific AP-1-like factor functionally cooperates with the tissue-specific factor Pit-1 to activate the hTSHbeta gene.	NIDDKD,MOLEC & CELLULAR ENDOCRINOL BRANCH,BLDG 10,RM 8014,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BENBROOK DM, 1990, ONCOGENE, V5, P295; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; BUSCHER M, 1988, ONCOGENE, V3, P301; CARR FE, 1991, BIOCHEMISTRY-US, V30, P3721, DOI 10.1021/bi00229a019; CARR FE, 1989, MOL ENDOCRINOL, V3, P709, DOI 10.1210/mend-3-4-709; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CONDLIFFE PG, 1979, HORM BLOOD, P499; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FRANKLYN JA, 1986, J ENDOCRINOL, V111, pR1, DOI 10.1677/joe.0.111R001; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FURTH J, 1955, RECENT PROG HORM RES, V11, P221; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GORDON DF, 1992, 74TH END SOC ANN M S; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; SAKURAI A, 1990, MOL ENDOCRINOL, V4, P1988, DOI 10.1210/mend-4-12-1988; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHUPNIK MA, 1985, J BIOL CHEM, V260, P2900; SHUPNIK MA, 1990, MOL ENDOCRINOL, V4, P829, DOI 10.1210/mend-4-6-829; SHUPNIK MA, 1986, J BIOL CHEM, V261, P981; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STEINFELDER HJ, 1992, J CLIN INVEST, V89, P409, DOI 10.1172/JCI115600; STEINFELDER HJ, 1991, P NATL ACAD SCI USA, V88, P3130, DOI 10.1073/pnas.88.8.3130; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; TATSUMI K, 1992, NAT GENET, V1, P56, DOI 10.1038/ng0492-56; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; WONDISFORD FE, 1993, J BIOL CHEM, V268, P2749; WOOD WM, 1990, MOL ENDOCRINOL, V4, P1897, DOI 10.1210/mend-4-12-1897; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	79	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23366	23375						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226861				2022-12-25	WOS:A1993MF51500065
J	LATHAM, GJ; ZHOU, L; HARRIS, CM; HARRIS, TM; LLOYD, RS				LATHAM, GJ; ZHOU, L; HARRIS, CM; HARRIS, TM; LLOYD, RS			THE REPLICATION FATE OF R-STYRENE AND S-STYRENE OXIDE ADDUCTS ON ADENINE N6 IS DEPENDENT ON BOTH THE CHIRALITY OF THE LESION AND THE LOCAL SEQUENCE CONTEXT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; REPAIR; OLIGODEOXYNUCLEOTIDES; O-6-METHYLGUANINE; INSERTION; KINETICS; OLIGONUCLEOTIDE; MUTAGENICITY; MUTAGENESIS; OXIDATION	In order to deduce the biological fate of adducts formed by the reaction of styrene oxide, a suspected carcinogen, with DNA, four oligodeoxynucleotides were synthesized which contained either R- or S-styrene oxide lesions on the N6 position of neighboring adenines within the human N-ras codon 61. When these adducted oligodeoxynucleotides were ligated into the single-stranded vector M13mp7L2 and the modified DNA used to transform repair-deficient Escherichia coli, the resultant plaque-forming abilities were found to vary as much as 300-fold, depending on the stereochemical configuration of the styrene oxide lesion and the sequence context in the vicinity of the damage. The frequency of mutations caused by the various styrene oxide adducts were similarly dependent on both their chirality and local sequence context. Oligodeoxynucleotide templates bearing these same four adducts were also constructed in order to evaluate their replication in vitro by the Klenow fragment. Three of the four styryl-modified templates yielded significant levels of fully extended primer upon polymerization. In contrast, the template containing R-styrene oxide at the second position of N-ras 61 was a very poor substrate for replication, a result which correlates well with the observed lethality of this lesion in vivo.	UNIV TEXAS, MED BRANCH, SEALY CTR MOLEC SCI, GALVESTON, TX 77550 USA; VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37235 USA; VANDERBILT UNIV, SCH MED, DEPT CHEM, NASHVILLE, TN 37235 USA; VANDERBILT UNIV, SCH MED, CTR MOLEC TOXICOL, NASHVILLE, TN 37235 USA	University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University; Vanderbilt University; Vanderbilt University				Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES005355, R01ES005509, P30ES000267] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00267, ES05355, ES5509] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEN DJ, 1989, BIOCHEMISTRY-US, V28, P4601, DOI 10.1021/bi00437a014; BASU AK, 1990, MUTAT RES, V233, P189, DOI 10.1016/0027-5107(90)90162-W; BASU AK, 1988, CHEM RES TOXICOL, V1, P1, DOI 10.1021/tx00001a001; BISHOP RE, 1991, CHEM RES TOXICOL, V4, P647, DOI 10.1021/tx00024a009; BONATTI S, 1978, MUTAT RES, V52, P295, DOI 10.1016/0027-5107(78)90151-3; BOND JA, 1989, CRC CR REV TOXICOL, V19, P227, DOI 10.3109/10408448909037472; BOROWYBOROWSKI H, 1987, BIOCHEMISTRY-US, V26, P2465, DOI 10.1021/bi00383a010; CMARIK JL, 1992, J BIOL CHEM, V267, P6672; DEMEESTER C, 1977, MUTAT RES, V56, P147, DOI 10.1016/0027-5107(77)90202-0; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P11595, DOI 10.1021/bi00113a015; FOUREMAN GL, 1989, J PHARMACOL EXP THER, V248, P492; FUCHS RPP, 1984, J MOL BIOL, V177, P173, DOI 10.1016/0022-2836(84)90063-9; HARRIS CM, 1991, J AM CHEM SOC, V113, P4328, DOI 10.1021/ja00011a044; HEMMINKI K, 1986, J CANCER RES CLIN, V112, P181, DOI 10.1007/BF00395910; HEMMINKI K, 1983, ARCH TOXICOL, V52, P249, DOI 10.1007/BF00316495; HEMMINKI K, 1984, PROG CLIN BIOL RES, V141, P227; HORSFALL MJ, 1990, ENVIRON MOL MUTAGEN, V15, P107, DOI 10.1002/em.2850150208; KAUFMANN WK, 1989, CARCINOGENESIS, V10, P1, DOI 10.1093/carcin/10.1.1; LATIF F, 1988, CHEM RES TOXICOL, V1, P364, DOI 10.1021/tx00006a007; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; NORPPA H, 1981, MUTAT RES, V91, P243, DOI 10.1016/0165-7992(81)90040-3; NORPPA H, 1980, CARCINOGENESIS, V1, P357, DOI 10.1093/carcin/1.4.357; PANIGRAHI GB, 1990, BIOCHEMISTRY-US, V29, P2122, DOI 10.1021/bi00460a023; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; RODRIGUEZ H, 1993, CARCINOGENESIS, V14, P373, DOI 10.1093/carcin/14.3.373; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVELA K, 1986, ARCH TOXICOL, P281; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; SINGER B, 1991, CARCINOGENESIS, V12, P949; Singer B., 1983, MOL BIOL MUTAGENS CA; TOPAL MD, 1986, J BIOL CHEM, V261, P9879; TOPAL MD, 1988, CARCINOGENESIS, V9, P691, DOI 10.1093/carcin/9.5.691; WADE DR, 1978, MUTAT RES, V58, P217, DOI 10.1016/0165-1218(78)90012-5; 1983, ENV HLTH CRITERIA, V26; 1987, IARC MONOGRAPH EVALU, V7	37	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23427	23434						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226868				2022-12-25	WOS:A1993MF51500073
J	KISHIDA, S; SHIRATAKI, H; SASAKI, T; KATO, M; KAIBUCHI, K; TAKAI, Y				KISHIDA, S; SHIRATAKI, H; SASAKI, T; KATO, M; KAIBUCHI, K; TAKAI, Y			RAB3A GTPASE-ACTIVATING PROTEIN-INHIBITING ACTIVITY OF RABPHILIN-3A, A PUTATIVE RAB3A TARGET PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GDP DISSOCIATION INHIBITOR; GDP/GTP EXCHANGE PROTEIN; BINDING PROTEIN; SMG P25A; REGULATORY PROTEIN; SYNAPTIC VESICLES; KINASE-C; RAS; SMG-P25A; TISSUE	Rabphilin-3A is a putative target protein for Rab3A, a member of the small G protein superfamily that is implicated in regulated secretion, particularly in neuro-transmitter release. Rabphilin-3A contains at least two functionally different domains: the N-terminal Rab3A-binding domain and the C-terminal C2 domain, which interacts with both Ca2+ and phospholipid. Because Rabphilin-3A interacts preferentially with GTP-Rab3A rather than with GDP-Rab3A, we have examined here whether Rabphilin-3A affects the GTPase activity of Rab3A. Rabphilin-3A and its N-terminal fragment, but not its C-terminal fragment, very weakly stimulated the basal GTPase activity of Rab3A. However, Rabphilin-3A and its N-terminal fragment strongly inhibited the Rab3A GAp-stimulated GTPase activity of Rab3A. Ca2+ and phospholipid showed no effect on these activities of Rabphilin-3A. The physiological significance of the GAP activity of Rabphilin-3A is obscure, but it is likely that Rabphilin-3A inhibits Rab3A GAP activity and keeps Rab3A in the GTP-bound active form during its action as a target molecule for Rab3A.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Kobe University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)				kishida, shosei/0000-0003-0405-851X				ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN E, 1989, MOL CELL BIOL, V9, P4807, DOI 10.1128/MCB.9.11.4807; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MIZOGUCHI A, 1992, BIOCHEM BIOPH RES CO, V186, P1345, DOI 10.1016/S0006-291X(05)81554-2; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; MORII M, 1991, J BIOL CHEM, V12, P7646; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLOFSSON B, 1988, ONCOGENE, V3, P231; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988	27	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22259	22261						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226731				2022-12-25	WOS:A1993MD34800012
J	WOJTKOWIAK, D; GEORGOPOULOS, C; ZYLICZ, M				WOJTKOWIAK, D; GEORGOPOULOS, C; ZYLICZ, M			ISOLATION AND CHARACTERIZATION OF CLPX, A NEW ATP-DEPENDENT SPECIFICITY COMPONENT OF THE CLP PROTEASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-DNA REPLICATION; HEAT-SHOCK PROTEIN; SPECIALIZED NUCLEOPROTEIN STRUCTURES; BACTERIOPHAGE-LAMBDA; O-PROTEIN; REGULATORY SUBUNIT; LON PROTEASE; DEGRADATION; PROTEOLYSIS; INITIATION	We have used C-14-labeled bacteriophage lambdaO-DNA replication protein as a probe to identify and purify Escherichia coli proteases capable of its degradation. In this manner, five different proteases (termed Lop) have been identified capable of degrading lambdaO protein to acid-soluble fragments in an ATP-dependent fashion. One of these activities was purified to homogeneity and shown to be composed of two different polypeptides. The 23,000-Da component (LopP) was identified as the previously characterized ClpAP protein, known to complex with ClpA to form the ClpAP, an ATP-dependent protease, capable of degrading casein. The second 46,000-Da component was identified as ClpX (LopC), coded by a gene located in the same operon, but promoter distal to that coding for ClpP (Gottesman, S., Clark, W. P., de Crecy-Lagard, V., and Maurizi, M. R. (1993) J. Biol. Chem. 268, 22618-22626). This identification was based on the determination of the sequence of the first 24 amino acid residues of the purified ClpX protein and its identity with that predicted by the DNA sequence. The ClpXP protease is substrate specific, since it degrades casein (known to be degraded by ClpAP), lambdaP, or DnaK proteins slowly or not at all. These results suggest that ClpX protein directs ClpP protease to specific substrates. It is estimated that 50% of all lambdaO-specific protease activity present in crude E. coli extracts is due to the ClpXP protease. We propose that transient inhibition of lambdaO degradation observed in vivo during the later stages of lambda-DNA replication in vivo is responsible for the switch from bidirectional to unidirectional replication. One round unidirectional replication will lead to strand separation resulting in a switch from early (theta) to late (sigma) mode of lambda-DNA replication.	UNIV GDANSK,DEPT MOLEC BIOL,DIV BIOPHYS,KLADKI 24,PL-80952 GDANSK,POLAND; UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND	Fahrenheit Universities; University of Gdansk; University of Geneva								BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; DERBYSHIRE KM, 1990, P NATL ACAD SCI USA, V87, P4048, DOI 10.1073/pnas.87.11.4048; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; Furth M., 1983, LAMBDA 2, P145; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1981, CELL, V24, P225, DOI 10.1016/0092-8674(81)90518-3; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; KROH HE, 1990, J BACTERIOL, V172, P6026, DOI 10.1128/jb.172.10.6026-6034.1990; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIPINSKA B, 1980, BIOCHEM BIOPH RES CO, V92, P120, DOI 10.1016/0006-291X(80)91528-4; LIPINSKA B, 1990, J BACTERIOL, V172, P1791, DOI 10.1128/jb.172.4.1791-1797.1990; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MCMACKEN R, 1983, MECHANISMS DNA REPLI, P819; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; MILLER CG, 1987, ESCHERICHIA COLI SAL, P680; MIZUSAWA S, 1983, P NATL ACAD SCI-BIOL, V80, P358, DOI 10.1073/pnas.80.2.358; PHILLIPS TA, 1984, J BACTERIOL, V159, P283, DOI 10.1128/JB.159.1.283-287.1984; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROBERTS JD, 1983, NUCLEIC ACIDS RES, V11, P7435, DOI 10.1093/nar/11.21.7435; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SCHOULAKERSCHWARZ R, 1991, P NATL ACAD SCI USA, V88, P4996, DOI 10.1073/pnas.88.11.4996; SHERMAN MY, 1992, EMBO J, V11, P71; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; TILLY K, 1989, J BACTERIOL, V171, P1585, DOI 10.1128/jb.171.3.1585-1589.1989; TORRESCABASSA AS, 1987, J BACTERIOL, V169, P981, DOI 10.1128/jb.169.3.981-989.1987; TREMPY JE, 1989, J BACTERIOL, V171, P3348, DOI 10.1128/jb.171.6.3348-3353.1989; TSURIMOTO T, 1982, MOL GEN GENET, V187, P79, DOI 10.1007/BF00384387; VOELLMY RW, 1981, NATURE, V290, P419, DOI 10.1038/290419a0; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P6176, DOI 10.1073/pnas.79.20.6176; WOO KM, 1989, J BIOL CHEM, V264, P2088; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	48	215	217	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22609	22617						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226769				2022-12-25	WOS:A1993MD34800064
J	WONG, SH; HONG, WJ				WONG, SH; HONG, WJ			THE SXYQRL SEQUENCE IN THE CYTOPLASMIC DOMAIN OF TGN38 PLAYS A MAJOR ROLE IN TRANS-GOLGI NETWORK LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; 2 INTERNALIZATION SIGNALS; INTEGRAL MEMBRANE-PROTEIN; HUMAN GLYCOPHORIN-A; BREFELDIN-A; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; MDCK CELLS; ORGANELLE STRUCTURE; SECRETORY PATHWAY	The trans-Golgi network (TGN) plays a central role in protein sorting/targeting. TGN38 is an integral membrane protein confined mainly to the TGN. When the cytoplasmic 32-residue sequence of TGN38 was fused to the ecto- and transmembrane domains of glycophorin A (a surface protein), the resulting chimeric protein was localized to the TGN. Detailed mutagenesis of the 32-residue sequence revealed that the Ser, Tyr, and Leu residues at positions 23, 25, and 28, respectively, are essential for TGN localization. Further studies demonstrate that the sequence SXYQRL can by itself confer significant TGN localization.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,MEMBRANE BIOL LAB,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			HONG, Wanjin/E-9927-2010					AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BURKE J, 1992, J BIOL CHEM, V267, P24433; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; HONG WJ, 1993, BIOESSAYS, V15, P231, DOI 10.1002/bies.950150403; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LADINSKY MS, 1992, EUR J CELL BIOL, V59, P92; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LOW SH, 1991, J BIOL CHEM, V266, P19710; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MORROW B, 1987, J BIOL CHEM, V262, P13812; MORROW K, 1992, J CELL BIOL, V116, P577; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; REMALEY AT, 1991, J BIOL CHEM, V266, P24176; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SIEBERT PD, 1986, P NATL ACAD SCI USA, V83, P1665, DOI 10.1073/pnas.83.6.1665; SPIESS M, 1985, J BIOL CHEM, V260, P1979; SWIFT AM, 1991, J CELL BIOL, V115, P9; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TANG BL, 1992, J BIOL CHEM, V267, P10122; TANG BL, 1992, EUR J CELL BIOL, V59, P228; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	56	121	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22853	22862						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226795				2022-12-25	WOS:A1993MD34800098
J	LEE, WNP				LEE, WNP			APPENDIX - ANALYSIS OF TRICARBOXYLIC-ACID CYCLE USING MASS ISOTOPOMER RATIOS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCONEOGENESIS; CARBON	Since the early work by Strisower et al. (1) describing the incorporation of acetate carbon in glucose, models of varying complexity have been developed for the estimation of tracer dilution through the tricarboxylic acid cycle. These models differ from each other in the number of parameters involved and the mathematical technique used (2-4). The models relate the steady state distribution of labeled carbon in oxaloacetate, citrate, glutamate, glucose, or pyruvate from a specifically labeled precursor (acetate or pyruvate labeled in one of its carbons) to rates of several key reactions (parameters) of the tricarboxylic acid cycle. From the experimentally determined distributions of isotope carbon in glucose and other compounds, parameters of tricarboxylic acid cycle metabolism and tracer dilution for gluconeogenesis can be estimated. A typical example is the determination of pyruvate carboxylase flux from the glucose labeling ratio of an experiment using C2-labeled acetate. For complex models having two or more parameters, a solution for these parameters usually requires the determination of isotope distributions in multiple tricarboxylic acid cycle intermediates. The use of precursors jointly labeled in several positions and mass isotopomer analysis offers a new and powerful approach to the study of complex metabolic systems. While singly labeled precursor yields carbon label in a maximum of three distinct positions of glucose (label in C-1, C-2, and C-3), prelabeled lactate potentially gives six labeled species (one mass isotopomer of m3, two positional isotopomers of m2, and three isotopomers of ml) doubling the amount of information from a single experiment. In the sections to follow, we detail the transformation of labeled lactate into the various isotopomers of oxaloacetate (OAA)1 and the three-carbon precursor of glucose (PEP) and present a mathematical model describing the relationship between these isotopomers and the parameters of the tricarboxylic acid cycle. Algebraic solutions of these parameters from mass isotopomers in PEP and lactate are provided.			LEE, WNP (corresponding author), UCLA,HARBOR MED CTR,TORRANCE,CA 90048, USA.							GOEBEL R, 1982, FED PROC, V41, P96; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; KATZ J, 1989, J BIOL CHEM, V264, P12994; KATZ J, 1979, TECHNIQUES METABOLIC, P1; KELLEHER JK, 1986, AM J PHYSIOL, V250, pE296, DOI 10.1152/ajpendo.1986.250.3.E296; STRISOWER EH, 1952, J BIOL CHEM, V198, P115	6	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25522	25526						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244987				2022-12-25	WOS:A1993MK10000038
J	SKOWYRA, D; WICKNER, S				SKOWYRA, D; WICKNER, S			THE INTERPLAY OF THE GRPE HEAT-SHOCK PROTEIN AND MG2+ IN REPA MONOMERIZATION BY DNAJ AND DNAK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIALIZED NUCLEOPROTEIN STRUCTURES; ESCHERICHIA-COLI DNAJ; F PLASMID REPLICATION; BACTERIOPHAGE-LAMBDA; CELLULAR DEFECTS; GENE GROPC; INITIATION; CHAPERONE; ORIGIN; MUTANTS	Genetic and biochemical studies have established that the sole function of the Escherichia coli DnaJ, DnaK, and GrpE heat shock proteins in plasmid P1 DNA replication is to convert RepA dimers to monomers. Monomers bind avidly to oriP1 DNA and initiate DNA replication. However, with purified heat shock proteins, only DnaJ, DnaK, and ATP were required for the monomerization of RepA; GrpE was not required. We have found reaction conditions that mimic the physiological situation. GrpE function is absolutely necessary for RepA activation in vitro with DnaJ and DnaK when the free Mg2+ concentration is maintained at a level of approximately 1 muM by a metal ion buffer system. EDTA or physiological metabolites, including citrate, phosphate, pyrophosphate, and ATP, all elicit the GrpE requirement. With these metal ion-buffering systems, GrpE specifically lowers the concentration of Mg2+ required for the RepA activation reaction. The absence of Mg2+ blocks activation and high levels of Mg2+ in solution bypass the requirement for GrpE but not for the other two heat shock proteins. Our results imply that GrpE facilitates the utilization of Mg2+ for an essential step in RepA activation.	NCI,MOLEC BIOL LAB,BLDG 37,RM 2D19,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALFANO C, 1989, J BIOL CHEM, V264, P10709; ANG D, 1991, J BIOL CHEM, V266, P24233; ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; BAKER JO, 1988, METHOD ENZYMOL, V158, P33, DOI 10.1016/0076-6879(88)58046-1; BAKER TA, 1992, ANNU REV GENET, V26, P447; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; DODSON M, 1989, J BIOL CHEM, V264, P10719; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; EZAKI B, 1989, MOL GEN GENET, V218, P183, DOI 10.1007/BF00331267; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GEORGOPOULOS CP, 1977, MOL GEN GENET, V151, P35, DOI 10.1007/BF00446910; GROSS CA, 1990, STRESS PROTEINS BIOL, P167; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MARTIN MT, 1988, METHOD ENZYMOL, V158, P365, DOI 10.1016/0076-6879(88)58068-0; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PERRIN DD, 1974, BUFFERS PH METAL ION, P96; SAITO H, 1977, J MOL BIOL, V113, P1, DOI 10.1016/0022-2836(77)90038-9; SELL SM, 1990, J BACTERIOL, V172, P4827, DOI 10.1128/jb.172.9.4827-4835.1990; Sillen L.G., 1964, STABILITY CONSTANTS, V17; SUNSHINE M, 1977, MOL GEN GENET, V151, P27, DOI 10.1007/BF00446909; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	37	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25296	25301						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244960				2022-12-25	WOS:A1993MK10000007
J	GEORGE, SE; SU, ZH; FAN, DJ; MEANS, AR				GEORGE, SE; SU, ZH; FAN, DJ; MEANS, AR			CALMODULIN-CARDIAC TROPONIN-C CHIMERAS - EFFECTS OF DOMAIN EXCHANGE ON CALCIUM-BINDING AND ENZYME ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CA2+-DEPENDENT PROTEIN MODULATOR; CENTRAL HELIX; STIMULATED PHOSPHODIESTERASE; TARGET ENZYMES; CA2+ BINDING; CHEMICAL MODIFICATION; COOPERATIVE BINDING; MAGNESIUM BINDING; PEPTIDE COMPLEX	Calmodulin (CaM) and the cardiac isoform of troponin C (cTnC) are close structural homologs, but cTnC cannot activate most CaM target enzymes. To investigate structure-function relationships, we constructed a series of CaM.cTnC chimeras and determined their ability to bind Ca2+ and activate CaM target enzymes. Previously, we exchanged domain 1 and found that the chimeras exhibited profoundly impaired activation of smooth muscle myosin light chain kinase (smMLCK) and had differential effects on other CaM target enzymes (George, S. E., VanBerkum, M. F. A., Ono, T., Cook, R., Hanley, R. M., Putkey, J. A., and Means, A. R. (1990) J. Biol. Chem. 265, 9228-9235). One of the domain 1 chimeras was a potent competitive inhibitor of smMLCK. We now extend our study of CaM.cTnC chimeras by exchanging all of the remaining functional domains of CaM and cTnC. We determined the ability of the chimeras to bind Ca2+ and activate phosphodiesterase (PDE) and smMLCK. Chimeras containing both domains 3 and 4 of cTnC exhibited high affinity Ca'' binding that was indistinguishable from cTnC, whereas chimeras containing either domain 3 or 4 of cTnC demonstrated Ca2+ affinity that was intermediate between CaM and cTnC. All of the CaM.cTnC chimeras showed near-maximal PDE activation but required 5-775-fold higher concentrations than CaM to produce half-maximal PDE activation. In contrast, all of the chimeras showed impaired ability to activate smMLCK, and some were potent competitive inhibitors of smMLCK activation by CaM.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA	Duke University	GEORGE, SE (corresponding author), DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOVASC, BOX 3060, DURHAM, NC 27710 USA.				NIGMS NIH HHS [GM-33976] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; CRAIG TA, 1987, J BIOL CHEM, V262, P3278; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; DEDMAN JR, 1977, J BIOL CHEM, V252, P8415; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; GRABAREK Z, 1983, J BIOL CHEM, V258, P4098; GRABAREK Z, 1983, J BIOL CHEM, V258, P4103; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; JOHNSON JD, 1978, J BIOL CHEM, V253, P3775; KINCAID RL, 1984, J BIOL CHEM, V259, P5158; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; LEAVIS PC, 1978, ARCH BIOCHEM BIOPHYS, V186, P411, DOI 10.1016/0003-9861(78)90453-8; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LINSE S, 1991, BIOCHEMISTRY-US, V30, P154, DOI 10.1021/bi00215a023; LINSE S, 1991, J BIOL CHEM, V266, P8050; LINSE S, 1988, NATURE, V335, P651, DOI 10.1038/335651a0; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PUTKEY JA, 1987, MOL CELL BIOL, V7, P1549, DOI 10.1128/MCB.7.4.1549; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; PUTKEY JA, 1986, J BIOL CHEM, V261, P9896; REID RE, 1985, J THEOR BIOL, V114, P353, DOI 10.1016/S0022-5193(85)80171-5; REID RE, 1980, J THEOR BIOL, V84, P401, DOI 10.1016/S0022-5193(80)80013-0; Sambrook J, 1989, MOL CLONING LABORATO; SEKHARUDU YC, 1988, PROTEIN ENG, V2, P139, DOI 10.1093/protein/2.2.139; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; WALSH M, 1977, BIOCHEMISTRY-US, V16, P2742, DOI 10.1021/bi00631a024; WALSH M, 1978, BIOCHEMISTRY-US, V17, P3924, DOI 10.1021/bi00612a006; WALSH MP, 1980, J BIOL CHEM, V255, P335; WANG JH, 1990, MOL PHARM CELL REGUL, V2, P19; WU ZF, 1992, ADV SEC MESS PHOSPH, V25, P29	48	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25213	25220						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227086				2022-12-25	WOS:A1993MG67300099
J	KINANE, TB; SHANG, C; FINDER, JD; ERCOLANI, L				KINANE, TB; SHANG, C; FINDER, JD; ERCOLANI, L			CAMP REGULATES G-PROTEIN-ALPHA(I-2) SUBUNIT GENE-TRANSCRIPTION IN POLARIZED LLC-PK(1) CELLS BY INDUCTION OF A CCAAT BOX NUCLEAR-BINDING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RESPONSE ELEMENT; G-PROTEIN; ADENYLATE-CYCLASE; DOWN-REGULATION; CYCLIC-AMP; EXPRESSION; SEQUENCE; DESENSITIZATION; IDENTIFICATION; INHIBITION	Heterotrimeric G-proteins function as signal transducers for a variety of hormone-coupled enzyme systems in eukaryotic cells. In LLC-PK1 renal cells, vasopressin-stimulated adenylylcyclase activity is regulated in part, by the counterbalancing activity of stimulatory G-proteins (G(s)) and inhibitory pertussis toxin-sensitive G-proteins (G(i)). Two G(i) genes encoding the G(i) isoforms Galpha(i-2) and Galpha(i-3) are expressed in LLC-PK1 cells. In polarized cells, these isoforms are topographically segregated to different membranes, which allows for the selective inhibition of adenylylcyclase by Galpha(i-2). The genes encoding these isoforms are similarly regulated in these cells during growth and differentiation but differ in response to steroid hormone signals (Holtzman, E. J., Kinane, T. B., West, K., Soper, B. W., Karga, H., Ausiello, D. A., and Ercolani, L. (1993) J. Biol. Chem. 268, 3964-3975). We now demonstrate after stimulating polarized LLC-PK1 cells with forskolin, which raises intracellular cAMP levels 50-fold, Galpha(i-2) but not Galpha(i-3) protein is increased 3-fold at 12 h and remains elevated above control values by 24 h. In cells stably transfected with Galpha(i-2) or Galpha(i-3) gene 5'-flanking sequences fused to firefly luciferase cDNA reporter gene, forskolin treatment increased Galpha(i-2) transcription 3-fold but inhibited Galpha(i-3) transcription by 50% at 12 h. In vivo footprinting of forskolin-treated cells was performed to examine the molecular basis for activation of the Galpha(i-2) gene. Protected guanosines were identified in a 135-base pair (bp) area previously associated with enhancer activity of this gene in non-polarized cells. This DNA segment did not contain the classical cAMP response element 5'-TGACGTCA-3'. Utilizing the 135-bp DNA segment as a probe in mobility shift assays, which compared nuclear extracts from cells before and after forskolin treatment, an induced nuclear protein complex was identified. Following systematic reduction and mutation of this DNA segment, a ''CCAAT'' box motif was identified that bound the induced nuclear protein complex during forskolin-induced Galpha(i-2) gene transcriptional activation. Induction of this nuclear protein complex was prevented in forskolin-treated cells by cycloheximide. To demonstrate functional activity of the CCAAT box motif, cells were transiently transfected with plasmids encoding either the minimal 135-bp segment or a multimerized CCAAT box segment fused to a Rous sarcoma minimal promoter/firefly luciferase reporter gene. The transcriptional response of these plasmids in polarized forskolin-treated cells was similar in magnitude but retarded temporally to that observed in cells stably transfected with the Galpha(i-2) firefly luciferase gene. These studies demonstrate that chronic cAMP elevation initiates a counter-regulatory response in fully polarized renal cells that includes increased transcription of the Galpha(i-2) gene. In contrast to other cAMP-responsive genes, increased Galpha(i-2) gene transcription appears to be mediated by a cAMP pathway that requires induction of a member of the CCAAT box family of DNA-binding proteins.	MASSACHUSETTS GEN HOSP,DEPT MED,RENAL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,PEDIAT PULM UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Finder, Jonathan/AAB-2651-2021	Shang, Charles/0000-0003-4450-9557	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042543, F32DK008838, T32DK007540] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42543, T32 DK07540, F32 DK08838] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER L, 1990, CRIT REV BIOCHEM MOL, V25, P225, DOI 10.3109/10409239009090610; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; ERCOLANI L, 1983, CELL IMMUNOL, V77, P222, DOI 10.1016/0008-8749(83)90023-0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREEN A, 1992, J BIOL CHEM, V267, P3223; GREEN A, 1990, J BIOL CHEM, V265, P5206; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; HOLTZMAN EJ, 1991, J BIOL CHEM, V266, P1763; HOLTZMAN EJ, 1993, J BIOL CHEM, V268, P3964; JAKOBS KH, 1983, NATURE, V303, P177, DOI 10.1038/303177a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3440; MONTMINY MR, 1990, METABOLISM, V39, P6, DOI 10.1016/0026-0495(90)90198-L; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURO AF, 1992, J BIOL CHEM, V267, P12767; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SKORECKI KL, 1987, BIOCHEMISTRY-US, V26, P639, DOI 10.1021/bi00376a040; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801	28	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24669	24676						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227026				2022-12-25	WOS:A1993MG67300027
J	ROBBEN, J; VANDERSCHUEREN, J; VOLCKAERT, G				ROBBEN, J; VANDERSCHUEREN, J; VOLCKAERT, G			CARBOXYL-TERMINUS IS ESSENTIAL FOR INTRACELLULAR FOLDING OF CHLORAMPHENICOL ACETYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NUCLEOTIDE-SEQUENCE ANALYSIS; HUMAN INTERFERON-GAMMA; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; CLOSTRIDIUM-PERFRINGENS; RESISTANCE DETERMINANT; GENE; PROTEIN; PLASMID; EXPRESSION	Chloramphenicol acetyltransferase (CAT, EC 2.3.1.28) is a bacterial chloramphenicol resistance marker that is commonly used as a reporter enzyme in gene expression studies and as a carrier protein for the production of fused peptides. The latter can be done by insertion of target sequences into the native ScaI site near the 3'-end of the Tn9 cat gene. CAT activity in the resulting fusion proteins is retained. We observed that creation of a stop codon at this ScaI, which causes a COOH-terminal 9-amino acid deletion, results in loss of chloramphenicol resistance and total deposition of the mutant protein in inclusion bodies in Escherichia coli. Cytoplasmic solubility and enzyme activity are completely regained by elongation of this mutant with only 2 residues. Apparently, terminal residues of the alpha5-helix play a crucial role in achieving the native conformation of nascent CAT molecules. Thus, CAT provides an interesting model system for mutational analysis of protein folding in vivo.			ROBBEN, J (corresponding author), CATHOLIC UNIV LEUVEN,GENE TECHNOL LAB,WILLEM DE CROYLAAN 42,B-3001 LOUVAIN,BELGIUM.							ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; ARAKAWA T, 1990, J INTERFERON RES, V10, P321, DOI 10.1089/jir.1990.10.321; BANNAM TL, 1991, ANTIMICROB AGENTS CH, V35, P471, DOI 10.1128/AAC.35.3.471; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BRENNER DG, 1985, EMBO J, V4, P561, DOI 10.1002/j.1460-2075.1985.tb03665.x; BRUCKNER R, 1984, GENE, V32, P151, DOI 10.1016/0378-1119(84)90043-X; CARDOSO M, 1992, J APPL BACTERIOL, V72, P289, DOI 10.1111/j.1365-2672.1992.tb01837.x; CHARLES IG, 1985, J BACTERIOL, V164, P123, DOI 10.1128/JB.164.1.123-129.1985; DYKES CW, 1988, EUR J BIOCHEM, V174, P411, DOI 10.1111/j.1432-1033.1988.tb14113.x; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; GENTZ R, 1988, J BACTERIOL, V170, P2212, DOI 10.1128/jb.170.5.2212-2220.1988; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; HARWOOD CR, 1983, GENE, V24, P163, DOI 10.1016/0378-1119(83)90076-8; HEINZ DW, 1993, NATURE, V361, P561, DOI 10.1038/361561a0; HOGEFREE HH, 1989, J BIOL CHEM, V264, P12179; HORINOUCHI S, 1982, J BACTERIOL, V150, P815, DOI 10.1128/JB.150.2.815-825.1982; HUGGINS AS, 1992, ANTIMICROB AGENTS CH, V36, P2548, DOI 10.1128/AAC.36.11.2548; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KEEFE LJ, 1993, P NATL ACAD SCI USA, V90, P3275, DOI 10.1073/pnas.90.8.3275; KENNY B, 1991, MOL MICROBIOL, V5, P2557, DOI 10.1111/j.1365-2958.1991.tb02102.x; KIM HB, 1991, BIOCHEM INT, V25, P381; LESLIE AGW, 1990, J MOL BIOL, V213, P167, DOI 10.1016/S0022-2836(05)80129-9; LEWENDON A, 1988, BIOCHEMISTRY-US, V27, P7385, DOI 10.1021/bi00419a032; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MITRAKI A, 1992, FEBS LETT, V307, P20, DOI 10.1016/0014-5793(92)80894-M; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MURRAY IA, 1989, GENE, V85, P283, DOI 10.1016/0378-1119(89)90420-4; MURRAY IA, 1990, BIOCHEM J, V272, P505, DOI 10.1042/bj2720505; MURRAY IA, 1988, BIOCHEM J, V252, P173, DOI 10.1042/bj2520173; NOVICK R, 1976, J BACTERIOL, V127, P1177, DOI 10.1128/JB.127.3.1177-1187.1976; OCHMAN H, 1988, GENETICS, V120, P621; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RAMIREZ DM, 1993, BIOTECHNOL BIOENG, V41, P557, DOI 10.1002/bit.260410508; ROBBEN J, 1993, GENE, V126, P109, DOI 10.1016/0378-1119(93)90597-V; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; SCHWARZ S, 1991, ANTIMICROB AGENTS CH, V35, P1551, DOI 10.1128/AAC.35.8.1551; SCHWARZ S, 1991, ANTIMICROB AGENTS CH, V35, P1277, DOI 10.1128/AAC.35.7.1277; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; STEFFEN C, 1989, GENE, V75, P349, DOI 10.1016/0378-1119(89)90282-5; TRIEUCUOT P, 1992, PLASMID, V28, P272, DOI 10.1016/0147-619X(92)90060-N; TURNER SL, 1992, PROTEIN ENG, V5, P535, DOI 10.1093/protein/5.6.535; WETZEL R, 1991, BIO-TECHNOL, V9, P731, DOI 10.1038/nbt0891-731; WREN BW, 1989, NUCLEIC ACIDS RES, V17, P4877, DOI 10.1093/nar/17.12.4877	43	17	17	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24555	24558						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227013				2022-12-25	WOS:A1993MG67300011
J	RUSINOL, AE; CHAN, EYW; VANCE, JE				RUSINOL, AE; CHAN, EYW; VANCE, JE			MOVEMENT OF APOLIPOPROTEIN-B INTO THE LUMEN OF MICROSOMES FROM HEPATOCYTES IS DISRUPTED IN MEMBRANES ENRICHED IN PHOSPHATIDYLMONOMETHYLETHANOLAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEP G2 CELLS; ENDOPLASMIC-RETICULUM; RAT HEPATOCYTES; INTRACELLULAR DEGRADATION; SECRETION; GOLGI; TRANSPORT; PROTEIN; LIVER	When monolayer cultures of rat hepatocytes are incubated with the ethanolamine/choline analogue, monomethylethanolamine, the secretion of apolipoproteins B100 and B48, as well as the lipid constituents, of very low density lipoprotein (VLDL) is inhibited by approximately 50% (Vance, J. E. (1991) J. Lipid Res. 32, 1971-1982). In the present study we have investigated the mechanism by which monomethylethanolamine disrupts VLDL secretion. Hepatocytes were treated with 400 muM monomethylethanolamine overnight, which resulted in an increase in the cellular content of the derived phospholipid, phosphatidylmonomethylethanolamine, from 0.32 +/- 0.15 to 2.92 +/- 0.74 nmol/mg of cell protein. The biosynthesis of apoproteins B100 and B48 was not impaired by treatment of cells with monomethylethanolamine. However, monomethylethanolamine decreased by approximately 50% the amount of apoproteins B, but not of the typical secretory protein, albumin, present in the luminal content subfraction of microsomes. The intracellular degradation of apoproteins B was also increased in phosphatidylmonomethylethanolamine-enriched, compared with control, cells. Moreover, the pool of apoprotein B present in intact microsomes from hepatocytes incubated with monomethylethanolamine was more accessible to exogenously added trypsin, presumably because a larger pool of the apoprotein B was exposed on the cytosolic surface of these microsomes. The data strongly suggest that an increase in the microsomal content of phosphatidylmonomethylethanolamine diminishes the ability of apoprotein B to translocate across the endoplasmic reticulum membrane into the luminal compartment. Consequently, the association of apoprotein B with lipids and/or the normal assembly of mature VLDL particles is impaired.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,315 HERITAGE MED RES CTR,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,DEPT MED,EDMONTON T6G 2S2,AB,CANADA	University of Alberta; University of Alberta								ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; BAMBERGER MJ, 1990, P NATL ACAD SCI USA, V87, P2390, DOI 10.1073/pnas.87.7.2390; BAMBERGER MJ, 1988, J BIOL CHEM, V263, P11868; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; DASHTI N, 1989, J LIPID RES, V30, P1365; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; ELOVSON J, 1988, J LIPID RES, V29, P1461; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; HOWELL KE, 1982, J CELL BIOL, V92, P833, DOI 10.1083/jcb.92.3.833; JANERO DR, 1983, J BIOL CHEM, V258, P4496; KHAN BV, 1990, BIOCHIM BIOPHYS ACTA, V1044, P297, DOI 10.1016/0005-2760(90)90073-7; LACKNER KJ, 1986, J CLIN INVEST, V78, P1707, DOI 10.1172/JCI112766; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PULLINGER CR, 1989, J LIPID RES, V30, P1065; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; SATO R, 1990, J BIOL CHEM, V265, P11880; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; VANCE JE, 1991, J LIPID RES, V32, P1971; WETTERAU JR, 1992, SCIENCE, V258, P999; YAO ZM, 1988, J BIOL CHEM, V263, P2998	35	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25168	25175						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227080				2022-12-25	WOS:A1993MG67300093
J	IBA, K; GIBSON, S; NISHIUCHI, T; FUSE, T; NISHIMURA, M; ARONDEL, V; HUGLY, S; SOMERVILLE, C				IBA, K; GIBSON, S; NISHIUCHI, T; FUSE, T; NISHIMURA, M; ARONDEL, V; HUGLY, S; SOMERVILLE, C			A GENE ENCODING A CHLOROPLAST OMEGA-3-FATTY-ACID DESATURASE COMPLEMENTS ALTERATIONS IN FATTY-ACID DESATURATION AND CHLOROPLAST COPY NUMBER OF THE FAD7 MUTANT OF ARABIDOPSIS-THALIANA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; POLYMORPHISM LINKAGE MAP; ENVELOPE MEMBRANES; YEAST; MUTATIONS; SEQUENCE	Mutations at the fad7 locus of Arabidopsis thaliana (previously called fadD) cause decreased desaturation of dienoic fatty acids in chloroplast lipids in plants grown at elevated temperatures. This suggested that the fad7 locus encodes a chloroplast omega-3 desaturase that catalyzes the desaturation of lipid-linked 18:2 and 16:2 fatty acids. In order to clone the fad7 gene, it was first genetically mapped relative to the flanking restriction fragment length polymorphism markers 4547 and 2488A on chromosome 3, and yeast artificial chromosomes covering the locus were identified. A putative desaturase cDNA clone that was isolated by low stringency heterologous probing with a cDNA for an endoplasmic reticulum-localized omega-3 desaturase (fad3) hybridized to the yeast artificial chromosomes and could not be resolved from the locus by restriction fragment length polymorphism mapping. Expression of the cDNA in transgenic fad7 mutant plants resulted in restoration of wild type fatty acid composition and suppression of a previously observed effect of the fad7 mutation on chloroplast number, indicating genetic complementation. The structural gene contained seven introns within a coding sequence of 1338 base pairs, which encodes a 446-amino acid polypeptide of 51,172 daltons. The amino-terminal region of the fad7 gene product contained a consensus chloroplast transit peptide. Except for the amino-terminal domain, the deduced amino acid sequence of the fad7 gene product had high homology to the fad3 gene product, indicating that fad7 encodes an omega-3 desaturase and that the two genes arose from a common ancestral gene. There was no apparent effect of growth temperature on the steady-state levels of fad7 mRNA in wild type plants.	MICHIGAN STATE UNIV,DEPT ENERGY PLANT RES LAB,E LANSING,MI 48824	Michigan State University	IBA, K (corresponding author), KYUSHU UNIV 33,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN.		Somerville, Christopher R/A-4048-2009; Nishiuchi, Takumi/F-1708-2013	Somerville, Christopher R/0000-0003-4647-0094; Nishiuchi, Takumi/0000-0001-9429-5396				ARONDEL V, 1992, SCIENCE, V258, P1353, DOI 10.1126/science.1455229; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BROWSE J, 1986, PLANT PHYSIOL, V81, P859, DOI 10.1104/pp.81.3.859; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FOX BG, 1993, IN PRESS NATL ACAD S; Gibson S. I., 1992, Methods in Arabidopsis research., P119; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HAZEL JR, 1990, PROG LIPID RES, V29, P167, DOI 10.1016/0163-7827(90)90002-3; HUGLY S, 1991, J HERED, V82, P484, DOI 10.1093/oxfordjournals.jhered.a111132; KEARNS EV, 1991, ARCH BIOCHEM BIOPHYS, V284, P431, DOI 10.1016/0003-9861(91)90319-E; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; MCCOURT P, 1987, PLANT PHYSIOL, V84, P353, DOI 10.1104/pp.84.2.353; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; Rogers SO, 1988, PLANT MOL BIOL MAN A, VA6, P1, DOI DOI 10.1007/978-94-017-5294-7_; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT H, 1990, PLANT PHYSIOL, V94, P214, DOI 10.1104/pp.94.1.214; SCHMIDT H, 1990, P NATL ACAD SCI USA, V87, P9477, DOI 10.1073/pnas.87.23.9477; SHANKLIN J, 1991, P NATL ACAD SCI USA, V88, P2510, DOI 10.1073/pnas.88.6.2510; SINGH L, 1984, NUCLEIC ACIDS RES, V12, P5627, DOI 10.1093/nar/12.14.5627; UNFRIED I, 1989, NUCLEIC ACIDS RES, V17, P7513, DOI 10.1093/nar/17.18.7513; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WADA H, 1990, NATURE, V347, P200, DOI 10.1038/347200a0; WADA H, 1993, IN PRESS BIOCH MOL B; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; YADAV NS, 1993, IN PRESS PLANT PHYSL; YAMAMOTO KT, 1992, PLANT CELL PHYSIOL, V33, P13	29	172	206	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24099	24105						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226956				2022-12-25	WOS:A1993MF29400060
J	MACCARANA, M; CASU, B; LINDAHL, U				MACCARANA, M; CASU, B; LINDAHL, U			MINIMAL SEQUENCE IN HEPARIN HEPARAN-SULFATE REQUIRED FOR BINDING OF BASIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; 3-DIMENSIONAL STRUCTURE; SUBSTRATE-SPECIFICITY; NITROUS-ACID; BIOSYNTHESIS; OLIGOSACCHARIDES; DEPOLYMERIZATION; RECEPTOR; CELLS; GLYCOSAMINOGLYCANS	Experiments based on interaction in free solution between basic fibroblast growth factor (FGF-2) and saccharides related to heparin/heparan sulfate showed that the growth factor binds to heparin and to selectively glucosaminyl 6-O-desulfated heparin but poorly to iduronosyl 2-O-desulfated heparin. 2-O-sulfate groups thus are essential to the interaction, whereas 6-O-sulfates are not required nor do they interfere with FGF-2 binding. Comparison of various bound/nonbound oligosaccharides implicated a minimal pentasaccharide sequence for FGF-2 binding, with the structure: -hexuronic acid-glucosamine N-sulfate-hexuronic acid-glucosamine N-sulfate-iduronic acid 2-O-sulfate- (reducing terminus to the right). Such (overlapping) sequences are abundant in heparin, albeit heavily obscured by irrelevant O-sulfate groups, and occur also in heparan sulfate, with or without additional O-sulfates.	UNIV UPPSALA, CTR BIOMED, DEPT MED & PHYSIOL CHEM, BOX 575, S-75123 UPPSALA, SWEDEN; ITALFARMACO SPA, I-20126 MILAN, ITALY; G RONZONI INST CHEM & BIOCHEM RES, I-20133 MILAN, ITALY	Uppsala University; Italfarmaco			maccarana, marco/AAB-4764-2021	Maccarana, Marco/0000-0003-3549-8921				BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACOBSSON I, 1984, J BIOL CHEM, V259, P1056; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; KUSCHE M, 1988, BIOCHEM J, V253, P885, DOI 10.1042/bj2530885; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LAURENT TC, 1986, BIOCHEM J, V234, P653, DOI 10.1042/bj2340653; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; LYCKE E, 1991, J GEN VIROL, V72, P1131, DOI 10.1099/0022-1317-72-5-1131; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLWIN BB, 1990, J CELL BIOL, V110, P503, DOI 10.1083/jcb.110.2.503; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PEJLER G, 1988, J BIOL CHEM, V263, P5197; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIESENFELD J, 1982, J BIOL CHEM, V257, P421; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446	44	419	430	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23898	23905						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226930				2022-12-25	WOS:A1993MF29400032
J	MCCOY, JJ; MANN, BJ; VEDVICK, TS; PAK, Y; HEIMARK, DB; PETRI, WA				MCCOY, JJ; MANN, BJ; VEDVICK, TS; PAK, Y; HEIMARK, DB; PETRI, WA			STRUCTURAL-ANALYSIS OF THE LIGHT SUBUNIT OF THE ENTAMOEBA-HISTOLYTICA GALACTOSE-SPECIFIC ADHERENCE LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; PHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; TERMINAL SIGNAL PEPTIDE; GLYCOSYL-PHOSPHATIDYLINOSITOL; TRYPANOSOMA-BRUCEI; PHOSPHOLIPASE-C; CYTOPATHOGENIC MECHANISMS; SEQUENCE-ANALYSIS; BINDING LECTIN; PROTEINS	Adherence of Entamoeba histolytica trophozoites to colonic mucins and resistance to lysis by the membrane attack complex of complement are mediated by a galactose- and N-acetyl-D-galactosamine-specific cell-surface lectin. This lectin is a heterodimeric glycoprotein of heavy (170 kDa) and light (35/31 kDa) subunits. In this work, the amino acid sequence and membrane anchor of the light subunit were analyzed. The light subunit cDNA encoded a protein with a calculated molecular mass of 32 kDa containing two potential sites for N-linked glycosylation and putative amino- and carboxyl-terminal signal sequences characteristic of glycosylphosphatidylinositol (GPI)-anchored proteins. No classical carbohydrate-binding domains common to C- or S-type eukaryotic lectins were detected by sequence analysis of either the heavy or light subunits, leaving the location of the ligand-binding site of the lectin unknown. Analysis of restriction enzyme-digested E. histolytica DNA by Southern blotting was consistent with the presence of more than one light subunit gene. Two light subunit isoforms of 31 and 35 kDa were identified by SDS-polyacrylamide gel electrophoresis analysis of affinity-purified lectin, and the isoforms were shown on two-dimensional gel analysis to form distinct 170/35- and 170/31-kDa heterodimers. The amino acid compositions and cyanogen bromide peptide patterns of the two light subunit isoforms were nearly identical. The 35-kDa isoform labeled more efficiently than the 31-kDa isoform with [H-3] glucosamine, while only the 31-kDa isoform labeled with [H-3]myristate and [H-3]palmitate. Nitrous acid deamination released lipid from the 31-kDa isoform, which co-migrated on thin layer chromatography with acylphosphatidylinositol, a component of some GPI anchors. Gas chromatography and mass spectrometry of the deamination product from the 31-kDa subunit identified both myo- and chiro-inositols, supporting the presence of a GPI membrane anchor. The covalent association of a transmembrane protein with a GPI-anchored protein, as suggested by the cDNA sequences of the lectin heavy and light subunits, is novel and suggests unique roles for the two subunits in the pathogenesis of amebiasis.	UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT MED, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; SIBIA INC, LA JOLLA, CA 92037 USA	University of Virginia; University of Virginia; University of Virginia			Petri, William/AAL-3642-2020; Pak, Yunbae/Q-5783-2019; Petri, William A./D-3639-2019	Petri, William/0000-0002-7268-1218; Pak, Yunbae/0000-0002-8594-5673; 	NATIONAL CANCER INSTITUTE [T32CA009109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026649] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA 09109] Funding Source: Medline; NIAID NIH HHS [AI-26649] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOOTHROYD JC, 1981, NUCLEIC ACIDS RES, V9, P4735, DOI 10.1093/nar/9.18.4735; BRAGA LL, 1992, J CLIN INVEST, V90, P1131, DOI 10.1172/JCI115931; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAS S, 1991, J BIOL CHEM, V266, P21318; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FERGUSON MAJ, 1992, BIOCHEM SOC T, V20, P243, DOI 10.1042/bst0200243; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; GERBER LD, 1992, J BIOL CHEM, V267, P12168; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KLEIN CE, 1990, BRIT J DERMATOL, V123, P171, DOI 10.1111/j.1365-2133.1990.tb01844.x; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P1350, DOI 10.1073/pnas.89.4.1350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LOW MG, 1987, BIOCHEM J, V241, P615, DOI 10.1042/bj2410615; LUND B, 1987, P NATL ACAD SCI USA, V84, P5898, DOI 10.1073/pnas.84.16.5898; MANIATIS T., 1982, MOL CLONING LABORATO, P382; MANN BJ, 1993, INFECT IMMUN, V61, P1772, DOI 10.1128/IAI.61.5.1772-1778.1993; MANN BJ, 1991, P NATL ACAD SCI USA, V88, P3248, DOI 10.1073/pnas.88.8.3248; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYOR S, 1990, J BIOL CHEM, V265, P6174; PAK Y, 1992, J BIOL CHEM, V267, P16904; PAK YB, 1992, BIOCHEM BIOPH RES CO, V184, P1042, DOI 10.1016/0006-291X(92)90696-I; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETRI WA, 1991, INFECT IMMUN, V59, P97, DOI 10.1128/IAI.59.1.97-101.1991; PETRI WA, 1989, J BIOL CHEM, V264, P3007; PETRI WA, 1987, INFECT IMMUN, V55, P2327, DOI 10.1128/IAI.55.10.2327-2331.1987; PETRI WA, 1990, J IMMUNOL, V144, P4803; PURDY JE, 1993, IN PRESS MOL BIOCH P; RAVDIN JI, 1980, J EXP MED, V152, P377, DOI 10.1084/jem.152.2.377; RAVDIN JI, 1981, J CLIN INVEST, V68, P1305, DOI 10.1172/JCI110377; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; SAFFER LD, 1991, EXP PARASITOL, V72, P106, DOI 10.1016/0014-4894(91)90128-J; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAIN DC, 1992, INFECT IMMUN, V60, P2143, DOI 10.1128/IAI.60.5.2143-2146.1992; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; TANNICH E, 1991, P NATL ACAD SCI USA, V88, P1849, DOI 10.1073/pnas.88.5.1849; TANNICH E, 1992, MOL BIOCHEM PARASIT, V55, P225, DOI 10.1016/0166-6851(92)90144-9; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TORIAN BE, 1990, P NATL ACAD SCI USA, V87, P6358, DOI 10.1073/pnas.87.16.6358; WALTER EI, 1990, J IMMUNOL, V144, P1030; WILLIAMS RE, 1975, BIOCHEM BIOPH RES CO, V62, P462, DOI 10.1016/S0006-291X(75)80161-6	49	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24223	24231						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226970				2022-12-25	WOS:A1993MF29400076
J	MCGAVIN, MJ; GURUSIDDAPPA, S; LINDGREN, PE; LINDBERG, M; RAUCCI, G; HOOK, M				MCGAVIN, MJ; GURUSIDDAPPA, S; LINDGREN, PE; LINDBERG, M; RAUCCI, G; HOOK, M			FIBRONECTIN RECEPTORS FROM STREPTOCOCCUS-DYSGALACTIAE AND STAPHYLOCOCCUS-AUREUS - INVOLVEMENT OF CONSERVED RESIDUES IN LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 DIFFERENT GENES; NUCLEOTIDE-SEQUENCE; PROTEIN; EXPRESSION; PYOGENES; COLLAGEN; CLONING; FORM	The nucleotide sequence of two genes encoding fibronectin (Fn) receptors FnBA and FnBB of Streptococcus dysgalactiae S2 revealed the presence of repeated motifs (called R(A1-A3) and R(B1-B3), respectively) which encode Fn binding activity (Lindgren, P.-E., McGavin, M. J., Signas, C., Guss, B., Gurusiddappa, S., Hook, M., and Lindberg, M. (1993) Eur. J. Biochem. 214, 819-827). Synthetic peptides of 32-37 amino acids, corresponding to individual repeated motifs, were assayed for the ability to inhibit Fn binding to cells of S. dysgalactiae. Within the R(A) Motifs, peptide A2 was 10-fold more active than either A1 or A3, while in the R(B) motifs, only B3 was active. The same level of activity is observed when these synthetic peptides were assayed for inhibition of Fn binding to cells of Staphylococcus aureus. Likewise, synthetic peptides corresponding to the R(D1-D3) motifs, which comprise a ligand binding domain in a Fn receptor from S. aureus, inhibit binding of Fn to both S. aureus and S. dysgalactiae. Assays of chemically modified peptides and peptide fragments derived from chemical or proteolytic cleavage suggest that a conserved core sequence, defined as ED(T/S)(X9,10)GG(X3,4)(I/V)DF, within a 30-amino acid-long segment is present in the active R(A) and R(D) motifs. Analyses of the importance of individual residues of this core sequence indicate that the ED(T/S) motif is nonessential, whereas the GG and the (I/V)DF together with additional acidic residues in the C-terminal half of the peptide are required for activity.	UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294; SWEDISH UNIV AGR SCI,DEPT MICROBIOL,S-75007 UPPSALA,SWEDEN	University of Alabama System; University of Alabama Birmingham; Swedish University of Agricultural Sciences				McGavin, Martin/0000-0001-5955-0689	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHARYA AS, 1984, J CHROMATOGR, V297, P37, DOI 10.1016/S0021-9673(01)89027-0; BARON M, 1990, NATURE, V345, P642, DOI 10.1038/345642a0; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FLOCK JI, 1987, EMBO J, V6, P697; FROMAN G, 1987, J BIOL CHEM, V262, P6564; HUNTER W, 1978, HDB EXPT IMMUNOLOGY; Hynes RO, 1990, FIBRONECTINS; JONSSON K, 1991, EUR J BIOCHEM, V202, P1041, DOI 10.1111/j.1432-1033.1991.tb16468.x; KUUSELA P, 1984, INFECT IMMUN, V45, P433, DOI 10.1128/IAI.45.2.433-436.1984; KUUSELA P, 1978, NATURE, V276, P718, DOI 10.1038/276718a0; LINDGREN PE, 1993, EUR J BIOCHEM, V214, P819, DOI 10.1111/j.1432-1033.1993.tb17985.x; LINDGREN PE, 1992, J BIOL CHEM, V267, P1924; LOFDAHL S, 1983, P NATL ACAD SCI-BIOL, V80, P697, DOI 10.1073/pnas.80.3.697; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V1, P105; MCGAVIN MJ, 1991, J BIOL CHEM, V266, P8343; MCGAVIN MJ, 1990, CELL DIFFER DEV, V32, P433; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; PATTI JM, 1992, J BIOL CHEM, V267, P4766; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; SPEZIALE P, 1984, J BACTERIOL, V157, P420, DOI 10.1128/JB.157.2.420-427.1984; TALAY SR, 1992, INFECT IMMUN, V60, P3837, DOI 10.1128/IAI.60.9.3837-3844.1992	23	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23946	23953						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226935				2022-12-25	WOS:A1993MF29400038
J	ROBERDS, SL; ANDERSON, RD; IBRAGHIMOVBESKROVNAYA, O; CAMPBELL, KP				ROBERDS, SL; ANDERSON, RD; IBRAGHIMOVBESKROVNAYA, O; CAMPBELL, KP			PRIMARY STRUCTURE AND MUSCLE-SPECIFIC EXPRESSION OF THE 50-KDA DYSTROPHIN-ASSOCIATED GLYCOPROTEIN (ADHALIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SKELETAL-MUSCLE; MUSCULAR-DYSTROPHY; PROTEINS; COMPLEX; ORGANIZATION; PURIFICATION; DEFICIENCY; SARCOLEMMA; CLEAVAGE; CLONING	The 50-kDa dystrophin-associated glycoprotein (50-DAG) is a component of the dystrophin-glycoprotein complex, which links the muscle cytoskeleton to the extracellular matrix. 50-DAG is specifically deficient in skeletal muscle of patients with severe childhood autosomal recessive muscular dystrophy and in skeletal and cardiac muscles of BIO 14.6 cardiomyopathic hamsters. The lack of 50-DAG leads to a disruption and dysfunction of the dystrophin-glycoprotein complex in these diseases. The cDNA encoding 50-DAG has now been cloned from rabbit skeletal muscle. The 50-DAG deduced amino acid sequence predicts a novel protein having 387 amino acids, a 17-amino acid signal sequence, one transmembrane domain, and two potential sites of N-linked glycosylation. Affinity-purified antibodies against rabbit 50-DAG fusion proteins or synthetic peptides specifically recognized a 50-kDa protein in skeletal muscle sarcolemma and the 50-kDa component of the dystrophin-glycoprotein complex. In contrast to dystroglycan, which is expressed in a wide variety of muscle and non-muscle tissues, 50-DAG is expressed only in skeletal and cardiac muscles and in selected smooth muscles. Finally, 50-DAG mRNA is present in mdx and Duchenne muscular dystrophy (DMD) muscle, indicating that the down-regulation of this protein in DMD and the mdx mouse is likely a post-translational event.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, 400 EMRB, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa			Roberds, Steven L/AAP-4985-2020	Roberds, Steven L/0000-0003-0676-272X; Campbell, Kevin/0000-0003-2066-5889				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AZIBI K, 1993, HUM MOL GENET, V2, P1423; BAJUSZ E, 1969, AM HEART J, V77, P686, DOI 10.1016/0002-8703(69)90556-0; BENOTHMANE K, 1992, NAT GENET, V2, P315, DOI 10.1038/ng1292-315; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; Homburger F, 1979, Ann N Y Acad Sci, V317, P1, DOI 10.1111/j.1749-6632.1979.tb56503.x; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JORGENSEN AO, 1990, J CELL BIOL, V110, P1173, DOI 10.1083/jcb.110.4.1173; KLIETSCH R, 1993, CIRC RES, V72, P349, DOI 10.1161/01.RES.72.2.349; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMURA K, 1993, J CLIN INVEST, V92, P866, DOI 10.1172/JCI116661; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PASSOSBUENO MR, 1993, IN PRESS HUM MOL GEN; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; Sambrook J, 1989, MOL CLONING LABORATO; SHARP AH, 1989, J BIOL CHEM, V264, P2816; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DB, 1987, CURRENT PROTOCOLS MO; STRYNADKA NCJ, 1988, J VIROL, V62, P3474, DOI 10.1128/JVI.62.9.3474-3483.1988; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMAMOTO H, 1993, J BIOCHEM-TOKYO, V114, P132, DOI 10.1093/oxfordjournals.jbchem.a124128; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	41	158	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23739	23742						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226900				2022-12-25	WOS:A1993MF29400002
J	TAFURI, SR; WOLFFE, AP				TAFURI, SR; WOLFFE, AP			SELECTIVE RECRUITMENT OF MASKED MATERNAL MESSENGER-RNA FROM MESSENGER-RIBONUCLEOPROTEIN PARTICLES CONTAINING FRGY2 (MESSENGER RNP4)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTE MATURATION; TRANSCRIPTION FACTOR; BINDING-PROTEINS; 5S RNA; TRANSLATIONAL CONTROL; ESCHERICHIA-COLI; CYTOPLASMIC POLYADENYLATION; GENE; IDENTIFICATION; ELEMENTS	In Xenopus, the germ cell-specific Y-box (CTGATTGGCCAA) factor, FRGY2, facilitates in vitro transcription in egg extracts from oocyte-selective promoters containing a Y-box. This same factor is a major component of the messenger ribonucleoprotein (mRNP) storage particles of the oocyte. These particles store maternal mRNAs and inhibit their translation. FRGY2 is identical to mRNP4 and homologous to mRNP3, two previously described oocyte-specific mRNP proteins. We demonstrate that FRGY2 associates with a broad spectrum of mRNAs exhibiting no apparent sequence specificity. These interactions suggest that FRGY2 has a general role in packaging mRNA analogous to that of histone with DNA. All mRNAs examined that accumulate in oocytes appear within these mRNP storage particles, including messages coding for proteins such as FRGY2 and TFIIIA, which are translated in the oocyte. Moreover, we show that mRNAs that are translationally repressed in oocytes, such as messages coding for the proteins histone H1 and FRGY1, accumulate only within the particles. These mRNAs are subsequently recruited from the particles to the ribosomes and utilized for translation during embryogenesis prior to transcriptional activation of the zygotic genome. We propose that the assembly of mRNP storage particles represents a default state and that translational regulation is achieved via specific recruitment of the messages from the mRNP fraction to the ribosomes.	NICHHD,MOLEC EMBRYOL LAB,BLDG 6,RM B1A-13,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ANDREWS MT, 1987, CELL, V51, P445, DOI 10.1016/0092-8674(87)90640-4; AUDET RG, 1987, DEV BIOL, V121, P58, DOI 10.1016/0012-1606(87)90138-2; BACHVAROVA R, 1962, CELL, V69, P895; BIENZ M, 1986, CELL, V46, P1037, DOI 10.1016/0092-8674(86)90703-8; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CRAWFORD DR, 1987, DEVELOPMENT, V101, P741; CUMMINGS A, 1988, J CELL BIOL, V107, P45, DOI 10.1083/jcb.107.1.45; DARNBROUGH CH, 1981, EUR J BIOCHEM, V113, P415, DOI 10.1111/j.1432-1033.1981.tb05081.x; DAVIDSON EH, 1986, GENE ACTIVITY EARLY, P1; DEARSLEY AL, 1985, EUR J BIOCHEM, V150, P95, DOI 10.1111/j.1432-1033.1985.tb08993.x; DESCHAMPS S, 1992, J BIOL CHEM, V267, P13799; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P283; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MCGREW LL, 1990, EMBO J, V9, P3743, DOI 10.1002/j.1460-2075.1990.tb07587.x; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; PARIS J, 1990, DEV BIOL, V140, P221, DOI 10.1016/0012-1606(90)90070-Y; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; RICHTER JD, 1988, TRENDS BIOCHEM SCI, V13, P483, DOI 10.1016/0968-0004(88)90236-8; RICHTER JD, 1984, J BIOL CHEM, V259, P2190; RICHTER JD, 1983, J BIOL CHEM, V258, P4864; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SCHWARTZ SP, 1992, IN PRESS P NATL ACAD; Spirin A. S., 1966, Current Topics in Developmental Biology, V1, P1; SWIDERSKI RE, 1988, DEV BIOL, V128, P349, DOI 10.1016/0012-1606(88)90297-7; Tafuri Sherrie R., 1993, Trends in Cell Biology, V3, P94, DOI 10.1016/0962-8924(93)90080-K; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TAFURI SR, UNPUB; VARNUM SM, 1992, DEV BIOL, V153, P283, DOI 10.1016/0012-1606(92)90113-U; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1989, NUCLEIC ACIDS RES, V17, P767, DOI 10.1093/nar/17.2.767; WOODLAND HR, 1979, CELL, V18, P165, DOI 10.1016/0092-8674(79)90365-9; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	45	101	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24255	24261						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226972				2022-12-25	WOS:A1993MF29400080
J	ARTEMYEV, NO; MILLS, JS; THORNBURG, KR; KNAPP, DR; SCHEY, KL; HAMM, HE				ARTEMYEV, NO; MILLS, JS; THORNBURG, KR; KNAPP, DR; SCHEY, KL; HAMM, HE			A SITE ON TRANSDUCIN ALPHA-SUBUNIT OF INTERACTION WITH THE POLYCATIONIC REGION OF CGMP PHOSPHODIESTERASE INHIBITORY SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ROD OUTER SEGMENTS; GTP-BINDING PROTEIN; RETINAL RODS; GAMMA-SUBUNIT; ACTIVATION MECHANISM; CHROMATOGRAPHY; PURIFICATION; COMPLEX; PEPTIDE	Activation of cGMP phosphodiesterase (PDE) by the rod G-protein transducin is a key event in visual signal transduction in vertebrate photoreceptor cells. Interaction between the GTP-bound form of the alpha-subunit of transducin (alpha(t)*) and the PDE inhibitory gamma-subunit (Pgamma) is a major component of PDE activation. The central polycationic region of Pgamma, Pgamma-24-45, has been implicated as one of the sites involved in alpha(t)*.Pgamma interaction. Here we determine the site on alpha(t) that interacts with Pgamma-24-45 using a photo-cross-linking approach. The synthetic peptides Cys(ACM)Tyr-Pgamma-24-45-Cys (where ACM indicates acetamidomethyl group) and Cys-Pgamma-24-45 were labeled with 4-(N-maleimido)benzophenone at the COOH and NH2 termini, respectively, and then cross-linked to alpha(t). When the photoprobe was attached to the COOH terminus of the peptide, a specific high yield cross-linked product (80%) was formed between the peptide and alpha(t)GTPgammaS (guanosine 5'-O-(thiotriphosphate)). A lower yield of cross-linking (35%) was seen between the peptide and alpha(t)GDP. The site of cross-linking between Cys(ACM)Tyr-Pgamma-24-45-Cys and alpha(t)GTPgammaS was localized to within alpha(t)-306-310 using a variety of chemical and proteolytic cleavages of the cross-linked product, analysis of the fragments with SDS-polyacrylamide gel electrophoresis, and matrix-assisted laser desorption ionization mass spectrometry.	UNIV ILLINOIS, COLL MED, DEPT PHYSIOL & BIOPHYS, BOX 6998, CHICAGO, IL 60680 USA; MED UNIV S CAROLINA, DEPT CELL & MOLEC PHARMACOL, CHARLESTON, SC 29425 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Medical University of South Carolina			Hamm, Heidi E/G-2374-2014	Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY006062] Funding Source: NIH RePORTER; NEI NIH HHS [EY-06062] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; Bornstein P, 1977, Methods Enzymol, V47, P132; BOYD ND, 1991, BIOCHEMISTRY-US, V30, P336, DOI 10.1021/bi00216a005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CLERC A, 1992, J BIOL CHEM, V267, P6620; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1983, J BIOL CHEM, V258, P503; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KAUER JC, 1986, J BIOL CHEM, V261, P695; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; STRYER L, 1991, J BIOL CHEM, V266, P10711; Tanaka K, 1988, RAPID COMMUN MASS SP, V2, P151, DOI [10.1002/RCM.1290020802, DOI 10.1002/RCM.1290020802, 10.1002/rcm.1290020802]; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702	34	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23611	23615						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226888				2022-12-25	WOS:A1993MF51500099
J	KOMATSU, M; MCDERMOTT, AM; GILLISON, SL; SHARP, GWG				KOMATSU, M; MCDERMOTT, AM; GILLISON, SL; SHARP, GWG			MASTOPARAN STIMULATES EXOCYTOSIS AT A CA2+-INDEPENDENT LATE SITE IN STIMULUS-SECRETION COUPLING - STUDIES WITH THE RINM5F BETA-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WASP VENOM MASTOPARAN; GTP-BINDING PROTEINS; INSULIN-SECRETION; CHROMAFFIN CELLS; CONFORMATIONAL CHANGE; GUANINE-NUCLEOTIDES; CA-2+ CONCENTRATION; PANCREATIC-ISLETS; ACINAR-CELLS; MAST-CELLS	Mastoparan, a tetradecapeptide from wasp venom, stimulated exocytosis in a concentration-dependent manner, which was enhanced by pertussis toxin pretreatment, in the insulin secreting beta-cell line RINm5F. Mastoparan (3-20 muM) also elevated cytosolic free calcium concentration ([Ca2+]i), a rise that was not attenuated by nitrendipine. Divalent cation-free Krebs-Ringer bicarbonate (KRB) medium with 0.1 mm EGTA nullified the mastoparan-induced increase in [Ca2+]i, suggesting that the peptide increased Ca2+ influx but not through the L-type voltage-dependent Ca2+ channel. Depletion of the intracellular Ca2+ pool did not affect the mastoparan-induced elevation of [Ca2+]i. Remarkably, in divalent cation-free KRB medium with 0.1 mM EGTA and 2 muM thapsigargin in which mastoparan reduced [Ca2+]i, the mastoparan-stimulated insulin release was similar to that in normal Ca2+-containing KRB medium. Inhibitors of protein kinase C, such as bisindolylmaleimide, staurosporine, and 1-O-hexadecyl-2-O-methyl-rac-glycerol did not suppress the mastoparan-stimulated insulin release. Mastoparan at 10-20 muM did not increase cellular cAMP levels, nor did mastoparan at 5-10 muM affect [H-3]arachidonic acid release. In conclusion, although mastoparan increased [Ca2+]i, this increase was not involved in the stimulation of insulin release. Rather, the data suggest that mastoparan directly stimulates exocytosis in a Ca2+-independent manner. As GTP-binding proteins (G proteins) are thought to be involved in the process of exocytosis and as mastoparan is known to exert at least some of its effects by activation of G proteins, an action of mastoparan to activate the putative stimulatory G(e) (exocytosis) protein is likely.			KOMATSU, M (corresponding author), CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853, USA.							ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; ARIDOR M, 1990, J CELL BIOL, V111, P909, DOI 10.1083/jcb.111.3.909; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; GOMPERTS BD, 1986, TRENDS BIOCHEM SCI, V11, P290, DOI 10.1016/0968-0004(86)90032-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSOVSKY F, 1991, EUR J PHARM-MOLEC PH, V206, P309, DOI 10.1016/0922-4106(91)90115-X; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HIGASHIJIMA T, 1984, BIOCHIM BIOPHYS ACTA, V802, P157, DOI 10.1016/0304-4165(84)90156-9; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HILLAIREBUYS D, 1992, MOL CELL BIOCHEM, V109, P133; HIRAI Y, 1979, CHEM PHARM BULL, V27, P1942; HOMAIDAN FR, 1991, P NATL ACAD SCI USA, V88, P8744, DOI 10.1073/pnas.88.19.8744; JOYCEBRADY M, 1991, J BIOL CHEM, V266, P6859; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KATSU T, 1990, BIOCHIM BIOPHYS ACTA, V1027, P185, DOI 10.1016/0005-2736(90)90083-Z; KOMATSU M, 1992, ENDOCRINOLOGY, V130, P221, DOI 10.1210/en.130.1.221; KRAMER IM, 1989, J BIOL CHEM, V264, P5876; KURIHARA H, 1986, CELL TISSUE RES, V243, P311; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; OKANO Y, 1985, FEBS LETT, V188, P363, DOI 10.1016/0014-5793(85)80403-8; OZAKI Y, 1990, BIOCHEM BIOPH RES CO, V170, P779, DOI 10.1016/0006-291X(90)92159-W; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; PERIANIN A, 1989, J IMMUNOL, V143, P1669; RIBEIRONETO FAP, 1989, P NATL ACAD SCI USA, V86, P2577, DOI 10.1073/pnas.86.8.2577; SCHERER NM, 1987, ARCH BIOCHEM BIOPHYS, V259, P431, DOI 10.1016/0003-9861(87)90509-1; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; SENYSHYN J, 1992, FEBS LETT, V309, P41, DOI 10.1016/0014-5793(92)80735-Y; SHARP GWG, 1989, J BIOL CHEM, V264, P7302; SONTAG JM, 1991, BIOCHEM J, V274, P339, DOI 10.1042/bj2740339; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TANIMURA A, 1991, BIOCHEM BIOPH RES CO, V177, P802, DOI 10.1016/0006-291X(91)91860-F; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; ULLRICH S, 1988, J BIOL CHEM, V263, P8615; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WAKAMATSU K, 1986, BIOPOLYMERS, V25, P193; WALLACE MA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P311, DOI 10.1016/0005-2760(89)90018-0; WHEELERJONES CPD, 1992, BIOCHEM J, V281, P465, DOI 10.1042/bj2810465; WILSON SP, 1989, FEBS LETT, V247, P239, DOI 10.1016/0014-5793(89)81343-2; WOJCIKIEWICZ RJH, 1989, FEBS LETT, V247, P341, DOI 10.1016/0014-5793(89)81366-3; YADA T, 1989, J BIOL CHEM, V264, P2455; YAMAMOTO S, 1982, EUR J PHARMACOL, V78, P225, DOI 10.1016/0014-2999(82)90240-0; YAZAWA M, 1987, J BIOL CHEM, V262, P10951; YOKOKAWA N, 1989, BIOCHEM BIOPH RES CO, V158, P712, DOI 10.1016/0006-291X(89)92779-4; YULE DI, 1991, BIOCHEM BIOPH RES CO, V177, P159, DOI 10.1016/0006-291X(91)91962-C	48	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23297	23306						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226853				2022-12-25	WOS:A1993MF51500055
J	PENG, SB; STONE, DK; XIE, XS				PENG, SB; STONE, DK; XIE, XS			RECONSTITUTION OF RECOMBINANT 40-KDA SUBUNIT OF THE CLATHRIN-COATED VESICLE H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON TRANSLOCATING COMPLEX; PROTEINS; PUMP	We have proposed a model of the ATP hydrolytic sector of the clathrin-coated vesicle H+-ATPase wherein significant catalysis requires four subunits of molecular masses of 70, 58, 40, and 33 kDa (Xie, X.-S., and Stone, D. K. (1988) J. Biol. Chem. 263, 9859-9867). We have cloned and expressed the 40-kDa component in Escherichia coli and have purified the recombinant protein to homogeneity. This subunit lacks ATP hydrolytic capacity, but when reconstituted to a 40 kDa-depleted hydrolytic sector, there is a greater than 20-fold increase in calcium-activated, N-ethylmaleimide-sensitive ATP hydrolysis, indicating that this subunit is required for vacuolar-type proton pump function.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOLEC TRANSPORT,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK RO1 33627] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1989, SHORT PROTOCOLS MOL; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Innis MA, 1990, PCR PROTOCOLS GUIDE; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NELSON H, 1990, J BIOL CHEM, V265, P20390; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; QIAGEN X, 1992, QIA EXPRESSIONIST; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STONE DK, 1984, J BIOL CHEM, V259, P2701; STONE DK, 1988, KIDNEY INT, V33, P403; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN SZ, 1987, J BIOL CHEM, V262, P14790; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1988, J BIOL CHEM, V263, P9859; XIE XS, 1983, J BIOL CHEM, V259, P11676	19	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23519	23523						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226880				2022-12-25	WOS:A1993MF51500086
J	WENGER, RH; ROCHELLE, JM; SELDIN, MF; KOHLER, G; NIELSEN, PJ				WENGER, RH; ROCHELLE, JM; SELDIN, MF; KOHLER, G; NIELSEN, PJ			THE HEAT-STABLE ANTIGEN (MOUSE-CD24) GENE IS DIFFERENTIALLY REGULATED BUT HAS A HOUSEKEEPING PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-GLOBIN GENE; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; CPG ISLANDS; CELL-LINES; B-CELLS; TRANSCRIPTION FACTORS; SURFACE-ANTIGENS; MESSENGER-RNA; LINKAGE MAP; SCG10 GENE	Expression of the mouse heat stable antigen (HSA or mouse CD24) shows tissue-specific as well as developmental regulation. During the maturation of several hematopoietic lineages, HSA expression is generally high in immature precursor cells and low or absent in terminally differentiated cells. We present evidence suggesting that this regulation of the HSA gene (Cd24a) occurs at the transcriptional level. In addition, sequence and methylation analysis of the Cd24a promoter revealed characteristics of both ''housekeeping'' and tissue-specific promoters, including a methylation-free, HpaII tiny fragment (HTF) island, multiple putative SP1 and AP-2 consensus binding sites, and a TATA box. Functional analysis of a 0.6-kilobase DNA fragment containing these elements fused to the CAT reporter gene in transient transfection experiments showed activity in both HSA expressing and non-expressing cell lines with a strength similar to that of the herpes-simplex virus-thymidine kinase promoter. Large fragments from the flanking region of the Cd24a promoter did not influence the ubiquitous nature of this promoter. Finally, we mapped the Cd24a, Cd24b, and Cd24c genes to mouse chromosomes 10, 8, and 14 respectively.	MAX PLANCK INST IMMUNBIOL,STUBEWEG 51,D-79108 FREIBURG,GERMANY; DUKE UNIV,MED CTR,MOLEC GENET LAB,DURHAM,NC 27710	Max Planck Society; Duke University			Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839	NHGRI NIH HHS [HG00101] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; ALTERMAN LA, 1990, EUR J IMMUNOL, V20, P1597, DOI 10.1002/eji.1830200728; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; AYANE M, 1989, NUCLEIC ACIDS RES, V17, P6722, DOI 10.1093/nar/17.16.6722; BARGOU RCEF, 1991, GENE, V99, P197, DOI 10.1016/0378-1119(91)90127-W; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; BLACKSHEAR PJ, 1992, GENOMICS, V14, P168, DOI 10.1016/S0888-7543(05)80300-3; BRUCE J, 1981, J IMMUNOL, V127, P2496; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLOMBO MP, 1992, MAMM GENOME, V2, P130, DOI 10.1007/BF00353861; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIETRICH W, 1992, GENETICS, V131, P423; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EDWARDS YH, 1990, PHILOS T R SOC B, V326, P207, DOI 10.1098/rstb.1990.0005; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FISCHER GF, 1990, J IMMUNOL, V144, P638; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Green EL, 1981, GENETICS PROBABILITY, P77; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HITSUMOTO Y, 1992, BIOCHEM BIOPH RES CO, V187, P773, DOI 10.1016/0006-291X(92)91262-O; HOWARD TA, 1991, GENOMICS, V10, P207, DOI 10.1016/0888-7543(91)90502-6; IGLESIAS A, 1991, EMBO J, V10, P2147, DOI 10.1002/j.1460-2075.1991.tb07749.x; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; KADMON G, 1992, J CELL BIOL, V118, P1245, DOI 10.1083/jcb.118.5.1245; KAY R, 1990, J IMMUNOL, V145, P1952; KAY R, 1991, J IMMUNOL, V147, P1412; KIM KJ, 1979, J IMMUNOL, V122, P549; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; LINTON PJ, 1989, CELL, V59, P1049, DOI 10.1016/0092-8674(89)90761-7; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; LIU Y, 1992, EUR J IMMUNOL, V22, P2855, DOI 10.1002/eji.1830221115; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MEEKER TC, 1990, MOL CELL BIOL, V10, P1680, DOI 10.1128/MCB.10.4.1680; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MULLER B, 1988, J EXP MED, V168, P2131, DOI 10.1084/jem.168.6.2131; NEDELEC J, 1992, EUR J BIOCHEM, V203, P433, DOI 10.1111/j.1432-1033.1992.tb16567.x; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; OAKEY RJ, 1991, GENOMICS, V10, P338, DOI 10.1016/0888-7543(91)90317-8; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; PIERRES M, 1987, EUR J IMMUNOL, V17, P1781, DOI 10.1002/eji.1830171216; ROUGON G, 1991, EUR J IMMUNOL, V21, P1397, DOI 10.1002/eji.1830210611; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS AM, 1990, GENOMICS, V8, P524; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SHOWE MK, 1992, NUCLEIC ACIDS RES, V20, P3153, DOI 10.1093/nar/20.12.3153; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STONE JC, 1989, GENOMICS, V5, P70, DOI 10.1016/0888-7543(89)90088-8; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; VYAS P, 1992, CELL, V69, P781, DOI 10.1016/0092-8674(92)90290-S; WATSON ML, 1992, MAMM GENOME, V2, P158, DOI 10.1007/BF00302874; WENGER RH, 1991, EUR J IMMUNOL, V21, P1039, DOI 10.1002/eji.1830210427; WHITELAW E, 1989, MOL CELL BIOL, V9, P241, DOI 10.1128/MCB.9.1.241; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X	65	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23345	23352						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226859				2022-12-25	WOS:A1993MF51500062
J	CHEN, SRW; AIREY, JA; MACLENNAN, DH				CHEN, SRW; AIREY, JA; MACLENNAN, DH			POSITIONING OF MAJOR TRYPTIC FRAGMENTS IN THE CA2+ RELEASE CHANNEL (RYANODINE RECEPTOR) RESULTING FROM PARTIAL DIGESTION OF RABBIT SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIGNANT HYPERTHERMIA; CALCIUM-RELEASE; FUNCTIONAL EXPRESSION; H-3 RYANODINE; IDENTIFICATION; PURIFICATION; BINDING; COMPLEX; VESICLES; MUTATION	Site-specific antibodies against different regions of the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum (ryanodine receptor) were developed and used as probes for immunoblotting of the major tryptic fragments resulting from partial digestion of the ryanodine receptor in sarcoplasmic reticulum membranes. Five major tryptic fragments, some of which migrated as doublets, with apparent masses of 150/140, 110/100, 55, 170/160, and 76 kDa were ordered so that they covered the bulk of the protein from the NH2 to the COOH terminus. Tryptic subfragments of 53, 63, and 115/95 kDa were also derived from the 150/140-, 110/100-, and 170/160-kDa fragments, respectively. All of these fragments and subfragments were detected only in the insoluble membrane fraction of the trypsinized sarcoplasmic reticulum. Upon Na2CO3 extraction, the 150/140-, 110/100-, and 55-kDa fragments could be solubilized, suggesting their origin in the cytoplasmic domain of the ryanodine receptor. The 170/160- and 76-kDa fragments and the 115/195-kDa subfragment remained insoluble, suggesting their origin in the transmembrane region of the ryanodine receptor. The 150/140-,110/100-,170/160-, and 76-kDa fragments and the 115/95 subfragment co-migrated near the bottom of a sucrose density gradient after CHAPS solubilization, suggesting that they were associated in an oligomeric complex. By contrast, the 53- and 63-kDa subfragments and the 55-kDa fragment were detected near the top of the sucrose gradient after CHAPS solubilization, suggesting that they were not involved in the formation of the core of the oligomeric complex. These studies identify 7 sites that are exposed to trypsin in the ryanodine receptor in sarcoplasmic reticulum, 3 of which are novel and 4 of which are in the same location as proteolytic cleavage sites identified previously (Marks, A. R., Fleischer, S., and Tempst, P. (1990) J. Biol. Chem. 265, 13143-13149).	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV NEVADA,SCH MED,DEPT PHARMACOL,RENO,NV 89557	University of Toronto; Nevada System of Higher Education (NSHE); University of Nevada Reno					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027470] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27470] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIREY JA, 1990, J BIOL CHEM, V265, P14187; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; CHU A, 1988, BIOCHEMISTRY-US, V27, P2827, DOI 10.1021/bi00408a025; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWKES MJ, 1992, J BIOL CHEM, V267, P6702; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; INUI M, 1987, J BIOL CHEM, V262, P1740; LAI FA, 1987, BIOCHEM BIOPH RES CO, V143, P704, DOI 10.1016/0006-291X(87)91411-2; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; MICKELSON JR, 1992, FEBS LETT, V301, P49, DOI 10.1016/0014-5793(92)80208-X; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; RARDON DP, 1990, CIRC RES, V67, P84, DOI 10.1161/01.RES.67.1.84; Sambrook J, 1989, MOL CLONING LABORATO; SHOSHANBARMATZ V, 1988, J BIOL CHEM, V263, P16772; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; ZHANG Y, 1993, NAT GENET, V5, P61; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	36	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22642	22649						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226772				2022-12-25	WOS:A1993MD34800068
J	ROSA, JL; VENTURA, F; TAULER, A; BARTRONS, R				ROSA, JL; VENTURA, F; TAULER, A; BARTRONS, R			REGULATION OF HEPATIC 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE 2,6-BISPHOSPHATASE GENE-EXPRESSION BY GLUCAGON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; RAT-LIVER; MULTIHORMONAL REGULATION; HORMONAL-CONTROL; BINDING-PROTEIN; FRUCTOSE-2,6-BISPHOSPHATASE; INSULIN; TRANSCRIPTION; HEPATOCYTES	The control of hepatic 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase gene expression by glucagon was studied. Intraperitoneal administration of glucagon rapidly decreased the fructose 2,6-bisphosphate content by phosphorylation of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase and diminution of its V(max). Immunologic studies using a specific liver antibody showed that the amount of enzyme rapidly decreased. Northern blot analysis showed that the isozyme expressed is the adult liver form. The 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase mRNA content decreased, whereas that of phosphoenolpyruvate carboxykinase increased, and that of albumin did not change. Run-on transcription assays with isolated nuclei showed inhibition in the relative transcription rate of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase gene and a stimulation of phosphoenolpyruvate carboxykinase gene. The regulation of mRNA stability of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase by glucagon was also studied. The half-life of mRNA decreased in the presence of glucagon, suggesting that proteins modulated by a glucagon-dependent process are regulating its stability. The time course of mRNA levels correlated with the transcription inhibition of gene and destabilization of mRNA, indicating that glucagon modulates 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase gene expression at both transcriptional and posttranscriptional levels.	UNIV BARCELONA,DEPT CIENCIES FISIOL HUMANES & NUTR,UNITAT BIOQUIM,CAMPUS BELLVITGE,E-08907 LHOSPITALET LLOBR,SPAIN	University of Barcelona			Rosa, Jose Luis/K-6685-2014; Ventura, Francesc/ABG-2285-2020; Ventura, Francesc/K-9700-2014; Tauler, Albert/D-5183-2014	Rosa, Jose Luis/0000-0002-6161-5688; Ventura, Francesc/0000-0001-9673-9405; Ventura, Francesc/0000-0001-9673-9405; Tauler, Albert/0000-0003-0193-0667; Bartrons, Ramon/0000-0001-9349-5847				ATWATER JA, 1990, ANNU REV GENET, V24, P519; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARTRONS R, 1983, BIOCHEM J, V214, P829, DOI 10.1042/bj2140829; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHRIST B, 1988, EUR J BIOCHEM, V178, P373, DOI 10.1111/j.1432-1033.1988.tb14460.x; CIFUENTES ME, 1991, J BIOL CHEM, V266, P1557; CLAYTON DF, 1985, MOL CELL BIOL, V5, P2623, DOI 10.1128/MCB.5.10.2623; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; CREPIN KM, 1989, BIOCHEM J, V264, P151, DOI 10.1042/bj2640151; DARVILLE MI, 1987, FEBS LETT, V224, P317, DOI 10.1016/0014-5793(87)80476-3; GIL J, 1986, BIOCHEM BIOPH RES CO, V136, P498, DOI 10.1016/0006-291X(86)90468-7; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; HOD Y, 1988, J BIOL CHEM, V263, P7747; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; IYNEDJIAN PB, 1977, J BIOL CHEM, V252, P655; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JOHNSON TR, 1991, P NATL ACAD SCI USA, V88, P5287, DOI 10.1073/pnas.88.12.5287; KUMMEL L, 1990, BIOCHEM BIOPH RES CO, V169, P406, DOI 10.1016/0006-291X(90)90346-O; LAITINEN J, 1990, J CELL BIOL, V111, P9, DOI 10.1083/jcb.111.1.9; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LANGE AJ, 1989, BIOCHEM BIOPH RES CO, V162, P753, DOI 10.1016/0006-291X(89)92374-7; LANGE AJ, 1992, J BIOL CHEM, V267, P15673; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARKER AJ, 1989, J BIOL CHEM, V264, P7000; MIRALPEIX M, 1992, DIABETOLOGIA, V35, P243, DOI 10.1007/BF00400924; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; ROSA JL, 1990, BIOCHEM J, V270, P645, DOI 10.1042/bj2700645; ROSA JL, 1992, BIOCHEM J, V287, P113, DOI 10.1042/bj2870113; ROSA JL, 1992, P NATL ACAD SCI USA, V89, P3746, DOI 10.1073/pnas.89.9.3746; Sambrook J, 1989, MOL CLONING LABORATO; SARGENT TD, 1979, P NATL ACAD SCI USA, V76, P3256, DOI 10.1073/pnas.76.7.3256; SASAKI K, 1984, J BIOL CHEM, V259, P5242; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VENTURA F, 1991, BIOCHEM J, V276, P455, DOI 10.1042/bj2760455; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	49	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22540	22545						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226764				2022-12-25	WOS:A1993MD34800055
J	OSWALD, F; LOVEC, H; MOROY, T; LIPP, M				OSWALD, F; LOVEC, H; MOROY, T; LIPP, M			E2F-DEPENDENT REGULATION OF HUMAN MYC - TRANSACTIVATION BY CYCLIN-D1 AND CYCLIN-A OVERRIDES TUMOR-SUPPRESSOR PROTEIN FUNCTIONS	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; HUMAN BREAST-CANCER; CELL-CYCLE; C-MYC; MESSENGER-RNA; MOLECULAR-CLONING; BINDING PROTEIN; DNA-BINDING	Transcription of the human proto-oncogene MYC is repressed in quiescent or non-dividing cells. Upon mitogenic stimulation expression of MYC is rapidly and transiently induced, maintained throughout G(1), and declines to a basal level throughout further cell cycle transitions. Regulation of MYC promoter activity critically depends on the presence of a binding site for transcription factor E2F. Human E2F has been implicated also in the control of cell cycle progression through it association with the retinoblastoma suppressor gene product RB, and with multimeric protein complexes containing the G(1)-S- and S-phase cyclins E and A, respectively. Using CAT reporter co-transfection assays we show here that transcription from the MYC P2 promoter is induced efficiently by E2F-1, but repressed by RB. Furthermore, overexpression of cyclin A strongly activates the MYC promoter and this effect is further enhanced by coexpression of E2F-1 and cyclin A. We also find that expression of G(1)-phase cyclin D1 leads to an E2F binding site-dependent trans-activation of the MYC promoter and that this activation can be abrogated by overexpression of RB. The interaction of D-type G(1) cyclins with RB resembles that of the adenovirus E1A protein with RB in that it can disrupt inhibitory E2F-RB complexes. Our results support a model in which intervention of distinct cyclins and their respective associated kinases promotes transcriptional activation of MYC throughout the cell cycle either by conversion of E2F within multimeric complexes into an active transcription factor or by liberation of free functional E2F.	MAX DELBRUCK CTR MOLEC MED, D-13122 BERLIN, GERMANY; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY; UNIV MUNICH, INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Philipps University Marburg; University of Munich			Moroy, Tarik/D-9923-2011; Lipp, Martin/G-2235-2010; Oswald, Franz/AAO-9584-2020	Lipp, Martin/0000-0002-0087-2672				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DESTONE J, 1987, MOL CELL BIOL, V7, P1697; Dobner T, 1991, DNA Seq, V1, P409, DOI 10.3109/10425179109020799; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALL FL, 1993, ONCOGENE, V8, P1377; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HARPER JW, 1993, CELL, V75, P805; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, ONCOGENE, V8, P3447; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LIPP M, 1989, ONCOGENE, V4, P535; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LOVEC H, 1994, ONCOGENE, V9, P323; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEEKER TC, 1989, BLOOD, V74, P1801; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NEVINS JR, 1992, SCIENCE, V258, P424; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; ROSENBERG CL, 1993, ONCOGENE, V8, P519; SCHUURING E, 1992, ONCOGENE, V7, P355; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SETO M, 1992, ONCOGENE, V7, P1401; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SPENCER CA, 1991, ADV CANCER RES, V56, P1; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	74	109	111	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2029	2036						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208548				2022-12-25	WOS:A1994NR68500027
J	THOMASON, PA; JAMES, SR; CASEY, PJ; DOWNES, CP				THOMASON, PA; JAMES, SR; CASEY, PJ; DOWNES, CP			A G-PROTEIN BETA-GAMMA-SUBUNIT-RESPONSIVE PHOSPHOINOSITIDE 3-KINASE ACTIVITY IN HUMAN PLATELET CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THROMBIN-STIMULATED PLATELETS; NUCLEOTIDE-BINDING PROTEIN; RECEPTOR TYROSINE KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; ADENYLYL CYCLASE; ALPHA-SUBUNITS; ADP-RIBOSYLATION; PERTUSSIS TOXIN; SH2 DOMAINS; ACTIVATION	Thrombin activates phosphoinositide 3-kinase (PI 3-kinase) in platelets via a mechanism involving G-proteins, possibly of both the heterotrimeric and the low molecular weight families. We have investigated the regulation of PI 3-kinase present in platelet cytosol, and we show that this activity can be stimulated by a mixed preparation of G-protein beta gamma-subunits. This stimulation is reversed by preincubation of the beta gamma-subunits with GDP-liganded alpha-subunits. The beta gamma-stimulated activity is inhibited by wortmannin, a recently identified inhibitor of PI 3-kinase in other systems. In addition, the activity associates with PDGF receptor phosphotyrosyl peptide and monoclonal antibody designed to interact with the p85 subunit of PI 3-kinase. We suggest that this beta gamma-sensitive activity is related to previously identified forms of PI 3-kinase.	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University	THOMASON, PA (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.			Thomason, Peter/0000-0003-3104-8392; Casey, Patrick/0000-0002-7366-9309				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BRASS LF, 1986, J BIOL CHEM, V261, P6838; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTER AN, 1994, IN PRESS BIOCH J; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Low M. G, 1990, METHODS INOSITIDE RE, P145; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251	39	158	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16525	16528						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206965				2022-12-25	WOS:A1994NR29600002
J	NAKAMURA, S; SUZUKI, H; KANAZAWA, T				NAKAMURA, S; SUZUKI, H; KANAZAWA, T			THE ATP-INDUCED CHANGE OF TRYPTOPHAN FLUORESCENCE REFLECTS A CONFORMATIONAL CHANGE UPON FORMATION OF ADP-SENSITIVE PHOSPHOENZYME IN THE SARCOPLASMIC-RETICULUM CA2+-ATPASE - STOPPED-FLOW SPECTROFLUOROMETRY AND CONTINUOUS-FLOW RAPID QUENCHING METHOD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR LINKED FUNCTIONS; NUCLEOTIDE-BINDING DOMAIN; ADENOSINE-TRIPHOSPHATASE; REACTION-MECHANISM; CATALYTIC SITE; CA-2+-TRANSPORTING ATPASE; INTRINSIC FLUORESCENCE; TRANSPORT ATPASE; TIGHT-BINDING; CA-2+ ATPASE	The ATP-induced change in the tryptophan fluorescence of the Ca2+-ATPase was determined with sarcoplasmic reticulum vesicles at pH 7.0 in the presence of Ca2+ under various conditions by steady-state measurements and stopped-flow spectrofluorometry, Formation of the phosphoenzyme intermediate was also determined by the continuous flow-rapid quenching method. The steady-state fluorescence at 0 degrees C decreased by 1.1% on addition of ATP, whereas no fluorescence change was induced by adenosine 5'-(beta,gamma-methylene)triphosphate (a nonhydrolyzable ATP analog incapable of phosphorylating the enzyme). The time course of the ATP-induced fluorescence drop agreed well with that of the phosphoenzyme formation under all of the conditions tested, and the phosphoenzyme formed was largely sensitive to ADP. When phosphoenzyme isomerization from the ADP-sensitive form to the ADP-insensitive form was almost completely prevented by N-ethylmaleimide treatment, the time course of the ATP induced fluorescence drop again agreed with that of the phosphoenzyme formation. These results show that the ATP-induced fluorescence drop occurs upon formation of the ADP-sensitive phosphoenzyme. The results further indicate that the tryptophan fluorescence of this enzyme is insensitive to the conformational change which was previously shown (Suzuki, H., Obara, M., Kuwayama, H., and Kanazawa, T. (1987) J. Biol. Chem. 262, 15448-15456) to occur upon formation of the calcium enzyme-substrate complex. Thus, we conclude that the ATP-induced drop in the tryptophan fluorescence reflects a conformational change occurring upon formation of the ADP-sensitive phosphoenzyme.	ASAHIKAWA MED COLL, DEPT BIOCHEM, ASAHIKAWA 078, JAPAN; ASAHIKAWA MED COLL, DEPT DERMATOL, ASAHIKAWA 078, HOKKAIDO, JAPAN	Asahikawa Medical College; Asahikawa Medical College								ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BASTIDE F, 1973, Journal of Biological Chemistry, V248, P8385; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHAMPEIL P, 1986, FEBS LETT, V206, P93, DOI 10.1016/0014-5793(86)81347-3; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; DEFORESTA B, 1990, EUR J BIOCHEM, V194, P383; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; DUPONT Y, 1978, NATURE, V273, P396, DOI 10.1038/273396a0; DUPONT Y, 1985, STRUCTURE FUNCTION S, P225; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; HARA H, 1986, J BIOL CHEM, V261, P6584; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; INESI G, 1992, ANN NY ACAD SCI, V671, P32, DOI 10.1111/j.1749-6632.1992.tb43782.x; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; KANAZAWA T, 1970, J BIOCHEM-TOKYO, V68, P593, DOI 10.1093/oxfordjournals.jbchem.a129392; KAWAKITA M, 1980, J BIOCHEM, V87, P609, DOI 10.1093/oxfordjournals.jbchem.a132785; KUBO K, 1990, BIOCHIM BIOPHYS ACTA, V1040, P251, DOI 10.1016/0167-4838(90)90084-S; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LACAPERE JJ, 1990, J BIOL CHEM, V265, P8583; LACAPERE JJ, 1993, BIOCHEMISTRY-US, V32, P3414, DOI 10.1021/bi00064a027; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINOSE M, 1967, PFLUG ARCH GES PHYS, V294, pR82; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; OBARA M, 1988, J BIOL CHEM, V263, P3690; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P356, DOI 10.1021/bi00052a044; SUZUKI H, 1987, J BIOL CHEM, V262, P15448; TAKAKUWA Y, 1979, BIOCHEM BIOPH RES CO, V88, P1209, DOI 10.1016/0006-291X(79)91108-2; TAKISAWA H, 1981, NATURE, V290, P271, DOI 10.1038/290271a0; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; YAMADA S, 1980, J BIOL CHEM, V255, P3108; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P452, DOI 10.1093/oxfordjournals.jbchem.a122291; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; YAMASAKI K, 1994, J BIOL CHEM, V269, P4129	48	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16015	16019						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206898				2022-12-25	WOS:A1994NQ72900013
J	WU, YY; LOCKYER, JM; SUGIYAMA, E; PAVLOVA, NV; LI, YT; LI, SC				WU, YY; LOCKYER, JM; SUGIYAMA, E; PAVLOVA, NV; LI, YT; LI, SC			EXPRESSION AND SPECIFICITY OF HUMAN G(M2) ACTIVATOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HEXOSAMINIDASE-A; ENZYMIC-HYDROLYSIS; GM2 GANGLIOSIDOSIS; SULFATIDE ACTIVATOR; CERAMIDE GLYCANASE; ESCHERICHIA-COLI; HUMAN-BRAIN; DEGRADATION; SAP-1; GENE	The cDNA encoding G(M2) activator was expressed in the Escherichia coli/pT7-7 system. The yield of the G(M2) activator with greater than 99% purity was about 3 mg per liter culture. The recombinant G(M2) activator was found to be as active as that isolated from human kidney. The availability of the recombinant G(M2) activator enabled us to critically examine the specificity of this activator protein. Our results show that the specificity of G(M2) activator is not as strict as that reported previously. Although G(M2) activator stimulates most efficiently the degradation of G(M2) carried out by beta-N-acetylhexosaminidase A (Hex A), this activator also stimulates the following reactions: (a) conversion of G(M2) to G(A2) by clostridial sialidase; (b) hydrolysis of GalNAc from dipalmitoylphosphatidylethanolamine-II(3)NeuAcGgOse(3) by Hex A; and (c) liberation of Gal from G(M1) by beta-galactosidase at a high activator concentration. Thus, this activator does not differentiate between G(M2) and dipalmitoylphosphatidylethanolamine-II(3)NeuAcGgOse(3) or between Hex A and clostridial sialidase. The micellar forms of G(D2) and GalNAc-G(D1a) were found to be more readily hydrolyzed by Hex A than G(M2) in the absence of G(M2) activator. Our results also show that saposin B can enhance the stimulatory activity of G(M2) activator, but it cannot promote the stimulatory activity of sodium taurodeoxycholate. Taken together, our results suggest that the mechanism of action of G(M2) activator is different from saposin B, and the action of G(M2) activator is more than to solubilize lipid substrates. The effectiveness of G(M2) activator in stimulating the hydrolysis of G(M2) may be due to its abil ity to recognize the specific trisaccharide structure of the G(M2) epitope, GalNAc beta 1 --> 4(NeuAc alpha 2 --> 3)Gal-, and to modify the GalNAc-NeuAc interaction in this structure.	TULANE UNIV,SCH MED,DEPT BIOCHEM,NEW ORLEANS,LA 70112; TULANE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA 70112	Tulane University; Tulane University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 09626] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO S, 1989, J BIOL CHEM, V264, P3478; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BURG J, 1985, ANN HUM GENET, V49, P41, DOI 10.1111/j.1469-1809.1985.tb01674.x; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; FUJIBAYASHI S, 1985, AM J HUM GENET, V37, P741; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; HARRIS G, 1954, CHEM IND-LONDON, P249; HECHTMAN P, 1982, PEDIATR RES, V16, P217, DOI 10.1203/00006450-198203000-00011; HIRABAYASHI Y, 1983, J NEUROCHEM, V40, P168, DOI 10.1111/j.1471-4159.1983.tb12667.x; INUI K, 1985, HUM GENET, V69, P197, DOI 10.1007/BF00293023; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLIMA H, 1993, BIOCHEM J, V292, P571, DOI 10.1042/bj2920571; KOERNER TAW, 1983, BIOCHEMISTRY-US, V22, P2676, DOI 10.1021/bi00280a014; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVERY SB, 1991, GLYCOCONJUGATE J, V8, P484, DOI 10.1007/BF00769848; LI SC, 1970, J BIOL CHEM, V245, P5153; LI SC, 1988, J BIOL CHEM, V263, P6588; LI SC, 1982, METHOD ENZYMOL, V83, P588; LI SC, 1981, J BIOL CHEM, V256, P6234; LI SC, 1976, J BIOL CHEM, V251, P1159; LI YT, 1991, J BIOL CHEM, V266, P10723; LI YT, 1973, J BIOL CHEM, V248, P7512; LI YT, 1984, LYSOSOM BIOL PATHOL, P99; MARSTON FAO, 1984, BIO-TECHNOL, V2, P800, DOI 10.1038/nbt0984-800; MEIER EM, 1991, J BIOL CHEM, V266, P1879; MURAYAMA JI, 1979, ANAL BIOCHEM, V73, P535; NAGARAJAN S, 1992, BIOCHEM J, V282, P807, DOI 10.1042/bj2820807; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; PASCHER I, 1977, CHEM PHYS LIPIDS, V20, P175, DOI 10.1016/0009-3084(77)90033-0; RADIN NS, 1972, METHOD ENZYMOL, V28, P300; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARSDALE JN, 1990, BIOCHEMISTRY-US, V29, P9843, DOI 10.1021/bi00494a014; SCHRODER M, 1989, FEBS LETT, V251, P197, DOI 10.1016/0014-5793(89)81454-1; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; SVENNERHOLM L, 1972, METHODS CARBOHYD CHE, V6, P464; TANG PW, 1985, BIOCHEM BIOPH RES CO, V132, P474, DOI 10.1016/0006-291X(85)91158-1; UDA Y, 1977, J BIOL CHEM, V252, P5194; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WU YY, 1993, T AM SOC NEUROCHEM, V24, P187; WYNN CH, 1986, BIOCHEM J, V240, P921, DOI 10.1042/bj2400921; XIE B, 1991, BIOCHEM BIOPH RES CO, V177, P1217, DOI 10.1016/0006-291X(91)90671-S; ZHOU B, 1989, J BIOL CHEM, V264, P12272	46	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16276	16283						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206933				2022-12-25	WOS:A1994NQ72900051
J	ZOLKIEWSKA, A; MOSS, J				ZOLKIEWSKA, A; MOSS, J			INTEGRIN-ALPHA-7 AS SUBSTRATE FOR A GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED ADP-RIBOSYLTRANSFERASE ON THE SURFACE OF SKELETAL-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RIBOSYLATION; PROTEINS; BINDING; INTEGRINS; ADHESION; LAMININ; ADULT	An arginine-specific mono-ADP-ribosyltransferase is expressed on the surface of differentiated mouse skeletal muscle cells and is anchored in the membrane via a glycosylphosphatidylinositol tail. Following incubation of intact cells with [adenylate-P-32]NAD and analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), a 97-kDa [P-32]ADP-ribosylated protein was observed under reducing conditions and a 140-kDa complex under nonreducing conditions. The ADP-ribosylated protein was purified on a laminin affinity column. Based on its N-terminal sequence (FNLDVMGAIRKEGEPGSLFGF) and a partial internal sequence (GLMRSEELSFVAGAP), the modified protein was identified as integrin alpha7. Following partial trypsin digestion, a 39-kDa/79-kDa radiolabeled fragment was produced (reduced/nonreduced SDS-PAGE), narrowing the ADP-ribosylation site to a 39-kDa segment in the extracellular domain of integrin alpha7. Labeling under optimal conditions was at least 0.4 mol of ADP-ribose/mol of integrin alpha7. Selective expression of both ADP-ribosyltransferase and integrin alpha7 in cardiac and skeletal muscle, a similar developmental appearance, and the apparently specific ADP-ribosylation, are consistent with a regulatory association between these proteins. ADP-ribosylation may modulate integrin receptor signaling and could play a significant role in the regulation of muscle cell function by the extracellular matrix.			ZOLKIEWSKA, A (corresponding author), NHLBI,CELLULAR METAB LAB,BLDG 10,RM 5N307,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BOZYCZKO D, 1989, EXP CELL RES, V183, P72, DOI 10.1016/0014-4827(89)90419-9; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FERGUSON MAJ, 1992, BIOCHEM SOC T, V20, P243, DOI 10.1042/bst0200243; HARA N, 1987, BIOCHEM BIOPH RES CO, V148, P989, DOI 10.1016/S0006-291X(87)80229-2; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAUFMAN SJ, 1985, DEV BIOL, V110, P1, DOI 10.1016/0012-1606(85)90057-0; KHARADIA SV, 1992, EXP CELL RES, V201, P33, DOI 10.1016/0014-4827(92)90345-9; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MEYER T, 1988, BIOL CHEM H-S, V369, P579, DOI 10.1515/bchm3.1988.369.2.579; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; PAYNE DM, 1985, BIOCHEMISTRY-US, V24, P7540, DOI 10.1021/bi00347a006; PETERSON JE, 1990, J BIOL CHEM, V265, P17062; PIRON KJ, 1990, BIOCHEM J, V270, P591, DOI 10.1042/bj2700591; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMSON KC, 1990, ADP RIBOSYLATING TOX, P151; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	21	141	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25273	25276						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244957				2022-12-25	WOS:A1993MK10000004
J	REYNISDOTTIR, I; LORIMER, HE; FRIEDMAN, PN; WANG, EH; PRIVES, C				REYNISDOTTIR, I; LORIMER, HE; FRIEDMAN, PN; WANG, EH; PRIVES, C			PHOSPHORYLATION AND ACTIVE ATP HYDROLYSIS ARE NOT REQUIRED FOR SV40 T-ANTIGEN HEXAMER FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-ANTIGEN; DNA-POLYMERASE-ALPHA; REPLICATION PROTEIN-A; VIRUS-40 CORE ORIGIN; SIMIAN VIRUS-40; BINDING-SITE; HELICASE ACTIVITIES; STRUCTURAL-CHANGES; UNWINDING ACTIVITY; INSECT CELLS	ATP induces structural alterations in SV40 large T antigen and promotes changes in its interaction with the viral replication origin. We have analyzed nucleotide-induced changes in T antigen structure in the absence of origin DNA. Most preparations of immunopurified T antigen contain several discrete species ranging in size from monomers through oligomers larger than hexamers. The predominant species consist of monomers and dimers. Incubation of T antigen with ATP or dATP leads to a dramatic and rapid increase in the appearance of T antigen hexamers. Weakly and nonhydrolyzable analogs of ATP are effective as well, indicating that hexamer formation does not require active ATP hydrolysis. After incubation of T antigen with [gamma-S-35]ATP, stable association of the labeled nucleotide with all detectable forms occurs. Removal of greater than 80% of the T antigen phosphate residues does not significantly affect the formation of T antigen hexamers, although changes in the distribution and mobility of the other species of T antigen are apparent. Furthermore, T antigen synthesized in and purified from Escherichia coli and, therefore, presumably un- or underphosphorylated, is capable of forming hexamers. Nucleotide-induced T antigen hexamer formation thus appears to require neither protein phosphorylation nor active ATP hydrolysis.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University				Reynisdottir, Inga/0000-0002-9730-7476	NCI NIH HHS [CA26905] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026905] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; BOROWIEC JA, 1991, J VIROL, V65, P1228, DOI 10.1128/JVI.65.3.1228-1235.1991; BRADLEY MK, 1987, P NATL ACAD SCI USA, V84, P4026, DOI 10.1073/pnas.84.12.4026; BRADLEY MK, 1990, J VIROL, V64, P4939, DOI 10.1128/JVI.64.10.4939-4947.1990; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CLERTANT P, 1982, J BIOL CHEM, V257, P6300; CLERTANT P, 1984, J BIOL CHEM, V259, P5196; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; DAN FB, 1992, J BIOL CHEM, V267, P14129; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1991, J BIOL CHEM, V266, P5062; DEAN P, 1988, TRENDS BIOTECHNOL, V6, P113, DOI 10.1016/0167-7799(88)90099-6; DEB S, 1987, J VIROL, V61, P2143, DOI 10.1128/JVI.61.7.2143-2149.1987; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DELUCIA AL, 1983, J VIROL, V46, P143, DOI 10.1128/JVI.46.1.143-150.1983; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GIACHERIO D, 1979, J BIOL CHEM, V254, P8113; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GRASSER FA, 1987, J VIROL, V61, P3373; Griffin J D, 1980, Cold Spring Harb Symp Quant Biol, V44 Pt 1,, P113; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOSS A, 1990, J VIROL, V64, P4799; JONES KA, 1984, CELL, V36, P155, DOI 10.1016/0092-8674(84)90084-9; KLAUSING K, 1988, J VIROL, V62, P1258, DOI 10.1128/JVI.62.4.1258-1265.1988; LORIMER HE, 1991, J VIROL, V65, P687, DOI 10.1128/JVI.65.2.687-699.1991; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; MOHR IJ, 1989, P NATL ACAD SCI USA, V86, P6479, DOI 10.1073/pnas.86.17.6479; MYERS RM, 1980, P NATL ACAD SCI-BIOL, V77, P6491, DOI 10.1073/pnas.77.11.6491; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PARSONS R, 1992, J VIROL, V66, P1933, DOI 10.1128/JVI.66.4.1933-1942.1992; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; REYNISDOTTIR I, 1992, J VIROL, V66, P6517; REYNISDOTTIR I, 1990, J VIROL, V64, P6234; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TJIAN R, 1979, P NATL ACAD SCI USA, V76, P610, DOI 10.1073/pnas.76.2.610; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P42883; WANG EH, 1991, VIROLOGY, V184, P399, DOI 10.1016/0042-6822(91)90858-9; WANG EH, 1991, J BIOL CHEM, V266, P12668; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	57	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24647	24654						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227024				2022-12-25	WOS:A1993MG67300024
J	WEDEGAERTNER, PB; CHU, DH; WILSON, PT; LEVIS, MJ; BOURNE, HR				WEDEGAERTNER, PB; CHU, DH; WILSON, PT; LEVIS, MJ; BOURNE, HR			PALMITOYLATION IS REQUIRED FOR SIGNALING FUNCTIONS AND MEMBRANE ATTACHMENT OF G(Q)ALPHA AND G(S)ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNIT; GS-ALPHA; BETA-GAMMA; COS CELLS; BINDING; ASSOCIATION; RECEPTOR; SITE; IDENTIFICATION; STIMULATION	We have identified the palmitoylated cysteine residues of alpha(q) and alpha(s), alpha subunits of two heterotrimeric G proteins. Mutational substitutions of serines for cysteines 9 and 10 in alpha(q) and cysteine 3 in alpha(s) profoundly alter behavior of the subunits expressed in HEK293 cells. Neither mutant alpha subunit incorporates palmitate; both mutant proteins are found in the soluble rather than the particulate fraction; mutant alpha(q) or alpha(s) cannot couple a co-expressed receptor to stimulation of phospholipase C or adenylylcyclase, respectively, cysteine substitution prevents a mutationally activated alpha(q) (R183C) from stimulating phospholipase C directly, and reduces but does not abolish the ability of a similarly activated alpha(s) (R201C) to stimulate cAMP synthesis. Substitution of a myristoylation sequence for the palmitoylation sites leads to labeling of alpha(q) and alpha(s) by myristate, rather than by palmitate. Myristoylation restores the abilities of both nonpalmitoylated alpha(q) and alpha(s) to attach to membranes and, in the case of alpha(q), restores its ability to stimulate phospholipase C, whether triggered by the R183C mutation or by receptor activation. These findings identify palmitoylation as a critical determinant of membrane attachment for alpha(q) and alpha(s) and show that this modification is required for normal signaling by these proteins.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT PHARMACOL,S1212,BOX 0450,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027800, R01GM027800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K21MH000961] Funding Source: NIH RePORTER; NCI NIH HHS [CA-54427] Funding Source: Medline; NIGMS NIH HHS [GM-27800] Funding Source: Medline; NIMH NIH HHS [K21MH00961] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERGER M, 1984, J BIOL CHEM, V259, P7245; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4263; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHAPMAN ER, 1992, J BIOL CHEM, V267, P25233; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; FIRNBAUMER L, 1990, ANN REV PHARM TOXICO, V30, P675; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; INIQUAZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES TL, 1990, P NATL ACAD SCI USA, V57, P568; JOURNOT L, 1991, P NATL ACAD SCI USA, V88, P10054, DOI 10.1073/pnas.88.22.10054; JUHNN YS, 1992, J CELL BIOL, V119, P523, DOI 10.1083/jcb.119.3.523; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUSZBEK L, 1993, J BIOL CHEM, V268, P8251; NEGISHI M, 1992, J BIOL CHEM, V267, P2364; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PANG IH, 1990, J BIOL CHEM, V265, P18707; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	51	277	281	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25001	25008						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227063				2022-12-25	WOS:A1993MG67300072
J	CHIESA, GL; JOHNSON, DF; YAO, ZM; INNERARITY, TL; MAHLEY, RW; YOUNG, SG; HAMMER, RH; HOBBS, HH				CHIESA, GL; JOHNSON, DF; YAO, ZM; INNERARITY, TL; MAHLEY, RW; YOUNG, SG; HAMMER, RH; HOBBS, HH			EXPRESSION OF HUMAN APOLIPOPROTEIN B100 IN TRANSGENIC MICE - EDITING OF HUMAN APOLIPOPROTEIN-B100 MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LOW-DENSITY-LIPOPROTEIN; RAT-LIVER; MONOCLONAL-ANTIBODIES; CHOROID-PLEXUS; STOP CODON; B GENE; APO-B; INTESTINE; ELEMENTS; INVITRO	Apolipoprotein B (apoB) is a large glycoprotein that circulates in plasma as a major constituent of numerous lipoproteins. ApoB exists in two forms: apoB48 and apoB100. ApoB48 is identical in sequence to the N-terminal region of apoB100 and is generated by sequence-specific mRNA editing of the apoB100 transcript. Here, we describe the development of a line of mice expressing a human apoB transgene driven by promoter/enhancer sequences from the transthyretin gene. In these mice, immunodetectable human apoB100 is synthesized by the liver, kidney, and brain. Human apoB100 is found in low concentration (approximately 0.1 mg/dl) in the plasma of the transgenic mice and circulates in the low density lipoprotein fraction. The hepatic human apoB100 transcripts undergo mRNA editing at only slightly lower efficiency than the endogenous mouse apoB100 message. Therefore, there is no absolute species specificity to the apoB100 mRNA editing process.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,DEPT PATHOL & MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of Alberta; University of Alberta			Chiesa, Giulia/G-8987-2012	Chiesa, Giulia/0000-0001-5553-1210; Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL-47619, HL-47660, HL-20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660, R01HL047619, P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; BAUM CL, 1990, J BIOL CHEM, V265, P19263; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; BROOKS AR, 1992, MOL CELL BIOL, V12, P1134, DOI 10.1128/MCB.12.3.1134; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHIESA G, 1992, J BIOL CHEM, V267, P24369; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COSTA RH, 1990, P NATL ACAD SCI USA, V87, P6589, DOI 10.1073/pnas.87.17.6589; CURTISS LK, 1982, J BIOL CHEM, V257, P14213; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; GARCIA ZC, 1992, ARTERIOSCLER THROMB, V12, P172, DOI 10.1161/01.ATV.12.2.172; GLICKMAN RM, 1986, P NATL ACAD SCI USA, V83, P5296, DOI 10.1073/pnas.83.14.5296; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HIGUCHI K, 1992, J LIPID RES, V33, P1753; JOHNSON DF, 1993, BIOCHEM BIOPH RES CO, V195, P1204, DOI 10.1006/bbrc.1993.2172; KRUL ES, 1988, J LIPID RES, V29, P937; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; MILNE R, 1989, J BIOL CHEM, V264, P19754; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; PEASE RJ, 1990, J BIOL CHEM, V265, P553; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1990, BIOCHEM BIOPH RES CO, V173, P74, DOI 10.1016/S0006-291X(05)81023-X; TENNYSON GE, 1989, P NATL ACAD SCI USA, V86, P500, DOI 10.1073/pnas.86.2.500; TOLLESHAUG H, 1983, CELL, V32, P941, DOI 10.1016/0092-8674(83)90079-X; WU JH, 1990, J BIOL CHEM, V265, P12312; XIONG WJ, 1992, J BIOL CHEM, V267, P21412; XIONG WJ, 1993, J BIOL CHEM, V268, P17647; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; YAO ZM, 1992, J BIOL CHEM, V267, P1175; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	36	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23747	23750						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226902				2022-12-25	WOS:A1993MF29400004
J	HANAI, R; WANG, JC				HANAI, R; WANG, JC			THE MECHANISM OF SEQUENCE-SPECIFIC DNA CLEAVAGE AND STRAND TRANSFER BY PHI-X174 GENE-A-ASTERISK PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; BACTERIOPHAGE-PHI-X174 GENE; MEDIATED TERMINATION; PHI-X; REPLICATION; RECOMBINATION; REINITIATION; GENOME; ORIGIN; SITE	We have examined the biological role and catalytic function of two juxtaposed tyrosyl residues in the bacteriophage phiX174 gene A protein, Tyr-343 and Tyr-347, which have been implicated in the catalysis of sequence-specific DNA strand transfer. Site-directed mutagenesis changing either tyrosine to phenylalanine abolishes phage viability. The biochemical basis of this inviability was studied using purified A* protein containing the carboxyl-terminal 341 amino acids of the A protein, as well as purified A* protein with a Y343F or Y347F mutation. All three proteins can cleave the phiX174 replication origin and perform strand transfer between oligodeoxy-nucleotides bearing the recognition sequence of the A protein; however, both Tyr-343 and Tyr-347 appear to be required for coordinated DNA strand transfer by a single A* protein molecule. The chirality of a phosphorothioate group at the site of strand transfer in the DNA was found to be retained following the strand-transfer reaction, which argues against transfer of Tyr-343-linked DNA to Tyr-347 on the same protein molecule or vice versa. These results support the current model of gene A protein function in which the two tyrosines of a single protein molecule alternate in catalyzing DNA strand transfer at the viral replication origin.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University				Hanai, Ryo/0000-0002-6561-7613	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024544, R01GM024544] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24544] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN DR, 1984, J BIOL CHEM, V259, P545; COLASANTI J, 1985, J VIROL, V53, P807, DOI 10.1128/JVI.53.3.807-813.1985; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DEMPSEY LA, 1992, P NATL ACAD SCI USA, V89, P3083, DOI 10.1073/pnas.89.7.3083; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; EISENBERG S, 1977, P NATL ACAD SCI USA, V74, P3198, DOI 10.1073/pnas.74.8.3198; EISENBERG S, 1980, NUCLEIC ACIDS RES, V8, P5305; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FERSHT A, 1984, ENZYME STRUCTURE MEC, P221; FLUIT AC, 1985, EUR J BIOCHEM, V149, P579, DOI 10.1111/j.1432-1033.1985.tb08964.x; GODSON GN, 1973, BIOCHIM BIOPHYS ACTA, V299, P516, DOI 10.1016/0005-2787(73)90223-2; GODSON GN, 1978, SINGLE STRANDED DNA, P51; Hayashi M., 1988, BACTERIOPHAGES, V2, P1; KODAIRA KI, 1992, BIOCHIM BIOPHYS ACTA, V1130, P277, DOI 10.1016/0167-4781(92)90440-B; KORNBERG A, 1992, DNA REPLICATION, P298; LANGEVELD SA, 1978, NATURE, V271, P417, DOI 10.1038/271417a0; LANGEVELD SA, 1979, NUCLEIC ACIDS RES, V7, P2177, DOI 10.1093/nar/7.8.2177; LANGEVELD SA, 1981, NUCLEIC ACIDS RES, V9, P545, DOI 10.1093/nar/9.3.545; LANGEVELD SA, 1980, FEBS LETT, V114, P269, DOI 10.1016/0014-5793(80)81131-8; LAU PCK, 1985, GENE, V40, P273, DOI 10.1016/0378-1119(85)90050-2; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; ROTH MJ, 1984, J BIOL CHEM, V259, P556; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SANHUEZA S, 1984, P NATL ACAD SCI-BIOL, V81, P4285, DOI 10.1073/pnas.81.14.4285; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMAS CD, 1990, J BIOL CHEM, V265, P5519; VANDERAVOORT HGAM, 1983, BIOCHIM BIOPHYS ACTA, V741, P94, DOI 10.1016/0167-4781(83)90014-3; VANDERENDE A, 1981, NUCLEIC ACIDS RES, V9, P2037, DOI 10.1093/nar/9.9.2037; VANDERENDE A, 1984, ADV EXP MED BIOL, V179, P221; VANMANSFELD ADM, 1986, NUCLEIC ACIDS RES, V14, P4229, DOI 10.1093/nar/14.10.4229; VANMANSFELD ADM, 1980, NATURE, V288, P561, DOI 10.1038/288561a0; Wang J.C., 1979, MOL GENETICS, P65, DOI [10.1016/B978-0-12-684403-0.50009-5., DOI 10.1016/B978-0-12-684403-0.50009-5]; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	36	54	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23830	23836						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226920				2022-12-25	WOS:A1993MF29400022
J	LADERMAN, KA; ASADA, K; UEMORI, T; MUKAI, H; TAGUCHI, Y; KATO, I; ANFINSEN, CB				LADERMAN, KA; ASADA, K; UEMORI, T; MUKAI, H; TAGUCHI, Y; KATO, I; ANFINSEN, CB			ALPHA-AMYLASE FROM THE HYPERTHERMOPHILIC ARCHAEBACTERIUM PYROCOCCUS-FURIOSUS - CLONING AND SEQUENCING OF THE GENE AND EXPRESSION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOGLOMUS-THERMOPHILUM; NUCLEOTIDE-SEQUENCE; AMYLOLYTIC ENZYME; SP-NOV; TRANSCRIPTION; SULFOLOBUS; PHYLOGENY	A gene encoding a highly thermostable alpha-amylase from the hyperthermophilic archaebacterium Pyrococcus furiosus was cloned and expressed in Escherichia coli. The nucleotide sequence of the gene predicts a 649-amino acid protein with a calculated molecular mass of 76.3 kDa, which corresponds well with the value obtained from purified enzyme using denaturing polyacrylamide gel electrophoresis. The NH2 terminus of the deduced amino acid sequence corresponds precisely to that obtained from the purified enzyme, excluding the NH2-terminal methionine. The amylase expressed in E. coli exhibits temperature-dependent activation characteristic of the original enzyme from P. furiosus, but has a higher apparent molecular weight which is attributed to the improper formation of the native quaternary structure. No homology was found with previously characterized promotor or termination sequences. The deduced amino acid sequence displayed strong homology to the alpha-amylase A of Dictyoglomus thermophilum, an obligately anaerobic, extremely thermophilic bacterium. Evolutionary implications of this homology are discussed.	JOHNS HOPKINS UNIV,DEPT BIOL,34TH & CHARLES ST,BALTIMORE,MD 21218; TAKARA SHUZO CO,OTSU,SHIGA 52021,JAPAN	Johns Hopkins University; Takara Holdings Inc.								BAHL H, 1991, APPL ENVIRON MICROB, V57, P1554, DOI 10.1128/AEM.57.5.1554-1559.1991; BROWN SH, 1990, APPL ENVIRON MICROB, V56, P1985, DOI 10.1128/AEM.56.7.1985-1991.1990; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FOX GE, 1980, SCIENCE, V209, P457, DOI 10.1126/science.6771870; FUKUSUMI S, 1988, EUR J BIOCHEM, V174, P15, DOI 10.1111/j.1432-1033.1988.tb14056.x; KOCH R, 1990, FEMS MICROBIOL LETT, V71, P21, DOI 10.1111/j.1574-6968.1990.tb03792.x; LADERMAN KA, 1993, J BIOL CHEM, V268, P24394; LUTHI E, 1990, APPL ENVIRON MICROB, V56, P1017; PACE NR, 1986, CELL, V45, P325, DOI 10.1016/0092-8674(86)90315-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REITER WD, 1988, NUCLEIC ACIDS RES, V16, P1, DOI 10.1093/nar/16.1.1; REITER WD, 1988, NUCLEIC ACIDS RES, V16, P2445, DOI 10.1093/nar/16.6.2445; SAIKI T, 1985, INT J SYST BACTERIOL, V35, P253, DOI 10.1099/00207713-35-3-253; SAMBROOK J, 1986, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TODA H, 1982, P JPN ACAD B-PHYS, V58, P208, DOI 10.2183/pjab.58.208; TSUKAGOSHI N, 1985, J BACTERIOL, V164, P1182, DOI 10.1128/JB.164.3.1182-1187.1985; Woese C.R., 1985, BACTERIA; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZWICKL P, 1990, J BACTERIOL, V172, P4329, DOI 10.1128/jb.172.8.4329-4338.1990	20	105	113	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24402	24407						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226990				2022-12-25	WOS:A1993MF29400101
J	TERAOKA, H; MINAMI, H; IIJIMA, S; TSUKADA, K; KOIWAI, O; DATE, T				TERAOKA, H; MINAMI, H; IIJIMA, S; TSUKADA, K; KOIWAI, O; DATE, T			EXPRESSION OF ACTIVE HUMAN DNA LIGASE-I IN ESCHERICHIA-COLI-CELLS THAT HARBOR A FULL-LENGTH DNA LIGASE-I CDNA CONSTRUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALF THYMUS; RAT-LIVER; DROSOPHILA-MELANOGASTER; FUNCTIONAL EXPRESSION; CATALYTIC DOMAIN; MAMMALIAN-CELLS; MOLECULAR-FORMS; BLOOMS SYNDROME; PURIFICATION; PROTEIN	A recombinant plasmid for expression of full-length human DNA ligase I (phLig-I) was constructed in a plasmid/phage chimeric vector, pTD-T7N, which was derived from pUC118 by oligonucleotide-directed mutagenesis. The insert contained a 2757-base pair coding sequence for a whole human DNA ligase I and an extra ACC codon adjacent to the ATG initiation codon. This ACC codon was required for achieving high levels of expression of full-length DNA ligase I in Escherichia coli strain BL21. The recombinant plasmid, which was designed to exploit the T7 late promoter and the ATG initiation codon for beta-galactosidase was transfected into E. coli BL21 cells that express T7 RNA polymerase. The recombinant clone produced relatively high levels of DNA ligase I with a molecular mass of 130 kDa, as estimated by SDS-polyacrylamide gel electrophoresis. The DNA ligase was purified to near-homogeneity by the two-step column chromatographic procedure from BLphLig-I cells that had been induced with isopropyl beta-D-thiogalactoside. The specific activity, chromatographic behavior, kinetic properties, molecular mass, and antigenicity of the recombinant human DNA ligase I were indistinguishable from those of purified mammalian DNA ligase I. Metabolically labeling experiments with P-32(i) indicate that the recombinant DNA ligase I was present as an enzyme-AMP reaction intermediate, but not as a phosphoprotein, in the E. coli cells.	TOKYO MED & DENT UNIV,MED RES INST,DEPT PATHOL BIOCHEM,TOKYO 101,JAPAN; AICHI CANC CTR,RES INST,BIOCHEM LAB,NAGOYA,AICHI 464,JAPAN	Tokyo Medical & Dental University (TMDU); Aichi Cancer Center	TERAOKA, H (corresponding author), KANAZAWA MED SCH,DEPT BIOCHEM,ISHIKAWA 92002,JAPAN.							ARRAND JE, 1986, J BIOL CHEM, V261, P9079; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN JYH, 1985, CARCINOGENESIS, V6, P1275, DOI 10.1093/carcin/6.9.1275; DATE T, 1990, GENE, V90, P141, DOI 10.1016/0378-1119(90)90450-6; ELDER RH, 1992, EUR J BIOCHEM, V203, P53, DOI 10.1111/j.1432-1033.1992.tb19826.x; ELDER RH, 1990, BIOCHEMISTRY-US, V29, P6009, DOI 10.1021/bi00477a019; HIGASHITANI A, 1990, CELL STRUCT FUNCT, V15, P67, DOI 10.1247/csf.15.67; IIJIMA S, 1992, EUR J BIOCHEM, V206, P595, DOI 10.1111/j.1432-1033.1992.tb16964.x; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; KURIHARA T, 1991, JPN J CANCER RES, V82, P51, DOI 10.1111/j.1349-7006.1991.tb01745.x; MEZZINA M, 1982, NUCLEIC ACIDS RES, V10, P5073, DOI 10.1093/nar/10.16.5073; NAKAYA N, 1977, J BIOCHEM-TOKYO, V81, P1575; PETRINI JHJ, 1991, P NATL ACAD SCI USA, V88, P7615, DOI 10.1073/pnas.88.17.7615; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; SODERHALL S, 1976, FEBS LETT, V67, P1, DOI 10.1016/0014-5793(76)80858-7; SODERHALL S, 1976, NATURE, V260, P640, DOI 10.1038/260640a0; SODERHALL S, 1975, J BIOL CHEM, V250, P8438; SODERHALL S, 1973, BIOCHEM BIOPH RES CO, V53, P910, DOI 10.1016/0006-291X(73)90178-2; STUDIER F, 1986, J MOL BIOL, V189, P141; TAKAHASHI M, 1987, FEBS LETT, V213, P345, DOI 10.1016/0014-5793(87)81520-X; TAKAHASHI M, 1990, EUR J BIOCHEM, V192, P735, DOI 10.1111/j.1432-1033.1990.tb19284.x; TERAOKA H, 1984, J BIOCHEM-TOKYO, V95, P1529, DOI 10.1093/oxfordjournals.jbchem.a134763; TERAOKA H, 1975, FEBS LETT, V54, P217, DOI 10.1016/0014-5793(75)80077-9; TERAOKA H, 1979, BIOCHIM BIOPHYS ACTA, V563, P535, DOI 10.1016/0005-2787(79)90072-8; TERAOKA H, 1986, BIOCHIM BIOPHYS ACTA, V873, P297, DOI 10.1016/0167-4838(86)90057-9; TERAOKA H, 1981, BIOCHIM BIOPHYS ACTA, V653, P408, DOI 10.1016/0005-2787(81)90196-9; TERAOKA H, 1987, J BIOCHEM-TOKYO, V101, P225, DOI 10.1093/oxfordjournals.jbchem.a121895; TERAOKA H, 1986, J BIOL CHEM, V261, P6888; TERAOKA H, 1992, BIOCHEM INT, V26, P963; TERAOKA H, 1983, BIOCHIM BIOPHYS ACTA, V747, P117, DOI 10.1016/0167-4838(83)90129-2; TERAOKA H, 1989, BIOCHEM INT, V18, P1203; TERAOKA H, 1982, J BIOL CHEM, V257, P4758; TERAOKA H, 1977, J BIOCHEM-TOKYO, V81, P1253; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; TSUKADA K, 1971, BIOCHEM BIOPH RES CO, V42, P1156, DOI 10.1016/0006-291X(71)90026-X; TSUKADA K, 1974, BIOCHEM BIOPH RES CO, V57, P758, DOI 10.1016/0006-291X(74)90611-1; TSUKADA K, 1972, J BIOCHEM-TOKYO, V72, P1299, DOI 10.1093/oxfordjournals.jbchem.a130023; TSUKADA K, 1972, CANCER RES, V32, P886; VERSHAVSKY A, 1992, CELL, V69, P725; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	43	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24156	24162						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226962				2022-12-25	WOS:A1993MF29400067
J	VALENZUELASOTO, EM; MUNOZCLARES, RA				VALENZUELASOTO, EM; MUNOZCLARES, RA			BETAINE-ALDEHYDE DEHYDROGENASE FROM LEAVES OF AMARANTHUS-HYPOCHONDRIACUS L EXHIBITS AN ISO ORDERED BI BI STEADY-STATE MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETIC MECHANISM; SPINACH LEAVES; WATER-STRESS; PURIFICATION; GLYCINEBETAINE; ACCUMULATION; CHLOROPLASTS; SALINITY; WHEAT	The kinetics of the oxidation of betaine aldehyde catalyzed by NAD+-betaine-aldehyde dehydrogenase, purified from amaranth leaves subjected to water deficit, were analyzed by steady state initial velocity and product and dead-end inhibition studies at low substrate concentrations. Only one product, NADH, gives inhibition. The other product of the reaction, glycine betaine, does not inhibit the enzyme even at concentrations as high as 10 mM. In dead-end inhibition experiments, AMP and choline were used as dead-end analogs of NAD+ and betaine aldehyde, respectively, The families of double-reciprocal plots in the range 0.010-0.500 mM NAD+ and 0.025-0.300 mM betaine aldehyde are linear and intersect at the left of the 1/v axis. NADH is a mixed inhibitor against NAD+ and betaine aldehyde. AMP is competitive with respect to NAD+ and mixed with betaine aldehyde. Choline is competitive against betaine aldehyde and uncompetitive with respect to NAD+. Our results are consistent with an Iso Ordered Bi Bi steady state mechanism in which NAD+ is the first substrate to bind to the enzyme and NADH is the last product to dissociate from it. To our knowledge, this is the first time that an Iso mechanism has been demonstrated by product inhibition studies, as predicted by Cleland (Cleland, W. W. (1963) Biochim. Biophys. Acta 67,104-137).	NATL AUTONOMOUS UNIV MEXICO,FAC QUIM,DEPT BIOQUIM,MEXICO CITY 04510,DF,MEXICO	Universidad Nacional Autonoma de Mexico			Valenzuela-Soto, Elisa M./A-4795-2011	Munoz-Clares, Rosario A./0000-0002-0115-3565				[Anonymous], PHYSL BIOCH DROUGHT; ARAKAWA K, 1990, PLANT CELL PHYSIOL, V31, P797; ARAKAWA K, 1987, J BIOCHEM-TOKYO, V101, P1485, DOI 10.1093/oxfordjournals.jbchem.a122019; BRADBURY SL, 1971, J BIOL CHEM, V246, P1834; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; DICKINSON FM, 1989, BIOCHEM SOC T, V17, P299, DOI 10.1042/bst0170299; FALKENBERG P, 1990, BIOCHIM BIOPHYS ACTA, V1034, P253, DOI 10.1016/0304-4165(90)90046-Y; FELDMAN RI, 1972, J BIOL CHEM, V247, P267; FISHER LM, 1986, BIOCHEMISTRY-US, V25, P2529, DOI 10.1021/bi00357a037; GAMBOA A, 1991, J PLANT PHYSIOL, V137, P586, DOI 10.1016/S0176-1617(11)80704-2; GOLBERG AM, 1968, BIOCHIM BIOPHYS ACTA, V167, P186; HANSON AD, 1982, ANNU REV PLANT PHYS, V33, P163, DOI 10.1146/annurev.pp.33.060182.001115; HANSON AD, 1985, P NATL ACAD SCI USA, V82, P3678, DOI 10.1073/pnas.82.11.3678; IMHOFF JF, 1984, J BACTERIOL, V160, P478, DOI 10.1128/JB.160.1.478-479.1984; JAKOBY WB, 1963, ENZYMES, V7, P203; MCDONNELL E, 1988, J EXP BOT, V39, P421, DOI 10.1093/jxb/39.4.421; MORI N, 1992, J FERMENT BIOENG, V73, P352, DOI 10.1016/0922-338X(92)90277-2; MORI N, 1980, AGR BIOL CHEM TOKYO, V44, P3015, DOI 10.1080/00021369.1980.10864450; NAGASAWA T, 1976, AGR BIOL CHEM TOKYO, V40, P1743, DOI 10.1080/00021369.1976.10862293; NARAYAN VS, 1990, PLANT SCI, V71, P159, DOI 10.1016/0168-9452(90)90004-8; PAN SM, 1981, PLANT PHYSIOL, V67, P1105, DOI 10.1104/pp.67.6.1105; RIVETT AJ, 1981, EUR J BIOCHEM, V117, P187; ROBINSON SP, 1986, AUST J PLANT PHYSIOL, V13, P659, DOI 10.1071/PP9860659; RYZEWSKI CN, 1980, BIOCHEMISTRY-US, V19, P4843, DOI 10.1021/bi00562a021; SEGEL IH, 1975, ENZYME KINETICS, P767; WERETILNYK EA, 1989, ARCH BIOCHEM BIOPHYS, V271, P56, DOI 10.1016/0003-9861(89)90255-5; WERETILNYK EA, 1990, P NATL ACAD SCI USA, V87, P2745, DOI 10.1073/pnas.87.7.2745; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; ZAGDANSKA B, 1989, J PLANT PHYSIOL, V134, P320, DOI 10.1016/S0176-1617(89)80250-0	30	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23818	23824						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226918				2022-12-25	WOS:A1993MF29400020
J	LOMAKO, J; LOMAKO, WM; WHELAN, WJ; DOMBRO, RS; NEARY, JT; NORENBERG, MD				LOMAKO, J; LOMAKO, WM; WHELAN, WJ; DOMBRO, RS; NEARY, JT; NORENBERG, MD			GLYCOGEN-SYNTHESIS IN THE ASTROCYTE - FROM GLYCOGENIN TO PROGLYCOGEN TO GLYCOGEN	FASEB JOURNAL			English	Note						ASTROCYTE; GLYCOGEN; GLYCOGENIN; PROGLYCOGEN; MACROGLYCOGEN; GLYCOGEN BIOGENESIS; GLYCOGEN SYNTHASE	RABBIT-MUSCLE GLYCOGEN; SKELETAL-MUSCLE; PROTEIN; BIOGENESIS; PRIMER; BIOSYNTHESIS; INITIATION; LINKAGE	The astrocyte of the newborn rat brain has proven to be a versatile system in which to study glycogen biogenesis. We have taken advantage of the rapid stimulation of glycogen synthesis that occurs when glucose is fed to astrocytes, and the marked limitation on this synthesis that occurs in astrocytes previously exposed to ammonium ions. These observations have been related to our earlier reports of the initiation of glycogen synthesis on a protein primer, glycogenin, and the discovery of a low-molecular-weight form of glycogen, proglycogen. The following conclusions have been drawn: 1) In the ammonia-treated astrocytes starved of glucose, free glycogenin is present. 2) When these astrocytes are fed with glucose, proglycogen is synthesized from the glycogenin primer by a glycogen-synthase-like UDPglucose transglucosylase activity (proglycogen synthase) distinct from the well-recognized glycogen synthase, and synthesis stops at this point. 3) Proglycogen is the precursor of macromolecular glycogen, which is synthesized from proglycogen by glycogen synthase when glucose is fed to untreated astrocytes, accounting for the much greater accumulation of total glycogen. 4) The stimulus to proglycogen and macroglycogen synthesis that occurs on feeding glucose to untreated or ammonia-treated astrocytes is the result of the activation of proglycogen synthase, not of glycogen synthase. 5) Therefore, in the synthesis of macromolecular glycogen from glycogenin via proglycogen, the step between glycogenin and proglycogen is rate-limiting. 6) The discovery of additional potential control points in glycogen synthesis, now emerging, may assist the identification of so-far-unexplained aberrations of glycogen metabolism.	UNIV MIAMI,SCH MED,DEPT BIOCHEM,1011 NW 15TH ST,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT MOLEC BIOL,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT SURG,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT PATHOL,MIAMI,FL 33101; VET ADM MED CTR,MIAMI,FL 33125	University of Miami; University of Miami; University of Miami; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIDDK NIH HHS [DK 38153, DK 37500] Funding Source: Medline; NINDS NIH HHS [NS 30291] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037500, R01DK038153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS030291] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADROUNY GA, 1956, ENDOCRINOLOGY, V59, P241, DOI 10.1210/endo-59-2-241; BAILEY JM, 1993, BIOCHEM SOC T, V21, P124; BARTLEY W, 1968, ANAL BIOCHEM, V25, P99, DOI 10.1016/0003-2697(68)90084-5; BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97; BUTLER NA, 1977, CARBOHYD RES, V55, P73, DOI 10.1016/S0008-6215(00)84444-4; CAMPBELL DG, 1989, EUR J BIOCHEM, V185, P119, DOI 10.1111/j.1432-1033.1989.tb15090.x; DOMBRO RS, 1993, MOL CHEM NEUROPATHOL, V19, P259, DOI 10.1007/BF03160004; GREGORIOS JB, 1985, J NEUROPATH EXP NEUR, V44, P397, DOI 10.1097/00005072-198507000-00003; JUDD C, 1992, FASEB J, V6, pA1520; KAY MJ, 1987, FASEB J, V46, P2151; Kennedy L., 1985, MEMBRANES MUSCLE, P65; KIMELBERG HK, 1989, SCI AM, V260, P66, DOI 10.1038/scientificamerican0489-66; KRISMAN CR, 1975, EUR J BIOCHEM, V52, P117, DOI 10.1111/j.1432-1033.1975.tb03979.x; LAST WD, 1975, ANAL BIOCHEM, V68, P328; LOMAKO J, 1991, FEBS LETT, V279, P223, DOI 10.1016/0014-5793(91)80154-U; LOMAKO J, 1990, BIOCHEM INT, V21, P251; LOMAKO J, 1988, Biofactors, V1, P261; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; LOMAKO J, 1990, FEBS LETT, V268, P8, DOI 10.1016/0014-5793(90)80959-M; LOMAKO J, 1991, FASEB J, pA1014; LOMAKO J, 1988, 14TH INT C BIOCH PRA, P198; PASSONNEAU JV, 1976, J BIOL CHEM, P2015; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; RODRIGUEZ IR, 1985, BIOCHEM BIOPH RES CO, V132, P829, DOI 10.1016/0006-291X(85)91206-9; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; ROE JH, 1961, J BIOL CHEM, V236, P1244; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; STETTEN D, 1960, PHYSIOL REV, V40, P505, DOI 10.1152/physrev.1960.40.3.505; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; WHELAN WJ, 1986, BIOESSAYS, V5, P136, DOI 10.1002/bies.950050312	31	84	85	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1386	1393		10.1096/fasebj.7.14.8224611	http://dx.doi.org/10.1096/fasebj.7.14.8224611			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	8224611				2022-12-25	WOS:A1993MH00800012
J	BHATTACHARYYA, DK; BANDYOPADHYAY, U; BANERJEE, RK				BHATTACHARYYA, DK; BANDYOPADHYAY, U; BANERJEE, RK			CHEMICAL AND KINETIC EVIDENCE FOR AN ESSENTIAL HISTIDINE RESIDUE IN THE ELECTRON-TRANSFER FROM AROMATIC DONOR TO HORSERADISH-PEROXIDASE COMPOUND-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; HORSE RADISH PEROXIDASE; PROSTHETIC HEME; TRANSFER COMPLEX; PARA CRESOL; RESONANCE; MECHANISM; OXIDATION; DIETHYLPYROCARBONATE; SPECTROSCOPY	Horseradish peroxidase, when incubated with diethyl pyrocarbonate (DEPC), a histidine-specific reagent, shows time-dependent inactivation to oxidize aromatic electron donor, guaiacol. The inactivation follows pseudo-first order kinetics with a second order rate constant of 0.67 min-1 M-1. The pH dependence of inactivation shows an inflection point at 6.02, indicating histidine derivatization by DEPC. A difference spectrum of modified versus native enzyme shows a peak at 244 nm for N-carbethoxyhistidine that is diminished by hydroxylamine. Stoichiometric studies indicate that out of 2 histidine residues modified, one is responsible for inactivation. A plot of log reciprocal half-time of inactivation against log DEPC concentration suggests that only 1 histidine is essential. From the computer-stimulated structure of horseradish peroxidase, we tentatively suggest that this critical histidine is most likely distal histidine 42. Binding studies show that this histidine is not involved in guaiacol binding. Modified enzyme forms compound I with H2O2 but not compound II, suggesting a block of electron transfer process. Modified compound I cannot oxidize guaiacol as evidenced by the absence of donor-induced spectral shift from 408 nm, suggesting a block of electron transfer from bound donor to compound I. We suggest that this tentatively identified distal histidine controls aromatic donor oxidation by regulating electron transport without affecting donor binding or compound I formation.	INDIAN INST CHEM BIOL, DEPT PHYSIOL, 4 RAJA SC MULLICK RD, CALCUTTA 700032, W BENGAL, INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)								AIBARA S, 1982, J BIOCHEM-TOKYO, V92, P531, DOI 10.1093/oxfordjournals.jbchem.a133961; ATOR MA, 1987, J BIOL CHEM, V262, P14954; ATOR MA, 1987, J BIOL CHEM, V262, P1542; BAEK HK, 1989, BIOCHEMISTRY-US, V28, P5714, DOI 10.1021/bi00440a003; BHATTACHARYYA DK, 1992, J BIOL CHEM, V267, P9800; BJORKSTEN F, 1970, BIOCHIM BIOPHYS ACTA, V212, P396, DOI 10.1016/0005-2744(70)90245-7; BLANKE SR, 1990, J BIOL CHEM, V265, P12454; BOSSHARD HR, 1984, J BIOL CHEM, V259, P5683; BURNS PS, 1975, J CHEM SOC CHEM COMM, P795, DOI 10.1039/c39750000795; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; CHANCE B, 1949, ARCH BIOCHEM, V21, P416; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P416, DOI 10.1016/0003-9861(52)90470-0; CHURCH FC, 1985, J BIOL CHEM, V260, P4936; CRITCHLOW JE, 1972, J BIOL CHEM, V247, P3703; CRITCHLOW JE, 1972, J BIOL CHEM, V247, P3714; DE SK, 1986, EUR J BIOCHEM, V160, P319, DOI 10.1111/j.1432-1033.1986.tb09974.x; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P41; DUNFORD HB, 1979, BIOCHEM BIOPH RES CO, V89, P764, DOI 10.1016/0006-291X(79)90695-8; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; Frew J. E., 1984, ADV INORG BIOINORG M, V3, P175; GEORGE P, 1952, NATURE, V169, P612, DOI 10.1038/169612a0; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; HOSOYA T, 1960, J BIOCHEM-TOKYO, V47, P794, DOI 10.1093/oxfordjournals.jbchem.a127127; HOSOYA T, 1989, BIOCHEMISTRY-US, V28, P2639, DOI 10.1021/bi00432a042; KEILIN D, 1951, BIOCHEM J, V49, P88, DOI 10.1042/bj0490088; LEIGH JS, 1975, FEBS LETT, V51, P304, DOI 10.1016/0014-5793(75)80913-6; LEVY HM, 1963, J BIOL CHEM, V238, P3654; Lundblad R.L, 1984, CHEM REAGENTS PROTEI, VI; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; MORISHIMA I, 1978, BIOCHEMISTRY-US, V17, P4384, DOI 10.1021/bi00614a005; MORRISON M, 1976, ANNU REV BIOCHEM, V45, P861, DOI 10.1146/annurev.bi.45.070176.004241; OERTLING WA, 1988, BIOCHEMISTRY-US, V27, P3331, DOI 10.1021/bi00409a032; OVADI J, 1967, ACTA BIOCHIM BIOPHYS, V2, P445; PAUL KG, 1978, ACTA CHEM SCAND B, V32, P395, DOI 10.3891/acta.chem.scand.32b-0395; PENNERHAHN JE, 1986, J AM CHEM SOC, V108, P7819, DOI 10.1021/ja00284a054; POULOS TL, 1980, J BIOL CHEM, V255, P322; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; POULOS TL, 1982, ELECTRON TRANSPORT O, V2, P217; RICARD J, 1974, EUR J BIOCHEM, V44, P359, DOI 10.1111/j.1432-1033.1974.tb03493.x; SAKURADA J, 1986, J BIOL CHEM, V261, P9657; SAMS CF, 1988, BIOCHEMISTRY-US, V27, P2277, DOI 10.1021/bi00407a005; SANTIMONE M, 1975, CAN J BIOCHEM CELL B, V53, P649, DOI 10.1139/o75-090; SAUNDERS BC, 1964, PEROXIDASE; SCHEJTER A, 1976, ARCH BIOCHEM BIOPHYS, V174, P36, DOI 10.1016/0003-9861(76)90321-0; SCHONBAUM GR, 1973, J BIOL CHEM, V248, P502; SCHONBAUM GR, 1971, PROBES STRUCTURE FUN, V2, P533; SHIGA T, 1975, ARCH BIOCHEM BIOPHYS, V167, P469, DOI 10.1016/0003-9861(75)90489-0; SHOEMAKER KR, 1988, PEPTIDES CHEM BIOL, P15; SMULEVICH G, 1991, BIOCHEMISTRY-US, V30, P9546, DOI 10.1021/bi00103a023; STRICKLAND EH, 1968, J BIOL CHEM, V243, P3560; TAKEUCHI M, 1986, J BIOCHEM-TOKYO, V99, P1571, DOI 10.1093/oxfordjournals.jbchem.a135630; Tien M, 1987, NATURE, V326, P520, DOI 10.1038/326520a0; WELINDER KG, 1979, EUR J BIOCHEM, V96, P483, DOI 10.1111/j.1432-1033.1979.tb13061.x; YAMAZAKI I, 1981, MOL CELL BIOCHEM, V40, P143; YAMAZAKI I, 1960, J BIOL CHEM, V235, P2444	60	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22292	22298						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226738				2022-12-25	WOS:A1993MD34800019
J	HOOPER, KP; PADMANABHAN, R; EBNER, KE				HOOPER, KP; PADMANABHAN, R; EBNER, KE			EXPRESSION OF THE EXTRACELLULAR DOMAIN OF THE RAT-LIVER PROLACTIN RECEPTOR AND ITS INTERACTION WITH OVINE PROLACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; ESCHERICHIA-COLI; MOLECULAR-CLONING; CELL-LINE; IDENTIFICATION; PURIFICATION; SEQUENCE; NECROSIS; FORMS	A clone of the extracellular domain of the rat liver prolactin receptor was generated by the RNA-based polymerase chain reaction, and the NH2-terminal 210 amino acids were expressed in HeLa cells using a vaccinia virus/T7 hybrid expression system. The protein was isolated from serum-free culture medium directly by chromatography on an ovine prolactin affinity column and yielded approximately 1.5 mg of protein/liter of suspension culture. The extracellular domain of the rat prolactin receptor inhibited the ovine prolactin-dependent mitogenesis of rat lymphoma Nb2 cells with an IC50 of 7.1 pM and bound I-125-labeled ovine prolactin with a K(d) of 1.21 +/- 0.19 nM. In contrast, the binding of the I-125-labeled extracellular domain to ovine prolactin exhibited positive cooperativity with a Hill coefficient of 1.73. High pressure gel filtration chromatography was used to demonstrate the formation of a complex consisting of one molecule of ovine prolactin and two molecules of the extracellular domain of the rat prolactin receptor. Complex formation occurred with human growth hormone, but not with ovine growth hormone, a non-lactogen.	UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, 3901 RAINBOW BLVD, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018584] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 18584] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALI S, 1991, J BIOL CHEM, V266, P20110; ANDREWS GK, 1987, DEVELOPMENT, V100, P463; BAJPAI A, 1991, BIOCHEM BIOPH RES CO, V180, P1312, DOI 10.1016/S0006-291X(05)81338-5; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; COOKE NE, 1989, ENDOCRINOLOGY, V1, P384; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUAN DSR, 1991, J BIOL CHEM, V266, P413; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; ELROYSTEIN O, 1992, CURRENT PROTOCOLS MO; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P13268; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOUT PW, 1980, CANCER RES, V40, P2433; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; HARRIS KW, 1992, J BIOL CHEM, V267, P15205; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX I, 1991, J BIOL CHEM, V266, P13828; MALISZEWSKI CR, 1990, J IMMUNOL, V144, P3028; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NECESSARY PC, 1984, J BIOL CHEM, V259, P6942; NECESSARY PC, 1985, MOL CELL ENDOCRINOL, V39, P247, DOI 10.1016/0303-7207(85)90068-1; NIALL HD, 1971, P NATL ACAD SCI USA, V68, P866, DOI 10.1073/pnas.68.4.866; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; POSTELVINAY MC, 1991, P NATL ACAD SCI USA, V88, P6687, DOI 10.1073/pnas.88.15.6687; PRASAD R, 1980, J BIOL CHEM, V255, P5834; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT P, 1992, MOL CELL ENDOCRINOL, V89, P47, DOI 10.1016/0303-7207(92)90210-W; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; TANAKA M, 1992, BIOCHEM BIOPH RES CO, V188, P490, DOI 10.1016/0006-291X(92)91082-2; VISSAVAJJHALA P, 1990, J BIOL CHEM, V265, P4746; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; WERENSKIOLD AK, 1992, EUR J BIOCHEM, V204, P1041, DOI 10.1111/j.1432-1033.1992.tb16726.x	52	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22347	22352						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226744				2022-12-25	WOS:A1993MD34800026
J	PRASAD, R; KUMAR, A; WIDEN, SG; CASASFINET, JR; WILSON, SH				PRASAD, R; KUMAR, A; WIDEN, SG; CASASFINET, JR; WILSON, SH			IDENTIFICATION OF RESIDUES IN THE SINGLE-STRANDED DNA-BINDING SITE OF THE 8-KDA DOMAIN OF RAT DNA POLYMERASE-BETA BY UV CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; VIRUS REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; PRIMER BINDING; DIRECTED MUTAGENESIS; HUMAN-CELLS; PROTEIN; LOCALIZATION; ENZYME; REGION	Rat DNA polymerase beta (beta-pol) is a 39-kDa monomeric protein, organized in two structurally and functionally distinct domains. The 8-kDa NH-2-terminal domain binds single-stranded (ss) DNA, whereas the 31-kDa COOH-terminal domain does not. To facilitate studies on ssDNA binding structure-function relationships of beta-pol, we overexpressed the 8-kDa domain in Escherichia coli, and purified the recombinant protein to homogeneity. Single-stranded nucleic acid binding of the recombinant 8-kDa domain was found to be similar to that previously reported for the 8-kDa fragment prepared by proteolysis of intact beta-pol (Kumar, A., Widen, S. G., Williams, K. R., Kedar, P., Karpel, R. L., and Wilson, S. H. (1990b) J. Biol. Chem. 265, 2124-2131; Casas-Finet, J. R., Kumar, A., Morris, G., Wilson, S. H., and Karpel, R. L. (1991) J. Biol. Chem. 266, 19618-19625). Residues in or near the DNA-binding pocket of the recombinant 8-kDa domain were examined by photochemical cross-linking to [P-32] p(dT)16. Cross-linking was localized to a tryptic fragment spanning residues 28 through 35 and a V8 protease fragment spanning residues 27 through 58. Sequence analysis of the various [P-32]p(dT)16-labeled proteins indicated that Ser30 and His34 were modified by cross-linking to p(dT)16. Therefore, these residues of the ssDNA-binding domain of beta-pol appear to be in close contact with this nucleic acid probe.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,1023 PROFESSIONAL BLDG,H-51,GALVESTON,TX 77555; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC,STRUCT BIOCHEM LAB,FREDERICK,MD 21702	University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P907, DOI 10.1021/bi00676a006; ANDERSON RS, 1987, GENE, V60, P163, DOI 10.1016/0378-1119(87)90224-1; BARUN F, 1975, BIOCHEMISTRY-US, V14, P558; BASU A, 1992, BIOCHEMISTRY-US, V31, P616, DOI 10.1021/bi00117a045; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAYER GD, 1983, J MOL BIOL, V169, P565, DOI 10.1016/S0022-2836(83)80065-5; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; CASASFINET JR, 1992, BIOCHEMISTRY-US, V31, P10272, DOI 10.1021/bi00157a014; CLEGHON V, 1992, J BIOL CHEM, V267, P17872; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; COLEMAN JE, 1978, BIOCHEMISTRY-US, V17, P5038, DOI 10.1021/bi00616a028; COLEMAN JE, 1976, BIOCHEMISTRY-US, V15, P5419, DOI 10.1021/bi00670a001; DATE T, 1990, BIOCHEMISTRY-US, V29, P5027, DOI 10.1021/bi00473a005; FARRAR YJK, 1991, BIOCHEMISTRY-US, V30, P3075, DOI 10.1021/bi00226a014; FRY M, 1986, ANIMAL CELL DNA POLY; HARVON A, 1977, BIOCHEMISTRY-US, V16, P5631; HOCKENSMITH JW, 1991, METHOD ENZYMOL, V208, P211; KIM SJ, 1993, IN PRESS J MOL BIOL; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALY P, 1980, BIOCHEMISTRY-US, V19, P4179, DOI 10.1021/bi00559a007; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MERRILL BM, 1984, J BIOL CHEM, V259, P850; MILLER MR, 1982, J BIOL CHEM, V257, P204; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; Sambrook J, 1989, MOL CLONING LABORATO; Shetlar M.D., 1980, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V5, P105; SMITH CA, 1984, BIOCHEMISTRY-US, V23, P1383, DOI 10.1021/bi00302a008; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; TIRUMALAI RS, 1991, BIOCHEMISTRY-US, V30, P6436, DOI 10.1021/bi00240a014; WILLIAMS KR, 1991, METHOD ENZYMOL, V208, P516; WILLIAMS KR, 1987, PROTEIN-STRUCT FUNCT, P45; WILSON S, 1988, BIOCHIM BIOPHYS ACTA, V949, P149, DOI 10.1016/0167-4781(88)90078-4; WILSON SH, 1991, CANCER BIOL BIOSYNTH, P55; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199	40	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22746	22755						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226785				2022-12-25	WOS:A1993MD34800082
J	SUCHER, NJ; BROSE, N; DEITCHER, DL; AWOBULUYI, M; GASIC, GP; BADING, H; CEPKO, CL; GREENBERG, ME; JAHN, R; HEINEMANN, SF; LIPTON, SA				SUCHER, NJ; BROSE, N; DEITCHER, DL; AWOBULUYI, M; GASIC, GP; BADING, H; CEPKO, CL; GREENBERG, ME; JAHN, R; HEINEMANN, SF; LIPTON, SA			EXPRESSION OF ENDOGENOUS NMDAR1 TRANSCRIPTS WITHOUT RECEPTOR PROTEIN SUGGESTS POST-TRANSCRIPTION CONTROL IN PC12-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA PC12 CELLS; RETINAL GANGLION-CELLS; EXCITATORY AMINO-ACIDS; NERVE GROWTH-FACTOR; MESSENGER-RNA; RAT-BRAIN; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; PURKINJE-CELLS; IONIC CURRENTS	Expression of RNA for the NMDAR1 subunit of the N-methyl-D-aspartate receptor was detected by Northern hybridization in both nerve growth factor-differentiated and undifferentiated rat pheochromocytoma (PC12) cells. The NMDA receptor type 1 (NMDAR1) message in PC12 cells was similar in size to that expressed in hippocampal neurons. PC12 cell cDNAs that were amplified by polymerase chain reaction with primers flanking the coding region of NMDAR1 corresponded to the NMDAR1 splice variant NMDA receptor type 1 isoform C (NMDAR1C). Using calcium imaging or patch-clamp recording, no functional NMDA-gated ion channels were found in PC12 cells. A monoclonal antibody against NMDAR1 was developed in order to investigate whether or not NMDAR1 protein was present in PC12 cells. Only trace amounts of NMDAR1 protein were found in native PC 12 cells. However, expression of NMDAR1 protein was detected in PC12 cells that were transfected with an expression vector containing an NMDAR1C clone under control of a cytomegalovirus promoter. These findings suggest that the expression of NMDAR1 protein in PC12 cells may be controlled by post-transcriptional mechanisms. The PC12 cell line may serve as a model system for the study of the transcriptional, post-transcriptional, and translational regulation of NMDAR1. Furthermore, the presence of NMDAR1 RNA in a particular cell type may not necessarily indicate expression of NMDAR1 protein.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02114; SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,LA JOLLA,CA 92037; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Salk Institute; Howard Hughes Medical Institute; Yale University	SUCHER, NJ (corresponding author), HARVARD UNIV,CHILDRENS HOSP,DEPT NEUROL,CELLULAR & MOLEC NEUROSCI LAB,BOSTON,MA 02115, USA.		Deitcher, David/K-6538-2019	Lipton, Stuart/0000-0002-3490-1259; Sucher, Nikolaus/0000-0001-6233-1612; Jahn, Reinhard/0000-0003-1542-3498; Deitcher, David/0000-0002-8512-8868	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD029587] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [T32EY007110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023021] Funding Source: NIH RePORTER; NEI NIH HHS [T32 EY07110] Funding Source: Medline; NICHD NIH HHS [P01 HD29587] Funding Source: Medline; NINDS NIH HHS [R01 NS23021] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIZENMAN E, 1988, J PHYSIOL-LONDON, V396, P75, DOI 10.1113/jphysiol.1988.sp016951; AUDINAT E, 1990, J PHYSIOL-LONDON, V430, P297, DOI 10.1113/jphysiol.1990.sp018292; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BAEV KV, 1992, NEUROSCIENCE, V46, P925, DOI 10.1016/0306-4522(92)90194-7; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BROSE N, 1990, J BIOL CHEM, V265, P10604; CHAZOT PL, 1992, J NEUROCHEM, V59, P1176, DOI 10.1111/j.1471-4159.1992.tb08364.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; GARTHWAITE G, 1987, DEV BRAIN RES, V36, P288, DOI 10.1016/0165-3806(87)90034-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELLEWELL SB, 1990, BRAIN RES, V527, P244, DOI 10.1016/0006-8993(90)91143-5; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KUMAR KN, 1991, NATURE, V354, P70, DOI 10.1038/354070a0; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN NM, 1981, ANNU REV PHYSIOL, V43, P653, DOI 10.1146/annurev.ph.43.030181.003253; LIEBHABER SA, 1992, J MOL BIOL, V226, P609, DOI 10.1016/0022-2836(92)90619-U; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; LOVINGER DM, 1988, NEUROSCI LETT, V94, P314, DOI 10.1016/0304-3940(88)90037-7; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ROGERS SW, 1991, J NEUROSCI, V11, P2713; ROSEMUND C, 1992, J NEUROPHYSIOL, V68, P1901, DOI 10.1152/jn.1992.68.5.1901; Sambrook J, 1989, MOL CLONING LABORATO; SCHUBERT D, 1992, P NATL ACAD SCI USA, V89, P8264, DOI 10.1073/pnas.89.17.8264; SHIGEMOTO R, 1992, NEUROSCI LETT, V144, P229, DOI 10.1016/0304-3940(92)90756-W; SUCHER NJ, 1991, J NEUROSCI RES, V30, P582, DOI 10.1002/jnr.490300316; SUCHER NJ, 1991, NEUROSCIENCE, V43, P135, DOI 10.1016/0306-4522(91)90423-L; SUCHER NJ, 1990, BRAIN RES, V533, P248, DOI 10.1016/0006-8993(90)91346-I; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; USOWICZ MM, 1989, NATURE, V339, P380, DOI 10.1038/339380a0; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A	59	146	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22299	22304						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226739				2022-12-25	WOS:A1993MD34800020
J	BOND, JA; WYLLIE, FS; WYNFORDTHOMAS, D				BOND, JA; WYLLIE, FS; WYNFORDTHOMAS, D			ESCAPE FROM SENESCENCE IN HUMAN-DIPLOID FIBROBLASTS INDUCED DIRECTLY BY MUTANT P53	ONCOGENE			English	Article							EPITHELIAL-CELLS; P53-DEFICIENT MICE; TUMOR SUPPRESSION; CANCER SYNDROME; IMMORTALIZATION; TRANSFORMATION; ABNORMALITIES; MECHANISMS; RB	Cellular senescence is thought to be a key restraint on the progression of human tumours, escape from which involves loss of function of tumour suppressor genes. The number and nature of the genes involved however is uncertain, in particular the role of p53 mutation, which is commonly correlated with tumour progression. To address this question, we used the novel approach of directly assessing the effect of mutant p53 on 'pre-aged' human diploid fibroblasts (HDF), thereby avoiding the uncertainty of additional cooperating events, inherent in transgenic models. HDF were passaged till near-senescent and then infected with an amphotropic retroviral vector encoding an ala143 human mutant p53. The results show conclusively that p53 mutation alone is sufficient to extend the proliferative lifespan of normal fibroblasts by approximately 17 population doublings, but has no phenotypic effect on 'young' fibroblasts. We conclude that a key tumour-limiting function of wild-type p53 is to mediate growth arrest after a given number of cell divisions, in agreement with data implicating a p53-regulated gene, WAF-1/sdi-1, in cellular senescence. This may be reconciled with its 'guardian of the genome' role, if telomere erosion, a key change in senescence, is perceived by the cell as a form of DNA 'damage'.	UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOUR BIOL GRP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University								BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BURNS JS, 1992, MOL CARCINOGEN, V6, P129, DOI 10.1002/mc.2940060208; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; NODA A, IN PRESS EXP CELL RE; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; TSUKADA T, 1993, ONCOGENE, V8, P3313; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1991, MOL CELL ENDOCRINOL, V76, P13, DOI 10.1016/0303-7207(91)90255-Q	18	175	184	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1885	1889						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208534				2022-12-25	WOS:A1994NR68500011
J	YU, X; HAO, LN; INESI, G				YU, X; HAO, LN; INESI, G			A PK CHANGE OF ACIDIC RESIDUES CONTRIBUTES TO CATION COUNTERTRANSPORT IN THE CA-ATPASE OF SARCOPLASMIC-RETICULUM - ROLE OF H+ IN CA2+-ATPASE COUNTERTRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED PROTEOLIPOSOMES; CALCIUM-TRANSPORT; PUMP CURRENT; CA-2+-ATPASE; VESICLES; CA-2+; ELECTROGENICITY; BINDING; PERMEABILITY; MEMBRANES	Proteoliposomal vesicles reconstituted with sarcoplasmic reticulum ATPase and exogenous lipids sustain ATP-dependent Ca2+ uptake and H+ ejection, as well as net charge displacement by Ca2+. We have studied the effect of lumenal (inner) and medium (extravesicular) pH variations on the countertransport ratios of H+ and Ca2+. We find that the Ca2+/H+ molar ratio is approximately 1 when the lumenal and medium pH is near neutrality, but changes with a specific pattern when the medium pH is varied in the presence of a constant lumenal pH and when the lumenal pH is varied in the presence of a constant medium pH. Empirical analysis of the experimental data shows that the apparent pK of the residue(s) releasing H+ into the medium is approximately 6.1, whereas the apparent pK of the residue(s) binding lumenal H+ is approximately 7.7. Assuming that the same acidic residues are involved in H+ and Ca2+ countertransport, our findings suggest a lower affinity for H+ in their outward orientation (prevalent in the ground state of the enzyme) and a higher affinity for H+ in lumenal orientation (prevalent in the phosphorylated state of the enzyme). Cyclic pK changes, coupled to ATP utilization, promote cation exchange, Ca2+ uptake, and H+ ejection by the vesicles. The stoichiometry of countertransport and net charge displacement is matched by a corresponding electrogenic behavior. A calculation of voltage development related to initial rates of charge transfer (dV/dt = (dQ/dt)/C-m) is given as a corrective replacement of a previous steady state calculation.			YU, X (corresponding author), UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201, USA.							AKERMAN KEO, 1979, FEBS LETT, V100, P291, DOI 10.1016/0014-5793(79)80354-3; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORNELIUS F, 1991, FEBS LETT, V284, P46, DOI 10.1016/0014-5793(91)80758-U; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; EISENRAUCH A, 1990, FEBS LETT, V268, P152, DOI 10.1016/0014-5793(90)80996-V; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; GARRET C, 1981, FEBS LETT, V136, P216, DOI 10.1016/0014-5793(81)80621-7; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1990, J MEMBRANE BIOL, V116, P1, DOI 10.1007/BF01871666; INESI G, 1994, CELL PHYSIOL BIOCHEM, V4, P135, DOI 10.1159/000154717; LEVY D, 1990, J BIOL CHEM, V265, P19524; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADEIRA VMC, 1978, ARCH BIOCHEM BIOPHYS, V185, P316, DOI 10.1016/0003-9861(78)90173-X; MEISSNER G, 1980, J BIOL CHEM, V255, P6814; MEISSNER G, 1981, J BIOL CHEM, V256, P636; MORIMOTO T, 1986, J BIOCHEM-TOKYO, V99, P1071, DOI 10.1093/oxfordjournals.jbchem.a135571; MURPHY AJ, 1992, J BIOL CHEM, V267, P16990; NISHIE I, 1990, J BIOL CHEM, V265, P2488; POSSMEYER EF, 1994, J BIOL CHEM, V269, P1896; RIGAUD JL, 1983, BIOCHEM BIOPH RES CO, V111, P373, DOI 10.1016/0006-291X(83)90316-9; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; SUMBILLA C, 1991, J BIOL CHEM, V266, P12682; UENO T, 1981, J BIOCHEM-TOKYO, V89, P1247; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9; ZIMNIAK P, 1978, J BIOL CHEM, V253, P4631	29	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16656	16661						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206985				2022-12-25	WOS:A1994NR29600024
J	MORRIS, TW; REED, KE; CRONAN, JE				MORRIS, TW; REED, KE; CRONAN, JE			IDENTIFICATION OF THE GENE ENCODING LIPOATE-PROTEIN LIGASE-A OF ESCHERICHIA-COLI - MOLECULAR-CLONING AND CHARACTERIZATION OF THE LPLA GENE AND GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DNA-POLYMERASE; PYRUVATE-DEHYDROGENASE COMPLEX; GLYCINE CLEAVAGE SYSTEM; LIPOIC ACID METABOLISM; BIOTIN BIOSYNTHESIS; BINDING DOMAINS; RNA-POLYMERASE; EXPRESSION; SEQUENCE; LIPOYLATION	R(+)-Lipoic acid is a cofactor required for function of the alpha-keto acid dehydrogenase and glycine cleavage enzyme complexes. The naturally occurring form of lipoate is attached by amide linkage to the epsilon-amino group of a specific lysine residue within conserved lipoate-accepting protein domains. Lipoate-protein ligase(s) catalyze the formation of this amide bond between lipoyl groups and specific apoproteins. We report the isolation of the lplA gene which encodes an Escherichia coli lipoate-protein ligase. Strains with lplA null mutations transport lipoic acid normally but have severe defects in the incorporation and utilization of exogenously supplied lipoic acid and lipoic acid analogs. These strains are also highly resistant to selenolipoate (a growth-inhibiting lipoate analog) and contain no detectable lipoate-protein Ligase activity in cell extracts. The lplA gene has been cloned, sequenced, and physically mapped to min 99.6 (4657 kilobases) of the E. coli chromosome. Upon over expression, the 38-kDa lplA gene product was purified to homogeneity and shown to have a mass, N-terminal sequence and amino acid composition consistent with the deduced 337 residue primary sequence. Enzyme assays show that purified LplA catalyzes the ATP-dependent attachment of [S-35]lipoic acid to apoprotein, thus confirming that lplA encodes lipoate-protein ligase A. Analysis of lplA null mutants also indicates the existence of a second (lplA-independent) lipoyl-ligase enzyme in E. coli, This is the first identification of a lipoate ligase gene and the first analysis of a purified lipoate ligase enzyme.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTT J, 1993, BIOCHEMISTRY-US, V32, P9649, DOI 10.1021/bi00088a017; ALI ST, 1990, MOL MICROBIOL, V4, P943, DOI 10.1111/j.1365-2958.1990.tb00667.x; BARKER DF, 1980, J BACTERIOL, V143, P789, DOI 10.1128/JB.143.2.789-800.1980; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CARAFA YD, 1990, J MOL BIOL, V216, P835, DOI 10.1016/S0022-2836(99)80005-9; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; CRONAN JE, 1989, CELL, V58, P427, DOI 10.1016/0092-8674(89)90421-2; Davis R., 1980, ADV BACTERIAL GENETI; DAVIS TN, 1982, VIROLOGY, V120, P287, DOI 10.1016/0042-6822(82)90031-9; DUPRE S, 1980, ARCH BIOCHEM BIOPHYS, V202, P361, DOI 10.1016/0003-9861(80)90438-5; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; GRANA D, 1988, GENETICS, V120, P319; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GUEST JR, 1985, J MOL BIOL, V185, P743, DOI 10.1016/0022-2836(85)90059-2; HAYDEN MA, 1993, BIOCHEMISTRY-US, V32, P3778, DOI 10.1021/bi00065a033; HERBERT AA, 1975, ARCH MICROBIOL, V106, P259, DOI 10.1007/BF00446532; HIPPS DS, 1992, BIOCHEM J, V283, P665, DOI 10.1042/bj2830665; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; Miller J.H., 1972, EXPT MOL GENETICS; MITRA SK, 1965, J BIOL CHEM, V240, P4072; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; NEUWALD AF, 1985, NUCLEIC ACIDS RES, V13, P7025, DOI 10.1093/nar/13.19.7025; NEUWALD AF, 1989, GENE, V82, P219, DOI 10.1016/0378-1119(89)90047-4; NOLL KM, 1988, J BACTERIOL, V170, P4315, DOI 10.1128/jb.170.9.4315-4321.1988; OH YK, 1969, CAN J MICROBIOL, V15, P183, DOI 10.1139/m69-030; PACKMAN LC, 1991, BIOCHEM J, V277, P153, DOI 10.1042/bj2770153; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; RAWLINGS M, 1988, FASEB J, V2, pA1559; REED KE, 1994, P NATL ACAD SCI USA, V91, P3720, DOI 10.1073/pnas.91.9.3720; REED KE, 1993, J BACTERIOL, V175, P1325, DOI 10.1128/JB.175.5.1325-1336.1993; REED LJ, 1958, J BIOL CHEM, V232, P123; ROEDER W, 1979, MOL GEN GENET, V176, P361, DOI 10.1007/BF00333098; Sambrook J, 1989, MOL CLONING LABORATO; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TSUNODA JN, 1967, ARCH BIOCHEM BIOPHYS, V118, P395, DOI 10.1016/0003-9861(67)90366-9; VANDENBOOM T, 1990, VIROLOGY, V177, P11; VANDENBOOM TJ, 1991, J BACTERIOL, V173, P6411, DOI 10.1128/jb.173.20.6411-6420.1991; Watson J. D., 1987, MOL BIOL GENE; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; WILSON K, 1987, CURRENT PROTOCOLS MO, V1; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257	50	143	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16091	16100						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206909				2022-12-25	WOS:A1994NQ72900024
J	KENNER, KA; HILL, DE; OLEFSKY, JM; KUSARI, J				KENNER, KA; HILL, DE; OLEFSKY, JM; KUSARI, J			REGULATION OF PROTEIN-TYROSINE PHOSPHATASES BY INSULIN AND INSULIN-LIKE GROWTH FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CELLS; RAT HEPATOMA-CELLS; MESSENGER-RNA; DIFFERENTIAL REGULATION; 3T3-L1 ADIPOCYTES; XENOPUS OOCYTES; GENE-EXPRESSION; HUMAN-PLACENTA; RECEPTORS; KINASE	In this study, we have examined the effects of insulin and insulin-like growth factor (IGF)-I on protein tyrosine phosphatase (PTPase) activity in rat L6 skeletal muscle cells. Under basal conditions, about 85% of total cellular PTPase activity was associated with the particulate (Triton X-100-soluble) fraction. Incubation of the cells with 100 nm insulin or IGF-I significantly increased particulate PTPase activity (p < 0.005) without altering activity in the supernatant or Triton X-100-insoluble fractions. Dose response studies suggested that the effect of each hormone was mediated through its own receptor. PTPase activity was regulated by both acute and chronic insulin and IGF-I treatment. Maximal stimulation by both ligands occurred at 32 h and then declined. By using an antibody and a cDNA specific for PTPase1B, we found that the chronic stimulation of PTPase activity was accompanied by enhanced expression of PTPase1B mRNA and protein. Maximal induction of PTPase1B mRNA and protein by insulin and IGF-I occurred at 12 and 24 h, respectively. Based on these data, it can be suggested that ligand-stimulated PTPase activity might oppose tyrosine kinase-mediated insulin or IGF-I signal transmission and thus desensitize cells to long-term action by insulin and IGF-I. However, it is also possible that PTPases act as positive mediators of insulin and IGF-I action.	ONCOGENE SCI,CAMBRIDGE,MA 02142; UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL METAB,LA JOLLA,CA 92093; VET ADM MED CTR,MED RES SERV,SAN DIEGO,CA 92161	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Hill, David E/B-6617-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033649, R37DK033651, R01DK033651, R37DK033649] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33651, DK 33649] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; BACKER JM, 1990, J BIOL CHEM, V265, P14828; BALLARD FJ, 1988, BIOCHEM J, V249, P721, DOI 10.1042/bj2490721; BEGUINOT F, 1986, ENDOCRINOLOGY, V118, P446, DOI 10.1210/endo-118-1-446; BEGUINOT F, 1985, J BIOL CHEM, V260, P5892; BEGUM N, 1991, DIABETES, V40, P1620, DOI 10.2337/diabetes.40.12.1620; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; BROWNSHIMER S, 1992, CANCER RES, V52, P478; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; BURANT CF, 1987, BIOCHEM BIOPH RES CO, V147, P100, DOI 10.1016/S0006-291X(87)80092-X; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; CLEMMONS DR, 1986, J CLIN INVEST, V77, P1548, DOI 10.1172/JCI112470; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAHL HHM, 1987, J BIOL CHEM, V262, P7398; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GOLDSTEIN BJ, 1992, J CELL BIOCHEM, V48, P33, DOI 10.1002/jcb.240480107; HILL DE, 1992, J CELL BIOCH S16B, V49, P144; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAYALAR C, 1989, J BIOL CHEM, V264, P8928; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KUSARI J, 1986, MOL CELL BIOL, V6, P2062, DOI 10.1128/MCB.6.6.2062; KUSARI J, 1992, DIABETES S, V41, pA184; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TS, 1989, J CLIN INVEST, V83, P90, DOI 10.1172/JCI113889; LIAO K, 1991, J BIOL CHEM, V266, P6544; MAHER F, 1989, MOL ENDOCRINOL, V3, P2128, DOI 10.1210/mend-3-12-2128; MCGUIRE MC, 1991, DIABETES, V40, P939, DOI 10.2337/diabetes.40.7.939; MEYEROVITCH J, 1989, J CLIN INVEST, V84, P976, DOI 10.1172/JCI114261; MEYEROVITCH J, 1991, J CLIN INVEST, V87, P1286, DOI 10.1172/JCI115131; MEYEROVITCH J, 1992, BIOCHEMISTRY-US, V31, P10338, DOI 10.1021/bi00157a023; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; POPOVICH BK, 1989, AM J PHYSIOL, V257, pE573, DOI 10.1152/ajpendo.1989.257.4.E573; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; SHACTER E, 1984, ANAL BIOCHEM, V138, P416, DOI 10.1016/0003-2697(84)90831-5; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1985, NATURE, V313, P7565; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WALKER PS, 1989, J BIOL CHEM, V264, P6587; WANG PH, 1989, J CLIN INVEST, V84, P62, DOI 10.1172/JCI114170; YANG SD, 1987, BIOCHEM BIOPH RES CO, V142, P38, DOI 10.1016/0006-291X(87)90448-7	54	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25455	25462						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244979				2022-12-25	WOS:A1993MK10000029
J	MA, JY; NASTUK, MA; MCKECHNIE, BA; FALLON, JR				MA, JY; NASTUK, MA; MCKECHNIE, BA; FALLON, JR			THE AGRIN RECEPTOR - LOCALIZATION IN THE POSTSYNAPTIC MEMBRANE, INTERACTION WITH AGRIN, AND RELATIONSHIP TO THE ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO ELECTRIC ORGAN; BASAL LAMINA; NEUROMUSCULAR-JUNCTIONS; CULTURED MYOTUBES; SYNAPTIC SITES; CELL-ADHESION; MUSCLE; AGGREGATION; MOLECULES; PROTEIN	Agrin is a component of the synaptic basal lamina that induces the aggregation of acetylcholine receptors (AChRs) and other elements of the postsynaptic membrane. We have determined the localization, binding characteristics, and biochemical profile of the agrin receptor in Torpedo electric organ membranes and defined domains of agrin that bind this receptor. Postsynaptic membranes from Torpedo electric organ bind agrin as judged by depletion of AChR clustering activity from solution. A ligand-based radioimmunoassay shows that agrin binding to postsynaptic membranes is saturable and calcium-dependent. Half-maximal binding is observed at agrin concentrations less-than-or-equal-to 10(-10) m. Identification of the bound agrin polypeptides shows that at least one membrane binding domain of agrin is located in a 70-kDa proteolytic fragment. Immunofluorescent visualization and radioimmunoassay of agrin binding demonstrates that the agrin receptor is selectively concentrated in postsynaptic membranes, with little binding detected on nonsynaptic or liver membranes. Agrin binding is greatly reduced if the membranes are pretreated with trypsin, but is unaffected by phosphatidylinositol-specific phospholipase C. Membranes stripped of peripheral proteins by alkaline treatment retain full ligand binding capacity. Alpha-bungarotoxin affinity columns bind AChRs but not agrin receptors. The ratio of agrin receptors to AChRs in postsynaptic membranes is approximately 1:200. We conclude that the agrin receptor is an integral membrane glycoprotein that is selectively concentrated in postsynaptic membranes, but that is not tightly complexed with the AChR. The results also indicate that the biological activity of agrin is mediated through intracellular signal transduction events triggered by ligand binding to the agrin receptor.	WORCESTER FDN EXPTL BIOL INC,NEUROBIOL GRP,SHREWSBURY,MA 01545	Worcester Foundation for Biomedical Research					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023924] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD023924, HD 23924] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURDEN SJ, 1979, J CELL BIOL, V82, P412, DOI 10.1083/jcb.82.2.412; BURDEN SJ, 1983, CELL, V35, P687, DOI 10.1016/0092-8674(83)90101-0; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; COHEN MW, 1992, J NEUROSCI, V12, P2982, DOI 10.1523/JNEUROSCI.12-08-02982.1992; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FALLON JR, 1985, NATURE, V315, P571, DOI 10.1038/315571a0; FALLON JR, 1989, J CELL BIOL, V108, P1527, DOI 10.1083/jcb.108.4.1527; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1992, CELL, V70, P1, DOI 10.1016/0092-8674(92)90525-H; FROEHNER SC, 1981, P NATL ACAD SCI-BIOL, V78, P5230, DOI 10.1073/pnas.78.8.5230; GODFREY EW, 1988, DEV BIOL, V130, P471, DOI 10.1016/0012-1606(88)90343-0; GODFREY EW, 1988, J CELL BIOL, V106, P1263, DOI 10.1083/jcb.106.4.1263; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; HALL ZW, 1993, NEURON S, V10, P99; HENDERSON LP, 1984, J NEUROSCI, V4, P3140; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; HUNTER DD, 1991, J NEUROSCI, V11, P3960; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IBRAGHIMOV BO, 1992, NATURE, V355, P696; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; LEITH E, 1993, J NEUROSCI, V13, P2509; LIETH E, 1992, DEV BIOL, V149, P41, DOI 10.1016/0012-1606(92)90262-F; NASTUK M A, 1991, Society for Neuroscience Abstracts, V17, P219; NASTUK MA, 1991, NEURON, V7, P807, DOI 10.1016/0896-6273(91)90283-6; NASTUK MA, 1993, TRENDS NEUROSCI, V16, P72, DOI 10.1016/0166-2236(93)90020-M; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; PARASCHOS A, 1982, BIOCHIM BIOPHYS ACTA, V691, P249, DOI 10.1016/0005-2736(82)90414-X; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; REIST NE, 1987, J CELL BIOL, V105, P2457, DOI 10.1083/jcb.105.6.2457; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1992, J NEUROSCI, V12, P3535; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; Salpeter MM, 1987, VERTEBRATE NEUROMUSC, V23, P1; SMITH MA, 1992, MOL CELL NEUROSCI, V3, P406, DOI 10.1016/1044-7431(92)90052-4; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; WALLACE BG, 1990, J NEUROSCI, V10, P3576; WALLACE BG, 1991, PHILOS T ROY SOC B, V331, P273, DOI 10.1098/rstb.1991.0016; WALLACE BG, 1988, J CELL BIOL, V107, P267, DOI 10.1083/jcb.107.1.267; YEADON JE, 1991, J CELL BIOL, V115, P1069, DOI 10.1083/jcb.115.4.1069	42	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25108	25117						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227074				2022-12-25	WOS:A1993MG67300085
J	SAIDO, TC; YOKOTA, M; NAGAO, S; YAMAURA, I; TANI, E; TSUCHIYA, T; SUZUKI, K; KAWASHIMA, S				SAIDO, TC; YOKOTA, M; NAGAO, S; YAMAURA, I; TANI, E; TSUCHIYA, T; SUZUKI, K; KAWASHIMA, S			SPATIAL-RESOLUTION OF FODRIN PROTEOLYSIS IN POSTISCHEMIC BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; DELAYED NEURONAL DEATH; GERBIL HIPPOCAMPUS; SYNAPTIC TRANSMISSION; CALPAIN INHIBITORS; PROTEIN-SYNTHESIS; ALPHA-FODRIN; MU-CALPAIN; ISCHEMIA; CALCIUM	One of the major obstacles in investigating in vivo proteolytic phenomena has been the inaccessibility to spatial information as to where in the tissue the reaction proceeds because the orthodox method employing electrophoretic analysis requires homogenization of samples and thus results in loss of such spatial information. To overcome this technical drawback, we have developed methodology to produce antibodies that specifically distinguish a proteolyzed form of a given protein from its intact form. Here we describe our immunohistochemical observation of calpain-catalyzed fodrin proteolysis in postischemic gerbil hippocampus, using an antibody exclusively specific to the proteolyzed 150-kDa form of fodrin alpha subunit. Our data establish a novel discovery that transient (10 min) global forebrain ischemia followed by reperfusion induces at least two distinct phases of fodrin proteolysis in hippocampus: an early phase in molecular layer and in stratum oriens of CA3 and CA1 sectors within 15 min and a late drastic and persistent phase in the entire CA1 after 4-24 h. The former may be one of the early events initiating the complex cascade leading to the delayed neuronal death, while the latter should be considered as a more direct cause for the actual degeneration in CA1.	HYOGO MED UNIV,DEPT NEUROSURG,NISHINOMIYA,HYOGO 663,JAPAN; SOPHIA UNIV,DEPT CHEM,CHIYODA KU,TOKYO 102,JAPAN; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	Hyogo College of Medicine; University of Hyogo; Sophia University; University of Tokyo	SAIDO, TC (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,BUNKYO KU,TOKYO 113,JAPAN.		Sado, Takaomi/AAN-2759-2021	Sado, Takaomi/0000-0003-1970-6903				ARLINGHAUS L, 1991, EUR J PHARMACOL, V209, P123, DOI 10.1016/0014-2999(91)90022-I; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DELCERRO S, 1990, BRAIN RES, V530, P91; DENNY JB, 1990, BRAIN RES, V534, P317, DOI 10.1016/0006-8993(90)90148-5; DISTASI AMM, 1991, NEURON, V6, P445, DOI 10.1016/0896-6273(91)90252-U; FRIEDRICH P, 1990, NEUROSCIENCE, V35, P1, DOI 10.1016/0306-4522(90)90115-K; GOLL ED, 1990, INTRACELLULAR CALCIU, P103; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P209, DOI 10.1007/BF00691854; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; LYNCH G, 1990, FID RES FDN, V4, P125; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MCMAHON AP, 1987, BIOCHEM SOC T, V15, P804, DOI 10.1042/bst0150804; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; OGURA A, 1988, EXP BRAIN RES, V73, P447, DOI 10.1007/BF00406601; OLNEY JW, 1979, BRAIN RES, V176, P91, DOI 10.1016/0006-8993(79)90872-2; RADER RK, 1989, NEUROSCI LETT, V99, P125, DOI 10.1016/0304-3940(89)90276-0; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; SIMAN R, 1985, NATURE, V313, P225, DOI 10.1038/313225a0; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SUZUKI K, 1991, BIOMED BIOCHIM ACTA, V50, P483; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; THILMANN R, 1986, ACTA NEUROPATHOL, V71, P88, DOI 10.1007/BF00687967; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; YOKOTA M, 1992, BRAIN RES, V587, P123, DOI 10.1016/0006-8993(92)91436-I; YOSHIDA S, 1986, J NEUROCHEM, V47, P744; YOSHIDOMI M, 1989, J NEUROCHEM, V53, P1589, DOI 10.1111/j.1471-4159.1989.tb08556.x	37	265	284	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25239	25243						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227089				2022-12-25	WOS:A1993MG67300102
J	WILLIAMS, AJ; WERNETTE, CM; KAGUNI, LS				WILLIAMS, AJ; WERNETTE, CM; KAGUNI, LS			PROCESSIVITY OF MITOCHONDRIAL-DNA POLYMERASE FROM DROSOPHILA EMBRYOS - EFFECTS OF REACTION CONDITIONS AND ENZYME PURITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; REPLICATION FACTOR-C; ESCHERICHIA-COLI; III HOLOENZYME; BETA-SUBUNIT; CALF THYMUS; ACCESSORY PROTEINS; SIZE CLASSES; ORIGIN; ALPHA	Mitochondrial DNA polymerase from Drosophila embryos has been characterized with regard to its mechanism of DNA synthesis under the influence of a variety of compounds in moderate salt (120 mM KCl), where the enzyme is most highly active and only moderately processive, and in low salt (30 mM KCl), where it is less active yet most highly processive. Disparate activity and processivity optima were obtained in low salt in the presence of varying pH or MgCl2 and ATP concentrations; in moderate salt, optimal activity and processivity were achieved coincidentally. Whereas no correlation between processivity and activity optima was observed upon addition of polyethylene glycol in either low or moderate salt, the optima were coincident at both salt levels on addition of glycerol. None of the reaction conditions examined allowed DNA polymerase gamma to exhibit maximal activity and processivity concurrently; maximal activity was always achieved in moderate salt and the highest processivity in low salt. However, while limiting the availability of primer termini had no effect on the mechanism of DNA synthesis, we found that the ability of mitochondrial DNA polymerase to copy singly primed M13 DNA was enhanced then diminished during the course of purification, suggesting loss of an accessory factor.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAMBARA RA, 1978, J BIOL CHEM, V253, P413; BERTAZZONI U, 1977, EUR J BIOCHEM, V81, P237, DOI 10.1111/j.1432-1033.1977.tb11945.x; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; BOLDEN A, 1977, J BIOL CHEM, V252, P3351; BRAND MD, 1987, BIOL REV, V62, P141, DOI 10.1111/j.1469-185X.1987.tb01265.x; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1474; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHA TA, 1988, CANCER CELLS EUKARYO, P1; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; DAS SK, 1979, J BIOL CHEM, V254, P1227; Fansler B S, 1974, Methods Enzymol, V29, P53; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FISHER PA, 1979, J BIOL CHEM, V254, P6128; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GODDARD JM, 1980, NUCLEIC ACIDS RES, V8, P741; GODDARD JM, 1978, P NATL ACAD SCI USA, V75, P3886, DOI 10.1073/pnas.75.8.3886; GRIEP MA, 1988, BIOCHEMISTRY-US, V27, P5210, DOI 10.1021/bi00414a040; HACKENBROCK CR, 1968, P NATL ACAD SCI USA, V61, P508; Hansford R.G., 1980, CURR TOP BIOENERG, VVolume 10, P217, DOI 10.1016/B978-0-12-152510-1.50012-2; HOCKENSMITH JW, 1981, BIOCHEMISTRY-US, V20, P227, DOI 10.1021/bi00504a038; HOHN KT, 1987, BIOCHEMISTRY-US, V26, P2870, DOI 10.1021/bi00384a031; HUBSCHER U, 1977, EUR J BIOCHEM, V81, P249, DOI 10.1111/j.1432-1033.1977.tb11946.x; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; HUTSON SM, 1989, BIOCHEMISTRY-US, V28, P4325, DOI 10.1021/bi00436a030; JARVIS TC, 1990, J BIOL CHEM, V265, P15160; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; KAGUNI J, 1979, J MOL BIOL, V135, P863, DOI 10.1016/0022-2836(79)90516-3; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; KWONSHIN O, 1987, J BIOL CHEM, V262, P2121; LYONS JW, 1964, J AM CHEM SOC, V86, P3634, DOI 10.1021/ja01072a009; MAKI S, 1988, J BIOL CHEM, V263, P6561; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; MORONEY PM, 1984, BIOCHEMISTRY-US, V23, P4991, DOI 10.1021/bi00316a025; NEWPORT JW, 1980, MECHANISTIC STUDIES, V19, P485; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; SABATINO RD, 1988, BIOCHEMISTRY-US, V27, P2998, DOI 10.1021/bi00408a050; SLATER JP, 1972, J BIOL CHEM, V247, P6784; SRERE PA, 1980, TRENDS BIOCHEM SCI, V5, P120, DOI 10.1016/0968-0004(80)90051-1; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; WERNETTE CM, 1988, BIOCHEMISTRY-US, V27, P6046, DOI 10.1021/bi00416a033; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WOLSTENHOLME DR, 1979, EXTRACHROMOSOMAL DNA, P409; ZIMMERMAN SB, 1987, P NATL ACAD SCI USA, V84, P1871, DOI 10.1073/pnas.84.7.1871	46	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24855	24862						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227047				2022-12-25	WOS:A1993MG67300052
J	FISCHER, KD; HAESE, A; NOWOCK, J				FISCHER, KD; HAESE, A; NOWOCK, J			COOPERATION OF GATA-1 AND SP1 CAN RESULT IN SYNERGISTIC TRANSCRIPTIONAL ACTIVATION OR INTERFERENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLOBIN GENE; NUCLEAR-PROTEIN FACTORS; DOMINANT CONTROL REGION; DNA-BINDING; ERYTHROID-DIFFERENTIATION; MAMMALIAN-CELLS; CTF/NF-I; PROMOTER; EXPRESSION; REPLICATION	GATA-1 is a lineage-restricted transcription factor. Virtually all erythroid-expressed genes contain GATA recognition sites in their regulatory elements. Co-transfection/transactivation assays have revealed that, although GATA-1 as the only cell-restricted transcription factor is sufficient to activate some of the erythroid-specific promoters, not all such promoters are responsive, suggesting a requirement for cooperation with other factors. To study the interaction of GATA-1 with other transactivators, we analyzed sequence motifs of the human gamma-globin promoter as response system by in vitro transcription and by transfections into erythroid K562 cells or into heterologous Drosophila SL2 cells. GATA-1 alone did not activate the promoter. However, GATA-1 exerted an effect in concert with the ubiquitous transactivator Sp1. Depending on the factor concentrations and the sequence context of the cognate binding sites, this interaction could result in synergistic transcriptional activation or in interference. GATA-1 and Sp1 did not cooperate in DNA binding when tested in vitro. This suggests that the functional cooperation is mediated by protein interactions with additional factor(s) which transmit the activator signal. The Sp1-binding CCACCC motif was found to be critical for high activity of the gamma-globin promoter. This site overlaps with a recognition sequence for members of the NFI/CTF family. NFI did not transactivate, but it interfered with Sp1-mediated stimulation and hence with Sp1/GATA-1 cooperation. These data, together with phylogenetic evidence, suggest that the CCACCC region is likely to represent a regulatory switch element.	UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, MARTINISTR 52, W-2000 HAMBURG 20, GERMANY	Heinrich Pette Institute; University of Hamburg								ANTONIOU M, 1990, GENE DEV, V4, P1007, DOI 10.1101/gad.4.6.1007; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CATALA F, 1989, NUCLEIC ACIDS RES, V17, P3811, DOI 10.1093/nar/17.10.3811; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; EMERSON BM, 1989, CELL, V57, P1189, DOI 10.1016/0092-8674(89)90056-1; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FISCHER KD, 1990, NUCLEIC ACIDS RES, V18, P5685, DOI 10.1093/nar/18.19.5685; FORSBERG M, 1991, EMBO J, V10, P2543, DOI 10.1002/j.1460-2075.1991.tb07794.x; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUMUCIO DL, 1991, BLOOD, V78, P1853; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; HERBOMEL P, 1990, New Biologist, V2, P1063; HULL JD, 1988, J CELL BIOL, V106, P1489, DOI 10.1083/jcb.106.5.1489; JACKSON PD, 1989, GENE DEV, V3, P1860, DOI 10.1101/gad.3.12a.1860; MACLEOD K, 1991, MOL CELL BIOL, V11, P4324, DOI 10.1128/MCB.11.9.4324; MANTOVANI R, 1988, NUCLEIC ACIDS RES, V16, P7783, DOI 10.1093/nar/16.16.7783; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NICOLIS S, 1989, NUCLEIC ACIDS RES, V17, P5509, DOI 10.1093/nar/17.14.5509; NOWOCK J, 1982, CELL, V30, P607, DOI 10.1016/0092-8674(82)90257-4; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RONCHI A, 1989, NUCLEIC ACIDS RES, V17, P10231, DOI 10.1093/nar/17.24.10231; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; TAGLE DA, 1988, J MOL BIOL, V203, P439, DOI 10.1016/0022-2836(88)90011-3; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3	50	104	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23915	23923						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226931				2022-12-25	WOS:A1993MF29400034
J	NACHALIEL, N; JAIN, D; HOD, Y				NACHALIEL, N; JAIN, D; HOD, Y			A CAMP-REGULATED RNA-BINDING PROTEIN THAT INTERACTS WITH PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP) MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; STEM-LOOP STRUCTURE; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; DEGRADATION; STABILIZATION; TRANSCRIPTION; LYMPHOKINE; COMPLEXES; HELICASES	Cyclic-AMP stabilizes phosphoenolpyruvate carboxykinase (GTP) (PEPCK) mRNA against degradation. To investigate the mechanism of this effect, RNA mobility shift assays were used to determine the interaction of cellular proteins with specific domains from the mRNA. We report here the identification of a protein with an affinity for sequences of PEPCK mRNA with a predicted stem-loop structure. RNA-protein complex formation was significantly reduced if the double-stranded RNA probe was preheated to 90-degrees-C. The RNA-binding protein did not bind to the hairpin structure of poly(rI)-poly (rC), indicating some degree of sequence specificity and that the RNA-binding protein is not the interferon-induced double-stranded RNA-activated protein kinase. The binding activity was contained in the cytosolic fraction (100,000 x g) of rat hepatoma FTO-2B cells and was significantly enhanced by high concentrations of KCl. Chromatography on an anion exchanger separated the binding activity from a factor which, upon reconstitution, inhibited the interaction with the RNA probe. Incubation of cells with cAMP resulted in a 3-4-fold decrease in the activity of the RNA-binding protein. An inhibition in complex formation was observed with extracts as early as 60 min after exposure of cells to cAMP. Liver extracts from rats starved for 72 h also had reduced binding activity compared to extracts from fed animals. Cellular extracts treated with alkaline phosphatase exhibited an elevated level of complex formation. An analysis by SDS-polyacrylamide gel electrophoresis of the RNA-protein complex after ultraviolet light cross-linking demonstrated that the RNA-binding protein had a molecular mass of approximately 100 kDa. On the basis of these results, we suggest that liver cells contain a protein whose interaction with PEPCK mRNA is regulated by cAMP-dependent phosphorylation and which may be responsible for the cAMP-mediated control of PEPCK mRNA half-life.	SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								BEALE EG, 1985, J BIOL CHEM, V260, P748; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHRIST B, 1991, BIOCHEM BIOPH RES CO, V177, P1273, DOI 10.1016/0006-291X(91)90679-2; CLAUS TH, 1981, BIOCHEM ACTION HORM, P209; COOK JS, 1986, P NATL ACAD SCI USA, V83, P7583, DOI 10.1073/pnas.83.20.7583; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HOD Y, 1988, J BIOL CHEM, V263, P7747; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; HUA JL, 1992, MOL ENDOCRINOL, V6, P1418, DOI 10.1210/me.6.9.1418; KILLARY AM, 1984, BIOCHEM GENET, V22, P201, DOI 10.1007/BF00484224; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90338-A; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; LIU J, 1991, MOL CELL BIOCHEM, V104, P89; MANZELLA JM, 1992, J BIOL CHEM, V267, P7007; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; PANDEY NB, 1991, NUCLEIC ACIDS RES, V19, P5653, DOI 10.1093/nar/19.20.5653; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; STOFFEL M, 1993, HUM MOL GENET, V2, P1, DOI 10.1093/hmg/2.1.1; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WICKS WD, 1972, BIOCHEM BIOPH RES CO, V48, P205, DOI 10.1016/0006-291X(72)90364-6	35	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24203	24209						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226967				2022-12-25	WOS:A1993MF29400073
J	KUPPER, TS; FERGUSON, TA				KUPPER, TS; FERGUSON, TA			A POTENTIAL PATHOPHYSIOLOGIC ROLE FOR ALPHA(2)BETA(1)-INTEGRIN IN HUMAN EYE DISEASES INVOLVING VITREORETINAL TRACTION	FASEB JOURNAL			English	Note						VITREOUS; INTEGRIN; RETINOPATHY; COLLAGEN; DIABETES-MELLITUS	HUMAN-SKIN FIBROBLASTS; CELL-ADHESION; COLLAGEN LATTICES; TISSUE-CULTURE; CONTRACTION; REORGANIZATION; FIBRONECTIN; DETACHMENT; IDENTIFICATION; PATHOGENESIS	Cell-mediated contraction of tissues containing fibrillar collagens can lead to organ compromise and loss of function. The same process that is biologically advantageous during the contraction phase of wound healing can be subverted in diseases such as hepatic cirrhosis, pulmonary fibrosis, and scleroderma, although the cellular and molecular mechanism of matrix tissue contraction is difficult to study in such chronic diseases. However, certain human eye diseases that result in tractional detachment of the retina and loss of vision are characterized by acute cell-mediated contraction of collagenous tissue in the vitreous cavity. In this study, we demonstrate that human cells can contract vitreous, a complex biological gel containing type II collagen, in vitro. This cell-mediated contraction can be blocked by antibodies and peptides that antagonize the function of alpha2beta1 integrin, and the potential for contraction can be conferred upon noncontracting cells by stable transfection of cells with alpha2 cDNA. We also show that this contractile process, if focally resisted, can result in remodeling vitreous from a gel to a structure that resembles a planar membrane, and that substantial isometric forces can be measured across this tissue. We propose that in diseases such as proliferative diabetic retinopathy and proliferative vitreoretinopathy, alpha2beta1 integrin-mediated contraction of the vitreous and tension at the site of vitreoretinal attachments contribute to the terminal event of tractional retinal detachment. By extension, we propose that alpha2beta1 integrin is a centrally important molecule in human diseases characterized by remodeling and contraction of collagenous tissue (i.e., fibrocontractive diseases).	WASHINGTON UNIV,DEPT OPHTHALMOL,ST LOUIS,MO 63110	Washington University (WUSTL)	KUPPER, TS (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV DERMATOL,75 FRANCIS ST,BOSTON,MA 02215, USA.		Kupper, Thomas/O-4962-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI025082, R01AI025082, R37AI025082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040124] Funding Source: NIH RePORTER; NEI NIH HHS [EY06765] Funding Source: Medline; NIAID NIH HHS [AI25082] Funding Source: Medline; NIAMS NIH HHS [AR40124] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARIYAN S, 1978, ARCH SURG-CHICAGO, V113, P1034; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BISSELL DM, 1990, HEPATOLOGY, V11, P488, DOI 10.1002/hep.1840110322; CAMPOCHIARO PA, 1985, ARCH OPHTHALMOL-CHIC, V103, P1403; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CLEARY PE, 1979, AM J OPHTHALMOL, V88, P221, DOI 10.1016/0002-9394(79)90469-0; CONSTABLE IJ, 1972, ARCH OPHTHALMOL-CHIC, V88, P544, DOI 10.1001/archopht.1972.01000030546016; CONSTABLE IJ, 1974, RETINA C, P245; CROUCH E, 1990, AM J PHYSIOL, V259, P159; DAVIS MD, 1965, ARCH OPHTHALMOL-CHIC, V74, P741; EBERHARDKLEIN CE, 1991, J CELL BIOL, V115, P127; EHRLICH HP, 1988, EYE, V2, P149, DOI 10.1038/eye.1988.28; FAULBORN J, 1978, A GRAEF ARCH KLIN EX, V205, P157, DOI 10.1007/BF00414395; FERGUSON T, 1992, CLIN RES, V40, pA251; FOOS RY, 1985, OPHTHALMOLOGY, V92, P563; FORRESTER JV, 1986, INVEST OPHTH VIS SCI, V27, P1085; GLOOR BP, 1981, ADLERS PHYSL EYE CLI; GRINNELL F, 1984, J CELL SCI, V66, P51; GUIDRY C, 1985, J CELL SCI, V79, P67; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kirchhof B, 1989, Dev Ophthalmol, V16, P1; KISHI S, 1986, INT OPHTHALMOL, V9, P253, DOI 10.1007/BF00137539; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; MACHEMER R, 1988, INVEST OPHTH VIS SCI, V29, P1771; MACHEMER R, 1988, AM J OPHTHALMOL, V105, P170, DOI 10.1016/0002-9394(88)90182-1; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PRATT RM, 1972, DEV BIOL, V27, P322, DOI 10.1016/0012-1606(72)90171-6; SCHEIFFARTH OF, 1988, GRAEF ARCH CLIN EXP, V226, P357, DOI 10.1007/BF02172967; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; SEBAG J, 1985, T OPHTHAL SOC UK, V104, P123; SEBAG J, 1989, VITREOUS, P3; SPENCER WH, 1985, OPHTHALMIC PATHOLOGY, P548; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STOPAK D, 1982, DEV BIOL, V90, P383, DOI 10.1016/0012-1606(82)90388-8; USSMANN JH, 1981, ARCH OPHTHALMOL-CHIC, V99, P869, DOI 10.1001/archopht.1981.03930010869016; van Nouhuys C E, 1989, Fortschr Ophthalmol, V86, P221; WALLOW IHL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1370; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133	42	30	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1401	1406		10.1096/fasebj.7.14.8224612	http://dx.doi.org/10.1096/fasebj.7.14.8224612			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	8224612				2022-12-25	WOS:A1993MH00800014
J	FRANCASTEL, C; GROISMAN, R; PFARR, CM; ROBERTLEZENES, J				FRANCASTEL, C; GROISMAN, R; PFARR, CM; ROBERTLEZENES, J			ANTISENSE C-JUN OVERCOMES A DIFFERENTIATION BLOCK IN A MURINE ERYTHROLEUKEMIA CELL-LINE	ONCOGENE			English	Article							ERYTHROID-DIFFERENTIATION; HEMOGLOBIN-SYNTHESIS; DOWN-REGULATION; PORPHOBILINOGEN DEAMINASE; RECEPTOR ACTIVITY; MYELOID-LEUKEMIA; GENE-EXPRESSION; CONTROL REGION; FOS PROTEINS; GLOBIN	We have studied the expression of the c-jun gene during dimethyl-sulfoxide (DMSO) induced differentiation of Friend erythroleukemia (F-MEL) cells. No expression of c-jun was detected in a differentiation-competent F-MEL cell line (745A) either before or after treatment with DMSO. By contrast, c-jun expression was constitutive in a F-MEL cell line (TFP10) resistant to DMSO-induced differentiation and increased with DMSO. We have investigated the possible role of c-jun in conferring this resistance by stably transfecting either sense or antisense c-jun constructs into both differentiation-sensitive 745A and defective TFP10 cell lines. Inhibition of c-jun expression by antisense transcripts in the TFP10 cells restored their ability to undergo erythroid differentiation when exposed to DMSO while expression of junB or junD antisense vectors failed to do so. In addition, c-jun overexpression in the 745A cells resulted in decreased DMSO-induced differentiation. These results indicate a correlation between the level of c-jun expression and the ability of F-MEL cells to undergo DMSO-induced differentiation and suggest that c-jun may be an important negative regulator in this process.	HOP PAUL BROUSSE,INSERM,U268,ONCOGENESE APPL LAB,F-94800 VILLEJUIF,FRANCE; INST PASTEUR,DEPT BIOTECHNOL,CNRS,UA 1644,F-75724 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)			Pfarr, Curt/HHD-1410-2022; Francastel, Claire/AAI-4798-2021	Groisman, Regina/0000-0003-3990-7622; Francastel, Claire/0000-0002-6353-4320				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BERKOFLINT Y, 1994, EMBO J, V13, P646, DOI 10.1002/j.1460-2075.1994.tb06303.x; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BLOCH A, 1984, CANCER TREAT REP, V68, P199; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHERN YJ, 1991, BLOOD, V78, P991, DOI 10.1182/blood.V78.4.991.bloodjournal784991; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGLIATI T, 1993, ONCOGENE, V8, P1263; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FRANCASTEL C, 1992, LEUKEMIA, V6, P935; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GRANDCHAMP B, 1985, J BIOL CHEM, V260, P9630; HOUSSET M, 1982, BRIT J HAEMATOL, V51, P125, DOI 10.1111/j.1365-2141.1982.tb07297.x; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JEANNESSON P, 1984, ANTICANCER RES, V4, P47; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MARKS PA, 1987, CANCER RES, V47, P657; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MECHTA F, 1989, New Biologist, V1, P297; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1990, J BIOL CHEM, V265, P22090; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PROCHOWNIK EV, 1990, BLOOD, V76, P1830; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REDDY PMS, 1993, MOL CELL BIOL, V13, P1093, DOI 10.1128/MCB.13.2.1093; ROBERTLEZENES J, 1988, CANCER RES, V48, P3972; RYSECK RP, 1991, ONCOGENE, V6, P533; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SARTORELLI AC, 1985, BRIT J CANCER, V52, P293, DOI 10.1038/bjc.1985.193; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRENTESAUX C, 1993, LEUKEMIA, V7, P452; TSIFTSOGLOU AS, 1985, ANTICANCER RES, V5, P81; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2	50	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1957	1964						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208542				2022-12-25	WOS:A1994NR68500020
J	GUJULUVA, CN; BAEK, JH; SHIN, KH; CHERRICK, HM; PARK, NH				GUJULUVA, CN; BAEK, JH; SHIN, KH; CHERRICK, HM; PARK, NH			EFFECT OF UV-IRRADIATION ON CELL-CYCLE, VIABILITY AND THE EXPRESSION OF P53, GADD153 AND GADD45 GENES IN NORMAL AND HPV-IMMORTALIZED HUMAN ORAL KERATINOCYTES	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENES; DNA-DAMAGING AGENTS; WILD-TYPE P53; HUMAN PAPILLOMAVIRUS; GROWTH ARREST; PROTEIN; CARCINOGENESIS; TRANSFORMATION; PARTICIPATION; INITIATION	We previously demonstrated neoplastic conversion of HPV-immortalized human oral keratinocytes by exposing cells to chemical carcinogens, but failed to transform normal human oral keratinocytes with same chemical carcinogens in vitro. Though the reason for different responses of normal and HPV-immortalized oral keratinocytes to chemical carcinogens remains speculative, the difference may be due to the capacity of normal cells and incapacity of HPV-immortalized cells for repairing damaged DNA induced by carcinogens, Since (1) the repair of damaged DNA takes place in G(1)/G(2) phases of cell cycle, (2) wild type p53 plays major role in the induction of transient G(1) and/or G(2) arrests, and (3) the expression of gadd45 and gadd153 is also associated with the cell cycle arrest and DNA damage, we investigated transient cell cycle arrest and the expression of p53, gadd45 and gadd153 in normal human oral keratinocytes, HPV-immortalized oral keratinocytes, and an oral cancer cell line expressing mutant p53 after exposing cells to UV light. Normal cells demonstrated transient G(1) arrest after exposure to UV light, but other tested cells did not. While UV-irradiation significantly increased the level of intranuclear wild type p53 protein in normal cells, it did not alter p53 protein levels in HPV-immortalized and oral cancer cells. The level of gadd45 transcripts was enhanced in all tested cells, but normal cells demonstrated higher increase in the level of gadd45 after UV-exposure compared to other tested cells. The level of gadd153 gene transcripts was only increased in normal oral keratinocytes after UV-irradiation. These data indicate that UV-induced transient G(1) arrest in normal oral keratinocytes may be associated with both enhanced levels of intranuclear wild type p53 protein and gadd45 and gadd153 transcripts.	UNIV CALIF LOS ANGELES,SCH DENT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010049] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE 10049] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDIERY WS, 1993, CELL, V75, P817; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KIM MS, 1993, ANTICANCER RES, V13, P1405; KIM MS, 1993, CANCER RES, V53, P4811; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI SL, 1992, CARCINOGENESIS, V13, P1981, DOI 10.1093/carcin/13.11.1981; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MIN BM, 1994, IN PRESS ORAL ONCOL; MULLAART E, 1990, MUTAT RES, V237, P189, DOI 10.1016/0921-8734(90)90001-8; NAGANO T, 1993, ARCH DERMATOL, V129, P1157, DOI 10.1001/archderm.129.9.1157; NAQUI A, 1986, ANNU REV BIOCHEM, V55, P137, DOI 10.1146/annurev.biochem.55.1.137; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SAKAI E, 1992, ONCOGENE, V7, P927; SCHAFFNER M, 1990, CELL, V63, P1129; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHIN KH, 1994, MOL CARCINOGEN, V9, P76, DOI 10.1002/mc.2940090205; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	40	99	103	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1819	1827						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208528				2022-12-25	WOS:A1994NR68500003
J	CSERJESI, P; LILLY, B; HINKLEY, C; PERRY, M; OLSON, EN				CSERJESI, P; LILLY, B; HINKLEY, C; PERRY, M; OLSON, EN			HOMEODOMAIN PROTEIN MHOX AND MADS PROTEIN MYOCYTE ENHANCER-BINDING FACTOR-II CONVERGE ON A COMMON ELEMENT IN THE MUSCLE CREATINE-KINASE ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; TRANSCRIPTION FACTORS; REGULATORY ELEMENTS; CARDIAC-MUSCLE; NUCLEAR FACTOR; FACTOR-II; GENE; EXPRESSION; PROMOTER; BRAIN	MHox is a mesoderm-specific homeodomain protein that binds an A/T-rich element that is essential for activity of the muscle creatine kinase (MCK) enhancer. The MHox binding site also binds the ubiquitous homeodomain protein Oct-1 as well as myocyte enhancer-binding factor-2 (MEF2), which belongs to the MADS superfamily of transactivators. To determine which of these proteins activates MCK transcription through the A/T element, we mutated this sequence such that it would selectively bind MHox, MEF2, or Oct-1 and tested the activities of the mutant enhancers in skeletal muscle cells. These mutant enhancers revealed that only MEF2 is able to activate the MCK enhancer through the A/T element. The convergence of homeodomain and MADS proteins on the A/T element in the MCK enhancer provides a mechanism through which a single DNA sequence can mediate positive and negative regulation of gene transcription and is reminiscent of the roles of these two classes of transcription factors in the control of other cell-specific genes.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			LILLY, BRENDA/N-6867-2015	LILLY, BRENDA/0000-0002-3125-7496				AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; ANDRES V, 1992, DEVELOPMENT, V116, P321; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P17; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HINKLEY C, 1991, MOL CELL BIOL, V11, P641, DOI 10.1128/MCB.11.2.641; HOBSON GM, 1988, NUCLEIC ACIDS RES, V16, P8925, DOI 10.1093/nar/16.18.8925; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KERN MJ, 1992, NUCLEIC ACIDS RES, V20, P5189, DOI 10.1093/nar/20.19.5189; KOMURO I, 1993, EMBO J, V12, P1387, DOI 10.1002/j.1460-2075.1993.tb05783.x; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; KURATANI S, 1994, DEV BIOL, V161, P357, DOI 10.1006/dbio.1994.1037; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NOHNO T, 1993, DEV BIOL, V158, P254, DOI 10.1006/dbio.1993.1184; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	38	60	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16740	16745						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206996				2022-12-25	WOS:A1994NR29600037
J	MUNZER, JS; DALY, SE; JEWELLMOTZ, EA; LINGREL, JB; BLOSTEIN, R				MUNZER, JS; DALY, SE; JEWELLMOTZ, EA; LINGREL, JB; BLOSTEIN, R			TISSUE-SPECIFIC AND ISOFORM-SPECIFIC KINETIC-BEHAVIOR OF THE NA,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; RED-BLOOD-CELLS; INFECTED INSECT CELLS; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; ENZYMATIC-PROPERTIES; RAT NA,K-ATPASE; XENOPUS OOCYTES; NA+/K+-ATPASE; SODIUM-PUMP	The objective of this study has been to delineate the side-specific effects of Na+ and K+ on the transport kinetics of tissue-specific Na/K pumps. Two experimental systems have been used. In one, Na/K pumps of exogenous microsomal membrane sources (rat axolemma, kidney) were delivered by membrane fusion into dog erythrocytes, and in the other, the three isoforms of the catalytic subunit of the rat enzyme were individually transfected into HeLa cells as in previous studies (Jewell, E. A., and Lingrel, J.B (1991) J. Biol. Chem. 266, 16925-16930), with the alpha(2) and alpha(3) isoforms rendered relatively resistant to ouabain by site-directed mutagenesis. Whereas the kidney microsomes comprise the alpha(1) catalytic isoform, the axolemma microsomes were predominantly alpha(3) (approximate to 60%) with lesser amounts of alpha(2) (approximate to 25%) and alpha(1) (approximate to 15%) as measured by the ouabain-sensitive profile of phosphoenzyme as well as by immunoblotting with isoform-specific antibodies using membranes of known specific activity as standards (alpha(1) of kidney, alpha(1) and alpha(2) of muscle). Both systems were analyzed with respect to the effects of varying concentrations of cytoplasmic Na+ and extracellular K+ on pump-mediated Rb-86(+)(K+) influx. With the individual isoform-transfected HeLa cells and monensin added to vary and control the intracellular Na+ concentration, differences in apparent affinities of the alpha(3) isoform compared with the alpha(1) and alpha(2) isoforms were observed, i.e. a approximate to 3-fold higher affinity for extracellular K+ and approximate to 4-fold lower affinity for cytoplasmic Na+. Thus, in the presence of 10 mM extracellular Na+, apparent K-0.5 values for extracellular K+ activation of K+(Rb+) influxes were 0.22 +/- 0.02 mM for alpha(1), 0.20 +/- 0.02 mM for alpha(2), and 0.09 +/- 0.01 mM for alpha(3). At high intracellular K+ (greater than or equal to 100 mM) and saturating extracellular K+ concentrations, apparent K-0.5 values for cytoplasmic Na+ activation were 17.6 +/- 1.1 mM for alpha(1), 19.7 +/- 1.0 mM for alpha(2), and 63.5 +/- 9.1 mM for alpha(3). The functional differences observed with the individual isoform-transfected cells were completely consistent with the kinetic differences observed with the axolemma and kidney pumps fused into erythrocytes. Axolemma pumps had a approximate to 3-fold lower K-0.5 for extracellular K+ and a approximate to 2-fold higher K-0.5 for cytoplasmic Na+. In the HeLa transfectants, differences in affinities for cytoplasmic Na+ were associated with differences in the steady-state intracellular Na+ concentration, i.e. 27.5 mM in alpha(3)-transfected cells compared with 15.7 and 19.7 mM in alpha(1)- and alpha(2)-transfected cells, respectively.	MCGILL UNIV, DEPT MED, MONTREAL H3G 1A4, PQ, CANADA; UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	McGill University; University of Cincinnati					PHS HHS [R0HIL28573] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERREBIBERTRAND I, 1990, BIOCHIM BIOPHYS ACTA, V1021, P148, DOI 10.1016/0005-2736(90)90027-L; BLANCO G, 1993, P NATL ACAD SCI USA, V90, P1824, DOI 10.1073/pnas.90.5.1824; BLANCO G, 1990, BIOCHIM BIOPHYS ACTA, V1027, P1, DOI 10.1016/0005-2736(90)90039-Q; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; BRINES ML, 1992, BRAIN RES, V591, P94, DOI 10.1016/0006-8993(92)90982-F; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; DHIR R, 1990, BIOCHIM BIOPHYS ACTA, V1026, P141, DOI 10.1016/0005-2736(90)90056-T; FORBUSH B, 1983, ANAL BIOCHEM, V128, P159, DOI 10.1016/0003-2697(83)90356-1; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P175, DOI 10.1113/jphysiol.1967.sp008295; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GRISAR T, 1979, BRAIN RES, V165, P87, DOI 10.1016/0006-8993(79)90047-7; HABER RS, 1987, AM J PHYSIOL, V253, pF26, DOI 10.1152/ajprenal.1987.253.1.F26; HARINDER HS, 1992, J BIOL CHEM, V267, P5040; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; INABA M, 1986, J BIOL CHEM, V261, P6099; INOUE N, 1974, SODIUM PUMP RECENT D, V46, P597; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1971, BIOCHIM BIOPHYS ACTA, V233, P366, DOI 10.1016/0005-2736(71)90334-8; KIMELBERG HK, 1978, BRAIN RES, V141, P305, DOI 10.1016/0006-8993(78)90200-7; KRNJEVIC K, 1975, CAN J PHYSIOL PHARM, V53, P923, DOI 10.1139/y75-126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LYTTON J, 1985, J BIOL CHEM, V260, P75; MAIRBAURL H, 1992, J GEN PHYSIOL, V99, P721, DOI 10.1085/jgp.99.5.721; Markwell M A, 1981, Methods Enzymol, V72, P296; MCGILL DL, 1991, J BIOL CHEM, V266, P15824; MUNZER JS, 1992, J BIOL CHEM, V267, P5202; MUNZER JS, 1993, 7TH P INT C SOD PUMP; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OBRIEN WJ, 1994, ARCH BIOCHEM BIOPHYS, V310, P32, DOI 10.1006/abbi.1994.1136; PARKER JC, 1983, AM J PHYSIOL, V244, pC324, DOI 10.1152/ajpcell.1983.244.5.C324; POLLACK LR, 1981, J CELL PHYSIOL, V106, P85, DOI 10.1002/jcp.1041060110; REICHENBACH A, 1992, CAN J PHYSIOL PHARM, V70, pS239, DOI 10.1139/y92-267; SCHWARZ W, 1988, BIOCHIM BIOPHYS ACTA, V945, P167, DOI 10.1016/0005-2736(88)90479-8; SHYJAN AW, 1990, J BIOL CHEM, V265, P5166; SHYJAN AW, 1990, P NATL ACAD SCI USA, V87, P1178, DOI 10.1073/pnas.87.3.1178; SKOU JC, 1962, BIOCHIM BIOPHYS ACTA, V58, P314, DOI 10.1016/0006-3002(62)91015-6; STIMERS JR, 1990, J GEN PHYSIOL, V95, P77, DOI 10.1085/jgp.95.1.77; Strehler B. L., 1974, METHOD ENZYMAT AN, P2112, DOI [10.1016/b978-0-12-091304-6.50065-3, DOI 10.1016/B978-0-12-091304-6.50065-3]; SWEADNER KJ, 1992, CAN J PHYSIOL PHARM, V70, pS255, DOI 10.1139/y92-269; SWEADNER KJ, 1985, J BIOL CHEM, V260, P1508; SWEADNER KJ, 1988, METHOD ENZYMOL, V156, P65; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; SYKOVA E, 1983, PROG BIOPHYS MOL BIO, V42, P135, DOI 10.1016/0079-6107(83)90006-8; URAYAMA O, 1988, BIOCHEM BIOPH RES CO, V156, P796, DOI 10.1016/S0006-291X(88)80914-8; URAYAMA O, 1979, J BIOCHEM, V86, P1371, DOI 10.1093/oxfordjournals.jbchem.a132654; WATTS AG, 1991, P NATL ACAD SCI USA, V88, P7425, DOI 10.1073/pnas.88.16.7425	56	177	177	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16668	16676						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206986				2022-12-25	WOS:A1994NR29600026
J	PANAGIOTIDIS, CA; BURKHOLDER, WF; GAITANARIS, GA; GRAGEROV, A; GOTTESMAN, ME; SILVERSTEIN, SJ				PANAGIOTIDIS, CA; BURKHOLDER, WF; GAITANARIS, GA; GRAGEROV, A; GOTTESMAN, ME; SILVERSTEIN, SJ			INHIBITION OF DNAK AUTOPHOSPHORYLATION BY HEAT-SHOCK PROTEINS AND POLYPEPTIDE SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAK; GLUCOSE-REGULATED PROTEIN; PEPTIDE BINDING DOMAIN; MOLECULAR CHAPERONES; STRESS PROTEINS; ATPASE ACTIVITY; HSP70 HOMOLOG; REPLICATION; GENE; PHOSPHORYLATION	DnaK, the Hsp70 of Escherichia coli, autophosphorylates in vitro. Of the two heat shock proteins that interact with DnaK, GrpE inhibits DnaK phosphorylation, whereas DnaJ has no effect on the reaction. Three synthetic peptides are shown to inhibit DnaK phosphorylation. The potency of a given peptide correlates with its affinity for the DnaK protein. A truncated DnaK that lacks the carboxyl-terminal peptide-binding domain autophosphorylates; this reaction is resistant to the inhibitory peptides. Phosphorylation of the truncated DnaK is still inhibited by GrpE, indicating that the GrpE-binding site resides in the DnaK amino-terminal domain. Thus, DnaK phosphorylation is regulated in vitro, and possibly in vivo, by physiologically relevant substrates and cofactors.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT MICROBIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, INST CANC RES, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, INTEGRATED PROGRAM CELLULAR MOLEC & BIOPHYS STUDI, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University				Panagiotidis, Christos/0000-0001-9683-7320	NCI NIH HHS [CA23767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIRSHAPIRA D, 1990, P NATL ACAD SCI USA, V87, P1749, DOI 10.1073/pnas.87.5.1749; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; CEGIELSKA A, 1989, BIOCHIMIE, V71, P1071, DOI 10.1016/0300-9084(89)90113-2; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; EZAKI B, 1989, MOL GEN GENET, V218, P183, DOI 10.1007/BF00331267; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREIDENPJ, 1992, EMBO J, V11, P63; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10342; GROSS CA, 1990, STRESS PROTEINS BIOL, P167; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HWANG DS, 1990, J BIOL CHEM, V265, P19244; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAUX PG, 1978, CELL, V13, P427, DOI 10.1016/0092-8674(78)90317-3; LEUSTEK T, 1991, ARCH BIOCHEM BIOPHYS, V289, P256, DOI 10.1016/0003-9861(91)90469-Y; LEUSTEK T, 1989, P NATL ACAD SCI USA, V86, P7805, DOI 10.1073/pnas.86.20.7805; LEUSTEK T, 1992, CELL MOL BIOL, V38, P1; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOOMIS WF, 1982, MOL CELL BIOL, V2, P484, DOI 10.1128/MCB.2.5.484; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MIZZEN LA, 1991, CELL REGUL, V2, P165, DOI 10.1091/mbc.2.2.165; Morimoto RI, 1990, STRESS PROTEINS BIOL; Neidhardt FC, 1987, HEAT SHOCK RESPONSE, P1334; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PELHAM HRB, 1990, STRESS PROTEINS BIOL, P287; RIEUL C, 1987, EUR J BIOCHEM, V168, P621, DOI 10.1111/j.1432-1033.1987.tb13461.x; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; SAKAKIBARA Y, 1988, J BACTERIOL, V170, P972, DOI 10.1128/jb.170.2.972-979.1988; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schlesinger M. J., 1982, HEAT SHOCK BACTERIA; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; SHERMAN MY, 1991, J BACTERIOL, V173, P7249, DOI 10.1128/jb.173.22.7249-7256.1991; SHERMAN MY, 1993, P NATL ACAD SCI USA, V90, P8648, DOI 10.1073/pnas.90.18.8648; SHI WY, 1992, J BACTERIOL, V174, P6256, DOI 10.1128/JB.174.19.6256-6263.1992; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; TILLY K, 1989, J BACTERIOL, V171, P1585, DOI 10.1128/jb.171.3.1585-1589.1989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG TF, 1993, J BIOL CHEM, V268, P26049; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	60	17	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16643	16647						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206983				2022-12-25	WOS:A1994NR29600022
J	QUADRONI, M; JAMES, P; CARAFOLI, E				QUADRONI, M; JAMES, P; CARAFOLI, E			ISOLATION OF PHOSPHORYLATED CALMODULIN FROM RAT-LIVER AND IDENTIFICATION OF THE IN-VIVO PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; NUCLEOTIDE PHOSPHODIESTERASE; PEPTIDE COMPLEX; ENZYME; BRAIN; STIMULATION; RECOGNITION; POLYLYSINE; MEMBRANE; CELLS	A procedure is described for the isolation of calmodulin (CaM) from rat liver which produces a fraction containing non phosphorylated, mono-, di-, and triphosphocalmodulin as determined by mass spectrometric analysis. The distribution of CaM between the various phospho-species varies from preparation to preparation even though the isolation procedure is rigidly defined, suggesting that CaM phosphorylation may be a very labile phenomenon dependent on the state of the liver as it is removed from the animal. Approximately 15% of CaM in the cell is phosphorylated. The in vivo phosphorylation sites were determined by mass spectrometric analysis of a combined CNBr and trypsin digestion of the phosphocalmodulin (phospho-CaM)-containing fractions. Phosphorylated peptides were sequenced using two mass scanning devices linked together for collisionally activated fragmentation studies to determine peptide sequences, and the phosphorylation sites were determined as Thr-79, Ser-81, and Ser-101. These correspond to three of the four in vitro target sites of calmodulin phosphorylation by casein kinase II, which indicates that this may be the enzyme responsible for the phosphorylation in vivo. A preliminary study on the modulatory activity of phosphorylated calmodulin using a sample extensively phosphorylated in vitro with casein kinase II confirmed that phospho-CaM has an altered biological activity, i.e. reduced activation of the erythrocyte plasma membrane Ca2+ pump.	ETH ZURICH,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND; ETH ZURICH,DEPT BIOL,PROT CHEM LAB,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094; Quadroni, Manfredo/0000-0002-2720-4084				AGOSTINIS P, 1992, J BIOL CHEM, V267, P9732; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BROOKS JC, 1973, J BIOL CHEM, V248, P4189; FUKAMI Y, 1986, P NATL ACAD SCI USA, V83, P4190, DOI 10.1073/pnas.83.12.4190; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; MCCLOSKEY JA, 1990, METHODS ENZYMOL, V193; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1987, FEBS LETT, V215, P241, DOI 10.1016/0014-5793(87)80154-0; NAKAJO S, 1986, BIOCHEM INT, V13, P687; NIGGLI V, 1981, J BIOL CHEM, V256, P395; NIGGLI V, 1981, J BIOL CHEM, V256, P359; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PLANCKE YD, 1983, MOL CELL BIOL, V3, P1412, DOI 10.1128/MCB.3.8.1412; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SACKS DB, 1992, BIOCHEM J, V283, P21, DOI 10.1042/bj2830021; SACKS DB, 1992, BIOCHEM J, V286, P211, DOI 10.1042/bj2860211; SARNO S, 1993, BIOCHEM BIOPH RES CO, V194, P83, DOI 10.1006/bbrc.1993.1788; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; WOLFF DJ, 1972, J BIOL CHEM, V247, P4180; WOLFF DJ, 1974, ARCH BIOCHEM BIOPHYS, V163, P349, DOI 10.1016/0003-9861(74)90486-X	26	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16116	16122						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206911				2022-12-25	WOS:A1994NQ72900027
J	CHEN, HM; LIAO, WSL				CHEN, HM; LIAO, WSL			DIFFERENTIAL ACUTE-PHASE RESPONSE OF RAT KININOGEN GENES INVOLVES TYPE-I AND TYPE-II INTERLEUKIN-6 RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; REACTIVE PROTEIN PROMOTER; CELL-SPECIFIC EXPRESSION; C/EBP-RELATED PROTEINS; HIGH MOLECULAR-WEIGHT; T-KININOGEN; BINDING-PROTEIN; TRANSCRIPTION FACTOR; ACTIVATOR PROTEIN	The serum concentration of rat T1 kininogen increases 20-30-fold in response to acute inflammation. This increase, induced in the liver, is regulated primarily at the transcriptional level. In contrast, synthesis of a homologous K kininogen is not induced. In this study, we further analyzed a 321-base pair interleukin (IL)-6 response element in the T1 kininogen promoter and showed that it consists of at least three functionally distinct sequences (A, B, and C boxes). All three sequences were required for full promoter activity. The B box, a strong C/EBP-binding site, was crucial for T1 kininogen's basal expression, whereas A and C boxes resembled the type II IL-6 response elements and were critical for the cytokine response. C/EBPalpha, -beta, and -delta interacted with the B box sequence; however, upon IL-6 stimulation, C/EBPdelta binding activity was dramatically induced and became the predominant factor binding to this site. Consistent with these binding studies were the cotransfection experiments, revealing that C/EBPdelta was the most potent transactivator under induced conditions and that its transactivation on the T1 kininogen promoter required an intact B box. These findings substantiated the importance of the B box in eliciting the full acute-phase response. A sequence comparison showed the K kininogen promoter contained identical A and B boxes but differed from the T1 kininogen promoter by two nucleotides at the C box. This divergence reduced the IL-6 response by approximately 4-fold, thus contributing to the differential inflammatory response. Our studies demonstrate that evolutionary divergence of a few nucleotides at a critical sequence in the promoter regions can profoundly alter the expression patterns of downstream genes.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,BOX 117,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; UTMD Anderson Cancer Center					NIAMS NIH HHS [AR 38858] Funding Source: Medline; NIA NIH HHS [AG 09853] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038858, R01AR038858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R55AG009853] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; ANDERSON KP, 1989, GENE, V81, P119, DOI 10.1016/0378-1119(89)90342-9; ANDERSON KP, 1990, MOL ENDOCRINOL, V4, P543, DOI 10.1210/mend-4-4-543; ANDUS T, 1988, EUR J IMMUNOL, V18, P739, DOI 10.1002/eji.1830180513; BAUMANN H, 1989, J BIOL CHEM, V264, P8046; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1987, J BIOL CHEM, V262, P9756; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN HM, 1991, J BIOL CHEM, V266, P2946; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FEY G, 1990, PROGR LIVER DIS, P89; FEY GH, 1987, MOL BIOL MED, V4, P323; FUNG WP, 1987, J BIOL CHEM, V262, P9298; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEIGER T, 1988, EUR J IMMUNOL, V18, P717, DOI 10.1002/eji.1830180510; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAYSON DR, 1989, ANN NY ACAD SCI, V557, P243; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; ISSHIKI H, 1991, NEW BIOL, V3, P63; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAGEYAMA R, 1985, J BIOL CHEM, V260, P2060; KAGEYAMA R, 1987, J BIOL CHEM, V262, P2345; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KITAGAWA H, 1987, J BIOL CHEM, V262, P2190; KITAMURA N, 1983, NATURE, V305, P545, DOI 10.1038/305545a0; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KOJ A, 1989, ANN NY ACAD SCI, V557, P1; KONOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473; LI XX, 1990, MOL CELL BIOL, V10, P6624, DOI 10.1128/MCB.10.12.6624; LI XX, 1991, J BIOL CHEM, V266, P15192; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MANN EA, 1991, J BIOL CHEM, V266, P16931; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; POLI V, 1989, NUCLEIC ACIDS RES, V17, P9351; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; SIERRA F, 1989, MOL CELL BIOL, V9, P5610, DOI 10.1128/MCB.9.12.5610; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; TONIATTI C, 1990, EMBO J, V9, P4467, DOI 10.1002/j.1460-2075.1990.tb07897.x; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	56	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25311	25319						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244962				2022-12-25	WOS:A1993MK10000009
J	GUO, LN; PHILLIPS, AT; ARTECA, RN				GUO, LN; PHILLIPS, AT; ARTECA, RN			AMINO-ACID N-MALONYLTRANSFERASES FROM MUNG BEANS - ACTION ON 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID AND D-PHENYLALANINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-AMINOCYCLOPROPANECARBOXYLATE MALONYLTRANSFERASE; ETHYLENE PRODUCTION; CONJUGATION; HYPOCOTYLS; PROTEINS	1-Aminocyclopropane-1-carboxylate (ACC) N-malonyltransferase from etiolated mung bean hypocotyls was examined for its relationship to D-phenylalanine N-malonyltransferase and other enzymes which transfer malonyl groups from malonyl-CoA to D-amino acids. Throughout a 3600-fold purification the ratio Of D-phenylalanine N-malonyltransferase activity to ACC N-malonyltransferase activity was unchanged. Antibodies raised against purified ACC N-malonyltransferase 55-kDa protein were also able to precipitate all D-phenylalanine-directed activity from partially purified mung bean extracts. The irreversible inhibitors phenylglyoxal and tetranitromethane reduced malonyltransferase activity towards D-phenylalanine to the same extent as that for ACC. In addition, several other D-amino acids, particularly D-tryptophan and D-tyrosine, were able to inhibit action towards both ACC and D-phenylalanine. These lines of evidence suggest that a single enzyme is capable of promoting malonylation of both ACC and D-phenylalanine. K(m) values for D-phenylalanine and malonyl-CoA were found to be 48 and 43 muM, respectively; these values are 10-fold lower than the corresponding values when ACC was substrate. Coenzyme A was a noncompetitive (mixed type) product inhibitor towards malonyl-CoA at both unsaturated and saturated ACC concentrations. The enzyme was also inhibited uncompetitively at high concentrations of malonyl-CoA. We propose that the enzyme follows an Ordered Bi-Bi reaction pathway, with the amino acid substrate being bound initially.	PENN STATE UNIV,DEPT HORT,UNIV PK,PA 16802; PENN STATE UNIV,DEPT MOLEC & CELL BIOL,UNIV PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University								AMRHEIN N, 1982, PLANT GROWTH SUBSTAN, P249; AMRHEIN N, 1987, P INT S CONJUGATED P, P102; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GALLARDO M, 1991, PLANT PHYSIOL, V97, P122, DOI 10.1104/pp.97.1.122; GLAZER AN, 1976, PROTEINS, V2, P1; Goding J., 1986, MONOCLONAL ANTIBODIE, P108; GUO LI, 1992, PLANT PHYSIOL, V100, P2041, DOI 10.1104/pp.100.4.2041; KAWASAKI Y, 1982, AGR BIOL CHEM TOKYO, V46, P1; KIONKA C, 1984, PLANTA, V162, P226, DOI 10.1007/BF00397444; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU Y, 1984, ARCH BIOCHEM BIOPHYS, V235, P319, DOI 10.1016/0003-9861(84)90204-2; LIU Y, 1985, PLANT PHYSIOL, V77, P891, DOI 10.1104/pp.77.4.891; MANSKE RHF, 1937, CANAD J RES        B, V15, P84; MATERN U, 1984, ARCH BIOCHEM BIOPHYS, V235, P218, DOI 10.1016/0003-9861(84)90271-6; PHILOSOPHHADAS S, 1985, PHYSIOL PLANTARUM, V63, P431, DOI 10.1111/j.1399-3054.1985.tb02322.x; REKOSLAVSKAYA NI, 1988, J PLANT PHYSIOL, V132, P86, DOI 10.1016/S0176-1617(88)80188-3; ROSA N, 1968, CAN J BIOCHEM CELL B, V46, P797, DOI 10.1139/o68-121; SANDERMANN H, 1991, ARCH BIOCHEM BIOPHYS, V287, P341, DOI 10.1016/0003-9861(91)90488-5; Segel I. H., 1975, ENZYME KINETICS BEHA, P505; SU LY, 1985, PHYTOCHEMISTRY, V24, P1141, DOI 10.1016/S0031-9422(00)81090-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103	22	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25389	25394						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244971				2022-12-25	WOS:A1993MK10000020
J	KOBSCONRAD, S; LEE, H; DIGEORGE, AM; KAUMAYA, PTP				KOBSCONRAD, S; LEE, H; DIGEORGE, AM; KAUMAYA, PTP			ENGINEERED TOPOGRAPHIC DETERMINANTS WITH ALPHA-BETA, BETA-ALPHA-BETA, AND BETA-ALPHA-BETA-ALPHA TOPOLOGIES SHOW HIGH-AFFINITY BINDING TO NATIVE PROTEIN ANTIGEN (LACTATE DEHYDROGENASE-C(4))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICAL COILED-COILS; ZINC FINGER PEPTIDE; SYNTHETIC PEPTIDES; 3-DIMENSIONAL STRUCTURE; CIRCULAR-DICHROISM; 4-HELIX BUNDLE; DENOVO DESIGN; T-CELL; IMMUNOGENIC DETERMINANTS; SECONDARY STRUCTURE	The use of peptides has attracted much interest in the development of synthetic vaccines. Although our current understanding of peptide antigens as immunogens has been greatly advanced recently, there still remain many obstacles. The B cell response elicited by a peptide antigen is governed by a number of poorly understood events such as epitope structure, T cell dependency and major histocompatibility complex restriction, adjuvancy, route of immunization, and immunogen stability. In this paper, we extend our previous studies on the problem of the topographical nature of antigenic sites on native protein antigens, in terms of how much molecular mimicry must be maintained in an antigenic determinant for the induction of high affinity antibodies specific for native protein. We show here that an antigenic epitope from the model contraceptive vaccine candidate lactate dehydrogenase (LDH-C4) can be rationally engineered into a highly structured conformation that mimics the corresponding site in the native three-dimensional protein. Our strategy is based on the selection of an antigenic segment which exhibits certain secondary structural properties and by design principles is fixed in three dimensions by appropriate grafting onto a supersecondary structural motif such as alphabeta, betaalphabeta, or betaalphabetaalpha. The biophysical data are consistent with the proposed secondary structures, and antibodies raised to the various construct show high affinity for the native protein. These studies lend further credence to the conformational nature of peptide epitopes and provide a basis for the rational design of peptide vaccines.	OHIO STATE UNIV, CTR COMPREHENS CANC, SUITE 302, 410 W 12TH AVE, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, COLL BIOL SCI, DEPT MICROBIOL, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, COLL MED, DEPT OBSTET & GYNECOL, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, COLL MED, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Kaumaya, Pravin T. P/E-3354-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI025790] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25790] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; Berzofsky J A, 1991, Semin Immunol, V3, P203; BIDART JM, 1990, SCIENCE, V248, P736, DOI 10.1126/science.1692160; BORRASCUESTA F, 1987, EUR J IMMUNOL, V17, P1213, DOI 10.1002/eji.1830170820; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; DEGRADO WF, 1985, J AM CHEM SOC, V107, P7684, DOI 10.1021/ja00311a076; DOROW DS, 1985, MOL IMMUNOL, V22, P1255, DOI 10.1016/0161-5890(85)90044-6; EDWARDS MS, 1987, PROTEIN ENG, V1, P173, DOI 10.1093/protein/1.3.173; EFIMOV AV, 1984, FEBS LETT, V166, P33, DOI 10.1016/0014-5793(84)80039-3; EFIMOV AV, 1991, PROTEIN ENG, V4, P245, DOI 10.1093/protein/4.3.245; ENGEL M, 1991, BIOCHEMISTRY-US, V30, P3161, DOI 10.1021/bi00227a002; FEDOROV AN, 1992, J MOL BIOL, V225, P927, DOI 10.1016/0022-2836(92)90092-X; FOURQUET P, 1988, INT J PEPT PROT RES, V32, P81; FRANCIS MJ, 1987, NATURE, V330, P168, DOI 10.1038/330168a0; GHADIRI MR, 1992, J AM CHEM SOC, V114, P4000, DOI 10.1021/ja00036a072; GOLDBERG E, 1973, SCIENCE, V181, P458, DOI 10.1126/science.181.4098.458; GOLDBERG E, 1981, FERTIL STERIL, V35, P214; GRASMASSE H, 1988, MOL IMMUNOL, V25, P673, DOI 10.1016/0161-5890(88)90102-2; GUTTE B, 1979, NATURE, V281, P650, DOI 10.1038/281650a0; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HODGES R S, 1990, Peptide Research, V3, P123; HODGES R S, 1988, Peptide Research, V1, P19; HOGREFE HH, 1989, J BIOL CHEM, V264, P10513; JEMMERSON R, 1987, P NATL ACAD SCI USA, V84, P9180, DOI 10.1073/pnas.84.24.9180; JEMMERSON R, 1990, EUR J IMMUNOL, V20, P579, DOI 10.1002/eji.1830200318; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KARLE IL, 1990, BIOCHEMISTRY-US, V29, P6747, DOI 10.1021/bi00481a001; KAUMAYA PTP, 1992, J BIOL CHEM, V267, P6338; KAUMAYA PTP, 1990, BIOCHEMISTRY-US, V29, P13, DOI 10.1021/bi00453a002; KAUMAYA PTP, 1992, PEPTIDES CHEM BIOL, P883; KAUMAYA PTP, IN PRESS J MOL RECOG; KAUMAYA PTP, 1990, PEPTIDES, P611; KAUMAYA PTP, 1993, PEPTIDES 1992, P139; KAUMAYA PTP, 1990, PEPTIDES CHEM STRUCT, P709; KOBSCONRAD S, 1992, PEPTIDES CHEM BIOL, P886; KOBSCONRAD S, 1993, PEPTIDES, P561; KRIZEK BA, 1991, J AM CHEM SOC, V113, P4518, DOI 10.1021/ja00012a021; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LECLERC G, 1987, EUR J IMMUNOL, V17, P1213; LEE H, 1992, PEPTIDES CHEM BIOL, P368; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LERNER RA, 1982, NATURE, V299, P592, DOI 10.1038/299592a0; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LOWENADLER B, 1992, MOL IMMUNOL, V29, P1185, DOI 10.1016/0161-5890(92)90054-2; MANAVALAN P, 1983, NATURE, V305, P831, DOI 10.1038/305831a0; MARGUERITE M, 1992, MOL IMMUNOL, V29, P793, DOI 10.1016/0161-5890(92)90189-5; MERKLE DL, 1991, J AM CHEM SOC, V113, P5450, DOI 10.1021/ja00014a045; MICHAEL SF, 1992, P NATL ACAD SCI USA, V89, P4796, DOI 10.1073/pnas.89.11.4796; Milich D R, 1990, Semin Immunol, V2, P307; MILICH DR, 1987, NATURE, V329, P547, DOI 10.1038/329547a0; MILNERWHITE EJ, 1986, BIOCHEM J, V240, P289, DOI 10.1042/bj2400289; MOSER R, 1987, PROTEIN ENG, V1, P339, DOI 10.1093/protein/1.4.339; MUTTER M, 1986, Z NATURFORSCH B, V41, P1315, DOI 10.1515/znb-1986-1020; MUTTER M, 1992, J AM CHEM SOC, V114, P1463, DOI 10.1021/ja00030a049; MUTTER M, 1988, HELV CHIM ACTA, V71, P835, DOI 10.1002/hlca.19880710419; MUTTER M, 1988, TETRAHEDRON, V44, P771, DOI 10.1016/S0040-4020(01)86116-0; Mutter M, 1989, ANGEW CHEM, V101, P551, DOI [DOI 10.1002/ANGE.19891010504, 10.1002/ange.19891010504]; OSTERHOUT JJ, 1992, J AM CHEM SOC, V114, P331, DOI 10.1021/ja00027a043; PABO CO, 1986, BIOCHEMISTRY-US, V25, P5987, DOI 10.1021/bi00368a023; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PARTIDOS C, 1992, MOL IMMUNOL, V29, P651, DOI 10.1016/0161-5890(92)90202-9; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; ROUAS N, 1992, MOL IMMUNOL, V29, P883, DOI 10.1016/0161-5890(92)90126-I; SCHULZEGAHMEN U, 1986, EUR J BIOCHEM, V159, P283, DOI 10.1111/j.1432-1033.1986.tb09865.x; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SELA M, 1969, SCIENCE, V166, P1365, DOI 10.1126/science.166.3911.1365; SEO YH, 1993, PEPTIDES, P866; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SPRANGLER BD, 1991, J IMMUNOL, V146, P1591; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STEWARD MW, 1987, IMMUNOL TODAY, V8, P51, DOI 10.1016/0167-5699(87)90239-8; VANREGENMORTEL MHV, 1989, IMMUNOL TODAY, V10, P266, DOI 10.1016/0167-5699(89)90140-0; XU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHU BY, 1992, INT J PEPT PROT RES, V40, P171	83	35	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25285	25295						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244959				2022-12-25	WOS:A1993MK10000006
J	LIU, SQ; BHATNAGAR, A; SRIVASTAVA, SK				LIU, SQ; BHATNAGAR, A; SRIVASTAVA, SK			BOVINE LENS ALDOSE REDUCTASE - PH-DEPENDENCE OF STEADY-STATE KINETIC-PARAMETERS AND NUCLEOTIDE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-CATALYZED REACTIONS; DIABETIC COMPLICATIONS; ALDEHYDE REDUCTASE; CHEMICAL MECHANISMS; INVOLVEMENT; SITE; RESIDUES; MUSCLE	The pH-dependence of nucleotide binding and steady-state kinetic parameters of aldehyde reduction and alcohol oxidation catalyzed by bovine lens aldose reductase were studied. The maximal velocity of aldehyde reduction with NADPH and p-chlorobenzaldehyde was pH independent at low pH but decreased at high pH with a pK of 7.6. The V/K of NADPH displayed a bell-shaped dependence on pH and decreased with a pK(a) of 5.3 and a pK(b) of 7.5. The dissociation constant of NADPH and 3-acetylpyridine adenine dinucleotide phosphate (3-APADP) increased at low pH with a pK of 5.6-5.8 and at high pH with a pK of 9.4-9.7. The pK(i) of NADP and NADPH decreased below a pH of 5 and 6.7 and above a pH of 8.5 and 9.7, respectively. The pK of 8.5-9.7 appears to be due to the interaction of the 2'-phosphate of the nucleotide with a protonated base, possibly a lysine residue. The maximal velocity of alcohol oxidation was pH independent at high pH but decreased at low pH with a pK of 6.5-7.0, when p-chlorobenzyl alcohol or benzyl alcohol and 3-APADP were used. The amino acid residue for alcohol binding has a pK of 7.5-8.2 and also appears in pK(i) profiles of sorbinil, a competitive inhibitor versus the alcohol. Large (3-3.5) isotope effects on maximal velocity obtained with benzyl alcohol and 3-APADP suggest that with these substrates the hydride transfer step is rate-limiting and a pK of 6.5-7.0 may he the true pK of the acid-base catalyst, possibly a histidine.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Bhatnagar, Aruni/H-7791-2013		NATIONAL EYE INSTITUTE [R01EY001677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036118, R01DK036118] Funding Source: NIH RePORTER; NEI NIH HHS [EY 01677] Funding Source: Medline; NIDDK NIH HHS [DK 36118] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHATNAGAR A, 1992, BIOCHEM MED METAB B, V48, P91, DOI 10.1016/0885-4505(92)90055-4; BHATNAGAR A, 1988, ARCH BIOCHEM BIOPHYS, V261, P264, DOI 10.1016/0003-9861(88)90341-4; BHATNAGAR A, 1989, MOL PHARMACOL, V36, P825; BHATNAGAR A, 1991, ARCH BIOCHEM BIOPHYS, V287, P329, DOI 10.1016/0003-9861(91)90486-3; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; CLELAND WW, 1982, METHOD ENZYMOL, V87, P390; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1797, DOI 10.1021/bi00510a014; DALZIEL K, 1973, ENZYMES, V11, P1; DAS B, 1985, ARCH BIOCHEM BIOPHYS, V238, P670, DOI 10.1016/0003-9861(85)90213-9; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FLYNN TG, 1982, BIOCHEM PHARMACOL, V31, P2705, DOI 10.1016/0006-2952(82)90123-X; GARCIAPEREZ A, 1991, J MEMBRANE BIOL, V119, P1, DOI 10.1007/BF01868535; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9936, DOI 10.1021/bi00494a026; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; LIU SQ, 1992, BIOCHIM BIOPHYS ACTA, V1120, P329, DOI 10.1016/0167-4838(92)90256-D; LIU SQ, 1992, BIOCHEM PHARMACOL, V44, P2427, DOI 10.1016/0006-2952(92)90693-D; MAS MT, 1984, BIOCHEMISTRY-US, V23, P1675, DOI 10.1021/bi00303a015; MORJANA NA, 1989, J BIOL CHEM, V264, P2912; MORRISON AD, 1970, BIOCHEM BIOPH RES CO, V40, P199, DOI 10.1016/0006-291X(70)91066-1; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; RASKIN P, 1987, AM J MED, V83, P298, DOI 10.1016/0002-9343(87)90702-9; RONDEAU JM, 1992, NATURE, V355, P469, DOI 10.1038/355469a0; Sarges R., 1989, ADV DRUG RES, V18, P139; SCHADE SZ, 1990, J BIOL CHEM, V265, P3628; SEGEL IH, 1975, ENZYME KINETICS, P574; VIOLA RE, 1979, ANAL BIOCHEM, V94, P334; WARD LD, 1985, METHOD ENZYMOL, V117, P400; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098	30	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25494	25499						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244985				2022-12-25	WOS:A1993MK10000035
J	BRAR, SK; SIU, CH				BRAR, SK; SIU, CH			CHARACTERIZATION OF THE CELL-ADHESION MOLECULE GP24 IN DICTYOSTELIUM-DISCOIDEUM - MEDIATION OF CELL-CELL ADHESION VIA A CA2+-DEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; SODIUM DODECYL-SULFATE; MONOCLONAL-ANTIBODIES; SURFACE GLYCOPROTEIN; POLYACRYLAMIDE GELS; CA-45 AUTORADIOGRAPHY; BLOCKING FAB; INHIBITION; EXPRESSION; STAGE	Dictyostelium discoideum cells express EDTA-sensitive cell-cell adhesion sites soon after the initiation of development and EDTA-resistant adhesion sites later at the aggregation stage. A glycoprotein of M(r) 24,000 (gp24) has been implicated in the mediation of the EDTA-sensitive type of intercellular cohesiveness (Knecht, D. A., Fuller, D. L., and Loomis, W. F. (1987) Dev. Biol. 121, 277-283). In this study, a relatively simple procedure was developed to purify gp24 to homogeneity. A highly specific rabbit antiserum was raised against gp24, and the localization of gp24 at the cell surface was shown by quantitative binding of the anti-gp24 antibodies to intact cells. To demonstrate the cell binding activity of gp24, the binding of solubilized gp24 to intact cells was examined. I-125-Labeled gp24 bound to cells in a dose-dependent and saturable manner, and the binding was displaced specifically by unlabeled gp24. Purified gp24 was capable of inhibiting the reassociation of dispersed cells previously undergoing EDTA-sensitive aggregation. Moreover, precoating cells with anti-gp24 IgG and Fab fragments blocked the binding of I-125-labeled gp24 to cells. Collectively, these in vitro assays provide direct evidence that gp24 is a cell adhesion molecule that most likely functions through a homophilic mode of interaction. The binding of gp24 to cells was sensitive to EGTA, suggesting that the activity of gp24 may involve calcium ions. Binding studies showed that Ca-45(2+) could bind to gp24 blotted onto nitrocellulose membrane. In addition, preincubation of the native protein with calcium ions resulted in a shift in its gel mobility. It is therefore likely that gp24 mediates cell-cell interactions via a Ca2+-dependent mechanism, rendering gp24 the first cell adhesion molecule in D. discoideum to utilize a Ca2+-based adhesion system.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto; University of Toronto								BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BONNER JT, 1959, P NATL ACAD SCI USA, V56, P379; BRODIE C, 1983, CELL, V32, P1115, DOI 10.1016/0092-8674(83)90295-7; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; CHOI AHC, 1987, J CELL BIOL, V104, P1375, DOI 10.1083/jcb.104.5.1375; COCUCCI SM, 1970, J CELL BIOL, V45, P399, DOI 10.1083/jcb.45.2.399; DESBARATS L, 1992, J BIOL CHEM, V267, P19655; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; FEINBERG AP, 1979, P NATL ACAD SCI USA, V76, P3977, DOI 10.1073/pnas.76.8.3977; FONTANA DR, 1989, DIFFERENTIATION, V41, P184, DOI 10.1111/j.1432-0436.1989.tb00746.x; FONTANA DR, 1991, MOL CELL BIOL, V11, P468, DOI 10.1128/MCB.11.1.468; FRITZ IB, 1989, J CELL PHYSIOL, V140, P18, DOI 10.1002/jcp.1041400104; GAO EN, 1992, J BIOL CHEM, V267, P9409; GARROD DR, 1972, EXP CELL RES, V72, P588, DOI 10.1016/0014-4827(72)90041-9; GELTOSKY JE, 1979, CELL, V18, P391, DOI 10.1016/0092-8674(79)90058-8; GELTOSKY JE, 1980, CELL, V21, P339, DOI 10.1016/0092-8674(80)90470-5; GERISCH G, 1961, EXP CELL RES, V25, P535, DOI 10.1016/0014-4827(61)90189-6; GERISCH G, 1980, CURR TOP DEV BIOL, V14, P234; GRAB DJ, 1979, J BIOL CHEM, V254, P8690; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMBOJ RK, 1989, CELL, V59, P615, DOI 10.1016/0092-8674(89)90007-X; KAMBOJ RK, 1990, CELL REGUL, V1, P715, DOI 10.1091/mbc.1.10.715; KNECHT DA, 1987, DEV BIOL, V121, P277, DOI 10.1016/0012-1606(87)90160-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM TY, 1981, DEV BIOL, V83, P127, DOI 10.1016/S0012-1606(81)80015-2; LAM TY, 1981, DIFFERENTIATION, V20, P22, DOI 10.1111/j.1432-0436.1981.tb01151.x; Loomis W F, 1991, Antisense Res Dev, V1, P255; LOOMIS WF, 1988, DEV GENET, V9, P549, DOI 10.1002/dvg.1020090431; LOOMIS WF, 1990, P NATL ACAD SCI USA, V87, P886, DOI 10.1073/pnas.87.3.886; LOOMIS WF, 1975, DICTYOSTELIUMDISCOID; MA PCC, 1990, MOL CELL BIOL, V10, P3297, DOI 10.1128/MCB.10.7.3297; MAEDA Y, 1969, DEV GROWTH DIFFER, V11, P232; MANN SKO, 1989, P NATL ACAD SCI USA, V86, P1924, DOI 10.1073/pnas.86.6.1924; MARCHAK DR, 1984, BIOCHEMISTRY-US, V23, P2891; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MULLER K, 1978, NATURE, V274, P445, DOI 10.1038/274445a0; MURRAY BA, 1981, J SUPRAMOL STR CELL, V17, P197, DOI 10.1002/jsscb.380170302; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; RATHI A, 1992, MECH DEVELOP, V36, P173, DOI 10.1016/0925-4773(92)90068-U; SAFFELL JL, 1992, J CELL BIOL, V118, P663, DOI 10.1083/jcb.118.3.663; SAXE CL, 1982, CELL, V29, P755, DOI 10.1016/0092-8674(82)90437-8; SCHIBECI A, 1980, ANAL BIOCHEM, V104, P335, DOI 10.1016/0003-2697(80)90084-6; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; Siu C.-H., 1988, P119; SIU CH, 1990, DEV GENET, V11, P377, DOI 10.1002/dvg.1020110509; SIU CH, 1988, BIOCHEM CELL BIOL, V66, P1089, DOI 10.1139/o88-126; SIU CH, 1992, J CELL PHYSIOL, V152, P157, DOI 10.1002/jcp.1041520120; SIU CH, 1988, BIOCHIM BIOPHYS ACTA, V968, P283, DOI 10.1016/0167-4889(88)90019-5; SIU CH, 1987, J CELL BIOL, V105, P2523, DOI 10.1083/jcb.105.6.2523; SIU CH, 1983, P NATL ACAD SCI-BIOL, V80, P6596, DOI 10.1073/pnas.80.21.6596; SIU CH, 1990, BIOESSAYS, V12, P357, DOI 10.1002/bies.950120802; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPRINGER WR, 1980, J CELL BIOL, V87, P703, DOI 10.1083/jcb.87.3.703; STEINEMANN C, 1980, NATURE, V286, P621, DOI 10.1038/286621a0; Sussman M., 1966, METHOD CELL PHYSIOL, V2, P397; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeuchi I., 1969, NUCL ACID METABOLISM, P297; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS RJP, 1986, CIBA F SYMP, V122, P145	66	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24902	24909						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227052				2022-12-25	WOS:A1993MG67300059
J	HEIKKILA, P; SOININEN, R; TRYGGVASON, K				HEIKKILA, P; SOININEN, R; TRYGGVASON, K			DIRECTIONAL REGULATORY ACTIVITY OF CIS-ACTING ELEMENTS IN THE BIDIRECTIONAL ALPHA-1(IV) AND ALPHA-2(IV) COLLAGEN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; IV COLLAGEN; DIHYDROFOLATE-REDUCTASE; DIVERGENT TRANSCRIPTS; CHAIN; EXPRESSION; REGION; ACTIVATION; BOX; IDENTIFICATION	The genes for the type IV collagen alpha1 and alpha2 chains are regulated by a common approximately 130-base pair (bp) bidirectional promoter. In an attempt to explore the regulation of expression of both genes, we have constructed a minilocus plasmid containing minigenes for the human alpha1(IV) and alpha2(IV) collagen genes located head-to-head like the endogenous genes. The directional regulation of this promoter was studied by introducing site-directed mutations into the promoter of the minigenes. In transient transfections the levels of transcripts of both minigenes were measured, and the influence of mutations on the direction of transcription was studied. The mutational analysis showed that a CCCTCCC motif and a GC box located in the center of the common promoter as well as GC boxes in exon 1 of the alpha2(IV) gene are potent activating elements for both genes. The promoter of the alpha1(IV) and alpha2(IV) collagen genes contains no classical TATA boxes. Even so, A+T-rich sequence motifs, which have no obvious homology to the TATA box located 25-30 bp upstream of exon 1 in each gene, direct the initiation of transcription predominantly about 30 bp downstream of their location. Disruption of the A+T-rich sequence decreased the activity of the promoter considerably, and in addition, the generated classical TATA boxes hindered maintenance of normal bidirectional transcription and changed the ratio of the alpha1(IV) and alpha2(IV) transcripts. The CCAAT box in the alpha2(IV) chain coding strand activated the promoter in the alpha2(IV) gene direction, but not in the alpha1(IV) gene direction.	UNIV OULU,BIOCTR,SF-90570 OULU,FINLAND; UNIV OULU,DEPT BIOCHEM,SF-90570 OULU,FINLAND	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu								ANAKA S, 1993, J BIOL CHEM, V268, P8862; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BRENNER DA, 1989, NUCLEIC ACIDS RES, V17, P6055, DOI 10.1093/nar/17.15.6055; BRYGGEMAN LA, 1992, ONCOGENE, V7, P1497; BURBELO PD, 1991, J BIOL CHEM, V266, P22297; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FARNHAM PJ, 1985, P NATL ACAD SCI USA, V82, P3978, DOI 10.1073/pnas.82.12.3978; FRIDELL YWC, 1992, MOL CELL BIOL, V12, P4571, DOI 10.1128/MCB.12.10.4571; FUJII H, 1992, FEBS LETT, V314, P33, DOI 10.1016/0014-5793(92)81455-U; HOSTIKKA SL, 1987, FEBS LETT, V224, P297, DOI 10.1016/0014-5793(87)80473-8; HOSTIKKA SL, 1987, FEBS LETT, V216, P281, DOI 10.1016/0014-5793(87)80706-8; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; JOHNSON P, 1990, GENE, V88, P207, DOI 10.1016/0378-1119(90)90033-N; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARIYAMA M, 1992, GENOMICS, V13, P809, DOI 10.1016/0888-7543(92)90157-N; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MORRISON KE, 1991, AM J HUM GENET, V49, P545; PIHLAJANIEMI T, 1985, J BIOL CHEM, V260, P7681; POLLNER R, 1990, ANN NY ACAD SCI, V580, P44, DOI 10.1111/j.1749-6632.1990.tb17916.x; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; RIZZO MG, 1990, EXP CELL RES, V188, P286, DOI 10.1016/0014-4827(90)90172-7; Sambrook J, 1989, MOL CLONING LABORATO; SAUS J, 1988, J BIOL CHEM, V263, P13374; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SOININEN R, 1986, EMBO J, V5, P2821, DOI 10.1002/j.1460-2075.1986.tb04574.x; SOININEN R, 1988, J BIOL CHEM, V263, P17217; SOININEN R, 1989, J BIOL CHEM, V264, P13565; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; XU LC, 1991, NUCLEIC ACIDS RES, V19, P6699, DOI 10.1093/nar/19.24.6699; ZHOU DX, 1991, J BIOL CHEM, V266, P23416; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449	40	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24677	24682						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227027				2022-12-25	WOS:A1993MG67300028
J	HIRATSUKA, T				HIRATSUKA, T			BEHAVIOR OF CYS-707 (SH1) IN MYOSIN ASSOCIATED WITH ATP HYDROLYSIS REVEALED WITH A FLUORESCENT-PROBE LINKED DIRECTLY TO THE SULFUR ATOM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; AMINO-ACID-SEQUENCE; HEAVY-CHAIN; ADENOSINE-TRIPHOSPHATASE; ENERGY-TRANSFER; CROSS-LINKING; SUBFRAGMENT-1; ACTIN; THIOLS; CONTRACTION	4-Fluoro-7-sulfamoylbenzofurazan (ABDF) has a rather small fluorophore that is linked directly to the sulfur atom of thiols without a flexible alkyl chain (Imai, K., and Toyo'oka, T. (1987) Methods Enzymol. 143, 67-75). In the present study I examined the fluorescent and chemical properties of ABDF as an environmentally sensitive probe for Cys-707 (SH1) of myosin subfragment-1 (S-1) to monitor the behavior of SH1 associated with ATP hydrolysis. ABDF was very stable to long irradiation and nonfluorescent before attachment to thiols, permitting the continuous monitoring of the labeling reaction. The fluorophore was useful as an environmentally sensitive probe for thiol groups in proteins. SH1 of S-1 was specifically labeled with ABDF. When ATP, adenyl-5'-yl imidodiphosphate, and ADP were added to the labeled S-1 (ABD-S-1), the fluorescence intensity at 500 nm increased by 110, 66, and 53%, respectively. Binding of actin to ABD-S-1 resulted in a decrease in the fluorescence by 30%. The fluorophore attached to SH1 was found to be located in a more hydrophobic environment in the presence of ATP than in the absence of ligand. KI fluorescence quenching studies suggested that the binding of ATP causes a movement of SH1 toward a more hydrophobic protein interior, whereas it goes back to the opposite direction after ATP hydrolysis. Thus, ABDF is very useful as an environmentally sensitive fluorescent probe for SH1 that monitors ligand-induced changes in the behavior of the thiol.			HIRATSUKA, T (corresponding author), ASAHIKAWA MED COLL, DEPT CHEM, ASAHIKAWA, HOKKAIDO 078, JAPAN.							AGUIRRE R, 1986, BIOCHEMISTRY-US, V25, P6827, DOI 10.1021/bi00370a015; AJTAI K, 1992, BIOCHEMISTRY-US, V31, P12431, DOI 10.1021/bi00164a019; AJTAI K, 1989, BIOCHEMISTRY-US, V28, P2204, DOI 10.1021/bi00431a035; BHANDARI DG, 1991, BIOCHIM BIOPHYS ACTA, V1077, P385, DOI 10.1016/0167-4838(91)90555-E; BOTTS J, 1984, P NATL ACAD SCI-BIOL, V81, P2060, DOI 10.1073/pnas.81.7.2060; BOTTS J, 1989, P NATL ACAD SCI USA, V86, P2204, DOI 10.1073/pnas.86.7.2204; CHANCE B, 1957, ARCH BIOCHEM BIOPHYS, V71, P130, DOI 10.1016/0003-9861(57)90015-2; CHEUNG HC, 1983, J BIOL CHEM, V258, P5775; CHEUNG HC, 1991, BIOPHYS CHEM, V40, P1, DOI 10.1016/0301-4622(91)85025-L; COLLINS JH, 1975, J BIOL CHEM, V250, P5915; DUKE J, 1976, P NATL ACAD SCI USA, V73, P302, DOI 10.1073/pnas.73.2.302; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fiske CH, 1925, J BIOL CHEM, V66, P375; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HIRATSUKA T, 1986, BIOCHEMISTRY-US, V25, P2101, DOI 10.1021/bi00356a039; HIRATSUKA T, 1986, J BIOL CHEM, V261, P7294; HIRATSUKA T, 1987, BIOCHEMISTRY-US, V26, P3168, DOI 10.1021/bi00385a034; HIRATSUKA T, 1990, J BIOL CHEM, V265, P18786; HIRATSUKA T, 1992, J BIOL CHEM, V267, P14941; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; IMAI K, 1987, METHOD ENZYMOL, V143, P67; KASPRZAK AA, 1989, BIOCHEMISTRY-US, V28, P9230, DOI 10.1021/bi00449a040; KENNER RA, 1971, BIOCHEMISTRY-US, V10, P4433, DOI 10.1021/bi00800a013; KONRAD M, 1982, EUR J BIOCHEM, V128, P547; MIYANISHI T, 1989, BIOCHEMISTRY-US, V28, P1287, DOI 10.1021/bi00429a051; MUELLER H, 1962, BIOCHEM J, V85, P431, DOI 10.1042/bj0850431; MULHERN SA, 1978, BIOCHEMISTRY-US, V17, P4419, DOI 10.1021/bi00614a010; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; PERKINS WJ, 1984, J BIOL CHEM, V259, P8786; PERRY SV, 1955, METHOD ENZYMOL, V2, P582, DOI 10.1016/S0076-6879(55)02258-1; REES MK, 1967, J BIOL CHEM, V242, P4449; REISLER E, 1982, METHOD ENZYMOL, V85, P84; SEKINE T, 1964, BIOCHIM BIOPHYS ACTA, V81, P336, DOI 10.1016/0926-6569(64)90049-5; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Stern O, 1919, PHYS Z, V20, P183; SUTOH K, 1981, BIOCHEMISTRY-US, V20, P3281, DOI 10.1021/bi00514a046; TAKASHI R, 1976, ARCH BIOCHEM BIOPHYS, V175, P279, DOI 10.1016/0003-9861(76)90509-9; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TONG SW, 1990, J BIOL CHEM, V265, P4893; TOYOOKA T, 1985, ANAL CHEM, V57, P1931, DOI 10.1021/ac00286a032; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WELLS JA, 1980, BIOCHEMISTRY-US, V19, P1711, DOI 10.1021/bi00549a030; WIEDNER H, 1978, J BIOL CHEM, V253, P2763; YAMAGUCHI M, 1966, J BIOCHEM, V59, P24, DOI 10.1093/oxfordjournals.jbchem.a128254	48	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24742	24750						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227033				2022-12-25	WOS:A1993MG67300036
J	KLETT, C; NOBILING, R; GIERSCHIK, P; HACKENTHAL, E				KLETT, C; NOBILING, R; GIERSCHIK, P; HACKENTHAL, E			ANGIOTENSIN-II STIMULATES THE SYNTHESIS OF ANGIOTENSINOGEN IN HEPATOCYTES BY INHIBITING ADENYLYLCYCLASE ACTIVITY AND STABILIZING ANGIOTENSINOGEN MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE BINDING-FACTOR; RAT ANGIOTENSINOGEN; ADENYLATE-CYCLASE; RENIN-SUBSTRATE; HORMONAL-CONTROL; GENE-EXPRESSION; PERTUSSIS TOXIN; BLOOD-PRESSURE; PHORBOL-ESTER; PROTEIN	Angiotensin II stimulates the hepatic synthesis and secretion of angiotensinogen, the substrate of renin. In the present study performed on freshly isolated rat hepatocytes we demonstrate that this effect of angiotensin II is mainly related to a transient inhibition of adenylylcyclase. Agents known to decrease intracellular cAMP (angiotensin II, vasopressin, guanfacine) or the cAMP-antagonist Rp-adenosine-3',5'-cyclic phosphothioate stimulated, whereas cAMP-stimulating agents (isoproterenol, forskolin, glucagon) or the cAMP-agonist Sp-adenosine-3',5'-cyclic phosphothioate inhibited angiotensinogen synthesis. In contrast, all agents known to affect intracellular concentrations of calcium, as confirmed in Fura-2-loaded hepatocytes (Bay K 8644, calcimycin, calmidazolium, ionomycin, or methoxamine) failed to influence the synthesis of angiotensinogen. The inhibitory effect of angiotensin II as well as the stimulatory effect of glucagon on cAMP were inversely related to angiotensinogen mRNA and angiotensinogen secretion over a wide concentration range of both peptides. Both the angiotensin II-dependent inhibition of cAMP and the angiotensin II-induced increase in angiotensinogen mRNA were abolished by a pertussis toxin pretreatment. In hepatocyte membranes, pertussis toxin ADP-ribosylated a single protein (approximately 41 kDa) probably representing the alpha-subunit of the G(i)-protein, coupling inhibitory receptors to adenylylcyclase. We further show that the increase of angiotensinogen mRNA and secretion mainly represents the result of mRNA stabilization, since in a nuclear run-on assay, angiotensin II pretreatment of hepatocytes does not significantly alter the rate of [P-32]UTP incorporation into angiotensinogen mRNA, whereas angiotensin II prolonged the half-life of angiotensinogen mRNA in transcription-arrested as well as in [H-3]uridine pulse-labeled hepatocytes about 2.5-fold from 80 to 190 min. It is concluded that angiotensin II induces an increase in angiotensinogen synthesis in hepatocytes by stabilizing of angiotensinogen mRNA and that this effect is mediated through inhibition of adenylylcyclase.	UNIV HEIDELBERG,DEPT PHARMACOL,NEUENHEIMER FELD 366,W-6900 HEIDELBERG,GERMANY; UNIV HEIDELBERG,DEPT PHYSIOL,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BARRETT G, 1989, CLIN EXP PHARMACOL P, V16, P631, DOI 10.1111/j.1440-1681.1989.tb01614.x; BING J, 1972, ACTA PATH MICRO IM A, VA 80, P646; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1989, MOL ENDOCRINOL, V3, P1022, DOI 10.1210/mend-3-6-1022; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CLARKE PA, 1991, NUCLEIC ACIDS RES, V19, P243, DOI 10.1093/nar/19.2.243; CLAUSER E, 1983, ENDOCRINOLOGY, V112, P1188, DOI 10.1210/endo-112-4-1188; DZAU BJ, 1982, LIFE SCI, V30, P577; FAIN JN, 1990, BIOCHIM BIOPHYS ACTA, V1053, P81, DOI 10.1016/0167-4889(90)90029-D; FELDMER M, 1991, J HYPERTENS, V9, P1005, DOI 10.1097/00004872-199111000-00005; GIERSCHIK P, 1989, EUR J PHARM-MOLEC PH, V172, P481, DOI 10.1016/0922-4106(89)90031-X; GIERSCHIK P, 1992, CURR TOP MICROBIOL, V175, P69; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HACKENTHAL E, 1977, CIRC RES, V41, pR249, DOI 10.1161/01.RES.41.4.49; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1076; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HECKER E, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1890; HELLMANN W, 1988, N-S ARCH PHARMACOL, V338, P327; JARD S, 1981, J BIOL CHEM, V256, P2603; JOHNSTON CI, 1990, DRUGS, V39, P21, DOI 10.2165/00003495-199000391-00005; KHAYYALL M, 1973, CLIN SCI, V44, P87, DOI 10.1042/cs0440087; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; KLETT C, 1987, CLIN EXP HYPERTENS A, V9, P2027, DOI 10.3109/10641968709159073; KLETT C, 1992, ENDOCRINOLOGY, V130, P3660, DOI 10.1210/en.130.6.3660; KLETT C, 1988, J HYPERTENS       S4, V6, P442; KLETT C, 1987, J HYPERTENS       S5, V5, pS19; KRUSKAL BA, 1984, J CELL BIOL, V99, P1167, DOI 10.1083/jcb.99.3.1167; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMEUR M, 1981, CELL, V23, P561, DOI 10.1016/0092-8674(81)90152-5; LEVIS R, 1977, CELL, V11, P105, DOI 10.1016/0092-8674(77)90321-X; LUDWIG G, 1986, J HYPERTENS, V4, pS431; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MALTER JS, 1991, J BIOL CHEM, V266, P3171; MORGAN NG, 1983, FEBS LETT, V153, P77, DOI 10.1016/0014-5793(83)80122-7; MURRAY RD, 1982, RENAL PHYSL, V5, P296; NASJLETTI A, 1971, CAN J PHYSIOL PHARM, V49, P931, DOI 10.1139/y71-129; NASJLETTI A, 1973, P SOC EXP BIOL MED, V142, P307; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; NOBILING R, 1989, J MICROSC-OXFORD, V156, P149, DOI 10.1111/j.1365-2818.1989.tb02914.x; OHKUBO H, 1983, P NATL ACAD SCI-BIOL, V80, P2196, DOI 10.1073/pnas.80.8.2196; PFEILSCHIFTER J, 1986, BIOCHEM J, V236, P289, DOI 10.1042/bj2360289; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SERNIA C, 1989, MOL CELL ENDOCRINOL, V61, P147, DOI 10.1016/0303-7207(89)90125-1; SHIONOIRI H, 1983, BIOCHEM MED METAB B, V29, P14, DOI 10.1016/0006-2944(83)90049-2; STUZMANN M, 1986, BIOCHIM BIOPHYS ACTA, V886, P48, DOI 10.1016/0167-4889(86)90210-7; TATEISHI H, 1972, P SOC EXP BIOL MED, V139, P304; TEWKSBURY TA, 1981, BIOCH REGULATION BLO, V5, P95; WATT GCM, 1992, J HYPERTENS, V10, P473, DOI 10.1097/00004872-199205000-00011; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	60	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25095	25107						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227073				2022-12-25	WOS:A1993MG67300084
J	LI, JY; ZHU, XM; BYRNES, M; NELSON, JW; CHANG, SH				LI, JY; ZHU, XM; BYRNES, M; NELSON, JW; CHANG, SH			SITE-DIRECTED MUTAGENESIS OF RABBIT MUSCLE PHOSPHOFRUCTOKINASE CDNA - MUTATIONS AT GLUTAMINE-200 AFFECT THE ALLOSTERIC PROPERTIES OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PHOSPHOFRUCTOKINASE; HIGH-LEVEL EXPRESSION; ESCHERICHIA-COLI; FRUCTOSE 2,6-BISPHOSPHATE; GENE; ISOENZYMES; DUPLICATION; INHIBITION; SUBUNITS; SEQUENCE	Full-length cDNA for rabbit muscle phosphofructokinase has been cloned and characterized (Li, J., Chen, Z., Lu, L., Byrnes, M., and Chang, S. H. (1990) Biochem. Biophys. Res. Commun. 170, 1056-1060). The 2.8-kilobase cDNA was inserted in the plasmid vector pPL2 and transformed into Escherichia coli cells deficient in endogenous phosphofructokinase activity (DF 1020). The recombinant phosphofructokinase so prepared is nearly identical in kinetic properties and size of subunits to the enzyme isolated from rabbit muscle. On the basis of the sequence homology between the muscle and the bacterial phosphofructokinases and the crystallographic structure of the latter, the glutamine at position 200 of the muscle enzyme is implicated in the allosteric transitions. This residue was replaced by alanine (Q200A), glutamate (Q200E), or arginine (Q200R). The purified enzymes were analyzed for quaternary structure, activity, and allosteric properties. The native and all the altered enzymes are tetramers. At pH 7.0, the wild-type enzyme is sensitive to inhibition by ATP at concentration above 0.6 mM, and its activity responds to fructose 6-phosphate concentration cooperatively at high ATP concentration. In contrast, the mutated enzyme Q200R is virtually insensitive to ATP inhibition up to 7 mM. Thus at high ATP concentration, its activity responds to fructose 6-phosphate concentration in a manner similar to the activated form of the native enzyme. Under the same conditions, mutant Q200E exhibits cooperative behavior only at much higher concentration of fructose 6-phosphate. Mutant Q200A is active at pH 8.0 but inactive at pH 7.0. The native enzyme and all three mutants are activated by inorganic phosphate and fructose 2,6-bisphosphate and inhibited by citrate.	LOUISIANA STATE UNIV,DEPT BIOCHEM,RM 322 CHOPPIN HALL,BATON ROUGE,LA 70803	Louisiana State University System; Louisiana State University					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031676] Funding Source: NIH RePORTER; NCRR NIH HHS [RR06710] Funding Source: Medline; NIDDK NIH HHS [DK31676] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bevington P. R., 1969, DATA REDUCTION ERROR; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAS GL, 1982, BIOCHEMISTRY-US, V21, P6656; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BROCK DJH, 1969, BIOCHEM J, V113, P235, DOI 10.1042/bj1130235; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; BUELL G, 1985, NUCLEIC ACIDS RES, V13, P1923, DOI 10.1093/nar/13.6.1923; CANTOR CH, 1980, BIOPHYSICAL CHEM, P939; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DALDAL F, 1983, J MOL BIOL, V168, P285, DOI 10.1016/S0022-2836(83)80019-9; DOTTO GP, 1983, VIROLOGY, V114, P463; DUNAWAY GA, 1983, MOL CELL BIOCHEM, V52, P75; DUNAWAY GA, 1988, BIOCHEM J, V251, P677, DOI 10.1042/bj2510677; DUNAWAY GA, 1987, BIOCHEM J, V242, P667, DOI 10.1042/bj2420667; DUNAWAY GA, 1974, ARCH BIOCHEM BIOPHYS, V162, P620, DOI 10.1016/0003-9861(74)90224-0; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FERSHT A, 1985, ENZYME STRUCTURE MEC, P263; FOE LG, 1985, J BIOL CHEM, V260, P726; FOE LG, 1982, J BIOL CHEM, V257, P6368; GEHNRICH SC, 1988, J BIOL CHEM, V255, P4240; GREER H, 1975, VIROLOGY, V66, P589, DOI 10.1016/0042-6822(75)90231-7; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HEINISCH J, 1989, GENE, V78, P309; HELLINGA HW, 1985, EUR J BIOCHEM, V149, P363, DOI 10.1111/j.1432-1033.1985.tb08934.x; JIANG JC, 1992, ENVIRON MOL MUTAGEN, V20, P260, DOI 10.1002/em.2850200404; KASTEN TP, 1983, BIOCHEM BIOPH RES CO, V111, P248; Kemp R G, 1975, Methods Enzymol, V42, P71; KOTLARZ D, 1981, EUR J BIOCHEM, V117, P569; LATSHAW SP, 1987, J BIOL CHEM, V262, P10672; LEE CP, 1987, J BIOL CHEM, V262, P4195; LEVANON D, 1989, DNA-J MOLEC CELL BIO, V8, P733, DOI 10.1089/dna.1989.8.733; LI J, 1990, BIOCHEM BIOPH RES CO, V166, P637; LING KH, 1965, J BIOL CHEM, V240, P1893; Maniatis T., 1982, MOL CLONING; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PASSONNEAU JV, 1963, BIOCHEM BIOPH RES CO, V13, P372, DOI 10.1016/0006-291X(63)90350-4; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; REINHART GD, 1980, BIOCHEMISTRY-US, V19, P1477, DOI 10.1021/bi00548a034; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; RYPNIEWSKI WR, 1989, J MOL BIOL, V207, P805, DOI 10.1016/0022-2836(89)90246-5; SCHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973; SCHIRMER T, 1990, NATURE, V343, P141; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UYEDA K, 1981, J BIOL CHEM, V256, P8394; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; VALAITIS AP, 1987, J BIOL CHEM, V262, P5044; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P887, DOI 10.1042/bj1920887; WADA K, 1991, NUCLEIC ACIDS RES, V19, P1981, DOI 10.1093/nar/19.suppl.1981	50	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24599	24606						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227018				2022-12-25	WOS:A1993MG67300017
J	LOW, MJ; LIU, B; HAMMER, GD; RUBINSTEIN, M; ALLEN, RG				LOW, MJ; LIU, B; HAMMER, GD; RUBINSTEIN, M; ALLEN, RG			POSTTRANSLATIONAL PROCESSING OF PROOPIOMELANOCORTIN (POMC) IN MOUSE PITUITARY MELANOTROPH TUMORS INDUCED BY A POMC-SIMIAN VIRUS-40 LARGE T-ANTIGEN TRANSGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIOMELANOCORTIN (POMC)-DERIVED PEPTIDES; PRO-OPIOMELANOCORTIN; GENE-EXPRESSION; CUSHINGS-SYNDROME; DEPENDENT HYPERADRENOCORTICISM; SECRETING TUMORS; MAMMALIAN-CELLS; RAT PITUITARY; MICE; PROHORMONE	Mice harboring a transgene composed of proopiomelanocortin (POMC) gene promoter sequences (nucleotides -706 to +64) ligated to the simian virus (SV) 40 early gene encoding large T antigen developed large POMC-expressing pituitary tumors. Histologically the tumors arose from the intermediate lobe, contained nuclear SV40 T antigen and POMC peptides, but did not express other pituitary hormones. POMC processing in the pituitary tumors was indistinguishable from normal mouse intermediate lobe melanotrophs and was characterized by high proportions of acetylated and carboxyl-terminal shortened beta-endorphins, and amino-terminal acetylated alpha-melanocyte-stimulating hormone, and virtually no adrenocorticotropic hormone (ACTH)(1-39), beta-lipotropin, or POMC. The tumors contained abundant levels of mRNA for the prohormone convertase PC2 and undetectable levels of PC1. Normal mouse neurointermediate lobe also has a high ratio of PC2/PC1 expression that is distinct from the relative abundance of PC1 in anterior lobe and AtT20 corticotroph cells. In contrast, extracts from tumors transplanted subcutaneously in nude mice contained predominantly nonacetylated forms of beta-endorphin(1-31) and -(1-27), very little ACTH(1-39), almost no corticotropin-like intermediate peptide or alpha-melanocyte-stimulating hormone, and higher proportions of intact POMC. Surprisingly, despite the less efficient proteolytic cleavage, a transplanted tumor expressed both PC1 and PC2. These studies are the first biochemical documentation of a melanotroph pituitary tumor in a rodent species and provide a new model for the investigation of pituitary oncogenesis and the molecular basis of tissue-specific prohormone post-translational processing.	OREGON HLTH SCI UNIV,CTR RES OCCUPAT & ENVIRONM TOXICOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University	LOW, MJ (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,L474,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.			Low, Malcolm/0000-0002-9900-3708	NIDDK NIH HHS [DK 40457] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040457] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIL H, 1981, PEPTIDES, V2, P289, DOI 10.1016/S0196-9781(81)80121-0; ALLEN RG, 1978, P NATL ACAD SCI USA, V75, P4972, DOI 10.1073/pnas.75.10.4972; ALLEN RG, 1988, DEV BIOL, V126, P156, DOI 10.1016/0012-1606(88)90249-7; ALLEN RG, 1984, DEV BIOL, V102, P43, DOI 10.1016/0012-1606(84)90173-8; ALSHAWI R, 1991, MOL CELL BIOL, V11, P4207, DOI 10.1128/MCB.11.8.4207; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; BRUBAKER PL, 1992, J BIOL CHEM, V267, P20728; CANNY BJ, 1988, NEUROENDOCRINOLOGY, V48, P603, DOI 10.1159/000125069; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; DEKEYZER Y, 1985, J CLIN INVEST, V76, P1982; DESOUZA EB, 1986, ENDOCRINOLOGY, V119, P1534, DOI 10.1210/endo-119-4-1534; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; Eipper B A, 1980, Endocr Rev, V1, P1; EIPPER BA, 1981, J BIOL CHEM, V256, P5689; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FURTH J, 1955, RECENT PROG HORM RES, V11, P221; GEE CE, 1983, NATURE, V306, P374, DOI 10.1038/306374a0; GILLIGAN A, 1989, DIABETES, V38, P1056, DOI 10.2337/diabetes.38.8.1056; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HALE AC, 1986, J ENDOCRINOL, V108, P49, DOI 10.1677/joe.0.1080049; HAMMANG JP, 1990, NEURON, V4, P775, DOI 10.1016/0896-6273(90)90204-S; HAMMER GD, 1992, ENDOCRINOLOGY, V130, P1975, DOI 10.1210/en.130.4.1975; HAMMER GD, 1990, MOL ENDOCRINOL, V4, P1689, DOI 10.1210/mend-4-11-1689; HATFIELD JM, 1988, DEV BIOL, V126, P164, DOI 10.1016/0012-1606(88)90250-3; HOGAN B, 1986, MANIPULATING MOUSE E; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; HOWLETT TA, 1986, CLIN ENDOCRINOL, V24, P699, DOI 10.1111/j.1365-2265.1986.tb01667.x; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; JEX RK, 1985, AM J SURG, V149, P276; KILPATRICK DL, 1987, P NATL ACAD SCI USA, V84, P5695, DOI 10.1073/pnas.84.16.5695; KRIEGER DT, 1983, ENDOCR REV, V4, P22, DOI 10.1210/edrv-4-1-22; LEE YC, 1992, J BIOL CHEM, V267, P10705; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LIU B, 1992, MOL CELL BIOL, V12, P3978, DOI 10.1128/MCB.12.9.3978; LONDON DR, 1992, 71TH P ANN M END SOC; LOW MJ, 1989, MOL ENDOCRINOL, V3, P2028, DOI 10.1210/mend-3-12-2028; LOW MJ, 1993, METHODS MOL BIOL, V13; MAINS RE, 1984, ENDOCRINOLOGY, V115, P1683, DOI 10.1210/endo-115-5-1683; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NOEL G, 1991, ENDOCRINOLOGY, V129, P1317, DOI 10.1210/endo-129-3-1317; PETERSON ME, 1982, ACTA ENDOCRINOL-COP, V101, P15, DOI 10.1530/acta.0.1010015; PETERSON ME, 1986, ENDOCRINOLOGY, V119, P720, DOI 10.1210/endo-119-2-720; PETERSON ME, 1987, FRONT HORM RES, V17, P37; RATTER SJ, 1983, CLIN ENDOCRINOL, V18, P211, DOI 10.1111/j.1365-2265.1983.tb03205.x; REYNOLDS RK, 1988, P NATL ACAD SCI USA, V85, P3135, DOI 10.1073/pnas.85.9.3135; RIUS RA, 1991, DEV BRAIN RES, V60, P179, DOI 10.1016/0165-3806(91)90046-L; RUBINSTEIN M, 1993, IN PRESS NEUROENDOCR; Sambrook J, 1989, MOL CLONING LABORATO; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; STEFANEANU L, 1992, ENDOCRINOLOGY, V130, P1789, DOI 10.1210/en.130.4.1789; STENZELPOORE MP, 1992, ENDOCRINOLOGY, V130, P3378, DOI 10.1210/en.130.6.3378; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; UHLER M, 1983, J BIOL CHEM, V258, P9444; VIEAU D, 1989, CLIN ENDOCRINOL, V31, P691, DOI 10.1111/j.1365-2265.1989.tb01294.x; WILSON MG, 1982, ENDOCRINOLOGY, V110, P941, DOI 10.1210/endo-110-3-941; ZAKARIAN S, 1989, NATURE, V339, P553, DOI 10.1038/339553a0	65	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24967	24975						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227058				2022-12-25	WOS:A1993MG67300067
J	NUSING, RM; HIRATA, M; KAKIZUKA, A; EKI, T; OZAWA, K; NARUMIYA, S				NUSING, RM; HIRATA, M; KAKIZUKA, A; EKI, T; OZAWA, K; NARUMIYA, S			CHARACTERIZATION AND CHROMOSOMAL MAPPING OF THE HUMAN THROMBOXANE-A(2) RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; HUMAN-PLATELETS; INSITU HYBRIDIZATION; MESSENGER-RNA; DNA-BINDING; SEQUENCE; PROTEIN; EXPRESSION; FAMILY; CELLS	The human thromboxane A2 gene, present as a single copy, spans over 15 kilobases (kb) and contains 3 exons divided by 2 introns. The first intron, intron 1, exists in the 5'-noncoding region, 83 base pairs upstream from the ATG start site and is 6.3 kb long. Intron 2 with a length of 4.3 kb is located at the end of the sixth transmembrane region, thereby separating it from the downstream coding sequences including the seventh transmembrane region and the 3'-untranslated region. By rapid amplification of 5'-cDNA ends, transcription initiation sites starting in two different putative promoter regions were determined. In the 5'-flanking region of these transcription initiation sites, no typical TATA box exists. The major promoter, the promoter region I, contains four potential SP-1 binding sites and several potential binding sites for other transcription factors. By polymerase chain reaction analysis, a small portion of the RNA transcribed from this gene was shown to contain an additional 115-base pair long noncoding exon, exon 1b, which is located in intron 1. No additional exon in intron 2 was detectable, indicating that a single type of thromboxane A2 receptor protein is encoded by this gene. Chromosomal localization was carried out by fluorescence in situ hybridization of cloned genomic DNA to the metaphase chromosome. The gene was assigned to 19p13.3 of human chromosome.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN; RIKEN,GENE BANK,TSUKUBA 305,JAPAN; RIKEN,DIV HUMAN GENOME RES,TSUKUBA 305,JAPAN	Kyoto University; RIKEN; RIKEN								BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; DORN GW, 1989, J CLIN INVEST, V84, P1883, DOI 10.1172/JCI114375; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEY GH, 1989, ANN NY ACAD SCI, V557, P317; FITZPATRICK FA, 1978, NATURE, V275, P764, DOI 10.1038/275764a0; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HANASAKI K, 1989, BIOCHEM PHARMACOL, V38, P2967, DOI 10.1016/0006-2952(89)90004-X; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MAIS DE, 1985, J PHARMACOL EXP THER, V233, P413; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MORINELLI TA, 1989, J PHARMACOL EXP THER, V251, P557; MORINELLI TA, 1989, P NATL ACAD SCI USA, V86, P5600, DOI 10.1073/pnas.86.14.5600; NAKAJIMA M, 1989, BIOCHEM BIOPH RES CO, V158, P958, DOI 10.1016/0006-291X(89)92815-5; NEEDLEMAN P, 1976, SCIENCE, V193, P163, DOI 10.1126/science.945611; OGLETREE ML, 1987, FED PROC, V46, P133; OGURA M, 1985, BLOOD, V66, P1384; OZAWA K, 1992, GENOMICS, V12, P214, DOI 10.1016/0888-7543(92)90368-3; OZAWA K, 1991, GENOMICS, V10, P1103, DOI 10.1016/0888-7543(91)90210-6; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SWAYNE GTG, 1988, EUR J PHARMACOL, V152, P311, DOI 10.1016/0014-2999(88)90726-1; TYMKEWYCZ PM, 1991, BRIT J PHARMACOL, V102, P607, DOI 10.1111/j.1476-5381.1991.tb12220.x; USHIKUBI F, 1989, J BIOL CHEM, V264, P16496; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932	44	139	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25253	25259						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227091				2022-12-25	WOS:A1993MG67300104
J	PEREZMARTIN, JM; REQUENA, JM; CRACIUNESCU, D; LOPEZ, MC; ALONSO, C				PEREZMARTIN, JM; REQUENA, JM; CRACIUNESCU, D; LOPEZ, MC; ALONSO, C			THE ANTI Z-DNA REACTIVITY OF Z-DNA FORMING SEQUENCES IS AFFECTED BY PLATINUM ANTITUMOR DRUGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANDED Z-DNA; MAJOR ADDUCT; B-DNA; CIS-DIAMMINEDICHLOROPLATINUM(II); BINDING; TRANSITION; CISPLATIN; PLASMIDS	The effect of binding of platinum antitumor drugs, cis-diamminedichloroplatinum (II) (cis-DDP) and Pt-pentamidine, on the Z-DNA reactivity of potential Z-DNA forming sequences has been studied by enzyme-linked immunosorbent assay. rhe results indicate that cis-DDP and Pt-pentamidine increase the Z-DNA reactivity of plasmids containing a (dG-dC)16 insert (pUCZ8) and a native Z-DNA forming sequence of Drosophila hydei (pF18). The molar ratio of platinum bound to nucleotides (r(b)) to produce 50% of Z-DNA reactivity was 0.10 for cis-DDP:pF18, 0.15 for Pt-pentamidine: pF18, and 0.10 for cis-DDP:pUCZ8 and Pt-pentamidine:pUCZ8. The efficacy of Pt-pentamidine to provoke Z-DNA reactivity is 2.5-fold higher than that of cis-DDP. While Pt-pentamidine was capable of inducing Z-DNA reactivity in a GC-rich DNA sequence of the hsp 70 protein of Trypanosoma cruzi (p2M4EO3) and in sequences of pUC8, cis-DDP suppresses Z-DNA reactivity. CD spectra of poly(dG-me5dC). poly(dG-me5dC) modified by the drugs suggest that the increase in Z-DNA reactivity observed in plasmids upon drug binding may be due to shifting towards Z-DNA or a Z-DNA like conformation	UNIV AUTONOMA MADRID, FAC CIENCIAS, CSIC, CTR BIOL MOLEC, E-28049 MADRID, SPAIN; UNIV COMPLUTENSE MADRID, FAC FARM, DEPT QUIM INORGAN, E-28040 MADRID, SPAIN; CSIC, INST PARASITOL LOPEZ NEYRA, E-18001 GRANADA, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)			Lopez, Manuel/Z-5641-2019; Requena, Jose M/I-2022-2019	Requena, Jose M/0000-0001-7550-0198; Lopez, Manuel Carlos/0000-0003-0002-3678				AZORIN F, 1983, EMBO J, V2, P649, DOI 10.1002/j.1460-2075.1983.tb01479.x; BARTON JK, 1985, P NATL ACAD SCI USA, V82, P6460, DOI 10.1073/pnas.82.19.6460; BIRBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; JIMENEZRUIZ A, 1989, NUCLEIC ACIDS RES, V17, P4579, DOI 10.1093/nar/17.12.4579; JIMENEZRUIZ A, 1991, P NATL ACAD SCI USA, V88, P31, DOI 10.1073/pnas.88.1.31; LAFER EM, 1985, EMBO J, V4, P3655, DOI 10.1002/j.1460-2075.1985.tb04131.x; LAFER EM, 1986, J BIOL CHEM, V261, P6438; MALFOY B, 1981, NUCLEIC ACIDS RES, V9, P5659, DOI 10.1093/nar/9.21.5659; MALINGE JM, 1984, EMBO J, V3, P1273, DOI 10.1002/j.1460-2075.1984.tb01962.x; MALINGE JM, 1984, NUCLEIC ACIDS RES, V12, P5767, DOI 10.1093/nar/12.14.5767; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PEREZ JM, 1991, CHEM-BIOL INTERACT, V77, P341, DOI 10.1016/0009-2797(91)90042-6; PINTO A L, 1985, Biochimica et Biophysica Acta, V780, P167, DOI 10.1016/0304-419X(85)90001-0; POHL FM, 1982, NATURE, V300, P545, DOI 10.1038/300545a0; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; REQUENA JM, 1989, NUCLEIC ACIDS RES, V17, P797, DOI 10.1093/nar/17.2.797; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; SHERMAN SE, 1985, SCIENCE, V230, P412, DOI 10.1126/science.4048939; THOMAS TJ, 1991, J BIOL CHEM, V266, P6137; THOMAS TJ, 1988, J MOL BIOL, V201, P463, DOI 10.1016/0022-2836(88)90155-6; THOMAS TJ, 1988, ANAL BIOCHEM, V168, P359; UMAPATHY P, 1989, COORDIN CHEM REV, V95, P129, DOI 10.1016/0010-8545(89)80025-6; USHAY HM, 1982, NUCLEIC ACIDS RES, V10, P3753; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4	25	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24774	24778						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227037				2022-12-25	WOS:A1993MG67300040
J	RESING, KA; ALALAWI, N; BLOMQUIST, C; FLECKMAN, P; DALE, BA				RESING, KA; ALALAWI, N; BLOMQUIST, C; FLECKMAN, P; DALE, BA			INDEPENDENT REGULATION OF 2 CYTOPLASMIC PROCESSING STAGES OF THE INTERMEDIATE FILAMENT-ASSOCIATED PROTEIN FILAGGRIN AND ROLE OF CA2+ IN THE 2ND STAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEUM BASIC-PROTEIN; EPIDERMAL DIFFERENTIATION; MAMMALIAN EPIDERMIS; GROWTH-FACTOR; CALPAIN-II; CALCIUM; PROFILAGGRIN; IDENTIFICATION; KERATOHYALIN; LOCALIZATION	One of the final events in cornification of epidermal cells is processing of profilaggrin to the keratin-associated protein filaggrin. Processing involves several proteolytic events and occurs in two discrete proteolytic stages (Resing, K. A., Walsh, K. A., and Dale, B. A. (1984) J. Cell Biol. 99, 1372-1378; Resing, K. A., Walsh, K. A., Haugen-Scofield, J., and Dale, B. A. (1989) J. Biol. Chem. 264, 1837-1846). In a keratinocyte cell line derived from newborn rat epidermis, these two stages are independently regulated. Profilaggrin was expressed when the cells reached confluence; processing to intermediates began 24-36 h later (stage one), with filaggrin appearing at 48 h (stage two). Stage two processing required calcium in the medium with maximum processing occurring at 5-10 mm. Furthermore, stage two processing was inhibited by nifedipine, a calcium channel blocker, suggesting that calcium influx activates this event. Second-stage processing was also inhibited by the protease inhibitor leupeptin, implicating calpain. Confluent cells had higher levels of calpain I than subconfluent cells; in confluent cells, two immunoreactive bands were detected, comigrating with inactive (80 kDa) and activated (78 kDa) calpain I. In cells processing profilaggrin, most of the calpain I was in the 78-kDa form, implying extensive activation, supporting a role for calpain in processing.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED DERMATOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT ORAL BIOL & PERIODONT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NIADDK NIH HHS [AM21557] Funding Source: Medline; NIAMS NIH HHS [AR39730] Funding Source: Medline; NIDCR NIH HHS [DE04660] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P01AM021557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE004660, R37DE004660] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARNOLD E, 1987, P NATL ACAD SCI USA, V84, P21, DOI 10.1073/pnas.84.1.21; BRENNAN JK, 1975, IN VITRO CELL DEV B, V11, P354, DOI 10.1007/BF02616371; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; DALE BA, 1987, J INVEST DERMATOL, V88, P306, DOI 10.1111/1523-1747.ep12466185; DALE BA, 1978, NATURE, V276, P729, DOI 10.1038/276729a0; DALE BA, 1979, J INVEST DERMATOL, V72, P257, DOI 10.1111/1523-1747.ep12531715; DALE BA, 1982, ARCH ORAL BIOL, V27, P529, DOI 10.1016/0003-9969(82)90066-8; DALE BA, 1985, ANN NY ACAD SCI, V455, P330, DOI 10.1111/j.1749-6632.1985.tb50420.x; DEMARTINO GN, 1986, J BIOL CHEM, V261, P2047; ELIAS PM, 1975, J INVEST DERMATOL, V65, P501, DOI 10.1111/1523-1747.ep12610196; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; HARDING CR, 1983, J MOL BIOL, V170, P651, DOI 10.1016/S0022-2836(83)80126-0; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HAYDOCK PV, 1990, DNA CELL BIOL, V9, P251, DOI 10.1089/dna.1990.9.251; HAYDOCK PV, 1991, J INVEST DERMATOL, V101, P118; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HIRAO T, 1984, J BIOCHEM-TOKYO, V96, P775, DOI 10.1093/oxfordjournals.jbchem.a134895; KAM E, 1993, IN PRESS J CELL SCI; KUBILUS J, 1985, J INVEST DERMATOL, V85, P513, DOI 10.1111/1523-1747.ep12277310; KUBILUS J, 1983, J INVEST DERMATOL, V80, P124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LONSDALEECCLES JD, 1980, J BIOL CHEM, V255, P2235; LONSDALEECCLES JD, 1982, BIOCHEMISTRY-US, V21, P5940, DOI 10.1021/bi00266a033; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MIYACHI Y, 1986, J INVEST DERMATOL, V86, P346, DOI 10.1111/1523-1747.ep12285556; Polakowska R. R., 1991, PHYSL BIOCH MOL BIOL, P168; PONTREMOLI S, 1986, J BIOL CHEM, V261, P8309; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; RESING KA, 1985, BIOCHEMISTRY-US, V24, P4167, DOI 10.1021/bi00336a053; RESING KA, 1989, J BIOL CHEM, V264, P1837; RESING KA, 1984, J CELL BIOL, V99, P1372, DOI 10.1083/jcb.99.4.1372; RESING KA, 1993, IN PRESS BIOCHEMISTR; ROTHNAGEL JA, 1990, J BIOL CHEM, V265, P1862; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SCOTT I R, 1981, Biochemical Society Transactions, V9, P388; SCOTT IR, 1981, BIOCHIM BIOPHYS ACTA, V669, P65, DOI 10.1016/0005-2795(81)90224-5; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; YUSPA SH, 1983, CANCER RES, V43, P5707	44	81	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25139	25145						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227077				2022-12-25	WOS:A1993MG67300089
J	ZHENG, YW; BEY, M; LIU, H; FELDER, MR				ZHENG, YW; BEY, M; LIU, H; FELDER, MR			MOLECULAR-BASIS OF THE ALCOHOL DEHYDROGENASE-NEGATIVE DEER MOUSE - EVIDENCE FOR DELETION OF THE GENE FOR CLASS-I ENZYME AND IDENTIFICATION OF A POSSIBLE NEW ENZYME CLASS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ETHANOL-METABOLISM; NUCLEOTIDE-SEQUENCE; ADH-1 GENE; INVIVO; LIVER; ACID; PEROMYSCUS; PURIFICATION; ISOZYMES; FAMILY	The molecular basis of the alcohol dehydrogenase (ADH)-negative deer mouse (Peromyscus maniculatus) has been investigated. Several classes of mammalian ADHs have been recognized based upon biochemical and structural properties. ADH cDNA clones identified by hybridization to a mouse class I ADH cDNA clone were obtained from a deer mouse ADH-positive liver cDNA library. This cDNA has been identified as being a class I sequence and represents the deer mouse Adh-1 gene. An additional cDNA sequence identified in both the ADH-positive and -negative deer mouse cDNA libraries was identified by weak cross-hybridization to the mouse cDNA. This cDNA encodes an amino acid sequence representing a new class of mammalian ADH, and the deer mouse gene for this ADH is named Adh-2. ADH-negative deer mice do not produce mRNA, that is detected by the Adh-1 cDNA probe. However, both stocks of deer mice produce high levels of Adh-2 mRNA in liver. Southern analysis using an essentially full-length Adh-1 cDNA probe has shown that the Adh-1 gene is deleted in the ADH-negative mice. Biochemical analysis of enzyme activity suggests at least three ADH polypeptides are expressed in different tissues and have somewhat different substrate specificities, as in the mouse.	UNIV S CAROLINA, DEPT BIOL SCI, COLUMBIA, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006608] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA 06608] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALDERMAN J, 1987, J BIOL CHEM, V262, P7497; ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENSON S A, 1984, Biotechniques, V2, P126; BURNETT KG, 1980, BIOCHEM PHARMACOL, V29, P125, DOI 10.1016/0006-2952(80)90318-4; BURNETT KG, 1978, BIOCHEM GENET, V16, P443, DOI 10.1007/BF00484210; BURNETT KG, 1978, BIOCHEM GENET, V16, P1093, DOI 10.1007/BF00484530; CECI JD, 1987, GENE, V59, P171, DOI 10.1016/0378-1119(87)90325-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUESTER G, 1986, J BIOL CHEM, V261, P2027; EDENBERG HJ, 1985, P NATL ACAD SCI USA, V82, P2262, DOI 10.1073/pnas.82.8.2262; FELDER MR, 1988, J BIOL CHEM, V263, P14531; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANDLER JA, 1986, BIOCHEM PHARMACOL, V35, P4487, DOI 10.1016/0006-2952(86)90768-9; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOLMES RS, 1981, J EXP ZOOL, V217, P151, DOI 10.1002/jez.1402170202; HOLMES RS, 1977, GENETICS, V87, P709; HUR MW, 1992, J DNA SEQUENCING MAP, V3, P167; IKUTA T, 1986, P NATL ACAD SCI USA, V83, P634, DOI 10.1073/pnas.83.3.634; JORNVALL H, 1987, P NATL ACAD SCI USA, V84, P2580, DOI 10.1073/pnas.84.9.2580; JULIA P, 1988, EUR J BIOCHEM, V172, P73, DOI 10.1111/j.1432-1033.1988.tb13857.x; KAISER R, 1988, BIOCHEMISTRY-US, V27, P1132, DOI 10.1021/bi00404a009; LEHRMAN MA, 1985, SCIENCE, V227, P140, DOI 10.1126/science.3155573; MYEROWITZ R, 1987, J BIOL CHEM, V262, P15396; NORSTEN C, 1989, J BIOL CHEM, V264, P5593; PARES X, 1990, FEBS LETT, V277, P115, DOI 10.1016/0014-5793(90)80822-Z; POSCH KC, 1989, ARCH BIOCHEM BIOPHYS, V274, P171, DOI 10.1016/0003-9861(89)90428-1; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI Y, 1991, J BIOL CHEM, V266, P13243; SHIGETA Y, 1984, BIOCHEM PHARMACOL, V33, P807, DOI 10.1016/0006-2952(84)90466-0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRYDOM DJ, 1982, ANAL BIOCHEM, V123, P422, DOI 10.1016/0003-2697(82)90467-5; SUN HW, 1992, J MOL EVOL, V34, P522, DOI 10.1007/BF00160465; TAKAGI T, 1986, BIOCHEM PHARMACOL, V35, P3601, DOI 10.1016/0006-2952(86)90632-5; VISSING H, 1991, J BIOL CHEM, V266, P5244; YASUNAMI M, 1991, P NATL ACAD SCI USA, V88, P7610, DOI 10.1073/pnas.88.17.7610	38	50	52	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24933	24939						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227055				2022-12-25	WOS:A1993MG67300063
J	CYR, DM; STUART, RA; NEUPERT, W				CYR, DM; STUART, RA; NEUPERT, W			A MATRIX ATP REQUIREMENT FOR PRESEQUENCE TRANSLOCATION ACROSS THE INNER MEMBRANE OF MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN IMPORT; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; RECEPTOR; IDENTIFICATION; TRANSPORT; OUTER	The mitochondrial presequence initiates protein translocation across the inner membrane of mitochondria in a DELTApsi-dependent step. We have investigated the role of matrix ATP in this process. When matrix ATP was reduced to interfere with the function of mitochondrial heat shock protein 70, presequence translocation across the inner membrane was strongly inhibited. This was accompanied by the accumulation of an import intermediate that was unprocessed and accessible to protease added to the intact mitochondria. Both DELTApsi and matrix ATP were required for further translocation of this intermediate into the matrix. When ATP levels are insufficient to support protein import, it appears that the presequence becomes translocated across the inner membrane, but DELTApsi does not maintain it in the matrix. Presequence translocation across the inner membrane is thus a reversible reaction, and a step dependent on matrix ATP is required to make it unidirectional. Based on these observations, a model on the role of DELTApsi, mthsp70, and matrix ATP in presequence translocation across the inner membrane is presented.	UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,D-80336 MUNICH,GERMANY	University of Munich				Cyr, Douglas/0000-0002-4928-3414				CHEN WJ, 1988, J BIOL CHEM, V263, P4997; CYR DM, 1991, J BIOL CHEM, V266, P21700; DAUM G, 1982, J BIOL CHEM, V257, P3028; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; HWANG ST, 1991, J BIOL CHEM, V266, P21083; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MILLER BR, 1993, J CELL BIOL, V121, P1021, DOI 10.1083/jcb.121.5.1021; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9	20	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23751	23754						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226903				2022-12-25	WOS:A1993MF29400005
J	ISENMAN, LD; DICE, JF				ISENMAN, LD; DICE, JF			SELECTIVE RELEASE OF PEPTIDES FROM LYSOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; T-CELLS; PROTEINS; DEGRADATION; ANTIGEN; FIBROBLASTS; PATHWAYS; GLYCOPROTEIN	We demonstrate a selective release of peptides by lysosomes in vitro. A lysosomal fraction from human fibroblasts that had previously endocytosed [H-3]ribonuclease A was incubated for 2 h, and radioactivity released into the medium and radioactivity retained within lysosomes were analyzed. A variety of radiolabeled molecules including peptides of an appropriate size to serve as antigens for T cell-mediated immunity were released. One small peptide was predominantly released, while others, as well as intact ribonuclease A, were predominantly retained. A 4-5-fold range was also evident in the relative release of three H-3-labeled tripeptide probes of similar charge derived from the sequence of ribonuclease A. This selectivity and the fact that similar peptide degradation fragments were also released and retained by intact cells after endocytosis of [H-3]ribonuclease A argues strongly that the release observed in vitro is physiological and not due to damaged lysosomal membranes.			ISENMAN, LD (corresponding author), TUFTS UNIV,SCH MED,DEPT PHYSIOL,136 HARRISON AVE,BOSTON,MA 02111, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006116] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG06116] Funding Source: Medline; NIDDK NIH HHS [T32 DK07542] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BJORK I, 1992, J BIOL CHEM, V267, P1976; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BUCHMASTER MJ, 1987, CELL BIOL INT REP, V11, P501; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; Dice J F, 1990, Semin Cell Biol, V1, P449; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GURLEY R, 1988, CELL BIOL INT REP, V12, P885, DOI 10.1016/0309-1651(88)90052-5; HAKIM FT, 1991, J IMMUNOL, V147, P2310; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HERMAN B, 1984, J CELL BIOL, V98, P565, DOI 10.1083/jcb.98.2.565; HOLTZMAN E, 1989, LYSOSOMES, P140; ISENMAN LD, 1989, J BIOL CHEM, V264, P21591; JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; MEANS GE, 1968, BIOCHEMISTRY-US, V7, P2192, DOI 10.1021/bi00846a023; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; NEFF NT, 1981, J CELL BIOL, V91, P184, DOI 10.1083/jcb.91.1.184; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; ROCK KL, 1993, J IMMUNOL, V150, P438; ROMISCH K, 1992, P NATL ACAD SCI USA, V89, P7227, DOI 10.1073/pnas.89.15.7227; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SCHAUDIES RP, 1987, BIOCHEM BIOPH RES CO, V143, P710, DOI 10.1016/0006-291X(87)91412-4; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; STORRIE B, 1984, J CELL BIOL, V98, P108, DOI 10.1083/jcb.98.1.108; WILEY HS, 1985, J BIOL CHEM, V260, P5290	33	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23856	23859						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226924				2022-12-25	WOS:A1993MF29400026
J	KOPKE, E; TUNG, YC; SHAIKH, S; ALONSO, AD; IQBAL, K; GRUNDKEIQBAL, I				KOPKE, E; TUNG, YC; SHAIKH, S; ALONSO, AD; IQBAL, K; GRUNDKEIQBAL, I			MICROTUBULE-ASSOCIATED PROTEIN-TAU - ABNORMAL PHOSPHORYLATION OF A NON-PAIRED HELICAL FILAMENT POOL IN ALZHEIMER-DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; NEUROFIBRILLARY TANGLES; MONOCLONAL-ANTIBODIES; BRAIN; UBIQUITIN; ASSAY; DEPHOSPHORYLATION; IDENTIFICATION; SUSCEPTIBILITY; POLYPEPTIDES	The major protein subunit of the paired helical filaments (PHF) of Alzheimer disease (AD) is the microtubule-associated protein tau. Tau is a family of phosphopolypeptides that are abnormally phosphorylated in PHF. In this study, a non-PHF pool of tau abnormally phosphorylated at Ser-199/202, and tau not phosphorylated at this site (AD P-tau and AD tau, respectively) were isolated from the 27,000 x g to 200,000 x g fraction of AD brain homogenate by extraction in 8 M urea, followed by dialysis against Tris buffer. AD P-tau and AD tau were further purified and separated from each other by acid precipitation, glial fibrillary acidic protein affinity chromatography, and phosphocellulose chromatography. The resulting AD P-tau and AD tau preparations were free of cytoskeletal proteins, ubiquitin, and beta-amyloid peptide. Immunochemical and morphological analysis of AD P-tau preparations revealed that most of the protein was of non-PHF origin. The AD P-tau was about 3-4-fold (approximately 8 mol P0(4)/mol protein, M(r) 41,318) more phosphorylated than cytosolic tau from AD and control brains. Unlike PHF, the AD P-tau lacked ubiquitin. In AD brain the levels of cytosolic tau were about half of those in control aged cases. These findings suggest that the abnormal phosphorylation of tau in AD occurs in the cytosol.	NEW YORK STATE INST BASIC RES DEV DISABIL,1050 FOREST HILLS RD,STATEN ISL,NY 10314	Institute for Basic Research in Developmental Disabilities					NIA NIH HHS [F32 AGO 5541, AG O4220] Funding Source: Medline; NINDS NIH HHS [NS 18105] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004220, F32AG005541] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BANCHER C, 1991, BRAIN RES, V539, P11, DOI 10.1016/0006-8993(91)90681-K; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BRAAK H, 1986, NEUROSCI LETT, V65, P351, DOI 10.1016/0304-3940(86)90288-0; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; CHEN M, 1989, J BIOL CHEM, V264, P14282; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Dustin P., 1982, AXOPLASMIC TRANSPORT, P131; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1985, ACTA NEUROPATHOL, V68, P279, DOI 10.1007/BF00690830; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; GRUNDKEIQBAL I, 1988, MOL BRAIN RES, V4, P43, DOI 10.1016/0169-328X(88)90017-4; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; IHARA Y, 1986, J BIOCHEM-TOKYO, V99, P1807, DOI 10.1093/oxfordjournals.jbchem.a135662; IQBAL K, 1986, LANCET, V2, P421; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; IQBAL K, 1984, ACTA NEUROPATHOL, V62, P167, DOI 10.1007/BF00691849; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KSIEZAKREDING H, 1992, BRAIN RES, V597, P209, DOI 10.1016/0006-8993(92)91476-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG E, 1992, BIOCHEM BIOPH RES CO, V187, P783, DOI 10.1016/0006-291X(92)91264-Q; LAUMAS S, 1989, P NATL ACAD SCI USA, V86, P3021, DOI 10.1073/pnas.86.9.3021; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; LIU WK, 1991, J BIOL CHEM, V266, P21723; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; NIETO A, 1990, NEUROSCIENCE, V37, P163, DOI 10.1016/0306-4522(90)90201-E; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; PAPASOZOMENOS SC, 1989, LAB INVEST, V60, P375; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; PERRY G, 1989, J NEUROCHEM, V52, P1523, DOI 10.1111/j.1471-4159.1989.tb09203.x; RUBEN GC, 1992, BRAIN RES, V590, P164, DOI 10.1016/0006-8993(92)91092-S; RUBEN GC, 1991, J BIOL CHEM, V266, P22019; RUBENSTEIN R, 1986, BRAIN RES, V372, P80, DOI 10.1016/0006-8993(86)91460-5; SAITOH T, 1986, P NATL ACAD SCI USA, V83, P9764, DOI 10.1073/pnas.83.24.9764; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; WANG GP, 1984, ACTA NEUROPATHOL, V62, P268, DOI 10.1007/BF00687608; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WISNIEWSKI HM, 1984, J NEUROPATH EXP NEUR, V43, P643, DOI 10.1097/00005072-198411000-00008; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509	55	554	590	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24374	24384						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226987				2022-12-25	WOS:A1993MF29400098
J	LAVOIE, JN; HICKEY, E; WEBER, LA; LANDRY, J				LAVOIE, JN; HICKEY, E; WEBER, LA; LANDRY, J			MODULATION OF ACTIN MICROFILAMENT DYNAMICS AND FLUID-PHASE PINOCYTOSIS BY PHOSPHORYLATION OF HEAT-SHOCK PROTEIN-27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MAMMALIAN STRESS PROTEINS; GROWTH-FACTORS; SMOOTH-MUSCLE; HUMAN HSP27; 27 KDA; CELLS; EXPRESSION; IDENTIFICATION; POLYMERIZATION	We recently reported that overexpression of heat shock protein 27 (HSP27) in rodent fibroblasts increases the stability of stress fibers during hyperthermia and partially prevents actin depolymerization during exposure to cytochalasin D (Lavoie, J. N., Gingras-Breton, G., Tanguay, R. M., and Landry, J. (1993) J. Biol. Chem. 268, 3420-3429). Because HSP27 is a ubiquitous target of phosphorylation upon cell stimulation with a variety of growth factors and agents that affect cellular differentiation, we examined the role of HSP27 phosphorylation in regulating actin filament dynamics. Here we show that HSP27 is enriched at the leading edge of polarized fibroblasts. HSP27 is localized in lamellipodia and membrane ruffles where most actin polymerization occurs. We developed Chinese hamster cell lines that constitutively overexpressed either human HSP27 or a non-phosphorylatable mutant form of the protein. Overexpression of HSP27 caused an increased concentration of filamentous actin (F-actin) at the cell cortex and elevated pinocytotic activity. In contrast, overexpression of the non-phosphorylatable mutant form of HSP27 reduced cortical F-actin concentration and decreased pinocytosis activity relative to control cells. Mitogenic stimulation of fibroblasts resulted in a rapid polymerization of submembranous actin filaments. HSP27 enhanced growth factor-induced F-actin accumulation, whereas mutant HSP27 exerted a dominant negative effect and inhibited this response to growth factors. Thus, HSP27 is a component of a signal transduction pathway that can regulate microfilament dynamics.	UNIV LAVAL, HOTEL DIEU, CTR RECH CANCEROL, 11 COTE PALAIS, QUEBEC CITY G1R 2J6, PQ, CANADA; UNIV NEVADA, DEPT BIOL, RENO, NV 89557 USA	Laval University; Nevada System of Higher Education (NSHE); University of Nevada Reno				Lavoie, Josee N/0000-0001-6912-1132	NIGMS NIH HHS [GM 43167] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043167] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BITAR KN, 1991, BIOCHEM BIOPH RES CO, V181, P1192, DOI 10.1016/0006-291X(91)92065-R; CHAMBARD JC, 1983, J BIOL CHEM, V258, P1706; DARBON JM, 1990, BIOCHEM BIOPH RES CO, V168, P527, DOI 10.1016/0006-291X(90)92353-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; GROSE JH, 1991, ADV PROSTAG THROMB L, V21, P145; GUESDON F, 1991, J IMMUNOL, V147, P3402; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; JAKOB U, 1993, J BIOL CHEM, V268, P1517; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MENDELSOHN ME, 1991, P NATL ACAD SCI USA, V88, P11212, DOI 10.1073/pnas.88.24.11212; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MICHISHITA M, 1991, BIOCHEM BIOPH RES CO, V176, P979, DOI 10.1016/0006-291X(91)90378-K; MING Z, 1993, J BIOL CHEM, V268, P35; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBAYE B, 1989, BIOCHEM BIOPH RES CO, V163, P301, DOI 10.1016/0006-291X(89)92135-9; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SHAKOORI AR, 1992, J CELL BIOCHEM, V48, P277, DOI 10.1002/jcb.240480308; SHIBANUMA M, 1992, BIOCHEM BIOPH RES CO, V187, P1418, DOI 10.1016/0006-291X(92)90460-3; SHIBANUMA M, 1991, CELL GROWTH DIFFER, V2, P583; SPECTOR NL, 1992, J IMMUNOL, V148, P1668; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STRAHLER JR, 1991, BIOCHEM BIOPH RES CO, V175, P134, DOI 10.1016/S0006-291X(05)81211-2; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; ZANTEMA A, 1989, J VIROL, V63, P3368, DOI 10.1128/JVI.63.8.3368-3375.1989	41	508	525	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24210	24214						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226968				2022-12-25	WOS:A1993MF29400074
J	MITSUI, K; SHIRAKATA, M; PATERSON, BM				MITSUI, K; SHIRAKATA, M; PATERSON, BM			PHOSPHORYLATION INHIBITS THE DNA-BINDING ACTIVITY OF MYOD HOMODIMERS BUT NOT MYOD-E12 HETERODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; MYOGENIC DETERMINATION FACTORS; MUSCLE-SPECIFIC TRANSCRIPTION; GENE FAMILY; ENHANCER; ACTIVATION; REGION; MEMBER; DIFFERENTIATION; DIMERIZATION	MyoD is a member of the basic helix-loop-helix (bHLH) family of muscle gene regulatory proteins that includes myogenin, myf-5, and MRF4. These proteins have been shown to heterodimerize with E2A bHLH proteins, E12/E47, and to bind to a consensus sequence known as an E-box, CANNTG, the target for transcriptional activation by these myogenic regulators. MyoD is also a phosphorylated nuclear protein that is present in muscle cells prior to the transcriptional activation of the muscle-specific genes, many of which contain E-box elements in their regulatory regions. Here we report that phosphorylated chicken MyoD, called CMD1, produced in sf9 cells using the baculovirus system, is qualitatively similar to CMD1 isolated by immunoaffinity purification from primary cultures of embryonic chick breast muscle. Functional analysis of phosphorylated and dephosphorylated CMD1 produced in sf9 cells indicates that, in the presence of magnesium, DNA binding of phosphorylated CMD1 is inhibited whereas binding in association with E12 is not affected. However, CMD1 binding alone is equally efficient when either EDTA is added in excess or dephosphorylated or bacterially expressed CMD1 is used in the assay. Our results suggest that cellular phosphorylation changes the CMD1 homodimer-heterodimer equilibrium which, in turn, modulates and/or eliminates binding site competition between CMD1 homodimers and CMD1/E-protein heterodimers in the cell.	NCI, BIOCHEM LAB, BLDG 37, RM 4A-21, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1991, EUR J BIOCHEM, V198, P187, DOI 10.1111/j.1432-1033.1991.tb16000.x; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRAUN T, 1991, NUCLEIC ACIDS RES, V19, P5645, DOI 10.1093/nar/19.20.5645; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1988, J BIOL CHEM, V263, P19670; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; MEEK DW, 1992, BIOCHEM J, V287, P1; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKAMURA S, 1993, J BIOL CHEM, V268, P11670; ONEILL MC, 1972, J CELL BIOL, V52, P52, DOI 10.1083/jcb.52.1.52; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; TAPSCOTT SJ, 1989, SCIENCE, V245, P532, DOI 10.1126/science.2547249; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WINTER B, 1993, J BIOL CHEM, V268, P9869; WINTER B, 1992, EMBO J, V11, P1843, DOI 10.1002/j.1460-2075.1992.tb05236.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	35	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24415	24420						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226992				2022-12-25	WOS:A1993MF29400103
J	NAGAYA, T; JAMESON, JL				NAGAYA, T; JAMESON, JL			DISTINCT DIMERIZATION DOMAINS PROVIDE ANTAGONIST PATHWAYS FOR THYROID-HORMONE RECEPTOR ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; 9-CIS RETINOIC ACID; C-ERBA PROTOONCOGENES; DNA-BINDING; X-RECEPTOR; TRANSCRIPTIONAL REGULATION; RESPONSE ELEMENTS; HUMAN TESTIS; RXR-BETA; PROTEIN	Transcriptional regulation by thyroid hormone is mediated through its nuclear receptors, which bind to target response elements as homodimers or as heterodimers with proteins such as retinoid X receptors (RXR). Thyroid hormone response elements exhibit remarkable flexibility in that the receptor binding half-sites can be arranged as direct repeats, inverted repeats, or everted repeats. We report that a limited region at the carboxyl-terminal end of the thyroid hormone receptor differentially contributes to the formation of receptor homo- and heterodimers. The functionally inactive thyroid hormone receptor splicing variant alpha2, which is altered at the juncture of the homo- and heterodimerization domains, cannot form homodimers. However, alpha2 can form a heterodimer when bound to half-sites arranged as a direct repeat spaced by 4 base pairs (DR4), but not with other arrangements of response element half-sites. The alpha2-RXR heterodimer strongly inhibits wild type receptor function mediated by the DR4 element, suggesting that the alpha2 isoform modulates thyroid hormone action by binding as an antagonist to a subset of response elements.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,THYROID UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital				Jameson, James/0000-0001-9538-4059	NIDDK NIH HHS [DK42144] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042144] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KATZ D, 1992, MOL ENDOCRINOL, V6, P805, DOI 10.1210/me.6.5.805; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEE JW, 1992, MOL ENDOCRINOL, V6, P1867, DOI 10.1210/me.6.11.1867; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAYA T, 1992, J BIOL CHEM, V267, P13014; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; NAKAI A, 1988, P NATL ACAD SCI USA, V85, P2781, DOI 10.1073/pnas.85.8.2781; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; RENTOUMIS A, 1990, MOL ENDOCRINOL, V4, P1522, DOI 10.1210/mend-4-10-1522; SAKURAI A, 1990, MOL ENDOCRINOL, V4, P1988, DOI 10.1210/mend-4-12-1988; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; YEN PM, 1992, J BIOL CHEM, V267, P23248; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	40	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24278	24282						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226975				2022-12-25	WOS:A1993MF29400084
J	OBRIEN, MC; MCKAY, DB				OBRIEN, MC; MCKAY, DB			THREONINE-204 OF THE CHAPERONE PROTEIN HSC70 INFLUENCES THE STRUCTURE OF THE ACTIVE-SITE, BUT IS NOT ESSENTIAL FOR ATP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; UNCOATING PROTEIN; UNFOLDED PROTEINS; STRESS PROTEINS; DNAK; CRYSTALLOGRAPHY; TRANSLOCATION; DISSOCIATION; FRAGMENT; BINDING	The chaperone protein Hsc70 is an ATPase of unknown mechanism, although the crystal structure of the 44-kDa ATPase domain has been solved. This structure shows that the hydroxyl of threonine 204 is located close to the gamma-phosphate of ATP, in a position where it might be an intermediate phosphate acceptor in the hydrolysis reaction. We made two point mutations at residue 204 of Hsc70, threonine to valine (T204V) and threonine to glutamic acid (T204E). The wild-type ATPase domain had a K(m) for ATP of approximately 1 muM; the mutants had K(m) values of approximately 90 muM. The k(cat) values for the mutant proteins were also increased. After crystallization, the structures of the T204V and T204E proteins were solved and refined with data to 2.3- and 2.4-angstrom resolution, respectively. The overall tertiary structure of the mutants showed little change from the wild type; however, significant changes were observed in the active site. Analysis of the structures suggested possible reasons for the changes in kinetic constants. Threonine 204 does not seem to be an obligatory intermediate phosphate acceptor in the hydrolysis reaction since the mutants retained appreciable ATPase activity.	STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,BECKMAN LABS STRUCT BIOL,SHERMAN FAIRCHILD BLDG,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928, F32GM015141] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 39928, GM 15141] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BRANDHUBER BJ, 1988, PROTEINS, V3, P146, DOI 10.1002/prot.340030303; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DELUCAFLAHERTY C, 1990, NUCLEIC ACIDS RES, V18, P5569, DOI 10.1093/nar/18.18.5569; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; HARLOW E, 1991, ANTIBODIES LABORATOR, V42, P1; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KOERBER SC, 1987, ANAL BIOCHEM, V165, P75, DOI 10.1016/0003-2697(87)90203-X; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; Orsi B A, 1979, Methods Enzymol, V63, P159; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012	24	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24323	24329						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226982				2022-12-25	WOS:A1993MF29400091
J	RALTON, JE; MILNE, KG; GUTHER, MLS; FIELD, RA; FERGUSON, MAJ				RALTON, JE; MILNE, KG; GUTHER, MLS; FIELD, RA; FERGUSON, MAJ			THE MECHANISM OF INHIBITION OF GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR BIOSYNTHESIS IN TRYPANOSOMA-BRUCEI BY MANNOSAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; VARIANT SURFACE GLYCOPROTEINS; LIPID-LINKED OLIGOSACCHARIDES; CELL-FREE SYSTEM; GLYCOSYL-PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE-C; GLYCOLIPID PRECURSORS; STRUCTURAL CHARACTERIZATION; RESISTANT GLYCOLIPIDS; GPI ANCHOR	The inhibition of glycosylphosphatidylinositol anchor biosynthesis by mannosamine has been described previously in the procyclic forms of Trypanosoma brucei and in mammalian cells (Lisanti, M. P., Field, M. C., Caras, I. W. J., Menon, A. K., and Rodriguez-Boulan, E. (1991) EMBO J. 10, 1969-1977). A recent report has suggested that mannosamine exerts these effects by becoming incorporated into glycosylphosphatidylinositol anchor intermediates (Pan, Y-T., Kamitani, T., Bhuvaneswaran, C., Hallaq, Y., Warren, C. D., Yeh, E. T. H., and Elbein, A. D. (1992) J. Biol. Chem.267, 21250-21255). In this paper we have analyzed the effects of mannosamine on glycosylphosphatidylinositol anchor and variant surface glycoprotein biosynthesis in the bloodstream form of T. brucei. Trypanosomes were biosynthetically labeled with [H-3]mannosamine, and [H-3]glucosamine in the presence of mannosamine, and the structures of the labeled glycolipids which accumulated were determined. The main glycolipid metabolite of mannosamine was shown to be ManN-Man-GlcN-PI. A trypanosome cell-free system preloaded with this compound was significantly impaired in its ability to synthesize glycosylphosphatidylinositol anchor intermediates beyond Manalpha1-6Manalpha1-4GlcNalpha1-6PI. This compound is therefore proposed to be an inhibitor of the Dol-P-Man:Manalpha1-6Manalpha1-4GlcNalpha1-6PI alpha1-2-mannosyltransferase of the GPI biosynthetic pathway. In living trypanosomes, 4 mM mannosamine had no effect on protein synthesis but reduced the rate of formation of mature glycosylphosphatidylinositol anchor precursors by 80%. This reduction in anchor precursor synthesis was insufficient to prevent the attachment of glycosylphosphatidylinositol anchors to newly synthesized variant surface glycoprotein molecules. These data suggest that the rate of anchor precursor synthesis in the bloodstream form of T. brucei, in contrast to mammalian cells and the procyclic form of T. brucei, is in large excess of the cellular requirements for protein anchorage.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714; Field, Rob/0000-0001-8574-0275	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1992, BIOCHEM SOC T, V20, P243, DOI 10.1042/bst0200243; FERGUSON MAJ, 1992, BIOCHEM J, V284, P297, DOI 10.1042/bj2840297; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; FIELD MC, 1992, J BIOL CHEM, V267, P5324; GEROLD P, 1992, Biochemical Society Transactions, V20, p297S; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HIROSE S, 1992, J BIOL CHEM, V267, P5272; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; KOBATA A, 1987, METHOD ENZYMOL, V138, P84; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; LISANTI MP, 1990, P NATL ACAD SCI USA, V87, P7419, DOI 10.1073/pnas.87.19.7419; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1991, EMBO J, V10, P2041, DOI 10.1002/j.1460-2075.1991.tb07734.x; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MENON AK, 1991, CELL BIOL INT REP, V15, P1007; MILNE KG, 1992, EUR J BIOCHEM, V208, P309, DOI 10.1111/j.1432-1033.1992.tb17188.x; PAN YT, 1992, J BIOL CHEM, V267, P8991; PAN YT, 1992, J BIOL CHEM, V267, P21250; PAN YT, 1985, ARCH BIOCHEM BIOPHYS, V242, P447, DOI 10.1016/0003-9861(85)90229-2; PUOTI A, 1992, J BIOL CHEM, V267, P22673; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; SINNOTT ML, 1987, ENZYME MECHANISMS, P291; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TOMAVO S, 1992, J BIOL CHEM, V267, P21446; ZAMZE SE, 1990, EUR J BIOCHEM, V187, P657, DOI 10.1111/j.1432-1033.1990.tb15350.x	43	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24183	24189						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226965				2022-12-25	WOS:A1993MF29400070
J	SCHAAPER, RM				SCHAAPER, RM			BASE SELECTION, PROOFREADING, AND MISMATCH REPAIR DURING DNA-REPLICATION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POLYMERASE-III HOLOENZYME; SPONTANEOUS MUTATION; EXONUCLEASE ACTIVITY; LACI GENE; MECHANISMS; FIDELITY; MUTD5; SPECIFICITY; MUTAGENESIS; INVITRO	The accuracy by which organisms duplicate their DNA is of considerable interest. At least three mechanisms operate, serially, to secure high fidelity: base selection, exonucleolytic proofreading, and postreplicative mismatch correction. To obtain insights into the efficiency and specificity of these steps in the bacterium Escherichia coli, we have performed DNA sequence analysis of mutations occurring in the bacterial lacI gene in a series of strains genetically disabled in one or more of these error avoidance pathways. The base selection efficiency was estimated from mutagenesis occurring in a mutDmutL strain, which is deficient in both proofreading (mutD5) and mismatch repair (mutL). The proofreading efficiency was derived comparing the mutD5 mutL strain to the mismatch repair-deficient mutL strain. The efficiency of mismatch repair was derived comparing the mutL strain to the wild-type strain. The results show that base selection discriminates against errors by 200,000-2,000,000-fold, proofreading by 40-200-fold, and mismatch repair by 20-400-fold, each depending on the type of error. Base selection and proofreading act more strongly against transversions than transitions, whereas mismatch repair does the opposite. The data are based on 866 sequenced lacI mutations in a target that allows the scoring of at least 127 different mutations in 76 distinct DNA sequence contexts in vivo. They may therefore have general significance.			SCHAAPER, RM (corresponding author), NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709, USA.		Schaaper, Roel M/E-6680-2019	Schaaper, Roel M/0000-0003-1344-3196				BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BRENOWITZ S, 1991, J BIOL CHEM, V266, P7888; CARRAWAY M, 1990, MOL MICROBIOL, V4, P1645, DOI 10.1111/j.1365-2958.1990.tb00541.x; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ECHOLS H, 1983, P NATL ACAD SCI-BIOL, V80, P2189, DOI 10.1073/pnas.80.8.2189; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; JOYCE CM, 1992, J BIOL CHEM, V267, P24485; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MILLER JH, 1978, OPERON, P31; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; SCHAAPER RM, 1991, GENETICS, V129, P317; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SCHAAPER RM, 1985, GENE, V39, P181, DOI 10.1016/0378-1119(85)90312-9; SCHAAPER RM, 1986, J MOL BIOL, V189, P273, DOI 10.1016/0022-2836(86)90509-7; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SCHAAPER RM, 1993, GENETICS, V134, P1031; SCHAAPER RM, 1992, J BACTERIOL, V174, P1974, DOI 10.1128/jb.174.6.1974-1982.1992; SCHAAPER RM, 1989, EMBO J, V8, P3511, DOI 10.1002/j.1460-2075.1989.tb08516.x; SINHA NK, 1987, P NATL ACAD SCI USA, V84, P915, DOI 10.1073/pnas.84.4.915; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465	26	244	248	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23762	23765						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226906				2022-12-25	WOS:A1993MF29400008
J	SCHUTZBACH, JS; ZIMMERMAN, JW; FORSEE, WT				SCHUTZBACH, JS; ZIMMERMAN, JW; FORSEE, WT			THE PURIFICATION AND CHARACTERIZATION OF RECOMBINANT YEAST DOLICHYL-PHOSPHATE-MANNOSE SYNTHASE - SITE-DIRECTED MUTAGENESIS OF THE PUTATIVE DOLICHOL RECOGNITION SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHOMANNOSE SYNTHASE; PROTEIN; ENZYME; MANNOSYLTRANSFERASE; GLYCOSYLATION; PHOSPHOLIPIDS; MODULATION; MEMBRANES; CLONING	Yeast dolichyl-phosphate-mannose synthase was purified from cultures of Escherichia coli carrying the gene for this enzyme in a high expression vector. The synthase contains a highly conserved hydrophobic amino acid sequence proposed to be involved in the recognition of dolichols (Albright, C. F., Orlean, P., and Robbins, P. W. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7366-7369) and amino acid residues in this sequence were altered by site-directed mutagenesis. Conservative substitutions had no effect on the affinity of the enzyme for dolichyl-P. The substitution of asparagine for isoleucine at position 253 resulted in higher values for the apparent K(m) for Dol-P when assayed in detergent solutions, but this substitution had no effect on K(m) when the enzyme was reconstituted with phosphatidylethanolamine. Enzyme containing a deletion of the entire putative dolichol recognition sequence retained catalytic activity. The apparent K(m) for Dol-P was increased when this enzyme was assayed in detergent solution but was the same as wild type enzyme when reconstituted in phosphatidylethanolamine. These results suggest that the amino acid composition and sequence of the conserved domain are not critically important for the recognition and binding of Dol-P when the synthase is present in a lipid matrix.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	SCHUTZBACH, JS (corresponding author), UNIV ALABAMA,DEPT BIOCHEM,309 VOLKER HALL,BIRMINGHAM,AL 35294, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047492, R01GM045188, R01GM038643] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45188, GM47492, GM38643] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; BABCZINSKI P, 1980, EUR J BIOCHEM, V105, P509, DOI 10.1111/j.1432-1033.1980.tb04526.x; BANERJEE DK, 1987, P NATL ACAD SCI USA, V84, P6389, DOI 10.1073/pnas.84.18.6389; BECK PJ, 1990, MOL CELL BIOL, V10, P4612, DOI 10.1128/MCB.10.9.4612; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V507, P207, DOI 10.1016/0005-2736(78)90417-0; DATTA AK, 1993, J BIOL CHEM, V268, P12663; DUCKCHONG CG, 1979, LIPIDS, V14, P492, DOI 10.1007/BF02533467; HASELBECK A, 1989, EUR J BIOCHEM, V181, P663, DOI 10.1111/j.1432-1033.1989.tb14774.x; HEIFETZ A, 1977, J BIOL CHEM, V252, P3057; JENSEN JW, 1985, EUR J BIOCHEM, V153, P41, DOI 10.1111/j.1432-1033.1985.tb09264.x; JENSEN JW, 1988, BIOCHEMISTRY-US, V27, P6315, DOI 10.1021/bi00417a017; JENSEN JW, 1989, BIOCHEMISTRY-US, V28, P851, DOI 10.1021/bi00428a066; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUTZBACH JS, 1992, BIOCHEM CELL BIOL, V70, P460, DOI 10.1139/o92-070; SCHUTZBACH JS, 1987, CHEM SCRIPTA, V27, P109; SCHUTZBACH JS, 1991, TRENDS BIOMEMBRANES, V1, P29; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; ZHU XY, 1990, J BIOL CHEM, V265, P14250; ZIMMERMAN JW, 1993, J BIOL CHEM, V268, P16746	27	35	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24190	24196						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226966				2022-12-25	WOS:A1993MF29400071
J	CHEN, GFT; FANG, L; INOUYE, M				CHEN, GFT; FANG, L; INOUYE, M			EFFECT OF THE RELATIVE POSITION OF THE UGA CODON TO THE UNIQUE SECONDARY STRUCTURE IN THE FDHF MESSENGER-RNA ON ITS DECODING BY SELENOCYSTEINYL TRANSFER-RNA IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMATE DEHYDROGENASE; GENE; IDENTIFICATION; PROTEIN	The fdhF mRNA for formate dehydrogenase H of Escherichia coli contains a UGA codon at position 140. This termination codon is decoded by selenocysteinyl tRNA (the selC product) with the aid of its own specific elongation factor, SelB. For this decoding, a unique secondary structure immediately downstream of the UGA codon has been shown to be essential (Zinoni, F., Heider, J., and Bock, A. (1990) Proc. NatL Acad. Sci. U. S. A. 87, 4660-4664). We examined the positional effect of the U codon relative to the secondary structure on its decoding using a fdhF-lacZ fusion gene. When the UGA codon was separated by one codon (position -1) from the secondary structure, the UGA decoding, as measured by the beta-galactosidase activity, dropped to approximately 76% of the normal level but was still almost as fully dependent upon selC and selenium in the culture medium as in the case of the UGA codon in the normal position (position 0). However, when the UGA codon was separated by two codons (position -2), the decoding level further dropped to 20% of the normal level, and in addition, became dependent only on selC but independent of selenium. When the UGA codon was further separated by three codons (position -3), the decoding level of UGA (-3) became higher than the decoding of UGA (-2) and was completely independent from selC and selenium, indicating that the UGA codon was nonspecifically suppressed. A similar nonspecific suppression was observed for the UGA codon at position -4, but at a lower level. When two UGA codons were tandemly placed at positions 0 and -1, they were still able to be decoded at 17% of the normal level in a selC- and selenium-dependent manner. In the absence of the SelB function, the decoding level of UGA(0) dropped to 1.6% of the normal level, whereas the UGA(-1) decoding dropped to 7.5%. These results indicate that the UGA codon at position 0 is not only most effectively decoded by selenocysteinyl tRNA but also tightly blocked from its nonspecific suppression in the absence of any components required for the decoding.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center								BERG BL, 1991, J BIOL CHEM, V266, P22386; BOCK A, 1991, TRENDS BIOCHEM SCI, V16, P463, DOI 10.1016/0968-0004(91)90180-4; BOCK A, 1991, MOL MICROBIOL, V5, P315; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHEN GT, 1992, MOL MICROBIOL, V6, P781, DOI 10.1111/j.1365-2958.1992.tb01528.x; COX JC, 1981, J BACTERIOL, V145, P1317, DOI 10.1128/JB.145.3.1317-1324.1981; FORCHHAMMER K, 1989, NATURE, V342, P453, DOI 10.1038/342453a0; FORSTER C, 1990, NUCLEIC ACIDS RES, V18, P487, DOI 10.1093/nar/18.3.487; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; INOUYE S, 1985, NUCLEIC ACIDS RES, V13, P3101, DOI 10.1093/nar/13.9.3101; KOHLI J, 1981, MOL GEN GENET, V182, P430, DOI 10.1007/BF00293932; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; LEINFELDER W, 1988, J BACTERIOL, V170, P540, DOI 10.1128/jb.170.2.540-546.1988; Miller J.H., 1972, EXPT MOL GENETICS; SAWERS G, 1991, J BACTERIOL, V173, P4983, DOI 10.1128/jb.173.16.4983-4993.1991; STADTMAN TC, 1991, J BIOL CHEM, V266, P16257; ZINONI F, 1987, P NATL ACAD SCI USA, V84, P3156, DOI 10.1073/pnas.84.10.3156; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	19	32	32	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23128	23131						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226830				2022-12-25	WOS:A1993MF51500029
J	DRINKWATER, CC; BARKER, PA; SUTER, U; SHOOTER, EM				DRINKWATER, CC; BARKER, PA; SUTER, U; SHOOTER, EM			THE CARBOXYL-TERMINUS OF NERVE GROWTH-FACTOR IS REQUIRED FOR BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; TYROSINE PROTEIN-KINASE; NEUROTROPHIC FACTOR; CHOLINERGIC NEURONS; RECOMBINANT HUMAN; NGF RECEPTOR; SURVIVAL; BINDING; DIFFERENTIATION; SPECIFICITY	A series of mouse nerve growth factor (NGF) deletion mutants have been constructed using in vitro mutagenesis to define domains of the protein essential for its activity. Deletions of the amino or carboxyl termini of mature NGF or of an internal domain, which normally produces a surface-exposed reverse turn, have been analyzed. Mutants with deletions in the amino terminus or in the reverse turn retain significant biological activity, whereas, in contrast, a mutant NGF lacking the seven most carboxyl-terminal amino acids is appropriately synthesized but shows no measurable biological activity. These results suggests that the flexible carboxyl tail of NGF, and perhaps other neurotrophins, plays a crucial role in mediating receptor recognition and/or ligand binding.	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Suter, Ueli/A-1624-2010		NINDS NIH HHS [NS04270] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARKER PA, 1993, J BIOL CHEM, V268, P15150; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BURTON LE, 1992, J NEUROCHEM, V59, P1937, DOI 10.1111/j.1471-4159.1992.tb11030.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DAUPIN S, 1992, SCIENCE, V258, P1161; DRINKWATER CC, 1991, P ROY SOC B-BIOL SCI, V246, P307, DOI 10.1098/rspb.1991.0159; EDWARDS RH, 1988, J BIOL CHEM, V263, P6810; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEFTI F, 1986, J NEUROSCI, V6, P2155; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAHLE P, 1992, J BIOL CHEM, V267, P22707; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; KOLIATSOS VE, 1990, J NEUROSCI, V10, P3801, DOI 10.1523/JNEUROSCI.10-12-03801.1990; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LUO Y, 1992, J BIOL CHEM, V267, P12275; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MOORE JB, 1974, BIOCHEMISTRY-US, V13, P833, DOI 10.1021/bi00701a030; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; ROVELLI G, 1993, IN PRESS P NATL ACAD; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMELZER CH, 1992, J NEUROCHEM, V59, P1675, DOI 10.1111/j.1471-4159.1992.tb10998.x; SCHWARZ MA, 1989, J NEUROCHEM, V52, P1203, DOI 10.1111/j.1471-4159.1989.tb01867.x; SHOOTER EM, 1989, FIDIA RES F NEUROSCI, V3, P21; SUTER U, 1992, J NEUROSCI, V12, P306; SWINDELLS MB, 1992, SCIENCE, V258, P1160, DOI 10.1126/science.1439827; TAKABE Y, 1988, MOL CELL BIOL, V8, P466; VALE RD, 1985, METHOD ENZYMOL, V109, P21; WESKAMP G, 1991, NEURON, V6, P1; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231	46	36	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23202	23207						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226840				2022-12-25	WOS:A1993MF51500041
J	HABIB, A; CREMINON, C; FROBERT, Y; GRASSI, J; PRADELLES, P; MACLOUF, J				HABIB, A; CREMINON, C; FROBERT, Y; GRASSI, J; PRADELLES, P; MACLOUF, J			DEMONSTRATION OF AN INDUCIBLE CYCLOOXYGENASE IN HUMAN ENDOTHELIAL-CELLS USING ANTIBODIES RAISED AGAINST THE CARBOXYL-TERMINAL REGION OF THE CYCLOOXYGENASE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; MESSENGER-RNA; G/H SYNTHASE; MONOCLONAL-ANTIBODIES; PHORBOL ESTER; H SYNTHASE; ENZYME; INTERLEUKIN-1; EXPRESSION; PROTEINS	Cyclooxygenase (Cox) exists in two forms in human endothelial cells (HUVEC). We have raised antibodies that recognize the sequence of the carboxyl-terminal portion of the human Cox-2 (C)-NASSSRSGLD-DINPTVLLK. Cyclooxygenase activity of HUVEC challenged with interleukin 1alpha or a phorbol ester increased in parallel with the mass of a protein doublet analyzed by Western blot using antibodies directed against the Cox-2 peptide; a monoclonal antibody directed against Cox-1 showed a small change in protein mass. A S-35-labeled protein doublet with a molecular mass of approximately 70,000 daltons was immunoprecipitated with the anti-Cox-2 antiserum in L-[S-35] methionine-labeled cells stimulated with interleukin 1alpha. This protein was not recovered by pretreating the antiserum with the Cox-2 peptide before immunoprecipitation. A minor variation in S-35-immunoprecipitated protein was obtained with the polyclonal anti-Cox-1 antibody. Both immunoprecipitated Cox-1 and Cox-2 possessed cyclooxygenase activity that was inhibited by flurbiprofen. Endoglycosidase H treatment of immunoprecipitated Cox-2 proteins caused a decline in the apparent molecular size similar to that observed with immunoprecipitated Cox-1 or sheep cyclooxygenase but did not suppress the doublet. These results show by direct protein measurement that HUVEC synthesize the novel Cox-2 under appropriate stimulation, with little changes of Cox-1.	HOP LARIBOISIERE,INSERM,U348,6 RUE GUY PATIN,F-75475 PARIS 10,FRANCE; CTR ETUD SACLAY,DEPT RECH IMAGERIE PHARMACOL & PHYSIOL,SERV PHARMACOL & IMMUNOL,F-91191 GIF SUR YVETTE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite				Habib, Aida/0000-0001-6027-0043				BALLOU LR, 1992, J BIOL CHEM, V267, P2004; DEWITT DL, 1982, METHOD ENZYMOL, V86, P229; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DIAZ A, 1992, J BIOL CHEM, V267, P10816; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GRASSI J, 1988, ANAL BIOCHEM, V168, P436, DOI 10.1016/0003-2697(88)90341-7; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JONES DA, 1993, J BIOL CHEM, V268, P9049; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1992, J BIOL CHEM, V267, P25934; LEVIN EG, 1991, J BIOL CHEM, V266, P174; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MCLAUGHLIN LL, 1987, BIOCHEM BIOPH RES CO, V144, P469, DOI 10.1016/S0006-291X(87)80533-8; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MOR A, 1989, FEBS LETT, V255, P269, DOI 10.1016/0014-5793(89)81104-4; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; RAZ A, 1988, J BIOL CHEM, V263, P3022; RENZI D, 1987, TRENDS CLUSTER HEADA, V125, P87; ROSSI V, 1985, SCIENCE, V229, P174, DOI 10.1126/science.2409598; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAITUKAITIS J, 1971, J CLIN ENDOCR METAB, V33, P988, DOI 10.1210/jcem-33-6-988; WHATLEY RE, 1987, SEMIN THROMB HEMOST, V13, P445, DOI 10.1055/s-2007-1003521; WU KK, 1988, J BIOL CHEM, V263, P19043; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	33	285	288	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23448	23454						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226870				2022-12-25	WOS:A1993MF51500076
J	IRONS, CE; MURRAY, SF; GLEMBOTSKI, CC				IRONS, CE; MURRAY, SF; GLEMBOTSKI, CC			IDENTIFICATION OF THE RECEPTOR SUBTYPE RESPONSIBLE FOR ENDOTHELIN-MEDIATED PROTEIN-KINASE-C ACTIVATION AND ATRIAL-NATRIURETIC-FACTOR SECRETION FROM ATRIAL MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; CARDIAC MYOCYTES; VASOCONSTRICTOR PEPTIDE; VENTRICULAR MYOCYTES; TISSUE DISTRIBUTION; GENE-EXPRESSION; RAT CARDIOCYTES; MESSENGER-RNA; CLONING; CALCIUM	Endothelin-1 (ET-1) is a potent stimulator of atrial natriuretic factor (ANF) secretion from myocardial cells. In heart tissue there are two ET receptor subtypes (ET(A)-R and ET(B)-R), which can be pharmacologically distinguished by the ET isopeptides ET-1 and ET-3. However, the identification of the ET-R subtype responsible for the rapid enhancement of ANF release, which occurs within minutes of exposing cardiac myocytes to ET, has not been investigated. In the present study ET-1 was about 100-fold more potent than ET-3 at stimulating membrane phosphoinositide hydrolysis, protein kinase C activation, and ANF release from purified primary atrial myocytes. These responses were completely abolished by BQ123, an ET(A)-R antagonist. Radioligand binding analyses showed that competitor peptides displaced I-125-ET-1 binding to atrial myocyte ET-Rs with a rank order of potency of ET-1 >> BQ123 > ET-3, a characteristic ET(A)-R pharmacological profile. While neither ET-1 or ET-3 altered forskolin-stimulated cAMP levels, suggesting the absence of the ET(B)-R, basal cAMP levels were also unaffected by the ETs. Northern analysis using ET-R subtype-specific probes demonstrated that the ETA-R transcript was present in the cultures at levels at least 50-fold greater than the ET(B)-R transcript. These findings demonstrate that the stimulation of the phosphatidylinositol/protein kinase C pathway, which is required for maximal ET-stimulated ANF release from primary atrial myocytes, is associated with the activation of only the ET(A)-R, thus defining a specific function for an endogenous ET-R in myocardial cells.	SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182; SAN DIEGO STATE UNIV,INST MOLEC BIOL,SAN DIEGO,CA 92182	California State University System; San Diego State University; California State University System; San Diego State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46345] Funding Source: Medline; NINDS NIH HHS [NS-25037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; CHIANG CS, 1987, CLIN CHEM, V33, P1245; EGUCHI S, 1993, ENDOCRINOLOGY, V132, P524, DOI 10.1210/en.132.2.524; FUKUDA Y, 1989, BIOCHEM BIOPH RES CO, V164, P1431, DOI 10.1016/0006-291X(89)91830-5; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; IRONS CE, 1992, J BIOL CHEM, V267, P5211; ISHIKAWA T, 1988, PFLUG ARCH EUR J PHY, V413, P108, DOI 10.1007/BF00581239; ISHIKAWA T, 1991, CIRC RES, V69, P918, DOI 10.1161/01.RES.69.4.918; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; JOHNSON CL, 1990, AM J PHYSIOL, V258, pC533, DOI 10.1152/ajpcell.1990.258.3.C533; JONES LG, 1988, CIRC RES, V62, P299, DOI 10.1161/01.RES.62.2.299; JONES LG, 1992, AM J PHYSIOL, V263, pH1447, DOI 10.1152/ajpheart.1992.263.5.H1447; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P111; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LITTLE PJ, 1992, BIOCHEM BIOPH RES CO, V183, P694, DOI 10.1016/0006-291X(92)90538-V; MARTIN ER, 1990, J BIOL CHEM, V265, P14044; MATSUBARA H, 1988, AM J PHYSIOL, V255, pH405, DOI 10.1152/ajpheart.1988.255.3.H405; MOLENAAR P, 1993, CIRC RES, V72, P526, DOI 10.1161/01.RES.72.3.526; MORAVEC CS, 1989, BIOCHEM BIOPH RES CO, V159, P14, DOI 10.1016/0006-291X(89)92397-8; ROSEKI C, 1989, J PHYSL, V256, pR858; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; SAKURAI T, 1991, BIOCHEM BIOPH RES CO, V175, P44, DOI 10.1016/S0006-291X(05)81197-0; SCHIEBINGER RJ, 1990, ENDOCRINOLOGY, V127, P119, DOI 10.1210/endo-127-1-119; SEI CA, 1992, MOL ENDOCRINOL, V6, P309, DOI 10.1210/me.6.3.309; SEI CA, 1991, J BIOL CHEM, V266, P15910; SEI CA, 1990, J BIOL CHEM, V265, P7166; SHIELDS PP, 1988, J BIOL CHEM, V263, P12619; SHIELDS PP, 1988, J BIOL CHEM, V263, P8091; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMONSON MS, 1992, J BIOL CHEM, V267, P8643; STOJILKOVIC SS, 1992, ENDOCRINOLOGY, V130, P465, DOI 10.1210/en.130.1.465; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; VIGNE P, 1991, J BIOL CHEM, V266, P5925; VIGNE P, 1989, FEBS LETT, V249, P143, DOI 10.1016/0014-5793(89)80611-8; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	42	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23417	23421						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226866				2022-12-25	WOS:A1993MF51500071
J	MACLACHLAN, I; NIMPF, J; WHITE, HB; SCHNEIDER, WJ				MACLACHLAN, I; NIMPF, J; WHITE, HB; SCHNEIDER, WJ			RIBOFLAVINURIA IN THE RD CHICKEN - 5'-SPLICE SITE MUTATION IN THE GENE FOR RIBOFLAVIN-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; BETA-GLOBIN GENE; SPLICE SITE; WHITE-RIBOFLAVIN; YOLK-RIBOFLAVIN; BASE CHANGE; SEQUENCE; ACID; REQUIREMENTS; SELECTION	Eggs of oviparous species must contain all components required for normal embryonic development. Among these, the vitamin riboflavin is deposited into egg white and yolk bound to the carrier protein, riboflavin-binding protein (ribBP). We have begun to investigate the mechanisms underlying ribBP transport pathways by molecular characterization of a relevant mutation in chicken. The autosomal recessive rd allele in Gallus gallus domesticus prevents the synthesis of functional ribBP and induces embryonic death on day 13. Polymerase chain reaction primers derived from the previously determined wild type cDNA sequence were used to amplify and clone cDNAs for ribBP from normal (Rd) and deficient (rd) animals. The rd allele was associated with a 100-nucleotide deletion in the messenger RNA for ribBP. Genomic clones were generated via polymerase chain reaction using primers flanking this 100-base pair deletion, and the resulting 2.1-kilobase pair clones were sequenced. The deletion in the rd ribBP cDNA corresponds precisely to an exon. The splice site following this exon contains a G --> A mutation at position 1 of the downstream 5'-splice donor sequence. The effect of this anomaly and the cause of the rd phenotype is the loss of the 100-base pair exon during the splicing process.	UNIV VIENNA, DEPT MOLEC GENET, DR BOHR GASSE 9-2, A-1030 VIENNA, AUSTRIA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2H7, ALBERTA, CANADA; UNIV DELAWARE, DEPT CHEM & BIOCHEM, NEWARK, DE 19716 USA; BIOCTR VIENNA, A-1030 VIENNA, AUSTRIA	University of Vienna; University of Alberta; University of Delaware; Vienna Biocenter (VBC)			White, Harold B/B-8024-2008	Nimpf, Johannes/0000-0002-9273-3492				AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; CHIMIENTI G, 1992, BIOCHEM BIOPH RES CO, V187, P620, DOI 10.1016/0006-291X(92)91240-Q; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWAN JW, 1966, POULTRY SCI, V45, P536, DOI 10.3382/ps.0450536; COWAN JW, 1966, POULTRY SCI, V45, P538, DOI 10.3382/ps.0450538; DAVIS LG, 1986, BASIC METHODS MOL BI, P388; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAMAZUME Y, 1984, J BIOCHEM-TOKYO, V95, P1633, DOI 10.1093/oxfordjournals.jbchem.a134776; HOHEISEL J, 1986, NUCLEIC ACIDS RES, V14, P3605, DOI 10.1093/nar/14.8.3605; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; MILLER MS, 1982, J BIOL CHEM, V257, P6818; MONTELL C, 1984, NUCLEIC ACIDS RES, V12, P3821, DOI 10.1093/nar/12.9.3821; MONTELL C, 1982, NATURE, V295, P380, DOI 10.1038/295380a0; NELSON KK, 1990, P NATL ACAD SCI USA, V87, P6253, DOI 10.1073/pnas.87.16.6253; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NORIOKA N, 1985, J BIOCHEM-TOKYO, V97, P19, DOI 10.1093/oxfordjournals.jbchem.a135044; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; Scharf SJ, 1990, PCR PROTOCOLS GUIDE, P84; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SOLNICK D, 1981, NATURE, V291, P508, DOI 10.1038/291508a0; TREISMAN R, 1982, CELL, V29, P903, DOI 10.1016/0092-8674(82)90452-4; Weatherall DJ, 1981, THALASSEMIA SYNDROME; WHITE HB, 1988, ANNU REV NUTR, V8, P279, DOI 10.1146/annurev.nu.08.070188.001431; WIERINGA B, 1983, NATURE, V301, P38, DOI 10.1038/301038a0; WINTER WP, 1967, COMP BIOCHEM PHYSIOL, V22, P897, DOI 10.1016/0010-406X(67)90780-3; WINTER WP, 1967, COMP BIOCHEM PHYSIOL, V22, P889, DOI 10.1016/0010-406X(67)90779-7; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZHENG DB, 1988, J BIOL CHEM, V263, P11126; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	32	23	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23222	23226						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226844				2022-12-25	WOS:A1993MF51500045
J	MURPHY, AJ; COLL, RJ				MURPHY, AJ; COLL, RJ			FORMATION OF A STABLE INACTIVE COMPLEX OF THE SARCOPLASMIC-RETICULUM CALCIUM-ATPASE WITH MAGNESIUM, BERYLLIUM, AND FLUORIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ATPASE; VANADATE; BINDING; INHIBITION; PHOSPHATE; CAATPASE; AFFINITY; ANALOGS; SITE; SLOW	Incubation of leaky or nonionic detergent-solubilized sarcoplasmic reticulum vesicles in solutions containing magnesium, beryllium, and fluoride caused a time-dependent complete inhibition of calcium ATPase activity. The inhibited state persisted through dialysis for 2 days versus EGTA and was reversed within minutes by the presence of 0.5 mm calcium. Calcium-independent ATPase activity was unaffected. Omission of magnesium or fluoride resulted in retention of activity, while omission of beryllium produced slower inactivation, as described previously (Murphy, A. J., and Coll, R. J. (1992) J. Biol. Chem. 267, 5229-5235). Incubation of nonleaky vesicles had a similar effect, although it occurred more than 10-fold more slowly, suggesting that a component, probably beryllium, must enter the vesicles for inhibition to occur. By contrast, inhibition of nonleaky vesicles by magnesium and fluoride developed less than 2-fold more slowly. Including calcium in the incubation mixtures resulted in partial protection, so that the time course of CaATPase activity leveled off at nonzero values (for example, at 0.1 mM calcium, the activity leveled off at 43% of control). This result is most simply accounted for by a model involving simultaneous binding of calcium and a form of fluoroberyllium to the CaATPase (e.g. Ca2EMgBeFn).			MURPHY, AJ (corresponding author), UNIV PACIFIC, SCH DENT, DEPT BIOCHEM, SAN FRANCISCO, CA 94115 USA.				NIGMS NIH HHS [GM31083] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031083] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KW, 1983, J BIOL CHEM, V258, P4276; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; COLL RJ, 1984, J BIOL CHEM, V259, P4249; COLL RJ, 1986, BIOCHEM BIOPH RES CO, V138, P652, DOI 10.1016/S0006-291X(86)80546-0; COLL RJ, 1992, J BIOL CHEM, V267, P21584; DUPUIS A, 1989, FEBS LETT, V255, P47, DOI 10.1016/0014-5793(89)81058-0; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; IKEMOTO N, 1975, J BIOL CHEM, V250, P7219; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MARKUS S, 1986, BIOCHIM BIOPHYS ACTA, V874, P128, DOI 10.1016/0167-4838(86)90109-3; MARKUS S, 1989, BIOCHEMISTRY-US, V28, P793, DOI 10.1021/bi00428a057; MEDDA P, 1983, EUR J BIOCHEM, V137, P7, DOI 10.1111/j.1432-1033.1983.tb07788.x; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY AJ, 1992, J BIOL CHEM, V267, P16995; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; MURPHY AJ, 1992, J BIOL CHEM, V267, P16990; MURPHY AJ, 1993, BIOPHYS J, V64, pA334; ONEAL SG, 1979, BIOCHEM BIOPH RES CO, V89, P845, DOI 10.1016/0006-291X(79)91855-2; PICK U, 1982, J BIOL CHEM, V257, P6111; PICKART CM, 1984, J BIOL CHEM, V259, P1629; PRAGER R, 1979, EUR J BIOCHEM, V97, P239, DOI 10.1111/j.1432-1033.1979.tb13108.x; SCHLOSS JV, 1988, ACCOUNTS CHEM RES, V21, P348, DOI 10.1021/ar00153a005; SMITH RL, 1980, J BIOL CHEM, V255, P9852; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; WEBER MM, 1992, BIOCHEMISTRY-US, V31, P7190	30	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23307	23310						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226854				2022-12-25	WOS:A1993MF51500056
J	PEARCE, KH; HOF, M; LENTZ, BR; THOMPSON, NL				PEARCE, KH; HOF, M; LENTZ, BR; THOMPSON, NL			COMPARISON OF THE MEMBRANE-BINDING KINETICS OF BOVINE PROTHROMBIN AND ITS FRAGMENT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOTAL INTERNAL-REFLECTION; SUPPORTED PLANAR MEMBRANES; COAGULATION FACTOR-VA; FLUORESCENCE MICROSCOPY; PHOTOBLEACHING RECOVERY; PHOSPHOLIPID-MEMBRANES; VARYING COMPOSITION; BLOOD-COAGULATION; COLLISIONAL LIMIT; SELF-ASSOCIATION	Total internal reflection fluorescence microscopy has been used to compare the membrane binding characteristics of fluorescein-labeled bovine prothrombin and fluorescein-labeled bovine prothrombin fragment 1. The Ca2+-dependent association of these proteins with quartz-supported planar membranes composed of mixtures of phosphatidylserine (2-10 mol %) and phosphatidylcholine was examined. Equilibrium binding measurements showed that the apparent equilibrium dissociation constants increased with decreasing molar fractions of phosphatidylserine and that the dissociation constants were somewhat lower for intact prothrombin. Kinetic measurements, using fluorescence photobleaching recovery, showed that the measured dissociation rates were approximately equivalent for prothrombin and fragment 1 and did not change with the protein solution concentration or the molar fraction of phosphatidylserine. The kinetic data also implied that the surface binding mechanism for both proteins is more complex than a simple reversible reaction between monovalent proteins and monovalent surface sites. Measured equilibrium and kinetic constants are reported and compared for prothrombin and fragment 1 on planar membranes.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Hof, Martin/F-5134-2014	Hof, Martin/0000-0003-2884-3037	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045916, R01HL020161, R37HL020161] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45916, HL-20161] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT AJ, 1987, BIOCHEMISTRY-US, V26, P7994, DOI 10.1021/bi00398a067; ABBOTT AJ, 1988, FASEB J, V2, P2858, DOI 10.1096/fasebj.2.13.2844615; ANDREE HAM, 1992, J BIOL CHEM, V267, P17907; Axelrod D, 1992, TOPICS FLUORESCENCE, P289; BANGHAM AD, 1961, NATURE, V192, P1197, DOI 10.1038/1921197a0; BODE AP, 1985, THROMB RES, V39, P49, DOI 10.1016/0049-3848(85)90121-5; CUTSFORTH GA, 1989, BIOCHEMISTRY-US, V28, P7453, DOI 10.1021/bi00444a045; DOMBROSE FA, 1979, J BIOL CHEM, V254, P5027; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; Hellen E H, 1991, J Fluoresc, V1, P113, DOI 10.1007/BF00865207; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; JACKSON CM, 1987, J BIOL CHEM, V262, P13472; JONES ME, 1985, THROMB RES, V39, P711, DOI 10.1016/0049-3848(85)90255-5; KOP JMM, 1984, J BIOL CHEM, V259, P3993; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; LENTZ BR, 1991, BIOPHYS J, V60, P942, DOI 10.1016/S0006-3495(91)82128-2; LIEBMANN LW, 1991, REV SCI INSTRUM, V62, P2083, DOI 10.1063/1.1142371; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1990, BLOOD, V76, P1; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; NAGLE JF, 1992, BIOPHYS J, V63, P366, DOI 10.1016/S0006-3495(92)81602-8; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NESHEIM ME, 1980, REGULATION COAGULATI, P145; PEARCE KH, 1992, BIOCHEMISTRY-US, V31, P5983, DOI 10.1021/bi00141a005; PEI G, 1993, J BIOL CHEM, V268, P3226; PISARCHICK ML, 1990, BIOPHYS J, V58, P1235, DOI 10.1016/S0006-3495(90)82464-4; PISARCHICK ML, 1992, BIOPHYS J, V63, P215, DOI 10.1016/S0006-3495(92)81592-8; POGLITSCH CL, 1990, BIOCHEMISTRY-US, V29, P248, DOI 10.1021/bi00453a033; POLLOCK JS, 1988, J BIOL CHEM, V263, P14216; SANDBERG H, 1985, THROMB RES, V39, P63, DOI 10.1016/0049-3848(85)90122-7; SANDBERG H, 1982, BIOCHEM J, V203, P3036; SCHMIDT CF, 1990, BIOPHYS J, V57, P577, DOI 10.1016/S0006-3495(90)82573-X; SCHWEITZERSTENNER R, 1992, BIOPHYS J, V63, P551, DOI 10.1016/S0006-3495(92)81609-0; SHEETZ MP, 1979, P NATL ACAD SCI USA, V76, P3314, DOI 10.1073/pnas.76.7.3314; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STEINBACH PJ, 1992, BIOPHYS J, V61, P235, DOI 10.1016/S0006-3495(92)81830-1; TARVERS RC, 1986, J BIOL CHEM, V261, P4855; TENDIAN SW, 1991, BIOCHEMISTRY-US, V30, P10991, DOI 10.1021/bi00109a026; TENDIAN SW, 1990, BIOCHEMISTRY-US, V29, P6720, DOI 10.1021/bi00480a023; Thompson N. L., 1988, Comments on Molecular and Cellular Biophysics. Comments on Modern Biology: Part A, V5, P109; THOMPSON NL, 1981, BIOPHYS J, V33, P435, DOI 10.1016/S0006-3495(81)84905-3; THOMPSON NL, 1988, COMMENTS MOL CELL BI, V5, P39; WEI GJ, 1982, BIOCHEMISTRY-US, V21, P1949, DOI 10.1021/bi00537a039; WRIGHT LL, 1988, BIOPHYS J, V54, P463, DOI 10.1016/S0006-3495(88)82979-5; WU JR, 1991, BIOPHYS J, V60, P70, DOI 10.1016/S0006-3495(91)82031-8	46	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22984	22991						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226813				2022-12-25	WOS:A1993MF51500008
J	PAN, GH; SADOWSKI, PD				PAN, GH; SADOWSKI, PD			IDENTIFICATION OF THE FUNCTIONAL DOMAINS OF THE FLP RECOMBINASE - SEPARATION OF THE NONSPECIFIC AND SPECIFIC DNA-BINDING, CLEAVAGE, AND LIGATION DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; 2-MU-M CIRCLE PLASMID; SACCHAROMYCES-CEREVISIAE; TARGET SITE; COPY NUMBER; PROTEIN; YEAST; SEQUENCES; TYROSINE; MUTANTS	The FLP recombinase of the 2-mum plasmid of Saccharomyces cerevisiae binds to its recognition target (FRT) site, induces a bend in the DNA, and promotes DNA cleavage and strand ligation. We have subjected this protein to limited proteolysis and have purified three polypeptides: P13 (13 kDa), P21 (21 kDa), and P32 (32 kDa). These peptides are derived from the following regions of FLP: P13, amino acids 2-123; P21, amino acids 148-346; P32, amino acids 124-423. In this report, we show that P13 binds to DNA nonspecifically and P32, like P21, binds to the FRT site specifically. A single molecule of P32 is able to induce a bend in the DNA of 55-degrees, similar to that induced by intact FLP (63-degrees). P13 enhances the binding of P21 or P32 to the FRT site. Both P32 and P21 can catalyze DNA ligation in combination with P13. P32 can cleave and covalently attach to the FRT site in combination with P13, whereas P21 cannot. These results suggest that FLP contains two DNA-binding domains. A nonspecific DNA-binding region is located in the NH-2-terminal 123 amino acids, whereas the region that imparts specific DNA-binding resides in amino acids 148-346. Only the regions in P13 and P21 are needed for ligation activity, but those in P13 and P32 are required for cleavage.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto								AMIN AA, 1990, J MOL BIOL, V214, P55, DOI 10.1016/0022-2836(90)90146-D; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; ANDREWS BJ, 1985, CELL, V40, P795, DOI 10.1016/0092-8674(85)90339-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCKNER RC, 1986, J BIOL CHEM, V261, P1798; CHEN JW, 1991, P NATL ACAD SCI USA, V88, P5944, DOI 10.1073/pnas.88.14.5944; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; EVANS BR, 1990, J BIOL CHEM, V265, P18504; FRIESEN H, 1992, J MOL BIOL, V225, P313, DOI 10.1016/0022-2836(92)90924-9; FUTCHER AB, 1984, J BACTERIOL, V157, P283, DOI 10.1128/JB.157.1.283-290.1984; FUTCHER AB, 1983, J BACTERIOL, V154, P612, DOI 10.1128/JB.154.2.612-622.1983; FUTCHER AB, 1986, J THEOR BIOL, V119, P197, DOI 10.1016/S0022-5193(86)80074-1; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P2320; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; KULPA J, 1993, J BIOL CHEM, V268, P1101; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBRETON B, 1988, GENETICS, V118, P393; MEYERLEON L, 1990, MOL CELL BIOL, V10, P235, DOI 10.1128/MCB.10.1.235; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3784, DOI 10.1128/MCB.8.9.3784; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; PAN GH, 1992, J BIOL CHEM, V267, P12397; PAN GH, 1993, J BIOL CHEM, V268, P3683; PAN H, 1991, J BIOL CHEM, V266, P11347; PROTEAU G, 1986, NUCLEIC ACIDS RES, V14, P4787, DOI 10.1093/nar/14.12.4787; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030	29	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22546	22551						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226765				2022-12-25	WOS:A1993MD34800056
J	SMITH, DL; TAO, T; MAGUIRE, ME				SMITH, DL; TAO, T; MAGUIRE, ME			MEMBRANE TOPOLOGY OF A P-TYPE ATPASE - THE MGTB MAGNESIUM TRANSPORT PROTEIN OF SALMONELLA-TYPHIMURIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SARCOPLASMIC-RETICULUM MEMBRANE; POSITIVELY CHARGED RESIDUES; X-RAY-DIFFRACTION; ESCHERICHIA-COLI; H+-ATPASE; NEUROSPORA-CRASSA; TRANSMEMBRANE SEGMENTS; CYTOPLASMIC LOCATION; COMPLEMENTARY-DNA	P-type ATPases are a family of cation transport enzymes present in all species from bacteria to mammals whose members mediate membrane flux of all common biologically relevant cations. More than 50 members of this family of transporters have been sequenced; extensive structural data are available, and several members have been analyzed by site-directed mutagenesis. Nonetheless, there is no current consensus regarding their membrane topology. In this work, the Salmonella typhimurium Mg2+ transporting P-type ATPase encoded by the MgtB locus has been used as a model for P-type ATPases. Unlike other prokaryotic P-type ATPases, the MgtB protein is similar in length, amino acid sequence, and hydropathy profile to known eukaryotic P-type ATPases. The membrane topology of MgtB was analyzed by several epitope insertions in MgtB and from the activity of 35 protein fusions between MgtB and the reporter enzymes BlaM (beta-lactamase) and LacZ (beta-galactosidase). The epitope insertions within MgtB all retained function as assessed by cation uptake assays and were regulated normally by the level of Mg2+ within the growth medium. The epitope insertion and fusion protein data are completely incompatible with the numerous previously proposed models for P-type ATPases predicting 7, 8, 9, or 12 transmembrane segments. Rather, they indicate that MgtB contains 10 transmembrane segments with both amino and carboxyl termini residing within the cytosol. By extension, we suggest that all eukaryotic P-type ATPases contain 10 transmembrane segments with both termini within the cytosol.			SMITH, DL (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA.				NHLBI NIH HHS [HL18708] Funding Source: Medline; NIGMS NIH HHS [GM39447] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039447] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; ASTURIAS FJ, 1991, BIOPHYS J, V59, P488, DOI 10.1016/S0006-3495(91)82242-1; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; BROOMESMITH JK, 1990, MOL MICROBIOL, V4, P1637, DOI 10.1111/j.1365-2958.1990.tb00540.x; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COLYER J, 1989, BIOCHEM J, V262, P439, DOI 10.1042/bj2620439; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; EPSTEIN W, 1990, BACTERIA, V12, P87; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GREEN NM, 1992, ANN NY ACAD SCI, V671, P104, DOI 10.1111/j.1749-6632.1992.tb43788.x; GRUBBS RD, 1989, METHOD ENZYMOL, V173, P546; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; HMIEL SP, 1989, J BACTERIOL, V171, P4742, DOI 10.1128/jb.171.9.4742-4751.1989; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JI, 1992, J BIOL CHEM, V267, P938; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; LLOYD AD, 1990, J BACTERIOL, V172, P1688, DOI 10.1128/jb.172.4.1688-1693.1990; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAGUIRE ME, 1992, J BIOENERG BIOMEMBR, V24, P319; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1988, TRENDS GENET, V4, P223, DOI 10.1016/0168-9525(88)90154-0; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MATTHEWS I, 1989, BIOCHEM BIOPH RES CO, V161, P683, DOI 10.1016/0006-291X(89)92653-3; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAKAMOTO RK, 1989, ANN NY ACAD SCI, V574, P165; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PASCOLINI D, 1988, BIOPHYS J, V54, P679, DOI 10.1016/S0006-3495(88)83003-0; PASCOLINI D, 1988, BIOPHYS J, V54, P669, DOI 10.1016/S0006-3495(88)83002-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; RAO US, 1991, J BIOL CHEM, V266, P14740; RICHARDSON JS, 1989, TRENDS BIOCHEM SCI, V14, P304, DOI 10.1016/0968-0004(89)90070-4; SACHS G, 1992, J BIOENERG BIOMEMBR, V24, P301; SACHS G, 1992, ANN NY ACAD SCI, V671, P204; SANMILLAN JL, 1989, J BACTERIOL, V171, P5536, DOI 10.1128/jb.171.10.5536-5541.1989; SCARBOROUGH GA, 1990, J BIOL CHEM, V265, P16145; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SMITH RL, 1993, J BIOL CHEM, V268, P14071; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; SNAVELY MD, 1989, J BACTERIOL, V171, P4761, DOI 10.1128/jb.171.9.4761-4766.1989; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; SOLIOZ M, 1987, J BIOL CHEM, V262, P7358; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; TUNWELL REA, 1991, BIOCHIM BIOPHYS ACTA, V1073, P585, DOI 10.1016/0304-4165(91)90234-8; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1990, PROTEIN ENG, V4, P109, DOI 10.1093/protein/4.2.109; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WU JH, 1992, J BIOL CHEM, V267, P12570; YUN CH, 1991, J BIOL CHEM, V266, P10967	72	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22469	22479						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226755				2022-12-25	WOS:A1993MD34800045
J	WILKS, A; DEMONTELLANO, PRO				WILKS, A; DEMONTELLANO, PRO			RAT-LIVER HEME OXYGENASE - HIGH-LEVEL EXPRESSION OF A TRUNCATED SOLUBLE FORM AND NATURE OF THE MESO-HYDROXYLATING SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CHICK LIVER; IX-ALPHA; PURIFICATION; MICROSOMES; DEGRADATION; CDNA; METALLOPORPHYRINS; OXIDATION; REDUCTASE	A rat heme oxygenase (HO-1) gene without the sequence coding for the last 23 amino acids has been constructed and expressed behind the pho A promoter in Escherichia coli. The enzyme is expressed at high levels as a soluble catalytically active protein that causes the bacterial cells to accumulate biliverdin. The purified truncated heme-heme oxygenase complex is spectroscopically indistinguishable from the complex with the native enzyme and converts heme to biliverdin when reconstituted with rat liver cytochrome P450 reductase. Reaction of the recombinant heme-heme oxygenase complex with H2O2 produces a species with the spectroscopic properties of verdoheme. Unidentified products are obtained when this intermediate is directly extracted from the protein, but biliverdin is obtained if the verdoheme-protein complex is exposed to cytochrome P450 reductase and NADPH before the extraction step. In contrast, reaction of the heme-heme oxygenase complex with meta-chloroperbenzoic acid (mCPBA), tert-butylhydroperoxide, or cumene hydroperoxide yields a ferryl (Fe(IV)=O) complex. Reaction of the heme-heme oxygenase complex with mCPBA also produces an EPR-detectable protein radical. In accord with formation of a ferryl intermediate, recombinant heme oxygenase catalyzes the mCPBA- and alkylhydroperoxide-dependent peroxidation of 2-methoxyphenol (guaiacol). Guaiacol oxidation is not observed during turnover of the enzyme by cytochrome P450 reductase/NADPH or H2O2. Conversely, biliverdin is not formed with tert-butylhydroperoxide or mCPBA. H2O2 thus supports the first step of the normal catalytic oxidation of heme by heme oxygenase, but alkyl and acyl hydroperoxides do not. These results suggest that the alpha-meso-hydroxylation required for biliverdin formation is mediated by the distal of the two oxygens in the iron-dioxygen intermediate (Fe-O-O) engendered by reaction with either cytochrome P450 reductase/NADPH or H2O2.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR LIVER, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIDDK NIH HHS [DK30297, 5 P30 DK26743] Funding Source: Medline; NIGMS NIH HHS [GM32488] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743, R01DK030297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEK HK, 1992, J AM CHEM SOC, V114, P718, DOI 10.1021/ja00028a046; BONKOVSKY HL, 1990, EUR J BIOCHEM, V189, P155, DOI 10.1111/j.1432-1033.1990.tb15472.x; BONNETT R, 1972, J CHEM SOC PERK T 1, P2540, DOI 10.1039/p19720002540; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DOCHERTY JC, 1984, J BIOL CHEM, V259, P3066; EVANS CO, 1991, BIOCHEM J, V273, P659, DOI 10.1042/bj2730659; GUENGERICH FP, 1978, BIOCHEMISTRY-US, V17, P3633, DOI 10.1021/bi00610a033; HEWSON WD, 1979, PORPHYRINS, V7, P295; ISHIKAWA K, 1991, EUR J BIOCHEM, V202, P161, DOI 10.1111/j.1432-1033.1991.tb16357.x; JACKSON AH, 1968, J CHEM SOC C, P302, DOI 10.1039/j39680000302; JACKSON AH, 1978, TETRAHEDRON LETT, P5135; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; KING NK, 1963, J BIOL CHEM, V238, P1520; KONDO T, 1971, BIOCHEM J, V121, P601, DOI 10.1042/bj1210601; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; MEUNIER B, 1992, CHEM REV, V92, P1411, DOI 10.1021/cr00014a008; OCARRA P, 1969, FEBS LETT, V5, P295; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; Sambrook J, 1989, MOL CLONING LABORATO; SANO S, 1986, P NATL ACAD SCI USA, V83, P531, DOI 10.1073/pnas.83.3.531; SCHAEFER WH, 1985, BIOCHEMISTRY-US, V24, P3254, DOI 10.1021/bi00334a027; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; TATSUMI K, 1981, INORG CHEM, V20, P3771, DOI 10.1021/ic50225a040; TENHUNEN R, 1972, BIOCHEMISTRY-US, V11, P1716, DOI 10.1021/bi00759a029; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; WILKS A, 1992, J BIOL CHEM, V267, P8827; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YONETANI T, 1967, J BIOL CHEM, V242, P1974; YOSHIDA T, 1991, EUR J BIOCHEM, V199, P729, DOI 10.1111/j.1432-1033.1991.tb16177.x; YOSHIDA T, 1984, J BIOCHEM-TOKYO, V96, P563, DOI 10.1093/oxfordjournals.jbchem.a134868; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; YOSHIDA T, 1989, BIOCHEM BIOPH RES CO, V163, P1086, DOI 10.1016/0006-291X(89)92332-2; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487; YOSHIDA T, 1982, J BIOL CHEM, V257, P9345; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; YOSHIDA T, 1980, J BIOCHEM-TOKYO, V88, P557, DOI 10.1093/oxfordjournals.jbchem.a133003; YOSHINAGA T, 1990, BIOCHEM J, V270, P659, DOI 10.1042/bj2700659; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7778	42	233	237	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22357	22362						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226746				2022-12-25	WOS:A1993MD34800028
J	BREIT, TM; WOLVERSTETTERO, ILM; VANDONGEN, JJM				BREIT, TM; WOLVERSTETTERO, ILM; VANDONGEN, JJM			LINEAGE-SPECIFIC DEMETHYLATION OF TAL-1 GENE BREAKPOINT REGION DETERMINES THE FREQUENCY OF TAL-1 DELETIONS IN ALPHA-BETA LINEAGE T-CELLS	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; SITE-SPECIFIC DELETIONS; LOOP-HELIX PROTEIN; V(D)J RECOMBINATION; METHYLATION STATUS; CHAIN GENE; SCL GENE; CHROMOSOME-TRANSLOCATION; CHROMATIN STRUCTURE; DNA METHYLATION	tal-1 deletions are caused by a site specific recombination, which exclusively occurs in 12-26% of T-cell acute lymphoblastic leukemias (T-ALL). In a previous study on a large series of T-ALL we demonstrated an apparent preferential occurrence of tal-1 deletions in CD3(-) and CD3(+) alpha beta lineage T-ALL with TcR-delta gene deletions on one or both alleles. In the present study we investigated whether accessibility of the tal-1 deletion breakpoint regions influences the preferential occurrence in specific T-ALL subgroups. Because DNA methylation is assumed to determine accessibility of DNA for recombination, the methylation status of the tal-1 deletion type 1 breakpoint regions (sildb and taldb1) was studied. Although the sildb were completely demethylated in all T-ALL, preferential (de)methylation configurations of the taldb1 were observed in the analysed 119 T-ALL. Most TcR-alpha beta(+) T-ALL contained completely demethylated taldb1 (77%), whereas in most TcR-gamma delta(+) T-ALL partial or complete methylation occurred (42% and 47%, respectively). In T-ALL subgroups defined by different TcR-delta gene configurations also preferential taldb1 (de)methylation patterns were seen, which was most prominent in T-ALL with both TcR-delta genes deleted (84% complete demethylation). The previously observed preferential occurrence of tal-1 deletion type 1 in TcR-alpha beta(+) vs CD3(-) T-ALL and in T-ALL with both vs one TcR-delta genes deleted, disappeared when we retricted to T-ALL with completely demethylated taldb1. Moreover, all T-ALL with a tal-1 deletion type 1 (n = 15) contained completely demethylated taldb1. We therefore conclude that complete demethylation of taldb1 is a prerequisite for tal-1 deletions type I and that the differences in tal-1 deletion frequencies observed in the various T-ALL subgroups are caused by differences in the (de)methylation status of taldb1 in these subgroups.	ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT IMMUNOL,3015 GE ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC			van Dongen, Jacques J.M./F-8537-2015	van Dongen, Jacques J.M./0000-0001-7686-0021; van Dongen, Jacques J.M./0000-0002-3650-7087				ADRIAANSEN HJ, 1991, LEUKEMIA, V5, P744; AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; APLAN PD, 1992, J EXP MED, V176, P1303, DOI 10.1084/jem.176.5.1303; APLAN PD, 1992, BLOOD, V79, P1327; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; APLAN PD, 1991, MOL CELL BIOL, V11, P5462, DOI 10.1128/MCB.11.11.5462; BASH RO, 1993, BLOOD, V81, P2110; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLACKWELL TK, 1989, J BIOL CHEM, V264, P10327; BORIES JC, 1991, BLOOD, V78, P2053, DOI 10.1182/blood.V78.8.2053.bloodjournal7882053; BREIT TM, 1993, J EXP MED, V177, P965, DOI 10.1084/jem.177.4.965; BREIT TM, 1993, BLOOD, V82, P3063; BREIT TM, 1993, LEUKEMIA, V7, P2004; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; BURGER C, 1990, EUR J IMMUNOL, V20, P2285, DOI 10.1002/eji.1830201018; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; DEVILLARTAY JP, 1988, NATURE, V335, P170, DOI 10.1038/335170a0; ENGLER P, 1991, J IMMUNOL, V146, P2826; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FITZGERALD TJ, 1991, BLOOD, V78, P2686; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HOCKETT RD, 1988, P NATL ACAD SCI USA, V85, P9694, DOI 10.1073/pnas.85.24.9694; HSIEH CL, 1992, J BIOL CHEM, V267, P15613; ISOBE M, 1988, P NATL ACAD SCI USA, V85, P3933, DOI 10.1073/pnas.85.11.3933; JONSSON OG, 1991, J CLIN INVEST, V87, P2029, DOI 10.1172/JCI115232; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LITZ CE, 1992, LEUKEMIA, V6, P35; MACINTYRE EA, 1992, BLOOD, V80, P1511; MARTIN D, 1991, J EXP MED, V173, P639, DOI 10.1084/jem.173.3.639; MINOWADA J, 1988, Cancer Reviews, V10, P1; OETTINGER MA, 1992, TRENDS GENET, V8, P413, DOI 10.1016/0168-9525(92)90323-V; OHYASHIKI JH, 1992, CANCER RES, V52, P6598; OHYASHIKI JH, 1993, LEUKEMIA, V7, P801; SATAYANARANA K, 1988, P NATL ACAD SCI USA, V85, P8166; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SHIEH CL, 1992, EMBO J, V11, P315; TAUCHI T, 1991, CANCER RES, V51, P2917; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TSUKAMOTO N, 1992, EXP HEMATOL, V20, P1061; VANDONGEN JJM, 1990, THYMUS, V16, P207; VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P1; WAALWIJK C, 1978, NUCLEIC ACIDS RES, V5, P3231, DOI 10.1093/nar/5.9.3231	55	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1847	1853						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208530				2022-12-25	WOS:A1994NR68500006
J	DECSI, A; PEIFFER, RL; QIU, TH; LEE, DC; FRIDAY, JT; BAUTCH, VL				DECSI, A; PEIFFER, RL; QIU, TH; LEE, DC; FRIDAY, JT; BAUTCH, VL			LENS EXPRESSION OF TGF-ALPHA IN TRANSGENIC MICE PRODUCES 2 DISTINCT EYE PATHOLOGIES IN THE ABSENCE OF TUMORS	ONCOGENE			English	Article							GROWTH-FACTOR-ALPHA; MESSENGER-RNAS; DEVELOPMENTAL EXPRESSION; GERM-LINE; GENE; DIFFERENTIATION; OVEREXPRESSION; BETA; EGF; SEQUENCES	Transgenic mice carrying the rat TGF alpha minigene linked to the alpha A crystallin promoter were generated to investigate the effects of expression of this growth factor in the lens of the eye. All transgenic mice exhibited eye abnormalities in the absence of overt tumors, and two distinct and heritable phenotypes were observed. Five lineages produced 'squinting' transgenic mice characterized by microphthalmic eyes with severe lens and retinal dysplasia, and four lineages produced 'bulged' transgenic mice with eyes that exhibited enlarged globes, lens epithelial hyperplasia, anterior segment dysgenesis, and in some cases retinal dysplasia. The eye perturbations of both phenotypes were evident histologically by 1 week of age, and the eyes of squinting mice were abnormal during embryonic development. The squinting phenotype was dominant over the bulged phenotype in intercrosses, suggesting that position effects from the transgene integration site resulted in differences in TGF alpha expression between the two phenotypes. In situ hybridization showed that TGF alpha transgene expression was confined to the lens or lens rudiment of all transgenic eyes despite the involvement of non-lenticular tissues in the pathology. These results show that inappropriate expression of TGF alpha in the eye can disrupt the communication required to coordinate normal eye development.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT OPHTHALMOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043174] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANCHAN RM, 1991, NEURON, V6, P923, DOI 10.1016/0896-6273(91)90233-P; BALKAN W, 1992, DEV BIOL, V151, P622, DOI 10.1016/0012-1606(92)90200-Z; BAUTCH VL, 1986, J VIROL, V60, P693, DOI 10.1128/JVI.60.2.693-701.1986; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; CAPETANAKI Y, 1989, J CELL BIOL, V109, P1653, DOI 10.1083/jcb.109.4.1653; CHEPELINSKY AB, 1985, P NATL ACAD SCI USA, V82, P2334, DOI 10.1073/pnas.82.8.2334; COULOMBRE AJ, 1964, J EXP ZOOL, V156, P39, DOI 10.1002/jez.1401560104; DELARCO JE, 1980, J CELL PHYSIOL, V102, P267, DOI 10.1002/jcp.1041020218; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; GORING DR, 1987, SCIENCE, V235, P456, DOI 10.1126/science.3099390; Green M.C., 1981, GENETIC VARIANTS STR; GRIEP A E, 1990, New Biologist, V2, P727; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HEM E, 1992, OPHTHALMIC PAEDIATRI, V13, P137; HOGEN B, 1986, MANIPULATING MOUSE E; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KHILLAN JS, 1987, GENE DEV, V1, P1327, DOI 10.1101/gad.1.10.1327; LEE DC, 1985, MOL CELL BIOL, V5, P3644, DOI 10.1128/MCB.5.12.3644; LILLIEN L, 1992, DEVELOPMENT, V115, P253; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCAVOY J W, 1990, Progress in Growth Factor Research, V2, P29, DOI 10.1016/0955-2235(90)90008-8; NAKAMURA T, 1989, New Biologist, V1, P193; NISTER M, 1988, CANCER RES, V48, P3910; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PEI YF, 1970, ANAT REC, V168, P105, DOI 10.1002/ar.1091680109; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; REISS M, 1991, CANCER RES, V51, P6254; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SCHULTZ GS, 1987, SCIENCE, V235, P350, DOI 10.1126/science.3492044; SCHULZ MW, 1993, DEVELOPMENT, V118, P117; SHIELDS MB, 1985, SURV OPHTHALMOL, V29, P387, DOI 10.1016/0039-6257(85)90205-X; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; VARNUM DS, 1968, J HERED, V59, P147, DOI 10.1093/oxfordjournals.jhered.a107667; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZWANN J, 1975, DEV BIOL, V44, P306	51	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1965	1975						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208543				2022-12-25	WOS:A1994NR68500021
J	GRIMSLEY, JK; TJALKENS, RB; STRAUCH, MA; BIRD, TH; SPIEGELMAN, GB; HOSTOMSKY, Z; WHITELEY, JM; HOCH, JA				GRIMSLEY, JK; TJALKENS, RB; STRAUCH, MA; BIRD, TH; SPIEGELMAN, GB; HOSTOMSKY, Z; WHITELEY, JM; HOCH, JA			SUBUNIT COMPOSITION AND DOMAIN-STRUCTURE OF THE SPO0A SPORULATION TRANSCRIPTION FACTOR OF BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE; PROTEIN; PHOSPHORELAY; INITIATION; REGULATOR; BINDING; ABRB; GENE; PHOSPHORYLATION; NTRC	The Spo0A transcription factor is responsible for the initiation of sporulation and is active in transcription only after phosphorylation by a specific signal transduction pathway, the phosphorelay. The effect of phosphorylation on the physical properties of Spo0A was determined. Spo0A and Spo0A similar to P both behaved as monomers during Sephacryl chromatography and gel electrophoresis, suggesting that phosphorylation did not modify the oligomerization state of the protein. Trypsin digested Spo0A at a single cleavage site between residues 142 and 143 within a hinge connecting two tightly folded domains. The amino domain retains ability to be phosphorylated by the phosphorelay. The carboxyl domain is active as a DNA-binding protein and retains the sequence specificity of the intact molecule for 0A boxes on the abrB promoter as revealed by footprinting studies. The carboxyl domain stimulated in vitro transcription from the spoIIG promoter 5-fold greater than an equal amount of Spo0A and about half as well as equivalent amounts of Spo0A similar to P. Thus, the unphosphorylated amino domain inhibits the transcription stimulation activity of the carboxyl domain. We suggest that phosphorylation activates transcription regulation functions of Spo0A by modifying the spatial relationships of the amino and carboxyl domains.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV CELL BIOL, LA JOLLA, CA 92037 USA; UNIV BRITISH COLUMBIA, DEPT MICROBIOL, VANCOUVER V6T 1Z3, BC, CANADA; AGOURON PHARMACEUT INC, LA JOLLA, CA 92037 USA	Scripps Research Institute; University of British Columbia; Pfizer					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019416, R01GM045727, R01GM019416] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45727, GM19416] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; BIRD TH, 1993, MOL MICROBIOL, V9, P741, DOI 10.1111/j.1365-2958.1993.tb01734.x; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; DRUMMOND M, 1986, EMBO J, V5, P441, DOI 10.1002/j.1460-2075.1986.tb04230.x; FERRARI FA, 1985, P NATL ACAD SCI USA, V82, P2647, DOI 10.1073/pnas.82.9.2647; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; KAHN D, 1991, MOL MICROBIOL, V5, P987, DOI 10.1111/j.1365-2958.1991.tb00774.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRICK MJ, 1983, EMBO J, V2, P39, DOI 10.1002/j.1460-2075.1983.tb01377.x; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEREGO M, 1988, MOL MICROBIOL, V2, P689, DOI 10.1111/j.1365-2958.1988.tb00079.x; SATOLA SW, 1992, J BACTERIOL, V174, P1448, DOI 10.1128/jb.174.5.1448-1453.1992; SIMMS SA, 1985, J BIOL CHEM, V260, P161; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x; TRACH K, 1991, RES MICROBIOL, V142, P815, DOI 10.1016/0923-2508(91)90060-N; YORK K, 1992, J BACTERIOL, V174, P2648, DOI 10.1128/jb.174.8.2648-2658.1992	20	56	57	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16977	16982						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207022				2022-12-25	WOS:A1994NR29600069
J	MACLELLAN, WR; LEE, TC; SCHWARTZ, RJ; SCHNEIDER, MD				MACLELLAN, WR; LEE, TC; SCHWARTZ, RJ; SCHNEIDER, MD			TRANSFORMING GROWTH-FACTOR-BETA RESPONSE ELEMENTS OF THE SKELETAL ALPHA-ACTIN GENE - COMBINATORIAL ACTION OF SERUM RESPONSE FACTOR, YY1, AND THE SV40 ENHANCER-BINDING PROTEIN, TEF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC EXPRESSION; LOOP-HELIX PROTEINS; ZINC FINGER PROTEIN; HEAVY-CHAIN GENE; NUCLEAR FACTOR-I; C-MYC PROMOTER; TRANSCRIPTION FACTOR; DNA-BINDING; CARDIAC-MUSCLE; XENOPUS EMBRYOS	Skeletal alpha-actin (SkA) is representative of the cardiac genes that are expressed at high levels in embryonic myocardium, down-regulated after birth, and reactivated by trophic signals including type beta-transforming growth factors (TGF beta). To investigate the molecular basis for cardiac-restricted and TGF beta-induced SkA transcription, we have undertaken a mutational analysis of the SkA promoter in ventricular myocytes, with emphasis on the role of three nominal serum response elements. Serum response factor (SRF) and the bifunctional factor YY1 are the predominant cardiac proteins contacting the proximal SRE (SRE1). Mutations of SRE1 that prevent recognition by SRF and YY1, or SRF alone, virtually abolish SkA transcription in both TGF beta- and vehicle-treated cells; mutation of distal SREs was ineffective. A mutation which selectively abrogates YY1 binding increases both basal and TGF beta-dependent expression, substantiating the predicted role of YY1 as an inhibitor of SRF effects. However, efficient SkA transcription requires combinatorial action of SRE1 with consensus sites for Sp1 and the SV40 enhancer-binding protein, TEF-1. As isolated motifs, either SRE1- or TEF-1-binding sites function as TGF beta response elements. Induction of the SkA promoter by TGF beta required SRF and TEF-1 in concert, unlike other pathways for TGF beta dependent gene expression.	BAYLOR COLL MED,DEPT MED,MOLEC CARDIOL UNIT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NHLBI NIH HHS [R01 HL47567, R01 HL39141, T32 HL07706] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047567, T32HL007706, R01HL039141] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRAND T, 1993, J BIOL CHEM, V268, P11500; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; LEE TC, 1992, NUCLEIC ACIDS RES, V20, P140, DOI 10.1093/nar/20.1.140; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LIN YCA, 1992, J IMMUNOL, V149, P2914; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MOHUN TJ, 1991, EMBO J, V10, P933, DOI 10.1002/j.1460-2075.1991.tb08027.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SANTORO IM, 1991, MOL CELL BIOL, V11, P6296, DOI 10.1128/MCB.11.12.6296; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; STRUTHERS RS, 1992, P NATL ACAD SCI USA, V89, P11451, DOI 10.1073/pnas.89.23.11451; TAYLOR M, 1989, DEVELOPMENT, V106, P67; TAYLOR MV, 1991, NUCLEIC ACIDS RES, V19, P2669, DOI 10.1093/nar/19.10.2669; Thompson NL, 1988, GROWTH FACTORS, V1, P91, DOI 10.3109/08977198809000251; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TUIL D, 1990, J MOL BIOL, V213, P677, DOI 10.1016/S0022-2836(05)80255-4; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	58	150	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16754	16760						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206998				2022-12-25	WOS:A1994NR29600039
J	CLARKLEWIS, I; DEWALD, B; LOETSCHER, M; MOSER, B; BAGGIOLINI, M				CLARKLEWIS, I; DEWALD, B; LOETSCHER, M; MOSER, B; BAGGIOLINI, M			STRUCTURAL REQUIREMENTS FOR INTERLEUKIN-8 FUNCTION IDENTIFIED BY DESIGN OF ANALOGS AND CXC CHEMOKINE HYBRIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE-2; PLATELET FACTOR-IV; BETA-THROMBOGLOBULIN; RECEPTOR-BINDING; 3-DIMENSIONAL STRUCTURE; TERMINAL SEQUENCE; GRO-ALPHA; CYTOKINE; PROTEIN; SPECTROSCOPY	Structure-activity relationships of human interleukin-8 (IL-8) were probed using chemically synthesized analogs with single or double amino acid substitutions, as well. as hybrids derived by substituting IL-8 regions into IP10, a related protein that lacks IL-8 activity. The analogs were tested for functional activity by measuring induction of elastase release from human neutrophils and competition for binding of radiolabeled IL-8. The hybrid studies indicated that Gly(31) and Pro(32), as well as the NH2-terminal region from IL-8 are required to convert IP10 into a fully functional protein, suggesting that these elements are critical for IL-8 activity. Both disulfide bridges, linking residue 7 to 34 and residue 9 to 50, were critical for function, as shown by substituting the cysteine pairs with alpha-aminobutyric acid. Single conservative substitutions were generally accepted into the 10-22 region of IL-8, which contrasts with the ELR motif (residues 4-6), previously shown to be essential for activity. The importance of residues within the 10-15 region and the 17-22 region was demonstrated with hybrids. In addition, some of the 4-22 residues have structural roles that may be important; for example, Tyr(13), Phe(17), and Phe(21) are involved in aromatic interactions in the IL-8 structure, and are also moderately sensitive to modification. Except for Cys(50), the results argue against a role for the 36-72 region, including the COOH-terminal alpha-helix, in receptor binding. We conclude that the disulfide bridges and 30-35 turn provide a structural scaffold for the NH2-terminal region which includes the primary receptor-binding site (the ELR motif) and secondary binding and conformational determinants between residues 10 and 22.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BERN,THEODOR KOCHER INST,CH-3000 BERN,SWITZERLAND	University of British Columbia; University of Bern	CLARKLEWIS, I (corresponding author), UNIV BRITISH COLUMBIA,BIOMED RES CTR,2222 HLTH SCI MALL,VANCOUVER V6T 1Z3,BC,CANADA.			Moser, Bernhard/0000-0002-4354-4572	NIGMS NIH HHS [R01 GM-50969-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050969] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLARKLEWIS I, 1988, P NATL ACAD SCI USA, V85, P7897, DOI 10.1073/pnas.85.21.7897; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLARKLEWIS I, 1989, USE HPLC RECEPTOR BI, P43; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; DEWALD B, 1992, IMMUNOL LETT, V32, P81, DOI 10.1016/0165-2478(92)90203-Z; FAIRBROTHER WJ, 1993, FEBS LETT, V330, P302, DOI 10.1016/0014-5793(93)80893-Y; GEISER T, 1993, J BIOL CHEM, V268, P15419; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HOLT JC, 1986, BIOCHEMISTRY-US, V25, P1988, DOI 10.1021/bi00356a023; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MOSER B, 1991, J BIOL CHEM, V266, P10666; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; PROOST P, 1993, BIOCHEMISTRY-US, V32, P10170, DOI 10.1021/bi00089a037; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; VANDAMME J, 1989, EUR J BIOCHEM, V181, P337; WALZ A, 1989, BIOCHEM BIOPH RES CO, V159, P969, DOI 10.1016/0006-291X(89)92203-1; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; YOSHIMURA T, 1989, MOL IMMUNOL, V26, P87; ZUCKER MB, 1991, P SOC EXP BIOL MED, V198, P693	36	165	222	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16075	16081						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206907				2022-12-25	WOS:A1994NQ72900022
J	NG, NFL; SHOOTER, EM				NG, NFL; SHOOTER, EM			ACTIVATION OF P21(RAS) BY NERVE GROWTH-FACTOR IN EMBRYONIC SENSORY NEURONS AND PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; TYROSINE KINASE-ACTIVITY; NEUROTROPHIC FACTOR; FACTOR RECEPTORS; LOW-AFFINITY; PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; P21RAS ACTIVATION; BINDING-SITES; GENE-TRANSFER	p21ras is believed to be involved in the neuronal differentiation of cells responsive to nerve growth factor (NGF). We show that NGF stimulates the activation of p21ras in embryonic sensory neurons and in PC12 cells. In the initial 5 min of exposure to NGF, the activation is concentration-dependent. In the sensory neurons and PC12 cells, the apparent maximal activation was reached at 50 and 10 ng/ml, respectively, with half-maximal activation at approximately 5 and 2-3 ng/ml, respectively. Kinetic analysis at low concentrations of NGF showed that p21ras activation slowly increases with time in both types of cells, while high concentrations result in rapid activation within 5 min. These results indicate that NGF regulates the activation state of p21ras in these cells and provides evidence suggesting that activation of p21ras is involved in NGF signal transduction. Treatment of PC12 cells with brain-derived neurotrophic factor or neurotrophin-3 (NT-3) failed to activate p21ras, suggesting that binding alone to p75LNFR is insufficient for ras activation. Treatment with the kinase inhibitor, K252a, which inhibits the NGF tyrosine kinase receptor p140trk, abolished ras activation, suggesting that p140trk is the major mediator of p21ras activation by NGF.	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University					NINDS NIH HHS [NINDS (NS04270)] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BERG MM, 1992, J BIOL CHEM, V267, P13; BERND P, 1984, J BIOL CHEM, V259, P5509; BORASIO GD, 1989, NEURON, V2, P1087; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; COHEN AI, 1964, P SOC EXP BIOL MED, V116, P784; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1977, DEV BIOL, V58, P106, DOI 10.1016/0012-1606(77)90077-X; GREENE LA, 1980, ANNU REV NEUROSCI, V3, P353, DOI 10.1146/annurev.ne.03.030180.002033; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LEVIMONTALCINI R, 1963, DEV BIOL, V7, P653, DOI 10.1016/0012-1606(63)90149-0; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MUROYA K, 1992, ONCOGENE, V7, P277; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; ROVELLI G, 1993, IN PRESS P NATL ACAD; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SONNENFELD KH, 1985, J NEUROSCI, V5, P1717; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUGIMOTO Y, 1988, J BIOL CHEM, V263, P12102; SUTTER A, 1979, J BIOL CHEM, V254, P5972; SUTTER A, 1979, TRANSMEMBRANE SIGNAL, P659; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAPLEY P, 1992, ONCOGENE, V7, P371; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; TORTI M, 1992, J BIOL CHEM, V267, P8293; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551	57	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25329	25333						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244964				2022-12-25	WOS:A1993MK10000011
J	KOBAYASHI, K; MIKI, M; OKAMOTO, K; NISHINO, T				KOBAYASHI, K; MIKI, M; OKAMOTO, K; NISHINO, T			ELECTRON-TRANSFER PROCESS IN MILK XANTHINE DEHYDROGENASE AS STUDIED BY PULSE-RADIOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER FLASH-PHOTOLYSIS; IRON-SULFUR CENTERS; O-2-DEPENDENT TYPES; MOLECULAR-OXYGEN; OXIDASE; PURIFICATION; REDUCTION; FLAVIN; REDOX; SITE	The reduction of milk xanthine dehydrogenase by salicylate anion radical (SL-), nicotinamide adenine dinucleotide radical (NAD.), and 1-methylnicotinamide (NMA) radicals was investigated by the use of pulse radiolysis. Reduction of the dehydrogenase with SL- proceeded via two phases. From the kinetic difference spectra obtained, the faster and slower phases of reduction represent that of one of the iron-sulfur centers and of FAD, respectively. The rate constant of the faster phase increased with the concentration of the enzyme, suggesting that the reduction follows a bimolecular reaction of SL- with the iron-sulfur center. In contrast, the rate constant of the slower phase (510 s-1) was independent of the concentration of the enzyme at pH 7.5. In order to elucidate the contribution of the molybdenum site in the reaction, a similar reaction was performed with enzyme modified with oxipurinol. In the modified enzyme, the slower phase was lost, whereas the faster phase was not affected. These results suggest that the slower phase is due to intramolecular electron transfer from the molybdenum center to FAD. On the other hand, NAD. reacted predominantly with FAD of the dehydrogenase to form the neutral semiquinone of FAD with a second order rate constant of 1.4 x 10(7) M-1 s-1 at pH 7.5, whereas a similar reaction in the oxidase, which was converted from xanthine dehydrogenase by proteolytical cleavage, was not observed. This suggests that NAD. transfers an electron via the binding site for NAD+ on the dehydrogenase. In contrast, NMA radical reduced only an iron-sulfur center of the dehydrogenase with a second order rate constant of 6.5 x 10(7) M-1 s-1 at pH 7.5.	OSAKA UNIV, INST SCI & IND RES, IBARAKI, OSAKA 567, JAPAN; YOKOHAMA CITY UNIV, SCH MED, DEPT BIOCHEM, YOKOHAMA 236, JAPAN	Osaka University; Yokohama City University			Kobayashi, Kazuo/H-9279-2012	Kobayashi, Kazuo/0000-0002-5586-9112				ANDERSON RF, 1986, J BIOL CHEM, V261, P5870; ANDERSON RF, 1984, J CHEM SOC FARAD T 1, V80, P2693, DOI 10.1039/f19848002693; BHATTACHARYYA A, 1983, BIOCHEMISTRY-US, V22, P5270, DOI 10.1021/bi00292a005; Coughlan M. P., 1980, Molybdenum and molybdenum-containing enzymes, P119; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; HILLE R, 1991, J BIOL CHEM, V266, P5608; HILLE R, 1986, J BIOL CHEM, V261, P1241; HUGHES RK, 1992, BIOCHEMISTRY-US, V31, P3073, DOI 10.1021/bi00127a007; HUNT J, 1992, J BIOL CHEM, V267, P21479; KOBAYASHI K, 1989, J BIOL CHEM, V264, P7976; KOBAYASHI K, 1988, J BIOL CHEM, V263, P7493; LAND EJ, 1968, BIOCHIM BIOPHYS ACTA, V162, P327, DOI 10.1016/0005-2728(68)90119-9; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1989, J BIOL CHEM, V264, P10567; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MASSEY V, 1969, J BIOL CHEM, V244, P1682; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; NISHINO T, 1989, J BIOL CHEM, V264, P5468; NISHINO T, 1981, FEBS LETT, V131, P369, DOI 10.1016/0014-5793(81)80406-1; NISHINO T, 1989, J BIOL CHEM, V264, P2518; NISHINO T, 1989, J BIOL CHEM, V264, P6075; OLSON JS, 1974, J BIOL CHEM, V249, P4350; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; SAITO T, 1989, J BIOL CHEM, V264, P10015; SAITO T, 1989, J BIOL CHEM, V264, P15930; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; STIRPE F, 1969, J BIOL CHEM, V244, P3855; WALKER MC, 1991, BIOCHEMISTRY-US, V30, P5912, DOI 10.1021/bi00238a015; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P354, DOI 10.1016/0003-9861(76)90087-4	29	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24642	24646						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227023				2022-12-25	WOS:A1993MG67300023
J	CHAI, KX; CHEN, LM; CHAO, J; CHAO, L				CHAI, KX; CHEN, LM; CHAO, J; CHAO, L			KALLISTATIN - A NOVEL HUMAN SERINE PROTEINASE-INHIBITOR - MOLECULAR-CLONING, TISSUE DISTRIBUTION, AND EXPRESSION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KALLIKREIN-BINDING-PROTEIN; SPONTANEOUSLY HYPERTENSIVE RATS; GENE FAMILY; SEQUENCE-ANALYSIS; URINARY KALLIKREIN; C INHIBITOR; PURIFICATION; ALPHA-1-ANTITRYPSIN; GROWTH; MOUSE	We have recently purified a novel human serine proteinase inhibitor (serpin), designated as kallistatin, which binds to tissue kallikrein and inhibits kallikrein's kininogenase and amidolytic activities. In the present studies, we have cloned a full-length cDNA encoding kallistatin from human liver RNA by the polymerase chain reaction. The cDNA is 1284 base pairs in length and encodes 427 amino acid residues, including a 26-residue signal peptide and a 401-residue mature peptide. The translated amino acid sequence of kallistatin matches with the protein sequence and shares 44-46% sequence identity with human alpha1-antichymotrypsin, protein C inhibitor, corticosteroid-binding globulin, alpha1-antitrypsin, thyroxin-binding globulin, and rat kallikrein-binding protein. Kallistatin is a new member of the serpin superfamily with a unique reactive site P1-P1' of Phe-Ser. Four potential glycosylation sites are found in the translated amino acid sequence of kallistatin. In a Southern blot analysis following reverse transcription and polymerase chain reaction, kallistatin was found to be expressed in human liver, stomach, pancreas, kidney, aorta, testes, prostate, artery, atrium, ventricle, lung, renal proximal tubular cell, and a colonic carcinoma cell line T84. A genomic Southern blot using the full-length kallistatin cDNA probe revealed simple banding patterns suggesting the gene encoding kallistatin is single-copied. The kallistatin cDNA encoding the mature peptide was expressed in Escherichia coli. The recombinant kallistatin forms an SDS-stable complex with I-125-human tissue kallikrein and has a molecular mass of 40 kDa. The cloning of human kallistatin cDNA established the identity of the novel kallikrein inhibitor and its expression in a functional form in E. coli provides means for studying its structure-function relationship through protein engineering.	MED UNIV S CAROLINA, DEPT BIOCHEM & MOLEC BIOL, CHARLESTON, SC 29425 USA	Medical University of South Carolina					NHLBI NIH HHS [HL44083] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AITKEN A, 1989, PEPTIDE PREPARATION, P63; BAIRD AW, 1991, AM J PHYSIOL, V261, pC822, DOI 10.1152/ajpcell.1991.261.5.C822; BERRY TD, 1989, HYPERTENSION, V13, P3, DOI 10.1161/01.HYP.13.1.3; BILLINGSLEY GD, 1993, AM J HUM GENET, V52, P343; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CHAI KX, 1991, J BIOL CHEM, V266, P16029; CHAI KX, 1991, BIOCHIM BIOPHYS ACTA, V1129, P127, DOI 10.1016/0167-4781(91)90227-D; CHAO J, 1990, J BIOL CHEM, V265, P16394; CHAO J, 1988, J HYPERTENS, V6, P551, DOI 10.1097/00004872-198807000-00006; CHAO J, 1986, BIOCHEM J, V239, P325, DOI 10.1042/bj2390325; CHAO S, 1990, BIOCHEMISTRY-US, V29, P323, DOI 10.1021/bi00454a004; CHEN LM, 1990, BIOCHEM J, V267, P79, DOI 10.1042/bj2670079; COLAU B, 1984, DNA-J MOLEC CELL BIO, V3, P327, DOI 10.1089/dna.1.1984.3.327; DETRISAC CJ, 1984, KIDNEY INT, V25, P383, DOI 10.1038/ki.1984.28; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKE S, 1992, J BIOL CHEM, V267, P7048; EVANS BA, 1987, J BIOL CHEM, V262, P8027; FLINK IL, 1986, P NATL ACAD SCI USA, V83, P7708, DOI 10.1073/pnas.83.20.7708; GEIGER R, 1981, H-S Z PHYSIOL CHEM, V362, P317, DOI 10.1515/bchm2.1981.362.1.317; HAMMOND GL, 1987, P NATL ACAD SCI USA, V84, P5153, DOI 10.1073/pnas.84.15.5153; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; INGLIS JD, 1991, EMBO J, V10, P255, DOI 10.1002/j.1460-2075.1991.tb07945.x; INGLIS JD, 1991, GENE, V106, P213, DOI 10.1016/0378-1119(91)90201-L; LILJA H, 1992, CANCER, V70, P230, DOI 10.1002/1097-0142(19920701)70:1+<230::AID-CNCR2820701310>3.0.CO;2-Y; MACDONALD RJ, 1988, BIOCHEM J, V253, P313, DOI 10.1042/bj2530313; Maniatis T., 1982, MOL CLONING; Marshall R D, 1974, Biochem Soc Symp, P17; MURANO G, 1985, J MED, V16, P17; PAGES G, 1990, GENE, V94, P273, DOI 10.1016/0378-1119(90)90398-B; Pisano J.J., 1979, HDB EXP PHARM S, V25, P273; PRAVENEC M, 1991, HYPERTENSION, V17, P242, DOI 10.1161/01.HYP.17.2.242; RIEGMAN PHJ, 1992, GENOMICS, V14, P6, DOI 10.1016/S0888-7543(05)80275-7; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHACHTER M, 1979, PHARMACOL REV, V31, P1; SERVEAU C, 1992, FEBS LETT, V309, P405, DOI 10.1016/0014-5793(92)80817-Z; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; STONE KL, 1989, PRACTICAL GUIDE PROT, P37; SUZUKI K, 1987, J BIOL CHEM, V262, P611; WANG J, 1991, BIOCHEM J, V276, P63, DOI 10.1042/bj2760063; WINES DR, 1989, J BIOL CHEM, V264, P7653; WOODLEYMILLER C, 1989, J HYPERTENS, V7, P865, DOI 10.1097/00004872-198911000-00003; YOON JB, 1987, J BIOL CHEM, V262, P4284; YOON JB, 1990, J BIOL CHEM, V265, P19947; ZHOU GX, 1992, J BIOL CHEM, V267, P25873	45	79	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24498	24505						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8227002				2022-12-25	WOS:A1993MF29400115
J	PRASAD, K; BAROUCH, W; GREENE, L; EISENBERG, E				PRASAD, K; BAROUCH, W; GREENE, L; EISENBERG, E			A PROTEIN COFACTOR IS REQUIRED FOR UNCOATING OF CLATHRIN BASKETS BY UNCOATING ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COATED VESICLES; HEAT-SHOCK; ASSEMBLY PROTEINS; STRESS PROTEINS; PURIFICATION; DISSOCIATION; TRANSLOCATION; POLYPEPTIDES; BINDING; HSP70	Immediately after clathrin-coated pits pinch off from the cell membrane to form clathrin-coated vesicles, clathrin dissociates from the vesicles. In vitro studies suggest that this dissociation is carried out by the uncoating ATPase, a constitutive member of the 70-kDa heat shock family. Aside from the requirement for ATP, nothing is known about the regulation of the uncoating process. We now show that clathrin baskets prepared from highly purified clathrin and AP2, the assembly protein associated with plasma membrane coated vesicles, cannot be uncoated by the bovine brain uncoating ATPase alone. A 100-kDa protein cofactor, which was isolated from coated vesicles, is essential for uncoating by the uncoating ATPase. This cofactor restores normal uncoating when present at a molar ratio of about 1 to 10 to clathrin and uncoating ATPase.			PRASAD, K (corresponding author), NHLBI,CELL BIOL LAB,BETHESDA,MD 20892, USA.							AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; GAO BC, 1991, J BIOL CHEM, V266, P19565; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; NANDI PK, 1982, P NATL ACAD SCI USA, V107, P5885; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1992, TRENDS CELL BIOL, V2, P295; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903	37	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23758	23761						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226905				2022-12-25	WOS:A1993MF29400007
J	SCHAEFFER, E; GUILLOU, F; PART, D; ZAKIN, MM				SCHAEFFER, E; GUILLOU, F; PART, D; ZAKIN, MM			A DIFFERENT COMBINATION OF TRANSCRIPTION FACTORS MODULATES THE EXPRESSION OF THE HUMAN TRANSFERRIN PROMOTER IN LIVER AND SERTOLI CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; ENHANCER BINDING-PROTEIN; DNA-BINDING; LEUCINE ZIPPER; GLUCOCORTICOID RECEPTOR; SIGNAL TRANSDUCTION; NUCLEAR-PROTEIN; RETINOIC ACID; C/EBP FAMILY; C-JUN	We have previously identified the functional regions involved in the regulation of human transferrin (Tf) gene expression in the liver and in Sertoli cells of the testis. Here, we show that a different cellular distribution of transcription factors, interacting with the same proximal promoter regions (PRI and PRII), modulates cell type-specific transcription. In the liver, hepatocyte nuclear factor 4 (HNF-4) and the chicken ovalbumin upstream promoter transcription factor (COUP-TF) act at the PRI site, while CCAAT/enhancer-binding proteins (C/EBPs) act at the PRII site. In the testis, distinct combinations of Sertoli proteins SP-A and SP-D and COUP-TF bind to the PRI site, while SP-alpha and SP-beta bind to the PRII site. Cotransfection experiments in Hep3B cells revealed that mostly HNF-4, C/EBP-alpha, C/EBP-delta, and, to a lesser extent, COUP-TF stimulated transcription driven by the -125/+39 region. In Sertoli cells, HNF-4 and COUP-TF appeared to repress, while the C/EBP factors were able to stimulate transcription driven by the -100/+39 region. However, the specific activating combination remains to be defined among the Sertoli proteins. In the non-Tf-expressing HeLa cells, the Tf promoter could be activated by C/EBP-delta. Our data revealed functional antagonism between HF-4 and COUP-TF, binding to PRI, as well as cross-coupling interactions between HNF-4 and C/EBP, binding to adjacent sites. Thus, cell type-specific DNA-protein interactions, together with protein-protein interactions, may explain the transcriptional regulation of the Tf gene in different cell types.	INST PASTEUR,UNITE EXPRESS GENES EUCARYOTES,F-75724 PARIS 15,FRANCE; INRA,PHYSIOL REPROD STN,F-37380 NOUZILLY,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; INRAE								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOISSIER F, 1991, J BIOL CHEM, V266, P9822; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; BRUNEL F, 1988, J BIOL CHEM, V263, P10180; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; COSTA R, 1990, MOL CELL BIOL, V9, P1415; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUILLOU F, 1991, J BIOL CHEM, V266, P9876; HUSSMAN M, 1991, MOL CELL BIOL, V11, P4097; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Maxam A M, 1980, Methods Enzymol, V65, P499; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; OCHOA A, 1989, NUCLEIC ACIDS RES, V17, P119, DOI 10.1093/nar/17.1.119; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SCHAEFFER E, 1987, GENE, V56, P109, DOI 10.1016/0378-1119(87)90163-6; SCHAEFFER E, 1989, J BIOL CHEM, V264, P7153; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SKINNER MK, 1980, J BIOL CHEM, V255, P9523; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Wang Lee-Ho, 1991, Gene Expression, V1, P207; WANG LH, 1989, MOLCELL BIOL, V12, P1708; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	40	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23399	23408						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226864				2022-12-25	WOS:A1993MF51500069
J	THORN, P; PETERSEN, OH				THORN, P; PETERSEN, OH			CALCIUM OSCILLATIONS IN PANCREATIC ACINAR-CELLS, EVOKED BY THE CHOLECYSTOKININ ANALOG JMV-180, DEPEND ON FUNCTIONAL INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ OSCILLATIONS; HEPARIN; RAT; TRISPHOSPHATE; RELEASE; ACTIVATION; CHANNELS; MEMBRANE; SIGNALS	It has been reported that the synthetic heptapeptide cholecystokinin (CCK) analogue JMV-180 evokes cytosolic Ca2+ signals in pancreatic acinar cells via mechanisms that do not include either the generation or action of inositol 1,4,5-trisphosphate (InsP3) (Saluja, A. K., Dawra, R. K., Lerch, M. M., and Steer, M. L. (1992) J. Biol. Chem. 267, 11202-11207; Yule, D. I., and Williams, J. A. (1992) J. Biol. Chem. 267,13830-13835). We have now investigated the CCK- and JMV-180-evoked cytosolic Ca2+ oscillations by measurement of the Ca2+-sensitive ion currents in internally perfused mouse pancreatic acinar cells. We find that the InsP3 receptor antagonist heparin (500 mug/ml) blocks Ca2+ oscillations induced by both CCK (5-20 pM) and JMV 180 (10-40 nM), whereas de-N-sulfated heparin (500 mug/ml), which does not affect InsP3 binding to its receptor, fails to inhibit the responses to the two agonists. We conclude that the cytosolic Ca2+ oscillations evoked by both CCK and JMV-180 are dependent on functional InsP3 receptors.			THORN, P (corresponding author), UNIV LIVERPOOL,PHYSIOL LAB,MRC,SECRETORY CONTROL RES GRP,POB 147,LIVERPOOL L69 3BX,ENGLAND.		Petersen, Ole H/E-8708-2010; Thorn, Peter/F-7030-2010	Thorn, Peter/0000-0002-3228-770X; Petersen, Ole/0000-0002-6998-0380				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; DASSO LLT, 1991, BIOCHEM J, V280, P791, DOI 10.1042/bj2800791; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; ITO H, 1990, PFLUG ARCH EUR J PHY, V417, P126, DOI 10.1007/BF00370783; MATOZAKI T, 1989, AM J PHYSIOL, V257, pG594, DOI 10.1152/ajpgi.1989.257.4.G594; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; OSIPCHUK YV, 1990, EMBO J, V9, P687; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; SMITH PM, 1992, J PHYSIOL-LONDON, V446, pP72; THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1992, PFLUG ARCH EUR J PHY, V422, P173, DOI 10.1007/BF00370417; TONES MA, 1989, FEBS LETT, V252, P105, DOI 10.1016/0014-5793(89)80898-1; WAKUI M, 1991, J MEMBRANE BIOL, V124, P179, DOI 10.1007/BF01870462; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; YULE DI, 1992, J BIOL CHEM, V267, P13830	23	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23219	23221						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226843				2022-12-25	WOS:A1993MF51500044
J	FAKLER, B; HERLITZE, S; AMTHOR, B; ZENNER, HP; RUPPERSBERG, JP				FAKLER, B; HERLITZE, S; AMTHOR, B; ZENNER, HP; RUPPERSBERG, JP			SHORT ANTISENSE OLIGONUCLEOTIDE-MEDIATED INHIBITION IS STRONGLY DEPENDENT ON OLIGO LENGTH AND CONCENTRATION BUT ALMOST INDEPENDENT OF LOCATION OF THE TARGET SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPA RECEPTOR CHANNELS; MESSENGER-RNA; XENOPUS-OOCYTES; COMPLEMENTARY-DNA; DIRECTED CLEAVAGE; HYBRID ARREST; OLIGODEOXYNUCLEOTIDES; TRANSLATION; OLIGODEOXYRIBONUCLEOTIDES; DEGRADATION	The inhibitory effect of short antisense oligodeoxynucleotides (aODNs) on cRNA expression in Xenopus oocytes was measured using an electrophysiological assay based on subunit-specific block of cloned alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors. The effect of both phosphorothioate modified (PS) and phosphodiester (PO) aODNs was strongly length dependent with a half-maximal inhibition calculated for an oligo length of 7.6 nucleotides (nt) and 9.9 nt, respectively. More than 95% inhibition was mediated by a PS aODN of 12 nt and by PO aODNs greater than or equal to 15 nt. At a given length PS and PO aODNs showed differential dependence of their inhibitory effect on the injected aODN concentration (half-maximal inhibition at 18 ng/mu l for a PO 12-mer and at 0.19 ng mu/l for a PS 12-mer) and differential saturation behavior. The inhibitory effect of aODNs, even as short as 8 nt for PS oligomers, was highly sequence specific, but almost independent of the position of the respective target site on the cRNA (for PS 8-mers, greater than or equal to 70% expression inhibition throughout the tested target sites from the translation initiation to the 3'-untranslated region). Thus, short PS aODNs can be reliably used in order to specifically inhibit protein expression in experiments addressing physiological, molecular biological, and perhaps even therapeutical issues.	UNIV TUBINGEN,HALS NASEN OHREN KLIN,SEKT SENSOR BIOPHYS,D-72076 TUBINGEN,GERMANY; MAX PLANCK INST MED RES,ZELLPHYSIOL ABT,D-69120 HEIDELBERG,GERMANY	Eberhard Karls University of Tubingen; Max Planck Society								AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401; BAKER C, 1990, NUCLEIC ACIDS RES, V18, P3537, DOI 10.1093/nar/18.12.3537; BOIZIAU C, 1992, P NATL ACAD SCI USA, V89, P768, DOI 10.1073/pnas.89.2.768; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P4717, DOI 10.1093/nar/15.12.4717; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; COSSTICK R, 1985, BIOCHEMISTRY-US, V24, P3630, DOI 10.1021/bi00335a035; DAGLE JM, 1990, NUCLEIC ACIDS RES, V18, P4751, DOI 10.1093/nar/18.16.4751; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; DRAGUHN A, 1991, NEUROSCI LETT, V132, P187, DOI 10.1016/0304-3940(91)90298-8; ELBARADI T, 1991, EMBO J, V10, P1407, DOI 10.1002/j.1460-2075.1991.tb07661.x; GAO WY, 1992, MOL PHARMACOL, V41, P223; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; HERLITZE S, 1993, NEURON, V10, P1131, DOI 10.1016/0896-6273(93)90061-U; KAWASAKI ES, 1985, NUCLEIC ACIDS RES, V13, P4991, DOI 10.1093/nar/13.13.4991; KITAJIAMA J, 1992, J BIOL CHEM, V267, P25881; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; LAPLANCHE LA, 1986, NUCLEIC ACIDS RES, V14, P9081, DOI 10.1093/nar/14.22.9081; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; LOTAN I, 1988, NEURON, V1, P963, DOI 10.1016/0896-6273(88)90153-5; MAHER LJ, 1988, NUCLEIC ACIDS RES, V16, P3341, DOI 10.1093/nar/16.8.3341; MINSHULL J, 1986, NUCLEIC ACIDS RES, V14, P6433, DOI 10.1093/nar/14.16.6433; MONIA BP, 1992, J BIOL CHEM, V267, P19954; SAISONBEHMOARAS T, 1991, EMBO J, V10, P1111, DOI 10.1002/j.1460-2075.1991.tb08051.x; SHAW JP, 1991, NUCLEIC ACIDS RES, V19, P747, DOI 10.1093/nar/19.4.747; SHUTTLEWORTH J, 1988, EMBO J, V7, P427, DOI 10.1002/j.1460-2075.1988.tb02830.x; SHUTTLEWORTH J, 1988, GENE, V72, P267, DOI 10.1016/0378-1119(88)90152-7; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SOMMER B, 1990, SCIENCE, V252, P1715; SPITZER S, 1988, NUCLEIC ACIDS RES, V16, P11691, DOI 10.1093/nar/16.24.11691; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STULL RA, 1992, NUCLEIC ACIDS RES, V20, P3501, DOI 10.1093/nar/20.13.3501; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WOOLF TM, 1990, NUCLEIC ACIDS RES, V18, P1763, DOI 10.1093/nar/18.7.1763; WOOLF TM, 1992, P NATL ACAD SCI USA, V89, P7305, DOI 10.1073/pnas.89.16.7305; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280	45	39	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16187	16194						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206920				2022-12-25	WOS:A1994NQ72900038
J	MCBROOM, LDB; SADOWSKI, PD				MCBROOM, LDB; SADOWSKI, PD			CONTACTS OF THE ABF1 PROTEIN OF SACCHAROMYCES-CEREVISIAE WITH A DNA-BINDING SITE AT MATA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTONOMOUSLY REPLICATING SEQUENCES; CRYSTAL-STRUCTURE; FLP RECOMBINASE; TARGET SEQUENCE; TRANSCRIPTIONAL ACTIVATOR; RNA-POLYMERASE; FACTOR-I; YEAST; GENE; EXPRESSION	The ABF1 protein of Saccharomyces cerevisiae is a multifunctional DNA-binding protein that is required for cell viability. The ABF1 protein has previously been shown to bind to a number of yeast sequences having a consensus of: 5'-A/G TC A/G C/T C/T NNNNACG-3'. A heretofore undiscovered ABF1-binding site was found in the MATa region. We have used missing contact analysis of this ABF1-binding site to show that removal of the conserved bases, as well as of some bases which are not conserved, reduces binding. We have probed contacts of ABF1 with the DNA-binding site using dimethyl sulfate and potassium permanganate and find that the protein makes extensive contacts with both the major and minor grooves. Ethylation interference studies indicate that numerous phosphate contacts are also important for ABF1 binding. Interference studies indicate that the ABF1 protein is also in close proximity to the DNA that is 5' and 3' of the conserved bases of the binding site. The extensive DNA contacts exhibited by ABF1 may play a role in the protein-induced bending of the DNA target (McBroom, L. D. B., and Sadowski, P. D. (1994) J. Biol. Chem. 169, 16461-16468).	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto								Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; ANDREWS BJ, 1985, CELL, V40, P795, DOI 10.1016/0092-8674(85)90339-3; ASTELL CR, 1981, CELL, V27, P15, DOI 10.1016/0092-8674(81)90356-1; BEATTY LG, 1988, J MOL BIOL, V204, P283, DOI 10.1016/0022-2836(88)90576-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; DELLASETA F, 1990, J BIOL CHEM, V265, P15168; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; EISENBERG S, 1988, P NATL ACAD SCI USA, V85, P743, DOI 10.1073/pnas.85.3.743; GOEL A, 1988, MOL CELL BIOL, V8, P2572, DOI 10.1128/MCB.8.6.2572; HALFTER H, 1989, EMBO J, V8, P3029, DOI 10.1002/j.1460-2075.1989.tb08453.x; HALFTER H, 1989, EMBO J, V8, P4265, DOI 10.1002/j.1460-2075.1989.tb08612.x; HAMIL KG, 1988, MOL CELL BIOL, V8, P4328, DOI 10.1128/MCB.8.10.4328; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HEDGE RS, 1992, NATURE, V359, P505; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOLLAND JP, 1990, MOL CELL BIOL, V10, P4863, DOI 10.1128/MCB.10.9.4863; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; JONES EW, 1977, GENETICS, V85, P23; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCBROOM LDB, 1994, J BIOL CHEM, V269, P16461; MCBROOM LDB, 1993, THESIS U TORONTO; PANIGRAHI GB, 1992, NUCLEIC ACIDS RES, V20, P5927, DOI 10.1093/nar/20.22.5927; RHODE PR, 1989, GENE DEV, V3, P1926, DOI 10.1101/gad.3.12a.1926; RHODE PR, 1992, MOL CELL BIOL, V12, P1064, DOI 10.1128/MCB.12.3.1064; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SILVE S, 1992, MOL CELL BIOL, V12, P4197, DOI 10.1128/MCB.12.9.4197; TAYLOR MJ, 1985, J BIOL CHEM, V260, P4531; TRAWICK JD, 1992, MOL CELL BIOL, V12, P2302, DOI 10.1128/MCB.12.5.2302; TSCHUMPER G, 1980, GENE, V10, P157, DOI 10.1016/0378-1119(80)90133-X; WALKER SS, 1989, MOL CELL BIOL, V9, P2914, DOI 10.1128/MCB.9.7.2914; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	45	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16455	16460						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206954				2022-12-25	WOS:A1994NQ72900075
J	PERRY, DK; STEVENS, VL; WIDLANSKI, TS; LAMBETH, JD				PERRY, DK; STEVENS, VL; WIDLANSKI, TS; LAMBETH, JD			A NOVEL ECTO-PHOSPHATIDIC ACID PHOSPHOHYDROLASE ACTIVITY MEDIATES ACTIVATION OF NEUTROPHIL SUPEROXIDE GENERATION BY EXOGENOUS PHOSPHATIDIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PHOSPHOLIPASE-D; NADPH OXIDASE; GROWTH-FACTOR; C ACTIVITY; HYDROLYSIS; KINASE	Phosphatidic acid (PA) added to intact cells activates a variety of processes including mitogenesis in fibroblasts and superoxide generation in neutrophils. We have investigated the mechanism of activation of superoxide generation in intact human neutrophils by a short-chain (dioctanoyl) PA (diC8PA). After a lag, diC8PA caused a high rate of superoxide production (19.6 nmol of cytochrome c reduced/min/10(6) cells). Activation did not require extracellular Ca2+ and coincided with near quantitative conversion of diC8PA to dioctanoylglycerol (diC8-glycerol). diC8PA also activated cellular phospholipase D with release of long-chain PA and secondary production of long-chain diradylglycerol (sn-1,2-diacylglycerol and 1-O-alkyl-2-acylglycerol). The metabolism of diC8PA to diC8-glycerol was catalyzed by a novel PA phosphohydrolase on the outer leaflet of the plasma membrane as demonstrated by the exclusive release of P(i) into the extracellular medium. This enzyme also showed activity toward PA containing long-chain unsaturated fatty acids. The ecto-PA phosphohydrolase differed from the intracellular PA phosphohydrolase based on its relative insensitivity to desipramine and N-ethylmaleimide. The enzyme was also present in Chinese hamster ovary (CHO) cells and its activity did not change in transfected CHO cells expressing the two membrane-associated isoforms of alkaline phosphatase, indicating that the PA phosphohydrolase was not alkaline phosphatase. Non-hydrolyzable phosphonate analogs of diC8PA poorly stimulated superoxide production. Activation of superoxide generation by diC8PA was inhibited by staurosporine, suggesting a protein kinase C-dependent mechanism. We suggest that the action of a novel ecto-PA phosphohydrolase permits exogenously added short-chain PA to serve as ''timed-release diacylglycerol'' and that its biological effects in neutrophils are secondary to diacylglycerol-mediated protein kinase C activation.	EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT RADIAT ONCOL, DIV CANC BIOL, ATLANTA, GA 30322 USA; INDIANA UNIV, DEPT CHEM, BLOOMINGTON, IN 47405 USA	Emory University; Emory University; Indiana University System; Indiana University Bloomington					NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER; NCI NIH HHS [CA46508] Funding Source: Medline; NIAID NIH HHS [AI22809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; DUNLOP ME, 1989, DIABETES, V38, P1187, DOI 10.2337/diabetes.38.9.1187; EPAND RM, 1990, BIOCHEM BIOPH RES CO, V171, P487, DOI 10.1016/0006-291X(90)91419-S; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, V268, P516, DOI 10.1016/0003-9861(89)90318-4; KONDO T, 1992, J BIOL CHEM, V267, P23609; LASSEGUE B, 1991, BIOCHEM J, V276, P19, DOI 10.1042/bj2760019; MOOLENAAR WH, 1991, ADV CANCER RES, V57, P87; MORITZ A, 1992, J BIOL CHEM, V267, P7207; PERRY DK, 1992, J IMMUNOL, V149, P2749; PEVERI P, 1990, BLOOD, V76, P751; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042	15	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25302	25310						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244961				2022-12-25	WOS:A1993MK10000008
J	BALAKRISHNAN, R; FROHLICH, M; RAHAIM, PT; BACKMAN, K; YOCUM, RR				BALAKRISHNAN, R; FROHLICH, M; RAHAIM, PT; BACKMAN, K; YOCUM, RR			APPENDIX - CLONING AND SEQUENCE OF THE GENE ENCODING ENZYME-E-1 FROM THE METHIONINE SALVAGE PATHWAY OF KLEBSIELLA-OXYTOCA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERSION; PNEUMONIAE	The methionine salvage pathway converts the methylthioribose moiety of 5'-(methylthio)-adenosine to methionine via a series of biochemical steps. One enzyme active in this pathway, a bifunctional enolase-phosphatase called E-1 that promotes oxidative cleavage of the synthetic substrate 2,3-diketo-1-phosphohexane to 2-ketopentanoate, has been purified from Klebsiella pneumoniae and is characterized in the preceding paper (Myers, R., Wray, J., Fish, S., and Abeles, R. H. (1993) J. Biol. Chem. 268, 24785-24791). We synthesized degenerate oligonucleotides corresponding to portions of the amino terminus of E-1. These oligonucleotides were used as polymerase chain reaction primers on whole genomic DNA from Klebsiella oxytoca. This resulted in an 82-base pair DNA fragment that was used as a hybridization probe to obtain a clone of the E-1 gene from a K. oxytoca gene library. The DNA sequence of the E-1 coding region was determined, and the amino acid sequence of E-1 was deduced. E-1 appears to represent a novel class of enzymes since no homology to known enzymes was found. Cloning the gene from K. oxytoca on a multicopy plasmid leads to overproduction of E-1 enzyme that has properties indistinguishable from those of the enzyme from K. pneumoniae.	OMNIGENE INC,763D CONCORD AVE,POB 9002,CAMBRIDGE,MA 02139									BACKMAN K, 1989, Patent No. 338790; BRENNER DJ, 1977, HEW CDC788356 CTR DI; FURFINE ES, 1988, J BIOL CHEM, V263, P9598; GHODA LY, 1988, J BIOL CHEM, V259, P6715; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; Maniatis T., 1982, MOL CLONING; MYERS RW, 1989, J BIOL CHEM, V264, P10547; MYERS RW, 1993, J BIOL CHEM, V268, P24785; REZNIKOFF WS, 1980, OPERON, P221; ROSE RE, 1988, NUCLEIC ACIDS RES, V16, P355, DOI 10.1093/nar/16.1.355; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; [No title captured]	13	20	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24792	24795						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227040				2022-12-25	WOS:A1993MG67300043
J	KANG, ME; DAHMUS, ME				KANG, ME; DAHMUS, ME			RNA POLYMERASE-IIA AND POLYMERASE-IIO HAVE DISTINCT ROLES DURING TRANSCRIPTION FROM THE TATA-LESS MURINE DIHYDROFOLATE-REDUCTASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; MAJOR LATE PROMOTER; LARGEST SUBUNIT; SACCHAROMYCES-CEREVISIAE; NONPHOSPHORYLATED FORM; FUNCTIONAL INTERACTION; PREINITIATION COMPLEX; INITIATION SITE; REPEAT DOMAIN; CALF THYMUS	The largest subunit of RNA polymerase II (RNAP II) contains a remarkable region of tandem heptapeptide repeats of the consensus sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser at its carboxyl terminus. This COOH-terminal domain (CTD) is unphosphorylated in RNAP IIA, extensively phosphorylated in RNAP IIO, and absent in RNAP IIB. The reversible phosphorylation of the CTD has been proposed to be integral to each cycle of transcription from the adenovirus-2 major late promoter. The adenovirus-2 major late promoter, however, may not be a good paradigm for the study of CTD function because in vitro transcription from this promoter is not dependent on the CTD. Previous studies suggest that transcription from the murine dihydrofolate reductase (DHFR) promoter requires the CTD. In an effort to investigate the role of the CTD and its phosphorylation, a RNAP II-dependent reconstituted transcription system specific for the DHFR promoter was established. In this reconstituted system, RNAP IIA, but not RNAP IIB, can transcribe from the DHFR promoter. Furthermore, RNAP IIB does not compete with RNAP IIA for preinitiation complex assembly. These results suggest that the CTD plays a critical role in the recruitment of RNAP II to the DHFR promoter. The analysis of preinitiation complexes assembled on the DHFR promoter indicates that RNAP IIA readily assembles into functional preinitiation complexes in contrast to the inefficient assembly of RNAP IIO. However, transcript elongation is catalyzed by RNAP IIO as demonstrated by the photoactivated cross-linking of nascent DHFR transcripts to subunit IIo. These results indicate that transcription from the DHFR promoter involves the reversible phosphorylation of the CTD and support the idea that RNAPs IIA and IIO have essential but distinct functions.	UNIV CALIF DAVIS,DIV BIOL SCI,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis					NIGMS NIH HHS [GM07377, GM33300] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300, T32GM007377] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1983, J BIOL CHEM, V258, P2303; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KIM WY, 1986, J BIOL CHEM, V261, P14219; KIM WY, 1989, J BIOL CHEM, V264, P3169; KIM WY, 1988, J BIOL CHEM, V263, P18880; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHMIDT EE, 1990, J BIOL CHEM, V265, P17397; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	48	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25033	25040						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227067				2022-12-25	WOS:A1993MG67300077
J	MILLERHANCE, WC; LACORBIERE, M; FULLER, SJ; EVANS, SM; LYONS, G; SCHMIDT, C; ROBBINS, J; CHIEN, KR				MILLERHANCE, WC; LACORBIERE, M; FULLER, SJ; EVANS, SM; LYONS, G; SCHMIDT, C; ROBBINS, J; CHIEN, KR			IN-VITRO CHAMBER SPECIFICATION DURING EMBRYONIC STEM-CELL CARDIOGENESIS - EXPRESSION OF THE VENTRICULAR MYOSIN LIGHT CHAIN-2 GENE IS INDEPENDENT OF HEART TUBE FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTRACTILE PROTEIN GENE; RAT MYOCARDIAL-CELLS; CARDIAC-MUSCLE; ADRENERGIC STIMULATION; INDUCIBLE EXPRESSION; MOUSE EMBRYOS; SKELETAL; BODIES; MODEL; INDUCTION	The molecular cues that control patterning of the heart tube during early cardiogenesis are largely unknown. The present study has explored the embryonic stem (ES) cell differentiation system to determine if this in vitro model could be useful in studying the process of regional specification of cardiac muscle cells at the earliest possible stages. As assessed by polymerase chain reaction, ribonuclease protection, in situ hybridization, and immunohistochemical analyses, ES cell differentiation into embryoid bodies is characterized by the transcriptional and translational activation of the ventricular regulatory (phosphorylatable) myosin light chain gene, demonstrating that ventricular specification occurs during ES cell cardiogenesis. The finding of a ventricular-specific marker in an in vitro system in the absence of an intact heart tube provides evidence for cardiae regional specification independent of positional cues or physiologic stimuli. The temporal expression of the myogenic regulatory factors, myogenin and MyoD, suggests activation of the skeletal muscle program following cardiac myogenesis in vitro, indicating temporal fidelity to the progression of in vivo myogenesis. These data establish the mouse embryonic stem cell system as a model for cardiac chamber specification and suggest a promising approach in the study of regional specification in genetically engineered cardiac muscle cells.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT MED, 0613-C, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC BIOL, AMER HEART ASSOC BUGHER FDN, LA JOLLA, CA 92093 USA; UNIV WISCONSIN, SCH MED, DEPT ANAT, MADISON, WI 53706 USA; MAX PLANCK INST IMMUNBIOL, W-7800 FREIBURG, GERMANY; UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, CINCINNATI, OH 45267 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Wisconsin System; University of Wisconsin Madison; Max Planck Society; University System of Ohio; University of Cincinnati			Evans, Sylvia/G-1980-2015		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036139, P01HL046345, R01HL045069] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45069, HL-46345, HL-36139] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADOLPH EA, 1993, J BIOL CHEM, V268, P5349; BARTON PJR, 1988, J BIOL CHEM, V263, P12669; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; DEGROOT IJM, 1989, ANAT REC, V224, P365, DOI 10.1002/ar.1092240305; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; LEE KJ, 1992, J BIOL CHEM, V267, P15875; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MAHDAVI V, 1982, NATURE, V297, P659, DOI 10.1038/297659a0; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; METCALF D, 1991, INT J CELL CLONING, V9, P95, DOI 10.1002/stem.5530090201; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P2602; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RISAU W, 1988, DEVELOPMENT, V102, P471; ROBBINS J, 1992, TRENDS CARDIOVAS MED, V2, P44, DOI 10.1016/1050-1738(92)90003-B; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; SANCHEZ A, 1991, J BIOL CHEM, V266, P22419; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; WANG R, 1992, DEVELOPMENT, V114, P303; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183; WIECZOREK DF, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P91; WILES MV, 1991, DEVELOPMENT, V111, P259; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHU H, 1993, MOL CELL BIOL, V13, P4432, DOI 10.1128/MCB.13.7.4432; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	40	150	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25244	25252						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227090				2022-12-25	WOS:A1993MG67300103
J	XIE, XS; CRIDER, BP; STONE, DK				XIE, XS; CRIDER, BP; STONE, DK			ISOLATION OF A PROTEIN ACTIVATOR OF THE CLATHRIN-COATED VESICLE PROTON PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING COMPLEX; ACIDIFICATION; RECONSTITUTION; TRANSPORT; PATHWAYS; ATPASES	An activator of the clathrin-coated vesicle proton translocating ATPase has been purified 1600-fold from bovine brain. The activator, which requires detergent (polyoxyethylene 9-lauryl ether) for release from clathrin-coated vesicles, is heat-stable, trypsin-sensitive, and has an apparent molecular mass of about 6 kDa as determined by high performance liquid chromotography. The activator stimulates the purified H+-ATPase of coated vesicles over 50-fold under acidic conditions. Similarly, the activator stimulates proton pumping catalyzed by the reconstituted proton pump. Importantly, this stimulation of proton pumping is observed only when the activator is reconstituted into the interior of the proteoliposomes. Moreover, the activator protein is demonstrated to protect, and co-sediment with, purified proton pump during glycerol gradient centrifugation performed in the presence of ATP. These observations support the notion that this activator serves to determine the pH set point of acidic endomembranes through interactions with the transmembranous sectors of the proton pump.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOLEC TRANSPORT,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK R01 33627] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ALPERN RJ, 1991, KIDNEY, P318; ANDERSON RGW, 1988, J CELL BIOL, V106, P529; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BENNETT AB, 1984, PLANT PHYSIOL, V74, P545, DOI 10.1104/pp.74.3.545; DICKMAN KG, 1992, AM J PHYSIOL, V263, pF342, DOI 10.1152/ajprenal.1992.263.2.F342; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; KELLY RB, 1987, NATURE, V326, P14, DOI 10.1038/326014a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Moriyama Y, 1988, Prog Clin Biol Res, V273, P387; MULBERG AE, 1991, J BIOL CHEM, V266, P20590; NANDI PK, 1982, P NATL ACAD SCI-BIOL, V79, P5881, DOI 10.1073/pnas.79.19.5881; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P261; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STONE DK, 1984, J BIOL CHEM, V259, P2701; STONE DK, 1983, J BIOL CHEM, V258, P4059; STONE DK, 1988, KIDNEY INT, V33, P403; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1989, J BIOL CHEM, V264, P18870; XIE XS, 1986, P NATL ACAD SCI USA, V83, P8913, DOI 10.1073/pnas.83.23.8913; XIE XS, 1983, J BIOL CHEM, V259, P11676; YAMASHIRO DJ, 1984, J CELL BIOCHEM, V26, P231, DOI 10.1002/jcb.240260404; ZHANG K, 1992, J BIOL CHEM, V267, P9701	26	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25063	25067						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227069				2022-12-25	WOS:A1993MG67300080
J	RASMUSSEN, C; GAREN, C				RASMUSSEN, C; GAREN, C			ACTIVATION OF CALMODULIN-DEPENDENT ENZYMES CAN BE SELECTIVELY INHIBITED BY HISTONE-H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CA-2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; CELL-CYCLE PROGRESSION; SUBSTRATE-SPECIFICITY; BINDING-PROTEIN; DNA-REPLICATION; CALCINEURIN; AUTOPHOSPHORYLATION; PHOSPHATASE; CHROMATIN; SUBUNIT	Calmodulin (CaM) and its target enzymes are important regulators of a variety of cellular processes including gene expression and cell cycle progression (Bading, H., Ginty, D. D., and Greenberg, M. E. (1993) Science 260, 181-186; Rasmussen, C. D., and Means,A. R. (1989) EMBO J. 8, 73-82). It has been previously accepted that regulation of CaM-dependent enzyme activity occurs via calcium/calmodulin-dependent activation. We have found that histone H1 is a potent inhibitor of the CaM-dependent activation of mouse calcium/calmodulin-dependent protein kinase II (CaMKII) and of the CaM-dependent protein phosphatase, calcineurin. Inhibition is mediated only by free histone H1; addition of DNA abolishes the inhibitory effect. The effect is not due to a simple interaction of basic (histone) and acidic (CaM) proteins since myelin basic protein and histone H2B, CamkII substrates more basic than histone H1, did not affect autophosphorylation of CaMKII, and myelin basic protein had no effect on calcineurin activity. The effect is specific to CaM since addition of parvalbumin, a related Ca2+-binding protein, did not reverse the effect of histone H1, whereas addition of CaM recovered enzyme activity. These results indicate that free histone H1 levels may specifically affect the ability of CaM to activate its target enzymes and suggests a novel level of control of CaM-dependent enzymes in eukaryotic cells.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV ALBERTA,DEPT ONCOL,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV ALBERTA,NATL CANC INST,MOLEC MECH GROWTH CONTROL GRP,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Alberta; University of Alberta; Queens University - Canada; Canadian Cancer Trials Group; University of Alberta	RASMUSSEN, C (corresponding author), UNIV ALBERTA,DEPT ANAT & CELL BIOL,EDMONTON T6G 2H7,ALBERTA,CANADA.							BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CHAFOULEAS JG, 1984, CELL, V36, P73, DOI 10.1016/0092-8674(84)90075-8; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; FOOR F, 1992, NATURE, V360, P682; HAMMOND RA, 1989, BIOCHIM BIOPHYS ACTA, V951, P315; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HILL CS, 1991, EMBO J, V10, P1939, DOI 10.1002/j.1460-2075.1991.tb07720.x; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; Kennedy MB, 1987, CALCIUM CELL FUNCTIO, P61; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; LOUTERS L, 1985, BIOCHEMISTRY-US, V24, P3080, DOI 10.1021/bi00334a002; MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROUSSEAU D, 1992, EUR J BIOCHEM, V208, P775, DOI 10.1111/j.1432-1033.1992.tb17247.x; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; SCHULMAN H, 1985, BIOCHEMISTRY-US, V24, P5320, DOI 10.1021/bi00341a008; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; SUBRAMANYAM C, 1990, J CELL PHYSIOL, V144, P423, DOI 10.1002/jcp.1041440309; SUN JM, 1990, EMBO J, V9, P1651, DOI 10.1002/j.1460-2075.1990.tb08285.x; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315	31	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23788	23791						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226913				2022-12-25	WOS:A1993MF29400015
J	ZHENG, CF; GUAN, KL				ZHENG, CF; GUAN, KL			PROPERTIES OF MEKS, THE KINASES THAT PHOSPHORYLATE AND ACTIVATE THE EXTRACELLULAR SIGNAL-REGULATED KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; ERK-1 GENE-PRODUCT; PHEROMONE RESPONSE PATHWAY; TYROSINE THREONINE KINASE; MAP KINASE; SKELETAL-MUSCLE; INSULIN; CELLS; IDENTIFICATION; PURIFICATION	Activation of extracellular signal-regulated kinase (ERK) or mitogen-activated protein kinase by MEK (mitogen-activated protein kinase or extracellular signal-regulated kinase kinase) is an essential event in the mitogenic growth factor signal transduction. We now demonstrate that three recombinant MEKs (MEK1, MEK2, MEK3) show remarkably different activity toward recombinant ERK1 and ERK2. MEK2 is the most active ERK activator. The recombinant MEK1 has an activity approximately seven times lower than that of MEK2. MEK3, which is identical to MEK1 except for missing an internal 26-amino acid residue and probably represents an alternative splicing product of MEK1, shows neither autophosphorylation nor ERK-activating activity. Recombinant MEK1 and MEK2 can be activated by epidermal growth factor-stimulated SWISS3T3 cell lysate. MEK1 and MEK2 can also be activated by autophosphorylation. Autophosphorylation of MEKs correlates with their ability to phosphorylate and activate ERKs. Phosphorylation of MEK is also stimulated by ERK. Phosphoamino acid analysis showed that ERK1 preferentially phosphorylated threonine residue of MEKs. MEKs complex with ERKs in vitro. Interestingly, MEK3 also forms a complex with ERK1, although it is totally inactive as an ERK activator.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,INST GERONTOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00042] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1990, J BIOL CHEM, V265, P2713; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SMITH DS, 1989, J NEUROCHEM, V53, P800, DOI 10.1111/j.1471-4159.1989.tb11776.x; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	50	176	178	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23933	23939						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226933				2022-12-25	WOS:A1993MF29400036
J	BORUKHOV, S; SAGITOV, V; JOSAITIS, CA; GOURSE, RL; GOLDFARB, A				BORUKHOV, S; SAGITOV, V; JOSAITIS, CA; GOURSE, RL; GOLDFARB, A			2 MODES OF TRANSCRIPTION INITIATION IN-VITRO AT THE RRNB-P1 PROMOTER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDO-TEMPLATED TRANSCRIPTION; FACTOR-INDEPENDENT ACTIVATION; RIBOSOMAL-RNA TRANSCRIPTION; TERNARY COMPLEXES; BETA-SUBUNIT; POLYMERASE; PURIFICATION; DISSECTION; ELONGATION; MECHANISM	The rrnB P1 promoter of Escherichia coli (starting sequence C-4-A-3-C-2-C-1-A+1-C+2-U+3-G+4) forms a binary complex with RNA polymerase that is highly unstable and requires the presence of transcription substrates ATP and CTP for stabilizing the enzyme-DNA association (Gourse, R. L. (1988) Nucleic Acids Res. 16, 9789-9809). We show that in the absence of UTP and GTP the stabilization is accomplished by short RNA oligomers synthesized in an unusual ''-3-->'' mode whereby the primer initiated at the +1 site presumably slips back by three nucleotides into the -3 site and is then extended yielding stable ternary complexes. By contrast, short oligomers initiated in the conventional ''+1-->'' mode without slippage do not exert the stabilization effect and are readily aborted from the promoter complex. The stable -3--> ternary complexes carry sigma factor but otherwise resemble elongation complexes in their high salt stability and in the fact that they are formed with a mutant RNA polymerase deficient in promoter binding. A model is proposed explaining the stability of the -3--> ternary complexes by RNA slipping into a putative ''tight RNA binding site'' in RNA polymerase which is normally occupied by RNA during elongation.	PUBL HLTH RES INST CITY NEW YORK INC,455 1ST AVE,NEW YORK,NY 10016; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Borukhov, Sergei/AAF-3195-2019	Borukhov, Sergei/0000-0002-3517-3003	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037048, R01GM049242] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM37048, R01 GM49242] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAMA T, 1985, NUCLEIC ACIDS RES, V13, P4085, DOI 10.1093/nar/13.11.4085; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BOURKHOV S, 1993, CELL, V72, P459; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; GOU HC, 1990, BIOCHEMISTRY-US, V29, P10702; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; JACQUES JP, 1990, GENE DEV, V4, P1801, DOI 10.1101/gad.4.10.1801; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KRUMMEL B, 1990, THESIS U CALIFORNIA; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; MARTIN E, 1992, J BIOL CHEM, V267, P20175; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; PARKER RC, 1986, BIOCHEMISTRY-US, V25, P6593, DOI 10.1021/bi00369a038; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; RHODES G, 1974, J BIOL CHEM, V249, P6675; RICHARDSON JP, 1966, J MOL BIOL, V21, P115, DOI 10.1016/0022-2836(66)90083-0; RUETSCH N, 1987, J BIOL CHEM, V262, P1674; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; ZACHARIAS M, 1991, BIOCHIMIE, V73, P699, DOI 10.1016/0300-9084(91)90050-B; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	27	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23477	23482						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226874				2022-12-25	WOS:A1993MF51500080
J	CAVALLARO, U; DELVECCHIO, A; LAPPI, DA; SORIA, MR				CAVALLARO, U; DELVECCHIO, A; LAPPI, DA; SORIA, MR			A CONJUGATE BETWEEN HUMAN UROKINASE AND SAPORIN, A TYPE-1 RIBOSOME-INACTIVATING PROTEIN, IS SELECTIVELY CYTOTOXIC TO UROKINASE RECEPTOR-EXPRESSING CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; ALPHA-2-MACROGLOBULIN RECEPTOR; SAPONARIA-OFFICINALIS; EUKARYOTIC RIBOSOMES; PRO-UROKINASE; SARCOMA-CELLS; DEGRADATION; IMMUNOTOXIN; COMPLEXES; BINDING	Urokinase-type plasminogen activator (uPA) confers invasive potential to transformed cells. Cancer cells express high numbers of uPA receptors (uPARs), which concentrate uPA activity at the invasive edge of cancer cells and the tumor mass. We synthesized a conjugate between human uPA and saporin (SAP), a ribosome-inactivating protein produced by Saponaria officinalis. Results of cell-killing assays showed that uPA is very effective at targeting saporin specifically to uPAR-expressing cells, whereas cell lines devoid of uPARs were not affected by the conjugate. Receptor-bound uPA is internalized only upon formation of a complex with one of its inhibitors (PAIs). However, our conjugate was highly cytotoxic even when the interaction between uPA and PAIs was prevented. Moreover, the alpha2-macroglobulin receptor, which has been reported to mediate the internalization of uPA.PAI complexes, seems not to be involved in cell killing caused by the uPA.SAP conjugate. Thus, uPA.SAP might follow a mechanism of internalization different from that of unconjugated uPA complexed to PAIs, although still uPAR-mediated. Our results also suggest that alpha2-Macroglobulin and/or its receptor could mediate the internalization and cytotoxicity of unconjugated saporin, as it has been shown for other toxins.	SAN RAFFAELE RES INST,DEPT BIOL & TECHNOL RES,DIBIT,VIA OLGETTINA 58,I-20132 MILAN,ITALY; WHITTIER INST DIABET & ENDOCRINOL,DEPT MOLEC & CELLULAR GROWTH BIOL,LA JOLLA,CA 92037				Cavallaro, Ugo/J-9745-2012	Cavallaro, Ugo/0000-0002-0884-6460; Lappi, Douglas/0000-0003-4239-7387	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK018811] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-18811] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; BARBIERI L, 1989, SCAND J IMMUNOL, V30, P369, DOI 10.1111/j.1365-3083.1989.tb01223.x; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; CORSARO CM, 1981, SOMAT CELL GENET, V7, P603, DOI 10.1007/BF01549662; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; ENDO Y, 1988, BIOCHEM BIOPH RES CO, V150, P1032, DOI 10.1016/0006-291X(88)90733-4; ENDO Y, 1987, J BIOL CHEM, V262, P5908; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; GETHIE MA, 1991, CANCER RES, V51, P1482; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LAPPI DA, 1989, BIOCHEM BIOPH RES CO, V160, P917, DOI 10.1016/0006-291X(89)92522-9; LAPPI DA, 1985, BIOCHEM BIOPH RES CO, V129, P934, DOI 10.1016/0006-291X(85)91981-3; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; NYKJAER A, 1992, FEBS LETT, V300, P13, DOI 10.1016/0014-5793(92)80154-9; OLSON D, 1992, J BIOL CHEM, V267, P9129; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; PYKE C, 1991, AM J PATHOL, V138, P1059; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; SCHMITT M, 1992, FIBRINOLYSIS, V6, P3; SIENA S, 1988, BLOOD, V72, P756; SORIA M, 1989, PHARMACOL RES, V21, P35, DOI 10.1016/S1043-6618(89)80016-7; SORIA M, 1992, GENETICALLY ENG TOXI, P193; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STIRPE F, 1992, BIO-TECHNOL, V10, P405, DOI 10.1038/nbt0492-405; STIRPE F, 1983, BIOCHEM J, V216, P617, DOI 10.1042/bj2160617; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TAZZARI PL, 1992, TRANSPLANTATION, V54, P351, DOI 10.1097/00007890-199208000-00029; THORPE PE, 1985, J NATL CANCER I, V75, P151; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86	36	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23186	23190						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226837				2022-12-25	WOS:A1993MF51500038
J	BURSTEIN, ES; BRONDYK, WH; MACARA, IG; KAIBUCHI, K; TAKAI, Y				BURSTEIN, ES; BRONDYK, WH; MACARA, IG; KAIBUCHI, K; TAKAI, Y			REGULATION OF THE GTPASE CYCLE OF THE NEURONALLY EXPRESSED RAS-LIKE GTP-BINDING PROTEIN RAB3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GDP DISSOCIATION INHIBITOR; SMG P25A; EXCHANGE PROTEIN; MEMBRANES; TISSUE; PROTEIN-P25RAB3A; PURIFICATION; P25RAB3A; SMG-P25A; RESIDUES	The small GTP-binding protein Rab3A (identical to smg p25A) is expressed in neural/exocrine/endocrine cells, is distributed between the cytosol and secretory vesicle membranes, and may cycle between these locations to regulate exocytosis. It is proposed that the GTP/GDP state of Rab3A controls this distribution. In PC12 cells, cytosolic Rab3A is predominantly GDP-bound, whereas membrane-associated Rab3A is approximately 50% GTP-bound. Two cytosolic factors, GDP dissociation inhibitor (GDI) and guanine nucleotide releasing factor (GRF), act only on GDP.Rab3A, and preferentially with post-translationally modified Rab3A. Rab3A GTPase-activating protein (GAP) does not preferentially act on processed Rab3A, and interacts selectively with GTP.Rab3A. GDI antagonizes GRF but not GAP activity toward Rab3A. These data are consistent with the concept of an ordered Rab3A cycle controlled by factors that regulate the guanine-nucleotide binding state of Rab3A.	UNIV VERMONT, DEPT PATHOL, BURLINGTON, VT 05405 USA; KOBE UNIV, SCH MED, DEPT BIOCHEM, KOBE 650, JAPAN	University of Vermont; Kobe University	BURSTEIN, ES (corresponding author), UNIV VERMONT, DEPT PSYCHIAT, BURLINGTON, VT 05405 USA.				NATIONAL CANCER INSTITUTE [R01CA056300] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [F32EY006411] Funding Source: NIH RePORTER; NCI NIH HHS [CA56300] Funding Source: Medline; NEI NIH HHS [F32EY06411] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BURSTEIN E, 1989, MOL CELL BIOL, V9, P4807, DOI 10.1128/MCB.9.11.4807; BURSTEIN ES, 1992, BIOCHEM J, V282, P387, DOI 10.1042/bj2820387; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; KURODA S, 1992, BIOCHEM BIOPH RES CO, V185, P473, DOI 10.1016/S0006-291X(05)81009-5; MOLLARD G, 1990, NATURE, V349, P79; NONAKA H, 1991, BIOCHEM BIOPH RES CO, V174, P556, DOI 10.1016/0006-291X(91)91453-J; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x	26	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22247	22250						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226729				2022-12-25	WOS:A1993MD34800009
J	GILON, P; SHEPHERD, RM; HENQUIN, JC				GILON, P; SHEPHERD, RM; HENQUIN, JC			OSCILLATIONS OF SECRETION DRIVEN BY OSCILLATIONS OF CYTOPLASMIC CA2+ AS EVIDENCED IN SINGLE PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INHIBIT INSULIN RELEASE; INTRACELLULAR CALCIUM; <CA2+>I OSCILLATIONS; PULSATILE SECRETION; CYTOSOLIC CALCIUM; CHROMAFFIN CELLS; B-CELL; MEMBRANE; PROLACTIN; ABILITY	It is often assumed, but has not been demonstrated, that the oscillations of cytoplasmic calcium (Ca2+i) that occur in various secretory cells induce oscillations in secretion. Here, we have used single pancreatic islets from normal mice to monitor simultaneously insulin release and Ca2+i in beta-cells for periods up to 25 min. Ca2+i and insulin secretion were found to oscillate in synchrony during stimulation by glucose. This synchrony persisted when the frequency of both events changed spontaneously or upon addition of the hypoglycaemic sulfonylurea tolbutamide, or when their relative amplitudes varied. Repolarizing the beta-cell membrane with diazoxide abolished both Ca2+i and insulin oscillations. In contrast, epinephrine suppressed insulin oscillations in spite of the persistence of Ca2+i oscillations. This study is the first direct demonstration that, in an intact organ, sustained oscillations of Ca2+i induced by a physiological stimulus entrain synchronous oscillations of the functional response, and that both events can vary simultaneously or be dissociated depending on the experimental conditions.	UNIV CATHOLIQUE LOUVAIN,FAC MED,UNITE ENDOCRINOL & METAB,UCL 55-30,AVE HIPPOCRATE 55,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain								ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BERGSTEN P, 1993, BIOCHEM BIOPH RES CO, V192, P1182, DOI 10.1006/bbrc.1993.1541; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; CHEEK TR, 1989, J CELL BIOL, V109, P1219, DOI 10.1083/jcb.109.3.1219; COOK DL, 1982, DIABETES, V31, P985, DOI 10.2337/diabetes.31.11.985; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P451, DOI 10.1111/j.1476-5381.1968.tb08474.x; DREWS G, 1990, ENDOCRINOLOGY, V126, P1646, DOI 10.1210/endo-126-3-1646; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; GILLIS KD, 1992, PFLUGERS ARCH, V420, P131; GILON P, 1992, J BIOL CHEM, V267, P20713; HENQUIN JC, 1982, BIOCHEM PHARMACOL, V31, P1407, DOI 10.1016/0006-2952(82)90036-3; HENQUIN JC, 1992, NUTRIENT REGULATION, P173; HOLL RW, 1988, J BIOL CHEM, V263, P9682; JONES PM, 1987, FEBS LETT, V219, P139, DOI 10.1016/0014-5793(87)81206-1; LAW GJ, 1989, MOL ENDOCRINOL, V3, P539, DOI 10.1210/mend-3-3-539; LAW GJ, 1989, BIOCHEM BIOPH RES CO, V158, P811, DOI 10.1016/0006-291X(89)92794-0; LEFEBVRE PJ, 1987, DIABETOLOGIA, V30, P443, DOI 10.1007/BF00279610; LINDAU M, 1992, BIOPHYS J, V61, P19, DOI 10.1016/S0006-3495(92)81812-X; MALGAROLI A, 1991, FEBS LETT, V283, P169, DOI 10.1016/0014-5793(91)80580-V; MEISSNER HP, 1976, NATURE, V262, P502, DOI 10.1038/262502a0; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; PENNER R, 1988, J EXP BIOL, V139, P329; Rosario L M, 1986, Adv Exp Med Biol, V211, P413; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; TAMAGAWA T, 1985, BIOMED RES-TOKYO, V6, P429, DOI 10.2220/biomedres.6.429; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; WATERS SB, 1992, ENDOCRINOLOGY, V130, P2091, DOI 10.1210/en.130.4.2091; WEIGLE DS, 1987, DIABETES, V36, P764, DOI 10.2337/diab.36.6.764	32	305	312	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22265	22268						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226733				2022-12-25	WOS:A1993MD34800014
J	HUIBREGTSE, JM; GOOD, PD; MARCZYNSKI, GT; JAEHNING, JA; ENGELKE, DR				HUIBREGTSE, JM; GOOD, PD; MARCZYNSKI, GT; JAEHNING, JA; ENGELKE, DR			GAL4 PROTEIN-BINDING IS REQUIRED BUT NOT SUFFICIENT FOR DEREPRESSION AND INDUCTION OF GAL2 EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; YEAST GENES; INVIVO; RNA; SEQUENCES; PHOSPHORYLATION; REPRESSION; COMPLEXES	The Saccharomyces cerevisiae GAL2 gene upstream activator sequence (UAS) region was examined for protein bound in vivo by chromatin footprinting at high resolution. Gal4 transcriptional activator protein binds to the two consensus UAS sites whether GAL2 expression is induced, uninduced, or repressed by growth with different carbon sources. Although wild type strains show loss of the Gal4 protein-specific footprint in repressing media containing glucose, constitutive high level expression of Gal4 protein restores the GAL2 UAS footprints without fully derepressing GAL2 transcription. Thus binding of the Gal4 activator to target sites in the DNA is required but not sufficient for GAL2 derepression and induction. Gal4-independent protein-DNA complexes were also detected in the region, including one over the previously noted centromere-binding protein (CP1) site upstream of the Gal4 complexes.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NCRR NIH HHS [MO1-RR00042] Funding Source: Medline; NIAID NIH HHS [R04 AI00874] Funding Source: Medline; NIGMS NIH HHS [R01 GM38101] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038101] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; AXELROD JD, 1989, NUCLEIC ACIDS RES, V17, P171, DOI 10.1093/nar/17.1.171; BAKER SM, 1987, MOL GEN GENET, V208, P127, DOI 10.1007/BF00330433; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; BRAM RJ, 1986, EMBO J, V5, P603, DOI 10.1002/j.1460-2075.1986.tb04253.x; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HUIBREGTSE JM, 1987, MOL CELL BIOL, V7, P3212, DOI 10.1128/MCB.7.9.3212; HUIBREGTSE JM, 1989, P NATL ACAD SCI USA, V86, P65, DOI 10.1073/pnas.86.1.65; HUIBREGTSE JM, 1989, MOL CELL BIOL, V9, P3244, DOI 10.1128/MCB.9.8.3244; HULL MW, 1991, METHOD CELL BIOL, V35, P384; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LONG RM, 1991, MOL CELL BIOL, V11, P2311, DOI 10.1128/MCB.11.4.2311; MYLIN LM, 1989, GENE DEV, V3, P1157, DOI 10.1101/gad.3.8.1157; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NEHLIN JO, 1989, GENE, V85, P313, DOI 10.1016/0378-1119(89)90423-X; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; PARTHUN MR, 1992, MOL CELL BIOL, V12, P4981, DOI 10.1128/MCB.12.11.4981; PARTHUN MR, 1992, MOL CELL BIOL, V12, P5683, DOI 10.1128/MCB.12.12.5683; SELLECK SB, 1988, P NATL ACAD SCI USA, V85, P5399, DOI 10.1073/pnas.85.15.5399; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; SELLECK SB, 1987, MOL CELL BIOL, V7, P3260, DOI 10.1128/MCB.7.9.3260; STONE G, 1993, EMBO J, V12, P1375, DOI 10.1002/j.1460-2075.1993.tb05782.x; SZKUTNICKA K, 1989, J BACTERIOL, V171, P4486, DOI 10.1128/JB.171.8.4486-4493.1989; ZAREL L, 1992, PROG NUCLEIC ACID RE, V44, P67	29	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22219	22222						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226724				2022-12-25	WOS:A1993MD34800002
J	RUTTER, GA; THELER, JM; MURGIA, M; WOLLHEIM, CB; POZZAN, T; RIZZUTO, R				RUTTER, GA; THELER, JM; MURGIA, M; WOLLHEIM, CB; POZZAN, T; RIZZUTO, R			STIMULATED CA2+ INFLUX RAISES MITOCHONDRIAL FREE CA2+ TO SUPRAMICROMOLAR LEVELS IN A PANCREATIC BETA-CELL LINE - POSSIBLE ROLE IN GLUCOSE AND AGONIST-INDUCED INSULIN-SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-HEART MITOCHONDRIA; PYRUVATE-DEHYDROGENASE; CALCIUM-TRANSPORT; EXTRACELLULAR ATP; CYTOSOLIC CA2+; RINM5F CELLS; B-CELLS; CA-2+; METABOLISM; ISLETS	The effects of stimulated Ca2+ influx on cytosolic ([Ca2+]c) or intramitochondrial free Ca2+ ([Ca2+]m) were examined in the new pancreatic beta-cell line, INS-1. [Ca2+]c was monitored by video imaging of single fura-2-loaded INS-1 cells, or in populations of cells transfected with non-targeted (cytosolic) aequorin. [Ca2+]m was measured after transfection with aequorin targeted to the mitochondria by fusion of the gene in frame with the signal peptide of cytochrome c oxidase subunit VIII. Two physiological stimuli of native beta-cells, glucose and ATP, raised [Ca2+]c in INS-1 cells largely by stimulating Ca2+ influx. Thus, glucose (20 mM) induced repetitive transient increases in [Ca2+]c (0.42 min-1, mean amplitude 229 nM above 102 nM basal). These transients were largely due to periodic stimulation of Ca2+ influx through voltage-sensitive Ca2+ channels, since they could be rapidly and reversibly blocked by chelation of external Ca2+, by addition of the hyperpolarizing agent diazoxide, or with the Ca2+ channel blocker SR 7037. ATP, by contrast, caused single transient [Ca2+]c increases, to about 300 nM above basal levels, which could be inhibited by >90% upon external Ca2+ chelation. Challenge of aequorin-transfected cells with ATP increased [Ca2+]m to 4 muM or above, an effect blocked by EGTA. Furthermore, plasma membrane depolarization with high K+, used as a glucose surrogate to mimic, in a synchronized fashion, the influx-induced Ca2+ transients observed at the single-cell level, also increased [Ca2+]m to >4 muM. Similar increases in [Ca2+]m were also measured in other aequorin-transfected insulin-secreting cells, RINm5F, during mobilization of internal Ca2+ with carbachol. In contrast, glucose-induced changes in [Ca2+]m were below the level of detection in INS-1 cell populations, consistent with the asynchrony of the [Ca2+]c transients induced by this nutrient at the single-cell level, and the consequent small average [Ca2+]c rise. These data are in line with the view that stimulated Ca2+ influx into excitable cells raises [Ca2+]m as efficiently as internal Ca2+ mobilization in nonexcitable cells. In the case of INS-1 and pancreatic beta-cells, this may be important both to enhance oxidative metabolism, hence fueling the secretory process, and also to maintain the production of metabolic signaling molecules.	UNIV PADUA, DIV BIOMED SCI, I-35121 PADUA, ITALY	University of Padua	RUTTER, GA (corresponding author), UNIV GENEVA, MED CTR, DEPT MED, DIV CLIN BIOCHEM, CH-1211 GENEVA 4, SWITZERLAND.		Rizzuto, Rosario/B-6312-2008	Rutter, Guy/0000-0001-6360-0343; Rizzuto, Rosario/0000-0001-7044-5097				AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; BARTHEL F, 1992, METHODS NEUROSCI, V9, P291; BERTRAND G, 1987, BRIT J PHARMACOL, V91, P783, DOI 10.1111/j.1476-5381.1987.tb11276.x; BRUN T, 1993, J BIOL CHEM, V268, P18905; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; Cobbold PH, 1991, CELLULAR CALCIUM PRA, P55; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DAVIDSON AM, 1989, BIOCHEM J, V258, P817, DOI 10.1042/bj2580817; DEAN PM, 1973, DIABETOLOGIA, V9, P115, DOI 10.1007/BF01230690; DENTON RM, 1980, FEBS LETT, V119, P1, DOI 10.1016/0014-5793(80)80986-0; GESCHWIND JF, 1989, BIOCHIM BIOPHYS ACTA, V1012, P107, DOI 10.1016/0167-4889(89)90018-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1991, CELL CALCIUM, V12, P229, DOI 10.1016/0143-4160(91)90023-8; HANSFORD RG, 1985, REV PHYSIOL BIOCH P, V102, P1, DOI 10.1007/BFb0034084; JANJIC D, 1992, DIABETOLOGIA, V35, P482, DOI 10.1007/BF02342448; JANJIC D, 1992, EUR J BIOCHEM, V210, P297, DOI 10.1111/j.1432-1033.1992.tb17421.x; KRAUSE E-G, 1988, Journal of Molecular and Cellular Cardiology, V20, pS54; LI GD, 1991, J BIOL CHEM, V266, P3449; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MARIE S, 1993, IN PRESS J BIOL CHEM, V268; MCCORMACK JG, 1990, BIOCHEM J, V267, P527, DOI 10.1042/bj2670527; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; PANTEN U, 1987, ISI ATLAS-PHARMACOL, V1, P307; PRALONG WF, 1992, P NATL ACAD SCI USA, V89, P132, DOI 10.1073/pnas.89.1.132; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RORSMAN P, 1992, EMBO J, V11, P2877, DOI 10.1002/j.1460-2075.1992.tb05356.x; ROSSIER JR, 1989, J BIOL CHEM, V264, P16598; RUTTER GA, 1988, BIOCHEM J, V252, P181, DOI 10.1042/bj2520181; RUTTER GA, 1989, BIOCHIM BIOPHYS ACTA, V1014, P263, DOI 10.1016/0167-4889(89)90222-X; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; RUTTER GA, 1990, INT J BIOCHEM, V22, P1081, DOI 10.1016/0020-711X(90)90105-C; RUTTER GA, 1990, BIOCHEM J, V271, P627, DOI 10.1042/bj2710627; SENER A, 1990, BIOCHIM BIOPHYS ACTA, V1019, P42, DOI 10.1016/0005-2728(90)90122-K; TANAHASHI H, 1990, GENE, V96, P249, DOI 10.1016/0378-1119(90)90260-X; THELER JM, 1992, J BIOL CHEM, V267, P18110; WENDTGALLITELLI MF, 1991, J PHYSIOL-LONDON, V435, P349, DOI 10.1113/jphysiol.1991.sp018514; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314	45	172	174	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22385	22390						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226749				2022-12-25	WOS:A1993MD34800032
J	ADAMSON, R; JONES, AS; FIELD, JK				ADAMSON, R; JONES, AS; FIELD, JK			LOSS OF HETEROZYGOSITY STUDIES ON CHROMOSOME-17 IN HEAD-AND-NECK-CANCER USING MICROSATELLITE MARKERS	ONCOGENE			English	Note							TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL CARCINOMA; POLYMERASE CHAIN-REACTION; BREAST-CANCER; COLORECTAL-CANCER; ALLELE LOSS; P53 GENE; OVARIAN-CARCINOMA; FREQUENT LOSS; DELETION	In this study we have analysed 38 squamous cell carcinomas (SCC) two basal cell carcinomas (BCC), a malignant salivary gland carcinoma, a neurosarcoma and a Warthins carcinoma, all isolated from patients with head and neck cancers. These tumour types have been examined by PCR for loss of heterozygosity (LOH) on both arms of chromosome 17 using nine polymorphic microsatellite markers. LOH on 17p in SCCHN was found to be 50% (19/38), and often involved TP53 (42%) but more frequently involved the CHRNB1 locus (56%). Twelve tumours showed loss of heterozygosity on 17q (34%) and ten of these also had loss on 17p. Four SCCHN tumours lost an entire copy of chromosome 17. It was of particular note that 77% (10/13) of the SCCHN at the hypopharyngeal site had LOH at CHRNB1. We propose from our data that the 17p12-p11 region contains a novel predisposing gene for hypopharyngeal SCCHN that may function as a tumour suppressor gene.	UNIV LIVERPOOL,SCH DENT,DEPT CLIN DENT SCI,LIVERPOOL L69 3BX,ENGLAND; UNIV LIVERPOOL,DEPT OTORHINOLARYNGOL,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool; University of Liverpool			Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BOYD JA, 1990, PHARMACOL THERAPEUT, V46, P469, DOI 10.1016/0163-7258(90)90028-Z; CANN CI, 1985, OTOLARYNG CLIN N AM, V18, P367; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DELATTRE O, 1989, LANCET, V2, P353; ECCLES DM, 1990, ONCOGENE, V5, P1599; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, CELL, V61, P757; Field J K, 1992, Eur J Cancer B Oral Oncol, V28B, P67, DOI 10.1016/0964-1955(92)90016-T; FIELD JK, 1991, BRIT J CANCER, V64, P573, DOI 10.1038/bjc.1991.352; FIELD JK, 1992, LANCET, V339, P502, DOI 10.1016/0140-6736(92)91122-O; FIELD JK, 1993, ARCH OTOLARYNGOL, V119, P1118; FIELD JK, 1994, INT J ONCOL, V4, P543; FIELD JK, 1994, IN PRESS CANCER DETE; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FULTS D, 1989, CANCER RES, V49, P6572; GUZZETTA V, 1992, GENOMICS, V13, P551, DOI 10.1016/0888-7543(92)90124-B; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JONES AS, 1993, CLIN OTOLARYNGOL, V17, P545; KELSELL DP, 1993, GENOMICS, V17, P522, DOI 10.1006/geno.1993.1362; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LARGEY JS, 1993, CANCER, V71, P1933, DOI 10.1002/1097-0142(19930315)71:6<1933::AID-CNCR2820710602>3.0.CO;2-D; LATIF F, 1992, CANCER RES, V52, P1451; LEONE A, 1991, CANCER RES, V51, P2490; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; MACKAY J, 1988, LANCET, V2, P1384; MAESTRO R, 1992, ONCOGENE, V7, P1159; MCKUSICK VA, 1993, J MED GENET, V10, P1; MELING GI, 1993, BRIT J CANCER, V67, P88, DOI 10.1038/bjc.1993.14; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; NAKSTAD B, 1992, TIDSSKR NOR LAEGEFOR, V113, P595; OMURA Y, 1993, ACUPUNCTURE ELECTRO, V18, P33, DOI 10.3727/036012993816357601; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; REES M, 1989, BRIT J CANCER, V59, P361, DOI 10.1038/bjc.1989.72; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SAKAI E, 1992, ONCOGENE, V7, P927; SATO T, 1992, CANCER RES, V52, P1643; SATO T, 1990, CANCER RES, V50, P7184; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STELL PM, 1989, EUR J SURG ONCOL, V15, P407; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TOGUCHIDA J, 1989, CANCER RES, V49, P6247; TSAO SW, 1991, ANTICANCER RES, V11, P1975; VIANI L, 1991, J LARYNGOL OTOL, V105, P24, DOI 10.1017/S0022215100114732; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAGATA T, 1993, CANCER RES, V53, P846; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; YIN Y, 1993, EUR J CANCER ORAL ON, V29, P257; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	58	61	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2077	2082						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208554				2022-12-25	WOS:A1994NR68500034
J	LEVEDAKOU, EN; HE, M; BAPTIST, EW; CRAVEN, RJ; CANCE, WG; WELCSH, PL; SIMMONS, A; NAYLOR, SL; LEACH, RJ; LEWIS, TB; BOWCOCK, A; LIU, ET				LEVEDAKOU, EN; HE, M; BAPTIST, EW; CRAVEN, RJ; CANCE, WG; WELCSH, PL; SIMMONS, A; NAYLOR, SL; LEACH, RJ; LEWIS, TB; BOWCOCK, A; LIU, ET			2 NOVEL HUMAN SERINE/THREONINE KINASES WITH HOMOLOGIES TO THE CELL-CYCLE REGULATING XENOPUS MO15, AND NIMA KINASES - CLONING AND CHARACTERIZATION OF THEIR EXPRESSION PATTERN	ONCOGENE			English	Article							PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; COLORECTAL-CANCER; CATALYTIC SUBUNIT; FISSION YEAST; LUNG-CANCER; GENE; QUERCETIN; CDC2	Using polymerase chain reaction (PCR)-based methods, we have isolated cDNA clones of two new members of serine/threonine kinases, STK1 and STK2, from a cDNA library constructed from the BT-20 human breast cancer cell line. STK1 is transcribed as a 1.4 kilobase (kb) mRNA encoding for a protein of 346 amino acids. Based on amino acid sequence analysis, STK1 is 86% identical to the Xenopus p40(mol5), a cdc2-related serine/threonine kinase recently found to be the activating kinase for p34(cdc2) and p33(cdk2). Thus, STK1 is most likely the human homologue of MO15. An alternatively spliced STK1 message expressed variably in cell lines and in primary carcinomas generates a predicted 58 amino acid protein that lacks the kinase domain. STK2 is transcribed into a 4.0 kb mRNA encoding for an 841 residue protein which exhibits 50% identity in the kinase domain with the mouse nek1 gene product, the relative of the fungal G(2)-M regulator, nimA. STK1 and STK2 display a variable pattern of expression among a series of primary carcinomas as well as cancer cell lines. Both STK1 and STK2 were expressed at the highest levels in the heart but were also detected in all other organs tested. Tn embryonal tissues, lower levels of expression were noted. Using cell cycle inhibitors, we have shown that both STK1 and STK2 mRNA levels remain relatively invariant through the cell cycle. Chromosomal assignment has localized STK1 on chromosome 2pcen-2p15, a region implicated in hereditary non-polyposis colorectal carcinoma, and STK2 on chromosome 3p21.1, a region frequently showing chromosomal alterations in renal cells carcinomas.	UNIV N CAROLINA, LINEBERGER CANC RES CTR, DEPT MED, CURRICULUM GENET, CHAPEL HILL, NC 27599 USA; UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DALLAS, TX USA; UNIV TEXAS, HLTH SCI CTR, DEPT CELLULAR & STRUCT BIOL, SAN ANTONIO, TX 78284 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Health San Antonio			Liu, Edison/C-4141-2008	Bowcock, Anne/0000-0001-8691-9090; Leach, Robin/0000-0002-3201-5579	NATIONAL CANCER INSTITUTE [R01CA027632, P50CA058223, K08CA001625] Funding Source: NIH RePORTER; NCI NIH HHS [CA27632, K08 CA01625, 1P50CA58223-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; ANGLARD P, 1992, CANCER RES, V52, P348; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOWCOCK A, 1993, GENOMICS, V15, P376, DOI 10.1006/geno.1993.1071; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; CANCE WG, 1993, INT J CANCEER, V54, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; GALE M, 1993, MOL BIOCHEM PARASIT, V59, P111, DOI 10.1016/0166-6851(93)90012-M; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GLOSSMANN H, 1981, N-S ARCH PHARMACOL, V317, P100, DOI 10.1007/BF00506266; GRAZIANI Y, 1983, EUR J BIOCHEM, V135, P583, DOI 10.1111/j.1432-1033.1983.tb07692.x; GRAZIANI Y, 1981, BIOCHIM BIOPHYS ACTA, V714, P415; GSCHWENDT M, 1984, BIOCHEM BIOPH RES CO, V124, P63, DOI 10.1016/0006-291X(84)90916-1; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HUNT T, 1989, NATURE, V342, P483, DOI 10.1038/342483a0; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOVACS G, 1991, P NATL ACAD SCI USA, V88, P194, DOI 10.1073/pnas.88.1.194; LANG DR, 1974, BIOCHIM BIOPHYS ACTA, V333, P180, DOI 10.1016/0005-2728(74)90002-4; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LEVEDAKOU EN, 1992, INT J CANCER, V52, P534, DOI 10.1002/ijc.2910520406; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; Melamed M. R., 1990, FLOW CYTOMETRY SORTI; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; MIURA I, 1992, CANCER RES, V52, P1322; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NANUS DM, 1991, ONCOGENE, V6, P2105; NEUBAUER A, 1990, NUCLEIC ACIDS RES, V18, P993, DOI 10.1093/nar/18.4.993; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RAPP UR, 1988, HDB ONCOGENES, P213; REED JC, 1992, CANCER RES, V52, P2802; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SETH A, 1988, ONCOGENE HDB, P195; SHOSHAN V, 1981, J BIOL CHEM, V256, P887; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SRIVASTAVA AK, 1985, BIOCHEM BIOPH RES CO, V131, P1, DOI 10.1016/0006-291X(85)91761-9; SUNARA U, 1991, CELL, V65, P145; Swofford D., 1998, PAUP PHYLOGENETIC AN; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; TODD SK, 1992, THESIS U TEXAS HLTH; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	62	61	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1977	1988						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208544				2022-12-25	WOS:A1994NR68500022
J	ANBORGH, PH; PARMEGGIANI, A				ANBORGH, PH; PARMEGGIANI, A			PROBING THE REACTIVITY OF THE GTP-BOUND AND GDP-BOUND CONFORMATIONS OF ELONGATION FACTOR-TU IN COMPLEX WITH THE ANTIBIOTIC GE2270-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; FACTOR EF-TU; PROTEIN-SYNTHESIS; SACCHAROMYCES-CEREVISIAE; POLYPEPTIDE-CHAIN; TERMINAL DOMAIN; MONO-VALENT; FACTOR-TS; KIRROMYCIN; MODULATION	The activity of Escherichia coli elongation factor Tu (EF-Tu) depends on its GTP- and GDP-bound conformations. In this work we have studied the influence of the antibiotic GE2270 A, a new EF-Tu-specific inhibitor of protein biosynthesis, on these two conformations with respect to the interaction with the various ligands and stability. One molecule of GE2270 A bound per EF-Tu is sufficient to block poly(U)-directed poly(Phe) incorporation. This drug binds stably to both EF-Tu.GTP and EF-Tu.GDP but only affects the reactivity of the GTP-bound conformation that is no longer able to interact efficiently with aminoacyl-tRNA (aa-tRNA) and ribosomes. Consequently, the protection by EF-Tu.GTP of the aminoacyl-ester bond against nonenzymatic hydrolysis is strongly weakened. The intrinsic EF-Tu GTPase is little affected, but its response to aa-tRNA and ribosomes is impaired. The specificity of GE2270 A to the GTP-bound form of EF-Tu is supported by the course of temperature- and urea-dependent inactivation or tryptic digestion. Furthermore, in its presence elongation factor Ts (EF-Ts) can enhance the dissociation of EF-Tu.GDP but not that of EF-Tu.GTP. Unlike kirromycin, this antibiotic can bind to EF-Tu.EF-Ts without causing dissociation of this complex. Evidence was obtained that the EF-Tu binding site for GE2270 A is also distinct from those for kirromycin, pulvomycin, and aa-tRNA, even though this antibiotic functionally interferes with all three of these ligands. GE2270 A appears to interact with a crucial regulatory region of the EF-Tu molecule that is activated in the GTP-bound state.	ECOLE POLYTECH,BIOCHIM LAB,CNRS,SDI 61840,F-91128 PALAISEAU,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris								ANBORGH PH, 1991, FEBS LETT, V292, P232, DOI 10.1016/0014-5793(91)80874-3; ANBORGH PH, 1991, EMBO J, V10, P779, DOI 10.1002/j.1460-2075.1991.tb08009.x; BLUMENTHAL T, 1977, P NATL ACAD SCI USA, V74, P3264, DOI 10.1073/pnas.74.8.3264; BOSCH L, 1983, PROG NUCLEIC ACID RE, V30, P91; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHINALI G, 1977, EUR J BIOCHEM, V75, P55, DOI 10.1111/j.1432-1033.1977.tb11503.x; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DOUGLASS J, 1979, J BIOL CHEM, V254, P5383; DUISTERWINKEL FJ, 1984, EMBO J, V3, P113, DOI 10.1002/j.1460-2075.1984.tb01770.x; FASANO O, 1978, EUR J BIOCHEM, V89, P557, DOI 10.1111/j.1432-1033.1978.tb12560.x; FASANO O, 1982, J BIOL CHEM, V257, P3145; GORDON J, 1968, P NATL ACAD SCI USA, V59, P179, DOI 10.1073/pnas.59.1.179; GUMUSEL F, 1990, BIOCHIM BIOPHYS ACTA, V1050, P215, DOI 10.1016/0167-4781(90)90169-3; IVELL R, 1981, BIOCHEMISTRY-US, V20, P6852, DOI 10.1021/bi00527a017; JACQUET E, 1992, J BIOL CHEM, V267, P24181; JACQUET E, 1988, EMBO J, V7, P2861, DOI 10.1002/j.1460-2075.1988.tb03142.x; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; MISTOU MY, 1992, EUR J BIOCHEM, V204, P179, DOI 10.1111/j.1432-1033.1992.tb16621.x; OTAKA T, 1974, EUR J BIOCHEM, V50, P101, DOI 10.1111/j.1432-1033.1974.tb03876.x; PARLATO G, 1983, J BIOL CHEM, V258, P995; PARMEGGIANI A, 1981, MOL CELL BIOCHEM, V35, P129, DOI 10.1007/BF02357085; PINGOUD A, 1982, EUR J BIOCHEM, V123, P261, DOI 10.1111/j.1432-1033.1982.tb19762.x; PINGOUD A, 1977, EUR J BIOCHEM, V78, P403, DOI 10.1111/j.1432-1033.1977.tb11752.x; SELVA E, 1991, J ANTIBIOT, V44, P693, DOI 10.7164/antibiotics.44.693; SWART GWM, 1987, BIOCHEMISTRY-US, V26, P2047, DOI 10.1021/bi00381a038; WEIJLAND A, 1992, MOL MICROBIOL, V6, P683, DOI 10.1111/j.1365-2958.1992.tb01516.x	29	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24622	24628						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227020				2022-12-25	WOS:A1993MG67300020
J	BARZILAI, N; ROSSETTI, L				BARZILAI, N; ROSSETTI, L			ROLE OF GLUCOKINASE AND GLUCOSE-6-PHOSPHATASE IN THE ACUTE AND CHRONIC REGULATION OF HEPATIC GLUCOSE FLUXES BY INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER GLUCOKINASE; MESSENGER-RNA; MICROSOMAL GLUCOSE-6-PHOSPHATASE; DIABETIC RATS; GENE; SEQUENCE; PATHOGENESIS; SUPPRESSION; EXTRACTS; ISLET	Increased hepatic glucose production (HGP) is the major cause of fasting hyperglycemia in all forms of diabetes. Glucokinase (GK) and glucose-6-phosphatase (Glc-6-Pase) are the proximal and the distal enzymatic steps, respectively, in the regulation of HGP. We examined the impact of changes in GK and Glc-6-Pase activities on in vivo hepatic glucose fluxes in diabetic (D) and control (C) rats. In particular, the acute regulation by insulin was investigated using the euglycemic hyperinsulinemic clamp technique in conscious rats. In experimental diabetes (6 weeks): (a) GK mRNA was decreased by almost-equal-to 40%; (b) the V(max) of GK was markedly decreased (almost-equal-to 4 versus 9 mumol/g wet weight/min) and that of Glc-6-Pase was 2-fold increased (almost-equal-to 30 versus 15 mumol/g wet weight/min, D versus C), while (c) the K(m) of GK (almost-equal-to 10 mM) and Glc-6-Pase (almost-equal-to 1.5 mM) were unchanged. HGP was increased by 65% in diabetes and correlated highly with the ratio of Glc-6-Pase/GK (r = 0.81, p < 0.01). Following acute hyperinsulinemia (2 h): (a) GK mRNA increased by approximately 2-fold in both C and D; (b) GK V(max) did not change in C, but doubled to near-normal in D; (c) Glc-6-Pase V(max) decreased by 23% in C and by 34% in D; (d) the K(m) of GK decreased by almost-equal-to 40% (p < 0.01) in C. Acute hyperinsulinemia almost completely inhibited HGP in both C and D, and no correlation was demonstrated between HGP and the ratio of Glc-6-Pase/GK in these groups. Our data suggest that GK and Glc-6-Pase are important determinants of fasting HGP in diabetes. However, acute changes in Glc-6-Pase and GK activities can account for only a small portion of the in vivo inhibition of hepatic glucose flux by insulin, suggesting additional mechanisms for the short-term regulation of HGP.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DIV ENDOCRINOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,CTR DIABET RES & TRAINING,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NIDDK NIH HHS [DK 20541, R029-DK 42177] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADER M, 1990, AM J PHYSIOL, V258, pE1020, DOI 10.1152/ajpendo.1990.258.6.E1020; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; ASHMORE J, 1959, VITAM HORM NY, V18, P91; BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910; BRADLEY DC, 1993, DIABETES, V42, P296, DOI 10.2337/diabetes.42.2.296; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DETHEUX M, 1991, EUR J BIOCHEM, V200, P553, DOI 10.1111/j.1432-1033.1991.tb16218.x; Foglia Virgilio G., 1944, REV SOC ARGENTINA BIOL, V20, P21; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GIACCA A, 1992, J CLIN INVEST, V90, P1769, DOI 10.1172/JCI116051; GIACCARI A, 1989, J CHROMATOGR-BIOMED, V497, P69, DOI 10.1016/0378-4347(89)80006-4; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; GIDHJAIN M, 1993, P NATL ACAD SCI USA, V90, P1932, DOI 10.1073/pnas.90.5.1932; HAYZER DJ, 1990, BIOCHEM J, V270, P261, DOI 10.1042/bj2700261; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; KEDZIERSKI W, 1991, BIOTECHNIQUES, V10, P210; KORANYI LI, 1992, DIABETES, V41, P807, DOI 10.2337/diabetes.41.7.807; LANGE AJ, 1986, J BIOL CHEM, V261, P101; LIANG Y, 1991, J BIOL CHEM, V266, P6999; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MICHAL G, 1985, METHODS ENZYMATIC AN, V6; MITHIEUX G, 1990, J BIOL CHEM, V265, P20364; NEWGARD CB, 1984, DIABETES, V33, P192, DOI 10.2337/diabetes.33.2.192; NIEWOEHNER CB, 1988, DIABETES, V37, P1559, DOI 10.2337/diabetes.37.11.1559; PILKIS SJ, 1970, BIOCHIM BIOPHYS ACTA, V215, P461, DOI 10.1016/0304-4165(70)90097-8; PRAGER R, 1987, DIABETES, V36, P607, DOI 10.2337/diabetes.36.5.607; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROSSETTI L, 1993, IN PRESS J CLIN INVE; SIBROWSKI W, 1984, J BIOL CHEM, V259, P343; SPENCE JT, 1983, J BIOL CHEM, V258, P9143; SPETH M, 1981, BIOCHEM BIOPH RES CO, V99, P134, DOI 10.1016/0006-291X(81)91723-X; SUZUKI S, 1984, BIOCHEM BIOPH RES CO, V118, P40, DOI 10.1016/0006-291X(84)91064-7; TANIZAWA Y, 1991, P NATL ACAD SCI USA, V88, P7294, DOI 10.1073/pnas.88.16.7294; TSANG SS, 1993, BIOTECHNIQUES, V14, P380; VRANIC M, 1992, DIABETES, V41, P1188, DOI 10.2337/diabetes.41.9.1188; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1	41	151	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25019	25025						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227065				2022-12-25	WOS:A1993MG67300075
J	VERKADE, HJ; FAST, DG; RUSINOL, AE; SCRABA, DG; VANCE, DE				VERKADE, HJ; FAST, DG; RUSINOL, AE; SCRABA, DG; VANCE, DE			IMPAIRED BIOSYNTHESIS OF PHOSPHATIDYLCHOLINE CAUSES A DECREASE IN THE NUMBER OF VERY-LOW-DENSITY LIPOPROTEIN PARTICLES IN THE GOLGI BUT NOT IN THE ENDOPLASMIC-RETICULUM OF RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEP G2 CELLS; APOLIPOPROTEIN-B; SECRETION; MEMBRANE; TRANSLOCATION; DEGRADATION; HEPATOCYTES; FRACTIONS; DEFICIENT; PROTEINS	We have investigated the mechanism by which inhibition of phosphatidylcholine biosynthesis in rat hepatocytes by choline deprivation causes a reduction in the secretion of very low density lipoprotein (VLDL) (Yao, Z., and Vance, D. E. (1988) J. Biol. Chem. 263, 2998-3004). Rats ingested a choline-deficient or control diet for 3 days, and subcellular fractions of liver were prepared. No change in the amount of apolipoprotein B in the lumina of the endoplasmic reticulum was observed, but there was a 40-50% decrease of apolipoprotein B in the lumina of the Golgi from choline-deficient compared with control rats. Incubation of microsomes, derived from choline-deficient and -supplemented hepatocytes, with trypsin showed similar degradation of apolipoprotein B, indicating similar quantities of this protein are present on the surface and within the lumina. The VLDL particles in the Golgi of liver cells and in plasma, on average, were larger in samples derived from choline-deficient compared with choline-supplemented animals. Incubation of plasma VLDL with proteases demonstrated that the apolipoprotein B of plasma VLDL particles from choline-deficient animals had a different susceptibility to digestion than did VLDL from choline-supplemented animals. These data indicate that the number of VLDL particles assembled in the endoplasmic reticulum of liver is similar in choline-deficient and -supplemented rats, but the number of particles is decreased in the Golgi from choline-deficient animals.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA	University of Alberta; University of Alberta				Verkade, Henkjan J/0000-0002-7034-2861				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, PROG LIPID RES, V30, P205; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; DASHTI N, 1991, PROG LIPID RES, V30, P219, DOI 10.1016/0163-7827(91)90018-Z; Davis R.A., 1991, BIOCH LIPIDS LIPOPRO, P403; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GIBBONS GF, 1990, BIOCHEM J, V268, P1; HAMILTON RL, 1991, J LIPID RES, V32, P529; HBOSTROM K, 1986, J BIOL CHEM, V261, P13800; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P412, DOI 10.1016/0003-2697(88)90208-4; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; ROBINSON BS, 1989, BIOCHEM J, V260, P207, DOI 10.1042/bj2600207; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; SATO R, 1990, J BIOL CHEM, V265, P11880; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANCE JE, 1990, ANNU REV NUTR, V10, P337, DOI 10.1146/annurev.nu.10.070190.002005; WETTERAU JR, 1992, SCIENCE, V258, P999; WILKINSON J, 1992, FEBS LETT, V304, P24, DOI 10.1016/0014-5793(92)80581-Z; YAO Z, 1990, BIOCHEM CELL BIOL, V68, P552, DOI 10.1139/o90-079; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1989, J BIOL CHEM, V264, P11373	33	91	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24990	24996						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227061				2022-12-25	WOS:A1993MG67300070
J	QUALLIOTINEMANN, D; AGWU, DE; ELLENBURG, MD; MCCALL, CE; MCPHAIL, LC				QUALLIOTINEMANN, D; AGWU, DE; ELLENBURG, MD; MCCALL, CE; MCPHAIL, LC			PHOSPHATIDIC-ACID AND DIACYLGLYCEROL SYNERGIZE IN A CELL-FREE SYSTEM FOR ACTIVATION OF NADPH OXIDASE FROM HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; PROTEIN-KINASE-C; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; DEPENDENT SUPEROXIDE PRODUCTION; CHRONIC GRANULOMATOUS-DISEASE; STIMULATED HUMAN-NEUTROPHILS; ADENINE-DINUCLEOTIDE PHOSPHATE; PHOSPHOLIPASE-D ACTIVATION; PHORBOL-MYRISTATE ACETATE; SODIUM DODECYL-SULFATE	NADPH oxidase, the respiratory burst enzyme of human neutrophils, is a multi-component complex that is assembled and activated during stimulation of the cells by inflammatory or phagocytic stimuli. The signal mechanisms leading to activation of the enzyme are unclear, but it is likely that phospholipases are involved. Recent work has shown that phosphatidic acid, the initial product of phospholipase D activation, is a weak activator of NADPH oxidase in a cell-free system. We now show that diacylglycerol enhances the cell-free activation of NADPH oxidase activation by phosphatidic acid. 1,2-Didecanoyl phosphatidic acid (10:0-PA) and 1,2-dioctanoylglycerol (8:0-DG) each increased levels of NADPH oxidase activity in mixtures of membrane and cytosolic fractions about 2-fold. The combination of both lipids increased NADPH oxidase activity approximately 12-fold, indicative of a synergistic response. Fatty acid and neutral lipid metabolites of 10:0-PA or 8:0-DG were ineffective, suggesting activation is directly mediated by phosphatidic acid and diacylglycerol. Activation was time- and concentration-dependent with maximum activation at 30-60 min and a sharp peak of maximal activity at 10 muM 10:0-PA and 30 muM 8:0-DG. In lipid specificity studies, activity of PA or DG decreased with increasing acyl chain length but was restored by introducing unsaturation in the acyl chain. Natural forms of PA stimulated levels of activity comparable to that seen with 10:0-PA. Synthetic and natural phosphatidylserines, but not other phospholipids, could replace phosphatidic acid in the synergistic response. These studies provide direct evidence for a synergistic interaction between phosphatidic acid and diacylglycerol in mediating a cellular function: the assembly and activation of NADPH oxidase. Our results support the concept that the generation of second messenger lipids by phospholipase D is a key step in activation of the respiratory burst enzyme.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT BIOCHEM, MED CTR BLVD, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, INFECT DIS SECT, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center			McPhail, Linda C/D-9505-2013	McPhail, Linda C/0000-0002-8670-306X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI009169, R01AI022564, R01AI009169] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI022564, AI-22564, AI-09169] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, J BIOL CHEM, V266, P23577; ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AGWU DE, 1989, BIOCHEM BIOPH RES CO, V159, P79, DOI 10.1016/0006-291X(89)92407-8; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BASS DA, 1987, J BIOL CHEM, V262, P6643; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; BURN P, 1988, TRENDS BIOCHEM SCI, V13, P79, DOI 10.1016/0968-0004(88)90043-6; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; COX CC, 1986, J IMMUNOL, V136, P4611; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; CURNUTTE JT, 1987, ADV HUM GENET, V16, P229; ENGLISH D, 1991, BIOCHEM BIOPH RES CO, V175, P423, DOI 10.1016/0006-291X(91)91581-V; ERICKSON RW, 1993, FASEB J, V7, pA1059; FUJITA I, 1984, BIOCHEM BIOPH RES CO, V120, P318, DOI 10.1016/0006-291X(84)91256-7; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HONEYCUTT PJ, 1986, J BIOL CHEM, V261, P5900; ISHITOYA J, 1987, BIOCHEM BIOPH RES CO, V144, P1025, DOI 10.1016/S0006-291X(87)80066-9; JALINK K, 1990, J BIOL CHEM, V265, P12232; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; LAMBETH JD, 1988, J BIOENERG BIOMEMBR, V20, P709, DOI 10.1007/BF00762549; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MCPHAIL LC, 1983, J CLIN INVEST, V72, P192, DOI 10.1172/JCI110957; MCPHAIL LC, 1992, GRANULOCYTE RESPONSE, P47; MCPHAIL LC, 1993, NATURAL IMMUNE SYSTE, P63; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; OHTSUKA T, 1989, J BIOCHEM-TOKYO, V106, P259, DOI 10.1093/oxfordjournals.jbchem.a122841; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; PARK JW, 1992, J BIOL CHEM, V267, P19901; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PERRY D, 1993, FASEB J, V7, pA1259; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; RIDER LG, 1987, J BIOL CHEM, V262, P5603; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SERHAN CN, 1983, BIOCHIM BIOPHYS ACTA, V762, P420, DOI 10.1016/0167-4889(83)90007-1; SMITH CD, 1985, J BIOL CHEM, V260, P5875; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RM, 1991, BLOOD, V77, P673; TAKENAWA T, 1985, BIOCHEM PHARMACOL, V34, P1931; TAMURA M, 1988, J BIOL CHEM, V263, P17621; TYAGI SR, 1988, J BIOL CHEM, V263, P13191; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VOLPI M, 1983, BIOCHEM BIOPH RES CO, V112, P957, DOI 10.1016/0006-291X(83)91711-4	69	96	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23843	23849						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226922				2022-12-25	WOS:A1993MF29400024
J	HSU, SL; LIN, YF; CHOU, CK				HSU, SL; LIN, YF; CHOU, CK			RETINOIC ACID BIPHASICALLY REGULATES THE GENE-EXPRESSION OF HEPATITIS-B VIRUS SURFACE-ANTIGEN IN HUMAN HEPATOMA HEP3B CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; X-RECEPTOR; HEPATOCELLULAR-CARCINOMA; RESPONSIVE ELEMENT; RXR-BETA; TRANSCRIPTION; BINDING; LINE; ACTIVATION; ENHANCER	We used human hepatoma Hep3B/C16 cells as a model to examine the effect of all-trans retinoic acid on the gene expression of hepatitis B surface antigen (HBsAg). Hep3B/C16 is a clonal derivative of human hepatoma Hep3B cell which was stably transfected with HBsAg DNA sequences and can produce hepatitis B virus surface antigen. We analyzed the HBsAg product and mRNA in Hep3B/C16 cells which were exposed to retinoic acid for different periods of time. The level of HBsAg started to increase after 24 h and reached maximum at 48 h of retinoic acid treatment. However, the level of HBsAg expression was severely suppressed compared to the control cells after long term (120 h) retinoic acid treatment. Such biphasic regulation of HBsAg production by retinoic acid was paralleled by the changes of HBsAg mRNA. Nuclear run-on assays also demonstrated that the retinoic acid-mediated regulation was determined at least in part at the transcriptional level. Furthermore, an exposure of the cells to retinoic acid for only 8 h was sufficient to show that up- and down-regulation of HBsAg gene occurred 2 and 5 days later. Using a transient expression system, we demonstrated that the retinoic acid response element is located within the 5'-flanking region of the HBsAg gene.	VET GEN HOSP TAIPEI,DEPT MED RES,201,SECT 2,SHIH PAI RD,TAIPEI 11217,TAIWAN; NATL YANG MING MED COLL,GRAD INST MICROBIOL & IMMUNOL,TAIPEI,TAIWAN; ACAD SINICA,INST BIOMED SCI,TAIPEI 112,TAIWAN	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan								ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; BYVOET P, 1986, BIOCH BIOPHY ACTA, V867, P152; CHOU CK, 1992, HEPATOLOGY, V16, P13, DOI 10.1002/hep.1840160104; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; HSU SL, 1992, BIOCHEM J, V283, P611, DOI 10.1042/bj2830611; HUAN BF, 1992, P NATL ACAD SCI USA, V89, P9059, DOI 10.1073/pnas.89.19.9059; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; NEILSEN DA, 1983, P NATL ACAD SCI USA, V80, P5198; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; Roberts A.B., 1984, RETINOIDS, V2, P210; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SPORN MB, 1983, CANCER RES, V43, P3034; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TURKASPA R, 1986, P NATL ACAD SCI USA, V83, P1627, DOI 10.1073/pnas.83.6.1627; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	25	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23093	23097						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226826				2022-12-25	WOS:A1993MF51500023
J	JOSEPH, SK; RYAN, SV				JOSEPH, SK; RYAN, SV			PHOSPHORYLATION OF THE INOSITOL TRISPHOSPHATE RECEPTOR IN ISOLATED RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-DEPENDENT PHOSPHORYLATION; 1,4,5-TRISPHOSPHATE RECEPTOR; OKADAIC-ACID; PROTEIN-KINASE; CA2+ RELEASE; LUMINAL CA2+; CALCIUM; CA-2+; LIVER; BIOSYNTHESIS	The inositol trisphosphate receptor (IP3R) in brain has been shown to be a substrate for several different protein kinases in vitro. We have studied the phosphorylation of the IP3R in intact cells by using isolated hepatocytes and an antibody to immunoprecipitate the receptor protein from detergent extracts. Stimulation of P-32-labeled hepatocytes with glucagon or N6,2'-O-dibutyryladenosine 3',5'-cyclic monophosphate (db-cAMP) markedly increased phosphorylation of the IP3R. However, no increase was observed in response to angiotensin II, vasopressin, 12-O-tetradecanoyl-phorbol-13-acetate, or epidermal growth factor. The kinetics of phosphorylation in response to glucagon was both rapid and transient. In agreement with previous studies, physiological concentrations of Ca2+ stimulated D-myo-inositol 1,4,5-trisphosphate (IP3) binding to permeabilized hepatocytes (Pietri, F., Hilly, M., and Mauger, J.-P. (1990) J. Biol. Chem. 265, 17478-17485). Pretreatment of cells with db-cAMP had no effect on binding in the absence of added Ca2+ but enhanced binding measured in the presence of basal low concentrations (0.16-0.25 muM) of Ca2+ and decreased the concentration of Ca2+ required for half-maximal stimulation. The effect of db-cAMP was associated with an increase in affinity of the IP3 binding site without a change in maximum number of binding sites. Preincubation of intact hepatocytes with okadaic acid alone produced an increase in basal phosphorylation of the IP3R, and maximal phosphorylation of the receptor was observed in the presence of both okadaic acid and db-cAMP. However, okadaic acid blocked the effect of db-cAMP and inhibited the effect of Ca2+ on IP3 binding. Detergent-solubilized binding sites were already fully activated and insensitive to modulation by Ca2+ or cAMP-dependent protein kinase. It is proposed that the receptor in native membranes is inhibited and that Ca2+ and cAMP-dependent protein kinase may act to relieve this inhibition.			JOSEPH, SK (corresponding author), THOMAS JEFFERSON UNIV,DEPT PATHOL & CELL BIOL,RM 230A JAH,1020 LOCUST ST,PHILADELPHIA,PA 19107, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-07186] Funding Source: Medline; NIDDK NIH HHS [R01-DK-34804] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLAIR JB, 1986, HORMONAL CONTROL GLU, P143; BOND JM, 1991, CELL SIGNAL, V3, P607, DOI 10.1016/0898-6568(91)90037-U; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; BUSHFIELD M, 1991, BIOCHEM J, V274, P317, DOI 10.1042/bj2740317; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DOSKELAND AP, 1992, EUR J BIOCHEM, V206, P161, DOI 10.1111/j.1432-1033.1992.tb16913.x; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GARCIASAINZ JA, 1991, BIOCHEM BIOPH RES CO, V179, P852, DOI 10.1016/0006-291X(91)91896-K; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HATCH GM, 1992, J BIOL CHEM, V267, P15751; HATCH GM, 1992, J BIOL CHEM, V267, P12443; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HIGASHI K, 1991, FASEB J, V5, pA796; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; JOSEPH SK, 1985, J BIOL CHEM, V260, P2508; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; LAI Y, 1990, J BIOL CHEM, V265, P20839; MATTER N, 1993, J BIOL CHEM, V268, P732; MATTINGLY RR, 1992, FEBS LETT, V296, P225, DOI 10.1016/0014-5793(92)80385-T; MAUGER JP, 1989, J BIOL CHEM, V264, P8821; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PIETRI F, 1990, J BIOL CHEM, V265, P17478; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROUXEL FP, 1992, J BIOL CHEM, V267, P2; STADDON JM, 1987, BIOCHEM J, V241, P729, DOI 10.1042/bj2410729; STADDON JM, 1989, EUR J BIOCHEM, V179, P47, DOI 10.1111/j.1432-1033.1989.tb14519.x; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAYLOR CW, 1992, TRENDS BIOCHEM SCI, V17, P403, DOI 10.1016/0968-0004(92)90009-X; TIJBURG LBM, 1992, BIOCHEM BIOPH RES CO, V182, P1226, DOI 10.1016/0006-291X(92)91862-K; VOLPE P, 1990, AM J PHYSIOL, V258, pC1086, DOI 10.1152/ajpcell.1990.258.6.C1086; ZAMMIT VA, 1992, BIOCHEM J, V284, P901, DOI 10.1042/bj2840901; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	51	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23059	23065						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226822				2022-12-25	WOS:A1993MF51500018
J	KRUPSKY, M; FINE, A; BERK, JL; GOLDSTEIN, RH				KRUPSKY, M; FINE, A; BERK, JL; GOLDSTEIN, RH			THE EFFECT OF RETINOIC ACID ON AMINO-ACID-UPTAKE AND PROTEIN-SYNTHESIS BY LUNG FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SYSTEM-A; GENE-EXPRESSION; THYROID-HORMONE; MESSENGER-RNA; RAT-LIVER; TRANSPORT; MEMBRANE; STIMULATION; RECEPTOR	The effect of retinoic acid (RA) on the uptake and utilization of extracellular amino acids by fetal lung fibroblasts was examined. RA decreased the incorporation of [H-3]proline into collagen and other proteins. The effect was maximal at a RA concentration of 10(-5) M; smaller decreases were observed at a RA concentration of 10(-6) M. This decrease in collagen formation was associated with a large decrease in intracellular [H-3] proline. The decrease in intracellular [H-3]proline was first observed at 2 h following the addition of RA to cell cultures. Transport studies employing radiolabeled amino acids revealed that RA decreased the uptake of proline, 2-aminoisobutyric acid, and 2-(methylamino) isobutyric acid but not leucine or methionine. Kinetic analysis of 2-aminoisobutyric acid uptake indicated that this effect was mediated primarily by an increase in apparent K(m), with a lesser decrease in V(max). RA-induced inhibition of proline uptake was not abolished by the presence of cycloheximide nor by pretreatment with indomethacin. Na+,K+-ATPase activity was not affected by RA treatment. These results suggest that RA modulates protein production in fibroblasts by altering the function of the Na+-dependent A transport system for amino acid uptake.	BOSTON UNIV, SCH MED, CTR PULM, K600, 80 E CONCORD ST, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA; VET ADM MED CTR JAMAICA PLAIN, BOSTON, MA 02130 USA	Boston University; Boston University				Berk, John/0000-0002-1768-2373; Fine, Alan/0000-0001-9351-3048	NHLBI NIH HHS [P01HL-46902] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046902] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALAVOINE S, 1992, J CELL PHYSIOL, V150, P149, DOI 10.1002/jcp.1041500120; BANGHAM AD, 1964, BIOCHEM J, V90, P133, DOI 10.1042/bj0900133; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHAKRABORTY AK, 1990, FEBS LETT, V276, P205, DOI 10.1016/0014-5793(90)80543-R; CHRISTENSEN HN, 1956, J BIOL CHEM, V220, P287; DALLASTA V, 1991, J BIOL CHEM, V266, P1591; DELIMPENS AMPJ, 1980, BRIT J DERMATOL, V103, P319, DOI 10.1111/j.1365-2133.1980.tb07251.x; DINGLE JT, 1965, BIOL REV, V40, P422, DOI 10.1111/j.1469-185X.1965.tb00809.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; GLAUERT AM, 1963, J CELL BIOL, V17, P111, DOI 10.1083/jcb.17.1.111; GOLDSTEIN RH, 1986, J BIOL CHEM, V261, P8734; GOSHIMA K, 1984, J CELL BIOL, V98, P801, DOI 10.1083/jcb.98.3.801; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; ISMAILBEIGI F, 1988, J BIOL CHEM, V263, P8162; JETTEN AM, 1981, ANN NY ACAD SCI, V359, P200, DOI 10.1111/j.1749-6632.1981.tb12748.x; JETTEN AM, 1979, EXP CELL RES, V119, P289, DOI 10.1016/0014-4827(79)90356-2; JETTEN AM, 1982, EXP CELL RES, V138, P494, DOI 10.1016/0014-4827(82)90207-5; JOHNSEN S, 1974, J CELL BIOL, V63, P357, DOI 10.1083/jcb.63.2.357; KAPLOWITZ PB, 1987, J CLIN ENDOCR METAB, V64, P563, DOI 10.1210/jcem-64-3-563; KLIP A, 1982, J CELL PHYSIOL, V113, P56, DOI 10.1002/jcp.1041130111; KRAEMER KH, 1988, NEW ENGL J MED, V318, P1633, DOI 10.1056/NEJM198806233182501; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE RO, 1991, J BIOL CHEM, V266, P16969; LEISTER KJ, 1988, J CELL PHYSIOL, V135, P163, DOI 10.1002/jcp.1041350203; LOGAN WJ, 1982, J CELL PHYSIOL, V112, P229, DOI 10.1002/jcp.1041120211; MENDIAZ E, 1986, IN VITRO CELL DEV B, V22, P66, DOI 10.1007/BF02623535; MOFFETT J, 1987, P NATL ACAD SCI USA, V84, P8040, DOI 10.1073/pnas.84.22.8040; OIKARINEN A, 1989, DERMATOLOGICA, V179, P14, DOI 10.1159/000248092; OIKARINEN H, 1985, J CLIN INVEST, V75, P1545, DOI 10.1172/JCI111859; PEARSON D, 1992, J BIOL CHEM, V267, P25364; QIAN NX, 1991, P NATL ACAD SCI USA, V88, P3416, DOI 10.1073/pnas.88.8.3416; SHOTWELL MA, 1983, BIOCHIM BIOPHYS ACTA, V737, P267, DOI 10.1016/0304-4157(83)90003-5; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; Snedecor G.W., 1967, STAT METHODS; SPORN MB, 1984, RETINOIDS, V1, P235; STILLWELL W, 1980, BIOCHEM BIOPH RES CO, V97, P148, DOI 10.1016/S0006-291X(80)80147-1; VILLEREAL ML, 1978, J BIOL CHEM, V253, P8257; WASSALL SR, 1990, METHOD ENZYMOL, V189, P383; WASSALL SR, 1988, BIOCHIM BIOPHYS ACTA, V939, P393, DOI 10.1016/0005-2736(88)90085-5; WHITE MF, 1983, J BIOL CHEM, V258, P8028; WILLIAMS ML, 1981, ARCH DERMATOL, V117, P611, DOI 10.1001/archderm.117.10.611	44	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23283	23288						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226851				2022-12-25	WOS:A1993MF51500053
J	SOMERS, CE; MOSHER, DF				SOMERS, CE; MOSHER, DF			PROTEIN-KINASE-C MODULATION OF FIBRONECTIN MATRIX ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMA FIBRONECTIN; HUMAN-FIBROBLASTS; BINDING; DEGRADATION; DOMAIN; SITES	Fibroblasts have cell surface sites that mediate the assembly of fibronectin (Fn) into the extracellular matrix. Treatment of fibroblasts with kinase inhibitors (ML-7, H7, HA1004, calphostin C, and staurosporine) resulted in the rapid decrease in the binding of I-125-labeled plasma Fn and iodinated amino-terminal fragments of Fn. The dose responses of the four inhibitors suggest that the target kinase is protein kinase C (PKC) rather than the cyclic AMP- or cyclic GMP-dependent kinases. Three different fibroblastic cells were similarly affected. The inhibition was rapid and reversible and could not be overcome by increasing concentrations of Fn. Treatment of fibroblasts with phorbol esters and other agents that activate PKC resulted in increased amounts of I-125-labeled Fn binding to the cell surface. These results imply that Fn matrix assembly is modulated by PKC-mediated phosphorylation.	UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	SOMERS, CE (corresponding author), UNIV WISCONSIN,DEPT MED,MADISON,WI 53706, USA.				NHLBI NIH HHS [HL21644] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ALLENHOFFMANN BL, 1987, J BIOL CHEM, V262, P14361; ALLENHOFFMANN BL, 1988, MOL CELL BIOL, V8, P4234, DOI 10.1128/MCB.8.10.4234; ASANO T, 1984, J PHARMACOL EXP THER, V231, P141; CHECOVICH WJ, 1992, ARTERIOSCLER THROMB, V12, P1122, DOI 10.1161/01.ATV.12.10.1122; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; FOGERTY FJ, 1990, CELL DIFFER DEV, V32, P439, DOI 10.1016/0922-3371(90)90061-Z; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; ITO M, 1986, BIOCHEMISTRY-US, V25, P4179, DOI 10.1021/bi00363a002; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MCKEOWNLONGO PJ, 1989, FIBRONECTIN, P163; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; RENNARD SI, 1981, ARCH BIOCHEM BIOPHYS, V206, P205, DOI 10.1016/0003-9861(81)90082-5; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAITOH M, 1986, BIOCHEM BIOPH RES CO, V140, P280, DOI 10.1016/0006-291X(86)91087-9; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; WOODS A, 1992, J CELL SCI, V101, P277; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	28	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22277	22280						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226736				2022-12-25	WOS:A1993MD34800017
J	STAGSTED, J; OLSSON, L; HOLMAN, GD; CUSHMAN, SW; SATOH, S				STAGSTED, J; OLSSON, L; HOLMAN, GD; CUSHMAN, SW; SATOH, S			INHIBITION OF INTERNALIZATION OF GLUCOSE TRANSPORTERS AND IGF-II RECEPTORS - MECHANISM OF ACTION OF MHC CLASS-I-DERIVED PEPTIDES WHICH AUGMENT THE INSULIN-RESPONSE IN RAT ADIPOSE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; HISTOCOMPATIBILITY ANTIGENS; STIMULATED TRANSLOCATION; POTENTIAL MECHANISM; INTRACELLULAR POOL; 3T3-L1 ADIPOCYTES; ASSOCIATION; BINDING; SURFACE; SYSTEMS	Peptides from the alpha1 domain of the major histocompatibility complex class I antigen (MHC class I), e.g. D(k)-(61-85) and D(k)-(62-85), have been shown previously to augment glucose uptake in insulin-stimulated cells and to inhibit insulin receptor internalization (Stagsted, J., Reaven, G. M., Hansen, T., Goldstein, A., and Olsson, L. (1990) Cell 62, 297-307). We now report that these peptides inhibit by 80-100% the internalization of glucose transporters (GLUT4) and insulin-like growth factor II (IGF-II) receptors in insulin-stimulated cells and correspondingly double insulin-stimulated glucose transport activity and the number of GLUT4 and IGF-II receptors on the cell surface. In addition, the peptides enhance the apparent affinity about 3-fold of IGF-II binding to its receptor. It is concluded that the effects of the peptides on glucose transport and IGF-II binding are a consequence of the peptide-mediated inhibition of internalization of GLUT4 and IGF-II receptor. The active peptides are derived from the alpha1 domain of a MHC class I molecule, suggesting that the latter is involved in regulation of internalization of cell surface integral membrane proteins such as the GLUT4 and IGF-II and insulin receptors.	RECEPTRON INC,CONCORD,CA 94520; UNIV BATH,DEPT BIOCHEM,BATH BA2 7AY,AVON,ENGLAND; NIDDKD,DIABET BRANCH,EXPTL DIABET METAB & NUTR SECT,BETHESDA,MD 20892	University of Bath; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Holman, Geoffrey/0000-0001-7045-1358				APPELL KC, 1988, J BIOL CHEM, V263, P10824; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DUE C, 1986, P NATL ACAD SCI USA, V83, P6007, DOI 10.1073/pnas.83.16.6007; EDIDIN M, 1990, MOL IMMUNOL, V27, P1313, DOI 10.1016/0161-5890(90)90036-Y; EDIDIN M, 1988, IMMUNOL TODAY, V9, P218, DOI 10.1016/0167-5699(88)91218-2; FEHLMANN M, 1985, P NATL ACAD SCI USA, V82, P8634, DOI 10.1073/pnas.82.24.8634; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; LIEGLER T, 1991, P NATL ACAD SCI USA, V88, P6755, DOI 10.1073/pnas.88.15.6755; MATTHAEI S, 1991, DIABETES, V40, P850, DOI 10.2337/diabetes.40.7.850; OKA Y, 1984, P NATL ACAD SCI-BIOL, V81, P4028, DOI 10.1073/pnas.81.13.4028; OKA Y, 1988, J BIOL CHEM, V263, P13432; PHILLIPS ML, 1986, P NATL ACAD SCI USA, V83, P3474, DOI 10.1073/pnas.83.10.3474; SATOH S, 1993, J BIOL CHEM, V268, P17820; SCHREIBER AB, 1984, J CELL BIOL, V98, P725, DOI 10.1083/jcb.98.2.725; SHARON M, 1988, J IMMUNOL, V141, P3512; SIMONSEN M, 1983, ANN INST PASTEUR IMM, VD134, P85, DOI 10.1016/S0769-2625(83)80059-2; SIMONSEN M, 1985, PROG ALLERGY, V36, P151; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SOLANO AR, 1988, P NATL ACAD SCI USA, V85, P5087, DOI 10.1073/pnas.85.14.5087; STAGSTED J, 1990, CELL, V62, P297, DOI 10.1016/0092-8674(90)90367-N; STAGSTED J, 1993, J BIOL CHEM, V268, P1770; STAGSTED J, 1993, P NATL ACAD SCI USA, V90, P7686, DOI 10.1073/pnas.90.16.7686; STAGSTED J, 1991, J BIOL CHEM, V266, P12844; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; VERLAND S, 1989, J IMMUNOL, V143, P945; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; YANG J, 1993, J BIOL CHEM, V268, P4600; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	34	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22809	22813						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226791				2022-12-25	WOS:A1993MD34800091
J	YAN, PF; LI, SL; LIANG, SJ; GIANNINI, S; FUJITAYAMAGUCHI, Y				YAN, PF; LI, SL; LIANG, SJ; GIANNINI, S; FUJITAYAMAGUCHI, Y			THE ROLE OF COOH-TERMINAL AND ACIDIC DOMAINS IN THE ACTIVITY AND STABILITY OF HUMAN INSULIN-RECEPTOR PROTEIN-TYROSINE KINASE STUDIED BY PURIFIED DELETION MUTANTS OF THE BETA-SUBUNIT DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; BACULOVIRUS EXPRESSION SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; BASIC POLYCATIONS; PURIFICATION; AUTOPHOSPHORYLATION; ASSOCIATION; SPECIFICITY; MITOGENESIS	We have previously expressed the human insulin receptor beta subunit domain containing transmembrane and cytoplasmic domains (IRTMTPK) in insect cells, and showed that the purified IRTMTPK was highly active (Li, S. L., Yan, P.-F., Pax, I. B., and Fujita-Yamaguchi, Y. (1992) Biochemistry 31, 12455-12462). To investigate the role of COOH-terminal and acidic domains of the insulin receptor kinase, we have expressed deletion mutants IRTMTPKDELTACT (DELTA76 amino acids) and IRTMTPKDELTAAcid (DELTA19 amino acids). Both enzymes were purified by a one-step method using the same immunoaffinity column as used for IRTMTPK. While K(m) and V(max) for prephosphorylated IRTMTPK and DELTAAcid mutant enzyme determined using poly(Glu, Tyr) (4:1) were similar, catalytic efficiency of the DELTACT mutant enzyme was significantly lower than those of IRTMTPK and DELTAAcid mutant enzyme as judged by K(m) and V(max). Experiments for thermostability and susceptibility to proteases revealed that T(m) of DELTACT mutant enzyme was 3.5-degrees-C lower than that of IRTMTPK enzyme (=33.3-degrees-C) and that DELTACT mutant enzyme was digested by either trypsin or Lys-C into a 28,000 core domain much faster than IRTMTPK. Activation of DELTACT mutant enzyme by polylysine was less significant than that of IRTMTPK and DELTAAcid mutant enzyme, approximately 4-versus approximately 17-fold. These studies suggested that the COOH-terminal domain plays important roles in both catalytic efficiency and stability of the insulin receptor kinase, and that the acidic domain by itself is not responsible for kinase activation by polylysine.	CITY HOPE NATL MED CTR,BECKMAN RES INT,DEPT MOLEC GENET,1450 E DUARTE RD,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034427] Funding Source: NIH RePORTER; NCI NIH HHS [CA33572] Funding Source: Medline; NIDDK NIH HHS [DK34427] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDO A, 1992, J BIOL CHEM, V267, P12788; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BIENER Y, 1990, EUR J BIOCHEM, V194, P243, DOI 10.1111/j.1432-1033.1990.tb19449.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FUJITAYAMAGUCHI Y, 1989, BIOCHEM J, V263, P813, DOI 10.1042/bj2630813; FUJITAYAMAGUCHI Y, 1983, J BIOL CHEM, V258, P5045; FUJITAYAMAGUCHI Y, 1985, CANCER CELL, V3, P123; FUNG MC, 1988, J VIROL METHODS, V19, P33, DOI 10.1016/0166-0934(88)90005-5; KATHURIA S, 1986, P NATL ACAD SCI USA, V83, P8570, DOI 10.1073/pnas.83.22.8570; KOCK CA, 1991, SCIENCE, V252, P668; KOHANSKI RA, 1989, J BIOL CHEM, V264, P20984; LI SL, 1992, BIOCHEMISTRY-US, V31, P12455, DOI 10.1021/bi00164a023; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MORRISON BD, 1989, J BIOL CHEM, V264, P9994; MYERS MG, 1991, J BIOL CHEM, V266, P10616; ROSEN OM, 1988, FEBS LETT, V231, P397, DOI 10.1016/0014-5793(88)80858-5; SAHAL D, 1988, ARCH BIOCHEM BIOPHYS, V260, P416, DOI 10.1016/0003-9861(88)90465-1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; THIES RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; XU ZY, 1991, BIOCHEMISTRY-US, V30, P11811; YAMAMOTO K, 1992, ENDOCRINOLOGY, V130, P1490, DOI 10.1210/en.130.3.1490; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZICK Y, 1983, J BIOL CHEM, V258, P3431	27	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22444	22449						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226752				2022-12-25	WOS:A1993MD34800041
J	DEMPSEY, PJ; COFFEY, RJ				DEMPSEY, PJ; COFFEY, RJ			BASOLATERAL TARGETING AND EFFICIENT CONSUMPTION OF TRANSFORMING GROWTH FACTOR-ALPHA WHEN EXPRESSED IN MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; TGF-ALPHA; CYTOPLASMIC DOMAIN; TRANSGENIC MICE; IMMUNOCYTOCHEMICAL LOCALIZATION; MEMBRANE-PROTEINS; KINASE-ACTIVITY; SORTING SIGNAL; MAMMARY-GLAND	To investigate the trafficking of transforming growth factor-alpha precursor (pro-TGF-alpha) in polarized epithelial cells, wild type and membrane-fixed human pro-TGF-alpha were introduced into Madin-Darby canine kidney (MDCK) cells. We show that wild type pro-TGF-alpha was synthesized and processed normally to release mature 5.6-KDa TGF-alpha into the basal medium while membrane-fixed pro-TGF-alpha remained cell-associated. Antibody (mAb-528) receptor blockade experiments demonstrated the efficient consumption of basally released TGF-alpha by basolateral epidermal growth factor receptors, indicating that TGF-alpha can act in an autocrine manner in these polarized epithelial cells. Biochemical analysis showed pro-TGF-alpha was expressed on the basolateral surface as either a 17- or 30-kDa species; the 17-kDa forms of both pro-TGF-alpha constructs had basolateral/apical ratios of >20:1. By confocal microscopy, membrane-fixed pro-TGF-alpha was immunolocalized to lateral membrane surfaces. In pulse-chase experiments combined with cell surface immunoprecipitation, we demonstrated that newly synthesized wild type and membrane-fixed pro-TGF-alpha are delivered directly to the basolateral surface with 94 and 96% efficiency, respectively. These results also provide direct evidence for sequential cleavage of pro-TGF-alpha at the basolateral membrane surface. Thus, pro-TGF-alpha is sorted intracellularly and vectorially targeted to the basolateral membrane domain in these polarized epithelial cells. The MDCK cell line provides an ideal in vitro model to examine the molecular basis for trafficking of pro-TGF-alpha and other epidermal growth factor-like growth factors in polarized epithelial cells and their potential interactions with basolateral epidermal growth factor receptors.	VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232	Vanderbilt University	DEMPSEY, PJ (corresponding author), VANDERBILT UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,C-2104 MED CTR N,NASHVILLE,TN 37232, USA.				NCI NIH HHS [CA46413, CA09592-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009592, R01CA046413] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; Bosenberg MW, 1993, CURR OPIN CELL BIOL, V5, P832, DOI 10.1016/0955-0674(93)90032-L; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRANDLI AW, 1991, J BIOL CHEM, V266, P8560; BREWER CB, 1991, J CELL BIOL, V114, P314; BURWEN SJ, 1984, J CELL BIOL, V99, P1259, DOI 10.1083/jcb.99.4.1259; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; FULLER SD, 1986, J CELL BIOL, V103, P1767, DOI 10.1083/jcb.103.5.1767; GILL GN, 1984, J BIOL CHEM, V259, P7755; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GRAEVE L, 1989, J CELL BIOL, V109, P2809, DOI 10.1083/jcb.109.6.2809; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALTER SA, 1992, AM J PATHOL, V140, P1131; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; JU WD, 1991, NEW BIOL, V3, P380; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MASUI H, 1993, J CELL BIOL, V120, P85, DOI 10.1083/jcb.120.1.85; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MULLIN JM, 1988, CANCER RES, V48, P4886; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; OJAKIAN GK, 1988, J CELL BIOL, V107, P2377, DOI 10.1083/jcb.107.6.2377; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SALIDO EC, 1986, J ULTRA MOL STRUCT R, V96, P105, DOI 10.1016/0889-1605(86)90011-X; SALIDO EC, 1986, J HISTOCHEM CYTOCHEM, V34, P1155, DOI 10.1177/34.9.2426343; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHEVING LA, 1989, J BIOL CHEM, V264, P1735; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SIEMERS KA, 1993, SCIENCE, V260, P554, DOI 10.1126/science.260.5107.554; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; STHILAIRE RJ, 1983, P NATL ACAD SCI-BIOL, V80, P3797; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; VAUGHAN TJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P322, DOI 10.1016/0167-4781(92)90170-5; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WOLNER DA, 1992, J CELL BIOL, V116, P889; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZURZOLO C, 1993, SCIENCE, V260, P550, DOI 10.1126/science.8386394	64	84	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16878	16889						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207010				2022-12-25	WOS:A1994NR29600056
J	BENDER, CJ; ROSENZWEIG, AC; LIPPARD, SJ; PEISACH, J				BENDER, CJ; ROSENZWEIG, AC; LIPPARD, SJ; PEISACH, J			NUCLEAR HYPERFINE COUPLING OF NITROGEN IN THE COORDINATION SPHERE OF THE DIIRON CENTER OF METHANE MONOOXYGENASE HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-ECHO; METHYLOCOCCUS-CAPSULATUS-BATH; METHYLOSINUS-TRICHOSPORIUM OB3B; IRON-SULFUR PROTEINS; PARAMAGNETIC RESONANCE; MONO-OXYGENASE; HEME COMPOUNDS; COMPONENT; MODULATION; COMPLEXES	Electron spin echo envelope modulation spectroscopy identified two ligand N-14 interactions with the mixed-valence, Fe(II/III) diiron center of methane monooxygenase hydroxylase from Methylococcus capsulatus (Bath). Characteristic features of the spectra obtained at 9 and 10 GHz were analyzed and fit by simulation. One of the nitrogens possessed superhyperfine parameters (A(iso) = 0.8 MHz, r(eff) = 3.2 Angstrom, e(2)Qq = 1.8 MHz, eta = 0.35) consistent with a non-coordinating amino nitrogen of a histidine imidazole ligand to a Fe(III). The second, more strongly interacting nitrogen (A(iso) = 5.0 MHz, r(eff) = 2.2 Angstrom e(2)Qq = 3.0 MHz, eta = 0.3) corresponds to the N-delta directly bound to the effective Fe(II). These findings extend the previous electron nuclear double resonance results on the Methylosinus trichosporium hydroxylase (Hendrich, M. P., Fox, B. G., Andersson, K. K,, Debrunner, P. G., and Lipscomb, J. D. (1992) J. Biol. Chem. 267, 261-269), which identified the N-delta-Fe(II) interaction but failed to quantify its magnitude. Measurement of the linear electric field g shift of this mixed-valence species indicated that the site is charge-polarized on to one of the iron atoms, and its symmetry suggests that either charge is shifted away from the Fe-Fe axis (if g(max) is defined by the Fe-Fe axis) or that g(mid) and g(max) are perpendicular to the Fe-Fe axis (charge strongly localized at Fe(III) and axis taken as g(min)).	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	BENDER, CJ (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NCRR NIH HHS [RR-02583] Funding Source: Medline; NIGMS NIH HHS [GM-40168, GM-32134] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032134, R01GM032134, R01GM040168, R37GM040168] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTANAITIS BC, 1985, J BIOL CHEM, V260, P4572; ANTHONY C, 1982, BIOCH METHYLOTROPHS, P296; ASHBY CIH, 1978, J AM CHEM SOC, V100, P6057, DOI 10.1021/ja00487a014; BLUMBERG WE, 1974, ARCH BIOCHEM BIOPHYS, V162, P502, DOI 10.1016/0003-9861(74)90210-0; CAMMACK R, 1988, BIOCHIM BIOPHYS ACTA, V956, P307, DOI 10.1016/0167-4838(88)90148-3; COLBY J, 1978, BIOCHEM J, V171, P461, DOI 10.1042/bj1710461; COLBY J, 1977, BIOCHEM J, V165, P395, DOI 10.1042/bj1650395; CORNELIUS JB, 1990, J PHYS CHEM-US, V94, P6977, DOI 10.1021/j100381a013; DEROSE VJ, 1993, J AM CHEM SOC, V115, P6440, DOI 10.1021/ja00067a081; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; ERICSON A, 1988, J AM CHEM SOC, V110, P2330, DOI 10.1021/ja00215a070; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1993, J AM CHEM SOC, V115, P3688, DOI 10.1021/ja00062a039; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V30, P1892; HENDRICH MP, 1992, J BIOL CHEM, V267, P261; KOSMAN DJ, 1980, BIOCHEMISTRY-US, V19, P1304, DOI 10.1021/bi00548a007; LOBRUTTO R, 1987, ADV MEMBRANE BIOCH B, P449; MAGLIOZZO RS, 1993, BIOCHEMISTRY-US, V32, P8446, DOI 10.1021/bi00084a009; MCCRACKEN J, 1987, J AM CHEM SOC, V109, P4064, DOI 10.1021/ja00247a037; MIMS WB, 1984, J MAGN RESON, V59, P291, DOI 10.1016/0022-2364(84)90174-4; MIMS WB, 1974, REV SCI INSTRUM, V45, P1583, DOI 10.1063/1.1686567; MIMS WB, 1972, PHYS REV B-SOLID ST, V5, P2409, DOI 10.1103/PhysRevB.5.2409; MIMS WB, 1976, J CHEM PHYS, V64, P1074, DOI 10.1063/1.432294; MIMS WB, 1974, BIOCHEMISTRY-US, V13, P3346, DOI 10.1021/bi00713a026; MIMS WB, 1978, J CHEM PHYS, V69, P4921, DOI 10.1063/1.436479; MIMS WB, 1976, LINEAR ELECTRIC FIEL; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; PEISACH J, 1977, J BIOL CHEM, V252, P5643; PEISACH J, 1979, J BIOL CHEM, V254, P2379; RIST GH, 1970, J CHEM PHYS, V52, P4633, DOI 10.1063/1.1673696; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; STENKAMP RE, 1984, J AM CHEM SOC, V106, P618, DOI 10.1021/ja00315a027; THOMANN H, 1993, J AM CHEM SOC, V115, P8881, DOI 10.1021/ja00072a068; WILKINS RG, 1992, CHEM SOC REV, V21, P171, DOI 10.1039/cs9922100171; WOODLAND MP, 1986, BIOCHIM BIOPHYS ACTA, V873, P237, DOI 10.1016/0167-4838(86)90050-6; WOODLAND MP, 1984, J BIOL CHEM, V259, P53	39	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15993	15998						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206895				2022-12-25	WOS:A1994NQ72900010
J	TSINOREMAS, NF; SCHAEFER, MR; GOLDEN, SS				TSINOREMAS, NF; SCHAEFER, MR; GOLDEN, SS			BLUE AND RED-LIGHT REVERSIBLY CONTROL PSBA EXPRESSION IN THE CYANOBACTERIUM SYNECHOCOCCUS SP STRAIN PCC-7942	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; PHOTOSYSTEM-II; GENE-EXPRESSION; HARVESTING COMPLEX; SP STRAIN-PCC-7942; HIGHER-PLANTS; TRANSCRIPTS; FAMILY; INTENSITY; PHYCOERYTHRIN	The three psbA genes encoding the photosystem II D1 protein in Synechococcus sp. strain PCC 7942 respond differentially to an increase in intensity of white light through transcriptional induction of psbAII and psbAIII and accelerated degradation of psbAI and psbAIII messages. We report that the genes exhibit a novel photoreversible response involving blue and red light that is almost indistinguishable from the high-white light response. Transfer of cells from white to low-fluence blue light caused a decrease in the level of the psbAI message and increased levels of psbAII and psbAIII messages, whereas transfer to red or far-red light had little effect. Five min of blue light was sufficient to trigger psbAII and psbAIII induction; five min of subsequent red irradiation attenuated this response, whereas subsequent green or far-red light (or darkness) had no effect. Response to both high and blue light was insensitive to inhibitors of photosynthetic electron transport. We propose that Synechococcus modulates photosystem II biosynthesis in a variable light environment through a photoreception signal pathway, which is independent of photosystem II activity and which is distinct from red/ green-reversible control of chromatically adapting cyanobacteria and the red/far-red-reversible phytochrome of plants.	TEXAS A&M UNIV, DEPT BIOL, COLLEGE STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station					NIGMS NIH HHS [R01 GM37040] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037040] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; Andersson B., 1991, CURRENT TOPICS BIOEN, V16, P1; AUSUBEL FM, 1987, CURR PROTOCOLS MOL B; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BLATT MR, 1983, PLANTA, V159, P267, DOI 10.1007/BF00397535; BRUSSLAN J, 1989, EMBO J, V8, P1237, DOI 10.1002/j.1460-2075.1989.tb03497.x; BRYANT DA, 1986, CAN B FISH AQUAT SCI, V214, P423; BUSTOS SA, 1991, J BACTERIOL, V173, P7525, DOI 10.1128/jb.173.23.7525-7533.1991; BUSTOS SA, 1990, J BACTERIOL, V172, P1998, DOI 10.1128/jb.172.4.1998-2004.1990; BUSTOS SA, 1992, MOL GEN GENET, V232, P221, DOI 10.1007/BF00280000; CAMPBELL D, 1993, PLANT CELL, V5, P451, DOI 10.2307/3869725; CLARKE AK, 1993, P NATL ACAD SCI USA, V90, P9973, DOI 10.1073/pnas.90.21.9973; CONLEY PB, 1985, SCIENCE, V230, P550, DOI 10.1126/science.3931221; CORROCHANO LM, 1988, PLANTA, V174, P315, DOI 10.1007/BF00959516; DEMARSAC NT, 1993, FEMS MICROBIOL LETT, V104, P119; DEMARSAC NT, 1988, METHOD ENZYMOL, V167, P318; FLUHR R, 1986, EMBO J, V5, P2063, DOI 10.1002/j.1460-2075.1986.tb04467.x; FLUHR R, 1986, P NATL ACAD SCI USA, V83, P2358, DOI 10.1073/pnas.83.8.2358; GALLAND P, 1987, P NATL ACAD SCI USA, V84, P104, DOI 10.1073/pnas.84.1.104; GAMBLE PE, 1989, EMBO J, V8, P2785, DOI 10.1002/j.1460-2075.1989.tb08424.x; GILMARTIN PM, 1992, PLANT CELL, V4, P839, DOI 10.1105/tpc.4.7.839; GOLDEN SS, 1986, EMBO J, V5, P2789, DOI 10.1002/j.1460-2075.1986.tb04569.x; GOLDEN SS, 1994, IN PRESS MOL BIOL CY; GROSSMAN AR, 1993, J BACTERIOL, V175, P575, DOI 10.1128/JB.175.3.575-582.1993; HARDING RW, 1981, PLANT PHYSIOL, V68, P745, DOI 10.1104/pp.68.3.745; HARRISON MA, 1991, FEBS LETT, V282, P295, DOI 10.1016/0014-5793(91)80499-S; JONES LW, 1965, J PHYCOL, V1, P7, DOI 10.1111/j.1529-8817.1965.tb04548.x; KALLA SR, 1988, J BACTERIOL, V170, P2961, DOI 10.1128/jb.170.7.2961-2970.1988; KAUFMAN LS, 1993, PLANT PHYSIOL, V102, P333, DOI 10.1104/pp.102.2.333; KUHLEMEIER C, 1987, ANNU REV PLANT PHYS, V38, P221; KULKARNI RD, 1994, J BACTERIOL, V176, P959, DOI 10.1128/JB.176.4.959-965.1994; KULKARNI RD, 1992, J BACTERIOL, V174, P3775, DOI 10.1128/JB.174.11.3775-3781.1992; LI RX, 1993, P NATL ACAD SCI USA, V90, P11678, DOI 10.1073/pnas.90.24.11678; LOMAX TL, 1987, J BACTERIOL, V169, P2675, DOI 10.1128/jb.169.6.2675-2684.1987; LOPEZDIAZ I, 1980, PLANTA, V150, P134, DOI 10.1007/BF00582356; MAZEL D, 1986, NUCLEIC ACIDS RES, V14, P8279, DOI 10.1093/nar/14.21.8279; MUELLER UW, 1991, IDENTIFICATION PROTE; MULLINEAUX CW, 1990, PHOTOSYNTH RES, V23, P297, DOI 10.1007/BF00034860; OELMULLER R, 1988, PLANT PHYSIOL, V88, P1084, DOI 10.1104/pp.88.4.1084; PERISIC O, 1992, PLANT CELL, V4, P831, DOI 10.1105/tpc.4.7.831; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; SCHAEFER MR, 1989, J BACTERIOL, V171, P3973, DOI 10.1128/jb.171.7.3973-3981.1989; SCHAEFER MR, 1990, CURRENT RES PHOTOSYN, P863; Senger H., 1987, BLUE LIGHT RESPONSES; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SMART LB, 1991, EMBO J, V10, P3289, DOI 10.1002/j.1460-2075.1991.tb04893.x; THOMPSON WF, 1991, ANNU REV PLANT PHYS, V42, P423, DOI 10.1146/annurev.pp.42.060191.002231; TOBIN EM, 1985, ANNU REV PLANT PHYS, V36, P569, DOI 10.1146/annurev.pp.36.060185.003033	49	61	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16143	16147						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206914				2022-12-25	WOS:A1994NQ72900031
J	GARCIA, P; SHOELSON, SE; GEORGE, ST; HINDS, DA; GOLDBERG, AR; MILLER, WT				GARCIA, P; SHOELSON, SE; GEORGE, ST; HINDS, DA; GOLDBERG, AR; MILLER, WT			PHOSPHORYLATION OF SYNTHETIC PEPTIDES CONTAINING TYR-MET-X-MET MOTIFS BY NONRECEPTOR TYROSINE KINASES IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; MURINE LEUKEMIA-VIRUS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; BACULOVIRUS EXPRESSION; SIGNAL TRANSDUCTION; P85-ALPHA SUBUNIT; TRANSFORMING GENE; ESCHERICHIA-COLI; SH2 DOMAINS	Several tyrosine phosphorylation sites in the insulin receptor kinase substrate IRS-1 are predicted to be within Tyr-Met-X-Met (YMXM) motifs, and synthetic peptides corresponding to these sequences are excellent substrates for the insulin receptor kinase in vitro (Shoelson, S. E., Chatterjee, S., Chaudhuri, M., and White, M. F. (1992) Proc. Natl. Acad. Sci. U. S. A 89, 2027-2031). In this study, YMXM-containing peptides are shown to act as substrates for two members of the nonreceptor subfamily of tyrosine kinases, v-Src and v-Abl (the transforming gene products of Rous sarcoma virus and Abelson murine leukemia virus, respectively). For v-Src, a baculovirus expression system was used which was capable of producing milligram quantities of pure 60-kDa v-Src in Spodoptera frugiperda (Sf9) cells. The source of v-Abl was an Escherichia coli expression vector that produces a fusion protein of glutathione S-transferase with the abl catalytic domain. The synthetic YMXM-containing peptides had among the highest apparent affinities described to date for either tyrosine kinase, with K(m) values as low as 97 muM for v-Src and v-Abl. Comparisons with the results obtained with the insulin receptor kinase revealed differences in substrate specificity among the enzymes. In particular, v-Src was more tolerant of substitutions at the Met+1 and Met+3 positions in the YMXM motif than either v-Abl or the insulin receptor kinase but was more dependent on the presence of a preceding acidic amino acid. For v-Abl, the presence of threonine at any position in the YMXM motif caused a reduction in catalytic efficiency. Phosphorylated YMXM motifs are recognition elements for binding to the src homology 2 domains of phosphatidylinositol 3'-kinase and additional proteins; hence, differences in specificity of tyrosine kinases toward YMXM-containing proteins may have relevance to downstream signaling events.	SUNY STONY BROOK, SCH MED, DEPT PHYSIOL & BIOPHYS, BASIC SCI TOWER T-6, STONY BROOK, NY 11794 USA; BRIGHAM & WOMENS HOSP, DEPT MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Rockefeller University								BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARNARD JP, 1980, VIROLOGY, V101, P286; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARSTENS EB, 1980, VIROLOGY, V101, P311, DOI 10.1016/0042-6822(80)90511-5; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ERIKSON RL, 1979, P NATL ACAD SCI USA, V76, P6260, DOI 10.1073/pnas.76.12.6260; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FERGUSON B, 1985, J BIOL CHEM, V260, P3652; FOULKES JG, 1985, J BIOL CHEM, V260, P8070; GEAHLEN RL, 1990, PEPT PROT PHOSPH, P239; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR, P302; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINSON AD, 1980, J BIOL CHEM, V255, P1973; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Maniatis T., 1982, MOL CLONING; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PARK S, 1992, J BIOL CHEM, V267, P11612; RADZIEJEWSKI C, 1989, BIOCHEMISTRY-US, V28, P9047, DOI 10.1021/bi00449a013; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TINKER DA, 1988, J BIOL CHEM, V263, P5024; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WONG TW, 1983, J BIOL CHEM, V258, P1022	40	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25146	25151						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227078				2022-12-25	WOS:A1993MG67300090
J	NILES, EG; CHRISTEN, L				NILES, EG; CHRISTEN, L			IDENTIFICATION OF THE VACCINIA VIRUS MESSENGER-RNA GUANYLTRANSFERASE ACTIVE-SITE LYSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-GUANYLATE INTERMEDIATE; CAPPING ENZYME; NUCLEOTIDE-SEQUENCE; DNA-LIGASE; ESCHERICHIA-COLI; (GUANINE-7-)METHYLTRANSFERASE COMPLEX; ADENYLYLATION SITE; LARGE SUBUNIT; GUANYLYLTRANSFERASE; GENE	The vaccinia virus mRNA capping enzyme is a heterodimeric protein containing subunits of 97 and 33 kDa, the products of genes D1R and D12L, respectively. The enzyme catalyzes the first three reactions in the mRNA cap formation pathway: mRNA triphosphatase, guanyltransferase and (guanine-7-)methyltransferase. The guanyltransferase reaction proceeds by way of a covalent enzyme GMP (E-GMP) intermediate (Shuman, S. and Hurwitz, J. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 187-191) in which the GMP is linked to the large subunit through a lysine residue (Toyama, R., Mizumoto, K., Nakahara, Y., Tatsuno, T., and Kaziro, Y. (1983) Eur. J. Biochem. 2, 2195-2201; Roth, M. J., and Hurwitz, J. (1984) J. Biol Chem. 259, 13488-13494). In order to identify the map position of the guanyltransferase active site lysine residue, high specific activity [P-32]E-GMP was prepared. Digestion of the E-GMP with hydroxylamine at pH 9.5 yielded a 31-kDa radioactive fragment derived from amino acids 1-273. Cleavage of E-GMP with cyanogen bromide produced a radioactive peptide of 14 kDa corresponding to amino acids 242-365. Lysine residues are found at positions 244 and 260. Staphylococcus aureus V8 protease digestion of cyanogen bromide-cleaved E-GMP yields a radioactive product of about 5 kDa in molecular mass corresponding to the peptide generated by cleavage at glutamic acid residues 253 and 297, demonstrating that lysine 260 is the site of linkage of GMP.			NILES, EG (corresponding author), SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT BIOCHEM,BUFFALO,NY 14214, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028824] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28824] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG J, 1983, NUCLEIC ACIDS RES, V11, P7145, DOI 10.1093/nar/11.20.7145; BAKER DG, 1985, NUCLEIC ACIDS RES, V13, P8323; BARBOSA E, 1978, J BIOL CHEM, V253, P7692; BARKER DG, 1987, EUR J BIOCHEM, V162, P659, DOI 10.1111/j.1432-1033.1987.tb10688.x; Bornstein P, 1977, Methods Enzymol, V47, P132; CONG PJ, 1993, J BIOL CHEM, V268, P7256; CONG PJ, 1992, J BIOL CHEM, V267, P16424; Drapeau G R, 1977, Methods Enzymol, V47, P189; DUNN JJ, 1981, J MOL BIOL, V148, P303, DOI 10.1016/0022-2836(81)90178-9; Gros E., 1967, METHOD ENZYMOL, V11, P238; GUO PX, 1990, P NATL ACAD SCI USA, V87, P4023, DOI 10.1073/pnas.87.11.4023; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; ISHINO Y, 1986, MOL GEN GENET, V204, P1, DOI 10.1007/BF00330179; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; MORGAN JR, 1984, J VIROL, V52, P206, DOI 10.1128/JVI.52.1.206-214.1984; NILES EG, 1986, VIROLOGY, V153, P96, DOI 10.1016/0042-6822(86)90011-5; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; PENA L, 1993, VIROLOGY, V193, P319, DOI 10.1006/viro.1993.1128; ROTH MJ, 1984, J BIOL CHEM, V259, P3488; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMITT MP, 1987, J MOL BIOL, V193, P479, DOI 10.1016/0022-2836(87)90261-0; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; SMITH GL, 1989, NUCLEIC ACIDS RES, V17, P9051, DOI 10.1093/nar/17.22.9051; THOGERSEN HC, 1985, EUR J BIOCHEM, V147, P325, DOI 10.1111/j.1432-1033.1985.tb08753.x; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; TOYAMA R, 1983, EMBO J, V2, P2195, DOI 10.1002/j.1460-2075.1983.tb01723.x; TUTAS DJ, 1977, J BIOL CHEM, V252, P3092; UPTON C, 1991, VIROLOGY, V183, P773, DOI 10.1016/0042-6822(91)91009-6; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004; [No title captured]	39	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24986	24989						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227060				2022-12-25	WOS:A1993MG67300069
J	WU, LNY; YOSHIMORI, T; GENGE, BR; SAUER, GR; KIRSCH, T; ISHIKAWA, Y; WUTHIER, RE				WU, LNY; YOSHIMORI, T; GENGE, BR; SAUER, GR; KIRSCH, T; ISHIKAWA, Y; WUTHIER, RE			CHARACTERIZATION OF THE NUCLEATIONAL CORE COMPLEX RESPONSIBLE FOR MINERAL INDUCTION BY GROWTH-PLATE CARTILAGE MATRIX VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTATE-DEHYDROGENASE ISOENZYMES; BOUND ALKALINE-PHOSPHATASE; BINDING-PROTEINS; CALCIUM CHANNELS; MEMBRANE; ACCUMULATION; INVITRO; IDENTIFICATION; ASSOCIATION; ANNEXINS	The factors that drive mineralization of matrix vesicles (MV) have proven difficult to elucidate; in the present studies, various detergent, chemical, and enzyme treatments were used to reveal the nature of the nucleational core. Incubation with detergents that permeabilized the membrane enhanced calcification of treated MV incubated in synthetic cartilage lymph. While detergents removed most of the membrane lipid, they left significant amounts of the MV annexins and nearly all of the Ca2+, P(i), and Zn2+. Extraction with 1 M NaCl removed much of the Ca2+ and P(i) present in MV, markedly reducing Ca2+ accumulation; these effects could be prevented by low levels of Ca2+ and P(i) in the NaCl extractant. Treatment with chymotrypsin appeared to damage proteins required for MV mineralization; further treatment with detergents to bypass the membrane reactivated MV mineralization. Treatment of MV with pH 6 citrate removed Ca2+ and P(i), destroying their ability to mineralize; subsequent treatment with detergents did not reactivate these MV. Incubation of the detergent-resistant core with o-phenanthroline complexed Zn2+ and stimulated mineralization; addition of Zn2+ to synthetic cartilage lymph blocked the ability of the core to mineralize. These studies show that once the nucleational core complex is formed, the membrane-enclosed domain is no longer essential for MV calcification. Our findings indicate that the MV core contains two main components as follows: a smaller membrane-associated complex of Ca2+, P(i), phosphatidylserine, and the annexins that nucleates crystalline mineral formation, and a larger pool of Ca2+ and P(i) bound to lumenal proteins. These proteins appear to bind large amounts of mineral ions, stabilize the nucleational complex, and aid its transformation to the first crystalline phase. Once nucleated, the crystalline phase appears to feed on protein-bound mineral ions until external ions enter through the MV ion channels. Zn2+ appears to regulate gating of the ion channels and conversion of the nucleational complex to the crystalline state.	UNIV S CAROLINA, SCH MED, DEPT CHEM & BIOCHEM, 424 A PHYS SCI BLDG, COLUMBIA, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018983] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR18983] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKISAKA T, 1988, CALCIFIED TISSUE INT, V42, P383, DOI 10.1007/BF02556357; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANDERSON HC, 1969, J CELL BIOL, V41, P59, DOI 10.1083/jcb.41.1.59; BAGINSKI ES, 1973, CLIN CHIM ACTA, V46, P46; Bailey R., 1989, CALCIFIED TISSUE INT, P93, DOI DOI 10.1007/978-1-349-09868-2; BANERJEE P, 1990, BIOCHIM BIOPHYS ACTA, V1044, P305, DOI 10.1016/0005-2760(90)90074-8; BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022-5320(67)80034-0; BOSKEY AL, 1980, CALCIFIED TISSUE INT, V32, P139, DOI 10.1007/BF02408533; BOSKEY AL, 1978, METAB BONE DIS RELAT, V1, P137, DOI 10.1016/0221-8747(78)90050-4; BOSKEY AL, 1976, CALCIF TISSUE RES S, V22, P197; CAO X, 1992, Bone and Mineral, V17, P298, DOI 10.1016/0169-6009(92)90757-5; COTMORE JM, 1971, SCIENCE, V172, P1339, DOI 10.1126/science.172.3990.1339; ENNEVER J, 1976, P SOC EXP BIOL MED, V152, P147; GENGE BR, 1992, J BONE MINER RES, V7, P807, DOI 10.1002/jbmr.5650070710; GENGE BR, 1990, J BIOL CHEM, V265, P4703; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GENGE BR, 1991, J BIOL CHEM, V266, P10678; GENGE BR, 1988, J BIOL CHEM, V263, P18513; HALE JE, 1987, J BIOL CHEM, V262, P1916; Holt C, 1989, CALCIFIED TISSUE, P175; HOSOKAWA R, 1992, BONE MINER, V17, P177, DOI 10.1016/0169-6009(92)90732-S; HOSOKAWA R, 1988, J BIOL CHEM, V263, P10045; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJESKA RJ, 1979, CALCIFIED TISSUE INT, V27, P41, DOI 10.1007/BF02441159; MCLEAN FM, 1987, J BIOL CHEM, V262, P10481; REGISTER TC, 1986, J BIOL CHEM, V261, P9354; ROJAS E, 1992, BONE MINER, V17, P214, DOI 10.1016/0169-6009(92)90739-Z; ROJAS E, 1990, J BIOL CHEM, V265, P21207; SAUER GR, 1988, J BIOL CHEM, V263, P13718; SAUER GR, 1989, BONE MINER, V7, P233, DOI 10.1016/0169-6009(89)90080-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALHMU WB, 1990, BONE MINER, V8, P195, DOI 10.1016/0169-6009(90)90105-O; WU LNY, 1991, J BIOL CHEM, V266, P1195; WU LNY, 1991, J BIOL CHEM, V266, P1187; WU LNY, 1989, BONE MINER, V7, P113, DOI 10.1016/0169-6009(89)90069-X; WUTHIER RE, 1975, BIOCHIM BIOPHYS ACTA, V409, P128, DOI 10.1016/0005-2760(75)90087-9; WUTHIER RE, 1977, CALC TISS RES, V23, P125, DOI 10.1007/BF02012777; WUTHIER RE, 1982, CLIN ORTHOP RELAT R, P219; WUTHIER RE, 1992, INT CONGR SER, V1002, P143; WUTHIER RE, 1993, J NUTR, V123, P301, DOI 10.1093/jn/123.suppl_2.301; WUTHIER RE, 1977, CALC TISS RES, V24, P163, DOI 10.1007/BF02223311	42	100	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25084	25094						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227072				2022-12-25	WOS:A1993MG67300083
J	CARRAWAY, KL; CERIONE, RA				CARRAWAY, KL; CERIONE, RA			INHIBITION OF EPIDERMAL GROWTH-FACTOR RECEPTOR AGGREGATION BY AN ANTIBODY-DIRECTED AGAINST THE EPIDERMAL GROWTH-FACTOR RECEPTOR EXTRACELLULAR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; EGF-RECEPTOR; SIGNAL TRANSDUCTION; PLASMA-MEMBRANES; CROSS-LINKING; BINDING-SITE; LIVING CELLS; ACTIVATION; KINASE; AUTOPHOSPHORYLATION	We have examined the perturbation of epidermal growth factor (EGF) receptor-receptor interactions by a monoclonal antibody (13A9) that binds to the receptor extracellular domain. While 13A9 did not inhibit EGF binding, it inhibited energy transfer between fluorescent-labeled EGF molecules bound to receptors in membranes from human A431 cells by 70-100%. This antibody also inhibited EGF-stimulated receptor dimerization in membranes as assessed by chemical cross-linking and Fab fragments of the antibody strongly inhibited the EGF-stimulated dimerization of solubilized receptors when assessed by velocity sedimentation. However, under conditions where 13A9 inhibited receptor-receptor interactions within the plasma membranes, the antibody had no effect on EGF-stimulated receptor autophosphorylation or tyrosine kinase activity toward an exogenous substrate. Moreover, although the antibody significantly inhibited receptor dimerization in A431 cells, it had no effect on EGF-stimulated changes in cytosolic free [Ca2+] or I-125-EGF uptake in these cells, or on EGF-stimulated DNA synthesis in Swiss 3T3 cells. We conclude that the dimerization of the EGF receptors in a membrane environment is not required for full activation of tyrosine kinase activity and that inhibition of the dimerization of a large fraction of EGF receptors in cells does not necessarily inhibit several EGF-mediated cellular responses.	CORNELL UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,SCHURMAN HALL,ITHACA,NY 14853; CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University; Cornell University					NIGMS NIH HHS [GM40654] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CARRAWAY KL, 1991, J BIOL CHEM, V266, P8899; CARRAWAY KL, 1989, J BIOL CHEM, V264, P8699; CARRAWAY KL, 1990, BIOCHEMISTRY-US, V29, P8741, DOI 10.1021/bi00489a034; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COCHET C, 1988, J BIOL CHEM, V263, P3290; CONNELLY PA, 1990, P NATL ACAD SCI USA, V266, P22035; ERICKSON JW, 1991, BIOCHEMISTRY-US, V30, P7112, DOI 10.1021/bi00243a011; FANGER BO, 1989, FASEB J, V3, P71, DOI 10.1096/fasebj.3.1.2783412; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; NORTHWOOD IC, 1989, J BIOL CHEM, V264, P5746; NORTHWOOD IC, 1988, J BIOL CHEM, V263, P7450; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	25	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23860	23867						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226925				2022-12-25	WOS:A1993MF29400027
J	QIU, ZH; DECARVALHO, MS; LESLIE, CC				QIU, ZH; DECARVALHO, MS; LESLIE, CC			REGULATION OF PHOSPHOLIPASE-A(2) ACTIVATION BY PHOSPHORYLATION IN MOUSE PERITONEAL-MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; GROWTH-FACTOR RECEPTOR; OKADAIC ACID; CELL-LINE; MOBILIZING PHOSPHOLIPASE-A2; PROSTAGLANDIN SYNTHESIS; HUMAN-NEUTROPHILS; TUMOR PROMOTER	The regulation of phospholipase A2 (PLA2) activation by phosphorylation, and phosphorylation of an 85-kDa, arachidonoyl-hydrolyzing PLA2 was investigated in mouse peritoneal macrophages. Phorbol 12-myristate 13-acetate (PMA) and okadaic acid, an inhibitor of serine/threonine phosphatases, stimulated arachidonic acid release, supporting a role for phosphorylation events in regulating PLA2 activation. In response to zymosan, PMA, or A23187, arachidonic acid was released at a linear rate up to 30-45 min after stimulation, whereas there was a 30-min lag preceding arachidonic acid release in response to okadaic acid. The 85-kDa PLA2 was phosphorylated on serine in the macrophages, and the level of phosphorylation increased in response to zymosan, PMA, okadaic acid, and, to a lesser extent, A23187. Two-dimensional phosphopeptide mapping revealed multiple phosphopeptides, several of which showed increased phosphorylation in response to zymosan, okadaic acid, and PMA. Zymosan, PMA, A23187, or okadaic acid stimulated time-dependent increases in PLA2 activity in the cytosolic fraction. PLA2 activation was most rapid in response to PMA, whereas activation in response to okadaic acid was delayed similar to the time course of arachidonic acid release. The cytosolic PLA2 had characteristics of the 85-kDa enzyme, including kinetic properties and substrate preference. Phosphatase treatment of the cytosols dephosphorylated the 85-kDa PLA2 and reversed the increase in activity. The results provide evidence that phosphorylation of the 85-kDa PLA2, induced by stimuli that induce arachidonic acid release, is an important mechanism for activation of the enzyme in macrophages.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, 1400 JACKSON ST, DENVER, CO 80206 USA; UNIV COLORADO, SCH MED, DEPT PATHOL, DENVER, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NHLBI NIH HHS [HL 34303, P01 HL034303] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEREM AA, 1986, J EXP MED, V163, P139, DOI 10.1084/jem.163.1.139; ALONSO F, 1986, BIOCHIM BIOPHYS ACTA, V878, P273, DOI 10.1016/0005-2760(86)90156-6; BALSINDE J, 1988, J BIOL CHEM, V263, P1929; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; BONNEY RJ, 1980, BIOCHIM BIOPHYS ACTA, V633, P410, DOI 10.1016/0304-4165(80)90199-3; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; CHAKRABORTI S, 1991, FEBS LETT, V285, P104, DOI 10.1016/0014-5793(91)80735-L; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CLARK MA, 1987, J BIOL CHEM, V262, P4402; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DIEZ E, 1992, J BIOL CHEM, V267, P18342; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DOLE VP, 1960, J BIOL CHEM, V235, P2595; EMILSSON A, 1986, BIOCHIM BIOPHYS ACTA, V876, P533, DOI 10.1016/0005-2760(86)90041-X; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GLASER KB, 1993, BIOCHEM PHARMACOL, V45, P711, DOI 10.1016/0006-2952(93)90147-O; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GOLDBERG HJ, 1990, BIOCHEM J, V267, P461, DOI 10.1042/bj2670461; GOPPELTSTRUBE M, 1987, BIOCHEM J, V247, P773, DOI 10.1042/bj2470773; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1990, METHOD ENZYMOL, V187, P216; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LESLIE CC, 1994, IN PRESS; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOEB LA, 1986, J BIOL CHEM, V261, P467; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OHUCHI K, 1989, BIOCHIM BIOPHYS ACTA, V1013, P86, DOI 10.1016/0167-4889(89)90132-8; PFANNKUCHE HJ, 1989, BIOCHEM J, V260, P471, DOI 10.1042/bj2600471; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RAMESHA CS, 1986, J BIOL CHEM, V261, P7592; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SILK ST, 1989, J BIOL CHEM, V264, P21466; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; SUGA K, 1990, J BIOL CHEM, V265, P12363; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WIJKANDER J, 1989, FEBS LETT, V244, P51, DOI 10.1016/0014-5793(89)81160-3; WIJKANDER J, 1992, FEBS LETT, V311, P299, DOI 10.1016/0014-5793(92)81124-5; XING MZ, 1992, J BIOL CHEM, V267, P25966; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	63	146	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24506	24513						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8227003				2022-12-25	WOS:A1993MF29400116
J	ROBERTSON, BJ; MOEHRING, JM; MOEHRING, TJ				ROBERTSON, BJ; MOEHRING, JM; MOEHRING, TJ			DEFECTIVE PROCESSING OF THE INSULIN-RECEPTOR IN AN ENDOPROTEASE-DEFICIENT CHINESE-HAMSTER CELL STRAIN IS CORRECTED BY EXPRESSION OF MOUSE FURIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS EXOTOXIN-A; MAMMALIAN-CELLS; POINT MUTATION; PRECURSOR; CLEAVAGE; RESISTANCE; PRORECEPTOR; PROTEINS	Characterization of an endoprotease-deficient mutant Chinese hamster ovary (CHO) cell, designated RPE.40, revealed that it bound less than 10% as much insulin as did its parent, CHO-K1. We examined processing of the endogenous insulin receptor in CHO-K1 and RPE.40 cells, and processing of the human insulin receptor expressed in these cells. RPE.40 cells did not process the endogenous insulin proreceptor to its subunit forms, and processed the human insulin proreceptor inefficiently. Accumulation of the proreceptor form of the insulin receptor was seen in both cases. Furin is a mammalian endoprotease that cleaves proproteins at a consensus sequence of basic amino acids found in the insulin proreceptor. Expression of mouse furin in RPE.40 cells restored normal processing of the endogenous and the human insulin receptor in these cells. In addition, expression of mouse furin corrected the reduced binding of insulin in RPE.40 cells, indicating that receptor function as well as processing was restored.	UNIV VERMONT,DEPT MICROBIOL & MOLEC GENET,MARKEY CTR MOLEC GENET,316 STAFFORD BLDG,BURLINGTON,VT 05405; UNIV VERMONT,COLL MED,VERMONT REG CANC CTR,BURLINGTON,VT 05405	University of Vermont; University of Vermont					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009100] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 09100] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; HARRIS RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P315, DOI 10.1016/0003-9861(89)90379-2; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; INOCENCIO NM, 1993, J VIROL, V67, P593, DOI 10.1128/JVI.67.1.593-595.1993; KAKEHI T, 1988, J CLIN INVEST, V81, P2020, DOI 10.1172/JCI113553; KAWAOKA Y, 1988, P NATL ACAD SCI USA, V85, P324, DOI 10.1073/pnas.85.2.324; KOBAYASHI M, 1988, BIOCHEM BIOPH RES CO, V153, P657, DOI 10.1016/S0006-291X(88)81145-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOEHRING JM, 1983, INFECT IMMUN, V41, P998, DOI 10.1128/IAI.41.3.998-1009.1983; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; MOEHRING TJ, 1979, SOMAT CELL GENET, V5, P469, DOI 10.1007/BF01538881; OLSON TS, 1988, J BIOL CHEM, V263, P7342; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; ROBBINS AR, 1984, J CELL BIOL, V99, P1296, DOI 10.1083/jcb.99.4.1296; STEINER DF, 1992, J BIOL CHEM, V267, P23435; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WATSON DG, 1991, J VIROL, V65, P2332, DOI 10.1128/JVI.65.5.2332-2339.1991; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938	22	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24274	24277						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226974				2022-12-25	WOS:A1993MF29400083
J	ROSTAND, KS; ESKO, JD				ROSTAND, KS; ESKO, JD			CHOLESTEROL AND CHOLESTEROL ESTERS - HOST RECEPTORS FOR PSEUDOMONAS-AERUGINOSA ADHERENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; EPITHELIAL-CELLS; CYSTIC-FIBROSIS; ADHESION; BINDING; MUCIN; GLYCOSYLATION; MUTANTS; LECTIN; PILI	Bacterial adherence to tissues is a necessary step in infection and results from interactions between surface molecules on the bacteria (adhesins) and plasma membrane receptors on host cells. Using a clinical isolate of Pseudomonas aeruginosa, we have examined the receptors required for adherence to Chinese hamster ovary (CHO) cells. In mutant CHO cell lines and mucin-producing lung epithelial cell lines, adherence did not depend on glycoproteins, glycolipids, or proteoglycans. Treating cells with glutaraldehyde and proteases also did not affect adherence. However, treating cells with ethanol diminished adherence and resulted in removal of factors that would facilitate binding of bacteria when coated on plastic culture plates. These factors were purified by solvent extraction and silica gel chromatography and were identified as cholesterol and cholesterol esters by coelution with authentic standards, gas chromatography, H-1 NMR, and mass spectrometry. Bacterial adherence was reduced to wild-type CHO cells treated with Lovastatin and to cholesterol-requiring insect cells grown in cholesterol-deficient medium, suggesting that the bacteria bound to plasma membrane cholesterol. Thus, this clinical isolate of Pseudomonas uses cholesterol and cholesterol esters for adherence. We propose that binding to cholesterol and cholesterol esters may affect the pathogenicity of similar Pseudomonas strains.	UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	ROSTAND, KS (corresponding author), UNIV ALABAMA,SCH MED,DEPT BIOCHEM,BIRMINGHAM,AL 35294, USA.				NCI NIH HHS [CA46462] Funding Source: Medline; NIGMS NIH HHS [GM33063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063, R01GM033063] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALOUF JE, 1980, PHARMACOL THERAPEUT, V11, P661, DOI 10.1016/0163-7258(80)90045-5; BADDOUR LM, 1990, PRINCIPLES PRACTICE, P9; BAKER N, 1990, INFECT IMMUN, V58, P2361, DOI 10.1128/IAI.58.7.2361-2366.1990; BHAKDI S, 1984, BACTERIAL PROTEIN TO, P173; BHASKAR K R, 1987, European Journal of Respiratory Diseases Supplement, V71, P215; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CERI H, 1986, INFECT IMMUN, V51, P1; CHI E, 1991, INFECT IMMUN, V59, P822, DOI 10.1128/IAI.59.3.822-828.1991; CRAWFORD SW, 1991, APPROACH PULMONARY I, P173; DALTON JP, 1991, EUR J BIOCHEM, V195, P789, DOI 10.1111/j.1432-1033.1991.tb15767.x; DOIG P, 1988, INFECT IMMUN, V56, P1641, DOI 10.1128/IAI.56.6.1641-1646.1988; DOIG P, 1989, CAN J MICROBIOL, V35, P1141, DOI 10.1139/m89-189; DOIG P, 1990, INFECT IMMUN, V58, P124, DOI 10.1128/IAI.58.1.124-130.1990; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; FEINGOLD DS, 1973, ANTIMICROB AGENTS CH, V4, P309; GALABERT C, 1987, CLIN CHIM ACTA, V164, P139, DOI 10.1016/0009-8981(87)90065-9; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; Krieger M, 1986, Methods Enzymol, V129, P227; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; LORY S, 1985, CURR TOP MICROBIOL, V118, P53; MACKINNON WB, 1992, EUR J BIOCHEM, V205, P827, DOI 10.1111/j.1432-1033.1992.tb16847.x; Miller V. L., 1992, AMS NEWS, V58, P26; MOORE GE, 1964, CANCER, V17, P170, DOI 10.1002/1097-0142(196402)17:2<170::AID-CNCR2820170206>3.0.CO;2-N; MOORHEAD PS, 1965, EXP CELL RES, V39, P190, DOI 10.1016/0014-4827(65)90022-4; PANJWANI N, 1990, INFECT IMMUN, V58, P114, DOI 10.1128/IAI.58.1.114-118.1990; PHALEN T, 1991, J CELL BIOL, V112, P615, DOI 10.1083/jcb.112.4.615; PITT TL, 1990, TOPLEY WILSONS PRINC, P256; Pollack M., 1990, PRINCIPLES PRACTICE, P1673; RAMPHAL R, 1987, INFECT IMMUN, V55, P600, DOI 10.1128/IAI.55.3.600-603.1987; RAMPHAL R, 1984, INFECT IMMUN, V44, P38, DOI 10.1128/IAI.44.1.38-40.1984; RAMPHAL R, 1991, INFECT IMMUN, V59, P1307, DOI 10.1128/IAI.59.4.1307-1311.1991; RAMPHAL R, 1991, INFECT IMMUN, V59, P700, DOI 10.1128/IAI.59.2.700-704.1991; RAVDIN JI, 1989, INFECT IMMUN, V57, P2179, DOI 10.1128/IAI.57.7.2179-2186.1989; REID LM, 1986, EUR J RESPIR DIS, V69, P26; SAIMAN L, 1990, J INFECT DIS, V161, P541, DOI 10.1093/infdis/161.3.541; SAJJAN U, 1992, J CLIN INVEST, V89, P657, DOI 10.1172/JCI115632; SEXTON M, 1992, INFECT IMMUN, V60, P3332, DOI 10.1128/IAI.60.8.3332-3338.1992; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STRANAHAN PL, 1992, CANCER RES, V52, P2923; TODD TRJ, 1989, AM REV RESPIR DIS, V140, P1585, DOI 10.1164/ajrccm/140.6.1585; WIDDICOMBE J G, 1987, European Journal of Respiratory Diseases Supplement, V71, P197; ZHANG JP, 1992, CELL, V69, P861, DOI 10.1016/0092-8674(92)90296-O	48	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24053	24059						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226950				2022-12-25	WOS:A1993MF29400053
J	TYTGAT, J; NAKAZAWA, K; GROSS, A; HESS, P				TYTGAT, J; NAKAZAWA, K; GROSS, A; HESS, P			PURSUING THE VOLTAGE SENSOR OF A VOLTAGE-GATED MAMMALIAN POTASSIUM CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SHAKER K+-CHANNELS; SODIUM-CHANNEL; SUBUNIT STOICHIOMETRY; GATING CHARGE; S4 REGION; RAT-BRAIN; DROSOPHILA; EXPRESSION; CLONING; S4-SEQUENCE	Ion channels are generally classified as voltage- or ligand-gated channels based upon their ability to respond to a change in the transmembrane voltage or to a specific ligand interaction. The voltage sensor of voltage-gated ion channels is thought to be contained within the fourth putative transmembrane segment, S4, and is characterized by basic residues typically spaced apart. Thus far, a full understanding of all charges contributing to the voltage sensor of voltage-gated potassium channels has been lacking since several neutralization mutants in S4 could not be functionally expressed. By construction of multimeric cDNAs encoding a mammalian RCK1 (Kv1.1) potassium channel, we now report functional expression of all charge neutralizations in the S4 segment, providing a more comprehensive insight into the functioning of the voltage sensor.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,PROGRAM NEUROSCI,BOSTON,MA 02115	Harvard University; Harvard Medical School			Tytgat, Jan/F-1560-2010	Tytgat, Jan/0000-0003-1778-6022				ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GILLY WF, 1980, BIOPHYS J, V29, P485, DOI 10.1016/S0006-3495(80)85147-2; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; HILLE B, 1992, IONIC CHANNELS EXCIT, P54; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KOREN G, 1990, NEURON, V2, P39; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; SWENSON RP, 1981, NATURE, V291, P427, DOI 10.1038/291427a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TYTGAT J, 1992, NATURE, V359, P420, DOI 10.1038/359420a0; TYTGAT J, 1993, BIOPHYS J, V64, pA226	29	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23777	23779						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226910				2022-12-25	WOS:A1993MF29400012
J	APODACA, G; MOSTOV, KE				APODACA, G; MOSTOV, KE			TRANSCYTOSIS OF PLACENTAL ALKALINE PHOSPHATASE-POLYMERIC IMMUNOGLOBULIN RECEPTOR FUSION PROTEINS IS REGULATED BY MUTATIONS OF SER(664)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; CYTOPLASMIC DOMAIN; MDCK CELLS; EXPRESSION; SIGNAL; MODEL; IGA	Two signals are known that regulate the entry of the polymeric immunoglobulin receptor (pIgR) into the transcytotic pathway: binding of the ligand, dimeric IgA, and phosphorylation of Ser664 in the cytoplasmic domain of the receptor. Mutation of Ser664 to an alanine residue generates a receptor that is transcytosed slowly and exhibits increased recycling at the basolateral plasma membrane. In contrast, if Ser664 is mutated to an aspartate (which bears a constant negative charge-like a phosphate group) the receptor is transcytosed at a rate that is greater than the wild-type pIgR. We have constructed fusions of placental alkaline phosphatase (PLAP) with the transmembrane region and cytoplasmic domain of the wild-type or mutant pIgRs described above (PLAP/WT, PLAP/Ala. and PLAP/Asp) in order to study transcytotic signals present in the cytoplasmic domain of the pIgR independently of those present in the lumenal domain. Transcytosis of the fusion proteins was measured by cell surface immunoprecipitation of a single cohort of basolaterally biotinylated fusion proteins as it arrived at the apical plasma membrane. Significantly more of the PLAP/WT fusion (27%) than the PLAP/Ala fusion protein (5%) was transcytosed during a 2-h chase period. In addition, it was found that approximately 10% of a pseudoligand, monovalent I-125-labeled Fabs (derived from affinity-purified anti-PLAP antibodies), was transcyosed by the PLAP/WT fusion, 7% by the PLAP/Ala fusion, and 22% by the PLAP/Asp fusion over a 4-h period. These data are consistent with the hypothesis that the cytoplasmic domain of the pIgR contains information necessary to direct proteins into the transcytotic pathway, albeit inefficiently, and that phosphorylation of Ser664 is at least a partially autonomous signal for transcytosis.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	APODACA, G (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, BOX 0452, SAN FRANCISCO, CA 94143 USA.		Apodaca, Gerard/HCJ-0048-2022	mostov, keith/0000-0002-8123-6247	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025144] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI25144] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APODACA G, 1991, J CLIN INVEST, V87, P1877, DOI 10.1172/JCI115211; BRANDTZAEG P, 1981, CLIN EXP IMMUNOL, V44, P221; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; HUNZIKER W, 1991, CELL, V57, P1; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; MCCOMB RB, 1972, CLIN CHEM, V18, P97; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SOLARI R, 1984, CELL, V36, P61, DOI 10.1016/0092-8674(84)90074-6; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327	22	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23712	23719						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226896				2022-12-25	WOS:A1993MF51500112
J	PANAGIOTIDIS, CH; REYES, M; SIEVERTSEN, A; BOOS, W; SHUMAN, HA				PANAGIOTIDIS, CH; REYES, M; SIEVERTSEN, A; BOOS, W; SHUMAN, HA			CHARACTERIZATION OF THE STRUCTURAL REQUIREMENTS FOR ASSEMBLY AND NUCLEOTIDE-BINDING OF AN ATP-BINDING CASSETTE TRANSPORTER - THE MALTOSE TRANSPORT-SYSTEM OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-COMPONENTS; ADENYLATE KINASE; CYTOPLASMIC MEMBRANE; BACTERIOPHAGE-LAMBDA; MULTIDRUG RESISTANCE; HISTIDINE PERMEASE; INDUCER EXCLUSION; ACTIVE-TRANSPORT; CHLORIDE CHANNEL; MALK PROTEIN	The periplasmic maltose-binding protein-dependent, maltose transport system of Escherichia coli is a well studied member of the ATP-binding cassette family of transport ATPases. In addition to the water-soluble maltose-binding protein, the system comprises three membrane proteins, MalF, MalG, and MalK, which form a heterotetrameric complex (FGK2) in the cytoplasmic membrane. The purified complex exhibits transport-associated ATPase activity. To characterize the requirements for nucleotide binding and hydrolysis by the FGK2 complex, we used plasmids to express different combinations of the individual subunits as well as mutant forms of the MalK subunit. Prior to measuring nucleotide binding, we examined membrane preparations for the presence of each subunit from strains that contained all possible permutations of the three structural genes, malF, malG, and malk. We found that when all three genes were present or when malF and malK were present together, the corresponding antigens were detected easily on Western immunoblots and were soluble in the non-ionic detergent, Triton X- 1 00. In contrast, all other permutations resulted in decreased amounts of antigen or antigen that was Triton X-100-insoluble. We relied on photocross-linking with 8-azido-[P-32]ATP and ATP hydrolysis as indicators of the ability of the transport complex to interact with purine nucleotides. 8-Azido-[P-32]ATP was photocross-linked to the MalK subunit. Photolabeling of MalK was inhibited by ATP, ADP, and GTP and not by other nucleotides. Photolabeling of MalK required the presence of MalF but not MalG. Mutations in malk that affect amino acid residues thought to be directly involved in nucleotide binding did indeed abolish labeling and resulted in loss of transport activity without affecting protein stability. In general, ATP hydrolysis correlated with the photocross-linking. A notable exception is the MalK941 mutant protein which retained the ability to be labeled by 8-azido-[P-32]ATP but was unable to catalyze detectable levels of ATP hydrolysis. Some, but not all, of the malK mutations were dominant to wild type. To study the mechanism of dominance we devised a means of measuring the ability of different wild-type and mutant MalK proteins to interact with the MalF and MalG subunits. This assay relies on the fact that, when a bifunctional MalK-LacZ hybrid protein is associated with the MalF and MalG subunits, it is membrane-bound. Excess MalK competed with the MalK-LacZ hybrid protein for sites in the membrane and resulted in the hybrid fractionating as a soluble protein. We found that the mutant MalK proteins encoded by the strongly dominant malk mutations competed with the MalK-LacZ protein as efficiently as wild type. In contrast, the recessive malK mutations encoded MalK mutant proteins that did not compete with the hybrid, indicating that they were partially defective in the ability to interact with either MalF and/or MalG.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; UNIV CONSTANCE,DEPT BIOL,W-7750 CONSTANCE,GERMANY	Columbia University; University of Konstanz					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019276] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19276] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BAVOIL P, 1980, J BIOL CHEM, V255, P8366; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BROSIUS J, 1985, J BIOL CHEM, V260, P3539; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHAPON C, 1982, J BACTERIOL, V150, P722, DOI 10.1128/JB.150.2.722-729.1982; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DASSA E, 1993, MOL MICROBIOL, V7, P29, DOI 10.1111/j.1365-2958.1993.tb01094.x; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DEAN DA, 1989, J BACTERIOL, V171, P503, DOI 10.1128/jb.171.1.503-510.1989; DEAN DA, 1992, MOL MICROBIOL, V6, P2033, DOI 10.1111/j.1365-2958.1992.tb01376.x; DEAN DA, 1990, J BIOL CHEM, V265, P21005; DUPLAY P, 1987, J MOL BIOL, V194, P663, DOI 10.1016/0022-2836(87)90243-9; EMR SD, 1980, J MOL BIOL, V141, P63, DOI 10.1016/S0022-2836(80)80029-5; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; FROSHAUER S, 1984, J BIOL CHEM, V259, P896; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; KUHNAU S, 1991, J BACTERIOL, V173, P2180; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCHAL C, 1978, J BACTERIOL, V136, P1109, DOI 10.1128/JB.136.3.1109-1119.1978; Miller J.H., 1972, EXPT MOL GENETICS; MIMIURA CS, 1991, P NATL ACAD SCI USA, V88, P84; MORALES VM, 1991, GENE, V97, P39, DOI 10.1016/0378-1119(91)90007-X; MULLER CW, 1992, J MOL BIOL, V244, P159; PAL PK, 1992, J BIOL CHEM, V267, P25003; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; RIORDAN JR, 1989, SCIENCE, V245, P1066; RONINSON IB, 1990, PEDIATR PULM, V5, P138; ROSE T, 1991, J BIOL CHEM, V266, P23654; Sambrook J, 1989, MOL CLONING LABORATO; Schwartz M, 1987, ESCHERICHIA COLI SAL, P1482; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SHUMAN HA, 1981, J BIOL CHEM, V256, P560; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Silhavy T.J., 1984, EXPT GENE FUSIONS; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAXLER B, 1992, P NATL ACAD SCI USA, V89, P10852, DOI 10.1073/pnas.89.22.10852; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALTER C, 1992, J BIOL CHEM, V267, P8863	49	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23685	23696						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226895				2022-12-25	WOS:A1993MF51500109
J	PAUDEL, HK; LEW, J; ALI, Z; WANG, JH				PAUDEL, HK; LEW, J; ALI, Z; WANG, JH			BRAIN PROLINE-DIRECTED PROTEIN-KINASE PHOSPHORYLATES TAU ON SITES THAT ARE ABNORMALLY PHOSPHORYLATED IN TAU ASSOCIATED WITH ALZHEIMERS PAIRED HELICAL FILAMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; BIOCHEMICAL-PROPERTIES; DEPENDENT KINASE; BINDING DOMAINS; DISEASE; EPITOPES; TANGLES; STATE; IDENTIFICATION; PURIFICATION	Brain proline-directed protein kinase (BPDK), which contains a catalytic subunit homologous to and displaying site-specific phosphorylation similar to p34cdc2 kinase (Lew,J., Winkfein, R. J., Paudel, H. K., and Wang, J. H. (1992) J. Biol. Chem. 267, 25922-25926), has been examined for possible involvement in tau phosphorylation. Immunoblot analyses using peptide antibodies specific for BPDK have revealed the presence of the kinase in bovine brain microtubules purified extensively by repeated polymerization and depolymerization cycles. When the microtubule proteins are separated into the tubulin and microtubule-associated protein fractions, BPDK is found exclusively in the latter fraction. BPDK phosphorylates both tau and MAP2, the former protein being phosphorylated to a stoichiometry of 3.8 mol of phosphate/mol of tau. Analysis of the phosphopeptides isolated from the tryptic digest of the phosphorylated bovine tau has revealed seven phosphorylation sites. Based on the sequence alignment between bovine and human tau proteins, these sites correspond to Ser-195, Ser-202, Thr-205, Thr-231, Ser-235, Ser-396, and Ser-404 of human tau. Mass spectrometric analysis of the tau protein isolated from Alzheimer's paired helical filaments (PHFs) has determined three abnormal phosphorylation sites and two phosphopeptides containing a total of five abnormal phosphates (Hasegawa, M., Morishima-Kawashima, M., Takio, K., Suzuki, M., Titani, K., and Ihara, Y. (1992) J. Biol. Chem. 267, 17047-17054). Two of the sites in tau phosphorylated by BPDK, Thr-231 and Ser-235, are among the abnormal phosphorylation sites, and the other sites phosphorylated by BPDK are within phosphopeptides from PHF-tau. These results suggest that BPDK may be one of the kinases responsible for the abnormal phosphorylation-associated PHF-tau.	UNIV CALGARY,FAC MED,DEPT MED BIOCHEM,MED RES COUNCIL,SIGNAL TRANSDUCT GRP,3330 HOSP DR NW,CALGARY T2N 4NI,AB,CANADA	University of Calgary								BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; FLAMENT S, 1989, J NEUROL SCI, V92, P133, DOI 10.1016/0022-510X(89)90131-7; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HAYES TE, 1991, NEW BIOL, V3, P259; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; HOSHI M, 1987, FEBS LETT, V217, P237, DOI 10.1016/0014-5793(87)80670-1; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOSIK KS, 1991, TRENDS NEUROSCI, V14, P218, DOI 10.1016/0166-2236(91)90116-C; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P420, DOI 10.1002/jnr.490250320; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee V M, 1992, Curr Opin Neurobiol, V2, P653, DOI 10.1016/0959-4388(92)90034-I; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MAYERSON M, 1992, EMBO J, V11, P2909; NIXON RA, 1982, J CELL BIOL, V94, P150, DOI 10.1083/jcb.94.1.150; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SELKOE DJ, 1982, SCIENCE, V215, P1243, DOI 10.1126/science.6120571; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; UEDA K, 1990, J NEUROSCI, V10, P3295; VINCENT IJ, 1990, BRAIN RES, V531, P127, DOI 10.1016/0006-8993(90)90765-4; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	50	279	288	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23512	23518						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226879				2022-12-25	WOS:A1993MF51500085
J	TECLEBRHAN, H; OLSSON, J; SWIEZEWSKA, E; DALLNER, G				TECLEBRHAN, H; OLSSON, J; SWIEZEWSKA, E; DALLNER, G			BIOSYNTHESIS OF THE SIDE-CHAIN OF UBIQUINONE-TRANS-PRENYLTRANSFERASE IN RAT-LIVER MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXAPRENYL PYROPHOSPHATE SYNTHETASE; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; MICROCOCCUS-LUTEUS; COENZYME-Q; DOLICHOL; TISSUES; IDENTIFICATION; QUANTITATION; SPECIFICITY	The trans-prenyltransferase activity present in rat liver microsomes was investigated using an in vitro system. Geranyl-PP, but not farnesyl-PP is utilized as substrate. The pH optimum is at 8.0, and Mn2+ and Mg2 activate, while Zn2+ completely inhibits the enzyme. Digitonin, taurodeoxycholate, and Tween 80 increase this activity, whereas deoxycholate and SDS are inhibitory. In contrast to the cis-prenyltransferase, the trans-prenyltransferase is not dependent on cytosolic protein factors. The trans-prenyltransferase is present at the cytoplasmic surface of rough and smooth microsomes. Solanesyl-PP and all-trans-geranylgeranyl-PP inhibit the transferase activity but poly-cis-polyprenyl-12-PP, an intermediate in the cis-prenyltransferase reaction, does not. The enzyme reaction gives rise to two products, solanesyl-PP and an unidentified polyprenyl metabolite. Mevinolin treatment distinguishes this enzyme from the cytoplasmic geranylgeranyl-PP synthase. The results demonstrate that rat liver microsomes synthesize solanesyl-PP via a trans-prenyltransferase, which is distinct from cis-prenyltransferase and geranylgeranyl-PP synthase.	KAROLINSKA INST,HUDDINGE HOSP,CLIN RES CTR,S-14186 HUDDINGE,SWEDEN; POLISH ACAD SCI,INST BIOCHEM & BIOPHYS,PL-02532 WARSAW,POLAND	Karolinska Institutet; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	TECLEBRHAN, H (corresponding author), UNIV STOCKHOLM,ARRHENIUS LAB,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN.			Swiezewska, Ewa/0000-0002-3439-8948				ABERG F, 1992, ARCH BIOCHEM BIOPHYS, V295, P230, DOI 10.1016/0003-9861(92)90511-T; APPELKVIST EL, 1991, BIOMED CLIN, V6, P141; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BEYER RE, 1987, CHEM SCRIPTA, V27, P145; BOSCH H, 1992, ANNU REV BIOCHEM, V61, P157; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY J, 1978, BIOCHIM BIOPHYS ACTA, V530, P487, DOI 10.1016/0005-2760(78)90168-6; CHOJNACKI T, 1975, ANAL BIOCHEM, V69, P505; Dallner G, 1974, Methods Enzymol, V31, P191; EDWARDS PA, 1991, BIOCH LIPIDS LIPOPRO, P383; EHRENREICH JH, 1973, J CELL BIOL, V59, P45, DOI 10.1083/jcb.59.1.45; ELMBERGER PG, 1987, EUR J BIOCHEM, V168, P1, DOI 10.1111/j.1432-1033.1987.tb13379.x; ELMBERGER PG, 1989, LIPIDS, V24, P919, DOI 10.1007/BF02544535; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; ERICSSON J, 1991, J BIOL CHEM, V266, P10602; ERICSSON J, 1992, J BIOL CHEM, V267, P19730; ERICSSON J, 1993, J BIOL CHEM, V268, P832; ERICSSON J, 1991, EUR J BIOCHEM, V202, P789, DOI 10.1111/j.1432-1033.1991.tb16434.x; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FARRANTS AKO, 1989, BIOCHIM BIOPHYS ACTA, V1002, P198, DOI 10.1016/0005-2760(89)90287-7; FUJII H, 1980, BIOCHEM BIOPH RES CO, V96, P1648, DOI 10.1016/0006-291X(80)91363-7; FUJII H, 1982, J BIOL CHEM, V257, P4610; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; ISHII K, 1983, J BIOCHEM-TOKYO, V93, P1635, DOI 10.1093/oxfordjournals.jbchem.a134302; KALEN A, 1990, J BIOL CHEM, V265, P1158; KEENAN RW, 1976, BIOCHEMISTRY-US, V15, P1586, DOI 10.1021/bi00652a032; LIM PH, 1983, BIOCHIM BIOPHYS ACTA, V753, P74, DOI 10.1016/0005-2760(83)90100-5; MEYER RE, 1990, HIGH LIGHTS UBIQUINO, P191; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; PAULTER CD, 1981, BIOSYNTHESIS ISOPREN, P161; POPJAK G, 1962, J BIOL CHEM, V237, P56; RAMSAMARA T, 1985, COENZYME Q, P67; RUNQUIST M, 1992, BIOCHEM BIOPH RES CO, V186, P157, DOI 10.1016/S0006-291X(05)80788-0; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; SWIEZEWSKA E, 1993, J BIOL CHEM, V268, P1494; TAKAHASHI I, 1980, J BIOL CHEM, V255, P4539; THELIN A, 1992, FEBS LETT, V313, P118, DOI 10.1016/0014-5793(92)81425-L; TRUMPOWER BL, 1981, J BIOENERG BIOMEMBR, V13, P1, DOI 10.1007/BF00744743; VOELKER DR, 1985, BIOCH LIPIDS MEMBRAN, P475; YUSHIDA I, 1987, BIOCHEMISTRY-US, V26, P6840	41	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23081	23086						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226825				2022-12-25	WOS:A1993MF51500021
J	ZHOU, W; TAKUWA, N; KUMADA, M; TAKUWA, Y				ZHOU, W; TAKUWA, N; KUMADA, M; TAKUWA, Y			PROTEIN KINASE-C-MEDIATED BIDIRECTIONAL REGULATION OF DNA-SYNTHESIS, RB PROTEIN-PHOSPHORYLATION, AND CYCLIN-DEPENDENT KINASES IN HUMAN VASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 FIBROBLASTS; RETINOBLASTOMA GENE-PRODUCT; SMOOTH-MUSCLE CELLS; HISTONE-H1 KINASE; FISSION YEAST; MITOGENIC RESPONSE; MESANGIAL CELLS; TUMOR PROMOTER; CDC28 MUTATION; S-PHASE	In human umbilical vein endothelial cells, activators of protein kinase C (PKC) exert cell cycle-dependent, bidirectional growth regulatory effects. Thus, phorbol 12,13-dibutyrate or 1,2-dioctanoylglycerol potentiates growth factor-induced DNA synthesis up to 3-fold when they act during the early G1 phase, whereas they completely inhibit the initiation of DNA synthesis when they act in the late G1 phase. In addition, the PKC activators induce a rapid inhibition of the ongoing DNA synthesis when they are applied after entry into the S phase. The effects of the PKC activators in both stimulatory and inhibitory directions are abolished in PKC-downregulated cells. The cell cycle-dependent, PKC-mediated bidirectional growth regulation is closely associated with either potentiation or inhibition of RB protein phosphorylation and the histone H1 kinase activity of cyclin-dependent kinases (cdks) cdc2 and cdk2, which normally accumulate along the G1 to the S phase transition. Northern and Western blot analyses of cdc2 and cdk2 have revealed that PKC regulates the cdks at multiple steps in distinct ways. Thus, for cdc2, the levels of mRNA and protein as well as the extent of post-translational modification are all subject to the PKC-mediated regulation. In contrast, the level of mRNA or protein of cdk2 is not affected by PKC stimulation at any phase of the cell cycle. These results demonstrate the existence of a complex array of PKC-cdk signaling pathways, which mediate temporally organized bimodal growth regulation in endothelial cells.	UNIV TOKYO,FAC MED,DEPT PHYSIOL,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT CARDIOVASC BIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo				TAKUWA, Noriko/0000-0002-4278-2704				AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DICKER P, 1978, NATURE, V276, P723, DOI 10.1038/276723a0; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HUANG CL, 1987, NATURE, V329, P849, DOI 10.1038/329849a0; ISSANDOU M, 1991, J BIOL CHEM, V266, P21037; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KARIYA K, 1987, FEBS LETT, V219, P119, DOI 10.1016/0014-5793(87)81202-4; KARIYA K, 1987, FEBS LETT, V217, P69, DOI 10.1016/0014-5793(87)81245-0; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1980, GENETICS, V96, P627; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; ROZENGURT E, 1987, J CELL PHYSIOL, V131, P218, DOI 10.1002/jcp.1041310211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TAKUWA N, 1987, BIOCHEM J, V243, P647, DOI 10.1042/bj2430647; TAKUWA N, 1993, J BIOL CHEM, V268, P138; TAKUWA N, 1992, FEBS LETT, V306, P173, DOI 10.1016/0014-5793(92)80993-Q; TAKUWA N, 1988, J BIOL CHEM, V263, P9738; TAKUWA N, 1989, AM J PHYSIOL, V257, pF431, DOI 10.1152/ajprenal.1989.257.3.F431; TAKUWA N, 1992, BIOCHEM BIOPH RES CO, V188, P1084, DOI 10.1016/0006-291X(92)91342-N; TAKUWA N, 1991, J BIOL CHEM, V266, P1403; TAKUWA N, 1987, J BIOL CHEM, V262, P182; TAKUWA N, 1991, J BIOL CHEM, V266, P14237; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; THOMAS NSB, 1989, J BIOL CHEM, V264, P13697; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	65	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23041	23048						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226819				2022-12-25	WOS:A1993MF51500015
J	ECCLES, MR; GRUBB, G; OGAWA, O; SZETO, J; REEVE, AE				ECCLES, MR; GRUBB, G; OGAWA, O; SZETO, J; REEVE, AE			CLONING OF NOVEL WILMS-TUMOR GENE (WT1) CDNAS - EVIDENCE FOR ANTISENSE TRANSCRIPTION OF WT1	ONCOGENE			English	Note							DENYS-DRASH SYNDROME; UROGENITAL DEVELOPMENT; MUTATIONS; EXPRESSION; REGION; REPRESSION; OPPOSITE; DELETION; SEQUENCE; PROMOTER	WT1 is a tumor suppressor gene that has been implicated in Wilms tumor, and is expressed in cells of mesodermal origin. The Wit-1 gene is located approximately 2 kb from the WT1 gene, and is expressed coordinately with WT1. WT1 and Wit-1 are bi-directionally transcribed from the same promoter region, We have screened a human fetal kidney cDNA library to identify novel WT1 cDNA clones. Here we report the cloning of cDNA clones which span part of intron 1 of WT1, exon 1, upstream sequences between WT1 and Wit-1 and part of the Wit-1 gene. Northern blot and RNAase protection analysis using subcloned fragments of the cDNAs corresponding to regions from within intron 1 of WT1 suggest that a 7-10 Kb RNA is expressed in human fetal kidney, which overlaps with WT1 and is transcribed in the same direction as Wit-1.			ECCLES, MR (corresponding author), UNIV OTAGO,DEPT BIOCHEM,CANC GENET LAB,POB 56,DUNEDIN,NEW ZEALAND.							ARMSTRONG BC, 1992, CELL GROWTH DIFFER, V3, P385; ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BAIRD PN, 1992, ONCOGENE, V7, P2141; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAMPBELL CE, 1993, IN PRESS ONCOGENE; COPPES MJ, 1992, CANCER RES, V52, P6125; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; COWELL JK, 1991, ONCOGENE, V6, P595; DEAN M, 1983, NATURE, V305, P443, DOI 10.1038/305443a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HOFMANN W, 1993, ONCOGENE, V8, P3123; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; KRIEDBERG JA, 1993, CELL, V74, P1; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LOWNDES NF, 1989, MOL CELL BIOL, V9, P3758, DOI 10.1128/MCB.9.9.3758; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; OGAWA O, 1993, HUM MOL GENET, V2, P203, DOI 10.1093/hmg/2.2.203; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SPICER DB, 1992, MOL CELL BIOL, V12, P1324, DOI 10.1128/MCB.12.3.1324; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; WANG ZY, 1992, J BIOL CHEM, V267, P21999; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	34	40	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2059	2063						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208551				2022-12-25	WOS:A1994NR68500031
J	PIM, D; STOREY, A; THOMAS, M; MASSIMI, P; BANKS, L				PIM, D; STOREY, A; THOMAS, M; MASSIMI, P; BANKS, L			MUTATIONAL ANALYSIS OF HPV-18 E6 IDENTIFIES DOMAINS REQUIRED FOR P53 DEGRADATION IN-VITRO, ABOLITION OF P53 TRANSACTIVATION IN-VIVO AND IMMORTALIZATION OF PRIMARY BMK CELLS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN KERATINOCYTES; MOUSE CELLS; PROTEIN; ASSOCIATION; EXPRESSION; GENE; E7; TRANSFORMATION; TRANSCRIPTION	The two major transforming proteins of oncogenic human papillomaviruses are encoded by the E6 and E7 oncogenes. Both viral proteins interact specifically with the products of cellular human tumour suppressor genes; E6 with p53 and E7 with Rb. However, the mechanism of action of E6 is still poorly understood in comparison with that of E7. Although extensive in vitro studies have been done with mutant E6 proteins, very little is known about the activities of E6 in vivo. In this study we have analysed the structure-function relationships of HPV-18 E6 in in vitro analyses and we correlate this with in vivo activity. These studies define a number of domains on the E6 molecule which are involved in the ability of E6 to target p53 for degradation in vitro. This analysis demonstrates that domains previously shown to be important in HPV-16 E6 (Crook et al., 1991; Mietz et al., 1992) are also conserved in HPV-18 and also reconciles the differences between these reports. A series of in vivo studies demonstrate that E6 mediated degradation of p53 in vitro is irrelevant both for cell transformation and for the ability of E6 to abolish p53 transcriptional activation. In addition, we show that at least four distinct regions of the E6 protein are involved in the p53 association in vivo.	INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY	International Center for Genetic Engineering & Biotechnology (ICGEB)				Storey, Alan/0000-0003-2001-9772				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, ONCOGENE, V4, P1529; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MUNGER K, 1989, J VIROL, V63, P4417; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	28	116	120	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1869	1876						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208532				2022-12-25	WOS:A1994NR68500009
J	PUCEAT, M; HILALDANDAN, R; STRULOVICI, B; BRUNTON, LL; BROWN, JH				PUCEAT, M; HILALDANDAN, R; STRULOVICI, B; BRUNTON, LL; BROWN, JH			DIFFERENTIAL REGULATION OF PROTEIN-KINASE-C ISOFORMS IN ISOLATED NEONATAL AND ADULT-RAT CARDIOMYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CARDIAC MYOCYTES; GENE-EXPRESSION; HEART MYOCYTES; CELLS; ACTIVATION; EPSILON; ISOZYMES; ENDOTHELIN; CALCIUM	We have immunologically identified the isoforms of protein kinase C (PKC) present in neonatal and adult rat cardiomyocytes and examined their regulation by hormones and phorbol ester. Both cell types express the Ca2+-dependent alpha-PKC and the Ca2+-independent epsilon- and delta-PKC isoforms. The atypical zeta-PKC isoform is also expressed in neonatal, but only weakly in adult cells. Stimulation of the alpha(1)-adrenergic or purinergic receptor with phenylephrine or ATP, respectively, increases membrane-associated immunoreactivity of both epsilon- and delta-PKC in neonatal and adult cells; endothelin and carbachol are also effective in adult cells. In contrast, none of the agonists leads to increases in membrane-associated alpha-PKC in cardiomyocytes. PKC zeta is also unaffected by receptor stimulation. The phorbol ester phorbol 12-myristate 13-acetate causes redistribution and subsequently down-regulation of alpha-, epsilon-, and delta- but not zeta-PKC. The three isoforms are down-regulated at distinctively different rates, with alpha-PKC being the most rapid and epsilon-PKC the slowest. We used selective down-regulation of alpha-, epsilon-, and delta-PKC to investigate the role of these isoforms in PKC phosphorylation-dependent events in neonatal myocytes. Our findings suggest that epsilon-PKC is responsible for the phenylephrine-induced phosphorylation of MARCKS, an endogenous PKC-specific substrate. In contrast, agonist-induced c-fos expression is unlikely to be mediated by epsilon-PKC since the response is rapidly down-regulated and apparently Ca2+-dependent. Our finding that the PKC isoforms are differentially responsive to neurohormones suggests that they play distinct and specific roles in cardiac function.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			PUCEAT, michel/R-6140-2017	PUCEAT, michel/0000-0001-9055-7563	NHLBI NIH HHS [HL41307, HL28143, HL46345] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345, R01HL041307, R01HL028143] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ALLEN BG, 1991, BIOCHEMISTRY-US, V30, P4334, DOI 10.1021/bi00231a032; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JH, 1992, TRENDS CARDIOVAS MED, V2, P209, DOI 10.1016/1050-1738(92)90026-O; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; IRONS CE, 1992, J BIOL CHEM, V267, P5211; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KAKU T, 1991, AM J PHYSIOL, V260, pC635, DOI 10.1152/ajpcell.1991.260.3.C635; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KOHOUT TA, 1993, AM J PHYSIOL, V264, pC1350, DOI 10.1152/ajpcell.1993.264.5.C1350; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KOSAKA Y, 1988, BIOCHEM BIOPH RES CO, V151, P973, DOI 10.1016/S0006-291X(88)80461-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASLIAH E, 1990, J NEUROSCI, V10, P2113; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; PUCEAT M, 1991, BIOCHEM J, V274, P55, DOI 10.1042/bj2740055; PUCEAT M, 1992, TRENDS PHARMACOL SCI, V13, P263, DOI 10.1016/0165-6147(92)90080-P; QU Y, 1991, MOL CELL BIOCHEM, V103, P171; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREJO J, 1991, J BIOL CHEM, V266, P7876; TRILIVAS I, 1989, J BIOL CHEM, V264, P3102; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	37	262	264	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16938	16944						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207017				2022-12-25	WOS:A1994NR29600064
J	SU, Y; ROSENTHAL, D; SMULSON, M; SPIEGEL, S				SU, Y; ROSENTHAL, D; SMULSON, M; SPIEGEL, S			SPHINGOSINE 1-PHOSPHATE, A NOVEL SIGNALING MOLECULE, STIMULATES DNA-BINDING ACTIVITY OF AP-1 IN QUIESCENT SWISS 3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDIC-ACID LEVELS; CELLULAR PROLIFERATION; TRANSDUCTION PATHWAYS; MAP KINASES; CELLS; JUN; FOS; TRANSCRIPTION; SPHINGOSINE-1-PHOSPHATE	Sphingosine and sphingosine 1-phosphate, metabolites of sphingolipids, stimulate cell proliferation in quiescent Swiss 3T3 fibroblasts and induce transient increases in intracellular free calcium (Zhang, H., Desai, N. N., Olivera, A., Seki, T., Brooker, G., and Spiegel, S. (1991) J. Cell Biol. 114, 155-167). However, little is yet known of the nuclear events that follow the early responses induced by sphingolipid metabolites. Using a gel retardation assay, we found that specific DNA binding activity of activator protein-1 (AP-1) was markedly increased after treatment of quiescent Swiss 3T3 fibro- blasts with sphingosine 1-phosphate and sphingosine. The DNA binding specificity of AP-1 was confirmed with competing probes containing consensus sequences of AP-1, AP-2, AP-3, SP-1, and NF1/CTF. The c-fos gene product was detected in the AP-1 complex using anti-c-Fos antibody. The dose response for stimulation of DNA binding activity of AP-1 by sphingosine 1-phosphate correlated closely with its effect on DNA synthesis. Furthermore, an inhibitor of sphingosine kinase, DL-threo-dihydrosphingosine, which inhibits sphingosine-induced DNA synthesis and the formation of sphingosine 1-phosphate, also inhibited sphingosine-stimulated AP-1 DNA binding activity. This result further supports our proposal that sphingosine 1-phosphate mediates the mitogenic effect of sphingosine. Our results indicate that sphingosine 1-phosphate-induced DNA synthesis and cell division may result from activation of AP-1 protein, linking signal transduction by sphingolipid metabolites to gene expression.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007	Georgetown University			Rosenthal, Dean S/J-2360-2014	Rosenthal, Dean/0000-0002-7624-0209	NIGMS NIH HHS [1RO1 GM43880] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GINSBERG D, 1990, ONCOGENE, V5, P1285; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1992, GLYCOCONJUGATE J, V9, P109; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SPIEGEL S, 1989, J BIOL CHEM, V264, P16512; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P1041, DOI 10.1515/bchm2.1970.351.2.1041; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; VANWIJNEN AJ, 1991, J CELL BIOCHEM, V47, P337, DOI 10.1002/jcb.240470408; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WU WS, 1992, ONCOGENE, V7, P2287; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309; [No title captured]	46	89	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16512	16517						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206962				2022-12-25	WOS:A1994NQ72900083
J	FRANCISCO, WA; ABUSOUD, HM; BALDWIN, TO; RAUSHEL, FM				FRANCISCO, WA; ABUSOUD, HM; BALDWIN, TO; RAUSHEL, FM			INTERACTION OF BACTERIAL LUCIFERASE WITH ALDEHYDE SUBSTRATES AND INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STABILIZATION; SITE	Bacterial luciferase catalyzes the reaction of FMNH2, O2, and an aliphatic aldehyde to yield the carboxylic acid, FMN, water and blue-green light. The kinetics of the bacterial luciferase reaction were measured by stopped-flow spectrophotometry at pH 7 and 25-degrees-C for the series of aldehydes from n-heptanal to n-undecanal. The rate of formation of the 4a-hydroperoxyflavin intermediate was dependent on the aldehyde concentration when mixtures of enzyme, FMNH2, and aldehyde were rapidly mixed with O2. At saturating aldehyde, the rate of formation of this intermediate was 100-fold slower than in the absence of aldehyde, demonstrating that an enzyme.FMNH2.aldehyde complex can be formed. Numerical simulation of the time courses for these experiments supported the formation of this intermediate and its direct reaction with O2. The kinetics of the light emitting reaction were dependent upon the chain length of the aldehyde substrate. Although the initial light intensity and the light emission decay rate were different for each aldehyde, the quantum yield for the reaction was independent of the aldehyde used. Luciferase was inhibited by high levels of the aldehyde substrate when the enzyme was assayed by mixing FMNH2 with an aerobic mixture of enzyme and aldehyde. The extent of inhibition was dependent on the particular aldehyde used, and the binding affinity of the aldehyde for the free enzyme increased in parallel with the aldehyde chain length. The kinetics of the formation and decay of the various intermediates were also studied in the presence of n-alkylaldehyde analogs. These compounds decreased the rate of formation of the 4a-hydroperoxyflavin intermediate in much the same way as the aldehyde substrate, presumably by the formation of the enzyme FMNH2.analog ternary complex.	TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLL STN,TX 77843; TEXAS A&M UNIV SYST,CTR MACROMOLEC DESIGN,COLL STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	RAUSHEL, FM (corresponding author), TEXAS A&M UNIV SYST,DEPT CHEM,COLL STN,TX 77843, USA.		Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NIGMS NIH HHS [GM33894] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033894] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD H, 1992, BIOCHEMISTRY-US, V31, P3807, DOI 10.1021/bi00130a011; ABUSOUD HM, 1993, J BIOL CHEM, V268, P7699; AHRENS M, 1991, PHOTOCHEM PHOTOBIOL, V54, P295, DOI 10.1111/j.1751-1097.1991.tb02019.x; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P40, DOI 10.1002/bio.1170040111; BALDWIN TO, 1992, CHEM BIOCH FLAVOENZY, P467; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BAUMSTARK AL, 1979, ARCH BIOCHEM BIOPHYS, V193, P449, DOI 10.1016/0003-9861(79)90051-1; CURRY S, 1990, BIOCHEMISTRY-US, V29, P4641, DOI 10.1021/bi00471a020; GIBSON QH, 1962, BIOCHEM J, V83, P368, DOI 10.1042/bj0830368; HAMMOCK BD, 1982, PESTIC BIOCHEM PHYS, V17, P76, DOI 10.1016/0048-3575(82)90128-6; HASTINGS JW, 1966, BIOLUMINESCENCE PROG, P151; Hastings JW., 1978, METHOD ENZYMOL, V57, P135; HASTINGS JW, 1963, J BIOL CHEM, V242, P720; MAKEMSON JC, 1992, ARCH BIOCHEM BIOPHYS, V294, P361, DOI 10.1016/0003-9861(92)90696-T; MASSEY V, 1971, FLAVINS FLAVOPROTEIN; TORSSELL K, 1957, ACTA CHEM SCAND, V11, P404, DOI 10.3891/acta.chem.scand.11-0404; TU SC, 1986, METHOD ENZYMOL, V133, P128; TU SC, 1979, BIOCHEMISTRY-US, V18, P5940, DOI 10.1021/bi00593a028; VERVOORT J, 1986, BIOCHEMISTRY-US, V25, P8086; WATANABE T, 1972, BIOCHEM J, V72, P647; WHITBY LG, 1953, BIOCHEM J, V54, P437, DOI 10.1042/bj0540437; Williams C H Jr, 1979, Methods Enzymol, V62, P185; ZIEGLER MM, 1981, CURR TOP BIOENERG, V12, P65; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	24	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24734	24741						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227032				2022-12-25	WOS:A1993MG67300035
J	KISSELEV, O; GAUTAM, N				KISSELEV, O; GAUTAM, N			SPECIFIC INTERACTION WITH RHODOPSIN IS DEPENDENT ON THE GAMMA-SUBUNIT TYPE IN A G-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOTORECEPTOR-G-PROTEIN; BETA-SUBUNIT; TRANSDUCIN; CDNA; RECONSTITUTION; IDENTIFICATION; RECEPTORS; HOMOLOGY; CONTAIN; SYSTEM	Interaction with a receptor is the first step in the process of signal transduction by heterotrimeric (alphabetagamma) G proteins. We have examined the role of the G protein gamma subunit in interaction between a receptor (rhodopsin) and a G protein, transducin (G(t)). We have obtained recombinant betagamma complexes containing the same beta subunit but three different gamma subunit types by expressing them in the baculovirus/insect cell system. We show that the different recombinant betagamma complexes interact equally well with the alpha subunit of transducin (alpha(t)) but only the gamma subunit specific to rod photoreceptors (gamma1) is able to support interaction of alpha(t) with rhodopsin. This indicates a direct role for the G protein gamma subunits, which are a family of proteins with diverse structures, in conferring specificity to receptor-G protein interaction.	WASHINGTON UNIV,SCH MED,DEPT GENET,BOX 8054,660 S EUCLID AVE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046963] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046963, GM 46963] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HAMM HE, 1991, CELL MOL NEUROBIOL, V11, P563, DOI 10.1007/BF00741446; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; LEE RH, 1992, J BIOL CHEM, V267, P24776; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SHINOZAWA T, 1980, P NATL ACAD SCI-BIOL, V77, P1408, DOI 10.1073/pnas.77.3.1408; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL AM, 1990, SOC GEN PHY, V45, P185; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	35	96	96	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24519	24522						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227005				2022-12-25	WOS:A1993MG67300002
J	ERICKSON, PR; HERZBERG, MC				ERICKSON, PR; HERZBERG, MC			EVIDENCE FOR THE COVALENT LINKAGE OF CARBOHYDRATE POLYMERS TO A GLYCOPROTEIN FROM STREPTOCOCCUS-SANGUIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GRAM-POSITIVE BACTERIA; HALOBACTERIUM-SALINARIUM; BACILLUS-THURINGIENSIS; SURFACE GLYCOPROTEIN; PLATELET AGGREGATION; CELL-WALLS; PURIFICATION; PROTEIN; POLYSACCHARIDE; PROTOPLASTS	The platelet aggregation-associated protein (PAAP) from Streptococcus sanguis contains 39% carbohydrate in rhamnose-rich polysaccharides. Synthesized by cultured protoplasts, these polysaccharides were shown to be covalently linked to this cell wall protein using specific inhibitors of glycosylation, glycosidase treatment, amino acid and carbohydrate analyses of prepared minimal glycopeptides and isolated protein, and NMR spectroscopy. To our knowledge, this is the first direct proof of an N-asparaginyl linkage of carbohydrate to a eubacterial protein.	UNIV MINNESOTA,SCH DENT,DEPT PREVENT SCI,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH DENT,GRAD PROGRAM ORAL BIOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NIDCR NIH HHS [2 R01 DE05501, 1 K15 DE00224] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005501, K15DE000224] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABEYGUNAWARDANA C, 1990, BIOCHEMISTRY-US, V29, P234, DOI 10.1021/bi00453a032; ABEYGUNAWARDANA C, 1989, CARBOHYD RES, V191, P279, DOI 10.1016/0008-6215(89)85071-2; ANDREU JM, 1978, FEBS LETT, V86, P1, DOI 10.1016/0014-5793(78)80084-2; ANDREU JM, 1976, FEBS LETT, V65, P198, DOI 10.1016/0014-5793(76)80479-6; ARAKI Y, 1989, CRIT REV MICROBIOL, V17, P121, DOI 10.3109/10408418909105745; BENCHETRIT LC, 1978, J BACTERIOL, V134, P221, DOI 10.1128/JB.134.1.221-228.1978; BERTRAM KC, 1981, J BACTERIOL, V148, P406, DOI 10.1128/JB.148.2.406-412.1981; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BLUMBERG K, 1982, ANAL BIOCHEM, V119, P397, DOI 10.1016/0003-2697(82)90604-2; BROWN WJ, 1984, CELL, V36, P295, DOI 10.1016/0092-8674(84)90223-X; BULLA LA, 1977, J BACTERIOL, V130, P375, DOI 10.1128/JB.130.1.375-383.1977; BUMOL TF, 1984, J BIOL CHEM, V259, P2733; CASSELS FJ, 1989, J BACTERIOL, V171, P4019, DOI 10.1128/jb.171.7.4019-4025.1989; CHIU TH, 1978, J BACTERIOL, V133, P185, DOI 10.1128/JB.133.1.185-195.1978; COLLEY KJ, 1987, J BIOL CHEM, V262, P10296; DEAN MF, 1984, BIOCHEM SOC T, V12, P513; DILL K, 1979, FEBS LETT, V107, P26, DOI 10.1016/0014-5793(79)80454-8; ERICKSON PR, 1990, J BIOL CHEM, V265, P14080; ERICKSON PR, 1993, ANAL BIOCHEM, V268, P1646; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; GEUSE HJ, 1984, J CELL BIOL, V98, P2047; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HERZBERG MC, 1983, INFECT IMMUN, V42, P394, DOI 10.1128/IAI.42.1.394-401.1983; HERZBERG MC, 1979, J BIOL CHEM, V254, P1487; HERZBERG MC, 1990, INFECT IMMUN, V58, P4117, DOI 10.1128/IAI.58.12.4117-4125.1990; HERZBERG MC, 1985, MOL BASIS ORAL MICRO, P53; KANAOKA M, 1987, JPN J CANCER RES, V78, P1409; KAWAMURA T, 1983, J BIOL CHEM, V258, P9514; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUAN SF, 1989, J BIOL CHEM, V264, P19271; KUPCU Z, 1984, FEBS LETT, V173, P185, DOI 10.1016/0014-5793(84)81043-1; LENNARZ WJ, 1982, BIOCHIM BIOPHYS ACTA, V585, P417; MAEBA PY, 1986, J BACTERIOL, V166, P644, DOI 10.1128/jb.166.2.644-650.1986; MCINTIRE FC, 1987, CARBOHYD RES, V166, P133, DOI 10.1016/0008-6215(87)80050-2; MESCHER MF, 1976, J BIOL CHEM, V251, P2005; MESCHER MF, 1976, P NATL ACAD SCI USA, V73, P2687, DOI 10.1073/pnas.73.8.2687; MESSNER P, 1988, FEBS LETT, V228, P317, DOI 10.1016/0014-5793(88)80023-1; MORRIS EJ, 1987, J BACTERIOL, V169, P164, DOI 10.1128/jb.169.1.164-171.1987; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; NISHIMOTA SK, 1982, BIOCHEM J, V202, P249; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V969, P176, DOI 10.1016/0167-4889(88)90073-0; PAUL G, 1986, J BIOL CHEM, V261, P1020; PFANNENSTIEL MA, 1987, J BACTERIOL, V169, P796, DOI 10.1128/jb.169.2.796-801.1987; ROE JH, 1955, J BIOL CHEM, V212, P335; ROGERS HJ, 1980, MICROBIAL CELL WALLS, P45; ROSAN B, 1988, ORAL MICROBIOL IMMUN, V3, P153, DOI 10.1111/j.1399-302X.1988.tb00002.x; Schwarz RT, 1979, BIOCHEM SOC T, V7, P322, DOI 10.1042/bst0070322; Sharon N., 1975, COMPLEX CARBOHYDRATE; SHOCKMAN GD, 1983, ANNU REV MICROBIOL, V37, P501, DOI 10.1146/annurev.mi.37.100183.002441; SIEWERT G, 1967, P NATL ACAD SCI USA, V57, P767, DOI 10.1073/pnas.57.3.767; TAKATSUKI A, 1975, AGR BIOL CHEM TOKYO, V39, P2089, DOI 10.1080/00021369.1975.10861914; TAKU A, 1976, J BIOL CHEM, V251, P1889; TERLECKYJ B, 1975, INFECT IMMUN, V11, P649, DOI 10.1128/IAI.11.4.649-655.1975; WEBSTER JR, 1981, APPL ENVIRON MICROB, V41, P371, DOI 10.1128/AEM.41.2.371-374.1981; WEERKAMP AH, 1982, INFECT IMMUN, V38, P233, DOI 10.1128/IAI.38.1.233-242.1982; WIELAND F, 1983, P NATL ACAD SCI-BIOL, V80, P5470, DOI 10.1073/pnas.80.18.5470; WILLINGHAM MC, 1983, J HISTOCHEM CYTOCHEM, V31, P1; YANG LL, 1979, BIOCHIM BIOPHYS ACTA, V556, P265, DOI 10.1016/0005-2736(79)90047-6	60	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23780	23783						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226911				2022-12-25	WOS:A1993MF29400013
J	HARDY, TA; ROACH, PJ				HARDY, TA; ROACH, PJ			CONTROL OF YEAST GLYCOGEN SYNTHASE-2 BY COOH-TERMINAL PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; CYCLIC-AMP; SUBSTRATE RECOGNITION; NUTRIENT LIMITATION; HOST STRAINS; 2ND GENE; 2 FORMS; METABOLISM; ENCODES	The budding yeast Saccharomyces cerevisiae expresses two isoforms of glycogen synthase, of which glycogen synthase-2 (GS-2) appears to be the most important determinant of glycogen accumulation (Farkas, I., Hardy, T. A., Goebl, M. G., and Roach, P. J. (1991) J. Biol. Chem. 266, 15602-15607). Partial proteolysis of purified yeast glycogen synthase activated the enzyme, mimicking the effects of dephosphorylation. The cleavage was localized to the COOH terminus of the molecule and trypsin treatment released P-32 from enzyme labeled in vivo with P-32 or in vitro by cyclic AMP-dependent protein kinase. Similarly, when cells were labeled with P-32, no radioactivity was incorporated into a mutant form of GS-2 truncated at residue 643 while the wild type enzyme was phosphorylated at both Ser and Thr residues. The 9 Ser and Thr residues COOH-terminal to position 643 were mutated individually to Ala, and the GS-2 mutants were expressed from a low copy plasmid in yeast that lacked functional chromosomal copies of the two glycogen synthase genes. Mutations at Ser-650, Ser-654, and Thr-667 resulted in significant activation of yeast glycogen synthase and elevation in the level of accumulated glycogen as compared with wild type. Likewise, expression of the truncated GS-2 resulted in hyperactive enzyme and the overaccumulation of glycogen. None of the other Ser or Thr mutations substantially affected glycogen synthase activity and glycogen storage. We conclude that Ser-650, Ser-654, and Thr-667 are regulatory phosphorylation sites in vivo. However, in vitro, cyclic AMP-dependent protein kinase modified Ser residue(s) COOH-terminal to position 659, and so the identity of the physiological GS-2 kinases is unclear. Yeast strains bearing glc7 and gac1 mutations are defective in genes encoding type 1 protein phosphatase components and are impaired in their ability to accumulate glycogen. Expression of the truncated GS-2 in these strains restored glycogen accumulation, as did the presence of GS-2 mutated at Ser-650, Ser-654, or Thr-667. These data are consistent with the hypothesis that type 1 phosphatase regulates GS-2 by controlling its phosphorylation state.			HARDY, TA (corresponding author), INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042576] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42576] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BAI G, 1990, J BIOL CHEM, V265, P7843; Bauminger S, 1980, Methods Enzymol, V70, P151; Bergmeyer H. U., 1974, METHOD ENZYMAT AN, V3, P1196; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CANNON JF, 1986, GENETICS, V113, P247; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CHESTER VE, 1963, BIOCHEM J, V86, P153, DOI 10.1042/bj0860153; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COHEN P, 1991, BIOCHIM BIOPHYS ACTA, V1094, P292, DOI 10.1016/0167-4889(91)90089-G; COHEN P, 1986, ENZYMES, V17, P462; DENIS CL, 1991, J BIOL CHEM, V266, P17932; EDENBERG HJ, 1987, GENE, V58, P297, DOI 10.1016/0378-1119(87)90384-2; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FENG ZH, 1991, J BIOL CHEM, V266, P23796; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P561, DOI 10.1111/j.1432-1033.1988.tb14135.x; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P551, DOI 10.1111/j.1432-1033.1988.tb14134.x; FRANCOIS J, 1991, J BIOL CHEM, V266, P6174; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUANG KP, 1974, J BIOL CHEM, V249, P3858; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; KEMP BE, 1977, J BIOL CHEM, V252, P4888; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PENG ZY, 1990, J BIOL CHEM, V265, P13871; POSAS F, 1993, J BIOL CHEM, V268, P1349; POSAS F, 1991, FEBS LETT, V279, P341, DOI 10.1016/0014-5793(91)80183-4; PROROK M, 1989, BIOCHEM BIOPH RES CO, V165, P368, DOI 10.1016/0006-291X(89)91079-6; Quain D. E, 1988, J I BREWING, V95, P315; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROTHMANDENES LB, 1971, BIOCHEMISTRY-US, V10, P1236; ROTHMANDENES LB, 1970, P NATL ACAD SCI USA, V66, P967, DOI 10.1073/pnas.66.3.967; ROWEN DW, 1992, MOL CELL BIOL, V12, P22, DOI 10.1128/MCB.12.1.22; Rubin G M, 1975, Methods Cell Biol, V12, P45; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHANG WM, 1989, FASEB J, V3, P2532, DOI 10.1096/fasebj.3.13.2509275; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	52	85	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23799	23805						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226915				2022-12-25	WOS:A1993MF29400017
J	PENG, H; MARIANS, KJ				PENG, H; MARIANS, KJ			ESCHERICHIA-COLI TOPOISOMERASE-IV - PURIFICATION, CHARACTERIZATION, SUBUNIT STRUCTURE, AND SUBUNIT INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID GYRASE; DNA GYRASE; CHROMOSOME SEGREGATION; SALMONELLA-TYPHIMURIUM; NUCLEOID SEGREGATION; CATALYTIC PROPERTIES; NALIDIXIC-ACID; GYRB-GENE; REPLICATION; SEQUENCE	DNA sequence analysis of Escherichia coli parC and parE, encoding the subunits of topoisomerase IV (Topo IV) (Kato, J.-I., Suzuki, H., and Ikeda, H. (1992) J. Biol. Chem. 267, 25676-25684), showed that ParC was 22 amino acids longer on the N terminus and ParE was 29 amino acids longer on the C terminus than reported previously. E. coli strains bearing bacteriophage T7 RNA polymerase-based expression plasmids carrying both intact and truncated parC and parE were used to overproduce the ParC and ParE proteins. Full-length ParC and ParE were required to reconstitute Topo IV activity, whereas the truncated ParC and ParE were inactive. Topo IV activity was supported only by ATP or dATP. The [ATP]1/2 for DNA relaxation was 0.45 mM, almost 25-fold higher than the [ATP]1/2 for decatenation of kinetoplast DNA. Topo IV activity was inhibited by the quinolone and coumarin antibiotics, although the concentrations required for 50% inhibition of activity were 3-30-fold higher than those required to inhibit DNA gyrase. The norfloxacin-induced DNA cleavage patterns of Topo IV and DNA gyrase were distinct but overlapping. The native forms of ParC and ParE were a dimer and a monomer, respectively; whereas the active form of Topo IV was a heterotetramer, ParC2ParE2. The inactivity of the truncated forms of ParC and ParE could be attributed to their failure to form the heterotetramer.	CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Cornell University	PENG, H (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI T, 1984, NUCLEIC ACIDS RES, V12, P6389, DOI 10.1093/nar/12.16.6389; ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; BEEN MD, 1981, P NATL ACAD SCI-BIOL, V78, P2883, DOI 10.1073/pnas.78.5.2883; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; Cohn E. J., 1943, PROTEINS AMINO ACIDS; DIGATE RJ, 1992, J BIOL CHEM, V267, P20532; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; FAIRWEATHER NF, 1980, J BACTERIOL, V142, P153, DOI 10.1128/JB.142.1.153-161.1980; FILUTOWICZ M, 1980, MOL GEN GENET, V177, P301, DOI 10.1007/BF00267443; FILUTOWICZ M, 1982, MOL GEN GENET, V191, P282; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; GOSS WA, 1965, J BACTERIOL, V89, P1068, DOI 10.1128/JB.89.4.1068-1074.1965; HELMSTETTER CE, 1987, ESCHERICHIA COLI SAL, P1595; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HUSSAIN K, 1987, MOL MICROBIOL, V1, P73, DOI 10.1111/j.1365-2958.1987.tb00529.x; HUSSAIN K, 1987, MOL MICROBIOL, V1, P259, DOI 10.1111/j.1365-2958.1987.tb01932.x; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1989, MOL GEN GENET, V217, P178, DOI 10.1007/BF00330959; KATO J, 1992, J BIOL CHEM, V267, P25676; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KLEVAN L, 1980, BIOCHEMISTRY-US, V19, P5229, DOI 10.1021/bi00564a012; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTTINGER AL, 1991, NEW BIOL, V3, P687; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; PENG H, 1993, IN PRESS P NATL ACAD; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; RAJI A, 1985, J BACTERIOL, V162, P1173, DOI 10.1128/JB.162.3.1173-1179.1985; RYAN MJ, 1976, BIOCHEMISTRY-US, V15, P3769, DOI 10.1021/bi00662a020; SAPORITO SM, 1988, J BACTERIOL, V170, P4542, DOI 10.1128/jb.170.10.4542-4547.1988; SCHMID MB, 1990, J BACTERIOL, V172, P5416, DOI 10.1128/jb.172.9.5416-5424.1990; SCHOFIELD MA, 1992, J BACTERIOL, V174, P5168, DOI 10.1128/JB.174.15.5168-5170.1992; SHEN LI, 1985, P NATL ACAD SCI USA, V74, P4767; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SPRINGER AL, 1993, NUCLEIC ACIDS RES, V21, P1805, DOI 10.1093/nar/21.8.1805; STAUDENBAUER WL, 1981, NUCLEIC ACIDS RES, V9, P3589, DOI 10.1093/nar/9.15.3589; STAUDENBAUER WL, 1976, EUR J BIOCHEM, V62, P491, DOI 10.1111/j.1432-1033.1976.tb10183.x; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767	48	228	236	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24481	24490						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8227000				2022-12-25	WOS:A1993MF29400113
J	ASAHI, M; TANIGUCHI, T; HASHIMOTO, E; INAZU, T; MAEDA, H; YAMAMURA, H				ASAHI, M; TANIGUCHI, T; HASHIMOTO, E; INAZU, T; MAEDA, H; YAMAMURA, H			ACTIVATION OF PROTEIN-TYROSINE KINASE P72(SYK) WITH CONCANAVALIN-A IN POLYMORPHONUCLEAR NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; SUPEROXIDE ANION; RECEPTOR; PHOSPHORYLATION; INHIBITOR; STIMULATION; GENERATION; MEMBRANE; BINDING; CELLS	We studied the abundance, subcellular distribution of a non-receptor protein-tyrosine kinase p72syk (Taniguchi, T., Kobayashi, T., Kondo, J., Takahashi, K., Nakamura, H., Suzuki, J., Nagai, K., Yamada, T., Nakamura, S., and Yamamura, H. (1991) J. Biol. Chem. 266, 15790-15796) in porcine polymorphonuclear neutrophils and the activation upon the stimulation with concanavalin A. The abundance was about 0.1% of total proteins and mainly distributed in the particulate fraction. Upon concanavalin A stimulation, the activity of p72syk increased within 30 s, attained to the maximum level at 1 min, and then returned to the basal level within 6 min. This activation was observed in a dose-dependent manner and abrogated by simultaneous addition of methyl alpha-mannopyranoside. When both extra- and intracellular Ca2+ were depleted, the activation of p72syk Was still persistent; in contrast, the deactivation process was completely abrogated even at 6 min after stimulation. The replenishment of Ca2+ in the presence of A23187 resulted in a similar deactivation pattern as seen in the Ca2+-rich condition. In addition, genistein and herbimycin A, potent protein-tyrosine-kinase inhibitors, were capable of reducing concanavalin A-evoked p72syk activation and Ca2+ mobilization as well as the aggregation and lysozyme release. Furthermore, A23187-induced Ca2+ accumulation in inhibitor-treated cells resulted in the restoration of those cellular responses. These lines of evidence suggest that p72syk is activated with concanavalin A in a Ca2+-independent manner, participating in a mechanism of Ca2+ recruitment, and negatively regulated by a feedback mechanism through Ca2+ in neutrophils.	KOBE UNIV,BIOSIGNAL RES CTR,KOBE 657,JAPAN	Kobe University	YAMAMURA, H (corresponding author), FUKUI MED SCH,DEPT BIOCHEM,FUKUI 91011,JAPAN.		Maeda, Hiroyuki/W-1934-2019					APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BECKER JW, 1976, CONCANAVALIN A TOOL, P34; BERKOW RL, 1990, BLOOD, V75, P2445; BERKOW RL, 1987, J LEUKOCYTE BIOL, V41, P441, DOI 10.1002/jlb.41.5.441; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; GEA CE, 1986, P NATL ACAD SCI USA, V83, P5131; GERARD C, 1986, J CLIN INVEST, V77, P61, DOI 10.1172/JCI112302; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HASHIMOTO E, 1976, J BIOL CHEM, V251, P6287; HUANG CK, 1990, BIOCHEM J, V269, P431, DOI 10.1042/bj2690431; KOBAYASHI T, 1990, EUR J BIOCHEM, V188, P535, DOI 10.1111/j.1432-1033.1990.tb15433.x; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; KORCHAK HM, 1984, FED PROC, V43, P2749; KUSUNOKI T, 1992, BIOCHEM BIOPH RES CO, V183, P789, DOI 10.1016/0006-291X(92)90552-V; LACAL PM, 1990, BIOCHEM J, V268, P707, DOI 10.1042/bj2680707; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; METCALF JA, 1986, LABORATORY MANUAL NE, P149; NACCACHE PH, 1990, BLOOD, V76, P2098; OHTA S, 1992, EUR J BIOCHEM, V206, P895, DOI 10.1111/j.1432-1033.1992.tb16998.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKEUCHI F, 1993, BIOCHEM BIOPH RES CO, V194, P91, DOI 10.1006/bbrc.1993.1789; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TANIGUCHI T, 1992, J BIOL CHEM, V185, P1128; TAUBER AI, 1987, BLOOD, V69, P711; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; YAMADA T, 1991, BIOCHEM BIOPH RES CO, V180, P1325, DOI 10.1016/S0006-291X(05)81340-3; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YU G, 1989, J BIOL CHEM, V264, P10276; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	33	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23334	23338						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226857				2022-12-25	WOS:A1993MF51500060
J	KIKUCHI, K; NAGANO, T; HAYAKAWA, H; HIRATA, Y; HIROBE, M				KIKUCHI, K; NAGANO, T; HAYAKAWA, H; HIRATA, Y; HIROBE, M			REAL-TIME MEASUREMENT OF NITRIC-OXIDE PRODUCED EX-VIVO BY LUMINOL-H2O2 CHEMILUMINESCENCE METHOD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RATS; RELAXING FACTOR; ENDOTHELIUM; RELEASE; ACTIVATION; ARGININE; BRAIN	Endothelium-derived relaxing factor, identified as nitric oxide (NO), is derived from a guanidino nitrogen of L-arginine via its metabolism by nitric oxide synthase. A newly developed aqua-chemiluminescence system was used to measure the amount of NO release from the isolated, perfused rat kidney concomitantly with the pressure changes (Kikuchi, K., Nagano, T., Hayakawa, H., Hirata, Y., and Hirobe, M. (1993) Anal. Chem. 65, 1794-1799). In normotensive rats, basal NO release was estimated to be 86 +/- 6 fmol min-1 (g of kidney weight)-1, and endothelium-dependent vasodilators increased NO release with a concomitant pressure reduction. Pretreatment of the kidney with detergents to damage the vascular endothelium diminished the responses of NO and perfusion pressure to acetylcholine, while infusion of authentic NO solution caused an increase in the chemiluminescence and a concomitant decrease in the pressure. The half-life of NO in O2-saturated Krebs-Henseleit buffer was determined as 6.41 s, and the decay constant (K(d)) was 0.108 s-1. The measuring system involves a lag time of 15 s after passage of the solution through the kidney, so that the measured value is 13.0% of the true luminal NO concentration in the kidney, up to 400 pM. These observations enabled us to quantitate the degree to which NO released from the rat kidney changes perfusion pressure. Acetylcholine-induced vasodilation and NO release were markedly attenuated in deoxycorticosterone acetate-salt hypertensive rats, in which the endothelium is known to be markedly damaged. Thus, this assay system may make it possible to evaluate the extent of injury to the endothelium in conditions involving vascular damage.	UNIV TOKYO,FAC PHARMACEUT SCI,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 2,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo			Kikuchi, Kazuya/D-2370-2009					BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; FEELISCH M, 1991, J CARDIOVASC PHARM, V17, pS25, DOI 10.1097/00005344-199117003-00006; FOSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788; FURCHGOTT RF, 1984, ANNU REV PHARMACOL, V24, P175, DOI 10.1146/annurev.pa.24.040184.001135; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; HIRATA Y, 1991, HYPERTENSION, V17, P1025, DOI 10.1161/01.HYP.17.6.1025; HUTTNER I, 1983, HYPERTENSION PHYSIOP, P473; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; KIKUCHI K, 1993, ANAL CHEM, V65, P1794, DOI 10.1021/ac00061a025; KOBAYASHI S, 1980, ANAL CHEM, V52, P1548, DOI 10.1021/ac50059a046; LUSCHER TF, 1986, J HYPERTENS, V4, pS81; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MORDVINTCEV P, 1991, ANAL BIOCHEM, V199, P142, DOI 10.1016/0003-2697(91)90282-X; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Stott R. A. W., 1987, BIOLUMINESCENCE CHEM, P237; SUGIMOTO T, 1986, LIFE SCI, V38, P1351, DOI 10.1016/0024-3205(86)90467-4; TESFAMARIAM B, 1988, HYPERTENSION, V11, P440, DOI 10.1161/01.HYP.11.5.440; VANHOUTTE PM, 1989, HYPERTENSION, V13, P658, DOI 10.1161/01.HYP.13.6.658; [No title captured]	23	108	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23106	23110						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226828				2022-12-25	WOS:A1993MF51500025
J	XIA, L; LU, ZM; LO, TCY				XIA, L; LU, ZM; LO, TCY			TRANSCRIPTS FOR THE HIGH AND LOW-AFFINITY HEXOSE TRANSPORTERS IN RAT MYOBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLUCOSE TRANSPORTER; PLASMA-MEMBRANE VESICLES; L6 MUSCLE-CELLS; SKELETAL-MUSCLE; MESSENGER-RNA; CYTOCHALASIN-B; 3T3-L1 ADIPOCYTES; DIFFERENTIAL REGULATION; FUNCTIONAL EXPRESSION; GENE LOCALIZATION	The present investigation examined the glucose transporter (GLUT) transcript levels in glucose-grown rat L6 myoblasts, which possessed a high (HAHT) and a low (LAHT) affinity hexose transport system. The most prominent GLUT transcript detected in these cells was a GLUT 3-recognizable 4.1-kilobase transcript. Mutants defective in HAHT contained only residual levels of the GLUT 3 transcript and transporter. Corresponding changes in GLUT 3 transcript levels and HAHT activity were observed in myotubes, confluent cultures, and myogenesis-impaired cells. The other prominent GLUT transcripts detected were the GLUT 4-recognizable 2.8- and 1.4-kilobase transcripts. The close correlation between the GLUT 4 isoform and LAHT activity was indicated by the absence of this isoform in LAHT- mutants, and their corresponding changes in myoblasts grown under different conditions. These findings suggested the HAHT and LAHT transporters might be coded or regulated by the genes responsible for the GLUT 3 and 4 transcripts, respectively. Although relatively high levels of the GLUT 1 transcript and transporter were detected in glucose-grown HAHT-LAHT- mutants, these cells did not exhibit any GLUT 1 transport activity. Since the GLUT 1 transporter was not functional, it was not likely responsible for the HAHT and LAHT activities observed in glucose-grown L6 myoblasts.	UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ONTARIO,CANADA	Western University (University of Western Ontario)								BATT ER, 1976, J BIOL CHEM, V251, P7184; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BURNOL AF, 1990, BIOCHEM J, V270, P277, DOI 10.1042/bj2700277; CARTERSU C, 1982, J BIOL CHEM, V257, P5419; CHEN SR, 1989, J CELL PHYSIOL, V138, P338, DOI 10.1002/jcp.1041380217; CHEN SR, 1988, BIOCHEM J, V251, P63, DOI 10.1042/bj2510063; CHEN SR, 1990, BIOCHEM INT, V20, P747; CHEUNG MO, 1984, CAN J BIOCHEM CELL B, V62, P1217, DOI 10.1139/o84-156; CHRISTOPHER CW, 1976, BIOCHEM J, V158, P439, DOI 10.1042/bj1580439; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; DAMORE T, 1988, BIOCHEM J, V250, P59, DOI 10.1042/bj2500059; DAMORE T, 1986, BIOCHEM J, V238, P831, DOI 10.1042/bj2380831; DAMORE T, 1986, J CELL PHYSIOL, V127, P95, DOI 10.1002/jcp.1041270113; DAMORE T, 1986, BIOCHEM CELL BIOL, V64, P1081, DOI 10.1139/o86-143; DAMORE T, 1986, J CELL PHYSIOL, V127, P106, DOI 10.1002/jcp.1041270114; DAMORE T, 1986, J CELL PHYSL, V126, P26; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; DAVIES A, 1987, J BIOL CHEM, V262, P9347; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; FLIER JS, 1987, J CLIN INVEST, V79, P657, DOI 10.1172/JCI112864; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GERHART DZ, 1992, P NATL ACAD SCI USA, V89, P733, DOI 10.1073/pnas.89.2.733; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HASPEL HC, 1988, J BIOL CHEM, V263, P398; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KELLER K, 1989, J BIOL CHEM, V264, P18884; KITAGAWA T, 1991, J BIOL CHEM, V266, P18066; KITZMAN HH, 1993, J BIOL CHEM, V268, P1320; KLIP A, 1992, J CELL BIOCHEM, V48, P51, DOI 10.1002/jcb.240480109; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; KOZKA IJ, 1984, BIOCHIM BIOPHYS ACTA, V797, P212, DOI 10.1016/0304-4165(84)90124-7; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; KRUPKA R M, 1986, P537; KUDO PA, 1990, J CELL PHYSIOL, V145, P347, DOI 10.1002/jcp.1041450221; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MAY JM, 1985, J BIOL CHEM, V260, P462; MESMER O, 1986, BIOCHEM BIOPH RES CO, V141, P124, DOI 10.1016/S0006-291X(86)80343-6; MESMER OT, 1990, BIOCHEM J, V265, P823, DOI 10.1042/bj2650823; MESMER OT, 1989, BIOCHEM J, V262, P15, DOI 10.1042/bj2620015; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; OKA Y, 1988, J BIOL CHEM, V263, P13432; OLEFSKY JM, 1978, BIOCHEM J, V172, P137, DOI 10.1042/bj1720137; PESSIN JE, 1984, FED PROC, V43, P2258; REED BC, 1990, ARCH BIOCHEM BIOPHYS, V279, P261, DOI 10.1016/0003-9861(90)90490-P; ROBERTS SJ, 1982, BIOCHEM J, V205, P139, DOI 10.1042/bj2050139; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR HK, 1988, P NATL ACAD SCI USA, V85, P5463, DOI 10.1073/pnas.85.15.5463; SHANAHAN MF, 1982, BIOCHEM BIOPH RES CO, V107, P38, DOI 10.1016/0006-291X(82)91666-7; SHANAHAN MF, 1987, J BIOL CHEM, V262, P5978; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; THORENS B, 1990, DIABETES, V39, P712, DOI 10.2337/diabetes.39.6.712; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER PS, 1989, J BIOL CHEM, V264, P6587; WALMSLEY AR, 1988, TRENDS BIOCHEM SCI, V13, P226, DOI 10.1016/0968-0004(88)90089-8; WANG C, 1987, J BIOL CHEM, V262, P15689; WEILAND M, 1990, BIOCHEM J, V270, P331, DOI 10.1042/bj2700331; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YAMADA Y, 1990, BIOCHEM BIOPH RES CO, V168, P1274, DOI 10.1016/0006-291X(90)91166-P	73	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23258	23266						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226848				2022-12-25	WOS:A1993MF51500050
J	KEEFER, JR; KENNEDY, ME; LIMBIRD, LE				KEEFER, JR; KENNEDY, ME; LIMBIRD, LE			UNIQUE STRUCTURAL FEATURES IMPORTANT FOR STABILIZATION VERSUS POLARIZATION OF THE ALPHA(2A)-ADRENERGIC RECEPTOR ON THE BASOLATERAL MEMBRANE OF MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; MDCK CELLS; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; ALPHA-2A-ADRENERGIC RECEPTOR; LIGAND-BINDING; ALPHA-2-ADRENERGIC RECEPTORS; MUTATIONAL ANALYSIS; INTRACELLULAR LOOP	The alpha(2A)-adrenergic receptor (alpha(2A)AR) is polarized to the basolateral membrane of Madin-Darby canine kidney cells via direct targeting. Examination of mutant <alpha >(2A)AR reveals that direct delivery is independent of NH,-terminal glycosylation, COOH-terminal acylation, or protein sequences within the large third cytoplasmic loop or COOH-terminal tail. Combined mutation of these structural features also does not perturb alpha(2A)AR delivery, suggesting that a three-dimensional structure imparted by non-contiguous endofacial sequences does not confer alpha(2A)AR targeting and that motifs in or near the bilayer must be involved in targeting of the alpha(2A)AR. Mutation of a conserved Asp residue in transmembrane two that alters receptor-G-protein interactions also does not impair alpha(2A)AR targeting. Finally, modification of sequences in transmembrane seven that resemble tyrosine-containing endocytosis motifs utilized for targeting by some proteins does not perturb alpha(2A)AR sorting. Interestingly, deletion of the large third cytoplasmic loop of the alpha(2A)AR decreases receptor half-life on the basolateral surface from approximately 11 to 4.5 h without altering the ability of the alpha(2A)AR to couple to G-proteins. These data suggest that although targeting of the alpha(2A)AR likely involves bilayer sequences, the third cytoplasmic loop may contain structural features that promote stabilization of the alpha(2A)AR on the basolateral surface of Madin-Darby canine kidney cells.	VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025182, R01HL043671, R37HL043671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 25182, HL 43671] Funding Source: Medline; NIDDK NIH HHS [DK 43879] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHABRE O, 1994, IN PRESS J BIOL CHEM, V269; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; GERHARDT MA, 1990, MOL PHARMACOL, V38, P214; GILLY WF, 1990, NEURON, V5, P663, DOI 10.1016/0896-6273(90)90220-A; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GUYER CA, 1990, J BIOL CHEM, V265, P17318; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LANIER SM, 1986, MOL PHARMACOL, V29, P219; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; RANDS E, 1990, J BIOL CHEM, V265, P10759; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SUMMERS RJ, 1984, FED PROC, V43, P2917; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; VALET P, 1993, J CLIN INVEST, V91, P2049, DOI 10.1172/JCI116427; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; WANG CD, 1991, MOL PHARMACOL, V40, P168; WANG Z, 1993, MOL ENDOCRINOL, V7, P85, DOI 10.1210/me.7.1.85	38	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16425	16432						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206950				2022-12-25	WOS:A1994NQ72900071
J	NORDMANN, B; LEBERT, MR; ALAM, M; NITZ, S; KOLLMANNSBERGER, H; OESTERHELT, D; HAZELBAUER, GL				NORDMANN, B; LEBERT, MR; ALAM, M; NITZ, S; KOLLMANNSBERGER, H; OESTERHELT, D; HAZELBAUER, GL			IDENTIFICATION OF VOLATILE FORMS OF METHYL-GROUPS RELEASED BY HALOBACTERIUM-SALINARIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSORY RHODOPSIN-I; ACCEPTING TAXIS PROTEINS; ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; BACILLUS-SUBTILIS; HALOBIUM; CHEMOTAXIS; MUTANTS; ARCHAEBACTERIA; PHOTOTAXIS	Halobacterium salinarium (formerly H. halobium) is a chemotactic and phototactic archaeon from which volatile methyl groups are released continually, a phenomenon related to its sensory system. We found that released methyl groups comprised two different chemical species, methanol and methanethiol, the sulfur analog of methanol. Radiolabeling experiments showed that the methyl groups of both compounds, as well as the sulfur of methanethiol, were derived from methionine but were donated to cellular components and subsequently cleaved to produce the respective volatile compounds. Previous work had shown that chemostimuli and photostimuli result in transient increases in the rate of release of volatile methyl groups. We found that these in creases reflected increased release of methanol but not of methanethiol. Thus, the methyl group chemistry of the H. salinarium sensory system is analogous to the well-studied chemotactic system of Escherichia coli. The reactions that result in methanethiol release are of unknown function and have unusual features. They may involve a methionine-gamma-lyase activity we detected in H. salinarium. Sulfur derived from methionine was found attached to specific proteins in reduction-sensitive disulfide linkages.	WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; TECH UNIV MUNCHEN WEIHENSTEPHAN,INST LEBENSMITTELTECHNOL & ANALYT CHEM,D-85350 FREISING,GERMANY	Washington State University; Max Planck Society; Technical University of Munich					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029963] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29963] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALAM M, 1989, EMBO J, V8, P631, DOI 10.1002/j.1460-2075.1989.tb03418.x; ALAM M, 1991, J BACTERIOL, V173, P5837, DOI 10.1128/jb.173.18.5837-5842.1991; BURROWS GG, 1989, J BIOL CHEM, V264, P17309; CHELSKY D, 1984, ANAL BIOCHEM, V141, P143, DOI 10.1016/0003-2697(84)90437-8; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; KEHRY MR, 1984, J BIOL CHEM, V259, P1828; NEISH AC, 1957, METHOD ENZYMOL, V3, P255, DOI 10.1016/S0076-6879(57)03386-8; NITZ S, 1991, J CHROMATOGR, V547, P516, DOI 10.1016/S0021-9673(01)88682-9; Oesterhelt D, 1974, Methods Enzymol, V31, P667; OESTERHELT D, 1990, BIOL CHEMOTACTIC RES, P219; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; SODA K, 1983, TRENDS BIOCHEM SCI, V8, P214, DOI 10.1016/0968-0004(83)90216-5; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; SPUDICH EN, 1989, P NATL ACAD SCI USA, V86, P7746, DOI 10.1073/pnas.86.20.7746; SPUDICH EN, 1988, J BACTERIOL, V170, P4280, DOI 10.1128/jb.170.9.4280-4285.1988; SPUDICH EN, 1982, P NATL ACAD SCI-BIOL, V79, P4308, DOI 10.1073/pnas.79.14.4308; SPUDICH JL, 1988, ANNU REV BIOPHYS BIO, V17, P193; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P931, DOI 10.1016/S0076-6879(57)03481-3; SUNDBERG SA, 1985, J BACTERIOL, V164, P282, DOI 10.1128/JB.164.1.282-287.1985; SUNDBERG SA, 1990, J BACTERIOL, V172, P2328, DOI 10.1128/jb.172.5.2328-2335.1990; THOELKE MS, 1990, J BIOL CHEM, V265, P1928; THOELKE MS, 1989, BIOCHEMISTRY-US, V28, P5585, DOI 10.1021/bi00439a037; YAO VJ, 1992, P NATL ACAD SCI USA, V89, P11915, DOI 10.1073/pnas.89.24.11915	23	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16449	16454						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206953				2022-12-25	WOS:A1994NQ72900074
J	UMAYAHARA, Y; KAWAMORI, R; WATADA, H; IMANO, E; IWAMA, N; MORISHIMA, T; YAMASAKI, Y; KAJIMOTO, Y; KAMADA, T				UMAYAHARA, Y; KAWAMORI, R; WATADA, H; IMANO, E; IWAMA, N; MORISHIMA, T; YAMASAKI, Y; KAJIMOTO, Y; KAMADA, T			ESTROGEN REGULATION OF THE INSULIN-LIKE GROWTH-FACTOR-I GENE-TRANSCRIPTION INVOLVES AN AP-1 ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; C-JUN; GLUCOCORTICOID RECEPTOR; THYROID-HORMONE; RETINOIC ACID; FOS-JUN; FUNCTIONAL ANTAGONISM; NEGATIVE REGULATION; OSTEOBLASTIC CELLS; RESPONSE ELEMENT	As a step toward elucidating the physiological role of insulin-like growth factor-I (IGF-I) in mediating estrogen action, we sought to determine the molecular basis of the phenomenon. In HepG2 cells expressing exogenous estrogen receptors (ER), a reporter gene plasmid containing 600 base pairs of the chicken IGF-I promoter enhanced expression of luciferase 8.6-fold in response to 10(-6) M 17 beta-estradiol, indicating that the IGF-I promoter is a target of estrogen regulation. Although no conventional estrogen-responsive element was identified within the promoter fragment, the AP-1 motif located therein was shown to be essential; the estrogen-responsive enhancement of the Fos-Jun binding to the AP-1 motif, which takes place by means of post-translational modification, mediates the estrogen action. A direct or indirect interaction between the estrogen-ER complex and the Fos-Jun complex seems to facilitate the Fos-Jun binding to the target DNA. Although ER binding to the target DNA was not considered to be involved in the signaling pathway, the DNA binding domain-deficient ER did not mediate the phenomenon, providing support for the existence of a unique function of the DNA binding domain of ER in facilitating some protein-protein interaction. In conclusion, our present observations demonstrate that the chicken IGF-I gene promoter is controlled by estrogen through a unique pathway involving Fos, Jun, and the DNA binding domain of ER.	OSAKA UNIV,SCH MED,DEPT MED 1,SUITA,OSAKA 565,JAPAN	Osaka University				Watada, Hirotaka/0000-0001-5961-1816				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ERNST M, 1991, MOL ENDOCRINOL, V5, P1081, DOI 10.1210/mend-5-8-1081; ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo-125-2-825; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRILL HJ, 1983, J CLIN CHEM CLIN BIO, V21, P175; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JENSEN DE, 1991, ONCOGENE, V6, P1219; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAJIMOTO Y, 1993, BIOCHEM BIOPH RES CO, V190, P767, DOI 10.1006/bbrc.1993.1115; KAJIMOTO Y, 1991, J BIOL CHEM, V266, P9724; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KIKUCHI K, 1992, J BIOL CHEM, V267, P21505; KIM SW, 1991, MOL ENDOCRINOL, V5, P1964, DOI 10.1210/mend-5-12-1964; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MURPHY LJ, 1990, ENDOCR REV, V11, P443, DOI 10.1210/edrv-11-3-443; MURPHY LJ, 1987, MOL ENDOCRINOL, V1, P445, DOI 10.1210/mend-1-7-445; MURPHY LJ, 1988, ENDOCRINOLOGY, V122, P325, DOI 10.1210/endo-122-1-325; MURPHY LJ, 1989, MOL CELL ENDOCRINOL, V64, P81, DOI 10.1016/0303-7207(89)90067-1; NAGAOKA I, 1990, J CLIN INVEST, V85, P448, DOI 10.1172/JCI114458; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; ROGERS SA, 1991, J CLIN INVEST, V87, P347, DOI 10.1172/JCI114992; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; Sambrook J, 1989, MOL CLONING LABORATO; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOLLET P, 1990, MOL ENDOCRINOL, V4, P1934, DOI 10.1210/mend-4-12-1934; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WEISZ A, 1988, MOL ENDOCRINOL, V2, P816, DOI 10.1210/mend-2-9-816; WOLF M, 1989, ENDOCRINOLOGY, V125, P2905, DOI 10.1210/endo-125-6-2905; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x	57	318	323	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16433	16442						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206951				2022-12-25	WOS:A1994NQ72900072
J	DONOSO, P; HIDALGO, C				DONOSO, P; HIDALGO, C			PH-SENSITIVE CALCIUM-RELEASE IN TRIADS FROM FROG SKELETAL-MUSCLE - RAPID FILTRATION STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-INDUCED CA-2+ RELEASE; SARCOPLASMIC-RETICULUM VESICLES; INTRACELLULAR FREE MAGNESIUM; FOOT PROTEIN ISOFORMS; RYANODINE RECEPTOR; GATING BEHAVIOR; CA2+ RELEASE; CHANNEL; CONTRACTION; FIBERS	Triad vesicles from frog skeletal muscle exhibited calcium-induced calcium release highly sensitive to extravesicular pH; calcium induced release at pH > 7.4 but not at pH 6.8. In contrast, triads isolated from rabbit skeletal muscle exhibited significant calcium-induced calcium release at pH 6.8. At pH 7.4, there was no stimulation of calcium release in triads from frog at pCa 7, maximum stimulation at pCa 5, and complete inhibition at pCa 3. Addition of ATP at pCa 5, pH 6.8, induced calcium release with the same high rate constants in both preparations. In triads from frog, ATP-induced calcium release at pCa 5 had the same kinetics at pH 6.8 and 7.4, whereas ATP-induced calcium release at pCa > 8, pH 6.8, was partial, with a decrease in the amounts released but not in rate constants. In contrast, triads from rabbit displayed the opposite behavior, with a decrease in rate constants but not in the amounts of calcium released at pCa > 8, pH 6.8. In triads from frog ATP-induced calcium release decreased at pCa < 4, to reach total inhibition at pCa 2; addition of magnesium (free > 0.5 mM) completely abolished ATP-induced calcium release at pH 6.8, pCa 7 or 5. The potential physiological relevance of these results is discussed.	CTR ESTUDIOS CIENT SANTIAGO, SANTIAGO, CHILE		DONOSO, P (corresponding author), UNIV CHILE, FAC MED, DEPT FISIOL & BIOFIS, CASILLA 70005, SANTIAGO 7, CHILE.		HIDALGO, Cecilia/H-7107-2013					AIREY JA, 1990, J BIOL CHEM, V265, P14187; ALVAREZLEEFMANS FJ, 1986, J PHYSIOL-LONDON, V378, P461, DOI 10.1113/jphysiol.1986.sp016230; BAYLOR SM, 1983, J PHYSIOL-LONDON, V344, P625, DOI 10.1113/jphysiol.1983.sp014959; BLATTER LA, 1990, PFLUG ARCH EUR J PHY, V416, P238, DOI 10.1007/BF00392059; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; BULL R, 1993, IN PRESS FEBS LETT; DETTBARN C, 1991, J BIOL CHEM, V266, P8993; DONOSO P, 1992, Biophysical Journal, V61, pA423; DULHUNTY AF, 1992, PROG BIOPHYS MOL BIO, V57, P181, DOI 10.1016/0079-6107(92)90024-Z; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GOLDSTEIN DA, 1979, BIOPHYS J, V26, P235, DOI 10.1016/S0006-3495(79)85247-9; HAIN J, 1993, BIOPHYS J, V64, P151; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HIDALGO C, 1993, J BIOL CHEM, V268, P15111; IINO M, 1992, BIOCHEM BIOPH RES CO, V185, P713, DOI 10.1016/0006-291X(92)91684-I; IKEMOTO N, 1989, J BIOENERG BIOMEMBR, V21, P247, DOI 10.1007/BF00812071; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JAIMOVICH E, 1986, BIOCHIM BIOPHYS ACTA, V855, P89, DOI 10.1016/0005-2736(86)90192-6; KAWAMOTO RM, 1986, J CELL BIOL, V103, P1405, DOI 10.1083/jcb.103.4.1405; KIM DH, 1983, J BIOL CHEM, V258, P9662; KONISHI M, 1993, BIOPHYS J, V64, P223, DOI 10.1016/S0006-3495(93)81359-6; LAI FA, 1992, AM J PHYSIOL, V263, pC365, DOI 10.1152/ajpcell.1992.263.2.C365; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P247; LAMB GD, 1992, J PHYSIOL-LONDON, V448, P211, DOI 10.1113/jphysiol.1992.sp019037; LAMB GD, 1992, NEWS PHYSIOL SCI, V7, P270; MA J, 1988, SCIENCE, V242, P99, DOI 10.1126/science.2459777; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MEISSNER G, 1990, SER CENT ES, P475; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MOUTIN MJ, 1988, J BIOL CHEM, V263, P4228; MURAYAMA T, 1992, J BIOCHEM, V112, P514, DOI 10.1093/oxfordjournals.jbchem.a123931; OGAWA Y, 1970, J BIOCHEM-TOKYO, V67, P667, DOI 10.1093/oxfordjournals.jbchem.a129295; OGAWA Y, 1976, J BIOCHEM-TOKYO, V80, P1149, DOI 10.1093/oxfordjournals.jbchem.a131370; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; RARDON DP, 1990, CIRC RES, V67, P84, DOI 10.1161/01.RES.67.1.84; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROUSSEAU E, 1990, PFLUG ARCH EUR J PHY, V415, P645, DOI 10.1007/BF02583520; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; Smith RM, 1974, CRITICAL STABILITY C, V1-6; SUMBILLA C, 1987, FEBS LETT, V210, P31, DOI 10.1016/0014-5793(87)81292-9; TRIMM JL, 1988, J BIOL CHEM, V263, P17443; VALDIVIA HH, 1990, BIOPHYS J, V58, P471, DOI 10.1016/S0006-3495(90)82392-4; VOLPE P, 1988, J BIOL CHEM, V263, P9901; WESTERBLAD H, 1991, AM J PHYSIOL, V261, pE195	52	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25432	25438						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244976				2022-12-25	WOS:A1993MK10000026
J	MCCORMICK, KA; DECKERSHEBESTREIT, G; ALTENDORF, K; CAIN, BD				MCCORMICK, KA; DECKERSHEBESTREIT, G; ALTENDORF, K; CAIN, BD			CHARACTERIZATION OF MUTATIONS IN THE B-SUBUNIT OF F(1)F(0) ATP SYNTHASE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; NUCLEOTIDE-SEQUENCE; PROPIONIGENIUM-MODESTUM; MEMBRANE-PROTEINS; CLONING VEHICLES; F0 SUBUNITS; F1F0 ATPASE; GENES; OPERON; ORGANIZATION	Site-directed mutagenesis was used to investigate the restrictions on Ala-79 of the b subunit in F1F0 adenosine triphosphate synthase. This amino acid had been previously identified as particularly sensitive to mutation (McCormick, K. A., and Cain, B. D. (1991) J. Bacteriol. 173, 7240-7248). Mutant uncF (b) genes were placed under control of the lac promoter and monitored for F1F0 ATP synthase function in an uncF(b) deletion strain. Three deleterious b(Ala-79) mutations were moved to the unc operon in the chromosome by homologous recombination. Decreases in enzymatic activity in the uncF (b) mutant strains resulted from reduced amounts of enzyme. With the exception of the b(Ala-79-->Pro) mutation, high expression of mutant uncF (b) genes resulted in increases in F1F0 ATP synthase activity which were sufficient to overcome the defects. In addition to the decrease in the amount of enzyme, the b(Ala-79-->Lys) mutation affected ATP synthesis to a much greater extent than ATP-driven proton translocation. The evidence supports our earlier hypothesis, in which b(Ala-79) was proposed to play an important, but not essential, structural role in F1F0 ATP synthase assembly or stability.	UNIV FLORIDA,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610; UNIV OSNABRUCK,FACHBEREICH BIOL CHEM,ARBEITSGRP MIKROBIOL,W-4500 OSNABRUCK,GERMANY	State University System of Florida; University of Florida; University Osnabruck					NIGMS NIH HHS [GM43495] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043495] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIS JP, 1985, J BIOL CHEM, V260, P1207; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRUSILOW WSA, 1989, J BIOL CHEM, V264, P1528; CAIN BD, 1986, J BIOL CHEM, V261, P43; CALOS MP, 1983, P NATL ACAD SCI-BIOL, V80, P3015, DOI 10.1073/pnas.80.10.3015; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COX GB, 1973, BIOCHEM J, V134, P1015, DOI 10.1042/bj1341015; COX GB, 1984, BIOCHIM BIOPHYS ACTA, V768, P201, DOI 10.1016/0304-4173(84)90016-8; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; DECKERSHEBESTREIT G, 1992, J BIOL CHEM, V267, P12364; DECKERSHEBESTREIT G, 1986, EUR J BIOCHEM, V161, P225, DOI 10.1111/j.1432-1033.1986.tb10146.x; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; DUNN SD, 1992, J BIOL CHEM, V267, P7630; ESSER U, 1990, NUCLEIC ACIDS RES, V18, P5887, DOI 10.1093/nar/18.19.5887; FALK G, 1988, BIOCHEM J, V254, P109, DOI 10.1042/bj2540109; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GAY NJ, 1981, NUCLEIC ACIDS RES, V9, P3919, DOI 10.1093/nar/9.16.3919; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GUNSALUS RP, 1982, P NATL ACAD SCI-BIOL, V79, P320, DOI 10.1073/pnas.79.2.320; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HUMBERT R, 1983, J BACTERIOL, V153, P416, DOI 10.1128/JB.153.1.416-422.1983; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; IVEY DM, 1991, MOL GEN GENET, V229, P292, DOI 10.1007/BF00272169; KAIM G, 1992, EUR J BIOCHEM, V207, P463, DOI 10.1111/j.1432-1033.1992.tb17072.x; KRUMHOLZ LR, 1989, NUCLEIC ACIDS RES, V17, P7993, DOI 10.1093/nar/17.19.7993; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCARN DF, 1988, J BACTERIOL, V170, P3448, DOI 10.1128/jb.170.8.3448-3458.1988; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; Miller J. H., 1972, EXPT MOL GENETICS, P431; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; PORTER ACG, 1985, J BIOL CHEM, V260, P8182; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIMMEL P, 1990, BIOCHEMISTRY-US, V29, P9495, DOI 10.1021/bi00493a001; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SENIOR AE, 1983, BIOCHIM BIOPHYS ACTA, V726, P81, DOI 10.1016/0304-4173(83)90001-0; SHIBATA C, 1992, J BACTERIOL, V174, P6117, DOI 10.1128/JB.174.19.6117-6124.1992; STEFFENS K, 1987, J BIOL CHEM, V262, P5866; TAMARAPPOO BK, 1992, J BIOL CHEM, V267, P2370; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER JE, 1982, NATURE, V298, P867, DOI 10.1038/298867a0; 1992, AMPLITAQ CYCLE SEQUE; 1987, K RT SEQUENCING SYST	50	22	22	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24683	24691						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227028				2022-12-25	WOS:A1993MG67300029
J	NAGATA, K; OZAWA, S; MIYATA, M; SHIMADA, M; GONG, DW; YAMAZOE, Y; KATO, R				NAGATA, K; OZAWA, S; MIYATA, M; SHIMADA, M; GONG, DW; YAMAZOE, Y; KATO, R			ISOLATION AND EXPRESSION OF A CDNA-ENCODING A MALE-SPECIFIC RAT SULFOTRANSFERASE THAT CATALYZES ACTIVATION OF N-HYDROXY-2-ACETYLAMINOFLUORENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL SULFOTRANSFERASE; COMPLEMENTARY-DNA; HYDROXYSTEROID SULFOTRANSFERASE; N-HYDROXYARYLAMINE; SEQUENCE-ANALYSIS; MAMMALIAN-CELLS; GROWTH-HORMONE; LIVER; PURIFICATION; CLONING	A cDNA (ST1C1 cDNA) encoding a N-hydroxyarylamine sulfotransferase (HAST-I) was isolated from a liver cDNA library of a male adult rat and was expressed in COS-1 cells. ST1C1 cDNA (1363 base pairs) encoded a protein of 304 amino acids with a molecular mass of 35,768 daltons, which shared 50.7 and 46.1% sequence identity with rat aryl (ST1A1 (PST-1)) and estrogen (rOST) sulfotransferases, respectively. N-terminal amino acid sequences of three digested polypeptide fragments of HAST-1 were completely identical with two portions of the ST1C1 amino acid sequence. The profile of age- and sex-related expression of ST1C1 mRNA was quite consistent with changes in the sulfating activity of N-hydroxyarylamine and HAST contents in rat livers. ST1C1 expressed in COS-1 cells catalyzed a sulfation of N-hydroxy-2-acetylaminofluorene (N-OH-AAF) at a rate of 4.98 nmol/mg of protein/min and mediated PAPS (3'-phosphoadenosine-5'-phosphosulfate)-dependent DNA binding of N-OH-AAF. Although ASTIV was believed to be responsible for the activation of N-OH-AAF, ST1A1 encoding an arylsulfotransferase ASTIV, showed only a marginal activity in a sulfation and covalent binding of N-OH-AAF. These data clearly indicate that ST1C1 cDNA codes a new form of a male-dominant sulfotransferase (HAST) responsible for the bioactivation of N-hydroxyarylamines in rat livers.			NAGATA, K (corresponding author), KEIO UNIV,SCH MED,DEPT PHARMACOL,35 SHINANOMACHI,SHINJUKU KU,TOKYO 160,JAPAN.		Gong, Dawei/AAB-4283-2020					ABUZEID M, 1992, CARCINOGENESIS, V13, P1307, DOI 10.1093/carcin/13.8.1307; BURTON K, 1960, BIOCHEM J, V75, P17, DOI 10.1042/bj0750017; CHEN X, 1992, PROTEIN EXPRES PURIF, V3, P421, DOI 10.1016/S1046-5928(05)80045-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COUGHTRIE MWH, 1990, BIOCHEM PHARMACOL, V40, P2305, DOI 10.1016/0006-2952(90)90727-3; DEBAUN JR, 1970, CANCER RES, V30, P577; DEININGER PL, 1983, ANAL BIOCHEM, V129, P216, DOI 10.1016/0003-2697(83)90072-6; DEMYAN WF, 1992, MOL ENDOCRINOL, V6, P589, DOI 10.1210/me.6.4.589; GONG DW, 1991, J BIOCHEM-TOKYO, V110, P226, DOI 10.1093/oxfordjournals.jbchem.a123561; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; JACKSON CD, 1972, CANCER RES, V32, P1590; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P199; KADLUBAR FF, 1976, CANCER RES, V36, P2350; KAUFMAN RJ, 1985, P NATL ACAD SCI USA, V82, P689, DOI 10.1073/pnas.82.3.689; KING CM, 1968, SCIENCE, V159, P1351, DOI 10.1126/science.159.3821.1351; KNUTSON JC, 1987, ANAL BIOCHEM, V164, P44, DOI 10.1016/0003-2697(87)90365-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CC, 1985, CARCINOGENESIS, V6, P1037, DOI 10.1093/carcin/6.7.1037; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1989, DECONTAMINATION DILU; MULDER GJ, 1984, PROG DRUG METAB, V8, P35; OGURA K, 1989, BIOCHEM BIOPH RES CO, V165, P168, DOI 10.1016/0006-291X(89)91050-4; OGURA K, 1990, BIOCHEM BIOPH RES CO, V166, P1494, DOI 10.1016/0006-291X(90)91036-R; OZAWA S, 1993, JPN J PHARMACOL, V61, P153, DOI 10.1254/jjp.61.153; OZAWA S, 1990, NUCLEIC ACIDS RES, V18, P4001, DOI 10.1093/nar/18.13.4001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKURA RD, 1981, ARCH BIOCHEM BIOPHYS, V211, P352, DOI 10.1016/0003-9861(81)90464-1; SEKURA RD, 1979, J BIOL CHEM, V254, P5658; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENGOORBERGH JAM, 1985, CARCINOGENESIS, V6, P1635, DOI 10.1093/carcin/6.11.1635; WATABE T, 1982, SCIENCE, V215, P403, DOI 10.1126/science.6800033; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WU SCG, 1976, J BIOL CHEM, V251, P6529; YAMAZOE Y, 1989, CARCINOGENESIS, V10, P1675, DOI 10.1093/carcin/10.9.1675; YAMAZOE Y, 1987, MOL PHARMACOL, V32, P536; YAMAZOE Y, 1993, IN PRESS ENV HLTH PE; YEROKUN T, 1992, CANCER RES, V52, P4779; 1990, APPLIED BIOSYSTEMS P, V42	40	120	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24720	24725						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227031				2022-12-25	WOS:A1993MG67300033
J	SHEN, FS; SEIDAH, NG; LINDBERG, I				SHEN, FS; SEIDAH, NG; LINDBERG, I			BIOSYNTHESIS OF THE PROHORMONE CONVERTASE PC2 IN CHINESE-HAMSTER OVARY CELLS AND IN RAT INSULINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROINSULIN-PROCESSING ENDOPEPTIDASE; MICROINJECTED XENOPUS OOCYTES; SITE-DIRECTED MUTAGENESIS; ENDOPLASMIC-RETICULUM; CHROMAFFIN GRANULES; KEX2; ENDOPROTEASE; FURIN; IDENTIFICATION; PITUITARY	The biosynthesis of the prohormone convertase PC2 was studied in Chinese hamster ovary cells stably transfected with PC2 cDNA (CHO/PC2) and in rat insulinoma cells (Rin5f). The major form of PC2 synthesized by CHO/PC2 cells was a 75-kDa protein corresponding to proPC2; this protein was retained intracellularly for 2-4 h following synthesis, suggesting prolonged intracellular residence. In contrast, the major form of PC2 within Rin cells initially exhibited a molecular mass of 72 kDa and was then progressively converted to a 64-kDa species. This 64-kDa species, which required 1-2 h to be released, was the major PC2 form detectable in Rin cell medium. Calcium-dependent benzyloxycarbonyl-Arg-Ser-Lys-Arg-aminomethylcoumarin cleaving activity was found in spent Rin cell medium; this activity could be immunoprecipitated with a carboxyl-terminal PC2 antibody, but not with preimmune serum. In neither cell line did intracellular PC2 become endoglycosidase H-resistant over time. PC2 released from Rin cells was also endoglycosidase H-sensitive. Microsequencing and endoglycosidase H results indicate that 75-kDa CHO cell PC2 and 72-kDa Rin cell PC2 both represent proPC2. We speculate that (a) PC2 undergoes unusual glycosylation, which may be related to its slow release from cells, and (b) the 64-kDa molecule detectable in spent Rin cell medium represents the enzymatically active form of PC2.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, 1901 PERDIDO ST, NEW ORLEANS, LA 70112 USA; CLIN RES INST MONTREAL, MONTREAL H2W 1R7, QUEBEC, CANADA	Louisiana State University System; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Lindberg, Iris/Q-3825-2019; Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342	NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 05084, R01 DA005084, R56 DA005084] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; GUEST PC, 1992, J BIOL CHEM, V267, P22401; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; KIRCHMAIR R, 1992, FEBS LETT, V297, P302, DOI 10.1016/0014-5793(92)80560-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG I, 1991, ENDOCRINOLOGY, V128, P1849, DOI 10.1210/endo-128-4-1849; LINDBERG I, 1992, BIOCHEM BIOPH RES CO, V183, P1, DOI 10.1016/0006-291X(92)91599-L; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; RHODES CJ, 1989, BIOCHEM J, V258, P305, DOI 10.1042/bj2580305; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; YI Z, 1993, J BIOL CHEM, V268, P5615	39	79	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24910	24915						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227053				2022-12-25	WOS:A1993MG67300060
J	CHEUNG, PH; LUO, WP; QIU, YH; ZHANG, XH; EARLEY, K; MILLIRONS, P; LIN, SH				CHEUNG, PH; LUO, WP; QIU, YH; ZHANG, XH; EARLEY, K; MILLIRONS, P; LIN, SH			STRUCTURE AND FUNCTION OF C-CAM1 - THE 1ST IMMUNOGLOBULIN DOMAIN IS REQUIRED FOR INTERCELLULAR-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOPROTEIN; CARCINOEMBRYONIC ANTIGEN; BILIARY GLYCOPROTEIN; MOLECULE UVOMORULIN; RAT HEPATOCYTES; ECTO-ATPASE; GENE FAMILY; N-CAM; PROTEIN; ISOFORMS	Cell-CAM105 proteins (also called C-CAM) are epithelial cell adhesion molecules of the immunoglobulin (Ig) superfamily. The sequences of C-CAM are highly homologous to those of human carcinoembryonic antigen (CEA)-family proteins. In previous studies using baculoviral vectors, we showed that expression of the L-form cell-CAM105 (also called C-CAM1) in insect cells resulted in cell aggregation (Cheung, P. H., Thompson, N. L., Earley, K., Culic, O., Hixson, D., and Lin, S. H. (1993) J. Biol. Chem. 268, 6139-6146). This result indicates that the insect-cell system is suitable for studying the adhesion function of C-CAM. Since C-CAM1 contains four extracellular Ig-domains, the structural features directly responsible for C-CAM1 adhesion function were investigated by site-directed deletion and expression in the baculovirus/insect cell system. Results from these studies indicated that the first Ig domain located in the NH2-terminal of C-CAM plays a crucial role in intercellular adhesion. Site-directed deletion producing mutants lacking the second, third, or fourth Ig domains had no effect on the adhesion function. In addition, adhesion function was retained when both the third and fourth Ig domains were deleted, although the adhesion activity was reduced to half that in control cells. However, simultaneous deletion of the second, third, and fourth domains abolished adhesion, suggesting that these domains affect the accessibility of the binding site localized in the first domain. In our previous studies, we showed that the cytoplasmic domains of C-CAM play a significant role in the isoforms' adhesion activity since expression of a C-CAM isoform containing only 6 instead of 71 amino acids intracellularly failed to show the adhesion phenotype (Cheung, P. H., Culic, O., Qiu, Y., Earley, K., Thompson, N., Hixson, D. C., and Lin, S.-H. (1993) Biochem. J. 295, in press). These results together suggest that both the cytoplasmic domain and the first N-terminal Ig-like domain are required for C-CAM-mediated cell adhesion activity.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,BOX 89,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	University of Texas System; UTMD Anderson Cancer Center; Harvard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043189] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08893] Funding Source: Medline; NIGMS NIH HHS [GM43189] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BLIKSTAD I, 1992, FEBS LETT, V302, P26, DOI 10.1016/0014-5793(92)80276-M; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; COLE GJ, 1986, NATURE, V320, P445, DOI 10.1038/320445a0; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM Y P, 1990, Journal of Cell Biology, V111, p355A; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; OCKLIND C, 1984, EXP CELL RES, V151, P29, DOI 10.1016/0014-4827(84)90353-7; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; THOMPSON JA, 1989, BIOCHEM BIOPH RES CO, V158, P996, DOI 10.1016/0006-291X(89)92821-0; TINGSTROM A, 1990, J CELL SCI, V96, P17; TURBIDE C, 1991, J BIOL CHEM, V266, P309; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	27	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24303	24310						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226979				2022-12-25	WOS:A1993MF29400088
J	MCCARTHY, SA; BICKNELL, R				MCCARTHY, SA; BICKNELL, R			INHIBITION OF VASCULAR ENDOTHELIAL-CELL GROWTH BY ACTIVIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; SERINE THREONINE KINASE; EXPRESSION CLONING; GENE-EXPRESSION; XENOPUS EMBRYOGENESIS; MESODERM INDUCTION; MOLECULAR-CLONING; AXIAL STRUCTURES; MESSENGER-RNA; FACTOR-BETA	The demonstration of type 2 activin receptor expression in human umbilical vein endothelial cells prompted an investigation of the effects of the activin/inhibin family of hormones on vascular endothelial cell growth. Recombinant activin-A inhibited [H-3]methylthymidine uptake and growth of a panel of endothelial cell types; recombinant inhibin-A was without effect. Affinity cross-linking studies demonstrated the presence of type 1 and type 2 activin receptors on the surface of bovine aortic endothelial cells, while detailed analysis of type 2 activin receptor expression revealed both type 2 and type 2B activin receptor mRNA in all endothelial cell types analyzed. In addition, capillary endothelial cells were found to express activin-beta(A) subunit mRNA and protein, the levels of which were increased in response to transforming growth factor (TGF)-beta. Furthermore, activin-A and TGF-beta caused additive inhibition of capillary endothelial cell [H-3]methylthymidine uptake. These findings implicate the activins in the regulation of endothelial cell function, and suggest that TGF-beta and activin may interact to inhibit capillary endothelial cell growth.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND	Cancer Research UK; University of Oxford			McCarthy, Sarah/HCI-8963-2022	Bicknell, Roy/0000-0002-0941-8919				ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; AUSUBL FM, 1987, CURRENT PROTOCOLS MO; BICKNELL R, 1991, EUR J CANCER, V27, P781, DOI 10.1016/0277-5379(91)90189-K; CAMPEN CA, 1988, BIOCHEM BIOPH RES CO, V157, P844, DOI 10.1016/S0006-291X(88)80326-7; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; DEJONG FH, 1988, PHYSIOL REV, V68, P555, DOI 10.1152/physrev.1988.68.2.555; DONALDSON CJ, 1992, BIOCHEM BIOPH RES CO, V184, P310, DOI 10.1016/0006-291X(92)91194-U; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FAWCETT J, 1991, BIOCHEM BIOPH RES CO, V174, P903, DOI 10.1016/0006-291X(91)91503-5; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FORAGE RG, 1986, P NATL ACAD SCI USA, V83, P3091, DOI 10.1073/pnas.83.10.3091; GONZALEZMANCHON C, 1989, ENDOCRINOLOGY, V125, P1666, DOI 10.1210/endo-125-3-1666; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GROOME N, 1991, HYBRIDOMA, V10, P309, DOI 10.1089/hyb.1991.10.309; HEDGER MP, 1989, MOL CELL ENDOCRINOL, V61, P133, DOI 10.1016/0303-7207(89)90198-6; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HINO M, 1989, J BIOL CHEM, V264, P10309; KOJIMA I, 1989, BIOCHEM BIOPH RES CO, V159, P1107, DOI 10.1016/0006-291X(89)92223-7; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; KONDO S, 1989, BIOCHEM BIOPH RES CO, V161, P1267, DOI 10.1016/0006-291X(89)91379-X; LEGERSKI R, 1992, BIOCHEM BIOPH RES CO, V183, P672, DOI 10.1016/0006-291X(92)90535-S; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P105, DOI 10.1016/0167-4781(92)90472-C; MCCARTHY SA, 1992, J BIOL CHEM, V267, P21617; MEUNIER H, 1988, P NATL ACAD SCI USA, V85, P247, DOI 10.1073/pnas.85.1.247; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; OGAWA Y, 1992, J BIOL CHEM, V267, P14233; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SAWCHENKO PE, 1988, NATURE, V334, P615, DOI 10.1038/334615a0; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SHAO LE, 1992, BLOOD, V79, P773; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SUGINO H, 1988, J BIOL CHEM, V263, P15249; TAKAHASHI S, 1990, BIOCHEM BIOPH RES CO, V167, P654, DOI 10.1016/0006-291X(90)92075-B; TAKAHASHI S, 1992, BIOCHEM BIOPH RES CO, V188, P310, DOI 10.1016/0006-291X(92)92386-C; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VALE W, 1990, PEPTIDE GROWTH FACTO, P211; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMASHITA T, 1992, BLOOD, V79, P304; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	52	140	142	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23066	23071						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226823				2022-12-25	WOS:A1993MF51500019
J	OBERMEIER, A; LAMMERS, R; WIESMULLER, KH; JUNG, G; SCHLESSINGER, J; ULLRICH, A				OBERMEIER, A; LAMMERS, R; WIESMULLER, KH; JUNG, G; SCHLESSINGER, J; ULLRICH, A			IDENTIFICATION OF TRK BINDING-SITES FOR SHC AND PHOSPHATIDYLINOSITOL 3'-KINASE AND FORMATION OF A MULTIMERIC SIGNALING COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; EGF RECEPTOR; PC12 CELLS; PHOSPHORYLATION; TRANSDUCTION; ASSOCIATION; ACTIVATION; PROTEINS	Phosphotyrosine-containing synthetic peptides were used to identify the binding sites for cellular polypeptides involved in nerve growth factor receptor/Trk-mediated signal transduction. In vitro association of SHC and the p85 subunit of phosphatidylinositol 3'-kinase with the Trk tyrosine kinase was prevented only by phosphorylated Y-490- and Y-751-containing peptides, respectively. In spite of the close proximity of the p85 binding site to that of phospholipase Cgamma (Y-785), both target proteins are able to interact with the same receptor molecule simultaneously.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY; UNIV TUBINGEN,INST ORGAN CHEM,W-7400 TUBINGEN 1,GERMANY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Max Planck Society; Eberhard Karls University of Tubingen; New York University								BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HERBST R, 1992, J BIOL CHEM, V267, P13210; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KITAS EA, 1989, TETRAHEDRON LETT, V30, P6229, DOI 10.1016/S0040-4039(01)93351-9; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; THORPE GHG, 1985, CLIN CHEM, V31, P1335; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	25	271	277	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22963	22966						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226808				2022-12-25	WOS:A1993MF51500003
J	MALEK, SN; DESIDERIO, S				MALEK, SN; DESIDERIO, S			SH2 DOMAINS OF THE PROTEIN-TYROSINE KINASES BLK, LYN, AND FYN(T) BIND DISTINCT SETS OF PHOSPHOPROTEINS FROM B-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SRC HOMOLOGY REGION-2; GROWTH-FACTOR RECEPTOR; C-SRC; PHOSPHORYLATED PROTEINS; SIGNAL TRANSDUCTION; HIGH-AFFINITY; PHOSPHATIDYLINOSITOL 3-KINASE; MEMBRANE IMMUNOGLOBULIN; STABLE ASSOCIATION	Several members of the Src family, including Blk, Lyn, Fyn(T), and Lck, are expressed in B cells. These kinases associate with the antigen receptor complex, and the activities of Blk, Fyn(T), and Lyn increase upon receptor engagement. Differences in the amino acid sequences and patterns of expression of these kinases suggest that they serve distinct functions. In this communication it is shown that the SH2 domains from Blk, Lyn, and Fyn(T) preferentially bind distinct sets of phosphoproteins from the mature B cell line A20. These interactions were found to depend on recognition of phosphotyrosine. The Blk SH2 domain bound more than 10 distinct phosphoprotein species, most of which reacted with an antiphosphotyrosine antibody; the phosphotyrosine content of these proteins was increased if surface immunoglobulin was cross-linked before extracts were made. Phosphoproteins of 72, 76, 115, and 130 kDa bound to the SH2 domains of Blk, Lyn, and Fyn(T). Phosphoamino acid analysis of these four proteins revealed that each contained phosphoserine, phosphothreonine, and phosphotyrosine. Proteins of 90 kDa, 130 kDa, and 150 kDa were preferentially bound by the Blk SH2 domain, while the Fyn(T) SH2 domain showed preferential binding to proteins of 76 and 180 kDa. The Lyn SH2 binding profile resembled that of Blk, but differences in the binding specificities of these kinases were also observed. Thus, among proteins that exhibit increased tyrosine phosphorylation following antigen receptor cross-linking, several have been identified that bind preferentially to SH2 domains of Blk, Fyn(T), or Lyn, suggesting that these kinases serve distinct functions. In addition, chimeric Fyn(T)-Blk SH2 domains were shown to be functional in binding assays and to exhibit binding specificities intermediate between those of the parent domains, consistent with the interpretation that the differences we observe in phosphoprotein binding by Fyn(T) and Blk SH2 domains reflect differences in their native structures.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	MALEK, SN (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.							APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COOKE M P, 1989, New Biologist, V1, P66; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; DAVIDPFEUTY T, 1990, EUR J BIOCHEM, V192, P55, DOI 10.1111/j.1432-1033.1990.tb19194.x; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VERDERAME MF, 1989, MOL CELL BIOL, V9, P338; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	36	36	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22557	22565						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226767				2022-12-25	WOS:A1993MD34800058
J	TEALE, B; KHANNA, KK; SINGH, SP; LAVIN, MF				TEALE, B; KHANNA, KK; SINGH, SP; LAVIN, MF			RADIATION-ACTIVATED DNA-BINDING PROTEIN CONSTITUTIVELY PRESENT IN ATAXIA-TELANGIECTASIA NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZING-RADIATION; HUMAN-CELLS; TRANSCRIPTION FACTOR; CHROMOSOME 11Q22-23; TOPOISOMERASE-II; KINASE-C; GENE; LOCALIZATION; IDENTIFICATION; EXPRESSION	We have recently described the appearance of a specific DNA-binding protein in nuclei from human cells exposed to ionizing radiation which was not detected in nuclear extracts from unperturbed cells (Singh, S. P., and Lavin, M. F. (1990) Mol. Cell. Biol. 10, 5279-5285). We report here a similar activity which is constitutively present in nuclei of both unirradiated and irradiated cells from patients with the human genetic disorder ataxia telangiectasia (A-T). Activity was present in unirradiated nuclear extracts from 3 A-T cell lines of different complementation groups, but was not detected or was present only at a low level in 4 controls. Active protein was detected in the cytoplasm of both cell types. Exposure to ionizing radiation did not change the amount of DNA binding activity in A-T nuclei but led to an increase in nuclei from 4 control cell lines. Purification of the binding activities from A-T nuclei and control cytoplasm was carried out by affinity chromatography, as described previously for control extracts (Teale, B., Singh, S. P., Khanna, K. K., Findik, D., and Lavin, M. F. (1992) J. Biol. Chem. 267, 10295-10301). Southwestern analysis and UV cross-linking confirmed the presence of a major DNA-binding species at 70 kDa in both cases with a minor binding activity at 47 kDa also evident. It was not possible to distinguish between the binding activities from A-T and control cells under different conditions, and phosphorylation was required for binding activity in both cases. Footprint analysis revealed that the same sequence was being recognized by the control and A-T proteins. The constitutive presence of a specific radiation-responsive DNA-binding protein in A-T cells may be indicative of a continuous state of stress in these cells.	QUEENSLAND INST MED RES,BANCROFT CTR,QUEENSLAND CANC FUND RES UNIT,PO ROYAL BRISBANE HOSP,HERSTON 4029,AUSTRALIA; CSIRO,DEPT PREVENT MED & COMMUNITY HLTH,CANBERRA,ACT 2601,AUSTRALIA	QIMR Berghofer Medical Research Institute; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			Lavin, Martin F/F-5961-2014; singh, surinder/C-9528-2009	Lavin, Martin F/0000-0002-5940-4769; singh, surinder/0000-0003-4488-8147; Khanna, Kum Kum/0000-0001-8650-5381				ANGULO JF, 1991, NUCLEIC ACIDS RES, V19, P5117, DOI 10.1093/nar/19.19.5117; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BATES PR, 1989, MUTAT RES, V218, P165, DOI 10.1016/0921-8777(89)90023-2; BAXTER G, 1988, IMMUNOL CELL BIOL, V67, P57; BODER E, 1985, ATAXIA TELANGIECTASI, P1; BOOTHMAN DA, 1989, CANCER RES, V49, P2871; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVIES SM, 1989, NUCLEIC ACIDS RES, V17, P1337, DOI 10.1093/nar/17.4.1337; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMASHENKO AD, 1990, INT J RADIAT BIOL, V57, P315, DOI 10.1080/09553009014552431; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FOROUD T, 1991, AM J HUM GENET, V49, P1263; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GLAZER PM, 1989, P NATL ACAD SCI USA, V86, P1163, DOI 10.1073/pnas.86.4.1163; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HANAWALT PC, 1986, TRENDS GENET, V2, P124, DOI 10.1016/0168-9525(86)90201-5; HOBSON K, 1991, ANAL BIOCHEM, V193, P220, DOI 10.1016/0003-2697(91)90012-I; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Jones N, 1990, Semin Cancer Biol, V1, P5; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAPP LN, 1992, AM J HUM GENET, V51, P45; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; KRAMER M, 1990, RADIAT ENVIRON BIOPH, V29, P303, DOI 10.1007/BF01210410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIN MF, 1988, MUTAT RES, V193, P193, DOI 10.1016/0167-8817(88)90030-2; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEYKO W, 1986, INT J RADIAT BIOL, V49, P743, DOI 10.1080/09553008514552971; MCCONVILLE CM, 1990, HUM GENET, V85, P215; MCFARLIN DE, 1972, MEDICINE, V51, P281, DOI 10.1097/00005792-197207000-00002; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PATERSON MC, 1976, NATURE, V260, P444, DOI 10.1038/260444a0; PETERSON RD, 1964, LANCET, V9, P1189; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PIPPARD EC, 1988, CANCER RES, V48, P2929; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SINGH SP, 1988, NUCLEIC ACIDS RES, V16, P3919, DOI 10.1093/nar/16.9.3919; SINGH SP, 1990, MOL CELL BIOL, V10, P5279, DOI 10.1128/MCB.10.10.5279; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TEALE B, 1992, J BIOL CHEM, V267, P10295	50	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22450	22455						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226753				2022-12-25	WOS:A1993MD34800042
J	GOLDBERG, Y; TREIER, M; GHYSDAEL, J; BOHMANN, D				GOLDBERG, Y; TREIER, M; GHYSDAEL, J; BOHMANN, D			REPRESSION OF AP-1-STIMULATED TRANSCRIPTION BY C-ETS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; ETS-RELATED PROTEIN; DNA-BINDING; C-ETS; ACTIVATION DOMAINS; RESPONSE ELEMENT; ANTIGEN RECEPTOR; LEUKEMIA-VIRUS; GENE FAMILY; V-JUN	The transcriptional activities of c-Ets-1 and v-Ets and their functional interaction with the AP-1 factor c-Jun were investigated. Several recombinant Ets proteins were produced and purified either from bacteria or from insect cells. Plasmid DNAs that contained the polyoma virus enhancer Ets/AP-1 element were used as templates for in vitro transcription assays in the presence of HeLa nuclear extract and Various combinations of the Jun and Ets proteins. Under these conditions full-length c-Ets-1 on its own does not markedly influence transcription but abolishes the strong transcriptional stimulation normally elicited by Jun. This repression depends on the Ets-binding site and on specific features of c-Ets-1 structure, as both v-Ets and a natural splicing variant c-Ets-1 (Delta VII) fail to inhibit Jun activity. These findings suggest that c-Ets may act both as a transcriptional repressor or activator depending on promoter context and splicing pattern.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			GHYSDAEL, Jacques/F-3377-2013; Treier, Mathias/AAD-6388-2021	Goldberg, Yves/0000-0001-7446-8595				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BONLUKOS KE, 1989, MOL CELL BIOL, V9, P5718; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GEGONNE A, 1992, NEW BIOL, V4, P512; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO IC, 1990, J EXP MED, V172, P1443, DOI 10.1084/jem.172.5.1443; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MIYAMOTO NG, 1984, NUCLEIC ACIDS RES, V12, P8778; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; POGNONEC P, 1990, ONCOGENE, V5, P603; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; RAO VN, 1992, ONCOGENE, V7, P65; REDDY ESP, 1988, ONCOGENE RES, V3, P239; Sambrook J, 1989, MOL CLONING LABORATO; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WERNERT N, 1992, AM J PATHOL, V140, P119; WILDEMAN AG, 1984, EMBO J, V3, P3129, DOI 10.1002/j.1460-2075.1984.tb02269.x; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	57	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16566	16573						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206973				2022-12-25	WOS:A1994NR29600010
J	VOGEL, U; JENSEN, KF				VOGEL, U; JENSEN, KF			EFFECTS OF GUANOSINE 3',5'-BISDIPHOSPHATE (PPGPP) ON RATE OF TRANSCRIPTION ELONGATION IN ISOLEUCINE-STARVED ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA OPERON; SOURCE SHIFT-DOWN; POOL SIZE; EXPRESSION; ORGANIZATION; TERMINATION; COMPONENTS; POLYMERASE; STARVATION; INVITRO	We measured the transcription elongation rate on two mRNA genes, i.e. infB and lacZ, and on a part of the rrnB gene under conditions when wild type (rel(+)) Escherichia coli and relaxed (relA) mutants were exposed to isoleucine starvation. The RNA chain growth rates were calculated from the time lag between induction of transcription and the appearance of specific hybridization to probes complementary to the 3' ends of the genes, i.e. from the transcription time. The rate of mRNA chain elongation responded differently in rel(+) and relA strains exposed to isoleucine starvation as it decreased (similar to 50%) in rel(+) strains that accumulated high concentrations of guanosine 3',5'-bisdiphosphate (ppGpp) and increased (similar to 15%) the relA mutant whose ppGpp pool decayed during starvation. These results show that ppGpp inhibits mRNA chain elongation in vivo. However, stable RNA chain elongation appeared unaffected by ppGpp pool size and was twice as fast as mRNA chain elongation in exponentially growing cells.			VOGEL, U (corresponding author), UNIV COPENHAGEN,INST MOLEC BIOL,DEPT BIOL CHEM,SOLVGADE 83,DK-1307 COPENHAGEN K,DENMARK.		Vogel, Ulla B/I-5048-2012; Vogel, Ulla/ABC-2212-2020	Vogel, Ulla B/0000-0001-6807-1524; Vogel, Ulla/0000-0001-6807-1524				ANDERSEN JT, 1991, MOL MICROBIOL, V5, P327, DOI 10.1111/j.1365-2958.1991.tb02113.x; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; BERG KL, 1989, J MOL BIOL, V209, P345, DOI 10.1016/0022-2836(89)90002-8; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; CONDON C, 1993, EMBO J, V12, P4305, DOI 10.1002/j.1460-2075.1993.tb06115.x; HANSEN MT, 1975, J BACTERIOL, V122, P585, DOI 10.1128/JB.122.2.585-591.1975; HERNANDEZ VJ, 1993, J BIOL CHEM, V268, P10851; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; JOHNSEN K, 1977, J BACTERIOL, V131, P18, DOI 10.1128/JB.131.1.18-29.1977; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; LAGOSKY PA, 1981, J BIOL CHEM, V256, P1651; LEAVITT RI, 1962, J BACTERIOL, V83, P624, DOI 10.1128/JB.83.3.624-630.1962; LINN T, 1985, PLASMID, V14, P134, DOI 10.1016/0147-619X(85)90073-3; MOLIN S, 1977, J BACTERIOL, V131, P7, DOI 10.1128/JB.131.1.7-17.1977; PLUMBRIDGE JA, 1983, J MOL BIOL, V167, P227, DOI 10.1016/S0022-2836(83)80333-7; SORENSEN MA, 1989, J MOL BIOL, V207, P365, DOI 10.1016/0022-2836(89)90260-X; SQUIRES CL, 1993, P NATL ACAD SCI USA, V90, P970, DOI 10.1073/pnas.90.3.970; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TURNBOUGH CL, 1983, P NATL ACAD SCI-BIOL, V80, P368, DOI 10.1073/pnas.80.2.368; VOGEL U, 1991, J BACTERIOL, V173, P1168, DOI 10.1128/jb.173.3.1168-1174.1991; VOGEL U, 1992, MOL MICROBIOL, V6, P2191, DOI 10.1111/j.1365-2958.1992.tb01393.x	25	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16236	16241						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206927				2022-12-25	WOS:A1994NQ72900045
J	DEGTYAREV, MY; SPIEGEL, AM; JONES, TLZ				DEGTYAREV, MY; SPIEGEL, AM; JONES, TLZ			INCREASED PALMITOYLATION OF THE G(S) PROTEIN-ALPHA SUBUNIT AFTER ACTIVATION BY THE BETA-ADRENERGIC-RECEPTOR OR CHOLERA-TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-2-ADRENERGIC RECEPTOR; GS; STIMULATION; ACYLATION; MEMBRANE; MUTATION; GTP; IDENTIFICATION; CELLS	The alpha subunit of the heterotrimeric G(s) protein that couples the beta-adrenergic receptor to adenylyl cyclase undergoes post-translational palmitoylation. We examined the dynamics of this modification of alpha(s) by metabolic labeling of COS and S49 lymphoma cells under different conditions. The endogenous alpha(s) proteins were immunoprecipitated with a peptide-specific antibody, separated by SDS-polyacrylamide gel electrophoresis, and analyzed by fluorography and densitometry. A pulse-chase study of COS cells incubated with [H-3]palmitate or [S-35]methionine showed that for alpha(s) the palmitate turnover (t1/2 almost-equal-to 50 min) was significantly faster than the protein degradation. Treatment of cells with 10 muM isoproterenol, a beta-adrenergic receptor agonist, in the presence of [H-3]palmitate led to a rapid 4-10-fold increase in the palmitoylation of alpha(s). This increase in palmitoylation was concentration-dependent (EC50 almost-equal-to 0.9 muM) and blocked by the antagonist propranolol. The mutant alpha(s) proteins in the unc and H21a S49 cell lines did not show an increase in [H-3]palmitate incorporation with isoproterenol treatment. Cholera toxin treatment of COS cells increased the [H-3]palmitate incorporation into the alpha(s) subunits. These data indicate that palmitoylation of the alpha(s) subunit is dynamic and regulated by activation of the alpha(s) subunit.	NIDDK,MPB,BLDG 10,RM 8C-101,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CHANG FH, 1989, J BIOL CHEM, V264, P5352; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DEGTYAREV MY, 1994, IN PRESS CELL SIGNAL; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; JAMES G, 1989, J BIOL CHEM, V264, P20998; JOCHEN A, 1991, BIOCHEM BIOPH RES CO, V177, P797, DOI 10.1016/0006-291X(91)91859-B; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JUHNN YS, 1992, J CELL BIOL, V119, P523, DOI 10.1083/jcb.119.3.523; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OSAWA S, 1990, MOL CELL BIOL, V10, P2931, DOI 10.1128/MCB.10.6.2931; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; STAUFENBIEL M, 1988, J BIOL CHEM, V263, P13615; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; VANDOP C, 1984, J BIOL CHEM, V259, P23	24	166	166	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23769	23772						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226908				2022-12-25	WOS:A1993MF29400010
J	KOUDELKA, GB; LAM, CY				KOUDELKA, GB; LAM, CY			DIFFERENTIAL RECOGNITION OF O(R)1 AND O(R)3 BY BACTERIOPHAGE-434 REPRESSOR AND CRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX; RESOLUTION; PHAGE-434; OPERATOR; HELIX	The developmental decisions of bacteriophage 434 depend on the ability of 434 repressor and Cro to bind O(R)1 and O(R)3 with different relative affinities; repressor binds O(R)1 tighter than O(R)3, whereas Cro slightly prefers O(R)3 over O(R)1. Studies with operator mutants show that repressor's lower relative affinity for O(R)3 results from a deviation in the sequence of O(R)3 from consensus; an A --> G change at position 4 in one half-site (O(R)1: A-C-A-A-A-C-T-T-T-C-T-T-G-T; O(R)3: A-C-A-G-T-T-T-T-T-C-T-T-G-T). Similar experiments show that Cro binds operators containing either A.T or G.C bases pairs at position 4 equally well, but cannot bind operators containing C.G or T.A base pairs at this position. A Gln33 --> Ala mutation in 434 repressor diminishes, but does not eliminate, its ability to distinguish between purines at position 4. This shows that a glutamine at amino acid 33 is not the sole determinant of repressor's position 4 specificity. Changing Gln33 --> Leu. the amino acid at the homologous position in Cro, does not confer ''Cro-like'' position 4 base specificity on repressor. Similarly, a Cro protein bearing Gln at this position does not exhibit repressor's position 4 base preferences. The residual specificities of these mutant proteins indicates that in each protein, more than 1 amino acid is responsible for recognizing bases at position 4. These were identified by analyzing the binding specificities of multiply mutated repressors, in vitro. The types of substitutions made were guided by sequence homologies between 434 repressor and Cro. At least three mutations are needed to eliminate repressor's position 4 base specificity; Gln33 --> Ala, Glu32 --> Gln, and Thr27 --> Lys, although no set of amino acid substitutions in repressor was able to confer Cro-like position 4 specificity to repressor. These results indicate that at least the amino acids at these positions are involved in recognition of the position 4 base. Other evidence suggests that Cro and repressor use identical amino acids present at homologous positions in the DNA recognition helix in different ways.			KOUDELKA, GB (corresponding author), SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260, USA.		Koudelka, Gerald B./AAI-3738-2020	Koudelka, Gerald B./0000-0001-6280-0837	NIGMS NIH HHS [GM42138] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042138, R29GM042138] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BELL AC, 1993, IN PRESS J MOL BIOL; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Maniatis T., 1982, MOL CLONING; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; Ptashne M., 1986, A GENETIC SWITCH; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0; WHARTON RP, 1984, CELL, V38, P361, DOI 10.1016/0092-8674(84)90491-4; WHARTON RR, 1986, THESIS HARVARD U CAM; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0	14	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23812	23817						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226917				2022-12-25	WOS:A1993MF29400019
J	LI, GP; STAHL, PD				LI, GP; STAHL, PD			STRUCTURE-FUNCTION RELATIONSHIP OF THE SMALL GTPASE RAB5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS PROTEIN; BINDING PROTEINS; MOLECULAR-CLONING; P21; MUTANTS; TRANSFERASE; INHIBITION; SECRETION; FARNESYL; DISTINCT	Overexpression of rab5 via a Sindbis virus vector resulted in a 2-3-fold stimulation of horseradish peroxidase uptake in BHK-21 cells. Based on this functional assay of rab5 activity, we conducted extensive mutational analysis of the structure-function relationship of rab5. A total of 21 deletion and substitution mutations were created and their effects on rab5 activity were examined. Deletion of the entire C-terminal tetrapeptide motif CCSN abolished rab5 activity. A mutant with the last three residues deleted, however, showed residual rab5 activity. Truncation of only two residues from the C terminus had no effect on the biological activity of rab5. A mutant containing a 4-residue deletion from the N terminus retained full activity in comparison with wild-type rab5. N-terminal deletion of 19 residues only partially blocked rab5 activity. Substitution mutations in the guanine nucleotide binding motifs showed dramatic effects on rab5 function. In addition to the previously reported N133I mutation, the S34N mutation also resulted in a guanine nucleotide binding defective form that was a dominant inhibitor of endogenous rab5 activity. The Q79L mutation (the ras equivalent Q61L decreases intrinsic and GTPase-activating protein-stimulated GTPase activities), however, had no effect on rab5 activity. The S35N mutation, which is immediately downstream of the first GTP/GDP binding motif, decreased guanine nucleotide binding by approximately 4-fold and partially inactivated rab5. Mutations in several other conserved residues (K22A, F57Y, and R81A) also resulted in partial loss of rab5 activity. Eight mutations in and around the putative effector domain had little effect on rab5 activity. In light of these data, the structure-function relationship of rab5 is discussed and compared with that of ras, the prototype of small GTPases.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Li, Guangpu/GRS-5397-2022; Stahl, Philip/D-6315-2012		NIGMS NIH HHS [GM42259-19] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; DER CJ, 1988, ONCOGENE, V3, P105; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAUBRUCK H, 1991, BIOCHIM BIOPHYS ACTA, V1072, P215, DOI 10.1016/0304-419X(91)90015-D; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LI GP, 1993, ARCH BIOCHEM BIOPHYS, V304, P471, DOI 10.1006/abbi.1993.1377; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; NUREKAMAL MSA, 1992, MOL BIOL CELL, V3, P1437, DOI 10.1091/mbc.3.12.1437; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PETER M, 1992, J CELL SCI, V102, P857; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TONG L, 1989, SCIENCE, V245, P244, DOI 10.1126/science.2665078; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WOLTERS G, 1976, J CLIN PATHOL, V29, P873, DOI 10.1136/jcp.29.10.873; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	41	185	188	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24475	24480						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226999				2022-12-25	WOS:A1993MF29400112
J	NAKAI, H				NAKAI, H			AMPLIFICATION OF BACTERIOPHAGE-MU DNA BY ROLLING CIRCLE DNA-REPLICATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; STRAND-TRANSFER; ENZYMATIC REPLICATION; DEOXYRIBONUCLEIC-ACID; END-PRODUCTS; POLYMERASE-I; B-PROTEIN; TRANSPOSITION; PURIFICATION; MECHANISM	When mini-Mu DNA was allowed to transpose and replicate in vitro over a prolonged period, the products consisted not only of simple inserts and cointegrates but also high molecular weight DNA many times the unit length of mini-Mu. This high molecular weight product contained predominantly full-length mini-Mu DNA and relatively little non-Mu DNA (the vector harboring the mini-Mu element and the target for transposition in the reaction system). It arose from rolling circle DNA replication of templates created by intramolecular strand transfer, which is catalyzed by Mu transposition proteins. A donor substrate, which is a supercoiled plasmid bearing a mini-Mu element, gave rise to large amounts of the high molecular weight product provided that the vector segment outside the mini-Mu element was 2 kilobase pairs or more. When a donor substrate had a vector segment of only 600 base pairs, the mini-Mu element first had to transpose to a larger circular target before giving rise to the high molecular weight product. These results suggest a mechanism by which Mu DNA can be amplified for lytic development without transposing multiple times. By establishing a circular template, multiple copies of Mu can be processively generated from a single initiation event.			NAKAI, H (corresponding author), GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007, USA.							BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; BUKHARI AI, 1976, NATURE, V264, P580, DOI 10.1038/264580a0; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHACONAS G, 1981, J MOL BIOL, V150, P341, DOI 10.1016/0022-2836(81)90551-9; CHACONAS G, 1980, P NATL ACAD SCI-BIOL, V77, P1778, DOI 10.1073/pnas.77.4.1778; CHACONAS G, 1983, VIROLOGY, V128, P48, DOI 10.1016/0042-6822(83)90317-3; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CRAIGIE R, 1985, J BIOL CHEM, V260, P1832; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; DANIELL E, 1975, J VIROL, V15, P739, DOI 10.1128/JVI.15.4.739-743.1975; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; FAELEN M, 1978, NATURE, V271, P580, DOI 10.1038/271580a0; FAELEN M, 1973, VIROLOGY, V54, P117, DOI 10.1016/0042-6822(73)90121-9; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; HARSHEY RM, 1981, P NATL ACAD SCI-BIOL, V78, P1090, DOI 10.1073/pnas.78.2.1090; HARSHEY RM, 1984, NATURE, V311, P580, DOI 10.1038/311580a0; HARSHEY RM, 1982, CELL, V29, P561, DOI 10.1016/0092-8674(82)90172-6; HOOPES BC, 1981, NUCLEIC ACIDS RES, V9, P5493, DOI 10.1093/nar/9.20.5493; HUBER HE, 1987, J BIOL CHEM, V262, P16224; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MIZUUCHI M, 1985, NUCLEIC ACIDS RES, V13, P1193, DOI 10.1093/nar/13.4.1193; NAKAI H, 1988, J BIOL CHEM, V263, P9831; NAKAI H, 1988, J BIOL CHEM, V263, P9818; O'Day KJ, 1978, MICROBIOLOGY 1978, P48; REUBEN RC, 1974, J BIOL CHEM, V249, P3843; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; TABOR S, 1987, J BIOL CHEM, V262, P16212; TOUSSAINT A, 1974, MOL GEN GENET, V131, P209, DOI 10.1007/BF00267960; TOUSSAINT A, 1983, MOBILE GENETIC ELEME, P105; WIJFFELMAN C, 1977, MOL GEN GENET, V151, P169, DOI 10.1007/BF00338691	43	7	8	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23997	24004						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226943				2022-12-25	WOS:A1993MF29400046
J	NICKELS, JT; CARMAN, GM				NICKELS, JT; CARMAN, GM			PHOTOAFFINITY-LABELING OF THE 45-KDA AND 55-KDA FORMS OF PHOSPHATIDYLINOSITOL 4-KINASE FROM THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PROLIFERATION; KINETIC-ANALYSIS; PLASMA-MEMBRANE; KINASE; PURIFICATION; BINDING; SPHINGOLIPIDS; METABOLISM; PROTEINS; TURNOVER	The membrane-associated 45- and 55-kDa forms of phosphatidylinositol (PI) 4-kinase (ATP:phosphatidylinositol 4-phosphotransferase, EC 2.7.1.67) from Saccharomyces cerevisiae are inhibited by ADP by a competitive mechanism with respect to ATP. We initiated studies toward defining the ATP and ADP sites on the PI 4-kinases using azidonucleotide photoaffinity labeling probes. The photoprobe 8-azido-ATP fulfilled the criteria of a specific photoaffinity label for the 45- and 55-kDa PI 4-kinases. 8-Azido-ATP was a substrate and a competitive inhibitor of the PI 4-kinases with K(i) values similar to the K(m) for ATP. 8-Azido-ATP photoinactivated the enzymes and was photoincorporated into the enzymes in a dose-dependent manner at concentrations similar to the K(i) values for the photoprobe. ATP, the true substrate, provided specific protection against photoinactivation and photoincorporation of the PI 4-kinases with 8-azido-ATP, whereas GTP, a nonspecific nucleotide, provided no protection against photoinactivation and photoincorporation. Photoaffinity labeling of the PI 4-kinases with 8-azido-ATP was specifically prevented with ADP. The photoprobe 8-azido-ADP also fulfilled the criteria needed to validate its use as a specific photoprobe for the PI 4-kinases. Photoinactivation of the PI 4-kinases with 8-azido-ADP was prevented specifically with ATP. Taken together, these data supported the conclusion that the ATP and ADP sites on the membrane-associated 45- and 55-kDa PI 4-kinases from S. cerevisiae were the same.	RUTGERS UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035655] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35655] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAYLEY H, 1984, AZIDES NITRENES, P457; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUXEDA RJ, 1993, J BIOL CHEM, V268, P6248; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; COLODZIN M, 1965, J BIOL CHEM, V240, P3771; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DAHL JS, 1985, BIOCHEM BIOPH RES CO, V133, P844, DOI 10.1016/0006-291X(85)91211-2; DAVIS CB, 1990, J BIOL CHEM, V265, P1300; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; FRASCOTTI G, 1990, FEBS LETT, V274, P19, DOI 10.1016/0014-5793(90)81319-J; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HAWKINS PT, 1993, J BIOL CHEM, V268, P3374; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATO H, 1989, J BIOL CHEM, V264, P3116; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS CT, 1989, BIOCHEMISTRY-US, V28, P9248, DOI 10.1021/bi00450a003; MCKENZIE MA, 1982, J FOOD BIOCHEM, V6, P77, DOI 10.1111/j.1745-4514.1982.tb00297.x; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; PATIL RV, 1988, EUR J BIOCHEM, V177, P569, DOI 10.1111/j.1432-1033.1988.tb14408.x; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; REIMANN A, 1988, BIOCHEM J, V254, P723, DOI 10.1042/bj2540723; RUSH J, 1990, J BIOL CHEM, V265, P4821; Segel IH., 1975, ENZYME KINETICS, P1, DOI 10.1016/0014-5793(75)80457-1; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; TALWALKAR RT, 1973, BIOCHIM BIOPHYS ACTA, V306, P412, DOI 10.1016/0005-2760(73)90180-X; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; VOLONTE C, 1992, J BIOL CHEM, V267, P21663	34	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24083	24088						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226954				2022-12-25	WOS:A1993MF29400058
J	SUQUET, C; SMERDON, MJ				SUQUET, C; SMERDON, MJ			UV DAMAGE TO DNA STRONGLY INFLUENCES ITS ROTATIONAL SETTING ON THE HISTONE SURFACE OF RECONSTITUTED NUCLEOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THYMINE DIMER FORMATION; PYRIMIDINE DIMERS; INTACT CHROMATIN; CORE PARTICLES; TRANSITIONS	The major photoproduct formed in DNA, following absorption of ultraviolet (UV) light, is the cis-syn cyclobutane pyrimidine dimer (CPD). Formation of CPDs in DNA packaged into chromatin prior to UV irradiation results in a striking preference for these photoproducts to be oriented away from the histone surface in nucleosomes (Gale, J. M., Nissen, K. A., and Smerdon, M. J. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 6644-6648). In this report, we show that formation of nucleosomes onto UV-irradiated DNA results in a similar distribution of these photoproducts, indicating that preexisting CPDs in the DNA molecule can influence its rotational setting on the histone surface during nucleosome formation. This bias is less pronounced in the central three helical turns encompassing the dyad axis of nucleosomes, where the helix is overwound (10.7 bases/turn) relative to the ''outer'' portion of core DNA (10.0 bases/turn). Such a change in the rotational setting of DNA on the surface of newly formed nucleosomes could expose normally inaccessible DNA sequences to factors which control DNA processing.			SUQUET, C (corresponding author), WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002614, R37ES002614, R01ES004106] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04106, ES02614] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARCHER TK, 1989, STEROID THYROID HORM, P221; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BROWN DW, 1993, IN PRESS BIOCHEMISTR; DREW HR, 1993, J MOL BIOL, V230, P824, DOI 10.1006/jmbi.1993.1204; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; GALE JM, 1987, P NATL ACAD SCI USA, V84, P6644, DOI 10.1073/pnas.84.19.6644; GALE JM, 1990, PHOTOCHEM PHOTOBIOL, V51, P411, DOI 10.1111/j.1751-1097.1990.tb01732.x; GALE JM, 1988, BIOCHEMISTRY-US, V27, P7197, DOI 10.1021/bi00419a006; GALE JM, 1988, J MOL BIOL, V204, P949, DOI 10.1016/0022-2836(88)90054-X; Harm W, 1980, BIOL EFFECTS ULTRAVI; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HUSAIN I, 1988, P NATL ACAD SCI USA, V85, P2558, DOI 10.1073/pnas.85.8.2558; JENSEN KA, 1990, BIOCHEMISTRY-US, V29, P4773, DOI 10.1021/bi00472a005; LIBERTINI LJ, 1988, BIOPHYS J, V53, P477, DOI 10.1016/S0006-3495(88)83126-6; LIBERTINI LJ, 1980, NUCLEIC ACIDS RES, V8, P3517, DOI 10.1093/nar/8.16.3517; LOW CML, 1986, NUCLEIC ACIDS RES, V14, P6785, DOI 10.1093/nar/14.17.6785; MOYER R, 1989, J BIOL CHEM, V264, P12226; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; PEHRSON JR, 1989, P NATL ACAD SCI USA, V86, P9149, DOI 10.1073/pnas.86.23.9149; PEHRSON JR, 1992, NUCLEIC ACIDS RES, V20, P1321, DOI 10.1093/nar/20.6.1321; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; van Holde KE., 1989, SPRINGER SERIES MOL; WANG CI, 1991, P NATL ACAD SCI USA, V88, P9072, DOI 10.1073/pnas.88.20.9072; Wang SY., 1976, PHOTOCHEM PHOTOBIOL; WOLFFE A, 1992, CHROMATIN STRUCTURE	28	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23755	23757						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226904				2022-12-25	WOS:A1993MF29400006
J	TASKEN, K; ANDERSSON, KB; SKALHEGG, BS; TASKEN, KA; HANSSON, V; JAHNSEN, T; BLOMHOFF, HK				TASKEN, K; ANDERSSON, KB; SKALHEGG, BS; TASKEN, KA; HANSSON, V; JAHNSEN, T; BLOMHOFF, HK			RECIPROCAL REGULATION OF MESSENGER-RNA AND PROTEIN FOR SUBUNITS OF CAMP-DEPENDENT PROTEIN-KINASE (RI-ALPHA AND C-ALPHA) BY CAMP IN A NEOPLASTIC B-CELL LINE (REH)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SERTOLI CELLS; 3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; CATALYTIC SUBUNIT; CYCLIC-AMP; MOLECULAR-CLONING; CDNA STRUCTURE; HUMAN TESTIS; SKELETAL-MUSCLE; ACTIVATION; BETA	The present study examines the activity, levels of expression and regulation of cAMP-dependent protein kinase subunits during cAMP-mediated inhibition of Reh cell proliferation. Human Reh cells express mRNAs for the RIalpha and Calpha subunits of cAK at high levels and are practically devoid of cAMP-dependent protein kinase type II Treatment with isoproterenol, forskolin, or a cAMP analog increased RIalpha mRNA in a time- and concentration-dependent manner (maximal, 4-fold, at 4-8 h). Messenger RNA for Calpha was also stimulated by cAMP, although with slower kinetics (maximal, 2-fold, at 16-24 h). Nuclear run-on assays showed a 2-fold increase in RIalpha gene transcription, whereas that of Calpha was unchanged. In spite of the stimulatory effects of cAMP on mRNAs for both RIalpha and Calpha phosphotransferase activity and specific [H-3]cAMP binding decreased rapidly after treatment with either cAMP or forskolin. Interestingly, the decrease in R and C activity preceded the increase in RIalpha and Calpha mRNA levels, raising the question whether increased mRNA levels may be secondary to the decrease in RIalpha or Calpha protein. The finding that the protein synthesis inhibitor cycloheximide gave changes in RIalpha and Calpha mRNA similar to cAMP and that co-treatment with cycloheximide and cAMP resulted in additive effects tend to support this notion.	NORWEGIAN RADIUM HOSP, DEPT IMMUNOL, OSLO 3, NORWAY; NATL HOSP, INST GEN & RHEUMATOL IMMUNOL, OSLO, NORWAY	University of Oslo; University of Oslo; National Hospital Norway	TASKEN, K (corresponding author), UNIV OSLO, INST MED BIOCHEM, POB 1112, N-0317 OSLO, NORWAY.		Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084; Tasken, Kjetil/0000-0003-2841-4697				ALHANATY E, 1979, BIOCHEM BIOPH RES CO, V89, P323, DOI 10.1016/0006-291X(79)90633-8; ANDERSSON KB, 1993, IN PRESS J CELL PHYS; ANTALIS TM, 1991, NUCLEIC ACIDS RES, V19, P4301, DOI 10.1093/nar/19.15.4301; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BEEBE SJ, 1986, ENZYMES, V17, P43; BLOMHOFF HK, 1987, J CELL PHYSIOL, V131, P426, DOI 10.1002/jcp.1041310315; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COBB CE, 1988, METHOD ENZYMOL, V159, P202; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; JAHNSEN T, 1985, J BIOL CHEM, V260, P5980; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LANDMARK BF, 1991, ENDOCRINOLOGY, V129, P2345, DOI 10.1210/endo-129-5-2345; LEE DC, 1983, P NATL ACAD SCI-BIOL, V80, P3608, DOI 10.1073/pnas.80.12.3608; LEVY FO, 1989, ENDOCRINOLOGY, V124, P430; LIU AYC, 1982, J BIOL CHEM, V257, P298; LORIMER IAJ, 1989, BIOCHEM J, V264, P305, DOI 10.1042/bj2640305; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURAGUCHI A, 1984, J IMMUNOL, V133, P1283; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; OYEN O, 1988, ENDOCRINOLOGY, V122, P2658; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; RICHARDSON JM, 1990, J BIOL CHEM, V265, P13635; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHWARTZ DA, 1983, J BIOL CHEM, V258, P777; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; SKALHEGG BS, 1992, J BIOL CHEM, V267, P5374; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; SOLBERG R, 1991, BIOCHEM BIOPH RES CO, V176, P166, DOI 10.1016/0006-291X(91)90904-L; STEINBERG RA, 1981, J BIOL CHEM, V256, P731; TASKEN K, 1990, BIOCHEM BIOPH RES CO, V172, P409, DOI 10.1016/0006-291X(90)90688-J; TASKEN K, 1993, IN PRESS J BIOL CHEM, V268; TASKEN KA, 1992, ENDOCRINOLOGY, V130, P1271, DOI 10.1210/en.130.3.1271; TASKEN KA, 1991, MOL ENDOCRINOL, V5, P21, DOI 10.1210/mend-5-1-21; THOMIS DC, 1992, J BIOL CHEM, V267, P10723; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WIEMANN S, 1991, J BIOL CHEM, V266, P5140	51	32	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23483	23489						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226875				2022-12-25	WOS:A1993MF51500081
J	TERLECKY, SR; DICE, JF				TERLECKY, SR; DICE, JF			POLYPEPTIDE IMPORT AND DEGRADATION BY ISOLATED LYSOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; MICROINJECTED RIBONUCLEASE-A; PEPTIDE SEQUENCES; AUTOPHAGIC VACUOLE; SERUM WITHDRAWAL; STRESS PROTEINS; MEMBRANE; FIBROBLASTS; PROTEOLYSIS; MECHANISMS	We reported previously that lysosomes derived from human diploid fibroblasts import and degrade polypeptides and that these processes are stimulated by ATP and by the heat shock cognate protein of 73 kDa (hsc73). We now report several new aspects of this in vitro proteolytic pathway. (a) Among four polypeptides tested, this pathway appears to be selective for those containing KFERQ-like peptide motifs. (b) Substrate proteins specifically bind to a protein-containing site on lysosomal membranes. (c) Lysosomes derived from serum-deprived cells are twice as active as those from serum-supplemented cells. (d) A portion of intracellular hsc73 is associated with lysosomes, and the amount of lysosomal hsc73 increases in response to serum withdrawal. Additional characterization of this proteolytic pathway not reported previously-shows that intact lysosomes are required, the import process is saturable with an apparent k(m) of 5 muM for RNase S-peptide, and reducing agents activate this lysosomal import and degradation pathway.	TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA	Tufts University					NATIONAL INSTITUTE ON AGING [R01AG006116, R37AG006116] Funding Source: NIH RePORTER; NIA NIH HHS [AGO6116] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHLBERG J, 1982, LAB INVEST, V47, P523; BACKER JM, 1983, P NATL ACAD SCI-BIOL, V80, P2166, DOI 10.1073/pnas.80.8.2166; BACKER JM, 1986, P NATL ACAD SCI USA, V83, P5830, DOI 10.1073/pnas.83.16.5830; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DICE JF, 1986, J BIOL CHEM, V261, P6853; DICE JF, 1987, FASEB J, V1, P347; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DOHERTY FJ, 1989, BIOCHEM J, V263, P47, DOI 10.1042/bj2630047; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; FALLON RJ, 1988, J BIOL CHEM, V263, P13159; GUIDON PT, 1986, J CELL PHYSIOL, V128, P239, DOI 10.1002/jcp.1041280215; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; KURIAKOSE NR, 1989, HISTOCHEMISTRY, V92, P499, DOI 10.1007/BF00524761; LINQUIST S, 1988, ANNU REV GENET, V22, P631; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADDEN EA, 1987, ARCH BIOCHEM BIOPHYS, V257, P27, DOI 10.1016/0003-9861(87)90539-X; MAEKAWA M, 1989, BIOL REPROD, V40, P843, DOI 10.1095/biolreprod40.4.843; MARZELLA L, 1982, LB INVEST, V47, P523; Marzella L, 1987, LYSOSOMES THEIR ROLE, P319; MCELLIGOTT MA, 1985, J BIOL CHEM, V260, P1986; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; NEFF NT, 1981, J CELL BIOL, V91, P184, DOI 10.1083/jcb.91.1.184; ORCI L, 1984, J CELL BIOL, V98, P222, DOI 10.1083/jcb.98.1.222; Pfeifer U., 1987, LYSOSOMES THEIR ROLE, P3; PISONI RL, 1990, J CELL BIOL, V110, P327, DOI 10.1083/jcb.110.2.327; ROME LH, 1981, J BIOL CHEM, V56, P10763; RUTTEN A, 1988, ACTA ANAT, V133, P217; Seglen P O, 1990, Semin Cell Biol, V1, P441; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; UENO T, 1991, J BIOL CHEM, V266, P18995; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WING SS, 1991, BIOCHEM J, V275, P165, DOI 10.1042/bj2750165	44	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23490	23495						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226876				2022-12-25	WOS:A1993MF51500082
J	ALI, MS; ROCHE, TE; PATEL, MS				ALI, MS; ROCHE, TE; PATEL, MS			IDENTIFICATION OF THE ESSENTIAL CYSTEINE RESIDUE IN THE ACTIVE-SITE OF BOVINE PYRUVATE-DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; ESCHERICHIA-COLI; BETA-SUBUNIT; COMPLEX; COMPONENT; SEQUENCE; KIDNEY; HEART; INACTIVATION; PURIFICATION	Pyruvate dehydrogenase (E1), the first catalytic component of the bovine pyruvate dehydrogenase complex, is composed of two nonidentical subunits in a tetrameric alpha2beta2 form. The sulfhydryl-specific reagent N-ethylmaleimide (NEM) was used to identify the reactivities and function of cysteinyl residues and subsequent identification of these residues in the active site of bovine E1. Treatment of E1 with 0.2 mM NEM resulted in loss (90%) of enzymatic activity; the inactivation followed bimolecular reaction kinetics. The inactivation was almost entirely prevented by thiamin pyrophosphate (TPP) and pyruvate; protection is probably due to formation of the hydroxyethylidene-TPP intermediate. To identify the reactive cysteinyl residues in the active site region, the nonessential SH groups in E1 were first modified with NEM in the presence of TPP and pyruvate. After quenching with dithiothreitol and removal of the substrate and cofactor by dialysis, the modified E1 was treated with [C-14]NEM to label the exposed cysteinyl residue(s) in or near the active site region. The data indicate that NEM reacted in the active site region of the E1 component with a stoichiometry of 2 mol of [C-14]NEM bound per mol of E1 tetramer. The initial rapid labeling of E1 with [C-14]NEM established that incorportaion was predominantly into the alpha subunit. A single radiolabeled peptide was isolated following V8 protease digestion of radiolabeled E1 by [C-14]NEM. Sequence analysis of the labeled peptide derived from bovine E1 demonstrated that the labeled cysteinyl residue was equivalent to Cys-62 in the alpha subunit (mature form) of human E1.	KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOCHEM, MANHATTAN, KS 66506 USA; CASE WESTERN RESERVE UNIV, DEPT BIOCHEM, CLEVELAND, OH 44106 USA	Kansas State University; Case Western Reserve University					NIDDK NIH HHS [DK18320, DK20478] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020478, R55DK018320, R01DK018320] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRERA CR, 1972, ARCH BIOCHEM BIOPHYS, V148, P343, DOI 10.1016/0003-9861(72)90152-X; BEHAL RH, 1989, BIOCHEM BIOPH RES CO, V164, P941, DOI 10.1016/0006-291X(89)91549-0; CATE RL, 1980, J BIOL CHEM, V255, P7556; FLOURNOY DS, 1989, BIOCHEMISTRY-US, V28, P9594, DOI 10.1021/bi00451a007; FREY PA, 1989, ANN NY ACAD SCI, V573, P21, DOI 10.1111/j.1749-6632.1989.tb14984.x; HAWKINS CF, 1990, EUR J BIOCHEM, V191, P337, DOI 10.1111/j.1432-1033.1990.tb19128.x; HO L, 1989, P NATL ACAD SCI USA, V86, P5330, DOI 10.1073/pnas.86.14.5330; HO L, 1990, GENE, V86, P297, DOI 10.1016/0378-1119(90)90294-2; KHAILOVA LS, 1985, BIOCHEM INT, V10, P291; KHAILOVA LS, 1989, ANN NY ACAD SCI, V573, P36, DOI 10.1111/j.1749-6632.1989.tb14985.x; KHAILOVA LS, 1982, BIOCHEM INT, V5, P525; KHAILOVA LS, 1983, BIOCHEM INT, V7, P223; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; MATUDA S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P1, DOI 10.1016/0167-4781(91)90076-X; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; ROCHE TE, 1972, BIOCHEM BIOPH RES CO, V48, P840, DOI 10.1016/0006-291X(72)90684-5; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; SCHWARTZ ER, 1970, J BIOL CHEM, V245, P183; STEPP LR, 1985, BIOCHEMISTRY-US, V24, P7187, DOI 10.1021/bi00346a026; TU GC, 1988, J BIOL CHEM, V263, P1212; URATA Y, 1991, J NUTR SCI VITAMINOL, V37, P257	23	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22353	22356						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226745				2022-12-25	WOS:A1993MD34800027
J	ANDERSON, GM; SHAW, AR; SHAFER, JA				ANDERSON, GM; SHAW, AR; SHAFER, JA			FUNCTIONAL-CHARACTERIZATION OF PROMOTER ELEMENTS INVOLVED IN REGULATION OF HUMAN B-BETA-FIBRINOGEN EXPRESSION - EVIDENCE FOR BINDING OF NOVEL ACTIVATOR AND REPRESSOR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-6 RESPONSE ELEMENT; RAT ALPHA-2-MACROGLOBULIN GENE; RISK FACTOR; DNA; TRANSCRIPTION; SEQUENCES; FAMILY; C/EBP; IDENTIFICATION; DEXAMETHASONE	A high level of plasma fibrinogen has been shown to be an important risk factor for myocardial infarction and stroke. Thus, we were prompted to investigate regulation of human fibrinogen biosynthesis, a process wherein expression of the Bbeta-chain of fibrinogen appears to be rate-limiting for fibrinogen secretion. Using electrophoretic mobility shift assays with synthetic probes representing portions of the human Bbeta-fibrinogen promoter, we have defined several elements that bind distinct classes of transcription factors present in human hepatoma cell nuclear extracts. The contribution of each element to promoter activity was demonstrated in transfection experiments using promoter-chloramphenicol acetyltransferase constructs and human hepatoma cells. Our observations indicate that two distinct sequence elements are required for maximal induction of transcription by interleukin-6. One of these sequences is an IL-6-RE core element similar to that reported for the rat alpha2-macroglobulin promoter and the other is a binding site for the C/EBP family of transcription factors. We also report two additional elements, one negative- and one positive-acting, that bind novel sequence-specific factors.	MERCK SHARP & DOHME LTD,DEPT CELLULAR & MOLEC BIOL,W POINT,PA 19486	Merck & Company	ANDERSON, GM (corresponding author), MERCK SHARP & DOHME LTD,DEPT BIOL CHEM,W POINT,PA 19486, USA.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BIRCH HE, 1986, J BIOL CHEM, V261, P8077; BRECHNER T, 1991, MOL BIOL MED, V8, P267; CROTHERS DM, 1987, NATURE, V325, P464, DOI 10.1038/325464a0; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; HUBER P, 1987, NUCLEIC ACIDS RES, V15, P1615, DOI 10.1093/nar/15.4.1615; HUBER P, 1990, J BIOL CHEM, V265, P5695; KANELL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183; KANT JA, 1985, P NATL ACAD SCI USA, V82, P2344, DOI 10.1073/pnas.82.8.2344; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Maniatis T., 1982, MOL CLONING; MANN EA, 1991, J BIOL CHEM, V266, P16931; MARINKOVIC S, 1989, J IMMUNOL, V142, P808; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROY SN, 1990, J BIOL CHEM, V265, P6389; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STONE MC, 1985, J ROY COLL GEN PRACT, V35, P565; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; YU S, 1983, J BIOL CHEM, V258, P3407	36	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22650	22655						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226773				2022-12-25	WOS:A1993MD34800069
J	SHIMOMURA, T; KONDO, J; OCHIAI, M; NAKA, D; MIYAZAWA, K; MORIMOTO, Y; KITAMURA, N				SHIMOMURA, T; KONDO, J; OCHIAI, M; NAKA, D; MIYAZAWA, K; MORIMOTO, Y; KITAMURA, N			ACTIVATION OF THE ZYMOGEN OF HEPATOCYTE GROWTH-FACTOR ACTIVATOR BY THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HAGEMAN-FACTOR; SINGLE CHAIN FORM; SCATTER FACTOR; BLOOD-COAGULATION; MOLECULAR-CLONING; EPITHELIAL-CELLS; HEPATOPOIETIN-A; FACTOR-XII; RAT-LIVER; PURIFICATION	Hepatocyte growth factor activator (HGF activator) is a serine protease which converts single-chain HGF to the active two-chain form. HGF activator purified from human serum has a molecular mass of 34 kDa and consists of two chains held together by a disulfide bond. The nucleotide sequence of HGF activator cDNA shows that HGF activator is derived from the COOH-terminal region of a precursor of 655 amino acids by proteolytic cleavage of the bonds between Arg372 and Val373 and between Arg407 and Ile408 and that the precursor consists of multiple domains homologous to those observed in blood coagulation factor XII. In this study, we identified the precursor of HGF activator in human plasma using an enzyme-linked immunosorbent assay system. The precursor was purified from plasma by a five-step procedure. The purified precursor did not activate single-chain HGF. The precursor was efficiently cleaved in vitro by thrombin, at the bond between Arg407 and Ile408, in the presence of negatively charged substances. The cleaved precursor activated single-chain HGF. These findings led us to conclude that HGF activator is present in plasma as an inactive zymogen and that the zymogen is activated by the cleavage of the bond between Arg407 and Ile408 by thrombin. Characteristic structural domains in the NH2-terminal region of the zymogen may be involved in the binding of the zymogen to negatively charged substances, which stimulates the activation of the zymogen by thrombin.	KANSAI MED UNIV, INST LIVER RES, MORIGUCHI, OSAKA 570, JAPAN	Kansai Medical University	SHIMOMURA, T (corresponding author), MITSUBISHI KASEI CORP, RES CTR, BIOSCI LAB, KAMOSHIDA CHO, MIDORI KU, YOKOHAMA 227, JAPAN.		Ochiai, Masanori/A-4372-2012; MIYAZAWA, KEIJI/I-9713-2014	Ochiai, Masanori/0000-0002-0022-347X; 				CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; DUNN JT, 1982, J BIOL CHEM, V257, P1779; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HERNANDEZ J, 1992, J CELL PHYSIOL, V150, P116, DOI 10.1002/jcp.1041500116; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KAPLAN AP, 1988, METHOD ENZYMOL, V163, P3; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MASUMOTO A, 1991, BIOCHEM BIOPH RES CO, V174, P90, DOI 10.1016/0006-291X(91)90489-T; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAITO K, 1991, J BIOL CHEM, V266, P7353; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; RAMADORI G, 1992, BIOCHEM BIOPH RES CO, V183, P739, DOI 10.1016/0006-291X(92)90545-V; REVAK SD, 1974, J CLIN INVEST, V54, P619, DOI 10.1172/JCI107799; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SCHIRMACHER P, 1992, HEPATOLOGY, V15, P5, DOI 10.1002/hep.1840150103; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; TANS G, 1987, SEMIN THROMB HEMOST, V13, P1, DOI 10.1055/s-2007-1003471; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; ZARNEGAR R, 1989, CANCER RES, V49, P3314	30	181	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22927	22932						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226803				2022-12-25	WOS:A1993MD34800107
J	OKAZAWA, H; KAMEI, M; IMAFUKU, I; KANAZAWA, I				OKAZAWA, H; KAMEI, M; IMAFUKU, I; KANAZAWA, I			GENE-REGULATION OF TRKB AND TRKC IN THE CHICK RETINA BY LIGHT/DARKNESS EXPOSURE	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; FACTOR MESSENGER-RNA; PROTEIN-TYROSINE KINASE; NEUROTROPHIC FACTOR; NEURONAL DEATH; TRANSCRIPTION FACTOR; RAT HIPPOCAMPUS; FACTOR PROMOTES; FACTOR PREVENTS; GANGLION-CELLS	The trk gene family members; the neurotrophic receptors for neurotrophins, are implicated in the survival and the differentiation of neurons. The roles of these protooncogenes have been argued in the pathological conditions and in the specific developmental stage when the programmed cell death occurs to neurons. Here we studied a physiological role of the trk family members in the retina through observations of their gene regulation by light/darkness exposure. Northern blot analysis and immunohistochemistry demonstrate that trkB and trkC are up-regulated by light exposure and down-regulated by darkness in the rod/cone layer, the outer nuclear layer, and the ganglion cell layer. This physiological regulation suggests that these trk family members play a protective role from the damaging effect of light exposure in the retinal neurons.			OKAZAWA, H (corresponding author), UNIV TOKYO, FAC MED, DEPT NEUROL, BUNKYO KU, 7-3-1 HONGO, TOKYO 113, JAPAN.							BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES AM, 1985, DEV BIOL, V111, P62, DOI 10.1016/0012-1606(85)90435-X; DECHANT G, 1993, DEVELOPMENT, V119, P545; DUGICHDJORDJEVIC MM, 1992, NEUROSCIENCE, V47, P303, DOI 10.1016/0306-4522(92)90246-X; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; FRISEN J, 1992, P NATL ACAD SCI USA, V89, P11282, DOI 10.1073/pnas.89.23.11282; GALL C, 1991, MOL BRAIN RES, V9, P113, DOI 10.1016/0169-328X(91)90136-L; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HEFTI F, 1986, J NEUROSCI, V6, P2155; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JELSMA TN, 1993, J NEUROBIOL, V24, P1207, DOI 10.1002/neu.480240907; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; JOHNSON JE, 1986, J NEUROSCI, V6, P3031; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KORSCHING S, 1993, J NEUROSCI, V13, P2739; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; OKAZAWA H, 1993, FEBS LETT, V329, P171, DOI 10.1016/0014-5793(93)80216-H; OKAZAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P683, DOI 10.1006/bbrc.1993.1876; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RICHTER A, 1975, J PHYSIOL-LONDON, V248, P317, DOI 10.1113/jphysiol.1975.sp010976; RODRIGUEZTEBAR A, 1989, DEV BIOL, V136, P296, DOI 10.1016/0012-1606(89)90256-X; RODRIGUEZTEBAR A, 1993, EUR J BIOCHEM, V211, P789, DOI 10.1111/j.1432-1033.1993.tb17610.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAGAR SM, 1990, MOL BRAIN RES, V7, P17, DOI 10.1016/0169-328X(90)90068-O; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SCHWARTZ EA, 1974, J PHYSIOL-LONDON, V236, P211, DOI 10.1113/jphysiol.1974.sp010431; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SHINTANI A, 1992, BIOCHEM BIOPH RES CO, V182, P325, DOI 10.1016/S0006-291X(05)80148-2; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VAIENZUELLA DM, 1993, NEURON, V10, P963; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; YOSHIDA K, 1993, NEURON, V10, P1049, DOI 10.1016/0896-6273(93)90053-T; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	54	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1813	1818						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208527				2022-12-25	WOS:A1994NR68500002
J	ALLAIN, F; DENYS, A; SPIK, G				ALLAIN, F; DENYS, A; SPIK, G			CHARACTERIZATION OF SURFACE BINDING-SITES FOR CYCLOPHILIN-B ON A HUMAN TUMOR T-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYCLOSPORINE-A; PROTEIN CYCLOPHILIN; S-CYCLOPHILIN; SEQUENCE; CALCINEURIN; SENSITIVITY; ACTIVATION; INHIBITION; ISOMERASE; COMPLEXES	Cyclophilin B (CyPB) is a cyclosporin-binding protein, known to be located mainly within the endoplasmic reticulum vesicles. Its previous characterization in human milk implies that the protein may be released from the secretory pathway and recovered in biological fluids. In an attempt to understand the role of the extracellular CyPB, we have investigated the binding capacity of the protein to cells derived from human T- and B-lymphocytes. We present here evidence that CyPB binds to T-lymphocytes and that the binding to the Jurkat T-cell surface is specific, saturable, and reversible. The dissociation constant K-d was 12 nM, and the number of binding sites was estimated to 35,000/cell. We report that the surface-bound CyPB was internalized at 37 degrees C and subsequently degraded in the cell. We also show that the immunosuppressive drug cyclosporin A does not inhibit the surface binding of CyPB, and does not interfere with internalization of the protein. These results support the hypothesis that the selective action of the immunosuppressive drug results in part from its interaction with the extracellular form of CyPB.	UNIV SCI & TECH LILLE FLANDRES ARTOIS, CHIM BIOL LAB, CNRS, UNITE MIXTE RECH 111, F-59655 VILLENEUVE DASCQ, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille				Allain, Fabrice/0000-0002-4484-6302				ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; CACALANO NA, 1992, P NATL ACAD SCI USA, V89, P4353, DOI 10.1073/pnas.89.10.4353; CARONI P, 1991, J BIOL CHEM, V266, P10739; DAVIS TR, 1991, BIOCHIM BIOPHYS ACTA, V1095, P145, DOI 10.1016/0167-4889(91)90077-B; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FISHER G, 1989, NATURE, V337, P476; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; INOUE T, 1993, BIOCHEM BIOPH RES CO, V190, P857, DOI 10.1006/bbrc.1993.1127; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; POVLSEN JV, 1990, SCAND J IMMUNOL, V32, P45, DOI 10.1111/j.1365-3083.1990.tb02890.x; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RYFFEL B, 1991, IMMUNOLOGY, V72, P399; SANDER B, 1986, SCAND J IMMUNOL, V23, P435; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511; SPIK G, 1991, J BIOL CHEM, V266, P10735; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; VAITUKAITIS J, 1971, J CLIN ENDOCR METAB, V33, P988, DOI 10.1210/jcem-33-6-988; XU Q, 1992, J BIOL CHEM, V267, P11968; YANG SY, 1986, J IMMUNOL, V137, P1097	27	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16537	16540						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206968				2022-12-25	WOS:A1994NR29600005
J	BEZOUSKA, K; VLAHAS, G; HORVATH, O; JINOCHOVA, G; FISEROVA, A; GIORDA, R; CHAMBERS, WH; FEIZI, T; POSPISIL, M				BEZOUSKA, K; VLAHAS, G; HORVATH, O; JINOCHOVA, G; FISEROVA, A; GIORDA, R; CHAMBERS, WH; FEIZI, T; POSPISIL, M			RAT NATURAL-KILLER-CELL ANTIGEN, NKR-P1, RELATED TO C-TYPE ANIMAL LECTINS IS A CARBOHYDRATE-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; ACTIVATION ANTIGEN; MONOCLONAL-ANTIBODIES; RECOGNITION DOMAINS; MOLECULAR-CLONING; ESCHERICHIA-COLI; LIGAND-BINDING; MOUSE NKR-P1; NK-CELLS; EXPRESSION	Natural killer receptor protein 1 (NKR-P1, a family of proteins), which is a dimeric transmembrane protein predominantly on rat and murine natural killer cells, contains an extracellular motif related to calcium-dependent animal lectins. The domain architecture of this protein and the finding that its cross-linking with antibody results in activation of natural killer cells make it a promising candidate for a receptor function. We have expressed a full-length NKR-P1 protein of the rat in COS cells and prepared soluble extracellular fragments by controlled proteolysis or by expression of truncated cDNA in bacteria. Dimerization of soluble NKR-P1 is predominantly dependent on the presence of an intact juxtamembrane stalk region and independent of N-glycosylation. Binding and inhibition studies using monosaccharides and neoglycoconjugates indicate that NKR-P1 is a lectin with a preference order of GalNAc > GlcNAc >> Fuc >> Gal > Man. At neutral pH, Ca2+ is tightly associated with the protein such that only a proportion can be removed by 10 mM EGTA. However, NKR-P1 can be decalcified completely at pH 10 with a total loss of carbohydrate binding. After recalcification at pH 8, carbohydrate binding is completely restored. Thus, NKR-P1 differs from other calcium-dependent animal lectins investigated so far in its pattern of monosaccharide recognition and in the tightness of Ca2+ binding.	ACAD SCI CZECH REPUBL, INST MICROBIOL, DEPT IMMUNOL & GNOTOBIOL, CR-14220 PRAGUE 4, CZECH REPUBLIC; UNIV PITTSBURGH, PITTSBURGH CANC INST, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15213 USA; MRC, CLIN RES CTR, GLYCOCONJUGATES SECT, HARROW HA1 3UJ, MIDDX, ENGLAND	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Medical Research Council Clinical Trials Unit	BEZOUSKA, K (corresponding author), CHARLES UNIV, INST BIOTECHNOL, HLAVOVA 8-2030, CR-12840 PRAGUE 2, CZECH REPUBLIC.		Giorda, Roberto/Q-6010-2019; Giorda, Roberto/J-1052-2014	Giorda, Roberto/0000-0001-8175-9606; Giorda, Roberto/0000-0001-8175-9606; Feizi, Ten/0000-0001-6495-0329				ANDERSON SK, 1993, P NATL ACAD SCI USA, V90, P542, DOI 10.1073/pnas.90.2.542; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; CHAMBERS WH, 1993, GLYCOBIOLOGY, V3, P9, DOI 10.1093/glycob/3.1.9; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; DARBRE A, 1988, PRACTICAL PROTEIN CH, P517; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; Feizi Ten, 1993, Current Opinion in Structural Biology, V3, P701, DOI 10.1016/0959-440X(93)90053-N; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; GIORDA R, 1991, J IMMUNOL, V147, P1701; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; HAMANN J, 1993, J IMMUNOL, V150, P4920; HARLOW E, 1988, ANTIBODIES LABORATOR, P424; HARRIS DT, 1989, J IMMUNOL, V143, P727; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOFER E, 1992, IMMUNOL TODAY, V13, P429, DOI 10.1016/0167-5699(92)90067-H; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIER LL, 1988, J EXP MED, V167, P1572, DOI 10.1084/jem.167.5.1572; LANIER LL, 1992, CURR OPIN IMMUNOL, V4, P38, DOI 10.1016/0952-7915(92)90121-T; LOEB JA, 1988, J BIOL CHEM, V263, P9752; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOOREHEAD WR, 1979, CLIN CHEM, V20, P1458; ORTALDO JR, 1981, J IMMUNOL, V127, P2401; PALMITER RD, 1977, J BIOL CHEM, V252, P6386; ROSENSTEIN IJ, 1992, INFECT IMMUN, V60, P5078, DOI 10.1128/IAI.60.12.5078-5084.1992; RYAN JC, 1992, J IMMUNOL, V149, P1631; RYAN JC, 1991, J IMMUNOL, V147, P3244; Sambrook J, 1989, MOL CLONING LABORATO; SILICIANO RF, 1985, NATURE, V317, P428, DOI 10.1038/317428a0; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1992, COLD SPRING HARB SYM, V57, P281, DOI 10.1101/SQB.1992.057.01.033; YABE T, 1993, IMMUNOGENETICS, V37, P455; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229	42	90	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16945	16952						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207018				2022-12-25	WOS:A1994NR29600065
J	CROSSLEY, M; ORKIN, SH				CROSSLEY, M; ORKIN, SH			PHOSPHORYLATION OF THE ERYTHROID TRANSCRIPTION FACTOR GATA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; BETA-GLOBIN LOCUS; CASEIN KINASE-II; PROTEIN-KINASE; GENE-TRANSCRIPTION; CONTROL REGION; HYPERSENSITIVE SITE-3; REGULATORY ELEMENT; MAMMALIAN-CELLS; DISTAL ENHANCER	GATA-1 is a zinc finger DNA-binding protein thought to be involved in the expression of the vast majority of erythroid specific genes. We have examined the phosphorylation of GATA-1 in murine erythroleukemia (MEL) cells and have mapped the sites of phosphorylation by overexpression of GATA-1 in monkey kidney COS cells. We show that GATA-1 is phosphorylated on 6 serines within its amino terminus in uninduced MEL cells and that a 7th site, serine 310, becomes phosphorylated after MEL cells are induced to differentiate by exposure to dimethyl sulfoxide. This site lies near the carboxyl boundary of the DNA-binding domain in a conserved region of the protein believed to be involved in DNA bending. Detailed analyses indicate, however, that phosphorylation at this site, or the other sites identified, does not significantly influence DNA-binding affinity or specificity, DNA bending, or transcriptional transactivation by GATA-1.	CHILDRENS HOSP, DANA FARBER CANC INST, DEPT PEDIAT, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute			Crossley, Merlin/D-7888-2011	Crossley, Merlin/0000-0003-2057-3642				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANTONIOU M, 1990, GENE DEV, V4, P1007, DOI 10.1101/gad.4.6.1007; BARTON MC, 1993, GENE DEV, V7, P1796, DOI 10.1101/gad.7.9.1796; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GALLARDA JL, 1989, GENE DEV, V3, P1845, DOI 10.1101/gad.3.12a.1845; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HIGGS DR, 1993, CURR BIOL, V3, P548, DOI 10.1016/0960-9822(93)90054-R; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LACRONIQUE V, 1992, NUCLEIC ACIDS RES, V20, P5669, DOI 10.1093/nar/20.21.5669; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ORKIN SH, 1992, BLOOD, V80, P575; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PILZ RB, 1992, J BIOL CHEM, V267, P16161; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; REDDY PMS, 1993, MOL CELL BIOL, V13, P1093, DOI 10.1128/MCB.13.2.1093; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ DA, 1983, J BIOL CHEM, V258, P777; SCHWARTZBAUER G, 1992, NUCLEIC ACIDS RES, V20, P4429, DOI 10.1093/nar/20.17.4429; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; WATT P, 1990, NUCLEIC ACIDS RES, V18, P1339, DOI 10.1093/nar/18.6.1339; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642	70	103	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16589	16596						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206977				2022-12-25	WOS:A1994NR29600014
J	KUDLICKI, W; ODOM, OW; KRAMER, G; HARDESTY, B				KUDLICKI, W; ODOM, OW; KRAMER, G; HARDESTY, B			ACTIVATION AND RELEASE OF ENZYMATICALLY INACTIVE, FULL-LENGTH RHODANESE THAT IS BOUND TO RIBOSOMES AS PEPTIDYL-TRANSFER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION TRANSLATION; PROTEIN; POLYPEPTIDES; BINDING; CHAINS; SYSTEM; GROEL; DNAJ	Synthesis of rhodanese in a cell-free coupled transcription/translation system derived from Escherichia coli leads to an accumulation of full length rhodanese protein on the ribosomes as well as to enzymatically active protein that is released from the ribosomes into the supernatant fraction. The ribosome-bound protein is enzymatically inactive but can be activated and released from the ribosomes without additional protein synthesis by subsequent incubation in the presence of the added chaperones DnaJ, DnaK, GrpE, GroEL, and GroES plus ATP. Efficient activation requires that all of the chaperones are present together during incubation which yields fully active rhodanese. Incubation in the presence of DnaJ only inhibits release whereas incubation with only GroES or DnaK promotes the release of enzymatically inactive protein. Incubation of the ribosome with puromycin leads to the release of enzymatically inactive protein whereas release and activation in the presence of all of the chaperones is blocked by sparsomycin. The effect of these antibiotics provides very strong evidence that enzymatically inactive, full-length rhodanese is bound to the ribosomes as peptidyl-tRNA and that the peptidyl transferase reaction is required for its release. Considered together, the data indicate that chaperone-mediated late stages of rhodanese folding into the enzymatically active, native conformation are intimately associated with the process of termination and release that occurs as part of the reaction cycle of protein synthesis.	UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712	University of Texas System; University of Texas Austin								ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAHR BR, 1954, J AM CHEM SOC, V76, P2838; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; Cundliffe E., 1980, RIBOSOMES STRUCTURE, P555; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; HARDESTY B, 1994, MEMBRANE PROTEIN TRA; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; JARABAK R, 1974, BIOCHEMISTRY-US, V13, P3233, DOI 10.1021/bi00713a006; KUDLICKI W, 1992, ANAL BIOCHEM, V206, P389, DOI 10.1016/0003-2697(92)90383-I; KUDLICKI W, 1994, ANAL BIOCHEM, V217, P12, DOI 10.1006/abio.1994.1077; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MILLER DM, 1991, J BIOL CHEM, V266, P4686; NATHANS D, 1963, NATURE, V197, P1076, DOI 10.1038/1971076a0; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; ODOM OW, 1992, J BIOL CHEM, V267, P19117; PICKING WD, 1992, BIOCHEMISTRY-US, V31, P2368, DOI 10.1021/bi00123a023; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; SPIRIN AS, 1988, SCIENCE, V242, P1162, DOI 10.1126/science.3055301; TATE WP, 1994, TRANSLATIONAL APPARA, P253; TSALKOVA T, 1993, BIOCHEMISTRY-US, V32, P3377, DOI 10.1021/bi00064a022; TSOU CL, 1988, BIOCHEMISTRY-US, V27, P1809, DOI 10.1021/bi00406a001	24	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16549	16553						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206970				2022-12-25	WOS:A1994NR29600007
J	VIEIRA, L; LAVAN, A; DAGGER, F; CABANTCHIK, ZI				VIEIRA, L; LAVAN, A; DAGGER, F; CABANTCHIK, ZI			THE ROLE OF ANIONS IN PH REGULATION OF LEISHMANIA-MAJOR PROMASTIGOTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; SENSITIVE NA+/H+ ANTIPORT; INTRACELLULAR PH; CYTOPLASMIC PH; CHLORIDE TRANSPORT; MEMBRANE; DONOVANI; CELLS; H+; IDENTIFICATION	The pH regulation of Leishmania major promastigotes was studied as a function of the ionic composition of the medium and in response to acid and alkali load. Intracellular pH (pH(i)) was monitored by on-line ratio fluorescence using the fluorescence dependent pH indicator 2',7'-bis-(carboxyethyl)-5,6-carboxyfluorescein (BCECF). In Cl--based medium (pH 7.4, 30 degrees C), the steady state pH(i) was maintained at 6.75 +/- 0.01. Only a minor (less than or equal to 0.07 +/- 0.02 unit) decrease in steady state pH(i) was observed when parasites were treated with H+-ATPase inhibitors such as vanadate, N-ethylmaleimide, or bafilomycin. After treatment with the impermeantanion transport blocker DIDS, or in the presence of the reduced analog H2DIDS, pH(i) decreased by greater than or equal to 0.2 unit. In gluconate-based medium, however, pH(i) gradually decreased to 6.53 +/- 0.05 and showed a swift but time dependent recovery (alkalinization) when Cl- or other halides or nitrate were restored to the medium. That recovery was also inhibited by pretreating cells with DIDS or exposing them to H2DIDS. The findings provide evidence for Cl- transport mechanisms that support a pH, regulatory process which is operative in acidic-neutral cytoplasmic milieu. Under alkali load induced by weak base treatment, parasites undergo a rapid alkalinization which was followed first by a fast but limited acidification and subsequently by a slower but more robust acidification (recovery) to reach a pH(i) of 6.85 +/- 0.05. The recovery of pH(i) was markedly reduced in the presence of H2DIDS and/or in the absence of Cl- in the medium. Based on these results and on the fact that the natural parasite environment is both alkaline and rich in HCO3-CO32- ions, we propose (Cl-)(o) (HCO3-)(i) or (Cl-)(o)-(OH-)(i) exchange as the major mechanism of regulatory cell acidification which is operative upon cell alkalinization. The possibility that similar pH regulatory mechanisms are operative in Leishmania promastigotes in both acidic and alkaline conditions is considered. The putative pH regulatory mechanisms might serve as potential targets for therapeutic intervention.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,KUVIN CTR STUDY INFECT DIS JERUSALEM,DEPT PARASITOL,IL-91904 JERUSALEM,ISRAEL; CENT UNIV VENEZUELA,FAC CIENCIAS,DEPT BIOL CELULAR,CARACAS 1041A,VENEZUELA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Central Venezuela					NIAID NIH HHS [AI20342] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI020342, R01AI020342] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; BARNOY S, 1984, BIOCHIM BIOPHYS ACTA, V778, P612, DOI 10.1016/0005-2736(84)90413-9; BILLINGSLEY PF, 1990, ARCH INSECT BIOCHEM, V15, P149, DOI 10.1002/arch.940150304; BORON WF, 1985, J GEN PHYSIOL, V85, P325, DOI 10.1085/jgp.85.3.325; BORON WF, 1986, ANNU REV PHYSIOL, V48, P377; BOSIA A, 1993, J CELL PHYSIOL, V154, P527, DOI 10.1002/jcp.1041540311; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC857, DOI 10.1152/ajpcell.1988.255.6.C857; BOYER JL, 1992, ANNU REV PHYSIOL, V54, P415, DOI 10.1146/annurev.ph.54.030192.002215; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CABANTCHIK ZI, 1994, HDB BIOMEMBRANES, P297; DAGGER F, 1992, EUR J CELL BIOL, V58, P182; DOW JAT, 1992, J EXP BIOL, V172, P355; GLASER TA, 1988, P NATL ACAD SCI USA, V85, P7602, DOI 10.1073/pnas.85.20.7602; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; ILLSLEY NP, 1988, AM J PHYSIOL, V255, pC789, DOI 10.1152/ajpcell.1988.255.6.C789; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; LIVEANU V, 1991, EUR J CELL BIOL, V54, P95; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MEADE JC, 1987, MOL CELL BIOL, V7, P3937, DOI 10.1128/MCB.7.11.3937; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; OLSNES S, 1987, J CELL PHYSIOL, V132, P192, DOI 10.1002/jcp.1041320203; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; PARIS S, 1983, J BIOL CHEM, V258, P3503; REUSS L, 1984, J GEN PHYSIOL, V83, P801, DOI 10.1085/jgp.83.6.801; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; SIMON BJ, 1992, BIOCHEM J, V287, P423, DOI 10.1042/bj2870423; TETI A, 1991, AM J PHYSIOL, V260, pC1315; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TONNESSEN TI, 1990, AM J PHYSIOL, V258, pC1117, DOI 10.1152/ajpcell.1990.258.6.C1117; VANHEEL B, 1984, AM J PHYSIOL, V246, pC391, DOI 10.1152/ajpcell.1984.246.5.C391; VAZHAIKKURICHI MR, 1993, AM J PHYSIOL, V264, pG874; XIE XS, 1989, J BIOL CHEM, V264, P18870; ZILBERSTEIN D, 1989, MOL BIOCHEM PARASIT, V36, P109, DOI 10.1016/0166-6851(89)90183-7; ZILBERSTEIN D, 1988, BIOCHEM J, V256, P13, DOI 10.1042/bj2560013; ZILBERSTEIN D, 1985, P NATL ACAD SCI USA, V82, P1716, DOI 10.1073/pnas.82.6.1716	40	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16254	16259						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206930				2022-12-25	WOS:A1994NQ72900048
J	ANTONETTI, DA; KIMBALL, SR; HORETSKY, RL; JEFFERSON, LS				ANTONETTI, DA; KIMBALL, SR; HORETSKY, RL; JEFFERSON, LS			REGULATION OF RDNA TRANSCRIPTION BY INSULIN IN PRIMARY CULTURES OF RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-CHAIN INITIATION; RIBOSOMAL-RNA SYNTHESIS; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MESSENGER-RNA; AMINO-ACID; RIBONUCLEIC-ACID; SKELETAL-MUSCLE; LIVER INVIVO; HEART-CELLS	The studies presented herein were designed to investigate the role of insulin in maintaining the steady-state number of ribosomes in primary cultures of rat hepatocytes. The RNA content of hepatocytes maintained in the presence of insulin did not change during the 7 days of culture. In contrast, the RNA content declined significantly following 2 days of insulin deprivation and after 4 days without insulin reached a new steady-state value that was approximately 60% of that observed for hepatocytes maintained in the presence of the hormone. Following addition of insulin, the RNA content of insulin-deprived hepatocytes started to increase within 6 h and was restored to the control value within 48 h. The amounts of 18 and 28 S RNA, and thus the number of ribosomes, changed in concert with the total RNA content. Furthermore, synthesis of total cellular protein responded in parallel to the changes in RNA content, suggesting that the number of ribosomes was the primary determinant of protein synthesis under the conditions of these experiments. About one-half of the increase in RNA content following the addition of insulin to insulin-deprived cells could be accounted for by a reduction in the rate of degradation of ribosomes. The remainder of the change in RNA content must have resulted from an increase in ribosome biogenesis. This possibility was confirmed by measuring [H-3]uridine incorporation into ribosomal RNA present in mature ribosomes. The rate of synthesis of ribosomal RNA was reduced in parallel with the fall in RNA content in insulin-deprived hepatocytes and was restored to the control value within 3 h of the addition of insulin. Alterations in the synthesis of ribosomal RNA in response to insulin deprivation and replacement were associated with parallel changes in transcription of rDNA as measured in nuclear run-on assays using a DNA probe corresponding to the external transcribed spacer region of rat rDNA. The data demonstrate that insulin regulates the number of ribosomes in primary cultures of rat hepatocytes by accelerating the rate of transcription of rDNA and by slowing the rate of ribosome degradation.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,POB 850,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health				antonetti, david/0000-0003-1130-6577	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013499, R37DK013499] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-13499] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHFORD AJ, 1986, J BIOL CHEM, V261, P4066; ASHFORD AJ, 1986, J BIOL CHEM, V261, P4059; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BLOBEL G, 1967, J MOL BIOL, V26, P279, DOI 10.1016/0022-2836(67)90297-5; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARNELL JE, 1968, BACTERIOL REV, V32, P262, DOI 10.1128/MMBR.32.3.262-290.1968; DEPHILIP RM, 1979, BIOCHEMISTRY-US, V18, P4812, DOI 10.1021/bi00589a008; EVERSON WV, 1989, AM J PHYSIOL, V256, pC18, DOI 10.1152/ajpcell.1989.256.1.C18; FLAIM KE, 1985, AM J PHYSIOL, V249, pE447, DOI 10.1152/ajpendo.1985.249.5.E447; FLAIM KE, 1982, J BIOL CHEM, V257, P2939; FLECK A, 1962, BIOCHIM BIOPHYS ACTA, V55, P571; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HAMMOND ML, 1988, J BIOL CHEM, V263, P17785; HIRSCH CA, 1966, J BIOL CHEM, V241, P5936; HSU CJ, 1993, AM J PHYSIOL, V263, pE1106; JEFFERSON LS, 1983, J BIOL CHEM, V258, P1369; KHYM JX, 1978, J BIOL CHEM, V253, P8741; KIMBALL SR, 1990, J BIOL CHEM, V265, P16794; KIMBALL SR, 1990, ELLENBERG RIFKINS DI, P41; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LARDEUX BR, 1987, J BIOL CHEM, V262, P14514; LLOYD CE, 1987, AM J PHYSIOL, V252, pC205, DOI 10.1152/ajpcell.1987.252.2.C205; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MCDERMOTT PJ, 1989, CIRC RES, V64, P542, DOI 10.1161/01.RES.64.3.542; MCDERMOTT PJ, 1989, J BIOL CHEM, V264, P18220; MCNURLAN MA, 1981, AM J PHYSIOL, V241, pE238, DOI 10.1152/ajpendo.1981.241.3.E238; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; NEELY AN, 1977, J BIOL CHEM, V252, P6948; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; PALMITER RD, 1974, J BIOL CHEM, V249, P6779; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PETERSON DT, 1973, J CLIN INVEST, V52, P3201, DOI 10.1172/JCI107520; PILKIS SJ, 1972, BIOCHIM BIOPHYS ACTA, V272, P327, DOI 10.1016/0005-2787(72)90257-2; PILKIS SJ, 1971, BIOCHIM BIOPHYS ACTA, V247, P597, DOI 10.1016/0005-2787(71)90695-2; RANNELS SR, 1978, AM J PHYSIOL, V235, pE134, DOI 10.1152/ajpendo.1978.235.2.E134; ROTHBLUM LI, 1982, GENE, V17, P75, DOI 10.1016/0378-1119(82)90102-0; ROTHBLUM LI, 1982, NUCLEIC ACIDS RES, V10, P7345, DOI 10.1093/nar/10.22.7345; SAMBROOK J, 1989, MOL CLONING LABORATO, P15113; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; STEINER DF, 1966, BIOCHIM BIOPHYS ACTA, V119, P510, DOI 10.1016/0005-2787(66)90127-4; TRAGL KH, 1972, DIABETES, V21, P84, DOI 10.2337/diab.21.2.84; TSURUGI K, 1974, EUR J BIOCHEM, V45, P119, DOI 10.1111/j.1432-1033.1974.tb03536.x; WATSON JD, 1987, MOL BIOL GENE, P1163; WIEGERS U, 1976, EUR J BIOCHEM, V64, P535, DOI 10.1111/j.1432-1033.1976.tb10333.x; WITTMAN JS, 1969, BIOCHIM BIOPHYS ACTA, V174, P536, DOI 10.1016/0005-2787(69)90282-2	48	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25277	25284						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244958				2022-12-25	WOS:A1993MK10000005
J	DRABKIN, HJ; HELK, B; RAJBHANDARY, UL				DRABKIN, HJ; HELK, B; RAJBHANDARY, UL			THE ROLE OF NUCLEOTIDES CONSERVED IN EUKARYOTIC INITIATOR METHIONINE TRANSFER-RNAS IN INITIATION OF PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYLMETHIONINE TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; STRUCTURAL GENE; DNA; SEQUENCE; YEAST; EXPRESSION; INVITRO; MUTATIONS; INVIVO	Mutant human initiator tRNA genes carrying changes in each of the three features unique to eukaryotic initiator tRNAs have been constructed, and introduced into CV-1 monkey kidney cells using SV40 virus vectors. The mutant tRNA genes are expressed, and the mutant tRNAs can all be aminoacylated with both rabbit liver and Escherichia coli methionyl-tRNA synthetases. Based on aminoacylation levels, the tRNAs are expressed to 5-15-fold over the level of endogenous initiator tRNA. The activity of the mutant [S-35]methionyl-tRNAs in initiation was studied in rabbit reticulocyte and wheat germ cell-free protein synthesis systems programmed with various mRNAs. Initiation is studied by using a mRNA that codes for a protein whose N-terminal methionine is stable and not removed by methionine aminopeptidase. Changing the A1:U72 base pair to a G1:C72 base pair greatly reduced activity of the tRNA in initiation. Changing the three consecutive G:C base pairs (G29G30G31: C39C40C41) in the anticodon stem to those found in elongator methionine tRNA also reduced initiation activity. Interestingly, changing the A54 and A60 residues in loop IV to T54 and U60 had less of an effect on activity. The tRNA with changes in all three conserved features had virtually no activity in initiation.			DRABKIN, HJ (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NIGMS NIH HHS [GM46942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASAVAPPA R, 1991, EMBO J, V10, P3105, DOI 10.1002/j.1460-2075.1991.tb07864.x; BOLLUM FJ, 1968, METHODS ENZYMOLOGY B, V12, P169; BYSTROM AS, 1989, MOL GEN GENET, V216, P276, DOI 10.1007/BF00334366; DRABKIN HJ, 1988, NUCLEIC ACIDS RES, V16, P11591, DOI 10.1093/nar/16.24.11591; DRABKIN HJ, 1985, J BIOL CHEM, V260, P5580; DRABKIN HJ, 1985, J BIOL CHEM, V260, P5588; DRABKIN HJ, 1985, J BIOL CHEM, V260, P5596; FRANCIS MA, 1990, MOL CELL BIOL, V10, P4486, DOI 10.1128/MCB.10.9.4486; GILL DS, 1986, P NATL ACAD SCI USA, V83, P8873, DOI 10.1073/pnas.83.23.8873; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; KEITH G, 1993, NUCLEIC ACIDS RES, V21, P2949, DOI 10.1093/nar/21.12.2949; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1983, MICROBIOL REV, V47, P1; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LEE CP, 1992, P NATL ACAD SCI USA, V89, P9262, DOI 10.1073/pnas.89.19.9262; LEONTIS N, 1988, NUCLEIC ACIDS RES, V16, P2537, DOI 10.1093/nar/16.6.2537; LO KM, 1984, P NATL ACAD SCI-BIOL, V81, P2285, DOI 10.1073/pnas.81.8.2285; MAO JI, 1980, CELL, V21, P509, DOI 10.1016/0092-8674(80)90488-2; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; Nishimura S, 1972, Prog Nucleic Acid Res Mol Biol, V12, P49; PEARSON RL, 1973, BIOCHIM BIOPHYS ACTA, V294, P236, DOI 10.1016/0005-2787(73)90296-7; RABA M, 1979, EUR J BIOCHEM, V97, P305, DOI 10.1111/j.1432-1033.1979.tb13115.x; RAJBHANDARY UL, 1969, J BIOL CHEM, V244, P1104; SACHS MS, 1989, MOL CELL BIOL, V9, P566, DOI 10.1128/MCB.9.2.566; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS T, 1981, CELL, V23, P699, DOI 10.1016/0092-8674(81)90433-5; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P8859, DOI 10.1073/pnas.84.24.8859; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; SIMSEK M, 1972, BIOCHEM BIOPH RES CO, V49, P508, DOI 10.1016/0006-291X(72)90440-8; SIMSEK M, 1973, P NATL ACAD SCI USA, V70, P1041, DOI 10.1073/pnas.70.4.1041; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; Stanley W M Jr, 1974, Methods Enzymol, V29, P530; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; VONPAWELRAMMINGEN U, 1992, MOL CELL BIOL, V12, P1432, DOI 10.1128/MCB.12.4.1432; WALLACE RB, 1979, NUCLEIC ACIDS RES, V6, P3543, DOI 10.1093/nar/6.11.3543; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	40	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25221	25228						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227087				2022-12-25	WOS:A1993MG67300100
J	WILLEMS, J; ZWIJSEN, A; SLEGERS, H; NICOLAI, S; BETTADAPURA, J; RAYMACKERS, J; SCARCEZ, T				WILLEMS, J; ZWIJSEN, A; SLEGERS, H; NICOLAI, S; BETTADAPURA, J; RAYMACKERS, J; SCARCEZ, T			PURIFICATION AND SEQUENCE OF RAT EXTRACELLULAR-SUPEROXIDE DISMUTASE-B SECRETED BY C(6) GLIOMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CELL-LINES; PROTEINS; BINDING; DNA; ELECTROPHORESIS; CHROMATOGRAPHY; EXPRESSION; QUANTITIES; SITE	An enzyme which converts radical oxygen, produced by phorbol 12-myristate 13-acetate activated neutrophils, into nonluminescent products is secreted by rat C6 glioma. The enzyme was purified from chemically defined conditioned media and identified as an extracellular superoxide dismutase (EC-SOD). The purified enzyme is distinct from human EC-SOD C (Hjalmarsson, K., Marklund, S. L., Engstrom, A., and Edlund, T. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 6340-6344) by its elution from heparin-Sepharose at 300-400 mM NaCl, its pI of 6.1-7.2, and its native M(r) of 85,000 +/- 20,000. The rat EC-SOD is a dimer with a subunit M(r) of 34,000-36,000 and is extensively modified by post-translational processing. Although rat EC-SOD has a high sequence homology with the catalytic center and the polybasic heparin-binding site near the COOH terminus of human EC-SOD C, its NH2-terminal sequence and the sequences flanking the heparin-binding site differ substantially. The sequence of the isolated rat EC-SOD cDNA fully confirms the data obtained from amino acid sequence analysis. The amino acid sequence of the enzyme and its biochemical properties support its identification as the rat EC-SOD B.	UNIV INSTELLING ANTWERP, DEPT BIOCHEM, UNIV PL 1, B-2610 Antwerp, BELGIUM; KULAK, INTERDISCIPLINARY RES CTR, B-8500 KORTRIJK, BELGIUM; INNOGENET NV, B-9050 ZWIJNAARDE, BELGIUM	University of Antwerp; KU Leuven; Innogenetics NV			Zwijsen, An/AAK-2897-2020	Zwijsen, An/0000-0002-8583-1721				ADACHI T, 1991, BIOCHEM J, V279, P263, DOI 10.1042/bj2790263; ADACHI T, 1992, ARCH BIOCHEM BIOPHYS, V297, P155, DOI 10.1016/0003-9861(92)90654-F; ADACHI T, 1989, J BIOL CHEM, V264, P8537; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; BOISSINOT M, 1993, BIOCHEM BIOPH RES CO, V190, P250, DOI 10.1006/bbrc.1993.1038; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALABRESE L, 1975, FEBS LETT, V59, P29, DOI 10.1016/0014-5793(75)80333-4; CARRICO RJ, 1969, J BIOL CHEM, V244, P6087; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FERRARI R, 1989, PHARMACOL RES, V21, P57, DOI 10.1016/S1043-6618(89)80018-0; GETZOFF ED, 1989, PROTEINS, V5, P322, DOI 10.1002/prot.340050408; Gros E., 1967, METHOD ENZYMOL, V11, P238; HIRS CHW, 1967, METHOD ENZYMOL, V11, P199; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; KARLSSON K, 1988, BIOCHEM J, V255, P223; KARLSSON K, 1987, BIOCHEM J, V242, P55, DOI 10.1042/bj2420055; KARLSSON K, 1989, LAB INVEST, V60, P659; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM R, 1986, CANCER RES, V46, P5241; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARKLUND SL, 1990, BIOCHEM J, V266, P213, DOI 10.1042/bj2660213; MARKLUND SL, 1984, BIOCHEM J, V222, P649, DOI 10.1042/bj2220649; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SAMBROOK I, 1989, MOL CLONING LABORATO; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SJOQUIST PO, 1992, CARDIOVASC RES, V26, P347, DOI 10.1093/cvr/26.4.347; STROMQVIST M, 1991, J CHROMATOGR, V548, P293, DOI 10.1016/S0021-9673(01)88611-8; TIBELL L, 1987, P NATL ACAD SCI USA, V84, P6634, DOI 10.1073/pnas.84.19.6634; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; TROUTT AB, 1992, P NATL ACAD SCI USA, V89, P9823, DOI 10.1073/pnas.89.20.9823; VANFLETEREN JR, 1992, BIOTECHNIQUES, V12, P550; WILLEMS J, 1989, IMMUNOLOGY, V67, P540; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1	42	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24614	24621						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227019				2022-12-25	WOS:A1993MG67300019
J	BROOKS, G; GOSS, MW; EAST, JA; HART, IR				BROOKS, G; GOSS, MW; EAST, JA; HART, IR			GROWTH OF MELANOCYTIC CELLS IS ASSOCIATED WITH DOWN-REGULATION OF PROTEIN-KINASE-C ALPHA-ISOFORM, DELTA-ISOFORM, AND EPSILON-ISOFORM - POSSIBLE ROLE OF DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL EXPRESSION; MURINE MELANOCYTES; GENE-EXPRESSION; PHORBOL ESTERS; RAS; 12-O-TETRADECANOYLPHORBOL-13-ACETATE; ACTIVATION; FIBROBLASTS; INDUCTION; MELANOMA	Protein kinase C (PKC) down-regulation has been shown to correlate with the growth of murine melanocytic cells in culture (Brooks, G., Wilson, R. E., Dooley, T. P., Goss, M. W., and Hart, I. R. (1991) Cancer Res. 51, 3281-3288). We now show that PKC alpha, delta, epsilon, and zeta isoforms are present at the protein level in quiescent, non-transformed Mel-ab melanocytes, maintained in the absence of phorbol ester. Proliferation of Mel-ab cells, achieved by incubation in the continual presence of phorbol 12,13-dibutyrate, was associated with a down-regulation of the PKC alpha, delta, and epsilon isozymes. Examination of two transformed syngeneic lines (the B16 murine melanoma and the long terminal repeat Ras.2 line), that grew in the absence of exogenous phorbol esters, showed that PKC alpha protein levels were either partially down-regulated or unaffected, the PKC delta and epsilon isoforms were down-regulated completely, and the levels of PKC zeta protein remained unaltered relative to quiescent Mel-ab cells. Basal levels of total diacylglycerol were elevated 5-fold in B16 melanoma cells compared with levels found in quiescent or proliferating Mel-ab melanocytes and appear to arise largely from the breakdown of phosphatidylinositol phospholipids accompanied by a significant rise in phospholipase C activity. Hourly treatments of quiescent Mel-ab melanocytes with the synthetic diacylglycerol analogue, 1,2-dioctanoyl-sn-glycerol, for 24 h, resulted in an induction of DNA synthesis which was associated with a significant down-regulation of PKC levels mediated largely via post-translational rather than transcriptional mechanisms. These results show for the first time that specific isoforms of PKC are down-regulated at the protein level during proliferation of murine melanocytic cells and suggest that the constitutive down-regulation of PKC in transformed melanoma cells may arise as a consequence of elevated endogenous phosphatidylinositol-derived diacylglycerol levels.	IMPERIAL CANC RES FUND,BIOL METASTASIS LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	BROOKS, G (corresponding author), ST THOMAS HOSP,RAYNE INST,LONDON SE1 7EH,ENGLAND.							ANDO H, 1990, PIGM CELL RES, V3, P200, DOI 10.1111/j.1600-0749.1990.tb00290.x; ARITA Y, 1992, CANCER RES, V52, P4514; BECKER D, 1990, ONCOGENE, V5, P1133; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS G, 1991, CANCER RES, V51, P3281; BROOKS G, 1992, MOL CARCINOGEN, V5, P328, DOI 10.1002/mc.2940050414; CHIARUGI V, 1989, BIOCHEM BIOPH RES CO, V164, P816, DOI 10.1016/0006-291X(89)91532-5; FARESE RV, 1987, SCIENCE, V236, P586, DOI 10.1126/science.3107122; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HANSEN LA, 1990, CANCER RES, V50, P5740; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1987, FEBS LETT, V226, P125, DOI 10.1016/0014-5793(87)80564-1; PREISS J, 1986, J BIOL CHEM, V261, P8597; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; STRULOVICI B, 1989, BIOCHEMISTRY-US, V28, P3569, DOI 10.1021/bi00434a063; WILKISON WO, 1989, ONCOGENE, V4, P625; WILSON RE, 1989, CANCER RES, V49, P711; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; YAMANISHI DT, 1991, CARCINOGENESIS, V12, P105, DOI 10.1093/carcin/12.1.105; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	28	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23868	23875						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226926				2022-12-25	WOS:A1993MF29400028
J	DOTSON, DG; PUTKEY, JA				DOTSON, DG; PUTKEY, JA			DIFFERENTIAL RECOVERY OF CA2+ BINDING-ACTIVITY IN MUTATED EF-HANDS OF CARDIAC TROPONIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MYOFIBRILLAR ADENOSINE-TRIPHOSPHATASE; X-RAY-SCATTERING; CALCIUM-BINDING; SKELETAL-MUSCLE; PEPTIDE COMPLEX; THIN FILAMENT; I PEPTIDE; CALMODULIN; SITES	Previous studies showed that conversion of the first Ca2+ ligand in Ca2+-binding sites III and IV from Asp to Ala decreased the affinity of cardiac TnC (cTnC) for the thin filament. Here, the functional consequences of mutation of the second ligand in the Ca2+-binding sites of cTnC were determined. Equilibrium dialysis and Tyr fluorescence studies showed that conversion of the second Ca2+ ligand to Ala (Asp-67, site II; Asn-107, site III; and Asn-143, site IV) inactivated all three Ca2+-binding sites in the free protein. Ca2+ binding to the mutated site II was not recovered upon association with a troponin complex, and proteins with this mutation were unable to regulate Ca2+-dependent ATPase activity in TnC-extracted myofibrils. However, Ca2+ binding was recovered at the mutated sites III and IV under the same conditions. Sequential addition of active and inactive cTnC proteins in a myofibril ATPase assay suggested that that Mg2+ binding was not recovered and that the recovered Ca2+ affinity of the mutated sites III and IV was much lower than that of the wild type in that the Ca2+ concentrations required for apparent thin filament binding by proteins containing mutations at sites III and/or IV were significantly greater than that required for the wild-type protein.			DOTSON, DG (corresponding author), UNIV TEXAS, HLTH SCI CTR,SCH MED,DEPT BIOCHEM & MOLEC BIOL, POB 20708, 6431 FANNIN, HOUSTON, TX 77225 USA.				NIAMS NIH HHS [AR-39210] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; BLECHNER SL, 1992, BIOCHEMISTRY-US, V31, P11326, DOI 10.1021/bi00161a010; BRITO RMM, 1993, J BIOL CHEM, V268, P20966; CAMPBELL AP, 1992, BIOCHIM BIOPHYS ACTA, V1160, P35, DOI 10.1016/0167-4838(92)90036-D; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; COX JA, 1981, BIOCHEM J, V195, P205, DOI 10.1042/bj1950205; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; HAIECH J, 1991, J BIOL CHEM, V266, P3427; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MORIMOTO S, 1987, J BIOCHEM-TOKYO, V101, P291, DOI 10.1093/oxfordjournals.jbchem.a121913; NEGELE JC, 1992, J BIOL CHEM, V267, P825; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; PUTKEY JA, 1991, J BIOL CHEM, V266, P14881; PUTKEY JA, 1993, J BIOL CHEM, V268, P6827; REINACH FC, 1986, NATURE, V322, P80, DOI 10.1038/322080a0; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SHAW GS, 1991, BIOCHEMISTRY-US, V30, P8339, DOI 10.1021/bi00098a009; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P9538, DOI 10.1073/pnas.87.24.9538; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; VANEERD JP, 1976, BIOCHEMISTRY-US, V15, P1171, DOI 10.1021/bi00650a033; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; VANEYK JE, 1991, BIOCHEMISTRY-US, V30, P9974, DOI 10.1021/bi00105a023; WANG CLA, 1986, EUR J BIOCHEM, V154, P225, DOI 10.1111/j.1432-1033.1986.tb09383.x; YOSHINO H, 1989, J BIOL CHEM, V264, P19706; ZOT HG, 1982, J BIOL CHEM, V257, P7678	41	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24067	24073						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226952				2022-12-25	WOS:A1993MF29400055
J	KIENER, PA; RANKIN, BM; BURKHARDT, AL; SCHIEVEN, GL; GILLILAND, LK; ROWLEY, RB; BOLEN, JB; LEDBETTER, JA				KIENER, PA; RANKIN, BM; BURKHARDT, AL; SCHIEVEN, GL; GILLILAND, LK; ROWLEY, RB; BOLEN, JB; LEDBETTER, JA			CROSS-LINKING OF FC-GAMMA RECEPTOR-I (FC-GAMMA-RI) AND RECEPTOR-II (FC-GAMMA-RII) ON MONOCYTIC CELLS ACTIVATES A SIGNAL-TRANSDUCTION PATHWAY COMMON TO BOTH FC-RECEPTORS THAT INVOLVES THE STIMULATION OF P72 SYK PROTEIN-TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; PHOSPHOLIPASE C-GAMMA-1; PHOSPHORYLATION; SRC; DOMAINS; GTPASE; IGG; GAP; ASSOCIATION; BINDING	Stimulation of the human monocytic cell line THP-1 by cross-linking either Fcgamma receptor I (FcgammaRI) or Fcgamma receptor II (FcgammaRII) gave rise to the rapid phosphorylation of multiple intracellular proteins. The pattern of proteins that were phosphorylated appeared to be identical. Analysis of these proteins by specific immunoprecipitation indicated that stimulation through either receptor did indeed give rise to phosphorylation of the same set of proteins. These included: FcgammaRII, phospholipase C (PLC) gamma1, PLCgamma2, Vav, GAP, and a protein that co-precipitated with the Fcgamma receptors and migrated with a molecular weight of about 70,000. Co-cross-linking an F(ab')2 anti-CD45 monoclonal antibody together with monoclonal antibodies to either of the Fcgamma receptors inhibited phosphorylation of all these proteins. Analysis of the tyrosine kinases in the cells revealed that both receptors stimulated the phosphorylation and activation of a kinase recognized by antibodies to Syk. Furthermore, the Syk kinase became associated with the Fc-gammaRII following receptor cross-linking. These data indicate that although the two Fcgamma receptors have different cytoplasmic tails, they are coupled to the same signal transduction cascade that is regulated by CD45 and involves the activation of Syk.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb	KIENER, PA (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT AUTOIMMUN & TRANSPLANTAT, 3005 1ST AVE, SEATTLE, WA 98121 USA.							ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOLANUS W, 1992, EMBO J, V11, P4861, DOI 10.1002/j.1460-2075.1992.tb05592.x; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; LIAO F, 1993, J IMMUNOL, V150, P2668; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PAWSON T, 1988, ONCOGENE, V3, P491; RANKIN BM, 1993, J IMMUNOL, V150, P605; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; TING AT, 1992, J EXP MED, V176, P1751, DOI 10.1084/jem.176.6.1751; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDEWINKEL JGJ, 1990, SCAND J IMMUNOL, V31, P315; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	177	177	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24442	24448						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226994				2022-12-25	WOS:A1993MF29400107
J	WANG, YH; ROACH, PJ				WANG, YH; ROACH, PJ			INACTIVATION OF RABBIT MUSCLE GLYCOGEN-SYNTHASE BY GLYCOGEN-SYNTHASE KINASE-3 - DOMINANT ROLE OF THE PHOSPHORYLATION OF SER-640 (SITE 3A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOSPHOSERINE RESIDUES INVIVO; SKELETAL-MUSCLE; CYCLIC-AMP; STATE; SUBSTRATE; SEQUENCE; CLONING; ABSENCE; INSULIN	Rabbit skeletal muscle glycogen synthase, a rate-limiting enzyme for glycogen biosynthesis, is regulated by multisite phosphorylation. The protein kinase glycogen synthase kinase 3 (GSK-3) phosphorylates 4 Ser residues (Ser-640, Ser-644, Ser-648, and Ser-652; also known as sites 3a, 3b, 3c, and 4, respectively) at the COOH terminus of the subunit. Phosphorylation of these sites by GSK-3 is sequential, from COOH- to NH2-terminal, and is wholly dependent on prior phosphorylation by casein kinase II at Ser-656 (site 5). Expression in Escherichia coli was used to generate mutant forms of glycogen synthase, S640A, S644A, and S648A, in which site 3a, site 3b, or site 3c was changed to Ala, respectively. The purified enzymes had -/+ glucose-6-P activity ratios in the range of 0.8-0.9. Phosphorylation by casein kinase II and GSK-3 gave results consistent with the model of obligate sequential action of GSK-3. Phosphorylation at site 5, sites 4 + 5, or sites 3c + 4 + 5 had no measurable effect on activity. When sites 3b + 3c + 4 + 5 were phosphorylated, modest inactivation resulted. Additional phosphorylation at site 3a, however, was potently inactivating, reducing the -/+ glucose-6-P activity ratio to 0.1 and increasing the glucose-6-P concentration needed for half-maximal activation by an order of magnitude. Introduction of each additional phosphate, in the order site 4, 3c, 3b, and 3a, caused an incremental reduction in the mobility of the subunit when analyzed by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate. The results of this study demonstrate that GSK-3 phosphorylation of site 3a (Ser-640), and to a lesser extent, site 3b, correlates with inactivation of glycogen synthase by GSK-3. Evidence is also presented for an allosteric mechanism of inactivation whereby modification of one subunit influences the activity state of adjacent subunits.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027221, R01DK027221] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27221] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAI G, 1990, J BIOL CHEM, V265, P7843; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; CAMICI M, 1984, J BIOL CHEM, V259, P2466; COHEN P, 1982, EUR J BIOCHEM, V124, P21, DOI 10.1111/j.1432-1033.1982.tb05902.x; COHEN P, 1991, BIOCHIM BIOPHYS ACTA, V1094, P292, DOI 10.1016/0167-4889(91)90089-G; Cohen P., 1986, ENZYMES, VXVII, P461; DEPAOLIROACH AA, 1979, J BIOL CHEM, V254, P4212; DEPAOLIROACH AA, 1983, J BIOL CHEM, V258, P702; DEPAOLIROACH AA, 1981, J BIOL CHEM, V256, P8955; EMBI N, 1981, EUR J BIOCHEM, V115, P405, DOI 10.1111/j.1432-1033.1981.tb05252.x; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUANG KP, 1984, ARCH BIOCHEM BIOPHYS, V232, P111, DOI 10.1016/0003-9861(84)90526-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PARKER PJ, 1982, EUR J BIOCHEM, V124, P47, DOI 10.1111/j.1432-1033.1982.tb05904.x; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, P147; POULTER L, 1988, EUR J BIOCHEM, V175, P497, DOI 10.1111/j.1432-1033.1988.tb14222.x; Roach P. J., 1986, ENZYMES, VXVII, P499; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1976, J BIOL CHEM, V241, P1913; RYLATT DB, 1980, EUR J BIOCHEM, V107, P529; SHEORAIN VS, 1984, J BIOL CHEM, V259, P7024; SHEORAIN VS, 1985, J BIOL CHEM, V260, P1567; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; WANG YH, 1986, J BIOL CHEM, V261, P6909; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; ZHANG W, 1989, FASEB J, V3, P2353; ZHANG W, 1993, IN PRESS ARCH BIOCH	35	59	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23876	23880						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226927				2022-12-25	WOS:A1993MF29400029
J	LI, SC; DEBER, CM				LI, SC; DEBER, CM			PEPTIDE ENVIRONMENT SPECIFIES CONFORMATION - HELICITY OF HYDROPHOBIC SEGMENTS COMPARED IN AQUEOUS, ORGANIC, AND MEMBRANE ENVIRONMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SECONDARY STRUCTURE; PROTEIN; GLYCINE; TRIFLUOROETHANOL; RESIDUES; CHAINS; SIGNAL	Transmembrane segments in integral membrane proteins exist characteristically as helices in lipid bilayers, yet are often rich in residues considered helix-destabilizing (Val, Ile, Gly) in soluble proteins. We propose that helicity of a transmembrane segment is likely to be affected by factors other than the ''intrinsic'' helical propensities of its component amino acids. This hypothesis is tested by comparing the conformation(s) in aqueous, organic, membrane-mimetic (micellar), and membrane (bilayer) environments of designed model peptides with systematically altered helical propensity and/or segmental hydrophobicity. Peptides of prototypic sequence NH2-(Ser-Lys)2-Ala5-Leu6-Ala7-Ala8-Leu9-Ala10-Trp11-Ala12-Leu13-Ala14-(Lys-Ser)3-OH were synthesized, which incorporate a hydrophobic core ''guest'' segment (residues 5-14) into a water-soluble hydrophilic host matrix. Related peptides featured substitution of Leu6,9,13 --> Gly, Leu6,9,13 --> Ala, and Ala7,10,14 --> Gly. Circular dichroism spectra revealed that algorithms for soluble proteins correctly predicted peptide helical proclivities in aqueous solutions, but peptide helicity in organic (trifluoroethanol) solvents, membrane-mimetic SDS micelles, and negatively charged lipid bilayer vesicles, was found to be governed almost exclusively by the segmental hydrophobicity of the peptide mid-hydrophobic core segment. In related Trp fluorescence studies, peptide-membrane association was similarly correlated with extent of hydrophobic interaction.	HOSP SICK CHILDREN, RES INST, DIV BIOCHEM RES, TORONTO M5G 1X8, ONTARIO, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BRUCH MD, 1990, J BIOL CHEM, V265, P3851; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DEBER CM, 1986, ARCH BIOCHEM BIOPHYS, V251, P68, DOI 10.1016/0003-9861(86)90052-4; EFTINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ENGEL M, 1991, BIOCHEMISTRY-US, V30, P3161, DOI 10.1021/bi00227a002; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI SC, 1992, INT J PEPT PROT RES, V40, P243; LI SC, 1992, FEBS LETT, V311, P217, DOI 10.1016/0014-5793(92)81106-V; LYU PC, 1991, P NATL ACAD SCI USA, V88, P5317, DOI 10.1073/pnas.88.12.5317; MCLEAN LR, 1990, BIOCHIM BIOPHYS ACTA, V1024, P1, DOI 10.1016/0005-2736(90)90201-X; MILIK M, 1992, P NATL ACAD SCI USA, V89, P9391, DOI 10.1073/pnas.89.20.9391; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; WALLACE BA, 1986, P NATL ACAD SCI USA, V83, P9423, DOI 10.1073/pnas.83.24.9423; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462	20	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22975	22978						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226811				2022-12-25	WOS:A1993MF51500006
J	SUNNERHAGEN, MS; PERSSON, E; DAHLQVIST, I; DRAKENBERG, T; STENFLO, J; MAYHEW, M; ROBIN, M; HANDFORD, P; TILLEY, JW; CAMPBELL, ID; BROWNLEE, GG				SUNNERHAGEN, MS; PERSSON, E; DAHLQVIST, I; DRAKENBERG, T; STENFLO, J; MAYHEW, M; ROBIN, M; HANDFORD, P; TILLEY, JW; CAMPBELL, ID; BROWNLEE, GG			THE EFFECT OF ASPARTATE HYDROXYLATION ON CALCIUM-BINDING TO EPIDERMAL GROWTH FACTOR-LIKE MODULES IN COAGULATION FACTOR-IX AND FACTOR-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HYDROXYASPARTIC ACID; GAMMA-CARBOXYGLUTAMIC ACID; FACTOR-LIKE DOMAIN; DEPENDENT PROTEIN-S; EGF-LIKE DOMAINS; BOVINE FACTOR-X; 3-DIMENSIONAL STRUCTURE; CONTAINING REGION; THROMBIN BINDING; MARFAN-SYNDROME	Hydroxylation of aspartic acid to erythro-beta-aspartic acid (Hya) occurs in epidermal growth factor (EGF)-like modules in numerous extracellular proteins with diverse functions. Several EGF-like modules with the consensus sequence for hydroxylation bind Ca2+, and it has therefore been suggested that the hydroxyl group is essential for Ca2+ binding. To determine directly the influence of beta-hydroxylation on calcium binding in the EGF-like modules from coagulation factors IX and X, we have now measured calcium binding to both the fully beta-hydroxylated and the non-beta-hydroxylated modules of the two proteins. At low ionic strength, the Hya-containing module of factor X has a slightly higher Ca2+ affinity, but at physiological salt concentrations this difference is no longer significant for either factor IX or X. Analysis of the H-1 NMR chemical shift differences between the hydroxylated and nonhydroxylated factor X modules show that hydroxylation has no effect on the domain fold. Furthermore, measurements on factor IX show that hydroxylation has no effect on the Ca2+/Mg2+ specificity of the ion binding site. We conclude that the hydroxyl group is not a direct ligand for the calcium ion in these EGF-like modules, nor is it essential for high-affinity Ca2+ binding.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND	Lund University; University of Oxford; University of Oxford	SUNNERHAGEN, MS (corresponding author), LUND UNIV,CTR CHEM,DEPT PHYS CHEM 2,POB 124,S-22100 LUND,SWEDEN.			Persson, Egon/0000-0003-3005-4926				ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BARON M, 1992, PROTEIN SCI, V1, P81; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DAHLBACK B, 1990, J BIOL CHEM, V265, P16082; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; GIANNELLI F, 1992, NUCLEIC ACIDS RES, V20, P2027, DOI 10.1093/nar/20.suppl.2027; GRONKE RS, 1989, P NATL ACAD SCI USA, V86, P3609, DOI 10.1073/pnas.86.10.3609; GRONKE RS, 1990, J BIOL CHEM, V265, P8558; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; IKEGAMI T, 1975, ACTA MED OKAYAMA, V29, P341; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KORNBERG HL, 1965, BIOCHEM J, V95, P577, DOI 10.1042/bj0950577; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LINSE S, 1991, BIOCHEMISTRY-US, V30, P154, DOI 10.1021/bi00215a023; LINSE S, 1988, NATURE, V335, P651, DOI 10.1038/335651a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; MCMULLEN BA, 1983, BIOCHEMISTRY-US, V22, P2875, DOI 10.1021/bi00281a016; MCMULLEN BA, 1983, BIOCHEM BIOPH RES CO, V115, P8, DOI 10.1016/0006-291X(83)90961-0; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; MORITA T, 1984, J BIOL CHEM, V259, P5698; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SELANDER M, 1990, BIOCHEMISTRY-US, V29, P8111, DOI 10.1021/bi00487a018; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; STENFLO J, 1991, BLOOD, V78, P1637; STENFLO J, 1988, J BIOL CHEM, V263, P21; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; SUGO T, 1986, J BIOL CHEM, V261, P5116; SUGO T, 1984, J BIOL CHEM, V259, P5705; SUZUKI K, 1989, J BIOL CHEM, V264, P4872; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; ULLNER M, 1992, BIOCHEMISTRY-US, V31, P5974, DOI 10.1021/bi00141a004; WAGNER R, 1990, J ORG CHEM, V55, P6289, DOI 10.1021/jo00313a015	44	34	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23339	23344						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226858				2022-12-25	WOS:A1993MF51500061
J	MAEKAWA, M; NAKAMURA, S; HATTORI, S				MAEKAWA, M; NAKAMURA, S; HATTORI, S			PURIFICATION OF A NOVEL RAS GTPASE-ACTIVATING PROTEIN FROM RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 GENE-PRODUCT; MOLECULAR-CLONING; GROWTH-FACTOR; PC12 CELLS; BOVINE BRAIN; GAP; P21; IDENTIFICATION; BINDING; STIMULATION	GTPase-activating protein (GAP) and neurofibromin, a gene product of neurofibromatosis type I gene, have been identified as factors that stimulate GTPase activity of ras p21. We have previously suggested the presence of novel GAP activity that is immunologically distinguishable from GAP or neurofibromin in both the cytosolic and the particulate fractions of rat brain (Hattori, S., Maekawa, M., and Nakamura, S. (1992) Oncogene 7, 481-485). We have purified this novel GAP molecule from the cytosolic fraction of rat brain by more than 200,000-fold by five successive column chromatographies with a recovery of 6%. Apparent molecular mass of this molecule was estimated to be 100 kDa (p100GAP(ras)). The same p100GAP(ras) was purified from the particulate fraction after extraction with high salt. The activation of GTPase was observed with normal ras p21 but not with oncogenic ras p21, Rap1B/smg21B, or Ram25K. The dissociation constant of p100GAP(ras) toward ras p21 estimated by competitive inhibition using ras p21 in complex with nonhydrolyzable analog of GTP was two times higher than that of neurofibromin and was lower than that of GAP by 2 orders of magnitude. These results clearly indicate that p100GAP(ras) is a novel ras GAP molecule.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,4-1-1 OGAWAHIGASHI,KODAIRA,TOKYO 187,JAPAN	National Center for Neurology & Psychiatry - Japan								BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HATTORI S, 1992, ONCOGENE, V7, P481; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; HOSHINO M, 1988, MOL CELL BIOL, V8, P4169, DOI 10.1128/MCB.8.10.4169; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORII N, 1991, J BIOL CHEM, V266, P7646; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUROYA K, 1992, ONCOGENE, V7, P277; NAGATA K, 1989, J BIOL CHEM, V264, P17000; NICE EC, 1992, J BIOL CHEM, V267, P1546; NISHIO K, 1982, ANAL BIOCHEM, V126, P239, DOI 10.1016/0003-2697(82)90509-7; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	49	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22948	22952						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226805				2022-12-25	WOS:A1993MD34800110
J	MIYASAKA, H; OKABE, S; ISHIGURO, K; UCHIDA, T; HIROKAWA, N				MIYASAKA, H; OKABE, S; ISHIGURO, K; UCHIDA, T; HIROKAWA, N			INTERACTION OF THE TAIL DOMAIN OF HIGH-MOLECULAR-WEIGHT SUBUNITS OF NEUROFILAMENTS WITH THE COOH-TERMINAL REGION OF TUBULIN AND ITS REGULATION BY TAU-PROTEIN KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; HELICAL FILAMENT EPITOPE; MAMMALIAN NEUROFILAMENTS; INTERMEDIATE FILAMENTS; NEURONAL CYTOSKELETON; TRIPLET PROTEINS; AXONAL-TRANSPORT; QUICK-FREEZE; PHOSPHORYLATION; INVITRO	We previously showed that neurofilaments interact with microtubules (MTs) via their high molecular weight subunits (NF-H) after alkaline phosphatase treatment. Here we studied the effects of phosphorylation of NF-H on this interaction. Tau protein kinase II, Ser/Thr protein kinase, phosphorylated NF-H in the tail domain, decreased its electrophoretic mobility to a native level, and also restored its property to be less interactive with MTs. Phosphorylation by cAMP-dependent protein kinase caused no shift of electrophoretic mobility or dissociation from MTs. We conclude that the tail domain of NF-H directly interacts with the MT surface, and the interaction is regulated via phosphorylation of the tail domain of NF-H by Ser/Thr protein kinase like tau protein kinase II. To characterize the binding domain of NF-H on MTs, subtilisin digestion of MTs and competition analysis with the MT binding fragment of tau protein were performed. The dissociation constant of NF-H to subtilisin MTs was higher than that to intact MTs. The maximum binding of NF-H was reduced when tau fragments existed. These results revealed that the COOH-terminal region of tubulin is involved in the binding to NF-H, and the NF-H and microtubule-associated protein binding domains are closely apposed on the surface of MTs.	UNIV TOKYO,FAC MED,DEPT ANAT & CELL BIOL,BUNKYO KU,TOKYO 113,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	University of Tokyo				Okabe, Shigeo/0000-0003-1216-8890				AAMODT EJ, 1984, BIOCHEMISTRY-US, V23, P6023, DOI 10.1021/bi00320a019; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; FLYNN G, 1987, J BIOL CHEM, V262, P15443; FREMISCO JR, 1980, J BIOL CHEM, V255, P4240; GARDNER EE, 1984, J NEUROSCI RES, V11, P145, DOI 10.1002/jnr.490110204; GEISLER N, 1983, EMBO J, V2, P1295, DOI 10.1002/j.1460-2075.1983.tb01584.x; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; GLASS DB, 1986, J BIOL CHEM, V261, P2987; GUAN RJ, 1992, J NEUROCHEM, V58, P1365, DOI 10.1111/j.1471-4159.1992.tb11351.x; HEIMANN R, 1985, J BIOL CHEM, V260, P2160; HIROKAWA N, 1988, J NEUROSCI, V8, P2769; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HIROKAWA N, 1985, J CELL BIOL, V101, P227, DOI 10.1083/jcb.101.1.227; HISANAGA S, 1989, J NEUROSCI, V9, P959; HISANAGA S, 1990, J BIOL CHEM, V265, P21852; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; ISHIGURO K, 1988, J BIOCHEM-TOKYO, V104, P319, DOI 10.1093/oxfordjournals.jbchem.a122465; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; JONES SM, 1982, J BIOL CHEM, V257, P9902; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LETTERRIER JF, 1984, J NEUROCHEM, V43, P1385; LIEM RKH, 1978, J CELL BIOL, V79, P637, DOI 10.1083/jcb.79.3.637; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MINAMI Y, 1983, J BIOCHEM-TOKYO, V94, P2023, DOI 10.1093/oxfordjournals.jbchem.a134557; MINAMI Y, 1984, J BIOCHEM-TOKYO, V96, P1481, DOI 10.1093/oxfordjournals.jbchem.a134977; NIXON R A, 1992, Current Opinion in Cell Biology, V4, P8, DOI 10.1016/0955-0674(92)90052-E; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; RUNGE MS, 1981, P NATL ACAD SCI USA, V78, P1385; Sambrook J, 1989, MOL CLONING LABORATO; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858	43	111	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22695	22702						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226779				2022-12-25	WOS:A1993MD34800075
J	SCHULTHEIS, PJ; WALLICK, ET; LINGREL, JB				SCHULTHEIS, PJ; WALLICK, ET; LINGREL, JB			KINETIC-ANALYSIS OF OUABAIN BINDING TO NATIVE AND MUTATED FORMS OF NA,K-ATPASE AND IDENTIFICATION OF A NEW REGION INVOLVED IN CARDIAC GLYCOSIDE INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ADENOSINE-TRIPHOSPHATASE; SITE-DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; SARCOPLASMIC-RETICULUM; COMPETITION KINETICS; SODIUM; DIGITALIS; NA+,K+-ATPASE; RESIDUES; SURFACE	Cardiac glycosides inhibit the Na,K-ATPase by binding to the catalytic alpha subunit of the enzyme. Site-directed mutagenesis of the H1-H2 domain has demonstrated the importance of this region in determining cardiac glycoside affinity. In this study, random mutagenesis was used to identify an amino acid, arginine 880, in the COOH-terminal portion of the alpha subunit which influences the sensitivity of the enzyme to ouabain. This residue is predicted to reside in the H7-H8 extracellular loop. Conversion of arginine 880 to a proline causes a 10-fold increase in the dissociation rate constant and a 2-fold increase in the association rate constant for [H-3]ouabain binding. This results in an enzyme with a K(D) for ouabain 5-fold higher than the wild-type sheep alpha1 isoform. These data are compatible with arginine 880 comprising a portion of the ouabain binding site. Furthermore, if arginine 880 is at the physical binding site, then this finding lends support to models that place this amino acid extracellularly since cardiac glycosides interact with the extracellular surface of the Na,K-ATPase. The ouabain binding characteristics of substitution R880P were compared with those of several different Na,K-ATPases, each of which contains a single amino acid substitution in the H1-H2 region of the alpha subunit. The substituted enzymes, C104A, Y108A, E116Q, P118K, and Y124F, vary considerably in their rates of dissociation (1-4-fold increase in the dissociation rate constant). In addition, the rate of association of [H-3]ouabain binding to substitution P118K is 2-fold slower than that of the wild-type enzyme. These results suggest that the H1-H2 domain may participate directly in ouabain binding as well as be involved in conformational changes, both of which could affect the sensitivity of the enzyme to ouabain.	UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, 231 BETHESDA AVE, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT PHARMACOL, CINCINNATI, OH 45267 USA	University of Cincinnati; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028573] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28573] Funding Source: Medline; PHS HHS [HW50613] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS RJ, 1983, J CARDIOVASC PHARM, V5, P468, DOI 10.1097/00005344-198305000-00020; AKERA T, 1977, PHARMACOL REV, V29, P187; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BALL WJ, 1982, BIOCHIM BIOPHYS ACTA, V719, P413, DOI 10.1016/0304-4165(82)90228-8; BALL WJ, 1988, METHOD ENZYMOL, V156, P87; BESANCON M, 1992, ACTA PHYSIOL SCAND, V146, P77; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; DEFFO T, 1983, BIOCHEMISTRY-US, V22, P6303, DOI 10.1021/bi00295a041; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; GOELDNER MP, 1983, BIOCHEMISTRY-US, V22, P4685, DOI 10.1021/bi00289a012; HALL C, 1980, P NATL ACAD SCI-BIOL, V77, P4529, DOI 10.1073/pnas.77.8.4529; HANSEN O, 1984, PHARMACOL REV, V36, P143; HOLZINGER F, 1992, FEBS LETT, V314, P477, DOI 10.1016/0014-5793(92)81530-Y; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JARV J, 1980, J BIOL CHEM, V255, P2649; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1982, J BIOL CHEM, V257, P7435; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KIRLEY TL, 1991, J BIOL CHEM, V266, P19953; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE LK, 1973, J BIOL CHEM, V248, P7197; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1991, SOC GEN PHY, V46, P1; LUCKIE DB, 1992, BIOPHYS J, V62, P220, DOI 10.1016/S0006-3495(92)81807-6; MACKNIGHT ADC, 1977, PHYSIOL REV, V57, P510, DOI 10.1152/physrev.1977.57.3.510; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; OBRIEN WJ, 1993, J BIOL CHEM, V268, P7707; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; ROGERS TB, 1979, BIOCHEMISTRY-US, V18, P135, DOI 10.1021/bi00568a021; ROSSI B, 1980, J BIOL CHEM, V255, P9936; RUOHO A, 1974, P NATL ACAD SCI USA, V71, P2352, DOI 10.1073/pnas.71.6.2352; SCHREIBER G, 1985, J BIOL CHEM, V260, P8789; SCHREIBER G, 1985, J BIOL CHEM, V260, P8795; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; SCHWARTZ A, 1969, J PHARMACOL EXP THER, V168, P31; SCHWARTZ A, 1975, PHARMACOL REV, V27, P3; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Thomas R., 1990, ADV DRUG RES, P311; THOMAS RC, 1972, PHYSIOL REV, V52, P563, DOI 10.1152/physrev.1972.52.3.563; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH KJ, 1979, ANNU REV PHYSIOL, V41, P181, DOI 10.1146/annurev.ph.41.030179.001145; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201; WALLICK ET, 1980, ARCH BIOCHEM BIOPHYS, V202, P442, DOI 10.1016/0003-9861(80)90448-8; YODA A, 1975, MOL PHARMACOL, V11, P653; YODA A, 1974, ANN NY ACAD SCI, V242, P598, DOI 10.1111/j.1749-6632.1974.tb19120.x	56	75	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22686	22694						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226778				2022-12-25	WOS:A1993MD34800074
J	MILNE, KG; FIELD, RA; MASTERSON, WJ; COTTAZ, S; BRIMACOMBE, JS; FERGUSON, MAJ				MILNE, KG; FIELD, RA; MASTERSON, WJ; COTTAZ, S; BRIMACOMBE, JS; FERGUSON, MAJ			PARTIAL-PURIFICATION AND CHARACTERIZATION OF THE N-ACETYLGLUCOSAMINYL-PHOSPHATIDYLINOSITO DE-N-ACETYLASE OF GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR BIOSYNTHESIS IN AFRICAN TRYPANOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; MEMBRANE ANCHORS; ZWITTERIONIC DETERGENT; TOXOPLASMA-GONDII; CLASS-H; BRUCEI; ETHANOLAMINE; PROTEIN; CELLS; DONOR	N-Acetylglucosaminylphosphatidylinositol (GlcNAc-PI) de-N-acetylase was solubilized from the bloodstream form of African trypanosomes using Zwittergent 3-14. The solubilized GlcNAc-PI de-N-acetylase was assayed using radiolabeled GlcNAc-PI substrates. The enzyme was partially purified about 140-fold from washed trypanosome membranes using conventional liquid chromatography. The enzyme has a K-m of 1.5 mu M. Replacement of the di-O-substituted D-myo-inositol of the natural GlcNAc-PI substrate by the L-myo-inositol isomer did not significantly alter the ability of the compound to act as a substrate for the de-N-acetylase, suggesting that the C-2 to C-5 hydroxyl groups of the myoinositol ring do not play a critical role in substrate recognition. A substrate analogue lacking fatty acids was a relatively poor substrate for the enzyme, indicating that the lipid component plays an important role in substrate recognition and/or presentation of the substrate to the enzyme in detergent micelles. Substrate analogues lacking the glycerophosphate component were not recognized by the enzyme, suggesting that this component is important in the substrate recognition process.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND; UNIV DUNDEE,DEPT CHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee; University of Dundee			Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714; cottaz, sylvain/0000-0001-8674-0162; Field, Rob/0000-0001-8574-0275	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILYES EM, 1982, BIOCHEM J, V203, P245, DOI 10.1042/bj2030245; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BROWN DA, 1993, CURR OPIN IMMUNOL, V5, P338; CORNISHB.A, 1974, BIOCHEM J, V139, P721, DOI 10.1042/bj1390721; COTTAZ S, 1993, J CHEM SOC PERK T 1, P2945, DOI 10.1039/p19930002945; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DOERING TL, 1989, J BIOL CHEM, V264, P11168; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1991, CELL BIOL INT REP, V15, P991, DOI 10.1016/0309-1651(91)90052-K; FERGUSON MAJ, 1992, BIOCHEM J, V284, P297, DOI 10.1042/bj2840297; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; GEROLD P, 1994, J BIOL CHEM, V269, P2597; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HOLDER AA, 1983, BIOCHEM J, V209, P261, DOI 10.1042/bj2090261; INOUE N, 1993, J BIOL CHEM, V268, P6882; KAFETZOPOULOS D, 1993, P NATL ACAD SCI USA, V90, P2564, DOI 10.1073/pnas.90.7.2564; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALPARTIDA F, 1980, FEBS LETT, V111, P69, DOI 10.1016/0014-5793(80)80763-0; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1991, EMBO J, V10, P2041, DOI 10.1002/j.1460-2075.1991.tb07734.x; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MILNE KG, 1992, EUR J BIOCHEM, V208, P309, DOI 10.1111/j.1432-1033.1992.tb17188.x; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; NEUGEBAUER J, 1992, GUIDE PROPERTIES USE, P25; PUOTI A, 1993, J BIOL CHEM, V268, P7215; TOMAVO S, 1992, J BIOL CHEM, V267, P21446; TOMAVO S, 1992, J BIOL CHEM, V267, P11721; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	37	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16403	16408						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206949				2022-12-25	WOS:A1994NQ72900068
J	HAUSNER, W; THOMM, M				HAUSNER, W; THOMM, M			PURIFICATION AND CHARACTERIZATION OF A GENERAL TRANSCRIPTION FACTOR, ATFB, FROM THE ARCHAEON METHANOCOCCUS-THERMOLITHOTROPHICUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE TRANSCRIPTION; SODIUM DODECYL-SULFATE; RNA-POLYMERASE; ARCHAEBACTERIAL PROMOTER; TATA BOX; INVITRO TRANSCRIPTION; INITIATION; VANNIELII; SITE; METHANOGENS	We have recently shown that cell-free transcription of homologous templates from the archaeon Methanococcus thermolithotrophicus requires an archaeal transcription factor (aTFA) that separated from the RNA polymerase during phosphocellulose chromatography. We report here the identification and extensive purification of a second activity, aTFB, required for in vitro transcription. This activity copurified with RNA polymerase during initial chromatographic steps but was positively identified as a distinct transcription factor after Superdex 200 sizing chromatography. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that the intensity of a M(r) = 28,000 polypeptide in silver-stained gels is correlated with transcription factor activity. The same polypeptide, when eluted from a denaturing polyacrylamide gel and subsequently renatured, showed the functional properties of the transcription factor. In conjunction with gel filtration and sedimentation studies, which indicated a molecular mass of 54,000 Da for the native protein, these results suggested that aTFB is a dimer with polypeptide chains of identical molecular mass. Functional studies with highly purified aTFB demonstrated that it is a general factor required for transcription of genes encoding tRNA and proteins.	CHRISTIAN ALBRECHTS UNIV KIEL,INST ALLGEMEINE MIKROBIOL,BOT GARTEN 1-9,W-2300 KIEL 1,GERMANY	University of Kiel								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JW, 1988, NUCLEIC ACIDS RES, V16, P135, DOI 10.1093/nar/16.1.135; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; FREY G, 1990, NUCLEIC ACIDS RES, V18, P1361, DOI 10.1093/nar/18.6.1361; GOHL HP, 1992, MOL GEN GENET, V231, P286, DOI 10.1007/BF00279802; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAUSNER W, 1991, J MOL BIOL, V222, P495, DOI 10.1016/0022-2836(91)90492-O; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HUDEPOHL U, 1990, P NATL ACAD SCI USA, V87, P5851, DOI 10.1073/pnas.87.15.5851; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; OUZOUNIS C, 1992, CELL, V71, P189, DOI 10.1016/0092-8674(92)90347-F; REINBERG D, 1987, J BIOL CHEM, V262, P3322; REITER WD, 1990, P NATL ACAD SCI USA, V87, P9509, DOI 10.1073/pnas.87.24.9509; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; THOMM M, 1985, EUR J BIOCHEM, V149, P345, DOI 10.1111/j.1432-1033.1985.tb08932.x; THOMM M, 1988, NUCLEIC ACIDS RES, V16, P151, DOI 10.1093/nar/16.1.151; THOMM M, 1986, BIOL CHEM H-S, V367, P473, DOI 10.1515/bchm3.1986.367.1.473; THOMM M, 1989, CAN J MICROBIOL, V35, P30, DOI 10.1139/m89-005; THOMM M, 1992, J BACTERIOL, V174, P3508, DOI 10.1128/JB.174.11.3508-3513.1992; XU L, 1992, NUCLEIC ACIDS RES, V24, P6699; Zillig W, 1991, CURR OPIN GENET DEV, V1, P544, DOI 10.1016/S0959-437X(05)80206-0	22	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24047	24052						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226949				2022-12-25	WOS:A1993MF29400052
J	INABA, T; SHIMANO, H; GOTODA, T; HARADA, K; SHIMADA, M; OHSUGA, J; WATANABE, Y; KAWAMURA, M; YAZAKI, Y; YAMADA, N				INABA, T; SHIMANO, H; GOTODA, T; HARADA, K; SHIMADA, M; OHSUGA, J; WATANABE, Y; KAWAMURA, M; YAZAKI, Y; YAMADA, N			EXPRESSION OF PLATELET-DERIVED GROWTH-FACTOR-BETA RECEPTOR ON HUMAN MONOCYTE-DERIVED MACROPHAGES AND EFFECTS OF PLATELET-DERIVED GROWTH-FACTOR BB DIMER ON THE CELLULAR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; FACTOR-I RECEPTOR; PDGF RECEPTOR; C-FMS; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODY; PHORBOL DIESTER; LEUKEMIA-CELLS	Platelet-derived growth factor (PDGF) plays an important role in the process of atherosclerosis which is characterized by the presence of macrophage-derived foam cells. In the present study, the induction of the mRNA of PDGF-beta receptor was demonstrated during cell differentiation of human monocyte-macrophages, whereas no mRNA was detected in the cells during the early days of culture. Flow cytometry analysis using antibodies specific for PDGF-beta receptor and CD14 showed the presence of both PDGF-beta receptor and CD14 on human monocyte-derived macrophages, whereas no PDGF-beta receptor was detected on human monocytes 4 h after cell adhesion to a culture dish. In the binding assay of PDGF-BB on human monocyte-derived macrophages, a saturable and high affinity binding site with K(d) of 27.5 pM and B(max) of 23.3 fmol/mg of cell protein was demonstrated. When human monocytes were cultured in the presence of the protein kinase C inhibitor staurosporine, PDGF-beta receptor induction was inhibited, and tetradecanoylphorbol acetate enhanced PDGF-beta receptor expression in human monocyte-derived macrophages, indicating that PDGF-beta receptor expression is associated with maturation and differentiation of monocyte-macrophages through the activation of protein kinase C. In response to PDGF-BB homodimer, PDGF-beta receptor was phosphorylated, and thymidine uptake and inositol trisphosphate production were stimulated in monocyte-derived macrophages. Furthermore, PDGF-BB suppressed the production of macrophage colony-stimulating factor in macrophages. The expression of PDGF-beta receptor on human monocyte-derived macrophages suggests that PDGF influences the process of atherosclerosis by regulating the function of macrophages as well as smooth muscle cells in the vascular wall.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN	University of Tokyo			Shimano, Hitoshi/AAI-5648-2020; Shimano, Hitoshi/V-1761-2019	Shimano, Hitoshi/0000-0002-5562-5572				ABBOUD SL, 1991, BLOOD, V78, P103; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOWENPOPE DF, 1982, J BIOL CHEM, V257, P5161; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; COHN ZA, 1959, J EXP MED, V110, P419, DOI 10.1084/jem.110.3.419; DEUEL TF, 1982, J CLIN INVEST, V69, P1046, DOI 10.1172/JCI110509; DICORLETO PE, 1984, EXP CELL RES, V153, P167, DOI 10.1016/0014-4827(84)90458-0; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; FALKENBURG JHF, 1990, J IMMUNOL, V144, P4657; FOWLER S, 1979, LAB INVEST, V41, P372; FRACKELTON AR, 1984, J BIOL CHEM, V259, P7909; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HANAMURA T, 1988, BLOOD, V72, P886; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; HART CE, 1987, J BIOL CHEM, V262, P10780; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; INABA T, 1992, J BIOL CHEM, V267, P5693; INABA T, 1992, J BIOL CHEM, V267, P13107; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; ISHIBASHI S, 1990, J BIOL CHEM, V265, P3040; JAYE M, 1985, SCIENCE, V228, P882, DOI 10.1126/science.3890179; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MOTOYOSHI K, 1989, EXP HEMATOL, V17, P68; NAVARRO S, 1989, J IMMUNOL, V142, P4339; PANTAZIS P, 1991, P NATL ACAD SCI USA, V88, P2481, DOI 10.1073/pnas.88.6.2481; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROSS R, 1976, NEW ENGL J MED, V295, P420, DOI 10.1056/NEJM197608192950805; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SHERR CJ, 1988, J CELL BIOCHEM, V38, P179, DOI 10.1002/jcb.240380305; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIMADA M, 1992, J BIOL CHEM, V267, P15455; SHIMANO H, 1990, J BIOL CHEM, V265, P12869; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; TSUCHIYA S, 1982, CANCER RES, V42, P1530; WARREN MK, 1986, J IMMUNOL, V137, P2281; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WILLIAMS LT, 1982, J CLIN INVEST, V69, P1759; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; YEUNG YG, 1987, P NATL ACAD SCI USA, V84, P1268, DOI 10.1073/pnas.84.5.1268	53	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24353	24360						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226985				2022-12-25	WOS:A1993MF29400095
J	LEE, JK; WANG, SQ; ERASO, JM; GARDNER, J; KAPLAN, S				LEE, JK; WANG, SQ; ERASO, JM; GARDNER, J; KAPLAN, S			TRANSCRIPTIONAL REGULATION OF PUC OPERON EXPRESSION IN RHODOBACTER-SPHAEROIDES - INVOLVEMENT OF AN INTEGRATION HOST FACTOR-BINDING SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RHODOPSEUDOMONAS-SPHAEROIDES; GENE-EXPRESSION; PHOTOSYNTHETIC MEMBRANES; B800-850 COMPLEX; RNA-POLYMERASE; DNA-SEQUENCE; PROTEIN; PROMOTER; SITES	The putative overlapping consensus sequences (-129 to -105) for binding of fumarate nitrate reductase regulator- and integration host factor (IHF)-like proteins to puc operon upstream DNA of Rhodobacter sphaeroides was protected from DNase I digestion by purified Escherichia coli IHF. The binding of E. coli IHF to the purported IHF-binding site in the puc upstream DNA is highly sequence-specific. The recorded binding affinity was significantly lower than that of E. coli IHF to the lambda attP site. Employing site-directed changes in the DNA sequence within the -129 to -105 region, a loss in IHF binding, as monitored through gel retardation analysis, was correlated with alterations in puc operon expression monitored through the use of puc=lacZ transcriptional fusions. These results suggest that the IHF-binding site is involved in repression of puc operon transcription by oxygen as well as modulation of puc operon transcription levels by incident light intensity. Mutations specific to the upstream half of the putative fumarate nitrate reductase regulator-binding site of the puc upstream DNA did not show any physiological effects under the experimental conditions employed. Taken together, these studies reveal that the DNA sequence between -129 to -105 may involve facilitation of the interaction between upstream and downstream cis-acting regulatory sequences involved in puc operon expression.	UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL & MOLEC GENET,POB 20708,HOUSTON,TX 77225; UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801	University of Texas System; University of Texas Health Science Center Houston; University of Illinois System; University of Illinois Urbana-Champaign				Eraso, Jesus/0000-0003-1383-8702	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28717, GM15590] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AAGAARD J, 1972, PHOTOCHEM PHOTOBIOL, V15, P209, DOI 10.1111/j.1751-1097.1972.tb06240.x; ALAZARD R, 1992, MOL MICROBIOL, V6, P1707, DOI 10.1111/j.1365-2958.1992.tb00895.x; BAUER CE, 1986, J MOL BIOL, V192, P513, DOI 10.1016/0022-2836(86)90273-1; BROYLES SS, 1986, J MOL BIOL, V187, P47, DOI 10.1016/0022-2836(86)90405-5; CHORY J, 1983, J BACTERIOL, V153, P465, DOI 10.1128/JB.153.1.465-474.1983; CHORY J, 1984, J BACTERIOL, V159, P540, DOI 10.1128/JB.159.2.540-554.1984; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DAVIS J, 1988, J BACTERIOL, V170, P320, DOI 10.1128/jb.170.1.320-329.1988; DEHOFF BS, 1988, J BACTERIOL, V170, P4681, DOI 10.1128/jb.170.10.4681-4692.1988; DISPENSA M, 1992, J BACTERIOL, V174, P5803, DOI 10.1128/jb.174.18.5803-5813.1992; DONOHUE TJ, 1986, J BACTERIOL, V168, P962, DOI 10.1128/jb.168.2.962-972.1986; DONOHUE TJ, 1986, ENCY PLANT PHYSL, V19, P632; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FLAMM EL, 1985, J MOL BIOL, V183, P117, DOI 10.1016/0022-2836(85)90206-2; FREUNDLICH M, 1992, MOL MICROBIOL, V6, P2557, DOI 10.1111/j.1365-2958.1992.tb01432.x; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GIBSON LCD, 1992, MOL MICROBIOL, V6, P3171, DOI 10.1111/j.1365-2958.1992.tb01773.x; GILADI H, 1992, J MOL BIOL, V227, P985, DOI 10.1016/0022-2836(92)90514-K; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; GUEST JR, 1992, J GEN MICROBIOL, V138, P2253, DOI 10.1099/00221287-138-11-2253; HALUZI H, 1991, J BACTERIOL, V173, P6297, DOI 10.1128/jb.173.19.6297-6299.1991; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KAPLAN S, 1983, J CELL BIOCHEM, V22, P15, DOI 10.1002/jcb.240220103; KAPLAN S, 1982, PHOTOSYNTHESIS, V1, P65; KILEY PJ, 1987, J BACTERIOL, V169, P3268, DOI 10.1128/jb.169.7.3268-3275.1987; LEE JK, 1992, J BACTERIOL, V174, P1158, DOI 10.1128/jb.174.4.1158-1171.1992; LEE JK, 1992, J BACTERIOL, V174, P1146, DOI 10.1128/jb.174.4.1146-1157.1992; LEE JK, 1989, J BACTERIOL, V171, P3391, DOI 10.1128/jb.171.6.3391-3405.1989; MCGLYNN P, 1992, J BIOL CHEM, V267, P11098; MILLER HI, 1984, COLD SPRING HARB SYM, V49, P691, DOI 10.1101/SQB.1984.049.01.078; RAMANI N, 1992, MOL GEN GENET, V231, P248, DOI 10.1007/BF00279798; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; Sambrook J, 1989, MOL CLONING LABORATO; SANTERO E, 1992, J MOL BIOL, V227, P602, DOI 10.1016/0022-2836(92)90211-2; Simon R., 1983, BIOTECHNOLOGY, V1, P37; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SUMMERTON J, 1983, ANAL BIOCHEM, V133, P79, DOI 10.1016/0003-2697(83)90224-5; TAI TN, 1988, PLASMID, V19, P175, DOI 10.1016/0147-619X(88)90037-6; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TICHY HV, 1989, J BACTERIOL, V171, P4914, DOI 10.1128/jb.171.9.4914-4922.1989; TICHY HV, 1991, EMBO J, V10, P2949, DOI 10.1002/j.1460-2075.1991.tb07845.x; TSUI P, 1991, J BACTERIOL, V173, P5800, DOI 10.1128/jb.173.18.5800-5807.1991; UNDEN G, 1991, ANTON LEEUW INT J G, V59, P65, DOI 10.1007/BF00445650; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	45	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24491	24497						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8227001				2022-12-25	WOS:A1993MF29400114
J	EMERICK, MC; FAMBROUGH, DM				EMERICK, MC; FAMBROUGH, DM			INTRAMOLECULAR FUSION OF NA-PUMP SUBUNITS ASSURES EXCLUSIVE ASSEMBLY OF THE FUSED ALPHA-SUBUNIT AND BETA-SUBUNIT DOMAINS INTO A FUNCTIONAL ENZYME IN CELLS ALSO EXPRESSING ENDOGENOUS NA-PUMP SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; INTRACELLULAR-TRANSPORT; NA,K-ATPASE; PROTEINS; K+	Experiments designed to identify Na pump structural features which tag the molecule for asymmetric cell-surface localization are inherently complex because either subunit, or both, may contain targeting information and because the cells which recognize those targeting signals and maintain asymmetric plasma membrane domains also express their own Na pumps, the subunits of which can assemble into hybrid pump molecules with pump subunits expressed from transfected cDNA clones. Cotransfecting cDNA for both subunits only complicates matters further by resulting in expression of four distinct dimeric molecular species. To eliminate the potential for cross-assembly in these and other experiments we have constructed cDNA encoding a ''single-subunit' Na pump (called ''alpha-beta'') in which the alpha and beta subunits are joined by a linker of 17 amino acids. By all criteria tested alpha-beta functioned as a normal heterodimeric Na pump. It was expressed in a variety of mammalian cell lines as a single, high molecular weight polypeptide located primarily on the surface membrane, with the beta subunit exposed to the extracellular medium. Binding of the conformation-sensitive monoclonal antibody 24 to the beta subunit indicated that the fusion protein was folded as a properly ''assembled' sodium pump. Expression of alpha-beta in ouabain-resistant mouse L cells resulted in high affinity ouabain binding and ouabain-sensitive, sodium-dependent rubidium transport. The enzyme was properly targeted to the basolateral plasma membrane in polarized epithelial cells. The functional integrity of the fusion protein renders it suitable for site-directed mutagenesis studies of targeting and enzymology where control of subunit assembly is desired. These results also support topological models in which the carboxyl terminus of the alpha subunit is cytoplasmic.			EMERICK, MC (corresponding author), JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023241] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44375-0141] Funding Source: Medline; NINDS NIH HHS [NS 23241] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		FAMBROUGH DM, 1983, J BIOL CHEM, V258, P3926; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; FORTE JG, 1989, HDB PHYSL, V3, P207; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GHOSH S, 1991, J CELL PHYSIOL, V149, P184, DOI 10.1002/jcp.1041490203; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; Gottardi C.J., 1992, J TISS CULT METHODS, V14, P173; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MATLIN KS, 1992, KIDNEY PHYSL PATHOPH, P447; PRESSLEY TA, 1986, J GEN PHYSIOL, V87, P591, DOI 10.1085/jgp.87.4.591; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009	24	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23455	23459						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226871				2022-12-25	WOS:A1993MF51500077
J	KIBAK, H; VANEECKHOUT, D; CUTLER, T; TAIZ, SL; TAIZ, L				KIBAK, H; VANEECKHOUT, D; CUTLER, T; TAIZ, SL; TAIZ, L			SULFITE BOTH STIMULATES AND INHIBITS THE YEAST VACUOLAR H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROSPORA-CRASSA; HALOBACTERIUM-SACCHAROVORUM; MEMBRANE ATPASES; CATALYTIC SITE; PROTON PUMP; MECHANISM; MITOCHONDRIAL; PURIFICATION; BINDING; ADP	The yeast vacuolar H+-ATPase (V-ATPase) exhibits nonlinear hydrolysis kinetics, i.e. an initial rapid rate followed by a slower, steadily declining rate. Sulfite (50-100 mM) stimulates the yeast V-ATPase specifically during the latter period. Sulfite activation has been observed for the F-ATPases and archaebacterial ATPases and is thought to be caused by the release of tightly bound nucleotide at the catalytic site. However, turnover-dependent inactivation of the yeast V-ATPase, and sulfite stimulation, were only observed at MgATP concentrations > 1.0 mM. Below 1.0 mM MgATP, the hydrolysis time course was linear, and sulfite was inhibitory. The inhibition during the initial phase and the stimulation during the later phase of the time course could be accounted for by a 5.5-fold sulfite-induced increase in the apparent K(m), and a small increase in the apparent V(max) Sulfite also protected the enzyme against inhibition by cold inactivation and by dicyclohexylcarbodiimide but not by bafilomycin. Sulfite stimulation during the later phase was antagonized by DELTAmu(H+)BAR, particularly by DELTApH. In contrast to its effects on hydrolysis, sulfite inhibited the formation of a pH gradient at all times and failed to enhance the membrane potential even when DELTApH was collapsed by nigericin. These results indicate that sulfite partially uncouples hydrolysis from proton transport in a way that preserves regulation by DELTAmu(H+)BAR.	UNIV CALIF SANTA CRUZ,SINSHEIMER LABS,DEPT BIOL,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz								ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; AUFFRET CA, 1981, BIOCHIM BIOPHYS ACTA, V648, P186, DOI 10.1016/0005-2736(81)90033-X; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; BENNETT AB, 1984, PLANT PHYSIOL, V74, P545, DOI 10.1104/pp.74.3.545; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1983, J BIOL CHEM, V258, P5238; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOWMAN EJ, 1982, J BACTERIOL, V151, P1326, DOI 10.1128/JB.151.3.1326-1337.1982; CHANSON A, 1985, PLANT PHYSIOL, V78, P232, DOI 10.1104/pp.78.2.232; CHERNYAK BV, 1986, TRENDS BIOCHEM SCI, V11, P32, DOI 10.1016/0968-0004(86)90229-X; CHERNYAK BV, 1988, FEBS LETT, V230, P159, DOI 10.1016/0014-5793(88)80662-8; DU ZY, 1990, BIOCHEMISTRY-US, V29, P402, DOI 10.1021/bi00454a014; EBEL RE, 1975, J BIOL CHEM, V250, P191; FENG Y, 1992, J BIOL CHEM, V267, P19769; FILLINGAME RH, 1909, ANN NY ACAD SCI, V671, P323; Fiske CH, 1925, J BIOL CHEM, V66, P375; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P337; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HARVEY WR, 1992, J EXP BIOL, V172, P1; KANE PM, 1989, J BIOL CHEM, V264, P19236; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; KOERBER SC, 1987, ANAL BIOCHEM, V165, P75, DOI 10.1016/0003-2697(87)90203-X; LARSON EM, 1989, BIOCHIM BIOPHYS ACTA, V973, P67, DOI 10.1016/S0005-2728(89)80404-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1988, ION PUMPS STRUCTURE, P387; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; MURATALIEV MB, 1992, BIOCHEMISTRY-US, V31, P12885, DOI 10.1021/bi00166a025; MURATALIEV MB, 1992, EUR J BIOCHEM, V209, P681, DOI 10.1111/j.1432-1033.1992.tb17336.x; NELSON N, 1972, J BIOL CHEM, V247, P7657; ORT DR, 1992, ANNU REV PLANT PHYS, V43, P269, DOI 10.1146/annurev.pp.43.060192.001413; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; SCHOBERT B, 1991, J BIOL CHEM, V266, P8008; SCHOBERT B, 1992, J BIOL CHEM, V267, P10252; SCHOBERT B, 1989, J BIOL CHEM, V264, P1208; SHIN K, 1992, J BIOL CHEM, V267, P20835; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; VULFSON EN, 1984, BIOL MEMBRANY, V1, P696; WANG YZ, 1985, J BIOL CHEM, V260, P434	41	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23325	23333						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226856				2022-12-25	WOS:A1993MF51500059
J	PEREZ, P; SCHONTHAL, A; ARANDA, A				PEREZ, P; SCHONTHAL, A; ARANDA, A			REPRESSION OF C-FOS GENE-EXPRESSION BY THYROID-HORMONE AND RETINOIC ACID RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT GROWTH-HORMONE; RESPONSE ELEMENTS; NUCLEAR RECEPTORS; X-RECEPTOR; BINDING; TRANSCRIPTION; PROMOTER; PROTEINS; MEDIATE; TARGET	Incubation with 1 nM triiodothyronine (T3) decreased cycloheximide-induced c-fos mRNA levels and the mRNA response to the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA; 100 nM) or to forskolin (15 muM). T3 also reduced the abundance of nuclear proteins that bind to an AP-1 binding site and the levels of c-Fos protein, as determined by Western blot. In transient transfection assays with a c-fos promoter reporter construct T3 decreased basal promoter activity by more than 50-60% and strongly inhibited the TPA and forskolin-induced activity. T3 further suppressed basal promoter activity and led to a drastic decrease of the response to both stimulatory agents after co-transfection of the promoter with an expression vector for the receptor. A truncated receptor that lacks the DNA binding domain abolished the inhibitory effect of the endogenous and transfected T3 receptor. Retinoic acid (RA) had an effect similar to T3 reducing basal CAT activity and the response to TPA and forskolin by 40-50% in cells co-transfected with the c-fos promoter and an expression vector for the RA receptor. The inhibitory effect of the nuclear receptors on c-Fos is reciprocal, since overexpression of c-Fos repressed induction of the activity of the growth hormone promoter by T3 and RA. Co-transfection with an antisense c-fos vector relieved this inhibition and restored the response to both ligands. These results show the antagonism between the nuclear receptors and the membrane signal transduction pathways that converge on the c-fos oncogene.	CSIC,INST INVEST BIOMED,ARTURO DUPERIER 4,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Perez, Paloma/K-8841-2017; Aranda, Ana/ABG-8820-2020	Perez, Paloma/0000-0002-7166-2824; Aranda, Ana/0000-0002-8338-9589; Schonthal, Axel/0000-0003-0662-5653				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; GARCIAVILLALBA P, 1993, BIOCHEM BIOPH RES CO, V191, P580, DOI 10.1006/bbrc.1993.1257; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PEREZ P, 1990, 20TH FEBS M; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YE ZS, 1988, J BIOL CHEM, V263, P7821; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	30	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23538	23543						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226882				2022-12-25	WOS:A1993MF51500089
J	SPARKS, DL; DAVIDSON, WS; LUNDKATZ, S; PHILLIPS, MC				SPARKS, DL; DAVIDSON, WS; LUNDKATZ, S; PHILLIPS, MC			EFFECT OF CHOLESTEROL ON THE CHARGE AND STRUCTURE OF APOLIPOPROTEIN-A-I IN RECOMBINANT HIGH-DENSITY-LIPOPROTEIN PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER PROTEIN; LECITHIN; PLASMA; ACYLTRANSFERASE; ESTER; PHOSPHATIDYLCHOLINES; CONFORMATION; APOPROTEIN; COMPLEXES; DISEASE	The effects of cholesterol on the conformation and net charge of apoA-1 have been investigated in homogeneous recombinant high density lipoprotein (HDL) particles. ApoA-I charge and structure in discoidal recombinant HDL complexes containing palmitoyloleoylphosphatidylcholine and cholesterol have been quantitated by guanidine HCl denaturation, circular dichroism, electrokinetic analysis, and NMR spectroscopy of [C-13[lysine-labeled apoA-I. In a discoidal particle containing 2 molecules of apoA-I and 160 molecules of palmitoyloleoylphosphatidylcholine, apoA-I exhibits an alpha-helix content of 75%, and the particle has a net negative surface charge of -5.2e/mol of apoA-I at pH 8.6. Addition of 2 molecules of cholesterol to this complex has no significant effect upon particle size, but slightly decreases the net charge (-5.0e) and alpha-helix content (68%) of apoA-I and enhances the stability of the helical segments, as reflected by an increase in the free energy of unfolding from 2.9 to 3.5 kcal/mol. In contrast, increasing the cholesterol content to 20 molecules/particle progressively increases particle size and apoA-I net negative charge (-6.1e), and there is a concomitant reduction in the free energy of stabilization of the a-helical structure in apoA-1 to 2.2 kcal/Mol. ((CH3)-C-13)2-Lys resonances from apoA-I in discoidal recombinant HDL exhibit six chemical shifts at pH 10; these peaks originate from dimethyl-Lys residues that have pK(a) values ranging from 8.4 to 10.3. The titration behavior of apoA-1 Lys residues is generally similar in the presence and absence of cholesterol, except that 4 Lys residues titrate at a significantly higher pH in the presence of cholesterol. These data are consistent with cholesterol having a direct effect on apoA-1 conformation and charge in HDL. Structural changes of this magnitude can affect the interactions between HDL and various plasma proteins and cell surfaces. It is therefore likely that the cholesterol content of HDL plays an important role in regulating the metabolism of this lipoprotein.	MED COLL PENN,DEPT BIOCHEM,2900 QUEEN LANE,PHILADELPHIA,PA 19129	Drexel University				Davidson, William/0000-0003-2756-2989; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; AZEMA C, 1990, BIOCHIM BIOPHYS ACTA, V1046, P73, DOI 10.1016/0005-2760(90)90096-G; BANKA CL, 1991, J BIOL CHEM, V266, P23886; COLLET X, 1991, J BIOL CHEM, V266, P9145; DAVIES JT, 1963, INTERFACIAL PHENOMEN, P56; DOBIASOVA M, 1991, ARTERIOSCLER THROMB, V11, P64, DOI 10.1161/01.ATV.11.1.64; JENTOFT JE, 1979, J BIOL CHEM, V254, P4366; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; JOHANSSON J, 1991, ARTERIOSCLER THROMB, V11, P174, DOI 10.1161/01.ATV.11.1.174; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1985, BIOCHEMISTRY-US, V24, P3508, DOI 10.1021/bi00335a018; Jonas A., 1992, STRUCTURE FUNCTION A, P217; JONAS A, 1987, PLASMA LIPOPROTEINS, P299; JONAS A, 1983, BIOCHIM BIOPHYS ACTA, V794, P361; JONES A, 1990, J BIOL CHEM, V265, P22123; KLAPPAUF E, 1979, HOPPESEYLERS Z PHYSL, V260, P1225; KLIMOV AN, 1992, CHEM PHYS LIPIDS, V62, P229, DOI 10.1016/0009-3084(92)90060-3; LAMBETH JD, 1986, ENDOCR RES, V12, P371, DOI 10.3109/07435808609035446; LONDON Y, 1974, BIOCHIM BIOPHYS ACTA, V332, P69, DOI 10.1016/0005-2736(74)90122-9; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; MASSEY JB, 1985, BIOCHEMISTRY-US, V24, P7110, DOI 10.1021/bi00346a014; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MILLER GJ, 1975, LANCET, V1, P16; MORTON RE, 1988, J BIOL CHEM, V263, P12235; PACE CN, 1986, METHOD ENZYMOL, V131, P267; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; SEGREST JP, 1992, J LIPID RES, V33, P141; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARKS DL, 1989, ATHEROSCLEROSIS, V77, P183, DOI 10.1016/0021-9150(89)90080-4; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SPARKS DL, 1989, J LIPID RES, V30, P1491; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; SPARKS DL, 1989, BIOCHEM CELL BIOL, V67, P358, DOI 10.1139/o89-056; TALL AR, 1978, BIOCHIM BIOPHYS ACTA, V513, P185, DOI 10.1016/0005-2736(78)90172-4; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1	38	78	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23250	23257						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226847				2022-12-25	WOS:A1993MF51500049
J	WOLFFLONG, VL; SARASWAT, LD; LOWEY, S				WOLFFLONG, VL; SARASWAT, LD; LOWEY, S			CYSTEINE MUTANTS OF LIGHT CHAIN-2 FORM DISULFIDE BONDS IN SKELETAL-MUSCLE MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 HEADS; SITES; PROTEINS; BINDING	Multiple disulfide bonds form in recombinant myosin light chain-2 mutants that contain an engineered cysteine at positions 2, 73, or 94, in addition to the endogenous cysteines at residues 126 and 155 (Saraswat, L. D., and Lowey, S. (1991) J. Biol. Chem. 266,19777). By replacing one of the native cysteines with an alanine, mutants with a single pair of thiols were created: Cys2/Cys155, Cys2/Cys126, Cys73/Cys55 and Cys94/Cys156. Oxidation of these mutants resulted in a fast migrating band on nonreducing SDS gels, which was attributed to an intramolecular disulfide bond. To determine if disulfide formation could also occur when the light chains (LC) are bound to the myosin heavy chains, LCs were added to myosin which had been depleted of its native LC2 by an immunoadsorbent. When the reconstituted myosin was reacted with 5,5'-dithiobis(2-nitrobenzoic acid) in the absence of divalent cations, intramolecular disulfide bonds formed in the mutant and wild type LCs, but the LCs did not remain bound to the myosin heavy chains. Addition of magnesium ions prevented LC dissociation, but intramolecular disulfide bonds no longer formed. Instead, mutants containing cysteines in the NH2-terminal domain formed intermolecular disulfide bonds between the two heads of myosin. The ability to cross-link the heads demonstrates the existence of close head/head interactions in the myosin molecule, a feature that may be essential for regulation.			WOLFFLONG, VL (corresponding author), BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,DEPT BIOCHEM,WALTHAM,MA 02254, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017350] Funding Source: NIH RePORTER; NIAMS NIH HHS [R37AR17350] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BOWER SM, 1992, FEBS LETT, V310, P132, DOI 10.1016/0014-5793(92)81313-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANTLER PD, 1988, J BIOL CHEM, V263, P938; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GAZITH J, 1970, J BIOL CHEM, V245, P15; HARDWICKE PMD, 1985, J MOL BIOL, V183, P203, DOI 10.1016/0022-2836(85)90213-X; HUBER PAJ, 1989, BIOCHEMISTRY-US, V28, P9116, DOI 10.1021/bi00449a024; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWEY S, 1971, NATURE, V234, P81, DOI 10.1038/234081a0; LOWEY S, 1986, MYOLOGY, P563; METZGER JM, 1992, BIOPHYS J, V63, P460, DOI 10.1016/S0006-3495(92)81614-4; MITCHELL EJ, 1989, J MOL BIOL, V208, P199, DOI 10.1016/0022-2836(89)90096-X; PASTRALANDIS SC, 1986, J BIOL CHEM, V261, P4811; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; Sambrook J, 1989, MOL CLONING LABORATO; SARASWAT LD, 1992, J BIOL CHEM, V267, P21112; SARASWAT LD, 1991, J BIOL CHEM, V266, P19777; SILBERSTEIN L, 1981, J MOL BIOL, V148, P153, DOI 10.1016/0022-2836(81)90510-6; SZENTGYORGYI AG, 1986, MYOLOGY, P589; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	24	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23162	23167						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226834				2022-12-25	WOS:A1993MF51500034
J	KEEN, AJ; KNOWLES, MA				KEEN, AJ; KNOWLES, MA			DEFINITION OF 2 REGIONS OF DELETION ON CHROMOSOME-9 IN CARCINOMA OF THE BLADDER	ONCOGENE			English	Article							TRANSITIONAL-CELL-CARCINOMA; ALLELIC LOSSES; CANCER; GENE; MELANOMA; LOCALIZATION; INTERFERON; AMPLIFICATION; PROGRESSION; ASSIGNMENT	Loss of heterozygosity (LOH) at loci on chromosome 9 can be detected in more than 50% of bladder tumours, suggesting the presence on this chromosome of one or more suppressor genes for bladder carcinogenesis, Localisation of the target gene(s) by deletion mapping has previously proved difficult due to the uneven distribution of polymorphic loci and the finding of LOH at all these loci in the majority of tumours. We have used a panel of 22 highly informative microsatellite markers, evenly distributed along chromosome 9 to analyse LOH in 95 cases of primary transitional cell carcinoma of the bladder. Forty nine tumours (53%) showed LOH at one or more loci. Of these, 30 had LOH at all informative loci, indicating probable monosomy 9. Nineteen tumours (22%) had subchromosomal deletions, 5 of 9p only, 9 of 9q only and 5 of both 9p and 9q with a clear region of retention of heterozygosity between. The patterns of LOH in these tumours indicated a common region of deletion on 9p between D9S126 (9p21) and IFNA (9p21). A single tumour showed a second site of deletion on 9p telomeric to IFNA indicating the possible existence of 2 target genes on 9p. All deletions of 9q were large, with a common region of deletion between D9S15 (9q13-q21.1) and D9S60 (9q33-q34.1), These results indicate a much higher frequency of subchromosomal deletion than has previously been detected and provide evidence for the simultaneous involvement of distinct suppressor loci on 9p and 9q in bladder carcinoma.	MARIE CURIE RES INST,MOLEC GENET LAB,OXTED RH8 0TL,SURREY,ENGLAND					Knowles, Margaret/0000-0002-9363-8657				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BERNUES M, 1993, CANCER GENET CYTOGEN, V69, P76, DOI 10.1016/0165-4608(93)90120-B; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1993, CANCER RES, V53, P1230; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DRACOPOLI NC, 1987, CANCER RES, V47, P3995; FOSS KB, 1992, CYTOGENET CELL GENET, V60, P22, DOI 10.1159/000133286; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GIBAS Z, 1984, CANCER RES, V44, P1257; GULCHER JR, 1990, GENOMICS, V6, P616, DOI 10.1016/0888-7543(90)90495-G; HABUCHI T, 1993, INT J CANCER, V53, P579, DOI 10.1002/ijc.2910530409; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; HUEBNER K, 1992, GENOMICS, V14, P220, DOI 10.1016/S0888-7543(05)80209-5; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAMES CD, 1991, CANCER RES, V51, P1684; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAO CH, 1993, GENE CHROMOSOME CANC, V8, P155, DOI 10.1002/gcc.2870080304; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KWIATKOWSKI DJ, 1988, AM J HUM GENET, V42, P565; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MIYAO N, 1993, CANCER RES, V53, P4066; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1992, CANCER RES, V52, P2523; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RUPPERT JM, 1993, CANCER RES, V53, P5093; SANDBERG AA, 1986, CANCER GENET CYTOGEN, V19, P335, DOI 10.1016/0165-4608(86)90063-4; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; SUNG LA, 1992, J BIOL CHEM, V267, P2616; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TSAI YC, 1990, CANCER RES, V50, P44; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; 1973, HISTOLOGICAL CLASSIF, V10; 1978, INT UNION CANCER	42	117	117	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2083	2088						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208555				2022-12-25	WOS:A1994NR68500035
J	LEGROS, Y; LAFON, C; SOUSSI, T				LEGROS, Y; LAFON, C; SOUSSI, T			LINEAR ANTIGENIC SITES DEFINED BY THE B-CELL RESPONSE TO HUMAN P53 ARE LOCALIZED PREDOMINANTLY IN THE AMINO AND CARBOXY-TERMINI OF THE PROTEIN	ONCOGENE			English	Note							TUMOR SUPPRESSOR GENE; LARGE T-ANTIGEN; MONOCLONAL-ANTIBODIES; BREAST-CANCER; ESCHERICHIA-COLI; IMMUNE-RESPONSE; LUNG-CANCER; MUTATIONS; EXPRESSION; CONFORMATION	Using a set of overlapping peptides of the human p53 protein, we analysed the epitopes recognized by 18 monoclonal antibodies specific far human p53. We showed that most of these epitopes correspond to linear antigenic determinants which lie predominantly in the amino- or carboxy-terminus of the p53 protein. Using either truncated p53 or the set of human p53 peptides, we directly analysed the sera of animals immunized with human p53, These sera contained antibodies which also recognized the regions corresponding to the extremity of the p53 protein. These p53 regions were similar to those recognized by p53-specific antibodies present in sera of patients with cancer. Preferential recognition of these regions by antibodies specific for non conformational epitopes suggested that these regions are localized at the surface of the p53 protein as unfolded structures.	INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; ESTBA,F-75020 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)				soussi, thierry/0000-0001-8184-3293				BAKER SJ, 1990, CANCER RES, V50, P7717; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DAVIDOFF AM, 1992, P NATL ACAD SCI USA, V89, P3439, DOI 10.1073/pnas.89.8.3439; DEFROMENTEL CC, 1987, INT J CANCER, V39, P185, DOI 10.1002/ijc.2910390211; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GILLET D, 1992, PROTEIN ENG, V5, P273, DOI 10.1093/protein/5.3.273; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HAINAUT P, 1993, CANCER RES, V53, P1739; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JONVEAUX P, 1991, ONCOGENE, V6, P2243; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; LEGROS Y, 1993, B CANCER, V80, P102; LUBIN R, 1993, CANCER RES, V53, P5872; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MAZARS R, 1991, ONCOGENE, V6, P1685; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILLER CW, 1990, CANCER RES, V50, P7950; PROSSER J, 1990, ONCOGENE, V5, P1573; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WINTER SF, 1992, CANCER RES, V52, P4168; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	39	67	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2071	2076						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208553				2022-12-25	WOS:A1994NR68500033
J	RODRIGUES, GA; PARK, M				RODRIGUES, GA; PARK, M			AUTOPHOSPHORYLATION MODULATES THE KINASE-ACTIVITY AND ONCOGENIC POTENTIAL OF THE MET RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; ATP-BINDING-SITE; FUJINAMI SARCOMA-VIRUS; INSULIN-RECEPTOR; BETA-SUBUNIT; PROTEIN-KINASE; EGF-RECEPTOR; PHOSPHORYLATION SITE; SIGNAL TRANSDUCTION	The met oncogene is activated by a genomic rearrangement that generates a hybrid protein containing tpr sequences at its amino terminus fused directly to the met (hepatocyte growth factor/scatter factor) receptor tyrosine kinase domain. The resultant p65(Tpr-Met) hybrid protein possesses tyrosine kinase activity and is constitutively phosphorylated on tyrosine in vivo. A substitution of the conserved lysine in the catalytic domain abolished kinase activity and the transforming potential of Tpr-Met demonstrating the requirement for kinase activity for transformation. To study the role of autophosphorylation at particular tyrosine residues on the transforming activity of Tpr-Met, the major autophosphorylation sites were identified by two dimensional phosphopeptide mapping. Two tyrosine residues in the catalytic domain, tyrosine 365 and tyrosine 366, were found to be the major autophosphorylation sites both in vitro and in vivo. Mutation of these sites singly or together modulates the biochemical and biological properties of Tpr-Met. Compared with the wild-type Tpr-Met, mutants have a reduced in vitro kinase activity when measured by levels of autophosphorylation and by their ability to phosphorylate an exogenous substrate and have little or no transforming activity. These results indicate that autophosphorylation at critical tyrosine residues is required for activation of the kinase activity of Tpr-Met and for cell transformation by this oncogene.	MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT ONCOL, MOLEC ONCOL GRP, MONTREAL H3A 1A1, PQ, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT MED, MONTREAL H3A 1A1, PQ, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT BIOCHEM, MONTREAL H3A 1A1, PQ, CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital								ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DICKENS M, 1992, BIOCHEM BIOPH RES CO, V186, P244, DOI 10.1016/S0006-291X(05)80799-5; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kriegler M., 1990, GENE TRANSFER EXPRES; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MECKLINGHANSEN K, 1987, EMBO J, V6, P659, DOI 10.1002/j.1460-2075.1987.tb04805.x; MITRA G, 1991, ONCOGENE, V6, P2237; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RODRIGUES GA, 1993, HEPATOCYTE GROWTH FA, P167; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI N, 1985, J BIOL CHEM, V260, P9793; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YU KT, 1984, J BIOL CHEM, V259, P5277; YU KT, 1986, J BIOL CHEM, V261, P1341; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHO H, 1994, CELL GROWTH DIFFER, V5, P1	64	96	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2019	2027						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208547				2022-12-25	WOS:A1994NR68500026
J	GARCIAMORALES, P; SACEDA, M; KENNEY, N; KIM, N; SALOMON, DS; GOTTARDIS, MM; SOLOMON, HB; SHOLLER, PF; JORDAN, VC; MARTIN, MB				GARCIAMORALES, P; SACEDA, M; KENNEY, N; KIM, N; SALOMON, DS; GOTTARDIS, MM; SOLOMON, HB; SHOLLER, PF; JORDAN, VC; MARTIN, MB			EFFECT OF CADMIUM ON ESTROGEN-RECEPTOR LEVELS AND ESTROGEN-INDUCED RESPONSES IN HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; SINGLE CALCIUM CHANNELS; GROWTH FACTOR-ALPHA; MCF-7 CELLS; GENE-TRANSCRIPTION; HEAVY-METALS; RAT-BRAIN; EXPRESSION; DNA; PROTEIN	The effects of cadmium on estrogen receptor and other estrogen-regulated genes in the human breast cancer cell line MCF-7 were studied. Treatment of MCF-7 cells with 1 mu M cadmium decreased the level of estrogen receptor 58%. Cadmium induced a parallel decrease in estrogen receptor mRNA (62%). Progesterone receptor levels increased 3.2-fold after cadmium treatment. This induction was blocked by the anti-estrogen ICI-164,384. Progesterone receptor mRNA was also increased by cadmium, as well as cathepsin D mRNA. An in vitro nuclear transcription run-on assay showed that cadmium increased the transcription of the progesterone receptor and pS2 genes and decreased transcription of the estrogen receptor gene. These are not general effects of heavy metals, as zinc, 25 and 100 mu M, did not affect progesterone receptor protein and mRNA levels. Cadmium stimulated pS2 and progesterone receptor mRNAs in a clone of MDA-MB-231 cells transfected with the human estrogen receptor, but had no effect in MDA-MB-231 cells transfected with antisense estrogen receptor. Cadmium also stimulated an estrogen response element in transient transfection experiments. These data suggest that the effects of cadmium are mediated by the estrogen receptor independent of estradiol. In addition to its effect on gene expression, cadmium induced the growth of MCF-7 cells 5.6-fold.	GEORGETOWN UNIV, VINCENT T LOMBARDI CANC RES CTR, DEPT BIOCHEM & MOLEC BIOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, VINCENT T LOMBARDI CANC RES CTR, DEPT MED ONCOL, WASHINGTON, DC 20007 USA; NCI, TUMOR GROWTH FACTOR SECT, TUMOR IMMUNOL & BIOL LAB, BETHESDA, MD 20892 USA; UNIV WISCONSIN, CTR COMPREHENS CANC, DEPT HUMAN ONCOL, MADISON, WI 53792 USA	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wisconsin System; University of Wisconsin Madison			Saceda, Miguel/A-1581-2008; JORDAN, V.Craig/AAX-3562-2020; Jordan, V. Craig/H-4491-2011; Garcia Morales, Pilar/ABD-4362-2021	Saceda, Miguel/0000-0002-1564-3602; 				ALAM J, 1989, J BIOL CHEM, V264, P6371; BAKO G, 1982, CAN J PUBLIC HEALTH, V73, P92; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BLOCK C, 1992, J BIOL CHEM, V267, P19824; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; DENTON RR, 1992, J BIOL CHEM, V267, P7263; DUBIK D, 1992, ONCOGENE, V7, P1587; ELINDER CG, 1985, BRIT J IND MED, V42, P651; EPNER DE, 1991, J CELL PHYSIOL, V148, P68, DOI 10.1002/jcp.1041480109; FISHMAN JH, 1988, BIOCHEM BIOPH RES CO, V152, P783, DOI 10.1016/S0006-291X(88)80106-2; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HINKLE PM, 1987, J BIOL CHEM, V262, P16333; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KEAVENEY M, 1991, J MOL ENDOCRINOL, V6, P111, DOI 10.1677/jme.0.0060111; KIPLING MD, 1967, LANCET, V1, P730; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; LEMEN RA, 1976, ANN NY ACAD SCI, V271, P273, DOI 10.1111/j.1749-6632.1976.tb23122.x; MARTIN MB, 1986, J BIOL CHEM, V261, P2355; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MISRA S, 1989, BIOCHIM BIOPHYS ACTA, V1007, P325, DOI 10.1016/0167-4781(89)90155-3; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935; NELSON MT, 1986, J GEN PHYSIOL, V87, P201, DOI 10.1085/jgp.87.2.201; PEI J, 1990, J BIOL CHEM, V265, P14061; PIVA R, 1992, BIOCHEM BIOPH RES CO, V183, P996, DOI 10.1016/S0006-291X(05)80289-X; PREDKI PF, 1992, J BIOL CHEM, V267, P5842; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; SABBAH M, 1987, J BIOL CHEM, V262, P8631; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; SHIBUYA I, 1992, ENDOCRINOLOGY, V131, P1936, DOI 10.1210/en.131.4.1936; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; SLATER EP, 1991, MOL ENDOCRINOL, V5, P386, DOI 10.1210/mend-5-3-386; SMITH JB, 1989, J BIOL CHEM, V264, P7115; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; SUSZKIW J, 1984, BRAIN RES, V323, P31, DOI 10.1016/0006-8993(84)90262-2; TANG N, 1991, CELL BIOL TOXICOL, V7, P401, DOI 10.1007/BF00124074; THEVENOD F, 1992, BIOPHYS J, V63, P162, DOI 10.1016/S0006-3495(92)81575-8; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041	44	232	238	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16896	16901						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207012				2022-12-25	WOS:A1994NR29600058
J	CHANG, PY; BENECKE, H; LEMARCHANDBRUSTEL, Y; LAWITTS, J; MOLLER, DE				CHANG, PY; BENECKE, H; LEMARCHANDBRUSTEL, Y; LAWITTS, J; MOLLER, DE			EXPRESSION OF A DOMINANT-NEGATIVE MUTANT HUMAN INSULIN-RECEPTOR IN THE MUSCLE OF TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; SIGNAL TRANSDUCTION; GLUCOSE-TRANSPORT; DIABETIC SUBJECTS; SKELETAL-MUSCLE; ADIPOSE-TISSUE; MORBIDLY OBESE; BETA-SUBUNIT; RESISTANCE; MUTATION	To examine the in vivo effects of a kinase-deficient mutant human insulin receptor, we used the muscle creatine kinase promoter to express a putative dominant-negative receptor: Ala(1134) --> Thr (Moller, D. E., Yokota, A., White, M. F., Pazianos, A G., and Flier, J. S. (1990) J. Biol. Chem. 265, 14979-14985) in transgenic mice, Two lines were generated, where receptor expression was restricted to striated muscle and was increased by 5-12-fold in skeletal muscle. Transgenic gluteal muscle insulin receptor kinase activity was reduced by approximate to 80% after maximal in vivo insulin stimulation. Glycogen content in this muscle was reduced by 45% in transgenic mice. Insulin levels were approximate to 2-fold higher, and glucose concentrations were 12% higher in transgenics fed ad libitum. Transgenic mice exhibited reduced in vivo sensitivity to low dose (0.1 milliunits/g) intravenous insulin. In isolated soleus muscles from transgenics, where mutant receptors were expressed at lower levels, insulin-stimulated receptor kinase activity was reduced by 42%, but insulin-stimulated 2-deoxyglucose uptake was unaffected. These results indicate that (i) overexpression of a kinase-deficient human insulin receptor in muscle causes dominant-negative effects at the level of receptor kinase activation, (ii) impairment of insulin-stimulated muscle receptor tyrosine kinase activity can cause decreased insulin sensitivity in vivo, (iii) kinase-defective receptor mutants may be used to create novel animal models of tissue-specific insulin resistance.	BETH ISRAEL HOSP, CHARLES A DANA RES INST, DIV ENDOCRINOL & METAB, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT MED, HARVARD THORNDIKE LAB, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; FAC MED NICE, INSERM, U145, F-06034 NICE, FRANCE	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045874] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45874] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BENECKE H, 1993, DIABETES, V42, P206, DOI 10.2337/diabetes.42.1.206; BENECKE H, 1992, J CLIN INVEST, V89, P2066, DOI 10.1172/JCI115819; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CAMA A, 1993, J BIOL CHEM, V268, P8060; CAMA A, 1991, J CLIN ENDOCR METAB, V73, P894, DOI 10.1210/jcem-73-4-894; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FREIDENBERG GR, 1991, J CLIN INVEST, V87, P2222, DOI 10.1172/JCI115257; FREIDENBERG GR, 1987, J CLIN INVEST, V79, P240, DOI 10.1172/JCI112789; GARVEY WT, 1988, J CLIN INVEST, V81, P1528, DOI 10.1172/JCI113485; GOTTSCHALK WK, 1991, J BIOL CHEM, V266, P8814; GRIGORESCU F, 1984, J BIOL CHEM, V259, P5003; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARUTA T, 1993, DIABETES, V42, P1837, DOI 10.2337/diabetes.42.12.1837; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; HOGAN B, 1986, MANIPULATING MOUSE E; IWANISHI M, 1993, DIABETOLOGIA, V36, P414, DOI 10.1007/BF00402277; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KIM H, 1992, DIABETOLOGIA, V35, P261, DOI 10.1007/BF00400927; KLEIN HH, 1993, DIABETES, V42, P883, DOI 10.2337/diabetes.42.6.883; KRAEGEN EW, 1985, AM J PHYSIOL, V248, pE353; LEMARCHANDBRUSTEL Y, 1978, AM J PHYSIOL, V234, pE348, DOI 10.1152/ajpendo.1978.234.4.E348; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MARSHALL S, 1980, J CLIN INVEST, V66, P763, DOI 10.1172/JCI109914; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOLLER DE, 1988, NEW ENGL J MED, V319, P1526, DOI 10.1056/NEJM198812083192306; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOLLER DE, 1994, DIABETES, V43, P247, DOI 10.2337/diabetes.43.2.247; MOLLER DE, 1990, MOL ENDOCRINOL, V4, P1183, DOI 10.1210/mend-4-8-1183; MOUNTJOY KG, 1990, BIOCHEM BIOPH RES CO, V169, P978, DOI 10.1016/0006-291X(90)91990-A; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; NOZAKI O, 1993, J CLIN ENDOCR METAB, V77, P169, DOI 10.1210/jc.77.1.169; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; ORAHILLY S, 1991, DIABETES, V40, P777, DOI 10.2337/diabetes.40.6.777; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; RAFAELOFF R, 1991, BIOCHEM BIOPH RES CO, V179, P912, DOI 10.1016/0006-291X(91)91905-R; ROACH P, 1992, CLIN RES, V40, pA311; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SINHA MK, 1987, DIABETES, V36, P620, DOI 10.2337/diabetes.36.5.620; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Taylor Simeon I., 1993, P83; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WHITE MF, 1994, INSULIN RESISTANCE, P9; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777	64	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16034	16040						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206901				2022-12-25	WOS:A1994NQ72900016
J	HUANG, TG; HACKNEY, DD				HUANG, TG; HACKNEY, DD			DROSOPHILA KINESIN MINIMAL MOTOR DOMAIN EXPRESSED IN ESCHERICHIA-COLI - PURIFICATION AND KINETIC CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; FAST AXONAL-TRANSPORT; HEAVY-CHAIN; CYTOPLASMIC MICROTUBULES; MUSCLE-CONTRACTION; BETA-TUBULIN; NCD PROTEIN; BINDING; ATPASE; MOTILITY	A truncated motor domain of the alpha subunit of Drosophila kinesin was obtained by expression in Escherichia coli and purified to homogeneity in the presence of MgATP. This domain (designated DKH340) extends from the N terminus to amino acid 340. The isolated protein contains a stoichiometric level of tightly bound ADP and has a low basal rate of ATP hydrolysis of 0.029 +/- 0.002 s(-1) in the absence of microtubules. The rate of release of bound ADP is 0.026 +/- 0.003 s(-1). The approximate equality of the ADP release rate and the steady state ATPase rate indicates that ADP release is the rate-limiting step in ATP hydrolysis in the absence of microtubules. The rate of ATP hydrolysis is stimulated 3000 fold by addition of microtubules (MT) (k(cat) = 80 s(-1); K-0.5,ATPase(MT) = 160 nM for half-saturation of the ATPase rate by microtubules at saturating ATP levels; K-0.5,ATPase(MT) = 43 mu M for half-saturation of the ATPase rate by ATP at saturating microtubule levels). Binding of DKH340 to MTs is biphasic in the presence of adenosine 5-(beta-gamma-imido)triphosphate. One DKH340 binds tightly per tubulin heterodimer, but greater than one DKH340/tubulin heterodimer can be bound at higher ratios of DKH340/ microtubules. In the presence of MgATP, K-0.5,Binding(MT) for physical binding of DKH340 to microtubules is weaker than K-0.5,ATPase(MT) for stimulation of hydrolysis. These re- sults are consistent with a model in which DKH340 cycles on and off the microtubule during hydrolysis of each ATP molecule. For this model, the kcat/K-0.5,ATPase(MT) ratio of 5 x 10(8) M(-1) s(-1) is at least as large as the bimolecular rate constant for association with microtubules, and this value approaches the diffusion controlled limit. Nucleotide-free DKH340 can be produced by gel filtration in the absence of Mg2+, but it reforms tightly bound ADP slowly in the presence of MgATP (t(1/2) greater than or equal to 10 min), and thus it is likely to be in a conformational state which is not produced during steady state ATP hydrolysis.	CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA	Carnegie Mellon University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028562] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28562] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; COHN SA, 1989, J BIOL CHEM, V264, P4290; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; ENDOW SA, 1991, P NATL ACAD SCI USA, V88, P4424, DOI 10.1073/pnas.88.10.4424; FERSHT A, 1984, ENZYME STRUCTURE MEC, P150; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GOLDSMITH M, 1991, CELL MOTIL CYTOSKEL, V20, P249, DOI 10.1002/cm.970200308; GREENE LE, 1980, J BIOL CHEM, V255, P543; HACKNEY DD, 1990, BIOPHYS J, V57, pA348; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1984, P NATL ACAD SCI-BIOL, V81, P5345, DOI 10.1073/pnas.81.17.5345; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1985, J BIOL CHEM, V260, P5505; HACKNEY DD, 1989, J BIOL CHEM, V264, P15943; HACKNEY DD, 1991, METHOD ENZYMOL, V196, P175; HACKNEY DD, 1990, ENZYMES, V19, P1; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16502; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4589; KAMIMURA S, 1992, J CELL BIOL, V118, P865, DOI 10.1083/jcb.118.4.865; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; ROZDZIAL MM, 1990, EUR J CELL BIOL, V52, P27; SADHU A, 1992, J BIOL CHEM, V267, P11352; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; STEIN LA, 1984, BIOCHEMISTRY-US, V23, P1555, DOI 10.1021/bi00302a033; STEWART RJ, 1991, P NATL ACAD SCI USA, V88, P8470, DOI 10.1073/pnas.88.19.8470; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	64	178	183	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16493	16501						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206959				2022-12-25	WOS:A1994NQ72900080
J	RAJPUT, B; MUNIAPPA, N; VIJAY, IK				RAJPUT, B; MUNIAPPA, N; VIJAY, IK			DEVELOPMENTAL AND HORMONAL-REGULATION OF UDP-GLCNAC-DOLICHOL PHOSPHATE GLCNAC-1-P TRANSFERASE IN MOUSE MAMMARY-GLAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN GENE-EXPRESSION; ASPARAGINE-LINKED GLYCOPROTEINS; N-ACETYLGLUCOSAMINYLPYROPHOSPHORYL POLYPRENOLS; EPITHELIAL-CELL LINE; BETA-CASEIN; NUCLEAR FACTOR; OVIDUCT DIFFERENTIATION; PROTEIN GLYCOSYLATION; EXTRACELLULAR-MATRIX; ALPHA-LACTALBUMIN	The developmental and hormonal regulation of UDP-GlcNAc:dolichol phosphate N-acetylglucosamine-1-phosphate transferase (GPT), the enzyme which initiates the biosynthesis of asparagine-linked glycoproteins, was investigated in mouse mammary glands. An anti-peptide antibody raised against the carboxyl-terminal 11 amino acids of mouse GPT, immunoadsorbed GPT activity and recognized a protein of expected size (similar to 48 kDa) on Western blots. Mouse mammary glands at different stages of development were examined for GPT activity, immunoreactive protein, and GPT mRNA. All three parameters showed a similar trend, i.e. they were low in tissues from virgin and pregnant animals, increased steadily during lactation, reaching a peak around mid to late lactation, and declined thereafter in glands from post-lactating animals. At mid-lactation, the increase in GPT activity, immunoreactive protein, and GPT mRNA relative to the virgin stage was 9.5-, 3.3- and 5.4 fold respectively, on a per cell basis. These data suggest possible transcriptional and post-transcriptional modulation of GPT gene expression during development of mouse mammary gland. The results on hormonal regulation of GPT in mouse mammary explants and primary mouse mammary epithelial cells showed that all three parameters cited above were stimulated maximally by the combined presence of insulin, hydrocortisone, and prolactin, indicating that the hormonal regulation of GPT expression is also mediated at the level of RNA.	UNIV MARYLAND,DEPT ANIM SCI,COLL PK,MD 20742; UNIV MARYLAND,CTR AGR BIOTECHNOL,COLL PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park					NIDDK NIH HHS [DK-19682] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019682] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMANT DR, 1986, DEV BIOL, V113, P228, DOI 10.1016/0012-1606(86)90125-9; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BHATTACHARJEE M, 1984, ENDOCRINOLOGY, V115, P1070, DOI 10.1210/endo-115-3-1070; BRADSHAW JP, 1985, INT J BIOCHEM, V17, P175, DOI 10.1016/0020-711X(85)90112-0; CARSON DD, 1990, J BIOL CHEM, V265, P2947; CHEN LH, 1987, J BIOL CHEM, V262, P17247; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; EMERMAN JT, 1977, IN VITRO CELL DEV B, V13, P316, DOI 10.1007/BF02616178; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRIGOR MR, 1990, BIOCHEM J, V267, P815, DOI 10.1042/bj2670815; GUYETTE WA, 1979, CELL, V17, P1013, DOI 10.1016/0092-8674(79)90340-4; HARLOW E, 1988, ANTIBODIES LABORATOR, P78; HAYES GR, 1983, J BIOL CHEM, V258, P5095; HOUDEBINE LM, 1978, BIOCHIMIE, V60, P57, DOI 10.1016/S0300-9084(78)80198-9; KAUSHAL GP, 1985, J BIOL CHEM, V260, P6303; KEAN EL, 1985, J BIOL CHEM, V260, P2561; KEAN EL, 1980, J BIOL CHEM, V255, P1921; KEAN EL, 1982, J BIOL CHEM, V257, P7952; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEE CS, 1992, J BIOL CHEM, V267, P5797; LEE EYH, 1984, J CELL BIOL, V98, P146, DOI 10.1083/jcb.98.1.146; LEE EYHP, 1985, P NATL ACAD SCI USA, V82, P1419, DOI 10.1073/pnas.82.5.1419; LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136; LUCAS JJ, 1977, J BIOL CHEM, V252, P4330; NAKHASI HL, 1979, J BIOL CHEM, V254, P6016; ONO M, 1981, IN VITRO CELL DEV B, V17, P121, DOI 10.1007/BF02618068; QASBA PK, 1984, NATURE, V308, P377, DOI 10.1038/308377a0; RAJPUT B, 1992, BIOCHEM J, V285, P985, DOI 10.1042/bj2850985; RUSH J S, 1991, Glycobiology, V1, P229, DOI 10.1093/glycob/1.2.229; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P9701; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; STARR CM, 1985, ARCH BIOCHEM BIOPHYS, V237, P261, DOI 10.1016/0003-9861(85)90277-2; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; VIJAY IK, 1986, EUR J BIOCHEM, V154, P57, DOI 10.1111/j.1432-1033.1986.tb09358.x; WELPLY JK, 1985, DEV BIOL, V107, P252, DOI 10.1016/0012-1606(85)90393-8; YOSHIMURA M, 1990, P NATL ACAD SCI USA, V87, P3670, DOI 10.1073/pnas.87.10.3670; ZHU XY, 1992, J BIOL CHEM, V267, P8895	43	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16054	16061						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206904				2022-12-25	WOS:A1994NQ72900019
J	CHAPPELL, DA; FRY, GL; WAKNITZ, MA; MUHONEN, LE; PLADET, MW				CHAPPELL, DA; FRY, GL; WAKNITZ, MA; MUHONEN, LE; PLADET, MW			LOW-DENSITY-LIPOPROTEIN RECEPTORS BIND AND MEDIATE CELLULAR CATABOLISM OF NORMAL VERY-LOW-DENSITY LIPOPROTEINS IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERITABLE HYPERLIPIDEMIC RABBITS; TRIGLYCERIDE-RICH LIPOPROTEINS; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE-ACTIVITY; PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; CULTURED HUMAN-FIBROBLASTS; MONOCLONAL-ANTIBODIES; APOLIPOPROTEIN-E; BLOOD-PLASMA; FAMILIAL HYPERCHOLESTEROLEMIA; STOICHIOMETRIC BINDING	Very low density lipoproteins (VLDL) are heterogeneous, triglyceride-rich particles that are precursors of low density lipoproteins (LDL). Before conversion to LDL, the majority of VLDL are irreversibly cleared from plasma by uncertain mechanisms. To investigate one potential mechanism for VLDL clearance, we studied the ability of LDL receptors to mediate VLDL uptake in vitro. Small, intermediate, and large VLDL from normolipidemic humans were found to bind and undergo catabolism via LDL receptors on normal human fibroblasts. Binding to cell surfaces was up-regulated by lovastatin, an inducer of LDL receptors. Both LDL and a monoclonal antibody against the LDL receptor (IgG-C7) prevented binding of I-125-VLDL. Also, VLDL binding to mutant fibroblasts lacking LDL receptors was low. Thus, LDL receptors mediated VLDL interactions with cells. Binding affinity decreased near saturation, and the apparent number of high affinity sites decreased with increasing VLDL particle size. Because LDL receptors are small (M(r) 115,000) relative to VLDL (M(r) 9-24 x 10(6)) and are clustered in clathrin-coated pits, these findings suggest that steric hindrance becomes an important binding determinant near saturation and are consistent with a lattice model for LDL receptor-ligand interactions. The capacity for cellular catabolism of VLDL decreased with increasing particle size, consistent with a lattice model. The lattice model was also supported by differences between I-125-VLDL binding to cell surfaces and binding to partially purified LDL receptors in solid-phase assays in which steric constraints resulting from clustering in clathrin-coated pits are not present. In both cell-surface and solid-phase assays, VLDL bound via apoE, not apoB-100. Our studies establish that normal VLDL interact with LDL receptors and that steric hindrance due to crowding of particles on clustered LDL receptors is an important determinant of their binding and catabolism. These findings suggest that LDL receptors may participate in normal VLDL clearance in vivo.			CHAPPELL, DA (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,E318 GH,IOWA CITY,IA 52242, USA.				NHLBI NIH HHS [T32 HL07413, HL49264] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264, T32HL007413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BRADLEY WA, 1984, J BIOL CHEM, V259, P4728; CAMPOS E, 1992, J LIPID RES, V33, P369; CATAPANO AL, 1979, J BIOL CHEM, V254, P1007; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHAPPELL DA, 1992, J BIOL CHEM, V267, P270; CHAPPELL DA, 1988, J CLIN INVEST, V82, P628, DOI 10.1172/JCI113642; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; DASHTI N, 1986, BIOCHIM BIOPHYS ACTA, V875, P473, DOI 10.1016/0005-2760(86)90067-6; DELALLERA M, 1979, BIOCHIM BIOPHYS ACTA, V574, P414, DOI 10.1016/0005-2760(79)90237-6; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DEMANT T, 1991, J CLIN INVEST, V88, P1490, DOI 10.1172/JCI115459; DESAI KS, 1980, BIOCHIM BIOPHYS ACTA, V620, P341, DOI 10.1016/0005-2760(80)90125-3; ESPER E, 1993, J LAB CLIN MED, V121, P97; FIELDING PE, 1986, J BIOL CHEM, V261, P5233; FREDRICKSON DS, 1968, J CLIN INVEST, V47, P2446, DOI 10.1172/JCI105927; GIANTURCO SH, 1978, J CLIN INVEST, V61, P320, DOI 10.1172/JCI108942; GIANTURCO SH, 1980, LIPIDS, V15, P456, DOI 10.1007/BF02534072; GIANTURCO SH, 1993, ARTERIOSCLER THROMB, V13, P472, DOI 10.1161/01.ATV.13.4.472; GIANTURCO SH, 1982, J LIPID RES, V23, P984; GIBSON JC, 1987, ARTERIOSCLEROSIS, V7, P401, DOI 10.1161/01.ATV.7.4.401; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOTTO AM, 1986, METHOD ENZYMOL, V128, P3; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; Innerarity T L, 1986, Methods Enzymol, V129, P542; JACKLE S, 1992, J LIPID RES, V33, P419; KARPE F, 1993, J CLIN INVEST, V91, P748, DOI 10.1172/JCI116293; KLEINBAUM DG, 1988, APPLIED REGRESSION A, P124; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KREMPLER F, 1987, J CLIN INVEST, V80, P401, DOI 10.1172/JCI113086; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAMO JCL, 1991, BIOCHIM BIOPHYS ACTA, V1081, P241, DOI 10.1016/0005-2760(91)90277-O; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MILNE RW, 1982, FEBS LETT, V146, P97, DOI 10.1016/0014-5793(82)80712-6; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; MULDER M, 1993, J BIOL CHEM, V268, P9369; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; PACKARD CJ, 1984, J CLIN INVEST, V74, P2178, DOI 10.1172/JCI111644; RANGANATHAN S, 1989, HEPATOLOGY, V9, P547, DOI 10.1002/hep.1840090407; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; SCHONFELD G, 1979, J CLIN INVEST, V64, P1288, DOI 10.1172/JCI109584; SCHROTT HG, 1982, CIRCULATION, V65, P300, DOI 10.1161/01.CIR.65.2.300; SEHAYEK E, 1991, J CLIN INVEST, V88, P553, DOI 10.1172/JCI115339; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; STALENHOEF AFH, 1984, P NATL ACAD SCI-BIOL, V81, P1839, DOI 10.1073/pnas.81.6.1839; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; VANDRIEL IR, 1989, J BIOL CHEM, V264, P9533; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMADA N, 1988, J CLIN INVEST, V82, P2106, DOI 10.1172/JCI113832; YAMADA N, 1987, J CLIN INVEST, V80, P507, DOI 10.1172/JCI113099; 1980, NIH801527 NAT HEART	62	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25487	25493						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244984				2022-12-25	WOS:A1993MK10000034
J	ZIEGLER, M; PENEFSKY, HS				ZIEGLER, M; PENEFSKY, HS			THE ADENINE-NUCLEOTIDE TRANSLOCASE MODULATES OLIGOMYCIN-INDUCED QUENCHING OF PYRANINE FLUORESCENCE IN SUBMITOCHONDRIAL PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP ATP TRANSLOCATOR; OXIDATIVE-PHOSPHORYLATION; ADP/ATP CARRIER; INNER MEMBRANE; MITOCHONDRIA; SYNTHASE; TRANSPORT; DERIVATIVES; DIFFUSION; GENETICS	Incorporation of the fluorescent, nonpermeant pH indicator pyranine into submitochondrial particles (pyranine-SMP) permitted monitoring of intravesicular pH changes brought about by proton translocation due to oxidation of respiratory chain substrates or to hydrolysis of ATP. Addition of oligomycin to beef heart pyranine-SMP was followed by a pH-independent quenching of pyranine fluorescence. Quenching was influenced by the presence of adenine nucleotides both inside and outside the submitochondrial particles. The nature of the nucleotides required for quenching resembled the specificity of the adenine nucleotide translocase rather than F1-ATPase. Removal of F1 from pyranine-SMP by treatment of the particles with urea did not alter oligomycin-induced quenching. Atractyloside, a specific inhibitor of the adenine nucleotide translocase, prevented oligomycin-induced quenching when the inhibitor was coincorporated into submitochondrial particles with pyranine. Bongkrekic acid prevented or reversed the oligomycin-dependent quenching when added to pyranine-SMP either before or after oligomycin, respectively, but only when ATP was present within the particles. A mutant of Saccharomyces cerevisiae, lacking translocase genes, exhibited oligomyc-independent fluorescence quenching which was not inhibited by bongkrekic acid. The results support the interpretation that oligomycin promotes sequestration of the fluorescent probe in a region of the submitochondrial particle, probably the F0F1 complex, that leads to a quenching of fluorescence. The observed quenching can be modulated in a way that suggests an interaction between the translocase and F0.			ZIEGLER, M (corresponding author), SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, SYRACUSE, NY 13210 USA.			Ziegler, Mathias/0000-0001-6961-2396	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021737] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21737] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEYER RE, 1967, METHOD ENZYMOL, V10, P186; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GAWAZ M, 1990, J BIOL CHEM, V265, P14202; GUPTE SS, 1991, BIOCHIM BIOPHYS ACTA, V1069, P131, DOI 10.1016/0005-2736(91)90114-N; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; HARRIS DA, 1977, BIOCHIM BIOPHYS ACTA, V459, P560, DOI 10.1016/0005-2728(77)90054-8; ISSARTEL JP, 1992, EXPERIENTIA, V48, P351, DOI 10.1007/BF01923429; KANO K, 1978, BIOCHIM BIOPHYS ACTA, V509, P289, DOI 10.1016/0005-2736(78)90048-2; KLINGENBERG M, 1984, BIOCHEMISTRY-US, V23, P2442, DOI 10.1021/bi00306a019; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDY HA, 1964, J BIOL CHEM, V12, P1961; LAWSON JE, 1990, J BIOL CHEM, V265, P14195; LESTER RL, 1967, METHOD ENZYMOL, V10, P264; Linnett P E, 1979, Methods Enzymol, V55, P472; MAYER I, 1984, BIOCHEMISTRY-US, V23, P2436, DOI 10.1021/bi00306a018; MULLER M, 1984, J BIOL CHEM, V259, P3037; NAGLEY P, 1988, TRENDS GENET, V4, P46, DOI 10.1016/0168-9525(88)90066-2; NELSON DR, 1993, J MOL BIOL, V230, P1159, DOI 10.1006/jmbi.1993.1233; PENEFSKY H, 1991, ADV ENZYMOL REL AREA, V64, P173; PENEFSKY HS, 1960, J BIOL CHEM, V235, P3330; PFAFF E, 1968, EUR J BIOCHEM, V6, P66, DOI 10.1111/j.1432-1033.1968.tb00420.x; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; RACKER E, 1967, J BIOL CHEM, V242, P2547; SCHAFER G, 1980, FEBS LETT, V109, P197, DOI 10.1016/0014-5793(80)81085-4; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SORGATO MC, 1982, BIOCHIM BIOPHYS ACTA, V682, P184, DOI 10.1016/0005-2728(82)90133-5; SORGATO MC, 1985, FEBS LETT, V181, P323, DOI 10.1016/0014-5793(85)80285-4; VIGNAIS PV, 1976, BIOCHIM BIOPHYS ACTA, V456, P1, DOI 10.1016/0304-4173(76)90007-0	31	16	17	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25320	25328						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244963				2022-12-25	WOS:A1993MK10000010
J	CLANCEY, CJ; CHANG, SC; DOWHAN, W				CLANCEY, CJ; CHANG, SC; DOWHAN, W			CLONING OF A GENE (PSD1) ENCODING PHOSPHATIDYLSERINE DECARBOXYLASE FROM SACCHAROMYCES-CEREVISIAE BY COMPLEMENTATION OF AN ESCHERICHIA-COLI MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; YEAST; EXPRESSION; DNA; SEQUENCE; PROTEIN; PHOSPHATIDYLETHANOLAMINE; TRANSFORMATION; IDENTIFICATION; TRANSLOCATION	A gene (PSD1) encoding a phosphatidylserine decarboxylase of Saccharomyces cerevisiae was cloned by complementation of a conditional lethal mutation in the homologous gene in Escherichia coli strain EH150. Expression of the cDNA clone in EH150 corrected growth, phospholipid, and phosphatidylserine decarboxylase activity defects. Expression of the genomic clone in wild type yeast resulted in 20-fold amplification of phosphatidylserine decarboxylase activity. A 1500-base pair open reading frame encodes a 56,558-Da protein with a potential mitochondrial targeting sequence. Upstream regulatory elements found in other enzymes of the phospholipid biosynthetic pathway are present in PSD1. The derived amino acid sequence shows 44 and 35% identity with the phosphatidylserine decarboxylases from Chinese hamster ovary cells and E. coli, respectively. Near the carboxyl terminus is an LGST sequence which, in E. coli, is the site of proteolytic cleavage of the proenzyme into the alpha and beta subunits and formation of the pyruvate prosthetic group (Dowhan, W., and Li, Q.-X. (1992) Methods Enzymol. 209, 348-359). Disruption of the PSD1 gene in a haploid strain of yeast resulted in loss of detectable decarboxylase activity but little alteration of the growth properties or phospholipid composition. These results suggest that yeast has a second phosphatidylserine decarboxylation activity.	UNIV TEXAS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77225 USA	University of Texas System					NIGMS NIH HHS [GM 35143] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035143] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADOLPHUS, 1983, EMBO J, V2, P1765, DOI 10.1002/j.1460-2075.1983.tb01655.x; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CIGAN AM, 1987, GENE, V59, P1; CUMSKY MG, 1985, P NATL ACAD SCI USA, V82, P2235, DOI 10.1073/pnas.82.8.2235; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; DOWHAN W, 1992, METHOD ENZYMOL, V209, P348; DOWHAN W, 1974, J BIOL CHEM, V249, P3079; DOWHAN W, 1992, METHOD ENZYMOL, V209, P7; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FERBEYRE G, 1993, BIOTECHNIQUES, V14, P386; FINE JB, 1982, J LIPID RES, V23, P660; GLICK B, 1991, ANNU REV GENET, V25, P21; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWROT E, 1975, P NATL ACAD SCI USA, V72, P1112, DOI 10.1073/pnas.72.3.1112; HENSCHKE PA, 1991, YEASTS, V4, P313; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; KODAKI T, 1991, J BIOCHEM-TOKYO, V109, P276; KODAKI T, 1991, J BACTERIOL, V173, P7992, DOI 10.1128/jb.173.24.7992-7995.1991; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; KUGE O, 1991, J BIOL CHEM, V266, P6370; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMPING E, 1991, J BACTERIOL, V173, P6432, DOI 10.1128/jb.173.20.6432-6437.1991; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; LI QX, 1988, J BIOL CHEM, V263, P11516; LI QX, 1990, J BIOL CHEM, V265, P4111; Maniatis T., 1982, MOL CLONING; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; NIKAWA JI, 1988, J BACTERIOL, V170, P4727, DOI 10.1128/jb.170.10.4727-4731.1988; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; OVERMEYER JH, 1991, ARCH BIOCHEM BIOPHYS, V290, P511, DOI 10.1016/0003-9861(91)90574-3; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; Sambrook J, 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATRE M, 1978, J BIOL CHEM, V253, P479; SCHATZ G, 1987, EUR J BIOCHEM, V165, P1, DOI 10.1111/j.1432-1033.1987.tb11186.x; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHERMAN F, 1986, LABORATORY COURSE MA, P117; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; TSUKAGOSHI Y, 1991, J BACTERIOL, V173, P2134, DOI 10.1128/jb.173.6.2134-2136.1991; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; VOELKER DR, 1991, MICROBIOL REV, V55, P543, DOI 10.1128/MMBR.55.4.543-560.1991; WARNER TG, 1975, J BIOL CHEM, V250, P8004; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991; 1991, PROGRAM MANUAL GCG P	61	126	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24580	24590						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227017				2022-12-25	WOS:A1993MG67300015
J	FONT, B; AUBERTFOUCHER, E; GOLDSCHMIDT, D; EICHENBERGER, D; VANDERREST, M				FONT, B; AUBERTFOUCHER, E; GOLDSCHMIDT, D; EICHENBERGER, D; VANDERREST, M			BINDING OF COLLAGEN-XIV WITH THE DERMATAN SULFATE SIDE-CHAIN OF DECORIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL PROTEOGLYCAN; BOVINE SKIN; PROTEIN; TENDON; PURIFICATION; CARTILAGE; SEQUENCE; MOLECULE; VARIANT; MATRIX	As an approach to elucidate the role of collagen XIV, which is still unclear, molecules exhibiting affinity for this collagen have been sought in connective tissue. Extracts from fetal bovine tendon were resolved by gel electrophoresis and electrophoretically transferred to nitrocellulose. The blot was overlaid with native collagen XIV and the collagen XIV-binding molecules revealed by immunodecoration with a monoclonal antitype XIV collagen antibody. This experimental approach allowed us to reveal in tendon extracts a diffuse band, with an apparent molecular mass of approximately 100 kDa, that binds collagen XIV. This molecule was also found associated with the fractions containing partially purified type XIV collagen. This 100-kDa molecule was sensitive to chondroitinase ABC and, after chondroitinase digestion, yielded a core protein of about 48 kDa. N-terminal sequence analysis of the proteoglycan after blotting allowed us to identify it as decorin. By solid phase assays we have studied this newly described association between decorin and type XIV collagen and shown that it is a saturable process. In addition, preliminary determination of the domains of the two molecules involved in the association has been performed. The possible role of these interactions is discussed.	INST BIOL & CHEM PROT, CNRS, UNITE PROPRE RECH 412, F-69367 LYON, FRANCE; UNIV LYON 1, F-69622 VILLEURBANNE, FRANCE; ECOLE NORMALE SUPER LYON, F-69367 LYON, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ecole Normale Superieure de Lyon (ENS de LYON)								AUBERTFOUCHER E, 1992, J BIOL CHEM, V267, P15759; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DUBLET B, 1991, J BIOL CHEM, V266, P6853; GEOURJON C, 1991, J MOL GRAPHICS, V9, P188, DOI 10.1016/0263-7855(91)80008-N; GEOURJON C, 1993, COMPUT APPL BIOSCI, V9, P87; GERECKE DR, 1993, J BIOL CHEM, V268, P12177; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETHIAS C, 1993, J INVEST DERMATOL, V101, P92, DOI 10.1111/1523-1747.ep12360433; LUNSTRUM GP, 1992, J BIOL CHEM, V267, P20087; OLSEN BR, 1989, CONNECT TISSUE RES, V23, P115, DOI 10.3109/03008208909002411; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; PEARSON CH, 1983, J BIOL CHEM, V258, P5101; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SCHUPPAN D, 1991, Journal of Cell Biology, V115, p106A; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; TRUEB J, 1992, EUR J BIOCHEM, V207, P549, DOI 10.1111/j.1432-1033.1992.tb17081.x; VOGEL KG, 1986, J BIOL CHEM, V261, P1334; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; WATT SL, 1992, J BIOL CHEM, V267, P20093; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209	30	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25015	25018						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227064				2022-12-25	WOS:A1993MG67300074
J	JEANG, KT; BERKHOUT, B; DROPULIC, B				JEANG, KT; BERKHOUT, B; DROPULIC, B			EFFECTS OF INTEGRATION AND REPLICATION ON TRANSCRIPTION OF THE HIV-1 LONG TERMINAL REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TAT PROTEIN; TRANS-ACTIVATION; PROCESSIVITY FACTOR; MUTATIONAL ANALYSIS; INDUCED EXPRESSION; NASCENT RNA; TRANSACTIVATION; TYPE-1; PROMOTER	The activity of a promoter is influenced by chromosomal and cell cycle/replication context. We analyzed the influences of integration and replication on transcription of the human immunodeficiency virus (HIV)-1 long terminal repeat (LTR). We found that one requirement for Tat trans-activated expression differed for integrated versus unintegrated HIV-1 LTR. Specifically, the second coding exon of Tat, previously regarded as functionally dispensable, plays a role in the optimal activation of integrated LTRs. We also found that the transcription profile produced from the HIV-1 LTR is influenced by replication. Autonomously replicating vectors that contain the HIV-1 LTR produced patterns of transcription different from counterpart vectors that do not replicate. Both replicating and nonreplicating HIV-1 LTRs remained responsive to Tat.			JEANG, KT (corresponding author), NIAID,MOLEC VIROL SECT,MOLEC MICROBIOL LAB,BETHESDA,MD 20892, USA.		Jeang, Kuan-Teh/A-2424-2008					ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BERKHOUT B, 1990, NUCLEIC ACIDS RES, V18, P1839, DOI 10.1093/nar/18.7.1839; Bohan Cindy A., 1992, Gene Expression, V2, P391; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; BRADDOCK M, 1991, NATURE, V350, P439, DOI 10.1038/350439a0; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; GREENBERG ME, 1989, CURRENT PROTOCOLS MO, P4101; Haseltine W. A., 1991, GENETIC STRUCTURE RE; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; Jeang K T, 1991, AIDS, V5 Suppl 2, pS3, DOI 10.1097/00002030-199101001-00002; JEANG KT, 1992, J BIOL CHEM, V267, P17891; JEANG KT, 1988, P NATL ACAD SCI USA, V85, P8291, DOI 10.1073/pnas.85.21.8291; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KASHANCHI F, 1989, P NATL ACAD SCI USA, V87, P7030; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KESSLER M, 1991, P NATL ACAD SCI USA, V88, P10018, DOI 10.1073/pnas.88.22.10018; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MATSUI T, 1986, MOL CELL BIOL, V6, P4149, DOI 10.1128/MCB.6.12.4149; MEYERS G, 1992, HUMAN RETROVIRUSES A; MICHAEL NL, 1991, J VIROL, V65, P1291, DOI 10.1128/JVI.65.3.1291-1303.1991; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; PROUDFOOT NJ, 1992, NEW BIOL, V4, P369; ROBINSON HL, 1990, J VIROL, V64, P4836, DOI 10.1128/JVI.64.10.4836-4841.1990; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; RUBEN S, 1989, J VIROL, V63, P1; SAKAI H, 1993, J VIROL, V67, P1169, DOI 10.1128/JVI.67.3.1169-1174.1993; SATO H, 1992, VIROLOGY, V186, P712, DOI 10.1016/0042-6822(92)90038-Q; SAVAGEAU MA, 1991, NEW BIOL, V3, P190; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SENGUPTA DN, 1990, P NATL ACAD SCI USA, V87, P7492, DOI 10.1073/pnas.87.19.7492; SIEGEL LJ, 1986, VIROLOGY, V148, P226; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; TOYAMA R, 1992, NUCLEIC ACIDS RES, V20, P2591, DOI 10.1093/nar/20.10.2591; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	56	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24940	24949						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227056				2022-12-25	WOS:A1993MG67300064
J	KAMBAYASHI, Y; BARDHAN, S; TAKAHASHI, K; TSUZUKI, S; INUI, H; HAMAKUBO, T; INAGAMI, T				KAMBAYASHI, Y; BARDHAN, S; TAKAHASHI, K; TSUZUKI, S; INUI, H; HAMAKUBO, T; INAGAMI, T			MOLECULAR-CLONING OF A NOVEL ANGIOTENSIN-II RECEPTOR ISOFORM INVOLVED IN PHOSPHOTYROSINE PHOSPHATASE INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AT2 BINDING-SITES; RAT-BRAIN; TYPE-1 RECEPTOR; TUMOR-CELLS; SUBTYPES; EXPRESSION; PROTEIN; IDENTIFICATION; MECHANISMS; DOMAINS	There are two major isoforms of the angiotensin II receptor, type 1 (AT1) and type 2 (AT2). AT2 is distinguished from AT1 with respect to its ligand selectivity, its insensitivity to non-hydrolyzable GTP analogues, and its as yet unidentified biological functions. In the present study we have expression-cloned AT2 cDNA from a cDNA library of a rat pheochromocytoma cell line (PC12w). Rat AT2 cDNA encodes a 363-amino acid protein that has seven transmembrane domains. AT, is the closest in homology to AT2 but with only a 32% identity of amino acid sequence. Stably expressed in COS-7 cells, the receptor showed selective binding to AT2-specific ligands PD123319 and CGP42112A but not to the AT1-specific ligand, losartan. Northern blot analysis revealed that the mRNA of rat AT2 was expressed not only in PC12w cells but also in the adrenal glands and in the inferior olive of the brain, both of which are known to contain AT2 type binding sites. The expressed AT2 receptor mediated angiotensin II-induced inhibition of protein tyrosine phosphatase, an action that was dependent on a pertussis toxin-sensitive G-protein-coupled mechanism in COS-7 cells. The AT2-specific ligand CGP42112A was an agonist rather than antagonist in the inhibition of phosphotyrosine phosphatase. AT2 did not cause a decrease in cGMP in PC12w or COS-7 cells expressing AT2 stably. These results indicate that the AT2 receptor is structurally and functionally different from AT1 and suggest novel functional roles of the renin-angiotensin system in cross-talk with phosphotyrosine signaling by modulating protein phosphotyrosine levels.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232	Vanderbilt University			Inui, Hiroshi/C-7721-2011	Tsuzuki, Satoshi/0000-0003-4385-0075	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014192, R01HL035323, T32HL007323] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35323, HL14192, HL07323] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOTTARI SP, 1991, EUR J PHARM-MOLEC PH, V207, P157, DOI 10.1016/0922-4106(91)90091-U; BOTTARI SP, 1992, BIOCHEM BIOPH RES CO, V183, P206, DOI 10.1016/0006-291X(92)91629-5; BRECHLER V, 1993, REGUL PEPTIDES, V44, P207, DOI 10.1016/0167-0115(93)90244-3; CATT KJ, 1987, J STEROID BIOCHEM, V27, P915, DOI 10.1016/0022-4731(87)90168-3; CHIU AT, 1989, BIOCHEM BIOPH RES CO, V165, P196, DOI 10.1016/0006-291X(89)91054-1; DUDLEY DT, 1991, MOL PHARMACOL, V40, P360; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; DUDLEY DT, 1991, FASEB J, V5, pA869; ELTON TS, 1992, BIOCHEM BIOPH RES CO, V184, P1067, DOI 10.1016/0006-291X(92)90700-U; FLORIO T, 1992, J BIOL CHEM, V267, P24169; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; IWAI N, 1991, BIOCHEM BIOPH RES CO, V177, P299, DOI 10.1016/0006-291X(91)91982-I; IWAI N, 1992, FEBS LETT, V298, P257, DOI 10.1016/0014-5793(92)80071-N; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JONES C, 1989, PEPTIDES, V10, P459, DOI 10.1016/0196-9781(89)90059-4; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V183, P1090, DOI 10.1016/S0006-291X(05)80302-X; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEUNG KH, 1992, EUR J PHARM-MOLEC PH, V227, P63, DOI 10.1016/0922-4106(92)90143-J; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PEACH MJ, 1981, BIOCHEM PHARMACOL, V30, P2745, DOI 10.1016/0006-2952(81)90410-X; PUCELL AG, 1991, ENDOCRINOLOGY, V128, P1947, DOI 10.1210/endo-128-4-1947; ROWE BP, 1992, NEUROENDOCRINOLOGY, V55, P563, DOI 10.1159/000126177; SANDBERG K, 1992, J BIOL CHEM, V267, P9455; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5663; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SPETH RC, 1990, BIOCHEM BIOPH RES CO, V169, P997, DOI 10.1016/0006-291X(90)91993-3; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; SUMNERS C, 1991, P NATL ACAD SCI USA, V88, P7567, DOI 10.1073/pnas.88.17.7567; TANAKA I, 1984, BIOCHEM BIOPH RES CO, V124, P663, DOI 10.1016/0006-291X(84)91606-1; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TSUTSUMI K, 1992, MOL PHARMACOL, V41, P290; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pR209, DOI 10.1152/ajpregu.1991.261.1.R209; WEBB ML, 1992, PEPTIDES, V13, P499, DOI 10.1016/0196-9781(92)90081-D; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	38	676	681	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24543	24546						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227011				2022-12-25	WOS:A1993MG67300008
J	SARCEVIC, B; ERIKSON, E; MALLER, JL				SARCEVIC, B; ERIKSON, E; MALLER, JL			PURIFICATION AND CHARACTERIZATION OF A MITOGEN-ACTIVATED PROTEIN-KINASE TYROSINE PHOSPHATASE FROM XENOPUS EGGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MAP KINASE; SIGNAL TRANSDUCTION; HUMAN-PLACENTA; CELL-CYCLE; PHOSPHORYLATION; THREONINE; INSULIN; ACID; QUANTITIES	The mitogen-activated protein (MAP) kinases are serine-threonine protein kinases that are activated by tyrosine and threonine phosphorylation by the dual specificity protein kinase MEK (MAP kinase/ERK kinase). The present report describes the purification to near homogeneity and characterization of a protein tyrosine phosphatase from Xenopus laevis eggs that dephosphorylates MAP kinase phosphorylated by MEK. Bacterially expressed Xenopus MAP kinase phosphorylated by purified Xenopus MEK was used as substrate throughout the purification. The purification procedure included anion-exchange, cation-exchange, gel filtration, heparin-Sepharose, and chromatography on a column of thiophosphorylated MAP kinase-Sepharose, resulting in a >3000-fold purification. Upon analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, a protein of 47 kDa correlated with activity. The phosphatase showed absolute specificity toward phosphotyrosine and no activity toward phosphothreonyl-phosphoseryl residues of MAP kinase. The pH optimum of the enzyme was 7.0 with a K(m) of 9.0 muM for phosphorylated MAP kinase. The phosphatase was inhibited by ammonium molybdate (IC50, 2 muM), vanadate (IC50, 250 muM), millimolar concentrations of MnCl2, ZnCl2 and p-nitrophenylphosphate but not by okadaic acid or microcystin. This tyrosine phosphatase may be involved in deactivating MAP kinase in vivo.	UNIV COLORADO, SCH MED, HOWARD HUGHES MED INST, DENVER, CO 80262 USA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Sarcevic, Boris/0000-0002-8063-1050				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; POTTS M, 1993, J BIOL CHEM, V268, P7632; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SETH A, 1992, J BIOL CHEM, V267, P24796; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPHO, V23, P1; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217	49	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25075	25083						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227071				2022-12-25	WOS:A1993MG67300082
J	WANG, W; SUPRENANT, K; DENTLER, WL				WANG, W; SUPRENANT, K; DENTLER, WL			REVERSIBLE ASSOCIATION OF A 97-KDA PROTEIN COMPLEX FOUND AT THE TIPS OF CILIARY MICROTUBULES WITH IN-VITRO ASSEMBLED MICROTUBULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-TUBULIN; STRUCTURAL POLARITY; DYNAMIC INSTABILITY; CAPPING STRUCTURES; KINETOCHORE MICROTUBULES; FLAGELLAR MICROTUBULES; ASPERGILLUS-NIDULANS; BACTERIAL FLAGELLA; TETRAHYMENA CILIA; MITOTIC SPINDLE	Using a human autoimmune CREST antiserum, we identified a 97-kDa polypeptide in Tetrahymena cilia at the plus ends of ciliary microtubules and mammalian kinetochores (Miller, J. M., Wang, W., Balczon, R., and Dentler, W. L. (1990) J. Cell Biol. 110, 703-714). In this study, we examined the interactions of the ciliary 97-kDa protein with microtubules assembled from purified bovine brain tubulin. The 97-kDa protein binds to microtubules and is released from them with 75 mM MgCl2, the same condition used to release it from ciliary microtubules. The 97-kDa protein-microtubule association can be disrupted by ATP and by adenosine 5'-O-(thiotriphosphate), and this ATP sensitivity requires a soluble factor in the crude 97-kDa protein fraction. Fractionation of the crude 97-kDa protein fractions by gel filtration chromatography or by sucrose gradient centrifugation causes the loss of the microtubule binding activity of the 97-kDa protein. Fractions containing a high molecular weight protein complex (molecular mass, approximately 1500-2000 kDa) from the column or gradient fractions can restore the microtubule binding ability of the 97-kDa protein. These results suggest that the 97-kDa protein is part of a high molecular weight protein complex and that the complex, not the 97-kDa protein alone, is required for the 97-kDa protein-microtubule association. The association of the 97-kDa protein with microtubules is sensitive to ATP, which suggests that the 97-kDa protein-microtubule interaction may be regulated by an ATPase(s) or protein kinase(s)/phosphatase(s).			WANG, W (corresponding author), UNIV KANSAS, DEPT PHYSIOL & CELL BIOL, LAWRENCE, KS 66045 USA.				NIGMS NIH HHS [GM32556] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032556] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALGAIER J, 1988, BIOCHIM BIOPHYS ACTA, V954, P235, DOI 10.1016/0167-4838(88)90078-7; ALLEN C, 1974, J MOL BIOL, V90, P381, DOI 10.1016/0022-2836(74)90381-7; BAAS PW, 1992, J CELL BIOL, V116, P1231, DOI 10.1083/jcb.116.5.1231; BAAS PW, 1987, P NATL ACAD SCI USA, V84, P5272, DOI 10.1073/pnas.84.15.5272; BAYLEY PM, 1990, J CELL SCI, V95, P329; BERGEN LG, 1980, J CELL BIOL, V84, P141, DOI 10.1083/jcb.84.1.141; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; Dentler W.L., 1990, P31; DENTLER WL, 1977, J CELL BIOL, V74, P747, DOI 10.1083/jcb.74.3.747; DENTLER WL, 1988, J CELL BIOL, V107, P2679, DOI 10.1083/jcb.107.6.2679; DENTLER WL, 1987, INT REV CYTOL, P391; DENTLER WL, 1980, J CELL SCI, V42, P207; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EMERSON SU, 1970, SCIENCE, V169, P190, DOI 10.1126/science.169.3941.190; EUTENEUER U, 1981, J CELL BIOL, V89, P338, DOI 10.1083/jcb.89.2.338; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; GORBSKY GJ, 1988, J CELL BIOL, V106, P1185, DOI 10.1083/jcb.106.4.1185; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; GROBSKY GJ, 1992, MOL BIOL CELL S, V3, pA344; HARLOW E, 1988, ANTIBODIES LABORATOR; HEIDEMANN SR, 1980, NATURE, V286, P517, DOI 10.1038/286517a0; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HYMAN AA, 1990, J CELL BIOL, V110, P1607, DOI 10.1083/jcb.110.5.1607; IINO T, 1969, J GEN MICROBIOL, V56, P227, DOI 10.1099/00221287-56-2-227; IKEDA T, 1985, J MOL BIOL, V184, P735, DOI 10.1016/0022-2836(85)90317-1; IKEDA T, 1987, J BACTERIOL, V169, P1168, DOI 10.1128/jb.169.3.1168-1173.1987; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P306; JOHNSON KA, 1992, J CELL BIOL, V119, P1605, DOI 10.1083/jcb.119.6.1605; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KIMBLE M, 1992, INT REV CYTOL, V136, P1, DOI 10.1016/S0074-7696(08)62049-5; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; LUCK DJL, 1984, J CELL BIOL, V98, P789, DOI 10.1083/jcb.98.3.789; MAEKAWA T, 1991, EUR J CELL BIOL, V54, P255; MILLER JM, 1990, J CELL BIOL, V110, P703, DOI 10.1083/jcb.110.3.703; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cellbio.4.1.527; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MITCHSON TJ, 1987, MOD CELL BIOL, V5, P11; NAMBA K, 1989, NATURE, V342, P648, DOI 10.1038/342648a0; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; PORTMAN RW, 1987, J CELL SCI, V87, P85; ROSENBAU.JL, 1969, J CELL BIOL, V41, P600, DOI 10.1083/jcb.41.2.600; Salmon ED, 1989, MITOSIS MOL MECHANIS, P119; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; SELLITTO C, 1992, CELL MOTIL CYTOSKEL, V22, P7, DOI 10.1002/cm.970220103; SHELDEN E, 1992, J CELL BIOL, V116, P1409, DOI 10.1083/jcb.116.6.1409; SOLTYS BJ, 1985, J CELL BIOL, V100, P1682, DOI 10.1083/jcb.100.5.1682; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; SUPRENANT KA, 1988, J CELL BIOL, V107, P2259, DOI 10.1083/jcb.107.6.2259; VALDIVIA MM, 1985, J CELL BIOL, V101, P1124, DOI 10.1083/jcb.101.3.1124; Witman G.B., 1990, P1; WITMAN GB, 1975, ANN NY ACAD SCI, V253, P178, DOI 10.1111/j.1749-6632.1975.tb19199.x	58	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24796	24807						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227041				2022-12-25	WOS:A1993MG67300044
J	ATTALI, B; LESAGE, F; ZILIANI, P; GUILLEMARE, E; HONORE, E; WALDMANN, R; HUGNOT, JP; MATTEI, MG; LAZDUNSKI, M; BARHANIN, J				ATTALI, B; LESAGE, F; ZILIANI, P; GUILLEMARE, E; HONORE, E; WALDMANN, R; HUGNOT, JP; MATTEI, MG; LAZDUNSKI, M; BARHANIN, J			MULTIPLE MESSENGER-RNA ISOFORMS ENCODING THE MOUSE CARDIAC KV1-5 DELAYED RECTIFIER K+ CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT POTASSIUM CHANNELS; HUMAN LYMPHOCYTES-T; FUNCTIONAL EXPRESSION; ION CHANNELS; DEVELOPMENTAL EXPRESSION; CHROMOSOMAL LOCALIZATION; MOLECULAR-CLONING; RAT-BRAIN; GENE; PROTEIN	The mouse Kv1-5 K+ channel cDNA has been cloned from heart. This channel was highly expressed in heart and, to a lesser extent, in other tissues, including brain and thymus. Two alternatively spliced isoforms were found. The longer form encoded a 602-amino acid protein, while in the short form (Kv1-5DELTA5'), the first 200 amino acids lying upstream the transmembrane segment S1 were deleted. RNase protection experiments showed that both Kv1-5 mRNA isoforms are present in the mouse tissues examined, the longer form being predominant. The short mRNA (Kv1-5DELTA5') arose by an unusual splicing event within the exonic sequence. An additional short cDNA clone (Kv1-5DELTA3') that codes for a carboxyl-terminal truncated protein has been isolated. The gene coding sequence contained a single exon and has been mapped on human chromosome 12 (p13) and on mouse chromosome 6 (band F). Expression in Xenopus oocytes revealed that the long (Kv1-5) and the amino-terminal deleted (Kv1-5DELTA5') isoforms elicited similar K+ currents with a drastically decreased efficacy for Kv1-5DELTA5'. The carboxyl-terminal truncated Kv1-5DELTA3' clone was not functional but inhibited the expression of the long isoform.	INST PHARMACOL MOLEC & CELLULAIRE,660 ROUTE LUCIOLES,SOPHIA ANTIPOLIS,F-06560 VALBONNE,FRANCE; HOP ENFANTS LA TIMONE,CTR GENET MED PHYSIOPATHOL CHROMOSOM,F-13385 MARSEILLE 05,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			Lesage, Florian/D-5097-2011; Lesage, Florian/P-9780-2019; Waldmann, Rainer/Q-2108-2016	Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106; Waldmann, Rainer/0000-0002-4599-2926; HONORE, Eric/0000-0002-8007-0919				ALDRICH R, 1993, NATURE, V362, P107, DOI 10.1038/362107a0; ATTALI B, 1992, J BIOL CHEM, V267, P8650; ATTALI B, 1992, FEBS LETT, V303, P229, DOI 10.1016/0014-5793(92)80526-M; BARRES BA, 1990, ANNU REV NEUROSCI, V13, P441, DOI 10.1146/annurev.neuro.13.1.441; BLUMENTHAL EM, 1992, NEUROCHEM RES, V17, P869, DOI 10.1007/BF00993262; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK NS, 1989, POTASSIUM CHANNELS S, P182; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; CURRAN ME, 1992, GENOMICS, V12, P729, DOI 10.1016/0888-7543(92)90302-9; DOUGLASS J, 1990, J IMMUNOL, V144, P4841; FISBURN CS, 1993, J BIOL CHEM, V268, P5872; GISSELMANN G, 1989, EMBO J, V8, P2359, DOI 10.1002/j.1460-2075.1989.tb08364.x; GRISSMER S, 1992, J BIOL CHEM, V267, P20971; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOGER JH, 1991, NEURON, V6, P227, DOI 10.1016/0896-6273(91)90358-7; HONORE E, 1992, EMBO J, V11, P2465, DOI 10.1002/j.1460-2075.1992.tb05311.x; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; KACZMAREK LK, 1991, NEW BIOL, V3, P315; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUOB Y, 1993, NATURE, V362, P127; LESAGE F, 1992, FEBS LETT, V310, P162, DOI 10.1016/0014-5793(92)81320-L; LEWIS RS, 1988, TRENDS NEUROSCI, V11, P214, DOI 10.1016/0166-2236(88)90129-4; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LUNEAU CJ, 1991, P NATL ACAD SCI USA, V88, P3932, DOI 10.1073/pnas.88.9.3932; MATSUBARA H, 1991, J BIOL CHEM, V266, P13324; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MCPHERSON JD, 1991, CYTOGENET CELL GENET, V58, P1979; MORAN O, 1992, FEBS LETT, V302, P21, DOI 10.1016/0014-5793(92)80275-L; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OKADA H, 1992, BIOCHEM BIOPH RES CO, V189, P430, DOI 10.1016/0006-291X(92)91576-C; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; RETTIG J, 1992, EMBO J, V11, P2473, DOI 10.1002/j.1460-2075.1992.tb05312.x; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; ROBERDS SL, 1991, FEBS LETT, V284, P152, DOI 10.1016/0014-5793(91)80673-Q; RUDY B, 1991, Molecular and Cellular Neuroscience, V2, P89, DOI 10.1016/1044-7431(91)90001-5; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SNYDERS DJ, 1993, J GEN PHYSIOL, V101, P513, DOI 10.1085/jgp.101.4.513; SPENCER R, 1992, FASEB J, V6, pA378; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TAMKUN MM, 1991, FASEB J, V5, P331, DOI 10.1096/fasebj.5.3.2001794; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0	51	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24283	24289						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226976				2022-12-25	WOS:A1993MF29400085
J	BLASCO, MA; LAZARO, JM; BLANCO, L; SALAS, M				BLASCO, MA; LAZARO, JM; BLANCO, L; SALAS, M			PHI-29 DNA-POLYMERASE ACTIVE-SITE - RESIDUE ASP(249) OF CONSERVED AMINO-ACID MOTIF DX(2)SLYP IS CRITICAL FOR SYNTHETIC ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; TERMINAL PROTEIN; ESCHERICHIA-COLI; REVERSE-TRANSCRIPTASE; DIRECTED MUTAGENESIS; EXONUCLEASE ACTIVITY; SECONDARY-STRUCTURE; DNTP BINDING; VIRUS; MUTANTS	Phi29 DNA polymerase shares with other alpha-like DNA polymerases several regions of amino acid sequence similarity and sensitivity to inhibitors of eukaryotic DNA polymerase alpha. In this paper, site-directed mutants in the phi29 DNA polymerase residues Asp249, Ser252, Leu253, and Pro255 of the conserved amino acid motif ''Dx2SLYP'' are described. Two mutants, D249E and S252R, were drastically affected in all the synthetic activities, whereas their 3' to 5' exonuclease activity and interaction with the TP primer was normal. Mutant D249E, slightly affected in template-primer binding, was completely inactive in all conditions tested, suggesting that Asp249 Could be playing a direct role in catalysis. On the other hand, mutant S252R, strongly affected in template-primer binding, showed some DNA polymerization activity in the presence of Mn2+. Mutants S252G and P255S showed a reduced template-primer binding ability; these mutants, together with mutant L253V, showed metal ion-dependent phenotypes in their synthetic activities and altered sensitivities to the PP(i) analog phosphonoacetic acid. All these results support the hypothesis that the Dx2SLYP motif forms part of the polymerization active site of the phi29 DNA polymerase, being the Asp249 residue critical both for protein-primed initiation and DNA polymerization.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Salas, Margarita/J-9873-2014; Blasco, Maria A./M-1694-2014	Salas, Margarita/0000-0001-5939-3441; Blasco, Maria A./0000-0002-4211-233X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01 GM27242-13] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BLANCO L, 1985, NUCLEIC ACIDS RES, V13, P1239, DOI 10.1093/nar/13.4.1239; BLANCO L, 1985, P NATL ACAD SCI USA, V82, P6404, DOI 10.1073/pnas.82.19.6404; BLANCO L, 1989, J BIOL CHEM, V264, P8935; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BLANCO L, 1986, VIROLOGY, V153, P179, DOI 10.1016/0042-6822(86)90021-8; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; BLANCO L, 1992, J BIOL CHEM, V267, P1225; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BLASCO MA, 1993, J BIOL CHEM, V268, P16763; BLASCO MA, 1991, J BIOL CHEM, V266, P7904; BLASCO MA, 1990, NUCLEIC ACIDS RES, V18, P4763; BLASCO MA, 1992, CHROMOSOMA, V102, P32; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; GARMENDIA C, 1992, J BIOL CHEM, V267, P2594; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBBS JS, 1988, P NATL ACAD SCI USA, V85, P6672, DOI 10.1073/pnas.85.18.6672; HALL JD, 1989, NUCLEIC ACIDS RES, V17, P9231, DOI 10.1093/nar/17.22.9231; HWANG CBC, 1992, J VIROL, V66, P1774, DOI 10.1128/JVI.66.3.1774-1776.1992; INCIARTE MR, 1976, VIROLOGY, V74, P314, DOI 10.1016/0042-6822(76)90338-X; INOKUCHI Y, 1987, J VIROL, V61, P3946, DOI 10.1128/JVI.61.12.3946-3949.1987; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JABLONSKI SA, 1991, J VIROL, V65, P4565, DOI 10.1128/JVI.65.9.4565-4572.1991; JUNG GH, 1990, BIOCHEM BIOPH RES CO, V170, P1294, DOI 10.1016/0006-291X(90)90534-T; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; MARCY AI, 1990, J VIROL, V64, P5883, DOI 10.1128/JVI.64.12.5883-5890.1990; MATSUMOTO K, 1990, VIROLOGY, V178, P337, DOI 10.1016/0042-6822(90)90416-O; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; RIBAS JC, 1992, P NATL ACAD SCI USA, V89, P2185, DOI 10.1073/pnas.89.6.2185; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SANKAR S, 1992, J BIOL CHEM, V267, P10168; SOENGAS MS, 1992, EMBO J, V11, P4227, DOI 10.1002/j.1460-2075.1992.tb05517.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WATABE K, 1984, BIOCHEM BIOPH RES CO, V123, P1019, DOI 10.1016/S0006-291X(84)80235-1; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; ZABALLOS A, 1989, GENE, V83, P187, DOI 10.1016/0378-1119(89)90104-2	49	46	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24106	24113						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226957				2022-12-25	WOS:A1993MF29400061
J	PORTER, DJT; AUSTIN, EA				PORTER, DJT; AUSTIN, EA			CYTOSINE DEAMINASE - THE ROLES OF DIVALENT METAL-IONS IN CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ADENOSINE-DEAMINASE; PURIFICATION; 5-FLUOROCYTOSINE; COMPOUND; GENE	Cytosine deaminase (CDase, EC 3.5.4.1) isolated from Escherichia coli contains a catalytically essential divalent metal ion. Fe2+ was efficiently removed from the enzyme with o-phenanthroline to yield an apoenzyme with less than 5% of the catalytic activity of native enzyme. The time courses for inactivation and for removal of Fe2+ from the enzyme by o-phenanthroline were similar. Apoenzyme reconstituted with Fe2+, Mn2+, Co2+, or Zn2+ (M2+CDase) had k(cat) values of 185, 88, 50, and 32 s-1, respectively. The K(m) values of these M2+CDases for cytosine were similar (0.22-0.39 mM). Cytosine potently inhibited reconstitution of the apoenzyme with Fe2+. Fe2+CDase was rapidly inactivated by 1 mM H2O2 (t1/2 < 1 s), whereas Mn2+CDase, Co2+CDase, and Zn2+CDase were not inactivated by H2O2. CDase was also inhibited by excess divalent cations. Cu2+ and Zn2+ reversibly inhibited Fe2+CDase activity with inhibition constants of 1.8 and 5.8 muM, respectively. Cu2+ dissociated slowly from the secondary binding on CDase with a rate constant of 2 x 10(-3) s-1.	WELLCOME RES LABS,DEPT CELL BIOL,RES TRIANGLE PK,NC 27709	Wellcome Research Laboratories	PORTER, DJT (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,3030 CORNWALLIS RD,RES TRIANGLE PK,NC 27709, USA.							AUSTIN EA, 1993, MOL PHARMACOL, V43, P380; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DANIELSEN S, 1992, MOL MICROBIOL, V6, P1335, DOI 10.1111/j.1365-2958.1992.tb00854.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; KATSURAGI T, 1989, AGR BIOL CHEM TOKYO, V53, P1313, DOI 10.1080/00021369.1989.10869490; KATSURAGI T, 1986, AGR BIOL CHEM TOKYO, V50, P1721, DOI 10.1080/00021369.1986.10867657; KURZ LC, 1992, BIOCHEMISTRY-US, V31, P39, DOI 10.1021/bi00116a008; MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33; NISHIYAMA T, 1985, CANCER RES, V45, P1753; ROMAN R, 1972, BIOCHEMISTRY-US, V11, P2076, DOI 10.1021/bi00761a013; SAKAI T, 1975, AGR BIOL CHEM TOKYO, V39, P1623, DOI 10.1080/00021369.1975.10861834; SAKAI T, 1975, AGR BIOL CHEM TOKYO, V39, P2015, DOI 10.1080/00021369.1975.10861902; STEER PL, 1972, ANN INTERN MED, V76, P15, DOI 10.7326/0003-4819-76-1-15; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WEST TP, 1982, BIOCHIM BIOPHYS ACTA, V719, P251, DOI 10.1016/0304-4165(82)90096-4; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; YANG C, 1992, BIOCHEMISTRY-US, V31, P4168, DOI 10.1021/bi00132a003; YU TS, 1991, J FERMENT BIOENG, V72, P266, DOI 10.1016/0922-338X(91)90161-9	19	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24005	24011						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226944				2022-12-25	WOS:A1993MF29400047
J	RYAN, KR; JENSEN, RE				RYAN, KR; JENSEN, RE			MAS6P CAN BE CROSS-LINKED TO AN ARRESTED PRECURSOR AND INTERACTS WITH OTHER PROTEINS DURING MITOCHONDRIAL PROTEIN IMPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOCHROME C1 PRESEQUENCE; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; INNER MEMBRANE; MATRIX; CLEAVAGE; SUFFICIENT; SITE	Mas6p is an integral membrane protein of the yeast mitochondrial inner membrane, which is essential for mitochondrial protein import (1). To determine whether Mas6p is directly involved in recognizing precursors or translocating them across the inner membrane, we asked if Mas6p was in close proximity to precursor proteins being imported into mitochondria. We report here that Mas6p can be chemically cross-linked to an imported protein arrested in transit through the mitochondrial inner membrane. Antiserum to Mas6p specifically immunoprecipitates one of several different mitochondrial proteins that are cross-linked to blocked precursors. Our results strongly suggest that Mas6p physically interacts with precursors during their translocation into the matrix. In addition, at least two other mitochondrial proteins that are each cross-linked to arrested precursors can be coimmunoprecipitated along with Mas6p under non-denaturing conditions. These observations provide evidence for a complex of proteins including Mas6p, each of which interacts with mitochondrial precursors during import.	JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, 725 N WOLFE ST, BALTIMORE, MD 21205 USA	Johns Hopkins University					NIGMS NIH HHS [1-RO1-GM46803, GM07309] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046803] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; DAUM G, 1982, J BIOL CHEM, V257, P3028; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HURT EC, 1984, FEBS LETT, V178, P306, DOI 10.1016/0014-5793(84)80622-5; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; HWANG ST, 1991, J BIOL CHEM, V266, P21083; JENSEN RE, 1992, MOL CELL BIOL, V12, P4677, DOI 10.1128/MCB.12.10.4677; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; MASON TL, 1973, J BIOL CHEM, V248, P1346; MCADA PC, 1982, J BIOL CHEM, V257, P3177; OHBA M, 1987, EMBO J, V6, P2117, DOI 10.1002/j.1460-2075.1987.tb02478.x; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; ROSE MD, 1988, METHODS YEAST GENETI; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SHERMAN F, 1964, GENETICS, V49, P39; Sherman F., 1982, METHODS YEAST GENETI; SMITH BL, 1991, J BIOL CHEM, V266, P6407; VANLOON APGM, 1987, EMBO J, V6, P2433, DOI 10.1002/j.1460-2075.1987.tb02522.x; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9	26	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23743	23746						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226901				2022-12-25	WOS:A1993MF29400003
J	DRISCOLL, WJ; MARTIN, BM; CHEN, HC; STROTT, CA				DRISCOLL, WJ; MARTIN, BM; CHEN, HC; STROTT, CA			ISOLATION OF 2 DISTINCT 3-HYDROXYSTEROID SULFOTRANSFERASES FROM THE GUINEA-PIG ADRENAL - EVIDENCE FOR 3-ALPHA-HYDROXY VERSUS 3-BETA-HYDROXY STEREOSPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNENOLONE-BINDING PROTEIN; ESTROGEN SULFOTRANSFERASE; POLYACRYLAMIDE GELS; RAT-LIVER; PURIFICATION; PHOSPHORYLATION; ANDROSTERONE	Two physically distinct hydroxysteroid sulfotransferases (HSTs) that demonstrate substrate specificity with respect to the orientation of the ring A 3-hydroxyl group have been isolated from the guinea pig adrenal gland. Nondenaturing liquid-phase isoelectric focusing permitted the separation of the activities, and reverse phase high performance liquid chromatography was used to purify the two proteins to homogeneity. The 3beta-HST had an apparent molecular mass of 33 kDa and utilized pregnenolone, 17-hydroxypregnenolone, and dehydroepiandrosterone as substrates. The 3alpha-HST was slightly smaller at 32 kDa and utilized allopregnanolone and androsterone as substrates. The proteins were further distinguished by isoelectric point, immunoreactivity, and tryptic peptide mapping. Peptides isolated from both guinea pig HSTs demonstrated significant amino acid sequence homology (approximately 65% identity) to rat liver HST; however, available sequence data from the two proteins did not yield differences that might account for their stereospecific substrate selectivity. This paper represents the first definitive report demonstrating the existence of discrete HSTs that exhibit substrate specificity based on the stereochemistry of the 3-hydroxyl group.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,ADRENAL CELL BIOL SECT,BETHESDA,MD 20892; NICHHD,ENDOCRINOL & REPROD RES BRANCH,MOLEC STRUCT & PROT CHEM,BETHESDA,MD 20892; NIMH,CLIN NEUROSCI BRANCH,MOLEC NEUROGENET SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ADAMS JB, 1988, MOL CELL ENDOCRINOL, V58, P231, DOI 10.1016/0303-7207(88)90159-1; ADAMS JB, 1974, BIOCHIM BIOPHYS ACTA, V370, P160, DOI 10.1016/0005-2744(74)90042-4; ADAMS JB, 1979, BIOCHIM BIOPHYS ACTA, V567, P144, DOI 10.1016/0005-2744(79)90181-5; Baird D T, 1969, Recent Prog Horm Res, V25, P611; BROOKS SC, 1978, J TOXICOL ENV HEALTH, V4, P283, DOI 10.1080/15287397809529662; DRISCOLL WJ, 1991, MOL ENDOCRINOL, V5, P1229, DOI 10.1210/mend-5-9-1229; FALANY CN, 1991, TRENDS PHARMACOL SCI, V12, P255, DOI 10.1016/0165-6147(91)90566-B; FALANY CN, 1989, BIOCHEM J, V260, P641, DOI 10.1042/bj2600641; FREEMAN DJ, 1983, J STEROID BIOCHEM, V18, P23, DOI 10.1016/0022-4731(83)90325-4; GLASIER MA, 1992, STEROIDS, V57, P295; HOBKIRK R, 1990, BIOCHEM J, V268, P759, DOI 10.1042/bj2680759; HOBKIRK R, 1985, CAN J BIOCHEM CELL B, V63, P1127, DOI 10.1139/o85-141; HOMMA H, 1991, CHEM PHARM BULL, V39, P1499; HUXTABLE RJ, 1986, BIOCH SULFUR, P316; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YC, 1990, P NATL ACAD SCI USA, V87, P2003, DOI 10.1073/pnas.87.5.2003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUI M, 1982, BIOCHEM J, V204, P441, DOI 10.1042/bj2040441; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Mulder G.J., 1990, CONJUGATION REACTION, P107; OGURA K, 1989, BIOCHEM BIOPH RES CO, V165, P168, DOI 10.1016/0006-291X(89)91050-4; OHL VS, 1977, ARCH BIOCHEM BIOPHYS, V180, P186, DOI 10.1016/0003-9861(77)90024-8; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; ROBERTS KD, 1970, CHEM BIOL ASPECTS ST, P219; Roy A.B., 1981, SULFATION DRUGS RELA, P83; SIGEL MB, 1983, METHOD ENZYMOL, V93, P3; STROTT CA, 1983, J STEROID BIOCHEM, V18, P489, DOI 10.1016/0022-4731(83)90070-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Webb E. C., 1992, ENZYME NOMENCLATURE	29	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23496	23503						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226877				2022-12-25	WOS:A1993MF51500083
J	KONG, HY; RAYNOR, K; YASUDA, K; MOE, ST; PORTOGHESE, PS; BELL, GI; REISINE, T				KONG, HY; RAYNOR, K; YASUDA, K; MOE, ST; PORTOGHESE, PS; BELL, GI; REISINE, T			A SINGLE RESIDUE, ASPARTIC ACID-95, IN THE DELTA-OPIOID RECEPTOR SPECIFIES SELECTIVE HIGH-AFFINITY AGONIST BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CLONING; IDENTIFICATION; NALTRINDOLE; ANTAGONIST; PEPTIDES; SODIUM	The enkephalins, dynorphins, and endorphins are endogenous opioids which function as neurotransmitters, neuromodulators, and hormones and are involved in the perception of pain, modulation of behavior, and regulation of autonomic and neuroendocrine function. Pharmacological studies have defined three classes of opioid receptors, designated as delta, kappa, and mu. To investigate mechanisms by which agonists and antagonists interact with the delta opioid receptor, we have substituted aspartic acid 95 in the transmembrane segment 2 of the cloned mouse delta opioid receptor with an asparagine (D95N). The D95N mutant receptor had reduced affinity for delta receptor-selective agonists such as enkephalin, [D-Pen2,D-Pen5]enkephalin and [D-Ser2,Leu5]enkephalin-Thr6 such that it did not bind these peptides even at micromolar concentrations. The binding of delta-selective non-peptide agonists was also reduced. In contrast, the delta receptor-selective antagonists, such as naltrindole, the benzofuran analog of naltrindole, and 7-benyllidenenaltrexone, bound equally well to the wild-type and mutant receptor. Similarly, non-selective opioid agonists such as bremazocine and buprenorphine, which interact with delta, kappa, and mu opioid receptors, showed no difference in binding to the wild-type and mutant delta receptor. The D95N mutant remained coupled to G proteins, and the receptor was functionally active since it mediated agonist inhibition of cAMP accumulation. These results indicate that selective agonists and antagonists bind differently to the delta receptor and show that Asp-95 contributes to high affinity delta-selective agonist binding. The identification of a key residue involved in selective agonist binding to the delta opioid receptor will facilitate the development of novel therapeutic reagents that can be used for the treatment of chronic pain and other conditions.	UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV MINNESOTA,DEPT MED CHEM,MINNEAPOLIS,MN 55455	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Minnesota System; University of Minnesota Twin Cities	KONG, HY (corresponding author), UNIV PENN,SCH MED,DEPT PHARMACOL,36TH ST & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048518] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48518, MH45533] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARAKAWA K, 1992, TRANSPLANTATION, V53, P952; CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; COWAN A, 1993, IN PRESS BUPRENORPHI; ERSPAMER V, 1989, P NATL ACAD SCI USA, V86, P5188, DOI 10.1073/pnas.86.13.5188; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FROEHLICH J, 1991, RES SOC ALCOHOLISM S; GACEI G, 1980, FEBS LETT, V118, P245, DOI 10.1016/0014-5793(80)80229-8; GILMAN AG, 1990, PHARMACOL BASIS, P485; HERZ A, 1993, OPIOIDS, V1, P6; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KONG H, 1993, IN PRESS MOL PHARM; KOOB G, 1992, SCIENCE, V242, P715; LEE PH, 1992, INT NARCOTICS RES C; MENKENS K, 1992, EUR J PHARMACOL, V219, P345, DOI 10.1016/0014-2999(92)90319-Y; MOSBERG HI, 1983, P NATL ACAD SCI-BIOL, V80, P5871, DOI 10.1073/pnas.80.19.5871; PERT CB, 1974, MOL PHARMACOL, V10, P868; PORTOGHESE PS, 1992, EUR J PHARMACOL, V218, P195, DOI 10.1016/0014-2999(92)90167-3; SIMON EJ, 1991, MED RES REV, V11, P357, DOI 10.1002/med.2610110402; SOFUOGLU M, 1991, J PHARMACOL EXP THER, V257, P676; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; YASUDA K, 1992, J BIOL CHEM, V267, P20422	23	176	180	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23055	23058						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226821				2022-12-25	WOS:A1993MF51500017
J	TSUNESHIGE, A; ZHOU, YX; YONETANI, T				TSUNESHIGE, A; ZHOU, YX; YONETANI, T			OXYGEN EQUILIBRIUM STUDIES OF CROSS-LINKED IRON-COBALT HYBRID HEMOGLOBINS - MODELS FOR PARTIALLY LIGATED INTERMEDIATES OF COBALT HEMOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; COOPERATIVE FREE-ENERGIES; EXPERIMENTAL RESOLUTION; QUATERNARY STRUCTURE; CARBON-MONOXIDE; MOLECULAR CODE; COBALTOHEMOGLOBIN; COBOGLOBINS; MYOGLOBINS; LINKAGE	To probe the molecular mechanism of allosteric function of cobaltous protoporphyrin-substituted hemoglobin (CoHb), a series of alpha, alpha-cross-linked symmetric and asymmetric Fe-Co hybrid hemoglobins, which contain (1Co porphyrin/3Fe porphyrins), (2Co porphyrins/2Fe porphyrins), and (3Co porphyrins/1Fe porphyrin) per tetramer, have been prepared. Because only Fe porphyrin-containing subunits react with CO, these Fe-Co hybrids are converted to mono-, di-, and tri-CO-ligated states in the presence of CO, respectively, and are proposed to stand as models for mono-, di-, and tri-ligated intermediates of CoHb, respectively. The oxygen binding properties of these Fe-Co hybrids were investigated by measuring oxygen binding isotherms in the presence of CO as a function of pH in the presence and absence of IHP. The ligation of CO to a beta subunit causes larger changes in the oxygen affinity and the Bohr effect than that to an alpha subunit, indicating that the ligation to a beta subunit induces larger affinity-related structural changes in cross-linked CoHb. Di- and tri-CO-ligated intermediates exhibited substantially increased oxygen affinity, reduced Bohr effect, and reduced IHP effect, indicating that they are in high affinity states. Calculation of the Adair equilibrium constants for the first and last oxygenation steps for each of these intermediates permitted the determination of the level of free energy of cooperation. The intermediately ligated species of cross-linked CoHb are distributed in multiple levels of free energy of cooperation within the free energy difference of 1.14 kcal mol-1 between deoxy and fully ligated states of cross-linked CoHb at pH 7.4. The ligation process in CoHb is determined by the number and distribution of the bound ligands, and ligation takes place through steps that require minimal free energy changes.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; TSING HUA UNIV,DEPT BIOL SCI & BIOTECHNOL,BEIJING 100084,PEOPLES R CHINA	University of Pennsylvania; Tsinghua University					NHLBI NIH HHS [HL14508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014508, R37HL014508] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; Adair GS, 1925, J BIOL CHEM, V63, P529; ARNONE A, 1974, NATURE, V249, P34, DOI 10.1038/249034a0; BERMAN M, 1971, ARCH BIOCHEM BIOPHYS, V145, P236; BRUNORI M, 1970, J MOL BIOL, V34, P357; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CASSOLY R, 1972, J BIOL CHEM, V247, P7332; CHATTERJEE R, 1986, J BIOL CHEM, V261, P9929; DAUGHERTY MA, 1991, P NATL ACAD SCI USA, V88, P1110, DOI 10.1073/pnas.88.4.1110; DICKINSON LC, 1973, J BIOL CHEM, V248, P5005; DOYLE ML, 1991, BIOCHEMISTRY-US, V30, P7263, DOI 10.1021/bi00243a031; DRABKIN DL, 1946, J BIOL CHEM, V164, P703; FUJII M, 1993, J BIOL CHEM, V268, P15386; FUNG LWM, 1975, BIOCHEMISTRY-US, V14, P2526, DOI 10.1021/bi00682a036; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HOFFMAN BM, 1970, P NATL ACAD SCI USA, V67, P637, DOI 10.1073/pnas.67.2.637; HSU GC, 1972, P NATL ACAD SCI USA, V69, P2122, DOI 10.1073/pnas.69.8.2122; IKEDASAITO M, 1978, J BIOL CHEM, V253, P7134; IKEDASAITO M, 1980, J MOL BIOL, V138, P845, DOI 10.1016/0022-2836(80)90068-6; IKEDASAITO M, 1977, J BIOL CHEM, V252, P8639; IMAI K, 1977, J MOL BIOL, V109, P83, DOI 10.1016/S0022-2836(77)80047-8; IMAI K, 1981, BIOCHIM BIOPHYS ACTA, V668, P1, DOI 10.1016/0005-2795(81)90143-4; IMAI K, 1973, BIOCHEMISTRY-US, V12, P798, DOI 10.1021/bi00729a003; IMAI K, 1977, BIOCHIM BIOPHYS ACTA, V490, P164, DOI 10.1016/0005-2795(77)90116-7; Imai K., 1982, ALLOSTERIC EFFECTS H; INUBUSHI T, 1986, J AM CHEM SOC, V108, P3799, DOI 10.1021/ja00273a040; JOHNSON ME, 1974, BIOCHEMISTRY-US, V13, P3653, DOI 10.1021/bi00715a005; KILMARTIN JV, 1977, TRENDS BIOCHEM SCI, V2, P247, DOI 10.1016/0968-0004(77)90214-6; KILMARTIN JV, 1973, P NATL ACAD SCI USA, V70, P1246, DOI 10.1073/pnas.70.4.1246; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LINDSTROM TR, 1972, P NATL ACAD SCI USA, V69, P1707, DOI 10.1073/pnas.69.7.1707; MIURA S, 1984, BIOCHEMISTRY-US, V23, P2492, DOI 10.1021/bi00306a027; MIURA S, 1987, BIOCHEMISTRY-US, V26, P2149, DOI 10.1021/bi00382a013; MIURA S, 1982, BIOCHEMISTRY-US, V21, P6280, DOI 10.1021/bi00267a037; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NISHIKURA K, 1978, Biochemical Journal, V173, P651; OGAWA S, 1972, J MOL BIOL, V70, P315, DOI 10.1016/0022-2836(72)90542-6; PERRELLA M, 1992, J BIOL CHEM, V267, P8744; PERRELLA M, 1990, BIOPHYS CHEM, V35, P97, DOI 10.1016/0301-4622(90)80064-E; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; SAROFF HA, 1972, SCIENCE, V175, P1253, DOI 10.1126/science.175.4027.1253; SHIBAYAMA N, 1987, BIOCHEMISTRY-US, V26, P2194, DOI 10.1021/bi00382a019; SMITH FR, 1985, P NATL ACAD SCI USA, V82, P5347, DOI 10.1073/pnas.82.16.5347; SMITH FR, 1987, P NATL ACAD SCI USA, V84, P7089, DOI 10.1073/pnas.84.20.7089; SPEROS PC, 1991, BIOCHEMISTRY-US, V30, P7254, DOI 10.1021/bi00243a030; WALDER JA, 1979, BIOCHEMISTRY-US, V18, P4265, DOI 10.1021/bi00587a001; WILLIAMS RC, 1973, ANAL BIOCHEM, V54, P137, DOI 10.1016/0003-2697(73)90256-X; YONETANI T, 1974, J BIOL CHEM, V249, P682	49	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23031	23040						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226818				2022-12-25	WOS:A1993MF51500014
J	ALBLAS, J; VANCORVEN, EJ; HORDIJK, PL; MILLIGAN, G; MOOLENAAR, WH				ALBLAS, J; VANCORVEN, EJ; HORDIJK, PL; MILLIGAN, G; MOOLENAAR, WH			G(I)-MEDIATED ACTIVATION OF THE P21(RAS)-MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY BY ALPHA(2)-ADRENERGIC RECEPTORS EXPRESSED IN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALPHA-2-ADRENERGIC RECEPTOR; RAT-1 FIBROBLASTS; LYSOPHOSPHATIDIC-ACID; ADRENERGIC-RECEPTORS; CELL-PROLIFERATION; PHOSPHOLIPASE-D; STIMULATION; P21RAS; GENE; RAS	The alpha2-adrenergic receptors are linked to inhibition of adenylylcyclase and, under certain circumstances, to stimulation of phospholipid hydrolysis via pertussis toxin-sensitive G proteins. Here we show that alpha2-adrenergic receptors can couple to an alternative signaling pathway. When expressed in Rat-1 cells, stimulation of the alpha2A receptor, which couples to G(i2) and G(i3), causes rapid, transient activation of the protooncogene product p21ras as measured by an increase in the amount of bound GTP. Furthermore, alpha2A receptor stimulation causes rapid phosphorylation of the p42 mitogen-activated protein (MAP) kinase. Pertussis toxin completely inhibits both p21ras activation and MAP kinase phosphorylation, but both responses appear to be independent of adenylylcyclase inhibition or phospholipase stimulation. Thus, alpha2-adrenergic receptors can couple to the p21ras-MAP kinase pathway via G(i), which may explain the mitogenic potential of alpha2 agonists in certain cell types; together with previous results, these findings further suggest that activation of this pivotal signaling pathway may be a common event in the action of G(i)-coupled receptors.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS; UNIV GLASGOW,DEPT BIOCHEM,GLASGOW G12 8QQ,SCOTLAND	Netherlands Cancer Institute; University of Glasgow			Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519; Alblas, Jacqueline/0000-0002-2996-9697; Hordijk, Peter/0000-0002-3348-078X				BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; KENNEDY MFG, 1983, CLIN EXP PHARMACOL P, V10, P577, DOI 10.1111/j.1440-1681.1983.tb00226.x; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIMBIRD LE, 1988, ALPHA 2 ADRENERGIC R; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MCCLUE SJ, 1992, BIOCHEM J, V284, P565, DOI 10.1042/bj2840565; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PLEVIN R, 1991, BIOCHEM J, V280, P609, DOI 10.1042/bj2800609; ROMAURY A, 1993, BIOCHEM J, V292, P283; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEUWEN K, 1990, CELL REGUL, V1, P445, DOI 10.1091/mbc.1.6.445; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; THOMAS G, 1992, CELL, V68, P1; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TUTTON PJM, 1987, ANTICANCER RES, V7, P1; ULLRICH S, 1988, J BIOL CHEM, V263, P8615; VALET P, 1993, J CLIN INVEST, V91, P2049, DOI 10.1172/JCI116427; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	34	218	221	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22235	22238						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226727				2022-12-25	WOS:A1993MD34800006
J	MENDOZAALVAREZ, H; ALVAREZGONZALEZ, R				MENDOZAALVAREZ, H; ALVAREZGONZALEZ, R			POLY(ADP-RIBOSE) POLYMERASE IS A CATALYTIC DIMER AND THE AUTOMODIFICATION REACTION IS INTERMOLECULAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION; REACTION-MECHANISM; CDNA SEQUENCE; PROTEIN; SYNTHETASE; CHROMATIN; HISTONES; CELLS; ELONGATION; ACCEPTOR	We have determined the molecular mechanism of the automodification reaction of poly(ADP-ribose) polymerase (PARP) (EC 2.4.2.30). While PARP-mono(ADP-ribose) conjugates were the predominant products of automodification at 200 nM NAD, enzyme-bound branched polymers were preferentially synthesized at 200 muM NAD. Thus, the initiation, elongation, and branching reactions catalyzed by PARP appear to be [NAD]-dependent. Initial rates of automodification increased with second order kinetics as a function of [PARP] at both 200 nM and 200 muM NAD. Therefore, 2 molecules of PARP, i.e. a catalytic dimer, are required for the auto-mono(ADP-ribosyl)ation and the auto-poly(ADP-ribosyl)ation reactions. Initial rates of automodification also increased with second order kinetics at low NAD concentrations. Therefore, the catalytic dimer also requires 2 molecules of NAD. These results are consistent with the conclusion that the automodification reaction of PARP is intermolecular and that the 2 monomeric units of PARP may simultaneously function as catalyst and acceptor molecules in the automodification reaction. Confirmatory evidence for the catalytic role of protein-protein interactions in the automodification reaction was manifested by a marked inhibition of auto-poly(ADP-ribosyl)ation at 40 nM or higher [PARP].			MENDOZAALVAREZ, H (corresponding author), UNIV N TEXAS,TEXAS COLL OSTEOPATH MED,DEPT MICROBIOL & IMMUNOL,FT WORTH,TX 76107, USA.		Gonzalez, Rafael Alvarez/I-4560-2019	Alvarez-Gonzalez, Rafael/0000-0003-1038-7512				ADAMIETZ P, 1987, EUR J BIOCHEM, V169, P365, DOI 10.1111/j.1432-1033.1987.tb13621.x; ALVAREZGONZALEZ R, 1988, J BIOL CHEM, V263, P17690; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; ALVAREZGONZALEZ R, 1983, ANAL BIOCHEM, V135, P69, DOI 10.1016/0003-2697(83)90732-7; ALVAREZGONZALEZ R, 1993, FASEB J, V7, pA1094; BAUER PI, 1986, FEBS LETT, V195, P331, DOI 10.1016/0014-5793(86)80188-0; BAUER PI, 1990, BIOCHEM J, V270, P17, DOI 10.1042/bj2700017; BOULIKAS T, 1988, EMBO J, V7, P57, DOI 10.1002/j.1460-2075.1988.tb02783.x; BOULIKAS T, 1990, J BIOL CHEM, V265, P14638; BUTT TR, 1980, BIOCHEMISTRY-US, V19, P5235, DOI 10.1021/bi00564a013; BUTT TR, 1980, BIOCHEMISTRY-US, V19, P5243, DOI 10.1021/bi00564a014; CAPLAN AI, 1979, ARCH BIOCHEM BIOPHYS, V198, P60, DOI 10.1016/0003-9861(79)90395-3; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; DEMURCIA G, 1988, BIOCHEM CELL BIOL, V66, P626, DOI 10.1139/o88-072; DESMARAIS Y, 1991, BIOCHIM BIOPHYS ACTA, V1078, P179, DOI 10.1016/0167-4838(91)99007-F; FERRO AM, 1983, J BIOL CHEM, V258, P6000; HOLTLUND J, 1983, EUR J BIOCHEM, V130, P309, DOI 10.1111/j.1432-1033.1983.tb07153.x; HULETSKY A, 1985, EUR J BIOCHEM, V146, P277, DOI 10.1111/j.1432-1033.1985.tb08650.x; IKEJIMA M, 1987, J BIOL CHEM, V262, P17641; JUMP DB, 1980, BIOCHEMISTRY-US, V19, P1024, DOI 10.1021/bi00546a030; KAMESHITA I, 1986, J BIOL CHEM, V261, P3863; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; KIEHLBAUCH CC, 1993, ANAL BIOCHEM, V208, P26, DOI 10.1006/abio.1993.1004; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LOETSCHER P, 1987, P NATL ACAD SCI USA, V84, P1286, DOI 10.1073/pnas.84.5.1286; MARTINEZ M, 1991, BIOCHEM BIOPH RES CO, V181, P1412, DOI 10.1016/0006-291X(91)92096-3; NAEGELI H, 1989, J BIOL CHEM, V264, P14382; OGATA N, 1980, BIOCHEM INT, V1, P229; PAINE A J, 1980, Biochemical Society Transactions, V8, P183; TANIGUCHI T, 1987, BIOCHEM BIOPH RES CO, V147, P1008, DOI 10.1016/S0006-291X(87)80170-5; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; UCHIDA K, 1992, OJI INT SEMINAR ADP; YOSHIHARA K, 1977, BIOCHEM BIOPH RES CO, V78, P1281, DOI 10.1016/0006-291X(77)91431-0; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x; ZAHRADKA P, 1982, EUR J BIOCHEM, V127, P579	36	192	201	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22575	22580						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226768				2022-12-25	WOS:A1993MD34800060
J	MORICE, WG; WIEDERRECHT, G; BRUNN, GJ; SIEKIERKA, JJ; ABRAHAM, RT				MORICE, WG; WIEDERRECHT, G; BRUNN, GJ; SIEKIERKA, JJ; ABRAHAM, RT			RAPAMYCIN INHIBITION OF INTERLEUKIN-2-DEPENDENT P33CDK2 AND P34CDC2 KINASE ACTIVATION IN T-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CELL-CYCLE; CDC2 PROTEIN-KINASE; P70 S6 KINASE; CYCLOSPORINE-A; IMMUNOSUPPRESSANT RAPAMYCIN; SIGNAL TRANSDUCTION; POSITIVE FEEDBACK; GENE-EXPRESSION; G1 CYCLINS; PHOSPHORYLATION	The immunosuppressant rapamycin (RAP) is a potent inhibitor of the entry of interleukin (IL)-2-stimulated T cells into S-phase. Earlier results indicated that RAP treatment arrested the growth of the murine IL-2-dependent T cell line CTLL-2 in late G1-phase. To explore further the interactions of RAP with the cell cycle control machinery in T cells, we examined the effects of RAP treatment on the activation of the cyclin-dependent kinases p34cdc2 and p33cdk2 in G1-phase CTLL-2 cells. Stimulation of factor-deprived cells with IL-2 led to the assembly of high molecular weight complexes containing active p34cdc2 and p33cdk2. The appearance of these complexes was explained, at least in part, by the association of both cyclin-dependent kinases with IL-2-induced cyclin A. RAP treatment profoundly inhibited both cyclin A expression and the appearance of active cyclin A-cyclin-dependent kinase complexes in IL-2-stimulated, late G1-phase CTLL-2 cells. Although p34cdc2 activation was largely dependent on association with cyclin A, a significant proportion of the active p33cdk2 pool was complexed with cyclin E. In contrast to cyclin A, the IL-2-induced accumulation of cyclin E in G1-phase cells was only partially suppressed by RAP, and cyclin E-p33cdk2 complexes were readily detected in drug-treated cells. These cyclin E-cyclin-dependent kinase complexes were nonetheless devoid of histone H1 kinase activity. The inhibitory effects of RAP on the activation of cyclin E- and cyclin A-associated cyclin-dependent kinases suggest that one or both events participate in the regulation of T cell entry into S-phase.	MAYO CLIN & MAYO FDN,DEPT IMMUNOL,RM 342B,GUGGENHEIM BLDG,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905; MERCK SHARP & DOHME LTD,DEPT IMMUNOL RES,RAHWAY,NJ 07065; IMMUNOBIOL RES INST,DEPT MOLEC IMMUNOL,ANNANDALE,NJ 08801	Mayo Clinic; Mayo Clinic; Merck & Company								ABRAHAM RT, 1986, J TISSUE CULTURE MET, V10, P93; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CROSS F, 1991, CELL, V66, P1217; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HEITMAN J, 1992, NEW BIOL, V4, P448; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Kirschner M W, 1992, Important Adv Oncol, P3; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MORICE WG, 1993, J BIOL CHEM, V268, P3734; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1992, Current Opinion in Cell Biology, V4, P144, DOI 10.1016/0955-0674(92)90024-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RUEGEMER JJ, 1990, J IMMUNOL, V144, P1767; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SIGAL NH, 1991, TRANSPLANT P, V23, P1; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WILKINSON M, 1991, NUCLEIC ACIDS RES, V19, P679, DOI 10.1093/nar/19.3.679	52	140	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22737	22745						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226784				2022-12-25	WOS:A1993MD34800081
J	GOTOH, Y; MATSUDA, S; TAKENAKA, K; HATTORI, S; IWAMATSU, A; ISHIKAWA, M; KOSAKO, H; NISHIDA, E				GOTOH, Y; MATSUDA, S; TAKENAKA, K; HATTORI, S; IWAMATSU, A; ISHIKAWA, M; KOSAKO, H; NISHIDA, E			CHARACTERIZATION OF RECOMBINANT XENOPUS MAP KINASE KINASES MUTATED AT POTENTIAL PHOSPHORYLATION SITES	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; THREONINE TYROSINE KINASE; SIGNAL-TRANSDUCTION; SUBSTRATE RECOGNITION; NUCLEOTIDE-SEQUENCE; A431 CELLS; IDENTIFICATION; YEAST; GENE; CASCADE	Xenopus mitogen-activated protein kinase kinase (MAPKK) previously inactivated with protein phosphatase 2A can be reactivated by serine phosphorylation catalyzed by a partially purified MAPKK kinase (MAPKK-K), and is phosphorylated by MAPK on a threonine residue. The sequence analysis of a threonine-phosphorylated tryptic peptide of Xenopus MAPKK from mature oocytes suggested that Thr388 is phosphorylated in vivo. A mutant MAPKK that has Thr388 changed to Ala (T388A-MAPKK) was not phosphorylated by purified MAPK, indicating that Thr388 is phosphorylated by MAPK. We then produced and analysed MAPKKs mutated at potential serine phosphorylation sites (S218A-MAPKK and S222A-MAPKK). The wild-type MAPKK (WT-MAPKK), T388A-MAPKK and a kinase-deficient (K97S)-MAPKK were phosphorylated efficiently by MAPKK-Ks purified from Xenopus eggs, and WT-MAPKK and T388A-MAPKK became activated. In contrast, neither S218A-MAPKK nor S222A-MAPKK was phosphorylated and activated efficiently by the Xenopus MAPKK-Ks. Similarly, WT-MAPKK, but not S218A-MAPKK or S222A-MAPKK, was activated efficiently by an active Raf-1 immunoprecipitate. However, when the recombinant STE11, a putative MAPKK-K in S. cerevisiae, was used as a source of MAPKK-K, S218A-MAPKK as well as WT-MAPKK, but not S222A-MAPKK, was phosphorylated and activated. Furthermore, replacement of Ser222 with an acidic residue (S222E) elevated substantially the basal kinase activity of MAPKK, while replacement of Ser218 (S218E) did not. These results may suggest an essential role for Ser222 phosphorylation in activating Xenopus MAPKK.	KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA 187,TOKYO,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,KANAZAWA KU,YOKOHAMA,KANAGAWA,JAPAN	Kyoto University; National Center for Neurology & Psychiatry - Japan; Kirin Brewery Company Limited								Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; AHN NG, 1991, J BIOL CHEM, V266, P4220; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVIN DE, 1993, CURR OPIN CELL BIOL, V5, P245; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEIMAN AM, 1994, IN PRESS P NATL ACAD; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OTSU M, 1993, FEBS LETT, V320, P246, DOI 10.1016/0014-5793(93)80596-M; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	56	67	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1891	1898						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208535				2022-12-25	WOS:A1994NR68500012
J	BLANER, WS; OBUNIKE, JC; KURLANDSKY, SB; ALHAIDERI, M; PIANTEDOSI, R; DECKELBAUM, RJ; GOLDBERG, IJ				BLANER, WS; OBUNIKE, JC; KURLANDSKY, SB; ALHAIDERI, M; PIANTEDOSI, R; DECKELBAUM, RJ; GOLDBERG, IJ			LIPOPROTEIN-LIPASE HYDROLYSIS OF RETINYL ESTER - POSSIBLE IMPLICATIONS FOR RETINOID UPTAKE BY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; PROTEIN MESSENGER-RNA; BINDING PROTEIN; RAT-LIVER; STELLATE CELLS; ACID-BINDING; VITAMIN-A; DIFFERENTIATION; TRIGLYCERIDE	Adipose tissue contains substantial stores of retinoid (retinol + retinyl ester) that, quantitatively, are second only to retinoid stores in the liver. Our studies show that retinoid levels in adipose tissue are markedly influenced by dietary retinoid intake. Because lipoprotein lipase (LPL) increases the uptake of lipoproteins and lipid emulsion particles by many cell types including adipocytes, we investigated whether LPL also increases retinoid uptake by adipocytes from lipid-containing particles. Addition of LPL (10 mu g/ml) to BFC-1 beta adipocytes produced a a fold increase in cellular uptake of [H-3]retinoid from a lipid emulsion containing [H-3]retinyl ester. Heparin, which displaces LPL from binding sites on cell surface proteoglycans, increased [H-3]retinoid uptake by an additional a fold. High performance liquid chromatography analyses showed that greater than 75% of the media and 85% of the cellular radioactivity was present as retinol. The conversion of retinyl ester to retinol by LPL was then assessed using model retinyl ester containing lipid emulsions. Although triglyceride appears to be the preferred substrate for LPL, after greater than 25% of the triglyceride was hydrolyzed, significant amounts of retinyl ester were hydrolyzed by LPL. Retinyl ester hydrolysis was increased approximately 20-fold in the presence of a source of apolipoprotein C-II. The physiologically significant palmitate, stearate, oleate, and linoleate esters of retinol were all hydrolyzed by LPL. When LPL was incubated with [H-3]retinyl ester containing rabbit mesenteric chylomicrons and in the presence of heparin and apolipoprotein C-II, the LPL was able to completely hydrolyze the retinyl ester to retinol. Thus, LPL is able to catalyze the hydrolysis of retinyl esters and, through the process of hydrolysis, may facilitate uptake of retinoid by adipocytes.	COLUMBIA UNIV,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT PEDIAT,NEW YORK,NY 10032	Columbia University; Columbia University	BLANER, WS (corresponding author), COLUMBIA UNIV,INST HUMAN NUTR,630 W 168TH ST,NEW YORK,NY 10032, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043097, R01DK047389] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21006] Funding Source: Medline; NIDDK NIH HHS [DK47389, DK43097] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; BLACKBERG L, 1980, FEBS LETT, V112, P51, DOI 10.1016/0014-5793(80)80125-6; Blaner William S., 1994, P229; BLANER WS, 1989, ENDOCR REV, V10, P308, DOI 10.1210/edrv-10-3-308; BLANER WS, 1987, J BIOL CHEM, V262, P53; BLANER WS, 1985, J NUTR, V115, P856, DOI 10.1093/jn/115.7.856; BLANER WS, 1986, J LIPID RES, V27, P1084; BLANER WS, 1990, METHOD ENZYMOL, V189, P193; BLANER WS, 1987, EUR J BIOCHEM, V164, P301, DOI 10.1111/j.1432-1033.1987.tb11058.x; BLANER WS, 1985, J LIPID RES, V26, P1241; BLOMHOFF R, 1982, P NATL ACAD SCI USA, V79, P7926; BOSNER MS, 1988, P NATL ACAD SCI USA, V85, P7438, DOI 10.1073/pnas.85.20.7438; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; DE LUCA LM, 1991, FASEB J, V5, P2924; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; EISENBERG S, 1992, J CLIN INVEST, V90, P1504; FOREST C, 1987, EXP CELL RES, V168, P218, DOI 10.1016/0014-4827(87)90430-7; FOREST C, 1987, EXP CELL RES, V168, P233, DOI 10.1016/0014-4827(87)90431-9; GOLDBERG IJ, 1986, ARCH BIOCHEM BIOPHYS, V244, P580, DOI 10.1016/0003-9861(86)90626-0; GOLDBERG IJ, 1986, BIOCHIM BIOPHYS ACTA, V878, P168, DOI 10.1016/0005-2760(86)90143-8; GOLDBERG IJ, 1988, BIOCHIM BIOPHYS ACTA, V959, P220, DOI 10.1016/0005-2760(88)90194-4; GOODMAN DS, 1965, J LIPID RES, V6, P390; GOODMAN DS, 1984, RETINOIDS, V2, P1; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KATO M, 1985, J BIOL CHEM, V260, P4832; KHOO JC, 1981, J BIOL CHEM, V256, P7105; MAKOVER A, 1989, J LIPID RES, V30, P171; MILLER M, 1993, ARTERIOSCLER THROMB, V13, P385, DOI 10.1161/01.ATV.13.3.385; MORIWAKI H, 1988, J LIPID RES, V29, P1523; MULDER M, 1993, J BIOL CHEM, V268, P9369; NYKAER A, 1993, J BIOL CHEM, V268, P15048; PATSCH JR, 1992, ARTERIOSCLER THROMB, V12, P1336, DOI 10.1161/01.ATV.12.11.1336; QUARFORDT SH, 1967, J LIPID RES, V8, P264; RAJAN N, 1990, J LIPID RES, V31, P821; ROBERTS AB, 1984, RETINOIDS, V2, P209; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; Soprano Dianne Robert, 1994, P257; STEIN O, 1983, BIOCHIM BIOPHYS ACTA, V750, P306, DOI 10.1016/0005-2760(83)90033-4; TRABER MG, 1990, GASTROENTEROLOGY, V98, P96, DOI 10.1016/0016-5085(90)91296-I; TRABER MG, 1985, J CLIN INVEST, V75, P1729, DOI 10.1172/JCI111883; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; ZOVICH DC, 1992, J BIOL CHEM, V267, P13884	45	102	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16559	16565						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206972				2022-12-25	WOS:A1994NR29600009
J	SCHMITTGEN, TD; DANENBERG, KD; HORIKOSHI, T; LENZ, HJ; DANENBERG, PV				SCHMITTGEN, TD; DANENBERG, KD; HORIKOSHI, T; LENZ, HJ; DANENBERG, PV			EFFECT OF 5-FLUOROURACIL AND 5-BROMOURACIL SUBSTITUTION ON THE TRANSLATION OF HUMAN THYMIDYLATE SYNTHASE MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CELLS; DNA	The synthesis of thymidylate synthase (TS) from 5-fluorouracil (FUra)- and 5-bromouracil (BrUra)-substituted mRNAs was examined to investigate the effect of incorporation of uracil (Ura) analogs on translation. Human TS cDNA was transcribed in the presence of Ura-, FUra-, or BrUTP to obtain 100% substituted mRNA The mRNAs were translated in a rabbit reticulocyte lysate system. The TS protein that was formed from each of the templates reacted identically with TS antibody in Western blots. Time courses of TS formation revealed a characteristic peak which occurred at 45 min for the Ura- and FUra-RNAs and at 2 h for the BrUra-RNA. Substitution of Ura with FUra did not alter the rate of translation, while substitution of BrU for Ura decreased the rate of translation. Substitution of Ura with FUra or BrUra enhanced the stability of the mRNAs in the rabbit reticulocyte lysate by 3- and 10-fold, respectively. Incor poration of BrUra influenced the binding and catalysis on the ribosome, resulting in a 3.5-fold greater rate of activation (K-act) and 6-fold lower V-max than the equivalent values for the Ura- and FUra-substituted mRNAs. Nondenaturing gel electrophoresis revealed that different conformations exist among the mRNAs. These data show that translation can be influenced by the incorporation of fraudulent bases into mRNA and those bases that stabilize RNA secondary structure will have the greatest inhibitory effect on translation.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM,LOS ANGELES,CA 90033; UNIV SO CALIF,KENNETH NORRIS JR COMPREHENS CANC CTR,SCH MED,LOS ANGELES,CA 90033	University of Southern California; University of Southern California								CARRICO CK, 1979, CANCER RES, V39, P3694; CHU E, 1990, CANCER RES, V50, P5834; CHU E, 1993, MOL PHARMACOL, V43, P527; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; DANENBERG PV, 1992, NUCLEIC ACIDS RES, V20, P573, DOI 10.1093/nar/20.3.573; DOLNICK BJ, 1985, J BIOL CHEM, V260, P3006; GLAZER RI, 1983, MOL PHARMACOL, V23, P540; GLAZER RI, 1981, MOL PHARMACOL, V19, P117; HARLOWE E, 1988, ANTIBODIES LABORATOR; HEIDELBERGER C, 1983, ADV ENZYMOL RAMB, V54, P57; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KOZAK M, 1980, CELL, V19, P79, DOI 10.1016/0092-8674(80)90390-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASSOULIE J, 1966, BIOCHIM BIOPHYS ACTA, V114, P16, DOI 10.1016/0005-2787(66)90249-8; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; SIERAKOWSKA H, 1989, J BIOL CHEM, V264, P19185; TAKEISHI K, 1985, NUCLEIC ACIDS RES, V13, P2035, DOI 10.1093/nar/13.6.2035; WASHTIEN WL, 1984, MOL PHARMACOL, V25, P171	20	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16269	16275						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206932				2022-12-25	WOS:A1994NQ72900050
J	STRUM, JC; DANIEL, LW				STRUM, JC; DANIEL, LW			IDENTIFICATION OF A LYSOPHOSPHOLIPASE-C THAT MAY BE RESPONSIBLE FOR THE BIOSYNTHESIS OF CHOLINE PLASMALOGENS BY MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN MICROSOMES; PHOSPHOLIPASE-C; D PATHWAY; ETHANOLAMINE; METABOLISM; PHOSPHATIDYLCHOLINE; PHOSPHOTRANSFERASE; PHOSPHATIDYLETHANOLAMINE; GLYCEROPHOSPHOLIPIDS; QUANTITATION	The biosynthesis of choline plasmalogens was investigated in Madin-Darby canine kidney cells to determine the source of the vinyl ether linkage. 1-O-[H-3] Alk-1'-enyl-2-lyso-sn-glycero-3-phosphoethanolamine was a better precursor than 1-O-[H-3]alkyl-2-lyso-sn-glycero-3-phosphocholine for the synthesis of 1-O-[H-3]alk-1'-enyl-2-acyl-sn-glycero-3-phosphocholine; this suggests that the vinyl ether linkage in choline phosphoglycerides originates from ethanolamine plasmalogens. The contribution of N-methylation and base exchange enzymes to choline plasmalogen biosynthesis was assessed using 1-O-[H-3]alkenyl-2-lyso-sn-glycero-3-[P-32]phosphoethanolamine. While 1-O-[H-3]alkenyl-2-acyl-sn-glycero-3-phosphocholine was formed from this precursor, the P-32 was lost indicating that N-methylation and base exchange enzymes do not contribute significantly to the synthesis of choline plasmalogens. The conversion of a phosphono analog of 1-O-[H-3]alkyl-2-lyso-sn-glycero-3-phosphoethanolamine, which is resistant to phospholipase D hydrolysis, to 1-O-[H-3]alkenyl-2-acyl-sn-glycero-2-phosphocholine was observed demonstrating that phospholipase D is not required for choline plasmalogen biosynthesis. A Mg2+-dependent lysophospholipase C activity was detected in microsomes that actively hydrolyzed ether-linked lysophosphoglycerides as well as the lysophosphono analog. To assess the role of lysophospholipase C in shuttling 1-O-alk-1'-enyl-sn-glycerol (alkenylglycerol) from ethanolamine plasmalogens to choline plasmalogens, cells prelabeled with 1-O-[H-3]alkenyl-2-lyso-sn-glycero-3-phosphoethanolamine were treated with 12-O-tetradecanoylphorbol-13-acetate. This resulted in the rapid deacylation of 1-O-[H-3]alkenyl-2-acyl-sn-glycero-3-phosphoethanolamine to 1-O-[H-3]alkenyl-2-lyso-sn-glycero-3-phosphoethanolamine and the subsequent generation of 1-O-[H-3]alkenylglycerol. A concomitant 2-3-fold increase in 1-O-[H-3]alkenyl-2-acyl-sn-glycero-3-phosphocholine was observed. These studies suggest that the alkenyl linkage in choline phosphoglycerides may originate from 1-O-alkenyl-2-lyso-sn-glycero-3-phosphoethanolamine through an enzymatic pathway involving lysophospholipase C to generate alkenylglycerol that is subsequently converted to choline plasmalogens.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT BIOCHEM, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center					NCI NIH HHS [CA12197, CA48995, CA43297] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012197, R01CA043297, R01CA048995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERT DH, 1977, LIPIDS, V12, P722, DOI 10.1007/BF02570902; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANSELL GB, 1965, BIOCHEM J, V94, P252, DOI 10.1042/bj0940252; ANSELL GB, 1982, PHOSPHOLIPIDS, P2; BLANK ML, 1993, BIOCHIM BIOPHYS ACTA, V1166, P309, DOI 10.1016/0005-2760(93)90112-M; BLANK ML, 1972, BIOCHEM BIOPH RES CO, V47, P1203, DOI 10.1016/0006-291X(72)90962-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNETTI M, 1979, LIPIDS, V14, P925, DOI 10.1007/BF02533507; CHRISTIANSEN K, 1975, ANAL BIOCHEM, V66, P93, DOI 10.1016/0003-2697(75)90728-9; DANIEL LW, 1981, J BIOL CHEM, V256, P2830; DOMSCHKE W, 1971, H-S Z PHYSIOL CHEM, V352, P275, DOI 10.1515/bchm2.1971.352.1.275; FLORINCHRISTENSEN J, 1986, TRENDS BIOCHEM SCI, V11, P354, DOI 10.1016/0968-0004(86)90198-2; FORD DA, 1992, J BIOL CHEM, V267, P11222; FORD DA, 1988, J BIOL CHEM, V263, P2644; GORACCI G, 1977, FEBS LETT, V80, P41, DOI 10.1016/0014-5793(77)80402-X; GORACCI G, 1981, BIOCHIM BIOPHYS ACTA, V664, P373, DOI 10.1016/0005-2760(81)90059-X; HANAHAN DJ, 1990, J LIPID RES, V31, P2113; HII CST, 1990, BIOCHIM BIOPHYS ACTA, V1052, P327, DOI 10.1016/0167-4889(90)90229-7; Horrocks L. A., 1972, ETHER LIPIDS CHEM BI, P177, DOI [DOI 10.1016/B978-0-12-654150-2.50016-6, 10.1016/b978-0-12-654150-2.50016-6]; HORROCKS LA, 1968, J LIPID RES, V9, P469; HORROCKS LA, 1982, PHOSPHOLIPIDS, P62; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUANG CF, 1990, J BIOL CHEM, V265, P14858; KANOH H, 1973, BIOCHIM BIOPHYS ACTA, V306, P203; KAPOULAS VM, 1969, BIOCHIM BIOPHYS ACTA, V176, P324, DOI 10.1016/0005-2760(69)90190-8; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KISS Z, 1989, J BIOL CHEM, V264, P1483; LEE TC, 1991, ARCH BIOCHEM BIOPHYS, V286, P498, DOI 10.1016/0003-9861(91)90071-P; LEE TC, 1991, FASEB J, V5, pA1154; Martonosi, 1985, ENZYMES BIOL MEMBR, V2, P1; MOGELSON S, 1981, BIOCHIM BIOPHYS ACTA, V666, P205, DOI 10.1016/0005-2760(81)90108-9; MOZZI R, 1981, FEBS LETT, V131, P115, DOI 10.1016/0014-5793(81)80900-3; NIWA Y, 1986, ARCH BIOCHEM BIOPHYS, V250, P345, DOI 10.1016/0003-9861(86)90736-8; PALTAUF F, 1973, J BIOL CHEM, V248, P1609; PALTAUF F, 1972, BIOCHIM BIOPHYS ACTA, V260, P352, DOI 10.1016/0005-2760(72)90049-5; PALTAUF F, 1972, FEBS LETT, V20, P79, DOI 10.1016/0014-5793(72)80021-8; REISS PD, 1984, ANAL BIOCHEM, V140, P162, DOI 10.1016/0003-2697(84)90148-9; SATO R, 1969, BIOCHIM BIOPHYS ACTA, V176, P748; SCHMID HHO, 1972, BIOCHIM BIOPHYS ACTA, V270, P317, DOI 10.1016/0005-2760(72)90196-8; SNYDER F, 1970, J BIOL CHEM, V245, P4016; STRUM JC, 1992, J BIOL CHEM, V267, P1576; Sugiura T., 1987, PLATELET ACTIVATING, P55; SURLES JR, 1985, J MED CHEM, V28, P73, DOI 10.1021/jm00379a015; THOMPSON GA, 1969, BIOCHIM BIOPHYS ACTA, V176, P330, DOI 10.1016/0005-2760(69)90191-X; THOMPSON GA, 1967, BIOCHEMISTRY-US, V6, P2015, DOI 10.1021/bi00859a020; TIETZ A, 1964, J BIOL CHEM, V239, P4081; VANDENBOSCH H, 1974, ANNU REV BIOCHEM, V43, P243; VIERBUCHEN M, 1979, H-S Z PHYSIOL CHEM, V360, P1091, DOI 10.1515/bchm2.1979.360.2.1091; WARNER HR, 1961, J BIOL CHEM, V236, P2404; WIENTZEK M, 1987, BIOCHEM CELL BIOL, V65, P860, DOI 10.1139/o87-112; WOLF RA, 1985, J BIOL CHEM, V260, P7295; WYKLE RL, 1970, FEBS LETT, V12, P57, DOI 10.1016/0014-5793(70)80595-6; WYKLE RL, 1991, METHOD ENZYMOL, V197, P583; WYKLE RL, 1972, J BIOL CHEM, V247, P5442; WYKLE RL, 1980, BIOCHIM BIOPHYS ACTA, V619, P58, DOI 10.1016/0005-2760(80)90242-8; WYKLE RL, 1974, J BIOL CHEM, V249, P1742; YATES AJ, 1979, J LIPID RES, V20, P428	58	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25500	25508						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244986				2022-12-25	WOS:A1993MK10000036
J	YU, FH; SHULL, GE; ORLOWSKI, J				YU, FH; SHULL, GE; ORLOWSKI, J			FUNCTIONAL-PROPERTIES OF THE RAT NA/H EXCHANGER NHE-2 ISOFORM EXPRESSED IN NA/H EXCHANGER-DEFICIENT CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-H+ EXCHANGER; MICROVILLUS MEMBRANE-VESICLES; GROWTH-FACTOR; MOLECULAR-CLONING; INTRACELLULAR PH; BRUSH-BORDER; ANTIPORTER; AMILORIDE; TRANSPORT; INHIBITION	The primary structure and functional expression of the rat Na/H exchanger (NHE) NHE-2 isoform has recently been reported (Wang, Z., Orlowski, J., and Shull, G. E. (1993) J. Biol. Chem. 268,11925-11928). To further characterize some of its functional properties, biochemical and pharmacological analyses were performed on exchanger-deficient Chinese hamster ovary cells (AP-1) that had been stably transfected with a full-length NHE-2 cDNA. Transport activity for NHE-2 was assayed by measuring amiloride-inhibitable Na-22+ influx following an acute intracellular acid load. Pharmacological analyses revealed that NHE-2 had a relatively high affinity for amiloride and some of its analogues. The most potent analogue was 5-(N-ethyl-N-isopropyl) amiloride (EIPA) (K0.5 = 79 nM), followed by 5-(N,N-dimethyl)amiloride (DMA) (K0.5 = 250 nM), amiloride (K0.5 = 1.4 muM), and benzamil (K0.5 = 320 muM). Nonamiloride compounds known to inhibit the activity of other Na/H exchanger isoforms also inhibited NHE-2 with the following order of potency: clonidine (K0.5 = 42 muM) > harmaline (K0.5 = 330 muM) almost-equal-to cimetidine (K0.5 = 330 muM). Biochemical analyses showed that the extracellular Na+ dependence of NHE-2 followed simple, saturating Michaelis-Menten kinetics with an apparent affinity constant for Na+ (K(Na)) Of 50 mM. In contrast, intracellular H+ appeared to activate NHE-2 by a positive cooperative mechanism with an apparent half-maximal activation value of pK 6.90. Other cations, such as extracellular Li+ and H+, acted as competitive inhibitors of Na-22+ influx by NHE-2, with apparent K(i) values of 3.0 mM and 10 nM, respectively. In contrast, extracellular K+ had no effect on the transport activity of NHE-2. These results indicated that the rat NHE-2 cDNA encodes a functional Na/H exchanger isoform with distinct properties compared to rat NHE-1 and -3.	MCGILL UNIV,DEPT PHYSIOL,MCINTYRE MED SCI BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA; UNIV CINCINNATI,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	McGill University; University System of Ohio; University of Cincinnati				Orlowski, John/0000-0001-7371-175X; Yu, Frank/0000-0001-9306-1731	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039626] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39626] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1983, J BIOL CHEM, V258, P6767; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1980, AM J PHYSIOL, V238, pF210, DOI 10.1152/ajprenal.1980.238.3.F210; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; ARSONSON PS, 1980, AM J PHYSIOL, V238, pF210; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; CLARK JD, 1991, AM J PHYSIOL, V261, pC945, DOI 10.1152/ajpcell.1991.261.6.C945; COLLINS JF, 1993, P NATL ACAD SCI USA, V90, P3938, DOI 10.1073/pnas.90.9.3938; COOKE R, 1988, J PHYSIOL-LONDON, V395, P77, DOI 10.1113/jphysiol.1988.sp016909; CUTHBERT AW, 1978, BRIT J PHARMACOL, V63, P139, DOI 10.1111/j.1476-5381.1978.tb07783.x; DONALDSON SKB, 1978, PFLUG ARCH EUR J PHY, V376, P55; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; FRANCHI A, 1986, J BIOL CHEM, V261, P4614; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAGGERTY C, 1988, P NATL ACAD SCI USA, V88, P6797; IVES HE, 1983, J BIOL CHEM, V258, P9710; KINSELLA JL, 1980, AM J PHYSIOL, V238, pF461, DOI 10.1152/ajprenal.1980.238.6.F461; KINSELLA JL, 1981, AM J PHYSIOL, V241, pF373; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KNICKELBEIN R, 1983, AM J PHYSIOL, V245, pG504, DOI 10.1152/ajpgi.1983.245.4.G504; KNICKELBEIN RG, 1990, AM J PHYSIOL, V259, pG802, DOI 10.1152/ajpgi.1990.259.5.G802; KULANTHAIVEL P, 1990, J BIOL CHEM, V265, P1249; LALLEMAIN G, 1984, J BIOL CHEM, V259, P4313; MAHENSMITH RL, 1985, J BIOL CHEM, V260, P12586; MAHENSMITH RL, 1985, CIRC RES, V56, P773; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; MRWA U, 1974, BLOOD VESSELS, V11, P277; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; PARIS S, 1983, J BIOL CHEM, V258, P3503; RAJENDRAN VM, 1990, J BIOL CHEM, V265, P8408; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; TAKAICHI K, 1992, AM J PHYSIOL, V262, pC1069, DOI 10.1152/ajpcell.1992.262.4.C1069; TAKAICHI K, 1993, AM J PHYSIOL, V264, pC944, DOI 10.1152/ajpcell.1993.264.4.C944; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; VIGNE P, 1985, J BIOL CHEM, V260, P8008; VIGNE P, 1988, J BIOL CHEM, V263, P18023; VIGNE P, 1984, MOL PHARMACOL, V25, P131; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WANG Z, 1993, J BIOL CHEM, V268, P11925	48	130	135	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25536	25541						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244989				2022-12-25	WOS:A1993MK10000040
J	VIDALINGIGLIARDI, D; RICHET, E; DANOT, O; RAIBAUD, O				VIDALINGIGLIARDI, D; RICHET, E; DANOT, O; RAIBAUD, O			A SMALL C-TERMINAL REGION OF THE ESCHERICHIA-COLI MALT PROTEIN CONTAINS THE DNA-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTIONAL ACTIVATOR; NUCLEOTIDE-SEQUENCE; POSITIVE REGULATOR; CRYSTAL-STRUCTURE; LAMBDA-REPRESSOR; PROMOTERS; OPERATOR; VECTORS; FRAGMENT; INDUCER	MalT, the transcriptional activator of the Escherichia coli maltose regulon, is a 901-amino acid-long protein that specifically binds to short, asymmetric nucleotide sequences present in several copies in the promoters of the regulon. We report that the protein structure involved in this specific binding is carried by a small C-terminal part of MalT encompassing the last 95 amino acid residues. This was demonstrated by fusing the last 95 codons of malT to the gene that encodes glutathione S-transferase, purifying the hybrid protein by affinity chromatography, and comparing the DNase I and dimethyl sulfate footprints of the hybrid and of wild-type MalT on different MalT-binding sites. MalT belongs to a large family of prokaryotic transcriptional activators, which share significant homology in their approximately 60-amino acid C-terminal regions. Our result strongly supports the suggestion that the region of homology corresponds to the DNA-binding domain of the proteins in this family.	INST PASTEUR, CNRS, URA 1149, UNITE GENET MOLEC, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Danot, Olivier/0000-0003-0002-7097				CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; CHOI SH, 1991, P NATL ACAD SCI USA, V88, P11115, DOI 10.1073/pnas.88.24.11115; COLE ST, 1986, GENE, V42, P201, DOI 10.1016/0378-1119(86)90297-0; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; GEISLER N, 1977, BIOCHEMISTRY-US, V16, P938, DOI 10.1021/bi00624a020; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; HOFNUNG M, 1971, J MOL BIOL, V61, P681, DOI 10.1016/0022-2836(71)90072-6; KAHN D, 1991, MOL MICROBIOL, V5, P987, DOI 10.1111/j.1365-2958.1991.tb00774.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; RAIBAUD O, 1985, J BACTERIOL, V161, P1201, DOI 10.1128/JB.161.3.1201-1208.1985; RAIBAUD O, 1989, J MOL BIOL, V205, P471, DOI 10.1016/0022-2836(89)90218-0; RAIBAUD O, 1987, J BACTERIOL, V169, P3059, DOI 10.1128/jb.169.7.3059-3061.1987; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; SAUER RT, 1979, NATURE, V279, P396, DOI 10.1038/279396a0; SCHWARTZ M, 1987, CELLULAR MOL BIOL, P1482; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRATT BG, 1986, GENE, V41, P337, DOI 10.1016/0378-1119(86)90117-4; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; STOUT V, 1991, J BACTERIOL, V173, P1738, DOI 10.1128/jb.173.5.1738-1747.1991; VIDALINGIGLIARDI D, 1991, J MOL BIOL, V218, P323, DOI 10.1016/0022-2836(91)90715-I; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; ZHENG LB, 1992, J MOL BIOL, V226, P1037, DOI 10.1016/0022-2836(92)91051-P	26	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24527	24530						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227007				2022-12-25	WOS:A1993MG67300004
J	HUANG, CC; TURCO, SJ				HUANG, CC; TURCO, SJ			DEFECTIVE GALACTOFURANOSE ADDITION IN LIPOPHOSPHOGLYCAN BIOSYNTHESIS IN A MUTANT OF LEISHMANIA-DONOVANI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATED-PHOSPHATIDYLINOSITOLS; GLYCOLIPIDS; EXPRESSION; VIRULENCE; ANTIGENS; SURVIVAL; FAMILY	A mutant cell line of Leishmania donovani (R2D2), previously selected for resistance to the cytotoxic lectin ricin agglutinin, was found to be totally deficient in the synthesis and expression of lipophosphoglycan, a dominant surface virulence factor. The metabolic defect in R2D2 parasites responsible for its lipophosphoglycan (LPG-) phenotype was investigated in this study. Following metabolic labeling of R2D2 parasites with either [H-3]galactose or [H-3]mannose, the main glycosylphosphatidylinositide product that accumulated was Glc-PO4-Man-Man-GlcN-lyso-1-O-alkylphosphatidylinositol (PI). The metabolic defect was further defined using a cell-free glycosylation system. When membrane preparations from wild-type cells were incubated with UDP-[H-3]galactose and unlabeled GDP-mannose in the absence of exogenous acceptors, radiolabeled lipophosphoglycan was synthesized. The addition of exogenous Man-Man-GlcN-PI or Gal(f)-Man-Man-GN-PI stimulated lipophosphoglycan synthesis in vitro. In contrast, when membrane preparations from R2D2 cells were incubated with exogenous Man-Man-GlcN-PI as an acceptor or in the absence of exogenous acceptor, the truncated glycosylphosphatidylinositide Glc-PO4-Man-Man-GlcN-PI was the main radioactive product synthesized. However, when exogenous Gal(f)-Man-Man-GN-PI was added to the R2D2 in vitro system, radioactive lipophosphoglycan was synthesized. Collectively, these results indicate that the mutant R2D2 cells are unable to complete the assembly of the glycan core of LPG because of a defect in the synthesis of the ''activated'' galactofuranosyl donor or the lack of a functional galactofuranosyltransferase.	UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky					NIAID NIH HHS [AI26355] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANET EFLJ, 1954, NATURE, V174, P930, DOI 10.1038/174930a0; CARVER MA, 1992, ARCH BIOCHEM BIOPHYS, V295, P309, DOI 10.1016/0003-9861(92)90523-Y; CARVER MA, 1991, J BIOL CHEM, V266, P10974; ELHAY M, 1990, MOL BIOCHEM PARASIT, V40, P255, DOI 10.1016/0166-6851(90)90047-P; HANDMAN E, 1986, J IMMUNOL, V137, P3608; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1991, CELL BIOL INT REP, V15, P779, DOI 10.1016/0309-1651(91)90033-F; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; Olsnes S, 1978, Methods Enzymol, V50, P330; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; ROSEN G, 1989, J BIOL CHEM, V264, P10457; ROSEN G, 1988, MOL BIOCHEM PARASIT, V27, P93, DOI 10.1016/0166-6851(88)90028-X; RYAN KA, 1993, IN PRESS P NATL ACAD; TREJO AG, 1971, BIOCHEM J, V122, P49, DOI 10.1042/bj1220049; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; VOLWERK JJ, 1989, J CELL BIOCHEM, V39, P315, DOI 10.1002/jcb.240390311	22	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24060	24066						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226951				2022-12-25	WOS:A1993MF29400054
J	HUNG, AY; HAASS, C; NITSCH, RM; QIU, WQ; CITRON, M; WURTMAN, RJ; GROWDON, JH; SELKOE, DJ				HUNG, AY; HAASS, C; NITSCH, RM; QIU, WQ; CITRON, M; WURTMAN, RJ; GROWDON, JH; SELKOE, DJ			ACTIVATION OF PROTEIN-KINASE-C INHIBITS CELLULAR PRODUCTION OF THE AMYLOID BETA-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; IDENTIFICATION; DERIVATIVES; SECRETION; MUTATION; CLEAVAGE; PEPTIDE; CELLS; LOCALIZATION	The 39-43-amino acid amyloid beta-protein (Abeta), which is progressively deposited in cerebral plaques and blood vessels in Alzheimer's disease (AD), is released by cultured human cells during normal metabolism. Here we show that agents which activate protein kinase C or otherwise enhance protein phosphorylation caused a substantial decrease in Abeta production in vitro. Protein kinase C activation also markedly decreased Abeta release from cells that express mutant forms of the beta-amyloid precursor protein genetically linked to familial AD. Inhibition of Abeta secretion could also be effected by direct stimulation of m1 muscarinic acetylcholine receptors with carbachol. These results demonstrate that activation of the protein kinase C signal transduction pathways down-regulates the generation of the amyloidogenic Abeta peptide. Pharmacologic agents that activate this system, including a variety of first messengers, could potentially slow the development or growth of some Abeta plaques during the early stages of AD.	HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115; MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital	HUNG, AY (corresponding author), HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115, USA.			Qiu, Wei Qiao (Wendy)/0000-0002-2082-2410				BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P355; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HUNG AY, 1992, P NATL ACAD SCI USA, V89, P9439, DOI 10.1073/pnas.89.20.9439; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SUZUKI T, 1992, NEUROSCIENCE, V48, P755, DOI 10.1016/0306-4522(92)90264-3; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	33	373	391	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22959	22962						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226807				2022-12-25	WOS:A1993MF51500002
J	MINOWA, MT; MINOWA, T; MOURADIAN, MM				MINOWA, MT; MINOWA, T; MOURADIAN, MM			ACTIVATOR REGION ANALYSIS OF THE HUMAN D(1A) DOPAMINE-RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; PROMOTER REGION; D1; EXPRESSION; DNA; BINDING; PROTEIN; SP1	The human D1A dopamine receptor gene is transcribed from a TATA-less promoter, and its main activator is between nucleotides -1342 and -1102 relative to the first ATG (Minowa, M. T., Minowa, T., Monsma, F. J., Jr., Sibley, D. R., and Mouradian, M. M. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 3045-3049). In the present study, additional serial deletion mutants fused with a reporter gene and used in transient transfections of the D1A-expressing cell line NS20Y further localized this activator to two regions: -1154 to -1137, which increases promoter activity 4-fold, and -1197 to 01154, which confers an additional 2-fold increase in transcriptional activity. Cell specificity of the D1A gene expression is contributed by both the -1197/-1154 region and the core promoter located downstream to -1102. DNase I footprinting and gel shift assays suggested that DNA-protein interactions occur primarily between -1197 and -1116. Competitive co-transfections using different portions of this segment, D1A-Act-1 (-1197 to -1152) and D1A-Act-2 (-1154 to -1116), confirmed the in vivo functional significance of these sequences in activating the D1A promoter. D1A-Act-1 has no consensus sequences for known transcription factors but binds to several proteins as a complex. Although D1A-Act-2 has AP2 consensus sequences and binds to recombinant AP2, the nuclear factors in NS20Y cells interacting with this region are distinct from AP2 itself. Despite the inability of Spl to directly bind to its consensus sequences in D1A-Act-2, Sp1 or another protein antigenically related to Sp1, as well as a novel nuclear factor, is included in the complex that binds to this activator.	NINCDS,EXPTL THERAPEUT BRANCH,GENET PHARMACOL UNIT,BLDG 10,RM 5C116,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Mouradian, M. Maral/0000-0002-9937-412X				AMMENDOLA R, 1990, MOL CELL BIOL, V10, P387, DOI 10.1128/MCB.10.1.387; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BERTORELLO AM, 1990, NATURE, V347, P386, DOI 10.1038/347386a0; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN XR, 1992, ONCOGENE, V7, P1805; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDER GA, 1992, NUCLEIC ACIDS RES, V20, P6281, DOI 10.1093/nar/20.23.6281; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; LEE T, 1978, NATURE, V274, P897, DOI 10.1038/274897a0; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MINOWA T, 1992, BIOCHEMISTRY-US, V31, P8389, DOI 10.1021/bi00151a001; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; MONSMA FJ, 1989, BRAIN RES, V492, P314, DOI 10.1016/0006-8993(89)90915-3; MOURADIAN MM, 1988, ANN NEUROL, V24, P372, DOI 10.1002/ana.410240304; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; RANEY AK, 1992, J VIROL, V66, P6912, DOI 10.1128/JVI.66.12.6912-6921.1992; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Sambrook J, 1989, MOL CLONING LABORATO; SIDHU A, 1990, BIOCHEM BIOPH RES CO, V166, P574, DOI 10.1016/0006-291X(90)90847-G; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WALTERS JR, 1987, SCIENCE, V236, P719; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; ZHANG P, 1993, J VIROL, V67, P1472, DOI 10.1128/JVI.67.3.1472-1481.1993; ZHOU QY, 1992, J NEUROCHEM, V59, P1875, DOI 10.1111/j.1471-4159.1992.tb11023.x; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	34	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23544	23551						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226883				2022-12-25	WOS:A1993MF51500090
J	NAUSEEF, WM; MCCORMICK, S; RENEE, J; LEIDAL, KG; CLARK, RA				NAUSEEF, WM; MCCORMICK, S; RENEE, J; LEIDAL, KG; CLARK, RA			FUNCTIONAL DOMAIN IN AN ARGININE-RICH CARBOXYL-TERMINAL REGION OF P47PHOX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; PROTEIN-KINASE-C; CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; NEUTROPHIL NADPH-OXIDASE; ADENINE-DINUCLEOTIDE PHOSPHATE; SODIUM DODECYL-SULFATE; 2 CYTOSOLIC COMPONENTS; SUPEROXIDE GENERATION; SUBCELLULAR-LOCALIZATION	Activation of the neutrophil respiratory burst oxidase involves phosphorylation-dependent translocation of the cytosolic proteins p47phox and p67phox to the plasma membrane, a process in intact cells that is inhibited by staurosporine. We now report that in a cell-free oxidase system, staurosporine and protein kinase C pseudosubstrate PKC(19-36) both inhibited p47phox phosphorylation but had no effect on superoxide generation. In contrast, p47phox phosphorylation, translocation, and superoxide generation were inhibited by a peptide, p47phox(323-332) (AYRRNSVRFL), based on a putative serine phosphorylation domain. This effect was specific for the 323-332 peptide, as it was not observed with two peptides based on other p47phox phosphorylation domains. All three peptides served as substrates for phosphorylation, but the extent of peptide phosphorylation did not correlate with inhibition of oxidase function. p47phox(325-330), which represents the serine phosphorylation motif of p47phox(323-332), did not inhibit translocation or superoxide production despite its ability to block phosphorylation of p47phox. These data indicate the presence of functionally important sites within the p47phox(323-332) peptide. Although serine 328 is in a consensus phosphorylation motif, the lack of correlation in the cell-free system between p47phox phosphorylation and either protein translocation or superoxide formation suggests that a phosphorylation-independent function resides in the 323-332 segment of p47phox.	DEPT VET AFFAIRS MED CTR,DEPT MED,IOWA CITY,IA 52242	US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	NAUSEEF, WM (corresponding author), UNIV IOWA,DEPT MED,200 HAWKINS DR,IOWA CITY,IA 52242, USA.		Clark, Robert/Q-6764-2019	Clark, Robert/0000-0002-4892-3619; Nauseef, William/0000-0003-4032-757X	NHLBI NIH HHS [HL 34327] Funding Source: Medline; NIAID NIH HHS [R37 AI020866, R01 AI020866, AI 20866, AI 28412] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028412, R37AI020866, R01AI020866] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BLRD VA; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs)		ABO A, 1991, J BIOL CHEM, V266, P23577; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CHIBA T, 1990, BIOCHEM BIOPH RES CO, V173, P376, DOI 10.1016/S0006-291X(05)81068-X; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1987, J BIOL CHEM, V262, P4065; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DEWALD B, 1989, BIOCHEM J, V264, P879, DOI 10.1042/bj2640879; DOUSSIERE J, 1988, BIOCHEM BIOPH RES CO, V152, P993, DOI 10.1016/S0006-291X(88)80382-6; GABIG TG, 1987, J BIOL CHEM, V262, P1685; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1986, BIOCHEM J, V239, P723, DOI 10.1042/bj2390723; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1989, BIOCHEM J, V260, P243, DOI 10.1042/bj2600243; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MALECH HL, 1993, CLIN RES, V41, pA323; MUID RE, 1991, FEBS LETT, V293, P169, DOI 10.1016/0014-5793(91)81178-B; NAUSEEF WM, 1990, BLOOD, V76, P2622; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; OKAMURA N, 1988, BLOOD, V72, P811; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PARK JW, 1992, J BIOL CHEM, V267, P19901; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAKO T, 1988, CANCER RES, V48, P4646; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAUBER AI, 1987, BLOOD, V69, P711; TEAHAN CG, 1990, BIOCHEM J, V267, P485, DOI 10.1042/bj2670485; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	46	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23646	23651						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226891				2022-12-25	WOS:A1993MF51500104
J	NUREKAMAL, MSA; VARGA, M; MARUTA, H				NUREKAMAL, MSA; VARGA, M; MARUTA, H			THE GTPASE-ACTIVATING NF1 FRAGMENT OF 91 AMINO-ACIDS REVERSES V-HA-RAS-INDUCED MALIGNANT PHENOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; GAP; EXPRESSION; PROTEIN; DOMAIN; TRANSFORMATION; INHIBITION; CLONING; RAS-P21; ENCODES	The human neurofibromatosis type 1 gene encodes a Ras GAP (GTPase-activating protein) of 2818 amino acids called NF1. This GAP contains a domain of 338 amino acids (residues 1194-1531) called NF1-GRD, which shares 26% sequence identity with the C-terminal domain (GAP1C, residues 709-1044) of another Ras GAP called GAP1. Both NF1-GRD and GAP1C activate normal Ras GTPases but not oncogenic mutants such as v-Ha-Ras. Any attempt to reverse the v-Ha-Ras-induced malignant transformation by the GAP1C has, so far, been unsuccessful. However, we have found that when the NF1-GRD is overexpressed in v-Ha-Ras-transformed NIH/3T3 cells, it greatly reduces their ability to form colonies in a soft agar, the property tightly associated with their malignancy. This is, so far, the first demonstration that a Ras-binding protein can act as a potent antagonist of the oncogenic Ras mutants in mammalian cells. In an attempt to further screen the smallest anti-oncogenic fragment derived from the NF1-GRD, we have prepared a series of its deletion mutants and examined their interaction with Ras first by monitoring their GAP activity (ability to activate the normal Ras GTPase). The deletion analysis has revealed that the N-terminal 247 amino acids (residues 1194-1440) of NF1-GRD are not required for its GAP activity, suggesting that its remaining domain of 91 amino acids (NF91, residues 1441-1531) is sufficient to bind the v-Ha-Ras, although its GAP activity is 20 times lower than the NF1-GRD. The NF91 is indeed able to reverse the v-Ha-Ras-induced malignant transformation as the NF1-GRD. The NF91 is, so far, the smallest among the tumor suppressor proteins that show the anti-v-Ha-Ras action in vivo. Thus, the NF91 appears to be a good starting material from which a smaller and more potent v-Ha-Ras antagonist could be devised to be used as a potential cure for the human cancers caused by the Ras mutants.			NUREKAMAL, MSA (corresponding author), LUDWIG INST CANC RES, PO ROYAL MELBOURNE HOSP, MELBOURNE, VIC 3050, AUSTRALIA.							ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; BUETTNER R, 1991, MOL CELL BIOL, V11, P3573, DOI 10.1128/MCB.11.7.3573; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; HATA Y, 1990, J BIOL CHEM, V265, P7104; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KYRITSIS AP, 1992, INT J ONCOL, V1, P149; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Maniatis T., 1982, MOL CLONING; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MARUTA H, 1991, J BIOL CHEM, V266, P11661; NISHI T, 1991, ONCOGENE, V6, P1555; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; NUREKAMAL MSA, 1992, MOL BIOL CELL, V3, P1437, DOI 10.1091/mbc.3.12.1437; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; STRAHEY M, 1987, SCIENCE, V238, P542; SUGIMOTO Y, 1991, CANCER RES, V51, P99; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	31	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22331	22337						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226742				2022-12-25	WOS:A1993MD34800024
J	RAMOSMORALES, F; DRUKER, BJ; FISCHER, S				RAMOSMORALES, F; DRUKER, BJ; FISCHER, S			VAV BINDS TO SEVERAL SH2/SH3 CONTAINING PROTEINS IN ACTIVATED LYMPHOCYTES	ONCOGENE			English	Article							T-CELL ACTIVATION; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL-3 KINASE; HEMATOPOIETIC-CELLS; PDGF RECEPTOR; BETA-SUBUNIT; EGF RECEPTOR; SH2 DOMAINS; SITE	In T lymphocytes, several proteins are rapidly phosphorylated on tyrosine after stimulation. In this study we examine the ability of tyrosine phosphorylated proteins from Jurkat T cells stimulated by CD2 or T cell receptor-CD3 to interact with the src homology 2 or src homology 3 domains from eight different proteins involved in signal transduction in lymphocytes: Vav, Shc, Nck, phosphatidylinositol-3-kinase, phospholipase C-gamma 1, Ras-GTPase activating protein, c-Crk and Grb2. Our data show that different SH2 domains have distinct pattern of binding to phosphotyrosine containing proteins. We show that Vav, a protein expressed only in hematopoietic cells that may have guanine nucleotide releasing factor activity, is able to interact with certain SH2-containing proteins depending on its tyrosine phosphorylation and with Grb2 in a manner independent of phosphorylation on tyrosine. Coimmunoprecipitation experiments support the idea of a trimolecular complex Shc-Grb2-Vav in vivo. These data suggest a central role played by Vav and provide insight in the complexity and specificity of protein-protein interactions in the signaling events in lymphocytes.	OREGON HLTH SCI UNIV, PORTLAND, OR 97201 USA	Oregon Health & Science University	RAMOSMORALES, F (corresponding author), HOP COCHIN, INSERM, U363, INST COCHIN GENET MOLEC, 27 RUE FAUBOURG ST JACQUES, F-75014 PARIS, FRANCE.		Ramos-Morales, Francisco/C-5734-2008	Ramos-Morales, Francisco/0000-0002-1151-4547; Druker, Brian/0000-0001-8331-8206				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HSI ED, 1989, J BIOL CHEM, V264, P10836; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOCH CA, 1991, SCIENCE, V252, P688; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PUIL L, 1992, Current Biology, V2, P275, DOI 10.1016/0960-9822(92)90396-R; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SONGYANG Z, 1993, CELL, V72, P1; WULF GM, 1993, EMBO J, V12, P5065, DOI 10.1002/j.1460-2075.1993.tb06200.x; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	38	76	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1917	1923						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208538				2022-12-25	WOS:A1994NR68500015
J	BIANCHI, V; FERRARO, P; BORELLA, S; BONVINI, P; REICHARD, P				BIANCHI, V; FERRARO, P; BORELLA, S; BONVINI, P; REICHARD, P			EFFECTS OF MUTATIONAL LOSS OF NUCLEOSIDE KINASES ON DEOXYADENOSINE 5'-PHOSPHATE DEOXYADENOSINE SUBSTRATE CYCLE IN CULTURED CEM AND V79 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEOSIDE-TRIPHOSPHATE POOLS; HAMSTER-CELLS; PICOMOLE AMOUNTS; MAMMALIAN-CELLS; DNA-SYNTHESIS; DEOXYCYTIDINE; LYMPHOBLASTS; METABOLISM; TOXICITY; DATP	The functions of a deoxynucleoside kinase and a deoxynucleotidase can give rise to substrate cycles in which the two enzymes catalyze in opposite directions the irreversible interconversion of a deoxynucleoside 5'-monophosphate (dNMP) and its deoxynucleoside. Earlier evidence showed that pyrimidine dNMP cycles occur in cultured cells and participate in the regulation of the size of dNMP pools there by affecting the transport of deoxyribonucleosides across the cell membrane. Here, we apply an isotope flow method using labeled adenine as precursor of dAMP and DNA to quantify deoxyadenosine excretion as a measure of the catabolic activity of a putative dAMP/deoxyadenosine cycle. A comparison of human CEM lymphoblasts and hamster V79 fibroblasts, including mutant cells lacking kinases for the phosphorylation of deoxyadenosine, shows a much lower deoxyadenosine excretion in CEM cells (0.05% of dATP synthesized by reduction of ADP) as compared with V79 cells (4% of dATP). Mutational loss of deoxycytidine kinase increases these values to 0.3% in CEM cells and to 10% in V79 cells. This strongly suggests the presence of a dAMP/deoxyadenosine cycle in both CEM and V79 cells. Additional loss of adenosine kinase only marginally affects deoxyadenosine excretion in CEM cells. The small excretion of deoxyadenosine (also in the absence of both kinases) demonstrates that in CEM cells the in situ activity of the deoxynucleotidase affecting the dAMP/deoxyadenosine substrate cycle is very low and that the cycle has mainly an anabolic function there.			BIANCHI, V (corresponding author), UNIV PADUA,DEPT BIOL,VIA TRIESTE 75,I-35121 PADUA,ITALY.		Bonvini, Paolo/J-9877-2018	Bonvini, Paolo/0000-0003-2889-108X				BIANCHI V, 1986, P NATL ACAD SCI USA, V83, P986, DOI 10.1073/pnas.83.4.986; BIANCHI V, 1992, EXP CELL RES, V199, P120, DOI 10.1016/0014-4827(92)90469-O; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; CARRERA CJ, 1987, MOL BASIS BLOOD DISE, P407; CARSON DA, 1981, J IMMUNOL, V126, P348; CARSON DA, 1991, BIOCHIM BIOPHYS ACTA, V1091, P22, DOI 10.1016/0167-4889(91)90216-K; De Serres F. S., 1985, GENETIC CONSEQUENCES; DURHAM JP, 1969, MOL PHARMACOL, V5, P358; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; HELLGREN D, 1979, BIOCHEM BIOPH RES CO, V88, P16, DOI 10.1016/0006-291X(79)91690-5; HERSHFIELD MS, 1982, J BIOL CHEM, V257, P6380; HOGLUND L, 1991, EUR J BIOCHEM, V196, P239, DOI 10.1111/j.1432-1033.1991.tb15810.x; HOGLUND L, 1988, CANCER RES, V48, P3681; IIZASA T, 1983, J IMMUNOL, V131, P1776; LINDBERG U, 1970, ANAL BIOCHEM, V34, P152, DOI 10.1016/0003-2697(70)90096-5; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; NICANDER B, 1985, J BIOL CHEM, V260, P9216; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SKOOG KL, 1973, EUR J BIOCHEM, V33, P428, DOI 10.1111/j.1432-1033.1973.tb02699.x; SKOOG L, 1970, EUR J BIOCHEM, V17, P202, DOI 10.1111/j.1432-1033.1970.tb01154.x	21	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16677	16683						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206987				2022-12-25	WOS:A1994NR29600027
J	HIRATA, Y; KIUCHI, K; CHEN, HC; MILBRANDT, J; GUROFF, G				HIRATA, Y; KIUCHI, K; CHEN, HC; MILBRANDT, J; GUROFF, G			THE PHOSPHORYLATION AND DNA-BINDING OF THE DNA-BINDING DOMAIN OF THE ORPHAN NUCLEAR RECEPTOR NGFI-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CASEIN KINASE-II; CHROMAFFIN CELLS; FIBER OUTGROWTH; PROTEIN; GENE; TRANSCRIPTION; MEMBER; SUPERFAMILY; NEURONS	NGFI-B is an orphan member of the nuclear receptor superfamily encoded by an immediate-early gene. It is rapidly synthesized and phosphorylated in PC12 cells in response to nerve growth factor (NGF) and other agents and is differentially phosphorylated dependent upon the inducing stimulus. The DNA-binding domain (DBD) of NGFI-B has been expressed in bacteria and purified. The purified protein is phosphorylated by protein kinase A or by extracts from NGF-treated PC12 cells. The phosphorylated residues within the DBD have been identified as Ser-340 and Ser-350. The use of mutants in which either or both of these residues were replaced with alanines revealed that phosphorylation of Ser-350, located within the ''A box,'' a motif necessary for DNA binding by NGFI-B, resulted in a decrease in binding to the NGFI-B response element, while phosphorylation of Ser-340 had little or no effect. These findings demonstrate that phosphorylation of a nuclear receptor DBD results in a change in DNA binding and provides another potential mechanism for regulating NGFI-B activity.	NICHHD,GROWTH FACTORS SECT,BLDG 49,RM 5A64,BETHESDA,MD 20892; WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV LAB MED,ST LOUIS,MO 63110	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Washington University (WUSTL); Washington University (WUSTL)			Hirata, Yoko/L-3142-2019; Hirata, Yoko/AAG-6798-2020	Hirata, Yoko/0000-0002-7081-4937; Milbrandt, Jeffrey/0000-0002-5477-7689				ALOE L, 1979, P NATL ACAD SCI USA, V76, P1246, DOI 10.1073/pnas.76.3.1246; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HEFTI F, 1985, NEUROSCIENCE, V14, P55, DOI 10.1016/0306-4522(85)90163-0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEVIMONTALCINI R, 1951, J EXP ZOOL, V116, P321, DOI 10.1002/jez.1401160206; LEVIMONTALCINI R, 1954, CANCER RES, V14, P49; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARTINEZ HJ, 1985, P NATL ACAD SCI USA, V82, P7777, DOI 10.1073/pnas.82.22.7777; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MOBLEY WC, 1985, SCIENCE, V229, P284, DOI 10.1126/science.2861660; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; TAYLOR LK, 1993, P NATL ACAD SCI USA, V90, P368, DOI 10.1073/pnas.90.2.368; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	36	96	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24808	24812						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227042				2022-12-25	WOS:A1993MG67300045
J	ROSSER, BG; POWERS, SP; GORES, GJ				ROSSER, BG; POWERS, SP; GORES, GJ			CALPAIN ACTIVITY INCREASES IN HEPATOCYTES FOLLOWING ADDITION OF ATP - DEMONSTRATION BY A NOVEL FLUORESCENT APPROACH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NEUTRAL PROTEASE; RAT HEPATOCYTES; EXTRACELLULAR ATP; CELL-DEATH; CALCIUM; LIVER; PROTEOLYSIS; NEUTROPHILS; ACTIVATION	Our aim was to measure calpain protease activity during increases in cytosolic free calcium (Ca2+i) after addition of extracellular ATP. The calpain protease substrate t-butoxycarbonyl-Leu-Met-7-amino-4-chloromethylcoumarin was synthesized. Nonfluorescent t-butoxycarbonyl-Leu-Met-7-amino-4-chloromethylcoumarin diffuses into the cell where it is conjugated to glutathione forming t-butoxycarbonyl-Leu-Met-7-amino-4-methylcoumarin glutathione conjugate (Boc-Leu-Met-MAC-SG). The nonfluorescent, membrane impermeant Boc-Leu-Met-MAC-SG accumulates in the cell. Intracellular proteolytic hydrolysis of Boc-Leu-Met-MAC-SG releases and unquenches the fluorescence of MAC-SG. Intracellular fluorescence of MAC-SG was quantitated in single, cultured rat hepatocytes using digitized video fluorescent microscopy. Enhancement of intracellular fluorescence generation by increases in Ca2+i and inhibition by a calpain inhibitor indicated the probe was a calpain substrate. After addition of ATP, calpain protease activity increased to 156 +/- 13% of basal concurrent with a 3-fold rise of Ca2+i for 2-4 min. Thereafter, Ca2+i decreased to values of 1.5-fold above basal and protease activity returned to normal. Incubation of cells in Ca2+-free buffer abolished the rise in Ca2+i and calpain protease activity. Calpain protease activity increases concomitantly with increases of Ca2+i supporting the hypothesis that calpain proteases participate in Ca2+-mediated signal transduction.	MAYO CLIN & MAYO FDN,MAYO MED SCH,CTR BASIC RES DIGEST DIS,DEPT INTERNAL MED,ROCHESTER,MN 55905	Mayo Clinic					NIDDK NIH HHS [DK45876] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTS B, 1983, MOL BIOL CELL, P332; ANAGLI J, 1991, BIOCHEM J, V274, P497, DOI 10.1042/bj2740497; BEAR CE, 1991, AM J PHYSIOL, V261, pC1018, DOI 10.1152/ajpcell.1991.261.6.C1018; BELLOMO G, 1992, P NATL ACAD SCI USA, V89, P4412, DOI 10.1073/pnas.89.10.4412; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BISSELL DM, 1987, J CLIN INVEST, V79, P801, DOI 10.1172/JCI112887; BRONK SF, 1991, HEPATOLOGY, V14, P626; BRONK SF, 1991, HEPATOLOGY, V14, P150, DOI 10.1002/hep.1840140125; BRONK SF, 1993, AM J PHYSIOL, V264, pG744, DOI 10.1152/ajpgi.1993.264.4.G744; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CHAREST R, 1985, J BIOL CHEM, V260, P5789; Crawford C., 1990, INTRACELLULAR CALCIU, P75; CROALL DE, 1990, INTRACELLULAR CALCIU, P103; DICKSON RC, 1992, GASTROENTEROLOGY, V102, P2098, DOI 10.1016/0016-5085(92)90338-Y; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P343, DOI 10.1016/0003-9861(84)90207-8; EXTON JH, 1990, ANN NY ACAD SCI, V603, P246; EXTON JH, 1988, HEPATOLOGY, V8, P152, DOI 10.1002/hep.1840080129; FOX JEB, 1983, J BIOL CHEM, V258, P9973; GEBHARD W, 1986, PROTEINASE INHIBITOR, P375; GORES GJ, 1989, J CLIN INVEST, V83, P386, DOI 10.1172/JCI113896; GROSKREUTZ JL, 1992, GASTROENTEROLOGY, V102, P1030, DOI 10.1016/0016-5085(92)90193-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MAKI M, 1989, J BIOL CHEM, V264, P18866; MASON RW, 1985, BIOCHEM J, V226, P233, DOI 10.1042/bj2260233; MCMILLIAN MK, 1988, BIOCHEM J, V255, P291; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MELLONI E, 1986, J BIOL CHEM, V261, P4101; NISHIURA I, 1978, J BIOCHEM-TOKYO, V84, P1657, DOI 10.1093/oxfordjournals.jbchem.a132296; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PONTREMOLI S, 1988, J BIOL CHEM, V263, P1915; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; Reed P W, 1979, Methods Enzymol, V55, P435; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; TAYLOR DL, 1992, AM SCI, V80, P322; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; ZIMNIAK P, 1993, HEPATOLOGY, V17, P330, DOI 10.1002/hep.1840170226	46	110	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23593	23600						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226886				2022-12-25	WOS:A1993MF51500097
J	SCHIRCH, D; DELLEFRATTE, S; IURESCIA, S; ANGELACCIO, S; CONTESTABILE, R; BOSSA, F; SCHIRCH, V				SCHIRCH, D; DELLEFRATTE, S; IURESCIA, S; ANGELACCIO, S; CONTESTABILE, R; BOSSA, F; SCHIRCH, V			FUNCTION OF THE ACTIVE-SITE LYSINE IN ESCHERICHIA-COLI SERINE HYDROXYMETHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE-AMINOTRANSFERASE; RABBIT LIVER; 10-FORMYLTETRAHYDROFOLATE SYNTHETASE; REACTION SPECIFICITY; PYRIDOXAL-PHOSPHATE; MUTANT; TETRAHYDROPTEROYLPOLYGLUTAMATES; RACEMIZATION; CONVERSION; MECHANISM	Serine hydroxymethyltransferase has a conserved lysine residue (Lys-229) that forms the internal aldimine with pyridoxal 5'-phosphate. In other pyridoxal 5'-phosphate enzymes investigated so far, this conserved lysine residue also plays a catalytic role as a base that removes the alpha-proton from the amino acid substrate. Three mutant forms of Escherichia coli serine hydroxymethyltransferase (K229Q, K229R, and K229H) were constructed, expressed, and purified. The absorbance spectra, rapid reaction kinetics, and thermal denaturation of the mutant analogs were studied. Only the K229Q mutant serine hydroxymethyltransferase resembled the wild-type enzyme. The results indicate that Lys-229 plays a critical role in expelling the product by converting the external aldimine to an internal aldimine. In the absence of Lys-229, ammonia can also catalyze the same function at a much slower rate. However, Lys-229 apparently is not the base that removes the alpha-proton from the amino acid substrate. The K229Q mutant enzyme could catalyze one turnover of either serine to glycine or glycine to serine at rates approaching those of the wild-type enzyme. After one turnover, the mutant enzyme could not expel the product and bind new substrate. The K229Q mutant enzyme can also transaminate D-alanine, which, like the hydroxymethyltransferase activity, also requires removing the alpha-proton from the substrate. The absorbance spectra of the K229R and K229H serine hydroxymethyltransferases showed that their pyridoxal 5'-phosphate could not readily form an external aldimine with substrates, suggesting that Lys-229 in the wild-type enzyme may never bear a positive charge, further evidence that it is not the base that removes the alpha-proton.	VIRGINIA COMMONWEALTH UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,BOX 614,MCV STN,RICHMOND,VA 23298; UNIV ROMA LA SAPIENZA,CNR,DIPARTIMENTO SCI BIOCHIM A ROSSI FANELLI,I-00185 ROME,ITALY; UNIV ROMA LA SAPIENZA,CNR,CTR BIOL MOLEC,I-00185 ROME,ITALY	Virginia Commonwealth University; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome			Angelaccio, Sebastiana/D-2842-2011; Contestabile, Roberto/J-3467-2019; IURESCIA, Sandra/B-9443-2015	Contestabile, Roberto/0000-0002-5235-9993; IURESCIA, Sandra/0000-0002-8200-9775	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028143] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28143] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGELACCIO S, 1992, BIOCHEMISTRY-US, V31, P155, DOI 10.1021/bi00116a023; ARNONE A, 1985, TRANSAMINASES, P326; BARRA D, 1991, BIOTECHNOL APPL BIOC, V13, P48; BHATIA MB, 1993, J BIOL CHEM, V268, P6932; BYRNE PC, 1992, BIOCHEM J, V286, P117, DOI 10.1042/bj2860117; DUNATHAN HC, 1974, P NATL ACAD SCI USA, V71, P3888, DOI 10.1073/pnas.71.10.3888; GRIMM B, 1992, EUR J BIOCHEM, V206, P579, DOI 10.1111/j.1432-1033.1992.tb16962.x; HARRUFF RC, 1976, ARCH BIOCHEM BIOPHYS, V176, P206, DOI 10.1016/0003-9861(76)90157-0; ILAG LL, 1992, BIOCHEMISTRY-US, V31, P7143, DOI 10.1021/bi00146a016; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; KOCHHAR S, 1992, EUR J BIOCHEM, V203, P563, DOI 10.1111/j.1432-1033.1992.tb16584.x; LU ZC, 1993, J BIOL CHEM, V268, P8727; MCCLUNG CR, 1992, MOL CELL BIOL, V12, P1412, DOI 10.1128/MCB.12.4.1412; NISHIMURA K, 1991, BIOCHEMISTRY-US, V30, P4072, DOI 10.1021/bi00230a036; PLANAS A, 1991, BIOCHEMISTRY-US, V30, P8268, DOI 10.1021/bi00247a023; SCHIRCH L, 1977, BIOCHEMISTRY-US, V16, P410, DOI 10.1021/bi00622a011; SCHIRCH L, 1978, ARCH BIOCHEM BIOPHYS, V189, P283, DOI 10.1016/0003-9861(78)90214-X; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; SHOSTAK K, 1988, BIOCHEMISTRY-US, V27, P8007, DOI 10.1021/bi00421a006; SMITH DL, 1989, BIOCHEMISTRY-US, V28, P8161, DOI 10.1021/bi00446a030; STOVER P, 1992, J BIOL CHEM, V267, P17679; STRONG W, 1987, J BIOL CHEM, V262, P12519; STRONG WB, 1989, BIOCHEMISTRY-US, V28, P9430, DOI 10.1021/bi00450a028; TONEY MD, 1992, PROTEIN SCI, V1, P107; TONEY MD, 1991, J BIOL CHEM, V266, P23900; VILLAR E, 1985, J BIOL CHEM, V260, P2245; YOSHIMURA T, 1992, BIOCHEMISTRY-US, V31, P11748, DOI 10.1021/bi00162a011; ZIAK M, 1993, EUR J BIOCHEM, V211, P475, DOI 10.1111/j.1432-1033.1993.tb17573.x	29	52	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23132	23138						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226831				2022-12-25	WOS:A1993MF51500030
J	RADINSKY, R; FIDLER, IJ; PRICE, JE; ESUMI, N; TSAN, R; PETTY, MC; BUCANA, CD; BARELI, M				RADINSKY, R; FIDLER, IJ; PRICE, JE; ESUMI, N; TSAN, R; PETTY, MC; BUCANA, CD; BARELI, M			TERMINAL DIFFERENTIATION AND APOPTOSIS IN EXPERIMENTAL LUNG METASTASES OF HUMAN OSTEOGENIC-SARCOMA CELLS BY WILD-TYPE P53	ONCOGENE			English	Article							CHRONIC MYELOCYTIC-LEUKEMIA; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; TUMOR PROGRESSION; MUTANT; MUTATIONS; PROTEIN; GROWTH; GENE; INDUCTION	Human SAOS-2 osteogenic sarcoma cells are not metastatic in nude mice and do not express p53. We have selected a variant line (SAOS-LM2) that is tumorigenic and metastatic in nude mice. These cells were transfected with the p53 wild-type (p53(wt)) or mutated (p53(mut) 143A) gene, whose expression was verified by reverse transcriptase PCR, cDNA sequencing, and protein immunoprecipitation. Cells were injected i.v. into nude mice, and 4 months later, the mice were necropsied. All cell lines produced a similar number of visible lung metastases, albeit of different sizes, Microscopic examination revealed that most lung metastases in mice injected with p53(wt) cells (but not p53(mut) 143A or control cells) consisted of osteoid matrix and apoptotic;cells. Expression of either p53(wt) or p53(mut) 143A verified the origin of the metastases. These data suggest that transfection of SAOS-LM2 cells with p53(wt) is associated with in vivo induction of terminal differentiation and apoptosis that inhibit progressive growth of metastases.			RADINSKY, R (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HMB 173,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NCI NIH HHS [R35-CA 42107, CA 41525, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042107, P30CA016672, R01CA041525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARELI M, 1993, ANTICANCER RES, V13, P1619; BARELI M, 1989, BLOOD, V73, P281; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Coolidge BJ, 1979, ANIMAL HISTOLOGY PRO; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIAS L, 1991, LEUKEMIA, V5, P879; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIDLER IJ, 1990, CANCER RES, V50, P6130; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; FOTI A, 1991, BLOOD, V77, P2441; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, ONCOGENE, V6, P131; KEY L, 1984, NEW ENGL J MED, V310, P409, DOI 10.1056/NEJM198402163100701; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUCA M, 1993, INT J ONCOL, V3, P19; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOTYKA B, 1991, EUR J IMMUNOL, V21, P1951, DOI 10.1002/eji.1830210825; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RADINSKY R, 1991, INT J CANCER, V48, P148; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Rodan GA, 1983, BONE MINERAL RES ANN, V2, P244; RODAN SB, 1987, CANCER RES, V47, P4961; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPIESS YH, 1986, ENDOCRINOLOGY, V118, P1340, DOI 10.1210/endo-118-4-1340; Thompson SW, 1966, SELECTED HISTOCHEMIC; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1993, ONCOGENE, V8, P2555	48	92	93	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1877	1883						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208533				2022-12-25	WOS:A1994NR68500010
J	DEMENDEZ, I; GARRETT, MC; ADAMS, AG; LETO, TL				DEMENDEZ, I; GARRETT, MC; ADAMS, AG; LETO, TL			ROLE OF P67-PHOX SH3 DOMAINS IN ASSEMBLY OF THE NADPH OXIDASE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; GTP-BINDING PROTEIN; RESPIRATORY BURST OXIDASE; PHOSPHATIDYLINOSITOL 3-KINASE; CRYSTAL-STRUCTURE; TYROSINE KINASES; NEUTROPHIL; COMPONENTS; REGION; GRB2	Src homology 3 (SH3) domains direct cellular localization and signal transduction through specific protein-protein interactions with proline-rich target sequences. The two SH3 domain in p67-phox, a cytosolic component of the phagocyte NADPH oxidase system, may mediate interactions within the oxidase complex and direct its translocation to membranes. The requirement for SH3 domains in p67-phox was studied both in cell-free and whole cell oxidase assay systems. The amino-terminal domain of p67-phox (amino acids 1-246) that lacks both SH3 domains was active in vitro. Various forms of p67-phox lacking one or both SH3 domains were produced in whole cells using episomal expression vectors to stably transfect p67-phox-deficient Epstein-Barr virus-B cells derived from chronic granulomatous disease patients. Complete restoration of NADPH oxidase activity was achieved with full-length p67-phox cDNA expression. Deletion of either SH3 domain resulted in dramatic reductions of NADPH oxidase activity relative to corrected transfected cells, which correlated with decreases in membrane binding. Deletion of both SH3 domains completely abolished p67-phox membrane binding and oxidase activity. Thus, in contrast to oxidase reconstitution in a cell-free system, we observed a requirement for both SH3 motifs for restoration of oxidase activity and binding of p67-phox to membranes.	NIAID,HOST DEF LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BRISTOL A, 1988, COLD SPRING HARB SYM, V53, P915, DOI 10.1101/SQB.1988.053.01.105; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	36	101	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16326	16332						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206939				2022-12-25	WOS:A1994NQ72900058
J	MUNDSCHAU, LJ; FORMAN, LW; WENG, HQ; FALLER, DV				MUNDSCHAU, LJ; FORMAN, LW; WENG, HQ; FALLER, DV			PLATELET-DERIVED GROWTH-FACTOR (PDGF) INDUCTION OF EGR-1 IS INDEPENDENT OF PDGF RECEPTOR AUTOPHOSPHORYLATION ON TYROSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS EXPRESSION; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; KINASE-ACTIVITY; DNA-SYNTHESIS; 3T3 CELLS; TRANSFORMING PROTEIN; PATHWAYS; ACTIVATION; BINDING	Autophosphorylation of the platelet-derived growth factor (PDGF) receptor on tyrosine, which is dependent upon and occurs immediately after ligand binding, has been linked to the activation of second messenger pathways thought to be necessary for the induction of gene expression, DNA synthesis, and mitogenesis. We have investigated PDGF signal transduction in Balb/c-3T3 and NIH-3T3 cells at the level of immediate early gene induction under three conditions in which PDGF receptor autophosphorylation in response 60 PDGF binding is blocked: cells transformed by v-ras(Ki), cells transformed by v-mos, and cells treated with genistein, a specific inhibitor of tyrosine kinases. PDGF induction of immediate-early genes c-myc, c-fos, and JE is blocked in these systems. Induction of another immediate-early gene, egr-1, occurs normally despite the absence of measurable tyrosine kinase activity. The same results were obtained when cells were stimulated with PDGF-AA or PDGF-BB. It is not yet clear if this receptor tyrosine kinase-independent signal utilizes known PDGF second messengers, but these results demonstrate a new arm of the PDGF signal transduction pathway which operates in the absence of, and independently from, autophosphorylation of the receptor on tyrosine.	BOSTON UNIV, SCH MED, CANC RES CTR, BOSTON, MA 02118 USA	Boston University				Kasman, Laura/0000-0002-8661-2918				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FALLER DV, 1994, J BIOL CHEM, V269, P5022; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; JAMIESON GA, 1989, J CELL PHYSIOL, V139, P262, DOI 10.1002/jcp.1041390207; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEE BA, 1991, J CELL BIOL, V113, P361, DOI 10.1083/jcb.113.2.361; LIM RW, 1987, ONCOGENE, V1, P263; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; RAKE JB, 1991, J BIOL CHEM, V266, P5348; SALHANY KE, 1992, J CELL PHYSIOL, V150, P386, DOI 10.1002/jcp.1041500223; SCHALASTA G, 1990, MOL CELL BIOL, V10, P5558, DOI 10.1128/MCB.10.10.5558; SEYFERT VL, 1990, J IMMUNOL, V145, P3647; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATERS CM, 1990, ONCOGENE, V5, P669; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080; ZWILLER J, 1991, ONCOGENE, V6, P219	42	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16137	16142						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206913				2022-12-25	WOS:A1994NQ72900030
J	CIOSEK, CP; MAGNIN, DR; HARRITY, TW; LOGAN, JVH; DICKSON, JK; GORDON, EM; HAMILTON, KA; JOLIBOIS, KG; KUNSELMAN, LK; LAWRENCE, RM; MOOKHTIAR, KA; RICH, LC; SLUSARCHYK, DA; SULSKY, RB; BILLER, SA				CIOSEK, CP; MAGNIN, DR; HARRITY, TW; LOGAN, JVH; DICKSON, JK; GORDON, EM; HAMILTON, KA; JOLIBOIS, KG; KUNSELMAN, LK; LAWRENCE, RM; MOOKHTIAR, KA; RICH, LC; SLUSARCHYK, DA; SULSKY, RB; BILLER, SA			LIPOPHILIC 1,1-BISPHOSPHONATES ARE POTENT SQUALENE SYNTHASE INHIBITORS AND ORALLY-ACTIVE CHOLESTEROL-LOWERING AGENTS IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; BETA-METHYLGLUTARYL COENZYME; DENSITY LIPOPROTEIN RECEPTOR; COMPETITIVE INHIBITOR; MOLECULAR-CLONING; BIOSYNTHESIS; SYNTHETASE; STEROL; RAT; 3-HYDROXY-3-METHYLGLUTARYL	Squalene synthase catalyzes the reductive dimerization of two molecules of farnesyl diphosphate to form squalene at the final branchpoint of the cholesterol biosynthetic pathway. We report herein that isoprenyl 1,1-bisphosphonates and related analogs are potent inhibitors of rat microsomal squalene synthase (I50 = 0.7-32 nM). In addition, members of this family are potent inhibitors of cholesterol biosynthesis in rats on intravenous and oral dosing, as well as cholesterol lowering agents in rats and hamsters. Significant inhibition of cholesterol biosynthesis in rats by lovastatin occurs with a concomitant inhibition of dolichol and coenzyme-Q9 synthesis. In contrast, bisphosphonate 4 has no effect on dolichol and coenzyme-Q9 biosynthesis in rats under conditions where cholesterol biosynthesis is >90% inhibited.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DIV DISCOVERY CHEM, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb	CIOSEK, CP (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT METAB DIS, PRINCETON, NJ 08543 USA.							AGNEW WS, 1985, METHOD ENZYMOL, V110, P359; AMIN D, 1992, J LIPID RES, V33, P1657; ARBEENY CM, 1991, BIOCHIM BIOPHYS ACTA, V1096, P238, DOI 10.1016/0925-4439(91)90011-W; BAXTER A, 1992, J BIOL CHEM, V267, P11705; BERGSTROM JD, 1993, P NATL ACAD SCI USA, V90, P80, DOI 10.1073/pnas.90.1.80; BILLER SA, 1993, BIOORG MED CHEM LETT, V3, P595, DOI 10.1016/S0960-894X(01)81236-1; BILLER SA, 1992, ACS SYM SER, V497, P65; BILLER SA, 1991, J MED CHEM, V34, P1912, DOI 10.1021/jm00110a024; BILLER SA, 1991, J AM CHEM SOC, V113, P8522, DOI 10.1021/ja00022a050; BILLER SA, 1992, Patent No. 5157027; CHRISTOPHE J, 1961, J LIPID RES, V2, P244; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; DUGAN RE, 1972, ARCH BIOCHEM BIOPHYS, V152, P21, DOI 10.1016/0003-9861(72)90188-9; ELMBERGER PG, 1987, EUR J BIOCHEM, V168, P1, DOI 10.1111/j.1432-1033.1987.tb13379.x; EPSTEIN WW, 1970, J BIOL CHEM, V245, P4597; FEGUEUR M, 1991, CURR GENET, V20, P365, DOI 10.1007/BF00317063; Fleisch H., 1988, HDB EXPT PHARM, V83, P441; GONZALEZPACANOWSKA D, 1988, J BIOL CHEM, V263, P1301; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; HOEG JM, 1987, JAMA-J AM MED ASSOC, V258, P3532, DOI 10.1001/jama.258.24.3532; HORIE M, 1990, J BIOL CHEM, V265, P18075; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; KELLER RK, 1989, CHEM PHYS LIPIDS, V51, P261, DOI 10.1016/0009-3084(89)90013-3; MA PTS, 1986, P NATL ACAD SCI USA, V83, P8370, DOI 10.1073/pnas.83.21.8370; MCKENZIE TL, 1992, J BIOL CHEM, V267, P21368; NAKAMURA CE, 1985, BIOCHEMISTRY-US, V24, P1364, DOI 10.1021/bi00327a014; Poulter C, 1981, BIOSYNTHESIS ISOPREN, P413; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; RAHIER A, 1990, BIOCHEM SOC T, V18, P48, DOI 10.1042/bst0180048; RILLING HC, 1985, BIOCHEM SOC T, V13, P997, DOI 10.1042/bst0130997; ROBINSON GW, 1993, MOL CELL BIOL, V13, P2706, DOI 10.1128/MCB.13.5.2706; SPADY DK, 1985, P NATL ACAD SCI USA, V82, P4526, DOI 10.1073/pnas.82.13.4526; TSUJITA Y, 1986, BIOCHIM BIOPHYS ACTA, V877, P50, DOI 10.1016/0005-2760(86)90117-7; WAREING JR, 1986, Patent No. 4613610	36	105	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24832	24837						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227045				2022-12-25	WOS:A1993MG67300049
J	PARYS, JB; MISSIAEN, L; DESMEDT, H; CASTEELS, R				PARYS, JB; MISSIAEN, L; DESMEDT, H; CASTEELS, R			LOADING DEPENDENCE OF INOSITOL 1,4,5-TRISPHOSPHATE-INDUCED CA2+ RELEASE IN THE CLONAL CELL-LINE A7R5 - IMPLICATIONS FOR THE MECHANISM OF QUANTAL CA2+ RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRISPHOSPHATE-SENSITIVE STORES; CALCIUM RELEASE; LUMINAL CA2+; INTRACELLULAR STORES; ENDOPLASMIC-RETICULUM; INTRALUMINAL CA2+; SMOOTH-MUSCLE; RECEPTOR; MOBILIZATION; INSP3	The Ca2+ content of the intracellular Ca2+ stores controls the inositol 1,4,5-trisphosphate receptor (InsPsR) in the clonal cell line A7r5. This regulation was characterized with respect to the understanding of the ''quantal'' release phenomenon. Independent of the loading protocol used, increasing the Ca2+ content of the stores increased the sensitivity of the inositol 1,4,5-trisphosphate (InsP3)-induced Ca2+ release until a Ca2+ content of about 30% of the steady-state value was reached. Loading of the stores to higher levels had only a marginal effect on the Ca2+ release. The effects of luminal Ca2+ were still observed in the presence of 10 mM BAPTA (1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), excluding the possibility that luminal Ca2+ acted indirectly via cytoplasmic binding sites. Conditions were developed to simultaneously measure [H-3]InsP3 binding to the InSP3R and the Ca-45(2+) content of the stores in the same cells. [H-3] InsP3 binding to a high affinity binding site was potentiated by luminal Ca2+. Analysis at the molecular level revealed the simultaneous expression of different splice variants of InsP3R-I, as well as the expression of InsP3R-III, and of the putative InsP3R-IV. We conclude that the control of the InSP3R by luminal Ca2+ could account for quantal release and that the observed heterogeneity of the InsP3R may also contribute to this behavior, especially at high levels of store loading.			PARYS, JB (corresponding author), CATHOLIC UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG O-N, B-3000 LOUVAIN, BELGIUM.			Parys, Jan/0000-0002-3591-4967				BAUMANN O, 1989, J COMP PHYSIOL A, V165, P627, DOI 10.1007/BF00610994; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COMBETTES L, 1992, FEBS LETT, V301, P287, DOI 10.1016/0014-5793(92)80258-I; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HILLY M, 1993, J BIOL CHEM, V268, P16488; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; ILYIN V, 1992, J PHYSIOL-LONDON, V448, P339, DOI 10.1113/jphysiol.1992.sp019045; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; LOOMISHUSSELBEE JW, 1993, BIOCHEM J, V289, P861, DOI 10.1042/bj2890861; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1993, BIOCHEM BIOPH RES CO, V193, P6, DOI 10.1006/bbrc.1993.1582; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NUNN DL, 1990, BIOCHEM J, V270, P227, DOI 10.1042/bj2700227; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1993, BIOCHEM J, V292, P631, DOI 10.1042/bj2920631; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PARYS JB, 1992, J BIOL CHEM, V267, P18776; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROUXEL FP, 1992, J BIOL CHEM, V267, P20017; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SAYERS LG, 1993, BIOCHEM J, V289, P883, DOI 10.1042/bj2890883; SCHELL MJ, 1993, MOL BRAIN RES, V17, P212, DOI 10.1016/0169-328X(93)90004-9; SHUTTLEWORTH TJ, 1992, J BIOL CHEM, V267, P3573; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; TAYLOR CW, 1992, TRENDS BIOCHEM SCI, V17, P403, DOI 10.1016/0968-0004(92)90009-X; TREGEAR RT, 1991, P ROY SOC B-BIOL SCI, V243, P263, DOI 10.1098/rspb.1991.0040; TSHIPAMBA M, 1993, J CELL PHYSIOL, V155, P96, DOI 10.1002/jcp.1041550113	54	100	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25206	25212						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227085				2022-12-25	WOS:A1993MG67300098
J	RUGOLO, M; MASTROCOLA, T; WHORLE, C; RASOLA, A; GRUENERT, DC; ROMEO, G; GALIETTA, LJV				RUGOLO, M; MASTROCOLA, T; WHORLE, C; RASOLA, A; GRUENERT, DC; ROMEO, G; GALIETTA, LJV			ATP AND A(1) ADENOSINE RECEPTOR AGONISTS MOBILIZE INTRACELLULAR CALCIUM AND ACTIVATE K+ AND CL- CURRENTS IN NORMAL AND CYSTIC-FIBROSIS AIRWAY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; PHOSPHOLIPASE-C; ACINAR-CELLS; CHANNELS; CA-2+; LINE; THAPSIGARGIN; SECRETION	The effect of purinergic compounds on [Ca2+]i and membrane currents of cell lines derived from the airway epithelium of normal and cystic fibrosis individuals has been investigated. 2-Chloroadenosine (2-CADO), as well as other agonists of the A1 adenosine receptors, causes a transient elevation of cytosolic [Ca2+] that is antagonized by the A1 adenosine receptor antagonist 8-cyclopentyl-1,3 dipropylxanthine (DPCPX). ATP is also effective, but at a lower extent. The [Ca2+]i increase induced by 2-CADO and ATP is abolished by preincubation with phorbol 12-myristate 13-acetate and the Ca2+-ATPase inhibitor thapsigargin. This latter result suggests that purinergic agonists mobilize Ca2+ from inositol 1,4,5-trisphosphate-sensitive stores. Pertussis toxin completely inhibits the effect of 2-CADO, whereas only it partially affects that of ATP, suggesting the involvement of different types of G proteins. Perforated patch clamp experiments carried out in both current clamp and voltage clamp modes show that 2-CADO and ATP activate K+- and Cl--selective membrane currents, with a mechanism inhibited by preincubation with DPCPX and thapsigargin. These data indicate that activation of adenosine A1 receptor, in a similar way to ATP receptor, causes [Ca2+]i increase and ion channels activation through a transduction mechanism that is not impaired in cystic fibrosis airway epithelial cells.	UNIV CALIF SAN FRANCISCO,CARDIOVASC & CANC RES INST,DEPT LAB MED,SAN FRANCISCO,CA 94143; IST GIANNINA GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY	University of California System; University of California San Francisco; University of Genoa; IRCCS Istituto Giannina Gaslini	RUGOLO, M (corresponding author), UNIV BOLOGNA,DIPARTIMENTO BIOL,BIOCHIM LAB,VIA IRNERIO 42,I-40126 BOLOGNA,ITALY.		Galietta, Luis JV/HCG-8692-2022; Rugolo, Michela/AAY-8640-2020	Rasola, Andrea/0000-0003-4522-3008; Galietta, Luis/0000-0001-8686-3461; Rugolo, Michela/0000-0002-4597-0452				ALI H, 1990, J BIOL CHEM, V265, P745; BROWN HA, 1991, MOL PHARMACOL, V40, P648; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; COZENS AL, 1991, ADV EXP MED BIOL, V290, P187; COZENS AL, 1992, P NATL ACAD SCI USA, V89, P5171, DOI 10.1073/pnas.89.11.5171; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GALIETTA LJV, 1991, BIOCHEM BIOPH RES CO, V179, P1155, DOI 10.1016/0006-291X(91)91692-6; GALIETTA LJV, 1992, FEBS LETT, V304, P61, DOI 10.1016/0014-5793(92)80589-9; GERWINS P, 1992, J BIOL CHEM, V267, P16081; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HORN R, 1988, J GEN PHYSIOL, V92, P85; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P264, DOI 10.1007/BF00585301; LAZAROWSKI ER, 1992, BRIT J PHARMACOL, V106, P774, DOI 10.1111/j.1476-5381.1992.tb14412.x; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; SCHWIEBERT EM, 1992, J CLIN INVEST, V89, P834, DOI 10.1172/JCI115662; STILES GL, 1992, J BIOL CHEM, V267, P6451; STONE TW, 1991, GEN PHARMACOL, V22, P25, DOI 10.1016/0306-3623(91)90305-P; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; TAN YP, 1992, P NATL ACAD SCI USA, V89, P11229, DOI 10.1073/pnas.89.23.11229; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Trivedi B. H., 1990, ADENOSINE ADENOSINE, P57; WATSON S, 1991, TRENDS PHARMACOL SCI, V12, P25; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	29	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24779	24784						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227038				2022-12-25	WOS:A1993MG67300041
J	CHEN, M; SCHNERMANN, J; SMART, AM; BROSIUS, FC; KILLEN, PD; BRIGGS, JP				CHEN, M; SCHNERMANN, J; SMART, AM; BROSIUS, FC; KILLEN, PD; BRIGGS, JP			CYCLIC-AMP SELECTIVELY INCREASES RENIN MESSENGER-RNA STABILITY IN CULTURED JUXTAGLOMERULAR GRANULAR CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; GLUCOSE-TRANSPORTER; CAMP; PROTEIN; CDNA; IDENTIFICATION; TRANSCRIPTION; DETERMINANTS; ELEMENTS; CLONING	This study was undertaken to examine the regulation of renin release and gene expression in primary cultures of juxtaglomerular granular (JGG) cells. JGG cells, isolated from mouse kidney, demonstrated high purity and showed regulated renin release in vitro. Changes in steady-state renin mRNA levels were assessed by quantitative polymerase chain reaction techniques, with polymerase chain reaction amplification efficiency monitored by co-amplification of experimental samples with a dilution series of cDNA for a mutant template. When the cells were incubated in the presence or absence of forskolin, isoproterenol, or 8-bromo-cAMP plus 3-isobutyl-1-methylxanthine for 24 h or cholera toxin for 12 h, renin mRNA levels were increased 3.9-, 4.4-, 5.1-, and 3.3-fold, respectively (all, p < 0.05). A significant increase in renin mRNA levels was observed 8 h after treatment with forskolin, but no change was detectable at 4 h. Cycloheximide did not prevent the increase in renin mRNA by isoproterenol. When RNA synthesis was inhibited by incubation with actinomycin D (5 mug/ml), renin mRNA levels declined with a half-life of 3.0 +/- 0.8 h. Treatment with forskolin increased renin mRNA half-life to 10.8 +/- 2.7 h (p < 0.025). The half-life of beta-actin, endothelin-1, or the facilitative glucose transporter-1 (GLUT-1) mRNA expressed in the same cells was not altered, although the steady-state levels of GLUT-1 mRNA increased 2.2-fold after treatment with forskolin. These data demonstrate that cAMP increases renin release and mRNA levels in JGG cells in vitro, that the stimulatory effect of cAMP on renin mRNA is delayed but does not require new protein synthesis, and that the increased renin mRNA levels induced by cAMP are due in part to a selective increase in renin mRNA stability.	UNIV MICHIGAN,DEPT INTERNAL MED,DIV NEPHROL,1150 W MED CTR DR,1560 MSRB 2,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Briggs, Josephine P/B-9394-2009	Briggs, Josephine P/0000-0003-0798-1190	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255, R01DK040042, R01DK037448] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-37448, DK-39255, DK40042] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BURNHAM CE, 1987, P NATL ACAD SCI USA, V84, P5605, DOI 10.1073/pnas.84.16.5605; BURT DW, 1989, J BIOL CHEM, V264, P7357; CHEN M, 1993, HYPERTENSION, V21, P36, DOI 10.1161/01.HYP.21.1.36; CORNELIUS P, 1991, J CELL PHYSIOL, V146, P298, DOI 10.1002/jcp.1041460215; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DONG Y, 1989, J BIOL CHEM, V264, P13679; DUNCAN KG, 1990, P NATL ACAD SCI USA, V87, P7588, DOI 10.1073/pnas.87.19.7588; DZAU VJ, 1988, AM J PHYSIOL, V255, pF563, DOI 10.1152/ajprenal.1988.255.4.F563; EVERETT AD, 1990, J CLIN INVEST, V86, P169, DOI 10.1172/JCI114680; FARAJ AH, 1992, APMIS, V100, P29, DOI 10.1111/j.1699-0463.1992.tb00836.x; FUKAMIZU A, 1988, J MOL BIOL, V201, P443, DOI 10.1016/0022-2836(88)90151-9; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; HORIUCHI M, 1991, J BIOL CHEM, V266, P16247; INOUE A, 1989, J BIOL CHEM, V264, P14954; IWAI N, 1992, J HYPERTENS, V10, P717; JUNGMANN RA, 1983, J BIOL CHEM, V258, P5312; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KRANE IM, 1991, MOL ENDOCRINOL, V5, P469, DOI 10.1210/mend-5-4-469; KURTZ A, 1991, KIDNEY INT, V39, pS13; KURTZ A, 1986, AM J PHYSIOL, V250, pC563, DOI 10.1152/ajpcell.1986.250.4.C563; LYKKEGARD S, 1976, ANAL BIOCHEM, V75, P250, DOI 10.1016/0003-2697(76)90076-2; MARSDEN PA, 1991, AM J PHYSIOL, V261, pF117, DOI 10.1152/ajprenal.1991.261.1.F117; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAKAMURA N, 1989, P NATL ACAD SCI USA, V86, P56, DOI 10.1073/pnas.86.1.56; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PANTHIER JJ, 1982, EMBO J, V1, P1417, DOI 10.1002/j.1460-2075.1982.tb01332.x; RAYSON BM, 1992, AM J PHYSIOL, V262, pC563, DOI 10.1152/ajpcell.1992.262.3.C563; RIGHTSEL WA, 1982, CIRC RES, V50, P822, DOI 10.1161/01.RES.50.6.822; RODGERS JR, 1985, METHOD ENZYMOL, V109, P572; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RUYTER JHC, 1925, Z ZELLFORSCH, V2, P242; SAKAUE M, 1991, J BIOL CHEM, V266, P5743; SAKURAI T, 1991, BIOCHEM BIOPH RES CO, V175, P44, DOI 10.1016/S0006-291X(05)81197-0; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; SMITH DL, 1991, MOL CELL ENDOCRINOL, V80, P139, DOI 10.1016/0303-7207(91)90150-Q; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; WANG Y, 1992, HYPERTENSION, V20, P776, DOI 10.1161/01.HYP.20.6.776; WILKINSON L, 1989, SYSTAT SYSTEM STATIS	41	100	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24138	24144						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226960				2022-12-25	WOS:A1993MF29400064
J	DIMARCO, E; CUTULI, N; GUERRA, L; CANCEDDA, R; DELUCA, M				DIMARCO, E; CUTULI, N; GUERRA, L; CANCEDDA, R; DELUCA, M			MOLECULAR-CLONING OF TRKE, A NOVEL TRK-RELATED PUTATIVE TYROSINE KINASE RECEPTOR ISOLATED FROM NORMAL HUMAN KERATINOCYTES AND WIDELY EXPRESSED BY NORMAL HUMAN TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; AFFINITY NGF RECEPTOR; NEUROTROPHIN RECEPTORS; CELL-LINES; PROTOONCOGENE; FAMILY; DIFFERENTIATION; INTERNALIZATION; EPITHELIUM; ADHESION	We have identified and cloned a new member of the trk gene family, termed trkE, which generates a 3.9-kilobase (kb) transcript in normal human keratinocytes and in a variety of normal human tissues, but not in liver. Albeit at low level, trkE transcript is expressed also by PC12 cells. The open reading frame codes for a polypeptide of 876 amino acids exhibiting the classic features of cell surface tyrosine protein kinases. trkE catalytic domain is 41% identical to trkA and shows several features unique to the trk gene family. Its extracellular domain does not show significant homology to any known proteins. trkE is the first member of this gene family found abundantly and widely expressed in normal human tissues. Several lines of evidence suggest that NGF is also the ligand for trkE; (i) normal human keratinocytes bind NGF with high affinity, (ii) NGF stimulates keratinocyte growth in an autocrine fashion, (iii) NGF exerts its biological effect on keratinocytes through the stimulation of a trk-specific tyrosine kinase, and (iv) keratinocytes lack trkA but do express large amount of trkE. trkE might also be the NGF receptor by other human peripheral tissues, such as pancreatic islets, and might represent a non-neuronal receptor for this ligand.	IST NAZL RIC CANC,IST,DIFFERENZIAMENTO CELLULARE LAB,VIALE BENEDETTO XV 10,I-16132 GENOA,ITALY	University of Genoa; IRCCS AOU San Martino IST			Guerra, Liliana/G-8849-2016; De Luca, Michele/N-5883-2014	De Luca, Michele/0000-0002-0850-8445; Guerra, Liliana/0000-0001-6274-6607				BARKER PA, 1993, J BIOL CHEM, V268, P15150; BERG MM, 1992, J BIOL CHEM, V267, P13; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DELUCA M, 1988, J CELL BIOL, V107, P1919, DOI 10.1083/jcb.107.5.1919; DELUCA M, 1990, TRANSPLANTATION, V50, P454, DOI 10.1097/00007890-199009000-00019; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; DIMARCO E, 1993, J BIOL CHEM, V268, P22838; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; EVELETH DD, 1992, J CELL BIOL, V117, P291, DOI 10.1083/jcb.117.2.291; EVELETH DD, 1988, NEURON, V1, P929, DOI 10.1016/0896-6273(88)90150-X; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GRECO A, 1992, ONCOGENE, V7, P237; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAHLE P, 1992, J BIOL CHEM, V267, P13917; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MARCHISIO PC, 1991, J CELL BIOL, V112, P761, DOI 10.1083/jcb.112.4.761; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; PARVINEN M, 1992, J CELL BIOL, V117, P629, DOI 10.1083/jcb.117.3.629; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; POLAK M, 1993, P NATL ACAD SCI USA, V90, P5781, DOI 10.1073/pnas.90.12.5781; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROMAGNOLI G, 1990, NEW ENGL J MED, V323, P527, DOI 10.1056/NEJM199008233230806; SAFFIONI S, 1993, ANN REV BIOCH, V62, P823; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; TAPLEY P, 1992, ONCOGENE, V7, P371; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; VALIUS B, 1993, CELL, V73, P321; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	57	81	87	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24290	24295						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226977				2022-12-25	WOS:A1993MF29400086
J	KOLODNEY, MS; ELSON, EL				KOLODNEY, MS; ELSON, EL			CORRELATION OF MYOSIN LIGHT-CHAIN PHOSPHORYLATION WITH ISOMETRIC CONTRACTION OF FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; STRESS FIBERS; DIFFERENTIAL EXPRESSION; CYTOPLASMIC MYOSINS; COLLAGEN GELS; KINASE; CELLS; INVITRO; ACTIVATION; CULTURE	In vitro studies have indicated that the enzymatic activity of myosin II from non-muscle cells is controlled by phosphorylation of its regulatory light chain (LC20). We have studied one likely functional consequence of phosphorylating LC20 in living chick embryo fibroblasts (CEF) by measuring contractile force developed by these cells. Using a recently developed method, we recorded quantitative changes in isometric force generated by a population of cells following mitogenic stimulation. Fetal bovine serum, thrombin, and lysophosphatidic acid stimulate rapid isometric contraction of CEF. Cells stimulated with thrombin develop maximal force within 5-10 min. Force development correlates temporally with a 3-5-fold increase in the overall fraction of LC20 phosphorylated and with the fractions of LC20 in both the monophosphorylated and diphosphorylated states. Unloaded shortening velocity also increases after thrombin stimulation. Although both force and phosphorylation begin to decline 10 min after stimulation, the level of phosphorylation declined more rapidly than the force. These results suggest that the role of LC20 phosphorylation in regulating fibroblast contractility is analogous to its well established role in regulating smooth muscle contraction and that quantitative measurements of the force developed by populations of fibroblasts (or other cultured cells) can be used to study the regulation of non-sarcomeric myosin at the molecular level in vivo.			KOLODNEY, MS (corresponding author), WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110, USA.			kolodney, Michael/0000-0003-1931-8644	NIGMS NIH HHS [GM-38838, T32 GM-07200] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200, R01GM038838] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1975, NATURE, V256, P597, DOI 10.1038/256597a0; BELLOWS CG, 1982, J CELL SCI, V58, P125; BURRIDGE K, 1981, NATURE, V294, P691, DOI 10.1038/294691a0; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; GIULIANO KA, 1990, CELL MOTIL CYTOSKEL, V16, P14, DOI 10.1002/cm.970160104; HARRIS AK, 1981, NATURE, V290, P249, DOI 10.1038/290249a0; HENDEY B, 1989, J BIOL CHEM, V264, P19540; HOLZAPFEL G, 1983, EXP CELL RES, V148, P117, DOI 10.1016/0014-4827(83)90192-1; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1986, J BIOL CHEM, V261, P36; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; KUMAR CC, 1989, BIOCHEMISTRY-US, V28, P4027, DOI 10.1021/bi00435a059; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; MURPHY RA, 1980, HDB PHYSL 2, V2, P325; PAUL RJ, 1983, FED PROC, V42, P62; RICHARDSON MR, 1987, IN VITRO CELL DEV B, V23, P21; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SOBIESZEK A, 1986, ELECTROPHORESIS, V7, P417, DOI 10.1002/elps.1150070906; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; TOMASEK JJ, 1992, ANAT REC, V232, P359, DOI 10.1002/ar.1092320305; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431	28	165	169	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23850	23855						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226923				2022-12-25	WOS:A1993MF29400025
J	PLATT, OS; LUX, SE; FALCONE, JF				PLATT, OS; LUX, SE; FALCONE, JF			A HIGHLY CONSERVED REGION OF HUMAN ERYTHROCYTE ANKYRIN CONTAINS THE CAPACITY TO BIND SPECTRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT-MEMBRANE INTERACTIONS; ANION-EXCHANGER; BRAIN ANKYRIN; HEREDITARY SPHEROCYTOSIS; CYTOPLASMIC DOMAIN; FUNCTIONAL DOMAINS; SITE-SPECIFICITY; STRUCTURAL BASIS; ATTACHMENT SITE; PLASMA-MEMBRANE	Ankyrin has a spectrin-binding region within a central 62-kDa chymotryptic peptide. We examined the spectrin binding ability of a series of smaller ankyrin fragments and recombinant peptides within the 62-kDa domain using a ligand blot assay. The smallest proteolytic fragment that bound was a 12-kDa tryptic peptide starting at amino acid 1068. Peptides containing this region expressed as glutathione S-transferase fusion products also bound spectrin and suggested that residues 1101-1192 were important. In contrast, a fusion protein containing residues 826-898 did not bind spectrin, a surprising finding since this region is known to influence binding affinity. Proteins that bound spectrin on ligand blots also competed for binding in solution, but did so with one-tenth the affinity of the native peptide. Comparing the 62-kDa domains of erythrocyte and brain ankyrins (species that bind spectrin but with 10-fold differences in affinity), the NH2-terminal regions are 0-40% identical, while the regions (1136-1160) common to all binding peptides are 80-90% identical. We hypothesize that the highly conserved region contains an important spectrin-binding site, while the poorly conserved region controls the binding affinity. We speculate that this unique NH2-terminal region is what gives different members of the ankyrin family their signature set of affinities, and accordingly their distinctive cellular localization.	CHILDRENS HOSP MED CTR, DEPT LAB MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	PLATT, OS (corresponding author), CHILDRENS HOSP MED CTR, DEPT MED, DIV HEMATOL ONCOL, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.				NHLBI NIH HHS [2P60 HL15157, 5P01 HL32262] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262, P60HL015157] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASS EB, 1983, ANN INTERN MED, V99, P192, DOI 10.7326/0003-4819-99-2-192; BENNETT V, 1979, J BIOL CHEM, V254, P2533; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1978, J BIOL CHEM, V253, P2292; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1977, J BIOL CHEM, V252, P2753; BODINE DM, 1984, CELL, V37, P721, DOI 10.1016/0092-8674(84)90408-2; CHILCOTE RR, 1987, BLOOD, V69, P156; CIANCI CD, 1988, J CELL BIOCHEM, V37, P301, DOI 10.1002/jcb.240370305; COETZER TL, 1988, NEW ENGL J MED, V318, P230, DOI 10.1056/NEJM198801283180407; COSTA FF, 1990, NEW ENGL J MED, V323, P1046, DOI 10.1056/NEJM199010113231507; DAVIS J, 1989, J BIOL CHEM, V264, P6417; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; DAVIS JQ, 1984, J BIOL CHEM, V259, P1874; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; GEORGATOS SD, 1985, J CELL BIOL, V100, P1955, DOI 10.1083/jcb.100.6.1955; GEORGATOS SD, 1987, P NATL ACAD SCI USA, V84, P6780, DOI 10.1073/pnas.84.19.6780; GEORGATOS SD, 1985, J CELL BIOL, V100, P1962, DOI 10.1083/jcb.100.6.1962; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HALL TG, 1987, J BIOL CHEM, V262, P10537; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; KIMBERLING WJ, 1975, AM J HUM GENET, V27, P586; KITATANI M, 1988, HUM GENET, V78, P94, DOI 10.1007/BF00291244; KLMBERLING WJ, 1978, BLOOD, V52, P859; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LU PW, 1985, J BIOL CHEM, V260, P4958; LUNA EJ, 1979, J BIOL CHEM, V254, P2526; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OTSUKA A J, 1991, Journal of Cell Biology, V115, p465A; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PETERS LL, 1992, BLOOD, V80, P2122; PLATT OS, 1985, J CLIN INVEST, V75, P266, DOI 10.1172/JCI111684; PLATT OS, 1988, J CLIN INVEST, V82, P1051, DOI 10.1172/JCI113661; SHINAR E, 1989, J CLIN INVEST, V83, P404, DOI 10.1172/JCI113898; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALLIN R, 1984, P NATL ACAD SCI-BIOL, V81, P4095, DOI 10.1073/pnas.81.13.4095; WEAVER DC, 1984, J BIOL CHEM, V259, P6170; WEAVER DC, 1984, J BIOL CHEM, V259, P6165; WHITE RA, 1992, MAMM GENOME, V3, P281, DOI 10.1007/BF00292156; WHITE RA, 1990, P NATL ACAD SCI USA, V87, P3117, DOI 10.1073/pnas.87.8.3117	47	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24421	24426						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226993				2022-12-25	WOS:A1993MF29400104
J	WEISS, RH; FLICKINGER, AG; RIVERS, WJ; HARDY, MM; ASTON, KW; RYAN, US; RILEY, DP				WEISS, RH; FLICKINGER, AG; RIVERS, WJ; HARDY, MM; ASTON, KW; RYAN, US; RILEY, DP			EVALUATION OF ACTIVITY OF PUTATIVE SUPEROXIDE-DISMUTASE MIMICS - DIRECT ANALYSIS BY STOPPED-FLOW KINETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULSE-RADIOLYSIS; CYTOCHROME-C; COMPLEXES; ASSAY; MECHANISM; AUTOXIDATION; ANION; EDTA; ACID; DESFERRIOXAMINE	By stopped-flow kinetic analysis, we have directly evaluated the superoxide dismutase (SOD) activity of a number of organic nitroxides and iron- and manganese-based complexes that have been attributed with having SOD activity based upon competition experiments with cytochrome c. In 60 mM HEPES buffer, pH 8.1, or 50 mM potassium phosphate buffer, pH 7.8, Mn(II) and manganese complexes of desferal had no detectable SOD activity by stopped-flow analysis (catalytic rate constant (k(cat) < 10(5.5) M-1 s-1), whereas Mn(II) and manganese complexes of desferal inhibited the reduction of cytochrome c by superoxide generated by the xanthine/xanthine oxidase system. Fe(II)-N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (FeTPEN) was eight times more active than Fe(III)-tris[N-(2-pyridylmethyl)-2-aminoethyl]amine(FeTPAA) in the cytochrome c assay, but only FeTPAA catalyzed the first-order decay of superoxide (k(cat) = 2.15 x 10(6) M-1 s-1) by stopped-flow. Fe(III)-tetrakis(4-N-methylpyridyl)porphine ( FeTMPP) was active at low micromolar concentrations in both the cytochrome c and stopped-flow assays. At high micromolar concentrations, the organic nitroxides 2,2,6,6-tetramethylpiperidin-1-yloxy (TEMPO) and 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-yloxy (TEMPOL) were inhibitory in the cytochrome c assay, but showed no detectable SOD activity by stopped-flow. None of the tested compounds inhibited xanthine oxidase activity as shown by the measurement of urate production. Under the conditions of the cytochrome c assay, FeTPEN, TEMPO, and TEMPOL oxidized reduced cytochrome c which rationalizes the false positives for these compounds in this assay. The inhibitory activities of Mn(II) and the manganese desferal complexes in the cytochrome c assay appear to be due to a stoichiometric, not catalytic, reaction with superoxide as catalytic amounts of these agents do not induce a first-order decay of superoxide as shown by stopped-flow.	MONSANTO CO, DEPT HLTH SCI, ST LOUIS, MO 63167 USA	Monsanto	WEISS, RH (corresponding author), MONSANTO CO, DEPT CHEM SCI, MAIL ZONE Q3C, 800 N LINDBERGH BLVD, ST LOUIS, MO 63167 USA.							BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEHAR D, 1970, J PHYS CHEM-US, V74, P3209, DOI 10.1021/j100711a009; BEYER WF, 1989, ARCH BIOCHEM BIOPHYS, V271, P149, DOI 10.1016/0003-9861(89)90265-8; BONNE C, 1991, B SOC CHIM BELG, V100, P673; BULL C, 1983, J AM CHEM SOC, V105, P5290, DOI 10.1021/ja00354a019; BULL C, 1982, ARCH BIOCHEM BIOPHYS, V215, P551, DOI 10.1016/0003-9861(82)90115-1; BUTLER J, 1975, BIOCHIM BIOPHYS ACTA, V408, P215, DOI 10.1016/0005-2728(75)90124-3; BUTLER J, 1982, J BIOL CHEM, V257, P747; CABELLI DE, 1984, J PHYS CHEM-US, V88, P6291, DOI 10.1021/j150669a047; Czapski G, 1988, Free Radic Res Commun, V4, P225, DOI 10.3109/10715768809055146; DARR D, 1987, ARCH BIOCHEM BIOPHYS, V258, P351, DOI 10.1016/0003-9861(87)90354-7; DEGRAFF WG, 1992, ENVIRON MOL MUTAGEN, V19, P21, DOI 10.1002/em.2850190105; DOWNEY JM, 1991, FREE RADICAL RES COM, V12-3, P703, DOI 10.3109/10715769109145850; ELSTNER EF, 1976, ANAL BIOCHEM, V70, P616, DOI 10.1016/0003-2697(76)90488-7; FEE JA, 1974, FEBS LETT, V39, P79, DOI 10.1016/0014-5793(74)80021-9; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; Fridovich I., 1982, SUPEROXIDE DISMUTASE, V1, P69; GOLDSTEIN S, 1988, FREE RADICAL BIO MED, V4, P295, DOI 10.1016/0891-5849(88)90050-0; GOLDSTEIN S, 1990, J AM CHEM SOC, V112, P6489, DOI 10.1021/ja00174a006; GOLDSTEIN S, 1991, FREE RADICAL RES COM, V12-3, P5, DOI 10.3109/10715769109145761; GRAY B, 1992, BIOCHEM J, V281, P795, DOI 10.1042/bj2810795; GRISHAM MB, 1988, DIGEST DIS SCI, V33, pS6, DOI 10.1007/BF01538126; HEIKKILA RE, 1976, ANAL BIOCHEM, V75, P356, DOI 10.1016/0003-2697(76)90089-0; HOWIE JK, 1976, J AM CHEM SOC, V98, P6698, DOI 10.1021/ja00437a046; ILAN Y, 1981, INORG NUCL CHEM LETT, V17, P93, DOI 10.1016/0020-1650(81)80035-9; IULIANO L, 1992, ARCH BIOCHEM BIOPHYS, V293, P153, DOI 10.1016/0003-9861(92)90378-A; KALCKAR HM, 1947, J BIOL CHEM, V167, P429; KOPPENOL WH, 1986, ARCH BIOCHEM BIOPHYS, V251, P594, DOI 10.1016/0003-9861(86)90368-1; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; LENGFELDER E, 1979, BIOCHIM BIOPHYS ACTA, V567, P492, DOI 10.1016/0005-2744(79)90135-9; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MCCLUNE GJ, 1977, J AM CHEM SOC, V99, P5220, DOI 10.1021/ja00457a074; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; NAGANO T, 1990, SEIKAGAKU, V62, P447; NAGANO T, 1989, J BIOL CHEM, V264, P9243; NAGANO T, 1991, FREE RADICAL RES COM, V12-3, P221, DOI 10.3109/10715769109145790; PASTERNACK RF, 1979, J AM CHEM SOC, V101, P1026, DOI 10.1021/ja00498a038; POGREBNIAK H, 1991, J SURG RES, V50, P469, DOI 10.1016/0022-4804(91)90026-I; RABINOWITCH HD, 1987, FREE RADICAL BIO MED, V3, P125, DOI 10.1016/S0891-5849(87)80007-2; RILEY DP, 1991, ANAL BIOCHEM, V196, P344, DOI 10.1016/0003-2697(91)90476-A; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; SAWYER DT, 1991, FREE RADICAL RES COM, V12-3, P75, DOI 10.3109/10715769109145770; SORENSON JRJ, 1984, J MED CHEM, V27, P1747, DOI 10.1021/jm00378a040; STEIN J, 1979, INORG CHEM, V18, P3511, DOI 10.1021/ic50202a044; SUN M, 1978, ANAL BIOCHEM, V90, P81, DOI 10.1016/0003-2697(78)90010-6; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; WEINSTEIN J, 1980, J AM CHEM SOC, V102, P4916, DOI 10.1021/ja00535a014	51	106	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23049	23054						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226820				2022-12-25	WOS:A1993MF51500016
J	MA, TH; FRIGERI, A; TSAI, ST; VERBAVATZ, JM; VERKMAN, AS				MA, TH; FRIGERI, A; TSAI, ST; VERBAVATZ, JM; VERKMAN, AS			LOCALIZATION AND FUNCTIONAL-ANALYSIS OF CHIP28K WATER CHANNELS IN STABLY TRANSFECTED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; KIDNEY PROXIMAL TUBULE; BRUSH-BORDER; ENDOSOMES; TRANSPORT; RECONSTITUTION; EXPRESSION; VESICLES; PERMEABILITY; PURIFICATION	CHIP28 is a major water transporting protein in erythrocytes and plasma membranes in kidney proximal tubule and thin descending limb of Henle. Chinese hamster ovary cells were stably transfected with the coding sequence of cloned rat kidney CHIP28k using expression vectors containing cytomegalovirus or Rous sarcoma virus promoters. Clonal cell populations expressed a 1.3-kilobase mRNA on Northern blot probed by CHIP28k cDNA and a 28-kDa protein on immunoblot probed by a polyclonal CHIP28 antibody. The clone with greatest expression produced approximately 8 x 10(6) copies of CHIP28k protein/cell. Plasma membrane osmotic water permeability (P(f)), measured by stopped-flow light scattering, was 0.004 cm/s in control (vector-transfected) cells (10-degrees-C) and 0.014 cm/s in the CHIP28k-transfected cells. P(f) in CHIP28k-transfected cells had an activation energy of 4.9 kcal/mol and was reversibly inhibited by HgCl2. CHIP28k expression did not affect the transport of protons and the small polar non-electrolytes urea and formamide. CHIP28k immunoreactivity and function was then determined in subcellular fractions. P(f) in 6-carboxyfluorescein-labeled endocytic vesicles, measured by a stopped-flow fluorescence quenching assay, was 0.002 cm/s (control cells) and 0.011 cm/s (CHIP28k-transfected cells); P(f) in transfected cells was inhibited by HgCl2. Immunoblotting of fractionated endoplasmic reticulum, Golgi, and plasma membranes revealed high densities of CHIP28k (approximately 5000 monomers/mum2 in plasma membrane) with different glycosylation patterns; functional water transport activity was present only in Golgi and plasma membrane vesicles. Antibody detection of CHIP28k by confocal fluorescence microscopy and immunogold electron microscopy revealed localization to plasma membrane and intracellular vesicles. These studies establish a stably transfected somatic cell line that strongly expresses functional CHIP28k water channels. As in the original proximal tubule cells, the expressed CHIP28k protein is a selective water channel that is functional in endocytic vesicles and the cell plasma membrane.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT MED & PHYSIOL, 1065 HLTH SCI E TOWER, SAN FRANCISCO, CA 94143 USA; MASSACHUSETTS GEN HOSP, DEPT MED & PHYSIOL, RENAL UNIT, BOSTON, MA 02114 USA	University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital				Frigeri, Antonio/0000-0002-5284-2934; Ma, Tonghui/0000-0001-9338-1030; Verbavatz, Jean-Marc/0000-0002-4654-1174	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BROWN D, 1989, AM J PHYSIOL, V256, pF1, DOI 10.1152/ajprenal.1989.256.1.F1; DENKER BM, 1988, J BIOL CHEM, V263, P15634; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P203; ECHEVARRIA M, 1992, J GEN PHYSIOL, V99, P573, DOI 10.1085/jgp.99.4.573; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; Finkelstein A., 1987, WATER MOVEMENT LIPID; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HASEGAWA H, 1993, AM J PHYSIOL, V264, pC237, DOI 10.1152/ajpcell.1993.264.1.C237; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KOTLIAR N, 1992, MOL ENDOCRINOL, V6, P337, DOI 10.1210/me.6.3.337; LUCY JA, 1989, BIOCHEM SOC T, V17, P623, DOI 10.1042/bst0170623; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; MEYER MM, 1987, J MEMBRANE BIOL, V96, P107, DOI 10.1007/BF01869237; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RODMAN JS, 1986, J CELL BIOL, V102, P77, DOI 10.1083/jcb.102.1.77; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SHI LB, 1990, J GEN PHYSIOL, V95, P941, DOI 10.1085/jgp.95.5.941; SHI LB, 1989, J GEN PHYSIOL, V94, P1101, DOI 10.1085/jgp.94.6.1101; SMITH BL, 1991, J BIOL CHEM, V266, P6407; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; VANHEESWIJK MPE, 1986, J MEMBRANE BIOL, V92, P183, DOI 10.1007/BF01870707; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VERBAVATZ JM, 1993, IN PRESS J CELL BIOL; VERKMAN AS, 1987, J BIOENERG BIOMEMBR, V19, P481; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; VERKMAN AS, 1989, J BIOL CHEM, V264, P20608; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; YE R, 1989, J GEN PHYSIOL, V93, P885, DOI 10.1085/jgp.93.5.885; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99; ZHANG R, 1990, J MEMBRANE BIOL, V117, P253, DOI 10.1007/BF01868455; ZHANG RB, 1993, BIOCHEMISTRY-US, V32, P2938, DOI 10.1021/bi00063a002; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	43	84	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22756	22764						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226786				2022-12-25	WOS:A1993MD34800083
J	PETERSEN, CCH; PETERSEN, OH; BERRIDGE, MJ				PETERSEN, CCH; PETERSEN, OH; BERRIDGE, MJ			THE ROLE OF ENDOPLASMIC-RETICULUM CALCIUM PUMPS DURING CYTOSOLIC CALCIUM SPIKING IN PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INOSITOL TRISPHOSPHATE; POTENTIAL OSCILLATIONS; CA-2+ OSCILLATIONS; DIFFERENT PATTERNS; TUMOR PROMOTER; THAPSIGARGIN; RELEASE; MEMBRANE; DEPENDENCE; ACTIVATION	Many cell types show repetitive short lasting cytosolic calcium spikes with long interspike periods when stimulated with submaximal concentrations of agonists linked to the phosphoinositide signaling pathway. In pancreatic acinar cells these spikes have been shown to be evoked by constant levels of inositol trisphosphate through a mechanism of calcium-induced calcium release and do not depend acutely on the presence of external calcium. However, the processes involved in the interspike period have remained unclear. Here we report that the endoplasmic reticulum Ca2+-ATPases play a significant role, not only in resequestering calcium after a spike, but also in regulating the long interspike period. Decreasing the activity of the endoplasmic reticulum calcium pumps leads to shorter interspike intervals and thus higher spiking frequencies, while the duration of each spike increases. The endoplasmic reticulum Ca2+-ATPases are able to entirely suppress a response that can subsequently be evoked by partial inhibition of the pumps. This suggests that during the interspike period there is a considerable amount of calcium released from intracellular stores, which is rapidly buffered by the endoplasmic reticulum calcium pumps and the cytosolic calcium-binding proteins. A calcium spike will be initiated by calcium-induced calcium release only when the buffering is saturated.	UNIV LIVERPOOL, PHYSIOL LAB, MRC, SECRETORY CONTROL GRP, LIVERPOOL L69 3BX, ENGLAND	University of Liverpool	PETERSEN, CCH (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, AFRC, MOLEC SIGNALING LAB, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		Petersen, Carl/M-5123-2017; Petersen, Ole H/E-8708-2010	Petersen, Carl/0000-0003-3344-4495; Petersen, Ole/0000-0002-6998-0380	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1988, J PHYSIOL-LONDON, V403, P589, DOI 10.1113/jphysiol.1988.sp017266; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KLINE D, 1992, J BIOL CHEM, V267, P17624; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEVY S, 1993, J GEN PHYSIOL, V101, P67, DOI 10.1085/jgp.101.1.67; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PARKER I, 1993, J PHYSIOL-LONDON, V461, P133, DOI 10.1113/jphysiol.1993.sp019506; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PETERSEN CCH, 1991, FEBS LETT, V293, P179, DOI 10.1016/0014-5793(91)81181-7; RAPP PE, 1981, J EXP BIOL, V93, P119; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	27	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22262	22264						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226732				2022-12-25	WOS:A1993MD34800013
J	FERNANDEZ, A; MARIN, MC; MCDONNELL, T; ANANTHASWAMY, HN				FERNANDEZ, A; MARIN, MC; MCDONNELL, T; ANANTHASWAMY, HN			DIFFERENTIAL SENSITIVITY OF NORMAL AND HA-RAS-TRANSFORMED C3H MOUSE EMBRYO FIBROBLASTS TO TUMOR-NECROSIS-FACTOR - INDUCTION OF BCL-2, C-MYC, AND MANGANESE SUPEROXIDE-DISMUTASE IN RESISTANT CELLS	ONCOGENE			English	Article							WILD-TYPE P53; FACTOR-MEDIATED CYTOTOXICITY; FACTOR-ALPHA; INTERFERON-GAMMA; MALIGNANT TRANSFORMATION; CHROMOSOMAL BREAKPOINT; ONCOGENE EXPRESSION; FOLLICULAR LYMPHOMA; DNA FRAGMENTATION; FACTOR RECEPTORS	In this study, we investigated the role of activated Ha-ras oncogene on the growth-regulatory properties of tumor necrosis factor (TNF) in C3H mouse embryo fibroblasts. TNF-resistant 10T1/2 cells transfected with an activated Ha-ras oncogene not only produced tumors in nude mice but also exhibited extreme sensitivity to cytolysis by TNF. TNF-induced cell death was mediated through apoptosis. The differential sensitivity of normal and Ha-ras transformed cells to TNF was not due to differences in the number of TNF receptors on their cell surface. However, TNF-resistant cells, but not sensitive cells, overexpressed bcl-2, c-myc, and manganese superoxide dismutase (MnSOD) mRNA following exposure to TNF. In addition, TNF treatment resulted in a marginal induction of p53 mRNA in both TNF-sensitive and resistant cells. These results suggest that TNF-induced cytotoxicity involves apoptosis and that TNF-induced over-expression of bcl-2, c-myc, and MnSOD genes is associated with TNF resistance in C3H mouse embryo fibroblasts.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Marín Vieira, María del Carmen/B-8108-2015; Marin, Maria C/G-1040-2010	Marín Vieira, María del Carmen/0000-0002-7149-287X; Marin, Maria C/0000-0002-7149-287X	NATIONAL CANCER INSTITUTE [R01CA046523] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09255-02, R01-CA-46523] Funding Source: Medline; NCRR NIH HHS [RR5S1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; ASHER A, 1987, J IMMUNOL, V138, P963; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BALKWILL FR, 1986, CANCER RES, V46, P3990; BARRETT K, 1991, EUR J IMMUNOL, V21, P1649, DOI 10.1002/eji.1830210710; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOSS JM, 1991, IMMUNOLOGY, V73, P309; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEALTRY GB, 1987, EUR J IMMUNOL, V17, P689, DOI 10.1002/eji.1830170517; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERNANDEZ A, 1992, LYMPHOKINE CYTOK RES, V11, P79; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GONEN B, 1992, CANCER IMMUNOL IMMUN, V35, P388, DOI 10.1007/BF01789017; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HELSON L, 1975, NATURE, V258, P731, DOI 10.1038/258731a0; HENNET T, 1993, CANCER RES, V53, P1456; HIMENO T, 1992, INT J CANCER, V50, P458, DOI 10.1002/ijc.2910500322; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HSIO WL, 1984, SCIENCE, V226, P552; HUANG MN, 1990, BIOTECHNIQUES, V9, P711; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; ITOH N, 1993, J IMMUNOL, V151, P621; KETTELHUT IC, 1987, P NATL ACAD SCI USA, V84, P4273, DOI 10.1073/pnas.84.12.4273; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LASTER SM, 1988, J IMMUNOL, V141, P2629; LEHMANN V, 1986, EUR J BIOCHEM, V158, P1, DOI 10.1111/j.1432-1033.1986.tb09712.x; LICHTENSTEIN A, 1990, CANCER RES, V50, P7364; Maniatis T., 1982, MOL CLONING; MATHEWS N, 1987, IMMUNOLOGY, V62, P153; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MONOHARAN TH, 1985, CARCINOGENESIS, V6, P1295; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; OLD LJ, 1987, NATURE, V326, P330, DOI 10.1038/326330a0; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROBAYE B, 1991, AM J PATHOL, V138, P447; RUBIN BY, 1988, CANCER RES, V48, P6006; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SATOMI N, 1988, J BIOL RESP MODIF, V7, P54; SELIGER B, 1988, J IMMUNOL, V141, P2138; SELIGER B, 1988, J CELL BIOCHEM, V38, P205, DOI 10.1002/jcb.240380308; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1989, ANTICANCER RES, V9, P1149; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STAUBER GB, 1989, J BIOL CHEM, V264, P3573; SUEN TC, 1990, LYMPHOKINE RES, V9, P15; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VANHAESEBROECK B, 1991, CANCER RES, V51, P2469; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIMMERMAN RJ, 1989, J IMMUNOL, V142, P1405	75	52	61	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2009	2017						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208546				2022-12-25	WOS:A1994NR68500025
J	PARK, DJ; NAKAMURA, H; CHUMAKOV, AM; SAID, JW; MILLER, CW; CHEN, DL; KOEFFLER, HP				PARK, DJ; NAKAMURA, H; CHUMAKOV, AM; SAID, JW; MILLER, CW; CHEN, DL; KOEFFLER, HP			TRANSACTIVATIONAL AND DNA-BINDING ABILITIES OF ENDOGENOUS P53 IN P53 MUTANT-CELL LINES	ONCOGENE			English	Article							TUMOR SUPPRESSOR GENE; WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; TRANSCRIPTIONAL ACTIVATION; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; MUTATIONS; EXPRESSION; ANTIGEN; CARCINOMAS	Cells with divergent mutant alleles of the p53 gene have different biological and biochemical properties in vitro. Increasing evidence indicates that p53 is a transcriptional activator, and recently, high affinity DNA binding sites for p53 have been identified. The purpose of this study was to determine in vivo, the effect that various mutant p53 proteins have on their ability to mediate transactivation and to bind specifically to DNA. Either a p53 responsive or control reporter gene was transfected into 18 human carcinoma cell lines, having various p53 mutations, either with or without a wild-type p53 expression vector, The CAT activity and DNA gel retardation were studied to measure transactivation and DNA binding by these endogenous p53s. As expected, the endogenously produced wild-type p53 binds to DNA binding sequences and can transactivate a reporter construct containing a p53 high affinity DNA binding site. Four of five cell lines with homozygous p53 mutations at codon 273 (273(His)), contained p53 which had the ability to bind to p53 DNA binding sequences and transactivate. In contrast, all the homozygous, non-codon 273 mutant p53s (156(Pro), 175(His), 223(Leu), 248(Gln), 248(Trp), 280(Lys)) present in the other cell lines had no transactivating ability. These findings suggest that the biology of cancers with mutations at codon 273 may be different than those with p53 mutations at other sites. The p53 from WRO, a thyroid carcinoma cell line with p53 mutation at codon 223 (223(Leu)), was able to bind p53 DNA recognition sequences, but was unable to transactivate. Interestingly, in a vulvar carcinoma cell line (A431) with a p53 mutation at codon 273 (273(His)), the p53 was unable to transactivate and gave an aberrant band on gel retardation. Both CEM and SK-UT-1, which have compound heterozygous mutations at codons 175/248 (175(His)/248(His)), produced p53 which can complex with DNA, as well as transactivate. In contrast, the p53 in cell lines with either homozygous 175(His) or 248(His) p53 mutations, were unable either to transactivate or bind to the p53 response element. A cell line (NPA) heterozygous for 266(Glu) p53 mutation, was able to efficiently transactivate a reporter containing a p53 DNA binding site, therefore showing no evidence of a dominant negative effect of the endogenous p53 mutant allele. In summary, this in vivo study further supports the idea that different p53 mutant alleles have various properties which may affect their function.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	PARK, DJ (corresponding author), UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DIV HEMATOL ONCOL,8700 BEVERLY BLVD,B-210,LOS ANGELES,CA 90048, USA.		Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166	NCI NIH HHS [CA42710] Funding Source: Medline; NIDDK NIH HHS [DK42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042710, P01CA042710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1993, EUR J CANCER, V29A, P101, DOI 10.1016/0959-8049(93)90584-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHEN JY, 1993, ONCOGENE, V8, P2159; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELDEIRY WS, 1992, NAT GENET, V1, P44; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEVINE AJ, 1992, CANCER SURV, V12, P59; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MILLER C W, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P386; MILLER CW, 1993, ONCOGENE, V8, P1815; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; SAID JW, 1992, AM J PATHOL, V141, P1343; SAKASHITA A, 1992, BLOOD, V79, P477; SAMBROOK J, 1989, MOL CLONING LABORATO, V1, P636; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SLINGERLAND JM, 1991, BLOOD, V77, P1500; STEINMEYER K, 1988, ONCOGENE, V3, P501; STRATTON MR, 1990, ONCOGENE, V5, P1297; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YAGINUMA Y, 1992, CANCER RES, V52, P4196; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1993, CANCER RES, V53, P4772; ZHANG W, 1993, ONCOGENE, V8, P2555	70	150	152	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1899	1906						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208536				2022-12-25	WOS:A1994NR68500013
J	TASHIRO, S; KOTOMURA, N; TANAKA, K; SUZUKI, K; KYO, T; DOHY, H; NIWA, O; KAMADA, N				TASHIRO, S; KOTOMURA, N; TANAKA, K; SUZUKI, K; KYO, T; DOHY, H; NIWA, O; KAMADA, N			IDENTIFICATION OF ILLEGITIMATE RECOMBINATION HOT-SPOT OF THE RETINOIC ACID RECEPTOR-ALPHA GENE INVOLVED IN 15,17-CHROMOSOMAL TRANSLOCATION OF ACUTE PROMYELOCYTIC LEUKEMIA	ONCOGENE			English	Article							MOLECULAR ANALYSIS; MAMMALIAN-CELLS; T(15-17) TRANSLOCATION; DNA FRAGMENTS; RAR-ALPHA; PML; SEQUENCES; ONCOGENE; REARRANGEMENTS; AMPLIFICATION	Acute promyelocytic leukemia (APL) has been characterized by 15;17 chromosomal translocation, which involves the retinoic acid receptor alpha (RARA) gene on chromosome 17 and the PML gene on chromosome 15. The breakpoints have been mapped to three cluster regions in the PML gene, and to RARA gene intron 2. We have examined the distribution of breakpoints within RARA gene intron 2. An extremely restricted region (ERR) of 50 bp within RARA gene intron 2 was identified as the duster region of breakpoints by polymerase chain reaction and sequence analysis of DNA from APL patients. To study experimentally the mechanism involved in the translocation, ERR was tested in NIH3T3 cells by in vitro transfection-recombination assay, in which target sequences were placed either downstream of the SV40 promoter or upstream of the neo gene. Cells were conferred resistance to G418 only when the promoter was fused to the neo gene by recombination of two target sequences during transfection. The molecular junctions were analysed in five clones, and all of them were shown to be confined within a 20 bp region in a 148 bp DNA fragment containing ERR. This suggests that ERR might be the illegitimate recombination hot spot in mammalian cells.	HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT HEMATOL,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT PATHOL,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT BIOPHYS & BIOCHEM,HIROSHIMA 734,JAPAN; HIROSHIMA RED CROSS HOSP,DEPT INTERNAL MED 4,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT PEDIAT,HIROSHIMA 734,JAPAN	Hiroshima University; Hiroshima University; Hiroshima University; Hiroshima University								BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHAKRABARTI S, 1986, MOL CELL BIOL, V6, P2520, DOI 10.1128/MCB.6.7.2520; CHAMPOUX JJ, 1988, GENETIC RECOMBINATIO, P655; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; DARBY MK, 1986, EMBO J, V5, P2257, DOI 10.1002/j.1460-2075.1986.tb04493.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DONG S, 1993, GENE CHROMOSOME CANC, V6, P133, DOI 10.1002/gcc.2870060302; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; JAEGER U, 1993, BLOOD, V81, P1833; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMADA N, 1981, BLOOD, V58, P1213; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MORRIS T, 1993, P NATL ACAD SCI USA, V90, P1392, DOI 10.1073/pnas.90.4.1392; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PONCE MR, 1992, NUCLEIC ACIDS RES, V20, P623, DOI 10.1093/nar/20.3.623; ROWLEY JD, 1977, LANCET, V1, P549; RUBNITZ J, 1986, MOL CELL BIOL, V6, P1608, DOI 10.1128/MCB.6.5.1608; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; STARY A, 1992, NUCLEIC ACIDS RES, V20, P4269, DOI 10.1093/nar/20.16.4269; TASHIRO S, 1992, ONCOGENE, V7, P573; TASHIRO S, 1992, CANCER-AM CANCER SOC, V70, P2809, DOI 10.1002/1097-0142(19921215)70:12<2809::AID-CNCR2820701214>3.0.CO;2-#; TASHIRO S, 1993, JPN J CANCER RES, V84, P110, DOI 10.1111/j.1349-7006.1993.tb02841.x; TSUKIYAMA T, 1989, MOL CELL BIOL, V9, P4670, DOI 10.1128/MCB.9.11.4670; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; Yunis J J, 1986, Important Adv Oncol, P93	33	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1939	1945						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208541				2022-12-25	WOS:A1994NR68500018
J	VELASCO, JA; CASTRO, R; AVILA, MA; LABORDA, J; DIPAOLO, JA; CANSADO, J; NOTARIO, V				VELASCO, JA; CASTRO, R; AVILA, MA; LABORDA, J; DIPAOLO, JA; CANSADO, J; NOTARIO, V			CPH, A NOVEL ONCOGENE WHICH COOPERATES WITH H-RAS IN THE TRANSFORMATION OF NIH3T3 FIBROBLASTS	ONCOGENE			English	Note							BLADDER-CARCINOMA ONCOGENE; POINT MUTATION; PROTO-ONCOGENE; NEU ONCOGENE; ACTIVATION; CELLS; GENE; SEQUENCES; CANCER; ACQUISITION	We have performed the molecular cloning of the non-ras transforming sequences previously detected in neoplastic Syrian hamster embryo fibroblasts initiated in vitro with 3-methylcholanthrene (MCA) (Notario et at, 1990). These sequences were isolated using cosmid-rescue techniques from a third-cycle NIH3T3 transformant obtained by sequential transfections of genomic DNA from MCA-initiated hamster fetal cells. Rescued (C-5) clones encompassed about 42.5 kbp of Syrian hamster genomic DNA containing hamster-specific repetitive elements (HRS). An internal 19 kbp BamHI fragment (B-1) was the only C-5 fragment which recognized specific transcripts in poly(A)(+) RNA from hamster embryo cells, The same mRNA species were present in both normal and MCA-initiated neoplastic cells: a major transcript of about 2.5 kb, and other less abundant ones, ranging from approximately 2.0 kb to 5.0 kb. These mRNA species were detected consistently by each of several B-1 DNA subfragments located at positions spanning almost the entire B-1 length. The nucleotide sequence of some transcript-positive (S5P2 and S-6) genomic B-1 fragments was determined. No significant homology exists between the nucleotide sequences of these B-1 subfragments and established DNA databases. Therefore, the C-5 cosmid clone contains novel genomic sequences. Transfection of C-5 DNA into mouse NIH3T3 cells resulted in the appearance of transformed foci (about five foci per mu g of DNA) within 25 days post-transfection, thus demonstrating the transforming activity of the C-5 clone, which was consequently renamed as the cph oncogene. Co-transfection of the cph oncogene with the human H-ras oncogene (T24), demonstrated a synergistic action between the two oncogenes in the transformation of murine fibroblasts.	GEORGETOWN UNIV,MED CTR,DEPT RADIAT MED,DIV EXPTL CARCINOGENESIS,WASHINGTON,DC 20007; NCI,BIOL LAB,BETHESDA,MD 20892	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			/AFP-0764-2022; /AAB-6461-2022; Cansado, Jose/ABC-6872-2020; Cansado, Jose/K-5212-2014; Avila, Matias A/Y-6342-2019; Laborda, Jorge/L-5726-2014	Cansado, Jose/0000-0002-2342-8152; Avila, Matias A/0000-0001-6570-3557; Laborda, Jorge/0000-0002-9210-838X	NATIONAL CANCER INSTITUTE [R29CA049858] Funding Source: NIH RePORTER; NCI NIH HHS [CA49858] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BERWALD Y, 1965, J NATL CANCER I, V35, P641; BOREK C, 1987, P NATL ACAD SCI USA, V84, P794, DOI 10.1073/pnas.84.3.794; BOS JL, 1989, CANCER RES, V49, P4682; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CASTRO R, 1990, CELL MOL NEUROBIOL, V10, P281, DOI 10.1007/BF00734581; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICHUTEK K, 1986, P NATL ACAD SCI USA, V83, P2340, DOI 10.1073/pnas.83.8.2340; CUADRADO A, 1993, ONCOGENE, V8, P2443; DIPAOLO JA, 1969, J NATL CANCER I, V42, P867; DIPAOLO JA, 1983, J NATL CANCER I, V70, P3; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GILMER TM, 1988, MOL CARCINOGEN, V1, P180, DOI 10.1002/mc.2940010306; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; LAU YF, 1983, P NATL ACAD SCI-BIOL, V80, P5225, DOI 10.1073/pnas.80.17.5225; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NOTARIO V, 1990, ONCOGENE, V5, P1425; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	34	29	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2065	2069						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208552				2022-12-25	WOS:A1994NR68500032
J	MINASSIAN, C; AJZANNAY, A; RIOU, JP; MITHIEUX, G				MINASSIAN, C; AJZANNAY, A; RIOU, JP; MITHIEUX, G			INVESTIGATION OF THE MECHANISM OF GLYCOGEN REBOUND IN THE LIVER OF 72-HOUR FASTED RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTES; GLUCOSE-6-PHOSPHATASE; GLUCOSE; STIMULATION; INHIBITION; GLUTAMINE; KINETICS	We have investigated the mechanism of the rebound of glycogen stores in the liver of 72-h fasted rats. The liver of 72- and 96-h fasted rats contains significant amounts of glycogen (about 5 mg/g, wet weight) as compared to the liver of 24- and 48-h fasted rats, which contains less than 2 mg of glycogen/g of liver, wet weight. Rebound of glycogen does not involve glycogen synthase activation or glycogen phosphorylase inhibition. It could be dependent on the concentration of the precursor substrate of glycogenesis, i.e. glucose 6-phosphate (Glc-6-P), which is higher by about 45% in the liver of 72- and 96-h fasted rats than in the liver of 48-h fasted rats. The 72-h increase of Glc-6-P compared with the 48-h values could not be explained either by late modifications of the total activities of glucokinase, hexokinases, Glc-6-P dehydrogenase, and glucose-6-phosphatase (Glc-6-Pase) or by changes in plasma glucose and insulin/glucagon ratio. In agreement with the fact that total glucose output tends to decrease upon prolonged fasting, the increase of Glc-6-P concentration in the liver of 72-h fasted rats suggests the involvement of a metabolite inhibition of Glc-6-Pase. The increase of the cy-ketoglutarate concentration in the 72- and 96-h fasted liver with regard to the 48-h fasted liver (about three times) might account for such an inhibition since we show here that Glc-6-Pase is inhibited in vitro in the presence of relevant concentrations of alpha-ketoglutarate, Glc-6-P, and Mg2+ ions.	FAC MED ALEXIS CARREL,INSERM,U197,F-69372 LYON 08,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)				Gilles, Mithieux/0000-0003-3579-8529				AJZANNAY A, 1993, EUR J BIOCHEM, V212, P335, DOI 10.1111/j.1432-1033.1993.tb17666.x; ARION WJ, 1965, BIOCHEM BIOPH RES CO, V20, P606, DOI 10.1016/0006-291X(65)90442-0; Baginski ES, 1974, METH ENZYMOL; BAQUET A, 1990, J BIOL CHEM, V265, P955; Bergmeyer H. U., 1974, METHOD ENZYMAT AN, V3, P1196; Bergmeyer H. U., 1974, METHOD ENZYMAT AN, P1577; BODE AM, 1992, J BIOL CHEM, V267, P2860; BOISJOYEUX B, 1987, DIABETES METAB, V13, P543; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BOYD ME, 1981, J CLIN INVEST, V68, P142, DOI 10.1172/JCI110230; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; HARRIS V, 1979, METHOD HORM RADIOIMM, P643; HEMS DA, 1972, BIOCHEM J, V129, P529, DOI 10.1042/bj1290529; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; KATZ J, 1976, P NATL ACAD SCI USA, V73, P3433, DOI 10.1073/pnas.73.10.3433; KATZ J, 1979, BIOCHEM J, V180, P389, DOI 10.1042/bj1800389; Keppler D., 1974, METHODS ENZYM ANALYS, V3, P1127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG G, 1974, METHOD ENZYMAT AN, V3, P1238; LAVOINNE A, 1987, BIOCHEM J, V248, P429, DOI 10.1042/bj2480429; Lohr G. W., 1974, METHODS ENZYMATIC AN, V2, P636, DOI [DOI 10.1016/B978-0-12-091302-2.50026-8, 10.1016/B978-0-12-091302-2.50026-8]; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEIJER AJ, 1992, J BIOL CHEM, V267, P5823; MEISTER A, 1984, GLUTAMINE METABOLISM, P3; MITHIEUX G, 1993, EUR J BIOCHEM, V213, P461, DOI 10.1111/j.1432-1033.1993.tb17782.x; MITHIEUX G, 1990, J BIOL CHEM, V265, P20364; MOUTERDE O, 1992, BIOCHEM J, V288, P795, DOI 10.1042/bj2880795; NORDLIE RC, 1968, J BIOL CHEM, V243, P1140; NORDLIE RC, 1976, GLUCONEOGENESIS ITS, P93; OWEN OE, 1969, J CLIN INVEST, V48, P574, DOI 10.1172/JCI106016; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; SASSE D, 1975, HISTOCHEMISTRY, V45, P237, DOI 10.1007/BF00507698; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V110, P1	34	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16585	16588						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206976				2022-12-25	WOS:A1994NR29600013
J	NISHIMORI, I; JOHNSON, NR; SANDERSON, SD; PERINI, F; MOUNTJOY, K; CERNY, RL; GROSS, ML; HOLLINGSWORTH, MA				NISHIMORI, I; JOHNSON, NR; SANDERSON, SD; PERINI, F; MOUNTJOY, K; CERNY, RL; GROSS, ML; HOLLINGSWORTH, MA			INFLUENCE OF ACCEPTOR SUBSTRATE PRIMARY AMINO-ACID-SEQUENCE ON THE ACTIVITY OF HUMAN UDP-N-ACETYLGALACTOSAMINE-POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE - STUDIES WITH THE MUC1 TANDEM REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; O-GLYCOSYLATION; EXPRESSION; GALNAC; CELLS; CORE; SPECIFICITY; CLONING; INVITRO; PROTEIN	Synthetic peptides (30 and 20 residues long) corresponding to the native MUC1 tandem repeat sequence (20 residues long) were glycosylated in vitro using UDP-[H-3]GalNAc and lysates from the human breast tumor cell line MCF7. Purified glycopeptides were sequenced on a gas-phase sequenator, and glycosylated positions were determined by measuring the incorporated radio activity in fractions collected following each round of Edman degradation. The results showed that 2 of 3 threonines on the MUC1 tandem repeat peptides were glycosylated at the following positions: GVTSAPDTRP-APGSTAPPAH (underlined Thr residues indicate positions of GalNAc attachment); no glycosylation of serine residues was detected. Determination of the mass of the glycopeptides by mass spectrometry showed that a maximum of two molecules of GalNAc were covalently linked to each 20-residue repeat unit in the peptides. The influence of substrate primary amino acid sequence in determining the substrate specificity of UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase activity was evaluated using as acceptor substrates a series of overlapping 9-residue peptides that represent a moving set through the tandem repeat of the MUC1 mucin. In addition, the influence of primary amino acid sequence on acceptor substrate activity was evaluated using several peptides that contained single or double amino acid substitutions (relative to the native human MUC1 sequence). These included substitutions in the residues that were glycosylated and substitutions in the surrounding primary amino acid sequence. This study demonstrates that primary amino acid sequence, length, and relative position of the residue to be glycosylated dramatically affect the ability of peptides to serve as acceptor substrates for UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC & ALLIED DIS, OMAHA, NE 68198 USA; KOCHI MED SCH, DEPT INTERNAL MED 1, KOCHI 783, JAPAN; UNIV NEBRASKA, DEPT CHEM, LINCOLN, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; Kochi University; University of Nebraska System; University of Nebraska Lincoln					NATIONAL CANCER INSTITUTE [R01CA057362, P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044762] Funding Source: NIH RePORTER; NCI NIH HHS [CA36727, CA57362] Funding Source: Medline; NIDDK NIH HHS [DK44762] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABERNATHY JL, 1992, TECHNIQUES PROTEIN C, P277; BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; BURCHELL J, 1983, J IMMUNOL, V131, P508; BURCHELL J, 1987, CANCER RES, V47, P5476; Damme E.J.V., 1991, EUR J BIOCHEM, V202, P23; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; EMBER JA, 1992, J IMMUNOL, V148, P3165; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; HOMA FL, 1993, J BIOL CHEM, V268, P12609; JEROME KR, 1991, CANCER RES, V51, P2908; LAN MS, 1990, CANCER RES, V50, P2997; LAN MS, 1990, J BIOL CHEM, V265, P15294; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; SCANLON MJ, 1992, BIOCHEM J, V284, P137, DOI 10.1042/bj2840137; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529	19	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16123	16130						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206912				2022-12-25	WOS:A1994NQ72900028
J	JOSEPH, S; BURKE, JM				JOSEPH, S; BURKE, JM			OPTIMIZATION OF AN ANTI-HIV HAIRPIN RIBOZYME BY IN-VITRO SELECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TOBACCO RINGSPOT VIRUS; CATALYZED CLEAVAGE; SATELLITE RNA; SEQUENCE; COMPLEMENTARY; REQUIREMENT; EVOLUTION; ENZYME; SITE; DNA	We have applied in vitro selection methods to achieve a large increase in the catalytic activity of a hairpin ribozyme targeted against a highly conserved 14-nucleotide sequence within HIV-1 pol RNA. The substrate specificity was changed by mutating 8 bases within the substrate-binding domain of the parental (-)sTRSV ribozyme. The resulting enzyme cleaved the HIV substrate specifically but with a 20-fold reduction in catalytic efficiency (k(cat)/K(M)). Following random mutagenesis, ribozymes with increased activity against the target sequence were selected through 10 rounds of in vitro selection. Selective pressure was increased by decreasing MgCl2 and spermidine concentrations, and reducing reaction time. Variant ribozymes with base substitutions A11 --> G and U39 --> C were selected in the population. These mutations were introduced singly and in combination into the trans-acting anti-HIV ribozyme. Each of the single-base substitutions significantly increased ribozyme activity, while the activity of double mutant was increased to nearly the level of the parental ribozyme. These findings demonstrate that in vitro selection is a powerful and efficient method to optimize ribozymes for the catalytic inactivation of targeted RNA molecules.	UNIV VERMONT, MARKEY CTR MOLEC GENET, DEPT MICROBIOL & MOLEC GENET, STAFFORD HALL, BURLINGTON, VT 05405 USA	University of Vermont			, John/AAB-5945-2021		NIAID NIH HHS [AI29892] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029892] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts B. D., 1989, MOL BIOL CELL, P301; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BERZALHERRANZ A, 1993, EMBO J, V12, P2567, DOI 10.1002/j.1460-2075.1993.tb05912.x; BURKE JM, 1993, FASEB J, V7, P106, DOI 10.1096/fasebj.7.1.8422956; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; CHOWRIRA BM, 1993, BIOCHEMISTRY-US, V32, P1088, DOI 10.1021/bi00055a014; FELDSTEIN PA, 1990, P NATL ACAD SCI USA, V87, P2623, DOI 10.1073/pnas.87.7.2623; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; HASELOFF J, 1989, GENE, V82, P43, DOI 10.1016/0378-1119(89)90028-0; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; JOSEPH S, 1993, GENE DEV, V7, P130, DOI 10.1101/gad.7.1.130; KIKUCHI Y, 1991, NUCLEIC ACIDS RES, V19, P6751, DOI 10.1093/nar/19.24.6751; OJWANG JO, 1992, P NATL ACAD SCI USA, V89, P10802, DOI 10.1073/pnas.89.22.10802; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; RUBINO L, 1990, J GEN VIROL, V71, P1897, DOI 10.1099/0022-1317-71-9-1897; SAENGER W, 1988, PRINCIPLES NUCLEIC A, P201; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121	27	80	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24515	24518						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227004				2022-12-25	WOS:A1993MG67300001
J	YAMADA, M; JAHANGIR, A; HOSOYA, Y; INANOBE, A; KATADA, T; KURACHI, Y				YAMADA, M; JAHANGIR, A; HOSOYA, Y; INANOBE, A; KATADA, T; KURACHI, Y			G(KAPPA)ASTERISK AND BRAIN G(BETA-GAMMA) ACTIVATE MUSCARINIC K+ CHANNEL THROUGH THE SAME MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEINS; ATRIAL CELL-MEMBRANE; ACETYLCHOLINE ACTIVATION; GAMMA-SUBUNIT; HEART; RECEPTORS	A pertussis toxin-sensitive G protein (G(K)) links muscarinic cholinergic and A1-purinergic receptors with an inwardly rectifying K+ (K(ACh)) channel in cardiac atrial cell membranes. Although the betagamma subunits of pertussis toxin-sensitive G proteins (G(betagamma)) have been reported to fully activate this channel, it is not known whether exogenously applied G(betagamma) interacts with the K(ACh) channel through the same mechanism as the active subunit of endogenous G(K) (G(K)*). We examined in inside-out patches the relationship between the concentration of GTP and K(ACh) channel activity with or without preactivation of the channels by either GTPgammaS (guanosine 5'-3-O-(thio)triphosphate) or G(betagamma) purified from bovine brain. In the control, K(ACh) channels were activated by intracellular GTP (with acetylcholine in the pipette) in a positive cooperative manner (Hill coefficient approximately 2.5). As the channels were preactivated by GTPgammaS to progressively higher levels, the GTP channel activity relationship shifted more to the left, but the Hill coefficients of the curves remained the same. The same changes were observed when K(ACh) channels were preactivated with brain G(betagamma). These results indicate that endogenous G(K)* and exogenous G(betagamma) share a common molecular mechanism to activate the K(ACh) channel.	MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,DIV CARDIOVASC DIS,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905; YAMAGATA UNIV,SCH MED,DEPT CELL BIOL & SIGNALING,YAMAGATA 99023,JAPAN; TOKYO INST TECHNOL,FAC SCI,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYS CHEM,BUNKYO KU,TOKYO 113,JAPAN	Mayo Clinic; Mayo Clinic; Yamagata University; Tokyo Institute of Technology; University of Tokyo					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047360] Funding Source: NIH RePORTER; NHLBI NIH HHS [R0 1 HL47360] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; COLQUHOUN D, 1983, FITTING STAT ANAL SI, P191; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; ITO H, 1991, J GEN PHYSIOL, V98, P517, DOI 10.1085/jgp.98.3.517; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; KURACHI Y, 1989, PFLUG ARCH EUR J PHY, V413, P325, DOI 10.1007/BF00583550; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P264, DOI 10.1007/BF00585301; KURACHI Y, 1986, AM J PHYSIOL, V251, pH681, DOI 10.1152/ajpheart.1986.251.3.H681; KURACHI Y, 1990, PFLUG ARCH EUR J PHY, V416, P216, DOI 10.1007/BF00370247; KURACHI Y, 1992, PROG NEUROBIOL, V39, P229, DOI 10.1016/0301-0082(92)90017-9; LOEWI O., 1926, PFLUGER S ARCH GES PHYSIOL, V214, P678, DOI 10.1007/BF01741946; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; NAKAJIMA T, 1992, J GEN PHYSIOL, V99, P665, DOI 10.1085/jgp.99.5.665; NANAVATI C, 1990, COMP ROLES PURIFIED, P29; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0	21	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24551	24554						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227012				2022-12-25	WOS:A1993MG67300010
J	FUKUMORI, F; HAUSINGER, RP				FUKUMORI, F; HAUSINGER, RP			PURIFICATION AND CHARACTERIZATION OF 2,4-DICHLOROPHENOXYACETATE ALPHA-KETOGLUTARATE DIOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOPENICILLIN-N SYNTHASE; PROLYL 4-HYDROXYLASE; BINDING-SITE; LYSYL HYDROXYLASE; MONOOXYGENASE; DEGRADATION; ASCORBATE; CLONING; ACID; EXPRESSION	The Alcaligenes eutrophus 2,4-dichlorophenoxyacetate/alpha-ketoglutarate dioxygenase, encoded by the tfdA gene of plasmid pJP4, is an Fe(II)-dependent enzyme that catalyzes the conversion of 2,4-dichlorophenoxyacetate to 2,4-dichlorophenol and glyoxylate concomitant with the decomposition of alpha-ketoglutarate to form succinate and carbon dioxide (Fukumori, F., and Hausinger, R. P. (1993) J. Bacteriol. 175, 2083-2086). Using recombinant Escherichia coli cells that overexpress the tfdA gene, the thermolabile enzyme (stable only up to 30-degrees-C) was purified to apparent homogeneity (specific activity of 16.9 mumol of substrate converted min-1 mg of protein-1) by a simple two-step procedure. The native protein has an apparent M(r) of 50,000 +/- 2,500, consistent with a homodimeric structure. Ferrous ion is absolutely required for activity and cannot be replaced by several other divalent cations tested. Ascorbic acid stimulates dioxygenase activity and reduces the rate of enzyme inactivation by a metal ion-mediated process. The enzyme exhibits maximum activity at pH 6.5-7, however, it is stable over a pH range of 6.5-11. Although capable of hydroxylating a wide range of phenoxyacetates and related compounds, the enzyme exhibits the greatest affinity (K(m) 17.5 +/- 1.0 muM) and highest catalytic efficiency for 2,4-dichlorophenoxyacetate. Similarly, alpha-ketoglutarate is the preferred co-substrate (K(m) 3.20 +/- 0.54 muM) for the enzyme, but it can utilize a range of other alpha-ketoacids with lower efficiency. Results from chemical modification studies are consistent with the presence of multiple essential histidine residues in the enzyme.	MICHIGAN STATE UNIV,CTR MICROBIAL ECOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; RES DEV CORP JAPAN,CHIYODA KU,TOKYO 100,JAPAN	Michigan State University; Michigan State University; Michigan State University; Japan Science & Technology Agency (JST)				Hausinger, Robert/0000-0002-3643-2054				Abbott MT, 1974, MOL MECHANISMS OXYGE, P167; BRADLEY FC, 1986, J BIOL CHEM, V261, P1693; CHAUDHRY GR, 1991, MICROBIOL REV, V55, P59, DOI 10.1128/MMBR.55.1.59-79.1991; COUNTS DF, 1978, P NATL ACAD SCI USA, V75, P2145, DOI 10.1073/pnas.75.5.2145; DEJONG L, 1982, BIOCHIM BIOPHYS ACTA, V704, P326, DOI 10.1016/0167-4838(82)90162-5; DON RH, 1985, J BACTERIOL, V161, P85, DOI 10.1128/JB.161.1.85-90.1985; FUKUMORI F, 1993, J BACTERIOL, V175, P2083, DOI 10.1128/JB.175.7.2083-2086.1993; HAGGBLOM MM, 1992, FEMS MICROBIOL LETT, V103, P29; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUGLAND RA, 1990, APPL ENVIRON MICROB, V56, P1357, DOI 10.1128/AEM.56.5.1357-1362.1990; HORVATH M, 1990, APPL MICROBIOL BIOT, V33, P213, DOI 10.1007/BF00176527; KING RJ, 1991, APPL ENVIRON MICROB, V57, P1790, DOI 10.1128/AEM.57.6.1790-1792.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBLAD B, 1977, J BIOL CHEM, V252, P5073; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJAMAA K, 1984, EUR J BIOCHEM, V138, P239, DOI 10.1111/j.1432-1033.1984.tb07907.x; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; Miles E W, 1977, Methods Enzymol, V47, P431; MING LJ, 1990, INORG CHEM, V29, P1111, DOI 10.1021/ic00331a001; MYLLYLA R, 1992, BIOCHEM J, V286, P923, DOI 10.1042/bj2860923; MYLLYLA R, 1978, BIOCHEM BIOPH RES CO, V83, P441, DOI 10.1016/0006-291X(78)91010-0; MYLLYLA R, 1984, J BIOL CHEM, V259, P5403; NG SF, 1991, J BIOL CHEM, V266, P1526; NURK A, 1991, GENE, V102, P13, DOI 10.1016/0378-1119(91)90531-F; PERKINS EJ, 1990, J BACTERIOL, V172, P2351, DOI 10.1128/jb.172.5.2351-2359.1990; PIEPER DH, 1989, ARCH MICROBIOL, V151, P365, DOI 10.1007/BF00406566; SAID WA, 1991, APPL ENVIRON MICROB, V57, P1498, DOI 10.1128/AEM.57.5.1498-1503.1991; SCOTT RA, 1992, BIOCHEMISTRY-US, V31, P4596, DOI 10.1021/bi00134a009; STREBER WR, 1987, J BACTERIOL, V169, P2950, DOI 10.1128/jb.169.7.2950-2955.1987; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	32	161	171	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24311	24317						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226980				2022-12-25	WOS:A1993MF29400089
J	WANG, RW; NEWTON, DJ; JOHNSON, AR; PICKETT, CB; LU, AYH				WANG, RW; NEWTON, DJ; JOHNSON, AR; PICKETT, CB; LU, AYH			SITE-DIRECTED MUTAGENESIS OF GLUTATHIONE-S-TRANSFERASE YAYA - MAPPING THE GLUTATHIONE-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-PI; ACTIVE-SITE; CATALYTIC ACTIVITY; 3-DIMENSIONAL STRUCTURE; CHEMICAL MODIFICATION; CYSTEINE RESIDUES; ESCHERICHIA-COLI; HUMAN PLACENTA; THIOL-GROUP; RAT	Previous studies from our laboratory have shown that aspartic acid 101 plays an important role in glutathione interaction to rat glutathione S-transferase YaYa, while tyrosine 9 is directly involved in catalysis. Based on the available structural information, site-directed mutagenesis was conducted to examine the function of arginine, lysine, glutamine, and proline residues surrounding the GSH binding pocket. Arginine mutants R13K, R15K, R20K, and R20I retained partial enzymatic activities, while R13I and R15I lost most of their activities. Kinetic studies showed a marked increase in K(m) toward GSH for R15I suggesting that arginine 15 contributes significantly to the binding of GSH in the active site of glutathione S-transferase YaYa. A drastic decrease in enzymatic activities for R13I suggested the importance of the charged group of arginine 13 either in maintaining the structural integrity of the enzyme or in serving a vital role in enzymatic function. Replacement of glutamine 54 and 67 with glutamic acid or asparagine resulted in decreased enzymatic activities. Moreover, an 11-, 17-, and 9-fold increase in K(m) values toward GSH for mutant Q54E, Q54N, and Q67N was observed, respectively. These results suggested that glutamine 54 and 67 also contributed significantly to the binding of GSH. Proline at position 56 appears to be important for maintaining the structural integrity of the enzyme since mutants P56A and P56F were much less active and extremely less stable than that of the wild type enzyme. Both lysine mutants, K45R and K45I, exhibited substantially higher catalytic efficiencies toward both 1-chloro-2,4-dinitrobenzene and GSH than the wild type enzyme. Our data clearly show that lysine 45 is not an essential residue for catalysis nor for GSH binding in glutathione S-transferase YaYa.	MERCK FROSST CTR THERAPEUT RES,POINTE CLAIRE H9R 4P8,PQ,CANADA	Merck & Company	WANG, RW (corresponding author), MERCK SHARP & DOHME LTD,DEPT DRUG METAB,RY80A12,POB 2000,RAHWAY,NJ 07065, USA.							ADANG AEP, 1991, BIOCHEM J, V278, P63, DOI 10.1042/bj2780063; ADANG AEP, 1988, BIOCHEM J, V255, P721; ADANG AEP, 1989, BIOCHEM J, V264, P759, DOI 10.1042/bj2640759; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; Asaoka K, 1989, J Enzyme Inhib, V3, P77, DOI 10.3109/14756368909030366; AWASTHI YC, 1987, BIOCHEM BIOPH RES CO, V143, P965, DOI 10.1016/0006-291X(87)90345-7; BENSON AM, 1977, P NATL ACAD SCI USA, V74, P158, DOI 10.1073/pnas.74.1.158; BENSON AM, 1976, BIOCHEM BIOPH RES CO, V69, P1073, DOI 10.1016/0006-291X(76)90482-4; BOYER TD, 1989, HEPATOLOGY, V9, P486, DOI 10.1002/hep.1840090324; CARNE T, 1979, BIOCHEM J, V177, P433, DOI 10.1042/bj1770433; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CHEN WJ, 1988, BIOCHEMISTRY-US, V27, P647, DOI 10.1021/bi00402a023; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; DELBOCCIO G, 1991, J BIOL CHEM, V266, P13777; DENIELSON UH, 1985, BIOCHEM J, P263; DESIDERI A, 1991, J BIOL CHEM, V266, P2063; DIRR HW, 1991, EUR J BIOCHEM, V196, P693, DOI 10.1111/j.1432-1033.1991.tb15867.x; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HSIEH JC, 1991, BIOCHEM J, V278, P293, DOI 10.1042/bj2780293; HUSKEY SEW, 1991, J AM CHEM SOC, V113, P2283, DOI 10.1021/ja00006a056; JAKOBY WB, 1984, BIOCHEM PHARMACOL, V33, P2539, DOI 10.1016/0006-2952(84)90621-X; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; KONG KH, 1992, BIOCHEM BIOPH RES CO, V184, P194, DOI 10.1016/0006-291X(92)91177-R; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; LIU SX, 1992, J BIOL CHEM, V267, P4296; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; Mannervik B, 1981, Methods Enzymol, V77, P231; MANOHARAN TH, 1992, J MOL BIOL, V226, P319, DOI 10.1016/0022-2836(92)90949-K; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REDDY CC, 1981, BIOCHEM BIOPH RES CO, V101, P970; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; STENBERG G, 1991, BIOCHEM J, V274, P549, DOI 10.1042/bj2740549; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAHIR MK, 1986, J BIOL CHEM, V261, P1048; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; TAMAI K, 1991, BIOCHEM BIOPH RES CO, V179, P790, DOI 10.1016/0006-291X(91)91886-H; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANOMMEN B, 1988, J BIOL CHEM, V263, P12939; VANOMMEN B, 1989, EUR J BIOCHEM, V181, P423; WANG RW, 1992, ARCH BIOCHEM BIOPHYS, V297, P86, DOI 10.1016/0003-9861(92)90644-C; WANG RW, 1989, ARCH BIOCHEM BIOPHYS, V269, P536, DOI 10.1016/0003-9861(89)90137-9; WANG RW, 1992, J BIOL CHEM, V267, P19866; WANG RW, 1991, ARCH BIOCHEM BIOPHYS, V286, P574, DOI 10.1016/0003-9861(91)90082-T; WIDERSTEIN M, 1992, BIOCHEM J, V285, P377, DOI 10.1042/bj2850377; WIDERSTEN M, 1991, FEBS LETT, V293, P156, DOI 10.1016/0014-5793(91)81175-8; ZHANG PH, 1991, J BIOL CHEM, V266, P19475	57	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23981	23985						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226940				2022-12-25	WOS:A1993MF29400043
J	MCENERY, MW; DAWSON, TM; VERMA, A; GURLEY, D; COLOMBINI, M; SNYDER, SH				MCENERY, MW; DAWSON, TM; VERMA, A; GURLEY, D; COLOMBINI, M; SNYDER, SH			MITOCHONDRIAL VOLTAGE-DEPENDENT ANION CHANNEL - IMMUNOCHEMICAL AND IMMUNOHISTOCHEMICAL CHARACTERIZATION IN RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENZODIAZEPINE-BINDING-SITES; MEMBRANE CONTACT SITES; DIMENSIONAL GEL-ELECTROPHORESIS; PORIN 31 HL; OUTER-MEMBRANE; LIVER MITOCHONDRIA; INTRACELLULAR-LOCALIZATION; NEURAL TISSUE; YEAST MUTANT; CELL-LINE	The purified mitochondrial benzodiazepine receptor (mBzR) is a complex comprising the voltage-dependent anion channel (VDAC), adenine nucleotide carrier, and an 18-kDa protein that binds isoquinoline carboxamide ligands (McEnery, M. W., Snowman, A. M., Trifiletti, R. R., and Snyder, S. H. (1992) Proc. Natl. Acad. Sci. U. S. A. 39, 3170-3174). An antiserum raised against the mBzR complex reacts selectively with VDAC and is used, along with purification, electrophysiological and immunohistochemical techniques, to characterize the properties and distribution of rat brain VDAC. Although purified VDAC displays biochemical and electrical conductance properties similar to VDAC from other sources, the immunohistochemical distribution of VDAC in rat brain is heterogeneous with pronounced regional variations; the pontine nuclei, the supraoptic nucleus, Purkinje cells of the cerebellum, and the caudate putamen evidence the highest density. The distribution of VDAC is inclusive of the more discretely localized 18-kDa mBzR protein, suggesting that only a portion of the total VDAC participates in the mBzR. The histochemical localizations of the mitochondrial marker enzymes glutamate dehydrogenase and cytochrome c oxidase also indicate marked regional variability in both mitochondrial content and composition. The discrete expression of VDAC reflects a striking heterogeneity of rat brain mitochondria and underlying differences in the utilization of mitochondrial outer membrane ion channels.	JOHNS HOPKINS MED INST,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT NEUROL,BALTIMORE,MD 21205; UNIV MARYLAND,DEPT ZOOL,CELL BIOL LAB,COLL PK,MD 20742	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland College Park			Colombini, Marco/A-1540-2014	Verma, Ajay/0000-0001-7715-0443	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00266, DA-00074] Funding Source: Medline; NINDS NIH HHS [CIDA NS 01578-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANHOLT RRH, 1984, J NEUROSCI, V4, P593; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; ANTKIEWICZMICHALUK L, 1988, J BIOL CHEM, V263, P17317; ARORA KK, 1988, J BIOL CHEM, V263, P17422; BELTRANDELRIO H, 1991, ARCH BIOCHEM BIOPHYS, V286, P183, DOI 10.1016/0003-9861(91)90026-F; BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BRDICZKA D, 1990, EXPERIENTIA, V46, P161, DOI 10.1007/BF02027312; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; BURGESS RW, 1991, J NEUROCHEM, V57, P441, DOI 10.1111/j.1471-4159.1991.tb03771.x; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; COLE T, 1992, BIOL CHEM H-S, V373, P891, DOI 10.1515/bchm3.1992.373.2.891; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; DEPINTO V, 1989, EUR J BIOCHEM, V183, P179; DEPINTO V, 1992, J BIOENERG BIOMEMBR, V24, P21, DOI 10.1007/BF00769526; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V894, P109, DOI 10.1016/0005-2728(87)90180-0; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; DEPINTO V, 1985, BIOCHIM BIOPHYS ACTA, V813, P230; DEPINTO V, 1994, MOL BIOL MITOCHONDRI; DIHANICH M, 1987, EMBO J, V6, P723, DOI 10.1002/j.1460-2075.1987.tb04813.x; DIHANICH M, 1989, EUR J BIOCHEM, V181, P703, DOI 10.1111/j.1432-1033.1989.tb14780.x; DOBLE A, 1987, MOL PHARMACOL, V31, P42; DORBANI L, 1987, ARCH BIOCHEM BIOPHYS, V252, P188, DOI 10.1016/0003-9861(87)90023-3; FELGNER PL, 1979, J BIOL CHEM, V254, P4946; FIEK C, 1982, BIOCHIM BIOPHYS ACTA, V688, P429, DOI 10.1016/0005-2736(82)90354-6; FORTE M, 1987, J MEMBRANE BIOL, V99, P65, DOI 10.1007/BF01870622; FORTE M, 1987, J BIOENERG BIOMEMBR, V19, P341, DOI 10.1007/BF00768537; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GUZMAN N, 1993, BIOPHYS J, V64, P343; HIRSCH JD, 1989, MOL PHARMACOL, V35, P157; KAOJEN J, 1980, J NEUROCHEM, V35, P667, DOI 10.1111/j.1471-4159.1980.tb03706.x; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KINNALLY KW, 1992, J BIOENERG BIOMEMBR, V24, P99, DOI 10.1007/BF00769536; KINNALLY KW, 1993, P NATL ACAD SCI USA, V90, P1374, DOI 10.1073/pnas.90.4.1374; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KOTTKE M, 1988, BIOCHIM BIOPHYS ACTA, V935, P87, DOI 10.1016/0005-2728(88)90111-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDEN M, 1982, FEBS LETT, V141, P189, DOI 10.1016/0014-5793(82)80044-6; LINDEN M, 1982, BIOCHEM J, V208, P77, DOI 10.1042/bj2080077; LIU MY, 1992, BIOCHIM BIOPHYS ACTA, V1098, P255, DOI 10.1016/S0005-2728(05)80344-5; MANNELLA CA, 1992, J BIOENERG BIOMEMBR, V24, P7, DOI 10.1007/BF00769525; MARANGOS PJ, 1982, MOL PHARMACOL, V22, P26; MCENERY MW, 1992, J BIOENERG BIOMEMBR, V24, P63, DOI 10.1007/BF00769532; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MORAN O, 1990, J BIOL CHEM, V265, P908; MORAN O, 1992, EUR BIOPHYS J BIOPHY, V20, P311, DOI 10.1007/BF00196590; MORAN O, 1992, J BIOENERG BIOMEMBR, V24, P91, DOI 10.1007/BF00769535; MOYNAGH PN, 1991, BIOCHEM J, V275, P419, DOI 10.1042/bj2750419; NAKASHIMA RA, 1986, BIOCHEMISTRY-US, V25, P1015, DOI 10.1021/bi00353a010; OHLENDIECK K, 1986, BIOCHIM BIOPHYS ACTA, V860, P672, DOI 10.1016/0005-2736(86)90567-5; PARRY DM, 1983, J BIOL CHEM, V258, P904; PARRY DM, 1990, J BIOL CHEM, V265, P1059; PERDEW GH, 1983, ANAL BIOCHEM, V135, P453, DOI 10.1016/0003-2697(83)90711-X; PERT CB, 1974, BRAIN RES, V70, P184, DOI 10.1016/0006-8993(74)90228-5; ROSE IA, 1967, J BIOL CHEM, V242, P1635; SANDRI G, 1988, CELL CALCIUM, V9, P159, DOI 10.1016/0143-4160(88)90020-6; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNYDER SH, 1987, FASEB J, V1, P282, DOI 10.1096/fasebj.1.4.2820823; SNYDER SH, 1990, NEUROCHEM RES, V15, P119, DOI 10.1007/BF00972201; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; THINNES FP, 1993, BIOPHYS J, V64, pA343; VERMA A, 1989, ANNU REV PHARMACOL, V29, P307; VLASUK GP, 1980, ANAL BIOCHEM, V105, P112, DOI 10.1016/0003-2697(80)90431-5; WEHRLE JP, 1978, J BIOL CHEM, V253, P8598; WHITE TK, 1990, ARCH BIOCHEM BIOPHYS, V277, P26, DOI 10.1016/0003-9861(90)90545-A; WILKIN GP, 1977, J NEUROCHEM, V29, P1039, DOI 10.1111/j.1471-4159.1977.tb06507.x; Wilson J E, 1980, Curr Top Cell Regul, V16, P1; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	70	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23289	23296						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226852				2022-12-25	WOS:A1993MF51500054
J	BOJANOWSKI, K; FILHOL, O; COCHET, C; CHAMBAZ, EM; LARSEN, AK				BOJANOWSKI, K; FILHOL, O; COCHET, C; CHAMBAZ, EM; LARSEN, AK			DNA TOPOISOMERASE-II AND CASEIN KINASE-II ASSOCIATE IN A MOLECULAR-COMPLEX THAT IS CATALYTICALLY ACTIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR PROTEIN; EPIDERMAL GROWTH-FACTOR; SACCHAROMYCES-CEREVISIAE; MITOTIC CHROMOSOMES; ATTACHMENT SITE; CLEAVAGE SITES; PHORBOL ESTER; FISSION YEAST; CELL-GROWTH; PHOSPHORYLATION	Immunoprecipitation of DNA topoisomerase II from yeast results in a preparation that contains casein kinase II; this suggests that the two proteins may associate in the intact cell. Purified recombinant topoisomerase II and casein kinase II associate to form a complex in vitro which is stable after topoisomerase II becomes phosphorylated by the kinase. Studies with isolated recombinant casein kinase II subunits disclosed that although the alpha (catalytic) subunit alone can efficiently phosphorylate topoisomerase II, the formation of a stable topoisomerase II-casein kinase II association requires the presence of the beta subunit of the kinase. Both proteins engaged in this complex retain their catalytic activities. Naturally occurring polyamines and polyanionic compounds appear to be crucial factors governing the interaction between the two proteins. Although the biological significance of a stable catalytically active topoisomerase II-casein kinase II molecular complex remains to be defined, these observations suggest the possibility of a novel mechanism regulating topoisomerase II and casein kinase II activities.	INST GUSTAVE ROUSSY,CNRS,UNITE RECH ASSOCIEE 147,INSERM,UNITE 140,F-94805 VILLEJUIF,FRANCE; CEN,INSERM,UNITE 244,F-38041 GRENOBLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm)			Filhol-Cochet, Odile/I-3962-2016	Cochet, Claude/0000-0002-1772-4270; Filhol, Odile/0000-0003-1964-7958				ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BOJANOWSKI K, 1992, P NATL ACAD SCI USA, V89, P3025, DOI 10.1073/pnas.89.7.3025; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; BRILL SJ, 1987, NATURE, V326, P812, DOI 10.1038/326812a0; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CARROLL D, 1989, J BIOL CHEM, V264, P7345; COCHET C, 1983, MOL CELL ENDOCRINOL, V30, P247, DOI 10.1016/0303-7207(83)90062-X; COCHET C, 1983, J BIOL CHEM, V258, P1403; CONSTANTINOU A, 1989, CANCER RES, V49, P1110; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; DEVORE RF, 1992, CANCER RES, V52, P2156; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DOWNES CS, 1991, P NATL ACAD SCI USA, V88, P8895, DOI 10.1073/pnas.88.20.8895; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIEH TS, 1980, CELL, V21, P115, DOI 10.1016/0092-8674(80)90119-1; HU ED, 1990, J BIOL CHEM, V265, P5072; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MARKOVITS J, 1989, CANCER RES, V49, P5111; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; POMMIER Y, 1990, J VIROL, V64, P419, DOI 10.1128/JVI.64.1.419-423.1990; POMMIER Y, 1989, BIOCHEMISTRY-US, V28, P995, DOI 10.1021/bi00429a012; POMMIER Y, 1991, J MOL BIOL, V222, P909, DOI 10.1016/0022-2836(91)90585-T; RAZIN SV, 1991, P NATL ACAD SCI USA, V88, P8515, DOI 10.1073/pnas.88.19.8515; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; ROSS W, 1984, CANCER RES, V44, P5857; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SANDER M, 1984, P NATL ACAD SCI-BIOL, V81, P6938, DOI 10.1073/pnas.81.22.6938; SCHNEIDER HR, 1986, EUR J BIOCHEM, V161, P733, DOI 10.1111/j.1432-1033.1986.tb10501.x; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P124; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WOOD ER, 1990, J CELL BIOL, V111, P2389; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	73	91	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22920	22926						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226802				2022-12-25	WOS:A1993MD34800106
J	SHEPHERD, PR; GNUDI, L; TOZZO, E; YANG, HM; LEACH, F; KAHN, BB				SHEPHERD, PR; GNUDI, L; TOZZO, E; YANG, HM; LEACH, F; KAHN, BB			ADIPOSE CELL HYPERPLASIA AND ENHANCED GLUCOSE DISPOSAL IN TRANSGENIC MICE OVEREXPRESSING GLUT4 SELECTIVELY IN ADIPOSE-TISSUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEPENDENT DIABETES-MELLITUS; INSULIN RESISTANCE; SKELETAL-MUSCLE; MESSENGER-RNA; TRANSPORTER; ADIPOCYTES; OBESITY; RAT; EXPRESSION; CLONING	To gain insight into the molecular pathogenesis of obesity and specifically the role of nutrient partitioning in the development of obesity, we overexpressed the insulin-responsive glucose transporter (GLUT4) in transgenic mice under the control of the fat-specific aP2 fatty acid-binding protein promoter/enhancer. Two lines of transgenic mice were generated, which overexpressed GLUT4 6-9-fold in white fat and 3-5-fold in brown fat with no overexpression in other tissues. In vivo glucose tolerance was enhanced in transgenic mice. In isolated epididymal, parametrial, and subcutaneous adipose cells from transgenic mice, basal glucose transport was 20-34-fold greater than in nontransgenic littermates. Insulin-stimulated glucose transport was 2-4-fold greater in cells from transgenic mice. Total body lipid was increased 2-3-fold in transgenic mice overexpressing GLUT4 in fat. Surprisingly, fat cell size was unaltered and fat cell number was increased >2-fold. This is the first animal model in which increased fat mass results solely from adipocyte hyperplasia and it will be a valuable model for understanding the mechanisms responsible for fat cell replication and/or differentiation in vivo.	BETH ISRAEL HOSP, DEPT MED, DIABET UNIT, 330 BROOKLINE AVE, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, THORNDIKE LAB, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center				gnudi, luigi/0000-0002-6353-630X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043051] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43051, R01 DK043051] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; BUSE JB, 1992, DIABETES, V41, P1436, DOI 10.2337/diabetes.41.11.1436; COUSIN B, 1992, EUR J BIOCHEM, V207, P377, DOI 10.1111/j.1432-1033.1992.tb17060.x; CUSHMAN SW, 1978, J LIPID RES, V19, P269; CUSHMAN SW, 1970, J CELL BIOL, V46, P326, DOI 10.1083/jcb.46.2.326; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DOLE VP, 1956, J CLIN INVEST, V19, P269; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GLIEMANN J, 1984, BIOCHIM BIOPHYS ACTA, V804, P68, DOI 10.1016/0167-4889(84)90100-9; HIRSCH J, 1976, CLIN ENDOCRINOL META, V5, P299, DOI 10.1016/S0300-595X(76)80023-0; HIRSCH J, 1968, J LIPID RES, V9, P110; JAMES DE, 1985, DIABETES, V34, P1049, DOI 10.2337/diabetes.34.10.1049; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KASHIWAGI A, 1983, J CLIN INVEST, V72, P1246, DOI 10.1172/JCI111080; KORANYI L, 1990, J CLIN INVEST, V85, P962, DOI 10.1172/JCI114526; MARIN P, 1987, METABOLISM, V36, P1154, DOI 10.1016/0026-0495(87)90242-3; PEDERSEN O, 1992, J CLIN INVEST, V89, P1964, DOI 10.1172/JCI115804; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SALMON DMW, 1985, INT J OBESITY, V9, P443; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; York D. A., 1979, Animal models of obesity., P39	25	430	444	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22243	22246						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226728				2022-12-25	WOS:A1993MD34800008
J	SRINIVAS, SK; SRINIVAS, RV; ANANTHARAMAIAH, GM; COMPANS, RW; SEGREST, JP				SRINIVAS, SK; SRINIVAS, RV; ANANTHARAMAIAH, GM; COMPANS, RW; SEGREST, JP			CYTOSOLIC DOMAIN OF THE HUMAN-IMMUNODEFICIENCY-VIRUS ENVELOPE GLYCOPROTEINS BINDS TO CALMODULIN AND INHIBITS CALMODULIN-REGULATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; LYMPHOCYTES-T; TAT PROTEIN; HTLV-III; TYPE-1; CYTOPATHOGENICITY; ASSOCIATION; REPLICATION; ACTIVATION; SEGMENTS	Calmodulin (CaM), the major intracellular receptor for calcium, is involved in regulation of diverse cellular functions. Positively charged amphipathic helical segments have been identified as an important structural motif in the recognition of CaM by different CaM-activated enzymes and peptides. The carboxyl-terminal domain of the envelope glycoproteins of human and simian immunodeficiency viruses (HIV-1, HIV-2, and SIV) contain regions that can fold into amphipathic helical segments, which closely resemble the amphipathic segments found in CaM-activated enzymes. We show here that synthetic peptide analogs corresponding to the two putative amphipathic helical regions of HIV-1/WMJ gp160 bind to CaM with high affinity (K(d) 31-41 nM) in the presence of calcium. They also bind CaM in the absence of calcium, although with much lower affinity. The peptides inhibit CaM-regulated activation of bovine brain phosphodiesterase in vitro. The peptides also inhibit mitogen-induced lymphocyte activation, a property shared by CaM antagonists. Purified HIV-1 gp160 binds to CaM, while gp120, which lacks the putative amphipathic helical segments, does not bind CaM. In HIV-infected cells, the putative CaM-binding regions of gp160 are located intracellularly and may therefore interact with the cytosolic CaM. We postulate that CaM binding by HIV envelope proteins is likely to exert diverse modulatory effects, and the mechanism for HIV-induced cytotoxicity may involve, in part, inhibition of CaM-regulated cellular functions.	UNIV ALABAMA, DEPT MED, 630 BDB UAB MED CTR, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT BIOCHEM, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, ATHEROSCLEROSIS RES UNIT, BIRMINGHAM, AL 35294 USA; EMORY UNIV, DEPT MICROBIOL & IMMUNOL, ATLANTA, GA 30322 USA; ST JUDE CHILDRENS RES HOSP, DEPT INFECT DIS, MEMPHIS, TN 38105 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Emory University; St Jude Children's Research Hospital			Compans, Richard W/I-4087-2013	Compans, Richard W/0000-0003-2360-335X	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025784, R01AI028928] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIAID NIH HHS [AI 28928, AI 25784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P627; ANDERSON SR, 1986, CALCIUM CELL FUNCTIO, V6, P2; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; COLOMBANI PM, 1985, SCIENCE, V228, P337, DOI 10.1126/science.3885394; COX JA, 1985, J BIOL CHEM, V260, P2527; EISENBERG D, 1990, BIOPOLYMERS, V29, P171, DOI 10.1002/bip.360290122; FISHER AG, 1986, SCIENCE, V233, P655, DOI 10.1126/science.3014663; FRANKEL AD, 1989, P NATL ACAD SCI USA, V86, P7397, DOI 10.1073/pnas.86.19.7397; GARRY RF, 1989, AIDS, V3, P683, DOI 10.1097/00002030-198911000-00001; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; HOFMANN B, 1990, J IMMUNOL, V145, P3699; JOHNSON JD, 1987, ANAL BIOCHEM, V162, P291, DOI 10.1016/0003-2697(87)90039-X; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KODAMA T, 1989, J VIROL, V63, P4709, DOI 10.1128/JVI.63.11.4709-4714.1989; KONG LI, 1988, SCIENCE, V240, P1525, DOI 10.1126/science.3375832; KOWALSKI M, 1991, J VIROL, V65, P281, DOI 10.1128/JVI.65.1.281-291.1991; LEE SJ, 1989, AIDS RES HUM RETROV, V5, P441, DOI 10.1089/aid.1989.5.441; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MCKEATING JA, 1989, AIDS, V3, pS35, DOI 10.1097/00002030-198901001-00005; MEREISH K A, 1990, Peptide Research, V3, P233; NELSON TY, 1987, MOL CELL BIOCHEM, V74, P83; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RIENZO AMD, 1992, J ACQ IMMUN DEF SYND, V5, P921; SAKAI K, 1988, J VIROL, V62, P4078, DOI 10.1128/JVI.62.11.4078-4085.1988; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SLAUGHTER GR, 1987, METHOD ENZYMOL, V139, P433; SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; VENABLE RM, 1989, AIDS RES HUM RETROV, V5, P7, DOI 10.1089/aid.1989.5.7; WEISLOW OS, 1989, JNCI-J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143	34	88	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22895	22899						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226798				2022-12-25	WOS:A1993MD34800102
J	GRANA, X; CLAUDIO, PP; DELUCA, A; SANG, NL; GIORDANO, A				GRANA, X; CLAUDIO, PP; DELUCA, A; SANG, NL; GIORDANO, A			PISSLRE, A HUMAN NOVEL CDC2-RELATED PROTEIN-KINASE	ONCOGENE			English	Article							GLUTATHIONE-S-TRANSFERASE; TRANSLATIONAL INITIATION; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; SEQUENCE HOMOLOGY; CDC28 MUTATION; GENE ENCODES; CYCLIN-A; FAMILY	The cell division cycle have been shown to be regulated by a closely-related family of protein kinases named CDKs (by cyclin-dependent kinases). Using a PCR-based cloning technique, we have isolated cDNAs encoding a human CDC2-related protein kinase. The full-length cDNA accommodates an open reading frame that does not contain any ATG initiation codon upstream of the sequence encoding the catalytic domain of this putative kinase. Three putative non-ATG initiation codons have been detected. Starting at the most 5' non-ATG initiation site, the encoded product is 316 amino acids long with a predicted molecular weight of 35.8 kDa. Analysis of the deduced amino acid sequence showed it to contain the XI subdomains present in all known protein kinases and a PSTAIRE-like motive, PISSLRE, which temporarily names this kinase. PISSLRE is most related to p58/GTA (55% identity in the catalytic domain), the galactosyl transferase associated protein, which has been shown to inhibit entry into S-phase when over-expressed in CHO cells. PISSLRE shares 38-45% identity with all CDKs and contains the regulatory Tyr and Thr residues present in most of the members of the CDK family of protein kinases, which suggests similar modes of regulation. PISSLRE is expressed in all human tissues tested, including those which contain high proportion of terminally differentiated cells. However, the levels of the PISSLRE transcripts are dissimilar among different tissues.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	GRANA, X (corresponding author), TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, DEPT PATHOL, 3307 N BROAD ST, PHILADELPHIA, PA 19140 USA.		Giordano, Antonio/F-1927-2010; Claudio, Pier Paolo/AAW-7282-2021	Giordano, Antonio/0000-0002-5959-016X; Claudio, Pier Paolo/0000-0001-7790-1622; Grana, Xavier/0000-0001-7134-0473	NCI NIH HHS [R01 CA 6099-01A1] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HARLOW E, 1988, ANTIBODIES LABORATOR; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEW J, 1992, J BIOL CHEM, V267, P25922; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEHDI H, 1990, GENE, V91, P173, DOI 10.1016/0378-1119(90)90085-6; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; OKUDA T, 1992, ONCOGENE, V7, P2249; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	43	56	60	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2097	2103						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208557				2022-12-25	WOS:A1994NR68500037
J	DIMRI, GP; HARA, E; CAMPISI, J				DIMRI, GP; HARA, E; CAMPISI, J			REGULATION OF 2 E2F-RELATED GENES IN PRESENESCENT AND SENESCENT HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F; DIHYDROFOLATE-REDUCTASE PROMOTER; CYCLE-DEPENDENT GENES; CELL-CYCLE; BINDING PROTEIN; RETINOBLASTOMA PROTEIN; DIPLOID FIBROBLASTS; MURINE FIBROBLASTS; COMPLEX-FORMATION; GROWTH-FACTOR	Several mammalian genes expressed in late G, are positively regulated by E2F, a heterodimeric transcription factor, Genes encoding two E2F proteins, E2F-1 and DP-1, were regulated differently during the cell cycle and replicative senescence of normal human fibroblasts. In presenescent cells, E2F-1 mRNA was cell-cycle regulated, appearing a few hours before S phase. Ey contrast, DP-1 mRNA was constitutively expressed, independent of position in the cell cycle. After a finite number of divisions, normal cells enter a state of irreversible growth arrest termed senescence. Many genes remain mitogen-inducible in senescent cells; there are, however, exceptions, including several late G(1) genes potentially regulated by E2F. Senescent cells expressed DP-1 at the presenescent level, but did not express E2F-1 mRNA. Senescent cells were also markedly deficient in E2F binding activity associated with the dihydrofolate reductase promoter. E2F-1 and DP-1 expression vectors only weakly induced DNA synthesis in quiescent or senescent human cells and immortal murine NIH3T3 cells, although the E2F-1 vector stimulated DNA synthesis in immortal murine A31 cells, and transactivated E2F-responsive promoters in NIH3T3 cells. The results suggest that senescent cells may fail to express late G, genes due to repression of E2F-1, leading to a deficiency of E2F activity. Furthermore, although E2F-1 stimulates DNA synthesis in some cells, other cells, including normal human fibroblasts, require additional factors.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DEPT CELL & MOLEC BIOL,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley					NATIONAL INSTITUTE ON AGING [R37AG009909, R56AG009909, R01AG009909] Funding Source: NIH RePORTER; NIA NIH HHS [AG09909] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHANG ZF, 1988, J BIOL CHEM, V263, P11431; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HARA E, 1994, J BIOL CHEM, V269, P2139; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOFBAUER R, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P247; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LIM K, 1989, BIOTECHNIQUES, V7, P576; LU KH, 1992, P NATL ACAD SCI USA, V89, P3889, DOI 10.1073/pnas.89.9.3889; LU KH, 1989, MOL CELL BIOL, V9, P3411, DOI 10.1128/MCB.9.8.3411; Naeve GS, 1991, CURR OPIN CELL BIOL, V3, P261, DOI 10.1016/0955-0674(91)90150-W; NEVINS JR, 1992, SCIENCE, V258, P424; PANG JH, 1993, J BIOL CHEM, V268, P2909; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; Sambrook J, 1989, MOL CLONING LABORATO; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SESHADRI T, 1993, J BIOL CHEM, V268, P18474; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014	44	103	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16180	16186						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206919				2022-12-25	WOS:A1994NQ72900037
J	LIEBERMAN, KR; DAHLBERG, AE				LIEBERMAN, KR; DAHLBERG, AE			THE IMPORTANCE OF CONSERVED NUCLEOTIDES OF 23-S RIBOSOMAL-RNA AND TRANSFER-RNA IN RIBOSOME CATALYZED PEPTIDE-BOND FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; RESISTANCE MUTATIONS; DOMAIN-V; A-SITES; P-SITES; CHLORAMPHENICOL; MUTAGENESIS; RECOGNITION; EFFICIENT; GENES	We have constructed the double mutant G2252C/ G2253C in Escherichia coli 23 S rRNA by site directed mutagenesis. These phylogenetically conserved residues are protected from chemical modification by the 3' CCA terminus of the peptidyl-tRNA site (P site)-bound tRNA. Expression of C2252/C2253 23 S rRNA in E. coli severely compromises cell growth. Mutant rRNA is assembled into 50 S subunits and 70 S ribosomes but is discriminated against in polysomes. Mutant ribosomes function at lower rates in peptidyltransferase assays than wild type ribosomes. To test whether this defect derives from disruption of base pairing with the 2 cytidines of the invariant 3' CCA terminus of tRNA, a mutant E. coli tRNA(Phe) gene was constructed, with the CCA sequence changed to GGA. As deacylated species, mutant and wild type tRNA(Phe) inhibit peptidyl transfer identically. Mutant tRNA(Phe) was aminoacylated in vitro but failed to react as a P site substrate, with either mutant or wild type ribosomes. These results support a role for G2252 and G2253 of 23 S rRNA in peptidyltransferase function and a role for the 3' residues of peptidyl-tRNA in catalytically productive P site interaction; but they fail to provide evidence supporting canonical base pairing between these 23 S residues and the 3' end of peptidyl-tRNA.	BROWN UNIV, DIV BIOL & MED, PROVIDENCE, RI 02912 USA	Brown University					NIGMS NIH HHS [GM19756] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bjork GR, 1992, TRANSFER RNA PROTEIN, P23; CHLADEK S, 1974, BIOCHEMISTRY-US, V13, P2727, DOI 10.1021/bi00710a011; DAHLBERG AE, 1989, CELL, V57, P525, DOI 10.1016/0092-8674(89)90122-0; GOURSE RL, 1985, P NATL ACAD SCI USA, V82, P1069, DOI 10.1073/pnas.82.4.1069; GREGORY ST, 1994, NUCLEIC ACIDS RES, V22, P279, DOI 10.1093/nar/22.3.279; GUTELL RR, 1990, NUCLEIC ACIDS RES, V18, P2319, DOI 10.1093/nar/18.suppl.2319; HAENNI AL, 1966, BIOCHIM BIOPHYS ACTA, V114, P135, DOI 10.1016/0005-2787(66)90261-9; HALL CC, 1988, BIOCHEMISTRY-US, V27, P3983, DOI 10.1021/bi00411a014; HARRINGTON KM, 1993, BIOCHEMISTRY-US, V32, P7617, DOI 10.1021/bi00081a003; HUMMEL H, 1987, NUCLEIC ACIDS RES, V15, P2431, DOI 10.1093/nar/15.6.2431; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEDER P, 1966, BIOCHEM BIOPH RES CO, V25, P233, DOI 10.1016/0006-291X(66)90586-9; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; LILL R, 1988, J MOL BIOL, V203, P699, DOI 10.1016/0022-2836(88)90203-3; MANKIN AS, 1991, J BACTERIOL, V173, P3559, DOI 10.1128/jb.173.11.3559-3563.1991; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MONRO RE, 1967, J MOL BIOL, V26, P147, DOI 10.1016/0022-2836(67)90271-9; MONRO RE, 1968, P NATL ACAD SCI USA, V61, P1042, DOI 10.1073/pnas.61.3.1042; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OCONNOR M, 1993, EMBO J, V12, P2559, DOI 10.1002/j.1460-2075.1993.tb05911.x; PETERSON ET, 1992, BIOCHEMISTRY-US, V31, P10380, DOI 10.1021/bi00157a028; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4693; SIGMUND CD, 1988, METHOD ENZYMOL, V164, P673; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; SUNDARI RM, 1977, J BIOL CHEM, V252, P3941; VESTER B, 1988, EMBO J, V7, P3577, DOI 10.1002/j.1460-2075.1988.tb03235.x; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	31	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16163	16169						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206917				2022-12-25	WOS:A1994NQ72900035
J	SUNDBY, C; MCCAFFERY, S; ANDERSON, JM				SUNDBY, C; MCCAFFERY, S; ANDERSON, JM			TURNOVER OF THE PHOTOSYSTEM-II D1-PROTEIN IN HIGHER-PLANTS UNDER PHOTOINHIBITORY AND NONPHOTOINHIBITORY IRRADIANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION CENTER PROTEIN; D1 PROTEIN; CHLOROPLAST MEMBRANES; SPINACH-CHLOROPLASTS; ELECTRON-TRANSPORT; LIGHT; DEGRADATION; PHOTOSYNTHESIS; RECOVERY; LEAVES	The turnover in vivo of the Photosystem II (PS II) reaction center D1 protein was investigated by [S-35]methionine labeling of leaf discs of Brassica napus and subsequent analysis after thylakoid SDS-gel electrophoresis. The rate of D1 protein degradation was found to have a t1/2 of approximately 2 h, at an irradiance corresponding to the growth irradiance. The rate of D1 protein degradation was not increased further by prior photoinhibitory treatment which inactivated 40% of the PS II centers, but the amount of [S-35]methionine label incorporated into the D1 protein during 1 h was increased 3-fold. Whether photoinhibited or not, the incorporation of label into the D1 protein increased with irradiance only up to approximately the growth irradiance and above that it decreased with increasing incident light. These data indicate that a high rate of D1 protein degradation occurs not only after photoinhibition but also under conditions where no net decrease in the number of functional PS II centers occurs and that the number of PS II centers that undergo D1 protein turnover varies depending on prior photoinhibitory damage and on incident irradiance. A down-regulation of PS II in leaves at high irradiances is discussed.	LUND UNIV, DEPT BIOCHEM, POB 124, S-22100 LUND, SWEDEN	Lund University	SUNDBY, C (corresponding author), CSIRO, DIV PLANT IND, GPO BOX 1600, CANBERRA, ACT 2601, AUSTRALIA.							ADIR N, 1990, J BIOL CHEM, V265, P12563; ANDERSSON B., 1991, CURR TOP BIOENERG, V16, P1; ARO EM, 1992, FEBS LETT, V297, P29, DOI 10.1016/0014-5793(92)80320-G; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; CALLAHAN FE, 1986, PLANT PHYSIOL, V82, P261, DOI 10.1104/pp.82.1.261; CHOW WS, 1989, BIOCHIM BIOPHYS ACTA, V973, P105, DOI 10.1016/S0005-2728(89)80408-6; CLELAND RE, 1990, AUST J PLANT PHYSIOL, V17, P641, DOI 10.1071/PP9900641; CRITCHLEY C, 1992, PHOTOSYNTHETICA, V27, P183; CURWIEL VB, 1993, Z NATURFORSCH C, V48, P278; FROMM H, 1985, EMBO J, V4, P291, DOI 10.1002/j.1460-2075.1985.tb03628.x; GODDE D, 1991, Z NATURFORSCH C, V46, P245; GREENBERG BM, 1989, P NATL ACAD SCI USA, V86, P6617, DOI 10.1073/pnas.86.17.6617; GREENBERG BM, 1990, CURRENT RES PHOTOSYN, V1, P209; GREER DH, 1986, PLANTA, V168, P253, DOI 10.1007/BF00402971; GUENTHER JE, 1990, PHOTOSYNTH RES, V23, P105, DOI 10.1007/BF00030070; HART JJ, 1990, PLANT PHYSIOL, V94, P1301, DOI 10.1104/pp.94.3.1301; HEBER U, 1988, PLANTA, V173, P267, DOI 10.1007/BF00403020; HURRY VM, 1992, PLANTA, V188, P369, DOI 10.1007/BF00192804; JEGERSCHOLD C, 1991, FEBS LETT, V280, P87, DOI 10.1016/0014-5793(91)80210-T; KETTUNEN R, 1991, FEBS LETT, V290, P153, DOI 10.1016/0014-5793(91)81247-6; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; MELIS A, 1987, PHOTOCHEM PHOTOBIOL, V45, P129, DOI 10.1111/j.1751-1097.1987.tb08413.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHAD I, 1988, BIOCHIM BIOPHYS ACTA, V933, P288, DOI 10.1016/0005-2728(88)90036-9; OHAD N, 1990, Z NATURFORSCH C, V45, P402; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; PRAZIL O, 1992, PHOTOSYSTEMS STRUCTU, P295; QUIST G, 1992, PLANTA, V186, P450; RICHTER M, 1990, PHOTOSYNTH RES, V24, P229, DOI 10.1007/BF00032310; SALTER AH, 1992, BIOCHEMISTRY-US, V31, P3990, DOI 10.1021/bi00131a014; SAMUELSSON G, 1987, PLANT PHYSIOL, V83, P438, DOI 10.1104/pp.83.2.438; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; SHIPTON CA, 1991, P NATL ACAD SCI USA, V88, P6691, DOI 10.1073/pnas.88.15.6691; SKOGEN D, 1986, J PLANT PHYSIOL, V126, P195, DOI 10.1016/S0176-1617(86)80021-9; SUNDBY C, 1993, PLANT PHYSIOL, V103, P105, DOI 10.1104/pp.103.1.105; TERASHIMA I, 1985, PLANT CELL PHYSIOL, V26, P781, DOI 10.1093/oxfordjournals.pcp.a076971; TYYSTJARVI E, 1992, PLANT PHYSIOL, V100, P1310, DOI 10.1104/pp.100.3.1310; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; VIRGIN I, 1991, FEBS LETT, V287, P125, DOI 10.1016/0014-5793(91)80031-W; WEIS E, 1987, BIOCHIM BIOPHYS ACTA, V894, P198, DOI 10.1016/0005-2728(87)90190-3	42	91	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25476	25482						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244982				2022-12-25	WOS:A1993MK10000032
J	ANDERSON, ED; THOMAS, L; HAYFLICK, JS; THOMAS, G				ANDERSON, ED; THOMAS, L; HAYFLICK, JS; THOMAS, G			INHIBITION OF HIV-1 GP160-DEPENDENT MEMBRANE-FUSION BY A FURIN-DIRECTED ALPHA(1)-ANTITRYPSIN VARIANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROCESSING ENDOPROTEASES; KEX2-LIKE ENDOPROTEASE; MUTATIONAL ANALYSIS; MAMMALIAN-CELLS; VACCINIA VIRUS; CLEAVAGE SITE; ANTI-THROMBIN; GENE ENCODES; EXPRESSION	Furin is a membrane-associated calcium-dependent serine endoprotease that cleaves proproteins on the carboxyl side of the consensus sequence -Arg-X-Lys/Arg-Arg-. Using site-directed mutagenesis, a variant alpha1-antitrypsin (alpha1-AT) was constructed which contains in its reactive site -Arg-X-X-Arg-, the minimal sequence required for efficient processing by furin (Molloy, S. S., Bresnahan, P. A., Leppla, S. H., Klimpel, K. R., and Thomas, G. (1992) J. Biol. Chem. 267,1639616402). This alpha1-AT variant, [Arg355Arg358]alpha1-AT (alpha1-PDX), is greater than 3,000-fold more effective than [Arg358]alpha1-AT (alpha1-AT Pittsburgh, alpha1-PIT) at inhibiting furin in vitro (K0.5 = 0.03 mug/ml). Furthermore, the P4 Arg in alpha1-PDX greatly attenuates the thrombin inhibitory properties of this serpin (>300-fold) compared with alpha1-PIT (which contains a P4 Ala), thus increasing the selectivity of alpha1-PDX for furin. Expression studies show that alpha1-PDX, and not alpha1-PIT, blocks the processing of two furin substrates, pro-beta-nerve growth factor and human immunodeficiency virus (HIV)-1 gp160 in transfected cells. In addition, a syncytium assay shows that alpha1-PDX blocks the membrane fusogenic properties of HIV-1 gp160. The potential use of alpha1-PDX in manipulating the activation of proproteins in a tissue- and time-specific manner is discussed.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University					NIDDK NIH HHS [DK-44629, DK-37274] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044629, R01DK037274] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BATHURST IC, 1987, SCIENCE, V235, P348, DOI 10.1126/science.3541206; BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; BRENNAN SO, 1984, BIOCHIM BIOPHYS ACTA, V802, P24, DOI 10.1016/0304-4165(84)90029-1; BRENNAN SO, 1988, FEBS LETT, V229, P167, DOI 10.1016/0014-5793(88)80819-6; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRESNAHAN PA, 1993, MECHANISMS INTRACELL, P225; BRESNAHAN PA, 1989, THESIS OREGON HLTH S; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; EDWARDS RH, 1988, MOL CELL BIOL, V8, P2456, DOI 10.1128/MCB.8.6.2456; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HAYFLICK JS, 1992, J NEUROSCI, V12, P705; HEEB MJ, 1990, J BIOL CHEM, V265, P2365; KARSCHIN A, 1992, METHOD ENZYMOL, V207, P408; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIS JH, 1978, BLOOD, V51, P129; LU WY, 1993, J BIOL CHEM, V268, P14583; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MCKEEHAN WL, 1977, DEV BIOL STAND, V37, P97; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; ODA K, 1992, BIOCHEM BIOPH RES CO, V189, P1353, DOI 10.1016/0006-291X(92)90223-8; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PERLMUTTER DH, 1989, AM J PHYSIOL, V257, pL147, DOI 10.1152/ajplung.1989.257.4.L147; ROBACK JD, 1992, DEV BRAIN RES, V70, P123, DOI 10.1016/0165-3806(92)90110-I; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SCHAPIRA M, 1987, J CLIN INVEST, V80, P582, DOI 10.1172/JCI113108; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; THORNE BA, 1989, J BIOL CHEM, V264, P3545; VANDERZEE CEEM, 1992, J COMP NEUROL, V326, P91, DOI 10.1002/cne.903260108; YANKER B, 1982, ANN REV BIOCH, V551, P845	40	192	202	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24887	24891						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227051				2022-12-25	WOS:A1993MG67300057
J	KUMAR, MA; TIMM, DE; NEET, KE; OWEN, WG; PEUMANS, WJ; RAO, AG				KUMAR, MA; TIMM, DE; NEET, KE; OWEN, WG; PEUMANS, WJ; RAO, AG			CHARACTERIZATION OF THE LECTIN FROM THE BULBS OF ERANTHIS-HYEMALIS (WINTER ACONITE) AS AN INHIBITOR OF PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; POKEWEED ANTIVIRAL PROTEIN; A-CHAIN; PLANT-LECTINS; ABRIN-A; FLUORESCENCE; RICIN; INVITRO; LEPIDOPTERA; EXPRESSION	The lectin from Eranthis hyemalis has been previously characterized as consisting of two polypeptide chains covalently linked by disulfide bond(s) (Cammue, B. P., Peeters, B., and Peumans, W. J. (1985) Biochem. J. 227, 949-955). We have further characterized the biochemical properties of the lee-tin and demonstrated that it possesses the property of inhibition of protein synthesis using in vitro eukaryotic translation systems. The protein also possesses antiviral activity against the plant virus, alfalfa mosaic virus, and larvicidal activity against the southern corn rootworm, Diabrotica undecimpunctata howardii, a major insect pest of the maize plant. Both isoelectric focusing on gels and chromatofocusing indicated heterogeneity of the protein, with three species having isoelectric points in the range 4-5. The disulfide bond(s) can be rapidly reduced with beta-mercaptoethanol under native conditions. The reduced alkylated polypeptide chains remain associated under native conditions to form a species, EHL', that elutes at the same position as the native protein and has the same molecular weight by sedimentation equilibrium experiments. However, circular dichroism and fluorescence measurements indicated conformational differences between the species.	PIONEER HI BRED INT INC, DEPT BIOTECHNOL RES, JOHNSTON, IA 50131 USA; CASE WESTERN RESERVE UNIV, DEPT BIOCHEM, CLEVELAND, OH 44106 USA; UNIV HLTH SCI CHICAGO MED SCH, DEPT BIOL CHEM, N CHICAGO, IL 60064 USA; MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOLEC BIOL, ROCHESTER, MN 55905 USA; CATHOLIC UNIV LEUVEN, PLANTENBIOCHEM LAB, B-3030 HEVERLEE, BELGIUM	DuPont; Pioneer Hi-Bred International, Inc.; Case Western Reserve University; Chicago Medical School; Mayo Clinic; KU Leuven								BALASUBRAMANIAM NK, 1991, ARCH BIOCHEM BIOPHYS, V288, P374, DOI 10.1016/0003-9861(91)90209-2; BALZARINI J, 1992, ANTIVIR RES, V18, P191, DOI 10.1016/0166-3542(92)90038-7; CAMMUE BP, 1985, BIOCHEM J, V227, P949, DOI 10.1042/bj2270949; COLLINS EJ, 1990, J BIOL CHEM, V265, P8665; CZAPLA TH, 1990, J ECON ENTOMOL, V83, P2480, DOI 10.1093/jee/83.6.2480; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Etzler ME, 1986, LECTINS PROPERTIES F, P371; FORDHAMSKELTON AP, 1991, MOL GEN GENET, V229, P460, DOI 10.1007/BF00267470; FUNATSU G, 1988, AGR BIOL CHEM TOKYO, V52, P1095; GATEHOUSE AMR, 1984, J SCI FOOD AGR, V35, P373, DOI 10.1002/jsfa.2740350402; GOLDSTEIN IJ, 1980, NATURE, V285, P66, DOI 10.1038/285066b0; HABUKA N, 1989, J BIOL CHEM, V264, P6629; HARLEY SM, 1982, P NATL ACAD SCI-BIOL, V79, P5935, DOI 10.1073/pnas.79.19.5935; HOUSTON LL, 1980, BIOCHEM BIOPH RES CO, V92, P319, DOI 10.1016/0006-291X(80)91555-7; Hull R, 1969, Adv Virus Res, V15, P365, DOI 10.1016/S0065-3527(08)60880-5; JANZEN DH, 1976, SCIENCE, V192, P795, DOI 10.1126/science.1265481; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KATAOKA J, 1992, PLANT MOL BIOL, V20, P879, DOI 10.1007/BF00027159; KUBO S, 1990, Annals of the Phytopathological Society of Japan, V56, P481, DOI 10.3186/jjphytopath.56.481; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; LAPPI DA, 1978, P NATL ACAD SCI USA, V75, P1096, DOI 10.1073/pnas.75.3.1096; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; MATHESON IBC, 1990, COMPUT CHEM, V14, P49, DOI 10.1016/0097-8485(90)80007-O; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCLURE WO, 1967, BIOCHEMISTRY-US, V6, P559, DOI 10.1021/bi00854a025; MORRIS KN, 1992, P NATL ACAD SCI USA, V89, P4869, DOI 10.1073/pnas.89.11.4869; MURDOCK LL, 1990, PHYTOCHEMISTRY, V29, P85, DOI 10.1016/0031-9422(90)89016-3; OUCHTERLONY O, 1948, ACTA PATHOL MIC SC, V25, P186; Parker C. A., 1968, PHOTOLUMINESCENCE SO, P220; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; READY MP, 1986, P NATL ACAD SCI USA, V83, P5053, DOI 10.1073/pnas.83.14.5053; READY MP, 1988, PROTEINS, V3, P53, DOI 10.1002/prot.340030105; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SHUKLE RH, 1983, ENVIRON ENTOMOL, V12, P787, DOI 10.1093/ee/12.3.787; STEINER M, 1980, BIOCHEMISTRY-US, V19, P4492, DOI 10.1021/bi00560a017; STIRPE F, 1992, BIO-TECHNOL, V10, P405, DOI 10.1038/nbt0492-405; STROSBERG D, 1986, LECTINS, P251; YORK WS, 1986, METHOD ENZYMOL, V118, P3	39	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25176	25183						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227081				2022-12-25	WOS:A1993MG67300094
J	MILEYKOVSKAYA, EI; DOWHAN, W				MILEYKOVSKAYA, EI; DOWHAN, W			ALTERATIONS IN THE ELECTRON-TRANSFER CHAIN IN MUTANT STRAINS OF ESCHERICHIA-COLI LACKING PHOSPHATIDYLETHANOLAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC RESPIRATORY-CHAIN; PERFORMANCE LIQUID-CHROMATOGRAPHY; DOUBLE QUINONE MUTANT; CYTOCHROME-C-OXIDASE; NADH DEHYDROGENASE; MEMBRANE-VESICLES; TERMINAL OXIDASES; BC1 COMPLEX; COENZYME-Q; UBIQUINONE	Inside-out sealed membrane vesicles were prepared from strains of Escherichia coli engineered to be lacking in the major phospholipid of this organism, phosphatidylethanolamine (DeChavigny, A., Heacock, P. N., and Dowhan, W. (1991) J. Biol. Chem. 266, 5323-5332). The energy transducing properties, namely the ability to generate a proton gradient directed inward and to transport electrons to molecular oxygen, were compared to those of membranes isolated from wild type cells containing normal levels of phosphatidylethanolamine. Membranes from both cell types were equal in their ability to oxidize succinate and lactate as well as hydrolyze ATP with the generation of proton gradients of similar magnitude, thus establishing the structural integrity of the membrane barrier and basic functionality of the energy transducing systems in the mutant membranes. However, mutant membranes were reduced by about 80% in their type II NADH dehydrogenase-dependent oxidase activity which resulted in a reduced ability to generate a proton gradient using NADH as an energy source. Use of artificial electron acceptors indicated that the level of type II NADH dehydrogenase activity was normal. Whole chain NADH oxidase activity could be restored by addition of short chain analogs of the naturally occurring Q8, even though the level of the Q8 pool in both cell types was the same. These results suggest that the function of Q8 in linking type II NADH dehydrogenase with the terminal oxidase(s) is dependent on the phosphatidylethanolamine content of the surrounding phospholipid matrix.	UNIV TEXAS,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77025	University of Texas System				Mileykovskaya, Eugenia/0000-0002-8775-4467	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020478, R37GM020478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG JM, 1964, BIOCHIM BIOPHYS ACTA, V86, P194; BERRY EA, 1991, J BIOL CHEM, V266, P9064; COX GB, 1983, BIOCHEM J, V216, P143, DOI 10.1042/bj2160143; COX GB, 1970, BIOCHEM J, V117, P551, DOI 10.1042/bj1170551; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; DOWHAN W, 1992, METHOD ENZYMOL, V209, P7; FINE JB, 1982, J LIPID RES, V23, P660; Haddock B A, 1974, Biochem J, V142, P703; HEACOCK PN, 1989, J BIOL CHEM, V264, P14972; HENKEL RD, 1988, ANAL BIOCHEM, V169, P312, DOI 10.1016/0003-2697(88)90290-4; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; HORECKER BL, 1948, J BIOL CHEM, V175, P385; JAWOROWSKI A, 1981, BIOCHEMISTRY-US, V20, P3621, DOI 10.1021/bi00515a049; KIMURA T, 1963, BIOCHEM BIOPH RES CO, V11, P83, DOI 10.1016/0006-291X(63)90070-6; KITA K, 1984, J BIOL CHEM, V259, P3368; KITA K, 1984, J BIOL CHEM, V259, P3375; KRANZ RG, 1983, J BIOL CHEM, V258, P614; LANG JK, 1987, J CHROMATOGR, V385, P109, DOI 10.1016/S0021-9673(01)94626-6; Lenaz G., 1985, COENZYME Q, P165; LESTER RL, 1959, BIOCHIM BIOPHYS ACTA, V33, P169, DOI 10.1016/0006-3002(59)90511-6; LORENCE RM, 1987, J BIOL CHEM, V262, P10532; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; MEINHARDT SW, 1989, BIOCHEMISTRY-US, V28, P2153, DOI 10.1021/bi00431a029; MILEYKOVSKAYA E, 1992, EBEC SHORT REPORTS, V7, P59; MILEYKOVSKAYA E, 1992, FASEB J, V6, P1125; Miller J.H., 1972, EXPT MOL GENETICS; Osborn M J, 1974, Methods Enzymol, V31, P642; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; POOLE RK, 1974, BIOCHEM J, V144, P77, DOI 10.1042/bj1440077; PUDEK MR, 1974, ARCH BIOCHEM BIOPHYS, V196, P682; RAGAN CI, 1978, BIOCHEM J, V136, P711; ROBINSON NC, 1990, BIOCHEMISTRY-US, V29, P8962, DOI 10.1021/bi00490a012; SCHAGGER H, 1990, EUR J BIOCHEM, V190, P123, DOI 10.1111/j.1432-1033.1990.tb15554.x; SINGER M, 1989, MICROBIOL REV, V53, P1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STROOBANT P, 1979, BIOCHEMISTRY-US, V18, P226, DOI 10.1021/bi00568a035; SZARKOWSKA L, 1966, ARCH BIOCHEM BIOPHYS, V113, P519, DOI 10.1016/0003-9861(66)90228-1; TSAI A, 1986, BIOCHIM BIOPHYS ACTA, V852, P100, DOI 10.1016/0005-2728(86)90061-7; TSAI AL, 1985, ANAL BIOCHEM, V151, P131, DOI 10.1016/0003-2697(85)90062-4; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; VONJAGOW G, 1990, HIGHLIGHTS UBIQUINON, P93; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; YAGI T, 1991, J BIOENERG BIOMEMBR, V23, P211, DOI 10.1007/BF00762218; YOUNG IG, 1978, GENE, V4, P25, DOI 10.1016/0378-1119(78)90012-4; ZHOU D, 1991, BIOCHEM J, V273, P627, DOI 10.1042/bj2730627	45	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24824	24831						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227044				2022-12-25	WOS:A1993MG67300048
J	MUKOYAMA, M; NAKAJIMA, M; HORIUCHI, M; SASAMURA, H; PRATT, RE; DZAU, VJ				MUKOYAMA, M; NAKAJIMA, M; HORIUCHI, M; SASAMURA, H; PRATT, RE; DZAU, VJ			EXPRESSION CLONING OF TYPE-2 ANGIOTENSIN-II RECEPTOR REVEALS A UNIQUE CLASS OF 7-TRANSMEMBRANE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SOMATOSTATIN RECEPTORS; RAT; SUBTYPES; IDENTIFICATION; KINASE; TISSUES; BINDING; ENCODES; PROTEIN; LIGAND	Angiotensin II acts on at least two distinct receptor subtypes (AT1 and AT2). Most known effects of angiotensin II in adult tissues are attributable to the AT1 receptor. The function of AT2 receptor is undefined, but its abundant expressions in fetal tissues, immature brain, skin wound, and atretic ovarian follicles suggest a role in growth and development. Previous studies suggested that AT2 receptor may not be G protein-coupled. Here, from a rat fetus expression library, we cloned a cDNA encoding a unique 363-amino acid protein with pharmacological specificity, tissue distribution, and developmental pattern of the AT2 receptor. It is 34% identical in sequence to the AT1 receptor, sharing a seven-transmembrane domain topology. A review of prior data on other receptors suggests that this receptor may belong to a unique class of seven-transmembrane receptors (including somatostatin SSTR1, dopamine D3, and frizzled protein Fz) for which G protein coupling has not been demonstrated. All members of this class exhibit fetal and developmental and/or neuronal-specific expression. A conserved motif in the third intracellular loop, distinguishing this class from ''classical'' G protein-coupled receptors, may mediate novel intracellular effects.	STANFORD UNIV,MED CTR,SCH MED,FALK CARDIOVASC RES CTR,300 PASTEUR DR,STANFORD,CA 94305	Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL035610, R01HL035252, R01HL046631, R01HL035610] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46631, HL35610, HL35252] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; CHIU AT, 1989, BIOCHEM BIOPH RES CO, V165, P196, DOI 10.1016/0006-291X(89)91054-1; DUDLEY DT, 1991, MOL PHARMACOL, V40, P360; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; GRESSENS P, 1993, NATURE, V362, P155, DOI 10.1038/362155a0; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; IWAI N, 1992, FEBS LETT, V298, P257, DOI 10.1016/0014-5793(92)80071-N; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PUCELL AG, 1991, ENDOCRINOLOGY, V128, P1947, DOI 10.1210/endo-128-4-1947; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; SHAW G, 1986, CELL, V46, P6596; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SREEDHARAN SP, 1991, P NATL ACAD SCI USA, V88, P4986, DOI 10.1073/pnas.88.11.4986; TSUTSUMI K, 1991, ENDOCRINOLOGY, V129, P1075, DOI 10.1210/endo-129-2-1075; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	30	710	726	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24539	24542						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227010				2022-12-25	WOS:A1993MG67300007
J	PREISS, T; HALL, AG; LIGHTOWLERS, RN				PREISS, T; HALL, AG; LIGHTOWLERS, RN			IDENTIFICATION OF BOVINE GLUTAMATE-DEHYDROGENASE AS AN RNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOCHROME-C-OXIDASE; MESSENGER-RNA; SUBUNIT-VIIA; 2 ISOFORMS; STABILITY; SEQUENCE; LIVER; EXPRESSION; POLYMERASE; HEART	Two RNA binding activities were demonstrated in bovine liver homogenate. One binding protein was isolated by a simple ion exchange and gel filtration protocol and was shown by N-terminal protein sequence analysis to be glutamate dehydrogenase. Using identical RNA substrate and assay conditions, no detectable RNA binding was observed with equimolar amounts of other representative dehydrogenases and proteins. Furthermore, excesses of tRNA, salmon testis DNA, or each of the four homoribopolymers were unable to compete for the RNA-binding site. Total cytosolic RNA, however, successfully prevented binding of radiolabeled RNA substrate. These data are consistent with glutamate dehydrogenase containing a binding site for heteropolymeric RNA with highest affinity for an as yet undefined nucleotide consensus sequence or structure. The potential physiological relevance of these observations is discussed.	UNIV NEWCASTLE UPON TYNE,SCH MED,DIV CLIN NEUROSCI,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,MED MOLEC BIOL GRP,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK			Hall, Andrew G/B-3485-2009; Hall, Andy/AAD-8622-2020; Preiss, Thomas/F-7355-2010	Preiss, Thomas/0000-0001-6273-784X				ATWATER JA, 1990, ANNU REV GENET, V24, P519; BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BERNARDI A, 1972, P NATL ACAD SCI USA, V69, P3033, DOI 10.1073/pnas.69.10.3033; BRUSILOW SW, 1989, METABOLIC BASIS INHE, V1, P629; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DEDUVE C, 1962, ADV ENZYMOL REL S BI, V24, P291; FABRIZI GM, 1989, NUCLEIC ACIDS RES, V17, P7107, DOI 10.1093/nar/17.17.7107; FISHER HF, 1985, METHOD ENZYMOL, V113, P16; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; KENNAWAY NG, 1990, PEDIATR RES, V28, P529; KWON TK, 1991, P NATL ACAD SCI USA, V88, P3548; LIGHTOWLERS R, 1990, J BIOL CHEM, V265, P2677; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P111; PREISS T, 1993, J BIOL CHEM, V268, P10659; SEELAN RS, 1991, J BIOL CHEM, V266, P19752; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Smith E.L., 1975, ENZYMES, P293, DOI DOI 10.1016/S1874-6047(08)60213-9; TELLER JK, 1992, EUR J BIOCHEM, V206, P151, DOI 10.1111/j.1432-1033.1992.tb16912.x; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VANBEEUMEN JJ, 1990, FEBS LETT, V263, P213, DOI 10.1016/0014-5793(90)81376-Y; VANKUILENBURG ABP, 1992, EUR J BIOCHEM, V203, P193; YANAMURA W, 1988, BIOCHEMISTRY-US, V27, P4909, DOI 10.1021/bi00413a048	25	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24523	24526						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227006				2022-12-25	WOS:A1993MG67300003
J	RODRIGUEZ, CG; MONTERO, M; ALVAREZ, J; GARCIASANCHO, J; CRESPO, MS				RODRIGUEZ, CG; MONTERO, M; ALVAREZ, J; GARCIASANCHO, J; CRESPO, MS			DISSOCIATION OF PLATELET-ACTIVATING-FACTOR PRODUCTION AND ARACHIDONATE RELEASE BY THE ENDOMEMBRANE CA2+-ATPASE INHIBITOR THAPSIGARGIN - EVIDENCE FOR THE INVOLVEMENT OF A CA2+-DEPENDENT ROUTE OF PRIMING IN THE PRODUCTION OF LIPID MEDIATORS BY HUMAN POLYMORPHONUCLEAR LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; ACETYL-COA ACETYLTRANSFERASE; LYSO-PAF-ACETYLTRANSFERASE; DEPENDENT PROTEIN-KINASE; RAT SPLENIC MICROSOMES; HUMAN-NEUTROPHILS; INDEPENDENT TRANSACYLASE; PHOSPHATIDIC-ACID; PLASMA-MEMBRANE; CALCIUM ENTRY	The production of platelet-activating factor (PAF) and the release of [H-3]arachidonate were studied in human polymorphonuclear leukocytes (PMN) stimulated with thapsigargin, an inhibitor of endomembrane Ca2+-ATPase. Concentrations of thapsigargin as low as 10-25 nM primed PMN for both PAF production and [H-3]arachidonate release in response to the chemotactic peptide (fMLP), whereas concentrations in the range 25-200 nM induced a time- and dose-dependent production of PAF, which occurred in the absence of both [H-3]arachidonate release and [H-3]phosphatidylethanol formation. Studies in fura-2/AM-loaded cells showed that concentrations of thapsigargin that elicited PAF production induced a protracted and long lasting elevation of cytosolic free calcium concentration ([Ca2+]i) between 200 and 700 nM. The lower concentrations primed the cells for a late [Ca2+]i elevation in response to fMLP similar to that elicited by cytochalasin B or ionomycin. PAF production showed a good correlation with the increase of [Ca2+]i (r = 0.91) irrespective of the procedure used to grade [Ca2+]i. In contrast, phorbol 12,13-dibutyrate failed to induce both PAF production and elevation of [Ca2+]i, but it was a very effective stimulator of [H-3]arachidonate release and [H-3]phosphatidylethanol production. These data indicate that PAF production and [H-3]arachidonate release in PMN differ in both biochemical pathway and modulatory mechanisms. Whereas PAF production seems extremely sensitive to changes in [Ca2+]i, which seems to exert its modulatory effect at the lyso-PAF:acetyl-CoA acetyltransferase step, [H-3] arachidonate release seems tightly modulated by protein kinase C-dependent mechanisms and is coincidental with activation of phospholipase D.			RODRIGUEZ, CG (corresponding author), FAC MED VALLADOLID,CSIC,DEPT BIOQUIM & BIOL MOLEC & FISIOL,E-47005 VALLADOLID,SPAIN.		Alvarez, Javier/K-8210-2014; Montero, Mayte/K-8212-2014; Garcia, Carmen/L-9961-2017; Garcia-Sancho, Javier/K-2975-2014	Alvarez, Javier/0000-0003-0636-5521; Montero, Mayte/0000-0001-7702-6653; Garcia, Carmen/0000-0002-7205-4572; Garcia-Sancho, Javier/0000-0003-4573-7930				ALBERT DH, 1983, J BIOL CHEM, V258, P97; ALONSO F, 1982, J BIOL CHEM, V257, P3376; ALVAREZ J, 1991, BIOCHEM J, V274, P194; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLANK ML, 1983, J CHROMATOGR, V273, P415, DOI 10.1016/S0378-4347(00)80963-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOURGOIN S, 1990, J EXP MED, V172, P767, DOI 10.1084/jem.172.3.767; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DIEZ FL, 1989, J CLIN INVEST, V83, P1733, DOI 10.1172/JCI114074; DOMENECH C, 1987, J BIOL CHEM, V262, P5671; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FRADIN A, 1989, J IMMUNOL, V143, P3680; GARCIA C, 1993, J BIOL CHEM, V268, P4001; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P511, DOI 10.1016/0167-4889(85)90218-6; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P516, DOI 10.1016/0167-4889(85)90219-8; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENSON PM, 1976, J EXP MED, V143, P937, DOI 10.1084/jem.143.4.937; HOLLAND MR, 1992, J BIOL CHEM, V267, P22883; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LEYRAVAUD S, 1989, J IMMUNOL, V143, P245; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN PY, 1991, J IMMUNOL, V146, P1609; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; NIETO ML, 1988, J BIOL CHEM, V263, P2217; NIETO ML, 1988, J BIOL CHEM, V263, P4607; NINIO E, 1987, J IMMUNOL, V139, P154; NINIO E, 1982, BIOCHIM BIOPHYS ACTA, V710, P23, DOI 10.1016/0005-2760(82)90185-0; PARKER J, 1987, J BIOL CHEM, V262, P5385; PRESCOTT SM, 1983, J BIOL CHEM, V258, P764; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SANCHEZCRESPO M, 1980, IMMUNOLOGY, V40, P645; SHARP JD, 1991, J BIOL CHEM, V266, P14850; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; THASTRUP O, 1987, BIOCHEM BIOPH RES CO, V142, P654, DOI 10.1016/0006-291X(87)91464-1; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; WYKLE RL, 1980, J BIOL CHEM, V255, P256	47	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24751	24757						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227034				2022-12-25	WOS:A1993MG67300037
J	NISHIMURA, H; TAKEYA, H; MIYATA, T; SUEHIRO, K; OKAMURA, T; NIHO, Y; IWANAGA, S				NISHIMURA, H; TAKEYA, H; MIYATA, T; SUEHIRO, K; OKAMURA, T; NIHO, Y; IWANAGA, S			FACTOR-IX FUKUOKA - SUBSTITUTION OF ASN(92) BY HIS IN THE 2ND EPIDERMAL GROWTH FACTOR-LIKE DOMAIN RESULTS IN DEFECTIVE INTERACTION WITH FACTORS-VIIIA/X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-IX; GAMMA-CARBOXYGLUTAMIC ACID; BOVINE FACTOR-IX; AFFINITY CALCIUM-BINDING; RUSSELLS VIPER VENOM; FACTOR-X ACTIVATION; CLOTTING FACTOR-IX; HUMAN FACTOR-VII; TRIMERESURUS-FLAVOVIRIDIS; CHRISTMAS FACTOR	Hemophilia B Fukuoka, a moderately severe bleeding disorder, is a naturally occurring mutant of factor IX. Plasma from our patient had 3% clotting activity even though 64% of factor IX antigen was present. The purified mutant protein was cleaved normally by factor Xla, factor VIIa-tissue factor complex, or RVV-X (factor X-activating enzyme from Russell's viper venom), yielding a two-chain factor IXa. Amino acid composition and sequence analyses of one of the lysyl endopeptidase peptides derived from factor IX Fukuoka revealed that Asn92 in the second epidermal growth factor (EGF)-like domain had been replaced by His. The active site of the factor IXa Fukuoka was normally competent for the incorporation of p-aminobenzamidine and for the hydrolysis of a synthetic substrate, N(alpha)-benzyloxycarbonyl-L-arginine p-nitrobenzyl ester. Factor Xa formation by factor IXa Fukuoka was only 8% of the normal factor IXa, even in the presence of polylysine, and only 0.2% of the normal in the system containing phospholipids, Ca2+, and factor VIIIa, thereby indicating a functional defect in interaction of the mutant with factors VIIIa/X. Furthermore, catalytic efficiency (k(cat)/K(m)) of factor IXa Fukuoka toward factor X in the presence of Ca2+, phospholipids, and factor VIIIa was only 2.3% of the normal factor IXa. These results suggest that an Asn-to-His substitution at position 92 in the second EGF-like domain of factor IX Fukuoka would have an untoward effect on the specific conformational state of factor IX for binding with factors VIIIa/X.	KYUSHU UNIV 33,FAC SCI,DEPT BIOL,HIGASHI KU,FUKUOKA 812,JAPAN; KYUSHU UNIV 33,FAC MED,DEPT INTERNAL MED 1,FUKUOKA 812,JAPAN; KYUSHU UNIV 33,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University; Kyushu University								AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; ASTERMARK J, 1991, J BIOL CHEM, V266, P2438; ATODA H, 1991, J BIOL CHEM, V266, P14903; ATODA H, 1989, J BIOCHEM, V106, P808, DOI 10.1093/oxfordjournals.jbchem.a122935; CHEUNG WF, 1991, J BIOL CHEM, V266, P8797; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ESNOUF MP, 1973, BIOCHEM J, V131, P781, DOI 10.1042/bj1310781; EVANS JP, 1989, BLOOD, V74, P207; FOSTER D, 1984, P NATL ACAD SCI-BIOL, V81, P4766, DOI 10.1073/pnas.81.15.4766; GIANNELLI F, 1990, NUCLEIC ACIDS RES, V18, P4053, DOI 10.1093/nar/18.14.4053; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HASE S, 1990, J BIOL CHEM, V265, P1858; HASE S, 1988, J BIOCHEM-TOKYO, V104, P867, DOI 10.1093/oxfordjournals.jbchem.a122571; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HOUGIE C, 1967, LANCET, V1, P698; JACKSON CM, 1972, BIOCHEMISTRY-US, V11, P4873, DOI 10.1021/bi00776a001; KATAYAMA K, 1979, P NATL ACAD SCI USA, V76, P4990, DOI 10.1073/pnas.76.10.4990; KAWABATA S, 1985, J BIOCHEM, V97, P1073, DOI 10.1093/oxfordjournals.jbchem.a135150; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTUS SP, 1984, P NATL ACAD SCI-BIOL, V81, P3699, DOI 10.1073/pnas.81.12.3699; LIN SW, 1990, J BIOL CHEM, V265, P144; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; LUNDBLAD RL, 1982, THROMB RES, V25, P319, DOI 10.1016/0049-3848(82)90232-8; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MCGRAW RA, 1985, P NATL ACAD SCI USA, V82, P2847, DOI 10.1073/pnas.82.9.2847; MONROE DM, 1988, ANAL BIOCHEM, V172, P427, DOI 10.1016/0003-2697(88)90465-4; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; PENDURTHI UR, 1992, THROMB RES, V65, P177, DOI 10.1016/0049-3848(92)90237-5; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; SPITZER SG, 1990, BLOOD, V76, P1530; SUEHIRO K, 1989, J BIOL CHEM, V264, P21257; SUGO T, 1990, THROMB RES, V58, P603, DOI 10.1016/0049-3848(90)90306-W; THOMPSON AR, 1986, BLOOD, V67, P565; WILLIAMS WJ, 1962, BIOCHEM J, V84, P52, DOI 10.1042/bj0840052; WU SM, 1990, GENE, V86, P275, DOI 10.1016/0378-1119(90)90290-8; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZUR M, 1978, J BIOL CHEM, V253, P2203	46	21	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24041	24046						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226948				2022-12-25	WOS:A1993MF29400051
J	OON, SH; HONG, A; YANG, XH; CHIA, W				OON, SH; HONG, A; YANG, XH; CHIA, W			ALTERNATIVE SPLICING IN A NOVEL TYROSINE PHOSPHATASE GENE (DPTP4E) OF DROSOPHILA-MELANOGASTER GENERATES 2 LARGE RECEPTOR-LIKE PROTEINS WHICH DIFFER IN THEIR CARBOXYL TERMINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; NERVOUS-SYSTEM AXONS; SIGNAL TRANSDUCTION; HUMAN-PLACENTA; HOMEOTIC GENE; CATALYTIC DOMAINS; KINASE; FAMILY; CLONING; ENCODES	A novel Drosophila receptor-like protein tyrosine phosphatase gene, DPTP4E, was isolated and characterized. DPTP4E, located at cytological position 4E1-2, is comprised of 10 exons; its RNA products are widely expressed during embryonic development, including the developing central nervous system. DPTP4E produces three major developmentally regulated transcripts of 6.5, 7.0, and 7.5 kilobases. The two major embryonic transcripts arise as the result of the alternative splicing of exon IX; as a consequence, two proteins (200 and 183 kDa) are produced which differ in their carboxyl-terminal sequences. The deduced extracellular domain, which lies between two putative hydrophobic transmembrane segments, contains 11 fibronectin type III-like repeats and 25 putative N-glycosylation sites. A single conserved protein tyrosine phosphatase (PTPase) catalytic domain, which shows a high level of amino acid identity to the Drosophila PTPase DPTP10D and human HPTPbeta, is found in the predicted intracellular domain; this PTPase domain, when expressed as a fusion protein in Escherichia coli, exhibits PTPase activity. The possible implications of these findings are discussed.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, DROSOPHILA NEUROBIOL LAB, SINGAPORE 0511, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								ALEXANDER D R, 1990, New Biologist, V2, P1049; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V88, P11266, DOI 10.1073/pnas.88.24.11266; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAUGHON A, 1985, COLD SPRING HARB SYM, V50, P253, DOI 10.1101/SQB.1985.050.01.032; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NORTON PA, 1990, CELL, V61, P15, DOI 10.1016/0092-8674(90)90209-W; Pallen Catherine J., 1992, Current Opinion in Cell Biology, V4, P1000, DOI 10.1016/0955-0674(92)90132-V; PALLEN CJ, 1991, BIOCHEM J, V276, P315, DOI 10.1042/bj2760315; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; Sambrook J, 1989, MOL CLONING LABORATO; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STREULI M, 1989, J EXP MED, V86, P3698; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	58	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23964	23971						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226938				2022-12-25	WOS:A1993MF29400041
J	RATCLIFFE, JV; FURIE, B; FURIE, BC				RATCLIFFE, JV; FURIE, B; FURIE, BC			THE IMPORTANCE OF SPECIFIC GAMMA-CARBOXYGLUTAMIC ACID RESIDUES IN PROTHROMBIN - EVALUATION BY SITE-SPECIFIC MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVITRO ANTICOAGULANT ACTIVITY; ACTIVATED PROTEIN-C; FACTOR-IX; BOVINE PROTHROMBIN; MEMBRANE-BINDING; RECOGNITION SITE; CALCIUM-BINDING; FACTOR-VA; FACTOR-X; PURIFICATION	Prothrombin has 10 gamma-carboxyglutamic acid residues which are essential for the metal ion binding properties and membrane binding function of the protein. To assess the importance of each gamma-carboxyglutamic acid residue we made, by site directed mutagenesis, a series of mutant human prothrombins each with a single glutamic acid to aspartic acid substitution at positions 6, 7, 14, 16, 19, 20, 25, 26, 29, or 32 which are gamma-carboxylated in native prothrombin. Along with wild-type prothrombin, the prothrombin mutants were expressed in Chinese hamster ovary cells, purified by immunoaffinity chromatography using polyclonal anti-prothrombin antibodies, and shown by amino acid analysis to contain the expected number of gamma-carboxyglutamic acid residues. Only substitution of gamma-carboxyglutamic acid 6 with aspartic acid yields a protein with procoagulant activity, affinity for phospholipid and K(M(app)) for prothrombinase indistinguishable from wild-type prothrombin. In contrast, the conservative gamma-carboxyglutamic acid to aspartic acid mutation at positions 16, 26, or 29 results in proteins with little or no procoagulant activity, K(d(app)) for binding to phospholipid at least 200-fold higher than wild-type prothrombin and a K(M(app)) for interaction with the prothrombinase complex nearly 100-fold higher than wild-type prothrombin. The mutations at residues 7, 14, 19, 20, 25, or 32 yielded proteins with intermediate procoagulant activities, between 15 and 52% of wild-type prothrombin. These data have been interpreted to suggest that there are certain gamma-carboxyglutamic acid residues which are important to maintaining the basic structure of the calcium-liganded Gla domain while other gamma-carboxyglutamic acid residues subserve other functions including membrane binding and interdomain interactions.	TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA; SACKLER SCH GRAD BIOMED SCI, BOSTON, MA 02111 USA	Tufts University; Tufts University	RATCLIFFE, JV (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, CTR HEMOSTASIS & THROMBOSIS RES, DIV HEMATOL ONCOL, BOSTON, MA 02111 USA.				NHLBI NIH HHS [HL42443, HL18834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018834, R37HL018834, P01HL042443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1988, J BIOL CHEM, V263, P9725; BAJAJ SP, 1982, J BIOL CHEM, V257, P3726; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BERKNER KL, 1989, THROMB HAEMOSTASIS, V62, P345; BLANCHARD RA, 1983, J LAB CLIN MED, V101, P242; BOROWSKI M, 1985, J BIOL CHEM, V260, P9258; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; BOROWSKI M, 1986, J BIOL CHEM, V261, P1624; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE BC, 1979, J BIOL CHEM, V254, P2521; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; JORGENSEN MJ, 1987, J BIOL CHEM, V262, P6729; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KOTKOW KJ, 1993, J BIOL CHEM, V268, P15633; KOTKOW KJ, 1993, METHOD ENZYMOL, V222, P435; KUSTER H, 1992, J BIOL CHEM, V267, P12782; KUWADA M, 1983, ANAL BIOCHEM, V131, P173, DOI 10.1016/0003-2697(83)90150-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; MALHOTRA OP, 1982, BIOCHIM BIOPHYS ACTA, V702, P178, DOI 10.1016/0167-4838(82)90500-3; MALHOTRA OP, 1979, THROMB RES, V15, P427, DOI 10.1016/0049-3848(79)90149-X; MALHOTRA OP, 1985, J BIOL CHEM, V260, P279; MANN KG, 1982, BIOPHYS J, V37, P106, DOI 10.1016/S0006-3495(82)84624-9; MCCRACKEN A A, 1984, Biotechniques, V2, P82; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PUSEY ML, 1983, BIOCHEM BIOPH RES CO, V114, P526, DOI 10.1016/0006-291X(83)90812-4; RATCLIFFE JV, 1991, BLOOD, V78, P180; ROSING J, 1980, J BIOL CHEM, V255, P274; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SZOKA F, 1980, BIOCHIM BIOPHYS ACTA, V601, P559, DOI 10.1016/0005-2736(80)90558-1; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4939, DOI 10.1021/bi00413a052; WINSHIP PR, 1991, BRIT J HAEMATOL, V77, P102, DOI 10.1111/j.1365-2141.1991.tb07955.x; ZAPATA GA, 1988, J BIOL CHEM, V263, P8150; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; ZHANG L, 1992, BLOOD, V80, P942; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	42	78	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24339	24345						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226983				2022-12-25	WOS:A1993MF29400093
J	WANG, Y; AGRWAL, N; ECKHARDT, AE; STEVENS, RD; HILL, RL				WANG, Y; AGRWAL, N; ECKHARDT, AE; STEVENS, RD; HILL, RL			THE ACCEPTOR SUBSTRATE-SPECIFICITY OF PORCINE SUBMAXILLARY UDP-GALNAC-POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE IS DEPENDENT ON THE AMINO-ACID-SEQUENCES ADJACENT TO SERINE AND THREONINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED GLYCOSYLATION; TRANSFERASE; MUCIN	The acceptor substrate specificity of a pure polypeptide N-acetylgalactosaminyltransferase has been examined with synthetic polypeptides with sequences identical, or similar to those found in porcine mucin or human erythropoietin. The sequences adjacent to either threonine or serine markedly influence the formation of GalNAc-O-Thr and GalNAc-O-Ser. Examination of the mucin-like peptide VLGXXAV, where X is Thr, Ser, or Ala, shows only Thr-containing peptides to be acceptors. The best substrate is formed when XX is TT. Peptides with XX as either AT or TA are less effective and those with XX as either ST or TS are much less effective acceptors. The amino acids adjacent to serine in the peptide formed by residues 121-131 in human erythropoietin, PPDAASAAPLR, also markedly influence the formation of GalNAc-O-Ser. Thus, PPDASSSAPLR and PPDVVSVVPLR are about 5- and 30-fold, respectively, less active than the erythropoietin peptide. The peptide PPDGGSGGPLR is inactive. The shorter peptide DAASAAPL is also about 5-fold less active than the full-length peptide, but the peptide AASAA is inactive. These studies indicate that one transferase can form both GalNAc-O-Ser and GalNAc-O-Thr residues when the sequences adjacent to the glycosylated residue are of the proper kind. Thus, in contrast to earlier suggestions, there is no evidence that different transferases form GalNAc-O-Ser and GalNAc-O-Thr. Examination of tissue homogenates from various tissues confirms this conclusion.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PEDIAT, DURHAM, NC 27710 USA	Duke University; Duke University					NIGMS NIH HHS [GM 25766] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025766, R01GM025766] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERNATHY JL, 1992, TECHNIQUES PROTEIN C, V3, P277; AUBERT JP, 1976, ARCH BIOCHEM BIOPHYS, V175, P410, DOI 10.1016/0003-9861(76)90528-2; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; HILL HD, 1977, J BIOL CHEM, V252, P3799; HUGHES RC, 1988, CARBOHYD RES, V178, P259, DOI 10.1016/0008-6215(88)80117-4; KILLEEN N, 1987, EMBO J, V6, P4029, DOI 10.1002/j.1460-2075.1987.tb02747.x; LAI PH, 1986, J BIOL CHEM, V261, P3116; NAKADA H, 1993, P NATL ACAD SCI USA, V90, P2495, DOI 10.1073/pnas.90.6.2495; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SIEBERT PD, 1986, P NATL ACAD SCI USA, V83, P1665, DOI 10.1073/pnas.83.6.1665; WANG YC, 1992, J BIOL CHEM, V267, P2728; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529	17	54	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22979	22983						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226812				2022-12-25	WOS:A1993MF51500007
J	ALBERS, MW; WILLIAMS, RT; BROWN, EJ; TANAKA, A; HALL, FL; SCHREIBER, SL				ALBERS, MW; WILLIAMS, RT; BROWN, EJ; TANAKA, A; HALL, FL; SCHREIBER, SL			FKBP-RAPAMYCIN INHIBITS A CYCLIN-DEPENDENT KINASE-ACTIVITY AND A CYCLIN D1-CDK ASSOCIATION IN EARLY G1 OF AN OSTEOSARCOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; PROTEIN-KINASE; IMMUNOSUPPRESSANT RAPAMYCIN; SACCHAROMYCES-CEREVISIAE; IMMUNOPHILIN; ACTIVATION; ENCODES	Upon entering a cell the natural product rapamycin, like the structurally related immunosuppressant FK506, associates with members of the FKBP family of proteins. One or more of the resulting FKBP-rapamycin complexes blocks signaling pathways emanating from some growth factor receptors. Recently, the addition of rapamycin was shown to inhibit the phosphorylation and activation of a 70-kDa ribosomal S6 protein kinase, which normally occurs minutes after the activation of certain cytokine and growth factor receptors. We now report that rapamycin can be added 4 to 6 h after the addition of serum growth factors to quiescent human osteosarcoma cells and still arrest these cells in G1. This window of action correlates with the inducible appearance of a cyclin-dependent kinase (cdk) activity, and the induction of this activity is inhibited by the addition of rapamycin. Furthermore, p36cyclin D1 associates with this cdk protein complex in lysates of untreated cells, but does not associate with this cdk protein complex in lysates of rapamycin-treated cells. Together, these studies demonstrate that FKBP-rapamycin can modulate a cyclin-dependent kinase activity and a cyclin D1-cdk association during early G1 in MG-63 human osteosarcoma cells.	HARVARD UNIV, DEPT CHEM, CAMBRIDGE, MA 02138 USA; UNIV SO CALIF, CHILDRENS HOSP LOS ANGELES, SCH MED, DIV ORTHOPED SURG, LOS ANGELES, CA 90089 USA; UNIV SO CALIF, SCH PHARM, DEPT MOLEC PHARMACOL & TOXICOL, LOS ANGELES, CA 90054 USA	Harvard University; Children's Hospital Los Angeles; University of Southern California; University of Southern California					NIGMS NIH HHS [GM-38627] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038627, R37GM038627] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRANCAVILLA A, 1992, HEPATOLOGY, V15, P871, DOI 10.1002/hep.1840150520; HALL FL, 1991, J BIOL CHEM, V266, P17430; HALL FL, 1993, ONCOGENE, V8, P1377; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1992, EMBO J, V11, P2902; MORICE WG, 1993, J BIOL CHEM, V268, P3734; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SHERR CJ, 1992, CIBA F SYMP, V170, P209; WIEDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029, DOI 10.1073/pnas.88.3.1029; WILLIAMS RT, 1993, J BIOL CHEM, V268, P8871; WILLIAMS RT, 1992, ONCOGENE, V7, P423; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	28	140	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22825	22829						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226793				2022-12-25	WOS:A1993MD34800094
J	GARFINKEL, MS; KATZE, MG				GARFINKEL, MS; KATZE, MG			TRANSLATIONAL CONTROL BY INFLUENZA-VIRUS - SELECTIVE TRANSLATION IS MEDIATED BY SEQUENCES WITHIN THE VIRAL MESSENGER-RNA 5'-UNTRANSLATED REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADENOVIRUS TRIPARTITE LEADER; INFECTED-CELLS; CELLULAR INHIBITOR; PROTEIN-KINASE; POLIOVIRUS RNA; EXPRESSION; INITIATION; METABOLISM; POLYMERASE; ELEMENTS	In cells infected by influenza virus type A, host cell protein synthesis declines rapidly and dramatically, while influenza viral protein synthesis occurs efficiently throughout infection. Previously, we had shown that the selective translation of influenza viral mRNAs in infected cells occurred in a cap-dependent manner and was due at least in part to structures inherent in the mRNAs. Using chimeras containing the noncoding and coding regions of cellular and viral mRNAs, we can now report that the selective translation is mediated by sequences within the 5'-untranslated regions (UTR) of the viral mRNAs. Polysome analysis confirmed that a 45-nucleotide sequence contained in the 5'-UTR of the influenza viral nucleocapsid protein was necessary and sufficient to allow the host cell translational machinery to discriminate between viral and cellular mRNAs. In reciprocal experiments in which the 5'-UTR of the cellular mRNA-secreted embryonic alkaline phosphatase replaced the nucleocapsid protein 5'-UTR, viral protein synthesis was inhibited in virus-infected cells, resembling host protein synthesis. Finally, we demonstrated that the 5'-UTR of another influenza viral mRNA, that encoding the nonstructural protein, also conferred resistance to the shutoff of protein synthesis in influenza virus-infected cells.	UNIV WASHINGTON, SCH MED, DEPT MICROBIOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00166] Funding Source: Medline; NIAID NIH HHS [AI-22646] Funding Source: Medline; NIGMS NIH HHS [T32-GM07270] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSOCAPLEN FV, 1988, J VIROL, V62, P1606, DOI 10.1128/JVI.62.5.1606-1616.1988; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DOLPH PJ, 1990, J VIROL, V64, P2669, DOI 10.1128/JVI.64.6.2669-2677.1990; ETKIND PR, 1975, J VIROL, V16, P1464, DOI 10.1128/JVI.16.6.1464-1475.1975; FEIGENBLUM D, 1993, J VIROL, V67, P3027, DOI 10.1128/JVI.67.6.3027-3035.1993; GARFINKEL MS, 1992, J BIOL CHEM, V267, P9383; GARFINKEL MS, 1993, IN PRESS GENE EXPRES; KATZE MG, 1990, ENZYME, V44, P265, DOI 10.1159/000468764; KATZE MG, 1984, MOL CELL BIOL, V4, P2198, DOI 10.1128/MCB.4.10.2198; KATZE MG, 1986, J VIROL, V60, P1027, DOI 10.1128/JVI.60.3.1027-1039.1986; KATZE MG, 1984, CELL, V37, P483, DOI 10.1016/0092-8674(84)90378-7; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAZAROWITZ SG, 1971, VIROLOGY, V46, P830, DOI 10.1016/0042-6822(71)90084-5; LEE TG, 1992, J BIOL CHEM, V267, P14238; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LENK R, 1979, CELL, V16, P289, DOI 10.1016/0092-8674(79)90006-0; LINDQUIST S, 1990, ENZYME, V44, P147, DOI 10.1159/000468754; LUYTJES W, 1989, CELL, V59, P1107, DOI 10.1016/0092-8674(89)90766-6; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SEONG BL, 1992, VIROLOGY, V186, P247, DOI 10.1016/0042-6822(92)90079-5; SKEHEL JJ, 1972, VIROLOGY, V49, P23, DOI 10.1016/S0042-6822(72)80004-7; Strauss E.G., 1990, VIROLOGY, P167; ZHANG Y, 1989, J BIOL CHEM, V264, P10679	31	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22223	22226						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226725				2022-12-25	WOS:A1993MD34800003
J	MA, CP; WILLY, PJ; SLAUGHTER, CA; DEMARTINO, GN				MA, CP; WILLY, PJ; SLAUGHTER, CA; DEMARTINO, GN			PA28, AN ACTIVATOR OF THE 20-S PROTEASOME, IS INACTIVATED BY PROTEOLYTIC MODIFICATION AT ITS CARBOXYL-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE; CATHEPSIN B2; PURIFICATION; INHIBITOR; COMPLEX; MACROPAIN; UBIQUITIN; COMPONENT; B1	PA28, a protein activator of the 20 S proteasome, was previously identified in soluble extracts of bovine red blood cells (Ma, C.-P., Slaughter, C. A., and De-Martino, G. N. (1992) J. Biol. Chem. 267, 10515-10523). To determine whether this regulatory protein is as widely distributed as the proteasome, PA28 content and activity were examined in various eukaryotic tissues by immunoblot analysis and by functional assays of tissue extracts. PA28 protein was present in all sources examined. PA28 activity, however, was not detected in many of these sources, including those with the highest level of PA28 protein. To determine the biochemical basis of this result, PA28 was purified from extracts of rat liver, which had high levels of PA28 protein but no PA28 activity. The resulting purified PA28 had no detectable activity but had native and subunit molecular weights indistinguishable from the active PA28 of bovine red blood cells. Using the inactivation of purified PA28 as an assay, a protein that inactivated PA28 without altering its apparent molecular weight on SDS-polyacrylamide gel electrophoresis was identified, purified, and characterized from bovine liver. It had biochemical and catalytic characteristics similar to those of lysosomal carboxypeptidase B. When leupeptin, an inhibitor of lysosomal carboxypeptidase B, was included in the buffers used for the preparation of PA28, PA28 activity was detected in tissues which otherwise failed to demonstrate this activity. A similar result was obtained when extracts were prepared in a manner that minimized disruption of lysosomes. Other carboxypeptidases such as carboxypeptidase Y and pancreatic carboxypeptidase B also inactivated PA28 without altering its apparent molecular weight. Active PA28 binds to the proteasome to form a protease-activator complex that can be isolated after velocity sedimentation centrifugation through glycerol density gradients. Carboxypeptidase-inactivated PA28 failed to form such a complex, suggesting that the carboxyl terminus of PA28 is required for binding to the proteasome. These results indicate the importance of the carboxyl terminus of PA28 for proteasome activation.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [HL-06296] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AFROZ H, 1976, BIOCHIM BIOPHYS ACTA, V452, P503, DOI 10.1016/0005-2744(76)90201-1; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; DEMARTINO GN, 1977, J BIOL CHEM, V252, P7511; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V205, P9; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOUGH R, 1987, J BIOL CHEM, V262, P8303; LI XC, 1991, BIOCHEMISTRY-US, V30, P9709, DOI 10.1021/bi00104a020; LI XCS, 1992, BIOCHEMISTRY-US, V31, P11963, DOI 10.1021/bi00163a001; LIPPERHEIDE C, 1986, BIOCHIM BIOPHYS ACTA, V880, P171, DOI 10.1016/0304-4165(86)90077-2; LONES M, 1983, ARCH BIOCHEM BIOPHYS, V221, P64, DOI 10.1016/0003-9861(83)90122-4; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MCDONALD JK, 1975, LIFE SCI, V17, P1269; MCDONALD JK, 1977, PROTEINASES MAMMALIA, P311; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; NINJOOR V, 1974, BIOCHIM BIOPHYS ACTA, V370, P308, DOI 10.1016/0005-2744(74)90055-2; OTTO K, 1975, BIOCHIM BIOPHYS ACTA, V379, P462, DOI 10.1016/0005-2795(75)90153-1; TANAKA K, 1992, NEW BIOL, V4, P173; TAYLOR S, 1973, ANAL BIOCHEM, V56, P140, DOI 10.1016/0003-2697(73)90178-4	23	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22514	22519						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226760				2022-12-25	WOS:A1993MD34800051
J	NAKANO, T; RAINES, EW; ABRAHAM, JA; WENZEL, FG; HIGASHIYAMA, S; KLAGSBRUN, M; ROSS, R				NAKANO, T; RAINES, EW; ABRAHAM, JA; WENZEL, FG; HIGASHIYAMA, S; KLAGSBRUN, M; ROSS, R			GLUCOCORTICOID INHIBITS THROMBIN-INDUCED EXPRESSION OF PLATELET-DERIVED GROWTH-FACTOR A-CHAIN AND HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH-FACTOR IN HUMAN AORTIC SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; HUMAN-ENDOTHELIAL-CELLS; 3' UNTRANSLATED REGION; FACTOR MESSENGER-RNA; GENE-EXPRESSION; MULTIPLE FORMS; ANGIOTENSIN-II; B-CHAIN; C-JUN; PDGF	Proliferation of smooth muscle cells (SMCs) in atherosclerosis may be modulated by several growth regulatory molecules. At least two mitogens for SMCs, platelet-derived growth factor (PDGF) A-chain and heparin-binding epidermal growth factor-like growth factor (HB-EGF), can be produced by SMCs themselves and may stimulate smooth muscle proliferation in an autocrine or paracrine fashion. We examined the effects of thrombin, which may be generated at the site of vascular injury during atherogenesis, and the potent anti-inflammatory glucocorticoid, dexamethasone (DEX), on the expression of the genes encoding these two growth factors. Since both PDGF A-chain and HB-EGF have affinity for heparin, we also examined the effect of thrombin and DEX on the release of heparin binding mitogenic activity from SMCs. Treatment of SMCs with thrombin resulted in increases both in the level of the PDGF-A and HB-EGF transcripts in the cells, as well as in released heparin-binding growth factor activity. DEX inhibits the thrombin-stimulated release of mitogenic activity in a dose-dependent manner. An enzyme-linked immunoadsorbent assay showed that DEX inhibits both constitutive and thrombin-stimulated release of PDGF-AA. DEX also decreases both constitutive and thrombin-stimulated mRNA levels for PDGF A-chain and HB-EGF and destabilizes the transcripts for both growth factors. A nuclear run-on assay revealed that DEX acts, in addition, to inhibit constitutive and thrombin-stimulated transcription of the PDGF A-chain and HB-EGF genes. Thus, these findings indicate that expression of PDGF A-chain and HB-EGF may be regulated by thrombin and glucocorticoid at the transcription level. Our results are consistent with the involvement of thrombin-induced growth factor expression in neointimal SMC proliferation and suggest the possibility that intimal proliferation may be attenuated by glucocorticoids.	UNIV WASHINGTON, SCH MED, DEPT PATHOL, SM-30, SEATTLE, WA 98195 USA; SCIOS NOVA INC, Mountain View, CA 94043 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT SURG RES & BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	University of Washington; University of Washington Seattle; Scios; Harvard University; Boston Children's Hospital; Harvard Medical School					NHLBI NIH HHS [HL18645, HL47151] Funding Source: Medline; NIGMS NIH HHS [GM47397] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047151, P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; BAIRD A, 1990, HDB EXPT PHARM, V95, P369; BARRETT TB, 1988, P NATL ACAD SCI USA, V85, P2810, DOI 10.1073/pnas.85.8.2810; BARSHAVIT R, 1992, AM J RESP CELL MOL, V6, P123, DOI 10.1165/ajrcmb/6.2.123; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BETSHOLTZ C, 1986, NATURE, V323, P226; BURNSTEIN KL, 1989, ANNU REV PHYSIOL, V51, P683, DOI 10.1146/annurev.ph.51.030189.003343; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; CHARRON J, 1986, P NATL ACAD SCI USA, V83, P8903, DOI 10.1073/pnas.83.23.8903; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORJAY MH, 1990, J CELL PHYSIOL, V145, P391, DOI 10.1002/jcp.1041450302; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; DROUIN J, 1987, J CELL BIOCHEM, V35, P293, DOI 10.1002/jcb.240350404; EHRLICH HP, 1971, P SOC EXP BIOL MED, V137, P936, DOI 10.3181/00379727-137-35698; EMILIE D, 1988, EUR J IMMUNOL, V18, P2043, DOI 10.1002/eji.1830181226; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FU JY, 1990, J BIOL CHEM, V265, P16737; GAY CG, 1990, J BIOL CHEM, V265, P3284; GESSANI S, 1988, J BIOL CHEM, V263, P7454; GUYRE PM, 1988, J STEROID BIOCHEM, V30, P89, DOI 10.1016/0022-4731(88)90080-5; HARAGUCHI T, 1991, J BIOL CHEM, V266, P18299; HARLAN JM, 1986, J CELL BIOL, V103, P1129, DOI 10.1083/jcb.103.3.1129; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1524, DOI 10.1073/pnas.85.5.1524; MURRAY MJ, 1988, BIOTECHNIQUES, V6, P196; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAKANO T, 1990, J BIOL CHEM, V265, P12745; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; RAGHOW R, 1986, J BIOL CHEM, V261, P4677; RAINES EW, 1985, METHOD ENZYMOL, V109, P749; RAINES EW, 1982, J BIOL CHEM, V257, P5154; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; Ross R., 1980, HDB PHYSL CARDIOVA 2, P69; SAREMBOCK IJ, 1991, CIRCULATION, V84, P232, DOI 10.1161/01.CIR.84.1.232; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEJERSEN T, 1986, P NATL ACAD SCI USA, V83, P6844, DOI 10.1073/pnas.83.18.6844; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHIRAISHI T, 1989, CLIN CHIM ACTA, V184, P65, DOI 10.1016/0009-8981(89)90257-X; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	63	63	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22941	22947						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226804				2022-12-25	WOS:A1993MD34800109
J	BAMBERG, K; SACHS, G				BAMBERG, K; SACHS, G			TOPOLOGICAL ANALYSIS OF H+,K+-ATPASE USING IN-VITRO TRANSLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NA,K-ATPASE ALPHA-SUBUNIT; SITE-DIRECTED MUTAGENESIS; GASTRIC H+/K+-ATPASE; SARCOPLASMIC-RETICULUM; MEMBRANE TOPOLOGY; COMPLEMENTARY-DNA; PROTEIN; EPITOPE; SURFACE	The membrane topology of the alpha subunit of the H+,K+-ATPase was investigated by using in vitro transcription/ translation of DNA sequences encoding fusion proteins that contained possible membrane-spanning segments. The vectors consisted of DNA sequences encoding (a) either the first 101 (M0 vectors) or the first 139 (M1 vectors) amino acids of the N-terminal region of the alpha subunit of the ATPase, (b) a variable region, and then (c) the C-terminal 177 amino acids of the C-terminal region of the beta subunit, with five N-linked glycosylation sites. The variable region of the fusion protein contained the cDNA sequences representing the possible eight or 10 membrane-spanning segments either alone or in various combinations. Transcription/translation was performed in the presence of [S-35]methionine using a coupled reticulocyte lysate in the absence and presence of microsomes. The fusion protein was identified by autoradiography following separation using SDS-polyacrylamide gel electrophoresis. Glycosylation of a translated sequence corresponded to membrane insertion and translocation of the C-terminal beta sequence. This method allowed analysis of signal anchor sequences using the M0 vector. The presence of a stop transfer sequence in the variable segment of the M1 vector resulted in inhibition of translocation of the C-terminal beta sequence. The sequences for the first four membrane segments could act as either signal anchor or stop transfer sequences. Therefore, this region of the a subunit has four membrane-spanning segments that are co-inserted with translation. The sequence corresponding to membrane segment M8 acted as a stop transfer sequence. The sequence corresponding to membrane segment M9 acted as a signal anchor sequence, and that corresponding to membrane segment M10 acted as a stop transfer sequence. The sequences representing the fifth, sixth, and seventh (M5, M6, and M7) membrane segments were unable to co-insert into the membrane. These data verify the first four and the eighth membrane-spanning segments of the alpha subunit of the gastric H+,K+-ATPase and provide evidence for translational insertion of an additional pair of membrane spanning segments, M9 and M10. It appears that insertion of membrane segments M5, M6, and M7 is determined differently from the other membrane-spanning segments. In combination with other methods, this in vitro transcription/translation method is useful for defining the membrane topology of the P type ATPases.	VET ADM WADSWORTH MED CTR,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90073	University of California System; University of California Los Angeles					NIDDK NIH HHS [R01 DK 40165, R01 DK 41301] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; HALL K, 1990, BIOCHEMISTRY-US, V29, P701, DOI 10.1021/bi00455a016; HOLLAND EC, 1986, J BIOL CHEM, V261, P1286; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATTHEWS I, 1990, J BIOL CHEM, V265, P1837; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; SACHS G, 1993, ALIMENT PHARM THER, V7, P4; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT DR, 1992, BIOCHIM BIOPHYS ACTA, V1112, P246, DOI 10.1016/0005-2736(92)90398-6; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SHIN JM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P223, DOI 10.1016/0005-2736(93)90133-K; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SMITH DL, 1993, J BIOL CHEM, V268, P22469; SUBRAHMANYESWARA-RAO U, 1991, Journal of Biological Chemistry, V266, P14740; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0	33	97	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16909	16919						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207013				2022-12-25	WOS:A1994NR29600060
J	FUJIWARA, K; OKAMURAIKEDA, K; MOTOKAWA, Y				FUJIWARA, K; OKAMURAIKEDA, K; MOTOKAWA, Y			PURIFICATION AND CHARACTERIZATION OF LIPOYL-AMP-N-EPSILON-LYSINE LIPOYLTRANSFERASE FROM BOVINE LIVER-MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE CLEAVAGE SYSTEM; H-PROTEIN; ESCHERICHIA-COLI; ACID; MUTAGENESIS; SEQUENCE	Lipoyl-AMP:N-epsilon-lysine lipoyltransferase (lipoyltransferase) catalyzes the transfer of the lipoyl group from lipoyl AMP to a lysine residue of the specific enzyme proteins. We have shown previously that the lipoyltransferase activities locate in mitochondria using apoH-protein of the glycine cleavage system as an acceptor of the lipoyl group (Fujiwara, K., Okamura-Ikeda, K., and Motokawa, Y. (1990) J. Biol. Chem. 265, 17463-17467). Here we describe the purification and the characterization of two isoforms of lipoyltransferase termed lipoyltransferase I and lipoyltransferase II from bovine liver mitochondria. Lipoyltransferase II was purified to apparent homogeneity, whereas the final product of lipoyltransferase I still contained a minor contaminant. Although the two forms could be resolved on a hydroxylapatite column chromatography, they were indistinguishable, as judged by: (a) behavior during purification on ion exchange, hydrophobic, or affinity columns; (b) molecular mass determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and gel exclusion chromatography (40 kDa); and (c) catalytic properties (substrate specificity, kinetic constants, and optimal pH), Both lipoyltransferase I and II could not use lipoic acid plus MgATP as a substrate in place of lipoyl-AMP. Surprisingly, the lipoyltransferases transferred not only the lipoyl group but also the acyl groups from hexanoyl-, octanoyl-, and decanoyl-AMP to apoH-protein to a similar extent.	UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN	Tokushima University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; FUJIWARA K, 1979, ARCH BIOCHEM BIOPHYS, V197, P454, DOI 10.1016/0003-9861(79)90267-4; FUJIWARA K, 1991, FEBS LETT, V293, P115, DOI 10.1016/0014-5793(91)81164-4; FUJIWARA K, 1990, J BIOL CHEM, V265, P17463; KOCHI H, 1979, ARCH BIOCHEM BIOPHYS, V198, P589, DOI 10.1016/0003-9861(79)90535-6; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1958, J BIOL CHEM, V232, P123; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; TSUMODA JN, 1967, ARCH BIOCHEM BIOPHYS, V118, P395	16	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16605	16609						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206978				2022-12-25	WOS:A1994NR29600016
J	BRUCE, LJ; ANSTEE, DJ; SPRING, FA; TANNER, MJA				BRUCE, LJ; ANSTEE, DJ; SPRING, FA; TANNER, MJA			BAND-3 MEMPHIS VARIANT-II - ALTERED STILBENE DISULFONATE BINDING AND THE DIEGO (DI(A)) BLOOD-GROUP ANTIGEN ARE ASSOCIATED WITH THE HUMAN ERYTHROCYTE-BAND 3 MUTATION PRO(854)-]LEU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSPORT PROTEIN; MEMBRANE; PHOSPHOENOLPYRUVATE; POLYMORPHISM; SEQUENCE; SITES; CELLS	Band 3 Memphis is a commonly occurring polymorphic form of the human red cell anion transporter (band 3, AE1). Band 3 Memphis migrates more slowly on an SDS-polyacrylamide gel than normal band 3 and results from a point mutation Lys(56) --> Glu. TWO types of band 3 Memphis, variants I and II, can be distinguished by their susceptibility to covalent labeling with H2DIDS (4,4'-diisothiocyanato-2,2'-dihydrostilbene disulfonate). Memphis variant II is more readily labeled than Memphis variant I or normal band 3. The Memphis variant II is also associated with the presence of the Diego (Di(a)) blood group antigen on the red cells. We have shown that Memphis variant II carries the polymorphism Pro(854) --> Leu as well as Lys(56) --> Glu. The blood group antigen (Di(a)) present at the surface of Memphis variant II type red cells suggests the mutation Pro(854) --> Leu causes a change in the structure of an extracellular loop of Memphis variant II band 3. We discuss possible ways in which the mutation Pro(854) --> Leu affects the reactivity of Lys(539) to covalent reaction with H2DIDS.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,ENGLAND; INT BLOOD GRP REFERENCE LAB,BRISTOL BS10 5ND,AVON,ENGLAND	University of Bristol			Anstee, David/AAE-9231-2020	Bruce, Lesley/0000-0001-5922-7072				BOODHOO A, 1984, J BIOL CHEM, V259, P785; BRUCE LJ, 1993, BIOCHEM J, V293, P317, DOI 10.1042/bj2930317; CABANTCHIK IZ, 1975, J BIOL CHEM, V250, P5130; CABANTCHIK ZI, 1972, J MEMBRANE BIOL, V10, P311, DOI 10.1007/BF01867863; HAMASAKI N, 1983, EUR J BIOCHEM, V132, P531, DOI 10.1111/j.1432-1033.1983.tb07394.x; HSU L, 1985, BIOCHEMISTRY-US, V24, P3086, DOI 10.1021/bi00334a003; IDEGUCHI H, 1992, BRIT J HAEMATOL, V82, P122, DOI 10.1111/j.1365-2141.1992.tb04603.x; JANAS T, 1989, AM J PHYSIOL, V257, pC601, DOI 10.1152/ajpcell.1989.257.4.C601; JAROLIM P, 1992, BLOOD, V80, P1592; JENKINS RE, 1975, BIOCHEM J, V147, P393, DOI 10.1042/bj1470393; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; KUSNIERZALEJSKA G, 1992, VOX SANG, V62, P124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOURANT AE, 1976, DISTRIBUTION HUMAN B, P20; MUELLER TJ, 1977, J BIOL CHEM, V252, P6573; OKUBO K, 1994, J BIOL CHEM, V269, P1918; OKUBO K, 1991, J BIOL CHEM, V266, P16420; PIMPLIKAR SW, 1986, J BIOL CHEM, V261, P9770; RACE RR, 1975, BLOOD GROUPS MAN, P372; RANNEY HM, 1990, BRIT J HAEMATOL, V76, P262; Sambrook J, 1989, MOL CLONING LABORATO; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; SPRING FA, 1992, BIOCHEM J, V288, P713, DOI 10.1042/bj2880713; TANNER MJA, 1988, CARBOHYD RES, V178, P203, DOI 10.1016/0008-6215(88)80112-5; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; WOOD PG, 1992, J MEMBRANE BIOL, V127, P139; YANNOUKAKOS D, 1991, BLOOD, V78, P1117	27	72	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16155	16158						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206915				2022-12-25	WOS:A1994NQ72900033
J	PERRINO, FW; MILLER, H; EALEY, KA				PERRINO, FW; MILLER, H; EALEY, KA			IDENTIFICATION OF A 3'-]5'-EXONUCLEASE THAT REMOVES CYTOSINE-ARABINOSIDE MONOPHOSPHATE FROM 3' TERMINI OF DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-ALPHA; EXONUCLEASE; BETA; ARABINOSYLCYTOSINE; PURIFICATION; INHIBITORS; ELONGATION; MECHANISM	Cytosine arabinoside monophosphate (araCMP) at the 3' terminus of DNA constitutes a lesion that impedes further synthesis by DNA polymerase alpha (DNA pol alpha). A biochemical assay has been designed to detect 3'-->5'-exonucleases in cell extracts that remove the 3'-araCMP lesion in an oligonucleotide template primer and permit subsequent extension by DNA pol alpha. The major 3'-->5'-exonuclease activity in human myeloblast extracts has been purified, and gel filtration chromatography of the purified enzyme indicates that the exonuclease has an apparent native molecular mass of 52 kDa. Incubation of the enzyme with a 5'-P-32-labeled araCMP template-primer results in exonucleolytic degradation of the primer exclusively in the 3'-->5' direction, demonstrating that the enzyme is a 3'-->5'-exonuclease. The products of the 3'-->5'-exonuclease reaction are 5'-mononucleotides. The apparent rate of araCMP removal by the exonuclease is approximately the same as the rate of deoxynucleoside monophosphate (dNMP) removal. Furthermore, the apparent rates of 3'-terminal excision are approximately the same whether the oligomer is hybridized to a complementary oligonucleotide, or not, indicating that the enzyme has both single- and double-stranded 3'-->5' exonuclease activity. The enzyme does not possess 5'-->3'-exonuclease activity, nor is it associated with DNA polymerase activity. In addition, the enzyme does not cleave 3'-phosphoryl-terminated DNA, and it does not cleave RNA. The enzymatic characteristics of the isolated 3'-->5'-exonuclease indicate that it is distinct from previously identified mammalian deoxyribonucleases.	WAKE FOREST UNIV,MED CTR,CTR COMPREHENS CANC,WINSTON SALEM,NC 27157	Wake Forest University	PERRINO, FW (corresponding author), WAKE FOREST UNIV,MED CTR,DEPT BIOCHEM,WINSTON SALEM,NC 27157, USA.		Miller, Holly/I-6942-2015	Miller, Holly/0000-0002-9076-5335	NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEARDSLEY GP, 1988, NUCLEIC ACIDS RES, V16, P9165, DOI 10.1093/nar/16.19.9165; CAPIZZI RL, 1991, SEMIN HEMATOL, V28, P54; COZZARELLI NR, 1977, ANNU REV BIOCHEM, V46, P641, DOI 10.1146/annurev.bi.46.070177.003233; GAO YG, 1991, BIOCHEMISTRY-US, V30, P9922, DOI 10.1021/bi00105a016; HOLLIS GF, 1981, J BIOL CHEM, V256, P8074; KEATING MJ, 1982, JAMA-J AM MED ASSOC, V248, P2481, DOI 10.1001/jama.248.19.2481; Kornberg A., 1992, DNA REPLICATION; KUFE DW, 1980, J BIOL CHEM, V255, P8997; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE MYWT, 1980, BIOCHEMISTRY-US, V19, P215, DOI 10.1021/bi00542a032; LINDAHL T, 1969, J BIOL CHEM, V244, P5014; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P239; OHNO Y, 1988, CANCER RES, V48, P1494; PERRINO FW, 1992, J BIOL CHEM, V267, P23043; REID R, 1988, J BIOL CHEM, V263, P3898; REIN DC, 1990, EUKARYOTIC NUCLEUS M, P95; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SKARNES W, 1986, J BIOL CHEM, V261, P6629; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WRIGHT GE, 1990, PHARMACOL THERAPEUT, V47, P447, DOI 10.1016/0163-7258(90)90066-B	24	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16357	16363						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206943				2022-12-25	WOS:A1994NQ72900062
J	DAS, G; HERR, W				DAS, G; HERR, W			ENHANCED ACTIVATION OF THE HUMAN HISTONE H2B PROMOTER BY AN OCT-1 VARIANT GENERATED BY ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN OCT-1; RNA POLYMERASE-III; TRANSCRIPTION FACTOR; POU DOMAIN; TRANSLATIONAL CONTROL; IMMUNOGLOBULIN GENES; REGULATORY ELEMENTS; CONSERVED SEQUENCE; U2 SNRNA; OCTAMER	POU homeodomain proteins are important regulators of ubiquitous as well as tissue-specific transcription. These factors include the broadly expressed octamer motif-binding protein Oct-1 and the related cell-specifically expressed protein Oct-2. These two proteins differ in the types of octamer motif-containing promoters they preferentially activate; Oct-1 can activate RNA polymerase II transcription from a small nuclear RNA promoter better than Oct-2, which can better activate an mRNA-type promoter. We describe a variant Oct-1-encoding cDNA resulting from two separate alternate splices of the human oct-1 primary transcript; these alternate splices were present in all cell lines tested. This cDNA encodes an amino-terminally and carboxyl-terminally truncated form of Oct-1, called Oct-1B, which retains the DNA-binding POU domain and acquires a unique 12-amino acid carboxyl-terminal extension. In a transient expression assay, Oct-1B displayed an enhanced ability compared to the larger form of Oct-1 (called Oct-1A in this report) to activate the human histone H2B promoter, an mRNA-type promoter where a natural octamer motif is involved in cell cycle dependent transcription. Thus, the ability of Oct-1 related proteins to activate a natural regulatory target can be influenced by alternative splicing.	COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Herr, Winship/E-6491-2012	Herr, Winship/0000-0002-3606-4546	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARK C, 1987, NATURE, V328, P356, DOI 10.1038/328356a0; BELL J, 1992, DEV BIOL, V150, P363, DOI 10.1016/0012-1606(92)90248-F; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; HARVEY RP, 1982, NUCLEIC ACIDS RES, V10, P7851, DOI 10.1093/nar/10.23.7851; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HERR W, 1992, TRANSCRIPTIONAL REGU, P1103; HINKLEY C, 1992, MOL CELL BIOL, V12, P4400, DOI 10.1128/MCB.12.10.4400; HSIEH CL, 1990, GENOMICS, V6, P666, DOI 10.1016/0888-7543(90)90502-L; HWANG IH, 1989, MOL CELL BIOL, V9, P1005, DOI 10.1128/MCB.9.3.1005; KEMLER I, 1991, NUCLEIC ACIDS RES, V19, P237, DOI 10.1093/nar/19.2.237; KESSEL M, 1988, NATURE, V332, P117, DOI 10.1038/332117c0; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MANFIOLETTI G, 1988, NUCLEIC ACIDS RES, V16, P2873, DOI 10.1093/nar/16.7.2873; MANGIN M, 1986, EMBO J, V5, P987, DOI 10.1002/j.1460-2075.1986.tb04313.x; MANIATIS T, 1978, MOL CLONING; MATTAJ IW, 1985, NATURE, V316, P163, DOI 10.1038/316163a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MORIMOTO R I, 1992, Current Opinion in Cell Biology, V4, P480, DOI 10.1016/0955-0674(92)90015-5; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SHEPARD A, 1988, J VIROL, V62, P3364, DOI 10.1128/JVI.62.9.3364-3370.1988; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; STURM RA, 1993, GENOMICS, V16, P333, DOI 10.1006/geno.1993.1194; SUZUKI N, 1993, NUCLEIC ACIDS RES, V21, P245, DOI 10.1093/nar/21.2.245; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	45	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25026	25032						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227066				2022-12-25	WOS:A1993MG67300076
J	HWANG, YW; ZHONG, JM; POULLET, P; PARMEGGIANI, A				HWANG, YW; ZHONG, JM; POULLET, P; PARMEGGIANI, A			INHIBITION OF SDC25-C-DOMAIN-INDUCED GUANINE-NUCLEOTIDE EXCHANGE BY GUANINE RING BINDING DOMAIN MUTANTS OF V-H-RAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; SACCHAROMYCES-CEREVISIAE CDC25; ESCHERICHIA-COLI; MOLECULAR MECHANISM; GENE-PRODUCT; FACTOR-TS; PROTEINS; IDENTIFICATION; ACTIVATION; MUTATIONS	Guanine-nucleotide exchange is the reaction that controls the activation of H-ras p21. This reaction is stimulated by the guanine-nucleotide exchange factor. In this study we show that H-ras p21 harboring guanine ring binding domain (the conserved NKXD motif) mutations, such as N116I or K117E, are potent inhibitors of H-ras p21 guanine-nucleotide exchange reaction promoted by SDC25C (Saccharomyces cerevisiae SDC25 C-domain gene product), a guanine-nucleotide exchange factor. The inhibition is due to the formation of a stable but catalytically inactive complex consisting of the H-ras mutant and SDC25C. By examining the interaction of v-H-ras(N116I) or v-H-ras(K117E) with SDC25C at different concentrations of guanine-nucleotide, we demonstrate that the mechanism of SDC25C-promoted guanine-nucleotide exchange proceeds through the following pathway. First, SDC25C binds to H-ras and forms an intermediate H-ras.SDC25C complex; subsequently, an incoming guanine-nucleotide dissociates the complex, releasing SDC25C from H-ras and causes guanine-nucleotide exchange. This mechanism is similar to the one proposed for Escherichia coli elongation factor Ts-catalyzed guanine-nucleotide exchange.	CSI,IBR,CTR DEV NEUROSCI,STATEN ISL,NY 10314; ECOLE POLYTECH,BIOCHIM LAB,F-91128 PALAISEAU,FRANCE	Institute for Basic Research in Developmental Disabilities; Institut Polytechnique de Paris	HWANG, YW (corresponding author), NEW YORK STATE INST BASIC RES DEV DISABIL,DEPT MOLEC BIOL,1050 FOREST HILL RD,STATEN ISL,NY 10314, USA.				NATIONAL CANCER INSTITUTE [R29CA053782] Funding Source: NIH RePORTER; NCI NIH HHS [CA53782] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BACCI C, 1992, CELL, V70, P715; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; CUNNINGHAM PR, 1990, BIOCHIM BIOPHYS ACTA, V1050, P18, DOI 10.1016/0167-4781(90)90135-O; DER CJ, 1988, ONCOGENE, V3, P105; DOWNWARD J, 1992, Current Biology, V2, P329, DOI 10.1016/0960-9822(92)90897-J; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GUMUSEL F, 1990, BIOCHIM BIOPHYS ACTA, V1050, P215, DOI 10.1016/0167-4781(90)90169-3; HALL A, 1986, J BIOL CHEM, V261, P963; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; HWANG YW, 1985, J BIOL CHEM, V260, P1498; HWANG YW, 1987, J BIOL CHEM, V262, P13081; HWANG YW, 1989, J BIOL CHEM, V264, P8304; HWANG YW, 1992, J BIOL CHEM, V267, P22198; JACQUET E, 1992, J BIOL CHEM, V267, P24181; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MILLER DL, 1977, FACTORS INVOLVED TRA, P323; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; OGISO Y, 1990, CELL GROWTH DIFFER, V1, P217; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; REY I, 1991, ONCOGENE, V6, P347; SATOH T, 1988, BIOCHIM BIOPHYS ACTA, V949, P97, DOI 10.1016/0167-4781(88)90059-0; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100	49	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24692	24698						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227029				2022-12-25	WOS:A1993MG67300030
J	SWOPE, SL; HUGANIR, RL				SWOPE, SL; HUGANIR, RL			MOLECULAR-CLONING OF 2 ABUNDANT PROTEIN-TYROSINE KINASES IN TORPEDO ELECTRIC ORGAN THAT ASSOCIATE WITH THE ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED MUSCLE-CELLS; GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; GENE-PRODUCT; SRC FAMILY; PHOSPHORYLATION; YES; PROTOONCOGENE; DOMAINS; IDENTIFICATION	The nicotinic acetylcholine receptor (AChR) is phosphorylated on tyrosine residues both in vitro and in vivo. This phosphorylation appears to regulate the rate of receptor desensitization and is associated with AChR clustering induced by the neuronal extracellular matrix protein agrin. To identify the protein tyrosine kinase(s) that phosphorylates the nicotinic receptor, we have used molecular cloning techniques to identify and characterize two protein tyrosine kinases that are highly expressed in Torpedo electric organ, a tissue enriched in synaptic components including the AChR. One of the kinases was identified as the Torpedo homolog of neuronal fyn, whereas the other was a novel kinase we have named fyk due to its homology to both fyn and yes protein tyrosine kinases. Using antibodies to fyn and fyk, Fyn was shown to be a 55-kDa protein phosphorylated on tyrosine residues, whereas Fyk was a 56-kDa/53-kDa doublet phosphorylated on serine and tyrosine residues. At the mRNA and/or protein level, fyn and fyk were present in Torpedo electric organ, skeletal muscle, and brain. Both kinases were detected in the membrane fractions enriched in the AChR, with Fyn and Fyk representing 36 and 8%, respectively, of the protein tyrosine kinase activity in these postsynaptic membranes. In addition, Fyn and Fyk were shown by coimmunoprecipitation to be specifically associated with the AChR. Furthermore, the AChR was phosphorylated in Fyn and Fyk immunoprecipitates. These results indicate that Fyn and Fyk are involved in the regulation of postsynaptic membrane function and suggest that these protein tyrosine kinases may phosphorylate the AChR.	JOHNS HOPKINS UNIV, SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI, 725 N WOLFE ST,900 PCTB, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University								ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; CHASE BA, 1987, NEUROSCIENCE, V21, P959, DOI 10.1016/0306-4522(87)90051-0; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1983, CURR TOP MICROBIOL, V107, P125; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Grant S. G. N., 1992, Society for Neuroscience Abstracts, V18, P638; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1982, J BIOL CHEM, V257, P9372; HUGANIR RL, 1983, P NATL ACAD SCI-BIOL, V80, P1130, DOI 10.1073/pnas.80.4.1130; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; HUGANIR RL, 1987, NEUROMODULATION BIOC, P86; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KAWAKAMI Y, 1989, ONCOGENE, V4, P389; KINGSTON RE, 1991, CURRENT PROTOCOLS MO; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI DOI 10.1083/JCB.108.2.229; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCHELLE WJ, 1986, J BIOL CHEM, V261, P5270; LEVEY AI, 1990, FEBS LETT, V275, P65, DOI 10.1016/0014-5793(90)81440-Y; Maniatis T., 1982, MOL CLONING LABORATO, P76; MOSS SJ, 1993, NEUROCHEM RES, V18, P105, DOI 10.1007/BF00966929; NASTUK MA, 1991, NEURON, V7, P807, DOI 10.1016/0896-6273(91)90283-6; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PENG HB, 1991, NEURON, V6, P237; PENG HB, 1985, J CELL BIOL, V100, P1698, DOI 10.1083/jcb.100.5.1698; PETERS DJ, 1990, ONCOGENE, V5, P1313; QU ZC, 1990, NEURON, V4, P367, DOI 10.1016/0896-6273(90)90049-L; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SAFRAN A, 1987, J BIOL CHEM, V262, P10506; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHORES CG, 1987, J BIOL CHEM, V262, P9477; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOBEL A, 1977, EUR J BIOCHEM, V80, P215, DOI 10.1111/j.1432-1033.1977.tb11874.x; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEELE RE, 1989, ONCOGENE RES, V4, P223; SUDOL M, 1993, ONCOGENE, V8, P823; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUDOL M, 1993, MOL BASIS HUMAN CANC, P203; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZAVOICO GB, 1984, BIOCHIM BIOPHYS ACTA, V770, P225, DOI 10.1016/0005-2736(84)90134-2	64	58	60	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25152	25161						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227079				2022-12-25	WOS:A1993MG67300091
J	AU, WC; SU, Y; RAJ, NBK; PITHA, PM				AU, WC; SU, Y; RAJ, NBK; PITHA, PM			VIRUS-MEDIATED INDUCTION OF INTERFERON-A GENE REQUIRES COOPERATION BETWEEN MULTIPLE BINDING-FACTORS IN THE INTERFERON-ALPHA PROMOTER REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IFN-INDUCIBLE GENES; BETA-GENE; REGULATORY ELEMENTS; DNA-BINDING; DIFFERENTIAL EXPRESSION; TRANSCRIPTION FACTOR; TYPE-1 PROVIRUS; ACTIVATION; CELLS	Transcriptional activation of interferon A (IFNA) gene in virus-infected cells is controlled by a 35-nucleotide inducible element that is cell type specific. Within this region, two elements, alphaF1 and IRF-1 binding sites, were shown by mutation analysis to play a crucial role in the expression of inducible element. In this study, we have analyzed the binding of nuclear proteins to the alphaF1 sequence and have shown that the induction is associated with the formation of a novel complex alphaF1/B, which contains at least two DNA binding proteins of 68 and 96 kDa. In contrast, no binding of the purified interferon regulatory factor 1 (IRF-1) either to the alphaF1 or IRF-1 binding sites could be detected in vitro. However, the oligonucleotides corresponding to alphaF1 or IRF-1 binding sites competed efficiently for the induction of IFNA4 promoter region in a transient transfection assay. We suggest that the induction of IFNA promoter region requires cooperation between alphaF1 binding proteins and IRF-1. Interestingly, our data also show that the inability of IFNA6 promoter to be expressed in infected L-cells may be a result of a viral-induced repressor, which could act by binding and inactivating alphaF1 or by competing for the IRF-1 binding site. These results suggest that cell-specific expression of IFNA genes results from corecruitment of trans-acting factors that bind to alphaF1 and the IRF-1 binding site with the cell-specific virus-induced activator or repressor.	JOHNS HOPKINS UNIV, CTR ONCOL, 418 N BOND ST, BALTIMORE, MD 21231 USA; JOHNS HOPKINS UNIV, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University					NIAID NIH HHS [AI19737] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI019737, R01AI019737] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADERKA D, 1986, J IMMUNOL, V136, P2938; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; BISAT F, 1988, NUCLEIC ACIDS RES, V16, P6067, DOI 10.1093/nar/16.13.6067; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; COHEN L, 1991, CELL GROWTH DIFFER, V2, P323; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HISCOTT J, 1984, NUCLEIC ACIDS RES, V12, P3727, DOI 10.1093/nar/12.9.3727; KELLER AD, 1992, MOL CELL BIOL, V12, P1940, DOI 10.1128/MCB.12.5.1940; KELLER AD, 1988, P NATL ACAD SCI USA, V85, P3309, DOI 10.1073/pnas.85.10.3309; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P825, DOI 10.1093/nar/13.3.825; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; POPIK W, 1992, VIROLOGY, V189, P435, DOI 10.1016/0042-6822(92)90567-9; RAJ NBK, 1989, J BIOL CHEM, V264, P11149; RAJ NBK, 1981, P NATL ACAD SCI-BIOL, V78, P7426, DOI 10.1073/pnas.78.12.7426; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; RAJ NBK, 1989, J BIOL CHEM, V264, P16658; RAJ NBK, 1983, P NATL ACAD SCI-BIOL, V80, P3923, DOI 10.1073/pnas.80.13.3923; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; REIS LFL, 1993, J INTERFERON RES S1, V12, P552; SHUTTLEWORTH J, 1983, EUR J BIOCHEM, V133, P399, DOI 10.1111/j.1432-1033.1983.tb07476.x; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SINGH H, 1989, BIOTECHNIQUES, V7, P252; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VLACH J, 1992, VIROLOGY, V187, P63, DOI 10.1016/0042-6822(92)90295-Z; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; WHITTEMORE LA, 1990, MOL CELL BIOL, V10, P1329, DOI 10.1128/MCB.10.4.1329	45	49	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24032	24040						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226947				2022-12-25	WOS:A1993MF29400050
J	DONG, Q; COPELAND, WC; WANG, TSF				DONG, Q; COPELAND, WC; WANG, TSF			MUTATIONAL STUDIES OF HUMAN DNA POLYMERASE-ALPHA - IDENTIFICATION OF RESIDUES CRITICAL FOR DEOXYNUCLEOTIDE BINDING AND MISINSERTION FIDELITY OF DNA-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISPAIR EXTENSION KINETICS; I KLENOW FRAGMENT; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; REPLICATION FIDELITY; INSERTION FIDELITY; GENE; SITE	Conserved site-directed mutations were introduced into the second most conserved amino acid region, region II, of the human DNA polymerase alpha catalytic subunit. These mutants were expressed in the baculovirus system and purified to near homogeneity. The mutants had polymerase activity ranging from 4 to 60% compared with the wild type polymerase alpha. Steady-state kinetic analysis of mutants G841A, D860A, D860S, D860N, Y865S, and Y865F demonstrated no significant difference in their K(m) values for primer-template compared with that of the wild type enzyme. In contrast, mutants D860A, Y865S, and Y865F showed a 5-10-fold increase in the K(m) for deoxynucleotide triphosphate (dNTP) compared with the wild type enzyme. DNA synthetic fidelity studies of these mutants showed that mutant Y865S but not Y865F had a greater than 10-fold higher misinsertion efficiency than the wild type enzyme Mg2+-catalyzed reactions. However, with Mn2+ as the metal activator, Y865S and Y865F demonstrated a 2- and 9-fold higher misinsertion efficiency, respectively. These results indicate that Asp860 and Tyr865 in region II of human DNA polymerase alpha are involved in incoming dNTP substrate binding. Using three deoxynucleotide structural analogs as probes, we show that the nucleotide base is the structural requirement for dNTP binding with Tyr865. Furthermore, abolishing the hydrophobic phenyl ring side chain of Tyr865 by replacing tyrosine with serine rendered the enzyme resistant to aphidicolin. Results of these studies strongly suggest that the phenyl ring of Tyr865 directly interacts with the nucleotide base moiety of the dNTP and plays a critical role in the misinsertion fidelity of DNA synthesis. Although mutation of Gly841 to Ala did not affect the binding of primer-template, it had a significant decrease in k(cat), an increase in K(m) for dNTP, a striking decrease of processivity, and also resistance to aphidicolin. Thus, mutation of this residue, Gly841, which is highly conserved among the alpha-like DNA polymerases, appears to affect both catalysis and substrate deoxynucleotide binding. This suggests that Gly841 is essential for the maintenance of the overall structure of the polymerase alpha catalytic site.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305	Stanford University			Copeland, William/C-4242-2019	Copeland, William/0000-0002-0359-0953	NATIONAL CANCER INSTITUTE [R01CA014835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028873] Funding Source: NIH RePORTER; NCI NIH HHS [CA14835] Funding Source: Medline; NIAID NIH HHS [AI28873] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663, DOI 10.1073/pnas.87.19.7663; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; CREIGHTON TE, 1984, PROTEINS STRUCTURES, P236; DAMAGNEZ V, 1991, MOL GEN GENET, V226, P182, DOI 10.1007/BF00273602; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DONG Q, 1993, J BIOL CHEM, V268, P24175; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; GOODMAN MF, 1988, MUTAT RES, V200, P11, DOI 10.1016/0027-5107(88)90067-X; HALL ZW, 1968, J MOL BIOL, V36, P321, DOI 10.1016/0022-2836(68)90158-7; HSI KL, 1990, NUCLEIC ACIDS RES, V18, P6231, DOI 10.1093/nar/18.21.6231; JOYCE CM, 1992, J BIOL CHEM, V267, P24485; KHAN NN, 1984, NUCLEIC ACIDS RES, V12, P3695, DOI 10.1093/nar/12.8.3695; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KORNBERG A, 1992, DNA REPLICATION, P127; KRAUSS SW, 1980, BIOCHEMISTRY-US, V19, P220, DOI 10.1021/bi00542a033; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; PARK H, 1993, MOL BIOL CELL, V4, P145, DOI 10.1091/mbc.4.2.145; PIZZAGALLI A, 1988, P NATL ACAD SCI USA, V85, P3772, DOI 10.1073/pnas.85.11.3772; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SEAL G, 1979, J BIOL CHEM, V254, P5229; SUMMERS M, 1988, TEX AGR EXP STN B, V1555, P3; TANAKA S, 1982, J BIOL CHEM, V257, P8386; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; ZHANG J, 1991, BIOCHEMISTRY-US, V30, P11742, DOI 10.1021/bi00115a002	44	78	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24163	24174						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226963				2022-12-25	WOS:A1993MF29400068
J	GIARDINA, C; LIS, JT				GIARDINA, C; LIS, JT			POLYMERASE PROCESSIVITY AND TERMINATION ON DROSOPHILA HEAT-SHOCK GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II ELONGATION COMPLEXES; TRANSCRIPTION TERMINATION; MECHANISM INVIVO; HSP70 GENE; RNA; PROMOTER; INVITRO; MELANOGASTER; DNA; 5,6-DICHLORO-1-BETA-D-RIBOFURANOSYLBENZIMIDAZOLE	5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) limits RNA polymerase II transcription to a gene's 5'-end. Transcription of the uninduced Drosophila hsp70 gene is likewise restricted to the 5'-end, where the polymerase resides in a paused state. Furthermore, paused elongation complexes formed on the uninduced hsp70 gene and in DRB-inhibited reactions can both be restarted by Sarkosyl or high salt. These similarities prompted us to explore whether these complexes were generated by a block at the same polymerase modification step. In vivo UV cross-linking and KMnO4 hyperreactive site mapping show that while the naturally paused polymerase is restricted to the first approximately 42 base pairs of hsp70, DRB treatment of heat-induced cells allows the polymerase to transcribe past this site. Therefore, the DRB-sensitive step is probably not rate-limiting for hsp70 transcription under uninduced conditions. DRB treatment did, however, lead to the reduction of KMnO4 hyper-reactivity on hsp70 and hsp26 in a region correlating with open polymerase and/or early elongation complexes, suggesting a site for the DRB-sensitive polymerase modification step. Finally, we used the techniques of polymerase-DNA cross-linking and KMnO4 hyper-reactive site mapping to analyze the natural polymerase termination process at the 3'-end of the hsp26 gene. The data obtained are consistent with polymerases terminating at multiple sites downstream of the polyadenylation site.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,BIOTECHNOL BLDG,ITHACA,NY 14853	Cornell University								CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CITRON B, 1984, NUCLEIC ACIDS RES, V12, P8723, DOI 10.1093/nar/12.22.8723; CONNELLY S, 1989, CELL, V57, P561, DOI 10.1016/0092-8674(89)90126-8; ENRIQUEZHARRIS P, 1991, EMBO J, V10, P1833, DOI 10.1002/j.1460-2075.1991.tb07709.x; FRASER NW, 1978, NATURE, V272, P590, DOI 10.1038/272590a0; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILMOUR DS, 1985, MOL CELL BIOL, V5, P2009, DOI 10.1128/MCB.5.8.2009; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; RASMUSSEN EB, 1993, IN PRESS P NATL ACAD; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Sambrook J, 1989, MOL CLONING LABORATO; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SOUTHGATE R, 1983, J MOL BIOL, V165, P35, DOI 10.1016/S0022-2836(83)80241-1; SPENCER CA, 1990, ONCOGENE, V5, P777; TAMM I, 1977, P NATL ACAD SCI USA, V74, P5011, DOI 10.1073/pnas.74.11.5011; TANTRAVAHI J, 1993, MOL CELL BIOL, V13, P578, DOI 10.1128/MCB.13.1.578; TOMIZAWA J, 1987, CELL, V51, P623, DOI 10.1016/0092-8674(87)90131-0; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; ZANDOMENI R, 1983, J MOL BIOL, V167, P561, DOI 10.1016/S0022-2836(83)80098-9	32	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23806	23811						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226916				2022-12-25	WOS:A1993MF29400018
J	MALI, M; ELENIUS, K; MIETTINEN, HM; JALKANEN, M				MALI, M; ELENIUS, K; MIETTINEN, HM; JALKANEN, M			INHIBITION OF BASIC FIBROBLAST GROWTH FACTOR-INDUCED GROWTH PROMOTION BY OVEREXPRESSION OF SYNDECAN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEOGLYCAN; HEPARAN-SULFATE PROTEOGLYCAN; MAMMARY EPITHELIAL-CELLS; FACTOR BINDING; TUMOR-CELLS; EXPRESSION; RECEPTOR; MATRIX; PROLIFERATION; LOCALIZATION	The expression of syndecan-1, the prototype member of the cell surface proteoglycan family, follows morphogenetic rather than histological boundaries during organ formation. As a heparan sulfate-containing cell surface molecule, syndecan-1 can simultaneously bind various components of the extracellular matrix and members of the heparin-binding growth factors. Indeed, syndecan-1 may act as a co-receptor for basic fibroblast growth factor (bFGF) (Salmivirta, M., Heino, J., and Jalkanen, M. (1992) J. Biol. Chem. 267, 17606-17610), allowing the growth factor to bind the tyrosine kinase bFGF receptor. We have studied the role of syndecan-1 in growth factor response by growing 3T3 cells transfected with syndecan-1 in the presence of bFGF. The enhanced expression of syndecan-1 caused down-regulation of bFGF-induced cell proliferation and, at the same time, enhancement of cell matrix interactions. Thus, the induced expression of the heparan sulfate co-receptor (syndecan-1) may provide a mechanism to restrict FGF action and modulate cell-matrix interactions to maintain co-ordinated growth of cells during organ formation.	TURKU CTR BIOTECHNOL,TYKISTOKATU 6,BIOCITY,POB 123,SF-20521 TURKU,FINLAND; UNIV TURKU,DEPT MED BIOCHEM,SF-20520 TURKU 52,FINLAND	University of Turku; University of Turku				Elenius, Klaus/0000-0001-5700-0827	NIDCR NIH HHS [DE09399-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009399] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INKI P, 1991, AM J PATHOL, V139, P1333; INKI P, 1992, LAB INVEST, V66, P314; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; JALKANEN M, 1993, TRENDS GLYCOSCI GLYC, V5, P107; JALKANEN M, 1991, RECEPTORS EXTRACELLU, P1; JOSEPHSILVERSTEIN J, 1989, J CELL BIOL, V108, P2459, DOI 10.1083/jcb.108.6.2459; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LEPPA S, 1991, CELL REGUL, V2, P1; MALI M, 1990, J BIOL CHEM, V265, P6884; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OLWIN B, 1992, J CELL BIOL, V118, P621; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAARNI H, 1977, BIOCHEM PHARMACOL, V27, P1029; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SALMIVIRTA M, 1992, J BIOL CHEM, V267, P17606; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTALA P, 1991, J BIOL CHEM, V266, P23505; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V107, P1199; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; STAHLI C, 1983, METHOD ENZYMOL, V92, P242; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA A, 1990, J STEROID BIOCHEM, V37, P23, DOI 10.1016/0960-0760(90)90368-U; THESLEFF I, 1988, DEV BIOL, V129, P565, DOI 10.1016/0012-1606(88)90401-0; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VAINIO S, 1992, DIFFERENTIATION, V50, P97, DOI 10.1111/j.1432-0436.1992.tb00490.x; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; VOGEL A, 1978, P NATL ACAD SCI USA, V75, P2810, DOI 10.1073/pnas.75.6.2810; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WRIGHT TC, 1989, P NATL ACAD SCI USA, V86, P3199, DOI 10.1073/pnas.86.9.3199; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	46	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24215	24222						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226969				2022-12-25	WOS:A1993MF29400075
J	MARIE, S; DIAZGUERRA, MJ; MIQUEROL, L; KAHN, A; IYNEDJIAN, PB				MARIE, S; DIAZGUERRA, MJ; MIQUEROL, L; KAHN, A; IYNEDJIAN, PB			THE PYRUVATE-KINASE GENE AS A MODEL FOR STUDIES OF GLUCOSE-DEPENDENT REGULATION OF GENE-EXPRESSION IN THE ENDOCRINE PANCREATIC BETA-CELL TYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POST-TRANSCRIPTIONAL REGULATION; GLUCOKINASE MESSENGER-RNA; INSULIN-I GENE; RAT-LIVER; CYCLIC-AMP; HEXOSAMINE BIOSYNTHESIS; HORMONAL-CONTROL; TRANSGENIC MICE; RIN-5F CELLS; B-CELLS	The insulinoma beta-cell line INS-1 expresses the L-type pyruvate kinase gene at high level and responds to a rise in extracellular glucose by strong induction of gene expression. Following the addition of glucose to the culture medium in the 3.5-33 mM concentration range, the cellular level of L-type pyruvate kinase mRNA increases within 2 h and reaches a maximum 15-fold above basal in 8-12 h. By run-on nuclear assay, the relative transcription rate of the pyruvate kinase gene is shown to increase 4-fold at maximal stimulation, suggesting that both transcriptional and post-transcriptional effects contribute to mRNA accumulation. The glucose effect is totally suppressed by the hexokinase inhibitor mannoheptulose, indicating a requirement for glucose phosphorylation. The mRNA induction is not inhibited in glutamine-free culture medium or by azaserine, suggesting that the hexosamine biosynthetic pathway is not involved. Moreover, metabolism along the glycolytic pathway does not appear to be an absolute requisite, since 2-deoxyglucose partly mimics the inductive effect of glucose. The glucose effect on the pyruvate kinase gene is reversibly antagonized by agents increasing intracellular cAMP. In addition, the effect is highly specific to the pyruvate kinase gene. Neither proinsulin I mRNA nor glucokinase mRNA are increased in glucose-stimulated INS-1 cells. Short term transfection with CAT plasmids driven by the pyruvate kinase L promoter reveals specific glucose-inducible reporter activity with the 183-base pair promoter region upstream of the cap site. Within this region, the previously described L4 cis-acting element is crucial for glucose responsiveness, as demonstrated by the fact that a plasmid with a mutation in this element does not elicit glucose-inducible CAT activity. Induction of L-type pyruvate kinase mRNA occurs in the islets of rats subjected to fasting and carbohydrate refeeding. In conclusion, the L-type pyruvate kinase gene provides an interesting model of glucose-regulated gene in the endocrine beta-cell type.	UNIV GENEVA,CTR MED UNIV,SCH MED,DIV CLIN BIOCHEM,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND; INST COCHIN GENET MOLEC,INSERM,U129,F-75014 PARIS,FRANCE	University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm)			Díaz-Guerra, María José M/M-2855-2014	Díaz-Guerra, María José M/0000-0003-3843-3912				AKLI S, 1991, GENOMICS, V11, P124, DOI 10.1016/0888-7543(91)90109-R; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BESSELL EM, 1973, BIOCHEM J, V131, P83, DOI 10.1042/bj1310083; BESSELL EM, 1973, BIOCHEM J, V131, P77, DOI 10.1042/bj1310077; BRUNSTEDT J, 1982, BIOCHEM BIOPH RES CO, V106, P1383, DOI 10.1016/0006-291X(82)91267-0; CARTIER N, 1992, ONCOGENE, V7, P1413; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGNET M, 1991, J BIOL CHEM, V266, P7368; COLLINS HW, 1990, P NATL ACAD SCI USA, V87, P5494, DOI 10.1073/pnas.87.14.5494; CUIF MH, 1993, J BIOL CHEM, V268, P13769; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; EFRAT S, 1991, J BIOL CHEM, V266, P11141; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GORUS FK, 1984, J BIOL CHEM, V259, P1196; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HAMMONDS P, 1987, FEBS LETT, V213, P149, DOI 10.1016/0014-5793(87)81481-3; HAYZER DJ, 1990, BIOCHEM J, V270, P261, DOI 10.1042/bj2700261; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; IMAMURA K, 1972, J BIOCHEM-TOKYO, V71, P1043, DOI 10.1093/oxfordjournals.jbchem.a129852; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; LONE YC, 1986, FEBS LETT, V195, P97, DOI 10.1016/0014-5793(86)80138-7; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MARIE J, 1986, EUR J BIOCHEM, V158, P33, DOI 10.1111/j.1432-1033.1986.tb09717.x; MARIE J, 1981, NATURE, V292, P70, DOI 10.1038/292070a0; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MUNNICH A, 1984, J BIOL CHEM, V259, P228; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; NOGUCHI T, 1991, BIOCHEM BIOPH RES CO, V181, P259, DOI 10.1016/S0006-291X(05)81411-1; PHILIPPE J, 1990, J BIOL CHEM, V265, P1465; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P824, DOI 10.1210/endo-117-3-824; Sambrook J, 1989, MOL CLONING LABORATO; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Sladek FM, 1992, CURR OPIN GENET DEV, V2, P256, DOI 10.1016/S0959-437X(05)80282-5; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; SUTTON R, 1986, TRANSPLANTATION, V42, P689, DOI 10.1097/00007890-198612000-00022; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; TRAXINGER RR, 1992, J BIOL CHEM, V267, P9718; TZE WJ, 1976, TRANSPLANTATION, V22, P201, DOI 10.1097/00007890-197608000-00017; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1984, BIOCHEM BIOPH RES CO, V125, P135, DOI 10.1016/S0006-291X(84)80345-9; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; WALKER D. G., 1966, ESSAYS BIOCHEM, V2, P33; WELSH M, 1985, J BIOL CHEM, V260, P3590; YAMADA K, 1990, J BIOL CHEM, V265, P19885	72	118	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23881	23890						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226928				2022-12-25	WOS:A1993MF29400030
J	NEYROZ, P; DESDOUITS, F; BENFENATI, F; KNUTSON, JR; GREENGARD, P; GIRAULT, JA				NEYROZ, P; DESDOUITS, F; BENFENATI, F; KNUTSON, JR; GREENGARD, P; GIRAULT, JA			STUDY OF THE CONFORMATION OF DARPP-32, A DOPAMINE-REGULATED AND CAMP-REGULATED PHOSPHOPROTEIN, BY FLUORESCENCE SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE INHIBITOR-1; TIME-RESOLVED FLUORESCENCE; 3'-5'-MONOPHOSPHATE-REGULATED NEURONAL PHOSPHOPROTEIN; RABBIT SKELETAL-MUSCLE; CASEIN KINASE-II; GLYCOGEN-PHOSPHORYLASE; ALCOHOL-DEHYDROGENASE; DECAY; TRYPTOPHAN; CLONING	DARPP-32 is a potent inhibitor of protein phosphatase 1 when it is phosphorylated on Thr34 by cAMP-dependent protein kinase. DARPP-32 is also phosphorylated on Ser45 and Ser102 by casein kinase II, resulting in a facilitation of phosphorylation by cAMP-dependent protein kinase. We have studied the conformation of recombinant rat DARPP-32 by steady-state and time-resolved fluorescence. The steady-state emission spectra and quenching of the intrinsic (Trp163) and extrinsic fluorescence (acrylodan or lucifer yellow linked to Cys72) were consistent with a complete exposure of these residues to the aqueous environment. The intrinsic fluorescence of DARPP-32 was resolved into three decay components with lifetimes of 1, 3.4, and 7 ns, with the intermediate lifetime component giving the major contribution. The ratio between the amplitudes associated with the short and long decay constants was decreased upon denaturation. The rotational behavior of DARPP-32 measured by anisotropy decay revealed that Trp163 is located in a highly flexible peptide chain, whereas Cys72 is embedded in a more rigid environment. Phosphorylation by cAMP-dependent protein kinase did not alter any of the fluorescence parameters, whereas only minor effects were associated with casein kinase II phosphorylation. These findings indicate that DARPP-32 contains at least two distinct domains and that phosphorylation has no dramatic effects on its conformation.	COLL FRANCE,CHAIR NEUROPHARMACOL,INSERM,U114,F-75231 PARIS 05,FRANCE; UNIV ROMA TOR VERGATA,DIPARTIMENTO MED SPERIMENTALE & SCI BIOCHIM,ROME,ITALY; NHLBI,CELL BIOL LAB,BETHESDA,MD 20892; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; University of Rome Tor Vergata; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Rockefeller University	NEYROZ, P (corresponding author), UNIV BOLOGNA,DIPARTIMENTO BIOCHIM G MORUZZI,SEZ BIOCHIM FARMACEUT,I-40126 BOLOGNA,ITALY.		Girault, Jean-Antoine/F-7518-2013	Girault, Jean-Antoine/0000-0002-7900-1705; NEYROZ, PAOLO/0000-0002-9790-4027				AITKEN A, 1982, EUR J BIOCHEM, V126, P235, DOI 10.1111/j.1432-1033.1982.tb06771.x; AMELOOT M, 1984, BIOPHYS J, V46, P525, DOI 10.1016/S0006-3495(84)84050-3; AZUMI T, 1962, J CHEM PHYS, V37, P2413, DOI 10.1063/1.1733019; Badea M G, 1979, Methods Enzymol, V61, P378; BARFORD D, 1991, BIOCHIM BIOPHYS ACTA, V1133, P55, DOI 10.1016/0167-4889(91)90241-O; BEECHEM JM, 1985, ANAL INSTRUM, V14, P379; BEECHEM JM, 1985, ANNU REV BIOCHEM, V54, P43, DOI 10.1146/annurev.biochem.54.1.43; BENFENATI F, 1990, J BIOL CHEM, V265, P12584; Bevington PR, 1969, DATA REDUCTION ERROR; Birks J., 1970, PHOTOPHYSICS AROMATI, DOI DOI 10.1002/BBPC.19700741223; CHEN RF, 1991, BIOCHEMISTRY-US, V30, P5184, DOI 10.1021/bi00235a011; CROSS AJ, 1984, BIOPHYS J, V46, P45, DOI 10.1016/S0006-3495(84)83997-1; DAHMS TES, 1993, BIOPHYS J, V64, pA55; DALE RE, 1977, J BIOL CHEM, V252, P7500; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EHRLICH ME, 1990, J MOL NEUROSCI, V2, P1, DOI 10.1007/BF02896920; ELBRECHT A, 1990, J BIOL CHEM, V265, P13415; FOULKES JG, 1983, EUR J BIOCHEM, V132, P309, DOI 10.1111/j.1432-1033.1983.tb07363.x; Gilbert C. W., 1983, TIME RESOLVED FLUORE, P605; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GRINVALD A, 1974, ANAL BIOCHEM, V59, P583, DOI 10.1016/0003-2697(74)90312-1; HALPAIN S, 1990, NATURE, V343, P369, DOI 10.1038/343369a0; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P317, DOI 10.1016/0076-6879(83)99067-5; Haugland R.P., 1992, HDB FLUORESCENT PROB; HEMMINGS HC, 1984, J NEUROSCI, V4, P99; HEMMINGS HC, 1987, TRENDS NEUROSCI, V10, P377, DOI 10.1016/0166-2236(87)90075-0; HEMMINGS HC, 1992, J NEUROCHEM, V59, P1053, DOI 10.1111/j.1471-4159.1992.tb08347.x; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4486; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; JOHNSON ML, 1983, BIOPHYS J, V44, P101, DOI 10.1016/S0006-3495(83)84281-7; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KING MM, 1984, J BIOL CHEM, V259, P8080; KNIGHT AEW, 1971, SPECTROCHIM ACTA A-M, VA 27, P1223, DOI 10.1016/0584-8539(71)80073-9; KNUTSON JR, 1982, BIOCHEMISTRY-US, V21, P4671, DOI 10.1021/bi00262a024; KNUTSON JR, 1983, CHEM PHYS LETT, V102, P501, DOI 10.1016/0009-2614(83)87454-5; KURIHARA T, 1988, J NEUROSCI, V8, P508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NEYROZ P, 1987, J BIOL CHEM, V262, P15900; O'Connor D. V., 1984, TIME CORRELATED SING; PAOLETTI J, 1969, ANAL BIOCHEM, V31, P33, DOI 10.1016/0003-2697(69)90238-3; Parker C. A., 1968, PHOTOLUMINESCENCE SO, P220; PETRICH JW, 1983, J AM CHEM SOC, V105, P3824, DOI 10.1021/ja00350a014; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; PRIVAT JP, 1980, BIOPHYS CHEM, V11, P239, DOI 10.1016/0301-4622(80)80026-3; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSS JBA, 1981, BIOCHEMISTRY-US, V20, P4369, DOI 10.1021/bi00518a021; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; SZABO AG, 1980, J AM CHEM SOC, V102, P554, DOI 10.1021/ja00522a020; TAO T, 1969, BIOPOLYMERS, V8, P609, DOI 10.1002/bip.1969.360080505; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; WAHL P, 1969, BIOCHIM BIOPHYS ACTA, V175, P55, DOI 10.1016/0005-2795(69)90145-7; WAHL P, 1974, REV SCI INSTRUM, V45, P28, DOI 10.1063/1.1686442; WARE RW, 1972, CREATION DETECTION A, V1, P213; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; Yguerabide J, 1972, Methods Enzymol, V26, P498	64	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24022	24031						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226946				2022-12-25	WOS:A1993MF29400049
J	QIN, J; PANDE, U; LAMAR, GN; ASCOLI, F; ASCENZI, P; CUTRUZZOLA, F; TRAVAGLINIALLOCATELLI, C; BRUNORI, M				QIN, J; PANDE, U; LAMAR, GN; ASCOLI, F; ASCENZI, P; CUTRUZZOLA, F; TRAVAGLINIALLOCATELLI, C; BRUNORI, M			H-1-NMR STUDY OF THE DYNAMICS OF THE PH MODULATION OF AXIAL COORDINATION IN APLYSIA-LIMACINA (VAL(E7)) AND SPERM WHALE DOUBLE MUTANT HIS(E7)-]VAL,THR(E10)-]ARG METMYOGLOBIN - ROLE OF DISTAL HYDROGEN-BONDING IN LIGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SPIN FERRIC HEMOPROTEINS; ELECTRONIC-STRUCTURE; IRON(III) PORPHYRINS; ANIONIC LIGANDS; CARBON-MONOXIDE; HEME CAVITY; MYOGLOBIN; EQUILIBRIUM; RESOLUTION	The molecular and electronic structure, thermodynamics, dynamics, and mechanism of interconversion of the pH-modulated reversible equilibria of Aplysia limacina metmyoglobin, (metMb), have been investigated by H-1 NMR spectroscopy. The four identified species which interconvert slowly on the NMR time scale (lifetime > 1 ms) are metMbOH (B) at alkaline pH, five coordinate metMb (N) at acidic to neutral pH, an acidic form, A, near pH approximately 4 and an extremely low pH form, D, attributed to an equilibrium unfolded species. The presence of strong distal hydrogen bonding by Arg (E10) to bound hydroxide is detected via a significant solvent isotope effect on the metMbOH (B) hyperfine shifts. Integration of the peak intensities yields pK values of 7.7 and approximately 4 for the B reversible N and N reversible A equilibria, respectively. Saturation transfer via chemical exchange is observed for B reversible N and N reversible A, where the rates for forming metMbOH (B) and the acidic form A from N are base- and acid-catalyzed, respectively, while the reverse rates are first-order. The much slower interconversion rate for N reversible B in A. limacina metMb than His(E7) containing mammalian metMb is attributed to the fact that a ligand bond is broken rather than just proton transferred and that the equilibrium involves a major rearrangement of the orientation of Arg(E10). This conclusion is supported by H-1 NMR data for the sperm whale double mutant His(E7) --> Val/Thr(E10) --> Arg metMb, which exhibits a pK approximately 8.7 for the equilibrium between five-coordinate metMb (N) and metMbOH (B) with an even slower interconversion rate than in A. limacina metMb. This double mutant metMbOH (B) exhibits hydrogen bonding by Arg (E10) with coordinated hydroxide similar to that in A. limacina metMbOH. The slow but acid-catalyzed rates of conversion of A. limacina metMb (N) to the acid species A with significantly weakened bonding of the heme iron to the axial His(F8) residue is consistent with protonation of an inaccessible residue and/or a structural change accompanying the protonation equilibrium. It is concluded that metMb will coordinate water strongly only when there is a distal hydrogen bond acceptor residue, while the hydroxide ion is coordinated strongly only if there is a distal hydrogen bond donor residue.	UNIV CALIF DAVIS,DEPT CHEM,DAVIS,CA 95616; UNIV ROMA TOR VERGATA,DEPT EXPTL MED & BIOCHEM SCI,I-00173 ROME,ITALY; UNIV ROMA LA SAPIENZA,DEPT BIOCHEM SCI A ROSSI FANELLI,I-00185 ROME,ITALY; UNIV ROMA LA SAPIENZA,CTR MOLEC BIOL,CNR,I-00185 ROME,ITALY	University of California System; University of California Davis; University of Rome Tor Vergata; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome			Cutruzzola', Francesca/G-4052-2011	Cutruzzola', Francesca/0000-0002-4621-2135; Travaglini-Allocatelli, Carlo/0000-0001-8735-1126; Qin, Jun/0000-0002-2647-9270; Brunori, Maurizio/0000-0002-7795-1635	NCRR NIH HHS [RR-04795] Funding Source: Medline; NHLBI NIH HHS [HL-16087] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004795] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016087, R37HL016087] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, P40; ASCENZI P, 1981, J BIOL CHEM, V256, P5383; BOERSMA AD, 1982, INORG CHEM, V21, P581, DOI 10.1021/ic00132a023; BOLOGNESI M, 1989, J MOL BIOL, V205, P529, DOI 10.1016/0022-2836(89)90224-6; BOLOGNESI M, 1990, J MOL BIOL, V213, P621, DOI 10.1016/S0022-2836(05)80249-9; BRUNORI M, 1972, J MOL BIOL, V63, P139, DOI 10.1016/0022-2836(72)90526-8; CHIU ML, 1992, THESIS U ILLINOIS UR; COLETTA M, 1985, J BIOL CHEM, V260, P4151; CUTRUZZOLA F, 1991, FEBS LETT, V282, P281, DOI 10.1016/0014-5793(91)80495-O; GIACOMETTI GM, 1981, J MOL BIOL, V151, P315, DOI 10.1016/0022-2836(81)90518-0; GIACOMETTI GM, 1975, BIOCHEMISTRY-US, V14, P1584, DOI 10.1021/bi00679a006; GIACOMETTI GM, 1979, BIOPHYS CHEM, V10, P119, DOI 10.1016/0301-4622(79)80012-5; GIACOMETTI GM, 1981, J MOL BIOL, V146, P363, DOI 10.1016/0022-2836(81)90393-4; GOFF H, 1980, J AM CHEM SOC, V102, P31, DOI 10.1021/ja00521a007; IIZUKA T, 1975, BIOCHIM BIOPHYS ACTA, V400, P143, DOI 10.1016/0005-2795(75)90135-X; ILLGENFRITZ G, 1971, PROBES STRUCTURE FUN, V2, P299; JANES SM, 1987, BIOPHYS J, V51, P653, DOI 10.1016/S0006-3495(87)83390-8; LAMAR GN, 1984, J AM CHEM SOC, V106, P6395, DOI 10.1021/ja00333a050; LAMAR GN, 1988, BIOCHIM BIOPHYS ACTA, V956, P267, DOI 10.1016/0167-4838(88)90143-4; LAMAR GN, 1980, J AM CHEM SOC, V102, P1822, DOI 10.1021/ja00526a011; LAMAR GN, 1978, PORPHYRINS         C, V4, P61; LECOMTE JTJ, 1987, J AM CHEM SOC, V109, P7219, DOI 10.1021/ja00257a068; Mattevi A, 1991, J Mol Recognit, V4, P1, DOI 10.1002/jmr.300040102; MCGRATH TM, 1978, BIOCHIM BIOPHYS ACTA, V534, P99, DOI 10.1016/0005-2795(78)90480-4; MORIKIS D, 1990, J BIOL CHEM, V265, P12143; PANDE U, 1986, BIOCHEMISTRY-US, V25, P5638, DOI 10.1021/bi00367a044; PEYTON DH, 1989, BIOCHEMISTRY-US, V28, P4880, DOI 10.1021/bi00437a053; QIN J, 1992, J MOL BIOL, V224, P891, DOI 10.1016/0022-2836(92)90456-T; RAJARATHNAM K, 1991, J AM CHEM SOC, V113, P7886, DOI 10.1021/ja00021a010; RIZZI M, 1993, FEBS LETT, V320, P13, DOI 10.1016/0014-5793(93)81647-I; ROSSIFANELLI A, 1957, BIOKHIMIYA, V22, P335; ROUSSEAU DL, 1989, J BIOL CHEM, V264, P7878; Sandstrom J., 1982, DYNAMIC NMR SPECTROS, P53; SANTUCCI RF, 1990, BIOPHYS CHEM, V37, P241; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; TENTORI L, 1973, INT J PEPT PROT RES, V5, P187; THANABAL V, 1988, J AM CHEM SOC, V110, P3027, DOI 10.1021/ja00218a005; TRAVAGLINIALLOC.C, 1993, BIOCHEMISTRY-US, V32, P6041; UNGER SW, 1985, J MAGN RESON, V64, P521, DOI 10.1016/0022-2364(85)90117-9; WITTENBERG BA, 1965, ARCH BIOCHEM BIOPHYS, V111, P576, DOI 10.1016/0003-9861(65)90237-7; YAMAMOTO Y, 1992, FEBS LETT, V310, P71, DOI 10.1016/0014-5793(92)81149-G; [No title captured]; [No title captured]; [No title captured]	45	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24012	24021						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226945				2022-12-25	WOS:A1993MF29400048
J	RENARDROONEY, DC; HAJNOCZKY, G; SEITZ, MB; SCHNEIDER, TG; THOMAS, AP				RENARDROONEY, DC; HAJNOCZKY, G; SEITZ, MB; SCHNEIDER, TG; THOMAS, AP			IMAGING OF INOSITOL 1,4,5-TRISPHOSPHATE-INDUCED CA2+ FLUXES IN SINGLE PERMEABILIZED HEPATOCYTES - DEMONSTRATION OF BOTH QUANTAL AND NONQUANTAL PATTERNS OF CA2+ RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC CALCIUM OSCILLATIONS; RAT-LIVER MICROSOMES; ENDOPLASMIC-RETICULUM; POSSIBLE MECHANISM; ACINAR-CELLS; TRISPHOSPHATE; CA-2+; MOBILIZATION; GTP; STORES	The subcellular organization and function of inositol 1,4,5-trisphosphate (InsP3)-sensitive Ca2+ stores has been investigated in permeabilized hepatocytes using fluorescent probe techniques that monitor InsP3 action at the level of the Ca2+ storage organelles. Chlortetracycline fluorescence was used to follow alterations in luminal Ca2+, and InsP3-activated Mn2+ quench of compartmentalized fura-2 was used as a measure of the distribution and permeability of the InsP3-sensitive channels. Fluorescence imaging of single permeabilized hepatocytes attached to coverslips demonstrated that InsP3-sensitive Ca2+ stores are distributed throughout the cytoplasm, but are not present within the nuclear matrix. When hepatocytes were permeabilized in suspension, InsP3, activation of channel opening and Ca2+ release occurred in a quantal manner, such that the incremental magnitude of the response was determined by the dose of InsP3. Under these conditions dose-dependent steps of InsP3-induced Mn2+ entry into the stores occurred in the absence of changes in cytosolic or luminal Ca2+, providing evidence for a series of separate compartments with different sensitivities to InsP3. Electron microscopy studies revealed that the endoplasmic reticulum was extensively vesicularized when hepatocytes were permeabilized in suspension, whereas essentially normal endoplasmic reticulum structure was retained in cells attached to coverslips. In these attached cells the Ca2+ release and channel opening responses to InsP3 occurred in a nonquantal manner at the single cell level. Submaximal doses of InsP3 gave the same magnitude of response as a maximal InsP3 dose, although the rates of Ca2+ release and Mn2+ permeation through the InsP3-activated channels increased in a dose-dependent manner. Thus, in each cell the entire Ca2+ store was accessible for mobilization by an effective InsP3 concentrations. We conclude that the quantal release properties of the InsP3 receptor are not expressed in attached permeabilized liver cells because there is extensive luminal continuity within the InsP3-sensitive Ca2+ stores. This continuity appears to be disrupted when hepatocytes are permeabilized in suspension.	THOMAS JEFFERSON UNIV,DEPT PATHOL & CELL BIOL,RM 271 JAH,PHILADELPHIA,PA 19107	Jefferson University			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038422, R01DK038422] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07215] Funding Source: Medline; NIDDK NIH HHS [DK38422] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; CASWELL AH, 1972, BIOCHEM BIOPH RES CO, V46, P1757, DOI 10.1016/0006-291X(72)90047-2; CHANDLER DE, 1978, J CELL BIOL, V76, P371, DOI 10.1083/jcb.76.2.371; CONROY DM, 1986, BIOCHIM BIOPHYS ACTA, V861, P457, DOI 10.1016/0005-2736(86)90454-2; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DAWSON AP, 1987, BIOCHEM J, V244, P87, DOI 10.1042/bj2440087; DAWSON AP, 1985, FEBS LETT, V185, P147, DOI 10.1016/0014-5793(85)80759-6; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GIRARD S, 1992, BIOPHYS J, V61, P509, DOI 10.1016/S0006-3495(92)81855-6; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1990, CELL CALCIUM, V11, P241, DOI 10.1016/0143-4160(90)90075-6; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; JOSEPH SK, 1984, J BIOL CHEM, V259, P3077; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LUKACS GL, 1987, BIOCHIM BIOPHYS ACTA, V931, P251, DOI 10.1016/0167-4889(87)90213-8; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MIYAZAKI S, 1986, DEV BIOL, V118, P259, DOI 10.1016/0012-1606(86)90093-X; MOLLENHAUER HH, 1964, STAIN TECHNOL, V39, P111; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NEYLON CB, 1990, AM J PHYSIOL, V259, pC675, DOI 10.1152/ajpcell.1990.259.4.C675; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PAYNE R, 1988, PHILOS T ROY SOC B, V320, P359, DOI 10.1098/rstb.1988.0082; RAWLINGS SR, 1991, J BIOL CHEM, V266, P22755; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; ROONEY TA, 1991, PHARMACOL THERAPEUT, V49, P223, DOI 10.1016/0163-7258(91)90056-R; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; SCHNEIDER AS, 1983, BIOCHEMISTRY-US, V22, P1680, DOI 10.1021/bi00276a025; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; Thomas Andrew P., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P225; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; THOMAS AP, 1988, J BIOL CHEM, V263, P2704; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WAITE JH, 1983, J BIOL CHEM, V258, P2911	48	93	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23601	23610						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226887				2022-12-25	WOS:A1993MF51500098
J	CHUCK, SL; LINGAPPA, VR				CHUCK, SL; LINGAPPA, VR			ANALYSIS OF A PAUSE TRANSFER SEQUENCE FROM APOLIPOPROTEIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; ENDOPLASMIC-RETICULUM; STRUCTURAL DOMAINS; PROTEIN; TRANSLOCATION; MEMBRANE; TRANSLATION; SECRETION; BINDING; CHAINS	In contrast to typical secretory proteins, apolipoprotein B pauses at distinct points along the nascent chain during its translocation into the lumen of the endoplasmic reticulum. Specific pause transfer sequences mediate such discrete pauses in the translocation of apolipoprotein B. These sequences have been shown to confer this translocational behavior to heterologous chimeric proteins. To investigate the function of pause transfer sequences, we: (i) examine whether the multiple pause transfer sequences of apolipoprotein B act independently or are dependent upon the action of upstream pause transfer sequences, (ii) identify residues of the prototypical B' pause transfer sequence that are involved in pausing, and (iii) determine whether the stopping step of a translocational pause is a consequence of translational pausing, as has been suggested by other investigators. We conclude that pause transfer sequences act independently of each other and of translation; translocational pausing occurs even in the absence of ongoing protein synthesis. Furthermore, like other topogenic sequences such as signal sequences, pause transfer sequences are degenerate in structure yet have distinctive features necessary for their action. This characterization of the B' pause transfer sequence may aid in the identification of such sequences elsewhere in apolipoprotein B and in other proteins and has implications for the mechanism of translocational pausing.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045480] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45480] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHEN GC, 1989, J BIOL CHEM, V264, P14369; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PATERSON RG, 1987, CELL, V48, P441, DOI 10.1016/0092-8674(87)90195-4; PEASE R, 1992, NATURE, V356, P115, DOI 10.1038/356115c0; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; PESTKA S, 1971, ANNU REV MICROBIOL, V25, P487, DOI 10.1146/annurev.mi.25.100171.002415; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SIUTAMANGANO P, 1981, J BIOL CHEM, V256, P2094; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; VEGA GL, 1986, J CLIN INVEST, V78, P1410, DOI 10.1172/JCI112729; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	31	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22794	22801						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226789				2022-12-25	WOS:A1993MD34800089
J	CONSTANTINE, KL; MAPELLI, C; MEYERS, CA; FRIEDRICHS, MS; KRYSTEK, S; MUELLER, L				CONSTANTINE, KL; MAPELLI, C; MEYERS, CA; FRIEDRICHS, MS; KRYSTEK, S; MUELLER, L			MICELLE-BOUND CONFORMATIONAL PREFERENCES OF A PEPTIDE DERIVED FROM A MURINE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; COHERENCE-TRANSFER; COMPLETE SEQUENCE; CROSS-RELAXATION; NMR-SPECTROSCOPY; PROTEINS; MACROMOLECULES; ELUCIDATION; INITIATION; DYNAMICS	Models of the micelle-bound conformation of a 17-residue major histocompatibility complex-derived peptide, [Ala85]D(k)(69-85), have been determined by NMR spectroscopy and simulated annealing calculations. This peptide is a truncated, substituted version of D(k)(61-85), which is a fragment of the murine major histocompatibility complex class I molecule H-2D(k). D(k)(61-85) has been shown to adopt an ordered conformation required for augmentation of insulin-stimulated glucose uptake (Stagsted, J., Baase, W. A., Goldstein, A., and Olsson, L. (1991) J. Biol. Chem. 266, 12844-12847). [Ala85]D(k)(69-85) retains full biological activity. Thirty-eight converged NMR structures of [Ala85]D(k)(69-85) bound to dodecyl phosphocholine micelles have been generated. The NMR-derived models display a propensity for a type-I beta-bend involving residues 73-76 and an amphipathic helical region involving residues 77-84. CD spectra yield a helical content (8% at 20-25-degrees-C) consistent with transient, partial helix formation. The relative orientation of the beta-bend region with respect to the helical region is not well defined by the NMR data. This may reflect true heterogeneity of the micelle-bound conformation. The NMR structures were compared with a model of [Ala85]D(k)(69-85) derived from the x-ray coordinates of the human major histocompatibility complex class I allele HLA-Aw68 (Garrett, T. P. J., Saper, M. A., Bjorkmann, P. J., Strominger, T. L., and Wiley, D. C. (1989) Nature 342, 692-696). Structural features that are important for the bioactivity of [Ala85]D(k)(69-85) are discussed with reference to reported structure-activity relationships (Stagsted, J., Mapelli, C., Meyers, C., Matthews, B. W., Anfinsen, C. B., Goldstein, A., and Olsson, L. (1993) Proc. Natl. Acad. Sci. U. S. A., in press). A general description of the structural properties of the putative receptor site(s) that are likely to be required for binding [Ala85]D(k)(6985) is given.	BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT CARDIOVASC DIS & PEPTIDE CHEM,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MACROMOLEC MODELING,PRINCETON,NJ 08543	Bristol-Myers Squibb; Bristol-Myers Squibb	CONSTANTINE, KL (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MACROMOLEC NUCL MAGNET RESONANCE,POB 4000,PRINCETON,NJ 08543, USA.							BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BORGIAS BA, 1990, PROG NUCL MAG RES SP, V22, P83, DOI 10.1016/0079-6565(90)80015-A; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRUNGER AT, 1992, X PLOR VERSION 3 ZER, P311; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CONSTANTINE KL, 1992, J MOL BIOL, V223, P281, DOI 10.1016/0022-2836(92)90731-X; CONSTANTINE KL, 1990, BIOPOLYMERS, V30, P239, DOI 10.1002/bip.360300303; DUFOURC EJ, 1992, BIOPHYS J, V61, P42, DOI 10.1016/S0006-3495(92)81814-3; DYSON HJ, 1992, J MOL BIOL, V226, P819, DOI 10.1016/0022-2836(92)90634-V; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HANSEN T, 1989, P NATL ACAD SCI USA, V86, P3123, DOI 10.1073/pnas.86.9.3123; KESSLER H, 1988, J AM CHEM SOC, V110, P3393, DOI 10.1021/ja00219a008; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NEUHAUS D, 1989, NUCLEAR OVERHAUSER E; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; ROBSON B, 1986, INTRO PROTEINS PROTE, P86; SHRIVER J, 1993, BIOCHEMISTRY-US, V32, P1610, DOI 10.1021/bi00057a027; STAGSTED J, 1990, CELL, V62, P297, DOI 10.1016/0092-8674(90)90367-N; STAGSTED J, 1991, J BIOL CHEM, V266, P12844; STAGSTED J, 1993, IN PRESS P NATL ACAD; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC	31	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22830	22837						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226794				2022-12-25	WOS:A1993MD34800095
J	FLINT, DH; TUMINELLO, JF; EMPTAGE, MH				FLINT, DH; TUMINELLO, JF; EMPTAGE, MH			THE INACTIVATION OF FE-S CLUSTER CONTAINING HYDRO-LYASES BY SUPEROXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; AMINO-ACID BIOSYNTHESIS; ESCHERICHIA-COLI; ACTIVATED ACONITASE; HYPERBARIC-OXYGEN; 4FE-4S CLUSTER; DEHYDRATASE; ENZYME; PURIFICATION; IRON	We report in this paper that highly purified Escherichia coli dihydroxy-acid dehydratase, fumarase A, fumarase B, and mammalian aconitase are inactivated by O2- with second order rate constants in the range of 10(6) to 10(7) M-1 s-1. Each of these enzymes belongs to the hydrolyase class and contains catalytically active [4Fe-4S] clusters. Simultaneous with inactivation by O2- is the release of iron from their clusters. Our working hypothesis is O2- inactivates these enzymes by oxidizing their clusterS to an unstable oxidation state, and cluster degradation follows. Consistent with this hypothesis is our observation that spinach dihydroxy-acid dehydratase, a member of the hydro-lyase class that has a catalytically active [2Fe-2S] cluster, is not inactivated and does not lose iron in the presence of O2-. Porcine fumarase, a member of the hydro-lyase class that does not contain an Fe-S cluster, is also not inactivated by O2-. We also report the rate constants for the inactivation of E. coli dihydroxy-acid dehydratase, fumarase A, fumarase B, and mammalian aconitase by O2 are close to 2 x 10(2) M-1 s-1, and the rate constants for the inactivation of E. coli dihydroxy-acid dehydratase and mammalian aconitase by H2O2 are about 10(3) M-1 s-1. E. coli dihydroxy-acid dehydratase has been reported previously to be inactivated in vivo when cells are grown in hyperbaric O2, presumably due to the increased O2- generated under these conditions. We report here that E. coli fumarase A, fumarase B, and aconitase are also inactivated in vivo by hyperbaric O2. Thermodynamic parameters for the oxidation of the cluster of aconitase by O2- and O2 are calculated.			FLINT, DH (corresponding author), DUPONT CO INC, CENT RES & DEV, EXPTL STN, WILMINGTON, DE 19880 USA.							BOEHME DE, 1976, NATURE, V262, P418, DOI 10.1038/262418a0; Bray RC., 1975, ENZYMES, V12, P299, DOI DOI 10.1016/S1874-6047(08)60229-2; BROWN OR, 1978, BIOCHEM BIOPH RES CO, V85, P1219, DOI 10.1016/0006-291X(78)90672-1; DREYER JL, 1985, EUR J BIOCHEM, V150, P145, DOI 10.1111/j.1432-1033.1985.tb09000.x; EMPTAGE M H, 1990, P315; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; Fee J.A., 1977, SUPEROXIDE SUPEROXID, P19; FEE JA, 1980, BIOCHEM INT, V1, P304; FEE JA, 1981, METAL ACTIVATION DIO, P209; FLINT D H, 1990, P285; FLINT DH, 1992, BIOCHEMISTRY-US, V31, P10331, DOI 10.1021/bi00157a022; FLINT DH, 1993, J BIOL CHEM, V268, P14732; FLINT DH, 1988, J BIOL CHEM, V263, P3558; FRIDOVICH I, 1972, ACCOUNTS CHEM RES, V5, P321, DOI 10.1021/ar50058a001; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; FRIDOVICH I, 1975, AM SCI, V63, P54; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GOTTLIEB SF, 1971, ANNU REV MICROBIOL, V25, P111, DOI 10.1146/annurev.mi.25.100171.000551; GRABOWSKI R, 1991, EUR J BIOCHEM, V199, P89, DOI 10.1111/j.1432-1033.1991.tb16095.x; HASSAN HM, 1979, J BIOL CHEM, V254, P846; HASSAN HM, 1978, J BIOL CHEM, V253, P8143; HAUGAARD N, 1968, PHYSIOL REV, V48, P311, DOI 10.1152/physrev.1968.48.2.311; KELLY JM, 1986, FEBS LETT, V202, P274, DOI 10.1016/0014-5793(86)80700-1; KENNEDY MC, 1987, P NATL ACAD SCI USA, V84, P8854, DOI 10.1073/pnas.84.24.8854; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kiritani K., 1970, METHOD ENZYMOL, V17, P755; KLUG D, 1972, J BIOL CHEM, V247, P4839; KOPPENOL WH, 1976, BIOCHIM BIOPHYS ACTA, V449, P157, DOI 10.1016/0005-2728(76)90130-4; KUCHTA RD, 1985, J BIOL CHEM, V260, P3181; KUO CF, 1987, J BIOL CHEM, V262, P4724; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LIOCHEV SI, 1993, ARCH BIOCHEM BIOPHYS, V301, P379, DOI 10.1006/abbi.1993.1159; MAX B, 1992, TRENDS PHARMACOL SCI, V13, P272, DOI 10.1016/0165-6147(92)90084-J; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1971, P NATL ACAD SCI USA, V68, P1024, DOI 10.1073/pnas.68.5.1024; NIELSEN BE, 1969, ACTA CHEM SCAND, V23, P967, DOI 10.3891/acta.chem.scand.23-0967; POU S, 1992, J BIOL CHEM, V267, P24173; PRODROMOU C, 1991, J GEN MICROBIOL, V137, P2505, DOI 10.1099/00221287-137-11-2505; PRODROMOU C, 1992, EUR J BIOCHEM, V204, P599, DOI 10.1111/j.1432-1033.1992.tb16673.x; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROTILIO G, 1972, BIOCHEMISTRY-US, V11, P2182, DOI 10.1021/bi00761a027; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; SCHWEIGER G, 1987, EUR J BIOCHEM, V169, P441, DOI 10.1111/j.1432-1033.1987.tb13631.x; SCOPES RK, 1984, ANAL BIOCHEM, V136, P530, DOI 10.1016/0003-2697(84)90257-4; SMYKRANDALL E, 1993, FREE RADICAL BIO MED, V14, P609, DOI 10.1016/0891-5849(93)90142-H; TELSER J, 1986, J BIOL CHEM, V261, P4840; WIMPENNY J W T, 1969, Symposium of the Society for General Microbiology, V19, P161; WOODS SA, 1988, BIOCHIM BIOPHYS ACTA, V954, P14, DOI 10.1016/0167-4838(88)90050-7	49	527	538	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22369	22376						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226748				2022-12-25	WOS:A1993MD34800030
J	ZHANG, J; KING, WG; DILLON, S; HALL, A; FEIG, L; RITTENHOUSE, SE				ZHANG, J; KING, WG; DILLON, S; HALL, A; FEIG, L; RITTENHOUSE, SE			ACTIVATION OF PLATELET PHOSPHATIDYLINOSITIDE 3-KINASE REQUIRES THE SMALL GTP-BINDING PROTEIN-RHO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							C3 ADP-RIBOSYLTRANSFERASE; HUMAN BLOOD-PLATELETS; ALPHA-THROMBIN; GENE-PRODUCT; RECEPTOR; KINASE; PHOSPHOINOSITIDES; ASSOCIATION	The small GTP-binding protein Rho regulates the assembly of actin stress fibers and focal adhesions in cells responding to growth factors. ADP-ribosylation of Rho by C3 transferase blocks this function; however, an enzymatic target for Rho has not yet been defined. We now report that Rho activates phosphatidylinositide 3-kinase in soluble preparations of platelets. Activation of phosphatidylinositide 3-kinase by GTPgammaS is blocked by ADP-ribosylation of endogenous Rho, and Rho shifts to the cytoskeleton in platelets exposed to thrombin. The inhibitory effects of ADP-ribosylation are overcome by exogenous recombinant Rho but not by recombinant Rac, another member of the Ras superfamily. Exposure of platelets to thrombin has been reported to lead to activation of phosphatidylinositide 3-kinase, a shift of this enzyme to the platelet membrane skeleton, and rapid cytoskeletal reorganization. In other studies, ADP-ribosylation of Rho has been found to inhibit thrombin-induced platelet aggregation, a cytoskeletally linked event. We suggest that Rho may exert its effects on cytoskeletal reorganization via phosphatidylinositide 3-kinase.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,CARDEZA FDN HEMATOL RES,PHILADELPHIA,PA 19107; ARIAD PHARMACEUT,CAMBRIDGE,MA 02139; TUFTS UNIV,DEPT BIOCHEM,BOSTON,MA 02111; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Jefferson University; Jefferson University; Takeda Pharmaceutical Company Ltd; Takeda Oncology; Tufts University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK					NATIONAL CANCER INSTITUTE [R29CA047391, R01CA047391] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038622] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47391] Funding Source: Medline; NHLBI NIH HHS [HL 38622] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARNEY DH, 1978, CELL, V15, P1341, DOI 10.1016/0092-8674(78)90059-4; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; EBERLE M, 1990, J BIOL CHEM, V265, P16725; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P36224; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; MORII N, 1992, J BIOL CHEM, V267, P20921; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; ZHANG J, 1992, J BIOL CHEM, V267, P4686	20	216	224	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22251	22254						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226730				2022-12-25	WOS:A1993MD34800010
J	SAVOYSKY, E; MIZUNO, T; SOWA, Y; WATANABE, H; SAWADA, J; NOMURA, H; OHSUGI, Y; HANDA, H; SAKAI, T				SAVOYSKY, E; MIZUNO, T; SOWA, Y; WATANABE, H; SAWADA, J; NOMURA, H; OHSUGI, Y; HANDA, H; SAKAI, T			THE RETINOBLASTOMA BINDING-FACTOR-1 (RBF-1) SITE IN RB GENE PROMOTER BINDS PREFERENTIALLY E4TF1, A MEMBER OF THE ETS TRANSCRIPTION FACTORS FAMILY	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; DNA-BINDING; AFFINITY PURIFICATION; C-FOS; PROTEIN; EXPRESSION; SEQUENCE; DIFFERENTIATION; ACTIVATION; ONCOGENE	The tumor suppressor retinoblastoma gene product, pRB, is a well known regulator of G1/S cell cycle progression. Moreover, mutational inactivations within the retinoblastoma gene (RB) are found in many human malignant tumors, and thus, believed to be an essential step in tumor formation. The human RB gene is considered as a housekeeping gene with no characteristic TATA or CAAT elements in its promoter region, but the sequence between 206 and 185 bases upstream of the initiation codon, essential for RB promoter activity, contains putative Sp1 and ATF recognition sites. We have previously reported that point mutations in this region, causing low penetrance retinoblastomas, completely reduced RB promoter activity, and that a nuclear factor, named RBF-1 (retinoblastoma binding factor 1), could specifically bind to this sequence, overlapping Sp1 recognition sequence. We show here, that RBF-1 can recognize a specific DNA sequence, 5'-GGCGGAAGT-3', overlapping the Sp1 and ATF sites and corresponding to the consensus DNA binding site for members of Ets transcription factors family. When RBF-1 site was used for sequence specific DNA affinity purification from erythroleukemia cells, reconstitution assays, immunoblotting analysis and peptide mapping show that the two major co-purified proteins are identical to human E4TF1-60 and -53 proteins. This reveals that E4TF1 can bind to the RBF-1 site of RB gene promoter, which, thus, constitutes a new target for this member of Ets transcription factors family.	KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; CHUGAI PHARMACEUT CO LTD,FUJI GOTEMBA RES LABS,GOTEMBA,SHIZUOKA 412,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	Kyoto Prefectural University of Medicine; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Tokyo Institute of Technology								BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; FISHER RJ, 1991, ONCOGENE, V6, P2249; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GABRIELSEN OS, 1989, NUCLEIC ACIDS RES, V17, P6253, DOI 10.1093/nar/17.15.6253; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MURAKAMI K, 1993, ONCOGENE, V8, P1559; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SLACK RS, 1993, ONCOGENE, V8, P1585; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATANABE H, 1990, EMBO J, V9, P841, DOI 10.1002/j.1460-2075.1990.tb08181.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WATANABE H, 1988, MOL CELL BIOL, V8, P190; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343	41	45	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1839	1846						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208529				2022-12-25	WOS:A1994NR68500005
J	DEGOLS, G; CLARENC, JP; LEBLEU, B; LEONETTI, JP				DEGOLS, G; CLARENC, JP; LEBLEU, B; LEONETTI, JP			REVERSIBLE INHIBITION OF GENE-EXPRESSION BY A PSORALEN FUNCTIONALIZED TRIPLE-HELIX FORMING OLIGONUCLEOTIDE IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA DAMAGE; CROSS-LINKING; GROUP-F; REPAIR; RECOGNITION; EXTRACTS; REMOVAL; RANGE	Triple helix formation of nucleic acids is the most rational approach to designing site-specific transcription inhibitors. To increase their efficiency reactive moieties such as psoralen or ethenocytosine have been introduced on the third strand. In transfected cells, these compounds induce a site specific covalent binding of the third strand to the targeted sequence and efficiently block RNA polymerases. However, the stability of this transcription inhibition has never been checked. We have designed a plasmid containing a triple helix binding site in the coding region of the beta-galactosidase reporter gene and a polymerase chain reaction assay to follow quantitatively the cross-link of a psoralenderivatized third strand in transfected cells. This assay has revealed that the cross-link was removed within a few hours, leading only to a transitory inhibition of gene expression. Central experiments in DNA repair-deficient cells suggest the implication of repair enzymes in this process.	CNRS,INST MOLEC GENET,F-34033 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier								BOERRIGTER METI, 1991, MUTAT RES, V255, P49, DOI 10.1016/0921-8777(91)90017-J; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CALSOU P, 1992, NUCLEIC ACIDS RES, V20, P6363, DOI 10.1093/nar/20.23.6363; DERVAN PB, 1992, NATURE, V359, P87, DOI 10.1038/359087a0; EVANS MK, 1993, J BIOL CHEM, V268, P4839; FRIEDBERG EC, 1985, DNA REPAIR, P213; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GOVAN HL, 1990, NUCLEIC ACIDS RES, V18, P3823, DOI 10.1093/nar/18.13.3823; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; HAVRE PA, 1993, P NATL ACAD SCI USA, V90, P7879, DOI 10.1073/pnas.90.16.7879; KALINOWSKI DP, 1992, NUCLEIC ACIDS RES, V20, P3485, DOI 10.1093/nar/20.13.3485; KRAWCZYK SH, 1992, P NATL ACAD SCI USA, V89, P3761, DOI 10.1073/pnas.89.9.3761; Maniatis T., 1982, MOL CLONING; MILLER PS, 1992, BIOCHEMISTRY-US, V31, P6788, DOI 10.1021/bi00144a020; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; NIELSEN PE, 1991, BIOCONJUGATE CHEM, V2, P1, DOI 10.1021/bc00007a001; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; REARDON JT, 1991, NUCLEIC ACIDS RES, V19, P4623, DOI 10.1093/nar/19.17.4623; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; TAKASUGI M, 1991, P NATL ACAD SCI USA, V88, P5602, DOI 10.1073/pnas.88.13.5602; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; VOS JMH, 1991, MOL CELL BIOL, V11, P2245, DOI 10.1128/MCB.11.4.2245; YAGI T, 1983, MUTAT RES, V112, P59, DOI 10.1016/0167-8817(83)90024-X; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	26	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16933	16937						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207016				2022-12-25	WOS:A1994NR29600063
J	NEUZIL, J; STOCKER, R				NEUZIL, J; STOCKER, R			FREE AND ALBUMIN-BOUND BILIRUBIN ARE EFFICIENT CO-ANTIOXIDANTS FOR ALPHA-TOCOPHEROL, INHIBITING PLASMA AND LOW-DENSITY-LIPOPROTEIN LIPID-PEROXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BLOOD-PLASMA; VITAMIN-E CONSUMPTION; AQUEOUS DISPERSIONS; SYNERGISTIC INHIBITION; HOMOGENEOUS SOLUTION; METHYL LINOLEATE; MODEL MEMBRANES; HEME OXYGENASE; HEART-DISEASE; BILE-PIGMENTS	Peroxidation of the lipid moieties of low density lipoproteins (LDL) is regarded as an early event in atherogenesis. Because bilirubin is a physiological reductant with antioxidant activities, we investigated its inhibitory action on the radical-mediated oxidation of LDL and plasma lipids. Exposing fresh human blood plasma to lipophilic peroxyl radicals generated from 2,2'-azobis(2,4-dimethylvaleronitrile) (AMVN) resulted in rapid oxidation of ubiquinol-10, followed by that of ascorbate and bilirubin. Plasma lipids were well protected from peroxidation as long as these three antioxidants were present, as assessed by the amounts of cholesterylester hydroperoxides formed during this period. Following consumption of these antioxidants, and in the presence of alpha-tocopherol, the rate of hydroperoxide formation increased sharply with roughly 2 molecules of cholesterylester hydroperoxides being formed for each peroxidation initiating event. Supplementation of AMVN-oxidizing plasma with exogenous bilirubin at the onset of rapid lipid peroxidation, i.e. after depletion of endogenous ubiquinol-10, ascorbate, and bilirubin, led to a halt in both hydroperoxide formation and consumption of alpha-tocopherol. When isolated LDL was incubated with AMVN, approximate to 9 molecules of cholesterylester hydroperoxides were formed per peroxidation initiating event and while alpha-tocopherol was consumed. Addition of free or albumin-bound bilirubin to isolated LDL at the onset of oxidation resulted in a strong inhibition of hydroperoxide formation and alpha-tocopherol consumption, the effect being more pronounced with the free pigment. Addition of the corresponding amounts of albumin alone was without effect. In the presence of albumin-bound bilirubin, some 30% of the pigment was initially converted into biliverdin, whereas formation of this oxidation product was not observed with the free pigment. Also, the presence of bilirubin oxidase partially reversed the inhibitory activity of bilirubin on AMVN-induced LDL oxidation in the absence but not presence of albumin. An attenuation of hydroperoxide formation and a temporary increase in LDL's alpha-tocopherol concentration were observed when free- or albumin-bound bilirubin were added to AMVN-oxidizing, alpha-tocopherol-containing LDL. In contrast, hydroperoxide formation was not inhibited significantly when the albumin-bound pigment was added to oxidizing LDL after complete consumption of its alpha-tocopherol. Our results show that bilirubin inhibits oxidation of LDL lipids initiated within the lipoprotein core and indicate that this activity is mediated by interaction of the pigment with LDL's alpha-tocopherol.	HEART RES INST,BIOCHEM GRP,CAMPERDOWN,NSW 2050,AUSTRALIA	University of Sydney; Heart Research Institute			Stocker, Roland/AAV-4489-2021; Neuzil, Jiri/H-7204-2014	Neuzil, Jiri/0000-0002-2478-2460				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; APPLEGATE LA, 1991, CANCER RES, V51, P974; BARCLAY LRC, 1984, J AM CHEM SOC, V106, P2479, DOI 10.1021/ja00320a066; BARCLAY LRC, 1987, CAN J CHEM, V65, P2541, DOI 10.1139/v87-423; BARCLAY LRC, 1990, BIOCHIM BIOPHYS ACTA, V1047, P255, DOI 10.1016/0005-2760(90)90524-2; BEHRENS WA, 1987, ANAL BIOCHEM, V165, P102, DOI 10.1016/0003-2697(87)90206-5; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOWRY VW, 1992, BIOCHEM J, V288, P341, DOI 10.1042/bj2880341; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; BRODERSEN R, 1979, Critical Reviews in Clinical Laboratory Sciences, V11, P305; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; BURTON GW, 1986, ACCOUNTS CHEM RES, V19, P194, DOI 10.1021/ar00127a001; CONSTANTINESCU A, 1993, J BIOL CHEM, V268, P10906; DAVIES MJ, 1988, BIOCHEM J, V255, P513; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1987, J LIPID RES, V28, P495; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FREI B, 1990, ADV EXP MED BIOL, V264, P155; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; GEY KF, 1991, AM J CLIN NUTR, V53, pS326, DOI 10.1093/ajcn/53.1.326S; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HOLLEY AE, 1991, FREE RADICAL RES COM, V15, P51, DOI 10.3109/10715769109049125; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; KAGAN VE, 1992, J LIPID RES, V33, P385; KIMURA M, 1990, P SOC EXP BIOL MED, V195, P64; MOHR D, 1992, BIOCHIM BIOPHYS ACTA, V1126, P247, DOI 10.1016/0005-2760(92)90237-P; MOHR D, 1994, IN PRESS ARTERIOSCLE; MOTOYAMA T, 1989, ARCH BIOCHEM BIOPHYS, V270, P655, DOI 10.1016/0003-9861(89)90548-1; MUKAI K, 1990, BIOCHIM BIOPHYS ACTA, V1035, P77, DOI 10.1016/0304-4165(90)90176-W; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; NEWMAN TB, 1992, PEDIATRICS, V89, P809; NIKI E, 1986, B CHEM SOC JPN, V59, P471, DOI 10.1246/bcsj.59.471; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUBIN BY, 1988, J IMMUNOL, V141, P1180; SATO K, 1990, ARCH BIOCHEM BIOPHYS, V279, P402, DOI 10.1016/0003-9861(90)90508-V; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SCHWERTNER HA, 1994, CLIN CHEM, V40, P18; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STOCKER R, 1990, METHOD ENZYMOL, V186, P301; STOCKER R, 1989, BIOCHIM BIOPHYS ACTA, V1002, P238, DOI 10.1016/0005-2760(89)90293-2; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; TSUCHIYA J, 1985, B CHEM SOC JPN, V58, P326, DOI 10.1246/bcsj.58.326; YAMAMOTO Y, 1984, B CHEM SOC JPN, V57, P1260, DOI 10.1246/bcsj.57.1260	56	403	417	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16712	16719						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206992				2022-12-25	WOS:A1994NR29600033
J	PHILLIPS, JE; COOPER, ST; POTTER, EE; CHURCH, FC				PHILLIPS, JE; COOPER, ST; POTTER, EE; CHURCH, FC			MUTAGENESIS OF RECOMBINANT PROTEIN-C INHIBITOR REACTIVE-SITE RESIDUES ALTERS TARGET PROTEINASE SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANTITHROMBIN-III; HEPARIN COFACTOR-II; BLOOD-COAGULATION; SEMINAL PLASMA; THROMBIN; EXPRESSION; ALPHA-1-ANTITRYPSIN; BINDING; SERPINS; PURIFICATION	Protein C inhibitor (PCI) is a heparin-binding plasma serine proteinase inhibitor (serpin) which is thought to be a physiological regulator of activated protein C. We are using recombinant PCI (rPCI) to study structural determinants of target proteinase specificity. A cDNA encoding full-length PCI has been expressed as a fully active proteinase inhibitor using Autographa californica nuclear polyhedrosis virus (baculovirus). rPCI was expressed maximally 4 days after infection and could be expressed either in Sf9 or High-Five(TM) cells. rPCI bound heparin and was conveniently purified with heparin-Sepharose (eluting >0.5 M NaCl). The rPCI formed sodium dodecyl sulfate-polyacrylamide gel electrophoresis-stable complexes with thrombin and activated protein C (APC). The inhibitory properties of wild-type rPCI and plasma-derived PCI are essentially the same either in the absence or presence of heparin with thrombin, APC, trypsin, and urokinase. The residues Phe(353)-Arg(354)-Ser(355) (P2-P1-P1') constitute part of the reactive site loop of PCI with the Arg-Ser peptide bond being cleaved by the proteinase. Using site-directed mutagenesis we studied the contribution of the reactive site FRS for proteinase inhibition in rPCI. Changing the P1 residue Arg(-354) --> Met generated a reactive site similar to alpha(1)-proteinase inhibitor which was a much poorer inhibitor of thrombin, APC, trypsin, and urokinase. Changing the P2 residue Phe(353) --> Gly generated a mutant with a reactive site like antithrombin which was better at inhibiting thrombin or urokinase, but was much less active with APC or trypsin. Changing the P1' residue Ser(355) --> Met generated a reactive site like plasminogen activator inhibitor-1 and this protein inhibits all the proteinases essentially like wild-type rPCI. These results show the importance of PCI's Phe(353) (P2) and Arg(-354) (P1) in target proteinase specificity, and they further support the concept of reactive site sequences determining serpin function.	UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,SCH MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NHLBI NIH HHS [HL-06530, F32-HL08413, 5T32-HL07149] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008413, T32HL007149] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; BODE W, 1992, PROTEIN SCI, V1, P426; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CUNNINGHAM DD, 1992, ADV EXP MED BIOL, V313, P297; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; ECKE S, 1992, J BIOL CHEM, V267, P7048; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON CT, 1991, THROMB HAEMOSTASIS, V66, P160; ESPANA F, 1991, BLOOD, V77, P1754; ESPANA F, 1991, THROMB RES, V64, P309, DOI 10.1016/0049-3848(91)90002-E; FURIE B, 1992, NEW ENGL J MED, V326, P800; GEIGER M, 1989, BLOOD, V74, P722; GEIGER M, 1991, J BIOL CHEM, V266, P11851; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; GILLESPIE LS, 1991, J BIOL CHEM, V266, P3995; HEEB MJ, 1990, J BIOL CHEM, V265, P2365; HEEB MJ, 1991, J BIOL CHEM, V266, P17606; HEEB MJ, 1988, J BIOL CHEM, V263, P11613; HEEB MJ, 1988, THROMB RES, V52, P33, DOI 10.1016/0049-3848(88)90038-2; HERMANS JM, 1993, BIOCHEM J, V295, P239, DOI 10.1042/bj2950239; HOOGENDOORN H, 1991, BLOOD, V78, P2283, DOI 10.1182/blood.V78.9.2283.bloodjournal7892283; HOOGENDOORN H, 1990, BLOOD, V75, P2164; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL M, 1992, J CLIN INVEST, V89, P1094, DOI 10.1172/JCI115689; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P4231, DOI 10.1021/bi00412a005; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PRATT CW, 1992, J BIOL CHEM, V267, P8795; PRATT CW, 1989, THROMB RES, V53, P595, DOI 10.1016/0049-3848(89)90149-7; PRATT CW, 1993, BLOOD COAGUL FIBRIN, V4, P479, DOI 10.1097/00001721-199306000-00013; PRATT CW, 1992, J BIOL CHEM, V267, P8789; RAGG H, 1988, J BIOL CHEM, V263, P12129; REZAIE AR, 1993, J BIOL CHEM, V268, P19943; ROBERTS HR, 1992, HOSP PRACT, V27, P97; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCULLY MF, 1993, THROMB HAEMOSTASIS, V69, P448; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHIEH BH, 1987, J BIOL CHEM, V262, P6055; STEPHENS AW, 1988, J BIOL CHEM, V263, P15849; STEPHENS AW, 1987, P NATL ACAD SCI USA, V84, P3886, DOI 10.1073/pnas.84.11.3886; STONE SR, 1985, BIOCHEM J, V230, P497, DOI 10.1042/bj2300497; SUZUKI K, 1989, THROMB HAEMOSTASIS, V61, P337; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI K, 1983, J BIOL CHEM, V258, P163; TOLLEFSEN DM, 1992, ADV EXP MED BIOL, V313, P167; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WASLEY LC, 1987, J BIOL CHEM, V262, P14766; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; YORK JD, 1991, J BIOL CHEM, V266, P8495	60	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16696	16700						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206990				2022-12-25	WOS:A1994NR29600030
J	AHMED, SA; MILES, EW				AHMED, SA; MILES, EW			ALIPHATIC-ALCOHOLS STABILIZE AN ALTERNATIVE CONFORMATION OF THE TRYPTOPHAN SYNTHASE ALPHA(2)BETA(2) COMPLEX FROM SALMONELLA-TYPHIMURIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET FACTOR-IV; ESCHERICHIA-COLI; BETA-SUBUNIT; ORGANIC-SOLVENTS; ALPHA; IDENTIFICATION; ASSOCIATION; PROTEINS; CLEAVAGE; SITE	The conformational changes that accompany association of the tryptophan synthase alpha and beta(2) s are probed by investigating the effects of solvents on the catalytic and spectroscopic properties of tryptophan synthase. Low concentrations of ethanol, propanol, and butanol inhibit conversion of L-serine and indole to L-tryptophan by the alpha(2) beta(2) complex. Inhibition depends on the concentration, chain length, and hydrophobicity of the alcohol. In contrast, these alcohols increase the rates of conversion of beta-chloro-L-alanine and indole to L-tryptophan and of L-serine to pyruvate. Thus, alcohols alter the substrate specificity and reaction specificity of the alpha(2) beta(2) complex. These altered specificities are similar to those of the free beta(2) subunit in aqueous solution. The spectroscopic properties of enzyme-substrate intermediates formed by the alpha(2) beta(2) complex in 3 M ethanol and 0.5 M 1-butanol also resemble the intermediates formed by the free beta(2) subunit in aqueous solution. Experiments using gel-filtration, membrane ultrafiltration, and limited proteolysis show that the alpha(2) beta(2) complex does not dissociate at low concentrations of alcohols. Our results provide evidence that alcohols can stabilize an alternative conformation of the alpha(2) beta(2) complex which is similar to the open conformation of the free beta(2) aqueous solution.			AHMED, SA (corresponding author), NIDDK, BIOCHEM PHARMACOL LAB, BLDG 8, RM 2A-05, BETHESDA, MD 20892 USA.							AHMED SA, 1986, BIOCHEMISTRY-US, V25, P4233, DOI 10.1021/bi00363a010; AHMED SA, 1986, BIOCHEMISTRY-US, V25, P3118, DOI 10.1021/bi00359a008; AHMED SA, 1991, J BIOL CHEM, V266, P21548; AHMED SA, 1992, J BIOL CHEM, V267, P23309; CONIO G, 1970, J BIOL CHEM, V245, P3335; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; DOUZOU P, 1984, ADV PROTEIN CHEM, V36, P245, DOI 10.1016/S0065-3233(08)60299-5; DREYFUS M, 1978, FEBS LETT, V95, P185, DOI 10.1016/0014-5793(78)80080-5; FINK AL, 1986, CRYOBIOLOGY, V23, P28, DOI 10.1016/0011-2240(86)90015-5; GILLILAND GL, 1984, METHOD ENZYMOL, V104, P370; GOLDBERG ME, 1967, BIOCHEMISTRY-US, V6, P2113, DOI 10.1021/bi00859a032; HIGGINS W, 1979, BIOCHEMISTRY-US, V18, P4827, DOI 10.1021/bi00589a010; HOGBERGRAIBAUD A, 1977, BIOCHEMISTRY-US, V16, P4014, DOI 10.1021/bi00637a012; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; LAANE C, 1987, BIOTECHNOL BIOENG, V30, P81, DOI 10.1002/bit.260300112; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1978, J BIOL CHEM, V253, P6266; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1968, BIOCHEMISTRY-US, V7, P2742, DOI 10.1021/bi00848a008; MILES EW, 1991, INT UNION B, V199, P249; PARODI RM, 1973, J BIOL CHEM, V248, P4047; SAKURAI T, 1988, J AM CHEM SOC, V110, P7236, DOI 10.1021/ja00229a061; SINGH TJ, 1979, J BIOL CHEM, V254, P8466; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; YANG YQ, 1993, BIOCHEMISTRY-US, V32, P8661, DOI 10.1021/bi00084a038; YANG YQ, 1993, J BIOL CHEM, V268, P9223; Yanofsky C., 1972, ENZYMES, P1, DOI [10.1016/s1874-6047(08)60445-x, DOI 10.1016/S1874-6047(08)60445-X]	32	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16486	16492						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206958				2022-12-25	WOS:A1994NQ72900079
J	ANGLESON, JK; WENSEL, TG				ANGLESON, JK; WENSEL, TG			ENHANCEMENT OF ROD OUTER SEGMENT GTPASE ACCELERATING PROTEIN-ACTIVITY BY THE INHIBITORY SUBUNIT OF CGMP PHOSPHODIESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; PHOTORECEPTOR G-PROTEIN; BOVINE RETINAL RODS; BINDING-SITES; ALPHA-SUBUNIT; CONFORMATIONAL-CHANGES; ACTIVATION MECHANISM; VISUAL TRANSDUCTION; RHODOPSIN; MEMBRANES	The cGMP phosphodiesterase (PDE) of retinal rod outer segments (ROS) is activated by the GTP-bound form of the G protein, transducin (G(t alpha) ). This activation can be reversed by the inhibitory gamma subunit of PDE through two distinct mechanisms: acceleration of GTP hydrolysis and direct inactivation independent of GTP hydrolysis. We have found that acceleration of G(t alpha) GTPase by PDE(gamma) does not occur upon formation of a G(t alpha)-PDE(gamma) complex but rather reflects enhanced activity toward this complex of a membrane-bound GTPase accelerating protein. GTPase rate constants for G(t alpha) in the presence of 3.3 mu M PDE(gamma) were as high as 0.7 s(-1) with hypotonically washed ROS membranes at 40 mu M rhodop sin but were more than 10-fold lower when protein-free vesicles containing ROS lipids were substituted for ROS membranes. Acceleration of G(t alpha) GTPase by PDE(gamma) was also barely detectable at low ROS concentrations (e.g. 4 mu M rhodopsin) or if ROS treated with trypsin or urea were used. GTPase-independent inactivation by PDE(gamma) occurred efficiently at much lower membrane concentrations. Inhibition of G(t alpha)-activated PDE was much slower than inhibition of PDE(alpha beta) by PDE(gamma). Effects of PDE(gamma) upon successive additions of GTP suggested formation of a complex of PDE(gamma) and G(t alpha)-GDP that is refractory to reactivation.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07981, EY07001] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANTONNY B, 1993, BIOCHEMISTRY-US, V32, P8646, DOI 10.1021/bi00084a036; ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1993, INVEST OPHTH VIS SCI, V34, P1068; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CLERC A, 1992, J BIOL CHEM, V267, P6620; COTE RH, 1993, J BIOL CHEM, V268, P17190; DEGRIP WJ, 1979, BIOCHIM BIOPHYS ACTA, V558, P330, DOI 10.1016/0005-2736(79)90269-4; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; ERICKSON MA, 1992, SCIENCE, V257, P1255, DOI 10.1126/science.1519062; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GRAYKELLER MP, 1990, J BIOL CHEM, V265, P15323; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; HODGKIN AL, 1988, J PHYSIOL-LONDON, V403, P439, DOI 10.1113/jphysiol.1988.sp017258; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; KAHLERT M, 1991, BIOPHYS J, V59, P375, DOI 10.1016/S0006-3495(91)82231-7; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; KUHN H, 1981, P NATL ACAD SCI-BIOL, V78, P6873, DOI 10.1073/pnas.78.11.6873; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PAGES F, 1992, J BIOL CHEM, V267, P22018; PAGES F, 1993, J BIOL CHEM, V268, P26358; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; STRYER L, 1991, J BIOL CHEM, V266, P10711; TYMINSKI PN, 1984, BIOCHEMISTRY-US, V23, P3986, DOI 10.1021/bi00312a028; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1993, J BIOL CHEM, V268, P8899; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; ZERA E, 1993, BIOPHYS J, V64, pA383	52	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16290	16296						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206935				2022-12-25	WOS:A1994NQ72900053
J	JAIN, RG; RUSCH, SL; KENDALL, DA				JAIN, RG; RUSCH, SL; KENDALL, DA			SIGNAL PEPTIDE CLEAVAGE REGIONS - FUNCTIONAL LIMITS ON LENGTH AND TOPOLOGICAL IMPLICATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; ESCHERICHIA-COLI; ALKALINE-PHOSPHATASE; PROTEIN EXPORT; NUCLEOTIDE-SEQUENCE; PLASMA-MEMBRANE; WILD-TYPE; SITE; CONFORMATION; SECRETION	As a first step toward understanding the topology of the signal peptide with respect to the membrane during the protein export process, we have examined the constraints on the length of the cleavage region needed to achieve signal peptidase recognition and cleavage. Using the signal peptide of Escherichia coli alkaline phosphatase, a series of cleavage region mutants has been constructed. Variations in length were brought about by replacing the wild type cleavage region of the signal peptide with polymers of increasingly more residues. In each case, alanine residues are used exclusively in the -1 and -3 positions to provide only one viable cleavage site. Glutamine residues are used in all other positions in order to vary the length from 3 to 13 total residues. Analysis of these mutants revealed that cleavage regions ranging from 3 to 9 residues are completely and efficiently processed. The extent of processing drops substantially thereafter, with no processing observed for signal peptides with 13-residue long cleavage regions. A second mutant with a 13-residue long cleavage region was designed and analyzed to ensure that the lack of processing reflected a cleavage problem and not a translocation defect. The results are consistent with the notion that the signal peptidase active site is in close proximity to the periplasmic surface of the inner membrane and that interaction of the cleavage region with the signal peptidase probably depends on, and is constrained by, other interactions involving the signal peptide.	UNIV CONNECTICUT,DEPT MOLEC & CELL BIOL,STORRS,CT 06269	University of Connecticut					NIGMS NIH HHS [GM37639] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037639] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BILGIN N, 1990, EMBO J, V9, P2717, DOI 10.1002/j.1460-2075.1990.tb07458.x; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; Boyd D, 1987, PHOSPHATE METABOLISM, P89; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; BRIGGS MS, 1984, BIOCHEMISTRY-US, V23, P3111, DOI 10.1021/bi00309a001; BRUCH MD, 1989, BIOCHEMISTRY-US, V28, P8554, DOI 10.1021/bi00447a043; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; EBELING W, 1974, EUR J BIOCHEM, V47, P91, DOI 10.1111/j.1432-1033.1974.tb03671.x; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FIKES JD, 1990, J BIOL CHEM, V265, P3417; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; HALL MN, 1983, EMBO J, V2, P15, DOI 10.1002/j.1460-2075.1983.tb01373.x; INNIS MA, 1984, P NATL ACAD SCI-BIOL, V81, P3708, DOI 10.1073/pnas.81.12.3708; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFORET GA, 1991, J BIOL CHEM, V266, P1326; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; LI SC, 1993, J BIOL CHEM, V268, P22975; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHAELIS S, 1986, J BACTERIOL, V167, P160, DOI 10.1128/jb.167.1.160-167.1986; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J.H., 1972, EXPT MOL GENETICS; MOORE KE, 1987, J BIOL CHEM, V262, P8806; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NILSSON IM, 1991, J BIOL CHEM, V266, P3408; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P17202; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; ROSENBLATT M, 1980, P NATL ACAD SCI-BIOL, V77, P3983, DOI 10.1073/pnas.77.7.3983; RUSCH SL, 1992, J MOL BIOL, V224, P77, DOI 10.1016/0022-2836(92)90577-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schneider Gisbert, 1993, Protein Sequences and Data Analysis, V5, P227; SHINNAR AE, 1984, J AM CHEM SOC, V106, P5006, DOI 10.1021/ja00329a063; SUNG M, 1992, J BIOL CHEM, V267, P13154; VLASUK GP, 1984, J BIOL CHEM, V259, P6195; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; YU F, 1984, FEBS LETT, V173, P264, DOI 10.1016/0014-5793(84)81060-1; ZWIZINSKI C, 1981, J BIOL CHEM, V256, P3593	53	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16305	16310						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206936				2022-12-25	WOS:A1994NQ72900055
J	WHEELAN, P; ZIRROLLI, JA; MORELLI, JG; MURPHY, RC				WHEELAN, P; ZIRROLLI, JA; MORELLI, JG; MURPHY, RC			METABOLISM OF LEUKOTRIENE-B(4) BY CULTURED HUMAN KERATINOCYTES - FORMATION OF GLUTATHIONE CONJUGATES AND DIHYDRO METABOLITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; IONIZATION MASS-SPECTROMETRY; ISOLATED RAT HEPATOCYTES; OMEGA-OXIDATION; ARACHIDONIC-ACID; HUMAN-LUNG; IDENTIFICATION; CELLS; DIHYDRO-LEUKOTRIENE-B4; PATHWAY	Six previously unidentified leukotriene (LT) B4 metabolites formed during incubation of LTB4 with human keratinocytes in primary culture indicate the importance of the 12-hydroxyeicosanoid dehydrogenase pathway in LTB4 metabolism. The ultraviolet absorption spectra obtained for all keratinocyte metabolites revealed the presence of a conjugated diene structural moiety rather than the conjugated triene structure of LTB4. Metabolites were characterized using fast atom bombardment-mass spectrometry, gas chromatography-mass spectrometry of the pentafluorobenzyl ester, trimethylsilyl ether derivatives and specific degradation reactions. The previously identified 10,11-dihydro-LTB4 and 10,11-dihydro-12-epi-LTB4 were observed as well as 20-OH-10,11-dihydro-LTB4, consistent with the reductase pathway of LTB4 metabolism. This pathway involves initial formation of 12-oxo-LTB4-catalyzed by 12-hydroxyeicosanoid dehydrogenase followed by reduction by DELTA10-reductase. The most lipophilic metabolite of LTB4 was identified as 10-hydroxy-4,6,12-octadecatrienoic acid which could result from beta-oxidation reactions of LTB4 following reduction of the 10,11-double bond. One of the most abundant metabolites was characterized as 3,7,14-trihydroxy-8,10,16-docosatrienoic acid which could result from fatty acid elongation following reduction of the 10,11-double bond. Additional abundant LTB4 metabolites were identified that result from glutathione conjugation of 12-oxo-LTB4. These were characterized using fast atom bombardment-mass spectrometry and by chemical degradation using hypochlorous acid as well as transpeptidases. These metabolites were identified as 5,12-dihydroxy-6-glutathionyl-7,9,14-eicosatrienoic acid (c-LTB3), 5,12-dihydroxy-6-cysteinyl-glycyl-7,9,14-eicosatrienoic acid (d-LTB3), and 5,12-dihydroxy-6-cysteinyl-7,9,14-eicosatrienoic acid (eLTB3). We propose that these metabolites result from a 1,8 Michael-type addition of glutathione to the 12-oxo-LTB4 intermediate.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, 1400 JACKSON ST, DENVER, CO 80206 USA; UNIV COLORADO, SCH MED, DEPT DERMATOL, DENVER, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NHLBI NIH HHS [HL25785] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL025785, R01HL025785] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS J, 1989, J AM CHEM SOC, V111, P435, DOI 10.1021/ja00184a004; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; ATSMON J, 1990, CANCER RES, V50, P1879; ATSMON J, 1990, BIOCHEMISTRY-US, V29, P3760, DOI 10.1021/bi00467a023; BLAIR IA, 1990, METHOD ENZYMOL, V187, P13; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; BRAIN S, 1984, J INVEST DERMATOL, V83, P70, DOI 10.1111/1523-1747.ep12261712; CAGEN LM, 1976, J BIOL CHEM, V251, P6550; CAMP RDR, 1982, PROSTAGLANDINS, V23, P631, DOI 10.1016/S0090-6980(82)80003-8; CHAN CC, 1985, J INVEST DERMATOL, V85, P333, DOI 10.1111/1523-1747.ep12276933; CHAUDHARI A, 1978, BIOCHIM BIOPHYS ACTA, V531, P56, DOI 10.1016/0005-2760(78)90181-9; DELACLOS BF, 1993, BIOL MASS SPECTROM, V22, P9, DOI 10.1002/bms.1200220103; FAULER J, 1989, PROSTAG LEUKOTR ESS, V37, P193, DOI 10.1016/0952-3278(89)90085-9; FORDHUTCHINSON AW, 1983, PROSTAGLANDINS, V25, P29, DOI 10.1016/0090-6980(83)90132-6; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; HADJIAGAPIOU C, 1987, PROSTAG OTH LIPID M, V34, P579, DOI 10.1016/0090-6980(87)90100-6; HARPER TW, 1986, J BIOL CHEM, V261, P5414; HEAVEY DJ, 1987, PROSTAG OTH LIPID M, V33, P693, DOI 10.1016/0090-6980(87)90035-9; IVERSEN L, 1993, J INVEST DERMATOL, V100, P293, DOI 10.1111/1523-1747.ep12469865; JUBIZ W, 1982, J BIOL CHEM, V257, P6106; KAEVER V, 1987, BIOCHIM BIOPHYS ACTA, V922, P337, DOI 10.1016/0005-2760(87)90056-7; KAEVER V, 1988, FEBS LETT, V231, P385, DOI 10.1016/0014-5793(88)80855-X; KAEVER V, 1990, LIFE SCI, V46, P1465, DOI 10.1016/0024-3205(90)90463-2; KRAGBALLE K, 1985, BRIT J DERMATOL, V113, P43, DOI 10.1111/j.1365-2133.1985.tb02043.x; KRAGBALLE K, 1983, J INVEST DERMATOL, V81, P293; KUMLIN M, 1990, BIOCHEM BIOPH RES CO, V170, P23, DOI 10.1016/0006-291X(90)91235-K; LEE CW, 1982, P NATL ACAD SCI-BIOL, V79, P4166, DOI 10.1073/pnas.79.13.4166; MEDRANO EE, 1993, P NATL ACAD SCI USA, V90, P1790, DOI 10.1073/pnas.90.5.1790; MORELLI JG, 1990, J INVEST DERMATOL, V94, P681, DOI 10.1111/1523-1747.ep12876260; MORELLI JG, 1992, J INVEST DERMATOL, V98, P55, DOI 10.1111/1523-1747.ep12494602; MORELLI JG, 1992, J INVEST DERMATOL, V98, P290, DOI 10.1111/1523-1747.ep12497951; MORELLI JG, 1989, J INVEST DERMATOL, V93, P719, DOI 10.1111/1523-1747.ep12284392; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; MUKHTAR H, 1989, J INVEST DERMATOL, V93, P231, DOI 10.1111/1523-1747.ep12277578; PIPER PJ, 1989, LEUKOTRIENES CHEM BI, P215; POWELL WS, 1987, BIOCHEM BIOPH RES CO, V145, P991, DOI 10.1016/0006-291X(87)91533-6; POWELL WS, 1989, J BIOL CHEM, V264, P5364; RAFTERY MJ, 1990, BIOMED ENVIRON MASS, V19, P465, DOI 10.1002/bms.1200190804; SALA A, 1991, J AM SOC MASS SPECTR, V2, P314, DOI 10.1016/1044-0305(91)80023-Z; SCHONFELD W, 1988, IMMUNOLOGY, V65, P529; SHAK S, 1985, J CLIN INVEST, V76, P1218, DOI 10.1172/JCI112077; SHAK S, 1984, J BIOL CHEM, V259, P181; SHIRLEY MA, 1990, J BIOL CHEM, V265, P16288; SHIRLEY MA, 1992, J AM SOC MASS SPECTR, V3, P762, DOI 10.1016/1044-0305(92)87090-L; Smith W L, 1990, Methods Enzymol, V187, P1; SODERSTROM M, 1988, BIOCHEM J, V250, P713, DOI 10.1042/bj2500713; STRIFE RJ, 1984, J CHROMATOGR, V305, P3, DOI 10.1016/S0378-4347(00)83309-5; WAINWRIGHT S, 1990, BIOCHEMISTRY-US, V29, P1180, DOI 10.1021/bi00457a013; WAINWRIGHT SL, 1991, J BIOL CHEM, V266, P20899; WHEELAN P, 1993, BIOL MASS SPECTROM, V22, P465, DOI 10.1002/bms.1200220808; WHEELAN P, 1992, 40TH P ASMS C MASS S, P1077; YOHN JJ, 1993, J INVEST DERMATOL, V100, P23, DOI 10.1111/1523-1747.ep12349932	52	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25439	25448						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244977				2022-12-25	WOS:A1993MK10000027
J	MYERS, RW; WRAY, JW; FISH, S; ABELES, RH				MYERS, RW; WRAY, JW; FISH, S; ABELES, RH			PURIFICATION AND CHARACTERIZATION OF AN ENZYME INVOLVED IN OXIDATIVE CARBON-CARBON BOND-CLEAVAGE REACTIONS IN THE METHIONINE SALVAGE PATHWAY OF KLEBSIELLA-PNEUMONIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-METHYLTHIORIBOSE KINASE; 5'-METHYLTHIOADENOSINE; CONVERSION; 5'-DEOXY-5'-METHYLTHIOADENOSINE; 5'-S-METHYLTHIOADENOSINE; IDENTIFICATION; METABOLISM	The 5-methylthio-D-ribose moiety of 5'-(methylthio)-adenosine is converted to methionine in a wide variety of organisms. 2,3-Diketo-5-methylthio-1-phosphopentane is an advanced intermediate in the methionine recycling pathway present in the Gram-negative bacterium Klebsiella pneumoniae. This unusual metabolite is oxidatively cleaved to yield formate (from C-1), 2-keto-4-methylthiobutyrate (the transamination product of methionine), and 3-methylthiopropionate. To further characterize this oxidative conversion, the desthio analog of the naturally occurring diketone, namely 2,3-diketo-1-phosphohexane I, was synthesized. If the metabolism of I is analogous to that of 2,3-diketo-5-methylthio-1-phosphopentane it should be converted to formate, 2-ketopentanoate, and butyrate. An enzyme (E-1), which mediates the oxidative conversion of I to formate and 2-ketopentanoate, was isolated from extracts of K. pneumoniae. E-1 was purified 100-fold to homogeneity in 10% yield. The native enzyme is a monomeric protein of M(r) 27,000. The activity of E-1 requires magnesium ion as a cofactor. No other prosthetic groups were detected. Incubation of the enzyme with I, under anaerobic conditions, led to the discovery of two intermediates. These species have been identified by H-1 and C-13 NMR, UV-visible spectroscopy, and model chemistry studies as 2-hydroxy-3-keto-1-phospho-1-hexene II, generated by enolization of I; and 1,2-dihydroxy-3-keto-1-hexene III, generated by enzymatic dephosphorylation of II. Intermediates II and III are released from the active site of the enzyme; III accumulates under anaerobic conditions. Under aerobic conditions, III is non-enzymically oxidized to 2-ketopentanoate, formate, and other products. Compound II was also generated by heating I at pH 7.5 for 7 min. Action of alkaline phosphatase on II produces III.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM PARASITOL,RAHWAY,NJ 07065; BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Merck & Company; Brandeis University								BACKLUND PS, 1981, J BIOL CHEM, V256, P1533; BACKLUND PS, 1982, J BIOL CHEM, V257, P4196; BERGMEYER HU, 1990, METHOD ENZYMAT AN, V1, P470; DUERRE JA, 1962, J BIOL CHEM, V237, P3737; FERRO AJ, 1978, J BIOL CHEM, V253, P6021; FERRO AJ, 1976, BIOCHIM BIOPHYS ACTA, V438, P487, DOI 10.1016/0005-2744(76)90264-3; FURFINE ES, 1988, J BIOL CHEM, V263, P9598; GHODA LY, 1984, J BIOL CHEM, V259, P6715; GIANOTTI AJ, 1990, J BIOL CHEM, V265, P831; KUSHAD MM, 1983, PLANT PHYSIOL, V73, P257, DOI 10.1104/pp.73.2.257; MARCHITTO KS, 1985, J GEN MICROBIOL, V131, P2153; MYERS RW, 1990, J BIOL CHEM, V265, P16913; MYERS RW, 1989, J BIOL CHEM, V264, P10547; SCHLENK F, 1983, ADV ENZYMOL RAMB, V54, P195; SHAPIRO SK, 1980, BIOCHIM BIOPHYS ACTA, V633, P176, DOI 10.1016/0304-4165(80)90403-1; SHAPIRO SK, 1981, BIOCHEM BIOPH RES CO, V102, P302, DOI 10.1016/0006-291X(81)91521-7; SUGIMOTO Y, 1976, ARCH MICROBIOL, V108, P175, DOI 10.1007/BF00428948; TRACKMAN PC, 1981, BIOCHEM BIOPH RES CO, V103, P1238, DOI 10.1016/0006-291X(81)90255-2; TRACKMAN PC, 1983, J BIOL CHEM, V258, P6717; WANG SY, 1982, PLANT PHYSIOL, V70, P117, DOI 10.1104/pp.70.1.117; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; YUNG KH, 1982, BIOCHEM BIOPH RES CO, V104, P771, DOI 10.1016/0006-291X(82)90704-5	22	65	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24785	24791						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227039				2022-12-25	WOS:A1993MG67300042
J	RAMACHANDRAN, B; HOUBEN, K; ROZENBERG, YY; HAIGH, JR; VARPETIAN, A; HOWARD, BD				RAMACHANDRAN, B; HOUBEN, K; ROZENBERG, YY; HAIGH, JR; VARPETIAN, A; HOWARD, BD			DIFFERENTIAL EXPRESSION OF TRANSPORTERS FOR NOREPINEPHRINE AND GLUTAMATE IN WILD-TYPE, VARIANT, AND WNT1-EXPRESSING PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; SENSITIVE DOPAMINE TRANSPORTER; PHEOCHROMOCYTOMA CELLS; RAT-BRAIN; NEURONAL DIFFERENTIATION; FUNCTIONAL-CHARACTERIZATION; POSSIBLE INVOLVEMENT; GLYCINE TRANSPORTER; INT-1 PROTOONCOGENE; MEMBRANE-VESICLES	Wild type PC12 pheochromocytoma cells express a Na+-dependent norepinephrine transporter that operates in the uptake of catecholamines, including dopamine. This transporter is not expressed in two spontaneously occurring flat cell variants of PC12 or in two other flat cell variants whose phenotype was induced by expression of the Wnt-1 oncogene. However, each of the flat cell variants, including those that express Wnt-1, exhibit a Na+-dependent, Cl--independent glutamate/aspartate transporter activity that is not present in wild type PC12 cells. The flat cell variants took up glycine by a Na+-dependent process as well as did wild type cells. All of the flat cell variants have decreased levels of norepinephrine transporter mRNA but normal levels of glycine transporter mRNA. Glutamate/aspartate transporter mRNA was detected only in the variants that exhibited glutamate/aspartate transporter activity, and the nucleotide sequence of a partial glutamate/aspartate transporter cDNA from these cells demonstrated that it was the glial form of the transporter that was expressed. These variants were more sensitive than was wild type PC12 to alanosine, a toxic aspartate analog that enters cells by a transporter-mediated system such as the glutamate/aspartate transporter; however, these variants were as sensitive as wild type cells to another toxic aspartate analog, N-(phosphonacetyl)-L-aspartic acid, which is believed to enter cells by endocytosis. We suggest that the Wnt-1 gene product, or a homolog, may be involved in glial differentiation and that the mechanisms that alter the expression of the norepinephrine and glutamate/aspartate transporters in wild type and variant PC12 cells may also operate to regulate neurotransmitter transporter expression in vivo.			RAMACHANDRAN, B (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038633, R37MH038633] Funding Source: NIH RePORTER; NIMH NIH HHS [MH38633] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANANDARAJ SJ, 1980, BIOCHEM PHARMACOL, V29, P227, DOI 10.1016/0006-2952(80)90333-0; ANDERSEN JK, 1990, J NEUROCHEM, V55, P559, DOI 10.1111/j.1471-4159.1990.tb04170.x; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BANNON MJ, 1992, P NATL ACAD SCI USA, V89, P7095, DOI 10.1073/pnas.89.15.7095; BITLER CM, 1986, J NEUROCHEM, V47, P1286; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI DW, 1992, SCIENCE, V258, P241, DOI 10.1126/science.1357748; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; DENTON T, 1987, J NEUROCHEM, V49, P622, DOI 10.1111/j.1471-4159.1987.tb02909.x; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1977, BRAIN RES, V129, P247, DOI 10.1016/0006-8993(77)90005-1; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; Iversen L L, 1970, Adv Biochem Psychopharmacol, V2, P109; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KOIDE M, 1986, J NEUROCHEM, V47, P1277; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1992, CELL, V69, P103; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHNEIDER EG, 1980, J BIOL CHEM, V255, P7650; Schousboe A, 1981, Int Rev Neurobiol, V22, P1, DOI 10.1016/S0074-7742(08)60289-5; SHACKLEFORD GM, 1993, IN PRESS NEURON; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SIPS HJ, 1982, EUR J BIOCHEM, V122, P259, DOI 10.1111/j.1432-1033.1982.tb05875.x; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SUGIMOTO Y, 1988, J BIOL CHEM, V263, P12102; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TYAGI AK, 1984, ADV PHARMACOL CHEMOT, V20, P69, DOI 10.1016/S1054-3589(08)60265-3; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; WHITE JC, 1984, CANCER RES, V44, P507	50	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23891	23897						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226929				2022-12-25	WOS:A1993MF29400031
J	WRENN, CK; KATZENELLENBOGEN, BS				WRENN, CK; KATZENELLENBOGEN, BS			STRUCTURE-FUNCTION ANALYSIS OF THE HORMONE-BINDING DOMAIN OF THE HUMAN ESTROGEN-RECEPTOR BY REGION-SPECIFIC MUTAGENESIS AND PHENOTYPIC SCREENING IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL ACTIVATION; BREAST-CANCER-CELLS; ZINC FINGER REGION; SACCHAROMYCES-CEREVISIAE; STEROID-RECEPTORS; DNA-BINDING; ANTIESTROGEN; EXPRESSION; PROMOTER; IDENTIFICATION	To investigate the structural requirements for recognition and response to ligands by the human estrogen receptor (hER), a series of point mutations were generated in the hormone binding domain (HBD) of the receptor using a limited formic acid treatment of its cDNA. Receptors having a reduced sensitivity to the estrogen, 17beta-estradiol (E2), or to the antiestrogen, trans-hydroxytamoxifen, were selected from a library of intact hER cDNAs containing these mutant HBDs by expression and phenotypic screening in yeast (Saccharomyces cerevisiae). Several were sequenced, and the encoded receptors were characterized in both yeast and mammalian (Chinese hamster ovary) cells using hormone-binding and transactivation assays. In general, parallel phenotypes were observed in yeast and in Chinese hamster ovary cells following estrogen exposure. We report on 15 receptors having point mutations located at various positions throughout the HBD. Four categories of mutants were identified: 1) those showing no change from wild type in their response to E2; 2) those showing a greatly reduced transactivation response over the range of ligand concentrations tested; 3) those requiring much higher concentrations of E2 for maximal transactivation, indicating a reduced sensitivity to ligand; and 4) those showing reduced response to E2, but little change in response to trans-hydroxytamoxifen in yeast. Two mutations in the carboxyl terminus of the HBD eliminated hormone-dependent transactivation despite the continued ability to bind E2 with high affinity. Therefore, our results show a separation of the transactivation and hormone-binding functions of the hER, and indicate that the integrity of many regions throughout the large, approximately 250-amino acid HBD is important for these functions. Our studies also demonstrate the advantages of using regional mutagenesis combined with phenotypic screening in yeast to complement site-directed mutagenesis when investigating a large, functionally complex region.	UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,URBANA,IL 61801; UNIV ILLINOIS,COLL MED,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NCI NIH HHS [CA18119] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA018119, R01CA018119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; CHANG TC, 1990, J BIOL CHEM, V265, P8176; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; ECKERT RL, 1982, J BIOL CHEM, V257, P8840; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; GARABEDIAN MJ, 1992, MOL BIOL CELL, V3, P1245, DOI 10.1091/mbc.3.11.1245; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Ham J, 1989, CURR OPIN CELL BIOL, V1, P503, DOI 10.1016/0955-0674(89)90012-4; HARLOW KW, 1989, J BIOL CHEM, V264, P17476; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LYTTLE CR, 1992, J STEROID BIOCHEM, V42, P677, DOI 10.1016/0960-0760(92)90108-U; MCDONNELL DP, 1991, J STEROID BIOCHEM, V39, P291, DOI 10.1016/0960-0760(91)90038-7; MCDONNELL DP, 1992, P NATL ACAD SCI USA, V89, P10563, DOI 10.1073/pnas.89.22.10563; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; PAKDEL F, 1992, J BIOL CHEM, V267, P3429; PHAM TA, 1991, P NATL ACAD SCI USA, V88, P3125, DOI 10.1073/pnas.88.8.3125; REESE JC, 1992, J BIOL CHEM, V267, P9868; REESE JC, 1992, MOL ENDOCRINOL, V6, P2160, DOI 10.1210/me.6.12.2160; REESE JC, 1991, J BIOL CHEM, V266, P10880; Sambrook J, 1989, MOL CLONING LABORATO; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	37	172	175	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24089	24098						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226955				2022-12-25	WOS:A1993MF29400059
J	JUNG, M; JUST, I; VANDAMME, J; VANDEKERCKHOVE, J; AKTORIES, K				JUNG, M; JUST, I; VANDAMME, J; VANDEKERCKHOVE, J; AKTORIES, K			NAD-BINDING SITE OF THE C3-LIKE ADP-RIBOSYLTRANSFERASE FROM CLOSTRIDIUM-LIMOSUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-GENE-PRODUCT; BOTULINUM TYPE-C; DIPHTHERIA-TOXIN; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; STAPHYLOCOCCUS-AUREUS; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE; EXOTOXIN-A; PROTEIN	Treatment of the Rho-ADP-ribosylating C3-like transferase from Clostridium limosum by ultraviolet irradiation in the presence of [carbonyl-C-14]NAD incorporated 1 mol of label/mol of exoenzyme. Concomitantly, the transferase and NAD glycohydrolase activity was impaired. A peptide containing the radiolabel was obtained by proteolysis with either staphylococcal protease V8 or trypsin. Their amino acid sequences were Ala/Asp-Gly-Tyr-Ile-Glu-Pro-Ile-Ser-Thr-Phe-Lys-Gly-Gln-Leu-X-Val-Leu-Leu-Pro-Arg and Gly-Gln-Leu-X-Val-Leu-Leu-Pro-Arg, respectively. These sequences correspond with regions Ala-160 through Arg-179 and Gly-171 through Arg-179, respectively, of the very similar Clostridium botulinum C3 transferase, with X being Glu in the unlabeled enzyme. This identifies the glutamic acid residue that corresponds to Glu-174 of C. botulinum C3 transferase as part of the NAD-binding site of the catalytic center of the C. limosum exoenzyme.	UNIV SAARLAND, INST PHARMAKOL & TOXIKOL, D-66421 HOMBURG, GERMANY; LAB FYSIOL SCHEIKUNDE, B-9000 GHENT, BELGIUM	Saarland University			Jung, Martin/AAM-4547-2021; Jung, Martin/D-2207-2012; Aktories, Klaus/CAJ-5682-2022	Jung, Martin/0000-0002-1482-7020; Jung, Martin/0000-0002-1482-7020; Aktories, Klaus/0000-0002-5397-0436				AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BARBIERI JT, 1989, INFECT IMMUN, V57, P3549, DOI 10.1128/IAI.57.11.3549-3554.1989; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CARROLL SF, 1985, P NATL ACAD SCI USA, V82, P7237, DOI 10.1073/pnas.82.21.7237; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHAVAN AJ, 1992, J BIOL CHEM, V267, P14866; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; INOUE S, 1991, BIOCHEM BIOPH RES CO, V174, P459, DOI 10.1016/0006-291X(91)91438-I; JAKOBS KH, 1982, J BIOL CHEM, V257, P2829; JUST I, 1992, J BIOL CHEM, V267, P10274; JUST I, 1992, BIOCHEM BIOPH RES CO, V183, P931, DOI 10.1016/S0006-291X(05)80279-7; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; POPOFF M, 1990, NUCLEIC ACIDS RES, V18, P1291, DOI 10.1093/nar/18.5.1291; POPOFF MR, 1991, INFECT IMMUN, V59, P3673, DOI 10.1128/IAI.59.10.3673-3679.1991; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SUGAI M, 1990, BIOCHEM BIOPH RES CO, V173, P92, DOI 10.1016/S0006-291X(05)81026-5; UI M, 1990, ADP RIBOSYLATING TOX, P45; WICK MJ, 1990, ADP RIBOSYLATING TOX, P31	29	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23215	23218						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226842				2022-12-25	WOS:A1993MF51500043
J	SCHECHTER, NM; JORDAN, LM; JAMES, AM; COOPERMAN, BS; WANG, ZM; RUBIN, H				SCHECHTER, NM; JORDAN, LM; JAMES, AM; COOPERMAN, BS; WANG, ZM; RUBIN, H			REACTION OF HUMAN CHYMASE WITH REACTIVE-SITE VARIANTS OF ALPHA-1-ANTICHYMOTRYPSIN - MODULATION OF INHIBITOR VERSUS SUBSTRATE PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHYMOTRYPSIN-LIKE PROTEINASE; MAST-CELL; ANGIOTENSIN-II; CRYSTAL-STRUCTURE; CATHEPSIN-G; IDENTIFICATION; ANTITHROMBIN; SPECIFICITY; CONVERSION; PURIFICATION	Inhibition of human chymase by alpha1-antichymotrypsin produces 3.5 mol of degraded inhibitor for every mol of chymase inhibited, resulting in a stoichiometry of inhibition (SI) of 4.5. In the present study, the substrate versus inhibitor properties of this reaction were examined further using wild type and mutant recombinant antichymotrypsins (rACT). Titration of chymase hydrolytic activity with rACT-L358 (wild type) and reactive site (P1) variants of ACT, L358W, L358M, and L358F revealed that the SI was sensitive to P1 residue replacements. SI values increased in the order of Trp < Met < Leu < Phe where SI values were 1.5, 2, 4, and 7, respectively. Chymase inhibitor complex and cleaved inhibitor were demonstrated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis for all variants; the relative intensities of each band were consistent with SI values established by titration. NH2-terminal sequence analyses of the products formed in the reaction of chymase with rACT-L358F indicated that the P1-P1' bond was the primary site of cleavage resulting in the hydrolysis and inactivation of this variant. The apparent second-order rate constant for chymase inhibition (k'/[I]) by rACT also was affected by P1 substitution. k'/[I] values increased in an order opposite that obtained for SI values (Phe < Leu < Met < Trp). The reactive loop mutant (rACT-P3P3') produced by replacing the reactive site region of ACT (Thr356 Val) with that of alpha1-proteinase inhibitor (Ile356-Pro361) revealed a different reaction pattern. Although its SI was near 1, the value for k'/[I] was the lowest among variants. rACT-L358R, another P1 variant, did not inhibit chymase. These results are evaluated with respect to the substrate preferences of human chymase and with respect to partitioning schemes proposed to explain SI values greater than 1.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED & MICROBIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	SCHECHTER, NM (corresponding author), UNIV PENN,SCH MED,DEPT DERMATOL,CLIN RES BLDG,422 CURIE BLVD,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039674] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39674] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BJORK I, 1982, J BIOL CHEM, V257, P9487; BJORK I, 1992, J BIOL CHEM, V267, P19047; BOCK SC, 1991, PROTEIN ENG, V4, P221; BOSWELL DR, 1983, BIOCHIM BIOPHYS ACTA, V744, P212, DOI 10.1016/0167-4838(83)90093-6; CARRELL RW, 1986, RES MONOGRAPHS CELL, V12, P403; CHASE T, 1970, METHOD ENZYMOL, V19, P20; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; JENNE DE, 1991, BIOCHEM J, V276, P567, DOI 10.1042/bj2760567; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; KINOSHITA A, 1991, J BIOL CHEM, V266, P19192; MORII M, 1979, J BIOCHEM, V86, P915, DOI 10.1093/oxfordjournals.jbchem.a132623; OLSON ST, 1985, J BIOL CHEM, V260, P153; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PETERSEN LC, 1981, BIOCHEM J, V199, P121, DOI 10.1042/bj1990121; POWERS JC, 1985, BIOCHEMISTRY-US, V24, P2048, DOI 10.1021/bi00329a037; REILLY CF, 1982, J BIOL CHEM, V257, P8619; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SAYAMA S, 1987, J BIOL CHEM, V262, P6808; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schechter N M, 1990, Monogr Allergy, V27, P114; SCHECHTER NM, 1989, J BIOL CHEM, V264, P21308; SCHECHTER NM, 1988, ARCH BIOCHEM BIOPHYS, V262, P232, DOI 10.1016/0003-9861(88)90185-3; SCHECHTER NM, 1986, J IMMUNOL, V137, P962; SCHECHTER NM, 1990, J IMMUNOL, V145, P2652; SCHELLENBERGER V, 1991, EUR J BIOCHEM, V199, P623, DOI 10.1111/j.1432-1033.1991.tb16163.x; SCHONBAUM G, 1961, J BIOL CHEM, V236, P2930; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P1301, DOI 10.1021/bi00379a015; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WINTROUB BU, 1984, J INVEST DERMATOL, V83, P336, DOI 10.1111/1523-1747.ep12264144	36	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23626	23633						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226889				2022-12-25	WOS:A1993MF51500101
J	XING, H; SHAPIRO, DJ				XING, H; SHAPIRO, DJ			AN ESTROGEN-RECEPTOR MUTANT EXHIBITING HORMONE-INDEPENDENT TRANSACTIVATION AND ENHANCED AFFINITY FOR THE ESTROGEN RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLUCOCORTICOID RECEPTOR; CANCER CELL-LINE; XENOPUS-LAEVIS; TRANSCRIPTIONAL ACTIVATION; VITELLOGENIN SYNTHESIS; GENE-TRANSCRIPTION; MAMMALIAN-CELLS; STEROID BINDING; DNA COMPLEXES; TARGET GENE	To study transactivation by the Xenopus laevis estrogen receptor (XER), we inserted one or two copies of a synthetic amphipathic helix at amino acid 276 of the XER. The XER mutants containing one or two copies of the amphipathic helix (XER/1AH and XER/2AH, respectively) and wild-type XER were expressed at similar levels. In transient transfection assays, XER/1AH exhibited only a modest, promoter-specific increase in transactivation. Constitutive (estrogen-independent) transcription of a synthetic promoter containing two estrogen response elements (EREs) was approximately 10-fold higher for the XER/2AH mutant than for wild-type XER. The XER/2AH mutant and wild-type XER exhibited similar l7beta-estradiol dose-response curves for transactivation. In studies carried out over a broad range of DNA concentrations using the simple 2ERE-TATA promoter or a complex vitellogenin-derived promoter, the XER/2AH mutant exhibited an estrogen-dependent 2-3-fold increase in transactivation. A 2-3-fold increase in transactivation by XER/2AH was also observed using synthetic promoters in which the two EREs exhibit synergistic interactions with the NF1, AP1, or vitellogenin activator upstream activator sequences. Using a promoter interference assay to investigate intracellular interactions between the estrogen receptor and the ERE, we showed that binding of wild-type XER to the ERE was strongly estrogen-dependent. In the presence of 17beta-estradiol, XER/2AH and wild-type XER exhibited similar promoter interference curves. In the absence of 17beta-estradiol, the expression plasmid encoding the XER/2AH mutant achieved levels of promoter interference with 0.25-0.5 mug of transfected DNA that were similar to those observed with 5-10 mug of the expression plasmid encoding wild-type XER. The ability of the XER/2AH mutant to activate transcription in the absence of estrogen therefore is likely to be related to the approximately 20-fold increase in its apparent ability to bind to the ERE. Since XER/2AH was unable to activate transcription from a glucocorticoid response element, enhanced binding of XER/2AH to the ERE did not result from a general increase in binding to DNA. The XER/2AH mutant appears to be the first nuclear receptor mutant to retain hormone-dependent transactivation and to exhibit enhanced hormone-independent binding to its hormone response element.	UNIV ILLINOIS, DEPT BIOCHEM, B-4 RAL, 600 S MATHEWS AVE, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16720] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAGCHI MK, 1991, MOL CELL BIOL, V11, P4998, DOI 10.1128/MCB.11.10.4998; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; BROWN M, 1990, J BIOL CHEM, V265, P11238; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; CHANG TC, 1990, J BIOL CHEM, V265, P8176; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; CURTIS SW, 1990, MOL ENDOCRINOL, V4, P276, DOI 10.1210/mend-4-2-276; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; ELLISTON JF, 1990, J BIOL CHEM, V265, P11517; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; HAYWARD MA, 1980, J BIOL CHEM, V255, P1308; HIGUCHI K, 1970, J CELL PHYSIOL, V75, P65, DOI 10.1002/jcp.1040750108; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; INCE BA, 1993, J BIOL CHEM, V268, P14026; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; MCDONNELL DP, 1991, MOL CELL BIOL, V11, P4350, DOI 10.1128/MCB.11.9.4350; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; NARDULLI AM, 1991, J BIOL CHEM, V266, P24070; NARDULLI AM, 1993, MOL ENDOCRINOL, V7, P331, DOI 10.1210/me.7.3.331; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; RODRIGUEZ R, 1989, MOL ENDOCRINOL, V3, P356, DOI 10.1210/mend-3-2-356; SEILERTUYNS A, 1986, NUCLEIC ACIDS RES, V14, P8755, DOI 10.1093/nar/14.22.8755; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TZUKERMAN M, 1990, New Biologist, V2, P613; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEILER IJ, 1987, MOL ENDOCRINOL, V1, P355, DOI 10.1210/mend-1-5-355; WESTLEY B, 1978, CELL, V15, P367, DOI 10.1016/0092-8674(78)90005-3	44	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23227	23233						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226845				2022-12-25	WOS:A1993MF51500046
J	ZHANG, MJ; VOGEL, HJ				ZHANG, MJ; VOGEL, HJ			DETERMINATION OF THE SIDE-CHAIN PK(A) VALUES OF THE LYSINE RESIDUES IN CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR-SPECTROSCOPY; HETERONUCLEAR CORRELATION; MULTIDIMENSIONAL NMR; PEPTIDE COMPLEX; LYSYL RESIDUES; BINDING-SITES; TROPONIN-C; PROTEINS; REACTIVITIES; PROTON	The 7 Lys residues in mammalian calmodulin (CaM) were reductively methylated with C-17-enriched formaldehyde and studied by (H-1, C-13)-heteronuclear multiple quantum coherence (HMQC) NMR. The apo- and Ca2+-forms of CaM, as well as a complex with a 22-residue peptide which comprises the CaM binding region of myosin light chain kinase were studied. The complete assignment of the two-dimensional NMR spectra was obtained by site-directed mutagenesis (Lys-->Gln) of all the Lys. The pK(a) values for the individual Lys could be determined by pH titration experiments. In Ca2+-CaM, the pK(a) values range from 9.29 (Lys-75) to 10.23 (Lys-77). The Lys in apo-CaM have higher pK(a) values than those in Ca2+-CaM. The binding of the myosin light chain kinase peptide gives rise to an increase of the pK(a) values of Lys-148 and Lys-75 by 0.5 and 0.8 pH units, respectively; this results from the relocation of their side chains to a completely solvent accessible state. The changes in the pK(a) values upon binding Ca2+ or the myosin light chain kinase peptide show a remarkable correlation with earlier reported chemical reactivity changes. Thus, our results indicate that pK(a) values, rather than structural and steric effects, play the dominant role in determining the reactivity of Lys side chains towards small electrophilic chemical modification reagents. The methodology used here could prove useful for the determination of individual pK(a) values in other proteins.	UNIV CALGARY, DEPT BIOL SCI, 2500 UNIV DR NW, CALGARY T2N 1N4, ALBERTA, CANADA	University of Calgary				Zhang, Mingjie/0000-0001-9404-0190				ANDERSSON A, 1983, BIOCHEMISTRY-US, V22, P2039; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BRADBURY JH, 1973, EUR J BIOCHEM, V40, P565, DOI 10.1111/j.1432-1033.1973.tb03228.x; BRODIN P, 1989, PROTEIN ENG, V2, P353, DOI 10.1093/protein/2.5.353; BROWN LR, 1975, EUR J BIOCHEM, V54, P219, DOI 10.1111/j.1432-1033.1975.tb04131.x; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CACECI MS, 1984, BYTE, V9, P340; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; DWYER LD, 1992, J BIOL CHEM, V267, P22606; FAUST FM, 1987, J BIOL CHEM, V262, P1938; Fersht A., 1985, ENZYME STRUCTURE MEC; FORSEN S, 1986, CALCIUM CELL FUNCTIO, V6, P113; GERKEN TA, 1984, BIOCHEMISTRY-US, V23, P4688, DOI 10.1021/bi00315a026; GIEDROC DP, 1985, J BIOL CHEM, V260, P3406; GIEDROC DP, 1987, ARCH BIOCHEM BIOPHYS, V252, P136, DOI 10.1016/0003-9861(87)90017-8; GUERINI D, 1987, EUR J BIOCHEM, V170, P35, DOI 10.1111/j.1432-1033.1987.tb13664.x; HIRAOKI T, 1987, J CARDIOVASC PHARM, V10, pS14, DOI 10.1097/00005344-198710001-00004; HUQUE ME, 1993, IN PRESS J PROTEIN C; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1991, BIOCHEMISTRY-US, V30, P9216, DOI 10.1021/bi00102a013; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JACKSON AE, 1984, J BIOL CHEM, V259, P4985; JACKSON AE, 1986, J BIOL CHEM, V261, P2226; JARRETT HW, 1984, J BIOL CHEM, V259, P136; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; Lundblad R.L, 1984, CHEM REAGENTS PROTEI, VI; MANALAN AS, 1987, BIOCHEMISTRY-US, V26, P1382, DOI 10.1021/bi00379a026; MANN DM, 1988, J BIOL CHEM, V263, P11284; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MONTELIONE GT, 1989, J AM CHEM SOC, V111, P3096, DOI 10.1021/ja00190a072; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NEWTON DL, 1989, BIOCHEMISTRY-US, V28, P3750, DOI 10.1021/bi00435a019; PITNER TP, 1974, NATURE, V250, P582, DOI 10.1038/250582a0; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; RAO ST, 1993, PROTEIN SCI, V2, P436; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SPERA S, 1991, Journal of Biomolecular NMR, V1, P155, DOI 10.1007/BF01877227; STRYNADKA NCJ, 1988, PROTEINS, V3, P1, DOI 10.1002/prot.340030102; TANFORD C, 1972, BIOCHEMISTRY-US, V11, P2192, DOI 10.1021/bi00761a029; TYBURN JM, 1992, J MAGN RESON, V97, P305, DOI 10.1016/0022-2364(92)90315-X; UHLIN BE, 1983, GENE, V22, P255, DOI 10.1016/0378-1119(83)90110-5; VOGEL HJ, 1983, FEBS LETT, V157, P241, DOI 10.1016/0014-5793(83)80554-7; WANNER BL, 1977, J BACTERIOL, V130, P212, DOI 10.1128/JB.130.1.212-222.1977; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WINKLER MA, 1987, J BIOL CHEM, V262, P15466; YANG AS, 1993, PROTEINS, V15, P252, DOI 10.1002/prot.340150304; ZHANG M, 1993, B MAGN RESON, V15, P95	57	92	95	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22420	22428						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226750				2022-12-25	WOS:A1993MD34800038
J	CHEN, W; DIECKMANN, CL				CHEN, W; DIECKMANN, CL			CBP1P IS REQUIRED FOR MESSAGE STABILITY FOLLOWING 5'-PROCESSING OF COB MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-MEMBRANE SYSTEM; YEAST NUCLEAR GENE; PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; CYTOCHROME-B; TRANSCRIPTS; TRANSFORMATION; IDENTIFICATION; RECOMBINATION; MUTAGENESIS	Cbp1p is a nuclear encoded protein required for the stabilization of mitochondrial COB mRNA, which codes for apocytochrome b in the yeast Saccharomyces cerevisiae. The COB gene is cotranscribed with the upstream tRNA(Glu) gene. Release of tRNA(Glu) from the initial transcript generates a precursor mRNA with a 5'-end at position -1098. The 5'-end of mature COB message is generated by cleavage of the pre-mRNA at nucleotide -955 or -954. Previous work indicated that Cbp1p acts through cis-elements near these cleavage sites. Here we have tested whether Cbp1p stabilizes COB mRNA solely by stimulating the processing of COB precursor RNA at nucleotide -955/-954. Yeast strain TG955 was constructed such that the -955 COB mRNA 5'-processing site coincides with the upstream tRNA 3'-endonuclease site at position -1098, allowing the 5-'end of COB mRNA to be formed by the tRNA 3'-processing enzyme. Respiratory growth and stability of COB mRNA in TG955 are Cbp1p-dependent. Therefore, we conclude that Cbp1p is important for the stabilization of COB mRNA after 5'-processing.	UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721	University of Arizona					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034893] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER NJ, 1980, CELL, V20, P199, DOI 10.1016/0092-8674(80)90247-0; BOLOTINFUKUHARA M, 1992, ANTON LEEUW INT J G, V62, P131, DOI 10.1007/BF00584467; BONITZ SG, 1982, J BIOL CHEM, V257, P6268; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CHEN JY, 1988, J BIOL CHEM, V263, P13677; COHEN SN, 1972, P NATL ACAD SCI USA, V80, P5564; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DIECKMANN CL, 1994, INT REV CYTOL, V152, P145, DOI 10.1016/S0074-7696(08)62556-5; DIECKMANN CL, 1984, J BIOL CHEM, V259, P4722; FOURY F, 1978, J BIOL CHEM, V253, P3792; FOX TD, 1988, P NATL ACAD SCI USA, V85, P7288, DOI 10.1073/pnas.85.19.7288; HOLLINGSWORTH MJ, 1986, MOL CELL BIOL, V6, P1058, DOI 10.1128/MCB.6.4.1058; JOHNSTON SA, 1988, SCIENCE, V240, P1538, DOI 10.1126/science.2836954; KUCHKA MR, 1989, CELL, V58, P869, DOI 10.1016/0092-8674(89)90939-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARTIN NC, 1985, J BIOL CHEM, V260, P1479; MAYER SA, 1989, MOL CELL BIOL, V9, P4161, DOI 10.1128/MCB.9.10.4161; MCGRAW P, 1983, J BIOL CHEM, V258, P9459; MIN JJ, 1993, MOL CELL BIOL, V13, P4167, DOI 10.1128/MCB.13.7.4167; MITTELMEIER TM, 1990, CURR GENET, V18, P421, DOI 10.1007/BF00309911; MITTELMEIER TM, 1993, MOL CELL BIOL, V13, P4203, DOI 10.1128/MCB.13.7.4203; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; RODEL G, 1985, CURR GENET, V9, P641, DOI 10.1007/BF00449816; RODEL G, 1986, CURR GENET, V11, P41, DOI 10.1007/BF00389424; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; STAPLES RR, 1993, GENETICS, V135, P981; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; WEBER ER, 1990, J BIOL CHEM, V265, P1594; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P469	33	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16574	16578						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206974				2022-12-25	WOS:A1994NR29600011
J	HOFFMAN, L; RECHSTEINER, M				HOFFMAN, L; RECHSTEINER, M			ACTIVATION OF THE MULTICATALYTIC PROTEASE - THE 11-S REGULATOR AND 20-S ATPASE COMPLEXES CONTAIN DISTINCT 30-KILODALTON SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYTIC COMPLEX; PROTEINASE COMPLEX; 26S COMPLEX; THERMOPLASMA-ACIDOPHILUM; 26-S PROTEASE; UBIQUITIN; PURIFICATION; MICROSCOPY; RESOLUTION; COMPONENTS	The multicatalytic protease (MCP) associates with a 20 S ATPase complex in the presence of ATP to form the 26 S ubiquitin/ATP dependent protease. This association results in a uniform 3-fold activation of peptide hydrolysis by MCP. In the absence of nucleotides, an 11 S regulator binds MCP and differentially stimulates its peptidase activities from 3-fold to 25-fold depending upon the peptide. When incubated separately with ATPase complex or regulator, ah MCP molecules are converted to 26 S protease or to an activated MCP, respectively. Competition between ATPase complex and regulator for limiting amounts of MCP results in the 26 S protease as the only assembled species. Rabbit reticulocyte regulator is composed of a single 30-kDa protein. Among the 15 subunits in the ATPase complex, there is also a 30-kDa protein. Three findings demonstrate that the 30-kDa subunits in each complex are distinct proteins. First, two-dimensional polyacrylamide gel revealed different isoelectric points for each 30-kDa protein. Second, anti-regulator antibodies did not cross-react with proteins in the ATPase complex or in the 26 S protease. Third, directly sequenced peptides from the 30-kDa subunit of the ATPase complex are not present in the deduced amino acid sequence of the regulator. Thus, the regulator and ATPase complex are independent activators of MCP.			HOFFMAN, L (corresponding author), UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132, USA.				NCI NIH HHS [CA-09602] Funding Source: Medline; NIGMS NIH HHS [GM-37009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMON T, 1990, J BIOL CHEM, V265, P20723; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DICOLA D, 1992, ITAL J BIOCHEM, V41, P213; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; IKAI A, 1991, FEBS LETT, V292, P21, DOI 10.1016/0014-5793(91)80824-M; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; LINGRELL J, 1972, PROTEIN BIOSYNTHESIS, P234; MA CP, 1992, J BIOL CHEM, V267, P10515; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PETERS JM, 1991, EUR J CELL BIOL, V56, P422; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; REALINI C, 1994, IN PRESS J BIOL CHEM; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; TANAKA K, 1992, NEW BIOL, V4, P173; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YUKAWA M, 1991, BIOCHEM BIOPH RES CO, V178, P256, DOI 10.1016/0006-291X(91)91807-O; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	33	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16890	16895						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207011				2022-12-25	WOS:A1994NR29600057
J	MCBROOM, LDB; SADOWSKI, PD				MCBROOM, LDB; SADOWSKI, PD			DNA BENDING BY SACCHAROMYCES-CEREVISIAE ABF1 AND ITS PROTEOLYTIC FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; TRANSCRIPTIONAL REPRESSION; NUCLEOPROTEIN STRUCTURES; YEAST SILENCER; BINDING-SITES; FACTOR-I; PROTEIN; REPLICATION; SEQUENCE; RAP1	The ABF1 protein of the yeast Saccharomyces cerevisiae has been found to bend the DNA containing the target site for DNA binding. A bend angle of about 120 degrees was measured and the bend center was 7 base pairs to the 5' end of the ABF1 consensus-containing sequence. Phasing analysis showed that intact ABF1 bends the DNA towards the minor groove. We have subjected ABF1 to partial proteolysis and have found that proteolytic fragments were able to bind to the DNA-binding site and induce partial bends in the DNA Interestingly, the locations of the bend centers, the bend angles, and the plane of the bends induced by the proteolytic peptides of ABF1 were different from those of the intact protein. We present a model for the mechanism of bending of DNA by ABF1.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto								BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; HALFTER H, 1989, EMBO J, V8, P3029, DOI 10.1002/j.1460-2075.1989.tb08453.x; HALFTER H, 1989, EMBO J, V8, P4265, DOI 10.1002/j.1460-2075.1989.tb08612.x; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; MAHONEY DJ, 1991, GENE DEV, V5, P605, DOI 10.1101/gad.5.4.605; MCBROOM LDB, 1994, J BIOL CHEM, V269, P16455; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; RHODE PR, 1992, MOL CELL BIOL, V12, P1064, DOI 10.1128/MCB.12.3.1064; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAWICK JD, 1992, MOL CELL BIOL, V12, P2302, DOI 10.1128/MCB.12.5.2302; VIGNAIS ML, 1989, J BIOL CHEM, V264, P8463; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	23	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16461	16468						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206955				2022-12-25	WOS:A1994NQ72900076
J	SCHWARZ, PM; HANSEN, JC				SCHWARZ, PM; HANSEN, JC			FORMATION AND STABILITY OF HIGHER-ORDER CHROMATIN STRUCTURES - CONTRIBUTIONS OF THE HISTONE OCTAMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY REPLICATED CHROMATIN; RNA POLYMERASE-II; ONE H2A.H2B DIMER; HYPERSENSITIVE SITES; ACTIVE CHROMATIN; MMTV PROMOTER; CORE HISTONES; BETA-GLOBIN; TRANSCRIPTION; NUCLEOSOME	Unique roles have been identified for the histone octamer in the formation and stabilization of higher order chromatin structures. Histone octamers were assembled onto 12 tandem repeats of Lytechinus 5 S rDNA, at either saturating or subsaturating ratios. The extent of oligonucleosome folding and intermolecular association in divalent salts was monitored using analytical and differential sedimentation techniques. Saturated oligonucleosomes (12 nucleosomes/DNA) sedimented at 29 S in very low salt buffer. In 1.0-2.0 mM MgCl2, saturated oligonucleosomes formed a maximally folded 55 S structure whose extent of compaction was equivalent to that of classical higher order 30-nm diameter chromatin structures. These results are in marked contrast to those obtained previously in NaCl, where the maximally folded oligonucleosome species sedimented at only similar to 40 S (Hansen, J.C., Ausio, J., Stanik, V.H., and van Holde, K.E. (1989) Biochemistry 28, 9129-9136). Mg2+-dependent formation of the 55 S conformation was inhibited by histone octamer depletion; the maximum sedimentation coefficient observed for rDNA molecules containing 10-11 nucleosomes in 2.0 mM MgCl2 was only 40 S. Above 2.0 mM MgCl2, the equilibrium was progressively shifted toward formation of large associated oligonucleosome species. The implications of these results to the mechanism of chromatin folding and its relationship to the biological activity of the chromatin fiber are discussed.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR008352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045916, R01GM045916] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08352] Funding Source: Medline; NIGMS NIH HHS [GM45916] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1981, J CELL BIOL, V90, P279, DOI 10.1083/jcb.90.2.279; ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1981, DOI 10.1021/bi00356a022; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; BLOOMFIE.V, 1967, BIOPOLYMERS, V5, P135, DOI 10.1002/bip.1967.360050202; BOROCHOV N, 1984, NUCLEIC ACIDS RES, V12, P3089, DOI 10.1093/nar/12.7.3089; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; CARPENTER BG, 1976, NUCLEIC ACIDS RES, V3, P1739, DOI 10.1093/nar/3.7.1739; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; CLARK DJ, 1986, J MOL BIOL, V140, P505; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; CUSICK ME, 1983, BIOCHEMISTRY-US, V22, P3873, DOI 10.1021/bi00285a024; DUBOCHET J, 1978, SCIENCE, V202, P280, DOI 10.1126/science.694532; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FEDOR M J, 1992, Current Opinion in Cell Biology, V4, P436, DOI 10.1016/0955-0674(92)90009-2; FELSENFELD G, 1986, CELL, V44, P375, DOI 10.1016/0092-8674(86)90456-3; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FISHER EA, 1986, BIOCHEMISTRY-US, V25, P8010, DOI 10.1021/bi00372a033; FLETCHER TM, 1994, BIOCHEMISTRY-US, V33, P2226, DOI 10.1021/bi00174a032; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; GALE JM, 1988, BIOCHEMISTRY-US, V27, P7197, DOI 10.1021/bi00419a006; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARRARD WT, 1991, BIOESSAYS, V13, P87, DOI 10.1002/bies.950130208; GEORGEL P, 1993, J BIOL CHEM, V268, P1947; GONZALEZ PJ, 1989, J BIOL CHEM, V264, P18457; GONZALEZ PJ, 1987, J BIOL CHEM, V262, P11280; GRAU LP, 1982, CHROMOSOMA, V87, P437; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; GUO XW, 1989, J BIOL CHEM, V264, P11653; GUO XW, 1989, J BIOL CHEM, V264, P16873; HANSEN JC, 1992, TRENDS BIOCHEM SCI, V17, P187, DOI 10.1016/0968-0004(92)90264-A; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1993, J BIOL CHEM, V268, P5840; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; JIN YJ, 1986, J BIOL CHEM, V261, P5805; JORCANO JL, 1980, P NATL ACAD SCI-BIOL, V77, P6443, DOI 10.1073/pnas.77.11.6443; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KIMURA T, 1983, NATURE, V306, P709, DOI 10.1038/306709a0; KNOLL DA, 1988, STRUCTURE EXPRESSION, V2, P123; LEWIS EA, 1976, BIOCHEMISTRY-US, V15, P186, DOI 10.1021/bi00646a029; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; RENZ M, 1977, P NATL ACAD SCI USA, V74, P1879, DOI 10.1073/pnas.74.5.1879; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RISDALE AJ, 1990, J BIOL CHEM, V265, P5150; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SEN D, 1986, BIOCHEMISTRY-US, V25, P1495, DOI 10.1021/bi00355a004; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SMITH PA, 1984, BIOCHEMISTRY-US, V23, P1576, DOI 10.1021/bi00302a036; STRATLING WH, 1979, BIOCHEMISTRY-US, V18, P596, DOI 10.1021/bi00571a008; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; THOMA F, 1977, CELL, V12, P101, DOI 10.1016/0092-8674(77)90188-X; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1980, EUR J BIOCHEM, V112, P501; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VANHOLDE KE, 1978, BIOPOLYMERS, V25, P1981; VANHOLDE KE, 1988, CHROMATIN, P320; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; WIDOM J, 1986, J MOL BIOL, V190, P411, DOI 10.1016/0022-2836(86)90012-4; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; Wolffe A P, 1991, Trends Cell Biol, V1, P61, DOI 10.1016/0962-8924(91)90091-M; WOLFFE AP, 1992, FASEB J, V6, P3352; WOLFFE AP, 1993, CHROMATIN STRUCTURE, P31; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; YAO J, 1991, BIOCHEMISTRY-US, V30, P8408, DOI 10.1021/bi00098a019; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E	75	147	150	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16284	16289						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206934				2022-12-25	WOS:A1994NQ72900052
J	WILSON, RB; MASTICK, CC; MURPHY, RF				WILSON, RB; MASTICK, CC; MURPHY, RF			A CHINESE-HAMSTER OVARY CELL-LINE WITH A TEMPERATURE-CONDITIONAL DEFECT IN RECEPTOR RECYCLING IS PLEIOTROPICALLY DEFECTIVE IN LYSOSOME BIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; HUMAN HEPATOMA-CELLS; TRANSFERRIN RECEPTOR; MANNOSE 6-PHOSPHATE; ENDOCYTIC VESICLES; HUMAN-FIBROBLASTS; RAT HEPATOCYTES; ASIALOGLYCOPROTEIN RECEPTOR; HORSERADISH-PEROXIDASE; MEDIATED ENDOCYTOSIS	We have previously described the isolation of a Chinese hamster ovary cell line, TfT1.11, that has a pleiotropic, temperature-conditional defect in receptor recycling (Cain, C. C., Wilson, R. B., and Murphy, R. F. (1991) J. Biol. Chem. 266, 11746-11752). These cells show a rapid loss of cell surface receptors upon temperature shift due to a reduction in the rate of receptor recycling. We show here that, in addition to altered receptor recycling, TfT1.11 cells show three defects in lysosome biogenesis. At the nonpermissive temperature, they 1) redistribute at least one lysosomal enzyme from lysosomes to endosomes, 2) fail to transfer fluid-phase material from early endosomes to later compartments, and 3) fail to accumulate fluid-phase markers due to increased efflux of internalized material. The results suggest that the processes of recycling from the endosome and movement of material from endosomes to lysosomes are tightly linked.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,4400 5TH AVE,PITTSBURGH,PA 15213; CARNEGIE MELLON UNIV,CTR LIGHT MICROSCOPE IMAGING & BIOTECHNOL,PITTSBURGH,PA 15213	Carnegie Mellon University; Carnegie Mellon University			Mastick, Cynthia/G-9841-2017	Mastick, Cynthia/0000-0003-4769-5412	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013179, R01GM032508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13179, GM32508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BERG T, 1983, EXP CELL RES, V148, P319, DOI 10.1016/0014-4827(83)90156-8; CAIN CC, 1991, J BIOL CHEM, V266, P11746; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CHANG PL, 1988, EXP CELL RES, V176, P258, DOI 10.1016/0014-4827(88)90329-1; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; COLBAUGH PA, 1989, J CELL BIOL, V108, P2211, DOI 10.1083/jcb.108.6.2211; COLBAUGH PA, 1993, ADV CELL MOL BIOL M, V1, P169; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; DUNN WA, 1980, J BIOL CHEM, V255, P5971; EBERT DL, 1989, J CELL BIOL, V109, P1445, DOI 10.1083/jcb.109.4.1445; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; GREEN SA, 1992, J CELL BIOL, V117, P47, DOI 10.1083/jcb.117.1.47; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HARDING CV, 1990, EUR J IMMUNOL, V20, P323, DOI 10.1002/eji.1830200214; HARFORD J, 1983, J CELL BIOL, V96, P1824, DOI 10.1083/jcb.96.6.1824; HEDLEY DW, 1986, BIOCHEM BIOPH RES CO, V138, P1216, DOI 10.1016/S0006-291X(86)80412-0; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; KAPLAN J, 1981, CELL, V24, P925, DOI 10.1016/0092-8674(81)90118-5; KINDBERG GM, 1990, J BIOL CHEM, V265, P8999; LINDERMAN JJ, 1988, J THEOR BIOL, V132, P203, DOI 10.1016/S0022-5193(88)80157-7; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MERION M, 1983, J CELL BIOL, V96, P644, DOI 10.1083/jcb.96.3.644; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; MURPHY RF, 1988, ADV CELL BIOL, V2, P159; OKA JA, 1983, J BIOL CHEM, V258, P253; ROBBINS AR, 1979, P NATL ACAD SCI USA, V76, P1911, DOI 10.1073/pnas.76.4.1911; Rodman JS, 1990, CURR OPIN CELL BIOL, V2, P664, DOI 10.1016/0955-0674(90)90108-Q; ROEDERER M, 1989, EUR J CELL BIOL, V48, P37; ROFF CF, 1986, J CELL BIOL, V103, P2283, DOI 10.1083/jcb.103.6.2283; SAKAI T, 1991, J BIOCHEM-TOKYO, V109, P528, DOI 10.1093/oxfordjournals.jbchem.a123415; SIPE DM, 1991, J BIOL CHEM, V266, P3469; SIPE DM, 1987, P NATL ACAD SCI USA, V84, P7119, DOI 10.1073/pnas.84.20.7119; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; STEIN BS, 1986, J BIOL CHEM, V261, P319; STEINMAN RM, 1972, J CELL BIOL, V55, P186, DOI 10.1083/jcb.55.1.186; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; STROUS GJ, 1985, J CELL BIOL, V101, P531, DOI 10.1083/jcb.101.2.531; SULLIVAN PC, 1987, J CELL PHYSIOL, V131, P58, DOI 10.1002/jcp.1041310110; WARD DM, 1989, J BIOL CHEM, V264, P8164; WHITTERS EA, 1993, ADV CELL MOL BIOL M, V1, P307; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375	55	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25357	25363						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244967				2022-12-25	WOS:A1993MK10000015
J	COLEMAN, CS; STANLEY, BA; PEGG, AE				COLEMAN, CS; STANLEY, BA; PEGG, AE			EFFECT OF MUTATIONS AT ACTIVE-SITE RESIDUES ON THE ACTIVITY OF ORNITHINE DECARBOXYLASE AND ITS INHIBITION BY ACTIVE-SITE-DIRECTED IRREVERSIBLE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-PHOSPHATE-DEPENDENT HISTIDINE-DECARBOXYLASE; COENZYME-BINDING-SITES; ESCHERICHIA-COLI; AMINO-ACID; ALPHA-DIFLUOROMETHYLORNITHINE; POLYAMINE METABOLISM; PYRIDOXAL-PHOSPHATE; LEISHMANIA-DONOVANI; MOLECULAR-CLONING; INACTIVATION	Mouse ornithine decarboxylase (ODC) and mutant changing residues thought to be involved at the active site were expressed in Escherichia coli, purified to homogeneity by affinity chromatography on a pyridoxamine 5'-phosphate-agarose affinity column, and tested for their kinetic properties and their inactivation by enzyme-activated irreversible inhibitors. All of the mutant enzymes were expressed at comparable levels to the wild type protein (2-4% of the total soluble protein), all bound to the affinity column, and there were only small differences in the apparent K(m) values for L-ornithine providing strong evidence that the mutations did not lead to any gross changes in the protein structure. The mutation K69A led to a change in the spectrum of the enzyme and a 550-fold decrease in the k(cat)/K(m) (specificity constant) value. These results are consistent with lysine 69 being the residue that forms a Schiff base with the pyridoxal 5'-phosphate co-factor. Mutation C70S did not greatly affect the activity despite its proximity to this lysine but increased the K(m) about 2-fold. In contrast, the mutation C360A greatly reduced the specificity constant (by 26-fold) despite a 2-fold decrease in the K(m), suggesting that this cysteine residue is critically involved at the active site. Although cysteine 360 is known to be the major site of binding of the inhibitor, alpha-difluoromethylornithine (DFMO), the C360A mutant was still sensitive to inhibition by this drug. However, the kinetics of inactivation were altered, the partition ratio was 10 times greater, and the labeled adduct formed by reaction with [5-C-14]DFMO was removed from the protein under some denaturing conditions. This adduct was found to occur at lysine 69. The K69A mutant was also sensitive to DFMO with a lower partition ratio than the wild type enzyme. These results indicate that inactivation of ODC by DFMO can occur via interaction with either of two separate residues that form essential parts of the active site. This renders it unlikely that resistant mutants will arise from changes in the enzyme structure. In contrast to the results with DFMO, the C360A mutant ODC was completely resistant to inactivation by (R,R)-delta-methyl-alpha-acetylenicputrescine and was much less sensitive than the wild type enzyme to alpha-monofluoromethyldehydromethylornithine, showing that the reactive species formed from these inhibitors either cannot be formed by this mutant or are unable to react with lysine 69. Finally, the well known, extreme reliance of mammalian ODC on the presence of thiol-reducing agents to maintain activity is probably explained by the critical role of cysteine 360, since the C360A mutant was much less sensitive to inactivation by incubation in the absence of dithiothreitol.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,POB 850,HERSHEY,PA 17033; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT PHARMACOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health			Stanley, Bruce/R-9856-2019	Stanley, Bruce/0000-0003-1338-2928	NATIONAL CANCER INSTITUTE [R01CA018138, R37CA018138] Funding Source: NIH RePORTER; NCI NIH HHS [CA-18138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACCHI CJ, 1993, PARASITOL TODAY, V9, P190, DOI 10.1016/0169-4758(93)90145-6; BEY P, 1983, J MED CHEM, V26, P1551, DOI 10.1021/jm00365a002; Bey P., 1987, INHIBITION POLYAMINE, P1; BHATTACHARJEE MK, 1990, J BIOL CHEM, V265, P6664; BOEKER EA, 1972, ENZYMES, V6, P217; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COONS T, 1990, MOL BIOCHEM PARASIT, V39, P77, DOI 10.1016/0166-6851(90)90010-J; DANZIN C, 1982, BIOCHEM PHARMACOL, V31, P3871, DOI 10.1016/0006-2952(82)90304-5; DANZIN C, 1983, BIOCHEM BIOPH RES CO, V116, P237, DOI 10.1016/0006-291X(83)90406-0; DEBIASE D, 1991, BIOCHEMISTRY-US, V30, P2239, DOI 10.1021/bi00222a029; DOMINICI P, 1991, EUR J BIOCHEM, V201, P393, DOI 10.1111/j.1432-1033.1991.tb16296.x; FARACI WS, 1989, BIOCHEMISTRY-US, V28, P431, DOI 10.1021/bi00428a004; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; FUTAKI S, 1990, J BIOL CHEM, V265, P22306; GOLDSMITH JO, 1991, J BIOL CHEM, V266, P18626; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HANSON S, 1992, J BIOL CHEM, V267, P2350; HAYASHI H, 1986, J BIOL CHEM, V261, P1003; HAYASHI H, 1990, ANNU REV BIOCHEM, V59, P87, DOI 10.1146/annurev.biochem.59.1.87; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P1; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; INOUYE S, 1985, NUCLEIC ACIDS RES, V13, P3101, DOI 10.1093/nar/13.9.3101; JANNE J, 1971, J BIOL CHEM, V246, P1725; JOHNSON R, 1992, ANIM GENET, V23, P403, DOI 10.1111/j.1365-2052.1992.tb02158.x; KITZ R, 1962, J BIOL CHEM, V237, P3245; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIKOS JJ, 1982, BIOCHEMISTRY-US, V21, P4377, DOI 10.1021/bi00261a029; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MALCOLM BA, 1985, BIOCHEM BIOPH RES CO, V132, P915, DOI 10.1016/0006-291X(85)91894-7; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; MCCANN PP, 1987, INHIBITION POLYAMINE, P1; NISHIMURA K, 1991, BIOCHEMISTRY-US, V30, P4072, DOI 10.1021/bi00230a036; Pegg  A., 1981, POLYAMINES BIOL MED, P3; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PEGG AE, 1987, BIOCHEM J, V241, P305, DOI 10.1042/bj2410305; PHILLIPS RS, 1989, J BIOL CHEM, V264, P10627; POULIN R, 1992, J BIOL CHEM, V267, P150; SEELY JE, 1982, BIOCHEMISTRY-US, V21, P3394, DOI 10.1021/bi00257a023; SEELY JE, 1982, J BIOL CHEM, V257, P7549; SILVERMAN RB, 1986, BIOCHEMISTRY-US, V25, P6817, DOI 10.1021/bi00370a013; SJOERDSMA A, 1984, CLIN PHARMACOL THER, V35, P287, DOI 10.1038/clpt.1984.33; STANLEY BA, 1991, J BIOL CHEM, V266, P18502; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TSIRKA S, 1992, J BIOL CHEM, V267, P23057; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024	47	84	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24572	24579						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227016				2022-12-25	WOS:A1993MG67300014
J	GASQUE, P; ISCHENKO, A; LEGOEDEC, J; MAUGER, C; SCHOUFT, MT; FONTAINE, M				GASQUE, P; ISCHENKO, A; LEGOEDEC, J; MAUGER, C; SCHOUFT, MT; FONTAINE, M			EXPRESSION OF THE COMPLEMENT CLASSICAL PATHWAY BY HUMAN GLIOMA IN CULTURE - A MODEL FOR COMPLEMENT EXPRESSION BY NERVE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; INTERFERON-GAMMA; ALTERNATIVE PATHWAY; GENE-EXPRESSION; ALZHEIMER-DISEASE; EPITHELIAL-CELLS; BLOOD MONOCYTES; 1ST COMPONENT; C1 INHIBITOR; BIOSYNTHESIS	In this paper we demonstrate the synthesis of the components of the classical complement pathway, namely C1q, C1r, C1s, C1-Inh, C2, C4, and C5, by human glioma cell lines (U118MG, T193, and T98G). All these components were structurally, antigenically, and functionally similar to their serum counterparts as determined by biosynthetic labeling experiments, Western blot analysis, and hemolytic assays. Northern blot analysis of mRNA demonstrated that, for each of these components, their specific mRNA had the same size as the equivalent mRNA from hepatic tissue. We could not detect the synthesis of C4bp by these cell lines, and the secretion of C1q was only detected after stimulation by interferon-gamma. All these syntheses were up-regulated by interferon-gamma and tumor necrosis factor. Interleukin-1beta only increased C2 expression and reproducibly down-regulated C5 secretion when used at high doses. Glioma cell lines appear to be an efficient and convenient model for the analysis of complement expression in human astrocytic cells.			GASQUE, P (corresponding author), EUROPEAN INST PEPTIDE RES,INSERM,U78,BP 73,F-76233 BOIS GUILLAUME,FRANCE.							ALSALIHI A, 1982, ANN IMMUNOL I PAST C, V133, P299; BARNUM SR, 1992, J NEUROIMMUNOL, V38, P275, DOI 10.1016/0165-5728(92)90020-L; BARNUM SR, 1902, BIOCHEM J, V287, P595; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V95, P621, DOI 10.1111/1523-1747.ep12513524; BEATTY DW, 1981, CLIN IMMUNOL IMMUNOP, V18, P334, DOI 10.1016/0090-1229(81)90126-4; BOTTO M, 1992, J IMMUNOL, V149, P1348; BROOIMANS RA, 1989, J IMMUNOL, V142, P2024; BROOIMANS RA, 1991, J CLIN INVEST, V88, P379, DOI 10.1172/JCI115314; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOY LN, 1992, J BIOL CHEM, V267, P12736; DAUCHEL H, 1990, EUR J IMMUNOL, V20, P1669, DOI 10.1002/eji.1830200808; GASQUE P, 1992, J IMMUNOL, V149, P1381; GOUDIS D, 1987, BIOCHEM SOC T, V15, P650; JULEN N, 1992, EUR J IMMUNOL, V22, P213, DOI 10.1002/eji.1830220131; KATZ Y, 1989, J IMMUNOL, V142, P2041; KATZ Y, 1988, ARTHRITIS RHEUM, V31, P1365, DOI 10.1002/art.1780311104; KULICS J, 1990, J CLIN INVEST, V85, P943, DOI 10.1172/JCI114523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPPIN DF, 1992, BIOCHEM J, V281, P437, DOI 10.1042/bj2810437; LEMERCIER C, 1992, EUR J IMMUNOL, V22, P909, DOI 10.1002/eji.1830220405; LEVISTRAUSS M, 1987, J IMMUNOL, V139, P2361; LOOS M, 1982, PROTIDES BIOL FLUIDS, V29, P439; LOTZ M, 1987, J IMMUNOL, V139, P3382; MOFFAT GJ, 1992, J BIOL CHEM, V267, P20400; MORRIS KM, 1978, J EXP MED, V148, P1007, DOI 10.1084/jem.148.4.1007; MORRIS KM, 1982, J CLIN INVEST, V70, P906, DOI 10.1172/JCI110687; PETRY F, 1991, J IMMUNOL, V147, P3988; PLATASALAMAN CR, 1991, NEUROSCI BIOBEHAV R, V15, P185, DOI 10.1016/S0149-7634(05)80001-6; REID KBM, 1977, BIOCHEM J, V167, P647, DOI 10.1042/bj1670647; RIPOCHE J, 1988, J EXP MED, V168, P1917, DOI 10.1084/jem.168.5.1917; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; ROTHMAN BL, 1989, AM REV RESPIR DIS, V139, P212, DOI 10.1164/ajrccm/139.1.212; ROTHMAN BL, 1990, J IMMUNOL, V145, P592; RUSS HG, 1992, J IMMUNOL, V148, P928; SAKIYAMA H, 1991, J IMMUNOL, V146, P183; SANDERS KM, 1986, J IMMUNOL, V137, P876; SCHMAIER AH, 1989, J BIOL CHEM, V264, P18173; Shin Moon Lee, 1992, P801; SKOK J, 1981, NATURE, V292, P549, DOI 10.1038/292549a0; STRUNK RC, 1988, J CLIN INVEST, V81, P1419, DOI 10.1172/JCI113472; SUNDSTROM SA, 1989, J BIOL CHEM, V264, P16941; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER DG, 1992, MOL BRAIN RES, V14, P109, DOI 10.1016/0169-328X(92)90017-6; WHALEY K, 1980, J EXP MED, V151, P501, DOI 10.1084/jem.151.3.501	44	107	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25068	25074						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227070				2022-12-25	WOS:A1993MG67300081
J	VEYHL, M; SPANGENBERG, J; PUSCHEL, B; POPPE, R; DEKEL, C; FRITZSCH, G; HAASE, W; KOEPSELL, H				VEYHL, M; SPANGENBERG, J; PUSCHEL, B; POPPE, R; DEKEL, C; FRITZSCH, G; HAASE, W; KOEPSELL, H			CLONING OF A MEMBRANE-ASSOCIATED PROTEIN WHICH MODIFIES ACTIVITY AND PROPERTIES OF THE NA+-D-GLUCOSE COTRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER-MEMBRANE; XENOPUS-LAEVIS; NA+/GLUCOSE COTRANSPORTER; PHLORIZIN BINDING; INTESTINAL NA+; RAT-BRAIN; IMMUNOHISTOCHEMICAL LOCALIZATION; RADIATION-INACTIVATION; GLUTAMATE TRANSPORTER; MONOCLONAL-ANTIBODIES	An expression library from porcine kidney cortex was screened with a monoclonal antibody (R4A6) which stimulates high-affinity phlorizin binding in kidney and intestine but does not react with the membrane protein (SGLT1) which mediates Na+-coupled transport Of D-glucose (Hediger, M. A., Coady, M. J., Ikeda, T. S., and Wright, E. M. (1987) Nature 330, 379-381). A cDNA (RS1) was obtained which codes for a hydrophilic M(r) 66,832 polypeptide and contains a predicted hydrophobic alpha-helix at the COOH terminus. After expression in Xenopus oocytes RS1 protein was found associated with the plasma membrane. RS1-homologous mRNAs were detected in renal outer cortex and outer medulla, small intestine, liver, and LLCPK1 cells, but not in skeletal muscle, heart muscle, Madin-Darby canine kidney (MDCK) cells, renal inner medulla, and Xenopus oocytes. After nondenaturing gel electrophoresis of renal brush-border membranes comigration of RS1- and SGLT1-homologous proteins as a high molecular weight complex was demonstrated. RS1 altered the expression of Na+-glucose cotransport by SGLT1 in Xenopus oocytes. There was no effect on the expression of the nonhomologous transporters for Na+-gamma-aminobutyric acid cotransport and for Na+-independent glucose transport. However, RS1 also changed the expression of the SGLT1-homologous Na+-myo-inositol cotransporter from MDCK cells. The V(max) of methyl-alpha-D-glucopyranoside (AMG) transport expressed after injection of a small amount of SGLT1-cRNA was increased 40-fold when a stoichiometric amount of RS1-cRNA was coinjected. In addition the voltage and glucose dependence of expressed AMG uptake and the concentration dependence of transport inhibition by phlorizin were changed when stoichiometric amounts of RS1-cRNA were coinjected with SGLT1-cRNA. Thus with SGLT1 one apparent transport site (K0.5 about 100 muM) and one apparent phlorizin inhibition site (K(i) about 5 pm) was observed whereas with SGLT1 plus RS1 two apparent transport sites (K0.5(1) about 20 muM, K0.5(2) about 1 mM) and two apparent phlorizin inhibition sites (K(i)(1) about 0.3 muM, K(i)(2) about 30 muM) were found as has been described in brush-border membrane vesicles of kidney and intestine (see eg. Koepsell, H., Fritzsch, G., Korn, K., and Madrala, A. (1990) J. Membr. Biol. 114, 113-132). The data suggest that the Na+-D-glucose cotransporter and possibly also other SGLT1-type Na+-cotransporters contain RS1-type regulatory subunits.	MAX PLANCK INST BIOPHYS,D-60596 FRANKFURT,GERMANY	Max Planck Society								ARGOS P, 1982, EUR J BIOCHEM, V128, P565; ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; BARFUSS DW, 1981, AM J PHYSIOL, V240, pF322; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BELIVEAU R, 1988, BIOCHEM J, V252, P807, DOI 10.1042/bj2520807; BIRNIR B, 1990, BIOCHIM BIOPHYS ACTA, V1048, P100, DOI 10.1016/0167-4781(90)90028-Z; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLANK ME, 1989, AM J PHYSIOL, V257, pC385, DOI 10.1152/ajpcell.1989.257.2.C385; BROTLAROCHE E, 1988, P NATL ACAD SCI USA, V85, P6370, DOI 10.1073/pnas.85.17.6370; BROTLAROCHE E, 1986, J BIOL CHEM, V261, P6168; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; COADY MJ, 1990, AM J PHYSIOL, V259, pC605, DOI 10.1152/ajpcell.1990.259.4.C605; COLLINS FS, 1984, P NATL ACAD SCI-BIOL, V81, P6812, DOI 10.1073/pnas.81.21.6812; DEBIEC H, 1991, EUR J BIOCHEM, V201, P709, DOI 10.1111/j.1432-1033.1991.tb16332.x; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FREEMAN TC, 1992, BIOCHEM SOC T, V20, P1865; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAASE W, 1989, EUR J CELL BIOL, V48, P360; HAASE W, 1990, EUR J CELL BIOL, V52, P297; HAZZARD CE, 1992, AM J PHYSIOL, V262, pR412, DOI 10.1152/ajpregu.1992.262.3.R412; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HWANG ES, 1991, BIOCHEM BIOPH RES CO, V181, P1208, DOI 10.1016/0006-291X(91)92067-T; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KOEPSELL H, 1988, J BIOL CHEM, V263, P18419; KOEPSELL H, 1990, J MEMBRANE BIOL, V114, P113, DOI 10.1007/BF01869093; KONG CT, 1993, J BIOL CHEM, V268, P1509; KORNELUK RG, 1985, GENE, V40, P317, DOI 10.1016/0378-1119(85)90055-1; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KWON HM, 1992, J BIOL CHEM, V267, P6297; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESCALEMATYS L, 1993, BIOCHEM J, V291, P435, DOI 10.1042/bj2910435; LESCALEMATYS L, 1992, FASEB J, V6, P4817; LIN JT, 1984, BIOCHIM BIOPHYS ACTA, V777, P201, DOI 10.1016/0005-2736(84)90421-8; MALO C, 1990, BIOCHIM BIOPHYS ACTA, V1022, P8, DOI 10.1016/0005-2736(90)90394-4; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MIYAMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P1110, DOI 10.1016/0006-291X(91)92053-M; MORRISON AI, 1991, BIOCHIM BIOPHYS ACTA, V1089, P121, DOI 10.1016/0167-4781(91)90093-2; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; NOGUCHI S, 1992, BIOCHEM BIOPH RES CO, V182, P659, DOI 10.1016/0006-291X(92)91783-M; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; PAJOR AM, 1992, BIOCHIM BIOPHYS ACTA, V1106, P216, DOI 10.1016/0005-2736(92)90241-D; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; QUAMME GA, 1987, AM J PHYSIOL, V253, pF151, DOI 10.1152/ajprenal.1987.253.1.F151; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RESTREPO D, 1986, J MEMBRANE BIOL, V89, P269, DOI 10.1007/BF01870669; Sambrook J, 1989, MOL CLONING LABORATO; SANDER I, 1992, BIOCHIM BIOPHYS ACTA, V1112, P129, DOI 10.1016/0005-2736(92)90263-L; SCHLOSS P, 1992, FEBS LETT, V307, P76, DOI 10.1016/0014-5793(92)80905-V; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; SHIRAZIBEECHEY SP, 1991, J PHYSIOL-LONDON, V437, P699, DOI 10.1113/jphysiol.1991.sp018620; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH CD, 1992, BIOCHIM BIOPHYS ACTA, V1104, P151, DOI 10.1016/0005-2736(92)90144-B; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P505, DOI 10.1093/nar/12.1Part2.505; STEFFGEN J, 1991, BIOCHIM BIOPHYS ACTA, V1066, P14, DOI 10.1016/0005-2736(91)90244-3; STEVENS BR, 1990, P NATL ACAD SCI USA, V87, P1456, DOI 10.1073/pnas.87.4.1456; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TAKAHASHI M, 1985, J BIOL CHEM, V260, P551; TAKATA K, 1991, J HISTOCHEM CYTOCHEM, V39, P287, DOI 10.1177/39.3.1993828; TAKATA K, 1992, CELL TISSUE RES, V267, P3, DOI 10.1007/BF00318685; TOGGENBURGER G, 1982, BIOCHIM BIOPHYS ACTA, V688, P557, DOI 10.1016/0005-2736(82)90367-4; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; TURNER RJ, 1982, J MEMBRANE BIOL, V70, P37, DOI 10.1007/BF01871587; TURNER RJ, 1982, AM J PHYSIOL, V242, pF406, DOI 10.1152/ajprenal.1982.242.4.F406; VEYHL M, 1992, FASEB J, V6, pA1459; WEBER WM, 1991, BIOCHIM BIOPHYS ACTA, V1063, P73, DOI 10.1016/0005-2736(91)90355-C; WEBER WM, 1989, J MEMBRANE BIOL, V111, P93, DOI 10.1007/BF01869212; WELLS RG, 1992, AM J PHYSIOL, V263, pF459, DOI 10.1152/ajprenal.1992.263.3.F459; ZIEGLER K, 1990, J BIOL CHEM, V265, P3270	75	90	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25041	25053						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227068				2022-12-25	WOS:A1993MG67300078
J	SHAPIRO, SD; KOBAYASHI, DK; LEY, TJ				SHAPIRO, SD; KOBAYASHI, DK; LEY, TJ			CLONING AND CHARACTERIZATION OF A UNIQUE ELASTOLYTIC METALLOPROTEINASE PRODUCED BY HUMAN ALVEOLAR MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; MOLECULAR-CLONING; EXPRESSION; ELASTASE; INHIBITORS; LOCALIZATION; BIOSYNTHESIS; DEGRADATION; ENZYME	Human alveolar macrophages have the capacity to degrade elastin. As an approach to define proteinases responsible for this activity, we recently cloned a murine macrophage elastase cDNA and demonstrated that it is a member of the matrix metalloproteinase gene family (Shapiro, S. D., Griffin, G. L., Gilbert, D. J., Jenkins, N. A., Copeland, N. G., Welgus, H. G., Senior, R. M., and Ley, T. J. (1992) J. Biol. Chem. 267, 4664-4671). We now report that there is a human orthologue of murine macrophage metalloelastase that we call human macrophage metalloelastase (HME). The full-length HME cDNA spans 1.8 kilobases and contains an open reading frame of 1410 base pairs; the predicted molecular mass of the HME proenzyme is 54 kDa. HME mRNA and protein were detected in human alveolar macrophages. Similar to murine macrophage metalloelastase, HME readily undergoes NH2- and COOH-terminal processing to a mature 22-kDa form. Both recombinant HME expressed in Escherichia coli and native HME derived from human alveolar macrophage-conditioned media degraded insoluble elastin. HME is a unique human metalloproteinase that possesses elastolytic activity and is expressed in alveolar macrophages; it is therefore a candidate molecule for the causation of diseases characterized by damage to the extracellular matrix.	WASHINGTON UNIV,MED CTR,JEWISH HOSP,DEPT MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,JEWISH HOSP,DEPT GENET,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	SHAPIRO, SD (corresponding author), WASHINGTON UNIV,MED CTR,JEWISH HOSP,DEPT MED,DIV RESP & CRIT CARE,ST LOUIS,MO 63110, USA.				NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL29594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBIN RJ, 1987, AM REV RESPIR DIS, V135, P1281; BANDA MJ, 1981, BIOCHEM J, V193, P589, DOI 10.1042/bj1930589; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; BUSIEK DF, 1992, J BIOL CHEM, V267, P9087; CHAPMAN HA, 1984, J CLIN INVEST, V73, P806, DOI 10.1172/JCI111275; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; REILLY JJ, 1989, BIOCHEM J, V257, P493, DOI 10.1042/bj2570493; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SENIOR RM, 1989, AM REV RESPIR DIS, V139, P1251, DOI 10.1164/ajrccm/139.5.1251; SHAPIRO SD, 1990, J CLIN INVEST, V86, P1204, DOI 10.1172/JCI114826; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1992, J BIOL CHEM, V267, P13890; SHI GP, 1992, J BIOL CHEM, V267, P7258; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WERB Z, 1975, J EXP MED, V142, P361, DOI 10.1084/jem.142.2.361; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	23	396	419	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23824	23829						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226919				2022-12-25	WOS:A1993MF29400021
J	WAHLS, WP; SONG, JM; SMITH, GR				WAHLS, WP; SONG, JM; SMITH, GR			SINGLE-STRANDED-DNA BINDING-ACTIVITY OF C(1)-TETRAHYDROFOLATE SYNTHASE ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOHYDROLASE-FORMYLTETRAHYDROFOLATE SYNTHETASE; METHENYL-METHYLENETETRAHYDROFOLATE SYNTHETASE; RAT C1-TETRAHYDROFOLATE SYNTHASE; GAMMA-L-GLUTAMATES; 10-FORMYLTETRAHYDROFOLATE SYNTHETASE; METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE; SACCHAROMYCES-CEREVISIAE; PORCINE LIVER; CLOSTRIDIUM-FORMICOACETICUM; MULTIFUNCTIONAL ENZYME	In eukaryotes C1-5,6,7,8-tetrahydrofolate (THF) synthase is a trifunctional enzyme that catalyzes the interconversion of reduced forms of folate to supply activated one-carbon units required for a variety of metabolic pathways. The enzymatic activities include 10-formyl-THF synthetase (EC 6.3.4.3), 5,10-methenyl-THF cyclohydrolase (EC 3.5.4.9), and 5,10-methylene-THF dehydrogenase (EC 1.5.1.5). In bacteria separate, monofunctional or bifunctional polypeptides catalyze the same reactions. We have purified C1-THF synthase from the fission yeast Schizosaccharomyces pombe and found its physical and enzymatic properties similar to those of other eukaryotic C1-THF synthase enzymes. Unexpectedly, the S. pombe enzyme bound strongly (K(eq) = 100 pM) to single-stranded DNA, but not to double-stranded DNA or to RNA. The binding was sequence-independent, apparently not cooperative, and not detectably inhibited by C1-THF synthase substrates or cofactors. Trifunctional cytoplasmic enzyme from Saccharomyces cerevisiae and monofunctional (synthetase) enzyme from Clostridium acidiurici also bound tightly to single-stranded DNA, while bifunctional (dehydrogenase and cyclohydrolase) enzyme from Escherichia coli did not, suggesting that single-stranded DNA binding is a conserved function of the synthetase domain of C1-THF synthase enzymes.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	WAHLS, WP (corresponding author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.			Smith, Gerald/0000-0002-8747-1352	NATIONAL CANCER INSTITUTE [T32CA009437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031693, R56GM031693] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09437] Funding Source: Medline; NIDDK NIH HHS [DK02109-35] Funding Source: Medline; NIGMS NIH HHS [GM31693] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLING DR, 1985, BIOCHEMISTRY-US, V24, P3540, DOI 10.1021/bi00335a023; BLAKLEY RL, 1969, BIOCH FOLIC ACID REL, P219; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPERELLI CA, 1978, BIOCHEM BIOPH RES CO, V82, P403, DOI 10.1016/0006-291X(78)90890-2; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHEEK WD, 1989, ARCH BIOCHEM BIOPHYS, V270, P504, DOI 10.1016/0003-9861(89)90532-8; CLARK JE, 1982, J BIOL CHEM, V257, P3833; COWARD JK, 1975, BIOCHEMISTRY-US, V14, P1548, DOI 10.1021/bi00678a032; COWARD JK, 1974, BIOCHEMISTRY-US, V13, P3899, DOI 10.1021/bi00716a013; DARI L, 1991, J BIOL CHEM, V266, P23953; DEV IK, 1978, J BIOL CHEM, V253, P4245; Gutz H, 1974, HDB GENETICS, P395, DOI 10.1007/978-1-4899-1710-2_25; HUM DW, 1988, J BIOL CHEM, V263, P15946; JONES EW, 1977, GENETICS, V85, P209; KISLIUK RL, 1981, BIOCHEMISTRY-US, V20, P929, DOI 10.1021/bi00507a044; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ljungdahl L G, 1980, Methods Enzymol, V66, P599; LOVELL CR, 1990, BIOCHEMISTRY-US, V29, P5687, DOI 10.1021/bi00476a007; MacKenzie R E, 1984, FOLATES PTERINS CHEM, V1, P255; MACKENZIE RE, 1980, BIOCHIM BIOPHYS ACTA, V611, P187, DOI 10.1016/0005-2744(80)90054-6; MATTHEWS RG, 1980, BIOCHEMISTRY-US, V19, P2040, DOI 10.1021/bi00551a005; MCGUIRE JJ, 1978, J BIOL CHEM, V253, P1079; MOORE MR, 1974, J BIOL CHEM, V249, P5250; MUELLER WT, 1981, BIOCHEMISTRY-US, V20, P337, DOI 10.1021/bi00505a017; NOUR JM, 1991, J BIOL CHEM, V266, P18363; NOUR JM, 1992, J BIOL CHEM, V267, P16292; OBRIEN WE, 1973, J BIOL CHEM, V248, P403; PAUKERT JL, 1976, J BIOL CHEM, V251, P5104; PAUKERT JL, 1977, BIOCHEM BIOPH RES CO, V77, P147, DOI 10.1016/S0006-291X(77)80176-9; PERUCHO M, 1980, BIOCHIM BIOPHYS ACTA, V606, P181, DOI 10.1016/0005-2787(80)90028-3; Rabinowitz J.C., 1960, ENZYMES, V2, P185; RABINOWITZ JC, 1962, J BIOL CHEM, V237, P2898; RAGSDALE SW, 1984, J BIOL CHEM, V259, P3499; SCHIRCH L, 1978, ARCH BIOCHEM BIOPHYS, V189, P283, DOI 10.1016/0003-9861(78)90214-X; SHANNON KW, 1988, J BIOL CHEM, V263, P7717; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; STABEN C, 1986, J BIOL CHEM, V261, P4629; STABEN C, 1983, P NATL ACAD SCI-BIOL, V80, P6799, DOI 10.1073/pnas.80.22.6799; STRONG W, 1987, J BIOL CHEM, V262, P12519; SUAREZDEMATA Z, 1980, J BIOL CHEM, V255, P2569; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4; TAN LUL, 1979, CAN J BIOCHEM CELL B, V57, P806, DOI 10.1139/o79-100; TAN LUL, 1977, J BIOL CHEM, V252, P1117; TAN LUL, 1977, BIOCHIM BIOPHYS ACTA, V485, P52, DOI 10.1016/0005-2744(77)90192-9; THIGPEN AE, 1990, J BIOL CHEM, V265, P7907; UEMURA T, 1984, EMBO J, V9, P663; UYEDA K, 1967, J BIOL CHEM, V242, P24; VILLAR E, 1985, J BIOL CHEM, V260, P2245; WAHLS WP, 1991, NUCLEIC ACIDS RES, V19, P3269, DOI 10.1093/nar/19.12.3269; WAHLS WP, 1993, CHROMOSOMES TODAY, V11, P351; WHITEHEAD TR, 1988, J BACTERIOL, V170, P3255, DOI 10.1128/jb.170.7.3255-3261.1988	51	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23792	23798						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226914				2022-12-25	WOS:A1993MF29400016
J	WU, ZL; WONG, ST; STORM, DR				WU, ZL; WONG, ST; STORM, DR			MODIFICATION OF THE CALCIUM AND CALMODULIN SENSITIVITY OF THE TYPE-I ADENYLYL-CYCLASE BY MUTAGENESIS OF ITS CALMODULIN-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELLS; STIMULATION; EXPRESSION; RUTABAGA; MEMORY	The type I adenylyl cyclase is directly stimulated by Ca2+ and calmodulin in vitro, and the enzyme is also stimulated by increases in intracellular Ca2+ in vivo. Ca2+ stimulation of the enzyme in vivo may be due to direct interactions of the enzyme with Ca2+ and calmodulin or to an indirect mechanism involving stimulation of the enzyme by Ca2+-activated protein kinases. In this study, we have made several point mutations within the calmodulin binding domain to determine if the Ca2+ sensitivity of the enzyme can be modified by mutagenesis. The catalytic activities of the mutant enzymes were comparable to wild type type I adenylyl cyclase. Substitution of Cys-507 with Ser-507 did not have significant effects on the calmodulin or Ca2+ sensitivity of the enzyme. However, replacement of Lys-504 with Asp caused a 4-fold decrease in sensitivity to Ca2+. Ca2+ and calmodulin stimulation were abolished by substitution of Phe-503 with Arg-503. Stimulation of type I adenylyl cyclase activity in vivo by intracellular Ca2+ was also greatly diminished with the Arg-503 mutant indicating that Ca2+ stimulation of the enzyme in vivo is due primarily to direct interactions with calmodulin and Ca2+. These data demonstrate that the Ca2+ sensitivity of this enzyme can be modulated by point mutagenesis within the putative calmodulin binding domain and indicate that the enzyme can be directly regulated by Ca2+ and calmodulin in vivo.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NINDS NIH HHS [NS 20498] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020498] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; DEGRADO WF, 1987, PROTEINS, V2, P20, DOI 10.1002/prot.340020104; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; OLDENBURG DJ, 1992, BIOCHEMISTRY-US, V31, P8884, DOI 10.1021/bi00152a027; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T	21	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23766	23768						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226907				2022-12-25	WOS:A1993MF29400009
J	YAMADA, S; HATA, J; YAMASHITA, S				YAMADA, S; HATA, J; YAMASHITA, S			MOLECULAR-CLONING OF FISH PIT-1 CDNA AND ITS FUNCTIONAL BINDING TO PROMOTER OF GENE EXPRESSED IN THE PITUITARY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE GENE; TRANSCRIPTION FACTOR-TFIIB; TROUT SALMO-GAIRDNERI; RAINBOW-TROUT; PROLACTIN FAMILY; PLASMA PROLACTIN; SOMATOLACTIN; ADAPTATION; SEQUENCE; ACTIVATION	Pit-1 is a pituitary-specific transcription factor responsible for activating growth hormone (GH) and prolactin genes. Here, we describe the isolation of a rainbow trout cDNA clone that contains the entire Pit-1 coding region. The deduced amino acid sequence contains 358 residues, encoding a 39-kDa protein. Comparison of the protein sequences of the rainbow trout and rat Pit-1 shows that the 160 residue POU domain at the C terminus is highly conserved (86% identical). However, homology is much weaker in the N-terminal region (56% identical), and the rainbow trout Pit-1 contains segments of 29 and 33 amino acids that are not present in rat Pit-1. The protein produced by expression of rainbow trout Pit-1 cDNA in Escherichia coli binds specifically to at least four sites in the rainbow trout GH gene promoter. Moreover, we demonstrate that the promoter region of salmon somatolactin gene, which belongs to the GH prolactin gene family and is also expressed specifically in the pituitary, has at least five rainbow trout Pit-1 binding sites. The consensus sequence of these binding sites closely matches the 9-base pair motif, (T/A)(T/A)TATNCAT, recognized by rat Pit-1. Rainbow trout Pit-1 specifically activates rainbow trout GH promoter fusion gene expression, confirming the ability of Pit-1 to bind in a transcriptionally active conformation in GH gene promoter.	NIPPON SUISAN KAISHA LTD,CENT RES LAB,559-6 KITANOMACHI,HACHIOJI,TOKYO 192,JAPAN; NINCDS,MOLEC BIOL LAB,BETHESDA,MD 20892	Nippon Suisan Kaisha, Ltd.; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								AGELLON LB, 1988, P NATL ACAD SCI USA, V85, P5136, DOI 10.1073/pnas.85.14.5136; AGELLON LB, 1988, CAN J FISH AQUAT SCI, V45, P146, DOI 10.1139/f88-016; BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOLTON JP, 1987, J ENDOCRINOL, V112, P63, DOI 10.1677/joe.0.1120063; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; INOUE K, 1990, CELL DIFFER DEV, V29, P123, DOI 10.1016/0922-3371(90)90030-Z; INOUE K, 1991, NIPPON SUISAN GAKK, V57, P1511, DOI 10.2331/suisan.57.1511; INOUE K, 1990, BIOCHEM BIOPH RES CO, V173, P1311, DOI 10.1016/S0006-291X(05)80930-1; INOUE K, 1992, BIOCHEM BIOPH RES CO, V185, P1108, DOI 10.1016/0006-291X(92)91740-H; KAMEI Y, 1987, FISH PATHOL, V22, P147, DOI 10.3147/jsfp.22.147; KARIN M, 1990, TRENDS GENET, V6, P92, DOI 10.1016/0168-9525(90)90100-K; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LORETZ CA, 1982, NEUROENDOCRINOLOGY, V35, P292, DOI 10.1159/000123397; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MCCORMICK A, 1991, GENE DEV, V5, P1490, DOI 10.1101/gad.5.8.1490; NATHAN LC, 1989, FISH PHYSIOL BIOCHEM, V7, P315; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OGASAWARA T, 1989, FISH PHYSIOL BIOCHEM, V7, P309, DOI 10.1007/BF00004722; ONO M, 1990, P NATL ACAD SCI USA, V87, P4330, DOI 10.1073/pnas.87.11.4330; PRUNET P, 1989, GEN COMP ENDOCR, V74, P355, DOI 10.1016/S0016-6480(89)80031-0; SAKAMOTO T, 1991, GEN COMP ENDOCR, V82, P184, DOI 10.1016/0016-6480(91)90182-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO N, 1988, BIOCHIM BIOPHYS ACTA, V949, P35, DOI 10.1016/0167-4781(88)90051-6; SEKINE S, 1985, P NATL ACAD SCI USA, V82, P4306, DOI 10.1073/pnas.82.13.4306; TAKAYAMA Y, 1991, MOL ENDOCRINOL, V5, P778, DOI 10.1210/mend-5-6-778; TAKAYAMA Y, 1991, GEN COMP ENDOCR, V83, P366, DOI 10.1016/0016-6480(91)90141-R; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; YAMASHITA S, 1992, P NATL ACAD SCI USA, V89, P2839, DOI 10.1073/pnas.89.7.2839	32	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24361	24366						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226986				2022-12-25	WOS:A1993MF29400096
J	ALLEN, RM; HOMER, MJ; CHATTERJEE, R; LUDDEN, PW; ROBERTS, GP; SHAH, VK				ALLEN, RM; HOMER, MJ; CHATTERJEE, R; LUDDEN, PW; ROBERTS, GP; SHAH, VK			DINITROGENASE REDUCTASE-DEPENDENT AND MGATP-DEPENDENT MATURATION OF APODINITROGENASE FROM AZOTOBACTER-VINELANDII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; KLEBSIELLA-PNEUMONIAE; MOFE PROTEIN; NITROGENASE; GENE; PURIFICATION; MUTANTS; NIFB	The requirements for iron-molybdenum cofactor (FeMo-co) activation of apodinitrogenase from Azotobacter vinelandii strain UW97, which lacks dinitrogenase reductase activity as,assayed by substrate reduction, have been examined. Activation of apodinitrogenase from strain UW97 by FeMo-co requires the addition of both dinitrogenase reductase and MgATP. When the same apodinitrogenase is pretreated with dinitrogenase reductase and MgATP and then partially purified, however, it does not require these components for activation by FeMo-co. This suggests that dinitrogenase reductase and MgATP are involved in processing apodinitrogenase to a FeMo-co activatable form. This processing step coincides with a change in the subunit composition of apodinitrogenase from alpha2beta2 to a form with an additional subunit (gamma) attached. The apodinitrogenase with the associated gamma subunit is apparently the form of the protein that is competent for activation by FeMo-co.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BACTERIOL,MADISON,WI 53706; UNIV WISCONSIN,COLL AGR & LIFE SCI,CTR STUDY NITROGEN FIXAT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM 35332] Funding Source: Medline; PHS HHS [T326M07215] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035332, R37GM035332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P797; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GAVINI N, 1992, J BIOL CHEM, V267, P21179; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOMER MJ, 1993, J BACTERIOL, V175, P4907, DOI 10.1128/JB.175.15.4907-4910.1993; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; Shah V. K., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P115; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V292, P246, DOI 10.1016/0005-2728(73)90269-7; SHAH VK, 1985, J BIOL CHEM, V260, P3891; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAL S, 1991, J BIOL CHEM, V266, P10654; WHITE TC, 1992, J BIOL CHEM, V267, P24007; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643	25	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23670	23674						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226893				2022-12-25	WOS:A1993MF51500107
J	WHITING, JF; NARCISO, JP; CHAPMAN, V; RANSIL, BJ; SWANK, RT; GOLLAN, JL				WHITING, JF; NARCISO, JP; CHAPMAN, V; RANSIL, BJ; SWANK, RT; GOLLAN, JL			DECONJUGATION OF BILIRUBIN-IX-ALPHA GLUCURONIDES - A PHYSIOLOGICAL-ROLE OF HEPATIC-MICROSOMAL BETA-GLUCURONIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONJUGATED BILIRUBIN; NATIVE BILE; UDP-GLUCURONYLTRANSFERASE; RAT; EGASYN; MONOGLUCURONIDE; CHOLELITHIASIS; DIGLUCURONIDE; HYDROLYSIS; GALLSTONES	Beta-glucuronidase is an acid hydrolase located in both the lysosomal and microsomal compartments of the hepatocyte. The function of the latter remains undefined. We postulated that microsomal beta-glucuronidase may be responsible for the deconjugation of bilirubin-IXalpha glucuronides which are synthesized primarily in the hepatic microsomal compartment. We utilized two unique congenic strains of mice to characterize the role of hepatic beta-glucuronidase in the metabolism and disposition of bilirubin-IXalpha; the first exhibited less than 1% of total hepatic beta-glucuronidase activity (ATM), the second lacked only the microsomal enzyme activity (AT1). The biliary excretion of bilirubin-IXalpha conjugates was quantitated using reverse-phase high performance liquid chromatography. Under basal conditions, there was a 2-fold increase in the biliary excretion of bilirubin-IXalpha monoglucuronides and total glucuronides in the AT1 and ATM mutants compared to the normal controls. When the plasma bilirubin-IXalpha level was increased to almost-equal-to 7 mg/dl to simulate hyperbilirubinemia, by intravenous administration of [C-14]bilirubin-IXalpha, mathematical modeling of the biliary excretion curves of bilirubin-IXalpha glucuronides revealed qualitative differences between control and mutant animals, whereas both mutant groups were similar. Collectively, these data demonstrate that microsomal beta-glucuronidase modulates the net rate of bilirubin-IXalpha glucuronidation and glucuronide excretion in bile, under both basal and hyperbilirubinemic conditions, and that lysosomal beta-glucuronidase has no such effects. Hepatic microsomal beta-glucuronidase appears likely to influence the biliary excretion and hence the hepatic elimination of endogenous and xenobiotic substrates (e.g. carcinogens) which undergo hepatic glucuronidation.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV GASTROENTEROL,75 FRANCIS ST, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT MED, HARVARD THORNDIKE LAB, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; ROSWELL PK CANC INST, BUFFALO, NY 14214 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Roswell Park Cancer Institute					NIDDK NIH HHS [DK-36887] Funding Source: Medline; NIGMS NIH HHS [GM07806] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036887] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BILLING BH, 1964, CLIN SCI, V27, P245; BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010; BLANCKAERT N, 1980, BIOCHEM J, V185, P115, DOI 10.1042/bj1850115; BOONYAPISIT ST, 1978, GASTROENTEROLOGY, V74, P70; BRANDT EJ, 1975, J CELL BIOL, V67, P776; BROWN J, 1987, J CELL BIOL, V105, P1571, DOI 10.1083/jcb.105.4.1571; Burchell Brain, 1993, P489; CRAWFORD JM, 1992, J BIOL CHEM, V267, P16943; CRAWFORD JM, 1987, J CLIN INVEST, V79, P1171; CUYPERS HTM, 1984, HEPATOLOGY, V4, P918, DOI 10.1002/hep.1840040522; DWIVEDI C, 1987, FASEB J, V1, P303, DOI 10.1096/fasebj.1.4.3115856; GOLLAN J, 1981, J CLIN INVEST, V67, P1003, DOI 10.1172/JCI110111; GOURLEY GR, 1985, HEPATOLOGY, V5, P610, DOI 10.1002/hep.1840050415; HAUSER SC, 1984, J BIOL CHEM, V259, P4527; HAUSER SC, 1992, LIVER BILIARY DISEAS, P317; HO KJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P197, DOI 10.1016/0167-4838(85)90203-1; LARUSSO NF, 1979, J CLIN INVEST, V64, P948, DOI 10.1172/JCI109561; LILIENBLUM W, 1984, BIOCHEM PHARMACOL, V33, P2041, DOI 10.1016/0006-2952(84)90571-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSIAS AJ, 1977, ISOZYMES CURRENT TOP, P63; MAKI T, 1966, ANN SURG, V164, P90, DOI 10.1097/00000658-196607000-00010; MASUDA H, 1979, J LAB CLIN MED, V93, P353; MCDONAGH AF, 1972, BIOCHEM J, V129, P797, DOI 10.1042/bj1290797; MCDONAGH AF, 1971, FEBS LETT, V18, P315, DOI 10.1016/0014-5793(71)80475-1; MEDDA S, 1987, J BIOL CHEM, V262, P7248; MEDDA S, 1987, CELL, V50, P301, DOI 10.1016/0092-8674(87)90225-X; MYANT NB, 1961, J LIPID RES, V2, P363; OSTROW JD, 1961, J CLIN INVEST, V40, P1442, DOI 10.1172/JCI104375; PFISTER K, 1985, J BIOL CHEM, V260, P1588; SKUDLAREK MD, 1984, LYSOSOM BIOL PATHOL, P17; SPIVAK W, 1987, BIOCHEM J, V242, P323, DOI 10.1042/bj2420323; SPIVAK W, 1985, BIOCHEM J, V225, P787, DOI 10.1042/bj2250787; SPIVAK W, 1986, BIOCHEM J, V234, P101, DOI 10.1042/bj2340101; TALALAY PAUL, 1960, METHODS BIOCHEM ANAL, V8, P119; TROTMAN BW, 1981, GASTROENTEROLOGY, V81, P232; WALASZEK Z, 1984, CARCINOGENESIS, V5, P767, DOI 10.1093/carcin/5.6.767; WINCH J, 1969, GUT, V10, P954	37	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23197	23201						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226839				2022-12-25	WOS:A1993MF51500040
J	ISLAM, MR; GRUBB, JH; SLY, WS				ISLAM, MR; GRUBB, JH; SLY, WS			C-TERMINAL PROCESSING OF HUMAN BETA-GLUCURONIDASE - THE PROPEPTIDE IS REQUIRED FOR FULL EXPRESSION OF CATALYTIC ACTIVITY, INTRACELLULAR RETENTION, AND PROPER PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; HUMAN-FIBROBLASTS; MANNOSE 6-PHOSPHATE; LYSOSOMAL-ENZYMES; OLIGOSACCHARIDES; PINOCYTOSIS; EGASYN; CELLS; COMPARTMENTALIZATION; INVOLVEMENT	Beta-glucuronidase undergoes proteolytic C-terminal processing during or after its transport to lysosomes or endosomes. We determined the C-terminal processing site for human placental beta-glucuronidase to be the peptide bond between Thr633-Arg634. To evaluate the role of the 18-amino acid peptide removed in C-terminal processing, we changed the codon for Arg634 to a stop codon by site-directed mutagenesis and studied expression of the truncated mutant enzyme in COS-7 cells. An increased fraction of newly synthesized enzyme from R634Stop cDNA was secreted. Pulse-chase experiments provided no evidence for increased degradation of the intracellular R634Stop enzyme. The total amount of catalytic activity expressed from the R634Stop mutant cDNA was only half that seen with the wild type cDNA, and the K(cat) of the mutant enzyme was 52% that of wild type enzyme. These results indicate that the C-terminal propeptide in the precursor is important for beta-glucuronidase to achieve maximal activity. The truncated enzyme formed hybrid tetramers in cotransfection experiments with the cDNA for rat beta-glucuronidase. There appeared to be no decrease in stability of the R634Stop enzyme, since chaotropic agents, heat treatment, and pH had similar effects on the mutant and the wild type enzymes. The uptake rate of the truncated mutant (R634Stop) enzyme by beta-glucuronidase-deficient human fibroblast cells was only 55-60% that of the wild type enzyme. Binding to the immobilized cation-independent mannose-6-phosphate receptor and measurement of the P-32-labeled phosphorylated oligosaccharides revealed that the truncated mutant enzyme was 32-34% less phosphorylated and appeared to contain proportionately more covered phosphate groups than the wild type enzyme. These results suggest that the propeptide influences the accessibility to both processing enzymes that produce the mannose-6-phosphate recognition marker on beta-glucuronidase.	ST LOUIS UNIV,SCH MED,EDWARD A DOISY DEPT BIOCHEM & MOLEC BIOL,ST LOUIS,MO 63104	Saint Louis University					NIDDK NIH HHS [DK40163] Funding Source: Medline; NIGMS NIH HHS [GM34182] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034182, R01GM034182] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BROT FE, 1974, BIOCHEM BIOPH RES CO, V57, P1, DOI 10.1016/S0006-291X(74)80349-9; BROT FE, 1978, BIOCHEMISTRY-US, V17, P385, DOI 10.1021/bi00596a001; CREEK KE, 1982, J BIOL CHEM, V257, P9931; DONG J, 1989, J BIOL CHEM, V265, P4210; ERICKSON AH, 1979, BIOCHEMISTRY-US, V22, P5201; FISCHER HD, 1982, J BIOL CHEM, V257, P9938; FUNKENSTEIN B, 1988, MOL CELL BIOL, V8, P1160, DOI 10.1128/MCB.8.3.1160; GABEL CA, 1987, J CELL BIOL, V105, P1561, DOI 10.1083/jcb.105.4.1561; GABEL CA, 1984, J CELL BIOL, V99, P296, DOI 10.1083/jcb.99.1.296; GALLAGHER P M, 1988, Genomics, V2, P215, DOI 10.1016/0888-7543(88)90005-5; GANSCHOW R, 1967, P NATL ACAD SCI USA, V58, P939; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLDBERG DE, 1981, J BIOL CHEM, V256, P3060; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HASILIK A, 1980, P NATL ACAD SCI-BIOL, V77, P7074, DOI 10.1073/pnas.77.12.7074; Ho K J, 1991, Protein Expr Purif, V2, P63, DOI 10.1016/1046-5928(91)90011-7; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; ISHII SI, 1983, METHOD ENZYMOL, V91, P378; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KYLE JW, 1992, GUS PROTOCOLS USING, P189; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI H, 1990, J BIOL CHEM, V265, P14732; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEDDA S, 1986, BIOCHEM GENET, V24, P229, DOI 10.1007/BF00502791; MEDDA S, 1989, J BIOL CHEM, V264, P15824; MEDDA S, 1987, CELL, V50, P301, DOI 10.1016/0092-8674(87)90225-X; MERCOLINO TJ, 1980, J MOL BIOL, V139, P557, DOI 10.1016/0022-2836(80)90147-3; NATOWICZ MR, 1979, P NATL ACAD SCI USA, V76, P4322, DOI 10.1073/pnas.76.9.4322; NOVAK EK, 1991, J BIOL CHEM, V266, P6377; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; POWELL PP, 1988, BIOCHEM J, V250, P547, DOI 10.1042/bj2500547; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKUDLAREK MD, 1979, J BIOL CHEM, V254, P9939; TABAS I, 1980, J BIOL CHEM, V255, P6633; TALKAD V, 1983, J BIOL CHEM, V258, P7345; TANAKA J, 1992, BIOL CHEM H-S, V373, P57, DOI 10.1515/bchm3.1992.373.1.57; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330	43	42	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22627	22633						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226771				2022-12-25	WOS:A1993MD34800066
J	JEOUNG, DI; ALLEN, DL; GULLER, S; YEN, V; SONENBERG, M				JEOUNG, DI; ALLEN, DL; GULLER, S; YEN, V; SONENBERG, M			MITOGENIC AND RECEPTOR ACTIVITIES OF HUMAN GROWTH HORMONE-108-129	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICALLY-ACTIVE FRAGMENTS; EXTRACELLULAR DOMAIN; TRANSGENIC MICE; ADIPOSE DIFFERENTIATION; H-1-NMR SPECTROSCOPY; ALPHA-HELIX; HORMONE GH; BOVINE; CELLS; ANALOG	We have selectively synthesized a number of peptides encompassing the region of helix 3 of growth hormone (GH). These peptides and native human (h) GH have been evaluated for mitogenic and receptor activities in 3T3-F442A preadipocytes. In this system, wild type hGH is anti-mitogenic. In contrast, hGH 108-129 stimulated DNA synthesis while other GH-derived peptides were ineffective. hGH (L) 108-129 had an EC50 of about 0.2 nM and was maximally effective at about 0.5 nm in stimulating [H-3]thymidine incorporation in 3T3-F442A cells. hGH (L) 108-129 was mitogenically as active as insulin-like growth factor-I and more active than insulin. It was less effective than transforming growth factor-beta. By cell cycle analysis, hGH (L) 108-129 increased the proportion of cells in S/G2/M phases to 28%. hGH, when coincubated with hGH (L) 108-129, blocked the mitogenic response of the peptide. A monoclonal antibody to the GH receptor significantly reduced binding of I-125-hGH to its receptor but had no effect on binding of I-125-hGH (L) 108-129. Affinity cross-linking of I-125-hGH to its receptor was not duplicated with I-125-hGH (L) 108-129. No other GH peptides or insulin competed for binding of I-125-hGH 108-129. Scatchard analysis indicated a K(d) of 5.2 nM with 5.6 x 10(5) binding sites/cell for hGH (L) 108-129. These studies indicate that hGH (L) 108-129, a sequence encompassing helix 3 of hGH, acts by binding to a site other than the GH receptor and evokes high mitogenic responses.	MEM SLOAN KETTERING CANC CTR,1275 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,DEPT MED,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041931] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41931, DK 07313] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BREMS DN, 1987, BIOCHEMISTRY-US, V26, P7774, DOI 10.1021/bi00398a036; CHEN CH, 1977, BIOCHEMISTRY-US, V16, P2110, DOI 10.1021/bi00629a010; CHEN WY, 1991, J BIOL CHEM, V266, P2252; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHEN WY, 1990, P NATL ACAD SCI USA, V87, P5061, DOI 10.1073/pnas.87.13.5061; CHEN WY, 1991, ENDOCRINOLOGY, V129, P1402, DOI 10.1210/endo-129-3-1402; CORIN RE, 1990, P NATL ACAD SCI USA, V87, P7507, DOI 10.1073/pnas.87.19.7507; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAYHOFF MO, 1973, ATLAS PROTEIN SEQ S2, pS138; DAYHOFF MO, 1976, ATLAS PROTEIN SEQ S1, pS50; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EDMAN P, 1970, PROTEIN SEQUENCE DET, P211; FIDDES JC, 1979, P NATL ACAD SCI USA, V76, P4294, DOI 10.1073/pnas.76.9.4294; GOOLEY PR, 1988, BIOCHEMISTRY-US, V27, P802, DOI 10.1021/bi00402a047; GOOLEY PR, 1988, BIOCHEMISTRY-US, V27, P4032, DOI 10.1021/bi00411a020; GRAF L, 1974, BIOCHEMISTRY-US, V13, P5408, DOI 10.1021/bi00723a026; GRAF L, 1976, EUR J BIOCHEM, V64, P333, DOI 10.1111/j.1432-1033.1976.tb10306.x; GULLER S, 1988, ENDOCRINOLOGY, V122, P2084, DOI 10.1210/endo-122-5-2084; GULLER S, 1989, ENDOCRINOLOGY, V125, P2360, DOI 10.1210/endo-125-5-2360; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCANDREW SJ, 1991, J BIOL CHEM, V266, P15016; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; NIXON T, 1983, J CELL PHYSIOL, V115, P291, DOI 10.1002/jcp.1041150312; OKADA S, 1992, ENDOCRINOLOGY, V130, P2284, DOI 10.1210/en.130.4.2284; Roth J, 1975, Methods Enzymol, V37, P223; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEEBURG PH, 1983, DNA-J MOLEC CELL BIO, V2, P37, DOI 10.1089/dna.1.1983.2.37; SILVERMAN MS, 1989, ENDOCRINOLOGY, V125, P2600, DOI 10.1210/endo-125-5-2600; UCHIDA E, 1990, BIOCHEM BIOPH RES CO, V172, P357, DOI 10.1016/S0006-291X(05)80217-7; ULTSCH M, 1991, J MOL BIOL, V222, P865, DOI 10.1016/0022-2836(91)90578-T; YAMASAKI N, 1970, BIOCHEMISTRY-US, V9, P1107, DOI 10.1021/bi00807a009; YAMASAKI N, 1975, J BIOL CHEM, V250, P2510	36	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22520	22524						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226761				2022-12-25	WOS:A1993MD34800052
J	KORNER, C; HERZOG, A; WEBER, B; ROSORIUS, O; HEMER, F; SCHMIDT, B; BRAULKE, T				KORNER, C; HERZOG, A; WEBER, B; ROSORIUS, O; HEMER, F; SCHMIDT, B; BRAULKE, T			IN-VITRO PHOSPHORYLATION OF THE 46-KDA MANNOSE 6-PHOSPHATE RECEPTOR BY CASEIN KINASE-II - STRUCTURAL REQUIREMENTS FOR EFFICIENT PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOPLASMIC DOMAIN; CARBOXYL-TERMINUS; LYSOSOMAL-ENZYMES; GOLGI; TAIL; INTERNALIZATION; SIGNALS; PROTEIN; BINDING	Some steps in the receptor-mediated transport of newly synthesized mannose 6-phosphate-containing lysosomal enzymes are assumed to be accompanied by changes in the phosphorylation state of receptors. In vitro, the metabolically phosphorylated 46-kDa mannose 6-phosphate receptor (MPR 46) was dephosphorylated by protein phosphatase 2A. The synthetic cytoplasmic domain of MPR 46 was phosphorylated in vitro by casein kinase II. Tryptic phosphopeptide mapping showed that casein kinase II phosphorylates MPR 46 in vitro at the same site that is phosphorylated in vivo. Inhibition studies using synthetic peptides corresponding to different amino acid sequences of the cytoplasmic tail of MPR 46 revealed that the sequence 26-32 (ADGCDFV) contribute to efficient phosphorylation of serine 56. Baby hamster kidney cells were transfected with wild type human MPR 46 cDNA or cDNAs containing mutations in the cytoplasmic tail and assayed for their phosphorylation state in vivo. The phosphorylation of mutant receptors with deleted residues 23-28 (NLVADG) was strongly reduced. These data indicate that residues on the N-terminal side of the phosphorylatable serine 56 may influence the efficiency with which a casein-kinase II-like kinase phosphorylates MPR 46.	UNIV GOTTINGEN,INST BIOCHEM 2,D-37073 GOTTINGEN,GERMANY	University of Gottingen			Braulke, Thomas/AAV-9121-2020	Braulke, Thomas/0000-0002-2336-8532				BRAULKE T, 1992, J BIOL CHEM, V267, P17347; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; HEMER F, 1993, J BIOL CHEM, V268, P17108; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROSORIUS O, 1993, BIOCHEM J, V292, P833, DOI 10.1042/bj2920833; ROSORIUS O, 1993, J BIOL CHEM, V268, P21470; SAYERS JR, 1989, PROTEIN FUNCTION PRA, P279; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; WENDLAND M, 1991, J BIOL CHEM, V266, P2917	22	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16529	16532						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206966				2022-12-25	WOS:A1994NR29600003
J	LAWRENCE, DL; ENGELSBERG, BN; FARID, RS; HUGHES, EN; BILLINGS, PC				LAWRENCE, DL; ENGELSBERG, BN; FARID, RS; HUGHES, EN; BILLINGS, PC			LOCALIZATION OF THE BINDING REGION OF HIGH-MOBILITY GROUP PROTEIN-2 TO CISPLATIN-DAMAGED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX-DETERMINING REGION; TRANSCRIPTION FACTOR; OVARIAN-CANCER; ALPHA-ENHANCER; GENE; CIS-DIAMMINEDICHLOROPLATINUM(II); CHEMOTHERAPY; RESISTANCE; HOMOLOGY; SEQUENCE	Cisplatin (CDDP) is an effective cancer chemotherapeutic drug used in the treatment of several human malignancies. The effectiveness of cisplatin therapy is limited by intrinsic resistance of tumors to this drug as well as the development of secondary tumors, which are also drug resistant. A potential mechanism influencing the sensitivity of cells to CDDP may result from the interaction of specific proteins with CDDP-damaged DNA (CDDP-DNA). In an earlier report, we demonstrated that high mobility group (HMG) proteins 1 and 2 bind with high affinity to CDDP-DNA. In the present study partial proteolytic digestion was used to localize the binding region of HMG2. A proteolytic fragment of approximately 20 kDa, containing the amino-terminal region of the protein, maintains the ability to bind with high affinity to CDDP-DNA, while an amino-terminal fragment of 14 kDa binds with slightly reduced affinity. In contrast, a peptide fragment lacking 51 NH2-terminal amino acids from HMG2 has greatly reduced affinity for damaged DNA. Recombinant peptide fragments containing HMG box-1 or HMG box 2 bind weakly to damaged DNA, while a recombinant fragment containing HMG boxes 1 and 2 binds with high affinity. Hence, our results indicate that the amino-terminal region of HMG2 contains the damaged DNA binding recognition site and that both HMG boxes 1 and 2, present in the parental molecule, are required for high affinity binding of this protein to CDDP-DNA.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania	LAWRENCE, DL (corresponding author), UNIV PENN,SCH MED,DEPT RADIAT ONCOL,PHILADELPHIA,PA 19104, USA.				NATIONAL CANCER INSTITUTE [R01CA058526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027309, R01GM027309] Funding Source: NIH RePORTER; NCI NIH HHS [CA58526] Funding Source: Medline; NIGMS NIH HHS [GM27309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AISNER J, 1989, SEMIN ONCOL, V16, P2; ALBERTS DS, 1991, SEMIN ONCOL, V18, P11; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BILLINGS PC, 1992, BIOCHEM BIOPH RES CO, V188, P1286, DOI 10.1016/0006-291X(92)91371-V; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CLUGSTON CK, 1992, CANCER RES, V52, P6375; DEWIT L, 1987, INT J RADIAT ONCOL, V13, P403, DOI 10.1016/0360-3016(87)90015-0; EINHORN LH, 1990, J CLIN ONCOL, V8, P1777, DOI 10.1200/JCO.1990.8.11.1777; Fojo A T, 1991, Adv Intern Med, V36, P195; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GOODWIN GH, 1975, BIOCHIM BIOPHYS ACTA, V405, P280, DOI 10.1016/0005-2795(75)90094-X; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HAYES JD, 1990, BIOCHEM J, V272, P281, DOI 10.1042/bj2720281; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JAVAHERIAN K, 1979, NUCLEIC ACIDS RES, V6, P3569, DOI 10.1093/nar/6.11.3569; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAJUMDAR A, 1991, NUCLEIC ACIDS RES, V19, P6643, DOI 10.1093/nar/19.23.6643; OZOLS RF, 1991, SEMIN ONCOL, V18, P222; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; PINTO A L, 1985, Biochimica et Biophysica Acta, V780, P167, DOI 10.1016/0304-419X(85)90001-0; RAGHAVAN D, 1991, SEMIN ONCOL, V18, P56; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; SHIRAKATA M, 1991, MOL CELL BIOL, V11, P4528, DOI 10.1128/MCB.11.9.4528; SHIRAKAWA H, 1992, J BIOL CHEM, V267, P6641; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; 1991, SEMIN ONCOL       S3, V18, P1	35	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23940	23945						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226934				2022-12-25	WOS:A1993MF29400037
J	SANFORD, JC; PAN, Y; WESSLINGRESNICK, M				SANFORD, JC; PAN, Y; WESSLINGRESNICK, M			PRENYLATION OF RAB5 IS DEPENDENT ON GUANINE-NUCLEOTIDE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING; PROTEIN FARNESYLTRANSFERASE; CYSTEINE MOTIFS; ALPHA-SUBUNIT; YEAST; ISOPRENYLATION; SELECTION; DISTINCT; INVITRO; P21RAS	Rab5 is a small molecular weight GTP-binding protein that functions in endocytic vesicle traffic. Like other Ras-related proteins, Rab5 is prenylated on C-terminal cysteine residues, although it lacks the typical C-terminal CAAX motif (where A is any aliphatic amino acid and X is any amino acid) to direct this post-translational modification. We have investigated structural requirements for the in vitro geranylgeranylation of Rab5. Rab5N133I, a point mutant that has impaired ability to bind GTP or GDP, undergoes modification to a limited extent and at a severely reduced rate when compared to cognate Rab5. A second point mutant, Rab5Q79L, can be processed to approximately the same extent as wild-type albeit at a reduced rate. Since the latter mutation results in defective GTPase activity, these combined observations indicate that guanine nucleotide binding plays an important role in the geranylgeranylation reaction and suggest that the GDP-bound form of Rab5 is the preferred conformation for interaction with Rab prenyltransferase. This idea is supported by the finding that non-hydrolyzable GTP analogs inhibit Rab5 prenylation, while in vitro processing of both H-ras and the gamma2 subunit of regulatory G proteins is unaffected at concentrations of guanosine 5'-O-(thiotriphosphate) (GTP-gammaS) up to 400 muM. Moreover, a truncation mutant lacking the C-terminal cysteines, Rab5(1-211), serves as an inhibitor of Rab5wt geranylgeranylation when liganded with GDP but not GTPgammaS. Thus, the recognition of Rab5 as a substrate by Rab prenyltransferase involves structural elements exclusive of the C terminus and dependent upon the GDP-binding conformation of the protein.			SANFORD, JC (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115, USA.				NIDDK NIH HHS [DK45737] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045737] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1990, J BIOL CHEM, V265, P13007; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MOORES SL, 1991, J BIOL CHEM, V266, P14603; PETER M, 1992, J CELL SCI, V102, P857; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; STRUHL K, 1983, GENE, V26, P231, DOI 10.1016/0378-1119(83)90193-2; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WILSON AL, 1993, J BIOL CHEM, V268, P14561; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	24	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23773	23776						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226909				2022-12-25	WOS:A1993MF29400011
J	SHIMURA, H; IKUYAMA, S; SHIMURA, Y; KOHN, LD				SHIMURA, H; IKUYAMA, S; SHIMURA, Y; KOHN, LD			THE CAMP RESPONSE ELEMENT IN THE RAT THYROTROPIN RECEPTOR PROMOTER - REGULATION BY EACH DECANUCLEOTIDE OF A FLANKING TANDEM REPEAT USES DIFFERENT, ADDITIVE, AND NOVEL MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; GROWTH FACTOR-I; C-MYC GENE; H-DNA; TRANSCRIPTIONAL SILENCER; 5'-FLANKING REGION; EXPRESSION; ENHANCER; CELLS; IDENTIFICATION	A decanucleotide tandem repeat (TR) sequence, between -162 and -140 base pairs (bp) of the minimal thyrotropin receptor promoter, decreases gene expression by repressing constitutive enhancer activity of its cAMP response element (CRE). Each decanucleotide acts additively. CRE-binding proteins and liver or thyroid nuclear extracts footprint a region including the CRE and the 3' decanucleotide, -148 to -124 bp; nuclear proteins interacting with the 3' decanucleotide protect a smaller region, -148 to -135 bp. Separate groups of nuclear proteins interact with the CRE and the 3' decanucleotide; mutations of the CRE affect protein interactions with the 3' decanucleotide and the converse. Nuclear proteins bind to single- or double-stranded 3' decanucleotide DNA; those interacting with the CRE bind only double-stranded DNA. The repressor action of the 5' decanucleotide is associated with an interaction between the coding strand and a single-stranded binding protein in liver and thyroid nuclear extracts. The 5' decanucleotide is in a CT-rich region with Sl nuclease hypersensitivity, near perfect mirror images, and direct repeats. The data therefore indicate that each TR decanucleotide modulates CRE constitutive enhancer activity by different but additive mechanisms, competition versus interaction with a single-stranded binding protein, and each interacts with different nuclear proteins that are not thyroid-specific. The same region in the human thyrotropin receptor represses CRE constitutive enhancer activity by the same mechanisms, despite a nonidentical sequence and no overt TR.	NIDDKD,BIOCHEM & METAB LAB,CELL REGULAT SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; Ambesi Impiombato FS., 1986, United States Patent, Patent No. [US 4608341, 4608341]; Ambesi-Impiombato F S, 1979, Int Rev Cytol Suppl, P163; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; DAVIS LG, 1986, BASIC METHODS MOL BI, P93; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; EKHOLM R, 1989, ADV EXPT MED BIOL, V261, P1; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSS B, 1991, BIOCHEM BIOPH RES CO, V177, P679, DOI 10.1016/0006-291X(91)91842-Z; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P1701, DOI 10.1210/me.6.10.1701; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; KIYAMA R, 1991, P NATL ACAD SCI USA, V88, P10450, DOI 10.1073/pnas.88.23.10450; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LARSEN PR, 1986, P NATL ACAD SCI USA, V83, P8283, DOI 10.1073/pnas.83.21.8283; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; Maxam A M, 1980, Methods Enzymol, V65, P499; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAJI M, 1991, BIOCHEM BIOPH RES CO, V176, P94, DOI 10.1016/0006-291X(91)90894-D; SAJI M, 1992, ENDOCRINOLOGY, V130, P520, DOI 10.1210/en.130.1.520; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379; TAKADA K, 1990, J CLIN INVEST, V86, P1548, DOI 10.1172/JCI114874; TAKAHASHI S, 1990, ENDOCRINOLOGY, V126, P736, DOI 10.1210/endo-126-2-736; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; WOLOSHIN PI, 1992, MOL ENDOCRINOL, V6, P1725, DOI 10.1210/me.6.10.1725	46	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24125	24137						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226959				2022-12-25	WOS:A1993MF29400063
J	LUO, JH; WEINSTEIN, IB				LUO, JH; WEINSTEIN, IB			CALCIUM-DEPENDENT ACTIVATION OF PROTEIN-KINASE-C - THE ROLE OF THE C2 DOMAIN IN DIVALENT-CATION SELECTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; SUBSTRATE-SPECIFICITY; REGULATORY DOMAIN; CONTAINS; ZINC; REGION; PKC	Activation of certain isoforms of protein kinase C (cPKCs) requires Ca2+ and is associated with a conserved C2 domain that is not present in Ca2+-independent isoforms (nPKCs). The site(s) of Ca2+ binding and the role of the C2 domain have not been previously identified. We have analyzed phosphatidylserine-dependent Ca2+ binding to fusion proteins expressed in Escherichia coli that carry various modifications in the regulatory region of cPKCbeta1 or nPKCepsilon. Ca2+ is bound mainly to the C1 domain of PKCbeta1, but the C2 domain confers specificity for Ca2+ binding when compared with Mg2+ and Mn2+. We propose that in cPKCs there is selective binding of Ca2+ to a pocket formed by the C1 and C2 domains. This induces a change in conformation that activates the enzyme. In nPKCs, the cation binding pocket is less specific for Ca2+ because it lacks the C2 domain. Therefore, divalent cations like Mg2+ can bind to it, thereby abrogating the requirement of Ca2+ for enzyme activation.	COLUMBIA UNIV,DEPT MED,NEW YORK,NY 10027; COLUMBIA UNIV,DEPT GENET & DEV,NEW YORK,NY 10027; COLUMBIA UNIV,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10027	Columbia University; Columbia University; Columbia University					NCI NIH HHS [CA-02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P971, DOI 10.1021/bi00218a013; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CAZAUBON S, 1990, EUR J BIOCHEM, V194, P799, DOI 10.1111/j.1432-1033.1990.tb19472.x; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUBBARD SR, 1991, SCIENCE, V254, P1776; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1986, J BIOL CHEM, V261, P4867; LUO JH, 1993, J BIOL CHEM, V268, P3715; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORBY JG, 1980, ANAL BIOCHEM, V102, P318, DOI 10.1016/0003-2697(80)90160-8; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINSTEIN IB, 1991, ORIGINS OF HUMAN CANCER, P113	27	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23580	23584						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226885				2022-12-25	WOS:A1993MF51500095
J	CORCUFF, JB; GUERINEAU, NC; MARIOT, P; LUSSIER, BT; MOLLARD, P				CORCUFF, JB; GUERINEAU, NC; MARIOT, P; LUSSIER, BT; MOLLARD, P			MULTIPLE CYTOSOLIC CALCIUM SIGNALS AND MEMBRANE ELECTRICAL EVENTS EVOKED IN SINGLE ARGININE VASOPRESSIN-STIMULATED CORTICOTROPHS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR-PITUITARY-CELLS; THYROTROPIN-RELEASING-HORMONE; PROTEIN-KINASE-C; ACTIVATED POTASSIUM CURRENTS; RAT PITUITARY; ACTION-POTENTIALS; TUMOR-CELLS; ADRENOCORTICOTROPIN SECRETION; EXTRACELLULAR CALCIUM; INTRACELLULAR STORES	The action of arginine vasopressin (AVP) on cytosolic free Ca2+ concentration ([Ca2+]i) was investigated in single rat pituitary corticotrophs using indo-1 microfluorimetry, in part in combination with the monitoring of membrane electrical events with the perforated patch-clamp technique. In corticotrophs showing the series of short-lived [Ca2+]i rises (transient pattern) in response to corticotropin-releasing factor, 100 nM AVP evoked either the transient pattern or a [Ca2+]i spike followed by a sustained plateau (spike/plateau pattern). Not all corticotrophs responded to changes in AVP concentration in the same manner. Some cells exhibited a concentration-dependent increase in [Ca2+]i transient activity, whereas others showing the spike/plateau at high AVP concentrations responded to low agonist concentrations by two [Ca2+]i responses: a slow rising step or two to three sinusoidal-like oscillations. Combined [Ca2+]i and patch-clamp recordings as well as manipulation of extracellular Ca2+ showed that both transient pattern and the plateau of spike/plateau response depended on Ca2+ entry mainly through voltage-gated, dihydropyridine-sensitive Ca2+ channels. By contrast, step, oscillations, and spike were due to Ca2+ release from internal stores. These Ca2+-mobilizing responses caused the activation of Ca2+-activated, apamin-sensitive K+ channels, which led to a membrane hyperpolarization. These results reveal cell-specific [Ca2+]i signals and associated electrical events in individual AVP-stimulated corticotrophs.	UNIV BORDEAUX 2, CNRS, URA 1200, NEUROPHYSIOL LAB, F-33076 BORDEAUX, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux			Lussier, Benoit/B-9114-2012; Corcuff, jb/GWM-4201-2022	Lussier, Benoit/0000-0002-2152-6314; Guerineau, Nathalie/0000-0003-2517-4210; Mariot, Pascal/0000-0001-7226-9162				ABOUSAMRA AB, 1986, ENDOCRINOLOGY, V118, P212, DOI 10.1210/endo-118-1-212; ABOUSAMRA AB, 1987, J BIOL CHEM, V262, P1129; AGUILERA G, 1983, J BIOL CHEM, V258, P8039; ANTONI FA, 1984, NEUROENDOCRINOLOGY, V39, P186, DOI 10.1159/000123976; ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; ARMSTRONG DL, 1991, ANN NY ACAD SCI, V635, P26, DOI 10.1111/j.1749-6632.1991.tb36478.x; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BANDYOPADHYAY SK, 1989, J BIOL CHEM, V264, P14216; BILEZIKJIAN LM, 1987, MOL ENDOCRINOL, V1, P555, DOI 10.1210/mend-1-8-555; BROWN DA, 1988, J PHYSIOL-LONDON, V397, P149, DOI 10.1113/jphysiol.1988.sp016993; BRUHN TO, 1984, NEUROENDOCRINOLOGY, V39, P170, DOI 10.1159/000123974; CANNY BJ, 1992, J BIOL CHEM, V267, P8325; CARVALLO P, 1989, MOL ENDOCRINOL, V3, P1935, DOI 10.1210/mend-3-12-1935; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; DELIDOW BC, 1992, MOL ENDOCRINOL, V6, P1268, DOI 10.1210/me.6.8.1268; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P451, DOI 10.1111/j.1476-5381.1968.tb08474.x; DUCHEMIN AM, 1992, MOL ENDOCRINOL, V6, P563, DOI 10.1210/me.6.4.563; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GOLLASCH M, 1991, P NATL ACAD SCI USA, V88, P10262, DOI 10.1073/pnas.88.22.10262; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUERINEAU N, 1991, ENDOCRINOLOGY, V129, P409, DOI 10.1210/endo-129-1-409; GUERINEAU NC, 1992, CELL CALCIUM, V13, P521, DOI 10.1016/0143-4160(92)90020-S; GUILD S, 1987, J PHARMACOL EXP THER, V241, P125; GUILLON G, 1987, REGUL PEPTIDES, V18, P119, DOI 10.1016/0167-0115(87)90001-2; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; HOLMES MC, 1984, NEUROENDOCRINOLOGY, V39, P162, DOI 10.1159/000123973; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JARD S, 1986, MOL PHARMACOL, V30, P171; KORN SJ, 1991, J PHYSIOL-LONDON, V439, P423, DOI 10.1113/jphysiol.1991.sp018674; LABRIE F, 1982, SCIENCE, V216, P1007, DOI 10.1126/science.6281886; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; LANG DG, 1990, PFLUG ARCH EUR J PHY, V416, P704, DOI 10.1007/BF00370618; LEONG DA, 1991, J BIOL CHEM, V266, P9016; LEONG DA, 1988, J EXP BIOL, V139, P151; LEREA LS, 1992, J NEUROSCI, V12, P2973, DOI 10.1523/JNEUROSCI.12-08-02973.1992; LINK H, 1992, ENDOCRINOLOGY, V130, P2183, DOI 10.1210/en.130.4.2183; LLEDO PM, 1991, J PHYSIOL-LONDON, V437, P477, DOI 10.1113/jphysiol.1991.sp018607; LUINI A, 1985, P NATL ACAD SCI USA, V82, P8034, DOI 10.1073/pnas.82.23.8034; LUSSIER BT, 1991, ENDOCRINOLOGY, V128, P570, DOI 10.1210/endo-128-1-570; MARCHETTI C, 1987, AM J PHYSIOL, V252, pE340, DOI 10.1152/ajpendo.1987.252.3.E340; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MITSUHASHI M, 1989, J BIOL CHEM, V264, P18356; MOLLARD P, 1991, EUR J PHARM-MOLEC PH, V206, P271, DOI 10.1016/0922-4106(91)90109-U; MOLLARD P, 1988, ENDOCRINOLOGY, V123, P721, DOI 10.1210/endo-123-2-721; MOLLARD P, 1988, J BIOL CHEM, V263, P19570; MOLLARD P, 1992, BIOCHEM J, V284, P637, DOI 10.1042/bj2840637; MOLLARD P, 1989, BIOCHEM BIOPH RES CO, V164, P1045, DOI 10.1016/0006-291X(89)91775-0; MOLLARD P, 1990, BIOCHEM J, V268, P345, DOI 10.1042/bj2680345; MOLLARD P, 1988, FASEB J, V2, P2907, DOI 10.1096/fasebj.2.13.2844618; MUALLEM S, 1988, BIOCHEM J, V255, P301; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; PRIBNOW D, 1992, MOL ENDOCRINOL, V6, P1003, DOI 10.1210/me.6.7.1003; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RAYMOND V, 1985, FEBS LETT, V182, P196, DOI 10.1016/0014-5793(85)81183-2; RITCHIE AK, 1987, J PHYSIOL-LONDON, V385, P611, DOI 10.1113/jphysiol.1987.sp016510; RITCHIE AK, 1987, J PHYSIOL-LONDON, V385, P591, DOI 10.1113/jphysiol.1987.sp016509; SCHERUBL H, 1991, P ROY SOC LOND B BIO, V245, P125; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SCHULMAN H, 1992, CELL CALCIUM, V13, P401, DOI 10.1016/0143-4160(92)90053-U; SHANGOLD GA, 1988, P NATL ACAD SCI USA, V85, P6566, DOI 10.1073/pnas.85.17.6566; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; STOJILKOVIC SS, 1991, J BIOL CHEM, V266, P10377; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; THELER JM, 1992, J BIOL CHEM, V267, P18110; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; VALE W, 1983, ENDOCRINOLOGY, V113, P1121, DOI 10.1210/endo-113-3-1121; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; WINIGER BP, 1988, BIOCHEM J, V255, P161, DOI 10.1042/bj2550161; WON JGS, 1990, ENDOCRINOLOGY, V126, P849, DOI 10.1210/endo-126-2-849; WON JGS, 1990, ENDOCRINOLOGY, V126, P858, DOI 10.1210/endo-126-2-858; ZIMMERMAN G, 1970, ENDOCRINOLOGY, V87, P426, DOI 10.1210/endo-87-2-426	77	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22313	22321						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226740				2022-12-25	WOS:A1993MD34800022
J	DEMARTIN, R; COWLED, PA; SMITH, SE; PAPAVASSILIOU, AG; SORRENTINO, V; PHILIPSON, L; BOHMANN, D				DEMARTIN, R; COWLED, PA; SMITH, SE; PAPAVASSILIOU, AG; SORRENTINO, V; PHILIPSON, L; BOHMANN, D			STRUCTURE AND REGULATION OF THE GROWTH ARREST-SPECIFIC (GAS-1) PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; MOUSE FIBROBLASTS; GENE; DNA; EXPRESSION; SEQUENCES; PROTEIN; UPSTREAM; ONCOGENE; SIGNAL	We have isolated recombinant genomic clones encompassing several kilobase pairs of the 5'-flanking regions of both the human and murine gas-1 gene (growth arrest-specific gene 1). Both species share a highly conserved region of approximately 550 base pairs upstream of the gas-1 transcription start site. Deletion analysis of the murine gas-1 promoter demonstrated that a fragment containing the first 665 base pairs is sufficient to drive the serum-regulated expression of a luciferase reporter gene in NIH3T3 cells, in a manner qualitatively reflecting the activity of the endogenous gene. Gel retardation assays indicated the presence of a number of DNA-binding proteins specific for sequences contained within the gas-1 transcription regulatory region. Comparative studies with extracts prepared from growing and resting cells revealed several growth state-specific binding activities. One promoter fragment that bound prominent growth- and arrest-specific complexes was further analyzed by copper-phenanthroline footprinting. It was found that the same DNA element is a target both for growth- and for arrest-specific activities. The factors characterized in this study are the first candidates for transcriptional regulators mediating cell growth-specific repression and/or growth arrest-specific activation of gene expression.	EUROPEAN MOLEC BIOL LAB,POB 102209,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Sorrentino, Vincenzo/A-4793-2014; Karamouzis, Michalis/AAD-2860-2020	Sorrentino, Vincenzo/0000-0002-8573-8631; 				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANSORGE W, 1987, NUCLEIC ACIDS RES, V15, P4593, DOI 10.1093/nar/15.11.4593; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; DAILEY L, 1986, P NATL ACAD SCI USA, V83, P7241, DOI 10.1073/pnas.83.19.7241; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DEMARTIN R, 1993, GENE, V124, P137, DOI 10.1016/0378-1119(93)90776-Y; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVELETH DD, 1986, NUCLEIC ACIDS RES, V14, P6169, DOI 10.1093/nar/14.15.6169; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; Howard A, 1953, HEREDITY           S, V6, P261; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; PADMANABHAN R, 1987, MOL CELL BIOL, V7, P1894, DOI 10.1128/MCB.7.5.1894; PEPPERKOK R, 1988, P NATL ACAD SCI USA, V85, P6748, DOI 10.1073/pnas.85.18.6748; PEPPERKOK R, 1993, EXP CELL RES, V204, P278, DOI 10.1006/excr.1993.1034; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; SMITH SE, 1993, NUCLEIC ACIDS RES, V21, P1581, DOI 10.1093/nar/21.7.1581; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; THOMAS MJ, 1990, MOL CELL BIOL, V10, P5378, DOI 10.1128/MCB.10.10.5378; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	28	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22788	22793						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226788				2022-12-25	WOS:A1993MD34800088
J	FISCHER, H; GLOCKSHUBER, R				FISCHER, H; GLOCKSHUBER, R			ATP HYDROLYSIS IS NOT STOICHIOMETRICALLY LINKED WITH PROTEOLYSIS IN THE ATP-DEPENDENT PROTEASE LA FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LON GENE-PRODUCT; HEAT-SHOCK; ION GENE; SUBSTRATES ACTIVATE; DEGRADATION; PROTEINS; MUTAGENESIS; BREAKDOWN; EXPRESSION; PEPTIDES	Protein degradation in Escherichia coli involves the ATP-dependent serine protease La. Protease La is a homotetramer with one proteolytic and one ATP binding site per monomer. Its proteolytic activity has been shown to be highly increased by simultaneous hydrolysis of ATP, which is essential for the degradation of protein substrates by this enzyme. We have cloned and purified a proteolytically inactive La mutant, in which the catalytically active serine residue at position 679 was replaced by alanine. Fluorescence and circular dichroism spectra of the purified wild type and mutant enzyme revealed identical conformations of the proteins. Based on this observation, the catalytic properties of the wild type enzyme and the S679A mutant were compared. Although the S679A mutant lacks proteolytic activity toward both peptide and protein substrates under all conditions investigated, its ATPase activity is completely unaffected by the removal of the protease activity. Since protein substrates stimulate the ATP-dependent hydrolysis of peptides by protease La, it has been argued that this stimulation is due to interactions with a regulatory binding site on the enzyme. In accordance with this model, protein substrates such as alpha-casein and denatured bovine serum albumin stimulate the ATPase activity of the S679A mutant to the same degree as in the active protease. Therefore, the intrinsic ATPase activity of protease La as well as its stimulation is not dependent on the simultaneous hydrolysis of the protein substrate.	UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, UNIV STR 31, D-93053 REGENSBURG, GERMANY	University of Regensburg								AMERIK AY, 1991, FEBS LETT, V287, P211, DOI 10.1016/0014-5793(91)80053-6; AMERIK AY, 1988, BIOORG KHIM+, V14, P408; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOFF SA, 1987, J BIOL CHEM, V262, P4508; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GOLDBERG AL, 1985, J BIOL CHEM, V260, P2029; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HERSHKO A, 1982, ANNU REV BIOCHEM, V51, P335, DOI 10.1146/annurev.bi.51.070182.002003; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MENON AS, 1987, J BIOL CHEM, V262, P14921; MENON AS, 1987, J BIOL CHEM, V262, P14929; MENON AS, 1987, J BIOL CHEM, V262, P722; OLDEN K, 1978, BIOCHIM BIOPHYS ACTA, V542, P385, DOI 10.1016/0304-4165(78)90370-7; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHILLIPS TA, 1984, J BACTERIOL, V159, P283, DOI 10.1128/JB.159.1.283-287.1984; ROTHMAN JE, 1986, NATURE, V322, P209, DOI 10.1038/322209a0; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN MY, 1992, EMBO J, V11, P71; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TEALE FWJ, 1960, BIOCHEM J, V76, P381, DOI 10.1042/bj0760381; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAXMAN L, 1982, P NATL ACAD SCI-BIOL, V79, P4883, DOI 10.1073/pnas.79.16.4883; WAXMAN L, 1985, J BIOL CHEM, V260, P2022; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22502	22507						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226758				2022-12-25	WOS:A1993MD34800049
J	OTANI, H; ERDOS, M; LEONARD, WJ				OTANI, H; ERDOS, M; LEONARD, WJ			TYROSINE KINASE(S) REGULATE APOPTOSIS AND BCL-2 EXPRESSION IN A GROWTH FACTOR-DEPENDENT CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTATION; C-MYC; CHROMOSOMAL BREAKPOINT; CLONAL DELETION; B-CELLS; DEATH; GENE; THYMOCYTES; ACTIVATION; SURVIVAL	Apoptosis (programmed cell death) plays a critical role in many physiological processes, but the mechanism(s) which regulate apoptosis are poorly understood. We demonstrate that in a hematopoietic cell line, which can grow in either interleukin (IL)-2 or IL-3, both of these growth factors can increase bcl-2 mRNA levels and prevent apoptosis normally seen following growth factor withdrawal. Herbimycin A, a protein tyrosine kinase inhibitor, blocks the ability of IL-2 and IL-3 to up-regulate bcl-2 mRNA levels and induces apoptosis. Transfection of a bcl-2 expression vector not only prolongs survival following growth factor withdrawal but also confers resistance to the effect of herbimycin A. We conclude that herbimycin A-sensitive protein tyrosine kinases are involved in the regulation of apoptosis and bcl-2 expression, but these protein tyrosine kinases appear not to be required for the action of Bcl-2 since Bcl-2 can exert its growth survival effect even in the presence of herbimycin A.	NHLBI,OFF DIRECTOR,INTRAMURAL RES PROGRAM,PULM & MOLEC IMMUNOL SECT,BETHESDA,MD 20892; NICHHD,MOLEC GENET LAB,BETHESDA,MD 20892; SHIMANE MED UNIV,DEPT ANAT,IZUMO,SHIMANE 693,JAPAN	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Shimane University			Leonard, Warren/AAA-1397-2022					BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CAO MV, 1992, NEURON, V9, P583; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; CHOW SC, 1989, ANAL BIOCHEM, V183, P42, DOI 10.1016/0003-2697(89)90168-1; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COHEN JJ, 1984, J IMMUNOL, V132, P38; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GURFINKEL N, 1987, EUR J IMMUNOL, V17, P567, DOI 10.1002/eji.1830170421; ISFORT R, 1988, J BIOL CHEM, V263, P19203; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KACZMAREK L, 1987, J CELL BIOL, V104, P183, DOI 10.1083/jcb.104.2.183; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; MIYASHITA T, 1992, CANCER RES, V52, P5407; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAKAYAMA K, 1992, SCIENCE, V257, P94, DOI 10.1126/science.1621101; NUNEZ G, 1990, J IMMUNOL, V144, P3602; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	38	101	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22733	22736						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226783				2022-12-25	WOS:A1993MD34800080
J	MOGHUL, A; LIN, L; BEEDLE, A; KANBOURSHAKIR, A; DEFRANCES, MC; LIU, YH; ZARNEGAR, R				MOGHUL, A; LIN, L; BEEDLE, A; KANBOURSHAKIR, A; DEFRANCES, MC; LIU, YH; ZARNEGAR, R			MODULATION OF C-MET PROTOONCOGENE (HGF RECEPTOR) MESSENGER-RNA ABUNDANCE BY CYTOKINES AND HORMONES - EVIDENCE FOR RAPID DECAY OF THE 8 KB C-MET TRANSCRIPT	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; SCATTER FACTOR; EPITHELIAL-CELLS; TYROSINE KINASE; MOLECULAR-CLONING; HEPATOPOIETIN-A; CARCINOMA-CELLS; FACTOR-ALPHA; PROTOONCOGENE	The c-MET proto-oncogene product is a transmembrane tyrosine kinase receptor which was recently shown to transmit an array of important cellular responses induced by Hepatocyte Growth Factor (HGF). These biological effects include induction of mitogenesis, motogenesis, morphogenesis, metastogenesis and anti-tumor activity on a variety of epithelial cells, All of these processes are known to be associated with normal and abnormal tissue growth and development. The 190 kDa c-MET protein is encoded by a major transcript of 8 kilobases (Kb), which is reported to be expressed predominantly in epithelial tissues. The expression pattern of c-MET mRNA and protein are drastically modified in many tumor tissues and cell lines. Currently, no information is available on the molecular mechanisms that regulate c-MET mRNA level. In the present communication, we report for the first time that the inflammatory cytokines such as IL-1 alpha, IL-6 and TNF-alpha, as well as TGF-beta 1, EGF, HGF and the steroidal hormones (estrogen, progesterone, tamoxifen and dexamethasone) markedly influence the steady-state levels of the 8 kb c-MET mRNA in human carcinoma cell lines derived from human tissues such as ovary, breast and endometrium. We demonstrate that c-MET receptor protein is present at high levels in primary tumors of human ovaries (clear cell carcinomas). We present evidence that the 8 kb c-MET mRNA undergoes rapid degradation with a half-life of less than 30 min and that this decay can be quickly inhibited by cyclohex-imide. Our results suggests that the expression of the c-met proto-oncogene resembles that of an immediate early response gene.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,DIV CELLULAR & MOLEC PATHOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Liu, Youhua/0000-0002-4740-805X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES-06109] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CAPPUCCINI F, 1991, LYMPHOKINE CYTOK RES, V10, P225; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEFRANCES MC, 1992, DEVELOPMENT, V116, P38; ERROI A, 1989, INT J CANCER, V44, P795, DOI 10.1002/ijc.2910440508; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KOMADA M, 1993, ONCOGENE, V8, P2381; LIU C, 1992, ONCOGENE, V7, P181; LIU YH, 1994, J BIOL CHEM, V269, P4152; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RODRIGUES GA, 1993, HEPATOCYTE GROWTH FA, P167; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; SEOL DW, 1994, UNPUB; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SHYU AB, 1989, GENE DEV, V3, P70; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TAMURA M, 1993, J BIOL CHEM, V268, P8140; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; WAY DL, 1983, IN VITRO CELL DEV B, V19, P147; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; YANG XM, 1993, DEV BIOL, V157, P308, DOI 10.1006/dbio.1993.1137; YEE CJ, 1993, BIOCHEMISTRY-US, V32, P7922, DOI 10.1021/bi00082a013; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252	44	143	144	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2045	2052						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208549				2022-12-25	WOS:A1994NR68500029
J	ALBONE, EF; HAGEN, FK; VANWUYCKHUYSE, BC; TABAK, LA				ALBONE, EF; HAGEN, FK; VANWUYCKHUYSE, BC; TABAK, LA			MOLECULAR-CLONING OF A RAT SUBMANDIBULAR-GLAND APOMUCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCIN-LIKE PROTEIN; INTESTINAL MUCIN; SALIVARY MUCIN; SUBMAXILLARY; EXPRESSION; SEQUENCE; CONSERVATION; CLEAVAGE; DOMAINS; GENES	Overlapping cDNA clones which encode the protein core of a rat submandibular gland mucin-glycoprotein have been isolated and characterized. Sequence analysis revealed a translated region of 966 nucleotides encoding a protein of 322 amino acid residues. The translational start site begins with a putative signal sequence comprising the initial 22 N-terminal residues. The predicted- secreted portion of the apomucin revealed three distinct domains: an N-terminal domain which is enriched in glutamine (14%), proline (13%), and tyrosine (10%); a central region which consisted of eleven, 39-base pair tandem repeats with the consensus sequence PTTDSTTPAPTTK; and a C-terminal domain which is enriched in threonine and serine residues (47%) which are not part of a repeat motif. The expression of apomucin transcript appears restricted to the rat submandibular and sublingual glands. Southern blot analysis of rat genomic DNAs suggested a low copy number (1, 2) for this apomucin gene and a limited polymorphism in the number of tandem repeats. Collectively, our sequence and expression data indicate that the cloned rat submandibular gland apomucin is distinct from any of the other salivary (bovine, porcine, or human) or rat apomucins reported thus far.	UNIV ROCHESTER,SCH MED & DENT,DEPT DENT RES,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NIDCR NIH HHS [DE-08108] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008108, R01DE008108] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER LF, 1991, J BIOL CHEM, V266, P3532; ECKHARDT AE, 1987, J BIOL CHEM, V262, P11339; EDGE ASB, 1981, J BIOL CHEM, V226, P9678; GERKEN TA, 1992, BIOCHEMISTRY-US, V31, P639, DOI 10.1021/bi00118a002; GOTTSCHALK A, 1969, NATURE, V222, P452, DOI 10.1038/222452a0; GUM JR, 1991, J BIOL CHEM, V266, P22733; HOFFMAN MP, 1993, INFECT IMMUN, V61, P1940, DOI 10.1128/IAI.61.5.1940-1949.1993; HUANG SH, 1992, METHOD MOL BIOL, V16, P357; JOHANSSON M, 1993, J HERED, V84, P259, DOI 10.1093/oxfordjournals.jhered.a111336; KHATRI IA, 1993, BIOCHEM J, V294, P391, DOI 10.1042/bj2940391; KOZAK M, 1983, MICROBIOL REV, V47, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIRELS L, 1987, J BIOL CHEM, V262, P7289; MOREIRA JE, 1989, J HISTOCHEM, V3, P515; NUGENT J, 1984, CIBA F S MUCUS MUCOS, V109, P1; ORSTAVIK TB, 1977, ACTA PHYSIOL SCAND, V100, P33, DOI 10.1111/j.1748-1716.1977.tb05919.x; QUISSELL DO, 1989, HDB PHYSL SALIVARY P, P79; Sambrook J, 1989, MOL CLONING LABORATO; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SHARIFI BG, 1985, J CHROMATOGR, V324, P173, DOI 10.1016/S0021-9673(01)81316-9; SPICER AP, 1991, J BIOL CHEM, V266, P15099; TABAK LA, 1982, J ORAL PATHOL MED, V11, P1, DOI 10.1111/j.1600-0714.1982.tb00138.x; TABAK LA, 1985, ARCH BIOCHEM BIOPHYS, V242, P383, DOI 10.1016/0003-9861(85)90222-X; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; TSUDA T, 1993, BIOCHEM BIOPH RES CO, V195, P363, DOI 10.1006/bbrc.1993.2052; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WARREN L, 1959, J BIOL CHEM, V234, P1971; XU GQ, 1992, BIOCHEM J, V286, P335, DOI 10.1042/bj2860335	33	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16845	16852						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207007				2022-12-25	WOS:A1994NR29600052
J	LEGENDRE, L; YUEH, YG; CRAIN, R; HADDOCK, N; HEINSTEIN, PF; LOW, PS				LEGENDRE, L; YUEH, YG; CRAIN, R; HADDOCK, N; HEINSTEIN, PF; LOW, PS			PHOSPHOLIPASE-C ACTIVATION DURING ELICITATION OF THE OXIDATIVE BURST IN CULTURED PLANT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNIT; INOSITOL 1,4,5-TRISPHOSPHATE; SIGNAL TRANSDUCTION; DUNALIELLA-SALINA; PLASMA-MEMBRANE; SOYBEAN CELLS; RAPID CHANGES; PHOSPHATIDYLINOSITOL; STIMULATION; METABOLISM	Although phospholipase C hydrolysis of polyphosphoinositides constitutes one of the major second messenger pathways in animal cells, its participation in signal transduction in higher plants has not been established. To determine whether activation of phosphatidylinositol-directed phospholipase C might be involved in signaling the elicitor-induced oxidative burst in plants, suspension-cultured soybean cells were treated with two stimulants of the H2O2 burst and examined for polyphosphoinositide turnover. Both polygalacturonic acid elicitor and the G protein activator, mastoparan, promoted a transient increase in inositol 1,4,5-trisphosphate (IP3) content that exceeded basal IP3 levels (0.9 +/- 0.4 pmol of IP3/10(6) cells, n = 28) by 2.6- and 7-fold, respectively. In each case, intracellular IP3 content reached a maximum at 1 min post-stimulation and declined to near basal levels during the subsequent 5-10 min. Neomycin sulfate, an inhibitor of polyphosphoinositide hydrolysis, blocked the IP3 transient, and Mas-17, an inactive analogue of mastoparan, induced no change in IP3. Thin layer chromatography of lipid extracts of the soybean cells corroborated the above results by revealing a rapid decrease in phosphatidylinositol monophosphate and phosphatidylinositol 4,5-bisphosphate following polygalacturonic acid elicitor and mastoparan (but not Mas-17) stimulation. Since the rise in IP3 preceded H2O2 production and since neomycin sulfate inhibited the appearance of both, we hypothesize that phospholipase C activation might constitute one pathway by which elicitors trigger the soybean oxidative burst.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA; UNIV CONNECTICUT, DEPT MOLEC & CELL BIOL, STORRS, CT 06269 USA; PURDUE UNIV, DEPT MED CHEM & PHARMACOGNOSY, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Connecticut; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Yueh, Yir Gloria/U-1699-2019	Low, Philip/0000-0001-9042-5528				ANDERSON RA, 1989, RED BLOOD CELL MEMBR, P187; APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; APOSTOL I, 1987, PLANT PHYSIOL, V84, P1276, DOI 10.1104/pp.84.4.1276; BAGGIOLINI M, 1990, TRENDS BIOCHEM SCI, V15, P69, DOI 10.1016/0968-0004(90)90179-F; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLATT MR, 1990, NATURE, V346, P766, DOI 10.1038/346766a0; CHEN QY, 1990, PLANT PHYSIOL, V94, P1820, DOI 10.1104/pp.94.4.1820; CHEN QY, 1991, PLANT PHYSIOL, V96, P340, DOI 10.1104/pp.96.1.340; COTE GG, 1990, PLANT BIOL, V9, P113; COTE GG, 1993, ANNU REV PLANT PHYS, V44, P333, DOI 10.1146/annurev.pp.44.060193.002001; DILLENSCHNEIDER M, 1986, FEBS LETT, V208, P413, DOI 10.1016/0014-5793(86)81059-6; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DROBAK BK, 1991, ESSAYS BIOCHEM, V26, P27; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; EINSPAHR KJ, 1989, PLANT PHYSIOL, V90, P1115, DOI 10.1104/pp.90.3.1115; EINSPAHR KJ, 1990, PLANT PHYSIOL, V93, P361, DOI 10.1104/pp.93.2.361; EINSPAHR KJ, 1988, J BIOL CHEM, V263, P5775; ETTLINGER C, 1988, NATURE, V331, P176, DOI 10.1038/331176a0; HASEGAWA PM, 1980, PLANT CELL PHYSIOL, V21, P1347, DOI 10.1093/pcp/21.8.1347; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HORN MA, 1989, PLANT CELL, V1, P1003, DOI 10.1105/tpc.1.10.1003; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; KUROSAKI F, 1987, PLANT PHYSIOL, V85, P601, DOI 10.1104/pp.85.3.601; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LEGENDRE L, 1992, J BIOL CHEM, V267, P20140; LEGENDRE L, 1993, PLANT PHYSIOL, V102, P233, DOI 10.1104/pp.102.1.233; LOW PS, 1986, ARCH BIOCHEM BIOPHYS, V249, P472, DOI 10.1016/0003-9861(86)90024-X; MA H, 1991, GENE, V107, P189; MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/pnas.87.10.3821; MEMON AR, 1990, J BIOL CHEM, V265, P14817; MORRE DJ, 1984, J BIOL CHEM, V259, P5364; MORSE MJ, 1990, PLANT BIOL, V9, P201; MORSE MJ, 1989, PHYSIOL PLANTARUM, V76, P118, DOI 10.1111/j.1399-3054.1989.tb05462.x; NIGAM S, 1992, BIOCHIM BIOPHYS ACTA, V1135, P301, DOI 10.1016/0167-4889(92)90235-4; NORGAUER J, 1992, BIOCHEM J, V282, P393, DOI 10.1042/bj2820393; NOTHNAGEL EA, 1983, PLANT PHYSIOL, V71, P916, DOI 10.1104/pp.71.4.916; PALMER S, 1990, METHODS INOSITIDE RE, P127; PEELER TC, 1990, PHYSIOL PLANTARUM, V78, P324, DOI 10.1034/j.1399-3054.1990.780302.x; QUARMBY LM, 1992, J CELL BIOL, V116, P737, DOI 10.1083/jcb.116.3.737; RYAN CA, 1992, PLANT MOL BIOL, V19, P123, DOI 10.1007/BF00015610; RYAN CA, 1991, ANNU REV PLANT PHYS, V42, P651, DOI 10.1146/annurev.pp.42.060191.003251; SCHWACKE R, 1992, PLANTA, V187, P136, DOI 10.1007/BF00201635; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STRASSER H, 1986, Z NATURFORSCH C, V41, P717; VANHAASTERT PJM, 1989, ANAL BIOCHEM, V177, P115, DOI 10.1016/0003-2697(89)90024-9; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; YUEH YG, 1993, IN PRESS J CELL BIOL; ZBELL B, 1988, J PLANT PHYSIOL, V133, P353, DOI 10.1016/S0176-1617(88)80215-3	49	184	195	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24559	24563						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227014				2022-12-25	WOS:A1993MG67300012
J	LADERMAN, KA; DAVIS, BR; KRUTZSCH, HC; LEWIS, MS; GRIKO, YV; PRIVALOV, PL; ANFINSEN, CB				LADERMAN, KA; DAVIS, BR; KRUTZSCH, HC; LEWIS, MS; GRIKO, YV; PRIVALOV, PL; ANFINSEN, CB			THE PURIFICATION AND CHARACTERIZATION OF AN EXTREMELY THERMOSTABLE ALPHA-AMYLASE FROM THE HYPERTHERMOPHILIC ARCHAEBACTERIUM PYROCOCCUS-FURIOSUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUBACTERIUM THERMOTOGA-MARITIMA; COMPLETE NUCLEOTIDE-SEQUENCE; THERMAL-STABILITY; AMYLOLYTIC ENZYME; GENE; PROTEINS; SUBTILIS	The alpha-amylase from Pyrococcus furiosus, a hyperthermophilic archaebacterium, has been purified to homogeneity. The enzyme is a homodimer with a subunit molecular mass of 66 kDa. The isoelectric point is 4.3. The enzyme displays optimal activity, with substantial thermal stability, at 100-degrees-C, with the onset of activity at approximately 40-degrees-C. Unlike mesophilic alpha-amylases there is no dependence on Ca2+ for activity or thermostability. The enzyme displays a broad range of substrate specificity, with the capacity to hydrolyze carbohydrates as simple as maltotriose. No subtrate binding occurs below the temperature threshold of activity, and a decrease in K(m) accompanies an increase in temperature. Except for a decrease in Asp and an increase in Glu, the amino acid composition does not confirm previously defined trends in thermal adaption. Fourth derivative UV spectroscopy and intrinsic fluorescence measurements detected no temperature-dependent structural reorganization. Hydrogen exchange results indicate that the molecule is rigid, with only a slight increase in conformational flexibility at elevated temperature. Scanning microcalorimetry detected no considerable change in the heat capacity function, at the pH of optimal activity, within the temperature range in which activity is induced. The heat absorption peak due to denaturation, under these conditions, occurred within the temperature range of 90-120-degrees-C. When the pH was increased, a change in the shape of the heat absorption peak was observed, which when analyzed thermodynamically shows that the process of heat denaturation is complex and includes at least three stages, indicating that the protein structure consists of three domains. At temperatures below 90-degrees-C no excess heat absorption or change in the CD spectra were observed which could be associated with the cooperative conformational transition of the protein. According to the thermodynamic characteristics of the heat denaturation, the cold denaturation of this protein can be expected only at -3-degrees-C. Therefore, the observed inactivation of this enzyme is not caused by the cooperative change of its tertiary structure. It can be associated only with the gradual changes of protein domain interaction.	JOHNS HOPKINS UNIV,DEPT BIOL,34TH & CHARLES ST,BALTIMORE,MD 21218; NCI,PATHOL LAB,BETHESDA,MD 20892; NIH,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA								ANTRANIKIAN G, 1989, APPL BIOCHEM BIOTECH, V20-1, P267, DOI 10.1007/BF02936488; ARGOS P, 1979, BIOCHEMISTRY-US, V18, P5698, DOI 10.1021/bi00592a028; BAHL H, 1991, APPL ENVIRON MICROB, V57, P1554, DOI 10.1128/AEM.57.5.1554-1559.1991; BALDWIN R, 1987, PROTEIN ENG; BLUMENTALS II, 1990, APPL ENVIRON MICROB, V56, P1992, DOI 10.1128/AEM.56.7.1992-1998.1990; BROWN SH, 1990, APPL ENVIRON MICROB, V56, P1985, DOI 10.1128/AEM.56.7.1985-1991.1990; Efron B., 1982, JACKKNIFE BOOTSTRAP; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; GALLY J. A., 1964, BIOPOLYMERS SYMP, V1, P367; GLYMPH JL, 1977, APPL ENVIRON MICROB, V34, P391, DOI 10.1128/AEM.34.4.391-397.1977; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSEN SA, 1975, J CHROMATOGR, V105, P388, DOI 10.1016/S0021-9673(01)82270-6; HASEGAWA A, 1976, J BIOCHEM, V79, P35, DOI 10.1093/oxfordjournals.jbchem.a131055; HSIU J, 1964, BIOCHEMISTRY-US, V3, P61, DOI 10.1021/bi00889a011; IHARA H, 1985, J BIOCHEM-TOKYO, V98, P95, DOI 10.1093/oxfordjournals.jbchem.a135279; INGHAM KC, 1984, J BIOL CHEM, V259, P1901; KOCH R, 1990, FEMS MICROBIOL LETT, V71, P21, DOI 10.1111/j.1574-6968.1990.tb03792.x; KOCH R, 1991, ARCH MICROBIOL, V155, P572, DOI 10.1007/BF00245352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MS, 1992, ANAL ULTRACENTRIFUGA; MAKHATADZE GI, 1990, BIOPOLYMERS, V30, P1001, DOI 10.1002/bip.360301102; MANNING JB, 1961, J BIOL CHEM, V236, P2952; MELASNIEMI H, 1988, BIOCHEM J, V250, P813, DOI 10.1042/bj2500813; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOSELEY MH, 1970, BIOTECHNOL BIOENG, V12, P251, DOI 10.1002/bit.260120207; PIHL TD, 1991, J BACTERIOL, V173, P1839, DOI 10.1128/jb.173.6.1839-1844.1991; Privalov P L, 1986, Methods Enzymol, V131, P4; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1986, J MOL BIOL, V190, P487, DOI 10.1016/0022-2836(86)90017-3; SCHUMANN J, 1991, FEBS LETT, V282, P122, DOI 10.1016/0014-5793(91)80459-G; STONE KL, 1989, PRACTICAL GUIDE PROT, P33; TAKAGI T, 1971, ENZYMES; TEALE FWJ, 1960, BIOCHEM J, V76, P381, DOI 10.1042/bj0760381; VALLEE BL, 1959, J BIOL CHEM, V234, P2901; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007; YANG M, 1983, NUCLEIC ACIDS RES, V11, P237, DOI 10.1093/nar/11.2.237; YUUKI T, 1985, J BIOCHEM-TOKYO, V98, P1147, DOI 10.1093/oxfordjournals.jbchem.a135381	38	135	142	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24394	24401						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226989				2022-12-25	WOS:A1993MF29400100
J	NAGAO, M; PARIMOO, B; TANAKA, K				NAGAO, M; PARIMOO, B; TANAKA, K			DEVELOPMENTAL, NUTRITIONAL, AND HORMONAL-REGULATION OF TISSUE-SPECIFIC EXPRESSION OF THE GENES ENCODING VARIOUS ACYL-COA DEHYDROGENASES AND ALPHA-SUBUNIT OF ELECTRON-TRANSFER FLAVOPROTEIN IN RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; CARNITINE PALMITOYLTRANSFERASE SYNTHESIS; FATTY-ACID OXIDATION; NUCLEOTIDE-SEQUENCE; LIVER MITOCHONDRIA; MOLECULAR-CLONING; MEDIUM-CHAIN; GLUCOSE-UTILIZATION; PURIFICATION; ENZYMES	Short chain (SCAD), medium chain (MCAD), and long chain acyl-CoA dehydrogenases (LCAD) catalyze the first step of fatty acid oxidation, while isovaleryl-CoA dehydrogenase (IVD) is involved in leucine oxidation. They are homologous flavoproteins belonging to the acyl-CoA dehydrogenase (ACD) family. Electron transfer flavoprotein (ETF) serves as an obligatory electron acceptor for these reactions. We demonstrated that the expression of SCAD, MCAD, and LCAD and the alpha-subunit of ETF (alpha-ETF) showed a similar developmental pattern, while that of IVD was distinctly different from others. The ontogenic pattern of each enzyme in the liver differed distinctly from that in the heart. The degree of glucagon-enhanced ACD expression in vivo and in vitro in both the liver and heart was especially high in fasted rats. Dexamethasone induced all ACD mRNAs in the heart. In contrast, it strongly suppressed mRNAs of all ACDs and alpha-ETF mRNA in the liver, except IVD mRNA. Dexamethasone induced IVD mRNA in both the liver and heart. Starvation strongly stimulated expression of all five genes in various tissues, with the highest in the heart, except the IVD gene which was down-regulated. The degree of induction by 3-day starvation differed in different age groups of rats. Feeding the rats a fat-free diet for 7 days caused a marked increase of IVD mRNA in the heart, whereas the high fat diet for the same period resulted in a severe decrease of the same degree, suggesting a protein-sparing mechanism. However, these manipulations of dietary fat content had little effect on the expression of other ACD genes.	YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University					NIDDK NIH HHS [DK38154] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038154] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY E, 1973, ENZYME, V15, P239, DOI 10.1159/000481063; BRADY LJ, 1989, DIABETES, V38, P65, DOI 10.2337/diabetes.38.1.65; BRADY PS, 1988, J NUTR, V118, P1128, DOI 10.1093/jn/118.9.1128; BRADY PS, 1989, BIOCHEM J, V260, P93, DOI 10.1042/bj2600093; BRADY PS, 1989, BIOCHEM J, V258, P677, DOI 10.1042/bj2580677; BRADY PS, 1987, BIOCHEM J, V246, P641, DOI 10.1042/bj2460641; CAHILL GF, 1966, J CLIN INVEST, V45, P1751, DOI 10.1172/JCI105481; CARROLL JE, 1989, BIOL NEONATE, V55, P185; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COMPERE SJ, 1981, J BIOL CHEM, V256, P6341; DENNE SC, 1987, AM J PHYSIOL, V253, pE608, DOI 10.1152/ajpendo.1987.253.6.E608; DRAHOTA Z, 1964, BIOCHEM J, V93, P61, DOI 10.1042/bj0930061; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELIG P, 1970, NEW ENGL J MED, V282, P166; FINOCCHIARO G, 1988, J BIOL CHEM, V263, P15773; FOSTER PC, 1976, BIOCHEM J, V154, P49, DOI 10.1042/bj1540049; FRERMAN FE, 1983, J BIOL CHEM, V258, P7087; GIBBONS GF, 1991, BIOCHEM J, V275, P87, DOI 10.1042/bj2750087; Greengard O., 1971, Essays Biochem, V7, P159; HARANO Y, 1982, J BIOCHEM-TOKYO, V91, P1739, DOI 10.1093/oxfordjournals.jbchem.a133866; HOLNESS MJ, 1990, BIOCHEM J, V270, P245, DOI 10.1042/bj2700245; IKEDA Y, 1983, J BIOL CHEM, V258, P1066; IKEDA Y, 1983, J BIOL CHEM, V258, P9477; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; IKEDA Y, 1983, J BIOL CHEM, V258, P1077; INDO Y, 1991, GENOMICS, V11, P609, DOI 10.1016/0888-7543(91)90068-P; ISSAD T, 1987, BIOCHEM J, V246, P241, DOI 10.1042/bj2460241; KELLY DP, 1989, J BIOL CHEM, V264, P18921; KELLY DP, 1992, NEW DEV FATTY ACID O, P143; KILLEWICH LA, 1977, P NATL ACAD SCI USA, V74, P5392, DOI 10.1073/pnas.74.12.5392; KRAUS JP, 1985, NUCLEIC ACIDS RES, V13, P943, DOI 10.1093/nar/13.3.943; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1620; LAMERS WH, 1982, P NATL ACAD SCI USA, V6, P85; LEVINE S, 1967, ENDOCRINOLOGY, V80, P910, DOI 10.1210/endo-80-5-910; LIN ECC, 1957, BIOCHIM BIOPHYS ACTA, V26, P85, DOI 10.1016/0006-3002(57)90057-4; LOCKWOOD EA, 1970, BIOCHEM J, V120, P49, DOI 10.1042/bj1200049; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; MATSUBARA Y, 1987, J BIOL CHEM, V262, P10104; MILKOVIC K, 1963, ENDOCRINOLOGY, V73, P535, DOI 10.1210/endo-73-5-535; NAGAO M, 1992, J BIOL CHEM, V267, P17925; PARIMOO B, 1993, GENOMICS, V15, P582, DOI 10.1006/geno.1993.1111; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROSS NS, 1987, BIOCHEM J, V244, P387, DOI 10.1042/bj2440387; RUIZBRAVO N, 1985, ENDOCRINOLOGY, V116, P2489, DOI 10.1210/endo-116-6-2489; RYALL JC, 1986, EUR J BIOCHEM, V156, P453, DOI 10.1111/j.1432-1033.1986.tb09603.x; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; TESSARI P, 1986, J CLIN INVEST, V77, P575, DOI 10.1172/JCI112339; TOWBIN H, 1979, P NATL ACAD SCI USA, V79, P4530; VANVEEN LCP, 1987, METABOLISM, V36, P48, DOI 10.1016/0026-0495(87)90062-X; WARSHAW JB, 1972, DEV BIOL, V28, P537, DOI 10.1016/0012-1606(72)90001-2; WOHLHUET.RM, 1970, J BIOL CHEM, V245, P2391; ZHANG ZF, 1992, BIOCHEMISTRY-US, V31, P81, DOI 10.1021/bi00116a013	54	76	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24114	24124						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226958				2022-12-25	WOS:A1993MF29400062
J	SELBIE, LA; SCHMITZPEIFFER, C; SHENG, YH; BIDEN, TJ				SELBIE, LA; SCHMITZPEIFFER, C; SHENG, YH; BIDEN, TJ			MOLECULAR-CLONING AND CHARACTERIZATION OF PKC(IOTA), AN ATYPICAL ISOFORM OF PROTEIN-KINASE-C DERIVED FROM INSULIN-SECRETING CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; PANCREATIC-ISLETS; INOSITOL 1,4,5-TRISPHOSPHATE; CYTOSOLIC CA-2+; FAMILY; EXPRESSION; ZETA; ACTIVATION; RELEASE; GLUCOSE	The protein kinase C (PKC) family of serine-threonine kinases comprises at least eight members. These are differentially expressed, show varying affinities for activators such as Ca2+ and lipid species, and are therefore thought to play wide-ranging roles in the regulation of such cellular processes as differentiation, growth, and secretion. The aim of this study was to identify new PKC isoforms in the insulin-secreting cell line RINm5F that might be activated by the alterations in lipid metabolism that accompany nutrient-stimulated insulin release. Fragments of cDNA, derived from RINm5F cell mRNA, were amplified by the polymerase chain reaction using degenerate oligonucleotide primers corresponding to highly conserved regions in the catalytic domains of all known PKCs. A novel sequence generated by this approach was subsequently used to screen cDNA libraries. The entire 587-amino acid coding region of a new PKC isoform, PKCiota, was deduced from two overlapping clones isolated from a human kidney cDNA library. The amino acid sequence of PKCiota showed greatest homology to PKCzeta, with 72% identity overall rising to 84% in the catalytic domain. In contrast, the homology of PKCiota to the other isoforms was less pronounced, with <53% identity even in the highly conserved catalytic region. Further similarities between PKCzeta and PKCiota included a highly conserved pseudosubstrate sequence, the absence of an apparent Ca2+-binding region, and the presence of only one cysteine-rich, zinc finger-like domain. Northern blot analysis, using the full-length PKCiota clone as a probe, revealed a single 4.6-kilobase transcript present predominantly in lung and brain, but also expressed at lower levels in many tissues including pancreatic islets. In CHO-K1 cells stably expressing the PKCiota cDNA under the human beta-actin promoter, the protein was detected as a 65-kDa band by Western blotting using an antibody to the COOH terminus of PKCzeta (conserved in PKCiota). Extracts of transfected CHO-K1 cells also displayed a significantly increased kinase activity using myelin basic protein as a substrate. The results suggest that PKCiota should be included in the atypical subgroup of PKCs whose definitive member is PKCzeta. As such, PKCiota is unlikely to be activated by the diacylglycerol that is derived from phosphoinositide hydrolysis, but might be a target for novel lipid activators that are elevated during nutrient-stimulated insulin secretion.	ST VINCENTS HOSP,GARVAN INST MED RES,384 VICTORIA ST,DARLINGHURST,NSW 2010,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney			sheng, yong H/C-5052-2013; Schmitz-Peiffer, Carsten/J-6918-2012; Biden, Trevor/AAW-2829-2021	sheng, yong H/0000-0002-4623-9098; Schmitz-Peiffer, Carsten/0000-0001-7330-7255; Biden, Trevor/0000-0001-5211-0234				ARKHAMMAR P, 1989, BIOCHEM J, V264, P207, DOI 10.1042/bj2640207; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BAIER G, 1993, J BIOL CHEM, V268, P4997; BASTA P, 1992, BIOCHIM BIOPHYS ACTA, V1132, P154, DOI 10.1016/0167-4781(92)90006-L; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; EASOM RA, 1990, J BIOL CHEM, V265, P14938; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; GENESAN S, 1992, J CELL BIOL, V119, P313; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HII CST, 1987, BIOCHEM J, V246, P489, DOI 10.1042/bj2460489; HUBBARD SR, 1991, SCIENCE, V254, P1776; JONES PM, 1991, J MOL ENDOCRINOL, V6, P121, DOI 10.1677/jme.0.0060121; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; METZ SA, 1988, DIABETES, V37, P3, DOI 10.2337/diabetes.37.1.3; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; PERSAUD SJ, 1989, BIOCHEM J, V264, P753, DOI 10.1042/bj2640753; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; REGAZZI R, 1990, J BIOL CHEM, V265, P15003; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314; YAMATANI T, 1988, ENDOCRINOLOGY, V122, P2826, DOI 10.1210/endo-122-6-2826	42	330	341	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24296	24302						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226978				2022-12-25	WOS:A1993MF29400087
J	URATA, H; KARNIK, SS; GRAHAM, RM; HUSAIN, A				URATA, H; KARNIK, SS; GRAHAM, RM; HUSAIN, A			DIPEPTIDE PROCESSING ACTIVATES RECOMBINANT HUMAN PROCHYMASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL CHYMASE; VASOACTIVE INTESTINAL PEPTIDE; MOLECULAR-CLONING; ANGIOTENSIN-II; HUMAN HEART; SUBSTRATE-SPECIFICITY; SUBSTANCE-P; GENE; PROTEASE; IDENTIFICATION	Human chymase (h-chymase) is a serine protease that efficiently converts angiotensin I to II. Its structure and homology to other serine proteases suggest that it is synthesized as a zymogen, and is processed to the active form by cleavage of a 19-residue signal peptide and of a dipeptide pro-segment. To evaluate maturational processing of this enzyme, the proteins encoded by three h-chymase cDNA constructs (wild-type, lacking the pro- or lacking the prepro-segment) were characterized after expression in COS-1 cells. These recombinant proteins were not catalytically active. Purification and NH2-terminal sequence analysis of the protein expressed from the wild-type construct revealed processing to the proenzyme. Prochymase activation was achieved by incubation with a B-cell lymphoma homogenate, which apparently contains a heterologous processing enzyme sensitive to thiol protease inhibitors. NH2-terminal sequence analysis of the activated h-chymase revealed cleavage of the pro-segment, and its biochemical characteristics were identical to those of native h-chymase purified from the myocardium. These findings indicate that processing of the dipeptide pro-segment is necessary and sufficient for activation of human chymase. Such processing is probably also required for the activation of related serine proteases, e.g., cathepsin G, which have homologous dipeptide pro-segments.	CLEVELAND CLIN FDN,RES INST,DEPT CARDIOVASC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Case Western Reserve University			Karnik, Sadashiva/Y-2477-2019; Husain, Ahsan/J-6861-2012	Karnik, Sadashiva/0000-0003-0746-2753; Husain, Ahsan/0000-0003-3426-3469	NCRR NIH HHS [RR04871] Funding Source: Medline; NHLBI NIH HHS [HL33713, HL44201] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004871] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044201, P50HL033713] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENFEY PN, 1987, J BIOL CHEM, V262, P5377; BRAIN SD, 1988, NATURE, V335, P73, DOI 10.1038/335073a0; CAUGHEY GH, 1990, BIOCHEMISTRY-US, V29, P5166, DOI 10.1021/bi00473a024; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; CAUGHEY GH, 1991, J BIOL CHEM, V266, P12956; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; DEYOUNG MB, 1987, ARCH BIOCHEM BIOPHYS, V254, P222, DOI 10.1016/0003-9861(87)90098-1; FRANCONI GM, 1989, J PHARMACOL EXP THER, V248, P947; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KENDALL RL, 1992, J BIOL CHEM, V267, P20667; KINOSHITA A, 1991, J BIOL CHEM, V266, P19192; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P364; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; REILLY CF, 1982, J BIOL CHEM, V257, P8619; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; STROUD RM, 1977, ANNU REV BIOPHYS BIO, V6, P177, DOI 10.1146/annurev.bb.06.060177.001141; Trong H Le, 1989, BIOCHEMISTRY-US, V28, P391, DOI 10.1021/BI00427A054; URATA H, 1991, J BIOL CHEM, V266, P17173; URATA H, 1990, J BIOL CHEM, V265, P22348; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; WINTROUB BU, 1984, J INVEST DERMATOL, V83, P336, DOI 10.1111/1523-1747.ep12264144	31	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24318	24322						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226981				2022-12-25	WOS:A1993MF29400090
J	HU, G; QUERIMIT, LA; DOWNING, LA; CHARNESS, ME				HU, G; QUERIMIT, LA; DOWNING, LA; CHARNESS, ME			ETHANOL DIFFERENTIALLY INCREASES ALPHA-2-ADRENERGIC AND MUSCARINIC ACETYLCHOLINE-RECEPTOR GENE-EXPRESSION IN NG108-15 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEIN; GLIOMA HYBRID-CELLS; DELTA-OPIOID RECEPTORS; ADRENERGIC-RECEPTOR; ADENYLATE-CYCLASE; PERTUSSIS TOXIN; HETEROLOGOUS DESENSITIZATION; CHOLINERGIC RECEPTORS; SIGNAL TRANSDUCTION; ALCOHOL WITHDRAWAL	Modulation of alpha2-adrenergic and opioid neurotransmission may contribute to ethanol intoxication, tolerance, and physical dependence. We showed previously that ethanol increased the expression of functional delta-opioid receptors in NG108-15 cells (Charness, M. E., Querimit, L. A., and Diamond, 1. (1986) J. Biol. Chem. 261, 3164-3169). Here we report that long-term (2 days) treatment of NG108-15 cells with ethanol increased the binding of the alpha2-adrenergic receptor (alpha2AR) antagonist [H-3]rauwolscine and the muscarinic acetylcholine receptor (mAChR) antagonist [H-3]quinuclidinyl benzilate by 2.8- and 1.4-fold, respectively. Increased receptor expression was associated with a proportionate increase in the potency of oxymetazoline and carbachol in inhibiting cAMP accumulation. Ethanol did not change the expression of Galpha(i2) and reduced levels of Galpha(s). Pertussis toxin pretreatment did not prevent the ethanol-induced increase in alpha2AR, mAChR, and delta-opioid receptor expression. Ethanol caused a large (3.6-fold), dose-dependent increase in the abundance of alpha(2B)AR mRNA (rat cDNA probe RNG, 4.1-kb transcript). Ethanol-induced increases in alpha(2B)AR and alpha(2C)AR (rat probe RG10, 2.5-kb transcript) mRNAs were first detected after 6 h of exposure to 100 mM ethanol, became maximal after 24 h, and persisted for up to 5 days. In contrast, ethanol caused only a small (1.3-fold) increase in the abundance of hm4 mAChR mRNA and did not change levels of Galpha(i2) and Galpha(s). mRNAs. Our data indicate that clinically attainable concentrations of ethanol regulate alpha2AR gene expression within the time frame of a single session of drinking.	VET ADM MED CTR W ROXBURY,NEUROL SECT 127,1400 VFW PKWY,BOSTON,MA 02132; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV NEUROL,BOSTON,MA 02115; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIOL,SAN FRANCISCO,CA 94143	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of California System; University of California San Francisco				Charness, Michael/0000-0002-3301-8966	PHS HHS [R01 06662] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BELCHEVA MM, 1991, J PHARMACOL EXP THER, V259, P302; Bennett J., 1985, NEUROTRANSMITTER REC, V2nd, P61; BJORKQVIST SE, 1975, ACTA PSYCHIAT SCAND, V52, P256, DOI 10.1111/j.1600-0447.1975.tb00041.x; BLAXALL HS, 1991, J PHARMACOL EXP THER, V259, P323; BURGERMEISTER W, 1978, MOL PHARMACOL, V14, P751; BYLUND D B, 1984, Alcohol, V1, P369, DOI 10.1016/0741-8329(84)90005-3; BYLUND DB, 1992, FASEB J, V6, P832, DOI 10.1096/fasebj.6.3.1346768; BYLUND DB, 1992, MOL PHARMACOL, V42, P1; BYLUND DB, 1988, J PHARMACOL EXP THER, V245, P600; CHARNESS ME, 1986, J BIOL CHEM, V261, P3164; CHARNESS ME, 1988, BIOCHEM BIOPH RES CO, V155, P138, DOI 10.1016/S0006-291X(88)81060-X; CHARNESS ME, 1983, SCIENCE, V222, P1426; CHARNESS ME, 1992, DIAGNOSIS TREATMENT, P155; DIEHL AM, 1992, HEPATOLOGY, V16, P1212, DOI 10.1002/hep.1840160518; DUZIC E, 1992, J BIOL CHEM, V267, P9844; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREEDMAN JE, 1985, J NEUROSCI, V5, P3016; GAYER GG, 1991, J BIOL CHEM, V266, P22279; GEORGE ST, 1988, BIOCHEM BIOPH RES CO, V150, P655; GOLD MS, 1978, LANCET, V2, P599; GORDON AS, 1986, P NATL ACAD SCI USA, V83, P2105, DOI 10.1073/pnas.83.7.2105; HADCOCK JR, 1993, J NEUROCHEM, V60, P1, DOI 10.1111/j.1471-4159.1993.tb05816.x; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HILLER JM, 1984, MOL PHARMACOL, V25, P249; KAHN DJ, 1982, MOL PHARMACOL, V21, P17; KENAKIN TP, 1986, TRENDS PHARMACOL SCI, V7, P93, DOI 10.1016/0165-6147(86)90271-3; KUROSE H, 1983, J BIOL CHEM, V258, P4870; LANIER SM, 1988, J BIOL CHEM, V263, P14491; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LAW PY, 1982, MOL PHARMACOL, V22, P1; LEE S, 1988, FASEB J, V2, P52, DOI 10.1096/fasebj.2.1.2891579; LINNOILA M, 1987, ANN INTERN MED, V107, P875, DOI 10.7326/0003-4819-107-6-875; LORENZ W, 1990, MOL PHARMACOL, V38, P599; MCCLUE SJ, 1990, FEBS LETT, V269, P430, DOI 10.1016/0014-5793(90)81209-7; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MCKENZIE FR, 1990, J BIOL CHEM, V265, P17084; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MESSING RO, 1991, J BIOL CHEM, V266, P23428; MILES MF, 1991, J BIOL CHEM, V266, P2409; MILES MF, 1992, BIOCHIM BIOPHYS ACTA, V1138, P268, DOI 10.1016/0925-4439(92)90003-6; MOCHLYROSEN D, 1988, NATURE, V333, P848, DOI 10.1038/333848a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGY LE, 1989, MOL PHARMACOL, V36, P744; NAGY LE, 1990, J BIOL CHEM, V265, P1946; NORONHABLOB L, 1987, MOL PHARMACOL, V32, P669; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; TABAKOFF B, 1979, LIFE SCI, V25, P2173, DOI 10.1016/0024-3205(79)90089-4; TATSUMI H, 1990, J NEUROSCI, V10, P1675; THOMAS JM, 1990, J PHARMACOL EXP THER, V252, P616; THOMAS JM, 1986, ENDOCRINOLOGY, V119, P1305, DOI 10.1210/endo-119-3-1305; WAND GS, 1991, ALCOHOL CLIN EXP RES, V15, P705, DOI 10.1111/j.1530-0277.1991.tb00583.x; WILLIAMS RJ, 1993, MOL PHARMACOL, V43, P158; WILSON PD, 1986, J BIOL CHEM, V261, P1503; ZENG DW, 1991, MOL BRAIN RES, V10, P219, DOI 10.1016/0169-328X(91)90064-5; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102; ZHU XZ, 1987, LIFE SCI, V41, P1133, DOI 10.1016/0024-3205(87)90632-1	57	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23441	23447						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226869				2022-12-25	WOS:A1993MF51500075
J	MILGROM, YM; CROSS, RL				MILGROM, YM; CROSS, RL			NUCLEOTIDE-BINDING SITES ON BEEF-HEART MITOCHONDRIAL F(1)-ATPASE - COOPERATIVE INTERACTIONS BETWEEN SITES AND SPECIFICITY OF NONCATALYTIC SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHTLY BOUND ADP; COUPLING FACTOR-I; ADENOSINE-TRIPHOSPHATASE; ATP HYDROLYSIS; CATALYTIC SITES; CHLOROPLAST F1-ATPASE; ESCHERICHIA-COLI; OXIDATIVE-PHOSPHORYLATION; BETA-SUBUNIT; ADENINE-NUCLEOTIDES	We have studied the properties of beef heart mitochondrial F1 having inhibitory MgADP bound at one of the three catalytic sites and various levels of occupancy of the three noncatalytic nucleotide sites including zero, two, or three ADP/ATPs or two ADP/ATP plus one GTP. The properties examined include the rate of MgATP-dependent reactivation and the rate of increase in the fraction of F1 containing transiently bound intermediates. For each form of the enzyme tested, the rate of reactivation closely paralleled the rate of increase in the level of bound intermediates, indicating that when one catalytic site on F1 is blocked by inhibitory MgADP, the remaining two sites are incapable of residual uni- or bi-site activity. It was also found that the stability of the MgADP-inhibited complex decreases with full occupancy of the noncatalytic sites. This demonstrates that the noncatalytic sites modulate the properties of catalytic sites. Finally, it was found that the noncatalytic sites on mitochondrial F1 do not, as has long been believed, bind adenine nucleotides exclusively. Evidence is presented that both GTP and PP(i) bind tightly at noncatalytic sites.	SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, ADAMS ST, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023152, R37GM023152] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; BULYGIN VV, 1988, FEBS LETT, V236, P497, DOI 10.1016/0014-5793(88)80085-1; CNERNYAK BV, 1992, ARCH BIOCHEM BIOPHYS, V295, P247; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CROSS RL, 1982, J BIOL CHEM, V257, P2874; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; Cross RL, 1992, MOL MECHANISMS BIOEN, P317; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DAGGETT SG, 1985, ARCH BIOCHEM BIOPHYS, V236, P815, DOI 10.1016/0003-9861(85)90688-5; DIPIETRO A, 1980, BIOCHEMISTRY-US, V19, P5671, DOI 10.1021/bi00566a002; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; DUNCAN TM, 1985, J BIOL CHEM, V260, P4901; EBEL RE, 1975, J BIOL CHEM, V250, P191; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GUERRERO KJ, 1990, FEBS LETT, V270, P187, DOI 10.1016/0014-5793(90)81264-O; HACKNEY DD, 1979, BIOCHEM BIOPH RES CO, V91, P233, DOI 10.1016/0006-291X(79)90608-9; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V504, P364, DOI 10.1016/0005-2728(78)90060-9; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V463, P245, DOI 10.1016/0304-4173(78)90002-2; HARRIS DA, 1993, FEBS LETT, V316, P209, DOI 10.1016/0014-5793(93)81295-B; ISSARTEL JP, 1992, EXPERIENTIA, V48, P351, DOI 10.1007/BF01923429; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KALASHNIKOVA TY, 1988, FEBS LETT, V230, P163, DOI 10.1016/0014-5793(88)80663-X; KALASHNIKOVA TY, 1988, EUR J BIOCHEM, V177, P213, DOI 10.1111/j.1432-1033.1988.tb14364.x; KAYALAR C, 1977, J BIOL CHEM, V252, P2486; KIRONDE FAS, 1986, J BIOL CHEM, V261, P2544; KIRONDE FAS, 1987, J BIOL CHEM, V262, P3488; KNOWLES AF, 1972, J BIOL CHEM, V247, P6617; MELESE T, 1988, J BIOL CHEM, V263, P5833; MILGROM YM, 1986, BIOL MEMBRANY, V3, P781; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; MILGROM YM, 1991, EUR J BIOCHEM, V200, P789, DOI 10.1111/j.1432-1033.1991.tb16246.x; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; MOYLE J, 1975, FEBS LETT, V56, P55, DOI 10.1016/0014-5793(75)80110-4; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; MURATALIEV MB, 1992, BIOCHEMISTRY-US, V31, P12885, DOI 10.1021/bi00166a025; MURATALIEV MB, 1992, EUR J BIOCHEM, V209, P681, DOI 10.1111/j.1432-1033.1992.tb17336.x; ONEAL CC, 1984, J BIOL CHEM, V259, P5761; PAGAN J, 1990, FEBS LETT, V273, P147, DOI 10.1016/0014-5793(90)81071-U; PEINNEQUIN A, 1992, BIOCHEMISTRY-US, V31, P2088, DOI 10.1021/bi00122a028; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; ROVERI OA, 1980, BIOCHIM BIOPHYS ACTA, V589, P241, DOI 10.1016/0005-2728(80)90041-9; SCHAFER HJ, 1984, J BIOL CHEM, V259, P5301; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; VULFSON EN, 1986, BIOL MEMBR, V4, P339; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; XUE ZX, 1988, J BIOL CHEM, V263, P16880; XUE ZX, 1989, EUR J BIOCHEM, V179, P677, DOI 10.1111/j.1432-1033.1989.tb14600.x; YALAMOVA MV, 1982, BIOCHEM INT, V4, P337; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027; ZHUO SQ, 1992, J BIOL CHEM, V267, P12916; [No title captured]	63	46	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23179	23185						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226836				2022-12-25	WOS:A1993MF51500037
J	TU, AY; NISHIDA, HI; NISHIDA, T				TU, AY; NISHIDA, HI; NISHIDA, T			HIGH-DENSITY-LIPOPROTEIN CONVERSION MEDIATED BY HUMAN PLASMA PHOSPHOLIPID TRANSFER PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; ESTER TRANSFER PROTEIN; LIPID TRANSFER PROTEIN; A-II; EXCHANGE PROTEIN; HDL CONVERSION; PARTICLE-SIZE; FATTY-ACIDS; PURIFICATION; LIPOSOMES	Phospholipid transfer protein (PLTP) was purified from lipoprotein-free human plasma, obtained upon treatment of plasma with dextran sulfate and Ca2+, by employing a series of column chromatography. Upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the purified PLTP showed a single main band, corresponding to the molecular mass of 78 kDa. However, isoelectric focusing of the purified preparation gave multiple bands with pI ranging from 4.3 to 5.1, indicative of microheterogeneity. Purified PLTP was shown to possess not only phospholipid transfer activity, but also high density lipoprotein (HDL) conversion activity (Tu, A.-Y., Nishida, H. I., and Nishida, T. (1990), FASEB J. 4, A2148; Jauhiainen, M., Metso, J., Pahlman, R., Blomqvist, S., van Tol, A., and Ehnholm, C. (1993) J. Biol. Chem. 268, 4032-4036). Isolated HDL3 was enlarged to the size of HDL2b upon incubation with purified PLTP for 6 h at 37-degrees-C at the PLTP/HDL3 molar ratio of approximately 1:45. Both the HDL conversion and the phosphatidylcholine transfer activities of purified PLTP were effectively inhibited by rabbit anti-PLTP immunoglobulin G. The primary importance of PLTP in the HDL enlargement that occurs in human plasma upon incubation at 37-degrees-C was shown by the strong inhibitory effect of the anti-PLTP immunoglobulin G. The process of PLTP-mediated HDL enlargement was accompanied by the release of apoproteins, primarily apoA-I. HDL3 enlargement mediated by PLTP was effectively inhibited by the addition of free fatty acids.	UNIV ILLINOIS,DEPT FOOD SCI,BURNSIDES RES LAB,1208 W PENN AVE,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NHLBI NIH HHS [HL-17597] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017597, R37HL017597] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALAUPOVIC P, 1984, CLIN METABOLIC ASPEC, P1; ALBERS JJ, 1984, ARTERIOSCLEROSIS, V4, P49, DOI 10.1161/01.ATV.4.1.49; BARTER PJ, 1988, BIOCHEM J, V254, P179, DOI 10.1042/bj2540179; BARTER PJ, 1990, BIOCHIM BIOPHYS ACTA, V1045, P81, DOI 10.1016/0005-2760(90)90206-D; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; BREWSTER ME, 1978, BIOCHIM BIOPHYS ACTA, V529, P147, DOI 10.1016/0005-2760(78)90113-3; CHEUNG MC, 1982, J LIPID RES, V23, P747; DAMEN J, 1981, BIOCHIM BIOPHYS ACTA, V665, P538, DOI 10.1016/0005-2760(81)90268-X; DAMEN J, 1982, BIOCHIM BIOPHYS ACTA, V712, P444, DOI 10.1016/0005-2760(82)90271-5; DOI Y, 1983, J BIOL CHEM, V258, P5840; Doi Y, 1981, Methods Enzymol, V71 Pt C, P753; FIELDING C J, 1981, Proceedings of the National Academy of Sciences of the United States of America, V78, P3911, DOI 10.1073/pnas.78.6.3911; GAMBERT P, 1982, BIOCHIM BIOPHYS ACTA, V713, P1, DOI 10.1016/0005-2760(82)90159-X; GAMBLE W, 1978, J LIPID RES, V19, P1068; GROOT PHE, 1984, J LIPID RES, V25, P684; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; IHM J, 1980, BIOCHEM BIOPH RES CO, V93, P1114, DOI 10.1016/0006-291X(80)90604-X; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; KATO H, 1989, J BIOL CHEM, V264, P4082; KIM YC, 1979, J BIOL CHEM, V254, P9621; KUNITAKE ST, 1982, J LIPID RES, V23, P936; LAGROST L, 1991, BIOCHIM BIOPHYS ACTA, V1082, P204, DOI 10.1016/0005-2760(91)90195-N; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORTON RE, 1982, J LIPID RES, V23, P1058; MUESING RA, 1971, BIOCHEMISTRY-US, V10, P2952; NICHOLS AV, 1989, BIOCHIM BIOPHYS ACTA, V1001, P325, DOI 10.1016/0005-2760(89)90117-3; NICHOLS AV, 1985, BIOCHIM BIOPHYS ACTA, V834, P285, DOI 10.1016/0005-2760(85)90001-3; NICHOLS AV, 1976, BIOCHIM BIOPHYS ACTA, V446, P226, DOI 10.1016/0005-2795(76)90113-6; NISHIDA HI, 1986, J BIOL CHEM, V261, P2028; NISHIDA HI, 1993, FASEB J, V7, pA1269; NISHIDA HI, 1992, FASEB J, V6, pA371; NISHIDA HI, 1990, J BIOL CHEM, V265, P4876; PATTNAIK NM, 1978, BIOCHIM BIOPHYS ACTA, V530, P428, DOI 10.1016/0005-2760(78)90163-7; RYE KA, 1986, BIOCHIM BIOPHYS ACTA, V875, P429, DOI 10.1016/0005-2760(86)90062-7; Spector A., 1986, BIOCH BIOL PLASMA LI, P247; SWEENY SA, 1985, BIOCHIM BIOPHYS ACTA, V835, P279, DOI 10.1016/0005-2760(85)90283-8; Tall A R, 1986, Methods Enzymol, V129, P469; TALL AR, 1983, J BIOL CHEM, V258, P2174; TALL AR, 1977, BIOCHIM BIOPHYS ACTA, V487, P145, DOI 10.1016/0005-2760(77)90051-0; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; TU AY, 1991, FASEB J, V5, pA794; TU AY, 1991, THESIS U ILLINOIS UR; TU AY, 1990, FASEB J, V4, pA2148; YAMAZAKI S, 1983, J BIOL CHEM, V258, P5847	46	195	197	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23098	23105						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226827				2022-12-25	WOS:A1993MF51500024
J	WATTS, JD; SANGHERA, JS; PELECH, SL; AEBERSOLD, R				WATTS, JD; SANGHERA, JS; PELECH, SL; AEBERSOLD, R			PHOSPHORYLATION OF SERINE-59 OF P56(LCK) IN ACTIVATED T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; INTERLEUKIN-2 PRODUCTION; PHOSPHOLIPASE C-GAMMA-1; LYMPHOCYTES-T; P56LCK; CD4; ASSOCIATION; LCK	p56lck, a member of the src family of non-receptor protein tyrosine kinases, is expressed almost exclusively in cells of lymphoid origin. Recent evidence has implicated p56lck in a critical role both in T cell development and activation. A variety of T cell stimuli induce a shift in the electrophoretic mobility of p56lck from an apparent molecular mass of 56 kDa (p56lck) to 60 kDa (p60lck). This shift in electrophoretic mobility correlates with an increase in the phosphoserine content of the p60lck. We have shown that both 4alpha-phorbol 12beta-myristate acetate and OKT3 treatment of Jurkat cells, as well as 4alpha-phorbol 12beta-myristate acetate treatment of 171.CD4 and LSTRA cells, induced phosphorylation of serine-59 on p56lck in vivo, which correlated with the shift to p60lck. We also demonstrated that the same serine residue could be phosphorylated in vitro with mitogen-activated protein kinases and that this event was capable of reducing p56lck activity in vitro. Combined, these data suggest a novel pathway for the in vivo regulation of p56lck activity.	UNIV BRITISH COLUMBIA, BIOMED RES CTR, 2222 HLTH SCI MALL, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT BIOCHEM, VANCOUVER V6T 1W5, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V6T 1W5, BC, CANADA; KINETEK BIOTECHNOL CORP, RICHMOND V7C 1T6, BC, CANADA	University of British Columbia; University of British Columbia; University of British Columbia								ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ACRES RB, 1986, J BIOL CHEM, V261, P6210; AEBERSOLD R, 1991, ANAL BIOCHEM, V199, P51, DOI 10.1016/0003-2697(91)90268-X; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BLUE ML, 1987, J IMMUNOL, V139, P3949; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CASNELLIE JE, 1984, P NATL ACAD SCI-BIOL, V81, P6676, DOI 10.1073/pnas.81.21.6676; CASNELLIE JE, 1986, J BIOL CHEM, V261, P4921; CHALUPNY NJ, 1991, EMBO J, V10, P1201, DOI 10.1002/j.1460-2075.1991.tb08061.x; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COLLINS TL, 1992, J IMMUNOL, V148, P2159; DIANZANI U, 1992, J IMMUNOL, V148, P678; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLD MR, 1992, BIOCHEM J, V287, P269, DOI 10.1042/bj2870269; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HOXIE JA, 1986, J IMMUNOL, V137, P1194; HURLEY TR, 1989, ONCOGENE, V4, P265; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LUO K, 1990, ONCOGENE, V5, P803; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; MARTH JD, 1989, J IMMUNOL, V142, P2430; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NEL AE, 1990, J IMMUNOL, V145, P971; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RATNOFSKY SE, 1987, J EXP MED, V166, P1747, DOI 10.1084/jem.166.6.1747; ROSENSTEIN Y, 1989, J EXP MED, V169, P149, DOI 10.1084/jem.169.1.149; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TREVILLYAN JM, 1986, BIOCHIM BIOPHYS ACTA, V888, P286, DOI 10.1016/0167-4889(86)90228-4; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WATTS JD, 1992, J BIOL CHEM, V267, P901; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230	59	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23275	23282						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226850				2022-12-25	WOS:A1993MF51500052
J	PUISIEUX, A; GALVIN, K; TROALEN, F; BRESSAC, B; MARCAIS, C; GALUN, E; PONCHEL, F; YAKICIER, C; JI, JW; OZTURK, M				PUISIEUX, A; GALVIN, K; TROALEN, F; BRESSAC, B; MARCAIS, C; GALUN, E; PONCHEL, F; YAKICIER, C; JI, JW; OZTURK, M			RETINOBLASTOMA AND P53-TUMOR SUPPRESSOR GENES IN HUMAN HEPATOMA-CELL LINES	FASEB JOURNAL			English	Note						HEPATOCELLULAR CARCINOMA; RB GENE; IMMUNOCHEMICAL STUDIES; ANTI-RB PROTEIN ANTIBODIES; P53	HUMAN HEPATOCELLULAR-CARCINOMA; P53 GENE; EXPRESSION; MUTATION; TUMORS; DNA; PHOSPHORYLATION; INACTIVATION; SARCOMAS; SEGMENT	We analyzed the status of retinoblastoma and p53 genes in 10 human hepatoma cell lines. Polyclonal anti-peptide antibodies generated against peptides homologous to COOH-terminal and leucine-zipper domains of the retinoblastoma protein allowed us to identify two cell lines (Hep 3B and FOCUS) with abnormal expression. The same cell lines have both lacked p53 expression. In contrast to the retinoblastoma gene, the expression of the p53 gene was abnormal in six additional cell lines. Indeed, only the Hep G2 hepatoblastoma cell line (and its derivative Hep G2/2215) appeared to have normal p53 and retinoblastoma gene expression. Our studies indicate that p53 abnormalities are common but retinoblastoma gene aberrations are rare in human hepatoma cell lines.	MASSACHUSETTS GEN HOSP E,BOSTON,MA 02129; INST GUSTAVE ROUSSY,SERV IMMUNOL MOLEC,F-94805 VILLEJUIF,FRANCE; HADASSAH MED CTR,JERUSALEM,ISRAEL	UNICANCER; Gustave Roussy; Hebrew University of Jerusalem; Hadassah University Medical Center	PUISIEUX, A (corresponding author), CTR LEON BERARD,MOLEC ONCOL LAB,28 RUE LAENNEC,F-69008 LYON,FRANCE.		Galun, Eithan/AAD-9117-2022; ozturk, mehmet/G-3330-2014; OZTURK, MEHMET/AAS-7241-2021; Paillerets, Brigitte Bressac-de/D-8954-2018	Galun, Eithan/0000-0002-6243-6702; OZTURK, MEHMET/0000-0002-6092-9706; Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; PUISIEUX, Alain/0000-0002-9938-3798	NCI NIH HHS [CA-54567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALEXANDER JJ, 1984, ADV HEPATITIS RES, P190; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHANG C, 1983, MOL CELL BIOL, V3, P1133, DOI 10.1128/MCB.3.6.1133; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DOERR R, 1989, CANCER RES, V49, P384; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUJIMORI M, 1991, CANCER RES, V51, P89; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HE L, 1984, IN VITRO CELL DEV B, V20, P493, DOI 10.1007/BF02619623; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOSONO S, 1991, ONCOGENE, V6, P237; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KNOWLES BB, 1984, ADV HEPATITIS RES; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MCNAB GM, 1976, BRIT J CANCER, V34, P509; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MURAKAMI Y, 1991, CANCER RES, V51, P3356; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NISHIDA N, 1993, CANCER RES, V53, P368; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; OZTURK M, 1992, BONE MARROW TRANSPL, V9, P164; REISSMANN PT, 1989, ONCOGENE, V4, P839; Sambrook J, 1989, MOL CLONING LABORATO; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SLAGLE BL, 1991, CANCER RES, V51, P49; STEVENSON D, 1987, HEPATOLOGY, V7, P1291, DOI 10.1002/hep.1840070619; VARLEY JM, 1989, ONCOGENE, V4, P725; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YOKOTA J, 1988, ONCOGENE, V3, P471	44	132	142	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1407	1413		10.1096/fasebj.7.14.8224613	http://dx.doi.org/10.1096/fasebj.7.14.8224613			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	8224613				2022-12-25	WOS:A1993MH00800015
J	LEBORGNE, R; SCHMIDT, A; MAUXION, F; GRIFFITHS, G; HOFLACK, B				LEBORGNE, R; SCHMIDT, A; MAUXION, F; GRIFFITHS, G; HOFLACK, B			BINDING OF AP-1 GOLGI ADAPTERS TO MEMBRANES REQUIRES PHOSPHORYLATED CYTOPLASMIC DOMAINS OF THE MANNOSE 6-PHOSPHATE/INSULIN-LIKE GROWTH FACTOR-II RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREFELDIN-A; GUANINE-NUCLEOTIDE; CLATHRIN; PROTEIN; ENDOCYTOSIS; ENZYME; EXCHANGE; SIGNALS; ARF	In mammalian cells, clathrin-coated vesicles mediate transport of the lysosomal enzyme receptors from the trans-Golgi network to the endocytic pathway. A critical step of this process is the recruitment of Golgi-specific adaptors onto Golgi membranes for efficient clathrin polymerization. An in vitro assay was used here to quantitate this event in streptolysin-O-permeabilized NRK cells. At 37-degrees-C, these interactions are cytosol- and energy-dependent, sensitive to GTP(gamma)S (guanosine 5'-O-(thiotriphosphate)) and brefeldin A. We report that Golgi-specific adaptor binding is enhanced in mannose 6-phosphate/insulin-like growth factor II (IGF II) receptor-overexpressing cells and reduced in mannose 6-phosphate receptor-deficient cells. Furthermore, adaptor binding is partially inhibited after addition of soluble cytoplasmic domains of the mannose 6-phosphate/GF II receptor. Almost complete inhibition is only observed when this domain is phosphorylated on serines 2421 and 2492, a major modification acquired during exit of the receptor from the Golgi. These results show that the mannose 6-phosphate/IGF II receptor is part of the components that recruit the Golgi-specific adaptors and that its phosphorylation is an important feature for high affinity interactions with sorting components.	EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			MAUXION, Fabienne/ABE-3546-2021; HOFLACK, Bernard/AAZ-6668-2020	MAUXION, Fabienne/0000-0003-0554-8211; LE BORGNE, Roland/0000-0001-6892-278X; Schmidt, Anne/0000-0002-8326-0937				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Anderson R G, 1993, Trends Cell Biol, V3, P177, DOI 10.1016/0962-8924(93)90205-F; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GRAVOTTA D, 1990, J CELL BIOL, V111, P2983; Griffiths G., 1993, FINE STRUCTURE IMMUN, P459; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KOBAYASHI T, 1992, FEBS LETT, V300, P227, DOI 10.1016/0014-5793(92)80851-7; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; RODRIGUEZ JF, 1985, J VIROL, V56, P482, DOI 10.1128/JVI.56.2.482-488.1985; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; von Figura K, 1991, Curr Opin Cell Biol, V3, P642, DOI 10.1016/0955-0674(91)90035-W	32	85	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22552	22556						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226766				2022-12-25	WOS:A1993MD34800057
J	OHTSUKA, T; NISHIJIMA, M; AKAMATSU, Y				OHTSUKA, T; NISHIJIMA, M; AKAMATSU, Y			A SOMATIC-CELL MUTANT DEFECTIVE IN PHOSPHATIDYLGLYCEROPHOSPHATE SYNTHASE, WITH IMPAIRED PHOSPHATIDYLGLYCEROL AND CARDIOLIPIN BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; RAT-LIVER; PHOSPHOLIPID-COMPOSITION; PHOSPHATIDYLSERINE BIOSYNTHESIS; CYTOCHROME-OXIDASE; CONTACT SITES; MITOCHONDRIA; PURIFICATION; PHOSPHATIDYLINOSITOL; REQUIREMENT	Phosphatidylglycerophosphate (PGP) synthase catalyzes a reaction involved in the synthesis of phosphatidylglycerol (PG), which serves as a metabolic precursor for cardiolipin (CL), found primarily in the mitochondrial membranes of eukaryotic cells. We isolated a Chinese hamster ovary cell mutant (designated PGS-S) with a specific lesion in PGP synthase by using an in situ enzymatic assay for the enzyme. This mutant was obtained by introducing a second mutation into mutant PGS-P that had been generated by first-step mutagenesis. The PGP synthase activities in cell extracts of mutant PGS-S grown at 33 and 40-degrees-C were 14 and 1% of those in the wild type cells, respectively; in addition, PGP synthase in cell extracts of mutant PGS-S exhibited higher sensitivity to heat than that of the wild type. Mutant PGS-S also showed a temperature-dependent defect in the synthesis of PG and CL in vivo, together with temperature sensitivity for cell growth. A temperature-resistant revertant of mutant PGS-S simultaneously restored PGP synthase activity and the ability to synthesize PG and CL in vivo to nearly the same levels as those of mutant PGS-P. These results constitute genetic evidence that PGP synthase is responsible for PG synthesis and is essential for cell growth.	NATL INST HLTH, DEPT BIOCHEM & CELL BIOL, TOYAMA 1-23-1, SHINJUKU KU, TOKYO 162, JAPAN									ARDAIL D, 1990, J BIOL CHEM, V265, P18797; AWASTHI YC, 1971, BIOCHIM BIOPHYS ACTA, V226, P42, DOI 10.1016/0005-2728(71)90176-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1978, P NATL ACAD SCI USA, V75, P1190, DOI 10.1073/pnas.75.3.1190; ESKO JD, 1980, J BIOL CHEM, V255, P4474; FRY M, 1980, BIOCHEM BIOPH RES CO, V93, P1238, DOI 10.1016/0006-291X(80)90622-1; HELMS JB, 1991, J BIOL CHEM, V266, P21368; Hostetler K. Y., 1982, PHOSPHOLIPIDS, V4, P215; HOSTETLER KY, 1972, BIOCHIM BIOPHYS ACTA, V260, P507, DOI 10.1016/0005-2760(72)90065-3; HOSTETLER KY, 1972, BIOCHIM BIOPHYS ACTA, V260, P380, DOI 10.1016/0005-2760(72)90052-5; KIYASU JY, 1963, J BIOL CHEM, V238, P2293; KREBS JJR, 1979, J BIOL CHEM, V254, P5308; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1991, J BIOL CHEM, V266, P24184; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; KUGE O, 1991, J BIOL CHEM, V266, P6370; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASON RJ, 1980, BIOCHIM BIOPHYS ACTA, V617, P36, DOI 10.1016/0005-2760(80)90222-2; NISHIJIMA M, 1984, J BIOL CHEM, V259, P7101; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; RAND RP, 1972, BIOCHIM BIOPHYS ACTA, V225, P484, DOI 10.1016/0005-2736(72)90152-6; RIETVELD A, 1983, EMBO J, V2, P907, DOI 10.1002/j.1460-2075.1983.tb01520.x; ROONEY SA, 1975, J LIPID RES, V16, P418; SANDERS RL, 1975, BIOCHEMISTRY-US, V14, P835, DOI 10.1021/bi00675a030; SCHLAME M, 1991, J BIOL CHEM, V266, P22398; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; TAKENAWA T, 1977, J BIOL CHEM, V252, P5419; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; YAMASHITA S, 1972, EUR J BIOCHEM, V31, P565, DOI 10.1111/j.1432-1033.1972.tb02566.x	33	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22908	22913						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226800				2022-12-25	WOS:A1993MD34800104
J	SEEDORF, K; KOSTKA, G; LAMMERS, R; BASHKIN, P; DALY, R; BURGESS, WH; VANDERBLIEK, AM; SCHLESSINGER, J; ULLRICH, A				SEEDORF, K; KOSTKA, G; LAMMERS, R; BASHKIN, P; DALY, R; BURGESS, WH; VANDERBLIEK, AM; SCHLESSINGER, J; ULLRICH, A			DYNAMIN BINDS TO SH3 DOMAINS OF PHOSPHOLIPASE C-GAMMA AND GRB-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; EGF-RECEPTOR; SIGNAL TRANSDUCTION; PROTEIN; RAS; PHOSPHORYLATION; SITE; IDENTIFICATION; GTPASE	Src homology 3 (SH3) domains are found in a variety of proteins that are involved in signal transduction or represent components of the cytoskeleton. These domains are thought to serve as modules that mediate specific protein-protein interactions that include prolinerich sequences on the target protein. We have identified proteins of 110, 80, 65, and 43 kDa in human embryonic fibroblasts that bind specifically to the SH3 domain of phospholipase C gamma, a primary substrate of receptor tyrosine kinases, and characterized the 110-kDa band as the microtubule-activated GTPase dynamin. In addition, dynamin binds the son of sevenless adaptor protein GRB-2 with even higher affinity. This interaction does not require the dynamin GTPase function and involves a proline-rich target sequence between residues 812 and 820 of dynamin.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY; AMER RED CROSS,DEPT MOLEC BIOL,ROCKVILLE,MD 20855; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Max Planck Society; American Red Cross; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; New York University			Daly, Roger J/C-8179-2009	Daly, Roger/0000-0002-5739-8027				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHARDIN P, 1993, SCIENCE, V260, P1138; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HIRAI J, 1990, MOL CELL BIOL, V10, P1307; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1989, EMBO J, V8, P1369; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL S, 1985, J BIOL CHEM, V260, P4136; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; RODAWAY ARF, 1989, NATURE, V342, P324; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	52	146	150	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16009	16014						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206897				2022-12-25	WOS:A1994NQ72900012
J	FABER, S; OBRIEN, RM; IMAI, E; GRANNER, DK; CHALKLEY, R				FABER, S; OBRIEN, RM; IMAI, E; GRANNER, DK; CHALKLEY, R			DYNAMIC ASPECTS OF DNA-PROTEIN INTERACTIONS IN THE TRANSCRIPTIONAL INITIATION COMPLEX AND THE HORMONE-RESPONSIVE DOMAINS OF THE PHOSPHOENOLPYRUVATE CARBOXYKINASE PROMOTER IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; ENHANCER-BINDING-PROTEIN; GTP GENE; REGULATORY ELEMENTS; MULTIHORMONAL REGULATION; PREINITIATION COMPLEX; MECHANISM INVIVO; NUCLEAR FACTORS; IDENTIFICATION; EXPRESSION	Transcription initiation of the gene encoding phosphoenolpyruvate carboxykinase (PEPCK) is stimulated by glucocorticoids and glucagon, via cAMP, and dominantly inhibited by insulin in rat liver and H4IIE cells. Lysolecithin-permeabilized H4IIE cells recover completely and continue to multiply, yet are transiently penetrable by macromolecules. These cells, after various hormonal treatments, were utilized for in situ DNase I protection studies of the PEPCK promoter. Nearly all of the sites of protein interaction observed in vitro are protected in vivo as well as several additional sites. The DNase I protection pattern is the same in cells without or with any of the hormone treatments, suggesting that hormonal modulation of transcription does not involve addition or removal of factors from the hormone response elements of the promoter. We focused on the organization and stability of the transcription initiation complex as well as the dynamic nature of distal promoter factors in their interaction with DNA. The transcription initiation complex was detected, and it appears to be coexistent with a short region of naked single-stranded DNA over the TATA box on the template strand, as determined by potassium permanganate reactivity. This complex is quite stable, even under conditions of much reduced RNA synthesis, which suggests that the complex is not broken down and reformed with each round of initiation by RNA polymerase II. Other factors bind to the PEPCK promoter with half-lives ranging from a few minutes to more than 40 min. The cAMP response element apparently involves transcriptional modulation achieved through modification of a bound factor (presumably cAMP response element-binding protein), whereas the glucocorticoid/insulin-responsive region of the promoter functions through factors which are involved in a rapid exchange, suggesting quite different modes of transcriptional regulation.	VANDERBILT UNIV, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Vanderbilt University					NIDDK NIH HHS [DK 42502] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEALE EG, 1985, J BIOL CHEM, V260, P748; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHU DTW, 1986, J BIOL CHEM, V261, P6848; CONTRERAS R, 1981, NUCLEIC ACIDS RES, V9, P215, DOI 10.1093/nar/9.2.215; FABER S, 1991, NUCLEIC ACIDS RES, V19, P4681, DOI 10.1093/nar/19.17.4681; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IP YT, 1989, MOL CELL BIOL, V9, P1289, DOI 10.1128/MCB.9.3.1289; KLEMM DJ, 1990, MOL CELL BIOL, V10, P480, DOI 10.1128/MCB.10.2.480; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LI Z, 1989, GENE DEV, V3, P1814, DOI 10.1101/gad.3.11.1814; LIU JS, 1991, J BIOL CHEM, V266, P19095; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MANIATIS T, 1982, MOL CLONING LAB MANU, pE3; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MILLER MR, 1978, BIOCHEMISTRY-US, V17, P1073, DOI 10.1021/bi00599a021; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SALUZ H, 1989, P NATL ACAD SCI USA, V86, P2602, DOI 10.1073/pnas.86.8.2602; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; Tilghman SM, 1976, GLUCONEOGENESIS ITS, P47; TRUS M, 1990, MOL CELL BIOL, V10, P2418, DOI 10.1128/MCB.10.5.2418; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WYNSHAWBORIS A, 1986, J BIOL CHEM, V261, P9714; ZHANG L, 1990, NUCLEIC ACIDS RES, V18, P1797, DOI 10.1093/nar/18.7.1797	44	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24976	24985						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227059				2022-12-25	WOS:A1993MG67300068
J	HE, ZP; DUNKER, AK; WESSON, CR; TRUMBLE, WR				HE, ZP; DUNKER, AK; WESSON, CR; TRUMBLE, WR			CA2+-INDUCED FOLDING AND AGGREGATION OF SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM CALSEQUESTRIN - THE INVOLVEMENT OF THE TRIFLUOPERAZINE-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; CALMODULIN-BINDING; CALCIUM RELEASE; PHENYL-SEPHAROSE; TROPONIN-C; PROTEIN; PURIFICATION; LOCALIZATION; VESICLES; DOMAINS	Calsequestrin is an intermediate affinity, high capacity Ca2+-binding protein found in the lumen of the sarcoplasmic reticulum of both skeletal and cardiac muscle cells. Previous sequence analysis suggested that calsequestrin may contain a hydrophobic binding site for the drug trifluoperazine, a site shared by the calmodulin family and shown to play a role in calmodulin/calmodulin receptor interaction. Previous studies showed that, upon Ca2+ binding, calsequestrin undergoes a conformational change, burying the trifluoperazine-binding site, folding into a more compact structure that is trypsin-resistant, and increasing the negative ellipticity of the circular dichroism spectrum. In this study, the structural and functional roles of the trifluoperazine-binding site in the Ca2+-induced conformational change of calsequestrin are further studied using the calmodulin antagonists trifluoperazine and melittin. If trifluoperazine or melittin is added to calsequestrin prior to Ca2+ addition, then Ca2+-induced folding is inhibited as determined by the changes in circular dichroism spectra and protein sensitivity to trypsin digestion. If, however, Ca2+ is added prior to trifluoperazine or melittin, calsequestrin remains resistant to trypsin digestion, just as if the calmodulin antagonists are not present, suggesting that the conformational change is not affected. Aggregates of calsequestrin that exhibit high Ca2+ binding capacity have previously been shown to occur at high Ca2+ and calsequestrin concentrations. By preventing a prerequisite folding step, trifluoperazine or melittin also prevents the Ca2+-induced aggregation of calsequestrin, thus decreasing the maximal Ca2+ binding by calsequestrin. These data suggest that the trifluoperazine-binding site is critically involved in the Ca2+-induced intramolecular folding step required for the intermolecular interactions leading to high capacity Ca2+-binding by calsequestrin.	UNIV IDAHO, DEPT BACTERIOL & BIOCHEM, MOSCOW, ID 83843 USA; WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	Idaho; University of Idaho; Washington State University								AARON BMB, 1984, J BIOL CHEM, V259, P1876; BARNETTE MS, 1983, PSYCHOPHARMACOL BULL, V19, P387; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; CACHIA PJ, 1985, CALMODULIN ANTAGONIS, P63; CALA SE, 1983, J BIOL CHEM, V258, P1932; CHIESI M, 1981, J CELL BIOL, V91, P728, DOI 10.1083/jcb.91.3.728; CIFUENTES ME, 1989, ARCH BIOCHEM BIOPHYS, V273, P554, DOI 10.1016/0003-9861(89)90515-8; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COZENS B, 1984, J BIOL CHEM, V259, P6248; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; GARIEPY J, 1983, BIOCHEMISTRY-US, V22, P1586, DOI 10.1021/bi00276a010; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; IKEMOTO N, 1974, J BIOL CHEM, V249, P2357; IKEMOTO N, 1972, J BIOL CHEM, V247, P7835; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; IKEMOTO N, 1971, BIOCHEM BIOPH RES CO, V44, P1510, DOI 10.1016/S0006-291X(71)80257-7; JARRETT HW, 1984, J BIOL CHEM, V259, P136; JORGENSEN AO, 1979, J CELL BIOL, V80, P372, DOI 10.1083/jcb.80.2.372; JORGENSEN AO, 1983, J CELL BIOL, V97, P1573, DOI 10.1083/jcb.97.5.1573; KATOH N, 1982, BIOCHEM J, V202, P217, DOI 10.1042/bj2020217; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; KEMP BE, 1987, J BIOL CHEM, V262, P2542; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN RM, 1977, MOL PHARMACOL, V13, P690; MacLennan D., 1983, CALCIUM CELL FUNCT, V4, P151; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MASSOM L, 1990, BIOCHEMISTRY-US, V29, P671, DOI 10.1021/bi00455a012; MASSOM LR, 1991, BIOCHEMISTRY-US, V30, P663, DOI 10.1021/bi00217a011; MAURER A, 1985, P NATL ACAD SCI USA, V82, P4036, DOI 10.1073/pnas.82.12.4036; MEISSNER G, 1975, BIOCHIM BIOPHYS ACTA, V389, P51, DOI 10.1016/0005-2736(75)90385-5; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; OHNISHI M, 1987, BIOCHEMISTRY-US, V26, P7458, DOI 10.1021/bi00397a039; OSTWALD TJ, 1974, J BIOL CHEM, V249, P5867; PALLEROS DR, 1993, BIOCHEMISTRY-US, V32, P4314, DOI 10.1021/bi00067a021; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SOMLYO AV, 1981, J CELL BIOL, V90, P577, DOI 10.1083/jcb.90.3.577; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TANAKA M, 1986, ARCH BIOCHEM BIOPHYS, V251, P369, DOI 10.1016/0003-9861(86)90084-6; Weiss B, 1978, Adv Cyclic Nucleotide Res, V9, P285; WILLIAMS RW, 1986, J BIOL CHEM, V261, P2408	43	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24635	24641						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227022				2022-12-25	WOS:A1993MG67300022
J	LISSOOS, TW; BENO, DWA; DAVIS, BH				LISSOOS, TW; BENO, DWA; DAVIS, BH			1,25-DIHYDROXYVITAMIN-D(3) ACTIVATES RAF KINASE AND RAF PERINUCLEAR TRANSLOCATION VIA A PROTEIN-KINASE C-DEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ITO-CELL ACTIVATION; RETINOIC ACID; SIGNAL TRANSDUCTION; FOS/EGR EXPRESSION; PHOSPHORYLATION; LIPOCYTES; MEMBRANE; COLLAGEN; CASCADE; CULTURE	1,25-Dihydroxyvitamin D3's (D3) potential mitogenic mechanism of action was pursued in cultured rat hepatic Ito cells, a fibrogenic effector cell which proliferates in vivo during liver injury and fibrogenesis. D3 stimulated Ito cell DNA synthesis and potentiated platelet-derived growth factor-induced mitogenesis. D3's enhancement of [H-3]thymidine incorporation was associated with nuclear Egr expression. Recent studies have causally linked the activated proto-oncogene c-Raf with downstream Egr induction. The serine-threonine kinase Raf protein is phosphorylation-activated by a large array of agonists including plasma membrane and cytoplasmic tyrosine kinases but has not previously been associated with the steroid superfamily of mediators. To consider potential prenuclear acute pathways of D3-induced stimulation, the activation of Raf was examined following D3 exposure. D3 induced Raf activation as assessed via (a) enhanced Raf phosphorylation following in vivo P-32 labeling, (b) enhanced kinase function utilizing exogenous histone 1 protein as substrate, and (c) the shift in Raf physical localization changing from a diffuse cytoplasmic distribution to a perinuclear domain. A similar activation of Raf kinase was found in 3T3 cells exposed to D3 with enhanced histone phosphorylation detectable within 1 min following stimulation. The proximal cascade leading to Raf kinase activation may involve a protein kinase C-dependent pathway, since vitamin D-stimulated kinase activity was severely attenuated by previous phorbol ester treatment for 20 h or staurosporine pretreatment.	UNIV CHICAGO,DEPT MED,GASTROENTEROL SECT,MC 4076,5841 S MARYLAND AVE,CHICAGO,IL 60637	University of Chicago					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040223, T32DK007074, P30DK042086] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42086, DK40223, DK 07074-18] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENO DWA, 1992, HEPATOLOGY, V16, pA157; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; DAVIS BH, 1988, J CELL PHYSIOL, V136, P547, DOI 10.1002/jcp.1041360323; DAVIS BH, 1991, BIOCHEM J, V278, P43, DOI 10.1042/bj2780043; DAVIS BH, 1992, HEPATOLOGY, V16, pA96; DAVIS BH, 1990, J CLIN INVEST, V86, P2062, DOI 10.1172/JCI114943; DRITTANTI L, 1989, BIOCHIM BIOPHYS ACTA, V1014, P112, DOI 10.1016/0167-4889(89)90022-0; FRIEDMAN SL, 1992, HEPATOLOGY, V16, pA143; KOBAYASHI Y, 1992, HEPATOLOGY, V16, pA143; KOLCH W, 1990, ONCOGENE, V5, P713; LASKIN DL, 1990, SEMIN LIVER DIS, V10, P293, DOI 10.1055/s-2008-1040485; MITSUHASHI T, 1991, J CLIN INVEST, V87, P112; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; OBEID LM, 1990, J BIOL CHEM, V265, P2370; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAPP UR, 1991, ONCOGENE, V6, P495; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOZERI O, 1992, ONCOGENE, V7, P2259; SUKHATME VP, 1992, P NATL ACAD SCI USA, V89, P1; TIEN X Y, 1992, Gastroenterology, V102, pA581; TIEN XY, 1993, GASTROENTEROLOGY, V104, pA649; TIEN XY, 1992, CLIN RES, V40, pA265; WALI RK, 1990, J CLIN INVEST, V85, P1296, DOI 10.1172/JCI114567	26	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25132	25138						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227076				2022-12-25	WOS:A1993MG67300088
J	NAKAI, M; ENDO, T; HASE, T; MATSUBARA, H				NAKAI, M; ENDO, T; HASE, T; MATSUBARA, H			INTRAMITOCHONDRIAL PROTEIN SORTING - ISOLATION AND CHARACTERIZATION OF THE YEAST MSP1 GENE WHICH BELONGS TO A NOVEL FAMILY OF PUTATIVE ATPASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; PRECURSOR PROTEINS; ESCHERICHIA-COLI; IMPORT RECEPTOR; 70-KD PROTEIN; EXPRESSION; IDENTIFICATION; CYTOCHROME-C1; INSERTION; SIGNAL	Replacement of the presequence of yeast cytochrome cl by the amino-terminal 61 residues of MAS70, a yeast mitochondrial outer membrane protein, resulted in exclusive localization of the fusion protein (termed the 61mC1 protein) to the outer membrane. When a cytochrome c1-deficient yeast strain was transformed with a plasmid encoding the fusion protein, the cells could not grow on nonfermentable carbon sources such as glycerol. We isolated a novel yeast gene MSP1 (mitochondrial sorting of proteins) whose overexpression causes mislocalization of the 61mC1 fusion protein to the inner membrane, probably via the intermembrane space, and thereby allows the host cells to grow on glycerol. The predicted MSP1 protein (MSP1) is a hydrophilic 40-kDa polypeptide containing a putative membrane-spanning domain near the amino terminus. Further sequence analyses revealed that MSP1 is a member of a novel family of putative ATPases which share a highly conserved domain of about 185 amino acid residues, including a consensus motif for a nucleotide binding site. MSP1 was found to be an intrinsic mitochondrial outer membrane protein of an apparent molecular mass of 40 kDa with a large domain facing to the cytosol. The MSP1 gene is not essential for the cell growth either on fermentable or nonfermentable carbon sources.	OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,FAC SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN	Osaka University; Osaka University	NAKAI, M (corresponding author), NAGOYA UNIV,FAC SCI,DEPT CHEM,CHIKUSA KU,NAGOYA 46401,JAPAN.		Hase, Toshiharu/H-9271-2013					AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DREUSICKE D, 1986, FEBS LETT, V208, P301, DOI 10.1016/0014-5793(86)81037-7; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HASE T, 1986, FEBS LETT, V197, P199, DOI 10.1016/0014-5793(86)80326-X; HASE T, 1987, J BIOCHEM-TOKYO, V102, P411, DOI 10.1093/oxfordjournals.jbchem.a122068; HASE T, 1983, EMBO J, V2, P2169, DOI 10.1002/j.1460-2075.1983.tb01718.x; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HASE T, 1987, J BIOCHEM, V102, P401, DOI 10.1093/oxfordjournals.jbchem.a122067; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3192; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; JOHNSON LM, 1985, CELL, V43, P369, DOI 10.1016/0092-8674(85)90042-X; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI JM, 1992, BIOCHIM BIOPHYS ACTA, V1106, P233, DOI 10.1016/0005-2736(92)90001-3; LISOWSKY T, 1992, MOL GEN GENET, V232, P58, DOI 10.1007/BF00299137; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; MITOMA J, 1992, J BIOCHEM-TOKYO, V111, P20, DOI 10.1093/oxfordjournals.jbchem.a123712; MURAKAMI H, 1990, NATURE, V347, P488, DOI 10.1038/347488a0; NAKAI M, 1989, J BIOCHEM-TOKYO, V105, P513, DOI 10.1093/oxfordjournals.jbchem.a122698; NAKAI M, 1989, J BIOCHEM-TOKYO, V106, P181, DOI 10.1093/oxfordjournals.jbchem.a122811; NEBLOCK P, 1990, SCIENCE, V248, P1650; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; SAMBROOK J, 1988, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHATZ G, 1987, EUR J BIOCHEM, V165, P1, DOI 10.1111/j.1432-1033.1987.tb11186.x; SHERMAN F, 1986, LABORATORY COURSE MA; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; YAFFE MP, 1989, J BIOL CHEM, V264, P21091; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	47	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24262	24269						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226973				2022-12-25	WOS:A1993MF29400081
J	JI, IH; ZENG, HW; JI, TH				JI, IH; ZENG, HW; JI, TH			RECEPTOR ACTIVATION OF AND SIGNAL GENERATION BY THE LUTROPIN CHORIOGONADOTROPIN RECEPTOR - COOPERATION OF ASP(397) OF THE RECEPTOR AND ALPHA-LYS(91) OF THE HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HIGH-AFFINITY; CLONING; DOMAIN; BINDS; CDNA; GENE	We have developed a novel method of reciprocal substitution mutation to identify pairing of amino acids within a receptor and its ligand. Using this method, we demonstrate for the first time that a pair of counterionic amino acids, one from the lutropin/choriogonadotropin receptor and the other from the ligand (human choriogonadotropin), cooperate and perhaps interact with each other to activate the receptor and to generate hormonal signal. In this study, Asp397 of the receptor was converted to Lys while Lys91 of the alpha subunit of human choriogonadotropin was substituted with Asp, thus maintaining the counterionic nature of this pair of amino acids. Mutation at each of these positions does not affect the hormone-receptor interaction but results in the significant or complete loss of the bioactivity of both the receptor and the hormone. However, when the impotent mutant receptor and mutant hormone were paired to interact together, they induced cAMP synthesis, resulting in a potent receptor-hormone couple. Substitutions with other amino acids that eliminated the counterionic nature failed to induce cAMP synthesis. Our results shed light on the molecular mechanisms of receptor activation and will serve as a model for other G-protein-coupled peptide receptors, particularly glycoprotein hormone receptors.			JI, IH (corresponding author), UNIV WYOMING,DEPT MOLEC BIOL,LARAMIE,WY 82071, USA.				NHLBI NIH HHS [HL-18702] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; JI I, 1991, J BIOL CHEM, V266, P13076; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI I, 1990, GLYCOPROTEIN HORMONE, P355; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; JI J, 1993, J BIOL CHEM, V268, P20851; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MACFARLAND KC, 1989, SCIENCE, V245, P494; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; XIE YB, 1990, J BIOL CHEM, V265, P21411; YOO J, 1991, J BIOL CHEM, V266, P17741; YOO JK, 1993, J BIOL CHEM, V268, P13034	14	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22971	22974						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226810				2022-12-25	WOS:A1993MF51500005
J	LIU, YC; MATTHEWS, KS				LIU, YC; MATTHEWS, KS			DEPENDENCE OF TRP REPRESSOR-OPERATOR AFFINITY, STOICHIOMETRY, AND APPARENT COOPERATIVITY ON DNA-SEQUENCE AND SIZE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; TRYPTOPHAN-SPECIFIC PERMEASE; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; MET REPRESSOR; NMR ASSIGNMENTS; LAC REPRESSOR; BINDING; PROTEIN; APOREPRESSOR	A series of chemically synthesized trp and mutant operator DNAs was employed to examine trp repressor binding. Although only a single repressor-operator complex was observed for most DNAs as reported previously, varying DNA sequence revealed two retarded complexes with an additional band of faster mobility. The relative intensity of the two retarded bands with varying repressor concentrations suggests that cooperative interactions between dimers may occur in the formation of the predominant repressor-operator complex. Direct stoichiometry measurements demonstrated that a 2:1 stoichiometry (two dimers per operator) is found in the primary repressor-operator complex band and that a 1:1 stoichiometry is observed, when present, for the minor repressor-operator complex band of faster mobility. Similar retardation patterns with a single complex of 2:1 stoichiometry were observed for 40-base pair (bp) trp operators corresponding to TrpEDCBA, aroH, and Trp-PL (a derivative of TrpEDCBA with increased symmetry) operator sequences as well as to hybrid operators containing a half-binding site from TrpEDCBA in conjunction with lac operator sequences, although the apparent affinity for the half-site DNAs was diminished by 10-fold. In contrast, the prominence of the 1:1 dimer-operator complex for Trp-PR, a different derivative of TrpEDCBA with increased symmetry, suggests that sequence context may diminish cooperativity between dimers. The stoichiometry observed was also dependent on the length of TrpEDCBA operator DNA used, shifting from primarily 2:1 for 40- and 33-bp TrpEDCBA DNA to primarily 1:1 for 29-, 26-, and 20-bp TrpEDCBA DNAs. In addition, the stability of the repressor-operator complex to electrophoresis is reduced for DNA lengths of 33, 29, and 26 bp. Based on the binding data and footprinting patterns for two hybrid 40-bp TrpEDCBA/lac half-binding site DNAs, it appears that repressor associates tightly to the specific trp half-site, whereas the non-specific half of the DNA is more loosely bound. These results suggest that repressor dimer-dimer interaction may be an important feature in the trp repressor-operator interaction.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University					NIGMS NIH HHS [GM22441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARROWSMITH C, 1991, EUR J BIOCHEM, V202, P53, DOI 10.1111/j.1432-1033.1991.tb16344.x; ARROWSMITH CH, 1990, BIOCHEMISTRY-US, V29, P6332, DOI 10.1021/bi00479a002; ARROWSMITH CH, 1989, BIOCHEMISTRY-US, V28, P3875, DOI 10.1021/bi00435a037; ARROWSMITH CH, 1991, J AM CHEM SOC, V113, P4020, DOI 10.1021/ja00010a070; ARVIDSON DN, 1986, J BIOL CHEM, V261, P238; BASS S, 1987, GENE DEV, V1, P565, DOI 10.1101/gad.1.6.565; BENNETT GN, 1978, J MOL BIOL, V121, P179, DOI 10.1016/S0022-2836(78)80004-7; BORDEN KLB, 1992, EUR J BIOCHEM, V204, P137, DOI 10.1111/j.1432-1033.1992.tb16616.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; CANN JR, 1989, J BIOL CHEM, V264, P17032; CAREY J, 1989, J BIOL CHEM, V264, P1941; CAREY J, 1991, J BIOL CHEM, V266, P24509; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CHO KO, 1988, J MOL BIOL, V204, P51, DOI 10.1016/0022-2836(88)90598-0; CHOU WY, 1989, J BIOL CHEM, V264, P18314; FERNANDO T, 1992, BIOCHEMISTRY-US, V31, P3429, DOI 10.1021/bi00128a018; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GROVE CL, 1987, J BACTERIOL, V169, P2158, DOI 10.1128/jb.169.5.2158-2164.1987; GUNSALUS RP, 1986, J BACTERIOL, V167, P272, DOI 10.1128/jb.167.1.272-278.1986; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; HARAN TE, 1992, EMBO J, V11, P3021, DOI 10.1002/j.1460-2075.1992.tb05372.x; HAYDOCK PV, 1984, BIOCHEM BIOPH RES CO, V119, P926, DOI 10.1016/0006-291X(84)90862-3; HE JJ, 1990, J BIOL CHEM, V265, P731; HEATWOLE VM, 1991, J BACTERIOL, V173, P3601, DOI 10.1128/jb.173.11.3601-3604.1991; HEATWOLE VM, 1992, J BACTERIOL, V174, P331, DOI 10.1128/jb.174.1.331-335.1992; HEATWOLE VM, 1991, J BACTERIOL, V173, P108, DOI 10.1128/jb.173.1.108-115.1991; HURLBURT BK, 1992, J BIOL CHEM, V267, P16783; HURLBURT BK, 1992, NUCLEIC ACIDS RES, V20, P337, DOI 10.1093/nar/20.2.337; HURLBURT BK, 1990, J BIOL CHEM, V265, P7853; JOACHIMIAK A, 1983, P NATL ACAD SCI-BIOL, V80, P668, DOI 10.1073/pnas.80.3.668; KLEINSCHMIDT C, 1991, NUCLEIC ACIDS RES, V19, P1021, DOI 10.1093/nar/19.5.1021; KLIG LS, 1988, J MOL BIOL, V202, P769, DOI 10.1016/0022-2836(88)90557-8; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; LAWSON CL, 1988, NATURE, V333, P869, DOI 10.1038/333869a0; LEPECQ JB, 1966, ANAL BIOCHEM, V17, P100, DOI 10.1016/0003-2697(66)90012-1; LETILLY V, 1993, IN PRESS BIOCHEMISTR; LIU YC, 1991, THESIS RICE U HOUSTO; LUISI BF, 1990, BIOCHIM BIOPHYS ACTA, V1048, P113, DOI 10.1016/0167-4781(90)90047-6; Maniatis T., 1982, MOL CLONING; MARMORSTEIN RQ, 1991, BIOCHEMISTRY-US, V30, P1141, DOI 10.1021/bi00218a036; MARMORSTEIN RQ, 1987, J BIOL CHEM, V262, P4922; Maxam A M, 1980, Methods Enzymol, V65, P499; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PALUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851, DOI 10.1093/nar/14.20.7851; PHILLIPS SEV, 1989, NATURE, V341, P711, DOI 10.1038/341711a0; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; Sambrook J, 1989, MOL CLONING LABORATO; SARSERO JP, 1991, J BACTERIOL, V173, P4133, DOI 10.1128/jb.173.13.4133-4143.1991; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SCHMITZ A, 1979, NUCLEIC ACIDS RES, V6, P111, DOI 10.1093/nar/6.1.111; SCHNEIDER GJ, 1990, J BIOL CHEM, V265, P10198; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; STAACKE D, 1990, EMBO J, V9, P1963, DOI 10.1002/j.1460-2075.1990.tb08324.x; WICK KL, 1991, J BIOL CHEM, V266, P6106; YANOFSKY C, 1981, NUCLEIC ACIDS RES, V9, P6647, DOI 10.1093/nar/9.24.6647; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0; ZHAO D, 1993, J MOL BIOL, V229, P735, DOI 10.1006/jmbi.1993.1076	61	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23239	23249						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226846				2022-12-25	WOS:A1993MF51500048
J	LUNDKATZ, S; WEISGRABER, KH; MAHLEY, RW; PHILLIPS, MC				LUNDKATZ, S; WEISGRABER, KH; MAHLEY, RW; PHILLIPS, MC			CONFORMATION OF APOLIPOPROTEIN-E IN LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-BINDING DOMAIN; A-I; REDUCTIVE METHYLATION; HUMAN-FIBROBLASTS; PROTEIN; COMPLEXES; RESIDUES; CELLS	Lysine (Lys) residues in apolipoprotein (apo) E are known to be involved in binding of apoE-containing lipoproteins to the low density lipoprotein (LDL) receptor. To examine the microenvironments of the Lys residues of apoE-3 in a variety of lipid-associated states, we have used a high resolution C-13-NMR method in which Lys were reductively methylated with [C-13] formaldehyde. Over a wide pH range, the spectrum of apoE in canine HDL(c), a spherical lipoprotein particle, exhibited two peaks from Lys epsilon-amino groups. The two pools of Lys in HDL(c) titrate with pK(a) values of 10.4 (''normal') and 9.3 (''active''). In contrast, eight epsilon-[(CH3)-C-13]2Lys peaks (delta = 42.5-44.5 parts/million) with pK(a) values ranging from 8.2 to 10.1 and 7.8 to 10.5 were observed at pH 9.5 for human and canine apoE, respectively, in discoidal complexes with dimyristoyl glycerophosphocholine. A single Lys microenvironment was observed for apoE present in a disordered, lipid-free, state in 8 M urea, confirming the fact that the lipid environment is modulating the conformation of apoE. The above data demonstrate that the conformation of apoE, as reflected by the Lys microenvironments, on spherical HDL(c) particles is different from that on discoidal complexes.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, GLADSTONE INST CARDIOVASC DIS, DEPT PATHOL, SAN FRANCISCO, CA 94140 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, GLADSTONE INST CARDIOVASC DIS, DEPT MED, SAN FRANCISCO, CA 94140 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes	LUNDKATZ, S (corresponding author), MED COLL PENN, DEPT BIOCHEM, PHILADELPHIA, PA 19129 USA.			Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIRAM M, 1988, J BIOL CHEM, V263, P16842; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHEN GC, 1984, BIOCHEMISTRY-US, V23, P6530, DOI 10.1021/bi00321a039; CHEN GC, 1986, METHOD ENZYMOL, V128, P519; DICK LR, 1988, J BIOL CHEM, V263, P18864; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; GERKEN TA, 1982, J BIOL CHEM, V257, P2894; HAMILTON JA, 1986, METHOD ENZYMOL, V128, P472; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; JENTOFT JE, 1979, J BIOL CHEM, V254, P4366; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1989, J BIOL CHEM, V264, P4818; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1991, J BIOL CHEM, V266, P2701; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; MAHLEY RW, 1974, CIRC RES, V35, P722, DOI 10.1161/01.RES.35.5.722; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; MORRISET.JD, 1973, BIOCHEMISTRY-US, V12, P1290, DOI 10.1021/bi00731a008; NOBLE RP, 1968, J LIPID RES, V9, P693; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; POWNALL HJ, 1987, PLASMA LIPOPROTEINS, P75; RALL SC, 1986, METHOD ENZYMOL, V128, P273; REIJNGOUD DJ, 1984, BIOCHEMISTRY-US, V23, P726, DOI 10.1021/bi00299a022; SCANU A, 1968, P NATL ACAD SCI USA, V59, P890, DOI 10.1073/pnas.59.3.890; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TANFORD C, 1962, ADV PROTEIN CHEM, V17, P69; WARDELL MR, 1991, J LIPID RES, V32, P521; Weisgraber K H, 1986, Methods Enzymol, V129, P145; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1985, ADV EXP MED BIOL, V183, P159; WEISGRABER KH, 1978, J BIOL CHEM, V253, P4171; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	38	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23008	23015						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226815				2022-12-25	WOS:A1993MF51500011
J	AOKI, M; HAMADA, F; SUGIMOTO, T; SUMIDA, S; AKIYAMA, T; TOYOSHIMA, K				AOKI, M; HAMADA, F; SUGIMOTO, T; SUMIDA, S; AKIYAMA, T; TOYOSHIMA, K			THE HUMAN COT PROTOONCOGENE ENCODES 2 PROTEIN-SERINE THREONINE KINASES WITH DIFFERENT TRANSFORMING ACTIVITIES BY ALTERNATIVE INITIATION OF TRANSLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE SARCOMA-VIRUS; N-END RULE; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; CELL-CYCLE; V-RAF; FAMILY; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION	The cot gene is an oncogene encoding serine/threonine kinases isolated by DNA transfection assay. In this study, we isolated cDNA for the human cot proto-oncogene (proto-cot gene) and examined the structure and function of its gene products. The proto-cot gene has an open reading frame encoding 467 amino acids of which the first 397 amino acids are identical to those in the corresponding part of the cot gene. The protein products of the proto-cot gene were identified as 58- and 52-kDa proteins with intrinsic protein serine/threonine kinase activity. These two protein species were suggested to be generated by alternative initiation from two AUGs. The 58- and 52-kDa proteins are both localized predominantly in the cytosol, but the 58-kDa protein has a shorter half-life than the 52-kDa protein, suggesting the importance of the amino-terminal domain in regulating the stability of the proto-Cot protein. More interestingly, the 58-kDa protein showed stronger transforming activity than the 52-kDa protein, although this activity was much weaker than that of the Cot oncoprotein. Thus, the amino-terminal domain of the Cot protein may be necessary for cellular transformation, whereas the carboxyl-terminal domain may negatively regulate the transforming activity.	OSAKA UNIV,PHYS RES INST,DEPT ONCOGENE RES,3-1 YAMADA OKA,SUITA,OSAKA 565,JAPAN	Osaka University			Aoki, Masahiro/A-5149-2016	Aoki, Masahiro/0000-0003-4316-9490				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; AOKI M, 1991, ONCOGENE, V6, P1515; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLENIS J, 1991, CANCER CELLS, V3, P446; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN WS, 1987, NATURE, V328, P821; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU CK, 1987, J BIOL CHEM, V262, P1842; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FREEMAN RS, 1991, BIOCHEMISTRY-US, V30, P2293, DOI 10.1021/bi00223a001; FUKUI M, 1985, P NATL ACAD SCI USA, V82, P5954, DOI 10.1073/pnas.82.17.5954; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; IKAWA S, 1990, MOL CELL BIOL, V10, P2503; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SARIS CJM, 1991, EMBO J; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078	50	52	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22723	22732						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226782				2022-12-25	WOS:A1993MD34800079
J	BROSE, N; GASIC, GP; VETTER, DE; SULLIVAN, JM; HEINEMANN, SF				BROSE, N; GASIC, GP; VETTER, DE; SULLIVAN, JM; HEINEMANN, SF			PROTEIN CHEMICAL CHARACTERIZATION AND IMMUNOCYTOCHEMICAL LOCALIZATION OF THE NMDA RECEPTOR SUBUNIT NMDA R1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GLUTAMATE RECEPTOR; RAT-BRAIN; MEMBRANE-PROTEINS; MOLECULAR-CLONING; CHANNEL; CLEAVAGE; CELLS	In the rat central nervous system, the mRNA encoding the N-methyl-D-aspartate receptor subunit R1 is the most ubiquitously distributed among the cloned subunit mRNAs of this glutamate receptor subtype. The N-methyl-D-aspartate R1 mRNA is very abundantly expressed and N-methyl-D-aspartate R1 coexpression is necessary for functional expression of all other cloned N-methyl-D-aspartate receptor subunits. Therefore, the R1 subunit is likely to be an essential component of all known N-methyl-D-aspartate receptors in rat brain. By employing sequence specific polyclonal antibodies, we demonstrate that rat brain N-methyl-D-aspartate R1, as well as recombinantly expressed receptor protein, has an apparent molecular mass of 116 kDa in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The receptor protein is heavily glycosylated. It is specifically localized to the central nervous system, and it coenriches with synaptic membranes upon subcellular fractionation of the cerebral cortex. Chemical cross-linking of synaptic membrane proteins shows that the N-methyl-D-aspartate R1 protein is part of a receptor protein complex with a molecular mass of 730 kDa. By using immunocytochemical methods, we demonstrate a widespread but distinct distribution of N-methyl-D-aspartate R1 in neurons of the rat brain, with prominent immunostaining in certain layers of the cerebral cortex, in the hippocampus and dentate gyrus, as well as in the cerebellum.			BROSE, N (corresponding author), SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB H,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Vetter, Douglas E./O-8150-2019		NINDS NIH HHS [NS 28706, NS 11549] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011549] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134; ANANTHARAM V, 1992, FEBS LETT, V305, P27, DOI 10.1016/0014-5793(92)80648-Z; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROSE N, 1990, J BIOL CHEM, V265, P10604; CHANGEUX JP, 1987, TRENDS PHARMACOL SCI, V8, P459, DOI 10.1016/0165-6147(87)90039-3; CHAZOT PL, 1992, J NEUROCHEM, V59, P1176, DOI 10.1111/j.1471-4159.1992.tb08364.x; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; Friedrich Jr VL, 1981, NEUROANATOMICAL TRAC, P345; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LABORATOR; HUNTLEY GW, 1993, J NEUROSCI, V13, P2965; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MUGNAINI E, 1983, J HISTOCHEM CYTOCHEM, V31, P1435, DOI 10.1177/31.12.6355290; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; NAKANISHI S, 1992, SCIENCE, V258, P579; OLMSTEDT JB, 1987, METHOD ENZYMOL, V134, P467; ORDRONNEAU P, 1981, J HISTOCHEM CYTOCHEM, V29, P1397, DOI 10.1177/29.12.7033366; ROGERS SW, 1991, J NEUROSCI, V11, P2713; ROSEMUND C, 1992, J NEUROPHYSIOL, V68, P1901, DOI 10.1152/jn.1992.68.5.1901; Sambrook J, 1989, MOL CLONING LABORATO; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YAMAZAKI M, 1992, BIOCHEM BIOPH RES CO, V183, P886, DOI 10.1016/0006-291X(92)90566-4	37	153	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22663	22671						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226775				2022-12-25	WOS:A1993MD34800071
J	RAO, VN; REDDY, ESP				RAO, VN; REDDY, ESP			ELK-1 PROTEINS INTERACT WITH MAP KINASES	ONCOGENE			English	Article							ETS-RELATED PROTEIN; SERUM RESPONSE FACTOR; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; C-FOS; DNA-BINDING; C-ETS-1 PROTOONCOGENE; FACTOR P62TCF; PHOSPHORYLATION; SEQUENCE	Mitogen activated protein kinases (MAP) or extracellular signal regulated protein kinases (ERK) are a family of protein serine/threonine kinases that are activated very rapidly in response to many extracellular stimuli. elk-1, an ets related gene codes for two transcriptional factors elk-1, which regulates c-fos transcription and Delta elk-1, both of which are substrates for MAP kinases. A part of the C-terminal transcriptional activation domain (ETA-2) which is common to both the proteins was previously shown to function as an activator of MAP kinases. In this report, in an attempt to investigate the mechanism of activation of MAP kinases, purified preparations of recombinant elk-1 and P44(mpk)/ERK-1/ERK-2 proteins were used to show the association of elk-1 proteins with MAP kinases, The specific interactions of elk-1 proteins with MAP kinases were confirmed by co-immunoprecipitation studies. Thus elk-1 proteins appear to regulate the activity of MAP kinases by interacting with them ensuring a conformational change and stimulating their autophosphorylation and activation property. The activation was dependent on the presence of ATP and Mg2+. In vitro phosphorylation of elk-1 protein was not regulatory for autonomous DNA binding activity of elk-1 protein. Cells which were exposed to EGF showed a rapid stimulation of an elk-1 specific kinase activity, probably MAP kinase which phosphorylated MBP and was found to be associated with immobilized GST-elk-1. Furthermore, dephosphorylation studies indicate that elk-1 proteins can activate only tyrosine phosphorylated MAP kinase. These results demonstrate the presence of an alternative pathway/mechanism (other than MAP kinase kinase, MAPKK/Mek) for the activation of MAP kinases with tyrosine phosphorylation occurring before serine/threonine autophosphorylation and activation by elk-1 proteins.			RAO, VN (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.				NATIONAL CANCER INSTITUTE [P01CA050507] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CHENG HC, 1991, J BIOL CHEM, V266, P17919; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEWIS IC, 1991, J BIOL CHEM, V266, P15180; MARIAS R, 1993, CELL, V73, P381; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAO VN, 1993, CANCER RES, V53, P3449; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1991, ONCOGENE, V6, P2285; SANGHERA JS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P153, DOI 10.1016/0167-4889(91)90078-C; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	36	80	81	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1855	1860						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208531				2022-12-25	WOS:A1994NR68500007
J	SIYANOVA, EY; SERFAS, MS; MAZO, IA; TYNER, AL				SIYANOVA, EY; SERFAS, MS; MAZO, IA; TYNER, AL			TYROSINE KINASE GENE-EXPRESSION IN THE MOUSE SMALL-INTESTINE	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; HEMATOPOIETIC-CELLS; PROTEIN-KINASE; DIFFERENTIATED ENTEROCYTES; CATALYTIC DOMAIN; CARCINOMA-CELLS; STEM-CELLS; RECEPTOR; FAMILY; CRYPT	To identify tyrosine kinases that may regulate regeneration of the mammalian intestinal epithelium, we amplified portions of the catalytic domains of protein kinases expressed in intestinal crypt cells, using the polymerase chain reaction technique with primers directed against two invariant amino acid sequence motifs found in all kinases. These fragments were cloned and a library of kinase catalytic domains was generated, Sequence analysis of unique clones resulted in the identification of the catalytic domains of several characterized tyrosine kinases, including lyn, hck, c-fgr, tec, JAK2, itk, and the putative receptor kinase ryk, and expression of these kinases has not previously been described in the intestine. We compared the levels of mRNA encoding these kinases in multiple tissues using RNase protection assays, and we localized the expression of hck, lyn, and JAK2 in the intestine using in situ hybridization. In addition, we identified two novel putative catalytic domain sequences. One of these, which we have named sik (src-related intestinal kinase), is expressed at high levels in the gastrointestinal tract and may play a specific role in signal transduction in epithelial tissues.	UNIV ILLINOIS, COLL MED, DEPT GENET, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Mazo, Ilya A/G-6549-2014	Mazo, Ilya A/0000-0002-8587-4895; Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044525, R01DK044525] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK044525, DK44525, R01 DK044525-06] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BJERKNES M, 1981, ANAT REC, V199, P565, DOI 10.1002/ar.1091990412; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; BURGESS DR, 1989, J CELL BIOL, V109, P2139, DOI 10.1083/jcb.109.5.2139; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CERFBENSUSSAN N, 1991, GASTROENTEROL CLIN N, V20, P549; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FOSS FM, 1989, ONCOGENE RES, V5, P13; GILMAN M, 1987, CURRENT PROTOCOLS MO; GORDON JI, 1993, GASTROENTEROLOGY, V104, P315; GUYGRAND D, 1993, CURR OPIN IMMUNOL, V5, P247, DOI 10.1016/0952-7915(93)90012-H; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARPUR AG, 1992, ONCOGENE, V7, P1347; HOEKSTRA MF, 1991, TRENDS GENET, V7, P256, DOI 10.1016/0168-9525(91)90161-I; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; KLEMSZ MJ, 1987, NUCLEIC ACIDS RES, V15, P9600, DOI 10.1093/nar/15.22.9600; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; LEGUEN L, 1992, GENE, V120, P249, DOI 10.1016/0378-1119(92)90100-4; MAHER PA, 1988, J CELL BIOL, V106, P1747, DOI 10.1083/jcb.106.5.1747; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; NEUTRA MR, 1988, CELL TISSUE BIOL, P642; OTTILIE S, 1992, ONCOGENE, V7, P1625; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TRIER JS, 1991, GASTROENTEROL CLIN N, V20, P531; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	38	65	68	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2053	2057						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208550				2022-12-25	WOS:A1994NR68500030
J	WU, LT; YEE, A; LIU, L; CARBONAROHALL, D; VENKATESAN, N; TOLO, VT; HALL, FL				WU, LT; YEE, A; LIU, L; CARBONAROHALL, D; VENKATESAN, N; TOLO, VT; HALL, FL			MOLECULAR-CLONING OF THE HUMAN CAK1 GENE ENCODING A CYCLIN-DEPENDENT KINASE-ACTIVATING KINASE	ONCOGENE			English	Article							HUMAN OSTEOSARCOMA CELLS; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; TYROSINE PHOSPHATASE; CATALYTIC SUBUNIT; PHOSPHORYLATION; P34CDC2; IDENTIFICATION; INHIBITOR; P34(CDC2)	Cyclin-dependent, proline-directed protein kinases normally function to execute critical cell cycle transitions; abnormal expression and/or viral subversion of the positive (cyclins) and negative (Pic1) regulatory subunits may contribute to neoplastic transformation and tumorigenesis. In addition to the binding of regulatory subunits, the enzymatic activities of the cyclin-dependent kinases, Cdc2 and Cdk2, are tightly regulated by site-specific protein phosphorylation events, Recent studies have identified a critical phosphorylation site (Thr-161) located within kinase Subdomain VIII that is necessary for Cdc2 activation, and enzymatic activities capable of carrying out this heterologous phosphorylation event have been detected in both Xenopus oocytes and human somatic cells. In this report, we characterize by molecular cloning a human homologue of the Xenopus Cdk-activating kinase (Cak, encoded by MO15); the novel human gene is designated (HS)CAK1. While only 75% identity is observed at the nucleotide level, the deduced amino acid sequence encoded by (HS)CAK1 is approximately 87% identical to that of the Xenopus MO15 gene in corresponding regions. The catalytic domain of (HS)Cak1, defined by conserved kinase Subdomains I through XI, exhibits considerable homology with (HS)Cdc2, suggesting that this kinase cascade involves closely related enzymes. Immunological studies with anti-Cak antibodies confirm the presence of specific immunoreactivity in highly purified preparations of the human Cdc2-activating kinase. The molecular characterization of (HS)CAK1 should facilitate studies of its physiological regulation, as well as its potential utility as a target for therapeutic intervention in the treatment of proliferative disorders.	CHILDRENS HOSP LOS ANGELES, RES INST, DIV ORTHOPAED SURG, LOS ANGELES, CA 90027 USA; UNIV SO CALIF, SCH PHARM, DEPT MOLEC PHARMACOL & TOXICOL, LOS ANGELES, CA 90033 USA	Children's Hospital Los Angeles; University of Southern California					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049715] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01GM49715-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; DOU QP, 1993, CANCER RES, V53, P1493; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ERSHLER MA, 1993, GENE, V124, P305, DOI 10.1016/0378-1119(93)90411-U; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUERRUCCI M-A, 1991, Protein Sequences and Data Analysis, V4, P337; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PINES J, 1990, New Biologist, V2, P389; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; WHITE BA, 1982, J BIOL CHEM, V257, P8569; Williams R. T., 1993, Molecular Biology of the Cell, V4, p239A; WILLIAMS RT, 1993, J BIOL CHEM, V268, P8871; WILLIAMS RT, 1992, ONCOGENE, V7, P423; WU LT, 1993, INT J ONCOL, V3, P859; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	45	47	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2089	2096						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208556				2022-12-25	WOS:A1994NR68500036
J	MURAKAMI, N; ELZINGA, M; SINGH, SS; CHAUHAN, VPS				MURAKAMI, N; ELZINGA, M; SINGH, SS; CHAUHAN, VPS			DIRECT BINDING OF MYOSIN-II TO PHOSPHOLIPID-VESICLES VIA TAIL REGIONS AND PHOSPHORYLATION OF THE HEAVY-CHAINS BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE NONMUSCLE MYOSIN; ACTIVATED MG-ATPASE; AMINO-ACID-SEQUENCE; BRUSH-BORDER MYOSIN; FILAMENT FORMATION; SMOOTH-MUSCLE; BRAIN MYOSIN; LIGHT CHAIN; CELLULAR MYOSIN; NERVOUS-SYSTEM	Recent cloning and sequencing studies suggest that heavy chains of all non-muscle myosins II have a protein kinase C (PKC) phosphorylation site within their tail regions. A fragment of human macrophage myosin heavy chain, encompassing its COOH-terminal 396 amino acids (MIIA(F46)), was expressed in Escherichia coli to provide a model system for study of PKC-mediated phosphorylation. PKC phosphorylated this fragment when phosphatidylserine (PS) liposomes were present, but not when liposomes made from PS/phosphatidylcholine (PC) were used. The reaction required Ca2+, but not other activators such as diacylglycerol (DG) or phosphatidylinositol 4,5-bisphosphate. Phosphorylation of MIIA(F46),as not observed in the presence of micelles of PS or PS/DG. Similar results were obtained using native myosin II purified from bovine brain and chicken intestine brush border. Phosphorylation of light chains, in contrast, occurred even with PS/PC liposomes if DG was present. Addition of the PS and PS/DG liposomes significantly increased the turbidities at 340 nm of MIIA(F46) and native myosin II, and the extent of increase depended upon the type of myosin used. Also, PS and PS/DG liposomes shifted the gel filtration elution positions of MIIA(F48) and myosin II. In contrast, liposomes of PS/PC and PS/PC/DG gave only a slight increase in turbidity with all myosins and fragments and did not noticeably shift their gel filtration elution positions. These results suggest that myosins II bind to PS liposomes via the COOH-terminal regions of their heavy chains with affinities specific to each myosin isoform, that the binding is dependent upon the PS composition, and that PKC phosphorylates the PS-bound heavy chains.	NEW YORK STATE INST BASIC RES DEV DISABIL, DEPT NEUROCHEM, STATEN ISL, NY 10314 USA	Institute for Basic Research in Developmental Disabilities	MURAKAMI, N (corresponding author), NEW YORK STATE INST BASIC RES DEV DISABIL, DEPT PHARMACOL, 1050 FOREST HILL RD, STATEN ISL, NY 10314 USA.							ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; BAZZI MD, 1992, J BIOL CHEM, V267, P22891; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BHATIADEY N, 1993, P NATL ACAD SCI USA, V90, P2856, DOI 10.1073/pnas.90.7.2856; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUHAN VPS, 1988, BIOCHEM BIOPH RES CO, V155, P18, DOI 10.1016/S0006-291X(88)81043-X; CHENG TPO, 1992, FEBS LETT, V311, P91, DOI 10.1016/0014-5793(92)81374-U; CITI S, 1986, J MOL BIOL, V188, P369, DOI 10.1016/0022-2836(86)90161-0; COLLINS JH, 1982, BIOCHEMISTRY-US, V21, P6910, DOI 10.1021/bi00269a045; CONTI MA, 1991, BIOCHEMISTRY-US, V30, P966, DOI 10.1021/bi00218a012; COTE GP, 1984, J BIOL CHEM, V259, P2781; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HAYDEN SM, 1990, J CELL BIOL, V111, P443, DOI 10.1083/jcb.111.2.443; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IKEDA N, 1990, BIOCHEM BIOPH RES CO, V169, P1191, DOI 10.1016/0006-291X(90)92022-R; KAWAMOTO S, 1989, J BIOL CHEM, V264, P2258; KELLEY CA, 1993, BIOPHYS J, V64, pA144; KELLY CA, 1991, J BIOL CHEM, V265, P17876; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; KUROO M, 1991, J BIOL CHEM, V266, P3768; KUZNICKI J, 1983, J BIOL CHEM, V258, P6011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI DQ, 1994, P NATL ACAD SCI USA, V91, P853, DOI 10.1073/pnas.91.3.853; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MCNALLY E, 1991, METHOD ENZYMOL, V196, P368; MILLER M, 1992, NEURON, V8, P25, DOI 10.1016/0896-6273(92)90106-N; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; MURAKAMI N, 1990, J BIOL CHEM, V265, P1041; MURAKAMI N, 1984, J BIOCHEM-TOKYO, V95, P651, DOI 10.1093/oxfordjournals.jbchem.a134654; MURAKAMI N, 1993, DEV BIOL, V157, P19, DOI 10.1006/dbio.1993.1108; MURAKAMI N, 1991, FEBS LETT, V278, P23, DOI 10.1016/0014-5793(91)80074-D; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808; OGIHARA S, 1983, J BIOCHEM, V93, P205, DOI 10.1093/oxfordjournals.jbchem.a134155; PERRY SV, 1962, METHOD ENZYMOL, V5, P582; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; SAGARA J, 1983, BIOCHEM J, V214, P839, DOI 10.1042/bj2140839; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; Small J V, 1988, Electron Microsc Rev, V1, P155; SUN WD, 1992, J MOL BIOL, V224, P1185, DOI 10.1016/0022-2836(92)90482-Y; SWANLJUNGCOLLINS H, 1992, J BIOL CHEM, V267, P3445; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; TANAKA E, 1986, J NEUROCHEM, V47, P254; TRUONG T, 1992, J BIOL CHEM, V267, P9767; VAILLANCOURT JP, 1988, J BIOL CHEM, V263, P10082	51	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16082	16090						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206908				2022-12-25	WOS:A1994NQ72900023
J	NAH, HD; NIU, ZL; ADAMS, SL				NAH, HD; NIU, ZL; ADAMS, SL			AN ALTERNATIVE TRANSCRIPT OF THE CHICK TYPE-III COLLAGEN GENE THAT DOES NOT ENCODE TYPE-III COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2(I) COLLAGEN; MESSENGER-RNA; SPLICED TRANSCRIPTS; SEQUENCE-ANALYSIS; DNA-POLYMERASE; 5' END; EXPRESSION; CHONDROBLASTS; TRANSLATION; CHAIN	Type III collagen, a ubiquitous protein found in most connective tissues, is not present in hyaline cartilage. However, we have identified an alternative transcript of the type III collagen gene in cultured chondrocytes from several embryonic chick cartilages. This RNA contains exons 24-52, but exons 1-23 are replaced by 70 nucleotides of unique sequence, suggesting that transcription initiates at an alternative promoter. Two of the open reading frames in the alternative transcript are out of frame with the collagen coding sequence; a third open reading frame encodes the carboxyl-terminal two-thirds of the collagen sequence. Thus, this RNA cannot serve as a template for synthesis of normal type III collagen and may encode noncollagenous proteins and/or a truncated collagen. The alternative transcript has been detected as early as 2.5 days of embryogenesis and at later stages is present at low levels in many tissues, including limb mesenchyme and cartilage. These results, together with our previous identification of an alternative transcript of the chick alpha 2(I) collagen gene (Bennett, V. D., and Adams, S. L. (1990) J. Biol. Chem. 265, 2223-2230), suggest that some collagen genes may have alternative functions that are independent of their roles in collagen production.	UNIV PENN,SCH DENT MED,DEPT BIOCHEM,PHILADELPHIA,PA 19104	University of Pennsylvania					NIAMS NIH HHS [AR41042, AR41849] Funding Source: Medline; NIGMS NIH HHS [GM28840] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041849, R01AR041042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM128840] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SL, 1982, CELL, V30, P373, DOI 10.1016/0092-8674(82)90235-5; ADAMS SL, 1991, EXP CELL RES, V192, P190; AHO S, 1983, NUCLEIC ACIDS RES, V11, P5443, DOI 10.1093/nar/11.16.5443; BENNETT VD, 1989, J BIOL CHEM, V264, P8402; BENNETT VD, 1987, J BIOL CHEM, V262, P14806; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DROPCHO EJ, 1987, P NATL ACAD SCI USA, V84, P4552, DOI 10.1073/pnas.84.13.4552; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELLINI SA, 1978, AM J ANAT, V153, P451, DOI 10.1002/aja.1001530308; FINI ME, 1989, J CELL BIOL, V108, P2045, DOI 10.1083/jcb.108.6.2045; FOCHT RJ, 1984, MOL CELL BIOL, V4, P1843, DOI 10.1128/MCB.4.9.1843; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HENKEL W, 1982, EUR J BIOCHEM, V122, P205, DOI 10.1111/j.1432-1033.1982.tb05868.x; KEENE DR, 1987, J HISTOCHEM CYTOCHEM, V35, P311, DOI 10.1177/35.3.3546481; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P59, DOI 10.1177/39.1.1983874; KEENE DR, 1987, J CELL BIOL, V105, P2393, DOI 10.1083/jcb.105.5.2393; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MCMASTER K, 1977, P NATL ACAD SCI USA, V11, P4835; MURAGAKI Y, 1990, P NATL ACAD SCI USA, V87, P2400, DOI 10.1073/pnas.87.7.2400; MYERS JC, 1983, J BIOL CHEM, V258, P128; NAH HD, 1991, J BIOL CHEM, V266, P23446; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; PACIFICI M, 1985, EXP CELL RES, V161, P381, DOI 10.1016/0014-4827(85)90095-3; PACIFICI M, 1991, EXP CELL RES, V192, P266, DOI 10.1016/0014-4827(91)90185-W; PIHLAJANIEMI T, 1987, P NATL ACAD SCI USA, V84, P940, DOI 10.1073/pnas.84.4.940; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITTA B, 1990, J BIOL CHEM, V265, P6476; Sambrook J, 1989, MOL CLONING LABORATO; SANDBERG M, 1989, MATRIX, V9, P82, DOI 10.1016/S0934-8832(89)80025-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SU MW, 1991, J CELL BIOL, V115, P565, DOI 10.1083/jcb.115.2.565; SWASDISON S, 1992, MATRIX, V11, P56; TIKKA L, 1988, P NATL ACAD SCI USA, V85, P7491, DOI 10.1073/pnas.85.20.7491; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; YAMADA Y, 1983, J BIOL CHEM, V258, P4914; YAMADA Y, 1983, J BIOL CHEM, V258, P2758; YAMADA Y, 1984, NATURE, V310, P333, DOI 10.1038/310333a0; YAMADA Y, 1983, NUCLEIC ACIDS RES, V11, P2733, DOI 10.1093/nar/11.9.2733	46	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16443	16448						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206952				2022-12-25	WOS:A1994NQ72900073
J	SADEK, CM; ALLENHOFFMANN, BL				SADEK, CM; ALLENHOFFMANN, BL			CYTOCHROME P450IA1 IS RAPIDLY INDUCED IN NORMAL HUMAN KERATINOCYTES IN THE ABSENCE OF XENOBIOTICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE S-TRANSFERASES; HEAT-SHOCK PROTEIN; PLASMINOGEN-ACTIVATOR INHIBITOR-2; LIVER NAD(P)H-QUINONE REDUCTASE; ANTIOXIDANT RESPONSIVE ELEMENT; HUMAN EPIDERMAL-KERATINOCYTES; SUBUNIT GENE-EXPRESSION; AH-RECEPTOR; TERMINAL DIFFERENTIATION; SIGNAL-TRANSDUCTION	Cytochrome P450IA1 is a polycyclic aromatic hydrocarbon (PAH)-responsive monooxygenase enzyme with no known endogenous inducer or substrate. We investigated the effect of suspension on P450IA1 gene (CYP1A1) expression in cultured human keratinocytes without the addition of xenobiotics, To prohibit adhesion and trigger differentiation, human keratinocytes or dermal fibroblasts were suspended in medium made semisolid with methylcellulose. Following suspension, we observed dramatic increases (> 100-fold) in steady state P450IA1 mRNA in keratinocytes within 1 h; however, dermal fibroblasts were nonresponsive. This effect was not dependent on methylcellulose itself and could be achieved by suspension in medium alone or in Percoll solution. The induction of P450IA1 mRNA was independent of exogenous calcium or serum concentrations, agents commonly used to signal differentiation. Adherent keratinocytes overlaid with methylcellulose exhibited slight morphological changes accompanied by increased P450IA1 mRNA. The activity of the P450IA1 enzyme was found to parallel Northern analysis data. Changes in keratinocyte adhesion or shape also affect other PAH-responsive genes suggesting Ah receptor involvement. We report a novel mechanism for cell type-specific induction of CYP1A1 expression without the addition of xenobiotic inducers. These findings suggest a possible endogenous role for P450IA1 in stratified squamous epithelia.	UNIV WISCONSIN,CTR ENVIRONM TOXICOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	SADEK, CM (corresponding author), UNIV WISCONSIN,DEPT PATHOL,MADISON,WI 53706, USA.		Sadek, Christine/A-7356-2010		NIAMS NIH HHS [AR40284] Funding Source: Medline; NIEHS NIH HHS [T32 ES07015] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040284, R01AR040284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007015] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAYNEY RM, 1987, J BIOL CHEM, V262, P572; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; BURKE MD, 1985, BIOCHEM PHARMACOL, V34, P3337, DOI 10.1016/0006-2952(85)90355-7; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; COOMES MW, 1983, J PHARMACOL EXP THER, V255, P770; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DIGIOVANNI J, 1989, CANCER RES, V49, P5567; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GRADIN K, 1993, J BIOL CHEM, V268, P4061; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; GUO JF, 1990, J INVEST DERMATOL, V94, P86, DOI 10.1111/1523-1747.ep12873939; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; JAISWAL AK, 1985, NUCLEIC ACIDS RES, V13, P4503, DOI 10.1093/nar/13.12.4503; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KRUITHOF EKO, 1988, BIOCHEM BIOPH RES CO, V156, P383, DOI 10.1016/S0006-291X(88)80852-0; KURPAKUS MA, 1991, J CELL BIOL, V115, P1737, DOI 10.1083/jcb.115.6.1737; LAI HCJ, 1984, J BIOL CHEM, V259, P5536; MANOHARAN TH, 1987, J BIOL CHEM, V262, P3739; MARCHISIO PC, 1991, J CELL BIOL, V112, P761, DOI 10.1083/jcb.112.4.761; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; MOREL F, 1993, CANCER RES, V53, P231; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEBERT DW, 1989, INT J BIOCHEM, V21, P243, DOI 10.1016/0020-711X(89)90182-1; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; PAINE AJ, 1991, INT J EXP PATHOL, V72, P349; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1988, J BIOL CHEM, V263, P9848; PETERSEN DD, 1991, AM J HUM GENET, V48, P720; POHL RJ, 1984, DRUG METAB DISPOS, V12, P25; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; REINERS JJ, 1990, P NATL ACAD SCI USA, V87, P1825, DOI 10.1073/pnas.87.5.1825; REINERS JJ, 1992, DRUG METAB DISPOS, V20, P360; REINERS JJ, 1991, CHEM INDUCED CELL PR, P123; ROZEN F, 1992, ARCH BIOCHEM BIOPHYS, V292, P589, DOI 10.1016/0003-9861(92)90035-U; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; STAQUET MJ, 1990, EXP CELL RES, V187, P277, DOI 10.1016/0014-4827(90)90092-O; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; TU CPD, 1986, BIOCHEM BIOPH RES CO, V141, P229, DOI 10.1016/S0006-291X(86)80358-8; TU CPD, 1986, J BIOL CHEM, V261, P9540; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; WATT FM, 1987, J CELL SCI S, V8, P313; WILLIAMS JB, 1986, J BIOL CHEM, V261, P5524; YE RD, 1987, J BIOL CHEM, V262, P3718	66	94	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16067	16074						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206906				2022-12-25	WOS:A1994NQ72900021
J	HEISLER, LM; SUZUKI, H; LANDICK, R; GROSS, CA				HEISLER, LM; SUZUKI, H; LANDICK, R; GROSS, CA			4 CONTIGUOUS AMINO-ACIDS DEFINE THE TARGET FOR STREPTOLYDIGIN RESISTANCE IN THE BETA-SUBUNIT OF ESCHERICHIA-COLI RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-DEPENDENT TERMINATION; LAMBDA-PR PROMOTER; LAC UV5 PROMOTER; TRANSCRIPTION TERMINATION; FUNCTIONAL TOPOGRAPHY; COLIPHAGE-LAMBDA; RPOB GENE; INITIATION; DNA; ELONGATION	Streptolydigin (stl), a bacteriostatic inhibitor of transcription elongation, interacts with the beta subunit of Escherichia coli RNA polymerase. We have defined the target for stl resistance using chemical mutagenesis and mutagenic polymerase chain reaction. Mutations resulting in stl resistance are confined to a small cluster of contiguous amino acids, amino acids 543 to 546. These stl(r) mutants differ from one another in their levels of resistance to stl in vivo and in vitro. We have analyzed two of the mutants, A543V and F545S, for their effects on elongation and termination in vivo and in vitro. Neither affected termination at rho-dependent or rho-independent terminators. These mutants were indistinguishable from wild type in a T7 in vitro elongation assay. F545S, however, did exhibit slower elongation kinetics in a lambdaktR1 pausing assay. We conclude that mutations in the stl(r) region can influence transcription elongation, but that these amino acids are not directly involved in catalysis.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130	University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL)					NIAID NIH HHS [AI 19635] Funding Source: Medline; NIGMS NIH HHS [GM 38660] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038660, R37GM038660, R01GM038660] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRIGGS J, 1985, CELL, V42, P611; Burgess R.R., 1987, RNA POLYM REGULATION, P3; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CASSANI G, 1971, NATURE-NEW BIOL, V230, P197, DOI 10.1038/newbio230197a0; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; GLASS RE, 1986, MOL GEN GENET, V203, P492, DOI 10.1007/BF00422075; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GRACHEV MA, 1980, FEBS LETT, V115, P23, DOI 10.1016/0014-5793(80)80718-6; GROSS C, 1976, J BACTERIOL, V128, P382, DOI 10.1128/JB.128.1.382-389.1976; GUARENTE L, 1979, J MOL BIOL, V129, P295, DOI 10.1016/0022-2836(79)90283-3; GUARENTE LP, 1978, P NATL ACAD SCI USA, V75, P294, DOI 10.1073/pnas.75.1.294; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HALLING SM, 1978, NATURE, V272, P837, DOI 10.1038/272837a0; HEIL A, 1970, FEBS LETT, V11, P165, DOI 10.1016/0014-5793(70)80519-1; HUDSON GS, 1988, J MOL BIOL, V200, P639, DOI 10.1016/0022-2836(88)90477-9; IWAKURA Y, 1973, MOL GEN GENET, V121, P181, DOI 10.1007/BF00277531; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JIN J, 1989, MOL GEN GENET, V216, P269, DOI 10.1007/BF00334365; JOHNSTON DE, 1976, RNA POLYM, P101; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; LANDICK R, 1990, J BACTERIOL, V172, P2844, DOI 10.1128/jb.172.6.2844-2854.1990; LANDICK R, 1990, GENE DEV, V4, P1626; Leung D, 1988, TECHNIQUE, V1, P11; LUK KC, 1982, GENE, V20, P127, DOI 10.1016/0378-1119(82)90030-0; LUK KC, 1983, VIROLOGY, V125, P403, DOI 10.1016/0042-6822(83)90212-X; LYSITSYN NA, 1985, BIOORG KHIM, V11, P132; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MATHEWS DE, 1990, J BIOL CHEM, V265, P493; MCCLURE WR, 1979, J BIOL CHEM, V255, P1610; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3652; Miller J.H., 1972, EXPT MOL GENETICS; MORGAN WD, 1983, J BIOL CHEM, V258, P9565; MORGAN WD, 1983, J BIOL CHEM, V258, P9553; OOSAWA K, 1988, CELL, V53, P89, DOI 10.1016/0092-8674(88)90490-4; PATEL DD, 1989, J VIROL, V63, P1076, DOI 10.1128/JVI.63.3.1076-1086.1989; RABUSSAY D, 1969, FEBS LETT, V5, P104, DOI 10.1016/0014-5793(69)80305-4; Sambrook J, 1989, MOL CLONING LABORATO; SCHLEIF R, 1969, NATURE, V223, P1068, DOI 10.1038/2231068a0; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SIDDHIKOL C, 1969, J BACTERIOL, V99, P151, DOI 10.1128/JB.99.1.151-155.1969; SINGER M, 1989, MICROBIOL REV, V53, P1; SINGER M, 1993, J MOL BIOL, V231, P1, DOI 10.1006/jmbi.1993.1251; SIPPEL A, 1968, BIOCHIM BIOPHYS ACTA, V157, P218, DOI 10.1016/0005-2787(68)90286-4; SPARKOWSKI J, 1992, GENETICS, V130, P411; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; STUDIER W, 1975, FEBS P M, V10, P45; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; UMEZAWA H, 1968, J ANTIBIOT, V21, P234, DOI 10.7164/antibiotics.21.234; VONDERHELM K, 1972, NATURE-NEW BIOL, V235, P82, DOI 10.1038/newbio235082a0; YIN JCP, 1988, J MOL BIOL, V199, P35, DOI 10.1016/0022-2836(88)90377-4; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	66	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25369	25375						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244969				2022-12-25	WOS:A1993MK10000017
J	CASTUMA, CE; CROOKE, E; KORNBERG, A				CASTUMA, CE; CROOKE, E; KORNBERG, A			FLUID MEMBRANES WITH ACIDIC DOMAINS ACTIVATE DNAA, THE INITIATOR PROTEIN OF REPLICATION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOME-REPLICATION; MICROSOMAL MEMBRANE; ORIGIN; CHOLESTEROL; PHOSPHOLIPIDS	Acidic phospholipids in a fluid phase dissociate ADP or ATP tightly bound to DnaA protein and, in the presence of ATP and DNA, can restore an inactive ADP form to full activity (Sekimizu, K., and Kornberg, A. (1988) J. Biol. Chem. 263, 7131-7135). Further studies of the interactions between DnaA protein and lipids have used two functional assays: 1) release of ADP or ATP from DnaA and 2) DNA replication upon rejuvenation of an inactive ADP-DnaA protein complex. Among a variety of phospholipids tested were pure synthetic compounds and the mixtures from Escherichia coli auxotrophs (fabA), which are unable to synthesize unsaturated fatty acids and can be supplemented with different acyl derivatives. Fatty acid composition was determined by gas-liquid chromatography and membrane fluidity by fluorescence spectroscopy using 1,6-diphenyl-1,3,5-hexatriene as a probe. Lipid requirements of DnaA protein were shown to be: 1) phospholipids in a fluid phase (i.e. above the transition temperature), 2) a charged polar head group, 3) a lamellar phase (i.e. hexagonal II structures were inactive), and 4) a certain degree of fluidity imparted by the fatty acids esterified to the glycerol backbone. This conclusion was based on the incorporation of. 1) cholesterol, known to increase the packing of lipids, or 2) a branched fatty acyl derivative, which exhibits a fluidizing effect similar to that of a cis double bond. Both agents demonstrated that membrane fluidity is required for DnaA protein function in vitro, consistent with early studies of chromosome initiation in growing cells.			CASTUMA, CE (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305, USA.				NIGMS NIH HHS [GM07851] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CASTUMA CE, 1989, BIOCHEM J, V258, P723, DOI 10.1042/bj2580723; CASTUMA CE, 1991, BIOCHEMISTRY-US, V30, P9492, DOI 10.1021/bi00103a015; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CROOKE E, 1992, J BIOL CHEM, V267, P16779; FRALICK JA, 1973, J MOL BIOL, V80, P459, DOI 10.1016/0022-2836(73)90416-6; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; GRUNER SM, 1985, ANNU REV BIOPHYS BIO, V14, P211, DOI 10.1146/annurev.biophys.14.1.211; HANSEN FG, 1987, EMBO J, V6, P255, DOI 10.1002/j.1460-2075.1987.tb04747.x; HWANG DS, 1990, J BIOL CHEM, V265, P19244; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; Silbert D F, 1974, Methods Enzymol, V32, P856; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5121, DOI 10.1021/bi00390a034; STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V779, P89, DOI 10.1016/0304-4157(84)90005-4; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; YEAGLE PL, 1988, BIOCHEMISTRY-US, V27, P6449, DOI 10.1021/bi00417a037; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	23	105	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24665	24668						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227025				2022-12-25	WOS:A1993MG67300026
J	CEREGHINO, JL; HELINSKI, DR				CEREGHINO, JL; HELINSKI, DR			ESSENTIALITY OF THE 3 CARBOXYL-TERMINAL AMINO-ACIDS OF THE PLASMID RK2 REPLICATION INITIATION PROTEIN TRFA FOR DNA-BINDING AND REPLICATION ACTIVITY IN GRAM-NEGATIVE BACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-RANGE PLASMID-RK2; SITE-DIRECTED MUTAGENESIS; GENETIC-ANALYSIS; PSEUDOMONAS-AERUGINOSA; NUCLEOTIDE-SEQUENCE; COPY NUMBER; MAINTENANCE; MUTATIONS; ORIGIN; REGION	In a previous study of mutations in trfA, the gene encoding the replication initiation protein of the broad host-range plasmid RK2, a carboxyl-terminal deletion of 3 amino acids of the TrfA protein was found to be completely nonfunctional for RK2 replication in Escherichia coli and other Gram-negative bacteria. In this work site-directed mutagenesis of the trfA gene was carried out to construct TrfA proteins altered in the three carboxyl-terminal positions. Specifically, TrfA proteins with deletions or substitutions of the terminal cysteine, lysine, and arginine (codons 380-382, respectively) were constructed and characterized for their ability to initiate replication from an RK2 origin in vivo in E. coli, Azotobacter vinelandii, Pseudomonas putida, and Agrobacterium tumefaciens and for binding activity to the iterons at the replication origin. Substitutions of the cysteine at position 380 with a glycine or an arginine resulted in a TrfA protein defective in binding to the RK2 origin and, therefore, defective in replication initiation activity in all four Gram-negative bacteria. Substitution of a serine at that position preserved limited function in replication and DNA binding. The lysine at position 381 could be changed to a glutamine without any obvious change in TrfA function. Deletion of the terminal arginine at position 382 did not affect the ability of TrfA to bind to origin iterons but caused a complete loss of replication activity in all four bacteria. Substitution of this terminal arginine with alanine, serine, or glutamic acid also produced replication-defective TrfA protein in all four bacterial hosts while not affecting iteron binding activity. However, substitution of this arginine with a lysine resulted in a loss of replication activity in E. coli and A. vinelandii but had no effect in P. putida and A. tumefaciens. These observations suggest that the terminal arginine plays an essential role in the activity of the TrfA protein, possibly interaction with host proteins, which can be separated from its iteron binding activity.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,9500 GILMAN DR,LA JOLLA,CA 92093	University of California System; University of California San Diego					NIAID NIH HHS [AI-07194] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007194] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BISHOP PE, 1977, J BACTERIOL, V130, P954, DOI 10.1128/JB.130.2.954-956.1977; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CHAKRABARTY AM, 1975, P NATL ACAD SCI USA, V72, P3647, DOI 10.1073/pnas.72.9.3647; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DURLAND RH, 1990, J BACTERIOL, V172, P3859, DOI 10.1128/jb.172.7.3859-3867.1990; DURLAND RH, 1990, J BACTERIOL, V172, P3849, DOI 10.1128/jb.172.7.3849-3858.1990; DURLAND RH, 1987, PLASMID, V18, P164, DOI 10.1016/0147-619X(87)90044-8; DURLAND RH, 1988, THESIS U CALIFORNIA; FANG FC, 1991, J BACTERIOL, V173, P5861, DOI 10.1128/jb.173.18.5861-5868.1991; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; GARFINKEL DJ, 1981, CELL, V27, P143, DOI 10.1016/0092-8674(81)90368-8; GERMINO J, 1983, P NATL ACAD SCI USA, V79, P5475; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; INGRAM LC, 1973, ANTIMICROB AGENTS CH, V3, P279, DOI 10.1128/AAC.3.2.279; KAHN M, 1980, MOL GEN GENET, V177, P399, DOI 10.1007/BF00271478; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; KORNACKI JA, 1984, PLASMID, V11, P48, DOI 10.1016/0147-619X(84)90006-4; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN J, 1992, J BACTERIOL, V174, P4110, DOI 10.1128/jb.174.12.4110-4119.1992; Maniatis T., 1982, MOL CLONING; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; NEWTON JW, 1953, J BIOL CHEM, V204, P445; PERRI S, 1991, J BIOL CHEM, V266, P12536; PERRI S, 1993, J BIOL CHEM, V268, P3662; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; SCHMIDHAUSER TJ, 1983, PLASMID, V9, P325, DOI 10.1016/0147-619X(83)90010-0; SCHMIDHAUSER TJ, 1985, J BACTERIOL, V164, P446, DOI 10.1128/JB.164.1.446-455.1985; SHINGLER V, 1984, J MOL BIOL, V175, P229, DOI 10.1016/0022-2836(84)90346-2; SHINGLER V, 1989, BIOCHIM BIOPHYS ACTA, V1007, P301, DOI 10.1016/0167-4781(89)90152-8; SMITH CA, 1984, J MOL BIOL, V175, P251, DOI 10.1016/0022-2836(84)90347-4; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; STEMMER WPC, 1991, BIOTECHNIQUES, V10, P726; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TERAWAKI Y, 1988, J BACTERIOL, V170, P1261, DOI 10.1128/jb.170.3.1261-1267.1988; THOMAS CM, 1984, EMBO J, V3, P1513, DOI 10.1002/j.1460-2075.1984.tb02004.x; THOMAS CM, 1981, MOL GEN GENET, V181, P1, DOI 10.1007/BF00338996; THOMAS CM, 1981, PLASMID, V5, P277, DOI 10.1016/0147-619X(81)90005-6; THOMAS CM, 1980, J BACTERIOL, V141, P213, DOI 10.1128/JB.141.1.213-222.1980; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; VALLA S, 1991, PLASMID, V25, P131, DOI 10.1016/0147-619X(91)90025-R; VOCKE C, 1983, P NATL ACAD SCI-BIOL, V80, P6557, DOI 10.1073/pnas.80.21.6557; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZENG H, 1990, J BACTERIOL, V172, P2535, DOI 10.1128/jb.172.5.2535-2540.1990	47	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24926	24932						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227054				2022-12-25	WOS:A1993MG67300062
J	HUDER, JB; DIMROTH, P				HUDER, JB; DIMROTH, P			SEQUENCE OF THE SODIUM-ION PUMP METHYLMALONYL-COA DECARBOXYLASE FROM VEILLONELLA-PARVULA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXALOACETATE DECARBOXYLASE; KLEBSIELLA-PNEUMONIAE; GEL-ELECTROPHORESIS; MEMBRANE-PROTEIN; ALCALESCENS; SUBUNIT; TRANSPORT; BACTERIA; CARBOXYLTRANSFERASE; INHIBITORS	The genes encoding methylmalonyl-CoA decarboxylase from Veillonella parvula were cloned on plasmids using oligonucleotides derived from N-terminal amino acid sequences as specific probes. The entire DNA sequence of the methylmalonyl-CoA decarboxylase genes together with upstream and downstream regions was determined. The genes encoding subunits alpha (mmdA), delta (mmdD), epsilon (mmdE), gamma (mmdC), and beta (mmdB) of the decarboxylase were clustered on the chromosome in the given order. The previously unnoted epsilon-chain (M(r) 5,888) was clearly shown to be a subunit of the decarboxylase by correspondence of the N-terminal amino acid sequence with that deduced from the DNA sequence of mmdE. The alpha-subunit was 60% identical with the carboxyltransferase domain of rat liver propionyl-CoA carboxylase, the beta-subunit showed 61% sequence identity with the beta-subunit of oxaloacetate decarboxylase from Klebsiella pneumoniae, and the biotin-containing gamma-subunit was 29-39% identical with biotin-domains of other biotin enzymes. The delta-subunit of methylmalonyl-CoA decarboxylase and the gamma-subunit of oxaloacetate decarboxylase did not show significant sequence homology. The gross structure of both proteins, however, was similar, consisting of a hydrophobic membrane anchor near the N terminus, a proline/alanine linker, and a remarkable accumulation of charged amino acids in the C-terminal part. The sequence of the small epsilon-subunit could be aligned to the C-terminal region of the delta-subunit downstream of the proline/alanine linker, where the two subunits were 47% identical. Of considerable interest for the mechanism of Na+ transport are the long stretches of complete sequence identity between the hydrophobic beta-subunits of methylmalonyl-CoA decarboxylase and oxaloacetate decarboxylase and the presence of two conserved aspartic acid residues within putative membrane-spanning helices.	SWISS FED INST TECHNOL,INST MIKROBIOL,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich								BEATRIX B, 1990, ARCH MICROBIOL, V154, P362, DOI 10.1007/BF00276532; BENDRAT K, 1993, EUR J BIOCHEM, V211, P697, DOI 10.1111/j.1432-1033.1993.tb17598.x; BUCKEL W, 1986, EUR J BIOCHEM, V156, P281; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DELSAL G, 1988, NUCLEIC ACIDS RES, V16, P9878; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; DIMROTH P, 1983, EUR J BIOCHEM, V137, P107, DOI 10.1111/j.1432-1033.1983.tb07802.x; DIMROTH P, 1992, FEBS LETT, V300, P67, DOI 10.1016/0014-5793(92)80165-D; DIMROTH P, 1990, PHILOS T ROY SOC B, V326, P465, DOI 10.1098/rstb.1990.0025; HILPERT W, 1986, METHOD ENZYMOL, V125, P540; HILPERT W, 1983, EUR J BIOCHEM, V132, P579, DOI 10.1111/j.1432-1033.1983.tb07403.x; HILPERT W, 1991, EUR J BIOCHEM, V195, P79, DOI 10.1111/j.1432-1033.1991.tb15678.x; HOFFMANN A, 1989, EUR J BIOCHEM, V179, P645, DOI 10.1111/j.1432-1033.1989.tb14596.x; KUMAR GK, 1982, J BIOL CHEM, V257, P13828; LAMHONWAH AM, 1987, ARCH BIOCHEM BIOPHYS, V254, P631, DOI 10.1016/0003-9861(87)90146-9; LAUSSERMAIR E, 1989, J BIOL CHEM, V264, P14710; MALOY WL, 1979, J BIOL CHEM, V254, P1615; MILES JS, 1988, J MOL BIOL, V202, P97, DOI 10.1016/0022-2836(88)90522-0; NORTHROP DB, 1969, J BIOL CHEM, V244, P5801; Rodriguez R.L., 1983, RECOMBINANT DNA TECH; Sambrook J, 1989, MOL CLONING LABORATO; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWARZ E, 1988, J BIOL CHEM, V263, P9640; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WOEHLKE G, 1992, J BIOL CHEM, V267, P22798	30	37	65	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24564	24571						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227015				2022-12-25	WOS:A1993MG67300013
J	NOHARA, K; SANO, T; SHIRAISHI, F				NOHARA, K; SANO, T; SHIRAISHI, F			AN ACTIVATION-ASSOCIATED GANGLIOSIDE IN RAT THYMOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; CELL ACTIVATION; SPLEEN; DISIALOGANGLIOSIDE; LYMPHOCYTES; PROLIFERATION; BRAIN	During the activation of rat thymocytes elicited by stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA) and calcium ionophore A23187, the total amount of gangliosides per cell was demonstrated to increase, reaching a maximum level several times higher than that of resting cells at 48 h after activation when measured at 24-h intervals. The amount of the overwhelmingly predominant ganglioside in resting thymocytes, G(D1c)(NeuGc,NeuGc) (Nohara, K., Suzuki, M., Inagaki, F., and Kaya, K. (1991) J. Biochem. (Tokyo) 110, 274-278), was found to increase further as a result of activation. Furthermore, another ganglioside, which was barely recognizable in resting thymocytes, was found to increase in activated and proliferating thymocytes to a level similar to that of G(D1c). This activation-associated ganglioside was isolated and its structure examined. On the basis of the results of compositional analysis, methylation analysis, sialidase hydrolysis followed by detection with cholera toxin B subunit on TLC, and proton NMR spectroscopy, this ganglioside was clarified to be a rare species of G(D1b) containing two N-glycolylneuraminic acid residues. On the other hand, when the thymocytes were activated using concanavalin A (ConA) as a stimulant, the amount of gangliosides per cell was increased more strikingly than that in thymocytes activated with TPA and A23187. In the ConA-activated thymocytes, many other gangliosides, in addition to G(D1c) and G(D1b)(NeuGc,NeuGc), were demonstrated to appear in large amounts. The cause of this difference in gangliosides between thymocytes activated with a combination of TPA and A23187 and those activated with ConA is also discussed.	NATL INST ENVIRONM STUDIES,DIV ENVIRONM CHEM,YATABE,IBARAKI 305,JAPAN	National Institute for Environmental Studies - Japan	NOHARA, K (corresponding author), NATL INST ENVIRONM STUDIES,DIV ENVIRONM HLTH SCI,YATABE,IBARAKI 305,JAPAN.							AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; FELDINGHABERMANN B, 1990, BIOCHEMISTRY-US, V29, P6314, DOI 10.1021/bi00478a028; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HERSEY P, 1986, CANCER RES, V46, P6083; INOUYE Y, 1974, J BIOCHEM-TOKYO, V76, P791; MUTHING J, 1987, EUR J BIOCHEM, V163, P407, DOI 10.1111/j.1432-1033.1987.tb10813.x; MUTHING J, 1989, BIOCHEMISTRY-US, V28, P2923; NAKAMURA K, 1991, J BIOCHEM-TOKYO, V110, P832, DOI 10.1093/oxfordjournals.jbchem.a123667; NARASIMHAN R, 1976, BIOCHIM BIOPHYS ACTA, V431, P578, DOI 10.1016/0005-2760(76)90222-8; NOHARA K, 1990, J BIOCHEM, V108, P684, DOI 10.1093/oxfordjournals.jbchem.a123263; NOHARA K, 1990, J BIOL CHEM, V265, P14335; NOHARA K, 1992, J BIOL CHEM, V267, P14982; NOHARA K, 1991, J BIOCHEM-TOKYO, V110, P274, DOI 10.1093/oxfordjournals.jbchem.a123570; OFFNER H, 1987, J IMMUNOL, V139, P3295; SELA BA, 1978, EUR J IMMUNOL, V8, P268, DOI 10.1002/eji.1830080410; SPIEGEL S, 1985, SCIENCE, V230, P1285, DOI 10.1126/science.2999979; STOUT RD, 1987, J IMMUNOL, V139, P2123; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; VANEIJK RVW, 1977, EUR J BIOCHEM, V78, P41; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WELTE K, 1987, J IMMUNOL, V139, P1763; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x	26	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24997	25000						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227062				2022-12-25	WOS:A1993MG67300071
J	PAN, QW; TANASE, S; FUKUMOTO, Y; NAGASHIMA, F; RHEE, S; ROGERS, PH; ARNONE, A; MORINO, Y				PAN, QW; TANASE, S; FUKUMOTO, Y; NAGASHIMA, F; RHEE, S; ROGERS, PH; ARNONE, A; MORINO, Y			FUNCTIONAL ROLES OF VALINE-37 AND GLYCINE-38 IN THE MOBILE LOOP OF PORCINE CYTOSOLIC ASPARTATE-AMINOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVE-SITE; ENZYME; CONSTRUCTION; EXPRESSION; INHIBITORS; CLOSURE; CHICKEN; YEAST	The functional roles of Val37 and Gly38 in porcine cytosolic aspartate aminotransferase have been studied in the site-directed mutants V37A, G38A, and G38S where the size and hydrophobic character of these residues has been altered. Previous x-ray studies have shown that Val37 and Gly38, which are part of a flexible loop, interact directly with bound substrate. From x-ray and solution experiments we find that the V37A, G38A, and G38S mutations do not cause significant perturbations to the unliganded enzyme. Replacing Val37 with a less bulky alanine residue does not affect the maximal catalytic rate (k(cat)), but it does increase significantly the Michaelis constants for substrates in the overall transamination reaction between aspartate and 2-oxoglutarate. On the other hand, replacing Gly38 with alanine or serine results in striking decreases in k(cat) to 5 and 0.6%, respectively, of the value observed for the wild-type enzyme, as well as in considerable increases in K(m) values. Consequently, the catalytic competence, k(cat)/K(m), decreases by 3 orders of magnitude for G38A and by 4 orders of magnitude for G38S. Single turnover reactions of G38A and G38S with four individual substrates (aspartate, glutamate, oxalacetate, and 2-oxoglutarate) are characterized by kinetic parameters that are largely consistent with those of the overall reaction. In addition, the mutations at position 38 impair more seriously the catalytic competence of the enzyme toward C5-substrates than toward C4-substrates. We conclude that Gly38 is probably required for proper function of the enzyme because it permits a high level of flexibility for the 36-39 peptide, which in turn allows the essential substrate-induced movement of the small domain.	KUMAMOTO UNIV, SCH MED, DEPT BIOCHEM, KUMAMOTO 860, JAPAN; UNIV IOWA HOSP & CLIN, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	Kumamoto University; University of Iowa					NIGMS NIH HHS [GM-40852] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040852] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNONE A, 1977, J MOL BIOL, V112, P509, DOI 10.1016/S0022-2836(77)80196-4; Arnone A, 1985, TRANSAMINASES, P138; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; Cleland W W, 1979, Methods Enzymol, V63, P103; DREUSICKE D, 1988, J MOL BIOL, V203, P1021, DOI 10.1016/0022-2836(88)90126-X; FASELLA P, 1966, BIOCHEMISTRY-US, V5, P197, DOI 10.1021/bi00865a026; FUKUMOTO Y, 1991, J BIOL CHEM, V266, P4187; GERSTEIN M, 1991, J MOL BIOL, V220, P133, DOI 10.1016/0022-2836(91)90387-L; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; JANSONIUS JN, 1985, TRANSAMINASES, P110; JENKINS WT, 1966, BIOCHEM BIOPH RES CO, V22, P376, DOI 10.1016/0006-291X(66)90656-5; JENKINS WT, 1959, J BIOL CHEM, V234, P51; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; Metzler C M, 1979, Methods Enzymol, V62, P551; MICHUDA CM, 1969, J BIOL CHEM, V244, P5920; MIKI T, 1987, PROTEIN ENG, V1, P327, DOI 10.1093/protein/1.4.327; MORINO Y, 1977, J BIOCHEM, V82, P847, DOI 10.1093/oxfordjournals.jbchem.a131760; MURAO S, 1984, AGR BIOL CHEM TOKYO, V48, P2163, DOI 10.1080/00021369.1984.10866470; NAGASHIMA F, 1989, BIOCHEMISTRY-US, V28, P1153, DOI 10.1021/bi00429a033; NAGASHIMA F, 1986, J BIOCHEM, V99, P1017, DOI 10.1093/oxfordjournals.jbchem.a135565; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAYLOR JE, 1990, ANN NY ACAD SCI, V585, P58, DOI 10.1111/j.1749-6632.1990.tb28041.x; VELICK SF, 1962, J BIOL CHEM, V237, P2109; WIERENGA RK, 1992, J MOL BIOL, V224, P1115, DOI 10.1016/0022-2836(92)90473-W	28	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24758	24765						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227035				2022-12-25	WOS:A1993MG67300038
J	RYE, HS; DREES, BL; NELSON, HCM; GLAZER, AN				RYE, HS; DREES, BL; NELSON, HCM; GLAZER, AN			STABLE FLUORESCENT DYE-DNA COMPLEXES IN HIGH-SENSITIVITY DETECTION OF PROTEIN-DNA INTERACTIONS - APPLICATION TO HEAT-SHOCK TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED DNA; ELECTROPHORETIC MOBILITY SHIFT; GEL-ELECTROPHORESIS; BINDING-PROTEIN; NEGATIVE REGULATION; ETHIDIUM HOMODIMER; MOLECULAR-CLONING; THIAZOLE ORANGE; FACTOR CONTAINS; LAC PROMOTER	The gel mobility-shift assay is an important tool for the study of protein-nucleic acid interactions. High detection sensitivity is typically attained by radioisotopic labeling of the target nucleic acid fragments. A novel fluorescence methology offers significant advantages over this conventional approach. Ethidium, thiazole orange, and oxazole yellow homodimers form stable, highly fluorescent complexes with double-stranded DNA that can be detected in gels by a laser-excited, confocal, fluorescence scanning system with a sensitivity higher than that attainable with radioisotopic labeling. We describe here the use of these dyes in a gel-mobility assay to detect complexes of a truncation of the Kluyveromyces lactis heat shock transcription factor, containing the trimerization and DNA-binding domains (HSF(DT)), with target DNA. At an appropriate molar DNA base pair to dye ratio, the labeling of a DNA fragment with dimeric dye did not affect the binding to HSF(DT). The detection of the fluorescent-dye labeled HSF(DT)-DNA complexes with the laser scanner achieves a spatial resolution far superior to that of conventional autoradiography and permits analysis of multimer protein-DNA complexes that are not resolved by traditional detection methods. We have used this technique to demonstrate that HSF forms multimeric complexes on DNA by addition of trimeric units. The latter conclusion is based on an analysis of the mobilities of the multiple HSF(DT)-DNA complexes and on a two-color mobility-shift fluorescence assay that uses a mutant of HSF(DT) engineered for site-specific labeling with fluorescein and target DNA labeled with an ''energy transfer'' dye, thiazole orange-thiazole blue heterodimer.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				Rye, Hays/0000-0002-9420-3137	NIGMS NIH HHS [GM-44086, GM-07232C] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044086, T32GM007232] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BADING H, 1988, NUCLEIC ACIDS RES, V16, P5241, DOI 10.1093/nar/16.12.5241; BENSON SC, 1993, ORNLM2588 US DEP EN, P91; BIENZ M, 1987, ADV GENET, V24, P31, DOI 10.1016/S0065-2660(08)60006-1; BOORSTEIN WR, 1990, J BIOL CHEM, V265, P18912; CHEN JJ, 1993, J BIOL CHEM, V268, P7442; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GALLO GJ, 1993, MOL CELL BIOL, V13, P749, DOI 10.1128/MCB.13.2.749; GARNER MM, 1982, BIOCHEMISTRY-US, V21, P6032, DOI 10.1021/bi00267a001; GLAZER AN, 1992, NATURE, V359, P859, DOI 10.1038/359859a0; GLAZER AN, 1990, P NATL ACAD SCI USA, V87, P3851, DOI 10.1073/pnas.87.10.3851; GRANGERSCHNARR M, 1988, ANAL BIOCHEM, V174, P235, DOI 10.1016/0003-2697(88)90540-4; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; HAUGLAND RP, 1992, MOL PROBES HDB FLUOR, P221; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; KOLB A, 1983, NUCLEIC ACIDS RES, V11, P7833, DOI 10.1093/nar/11.22.7833; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; LEE LG, 1986, CYTOMETRY, V7, P508, DOI 10.1002/cyto.990070603; MATHIES RA, 1992, NATURE, V359, P167, DOI 10.1038/359167a0; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; PARK CW, 1992, J BIOL CHEM, V267, P15642; PARK HO, 1989, MOL CELL BIOL, V9, P2025, DOI 10.1128/MCB.9.5.2025; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; QUESADA MA, 1991, BIOTECHNIQUES, V10, P616; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; RYE HS, 1991, NUCLEIC ACIDS RES, V19, P327, DOI 10.1093/nar/19.2.327; RYE HS, 1993, ANAL BIOCHEM, V208, P144, DOI 10.1006/abio.1993.1020; RYE HS, 1992, NUCLEIC ACIDS RES, V20, P2803, DOI 10.1093/nar/20.11.2803; RYE HS, 1993, METHOD ENZYMOL, V217, P414; RYE HS, 1993, ORNLM2588 US DEP EN, P96; SAMBROOK J, 1966, MOL CLONING LABORATO; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SHUEY DJ, 1986, J BIOL CHEM, V261, P7934; SHUEY DJ, 1986, NATURE, V323, P459, DOI 10.1038/323459a0; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOPOL J, 1985, CELL, V42, P527, DOI 10.1016/0092-8674(85)90110-2; WEI R, 1986, NUCLEIC ACIDS RES, V14, P8183, DOI 10.1093/nar/14.20.8183; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q	57	39	41	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25229	25238						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227088				2022-12-25	WOS:A1993MG67300101
J	ALI, H; RICHARDSON, RM; TOMHAVE, ED; DIDSBURY, JR; SNYDERMAN, R				ALI, H; RICHARDSON, RM; TOMHAVE, ED; DIDSBURY, JR; SNYDERMAN, R			DIFFERENCES IN PHOSPHORYLATION OF FORMYLPEPTIDE AND C5A CHEMOATTRACTANT RECEPTORS CORRELATE WITH DIFFERENCES IN DESENSITIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MUSCARINIC CHOLINERGIC RECEPTORS; BETA-ADRENERGIC-RECEPTOR; GTP-BINDING PROTEIN; POLYMORPHONUCLEAR LEUKOCYTES; BETA-2-ADRENERGIC RECEPTOR; DEPENDENT PHOSPHORYLATION; SIGNAL TRANSDUCTION; HUMAN-NEUTROPHILS; PERTUSSIS TOXIN	To define the regulation of chemoattractant receptors, epitope-tagged human formyl peptide and C5a receptor cDNAs (ET-FR and ET-C5aR) were stably expressed in rat basophilic leukemia, RBL-2H3 cells. An antibody (12CA5) specific to ''ET'' was used to immunoprecipitate ET-FR and ET-C5aR. fMLP and C5a caused time- and dose-dependent phosphorylation of their respective receptors. Phosphorylated ET-FR migrated as a single broad band between 50 and 70 kDa on SDS-polyacrylamide gel electrophoresis, whereas ET-C5aR exhibited both fast (39-45 kDa) and broadly (39-52 kDa) migrating forms. Fast form phosphorylation alone was observed at low concentrations of C5a (0.001-0.01 muM), or at early times (5-30 s) with a higher concentration of C5a (0.1 muM). Phorbol 12-myristate 13-acetate, thrombin, or antigen caused no phosphorylation of ET-FR but stimulated exclusively fast form phosphorylation of ET-C5aR. The protein kinase C inhibitor staurosporine did not inhibit phosphorylation of ET-FR but blocked the fast migrating component of phosphorylated ET-C5aR. Homologous desensitization correlated with ligand-induced phosphorylation of both receptors. Of note, ET-C5aR but not ET-FR underwent heterologous desensitization by antigen, phorbol 12-myristate 13-acetate, and thrombin. The data suggest that protein kinase C mediates heterologous phosphorylation and desensitization of C5aR but not FR, yet, both receptors are homologously desensitized by a staurosporine-resistant kinase.			ALI, H (corresponding author), DUKE UNIV, MED CTR, DEPT MED, BOX 3680, DURHAM, NC 27710 USA.				NCI NIH HHS [CA-29589] Funding Source: Medline; NIDCR NIH HHS [DE-03738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBER G, 1992, J IMMUNOL, V149, P2428; ALI H, 1990, J BIOL CHEM, V265, P745; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BENHAMOU M, 1990, J IMMUNOL, V144, P3071; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BRAUNWALDER AF, 1992, MOL IMMUNOL, V29, P1319, DOI 10.1016/0161-5890(92)90168-W; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; DIDSBURY JR, 1992, FEBS LETT, V297, P275, DOI 10.1016/0014-5793(92)80555-U; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GERARD NP, 1990, BIOCHEMISTRY-US, V29, P9274, DOI 10.1021/bi00491a024; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HIDE M, 1991, MOL PHARMACOL, V40, P473; HOWARD TH, 1984, J CELL BIOL, V98, P1265, DOI 10.1083/jcb.98.4.1265; JANECZEK AH, 1989, J CELL SCI, V94, P155; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLEIN P, 1987, J BIOL CHEM, V262, P358; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOO C, 1982, BIOCHEM BIOPH RES CO, V106, P442, DOI 10.1016/0006-291X(82)91130-5; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MCLEISH KR, 1989, MOL PHARMACOL, V36, P384; MILLER L, 1990, J BIOL CHEM, V265, P12444; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; ROLLINS TE, 1991, P NATL ACAD SCI USA, V88, P971, DOI 10.1073/pnas.88.3.971; SCHICHI H, 1989, RECEPTOR PHOSPHORYLA, P177; SKLAR LA, 1985, J CELL BIOL, V101, P1161, DOI 10.1083/jcb.101.3.1161; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; SNYDERMAN R, 1990, ADP RIBOSYLATING TOX, P295; STADEL JM, 1983, P NATL ACAD SCI-BIOL, V80, P3173, DOI 10.1073/pnas.80.11.3173; TARDIF M, 1993, J IMMUNOL, V150, P3534; WILDE MW, 1989, J BIOL CHEM, V264, P190	50	164	167	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24247	24254						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226971				2022-12-25	WOS:A1993MF29400079
J	MCKIERNAN, CJ; BRONDYK, WH; MACARA, IG				MCKIERNAN, CJ; BRONDYK, WH; MACARA, IG			THE RAB3A GTPASE INTERACTS WITH MULTIPLE FACTORS THROUGH THE SAME EFFECTOR DOMAIN - MUTATIONAL ANALYSIS OF CROSS-LINKING OF RAB3A TO A PUTATIVE TARGET PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-RELEASING FACTOR; RAS-LIKE PROTEIN-P25RAB3A; BINDING PROTEIN; 3-DIMENSIONAL STRUCTURES; GUANINE-NUCLEOTIDES; SYNAPTIC VESICLES; MOLECULAR-CLONING; ENCODED PROTEINS; BOVINE BRAIN; SMG P25A	Rab3A/smg25A is a small Ras-like guanine nucleotide binding protein implicated in the control of regulated secretion from cells. Rab3A is approximately 30% cytosolic and 70% associated with the membranes of secretory vesicles. It cross-links specifically to a rat brain membrane protein of about 85 kilodaltons (p85). To identify epitopes on Rab3A that are important for its interaction with this putative target protein, we have determined the effects of point mutations on the cross-linking efficiency of Rab3A to p85. Rab3A, which was preincubated with a non-hydrolyzable analog of GTP, cross-linked more efficiently to p85 than did Rab3A.GDP. Rab3A mutants that had decreased nucleotide binding also exhibited poor cross-linking to p85. Mutations in the effector domain, a site important for the interaction of Rab3A with its guanine nucleotide releasing factor, guanine nucleotide dissociation inhibitor, and GTPase-activating protein, eliminated the ability of Rab3A to cross-link to p85. However, short peptides corresponding to the effector domain did not reduce cross-linking efficiency when present at a concentration of 50 muM.	UNIV VERMONT,COLL MED,VERMONT COMPREHENS CANC CTR,BURLINGTON,VT 05405	University of Vermont	MCKIERNAN, CJ (corresponding author), UNIV VERMONT,COLL MED,DEPT PATHOL,MED ALUMNI BLDG,BURLINGTON,VT 05405, USA.				NATIONAL CANCER INSTITUTE [R01CA056300] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [F32EY006411] Funding Source: NIH RePORTER; NCI NIH HHS [CA56300] Funding Source: Medline; NEI NIH HHS [F32EY06411] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BURSTEIN E, 1989, MOL CELL BIOL, V9, P4807, DOI 10.1128/MCB.9.11.4807; BURSTEIN ES, 1992, BIOCHEM J, V282, P387, DOI 10.1042/bj2820387; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; EDWARDSON JM, 1993, FEBS LETT, V320, P52, DOI 10.1016/0014-5793(93)81656-K; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JACOB J, 1993, J BIOL CHEM, V268, P923; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MUSHA T, 1992, J BIOL CHEM, V267, P9821; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATEL G, 1992, ONCOGENE, V7, P283; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VALENCIA A, 1991, P NATL ACAD SCI USA, V88, P5443, DOI 10.1073/pnas.88.12.5443; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	38	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24449	24452						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226995				2022-12-25	WOS:A1993MF29400108
J	SASAKI, T; KATO, M; TAKAI, Y				SASAKI, T; KATO, M; TAKAI, Y			CONSEQUENCES OF WEAK INTERACTION OF RHO GDI WITH THE GTP-BOUND FORMS OF RHO P21 AND RAC P21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP/GTP EXCHANGE PROTEINS; BOVINE BRAIN CYTOSOL; BOTULINUM ADP-RIBOSYLTRANSFERASE; BINDING PROTEIN; ACTIVATING PROTEIN; NADPH OXIDASE; GENE-PRODUCT; DISSOCIATION INHIBITOR; REGULATORY PROTEIN; POSTTRANSLATIONAL MODIFICATIONS	rho GDI is an inhibitory GDP/GTP exchange protein for the rho family. Recently, rho GDI has been reported to interact with the GTP-bound form of G25K and rac1 p21 and to inhibit their basal and GTPase-activating protein (GAP)-stimulated GTPase activity. Here, we examined whether rho GDI interacts with the GTP-bound form of rho p21 and rac p21 and inhibits their basal and rho GAP-stimulated GTPase activity. rho GDI interacted with both the GDP- and GTP-bound forms of rhoA p21 and rac1 p21 as estimated by measuring its ability to form a complex with both forms and to inhibit the membrane-binding activity of both forms. The efficiency of rho GDI for interaction with the GTP-bound form was, however, about 10% that for interaction with the GDP-bound form. Moreover, rho GDI inhibited both the basal and rho GAP-stimulated GTPase activity of rhoA p21 and rac1 p21 in a dose-dependent manner. The doses of rho GDI necessary for this action were, however, about 10-fold higher than those necessary for the action to inhibit their GDP/GTP exchange reaction. These results indicate that rho GDI interacts with the GTP-bound form of its substrate small G proteins, as well as with the GDP-bound form, but much less efficiently than with the GDP-bound form.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Kobe University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)								ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDO S, 1992, J BIOL CHEM, V267, P25709; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHUANG TH, 1993, J BIOL CHEM, V268, P775; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HORI Y, 1991, ONCOGENE, V6, P515; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; ISOMURA M, 1991, ONCOGENE, V6, P119; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MIURA Y, 1993, J BIOL CHEM, V268, P510; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MORII N, 1991, J BIOL CHEM, V266, P7646; MORII N, 1992, J BIOL CHEM, V267, P20921; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SUGAI M, 1990, BIOCHEM BIOPH RES CO, V173, P92, DOI 10.1016/S0006-291X(05)81026-5; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	49	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23959	23963						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226937				2022-12-25	WOS:A1993MF29400040
J	WALES, R; ROBERTS, LM; LORD, JM				WALES, R; ROBERTS, LM; LORD, JM			ADDITION OF AN ENDOPLASMIC-RETICULUM RETRIEVAL SEQUENCE TO RICIN-A CHAIN SIGNIFICANTLY INCREASES ITS CYTOTOXICITY TO MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-GLYCOSIDASE ACTIVITY; TRANS-GOLGI NETWORK; BREFELDIN-A; PSEUDOMONAS EXOTOXIN; GALACTOSE BINDING; INTRACELLULAR FUNCTIONS; EUKARYOTIC RIBOSOMES; NUCLEOTIDE-SEQUENCE; INTERNALIZED RICIN; SHIGA TOXIN	An Escherichia coli expression system was used to produce recombinant ricin A chain (RTA) and RTA modified either by the addition of a carboxyl-terminal endoplasmic reticulum retrieval sequence Lys-Asp-Glu-Leu (RTAKDEL) or a nonfunctional analogue Lys-Asp-Glu-Ala (RTAKDEA). These RTA molecules can enter mammalian cells by fluid phase endocytosis. RTAKDEL was significantly more cytotoxic than either RTA or RTAKDEA to both Vero cells and HeLa cells (250- and 10-fold, respectively), despite the fact that all these RTA molecules had comparable enzymatic activities. This difference did not result from KDEL-mediated binding of RTAKDEL to the cell surface. Enhanced cytotoxicity could be correlated with an increased level of ribosome inactivation, measured as the RTA-catalyzed depurination of 28 S ribosomal RNA. These results indicate that the added KDEL sequence facilitated RTA entry into the cytosol. We propose that interaction with the intracellular KDEL receptor promotes retrograde transport of the toxin to the endoplasmic reticulum, where translocation of RTA into the cytosol occurs.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick								ANDRES DA, 1990, J BIOL CHEM, V265, P5952; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GONATAS NK, 1977, J CELL BIOL, V73, P1, DOI 10.1083/jcb.73.1.1; GREEN SA, 1990, J BIOL CHEM, V265, P21269; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LORD JM, 1992, BIOCHEM SOC T, V20, P734, DOI 10.1042/bst0200734; MAY MJ, 1989, EMBO J, V8, P301, DOI 10.1002/j.1460-2075.1989.tb03377.x; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NEWTON DL, 1992, J BIOL CHEM, V267, P11917; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; OLSNES S, 1976, J BIOL CHEM, V251, P3985; OLSNES S, 1985, ENDOCYTOSIS, P195; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PATZAK A, 1986, J CELL BIOL, V102, P510, DOI 10.1083/jcb.102.2.510; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PETER F, 1992, J BIOL CHEM, V267, P10631; ROTH J, 1980, J CELL BIOL, V92, P223; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SIMMONS BM, 1986, J BIOL CHEM, V261, P7912; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; SPICER EK, 1982, J BIOL CHEM, V257, P5716; THOMAS L, 1990, J BIOL CHEM, V265, P10821; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; WALES R, 1991, J BIOL CHEM, V266, P19172; WALES R, 1992, EXP CELL RES, V203, P1, DOI 10.1016/0014-4827(92)90032-4; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; YOULE RJ, 1987, J BIOL CHEM, V262, P4676	42	98	101	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23986	23990						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226941				2022-12-25	WOS:A1993MF29400044
J	HARTINGER, J; JAHN, R				HARTINGER, J; JAHN, R			AN ANION-BINDING SITE THAT REGULATES THE GLUTAMATE TRANSPORTER OF SYNAPTIC VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR AMINE TRANSPORTER; FUNCTIONAL RECONSTITUTION; ENERGY-DEPENDENCE; CEREBRAL-CORTEX; RAT-LIVER; QUANTITATION; GRADIENTS; GABA	Glutamate, the major excitatory neurotransmitter of the mammalian central nervous system, is stored in synaptic vesicles and released by exocytosis upon depolarization of the, presynaptic nerve terminal. Synaptic vesicles possess an active glutamate-specific transporter that is driven by an electrochemical proton gradient across the vesicle membrane and requires chloride for maximal activity. In this study, we have characterized the role of chloride in vesicular glutamate transport using 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS), a potent inhibitor of anion translocators. DIDS inhibited glutamate uptake with an IC50 of 0.7 muM or less. In contrast, all energy gradient parameters (membrane potential, pH gradient, and ATPase activity) required at least 5-fold higher concentration of DIDS for inhibition. Furthermore, high concentrations of chloride but not of glutamate or other anions prevented DIDS inhibition of glutamate uptake. In contrast to uptake, glutamate efflux from glutamate-loaded vesicles was independent of chloride over a wide concentration range. However, efflux was still susceptible to DIDS inhibition. DIDS inhibition was prevented by excess chloride. We conclude that the vesicular glutamate transporter possesses a DIDS-sensitive chloride binding site on the cytoplasmic side, distinct from the substrate binding site, which regulates transport activity.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,POB 9812,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University; Yale University				Jahn, Reinhard/0000-0003-1542-3498				BAHR BA, 1992, BIOCHEMISTRY-US, V31, P5763, DOI 10.1021/bi00140a011; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; CARLSON MD, 1990, NEUROSCI LETT, V110, P325, DOI 10.1016/0304-3940(90)90868-A; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FYKSE EM, 1991, BIOCHEM J, V276, P363, DOI 10.1042/bj2760363; HELL JW, 1991, BIOCHEMISTRY-US, V30, P11795, DOI 10.1021/bi00115a009; HELL JW, 1990, J BIOL CHEM, V265, P2111; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MAYCOX PR, 1990, EMBO J, V9, P1465, DOI 10.1002/j.1460-2075.1990.tb08263.x; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MAYCOX PR, 1990, TRENDS NEUROSCI, V13, P83, DOI 10.1016/0166-2236(90)90178-D; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; PASSOW H, 1986, REV PHYSL BIOCH PHAR, V103, P62; SHIOI J, 1990, BIOCHEM J, V267, P63, DOI 10.1042/bj2670063; STERNBACH Y, 1992, P NATL ACAD SCI USA, V89, P9730, DOI 10.1073/pnas.89.20.9730; TABB JS, 1992, J BIOL CHEM, V267, P15412; VANDYKE RW, 1984, P NATL ACAD SCI-BIOL, V81, P3108; VANDYKE RW, 1988, J BIOL CHEM, V263, P2603; WINTER HC, 1993, NEUROCHEM RES, V18, P79, DOI 10.1007/BF00966925; XIE XS, 1983, J BIOL CHEM, V258, P4834	25	91	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23122	23127						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226829				2022-12-25	WOS:A1993MF51500028
J	MOHAMEDALI, KA; GUICHERIT, OM; KELLEMS, RE; RUDOLPH, FB				MOHAMEDALI, KA; GUICHERIT, OM; KELLEMS, RE; RUDOLPH, FB			THE HIGHEST LEVELS OF PURINE CATABOLIC ENZYMES IN MICE ARE PRESENT IN THE PROXIMAL SMALL-INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER XANTHINE DEHYDROGENASE; SEVERE COMBINED IMMUNODEFICIENCY; ADENOSINE-DEAMINASE DEFICIENCY; NUCLEOSIDE PHOSPHORYLASE; URIC-ACID; DEVELOPMENTAL EXPRESSION; OXIDASE ACTIVITIES; MOUSE; TISSUES; EMBRYO	Recent studies on the tissue distribution and developmental regulation of adenosine deaminase (ADA) activity in mice show that very high ADA levels exist in the murine alimentary tract (tongue, esophagus, forestomach, proximal small intestine) and at the fetal-maternal interface. To understand the role of ADA in these tissues, we measured the levels of three other enzymes involved in purine catabolism, purine nucleoside phosphorylase (PNP), guanine deaminase (GDA), and xanthine dehydrogenase (XDH), to see how their levels correlated with ADA activity. Our results show that the highest level of PNP, GDA, and XDH is present in the proximal small intestine. Levels of these purine catabolic enzymes are much lower in the tongue, esophagus, forestomach, and fetal-maternal interface in marked contrast to ADA distribution. We also determined mRNA levels encoding PNP, XDH, and ADA in a variety of tissues. Tissue-specific differences in PNP, XDH, and ADA activity correlated with RNA abundance, indicating that the regulation of gene expression is at the level of mRNA production. Thus, ADA is part of a purine catabolic pathway leading to the production of uric acid that is present at the highest known level in the proximal small intestine. ADA may have additional roles in other tissues.	RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77005 USA; RICE UNIV, INST BIOSCI & BIOENGN, HOUSTON, TX 77005 USA; BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	Rice University; Rice University; Baylor College of Medicine; Baylor College of Medicine					NCI NIH HHS [CA14030] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline; NIGMS NIH HHS [GM30204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS A, 1976, CLIN EXP IMMUNOL, V26, P647; AMAYA Y, 1990, J BIOL CHEM, V265, P14170; AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BATTELLI MG, 1972, BIOCHEM J, V126, P747, DOI 10.1042/bj1260747; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLACKBURN MR, 1992, DEV DYNAM, V194, P155, DOI 10.1002/aja.1001940208; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY TG, 1965, COMP BIOCHEM PHYSIOL, V14, P101, DOI 10.1016/0010-406X(65)90011-3; BRONK JR, 1986, J PHYSIOL-LONDON, V378, P229, DOI 10.1113/jphysiol.1986.sp016216; CARSON DA, 1977, P NATL ACAD SCI USA, V74, P5677, DOI 10.1073/pnas.74.12.5677; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; CHINSKY JM, 1989, GENE TRANSFER GENE T, P255; DARDENNE SC, 1990, BIOCHEMISTRY-US, V29, P9046, DOI 10.1021/bi00490a023; ELSAYED NM, 1989, ARCH BIOCHEM BIOPHYS, V273, P281, DOI 10.1016/0003-9861(89)90485-2; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GIUSTI G, 1974, METHOD ENZYMAT AN, V2, P1086; HENDERSON JF, 1985, P SOC EXP BIOL MED, V179, P419; HINDMAN HB, 1978, ENZYME, V23, P395, DOI 10.1159/000458608; HIRSCHHORN R, 1978, CLIN IMMUNOL IMMUNOP, V9, P287, DOI 10.1016/0090-1229(78)90100-9; HONG L, 1991, BIOL REPROD, V44, P83, DOI 10.1095/biolreprod44.1.83; JOYCE P, 1971, BIOCHEM J, V125, pP111, DOI 10.1042/bj1250111Pa; KIZAKI H, 1983, CELL IMMUNOL, V82, P343, DOI 10.1016/0008-8749(83)90168-5; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KNUDSEN TB, 1992, TERATOLOGY, V45, P91, DOI 10.1002/tera.1420450109; KNUDSEN TB, 1987, DIFFERENTIATION, V33, P270, DOI 10.1111/j.1432-0436.1987.tb01567.x; KNUDSEN TB, 1989, TERATOLOGY, V40, P615, DOI 10.1002/tera.1420400609; KNUDSEN TB, 1988, BIOL REPROD, V39, P937, DOI 10.1095/biolreprod39.4.937; KORNBERG A, 1953, BIOCHEM PREP, V3, P23; KREDICH NM, 1989, METABOLIC BASIS INHE, P1045; KRENITSKY TA, 1974, COMP BIOCHEM PHYSIOL, V49, P687, DOI 10.1016/0305-0491(74)90256-9; KURASHIGE S, 1982, MICROBIOL IMMUNOL, V26, P77, DOI 10.1111/j.1348-0421.1982.tb00155.x; LEE PC, 1973, DEV BIOL, V31, P227, DOI 10.1016/0012-1606(73)90259-5; LYERLA TA, 1983, COMP BIOCHEM PHYS B, V76, P497, DOI 10.1016/0305-0491(83)90282-1; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; NARDIELLO S, 1978, ENZYME, V23, P353, DOI 10.1159/000458600; NELSON DM, 1992, GENE, V113, P215, DOI 10.1016/0378-1119(92)90398-9; PARKMAN R, 1975, NEW ENGL J MED, V292, P714, DOI 10.1056/NEJM197504032921402; PEDEN DB, 1990, P NATL ACAD SCI USA, V87, P7638, DOI 10.1073/pnas.87.19.7638; PROCTOR P, 1970, NATURE, V228, P868, DOI 10.1038/228868a0; PUGH ME, 1984, COMP BIOCHEM PHYS B, V77, P619, DOI 10.1016/0305-0491(84)90286-4; RAMAGOPAL S, 1984, CELL BIOL INT REP, V8, P401, DOI 10.1016/0309-1651(84)90142-5; RAMAMURTHY V, 1989, MOL CELLULAR MECHANI, P125; RATECH H, 1989, AM J PATHOL, V135, P1145; RAVID K, 1989, BIOCHEM J, V258, P653, DOI 10.1042/bj2580653; SEEGMILLER JE, 1985, ANN NY ACAD SCI, V451, P9, DOI 10.1111/j.1749-6632.1985.tb27091.x; SENBA E, 1987, J COMP NEUROL, V255, P217, DOI 10.1002/cne.902550206; SEVINIAN A, 1985, J FREE RADICAL BIOL, V1, P117; SHAW MI, 1984, BIOCHIM BIOPHYS ACTA, V778, P530, DOI 10.1016/0005-2736(84)90404-8; SMITS P, 1987, J CARDIOVASC PHARM, V10, P136, DOI 10.1097/00005344-198708000-00002; SNYDER SL, 1982, THESIS RICE U HOUSTO; STIRPE F, 1969, J BIOL CHEM, V244, P3855; STOCKER R, 1986, BIOCHEM BIOPH RES CO, V134, P152, DOI 10.1016/0006-291X(86)90540-1; TERAO J, 1988, FREE RADICAL BIO MED, V4, P205, DOI 10.1016/0891-5849(88)90040-8; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; TUTTLE JV, 1984, J BIOL CHEM, V259, P4065; VANDERWEYDEN MB, 1976, J BIOL CHEM, V251, P5448; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; WAJNER M, 1989, BIOCHIM BIOPHYS ACTA, V991, P79, DOI 10.1016/0304-4165(89)90031-7; WINSTON JH, 1992, J BIOL CHEM, V267, P13472; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179; YEUNG CY, 1985, J BIOL CHEM, V260, P299; ZIELKE CL, 1971, ENZYMES, V4, P47; ZUBAY G, 1988, BIOCHEMISTRY-US, P818	64	54	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23728	23733						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226898				2022-12-25	WOS:A1993MF51500114
J	PING, J; SCHILDBACH, JF; SHAW, SY; QUERTERMOUS, T; NOVOTNY, J; BRUCCOLERI, R; MARGOLIES, MN				PING, J; SCHILDBACH, JF; SHAW, SY; QUERTERMOUS, T; NOVOTNY, J; BRUCCOLERI, R; MARGOLIES, MN			EFFECT OF HEAVY-CHAIN SIGNAL PEPTIDE MUTATIONS AND NH(2)-TERMINAL CHAIN-LENGTH ON BINDING OF ANTIDIGOXIN ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SEQUENCE CLEAVAGE SITES; B-CELL DEVELOPMENT; 3-DIMENSIONAL STRUCTURE; SOMATIC MUTATION; ANTIDIGOXIN ANTIBODIES; IMMUNOGLOBULIN GENES; INCREASED AFFINITY; A-II; SPECIFICITY	In certain instances, antibody variable region mutations outside of the antigen-combining site influence antigen binding. We reported previously that a heavy chain mutation (Ser-94 --> Arg) decreased binding of the anti-digoxin antibody 40-150, whereas an additional signal peptide mutation at the -2 position (Gln --> Pro) causing NH2-terminal 2-residue truncation partially restored binding. To assess the combined effects on binding of two seemingly distant mutations, we constructed signal peptide mutations and NH2-terminal deletions in the presence of Ser-94 and Arg-94. Deletions of one to three amino acids had little effect on binding for Ser-94 mutants, whereas 2-residue truncations produced directly or by signal peptide mutation increased affinity approximately 40-fold for Arg-94 mutants. These observations are consistent with the reported computer-generated model of antibody 40-150. Introduction of Pro at the signal peptide -3 position in 40-150 resulted in cleavage at alternative sites, with varying effects on affinity. Introduction of Pro at -2 into the anti-digoxin antibody 26-10 resulted, unexpectedly, in expression of heavy chains with 3 extra NH2-terminal residues,.causing an approximately 100-fold reduction in affinity. Thus, both extensions and deletions of the heavy chain amino terminus can enhance or reduce antigen binding, depending on the structural context of specific antigen combining sites.	MASSACHUSETTS GEN HOSP,DEPT SURG,JACKSON 4,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,PRINCETON,NJ 08543	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Bristol-Myers Squibb				Schildbach, Joel/0000-0002-3038-9745; Quertermous, Thomas/0000-0002-7645-9067	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047415] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL47415-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BATRA JK, 1990, BIOCHEM BIOPH RES CO, V171, P1, DOI 10.1016/0006-291X(90)91347-U; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BRUCCOLERI RE, 1987, BIOPOLYMERS, V26, P137, DOI 10.1002/bip.360260114; CHIEN NC, 1989, P NATL ACAD SCI USA, V86, P5532, DOI 10.1073/pnas.86.14.5532; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CLAFLIN JL, 1987, J IMMUNOL, V138, P3060; CLARKE C, 1982, NUCLEIC ACIDS RES, V10, P7731, DOI 10.1093/nar/10.23.7731; CLARKE S, 1990, J IMMUNOL, V145, P2286; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; FOLZ RJ, 1986, J BIOL CHEM, V261, P4752; FOLZ RJ, 1988, J BIOL CHEM, V263, P2070; FRENCH DL, 1989, SCIENCE, V244, P1152, DOI 10.1126/science.2658060; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HUDSON NW, 1987, J IMMUNOL, V139, P2715; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Kabat EA, 1991, SEQUENCES PROTEINS I; KELLEY DE, 1982, CELL, V29, P681, DOI 10.1016/0092-8674(82)90184-2; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; LAVOIE TB, 1992, J IMMUNOL, V148, P503; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MOOS M, 1988, J BIOL CHEM, V263, P6005; MUDGETTHUNTER M, 1985, MOL IMMUNOL, V22, P477, DOI 10.1016/0161-5890(85)90132-4; MUDGETTHUNTER M, 1982, J IMMUNOL, V129, P1165; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; NEAR RI, 1990, MOL IMMUNOL, V27, P901, DOI 10.1016/0161-5890(90)90157-U; NEAR RI, 1991, J IMMUNOL, V146, P627; NEWELL N, 1980, SCIENCE, V209, P1128, DOI 10.1126/science.6250219; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; NOVOTNY J, 1990, PROTEINS, V7, P93, DOI 10.1002/prot.340070109; PANKA DJ, 1988, P NATL ACAD SCI USA, V85, P3080, DOI 10.1073/pnas.85.9.3080; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; Sambrook J, 1989, MOL CLONING LABORATO; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHILDBACH JF, 1993, PROTEIN SCI, V2, P206; SCHILDBACH JF, 1991, J BIOL CHEM, V266, P4640; SHAW SY, 1992, MOL IMMUNOL, V29, P525, DOI 10.1016/0161-5890(92)90010-U; SMITH TW, 1970, BIOCHEMISTRY-US, V9, P331, DOI 10.1021/bi00804a020; TAI MS, 1990, BIOCHEMISTRY-US, V29, P8024, DOI 10.1021/bi00487a005; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WEISMAN LS, 1986, J BIOL CHEM, V261, P2309; WU TT, 1970, J EXP MED, V32, P221; 1968, J BIOL CHEM, V243, P3557	49	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23000	23007						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226814				2022-12-25	WOS:A1993MF51500010
J	STRITTMATTER, P; KITTLER, JM; COGHILL, JE; OZOLS, J				STRITTMATTER, P; KITTLER, JM; COGHILL, JE; OZOLS, J			INTERACTION OF NON-MYRISTOYLATED NADH-CYTOCHROME-B(5) REDUCTASE WITH CYTOCHROME-B(5)-DIMYRISTOYLPHOSPHATIDYLCHOLINE VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME B5 REDUCTASE; RAT-LIVER MICROSOMES; SITE-DIRECTED MUTAGENESIS; COENZYME-A DESATURASE; ACTIVE-SITES; ACID; BINDING; PARTICIPATION; INVOLVEMENT; OXIDATION	An expression vector for NADH-cytochrome b5 reductase containing a thrombin cleavage site directly before the N-terminal glycine residue of the flavoprotein was used to isolate the non-myristoylated enzyme by thrombin cleavage of the initial fusion protein of a short segment of the multiple cloning site of the plasmid vector and the reductase. This flavoprotein preparation, containing only the 28-residue N-terminal peptide segment of the membrane-binding domain of the mammalian enzyme, binds to phospholipid vesicles and interacts with membrane-bound cytochrome b5. The effect of N-myristoylation of the enzyme therefore appears to be limited to facilitating and stabilizing interactions with phospholipid vesicles. However, the relatively short intervening peptide sequence that separates the crucial peptide membrane-binding domain from lysine 41, which has been implicated in the active-site interaction with cytochrome b5, (Strittmatter, P., Kittler, J. M., Coghill, J. E., and Ozols, J. (1992) J. Biol. Chem. 267, 2519-2523), provides some limitation of the distance from the membrane surface for the interactions required for rapid electron transfer from the flavin of the reductase to the heme of cytochrome b5.			STRITTMATTER, P (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06030 USA.				NIGMS NIH HHS [GM-26351, GM-15924] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026351] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARINC E, 1987, J BIOL CHEM, V262, P15563; CHESTER DW, 1987, BIOPHYS J, V52, P1021, DOI 10.1016/S0006-3495(87)83295-2; DAILEY HA, 1980, J BIOL CHEM, V255, P5184; DAILEY HA, 1979, J BIOL CHEM, V254, P5388; HACKETT CS, 1984, J BIOL CHEM, V259, P3275; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; KENSIL CR, 1986, J BIOL CHEM, V261, P7316; KEYES SR, 1979, J BIOL CHEM, V254, P7778; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MATHEWS FS, 1976, ENZYMES BIOL MEMBR, V4, P143; OKAYASU T, 1977, LIPIDS, V12, P267, DOI 10.1007/BF02533345; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; OZOLS J, 1989, BIOCHIM BIOPHYS ACTA, V997, P121, DOI 10.1016/0167-4838(89)90143-X; OZOLS J, 1985, J BIOL CHEM, V260, P1953; REDDY VVR, 1977, J BIOL CHEM, V252, P2797; ROGERS MJ, 1973, J BIOL CHEM, V248, P800; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; SPATZ L, 1973, J BIOL CHEM, V248, P793; Strittmatter P, 1978, Methods Enzymol, V52, P97; STRITTMATTER P, 1975, P NATL ACAD SCI USA, V72, P2658, DOI 10.1073/pnas.72.7.2658; STRITTMATTER P, 1992, J BIOL CHEM, V267, P20164; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; STRITTMATTER P, 1972, J BIOL CHEM, V247, P2768; STRITTMATTER P, 1992, J BIOL CHEM, V267, P2519; STRITTMATTER P, 1990, J BIOL CHEM, V265, P21709; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348	27	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23168	23171						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226835				2022-12-25	WOS:A1993MF51500035
J	UENO, H; ESCOBEDO, JA; WILLIAMS, LT				UENO, H; ESCOBEDO, JA; WILLIAMS, LT			DOMINANT-NEGATIVE MUTATIONS OF PLATELET-DERIVED GROWTH-FACTOR (PDGF) RECEPTORS - INHIBITION OF RECEPTOR FUNCTION BY LIGAND-DEPENDENT FORMATION OF HETERODIMERS BETWEEN PDGF ALPHA-RECEPTORS AND BETA-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHAIN; SIGNAL TRANSDUCTION; KINASE ACTIVATION; EXPRESSION; PHOSPHORYLATION; DIMERIZATION; DEGRADATION; ESTABLISHES; CLONING; BINDING	We showed previously that a truncated form of the platelet-derived growth factor (PDGF) beta-receptor lacking its kinase region can form a nonfunctional heterodimer with the wild-type beta-receptor and thereby inhibit its signal transduction. In this paper we investigated whether the truncated form of either alpha- or beta-receptor could block the function of the other type of wild-type PDGF receptor. When the truncated alpha-receptor was expressed in Xenopus oocytes in excess over either the wild-type alpha- or beta-receptor, the Ca2+ mobilization signal elicited by either the wild-type alpha- or beta-receptor was completely blocked. The truncated beta-receptor abolished signaling by the wild-type alpha-receptor in response to PDGF-AB or -BB. However signal transduction by the alpha-receptor in response to PDGF-AA was not affected by the truncated beta-receptor. In the presence of PDGF-AB or -BB, both the wild-type and truncated beta-receptors formed a heterologous complex with the alpha-receptor in intact cells. A kinase-inactive beta-receptor (an ATP-binding site mutation) became cross-phosphorylated on tyrosine residues by the co-expressed wild-type alpha-receptor in response to PDGF-AB or -BB but not in response to PDGF-AA. These findings indicate that the alpha- and beta-receptors interact in response to PDGF-AB or -BB and are consistent with the hypothesis that the truncated alpha-receptor inhibits function of the wild-type beta-receptor through formation of a ligand-dependent nonfunctional alphabeta-heterodimer. A similar heterodimer can form between the truncated beta-receptor and the wild-type alpha-receptor. These observations provide useful information for future studies using dominant-negative mutations of PDGF receptors to selectively inhibit the actions of specific PDGFs in animals.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco					NHLBI NIH HHS [R0-1 HL-32898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ESCOBEDO JA, 1988, SCIENCE, V240, P1532, DOI 10.1126/science.2836953; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HART CE, 1987, J BIOL CHEM, V262, P10780; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; JOSEPHS SF, 1984, SCIENCE, V223, P487, DOI 10.1126/science.6318322; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KEATING MT, 1987, J BIOL CHEM, V262, P7932; KELLY JD, 1991, J BIOL CHEM, V266, P8987; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; OLASHAW NE, 1991, J BIOL CHEM, V266, P10234; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; STROOBANT P, 1984, EMBO J, V12, P2963; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; WERNER S, 1993, IN PRESS EMBO; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	30	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22814	22819						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226792				2022-12-25	WOS:A1993MD34800092
J	WATERS, SB; YAMAUCHI, K; PESSIN, JE				WATERS, SB; YAMAUCHI, K; PESSIN, JE			FUNCTIONAL EXPRESSION OF INSULIN-RECEPTOR SUBSTRATE-1 IS REQUIRED FOR INSULIN-STIMULATED MITOGENIC SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHATIDYLINOSITOL 3'-KINASE; IRS-1; ASSOCIATION; 3-KINASE; PROTEIN; KINASE	To examine the role of the insulin receptor substrate-1 (IRS-1) in mediating insulin biological responsiveness, we generated Chinese hamster ovary cell lines expressing antisense IRS-1 RNA. These cells displayed morphological alterations as well as markedly reduced growth rates compared to the parental cells. Furthermore, the antisense IRS-1 cell lines had decreased insulin-stimulated IRS-1 tyrosine phosphorylation, reduced phosphatidylinositol 3-kinase activation, and decreased thymidine incorporation relative to the parental cell line. Insulin-dependent transcriptional regulation of a serum response element/luciferase reporter construct (SRE-Luc) was also reduced in the antisense IRS-1-expressing cell lines. However, co-transfection with a plasmid directing the expression of rat IRS-1 fully restored insulin-stimulated SRE-Luc activity in the IRS-1 antisense cell lines. Thus, the inhibition in insulin signaling was a specific effect of decreased IRS-1 tyrosine phosphorylation. Taken together, these data demonstrate that insulin regulation of mitogenic signaling requires the functional expression of IRS-1 and documents its central importance in the insulin intracellular signaling pathway.	UNIV IOWA HOSP & CLIN, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R37DK033823, R01DK033823] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33823, DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; FOLLI F, 1992, J BIOL CHEM, V267, P22171; HADARI YR, 1993, J BIOL CHEM, V268, P9156; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TOBE K, 1993, J BIOL CHEM, V268, P11167; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	114	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22231	22234						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226726				2022-12-25	WOS:A1993MD34800005
J	XU, YZ; PLUNKETT, W				XU, YZ; PLUNKETT, W			REGULATION OF THYMIDINE KINASE AND THYMIDYLATE SYNTHASE IN INTACT HUMAN LYMPHOBLAST CCRF-CEM CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DNA-POLYMERASES; LEUKEMIA-CELLS; MESSENGER-RNA; DEOXYCYTIDYLATE DEAMINASE; ALLOSTERIC INTERACTION; BIOSYNTHETIC-ENZYMES; REPLITASE COMPLEX; 3T6 FIBROBLASTS; MAMMALIAN-CELLS; L1210 CELLS	It has been reported that thymidylate synthase (TS) is a component of a multienzyme complex associated with DNA replication based on observations that enzyme activity was decreased when cells were treated with various DNA synthesis inhibitors (Plucinski, T. M., Fager, R. S., and Reddy, G. P. V. (1990) MoL Pharmacol. 38, 114-120). The veracity of the TS assay (known as the tritium release assay) employed in these experiments may be compromised, however, because it requires the S phase-specific enzyme thymidine kinase (TK) to phosphorylate the substrate [5-H-3]dUrd. In our study, this problem was further illustrated as the phosphorylated products of [C-14]dCyd and [6-H-3]dUrd were simultaneously quantitated to determine the activities of TS, TK, and dCyd kinase in intact CCRF-CEM cells. TS and dCyd kinase were unaffected by aphidicolin, hydroxyurea, and 1-beta-D-arabinofuranosylcytosine, whereas TK was strongly inhibited by these agents. Elevation of the cellular dTTP pool that accompanied drug treatment was not the primary mechanism affecting TK activity because incubation of cells with dCyd elevated the dTTP pool to similar levels, but did not inhibit TK to the same extent as did the drugs. Furthermore, after cells were washed from aphidicolin, [6-H-3]dCyd incorporation, which primarily labels dTMP in DNA, proceeded at a linear rate, whereas a lag period of 15 min was observed before [H-3]dThd was incorporated at a linear rate. These results suggest that TK activity is affected by more than one mechanism in intact cells. Because the activities of dCyd kinase and dCMP deaminase do not fluctuate as much as that of TK in response to changes in DNA synthesis activity and cell cycle, dCyd incorporation appears to be a more reliable assay of TS in intact cells than does dUrd incorporation. Our findings also imply that [H-3]dThd incorporation assays may overestimate inhibition of DNA synthesis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN INVEST,BOX 52,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA28596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG RD, 1982, J BIOCHEM BIOPH METH, V6, P141, DOI 10.1016/0165-022X(82)90060-4; ARNER ESJ, 1988, EXP CELL RES, V178, P335, DOI 10.1016/0014-4827(88)90403-X; BALZARINI J, 1984, BIOCHIM BIOPHYS ACTA, V785, P36, DOI 10.1016/0167-4838(84)90231-0; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; BLACK ME, 1992, J BIOL CHEM, V267, P9743; BODYCOTE J, 1986, P NATL ACAD SCI USA, V83, P4749, DOI 10.1073/pnas.83.13.4749; BRESNICK E, 1964, CANCER RES, V24, P841; CHIBA P, 1984, BIOCHEM BIOPH RES CO, V123, P656, DOI 10.1016/0006-291X(84)90279-1; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; COPPOCK DL, 1985, J CELL PHYSIOL, V124, P269, DOI 10.1002/jcp.1041240215; DESAINTVINCENT BR, 1980, J BIOL CHEM, V255, P162; DUNLAP RB, 1971, BIOCHEMISTRY-US, V10, P88, DOI 10.1021/bi00777a014; ERIKSSON S, 1987, EXP CELL RES, V168, P79, DOI 10.1016/0014-4827(87)90417-4; FEDER JN, 1990, J CELL BIOL, V111, P2693, DOI 10.1083/jcb.111.6.2693; FITZGERALD GB, 1987, ANTI-CANCER DRUG DES, V1, P281; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FRIDLAND A, 1987, SEMIN ONCOL, V14, P262; FRIEDKIN M, 1973, ADV ENZYMOL RAMB, V38, P235; HARVEY G, 1988, J CELL PHYSIOL, V134, P25, DOI 10.1002/jcp.1041340104; HASHIMOTO Y, 1988, CANCER BIOCHEM BIOPH, V10, P1; HEINEMANN V, 1989, BIOCHEM PHARMACOL, V38, P4115, DOI 10.1016/0006-2952(89)90693-X; HEINEMANN V, 1990, MOL PHARMACOL, V38, P567; HUANG P, 1991, CANCER RES, V51, P6110; HUANG P, 1990, J BIOL CHEM, V265, P16617; ITO M, 1990, J BIOL CHEM, V265, P6954; JACKSON RC, 1978, J BIOL CHEM, V253, P7440; JENH CH, 1985, MOL CELL BIOL, V5, P2527, DOI 10.1128/MCB.5.10.2527; JOHNSON LF, 1982, EXP CELL RES, V138, P79, DOI 10.1016/0014-4827(82)90093-3; KARLE JM, 1983, CANCER LETT, V19, P147, DOI 10.1016/0304-3835(83)90148-9; KUCERA R, 1986, EXP CELL RES, V167, P417, DOI 10.1016/0014-4827(86)90182-5; LEEDS JM, 1987, MOL CELL BIOL, V7, P532, DOI 10.1128/MCB.7.1.532; MATHERLY LH, 1989, ANAL BIOCHEM, V182, P338, DOI 10.1016/0003-2697(89)90605-2; MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502; MATHEWS CK, 1988, TRENDS BIOCHEM SCI, V13, P394, DOI 10.1016/0968-0004(88)90182-X; MAURER HR, 1981, CELL TISSUE KINET, V14, P111, DOI 10.1111/j.1365-2184.1981.tb00516.x; MCINTOSH EM, 1986, MOL CELL BIOL, V6, P1711, DOI 10.1128/MCB.6.5.1711; NEWMAN CN, 1988, MUTAT RES, V200, P201, DOI 10.1016/0027-5107(88)90083-8; NICANDER B, 1985, J BIOL CHEM, V260, P5376; NOGUCHI H, 1983, CELL, V32, P443, DOI 10.1016/0092-8674(83)90464-6; NYGAARD P, 1987, LEUKEMIA RES, V11, P681, DOI 10.1016/0145-2126(87)90002-6; OHNO Y, 1988, CANCER RES, V48, P1494; PEDRALINOY G, 1979, BIOCHEM BIOPH RES CO, V88, P1194, DOI 10.1016/0006-291X(79)91106-9; PELLINIEMI TT, 1980, J CLIN INVEST, V65, P449, DOI 10.1172/JCI109688; PLUCINSKI TM, 1990, MOL PHARMACOL, V38, P114; REDDY GPV, 1982, BIOCHEM BIOPH RES CO, V109, P908, DOI 10.1016/0006-291X(82)92026-5; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; REDDY GPV, 1983, NATURE, V303, P86; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROBERTS D, 1966, BIOCHEMISTRY-US, V5, P3546, DOI 10.1021/bi00875a022; RODE W, 1985, BIOCHEM BIOPH RES CO, V128, P345, DOI 10.1016/0006-291X(85)91685-7; RODE W, 1980, J BIOL CHEM, V255, P1305; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; SPASOKUKOTSKAJA T, 1992, FEBS LETT, V297, P151, DOI 10.1016/0014-5793(92)80348-K; SPYROU G, 1987, J BIOL CHEM, V262, P16425; SPYROU G, 1989, J BIOL CHEM, V264, P960; TANAKA M, 1987, JPN J CANCER RES, V78, P851; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; WANG LM, 1990, CANCER CHEMOTH PHARM, V25, P418, DOI 10.1007/BF00686052; WICKREMASINGHE RG, 1983, FEBS LETT, V159, P175, DOI 10.1016/0014-5793(83)80441-4; XU Y-Z, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P416; XU YZ, 1992, BIOCHEM PHARMACOL, V44, P1819; YALOWICH JC, 1985, BIOCHEM PHARMACOL, V34, P2319, DOI 10.1016/0006-2952(85)90788-9; YOUDALE T, 1975, J CELL PHYSIOL, V86, P495, DOI 10.1002/jcp.1040860306	65	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22363	22368						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226747				2022-12-25	WOS:A1993MD34800029
J	MAYO, MW; STEELMAN, LS; MCCUBREY, JA				MAYO, MW; STEELMAN, LS; MCCUBREY, JA			PHORBOL ESTERS SUPPORT THE PROLIFERATION OF A HEMATOPOIETIC-CELL LINE BY UP-REGULATING C-JUN EXPRESSION	ONCOGENE			English	Article							PROTEIN-KINASE-C; TRANSCRIPTION FACTOR AP-1; EARLY GENE-EXPRESSION; MESSENGER-RNA; METALLOTHIONEIN GENE; GROWTH-FACTORS; FOS; ONCOGENE; INDUCTION; DNA	FD/PMA, a derivative of the interleukin-3 (IL-3) dependent FDC-P1 cell line, proliferates in response to either phorbol esters (phorbol 12-myristate 13-acetate, PMA) or IL-3. Analysis of immediate-early gene expression revealed that FD/PMA cells contained elevated levels of c-jun transcripts when grown in the presence of phorbol esters. Upregulation of c-jun mRNA was specific since other jun family members (namely jun-B and jun-D) displayed similar patterns of gene expression as observed in the parental cell line. The accumulation of c-jun RNA was due to increased c-jun transcription and not the result of altered message stability, Furthermore, elevated c-jun expression resulted in increased AP-1 binding activity in FD/PMA cells, Antisense c-jun oligonucleotides suppressed proliferation of FD/PMA cells by 80% and resulted in a significant reduction in both AP-1 binding activity and c-jun message levels. Collectively, these results demonstrate that FD/PMA cells require elevated levels of c-jun expression for PMA-responsive proliferation and indicate that tumor promoters have the ability to abrogate IL-3 dependency by elevating AP-1 activity.	E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858	University of North Carolina; East Carolina University				McCubrey, James/0000-0001-6027-3156	NATIONAL CANCER INSTITUTE [R01CA051025] Funding Source: NIH RePORTER; NCI NIH HHS [NCI RO1CA51025] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; CARTER TH, 1987, MECHANISMS ENV CARCI, V1, P47; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAVOLORO J, 1980, METHOD ENZYMOL, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HERRMANN F, 1992, CYTOKINES HEMATOLOGY, V2; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; KALB VF, 1977, ANAL BIOCHEM, V82, P362, DOI 10.1016/0003-2697(77)90173-7; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; MCCUBREY JA, 1991, ONCOGENE RES, V6, P1; MCCUBREY JA, 1990, BLOOD, V76, P63; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; WAYS DK, 1991, BLOOD, V78, P2633; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YANG-YEN H-F, 1990, New Biologist, V2, P351	46	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1999	2008						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208545				2022-12-25	WOS:A1994NR68500024
J	ZHANG, JD; CHANG, CC; LOMBARDI, L; DALLAFAVERA, R				ZHANG, JD; CHANG, CC; LOMBARDI, L; DALLAFAVERA, R			REARRANGED NFKB2 GENE IN THE HUT78 T-LYMPHOMA CELL-LINE CODES FOR A CONSTITUTIVELY NUCLEAR FACTOR LACKING TRANSCRIPTIONAL REPRESSOR FUNCTIONS	ONCOGENE			English	Article							NF-KAPPA-B; DNA-BINDING; RETICULOENDOTHELIOSIS VIRUS; ONCOPROTEIN BCL-3; REL; SUBUNIT; P50; ONCOGENE; CLONING; INHIBITION	Rearrangements of the NFKB2 gene are associated with lymphoid malignancies, but the functional significance of these alterations is not known. Here we characterize structurally and functionally a rearranged NFKB2 gene identified at the T cell lymphoma line, HUT78. The rearrangement has truncated NFKB2 sequences within the 3' ankyrin domain, leading to the production of truncated mRNA species and proteins as detected by Northern blot and immunoprecipitation analysis, respectively. Cloning and sequencing of the corresponding cDNAs indicates that, via alternative splicing, the rearranged gene codes for two proteins of 84 and 85 kD (p84/85) which retain the DNA-binding rel domain and the first five ankyrin repeats, but have lost their carboxy-terminus including the seventh ankyrin repeat. Immunofluorescence and immunoprecipitation analysis of HUT78 cells indicate that p84/85 are abnormally located in the nucleus in an unprocessed form, suggesting that these proteins can escape the cytoplasmic retention typical of the normal NFKB2 p100 protein before it is processed into p52. Electrophoretic mobility shift assays performed on HUT78 nuclear extracts indicate that the abnormal NFKB2 proteins bind kappa B sites specifically and alter the composition of NF-kappa B complexes in HUT78 cells. Transient co-transfection assays involving NFKB2 expression vectors and kappa B-driven reporter plasmids indicate that NFKB2 p85 has lost the transcriptional repressor functions typical of normal NFKB2 p52. These data indicate that the NFKB2 gene rearrangement detected in HUT78 cells leads to the production of abnormal NFKB2 proteins capable of altering the function of the NF-kappa B transcription system. Since analogous rearrangements are found in lymphoid malignancies, these findings further support a role of NFKB2 alterations in tumorigenesis.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY 10032; UNIV MILAN,OSPED MAGGIORE,IRCCS,IST SCI MED,EMATOL LAB,MILAN,ITALY	Columbia University; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan					NCI NIH HHS [CA 44029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1989, ONCOGENE, V4, P935; CHANG CC, 1994, ONCOGENE, V9, P923; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GAZDAR AF, 1980, BLOOD, V55, P409; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRILLI M, 1992, INT REV CYTOL, V48, P1; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LU D, 1991, ONCOGENE, V6, P1235; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OFFIT K, 1991, BLOOD, V77, P1508; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAGLIO G, 1986, CANCER RES, V46, P1413; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; YANO T, 1993, BLOOD, V82, P1813, DOI 10.1182/blood.V82.6.1813.bloodjournal8261813	38	57	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1931	1937						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208540				2022-12-25	WOS:A1994NR68500017
J	LIU, ZJ; JACOB, ST				LIU, ZJ; JACOB, ST			CHARACTERIZATION OF A PROTEIN THAT INTERACTS WITH THE RAT RIBOSOMAL GENE PROMOTER AND MODULATES RNA-POLYMERASE-I TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-TIF-IA; FRACTIONATED NUCLEAR EXTRACT; UPSTREAM SPACER REGION; ENHANCER ELEMENT; FACTOR E1BF; INITIATION; RDNA; HEPATOMA; BINDING; LIVER	An RNA polymerase I core promoter binding factor (CPBF) was purified to apparent homogeneity from rat adenocarcinoma ascites cells by chromatographic fractionation on a series of columns including an oligodeoxynucleotide affinity column. The final preparation contained two polypeptides with molecular masses of 44,000 and 39,000 daltons. The binding of the factor to the promoter was demonstrated by Southwestern blotting, UV cross-linking and electrophoretic mobility shift assay. The specificity of its binding to the core promoter was confirmed by competitive electrophoretic mobility shift assay using several unlabeled oligo probes in the assay. The addition of increasing amounts of purified CPBF to the in vitro transcription reaction that contains a limiting quantity of the factor resulted in dramatic stimulation of RNA polymerase I (pol I) transcription of rat ribosomal RNA gene. The transcription stimulatory activity associated with the purified CPBF fractions copurified with the core promoter binding activity in an electrophoretic mobility shift assay. Finally, in a reconstitution transcription system which is devoid of the factor and is incapable of ribosomal gene transcription, purified CPBF could trans-activate the pol I promoter. These data indicate that CPBF is a novel pol I promoter binding factor required for ribosomal gene transcription.	CHICAGO MED SCH, DEPT MOLEC BIOL & PHARMACOL, N CHICAGO, IL 60064 USA	Chicago Medical School					NCI NIH HHS [CA 31894] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031894] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; CAVANAUGH AH, 1984, P NATL ACAD SCI-BIOL, V81, P718, DOI 10.1073/pnas.81.3.718; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DIXIT A, 1987, J BIOL CHEM, V262, P11616; DUCEMAN BW, 1980, BIOCHEM J, V190, P781, DOI 10.1042/bj1900781; GARG LC, 1989, J BIOL CHEM, V264, P220; GHOSH AK, 1993, GENE, V125, P217, DOI 10.1016/0378-1119(93)90332-W; GOKAL PK, 1986, J BIOL CHEM, V261, P2536; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; HOFF CM, 1993, BIOCHEM BIOPH RES CO, V190, P747, DOI 10.1006/bbrc.1993.1112; JACOB ST, 1986, MOL CELL BIOCHEM, V70, P11; JACOB ST, 1969, EUR J BIOCHEM, V7, P449; JI Z, 1990, MOL CELL BIOL, V10, P5177, DOI 10.1128/MCB.10.10.5177; KANADOGA JT, 1986, P NATL ACAD SCI USA, V82, P6672; KURL RN, 1985, NUCLEIC ACIDS RES, V13, P89, DOI 10.1093/nar/13.1.89; KURL RN, 1985, P NATL ACAD SCI USA, V82, P1059, DOI 10.1073/pnas.82.4.1059; KURL RN, 1984, P NATL ACAD SCI-BIOL, V81, P6672, DOI 10.1073/pnas.81.21.6672; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; MAGUIRE KA, 1987, J BIOL CHEM, V262, P3932; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; MURAMATSU M, 1970, J MOL BIOL, V53, P91; Paule Marvin R., 1993, Gene Expression, V3, P1; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; RUBINSTEIN SJ, 1989, J VIROL, V63, P4689, DOI 10.1128/JVI.63.11.4689-4696.1989; SCHNAPP A, 1990, NUCLEIC ACIDS RES, V18, P1385, DOI 10.1093/nar/18.6.1385; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHNAPP A, 1993, MOL CELL BIOL, V13, P6723, DOI 10.1128/MCB.13.11.6723; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; TANAKA N, 1990, J BIOL CHEM, V265, P13836; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WEBB ML, 1989, MOL ENDOCRINOL, V3, P1861, DOI 10.1210/mend-3-11-1861; WENDLER I, 1988, ANAL BIOCHEM, V172, P29, DOI 10.1016/0003-2697(88)90407-1; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235	38	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16618	16625						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206980				2022-12-25	WOS:A1994NR29600018
J	VARRAULT, A; LENGUYEN, D; MCCLUE, S; HARRIS, B; JOUIN, P; BOCKAERT, J				VARRAULT, A; LENGUYEN, D; MCCLUE, S; HARRIS, B; JOUIN, P; BOCKAERT, J			5-HYDROXYTRYPTAMINE(1A) RECEPTOR SYNTHETIC PEPTIDES - MECHANISMS OF ADENYLYL-CYCLASE INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; PHOSPHOLIPID-VESICLES; CYTOPLASMIC DOMAINS; REGULATORY PROTEINS; LIGAND-BINDING; ALPHA; SITE; GI; MASTOPARAN; ACTIVATION	The 5-hydroxytryptamine(1A) receptor (5-HT(1A)R) is a G-protein-coupled receptor negatively coupled to adenylyl cyclase (AC). We have studied the functional domains of 5-HT(1A)R using synthetic peptides to block or mimic receptor function. The entire second intracellular loop (5-HT(1A)R-i(2)) and the carboxyl end of the third intracellular loop (5-HT(1A)R-i(3)-C) strongly inhibited forskolin-stimulated AC activity. These effects were not additive with those of 5-HT. Like 5-HT, the peptides 5-HT(1A)R-i(3)-C and -i(2) weakly inhibited AlF4- and Mn2+ stimulated AC activity. 5-HT(1A)R binding assays indicated that peptides could interact with the same G-protein pool as the 5-HT(1A)R. 5-HT(1A)R-i(3)-C- and -i(2)-stimulated [S-35]guanosine 5'-O-(thiotriphosphate) binding on G(o)/G(i) proteins. Only 5-HT(1A)R-i(3)-C partially adopted an alpha-helical conformation in solution. These data show that different domains in the 5-HT(1A)R second and third intracellular loops can couple to and activate G(i) proteins in order to mediate AC inhibition. Peptide-induced AC inhibition was not sensitive to pertussis toxin as opposed to the 5-HT(1A)R-mediated effect. Our data show that the 5-HT(1A)R and the 5-HT(1A)R peptides activate G(i) proteins in a slightly different manner.	CNRS,UPR 9023,F-34094 MONTPELLIER 05,FRANCE; MARION MERRELL DOW RES INST,STRASBOURG RES CTR,F-67046 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS)								ASANO T, 1984, J BIOL CHEM, V259, P9351; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOCKAERT J, 1987, N-S ARCH PHARMACOL, V335, P588; BUSHFIELD M, 1990, MOL PHARMACOL, V38, P848; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; COTE TE, 1984, J BIOL CHEM, V259, P8693; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DEVIVO M, 1986, J PHARMACOL EXP THER, V238, P248; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; KISS Z, 1990, J BIOL CHEM, V265, P7345; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LENGUYEN D, 1987, J CHEM SOC PERK T 1, P1915, DOI 10.1039/p19870001915; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MALEK D, 1993, FEBS LETT, V325, P215; MARGALIT H, 1987, J IMMUNOL, V138, P2213; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1991, BIOCHEM BIOPH RES CO, V179, P10, DOI 10.1016/0006-291X(91)91326-8; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OPPI C, 1992, P NATL ACAD SCI USA, V89, P8268, DOI 10.1073/pnas.89.17.8268; ROSS EM, 1977, J BIOL CHEM, V252, P5761; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; SMIGEL M, 1984, ADV CYCLIC NUCL PROT, V17, P1; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; VARRAULT A, 1992, MOL BIOL CELL, V3, P961, DOI 10.1091/mbc.3.9.961; VARRAULT A, 1991, J PHARMACOL EXP THER, V257, P433; VOSS T, 1993, J BIOL CHEM, V268, P4637; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WONG SKF, 1990, J BIOL CHEM, V265, P6219	40	56	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16720	16725						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8206993				2022-12-25	WOS:A1994NR29600034
J	YAO, M; HATAHET, Z; MELAMEDE, RJ; KOW, YW				YAO, M; HATAHET, Z; MELAMEDE, RJ; KOW, YW			PURIFICATION AND CHARACTERIZATION OF A NOVEL DEOXYINOSINE-SPECIFIC ENZYME, DEOXYINOSINE 3' ENDONUCLEASE, FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-DNA GLYCOSYLASE; BASE-PAIRS; CRYSTAL-STRUCTURE; DAMAGE; URACIL; RESIDUES; EXCISION; PROTEINS; RELEASE; INVITRO	We have purified a novel endonuclease from Escherichia coli that recognizes deoxyinosine, a deamination product of deoxyadenosine in DNA. This activity, which we named deoxyinosine 3' endonuclease, is different from the known hypoxanthine DNA N-glycosylases which have been partially characterized in E. coli and other organisms. The enzyme was purified 24,800-fold to apparent homogeneity. SDS- and activity PAGE analyses indicate that the enzyme has an apparent molecular mass of 25 kDa. Deoxyinosine 3' endonuclease recognized deoxyinosine in both single- and double-stranded DNA but exhibited a 4-fold preference for double stranded over single-stranded DNA In addition to deoxyinosine, the enzyme recognized urea residues and AP sites. Deoxyinosine 3' endonuclease has an obligatory requirement for Mg2+, but other cations such as Co(2+)and Mn2+ could partially replace Mg2+. The optimal pH for deoxyinosine 3' endonuclease was around 7.5. In contrast to most of the known repair enzymes, deoxyinosine 3' endonuclease makes an incision at the second phosphodiester bond 3' to a deoxyinosine or AP site, leaving behind the intact lesion on the nicked DNA. Therefore, deoxyinosine 3' endonuclease recognizes, but does not remove, the lesion from the DNA molecule. The biological significance of this novel activity is discussed with reference to other repair activities in E. coli.	UNIV VERMONT,MARKEY CTR MOLEC GENET,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405	University of Vermont					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, DNA REPAIR; ASHARA H, 1989, BIOCHEMISTRY-US, V28, P4444; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; CORFIELD PWR, 1987, NUCLEIC ACIDS RES, V15, P7935, DOI 10.1093/nar/15.19.7935; CRUSE WBT, 1989, NUCLEIC ACIDS RES, V17, P55, DOI 10.1093/nar/17.1.55; DEHAZYA P, 1986, CANCER RES, V46, P3756; DIANOV G, 1991, NUCLEIC ACIDS RES, V19, P3829, DOI 10.1093/nar/19.14.3829; DUNCAN BK, 1984, GENE, V28, P211, DOI 10.1016/0378-1119(84)90258-0; EFTEDAL I, 1993, NUCLEIC ACIDS RES, V21, P2095, DOI 10.1093/nar/21.9.2095; HARADA K, 1993, NUCLEIC ACIDS RES, V21, P2287, DOI 10.1093/nar/21.10.2287; HAROSH I, 1988, J BIOL CHEM, V263, P3328; HATAHET Z, 1989, BIOCHEM CELL BIOL, V67, P632, DOI 10.1139/o89-095; HILLPERKINS M, 1986, MUTAT RES, V162, P153, DOI 10.1016/0027-5107(86)90081-3; KARRAN P, 1980, BIOCHEMISTRY-US, V19, P6005, DOI 10.1021/bi00567a010; KARRAN P, 1978, J BIOL CHEM, V253, P5877; KLAND MJ, 1957, J AM CHEM SOC, V79, P6187, DOI 10.1021/ja01580a022; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; KOWALSKI D, 1979, ANAL BIOCHEM, V93, P346, DOI 10.1016/S0003-2697(79)80090-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; LONGLEY MJ, 1993, METHOD ENZYMOL, V218, P587; MYRNES B, 1982, NUCLEIC ACIDS RES, V10, P3693, DOI 10.1093/nar/10.12.3693; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; POEHLING HM, 1981, ELECTROPHORESIS, V2, P141, DOI 10.1002/elps.1150020304; PONNAMPERUMA C, 1961, SCIENCE, V134, P113, DOI 10.1126/science.134.3472.113; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SCHUSTER H., 1959, BIOCHEM AND BIOPHYS RES COMMUNICATIONS, V2, P320; Shapiro R, 1981, CHROMOSOME DAMAGE RE, P3; SNOWDEN A, 1990, BIOCHEMISTRY-US, V29, P7251, DOI 10.1021/bi00483a013; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WALLACE SS, 1981, DNA REPAIR LABORATOR, V1, P113; WEISS B, 1981, ENZYMES, V14, P203; XUAN JC, 1992, NUCLEIC ACIDS RES, V20, P5457, DOI 10.1093/nar/20.20.5457	36	104	115	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16260	16268						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206931				2022-12-25	WOS:A1994NQ72900049
J	BLANK, JL; SHAW, K; ROSS, AH; EXTON, JH				BLANK, JL; SHAW, K; ROSS, AH; EXTON, JH			PURIFICATION OF A 110-KDA PHOSPHOINOSITIDE PHOSPHOLIPASE-C THAT IS ACTIVATED BY G-PROTEIN BETA-GAMMA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; ALPHA-SUBUNITS; ADENYLYL CYCLASE; BOVINE BRAIN; IMMUNOLOGICAL IDENTIFICATION; SIGNAL TRANSDUCTION; ISOZYMES; STIMULATION; RECEPTOR; CELLS	We report the purification from bovine brain cytosol of a 110-kDa phosphoinositide-specific phospholipase C (PLC-110) that was markedly stimulated by G-protein betagamma-subunits. The enzyme was purified approximately 2000-fold with a yield of 4%. On the basis of size and immunological cross-reactivity, PLC-110 was distinct from 150-kDa PLC-beta1, 145-kDa PLC-gamma1, and 85-kDa PLC-delta1. An antiserum to a peptide corresponding to a conserved PLC Y domain sequence cross-reacted with PLC-110. PLC-110 was also recognized by two antisera selective for NH2-terminal and internal sequences in PLC-beta3, but not by a third peptide antiserum to the COOH terminus of this enzyme, suggesting that PLC-110 is related to PLC-beta3. Reconstitution of purified PLC-110 with betagamma-subunits produced greater than 100-fold activation, indicating that no other proteins were required. Half-maximal activation was observed at approximately 60 nM betagamma and full activation at approximately 500 nM betagamma. PLC-110 maximally hydrolyzed phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate at 1 muM Ca2+, but showed no activity toward phosphatidylinositol at Ca2+ concentrations up to 1 mM. Concentrations of purified guanosine 5'-O-(3-thiotriphosphate)-liganded alpha(q) that fully activated PLC-beta1 failed to stimulate PLC-110. This observation indicates that the site at which betagamma interacts with PLC-110 is distinct from that at which alpha(q) regulates the activity of PLC-beta isozymes.	VANDERBILT UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University								ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BRISTOL A, 1988, COLD SPRING HARB SYM, V53, P915, DOI 10.1101/SQB.1988.053.01.105; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; CAROZZI AJ, 1992, EUR J BIOCHEM, V210, P521, DOI 10.1111/j.1432-1033.1992.tb17450.x; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; FAIN JN, 1990, BIOCHIM BIOPHYS ACTA, V1053, P81, DOI 10.1016/0167-4889(90)90029-D; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JHON DY, 1993, J BIOL CHEM, V268, P6654; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KRIZ R, 1990, CIBA F SYMP, V150, P112; LEE CH, 1992, J BIOL CHEM, V267, P16044; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PANG IH, 1990, J BIOL CHEM, V265, P18707; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARK DG, 1993, J BIOL CHEM, V268, P3710; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RUY SH, 1987, J BIOL CHEM, V262, P12511; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SUH PG, 1988, J BIOL CHEM, V263, P14497; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TAYLOR SJ, 1991, FEBS LETT, V286, P214, DOI 10.1016/0014-5793(91)80976-A; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU DQ, 1992, J BIOL CHEM, V267, P1811	50	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25184	25191						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227082				2022-12-25	WOS:A1993MG67300095
J	DOOIJES, D; VANDEWETERING, M; KNIPPELS, L; CLEVERS, H				DOOIJES, D; VANDEWETERING, M; KNIPPELS, L; CLEVERS, H			THE SCHIZOSACCHAROMYCES-POMBE MATING-TYPE GENE MAT-MC ENCODES A SEQUENCE-SPECIFIC DNA-BINDING HIGH-MOBILITY GROUP BOX PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX-DETERMINING REGION; TRANSCRIPTION FACTOR; CELL-TYPE; FISSION YEAST; REGULATORY PROTEINS; ALPHA-ENHANCER; MINOR GROOVE; HMG DOMAIN; FACTOR-I; MOTIF	The Schizosaccharomyces pombe gene mat-Mc plays a determinative role in the sexual differentiation of the fission yeast. The mat-Mc protein has been suggested to belong to a novel family of so-called high mobility group (HMG) box proteins, characterized by homology to high mobility group-1 and -2 proteins. Several HMG box proteins, including the mammalian sex-determining gene product SRY and the lymphoid transcription factors TCF-1 and LEF-1, have been shown to bind to DNA in a sequence-specific fashion. To analyze possible DNA-binding properties of mat-Mc, we have cloned and expressed its putative HMG box in Escherichia coli. Gel retardation analysis revealed that the mat-Mc HMG box recognizes the AACAAAG heptamer in a sequence-specific fashion. Combined T-->C and A-->I substitutions on both strands of the AACAAAG heptamer, which change the surface of the major groove while leaving the minor groove intact, did not interfere with sequence-specific binding of mat-Mc. Methylation interference analysis confirmed that the mat-Mc HMG box contacts adenine residues in the minor groove. By using a circular permutation assay, the mat-Mc HMG box was observed to bend DNA. These results indicate that mat-Mc is indeed a member of the HMG box family with DNA-binding characteristics assigned earlier to other members of this novel transcription factor family.			DOOIJES, D (corresponding author), UNIV HOSP UTRECHT,DEPT IMMUNOL,POB 88500,3508 GA UTRECHT,NETHERLANDS.							BEACH DH, 1983, NATURE, V305, P682, DOI 10.1038/305682a0; BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; EGEL R, 1984, CURR GENET, V8, P199, DOI 10.1007/BF00417816; EGEL R, 1981, CURR GENET, V3, P5, DOI 10.1007/BF00419574; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HERSKOWITZ I, 1981, MOL BIOL YEAST SACCH, P180; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAUDET V, 1993, IN PRESS NUCLEIC ACI; LEUPOLD U., 1950, Comptes rendus des Travaux du Laboratoire Carlsberg, V24, P381; LEUPOLD U, 1958, COLD SPRING HARB SYM, V23, P161, DOI 10.1101/SQB.1958.023.01.020; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; NER S S, 1992, Current Biology, V2, P208, DOI 10.1016/0960-9822(92)90541-H; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; PABO CO, 1984, ANN REV BIOCH, V53, P2932; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRATHERN J, 1981, J MOL BIOL, V147, P357, DOI 10.1016/0022-2836(81)90488-5; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VANDEWETERING M, 1993, IN PRESS EMBO J; VANHOUTE L, 1993, J BIOL CHEM, V268, P18083; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656	38	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24813	24817						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227043				2022-12-25	WOS:A1993MG67300046
J	FRANCO, M; CHARDIN, P; CHABRE, M; PARIS, S				FRANCO, M; CHARDIN, P; CHABRE, M; PARIS, S			MYRISTOYLATION IS NOT REQUIRED FOR GTP-DEPENDENT BINDING OF ADP-RIBOSYLATION FACTOR-ARF1 TO PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHOLERA-TOXIN; GUANINE-NUCLEOTIDE; ESCHERICHIA-COLI; FACTOR ARF; BOVINE BRAIN; BREFELDIN-A; PROTEIN; PURIFICATION; EXPRESSION; MEMBRANES	Membrane binding of ADP-ribosylation factors (ARFs) is GTP-dependent and seems to require amino-terminal myristoylation. Recently it has been proposed that myristoylation is needed not for the activation of ARF by GTP but for its subsequent association to membranes. Here we show that unmyristoylated bovine ARF1, expressed in bacteria, can be efficiently loaded with GTPgammaS (guanosine 5'-O-(thio)triphosphate) at 1 muM free Mg2+, in the presence of phospholipids. Unmyristoylated ARF(GTPgammaS) cosediments with phospholipid vesicles and totally binds to phospholipid-cholate micelles, as seen by gel filtration chromatography. We therefore propose that, in vivo, myristoylation is required for the interaction of ARF(GDP) with its membrane-bound exchange factor rather than for the association of ARF(GTP) with lipid membranes. Phospholipid-bound ARF(GTPgammaS) pan also stably interact with and activate the catalytic subunit of cholera toxin, suggesting that ARF(GTP) provides a membrane anchor for cholera toxin and thereby facilitates its access to membrane-bound substrates.			FRANCO, M (corresponding author), INST PHARMACOL MOLEC & CELLULAIRE, CNRS, 660 ROUTE LUCIOLES, F-06560 VALBONNE, FRANCE.		FRANCO, michel/AAA-9735-2021; Franco, Michel/ABH-4993-2020	Franco, Michel/0000-0003-1853-8661				BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BOBAK DA, 1990, ADP RIBOSYLATING TOX, P439; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BORNANCIN F, 1993, J BIOL CHEM, V268, P17026; BORNANCIN F, 1991, FEBS LETT, V291, P273, DOI 10.1016/0014-5793(91)81300-W; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LOOMAN AC, 1987, EMBO J, V6, P2489, DOI 10.1002/j.1460-2075.1987.tb02530.x; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PRICE SR, 1992, J BIOL CHEM, V267, P17766; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TSAI SC, 1993, J BIOL CHEM, V268, P10820; TSAI SC, 1991, BIOCHEMISTRY-US, V30, P3697, DOI 10.1021/bi00229a015; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WEISS O, 1989, J BIOL CHEM, V264, P21066; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	30	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24531	24534						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227008				2022-12-25	WOS:A1993MG67300005
J	LEAMON, CP; PASTAN, I; LOW, PS				LEAMON, CP; PASTAN, I; LOW, PS			CYTOTOXICITY OF FOLATE-PSEUDOMONAS EXOTOXIN CONJUGATES TOWARD TUMOR-CELLS - CONTRIBUTION OF TRANSLOCATION DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; GLYCOSYL-PHOSPHATIDYLINOSITOL; RECOMBINANT FORM; RECEPTOR; MEMBRANE; CYTOSOL; TRANSPORT; CLEAVAGE; FRAGMENT; ABRIN	Folate-protein conjugates can be nondestructively delivered into a cell's cytoplasm via folate receptor-mediated endocytosis if (i) the target cells express a folate-binding protein, and (ii) if the folate is linked to its attached protein at a site that does not interfere with receptor recognition. Because such conjugates have been observed to remain in endosomal compartments for extended periods following cellular uptake, we decided to evaluate whether release into the cytoplasm might be expedited by inclusion of a translocation domain in the folate-protein construct. To test this possibility, momordin-folate and truncated Pseudomonas exotoxin-folate conjugates (LysPE38 and CysPE35), i.e. protein synthesis inhibitors either lacking or containing the desired translocation domain, respectively, were examined for their abilities to block protein synthesis in a variety of cell types. The translocation competent LysPE38-folate construct was found to kill cells six times more rapidly with 10-fold greater potency than the permeation-incompetent momordin-folate. Further, cells expressing low levels of folate receptors could only be exterminated by the translocation competent Pseudomonas exotoxin-folate conjugates. When the translocation capability of CysPE35-folate was inactivated by modification of Cys287, the construct also lost most of its cytotoxicity. These data suggest that autocatalysis of transport from an internal vesicular compartment into the cytoplasm can greatly augment the cytotoxicity of a protein toxin entering cells via the folate endocytosis pathway. Because the folate ligand can selectively target a protein conjugate to cancer cells in the presence of normal cells, such translocatable toxin-folate constructs warrant further study as a possible treatment for some malignancies.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA; GLAXO RES INST, DEPT OLIGOMER DEV, RES TRIANGLE PK, NC 27709 USA; NCI, DEPT MOLEC BIOL, BETHESDA, MD 20892 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; GlaxoSmithKline; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; Low, Philip/0000-0001-9042-5528				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BATRA JK, 1989, P NATL ACAD SCI USA, V86, P8545, DOI 10.1073/pnas.86.21.8545; BIRN H, 1993, AM J PHYSIOL, V264, pC302, DOI 10.1152/ajpcell.1993.264.2.C302; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CONEY LR, 1991, CANCER RES, V51, P6125; EIKLID K, 1980, EXP CELL RES, V126, P321, DOI 10.1016/0014-4827(80)90270-0; ELWOOD PC, 1991, J BIOL CHEM, V266, P2346; FAN J, 1992, ADV ENZYME REGUL, V32, P3; HJELLE JT, 1991, AM J PHYSIOL, V260, pC338, DOI 10.1152/ajpcell.1991.260.2.C338; HOLM J, 1991, BIOCHEM J, V280, P267, DOI 10.1042/bj2800267; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; KANE MA, 1989, LAB INVEST, V60, P737; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572; LEAMON CP, 1993, BIOCHEM J, V291, P855, DOI 10.1042/bj2910855; LEAMON CP, 1992, J BIOL CHEM, V267, P24966; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; OGATA M, 1990, J BIOL CHEM, V265, P20678; OGATA M, 1992, J BIOL CHEM, V267, P25396; OLSNES S, 1974, NATURE, V249, P627, DOI 10.1038/249627a0; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SIEGALL CB, 1990, J BIOL CHEM, V265, P16318; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; STIRPE F, 1988, NUCLEIC ACIDS RES, V16, P1349, DOI 10.1093/nar/16.4.1349; THEUER CP, 1992, J BIOL CHEM, V267, P16872; THEUER CP, 1993, CANCER RES, V53, P1; VERMA RS, 1992, J BIOL CHEM, V267, P4119; WEITMAN SD, 1992, CANCER RES, V52, P6708	31	162	200	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24847	24854						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227046				2022-12-25	WOS:A1993MG67300051
J	VANNOCKER, S; VIERSTRA, RD				VANNOCKER, S; VIERSTRA, RD			MULTIUBIQUITIN CHAINS LINKED THROUGH LYSINE-48 ARE ABUNDANT IN-VIVO AND ARE COMPETENT INTERMEDIATES IN THE UBIQUITIN PROTEOLYTIC PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER PROTEIN; ARABIDOPSIS-THALIANA; DEGRADATION; ENZYME; GENE; CONJUGATE; WHEAT; E2	A prerequisite for the selective degradation of intracellular proteins by the ubiquitin-dependent proteolytic pathway is the attachment of a chain of ubiquitin monomers to the targeted protein. In these multiubiquitin chains, the carboxyl-terminal glycine 76 of ubiquitin is linked via an isopeptide bond to the epsilon-amino group of lysine 48 in the adjacent ubiquitin. It remains to be determined whether these chains are preassembled and attached en masse to the target, are made by sequential conjugation of ubiquitin monomers to ubiquitins already linked to the protein, or both. Using the 20-kDa ubiquitin-conjugating enzyme TaUBC7 from wheat, we have generated free, glycine 76-->lysine 48-linked multiubiquitin chains (Ubq(n)), and have individually purified Ubq(n) species (n less-than-or-equal-to 6) by anion-exchange, high pressure liquid chromatography. The migration of these chains during SDS-polyacrylamide gel electrophoresis was indistinguishable from those of major ubiquitin immunoreactive proteins in cell lysates from a variety of eukaryotes suggesting that free, multiubiquitin chains are abundant in vivo. One of these chain members (Ubq2) was purified from wheat and was demonstrated via amino acid sequence analysis of tryptic fragments to consist of two ubiquitin monomers joined via a glycine 76-->lysine 48 linkage. We also show in vitro that purified Ubq2 and Ubq4 are competent in activation by ubiquitin-activating enzyme (E1), in transfer to E2s, and in ubiquitin-protein ligase (E3)-independent conjugation to other Ubq(n) species and to histones H2A/B. These data demonstrate that multiubiquitin chains exist as free, functional structures in vivo and support the possibility that at least a portion of free ubiquitin is preassembled into multiubiquitin chains prior to its attachment to proteolytic substrates.	UNIV WISCONSIN,DEPT HORT,1575 LINDEN DR,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NIGMS NIH HHS [2T32GM07215] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; BAMEZAI S, 1989, BIOCHEM BIOPH RES CO, V162, P89, DOI 10.1016/0006-291X(89)91966-9; BEERS EP, 1992, J BIOL CHEM, V267, P15432; BOND U, 1986, MOL CELL BIOL, V6, P4602, DOI 10.1128/MCB.6.12.4602; BURKE TJ, 1988, MOL GEN GENET, V213, P435, DOI 10.1007/BF00339613; Callis J., 1989, OXFORD SURV PLANT MO, V6, P1; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; COOK WJ, 1992, J BIOL CHEM, V267, P16467; COX MJ, 1986, ANAL BIOCHEM, V154, P345, DOI 10.1016/0003-2697(86)90535-X; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GIROD PA, 1993, J BIOL CHEM, V268, P955; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HADARI T, 1992, J BIOL CHEM, V267, P719; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HTFIELD PM, 1990, J BIOL CHEM, V265, P15813; JABBEN M, 1989, J BIOL CHEM, V264, P4998; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORI S, 1992, J BIOL CHEM, V267, P6429; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SULLIVAN ML, 1989, P NATL ACAD SCI USA, V86, P9861, DOI 10.1073/pnas.86.24.9861; SWERDLOW PS, 1986, ANAL BIOCHEM, V156, P147, DOI 10.1016/0003-2697(86)90166-1; VANNOCKER S, 1991, P NATL ACAD SCI USA, V88, P10297, DOI 10.1073/pnas.88.22.10297; VIERSTRA RD, 1986, BIOCHEMISTRY-US, V25, P3105, DOI 10.1021/bi00359a006; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; VIERSTRA RD, 1985, J BIOL CHEM, V260, P1015	32	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24766	24773						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227036				2022-12-25	WOS:A1993MG67300039
J	DONG, Q; COPELAND, WC; WANG, TSF				DONG, Q; COPELAND, WC; WANG, TSF			MUTATIONAL STUDIES OF HUMAN DNA POLYMERASE-ALPHA - SERINE 867 IN THE 2ND MOST CONSERVED REGION AMONG ALPHA-LIKE DNA-POLYMERASES IS INVOLVED IN PRIMER BINDING AND MISPAIR PRIMER EXTENSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLENOW FRAGMENT; KINETICS; FIDELITY; SITE; MUTAGENESIS; EXPRESSION	The second most conserved region of alpha-like DNA polymerases, region II, spans a block of 40 amino acid residues centered at the core sequence -DFNSLYPSII-. In the previous paper, we described mutational studies of 3 amino acid residues in region II which includes 2 amino acid residues in the core sequence. We showed that residues Asp860 and Tyr865 in the core sequence are involved in substrate deoxynucleotide triphosphate (dNTP) binding. We further showed that the phenyl moiety of the Tyr865 side chain interacts with the incoming dNTP and is responsible for the misinsertion fidelity of the enzyme. In this report, we investigated the function of 2 serine residues, Ser863 and Ser867, in this core sequence. Mutation of these 2 Ser residues to either Ala or Thr yielded mutant enzymes with similar K(m) for dNTPs, k(cat), processivity, and misinsertion fidelity of DNA synthesis as the wild type enzyme. However, mutation of Ser867 to Ala demonstrated a 30-fold increase in K(m) for primer-template and a 5-fold higher K(D) for binding primer-template. DNA footprinting experiments of primer with the dideoxynucleotide terminus indicated that the structural feature of the primer recognized by Ser867 is the 3'-OH terminus. Single-stranded DNA inhibition data suggest that removal of the hydroxyl side chain of Ser867 affects the polymerase's interaction with primer and not with template. Mutation of Ser867 to Ala also decreases the mutant enzyme's K(m) for dNTP to extend a mispaired primer and thus enhances its capacity to extend a mispaired primer terminus. These data support the conclusion that the hydroxyl side chain of Ser867 of human DNA polymerase alpha is involved in primer interaction during DNA synthesis and plays an essential role in mispair extension fidelity of DNA synthesis.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305	Stanford University			Copeland, William/C-4242-2019	Copeland, William/0000-0002-0359-0953	NCI NIH HHS [CA14835] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014835] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DONG Q, 1993, J BIOL CHEM, V268, P24163; GOODMAN MF, 1988, MUTAT RES, V200, P11, DOI 10.1016/0027-5107(88)90067-X; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P8759, DOI 10.1021/bi00100a007; HSI KL, 1990, NUCLEIC ACIDS RES, V18, P6231, DOI 10.1093/nar/18.21.6231; KESTI T, 1993, J BIOL CHEM, V268, P10238; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NG L, 1989, J BIOL CHEM, V264, P13018; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SUMMERS M, 1988, TEX AGR EXP STN B, V1555, P3; TANAKA S, 1982, J BIOL CHEM, V257, P8386; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	23	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24175	24182						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226964				2022-12-25	WOS:A1993MF29400069
J	FURUKAWA, K; TAGAYA, M; TANIZAWA, K; FUKUI, T				FURUKAWA, K; TAGAYA, M; TANIZAWA, K; FUKUI, T			ROLE OF THE CONSERVED LYS-X-GLY-GLY SEQUENCE AT THE ADP-GLUCOSE-BINDING SITE IN ESCHERICHIA-COLI GLYCOGEN-SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE KINASE; ADENOSINE DIPHOSPHOPYRIDOXAL; SKELETAL-MUSCLE; ACTIVE-SITE; PROTEIN; GENE; PHOSPHORYLASE; BACTERIAL; CLONING; ENZYMES	Although bacterial and mammalian glycogen synthases differ in the primary structure and specificity for glucosyl donor, lysyl residues identified at their substrate-binding sites by affinity labeling are present in a conserved tetrapeptide sequence, Lys-X-Gly-Gly, where X is a residue not conserved (Tagaya, M., Nakano, K., and Fukui, T. (1985) J. Biol. Chem. 260, 6670-6676; Furukawa, K., Tagaya, M., Inouye, M., Preiss, J., and Fukui, T. (1990) J. Biol. Chem. 265, 2086-2090). To elucidate the functional role of this conserved sequence, Lys-15, Gly-17, and Gly-18 in Escherichia coli glycogen synthase have been replaced by other amino acid residues via site-directed mutagenesis. Kinetic analyses of the Lys-15 mutant enzymes showed that the epsilon-amino group of Lys-15 is mainly involved in binding of the phosphate moiety adjacent to the glycosidic linkage in the substrate ADP-glucose, presumably through an ionic interaction. The mutant enzyme in which Ala was substituted for Gly-17 had a catalytic rate constant 3 orders of magnitude smaller than that of the wild-type enzyme with a slightly increased Michaelis constant for ADP-glucose, whereas the Gly-18 --> Ala mutant showed a rate constant only 3.2-fold smaller. In addition, mutations of Gly-17 and Gly-18 resulted in marked changes in the reactivity of Lys-15 with affinity labeling reagents. These results suggest that the 2 glycyl residues in the conserved Lys-X-Gly-Gly sequence, in particular the one closer to the ADP-glucose-binding lysyl residue, participate in catalysis by assisting conformational change(s) of the active site or stabilizing the transition state.	OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN	Osaka University			Furukawa, Koji/L-6909-2018	Furukawa, Koji/0000-0002-5701-2497				BAI G, 1990, J BIOL CHEM, V265, P7843; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; Cleland W W, 1979, Methods Enzymol, V63, P103; Cohen P, 1978, Curr Top Cell Regul, V14, P117; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FOX J, 1972, METHOD ENZYMOL, V28, P539; FURUKAWA K, 1990, J BIOL CHEM, V265, P2086; Higuchi R., 1989, PCR TECHNOLOGY, P61; KLOESGEN R B, 1986, Molecular and General Genetics, V203, P237; KUMAR A, 1986, J BIOL CHEM, V261, P6256; MOHRENHOLZ AM, 1988, J BIOL CHEM, V263, P10561; PREISS J, 1969, CURRENT TOPICS CELLU, V1, P125; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; STALMANS W, 1973, ENZYMES, V9, P309; TAGAYA M, 1984, J BIOL CHEM, V259, P4860; TAGAYA M, 1987, J BIOL CHEM, V262, P8257; TAGAYA M, 1985, J BIOL CHEM, V260, P6670; TAGAYA M, 1986, BIOCHEMISTRY-US, V25, P2958, DOI 10.1021/bi00358a034; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YAGAMI T, 1988, FEBS LETT, V229, P261, DOI 10.1016/0014-5793(88)81137-2; YONEYA T, 1989, J BIOCHEM-TOKYO, V105, P158, DOI 10.1093/oxfordjournals.jbchem.a122631; YU F, 1988, J BIOL CHEM, V263, P13706; ZHANG WM, 1989, FASEB J, V3, P2532, DOI 10.1096/fasebj.3.13.2509275	26	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23837	23842						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226921				2022-12-25	WOS:A1993MF29400023
J	HOLLANDER, MC; ALAMO, I; JACKMAN, J; WANG, MG; MCBRIDE, OW; FORNACE, AJ				HOLLANDER, MC; ALAMO, I; JACKMAN, J; WANG, MG; MCBRIDE, OW; FORNACE, AJ			ANALYSIS OF THE MAMMALIAN GADD45 GENE AND ITS RESPONSE TO DNA-DAMAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSITU HYBRIDIZATION; CHROMOSOMAL LOCALIZATION; CELLS; EXPRESSION; DIFFERENTIATION; SEQUENCE; PROTEIN; AGENTS; PROBE; STEP	The gadd45 gene is transcriptionally activated through at least two different mechanisms; one following treatment with base-damaging agents such as methylmethane sulfonate and UV radiation and the other following ionizing radiation. To investigate the sequences involved in induction of gadd45 by agents producing high levels of base damage, the hamster, human, and mouse genes were sequenced. Comparison of these sequences revealed a high level of conservation between species of 1500 base pairs of the proximal promoter and 700 base pairs within the third intron. However, in the promoter regions, there was no conservation between species of any transcription factor binding sites known to confer DNA damage responsiveness. The promoter of the hamster gene was inducible by base-damaging agents in both rodent and human cell lines and the human gene was inducible in a rodent cell line. This indicates that both sequence elements in the gadd45 promoter and factors binding to these sites are conserved in mammalian cells. Deletion analysis of the hamster promoter did not reveal any specific sequence which conferred damage inducibility and the maximal response required a large portion of the promoter. The hamster promoter was not inducible by ionizing radiation, suggesting that sequences outside the promoter region used, such as a p53 binding site in the third intron, are necessary. The human GADD45 gene was mapped to chromosome 1p31.1-31.2.	NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HOLLANDER, MC (corresponding author), NCI, DIV CANC TREATMENT, DEV THERAPEUT PROGRAM, MOLEC PHARMACOL LAB, BETHESDA, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BOHR VA, 1989, LAB INVEST, V61, P143; CALLIS J, 1987, NUCLEIC ACIDS RES, V15, P5823; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; GARSON JA, 1987, CYTOGENET CELL GENET, V45, P10, DOI 10.1159/000132417; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GHOSH D, 1992, NUCLEIC ACIDS RES, V20, P2091, DOI 10.1093/nar/20.suppl.2091; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; LANDEGENT JE, 1985, NATURE, V317, P175, DOI 10.1038/317175a0; LORD KA, 1990, ONCOGENE, V5, P387; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; SHAH G, 1993, CANCER RES, V53, P38; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; YAROSH DB, 1993, J INVEST DERMATOL, V100, P790, DOI 10.1111/1523-1747.ep12476573; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	28	220	231	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24385	24393						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226988				2022-12-25	WOS:A1993MF29400099
J	HUANG, ZX; DOSTAL, L; ROSAZZA, JPN				HUANG, ZX; DOSTAL, L; ROSAZZA, JPN			MECHANISMS OF FERULIC ACID CONVERSIONS TO VANILLIC ACID AND GUAIACOL BY RHODOTORULA-RUBRA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS SPOROTRICHUM-PULVERULENTUM; HYDROXYCINNAMIC ACIDS; STREPTOMYCES-SETONII; HPLC DETERMINATION; ORANGE JUICE; METABOLISM; DECARBOXYLATION; CATABOLISM	Resting cells of Rhodotorula rubra converted trans-ferulic acid (1) to vanillic acid (2), then to guaiacol (3) and protocatechuic acid (4), under aerobic conditions. In an argon atmosphere, R. rubra transformed ferulic acid to vanillic acid and 4-hydroxy-3-methoxystyrene (5). Metabolites were isolated by solid-phase extraction and characterized by mass spectrometry, H-1, and C-13-nuclear magnetic resonance spectroscopy (NMR). The biotransformation of ferulic acid to vanillic acid by R. rubra cell-free extracts required CoA, ATP, and NAD+. Mass spectrometry and C-13-NMR were used to demonstrate the incorporation of oxygen from (H2O)-O-18 during the conversion of ferulic acid to vanillic acid. The results suggest a parallel between this bioconversion reaction and the beta-oxidation of fatty acids. Proton-carbon correlation NMR spectroscopy was used to demonstrate the specific incorporation of deuterium from D2O into guaiacol obtained from vanillic acid. The incorporation of deuterium implicates the involvement of a quinoid vanillic acid tautomer as an intermediate in the decarboxylation reaction.	UNIV IOWA,COLL PHARM,DIV MED & NAT PROD CHEM,IOWA CITY,IA 52242; UNIV IOWA,COLL PHARM,CTR BIOCATALYSIS & BIOPROC,IOWA CITY,IA 52242	University of Iowa; University of Iowa								ANDER P, 1988, CELL CHEM TECHNOL, V22, P255; ANDER P, 1980, ARCH MICROBIOL, V125, P189, DOI 10.1007/BF00446876; ANDREONI V, 1984, SYST APPL MICROBIOL, V5, P299, DOI 10.1016/S0723-2020(84)80032-6; ARFMANN HA, 1989, Z NATURFORSCH C, V44, P765; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BETTS RE, 1974, J MED CHEM, V17, P599, DOI 10.1021/jm00252a006; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSWELL JA, 1982, ARCH MICROBIOL, V131, P366, DOI 10.1007/BF00411188; BUSWELL JA, 1979, FEBS LETT, V104, P258, DOI 10.1016/0014-5793(79)80827-3; BUSWELL JA, 1981, J CHROMATOGR, V215, P99, DOI 10.1016/S0021-9673(00)81390-4; BUSWELL JA, 1979, FEBS LETT, V103, P98, DOI 10.1016/0014-5793(79)81258-2; CRAWFORD RL, 1978, APPL ENVIRON MICROB, V36, P539, DOI 10.1128/AEM.36.4.539-543.1978; FINKLE BJ, 1962, J BIOL CHEM, V237, P2926; FRENCH CJ, 1976, PHYTOCHEMISTRY, V15, P564, DOI 10.1016/S0031-9422(00)88979-7; GRBICGALIC D, 1985, APPL ENVIRON MICROB, V50, P1052; GURUJEYALAKSHMI G, 1987, CURR MICROBIOL, V16, P69, DOI 10.1007/BF01588174; HUANG ZX, 1993, APPL ENVIRON MICROB, V59, P2244, DOI 10.1128/AEM.59.7.2244-2250.1993; JONES CA, 1992, J ANTIBIOT, V45, P1492, DOI 10.7164/antibiotics.45.1492; KIRK TK, 1973, APPL MICROBIOL, V26, P173, DOI 10.1128/AEM.26.2.173-175.1973; NALI M, 1985, EXPERIENTIA, V41, P1351, DOI 10.1007/BF01952091; NAZARETH S, 1986, CAN J MICROBIOL, V32, P494, DOI 10.1139/m86-090; POMETTO AL, 1981, CAN J MICROBIOL, V27, P636, DOI 10.1139/m81-097; RAHOUTI M, 1989, APPL ENVIRON MICROB, V55, P2391, DOI 10.1128/AEM.55.9.2391-2398.1989; ROUSEFF RL, 1992, J CHROMATOGR SCI, V30, P383, DOI 10.1093/chromsci/30.10.383; ROUSEFF RL, 1992, J AGR FOOD CHEM, V40, P1139, DOI 10.1021/jf00019a010; SAMEJIMA M, 1987, MOKUZAI GAKKAISHI, V33, P728; SUTHERLAND JB, 1983, CAN J MICROBIOL, V29, P1253, DOI 10.1139/m83-195; TOMS A, 1970, BIOCHEMISTRY-US, V9, P337, DOI 10.1021/bi00804a021	28	96	103	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23954	23958						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226936				2022-12-25	WOS:A1993MF29400039
J	LEE, S; WOLFRAIM, LA; WANG, E				LEE, S; WOLFRAIM, LA; WANG, E			DIFFERENTIAL EXPRESSION OF S1 AND ELONGATION FACTOR-1-ALPHA DURING RAT DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; FACTOR EF-1-ALPHA; XENOPUS-LAEVIS; 2 GENES; NUCLEOTIDE-SEQUENCE; 1-ALPHA EF-1-ALPHA; PROTEIN-SYNTHESIS; CHROMOSOMAL GENE; BINDING PROTEIN; 3 GENES	Elongation factor-1alpha (EF-1alpha) is a highly conserved protein functioning in peptide elongation during translation. A cDNA, S1, was isolated; its deduced amino acid sequence shares high similarity with mammalian EF-1alphas (92%). While EF-1alpha is present in all tissues, S1 mRNA can only be detected in brain, heart, and muscle. We report here that the retropseudogene phenomenon is attributable to EF-1alpha and not S1, the latter being represented by a single copy in the rat genome. The S1 steady-state mRNA levels are consistently higher than EF-1alpha in S1-positive tissues. S1 mRNA can only be detected late during brain, heart, and muscle development in vivo and increases to a plateau in early postnatal life. In a cultured muscle system, S1 expression is dependent upon the formation of myotubes, although the accumulation of S1 mRNA is significantly lower than that observed in adult skeletal muscle. EF-1alpha mRNA levels are down-regulated during brain, heart, and muscle development, but stay relatively steady in liver. We show here that EF-1alpha and S1 are differentially expressed during rat development and that the activation of S1 gene expression is subsequent to the terminal differentiation process in brain, heart, and muscle.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,BLOOMFIELD CTR RES AGING,MONTREAL H3T 1E2,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3T 1E2,PQ,CANADA	Lady Davis Institute; McGill University; McGill University					NIA NIH HHS [AG07444] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007444, R37AG007444] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABDALLAH B, 1991, P NATL ACAD SCI USA, V88, P9277, DOI 10.1073/pnas.88.20.9277; ANN DK, 1992, J BIOL CHEM, V267, P699; ANN DK, 1991, J BIOL CHEM, V266, P10429; BEC G, 1989, J BIOL CHEM, V264, P21131; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; CAVALLIUS J, 1992, NUCLEIC ACIDS RES, V20, P1422, DOI 10.1093/nar/20.6.1422; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVER TE, 1989, J BIOL CHEM, V264, P20518; DEVLIN BH, 1983, DEV BIOL, V95, P175, DOI 10.1016/0012-1606(83)90016-7; DJE MK, 1990, NUCLEIC ACIDS RES, V18, P3489, DOI 10.1093/nar/18.12.3489; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FRYDENBERG J, 1991, GENE, V109, P185, DOI 10.1016/0378-1119(91)90608-E; GILMAN M, 1993, CURRENT PROTOCOLS MO, P471; GRANT AG, 1992, INT J CANCER, V50, P740, DOI 10.1002/ijc.2910500513; GREENBERG JR, 1987, FEBS LETT, V224, P54, DOI 10.1016/0014-5793(87)80421-0; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; HAYASHI Y, 1989, J BIOCHEM-TOKYO, V106, P560, DOI 10.1093/oxfordjournals.jbchem.a122895; HERSHEY JWB, 1990, ENZYME, V44, P17, DOI 10.1159/000468744; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVEMANN B, 1988, NUCLEIC ACIDS RES, V16, P3175, DOI 10.1093/nar/16.8.3175; KOCH I, 1990, ONCOGENE, V5, P839; KREIG PA, 1989, DEV BIOL, V133, P93; LEE S, 1992, J BIOL CHEM, V267, P24064; LEE S, 1993, J HISTOCHEM CYTOCHEM, V41, P1093, DOI 10.1177/41.7.8515051; LEMISCHKA I, 1982, NATURE, V300, P330, DOI 10.1038/300330a0; LENSTRA JA, 1986, EUR J BIOCHEM, V155, P475, DOI 10.1111/j.1432-1033.1986.tb09514.x; LINZ JE, 1987, MOL CELL BIOL, V7, P1925, DOI 10.1128/MCB.7.5.1925; MADSEN HO, 1990, NUCLEIC ACIDS RES, V18, P1513, DOI 10.1093/nar/18.6.1513; MERRICK WC, 1990, ENZYME, V44, P7, DOI 10.1159/000468743; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MINTY A, 1986, MOL CELL BIOL, V6, P2137, DOI 10.1128/MCB.6.6.2137; MORALES J, 1991, BIOCHIMIE, V73, P1249, DOI 10.1016/0300-9084(91)90011-O; MOTORIN YA, 1988, FEBS LETT, V238, P262, DOI 10.1016/0014-5793(88)80492-7; NAGATA S, 1984, EMBO J, V3, P1825, DOI 10.1002/j.1460-2075.1984.tb02053.x; OHTA K, 1990, J BIOL CHEM, V265, P3240; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; RYAZANOV AG, 1991, FEBS LETT, V285, P170, DOI 10.1016/0014-5793(91)80798-8; Sambrook J, 1989, MOL CLONING LABORATO; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; SASSOON DA, 1989, NATURE, V342, P303; SCHIRMAIER F, 1984, EMBO J, V3, P3311, DOI 10.1002/j.1460-2075.1984.tb02295.x; SHIRASAWA T, 1992, NUCLEIC ACIDS RES, V20, P909, DOI 10.1093/nar/20.4.909; SUNDSTROM P, 1990, J BACTERIOL, V172, P2036, DOI 10.1128/jb.172.4.2036-2045.1990; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	51	69	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24453	24459						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226996				2022-12-25	WOS:A1993MF29400109
J	POITRAS, M; BERNIER, S; SERVANT, M; RICHARD, DE; BOULAY, G; GUILLEMETTE, G				POITRAS, M; BERNIER, S; SERVANT, M; RICHARD, DE; BOULAY, G; GUILLEMETTE, G			THE HIGH-AFFINITY STATE OF INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR IS A FUNCTIONAL-STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-CORTEX; TRISPHOSPHATE RECEPTOR; CALCIUM RELEASE; ACINAR-CELLS; SMOOTH-MUSCLE; CA2+ RELEASE; HAMSTER EGGS; THIMEROSAL; BINDING; OSCILLATIONS	Inositol 1,4,5-trisphosphate (InsP3) is a second messenger responsible for the rapid and discontinuous release of Ca2+ from intracellular stores. In this study, the effects of the sulfhydryl reagent thimerosal were investigated on Ca2+ mobilization and on InsP3 binding. Thimerosal was shown to release Ca2+, in a dose-dependent manner, with an EC50 of 135.8 +/- 5.2 muM, from bovine adrenal cortex microsomes. Thimerosal-induced Ca2+ release was not prevented by heparin (250 mug/ml), ruling out a participation of InsP3 receptor in that effect. The slow rate of thimerosal-induced Ca2+ release rather suggested an inhibition of microsomal Ca2+ ATPase. At submaximal concentration, thimerosal (100 muM) was also shown to potentiate the release of Ca2+ induced by InsP3. Dose-response experiments revealed that thimerosal enhanced the apparent affinity of InsP3 by a factor 2.21 +/- 0.28, without modifying the maximal amount of Ca2+ released by InsP3. Thimerosal also enhanced, in a dose-dependent manner, [H-3]InsP3 binding to adrenal cortex microsomes (EC50 = 43.3 +/- 7.6 muM). A similar effect was also observed on [H-3]InsP3 binding to solubilized receptors, suggesting a direct modification of the receptor protein by thimerosal. The effects of thimerosal on Ca2+ release and [H-3]InsP3 binding were abolished in the presence of the reducing agent dithiothreitol (1 mM), suggesting a modification by thimerosal of specific thiol groups on these microsomal proteins. Scatchard analysis revealed that thimerosal (100 muM) increased InsP3 receptor affinity by 1.87 +/- 0.26-fold. Kinetic analysis indicated that this increased affinity was due to an enhancement of InsP3 association rate constant. The concomitant increases of binding affinity and Ca2+ releasing potency suggest that the high affinity state of InsP3 receptor is a functional state.	UNIV SHERBROOKE,FAC MED,DEPT PHARMACOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA	University of Sherbrooke			Boulay, Guylain/D-9773-2010; Richard, Darren E./K-6760-2019	Richard, Darren/0000-0003-2690-0480				ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1992, J BIOL CHEM, V267, P17722; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GUILLEMETTE G, 1988, MOL ENDOCRINOL, V2, P1249, DOI 10.1210/mend-2-12-1249; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; GUILLEMETTE G, 1987, J BIOL CHEM, V262, P1010; GUILLEMETTE G, 1989, MOL PHARMACOL, V35, P339; GUILLEMETTE G, 1987, P NATL ACAD SCI USA, V84, P8195, DOI 10.1073/pnas.84.23.8195; HATZELMANN A, 1990, BIOCHEM PHARMACOL, V39, P559, DOI 10.1016/0006-2952(90)90064-R; HECKER M, 1989, BIOCHEM BIOPH RES CO, V159, P961, DOI 10.1016/0006-291X(89)92202-X; MAUGER JP, 1989, J BIOL CHEM, V264, P8821; MAYRLEITNER M, 1991, CELL CALCIUM, V12, P505, DOI 10.1016/0143-4160(91)90032-A; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; MOUILLAC B, 1992, EUR J PHARM-MOLEC PH, V225, P179, DOI 10.1016/0922-4106(92)90019-R; MUALLEM S, 1989, J BIOL CHEM, V264, P205; PARYS JB, 1992, J BIOL CHEM, V267, P18776; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RIBEIRODOVALLE RM, 1993, IN PRESS CELL CALCIU; SAYERS LG, 1993, BIOCHEM J, V289, P883, DOI 10.1042/bj2890883; SPAT A, 1986, BIOCHEM J, V233, P929; SPAT A, 1986, NATURE, V319, P514, DOI 10.1038/319514a0; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	40	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24078	24082						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226953				2022-12-25	WOS:A1993MF29400057
J	RISINGER, C; BLOMQVIST, AG; LUNDELL, I; LAMBERTSSON, A; NASSEL, D; PIERIBONE, VA; BRODIN, L; LARHAMMAR, D				RISINGER, C; BLOMQVIST, AG; LUNDELL, I; LAMBERTSSON, A; NASSEL, D; PIERIBONE, VA; BRODIN, L; LARHAMMAR, D			EVOLUTIONARY CONSERVATION OF SYNAPTOSOME-ASSOCIATED PROTEIN-25-KDA (SNAP-25) SHOWN BY DROSOPHILA AND TORPEDO CDNA CLONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL EXPRESSION; SYNAPTIC VESICLES; MEMBRANE-PROTEIN; NEUROPEPTIDE-Y; MESSENGER-RNAS; RAT-BRAIN; TRANSPORT; ORGANIZATION; POLYPEPTIDE; TERMINALS	The neuron-specific proteins SNAP-25 (synaptosome-associated protein 25 kDa), synaptobrevin and syntaxin, are localized to presynaptic terminals in mammals and have been found to associate with proteins involved in vesicle docking and membrane fusion. We describe here SNAP-25 cDNA clones from the fruit fly Drosophila melanogaster and the ray Torpedo marmorata. In situ hybridization showed that SNAP-25 mRNA is exclusively found in brain and ganglia in Drosophila with a pattern suggesting expression in most neurons. The Drosophila and Torpedo proteins show 61 and 81% amino acid identity to mouse SNAP-25, a degree of conservation similar to that previously reported for synaptobrevin. None of the SNAP-25 sequences has a membrane-spanning region, but all contain a cluster of cysteine residues that can be palmitoylated for membrane attachment. SNAP-25 displays sequence similarity to syntaxin A and B. These data show that SNAP-25 and synaptobrevin, which are both implicated in vesicle docking and/or membrane fusion, have both been highly conserved during evolution. This supports the existence of a basic molecular machinery for synaptic vesicle docking in vertebrate and invertebrate synapses.	UNIV UPPSALA,DEPT MED GENET,BOX 589,S-75123 UPPSALA,SWEDEN; UNIV OSLO,DEPT GENET,N-0315 OSLO,NORWAY; UNIV STOCKHOLM,DEPT ZOOL,S-10691 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT HISTOL & NEUROBIOL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,NOBEL INST NEUROPHYSIOL,S-10401 STOCKHOLM 60,SWEDEN	Uppsala University; University of Oslo; Stockholm University; Karolinska Institutet; Karolinska Institutet				Pieribone, Vincent/0000-0002-5836-5454				BARK IC, 1993, IN PRESS J MOL BIOL, V232; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BIRMAN S, 1990, FEBS LETT, V261, P303, DOI 10.1016/0014-5793(90)80577-6; BLOMQVIST AG, 1992, P NATL ACAD SCI USA, V89, P2350, DOI 10.1073/pnas.89.6.2350; BRANKS PL, 1986, MOL BRAIN RES, V1, P1, DOI 10.1016/0169-328X(86)90015-X; CATSICAS S, 1991, P NATL ACAD SCI USA, V88, P785, DOI 10.1073/pnas.88.3.785; CATSICAS S, 1992, J NEUROSCI RES, V33, P1, DOI 10.1002/jnr.490330102; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HESS DT, 1992, J NEUROSCI, V12, P4634; JAKOBSEN KS, 1990, NUCLEIC ACIDS RES, V18, P3669, DOI 10.1093/nar/18.12.3669; LOEWY A, 1991, J NEUROSCI, V11, P3412; Nei M., 1987, MOL EVOLUTIONARY GEN; OCONNOR M, 1988, EMBO J, V7, P534; OYLER GA, 1991, P NATL ACAD SCI USA, V88, P5247, DOI 10.1073/pnas.88.12.5247; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; OYLER GA, 1992, DEV BRAIN RES, V65, P133, DOI 10.1016/0165-3806(92)90172-S; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; PERIN MS, 1991, J BIOL CHEM, V266, P615; PIERIBONE VA, 1992, J NEUROSCI, V12, P3361; RISINGER C, 1993, IN PRESS P NATL ACAD; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; WARREN G, 1993, NATURE, V362, P297, DOI 10.1038/362297a0; WILLARD M, 1974, P NATL ACAD SCI USA, V71, P2183, DOI 10.1073/pnas.71.6.2183	30	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24408	24414						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226991				2022-12-25	WOS:A1993MF29400102
J	SCHIAVO, G; ROSSETTO, O; CATSICAS, S; DELAURETO, PP; DASGUPTA, BR; BENFENATI, F; MONTECUCCO, C				SCHIAVO, G; ROSSETTO, O; CATSICAS, S; DELAURETO, PP; DASGUPTA, BR; BENFENATI, F; MONTECUCCO, C			IDENTIFICATION OF THE NERVE-TERMINAL TARGETS OF BOTULINUM NEUROTOXIN SEROTYPE-A, SEROTYPE-D, AND SEROTYPE-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SYNAPTOSOMAL-ASSOCIATED PROTEIN; MEMBRANE-PROTEIN; NEUROTRANSMITTER RELEASE; SYNAPTIC VESICLES; TETANUS TOXIN; ZINC; TRANSPORT; SNAP-25; FUSION; GENES	Botulinum neurotoxins are metalloproteins with one zinc atom bound to the zinc binding motif of zinc endopeptidases. Here we show that botulinum neurotoxin serotypes A, D, and E are zinc endoproteases specific for components of the synaptic vesicle docking and fusion complex. Serotypes A and E cleave SNAP-25, a 25-kDa protein of the synaptic terminal, while serotype D is specific for VAMP/synaptobrevin, a membrane protein of synaptic vesicles. Both rat brain VAMP isoforms are cleaved at a single Lys-Leu peptide bond. The proteolytic activity of these neurotoxins is inhibited by EDTA and captopril.	UNIV PADUA,DIPARTIMENTO SCI BIOMED,I-35121 PADUA,ITALY; UNIV PADUA,CRIBI,I-35121 PADUA,ITALY; GLAXO INST MOLEC BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND; UNIV WISCONSIN,FOOD RES INST,MADISON,WI 53706; UNIV MODENA,IST FISIOL UMANA,I-41100 MODENA,ITALY	University of Padua; University of Padua; GlaxoSmithKline; University of Wisconsin System; University of Wisconsin Madison; Universita di Modena e Reggio Emilia	SCHIAVO, G (corresponding author), UNIV PADUA,CTR BIOMEMBRANE,CNR,VIA TRIESTE 75,I-35121 PADUA,ITALY.		rossetto, ornella/AAC-3866-2022	rossetto, ornella/0000-0002-6113-3857; Schiavo, Giampietro/0000-0002-4319-8745	NINDS NIH HHS [NS17742] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017742] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BINZ T, 1990, NUCLEIC ACIDS RES, V18, P5556, DOI 10.1093/nar/18.18.5556; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GANSEL M, 1987, PFLUG ARCH EUR J PHY, V409, P533, DOI 10.1007/BF00583812; HESS DT, 1992, J NEUROSCI, V12, P4634; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JANKOVIC J, 1991, NEW ENGL J MED, V324, P1186, DOI 10.1056/nejm199104253241707; KOCHWESER J, 1982, NEW ENGL J MED, V306, P214; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MCMAHON HT, 1992, J BIOL CHEM, V267, P21338; MOLGO J, 1990, J PHYSIOLOGY PARIS, V84, P152; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; POULAIN B, 1993, J NEUROCHEM, V61, P1175, DOI 10.1111/j.1471-4159.1993.tb03640.x; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, EMBO J, V11, P3577, DOI 10.1002/j.1460-2075.1992.tb05441.x; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; Schiavo G, 1993, Trends Microbiol, V1, P170, DOI 10.1016/0966-842X(93)90086-7; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; Smith L. D. S., 1988, BOTULISM ORGANISM IT; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; [No title captured]	31	372	403	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23784	23787						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226912				2022-12-25	WOS:A1993MF29400014
J	SHWORAK, NW; OCONNOR, T; WONG, NCW; GEDAMU, L				SHWORAK, NW; OCONNOR, T; WONG, NCW; GEDAMU, L			DISTINCT TATA MOTIFS REGULATE DIFFERENTIAL EXPRESSION OF HUMAN METALLOTHIONEIN-I GENES MT-I(F) AND MT-I(G)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; BINDING PROTEINS; MAMMALIAN-CELLS; HEAVY-METALS; ALBUMIN GENE; DNA; TRANSCRIPTION; PROMOTER; GLUCOCORTICOIDS; MUTAGENESIS	In this report, we have measured the cadmium (Cd2+)-induced expression of all known metallothionein I (MT-I) mRNAs in a human hepatoma cell line, Hep G2. Among the human MT-I gene family promoters, marked sequence conservation exists; despite this, the mRNA accumulation level for each species was found to be quite unique. This differential Cd2+ induction of MT-I family members provides an ideal opportunity to assess whether the characteristic response results from subtle isoform-specific variations in promoter structure. Accordingly, we have examined the mechanism for differential expression of two isoforms, MT-I(G) and MT-I(F), by transient transfection into Hep G2 cells. In the presence of Cd2+, MT-I(G) promoter activity and endogenous mRNA level were, respectively, 4.7- and 3-fold greater than those of MT-I(F). This close correlation between promoter activity and mRNA accumulation strongly suggests that differential expression occurs at the level of transcription. The difference in Cd2+-stimulated activity was found to be conferred by 240- and 243-base pair promoter fragments spanning nucleotides -174 to +66 and -172 to +71 of the MT-I(G) and MT-I(F) genes, respectively. One of the most striking nonhomologies between the promoters is a single A (TATAAA) to C (TATCAA) transversion in the TATA motifs of MT-I(G) and MT-I(F) genes, respectively. To determine whether such a subtle change in the TATA motif could account for the marked differences in promoter function, we constructed MT-I(G)-TATCA and MT-I(F)-TATAA promoters and measured their activities in transient transfection and cell-free transcription assays. Results of both assays showed a profound difference between the two motifs that paralleled the difference in Cd2+-stimulated MT-I(G) and MT-I(F) mRNA levels. In summary, we have shown that differential regulation of two MT-I promoters is primarily due to a single base alteration in their TATA motifs.	UNIV CALGARY,DEPT BIOL SCI,2500 UNIV DR NW,CALGARY T2N 1N4,ALBERTA,CANADA; UNIV CALGARY,DEPT MED,CALGARY T2N 1N4,ALBERTA,CANADA; UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 1N4,ALBERTA,CANADA	University of Calgary; University of Calgary; University of Calgary			Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FALASCHI A, 1963, J BIOL CHEM, V238, P3080; Favaloro J, 1980, Methods Enzymol, V65, P718; FOSTER R, 1988, J BIOL CHEM, V263, P11528; GARRITY PA, 1990, MOL CELL BIOL, V10, P5646, DOI 10.1128/MCB.10.11.5646; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAGER LJ, 1981, NATURE, V291, P340, DOI 10.1038/291340a0; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HEGUY A, 1986, MOL CELL BIOL, V6, P2149, DOI 10.1128/MCB.6.6.2149; JAHROUDI N, 1988, THESIS U CALGARY CAL; Kagi J.H.R., 1979, METALLOTHIONEIN; KAMBADUR R, 1990, P NATL ACAD SCI USA, V87, P9168, DOI 10.1073/pnas.87.23.9168; KARIN M, 1984, CELL, V36, P371, DOI 10.1016/0092-8674(84)90230-7; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P5494, DOI 10.1073/pnas.81.17.5494; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MCDONNELL RE, 1987, PLANT MOL BIOL REP, V5, P380; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; PETERSON MG, 1988, EUR J BIOCHEM, V174, P417, DOI 10.1111/j.1432-1033.1988.tb14114.x; PETERSON MG, 1988, EUR J BIOCHEM, V174, P425, DOI 10.1111/j.1432-1033.1988.tb14115.x; RICHARDS RI, 1984, CELL, V37, P263, DOI 10.1016/0092-8674(84)90322-2; SADHU C, 1989, MOL CELL BIOL, V9, P5738, DOI 10.1128/MCB.9.12.5738; SADHU C, 1988, J BIOL CHEM, V263, P2679; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHMIDT CJ, 1984, SCIENCE, V224, P1104, DOI 10.1126/science.6719135; SCHMIDT CJ, 1986, P NATL ACAD SCI USA, V83, P3346, DOI 10.1073/pnas.83.10.3346; SCHMIDT CJ, 1985, J BIOL CHEM, V260, P7731; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; VARSHNEY U, 1986, MOL CELL BIOL, V6, P26, DOI 10.1128/MCB.6.1.26; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WILLIAMS JG, 1985, NUCLEIC ACID HYBRIDI, P139; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	44	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24460	24466						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226997				2022-12-25	WOS:A1993MF29400110
J	SAKATA, N; WU, XJ; DIXON, JL; GINSBERG, HN				SAKATA, N; WU, XJ; DIXON, JL; GINSBERG, HN			PROTEOLYSIS AND LIPID-FACILITATED TRANSLOCATION ARE DISTINCT BUT COMPETITIVE PROCESSES THAT REGULATE SECRETION OF APOLIPOPROTEIN-B IN HEP-G2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MESSENGER-RNA LEVELS; LOW-DENSITY LIPOPROTEINS; ENDOPLASMIC-RETICULUM; G2 CELLS; APO-B; HEPG2 CELLS; INTRACELLULAR DEGRADATION; COMBINED HYPERLIPIDEMIA; RABBIT LIVER; OLEIC-ACID	Under lipid-poor conditions, most newly synthesized apolipoprotein B100 (apoB) undergoes rapid degradation in Hep G2 cells such that only a small fraction of newly synthesized apoB is actually secreted. Addition of oleate to Hep G2 culture medium stimulates apoB secretion by a post-translational mechanism. In the current studies we have explored oleate-stimulation of apoB secretion by using calpain inhibitor I, N-acetyl-leucyl-leucyl-norleucinal (ALLN), a compound that inhibits the intracellular degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and the T cell receptor alpha subunit. Preincubation of Hep G2 cells with ALLN (40 mug/ml) for 1 h markedly inhibited degradation of newly synthesized apoB. Whereas only 32% of newly labeled apoB remained intact (cells + medium) in control cells after a 10-min pulse with [H-3]leucine followed by a 60-min chase, 84% of labeled apoB was intact in ALLN-treated cells. However, most of the ALLN-protected apoB remained intracellular, as ALLN did not stimulate the rate of apoB secretion over the control rate (12 versus 9.2%). Although secretion of apoB was not accelerated, the protection afforded by ALLN continued for several hours, and labeled apoB continued to be secreted over 3 h of chase after which secretion ceased. The protection afforded by ALLN resulted in 37% of labeled apoB secreted by 3 h compared to 15% in control cells. In contrast, simultaneous treatment of cells with ALLN and oleate both accelerated and increased total apoB secretion, such that 36% of initially labeled apoB was recovered in the medium by 60 min and 71% of labeled apoB was secreted by 180 min of chase. These data show that ALLN and oleate affect apoB metabolism by different mechanisms. Although ALLN can protect nascent apoB from rapid early intracellular degradation, it does not accelerate apoB secretion. In contrast, although our results can not rule out the possibility that oleate may directly inhibit proteolysis of apoB, oleate appears to protect apoB mainly by facilitating transport of apoB out of a protease-containing compartment associated with the endoplasmic reticulum.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,630 W 168TH ST,NEW YORK,NY 10032; UNIV MISSOURI,DEPT FOOD SCI & HUMAN NUTR,COLUMBIA,MO 65211	Columbia University; University of Missouri System; University of Missouri Columbia			Sakata, Nobuhiro/ACN-9770-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047586, R01HL036000, R01HL047586, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-21006, HL-36000, HL-47586] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBERGER MJ, 1988, J BIOL CHEM, V263, P11868; ARAD Y, 1990, J LIPID RES, V31, P567; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; DASHTI N, 1989, J LIPID RES, V30, P1365; DASHTI N, 1992, J BIOL CHEM, V267, P7160; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON J L, 1989, Journal of Cell Biology, V109, p148A; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; HENNESSY LK, 1992, J LIPID RES, V33, P351; INOUE S, 1992, J BIOL CHEM, V267, P9080; JANUS ED, 1980, EUR J CLIN INVEST, V10, P161, DOI 10.1111/j.1365-2362.1980.tb02076.x; KISSEBAH AH, 1981, METABOLISM, V30, P856, DOI 10.1016/0026-0495(81)90064-0; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KROON PA, 1986, P NATL ACAD SCI USA, V83, P5071, DOI 10.1073/pnas.83.14.5071; KUSHWAHA RS, 1991, J LIPID RES, V32, P1929; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SATO R, 1990, J BIOL CHEM, V265, P11880; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; TAM SP, 1991, ATHEROSCLEROSIS, V91, P51, DOI 10.1016/0021-9150(91)90186-7; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; THERIAULT A, 1992, BIOCHEM BIOPH RES CO, V186, P617, DOI 10.1016/0006-291X(92)90791-I; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WILKINSON J, 1992, BIOCHEM J, V288, P413, DOI 10.1042/bj2880413; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0	39	130	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22967	22970						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226809				2022-12-25	WOS:A1993MF51500004
J	WELLING, PA; CAPLAN, M; SUTTERS, M; GIEBISCH, G				WELLING, PA; CAPLAN, M; SUTTERS, M; GIEBISCH, G			ALDOSTERONE-MEDIATED NA/K-ATPASE EXPRESSION IS ALPHA-1 ISOFORM-SPECIFIC IN THE RENAL CORTICAL COLLECTING DUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; RAT NA,K-ATPASE ALPHA-1; CULTURED KIDNEY-CELLS; BASOLATERAL MEMBRANE; TRANSPORT-PROPERTIES; SODIUM-TRANSPORT; MESSENGER-RNAS; TUBULES; SUBUNIT; PUMP	In the renal cortical collecting duct (CCD), mineral-ocorticoid hormones, like aldosterone, augment the abundance of Na/K-ATPase molecules. It has been postulated that this response involves an isoform switch of the Na/K-ATPase catalytic subunit, alpha, as the molecular basis for the differential regulation of mineralocorticoid-induced and constitutively expressed Na/K-ATPase pools. In opposition to this attractive hypothesis, three lines of independent evidence are presented which demonstrate that the CCD exclusively expresses the alpha1 form despite mineralocorticoid-mediated changes in functional Na/K pump density. First, aldosterone increased [H-3]ouabain binding in CCD 2.5-fold without changing the ouabain dissociation constant. Second, an electrophysiological assay for pump activity revealed that aldosterone increased maximum Na/K pump current in parallel with the change in ouabain binding without altering the apparent sodium affinity. Third, Western blot analysis with alpha isoform-specific, antipeptide antibodies demonstrated that aldosterone exclusively increased the total chemical pool of the alpha1 form of the pump without inducing other alpha subunit isoforms. In summary, aldosterone increases the abundance of Na/K-ATPase molecules in the CCD which are pharmacologically, physiologically, and chemically indistinguishable from those that are normally expressed.	YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, NEW HAVEN, CT 06510 USA	Yale University				Caplan, Michael/0000-0001-5768-4405	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 17433-18] Funding Source: Medline; PHS HHS [5T320K07259] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARYSTARKHOVA EA, 1989, FEBS LETT, V250, P545, DOI 10.1016/0014-5793(89)80793-8; ASKARI A, 1988, J BIOL CHEM, V263, P235; BARLETBAS C, 1990, J BIOL CHEM, V265, P7799; BARLETBAS C, 1988, P NATL ACAD SCI USA, V85, P1707, DOI 10.1073/pnas.85.5.1707; BARLETBAS CL, 1990, AM J PHYSIOL, V259, pF111; BLOTCHABAUD M, 1990, J BIOL CHEM, V265, P11676; BRODSKY JL, 1990, AM J PHYSIOL, V258, pC803, DOI 10.1152/ajpcell.1990.258.5.C803; BRODSKY JL, 1990, AM J PHYSIOL, V258, pC812, DOI 10.1152/ajpcell.1990.258.5.C812; CAPLAN MJ, 1990, J BIOL CHEM, V265, P3528; CHARLES PGP, 1992, RENAL PHYSIOL BIOCH, V15, P10; CHARLES PGP, 1972, RENAL PHYSL BIOCH, V15, P10; DOUCET A, 1986, J BIOL CHEM, V261, P990; ELMERNISSI G, 1984, AM J PHYSIOL, V247, pF158, DOI 10.1152/ajprenal.1984.247.1.F158; EMANUEL JR, 1988, J BIOL CHEM, V263, P7726; EMANUEL JR, 1989, MOL CELL BIOL, V9, P3744, DOI 10.1128/MCB.9.9.3744; FEIGE G, 1986, PROGR CLIN BIOL RES, P377; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GEERING K, 1982, J BIOL CHEM, V257, P338; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; HAMM DR, 1983, J GEN PHYSIOL, V82, P315; HARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P102, DOI 10.1016/0006-291X(89)92104-9; HELMAN SI, 1971, AM J PHYSIOL, V220, P1825, DOI 10.1152/ajplegacy.1971.220.6.1825; HENSLEY CB, 1992, AM J PHYSIOL, V262, pC484, DOI 10.1152/ajpcell.1992.262.2.C484; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KARLISH SJD, 1985, J PHYSIOL-LONDON, V359, P119, DOI 10.1113/jphysiol.1985.sp015578; KIRK KL, 1980, NATURE, V287, P237, DOI 10.1038/287237a0; KOEPPEN BM, 1983, AM J PHYSIOL, V244, pF35, DOI 10.1152/ajprenal.1983.244.1.F35; KOEPPEN BM, 1985, REGULATION DEV MEMBR, P89; KONE BC, 1990, SODIUM PUMP RECENT D, P265; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; LEWIS SA, 1983, J PHYSIOL-LONDON, V341, P169, DOI 10.1113/jphysiol.1983.sp014799; LEWIS SA, 1978, J MEMBRANE BIOL, V41, P117, DOI 10.1007/BF01972629; LYTTON J, 1985, J BIOL CHEM, V260, P75; MCGILL DL, 1991, J BIOL CHEM, V266, P15824; MUJAIS SK, 1985, J CLIN INVEST, V76, P170, DOI 10.1172/JCI111942; ONEIL RG, 1984, AM J PHYSIOL, V247, pC314, DOI 10.1152/ajpcell.1984.247.5.C314; ONEIL RG, 1984, AM J PHYSIOL, V247, pF14, DOI 10.1152/ajprenal.1984.247.1.F14; ONEIL RG, 1984, J MEMBRANE BIOL, V82, P281, DOI 10.1007/BF01871637; ONEIL RG, 1985, J MEMBRANE BIOL, V85, P169, DOI 10.1007/BF01871269; PACCOLAT MP, 1987, AM J PHYSIOL, V252, pC468, DOI 10.1152/ajpcell.1987.252.5.C468; PETTY KJ, 1981, J CLIN INVEST, V68, P1514, DOI 10.1172/JCI110405; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; ROSSIER BC, 1991, COLLOQ INSE, V215, P123; SANSOM S, 1987, AM J PHYSIOL, V253, pF753, DOI 10.1152/ajprenal.1987.253.4.F753; SANSOM SC, 1985, AM J PHYSIOL, V248, pF858, DOI 10.1152/ajprenal.1985.248.6.F858; SANSOM SC, 1986, AM J PHYSIOL, V251, pF743, DOI 10.1152/ajprenal.1986.251.4.F743; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWARTZ GJ, 1978, AM J PHYSIOL, V235, pF576, DOI 10.1152/ajprenal.1978.235.6.F576; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SHYJAN AW, 1990, P NATL ACAD SCI USA, V87, P1178, DOI 10.1073/pnas.87.3.1178; SKOU JC, 1962, BIOCHIM BIOPHYS ACTA, V58, P314, DOI 10.1016/0006-3002(62)91015-6; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; VERREY F, 1987, J CELL BIOL, V104, P1231, DOI 10.1083/jcb.104.5.1231; VERREY F, 1989, MOL ENDOCRINOL, V3, P1369, DOI 10.1210/mend-3-9-1369; VINAY P, 1981, AM J PHYSIOL, V241, pF403, DOI 10.1152/ajprenal.1981.241.4.F403; WARDEN DH, 1988, AM J PHYSIOL, V255, pF720, DOI 10.1152/ajprenal.1988.255.4.F720; YOUNG RM, 1987, BIOCHEM BIOPH RES CO, V145, P52, DOI 10.1016/0006-291X(87)91286-1	59	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23469	23476						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	8226873				2022-12-25	WOS:A1993MF51500079
J	OHTSUKA, T; NISHIJIMA, M; SUZUKI, K; AKAMATSU, Y				OHTSUKA, T; NISHIJIMA, M; SUZUKI, K; AKAMATSU, Y			MITOCHONDRIAL DYSFUNCTION OF A CULTURED CHINESE-HAMSTER OVARY CELL MUTANT DEFICIENT IN CARDIOLIPIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-OXIDASE; RESPIRATORY-CHAIN; ETHIDIUM BROMIDE; COMPLEX; BIOSYNTHESIS; REQUIREMENT; HELA	In our preceding paper, we reported that a temperature-sensitive Chinese hamster ovary cell mutant, PGS-S, with thermolabile phosphatidylglycerophosphate synthase was defective in the biogenesis of both phosphatidylglycerol and cardiolipin (CL) at a nonpermissive temperature (Ohtsuka, T., Nishijima, M., and Akamatsu, Y. (1993) J. Biol. Chem. 268, 22908-22913). To investigate the biological role of cardiolipin, we examined the structure and function of mitochondria in mutant PGS-S cells, since CL is primarily found in the mitochondrial membranes of eukaryotic cells. Under conditions where the formation of CL was impaired, this mutant had both morphological and functional mitochondrial abnormalities, manifested by more stringent temperature sensitivity for cell growth in glucose-deficient medium and by reduced ATP production, increased glycolysis, and reduced oxygen consumption in intact cells. Rotenone-sensitive NADH oxidase activity in cell extracts was also reduced in the mutant cultivated at a nonpermissive temperature, showing a defect(s) in the respiratory electron transport chain of mitochondria. Of the respiratory chain complexes, rotenone-sensitive NADH-ubiquinone reductase (Complex I) was most severely impaired in the mutant, whereas its activity was restored in a revertant of the mutant that had regained the ability to synthesize CL. These results suggest that CL plays a critical role in mitochondrial functions, at least in the respiratory electron transport chain.	NATL INST HLTH, DEPT BIOCHEM & CELL BIOL, TOYAMA 1-23-1, SHINJUKU KU, TOKYO 162, JAPAN									AWASTHI YC, 1971, BIOCHIM BIOPHYS ACTA, V226, P42, DOI 10.1016/0005-2728(71)90176-9; CHU EHY, 1972, P NATL ACAD SCI USA, V69, P3459, DOI 10.1073/pnas.69.11.3459; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; DITTA G, 1976, SOMAT CELL GENET, V2, P331, DOI 10.1007/BF01538838; ESKO JD, 1980, J BIOL CHEM, V255, P4474; FRY M, 1980, BIOCHEM BIOPH RES CO, V93, P1238, DOI 10.1016/0006-291X(80)90622-1; FRY M, 1981, J BIOL CHEM, V256, P1874; HANADA K, 1990, J BIOL CHEM, V265, P22137; Hostetler K. Y., 1982, PHOSPHOLIPIDS, V4, P215; KING ME, 1972, J CELL BIOL, V53, P127, DOI 10.1083/jcb.53.1.127; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORAIS R, 1980, J CELL PHYSIOL, V103, P455, DOI 10.1002/jcp.1041030311; OHTSUKA T, 1993, J BIOL CHEM, V268, P22908; RAGAN CI, 1978, BIOCHEM J, V172, P539, DOI 10.1042/bj1720539; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; Robinson B.H., 1989, METABOLIC BASIS INHE, P869; SCHEFFLER IE, 1974, J CELL PHYSIOL, V83, P219, DOI 10.1002/jcp.1040830208; SCHLAME M, 1990, BIOCHEM J, V265, P79, DOI 10.1042/bj2650079; SEGALBENDIRDJIAN E, 1988, CANCER RES, V48, P4982; SINGER TP, 1971, ADV ENZYMOL RAMB, V34, P79; SOSLAU G, 1971, J CELL BIOL, V51, P514, DOI 10.1083/jcb.51.2.514; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; SUN NC, 1975, P NATL ACAD SCI USA, V72, P469, DOI 10.1073/pnas.72.2.469; Tisdale HD, 1967, METHODS ENZYMOL, V10, P213, DOI DOI 10.1016/0076-6879(67)10042-6; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; Whitfield C. D., 1985, MOL CELL GENETICS, P545; YU CA, 1979, ARCH BIOCHEM BIOPHYS, V198, P314, DOI 10.1016/0003-9861(79)90424-7	29	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22914	22919						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226801				2022-12-25	WOS:A1993MD34800105
J	TANG, DG; CHEN, YQ; NEWMAN, PJ; SHI, L; GAO, X; DIGLIO, CA; HONN, KV				TANG, DG; CHEN, YQ; NEWMAN, PJ; SHI, L; GAO, X; DIGLIO, CA; HONN, KV			IDENTIFICATION OF PECAM-1 IN SOLID TUMOR-CELLS AND ITS POTENTIAL INVOLVEMENT IN TUMOR-CELL ADHESION TO ENDOTHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOEMBRYONIC ANTIGEN; ALPHA-IIB-BETA-3 INTEGRIN; MELANOMA-CELLS; MOLECULE; EXPRESSION; CARCINOMA; LINE; METASTASIS; MEMBRANE; PLATELET	PECAM-1 (CD31/EndoCAM) is an adhesion molecule in the immunoglobulin supergene family that is expressed on endothelial cells, platelets, and some hematopoietic lineage cells. In this paper, using several polyclonal and monoclonal antibodies against PECAM-1, we identified PECAM-1 molecules on human, rat, and murine solid tumor cell lines. Immunocytochemical labeling and flow cytometric analysis using either polyclonal, monoclonal, or Fab portion of the antibodies against PECAM-1 detected a distinct distribution on tumor cell surface. Immunoblotting revealed proteins ranging from 120 to 130 kDa in tumor cells derived from different species. Immunoprecipitation and subcellular fractionation studies indicated that PECAM-1 is constitutively expressed on the surface of human tumor cells (i.e. colon adenocarcinoma). The specificity of a major polyclonal anti-PECAM-1 used in the current study (i.e. SEW-3) was confirmed by the preabsorption studies. PECAM-1 molecules on tumor cells appear to bear terminal carbohydrate moieties (i.e. sialic acid residues) different from those on platelets, since neuraminidase treatment of tumor cells, unlike platelets, did not result in a mobility shift. Polymerase chain reaction (PCR) analysis of genomic DNA derived from tumor cell lines of different species revealed the presence of PECAM-1 gene in the genome. The mRNAs of PECAM-1 in tumor cells were detected by reverse transcription-PCR followed by Southern hybridization. Screening of more than 20 human, rat, and murine solid tumor cell lines indicated that PECAM-1 is widely expressed, although the level of expression varies considerably among different cell lines. The expression of PECAM-1 message in tumor cells was confirmed by Northern blotting. DNA sequencing of the PCR fragment revealed that human tumor cell PECAM-1 matches 100% to the human endothelial cell counterpart. Finally, it was demonstrated that tumor cell PECAM-1 is involved in mediating tumor cell adhesion to endothelium, as evidenced by the ability of anti-PECAM-1 antibodies to decrease the adhesion of unstimulated tumor cells to microvascular endothelial cells.	WAYNE STATE UNIV,DEPT RADIAT ONCOL,431 CHEM,DETROIT,MI 48202; WAYNE STATE UNIV,DEPT CHEM,DETROIT,MI 48202; WAYNE STATE UNIV,DEPT PATHOL,DETROIT,MI 48202; HARPER GRACE HOSP,GERSHENSON RADIAT ONCOL CTR,DETROIT,MI 48201; BLD CTR SE WISCONSIN,BLOOD RES INST,MILWAUKEE,WI 53233; MED COLL WISCONSIN,DEPT CELL BIOL & ANAT,MILWAUKEE,WI 53207	Wayne State University; Wayne State University; Wayne State University; Versiti Blood Center of Wisconsin; Medical College of Wisconsin			Chen, Yong Q/AAI-9864-2021; Tang, Dean/AAI-3457-2020	Chen, Yong Q/0000-0003-4747-4708; Tang, Dean/0000-0001-5029-1174	NATIONAL CANCER INSTITUTE [R01CA047115, R01CA029997] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040926] Funding Source: NIH RePORTER; NCI NIH HHS [CA 29997, CA 47115] Funding Source: Medline; NHLBI NIH HHS [HL-40926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BRACKENBURY R, 1985, CANCER METAST REV, V4, P41, DOI 10.1007/BF00047736; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTHMAN AR, 1989, INT J CANCER, V44, P898, DOI 10.1002/ijc.2910440525; CHANG YS, 1992, INT J CANCER, V51, P445, DOI 10.1002/ijc.2910510318; CHEN YQ, 1992, J BIOL CHEM, V267, P17314; CHOPRA H, 1990, CANCER RES, V50, P7686; CHOPRA H, 1988, CANCER RES, V48, P3787; DIGLIO CA, 1989, LAB INVEST, V60, P523; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; GROSSI IM, 1989, CANCER RES, V49, P1029; GROSSI IM, 1988, FASEB J, V2, P2385, DOI 10.1096/fasebj.2.8.2452113; HONN KV, 1992, CANCER METAST REV, V11, P353, DOI 10.1007/BF01307187; HONN KV, 1992, SEMIN THROMB HEMOST, V18, P390; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KNAPP W, 1989, BLOOD, V74, P1448; LAURI D, 1991, JNCI-J NATL CANCER I, V83, P1321, DOI 10.1093/jnci/83.18.1321; LEE KH, 1992, J INVEST DERMATOL, V98, P79, DOI 10.1111/1523-1747.ep12495643; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIU B, 1991, CELL REGUL, V2, P1045, DOI 10.1091/mbc.2.12.1045; MAJURI ML, 1992, BIOCHEM BIOPH RES CO, V182, P1376, DOI 10.1016/0006-291X(92)91885-T; MARTINPADURA I, 1991, CANCER RES, V51, P2239; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; NAYAK SK, 1977, BRIT J CANCER, V35, P142, DOI 10.1038/bjc.1977.21; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; NICHOLSON GL, 1988, CANCER METAST REV, V7, P143; PAULI BU, 1990, CANCER METAST REV, V9, P175, DOI 10.1007/BF00046359; SAMBROOK J, 1987, MOL CLONING LABORATO; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SIMMONS DL, 1990, J EXP MED, V171, P2147, DOI 10.1084/jem.171.6.2147; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TANG DG, 1993, INT J CANCER, V54, P102, DOI 10.1002/ijc.2910540117; TANG DG, 1993, J CELL BIOL, V121, P689, DOI 10.1083/jcb.121.3.689; TIBBETTS LM, 1977, CANCER, V40, P2651, DOI 10.1002/1097-0142(197711)40:5+<2651::AID-CNCR2820400939>3.0.CO;2-V; TURBIDE C, 1991, J BIOL CHEM, V266, P309; WEISS L, 1988, FASEB J, V2, P12, DOI 10.1096/fasebj.2.1.3275560; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243	45	64	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22883	22894						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226797				2022-12-25	WOS:A1993MD34800101
J	TONISSEN, K; WELLS, J; COCK, I; PERKINS, A; OROZCO, C; CLARKE, F				TONISSEN, K; WELLS, J; COCK, I; PERKINS, A; OROZCO, C; CLARKE, F			SITE-DIRECTED MUTAGENESIS OF HUMAN THIOREDOXIN - IDENTIFICATION OF CYSTEINE-74 AS CRITICAL TO ITS FUNCTION IN THE EARLY-PREGNANCY FACTOR SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; MUTANT THIOREDOXINS; REDUCTION; EXPRESSION; COMPONENTS; POLYMERASE; RESOLUTION; MOLECULES; SERUM	Thioredoxin has been identified as a key component of the ''early pregnancy factor'' system, a system of components present in pregnancy sera which expresses a lymphocyte modifying activity in an assay known as the rosette inhibition assay. Although thioredoxin alone is inactive, addition of thioredoxin to lymphocytes in combination with nonpregnancy sera or platelet-activating factor results in a positive response. We have changed several amino acids of human thioredoxin by site-directed mutagenesis to investigate the residues required for this cooperative function. Conversion of the two active site residues (cysteines 32 and 35) to serines results in a protein devoid of classical redox activity; however, this protein retained its ability to cooperate with non-pregnancy sera or platelet-activating factor in the rosette inhibition assay. Vertebrate thioredoxins contain an additional conserved pair of cysteine residues in the C-terminal portion of the protein. Changing both to serines resulted in no change in redox activity but completely abolished function in the rosette inhibition assay. Further study revealed this function was solely dependent on cysteine 74 as conversion of only cysteine 74 to serine abolished function, whereas replacement of only cysteine 70 with serine had no effect. The nonfunctional mutants counteracted the action of pregnancy serum in the assay stongly supporting the hypothesis that thioredoxin is an intergral part of the early pregnancy factor system with residue cysteine 74 having an important role.	GRIFFITH UNIV, FAC SCI & TECHNOL, NATHAN, QLD 4111, AUSTRALIA; UNIV ADELAIDE, DEPT BIOCHEM, ADELAIDE, SA 5001, AUSTRALIA	Griffith University; University of Adelaide			Perkins, Tony/K-6648-2019; Tonissen, Kathryn F/E-9424-2010	Perkins, Tony/0000-0002-9829-6772; Tonissen, Kathryn F/0000-0002-1018-2798; Cock, Ian/0000-0002-8732-8513				CLARKE FM, 1990, J REPROD FERTIL, V88, P459; CLARKE FM, 1991, J REPROD FERTIL, V93, P525, DOI 10.1530/jrf.0.0930525; CLARKE FM, 1992, REPROD FERT DEVELOP, V4, P423, DOI 10.1071/RD9920423; CRAWFORD NA, 1988, METHOD ENZYMOL, V167, P415; DITRAPANI G, 1991, HUM REPROD, V6, P450, DOI 10.1093/oxfordjournals.humrep.a137357; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ERICSON ML, 1992, LYMPHOKINE CYTOK RES, V11, P201; FORMANKAY JD, 1991, BIOCHEMISTRY-US, V30, P2685, DOI 10.1021/bi00224a017; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUBER HE, 1986, J BIOL CHEM, V261, P5006; KAMINSKY SM, 1992, PROTEIN SCI, V1, P22; KAMINSKY SM, 1992, PROTEIN SCI, V1, P10; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; MORTON H, 1977, LANCET, V1, P394; MORTON H, 1987, CURR TOP DEV BIOL, V23, P73; OROZCO C, 1990, J REPROD FERTIL, V88, P447, DOI 10.1530/jrf.0.0880447; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; SCHALLREUTER KU, 1989, FREE RADICAL BIO MED, V6, P519, DOI 10.1016/0891-5849(89)90045-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	29	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22485	22489						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	8226756				2022-12-25	WOS:A1993MD34800047
J	SHASHIDHARAN, P; MICHAELIDIS, TM; ROBAKIS, NK; KRESOVALI, A; PAPAMATHEAKIS, J; PLAITAKIS, A				SHASHIDHARAN, P; MICHAELIDIS, TM; ROBAKIS, NK; KRESOVALI, A; PAPAMATHEAKIS, J; PLAITAKIS, A			NOVEL HUMAN GLUTAMATE-DEHYDROGENASE EXPRESSED IN NEURAL AND TESTICULAR TISSUES AND ENCODED BY AN X-LINKED INTRONLESS GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROLOGICAL DISORDERS; RAT-BRAIN; LOCALIZATION; RETROPOSONS; CEREBELLUM; RECEPTORS; EVOLUTION; SEQUENCE; BINDING; CDNA	Glutamate dehydrogenase, an enzyme central to glutamate metabolism, is deficient in patients with heterogeneous neurological disorders characterized by multiple system atrophy. There is evidence for multiplicity of human glutamate dehydrogenase, which may account for the heterogeneity of the above disorders. However, only one mRNA that is encoded by an intron-containing gene (GLUD1) is presently known. Because blindness due to neuroretinal degeneration can occur in rare forms of multiple system atrophy, we searched for retina specific GLUD mRNA(s) by screening a lambda gt10 library derived from human retina. A novel cDNA encoded by an X chromosome-linked intronless gene, designated GLUD2, was isolated and characterized. Reverse transcription-polymerase chain reaction analysis of human tissues revealed that the novel cDNA is expressed in human retina, testis, and, at lower levels, brain. In vitro translation of mRNAs derived from GLUD1 and GLUD2 genes generated proteins with distinct electrophoretic characteristics. The retinal cDNA was expressed in the baculovirus heterologous system, producing a protein capable of catalyzing the oxidative deamination of glutamate. The mobility of the expressed protein on SDS-polyacrylamide gel electrophoresis and its catalytic properties were very similar to those of the naturally occurring human brain glutamate dehydrogenases. The novel gene will be useful for understanding the biology of human neural and testicular tissues and in the study of X-linked neurodegenerative disorders.	CUNY MT SINAI SCH MED, DEPT NEUROL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, FISHBERG RES CTR NEUROBIOL, NEW YORK, NY 10029 USA; UNIV CRETE, RES CTR CRETE, INST MOLEC BIOL & BIOTECHNOL, GR-71110 IRAKLION, GREECE; UNIV CRETE, DEPT BIOL, GR-71110 IRAKLION, GREECE; UNIV CRETE, SCH MED SCI, GR-71110 IRAKLION, GREECE	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Crete; University of Crete; University of Crete			Robakis, Nikolaos/AAA-1838-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016871] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-16871] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE T, 1992, INVEST OPHTH VIS SCI, V33, P447; ALBIN RL, 1990, BRAIN RES, V522, P37, DOI 10.1016/0006-8993(90)91574-Z; AMURO N, 1988, BIOCHEM BIOPH RES CO, V152, P1395, DOI 10.1016/S0006-291X(88)80440-6; ANAGNOU NP, 1993, HUM HERED, V43, P351, DOI 10.1159/000154158; AOKI C, 1987, J NEUROSCI, V7, P2214; BANNER C, 1987, J NEUROCHEM, V49, P246, DOI 10.1111/j.1471-4159.1987.tb03422.x; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; COLON AD, 1986, J NEUROCHEM, V46, P1811; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; EHINGER B, 1988, P NATL ACAD SCI USA, V85, P8321, DOI 10.1073/pnas.85.21.8321; HANAUER A, 1987, NUCLEIC ACIDS RES, V15, P6308, DOI 10.1093/nar/15.15.6308; HARLOW E, 1986, ANTIBODIES LABORATOR; Huang Y P, 1984, Adv Neurol, V41, P39; HUSSAIN MM, 1989, J BIOL CHEM, V264, P20730; LAI JCK, 1986, NEUROCHEM RES, V11, P733, DOI 10.1007/BF00965341; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAVROTHALASSITIS G, 1988, P NATL ACAD SCI USA, V85, P3494, DOI 10.1073/pnas.85.10.3494; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; MICHAELIDIS TM, 1993, GENOMICS, V16, P150, DOI 10.1006/geno.1993.1152; NAKATANI Y, 1988, NUCLEIC ACIDS RES, V16, P6237, DOI 10.1093/nar/16.13.6237; Plaitakis A, 1993, Can J Neurol Sci, V20 Suppl 3, pS109; PLAITAKIS A, 1984, ANN NEUROL, V15, P144, DOI 10.1002/ana.410150206; PLAITAKIS A, 1982, SCIENCE, V216, P193, DOI 10.1126/science.6121377; PLAITAKIS A, 1991, HDB CLIN NEUROLOGY, V16, P551; PLAITAKIS A, 1986, HDB CLIN NEUROL, V17, P218; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; Sambrook J, 1989, MOL CLONING LABORATO; Smith E.L., 1975, ENZYMES, P293, DOI DOI 10.1016/S1874-6047(08)60213-9; TSIOTOS P, 1989, BRAIN RES, V481, P87, DOI 10.1016/0006-8993(89)90487-3; YOUNG AB, 1990, TRENDS PHARMACOL SCI, V11, P126, DOI 10.1016/0165-6147(90)90199-I; YU ACH, 1984, J NEUROSCI RES, V11, P351, DOI 10.1002/jnr.490110403	32	136	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16971	16976						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	8207021				2022-12-25	WOS:A1994NR29600068
J	BUSCH, SJ; BARNHART, RL; MARTIN, GA; FITZGERALD, MC; YATES, MT; MAO, SJT; THOMAS, CE; JACKSON, RL				BUSCH, SJ; BARNHART, RL; MARTIN, GA; FITZGERALD, MC; YATES, MT; MAO, SJT; THOMAS, CE; JACKSON, RL			HUMAN HEPATIC TRIGLYCERIDE LIPASE EXPRESSION REDUCES HIGH-DENSITY-LIPOPROTEIN AND AORTIC CHOLESTEROL IN CHOLESTEROL-FED TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIC HEART-DISEASE; GEL-ELECTROPHORESIS; METABOLISM; ATHEROSCLEROSIS; DEFICIENCY; ESTER; GENE; MEN; RNA	We have produced a line of transgenic mice expressing human hepatic triglyceride lipase (hH-TGL) to examine the in vivo effects of hepatic lipase expression on high density lipoprotein catabolism. Activation of a metallothionine I promoter-hH-TGL cDNA transgene produced high levels of lipase mRNA in liver, heart, and kidney and elevated enzyme activity as assayed in post-heparin plasma. In a series of hyperlipidemic diet studies in which zinc was included in the diet to induce the transgene, hH-TGL expression was associated with a 34% lowering of plasma HDL-cholesterol levels (p < 0.01) when compared with animals on the same hyperlipidemic diet without zinc. This lowering of HDL cholesterol was paralleled by a decrease in total cholesterol and a decrease in HDL particle size. SDS-polyacrylamide gel electrophoresis analysis of the smaller HDL particles revealed that apolipoprotein AI was still the major apoprotein associated with the HDL. Quantitative analysis of abdominal aortic cholesterol content from the same animals suggests that the observed changes in plasma HDL by hH-TGL over-expression correlated with a decrease in the accumulation of aortic cholesterol (42%, p < 0.01). These data support the hypothesis that hH-TGL mediates a non-receptor pathway for the clearance of cholesterol from the plasma compartment.			BUSCH, SJ (corresponding author), MARION MERRELL DOW RES INST,2110 E GALBRAITH RD,CINCINNATI,OH 45267, USA.							AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHANG SF, 1991, FEBS LETT, V289, P69, DOI 10.1016/0014-5793(91)80910-U; ENGER SC, 1979, ARTERY, V5, P170; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GOLDBOURT U, 1979, AM J EPIDEMIOL, V109, P296, DOI 10.1093/oxfordjournals.aje.a112683; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HEGELE RA, 1991, BIOCHEM BIOPH RES CO, V179, P78, DOI 10.1016/0006-291X(91)91336-B; HEGELE RA, 1991, J CLIN ENDOCR METAB, V72, P730, DOI 10.1210/jcem-72-3-730; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACKSON RL, 1983, ENZYMES, V16, P141; KADOWAKI H, 1992, J LIPID RES, V33, P1689; KATZEL LI, 1992, ARTERIOSCLER THROMB, V12, P814, DOI 10.1161/01.ATV.12.7.814; KUUSI T, 1980, ATHEROSCLEROSIS, V36, P589, DOI 10.1016/0021-9150(80)90251-8; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; MARTIN GA, 1988, J BIOL CHEM, V263, P10907; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NOZAKI S, 1986, METABOLISM, V35, P53, DOI 10.1016/0026-0495(86)90095-8; PETERSON J, 1986, BIOCHIM BIOPHYS ACTA, V878, P65, DOI 10.1016/0005-2760(86)90344-9; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; SAMMETT D, 1985, J BIOL CHEM, V260, P6687; SHIRAI K, 1981, BIOCHEM BIOPH RES CO, V100, P591, DOI 10.1016/S0006-291X(81)80217-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TIKKANEN MJ, 1982, J CLIN ENDOCR METAB, V54, P1113, DOI 10.1210/jcem-54-6-1113	28	139	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16376	16382						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206946				2022-12-25	WOS:A1994NQ72900065
J	DEPALO, D; KINLAW, WB; ZHAO, CQ; ENGELBERGKULKA, H; STGERMAIN, DL				DEPALO, D; KINLAW, WB; ZHAO, CQ; ENGELBERGKULKA, H; STGERMAIN, DL			EFFECT OF SELENIUM DEFICIENCY ON TYPE-I 5'-DEIODINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE GENE; 3' UNTRANSLATED REGION; XENOPUS-LAEVIS-OOCYTES; RAT-LIVER; IODOTHYRONINE 5'-DEIODINASE; MESSENGER-RNA; THYROID-HORMONE; UGA CODON; SELENOCYSTEINE; SEQUENCES	The type I iodothyronine 5' deiodinase (5'-DI) present in rat liver and kidney has recently been demonstrated to be a selenoprotein. The goal of the present study was to examine in detail the effect of selenium (Se) deficiency on 5'-DI at the protein and mRNA levels. In weanling rats fed a selenium-deficient (Se(-)) diet for 6 weeks, 5'-DI activity was decreased 91 and 69% relative to control activities in liver and kidney, respectively. Administration of 3,5,3'-triiodothyronine resulted in a a-fold increase in 5'-DI activity in control animals, but had little or no effect on 5'-DI activity in Se(-) animals. Western analysis using a specific antiserum directed against a bacterial fusion protein containing the carboxyl-terminal half of the 5'-DI protein demonstrated that this decrease in 5'-DI activity in Se(-) animals was explained by a marked decrease in 5'-DI protein. Administration of Se to Se(-) animals resulted in parallel increases in 5'-DI protein and activity over a 72-h time period. It was also shown that selenium deficiency was accompanied by a 40% decrease in 5'-DI mRNA levels in the kidney, but not in the liver. In both tissues, the administration of 3,5,3'-triiodothyronine resulted in increased 5'-DI mRNA levels which were not altered by selenium status. These studies indicate that selenium deficiency decreases 5'-DI activity by decreasing the amount of 5'-DI protein. The mechanism of this impairment in enzyme synthesis appears to be a defect in translation, presumably due to a block in the UGA-directed selenocysteine incorporation in selenium deficiency.	DARTMOUTH COLL,SCH MED,DEPT MED,LEBANON,NH 03756; DARTMOUTH COLL,SCH MED,DEPT PHYSIOL,LEBANON,NH 03756; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOLEC BIOL,IL-91010 JERUSALEM,ISRAEL	Dartmouth College; Dartmouth College; Hebrew University of Jerusalem					NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042271, R01DK043142] Funding Source: NIH RePORTER; NCI NIH HHS [CA 23108] Funding Source: Medline; NIDDK NIH HHS [DK-42271, DK-43142] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKETT GJ, 1987, BIOCHEM J, V248, P443, DOI 10.1042/bj2480443; BECKETT GJ, 1991, J TRACE ELEM ELECT H, V5, P265; BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; CHANG M, 1991, BIOCHEM BIOPH RES CO, V181, P1431, DOI 10.1016/0006-291X(91)92099-6; CHRISTENSEN MJ, 1992, J NUTR, V122, P1620, DOI 10.1093/jn/122.8.1620; Cochran W.G, 1957, STAT METHODS, V6th ed; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; GROSS M, 1992, ACTA ENDOCRINOL-COP, V126, P175; HARLOWE E, 1988, ANTIBODIES LABORATOR; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; HILL KE, 1992, BIOCHEM BIOPH RES CO, V185, P260, DOI 10.1016/S0006-291X(05)80984-2; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; OMARA BA, 1993, ENDOCRINOLOGY, V133, P1715, DOI 10.1210/en.133.4.1715; SHEN QC, 1993, J BIOL CHEM, V268, P11463; STGERMAIN DL, 1989, J BIOL CHEM, V264, P3054; STGERMAIN DL, 1988, J CLIN INVEST, V81, P1476, DOI 10.1172/JCI113479; STGERMAIN DL, 1990, J BIOL CHEM, V265, P20087; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VISSER TJ, 1988, J CLIN ENDOCR METAB, V67, P17, DOI 10.1210/jcem-67-1-17; VISSER TJ, 1976, BIOCHEM J, V157, P479, DOI 10.1042/bj1570479; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	26	40	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16223	16228						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206925				2022-12-25	WOS:A1994NQ72900043
J	KRUKLITIS, R; NAKAI, H				KRUKLITIS, R; NAKAI, H			PARTICIPATION OF THE BACTERIOPHAGE-MU-A PROTEIN AND HOST FACTORS IN THE INITIATION OF MU-DNA-SYNTHESIS IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI MUTANTS; NUCLEOPROTEIN STRUCTURES; REPLICATION PROTEIN; GENE-PRODUCT; INVITRO TRANSPOSITION; ENZYMATIC REPLICATION; DEOXYRIBONUCLEIC-ACID; PHYSICAL-PROPERTIES; NALIDIXIC-ACID	During bacteriophage Mu transposition, strand transfer is catalyzed in the presence of phage-encoded A and B proteins and Escherichia coli HU protein, attaching Mu ends to target DNA and creating an intermediate in transposition. Bacteriophage Mu A protein, which remains tightly bound to the Mu ends in the native strand-transfer intermediate, blocked initiation of Mu DNA replication by a system of 8 host proteins (DnaB helicase, DnaC protein, DnaG primase, DNA polymerase III holoenzyme, DNA polymerase I, DNA gyrase, DNA ligase, and single-strand binding protein). This 8-protein system had all enzymatic activities to convert the deproteinized intermediate to a cointegrate; however, additional host factor(s) were required to replicate the native intermediate. While replication of the native intermediate absolutely required DnaB helicase, DnaC protein, and DNA polymerase III holoenzyme, the specific requirements were relaxed for the deproteinized intermediate. Other host factors were able to replace these specific factors. These results indicate that Mu A protein, in conjunction with additional host factor(s), acts to promote assembly of specific host replication proteins at the Mn replication fork. This process may alter the stable interaction of Mu A protein with the ends to allow initiation of Mu DNA synthesis.	GEORGETOWN UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WASHINGTON, DC 20007 USA	Georgetown University								ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; ARAI K, 1981, J BIOL CHEM, V256, P5247; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CAMPBELL JL, 1972, P NATL ACAD SCI USA, V69, P2090, DOI 10.1073/pnas.69.8.2090; CARL PL, 1970, MOL GEN GENET, V109, P107, DOI 10.1007/BF00269647; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHACONAS G, 1981, J MOL BIOL, V150, P341, DOI 10.1016/0022-2836(81)90551-9; CHACONAS G, 1983, VIROLOGY, V128, P48, DOI 10.1016/0042-6822(83)90317-3; CRAIGIE R, 1985, J BIOL CHEM, V260, P1832; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; DODSON M, 1989, J BIOL CHEM, V264, P10719; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GEFTER ML, 1971, P NATL ACAD SCI USA, V68, P3150, DOI 10.1073/pnas.68.12.3150; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; HARSHEY RM, 1984, NATURE, V311, P580, DOI 10.1038/311580a0; HIGGINS NP, 1983, J BIOL CHEM, V258, P4293; HIGGINS NP, 1983, CELL, V33, P623, DOI 10.1016/0092-8674(83)90443-9; HUBSCHER U, 1980, J BIOL CHEM, V255, P1698; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; KOBORI JA, 1982, J BIOL CHEM, V257, P13763; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LANKA E, 1983, NUCLEIC ACIDS RES, V11, P987, DOI 10.1093/nar/11.4.987; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6547; MASAI H, 1990, J BIOL CHEM, V265, P15134; MATSON SW, 1981, J BACTERIOL, V146, P275, DOI 10.1128/JB.146.1.275-284.1981; MCBETH DL, 1983, J VIROL, V48, P149, DOI 10.1128/JVI.48.1.149-156.1983; MCBETH DL, 1982, J VIROL, V44, P555, DOI 10.1128/JVI.44.2.555-564.1982; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOSES RE, 1970, P NATL ACAD SCI USA, V67, P674, DOI 10.1073/pnas.67.2.674; NAKAI H, 1993, J BIOL CHEM, V268, P23997; NAKAI H, 1988, J BIOL CHEM, V263, P9831; PATO M, 1987, J BACTERIOL, V169, P5504, DOI 10.1128/jb.169.12.5504-5509.1987; RESIBOIS A, 1984, PROTEINS INVOLVED DN, P69; ROSS W, 1986, J BACTERIOL, V167, P905, DOI 10.1128/jb.167.3.905-919.1986; ROWEN L, 1978, J BIOL CHEM, V253, P758; Sambrook J, 1989, MOL CLONING LABORATO; SCHALLER H, 1972, J MOL BIOL, V63, P183, DOI 10.1016/0022-2836(72)90369-5; SCHUBACH WH, 1973, J MOL BIOL, V74, P205, DOI 10.1016/0022-2836(73)90107-1; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; TOUSSAINT A, 1974, MOL GEN GENET, V131, P209, DOI 10.1007/BF00267960; TOUSSAINT A, 1983, MOBILE GENETIC ELEME, P105; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WECHSLER JA, 1975, J BACTERIOL, V121, P594, DOI 10.1128/JB.121.2.594-599.1975; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WEINER JH, 1975, J BIOL CHEM, V250, P1972; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER W, 1973, P NATL ACAD SCI USA, V70, P1764, DOI 10.1073/pnas.70.6.1764	66	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16469	16477						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206956				2022-12-25	WOS:A1994NQ72900077
J	SINGER, KL; STEVENSON, BR; WOO, PL; FIRESTONE, GL				SINGER, KL; STEVENSON, BR; WOO, PL; FIRESTONE, GL			RELATIONSHIP OF SERINE/THREONINE PHOSPHORYLATION/DEPHOSPHORYLATION SIGNALING TO GLUCOCORTICOID REGULATION OF TIGHT JUNCTION PERMEABILITY AND ZO-1 DISTRIBUTION IN NONTRANSFORMED MAMMARY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; NUCLEAR RECEPTORS; ZONULA-OCCLUDENS; GENE-EXPRESSION; PROTEIN ZO-1; 2 STRAINS; IDENTIFICATION; RESISTANCE; CINGULIN; GROWTH	The synthetic glucocorticoid dexamethasone regulates tight junction permeability resulting in an increased transepithelial electrical resistance (TER) of cultured 31EG4 mammary epithelial cells. Inhibition of cellular type 1 and type 2A protein phosphatase activity by okadaic acid reduced the TER of dexamethasone-treated monolayers of 31EG4 cells to basal levels within 24 h. Coincident with the increase in tight junction permeability, immunofluorescence revealed that okadaic acid caused a partial cellular redistribution of the ZO-1 tight junction-associated protein. The potent glucocorticoid antagonist RU486 had no effect on TER or ZO-1 distribution, indicating that the effects of okadaic acid are not a result of disrupting glucocorticoid receptor function. Immunoprecipitation of P-32-labeled cells and V8 protease peptide mapping demonstrated that dexamethasone did not alter ZO-1 phosphorylation. However, consistent with the changes in TER, dexamethasone induced a 2.3-fold stimulation in ZO-1 protein levels which was reduced to 73% of basal levels by okadaic acid. No effects on ZO-1 transcript levels were observed. Monolayers grown in the presence of glucocorticoids had only 28% less junction density and 16.5% more Linear junction/cell, which cannot account for the observed increases of TER and ZO-1 protein levels. Taken together, our results have shown that a disruption of phosphorylation/dephosphorylation activity overrides the glucocorticoid regulation of tight junction permeability in 31EG4 mammary cells.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720; UNIV ALBERTA,DEPT ANAT & CELL BIOL,EDMONTON T6G 2H7,AB,CANADA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Alberta					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042799, R01DK042799] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-42799] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; ANDERSON JM, 1989, J CELL BIOL, V109, P1047, DOI 10.1083/jcb.109.3.1047; BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; CEREIJIDO M, 1981, AM J PHYSIOL, V240, pC96, DOI 10.1152/ajpcell.1981.240.3.C96; CEREIJIDO M, 1991, TIGHT JUNCTIONS, P1; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; CITI S, 1992, J CELL BIOL, V117, P169, DOI 10.1083/jcb.117.1.169; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; GONZALEZMARISCAL L, 1985, J MEMBRANE BIOL, V86, P113, DOI 10.1007/BF01870778; GONZALEZMARISCAL L, 1990, AM J PHYSIOL, V259, pC978, DOI 10.1152/ajpcell.1990.259.6.C978; GOODMAN LJ, 1993, MOL ENDOCRINOL, V7, P94, DOI 10.1210/me.7.1.94; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; HARAGUCHI T, 1991, J BIOL CHEM, V266, P18299; HARLOW E, 1988, ANTIBODIES LABORATOR, P641; HOWARTH AG, 1994, J MEMBRANE BIOL, V137, P261; HOWARTH AG, 1992, AM J PHYSIOL, V262, P461; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINZELL JL, 1971, J PHYSIOL-LONDON, V216, P701, DOI 10.1113/jphysiol.1971.sp009548; MADARA JL, 1988, CELL, V53, P497, DOI 10.1016/0092-8674(88)90562-4; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MADARA JL, 1987, J MEMBRANE BIOL, V100, P49; MANDEL LJ, 1993, NATURE, V361, P552, DOI 10.1038/361552a0; MCROBERTS JA, 1992, AM J PHYSIOL, V262, pC207, DOI 10.1152/ajpcell.1992.262.1.C207; MCROBERTS JA, 1990, J CLIN INVEST, V85, P1127, DOI 10.1172/JCI114544; MOGUILEWSKY M, 1984, J STEROID BIOCHEM, V20, P271, DOI 10.1016/0022-4731(84)90216-4; NIGAM SK, 1991, BIOCHEM BIOPH RES CO, V181, P548, DOI 10.1016/0006-291X(91)91224-Z; OJAKIAN GK, 1981, CELL, V23, P95, DOI 10.1016/0092-8674(81)90274-9; PITELKA DR, 1973, J CELL BIOL, V56, P797, DOI 10.1083/jcb.56.3.797; PITELKA DR, 1978, LACTATION COMPREHENS, P141; RABITO CA, 1991, TIGHT JUNCTIONS, P203; REICHEL RR, 1993, FASEB J, V7, P427, DOI 10.1096/fasebj.7.5.8385039; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; SHORE EM, 1991, J BIOL CHEM, V266, P19672; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; STEVENSON BR, 1989, AM J PHYSIOL, V257, pC621, DOI 10.1152/ajpcell.1989.257.4.C621; STEVENSON BR, 1989, BIOCHEM J, V263, P597, DOI 10.1042/bj2630597; STEVENSON BR, 1988, J CELL BIOL, V107, P2401, DOI 10.1083/jcb.107.6.2401; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	52	97	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16108	16115						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206910				2022-12-25	WOS:A1994NQ72900026
J	TAYEH, MA; OLSON, ST; SHORE, JD				TAYEH, MA; OLSON, ST; SHORE, JD			SURFACE-INDUCED ALTERATIONS IN THE KINETIC PATHWAY FOR CLEAVAGE OF HUMAN HIGH-MOLECULAR-WEIGHT KININOGEN BY PLASMA KALLIKREIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; COAGULATION FACTOR-XII; LIGHT CHAIN; BLOOD-COAGULATION; CONTACT ACTIVATION; HAGEMAN-FACTOR; HMW KININOGEN; HEAVY-CHAIN; FUNCTIONAL-PROPERTIES; PROCOAGULANT ACTIVITY	We have studied the cleavage of human high molecular weight kininogen (HK) by plasma kallikrein in the absence and presence of the surfaces, dextran sulfate (DxSO(4)) and sulfatides. Using a combination of SDS-polyacrylamide gel electrophoresis, Western blotting with polyclonal antibodies that specifically recognize the COOH terminus of the bradykinin moiety, and high pressure liquid chromatography analyses of the cleavage reaction, we have identified two intermediates in the formation of bradykinin from intact kininogen and demonstrated that alternative cleavage pathways are followed in the absence and presence of surfaces. The COOH-terminal bradykinin cleavage occurred first both in the absence and presence of DxSO(4), producing a 103-kDa HK intermediate consisting of disulfide-linked heavy and light chains that retained the kinin moiety. In the presence of DxSO(4), this was followed exclusively by the NH2-terminal bradykinin cleavage and release of kinin with no apparent change in molecular mass. Subsequently, a slower cleavage of an 8-kDa peptide from the amino terminus of the HK light chain occurred to form a 95-kDa end product. In contrast to this sequential cleavage pattern, NH2-terminal bradykinin and light chain cleavages occurred randomly in the absence of DxSO(4), resulting in the production of an additional 95-kDa intermediate that retained bradykinin but had lost the 8-kDa peptide from the HK light chain. Comparison of the relative rates of the three kallikrein cleavages in the absence and presence of DxSO(4) indicated that the surface enhanced the rates of both bradykinin cleavages 2-4-fold, but inhibited the light chain cleavage rate similar to 10-fold, thereby accounting for the change from a partially random to a sequential cleavage pattern in the presence of the surface. Steady-state kinetic analysis revealed that DxSO(4) enhanced the K-cat/K-M for bradykinin release by the rate-limiting NH2-terminal bradykinin cleavage by similar to 2-fold due exclusively to an increase in K-cat. Sulfatides appeared to produce the same effects on the pattern of HK cleavages as DxSO(4). Blocking of the nonactive site, i.e. exosite, interaction between kallikrein and HK with excess prekallikrein or a synthetic peptide containing the region of HK that interacts with the kallikrein exosite significantly reduced the rate of bradykinin release as well as HK cleavages detected by SDS-polyacrylamide gel electrophoresis either in the absence or presence of DxSO(4), indicating that the exosite interaction facilitates bradykinin cleavage.	HENRY FORD HOSP,DIV BIOCHEM RES,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital					NHLBI NIH HHS [HL 25670] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025670] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BOCK PE, 1983, J BIOL CHEM, V258, P5079; BOCK PE, 1985, J BIOL CHEM, V260, P2434; BOUMA BN, 1983, BLOOD, V62, P1123; CHAO J, 1988, BIOCHIM BIOPHYS ACTA, V964, P329, DOI 10.1016/0304-4165(88)90033-5; COLMAN RW, 1985, BLOOD, V65, P311; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; Griffin J H, 1976, Methods Enzymol, V45, P56; HAN YN, 1975, J BIOCHEM-TOKYO, V77, P55; HEIMARK RL, 1981, METHOD ENZYMOL, V80, P157; HIGASHIYAMA S, 1987, BIOCHEMISTRY-US, V26, P7450, DOI 10.1021/bi00397a038; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; IKARI N, 1981, J BIOCHEM, V89, P1699, DOI 10.1093/oxfordjournals.jbchem.a133370; KATO H, 1981, METHOD ENZYMOL, V80, P172; KERBIRIOU DM, 1980, J BIOL CHEM, V255, P3952; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SD, 1985, J BIOL CHEM, V260, P192; MAIER M, 1983, P NATL ACAD SCI-BIOL, V80, P3928, DOI 10.1073/pnas.80.13.3928; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MEIER HL, 1977, J CLIN INVEST, V60, P18, DOI 10.1172/JCI108754; MELHADO LL, 1982, J AM CHEM SOC, V104, P7299, DOI 10.1021/ja00389a065; MORI K, 1981, J BIOCHEM-TOKYO, V89, P1465, DOI 10.1093/oxfordjournals.jbchem.a133339; MULLERESTERL W, 1985, FEBS LETT, V182, P310, DOI 10.1016/0014-5793(85)80322-7; MULLERESTERL W, 1986, TRENDS BIOCHEM SCI, V11, P336, DOI 10.1016/0968-0004(86)90293-8; NAKAYASU T, 1979, J BIOCHEM, V85, P249, DOI 10.1093/oxfordjournals.jbchem.a132318; NARAYANAN TK, 1984, J CHROMATOGR, V306, P109, DOI 10.1016/S0378-4347(00)80874-9; OHKUBO I, 1984, BIOCHEMISTRY-US, V23, P5691, DOI 10.1021/bi00319a005; OLSON ST, 1993, BIOCHEMISTRY-US, V32, P12148, DOI 10.1021/bi00096a027; OLSON ST, 1993, BIOCHEMISTRY-US, V32, P12136, DOI 10.1021/bi00096a026; REDDIGARI S, 1988, BLOOD, V71, P1334; RETZIOS AD, 1987, J BIOL CHEM, V262, P3074; SCHIFFMAN S, 1980, J BIOL CHEM, V255, P6433; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SCICLI AG, 1982, J LAB CLIN MED, V100, P81; SCOTT CF, 1984, J CLIN INVEST, V73, P954, DOI 10.1172/JCI111319; SHIMADA T, 1985, J BIOCHEM-TOKYO, V97, P1637, DOI 10.1093/oxfordjournals.jbchem.a135221; SHORE JD, 1987, BIOCHEMISTRY-US, V26, P2250, DOI 10.1021/bi00382a027; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; SUEYOSHI T, 1985, FEBS LETT, V182, P193, DOI 10.1016/0014-5793(85)81182-0; SUGO T, 1980, BIOCHEMISTRY-US, V19, P3215, DOI 10.1021/bi00555a018; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TANS G, 1987, J BIOL CHEM, V262, P11308; TANS G, 1983, J BIOL CHEM, V258, P8215; THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862; THOMPSON RE, 1978, J EXP MED, V147, P488, DOI 10.1084/jem.147.2.488; VANDERGRAAF F, 1982, J BIOL CHEM, V257, P4300; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; WIGGINS RC, 1977, P NATL ACAD SCI USA, V74, P4636, DOI 10.1073/pnas.74.10.4636	51	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16318	16325						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206938				2022-12-25	WOS:A1994NQ72900057
J	CHAPPEL, MS; ISENMAN, DE; OOMEN, R; XU, YY; KLEIN, MH				CHAPPEL, MS; ISENMAN, DE; OOMEN, R; XU, YY; KLEIN, MH			IDENTIFICATION OF A SECONDARY FC-GAMMA-RI BINDING-SITE WITHIN A GENETICALLY-ENGINEERED HUMAN-IGG ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-G; TUMOR-CELLS; RECEPTORS; EXPRESSION; AFFINITY; FRAGMENT; DISTINCT; DOMAIN; REGION	Although human IgG2 is not cytophilic, we have shown previously that an IgG2 antibody expressing the sequence PLLGG (underline = substitution) spanning C(H)2 domain residues 233-237 (Eu numbering) displayed IgG1-like FcgammaRI binding activity. In contrast, IgG1 PLLGG exhibited 3-fold less affinity, whereas IgG2 ELLGG was 3-fold more active than native IgG1. These results suggested that additional site(s) conferred enhanced binding properties to the engineered, cytophilic IgG2 variant. These sites were shown to reside in the IgG2 C(H)2 domain, since the IgG1 C(H)2 module did not have enhanced activity in a panel of hybrid IgG1/IgG2 antibodies. To map these sites further, human IgG1 and IgG2 constant region gene segments were modified to allow reciprocal COOH-terminal half segment exchanges of C(H)2 exons. These were cloned into a pSV2neo expression vector bearing a rearranged MOPC 315 heavy chain variable region gene and transfected into a MOPC 315 heavy chain deletion mutant. The dinitrophenol affinity-purified IgGs were radiolabeled and assessed for FcgammaRI binding activity in direct binding assays using U937 cells. The COOH terminus of the IgG2 C(H)2 domain was found to contain accessory site(s) since it enhanced the binding properties of both IgG1 PLLGG and native IgG1. In contrast, grafting of the COOH terminus of the IgG1 C(H)2 domain onto IgG2 PLLGG and IgG2 ELLGG diminished their cytophilic activity. The amino acid responsible for the enhancing properties of the COOH terminus of the IgG2 C(H)2 domain was shown to be threonine 339, since IgG1 PLLGG/Thr339 displayed increased FcgammaRI binding affinity. Kinetics studies revealed that this is accomplished through an increase in the forward rate constant of the IgG-FcgammaRI interaction.	UNIV TORONTO,DEPT IMMUNOL,MED SCI BLDG,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; CONNAUGHT CTR BIOTECHNOL RES,N YORK M2R 3T4,ON,CANADA	University of Toronto; University of Toronto								ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; BAKER MD, 1988, P NATL ACAD SCI USA, V85, P6432, DOI 10.1073/pnas.85.17.6432; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BERZOFSKY JA, 1981, MOL IMMUNOL, V18, P751, DOI 10.1016/0161-5890(81)90067-5; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; BURTON DR, 1985, MOL IMMUNOL, V22, P161, DOI 10.1016/0161-5890(85)90151-8; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; CHAPPEL MS, 1991, P NATL ACAD SCI USA, V88, P9036, DOI 10.1073/pnas.88.20.9036; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; GRAZIANO RF, 1987, J IMMUNOL, V139, P3536; LESK AM, 1988, NATURE, V335, P188, DOI 10.1038/335188a0; LUND J, 1991, J IMMUNOL, V147, P2657; LUND J, 1990, MOL IMMUNOL, V27, P1145, DOI 10.1016/0161-5890(90)90103-7; MATSUDA H, 1990, MOL IMMUNOL, V27, P571, DOI 10.1016/0161-5890(90)90076-C; MOSMANN TR, 1979, EUR J IMMUNOL, V9, P511, DOI 10.1002/eji.1830090705; MUNCK A, 1976, RECEPTORS MECHANIS 1; ORTALDO JR, 1987, J IMMUNOL, V138, P3566; RAYCHAUDHURI G, 1985, MOL IMMUNOL, V22, P1009, DOI 10.1016/0161-5890(85)90104-X; RINFRET A, 1990, J IMMUNOL, V145, P925; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEGAL DM, 1977, J IMMUNOL, V118, P1338; SHEN L, 1989, MOL IMMUNOL, V26, P959, DOI 10.1016/0161-5890(89)90114-4; SHOPES B, 1990, J IMMUNOL, V145, P3842; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; WARMERDAM PAM, 1991, J IMMUNOL, V147, P1338; WOOF JM, 1990, BIOCHEM SOC T, V18, P217, DOI 10.1042/bst0180217; WOOF JM, 1986, MOL IMMUNOL, V23, P319, DOI 10.1016/0161-5890(86)90059-3	31	16	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25124	25131						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227075				2022-12-25	WOS:A1993MG67300087
J	KUMAGAI, N; MORII, N; FUJISAWA, K; NEMOTO, Y; NARUMIYA, S				KUMAGAI, N; MORII, N; FUJISAWA, K; NEMOTO, Y; NARUMIYA, S			ADP-RIBOSYLATION OF RHO P21 INHIBITS LYSOPHOSPHATIDIC ACID-INDUCED PROTEIN-TYROSINE PHOSPHORYLATION AND PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION IN CULTURED SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GENE-PRODUCT; RIBOSYLTRANSFERASE; KINASE; IDENTIFICATION; BOMBESIN; BINDING; VASOPRESSIN; EXPRESSION; PP125(FAK); PLATELETS	Botulinum C3 exoenzyme was used to specifically ADP-ribosylate and inactivate rho p21, and the effects of rho p21 inactivation on lysophosphatidic acid (LPA)-induced tyrosine phosphorylation were examined in cultured Swiss 3T3 cells. LPA induced a rapid increase in the tyrosine phosphorylation of a number of proteins. Pretreatment of the cells with the C3 exoenzyme caused ADP-ribosylation of rho p21 in the cells and selectively attenuated the phosphorylation of several proteins, including p43 mitogen-activated protein kinase, p125 focal adhesion kinase, and two proteins of 72 and 88 kDa. C3 exoenzyme pretreatment did not block the initial phosphorylation and activation of mitogen-activated protein kinase but suppressed its subsequent rise. In contrast, the enzyme treatment inhibited the induction of phosphorylation of the 72- and 88-kDa proteins and suppressed the basal and LPA-induced tyrosine phosphorylation of p125 focal adhesion kinase. In addition, immunoprecipitation of cell lysates with an antibody directed against the 85-kDa subunit of phosphatidylinositol 3-kinase (PI 3-kinase) co-precipitated a tyrosine-phosphorylated band of 180 kDa. C3 exoenzyme pretreatment suppressed both the phosphorylation of this band and PI 3-kinase activation associated with LPA stimulation. These findings suggest that rho p21 works as a link between the LPA receptor signal and the subsequent tyrosine phosphorylation and PI 3-kinase activation in these cells.	KYOTO UNIV, FAC MED, DEPT PHARMACOL, SAKYO KU, KYOTO 606, JAPAN	Kyoto University			Watanabe, Mamoru/AHE-0489-2022					AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HIRATA K, 1992, J BIOL CHEM, V267, P8719; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MABUCHI I, 1993, IN PRESS ZYGOTE; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOOLENAAR WH, 1991, ADV CANCER RES, V57, P87; MORII N, 1992, J BIOL CHEM, V267, P20921; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TANAKA S, 1993, JPN J CANCER RES, V84, P279, DOI 10.1111/j.1349-7006.1993.tb02868.x; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YOSHIMASA T, 1992, FEBS LETT, V311, P195, DOI 10.1016/0014-5793(92)81100-Z; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	36	210	212	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24535	24538						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227009				2022-12-25	WOS:A1993MG67300006
J	PERIDES, G; HU, G; RUEGER, DC; CHARNESS, ME				PERIDES, G; HU, G; RUEGER, DC; CHARNESS, ME			OSTEOGENIC PROTEIN-1 REGULATES L1 AND NEURAL CELL-ADHESION MOLECULE GENE-EXPRESSION IN NEURAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NG108-15 HYBRID-CELLS; GROWTH-FACTOR-BETA; N-CAM; MESSENGER-RNA; TGF-BETA; PC12 CELLS; NERVE; NCAM; SURFACE; DIFFERENTIATION	Osteogenic protein-1 (OP-1) is a member of the TGF-beta superfamily that is expressed in the nervous system. We recently showed that human recombinant osteogenic protein-1 (hOP-1) strongly promotes the aggregation of dividing neuroblastoma x glioma hybrid NG108-15 cells, in part by inducing the major isoforms of the neural cell adhesion molecule (N-CAM) (Perides, G., Safran, R. M., Rueger, D. C., and Charness, M. E. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10326-10330). Here we show that hOP-1 induces L1 expression approximately 6-fold in NG108-15 cells without changing the levels of N-cadherin, neurofilament 200, Thy-1, tau, and Galpha(s). OP-1 induction of L1 and N-CAM was unassociated with changes in cell proliferation and was not reproduced by cellular differentiation. The increased adhesiveness of hOP-1-treated NG108-15 cells could be inhibited in part by Fab fragments of an anti-L1 polyclonal antiserum. L1 and N-CAM expression first increased 12-18 h after hOP-1 treatment, reached a maximum after 2-3 days, persisted for up to 5 days, and returned to control levels 3 days after hOP-1 withdrawal. The increases in L1 and N-CAM protein levels were preceded or accompanied by large increases in the abundance of L1 and all detectable N-CAM mRNAs. Actinomycin D prevented the induction by hOP-1 of L1 and N-CAM mRNAs, suggesting that hOP-1 regulates immunoglobulin CAM gene transcription. OP-1 is the first described growth factor that regulates both N-CAM and L1 gene expression.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; DEPT VET AFFAIRS MED CTR, SPINAL CORD INJURY LAB, BOSTON, MA 02132 USA; CREAT BIOMOLECULES INC, HOPKINTON, MA 01748 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV NEUROL, BOSTON, MA 02115 USA; DEPT VET AFFAIRS MED CTR, NEUROL SECT, BOSTON, MA 02132 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital				Charness, Michael/0000-0002-3301-8966	NIAAA NIH HHS [AA06662] Funding Source: Medline; NINDS NIH HHS [NS13034] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006662] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDERSSON AM, 1990, FEBS LETT, V263, P385, DOI 10.1016/0014-5793(90)81420-S; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; BARTON CH, 1990, BIOCHEM J, V268, P161, DOI 10.1042/bj2680161; BRAAS KM, 1983, J NEUROSCI, V3, P1713; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARNESS ME, 1986, J BIOL CHEM, V261, P3164; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUONG CM, 1987, J CELL BIOL, V104, P331, DOI 10.1083/jcb.104.2.331; COLWELL G, 1992, GENOMICS, V14, P875, DOI 10.1016/S0888-7543(05)80108-9; COVAULT J, 1985, P NATL ACAD SCI USA, V82, P4544, DOI 10.1073/pnas.82.13.4544; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DOHERTY P, 1988, J CELL BIOL, V107, P333, DOI 10.1083/jcb.107.1.333; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDLANDER DR, 1986, J CELL BIOL, V102, P413, DOI 10.1083/jcb.102.2.413; GENNARINI G, 1986, J NEUROSCI, V6, P1983; HEMPERLY JJ, 1990, J MOL NEUROSCI, V2, P71, DOI 10.1007/BF02876913; HIRN M, 1981, BRAIN RES, V214, P433, DOI 10.1016/0006-8993(81)91208-7; HUSMANN M, 1989, DEV BIOL, V136, P194, DOI 10.1016/0012-1606(89)90141-3; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2986; JORGENSEN OS, 1983, NEUROSCIENCE, V9, P665, DOI 10.1016/0306-4522(83)90182-3; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KOBAYASHI H, 1992, NEUROSCIENCE, V49, P437, DOI 10.1016/0306-4522(92)90108-E; KOHL A, 1992, J NEUROSCI RES, V32, P167, DOI 10.1002/jnr.490320206; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; LINNEMANN D, 1989, DEV NEUROSCI-BASEL, V11, P149, DOI 10.1159/000111896; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MANN DA, 1989, J NEUROCHEM, V53, P1581, DOI 10.1111/j.1471-4159.1989.tb08555.x; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; MURRAY BA, 1986, J CELL BIOL, V102, P189, DOI 10.1083/jcb.102.1.189; OHTA S, 1992, FEBS LETT, V314, P356, DOI 10.1016/0014-5793(92)81505-G; OZKAYNAK E, 1991, BIOCHEM BIOPH RES CO, V179, P116, DOI 10.1016/0006-291X(91)91342-A; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PERIDES G, 1992, P NATL ACAD SCI USA, V89, P10326, DOI 10.1073/pnas.89.21.10326; PRENTICE HM, 1987, EMBO J, V6, P1859, DOI 10.1002/j.1460-2075.1987.tb02444.x; RATHJEN FG, 1984, EMBO J, V3, P1; REID RA, 1992, J MOL NEUROSCI, V3, P127, DOI 10.1007/BF02919404; ROUBIN R, 1990, J CELL BIOL, V111, P673, DOI 10.1083/jcb.111.2.673; RUTISHAUSER U, 1991, TRENDS NEUROSCI, V14, P528, DOI 10.1016/0166-2236(91)90006-G; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; TACKE R, 1990, NEUROSCI LETT, V120, P227, DOI 10.1016/0304-3940(90)90045-B; THIERY JP, 1982, P NATL ACAD SCI-BIOL, V79, P6737, DOI 10.1073/pnas.79.21.6737; THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	50	49	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25197	25205						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227084				2022-12-25	WOS:A1993MG67300097
J	ZANOTTI, G; MALPELI, G; BERNI, R				ZANOTTI, G; MALPELI, G; BERNI, R			THE INTERACTION OF N-ETHYL RETINAMIDE WITH PLASMA RETINOL-BINDING PROTEIN (RBP) AND THE CRYSTAL-STRUCTURE OF THE RETINOID-RBP COMPLEX AT 1.9-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSTHYRETIN COMPLEX; HUMAN SERUM; PURIFICATION; METABOLISM; REFINEMENT	The three-dimensional structure of bovine plasma retinol-binding protein (RBP) complexed with N-ethyl retinamide has been determined at 1.9-angstrom resolution. The crystals of the complex (space group P2(1)2(1)2(1), a = 46.27, b = 49.11, c = 76.41 angstrom) are isomorphous with those of bovine holo and apoRBP. The final crystallographic R factor is 0.172 for 11,261 observed reflections. The model of the retinoid-RBP complex is nearly identical to that of bovine retinol-RBP complex; the root mean square deviations between the alpha-carbons in the two proteins is 0.15 angstrom. The N-ethyl retinamide molecule fits in the beta-barrel in the same position previously occupied by the vitamin. The ethyl group of the retinoid replaces the retinol hydroxyl group and a water molecule hydrogen bonded to it. This substitution has no consequence on the overall conformation of the protein. The modification of the functional end group of retinol does not lead to an apparent loss of affinity of the retinol analog for apoRBP, as established by means of fluorometric titrations with N-ethyl retinamide. However, the binding of the retinoid to RBP abolishes or greatly reduces the affinity of RBP for transthyretin. This behavior further supports the hypothesis that the area of the entrance of the beta-barrel, which includes the ethyl group of the retinoid bound to RBP, is involved in the interaction with transthyretin. Moreover, it indicates a high degree of complementarity of interacting surfaces between RBP and transthyretin. In fact, the replacement of the retinol hydroxyl group and quite small structural changes in the above region of the RBP molecule drastically affect the protein-protein recognition.	UNIV PARMA,INST BIOCHEM SCI,I-43100 PARMA,ITALY; CNR,BIOPOLYMER RES CTR,I-35131 PADUA,ITALY	University of Parma; Consiglio Nazionale delle Ricerche (CNR)	ZANOTTI, G (corresponding author), UNIV PADUA,DEPT ORGAN CHEM,I-35131 PADUA,ITALY.			Berni, Rodolfo/0000-0002-1839-0479; Malpeli, Giorgio/0000-0002-2996-2903; Zanotti, Giuseppe/0000-0002-0945-6501				AQVIST J, 1992, J MOL GRAPHICS, V10, P120, DOI 10.1016/0263-7855(92)80065-L; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O; BERNI R, 1992, EUR J BIOCHEM, V204, P99, DOI 10.1111/j.1432-1033.1992.tb16610.x; BERNI R, 1989, COMP BIOCHEM PHYS B, V94, P79, DOI 10.1016/0305-0491(89)90014-X; BERNI R, 1993, RETINOIDS PROGR RES, P91; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BOYD AS, 1989, AM J MED, V86, P568, DOI 10.1016/0002-9343(89)90386-0; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; GAWINOWICZ MA, 1985, J PROTEIN CHEM, V4, P199, DOI 10.1007/BF01025298; GOLLNICK H, 1990, METHOD ENZYMOL, V190, P291; GOODMAN DS, 1972, J LIPID RES, V13, P338; Goodman DS, 1984, RETINOIDS, V2, P42; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; MOON RC, 1990, METHOD ENZYMOL, V190, P395; NOY N, 1992, BIOCHEMISTRY-US, V31, P11118, DOI 10.1021/bi00160a023; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; PETERSON PA, 1971, J BIOL CHEM, V246, P34; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VAHLQUIS.A, 1973, EUR J CLIN INVEST, V3, P352, DOI 10.1111/j.1365-2362.1973.tb00362.x; VANBENNEKUM AM, 1993, BIOCHEMISTRY-US, V32, P1727, DOI 10.1021/bi00058a005; ZANOTTI G, 1993, J MOL BIOL, V230, P613, DOI 10.1006/jmbi.1993.1173; ZANOTTI G, 1993, J BIOL CHEM, V268, P10728	25	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24873	24879						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	8227049				2022-12-25	WOS:A1993MG67300055
J	MARTIN, A; GOMEZMUNOZ, A; WAGGONER, DW; STONE, JC; BRINDLEY, DN				MARTIN, A; GOMEZMUNOZ, A; WAGGONER, DW; STONE, JC; BRINDLEY, DN			DECREASED ACTIVITIES OF PHOSPHATIDATE PHOSPHOHYDROLASE AND PHOSPHOLIPASE-D IN RAS AND TYROSINE KINASE (FPS) TRANSFORMED FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE ACTIVATING PROTEIN; PHOSPHATIDYLCHOLINE BREAKDOWN; LYSOPHOSPHATIDIC ACID; HUMAN NEUTROPHILS; KINETIC-ANALYSIS; ALPHA-THROMBIN; MIXED MICELLES; 3T3 CELLS; GROWTH; HYDROLYSIS	The activity of N-ethylmaleimide-insensitive phosphatidate phosphohydrolase (PAP-2) was characterized in control, ras-transformed, and tyrosine kinase-(fps) transformed rat fibroblasts. PAP-2 was assayed in two different ways: 1) within its natural membrane using liposomes of phosphatidate and 2) in the presence of sufficient Triton X-100 to solubilize PAP-2, and to form mixed micelles with the phosphatidate. Harvesting the fibroblasts in medium containing orthovanadate and Zn2+ gave up to 3-fold higher PAP-2 activities when measured in the absence, but not in the presence, of Triton X-100. PAP-2-specific activities from both assays increased in the control fibroblasts as the cells reached confluence. Both specific activities were lower in the oncogenically transformed fibroblasts than in controls at all cell densities tested. The specific activities of PAP-2 did not increase with time in culture in transformed cells which continued to divide. The relative increase in activity of phospholipase D after stimulation with serum or phorbol myristate acetate was lower in the transformed fibroblasts compared to control cells. This indicates a coordinated decrease in. the phospholipase D/phosphatidate phosphohydrolase pathway at the level of both enzymes in ras and fps transformed fibroblasts. The ratio of the production of diacylglycerol relative to phosphatidate, after stimulation with serum, or phorbol ester, was lower in both transformed fibroblasts relative to the controls. This is compatible with the decreased specific activity of PAP-2 and indicates functional significance for the differences in PAP-2 activity in regulating the balance between the two mitogenic lipids, phosphatidate and diacylglycerol. Control of PAP-2 activity could be an important factor in regulating appropriate signals for cell division.	UNIV ALBERTA, HERITAGE MED RES CTR 328, DEPT BIOCHEM, EDMONTON T6G 2S2, AB, CANADA; UNIV ALBERTA, HERITAGE MED RES CTR 328, LIPID & LIPOPROT RES GRP, ALBERTA T6G 2S2, AB, CANADA	University of Alberta; University of Alberta				GOMEZ MUNOZ, ANTONIO/0000-0002-2539-016X				ARIDORPITERMAN O, 1992, EUR J BIOCHEM, V204, P561, DOI 10.1111/j.1432-1033.1992.tb16668.x; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BELL RM, 1991, J BIOL CHEM, V266, P4661; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINDLEY DN, 1987, CRC SERIES ENZYME BI, P1; COLLINS MLP, 1979, BIOCHIM BIOPHYS ACTA, V553, P40, DOI 10.1016/0005-2736(79)90029-4; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; EXTON JH, 1990, J BIOL CHEM, V265, P1; FREEMAN M, 1989, BIOCHEM J, V263, P589, DOI 10.1042/bj2630589; FU T, 1992, BIOCHEM J, V283, P347, DOI 10.1042/bj2830347; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GOMEZMUNOZ A, 1992, BIOCHIM BIOPHYS ACTA, V1127, P49, DOI 10.1016/0005-2760(92)90200-F; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; HUANG C, 1992, BIOCHIM BIOPHYS ACTA, V1127, P242, DOI 10.1016/0005-2760(92)90227-M; HUANG CF, 1990, J BIOL CHEM, V265, P17468; JALINK K, 1990, J BIOL CHEM, V265, P12232; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JOHNSON KA, 1990, J VIROL, V64, P3337, DOI 10.1128/JVI.64.7.3337-3349.1990; KATO H, 1988, BIOCHEM BIOPH RES CO, V154, P959, DOI 10.1016/0006-291X(88)90233-1; KELLY SJ, 1975, BIOCHEMISTRY-US, V14, P4983, DOI 10.1021/bi00693a030; KUMJIAN DA, 1991, J BIOL CHEM, V266, P3973; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LIN YP, 1990, J BIOL CHEM, V265, P166; MARTIN A, 1991, METHOD ENZYMOL, V197, P553; MARTIN A, 1987, BIOCHEM J, V245, P347, DOI 10.1042/bj2450347; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PREISS J, 1986, J BIOL CHEM, V261, P8597; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; STATHOPOULOS VM, 1990, BIOCHEM J, V272, P569, DOI 10.1042/bj2720569; STONE JC, 1991, MOL CELL BIOL, V11, P6158, DOI 10.1128/MCB.11.12.6158; TING AE, 1991, EUR J CELL BIOL, V56, P401; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TRUETT AP, 1992, FASEB J, V6, P2720, DOI 10.1096/fasebj.6.9.1612297; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VOLWERK JJ, 1992, J CELL PHYSIOL, V151, P613, DOI 10.1002/jcp.1041510322; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WRIGHT TM, 1992, BIOCHEM J, V285, P395, DOI 10.1042/bj2850395	58	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23924	23932						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226932				2022-12-25	WOS:A1993MF29400035
J	MEAH, YS; BRYANT, FR				MEAH, YS; BRYANT, FR			ACTIVATION OF A RECOMBINASE-DEFICIENT MUTANT RECA PROTEIN WITH ALTERNATE NUCLEOSIDE TRIPHOSPHATE COFACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; ESCHERICHIA-COLI; ATP HYDROLYSIS; ISOMERIZATION	We recently described two mutant recA proteins, (G160N)recA and (H163A)recA, which have full single-stranded DNA-dependent ATP hydrolysis activity but which are unable to promote the ATP-dependent strand exchange reaction under standard reaction conditions (pH 7.5). These mutant proteins, however, are able to promote strand exchange at pH 6.0 to 6.8. Here we show that this activation correlates with a pH-dependent decrease in the S0.5 value for ATP, with the (H163A)recA protein becoming active in strand exchange at pH values where the S0.5(ATP) decreases below 100 muM. We also show that the (H163A)recA protein is active in strand exchange over the range of pH 6.0-8.2 if dATP (or ddATP) is used in place of ATP as a cofactor; dATP is hydrolyzed by (H163A)recA protein at the same rate as ATP but has an S0.5, value lower than 100 muM across this pH range. These results are discussed with regard to the general significance of the S0.5 value in determining whether a nucleoside triphosphate will be able to stabilize the recA-single-stranded DNA filament in the strand exchange active conformational state.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036516] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36516] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYANT FR, 1988, J BIOL CHEM, V263, P8716; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; GRIFFITH JD, 1988, CRC CRIT REV BIOC S1, V23, P43; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7677, DOI 10.1021/bi00485a017; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7666, DOI 10.1021/bi00485a016; MENETSKI JP, 1989, BIOCHEMISTRY-US, V28, P5871, DOI 10.1021/bi00440a025; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MENGE KL, 1988, BIOCHEMISTRY-US, V27, P2635, DOI 10.1021/bi00407a055; MENGE KL, 1992, BIOCHEMISTRY-US, V31, P5151, DOI 10.1021/bi00137a009; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1483; MUENCH KA, 1991, J BIOL CHEM, V266, P844; MUENCH KA, 1990, J BIOL CHEM, V265, P11560; PINSINCE JM, 1993, IN PRESS J MOL BIOL; RADDING CM, 1982, ANNU REV GENET, V16, P495; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; STASIAK A, 1986, BIOPHYS J, V49, P5, DOI 10.1016/S0006-3495(86)83569-X; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; THRESHER RJ, 1988, J MOL BIOL, V201, P101, DOI 10.1016/0022-2836(88)90442-1; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126	23	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23991	23996						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226942				2022-12-25	WOS:A1993MF29400045
J	RABINOVICH, E; BARNUN, S; AMITAY, R; SHACHAR, I; GUR, B; TAYA, M; HAIMOVICH, J				RABINOVICH, E; BARNUN, S; AMITAY, R; SHACHAR, I; GUR, B; TAYA, M; HAIMOVICH, J			DIFFERENT ASSEMBLY SPECIES OF IGM ARE DIRECTED TO DISTINCT DEGRADATION SITES ALONG THE SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC GENES; ENDOPLASMIC-RETICULUM; LYMPHOCYTES-B; LIGHT-CHAIN; BREFELDIN-A; PROTEIN; MEMBRANE; EXPRESSION; OCCURS; GOLGI	In 38C B lymphocytes the membrane form of IgM is displayed on the cell surface whereas the secretory form of IgM is degraded. In the EH cell line, a light chain-deficient variant of 38C cells, the mu heavy chains are partially assembled with surrogate light chains characteristic of pre-B cells. In these cells neither the membrane (mum) nor the secretory (mus) forms of the mu heavy chain reach their final destination, and both are rapidly degraded. The degradation of mu chains in EH cells, like that of mus in 38C cells, is nonlysosomal and occurs prior to the trans-Golgi. However, while As degradation in 38C cells is inhibited by brefeldin A, in EH cells mus and mum are retained and degraded by a brefeldin A-insensitive mechanism. These results indicate that degradation in EH cells occurs within the endoplasmic reticulum, whereas degradation in 38C cells requires exit from this compartment. Thus, mu heavy chains can be degraded in multiple sites along the secretory pathway. The location of the degradation process is determined by the developmentally regulated assembly species of the mu chains with either ''classical'' or surrogate light chains.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL; TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University								AMITAY R, 1991, J BIOL CHEM, V266, P12568; AMITAY R, 1992, J BIOL CHEM, V267, P20694; BERGMAN Y, 1978, EUR J IMMUNOL, V8, P876, DOI 10.1002/eji.1830081210; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; CHUN KT, 1990, J BIOL CHEM, V265, P22004; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DULIS BH, 1983, J BIOL CHEM, V258, P2181; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRIENINGER G, 1984, J BIOL CHEM, V259, P4973; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LE AQ, 1992, J BIOL CHEM, V267, P1072; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; SCHIMKE RT, 1973, ADV ENZYMOL RAMB, V37, P135; SHACHAR I, 1992, J BIOL CHEM, V267, P24241; SIDMAN C, 1981, CELL, V23, P379, DOI 10.1016/0092-8674(81)90133-1; TAYA M, 1992, IMMUNOL LETT, V33, P173, DOI 10.1016/0165-2478(92)90044-O; TAYA M, 1991, CANCER IMMUNOL IMMUN, V34, P43, DOI 10.1007/BF01741323; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973	25	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24145	24148						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	8226961				2022-12-25	WOS:A1993MF29400065
